Novel proteins and nucleic acids encoding same

Abstract

The present invention provides novel isolated polynucleotides and small molecule target polypeptides encoded by the polynucleotides. Antibodies that immunospecifically bind to a novel small molecule target polypeptide or any derivative, variant, mutant or fragment of that polypeptide, polynucleotide or antibody are disclosed, as are methods in which the small molecule target polypeptide, polynucleotide and antibody are utilized in the detection and treatment of a broad range of pathological states. More specifically, the present invention discloses methods of using recombinantly expressed and/or endogenously expressed proteins in various screening procedures for the purpose of identifying therapeutic antibodies and therapeutic small molecules associated with diseases. The invention further discloses therapeutic, diagnostic and research methods for diagnosis, treatment, and prevention of disorders involving any one of these novel human nucleic acids and proteins.

Description

FIELD OF THE INVENTION

[0002] The present invention relates to novel polypeptides that are targets of small molecule drugs and that have properties related to stimulation of biochemical or physiological responses in a cell, a tissue, an organ or an organism. More particularly, the novel polypeptides are gene products of novel genes, or are specified biologically active fragments or derivatives thereof. Methods of use encompass diagnostic and prognostic assay procedures as well as methods of treating diverse pathological conditions.

BACKGROUND

[0003] Eukaryotic cells are characterized by biochemical and physiological processes which under normal conditions are exquisitely balanced to achieve the preservation and propagation of the cells. When such cells are components of multicellular organisms such as vertebrates, or more particularly organisms such as mammals, the regulation of the biochemical and physiological processes involves intricate signaling pathways. Frequently, such signaling pathways involve extracellular signaling proteins, cellular receptors that bind the signaling proteins and signal transducing components located within the cells.

[0004] Signaling proteins may be classified as endocrine effectors, paracrine effectors or autocrine effectors. Endocrine effectors are signaling molecules secreted by a given organ into the circulatory system, which are then transported to a distant target organ or tissue. The target cells include the receptors for the endocrine effector, and when the endocrine effector binds, a signaling cascade is induced. Paracrine effectors involve secreting cells and receptor cells in close proximity to each other, for example two different classes of cells in the same tissue or organ. One class of cells secretes the paracrine effector, which then reaches the second class of cells, for example by diffusion through the extracellular fluid. The second class of cells contains the receptors for the paracrine effector; binding of the effector results in induction of the signaling cascade that elicits the corresponding biochemical or physiological effect. Autocrine effectors are highly analogous to paracrine effectors, except that the same cell type that secretes the autocrine effector also contains the receptor. Thus the autocrine effector binds to receptors on the same cell, or on identical neighboring cells. The binding process then elicits the characteristic biochemical or physiological effect.

[0005] Signaling processes may elicit a variety of effects on cells and tissues including by way of nonlimiting example induction of cell or tissue proliferation, suppression of growth or proliferation, induction of differentiation or maturation of a cell or tissue, and suppression of differentiation or maturation of a cell or tissue.

[0006] Many pathological conditions involve dysregulation of expression of important effector proteins. In certain classes of pathologies the dysregulation is manifested as diminished or suppressed level of synthesis and secretion of protein effectors. In other classes of pathologies the dysregulation is manifested as increased or up-regulated level of synthesis and secretion of protein effectors. In a clinical setting a subject may be suspected of suffering from a condition brought on by altered or mis-regulated levels of a protein effector of interest. Therefore there is a need to assay for the level of the protein effector of interest in a biological sample from such a subject, and to compare the level with that characteristic of a nonpathological condition. There also is a need to provide the protein effector as a product of manufacture. Administration of the effector to a subject in need thereof is useful in treatment of the pathological condition. Accordingly, there is a need for a method of treatment of a pathological condition brought on by a diminished or suppressed levels of the protein effector of interest. In addition, there is a need for a method of treatment of a pathological condition brought on by a increased or up-regulated levels of the protein effector of interest.

[0007] Small molecule targets have been implicated in various disease states or pathologies. These targets may be proteins, and particularly enzymatic proteins, which are acted upon by small molecule drugs for the purpose of altering target function and achieving a desired result. Cellular, animal and clinical studies can be performed to elucidate the genetic contribution to the etiology and pathogenesis of conditions in which small molecule targets are implicated in a variety of physiologic, pharmacologic or native states. These studies utilize the core technologies at CuraGen Corporation to look at differential gene expression, protein-protein interactions, large-scale sequencing of expressed genes and the association of genetic variations such as, but not limited to, single nucleotide polymorphisms (SNPs) or splice variants in and between biological samples from experimental and control groups. The goal of such studies is to identify potential avenues for therapeutic intervention in order to prevent, treat the consequences or cure the conditions.

[0008] In order to treat diseases, pathologies and other abnormal states or conditions in which a mammalian organism has been diagnosed as being, or as being at risk for becoming, other than in a normal state or condition, it is important to identify new therapeutic agents. Such a procedure includes at least the steps of identifying a target component within an affected tissue or organ, and identifying a candidate therapeutic agent that modulates the functional attributes of the target. The target component may be any biological macromolecule implicated in the disease or pathology. Commonly the target is a polypeptide or protein with specific functional attributes. Other classes of macromolecule may be a nucleic acid, a polysaccharide, a lipid such as a complex lipid or a glycolipid; in addition a target may be a sub-cellular structure or extra-cellular structure that is comprised of more than one of these classes of macromolecule. Once such a target has been identified, it may be employed in a screening assay in order to identify favorable candidate therapeutic agents from among a large population of substances or compounds.

[0009] In many cases the objective of such screening assays is to identify small molecule candidates; this is commonly approached by the use of combinatorial methodologies to develop the population of substances to be tested. The implementation of high throughput screening methodologies is advantageous when working with large, combinatorial libraries of compounds.

SUMMARY OF THE INVENTION

[0010] The invention includes nucleic acid sequences and the novel polypeptides they encode. The novel nucleic acids and polypeptides are referred to herein as NOVX, or NOV1, NOV2, NOV3, etc., nucleic acids and polypeptides. These nucleic acids and polypeptides, as well as derivatives, homologs, analogs and fragments thereof, will hereinafter be collectively designated as “NOVX” nucleic acid, which represents the nucleotide sequence selected from the group consisting of SEQ ID NO: 2n−1, wherein n is an integer between 1 and 226, or polypeptide sequences, which represents the group consisting of SEQ ID NO: 2n, wherein n is an integer between 1 and 226.

[0011] In one aspect, the invention provides an isolated polypeptide comprising a mature form of a NOVX amino acid. One example is a variant of a mature form of a NOVX amino acid sequence, wherein any amino acid in the mature form is changed to a different amino acid, provided that no more than 15% of the amino acid residues in the sequence of the mature form are so changed. The amino acid can be, for example, a NOVX amino acid sequence or a variant of a NOVX amino acid sequence, wherein any amino acid specified in the chosen sequence is changed to a different amino acid, provided that no more than 15% of the amino acid residues in the sequence are so changed. The invention also includes fragments of any of these. In another aspect, the invention also includes an isolated nucleic acid that encodes a NOVX polypeptide, or a fragment, homolog, analog or derivative thereof.

[0012] Also included in the invention is a NOVX polypeptide that is a naturally occurring allelic variant of a NOVX sequence. In one embodiment, the allelic variant includes an amino acid sequence that is the translation of a nucleic acid sequence differing by a single nucleotide from a NOVX nucleic acid sequence. In another embodiment, the NOVX polypeptide is a variant polypeptide described therein, wherein any amino acid specified in the chosen sequence is changed to provide a conservative substitution. In one embodiment, the invention discloses a method for determining the presence or amount of the NOVX polypeptide in a sample. The method involves the steps of: providing a sample; introducing the sample to an antibody that binds immunospecifically to the polypeptide; and determining the presence or amount of antibody bound to the NOVX polypeptide, thereby determining the presence or amount of the NOVX polypeptide in the sample. In another embodiment, the invention provides a method for determining the presence of or predisposition to a disease associated with altered levels of a NOVX polypeptide in a mammalian subject. This method involves the steps of: measuring the level of expression of the polypeptide in a sample from the first mammalian subject; and comparing the amount of the polypeptide in the sample of the first step to the amount of the polypeptide present in a control sample from a second mammalian subject known not to have, or not to be predisposed to, the disease, wherein an alteration in the expression level of the polypeptide in the first subject as compared to the control sample indicates the presence of or predisposition to the disease.

[0013] In a further embodiment, the invention includes a method of identifying an agent that binds to a NOVX polypeptide. This method involves the steps of: introducing the polypeptide to the agent; and determining whether the agent binds to the polypeptide. In various embodiments, the agent is a cellular receptor or a downstream effector.

[0014] In another aspect, the invention provides a method for identifying a potential therapeutic agent for use in treatment of a pathology, wherein the pathology is related to aberrant expression or aberrant physiological interactions of a NOVX polypeptide. The method involves the steps of: providing a cell expressing the NOVX polypeptide and having a property or function ascribable to the polypeptide; contacting the cell with a composition comprising a candidate substance; and determining whether the substance alters the property or function ascribable to the polypeptide; whereby, if an alteration observed in the presence of the substance is not observed when the cell is contacted with a composition devoid of the substance, the substance is identified as a potential therapeutic agent. In another aspect, the invention describes a method for screening for a modulator of activity or of latency or predisposition to a pathology associated with the NOVX polypeptide. This method involves the following steps: administering a test compound to a test animal at increased risk for a pathology associated with the NOVX polypeptide, wherein the test animal recombinantly expresses the NOVX polypeptide. This method involves the steps of measuring the activity of the NOVX polypeptide in the test animal after administering the compound of step; and comparing the activity of the protein in the test animal with the activity of the NOVX polypeptide in a control animal not administered the polypeptide, wherein a change in the activity of the NOVX polypeptide in the test animal relative to the control animal indicates the test compound is a modulator of latency of, or predisposition to, a pathology associated with the NOVX polypeptide. In one embodiment, the test animal is a recombinant test animal that expresses a test protein transgene or expresses the transgene under the control of a promoter at an increased level relative to a wild-type test animal, and wherein the promoter is not the native gene promoter of the transgene. In another aspect, the invention includes a method for modulating the activity of the NOVX polypeptide, the method comprising introducing a cell sample expressing the NOVX polypeptide with a compound that binds to the polypeptide in an amount sufficient to modulate the activity of the polypeptide.

[0015] The invention also includes an isolated nucleic acid that encodes a NOVX polypeptide, or a fragment, homolog, analog or derivative thereof. In a preferred embodiment, the nucleic acid molecule comprises the nucleotide sequence of a naturally occurring allelic nucleic acid variant. In another embodiment, the nucleic acid encodes a variant polypeptide, wherein the variant polypeptide has the polypeptide sequence of a naturally occurring polypeptide variant. In another embodiment, the nucleic acid molecule differs by a single nucleotide from a NOVX nucleic acid sequence. In one embodiment, the NOVX nucleic acid molecule hybridizes under stringent conditions to the nucleotide sequence selected from the group consisting of SEQ ID NO: 2n−1, wherein n is an integer between 1 and 226, or a complement of the nucleotide sequence. In another aspect, the invention provides a vector or a cell expressing a NOVX nucleotide sequence.

[0016] In one embodiment, the invention discloses a method for modulating the activity of a NOVX polypeptide. The method includes the steps of: introducing a cell sample expressing the NOVX polypeptide with a compound that binds to the polypeptide in an amount sufficient to modulate the activity of the polypeptide. In another embodiment, the invention includes an isolated NOVX nucleic acid molecule comprising a nucleic acid sequence encoding a polypeptide comprising a NOVX amino acid sequence or a variant of a mature form of the NOVX amino acid sequence, wherein any amino acid in the mature form of the chosen sequence is changed to a different amino acid, provided that no more than 15% of the amino acid residues in the sequence of the mature form are so changed. In another embodiment, the invention includes an amino acid sequence that is a variant of the NOVX amino acid sequence, in which any amino acid specified in the chosen sequence is changed to a different amino acid, provided that no more than 15% of the amino acid residues in the sequence are so changed.

[0017] In one embodiment, the invention discloses a NOVX nucleic acid fragment encoding at least a portion of a NOVX polypeptide or any variant of the polypeptide, wherein any amino acid of the chosen sequence is changed to a different amino acid, provided that no more than 10% of the amino acid residues in the sequence are so changed.

[0018] In another embodiment, the invention includes the complement of any of the NOVX nucleic acid molecules or a naturally occurring allelic nucleic acid variant. In another embodiment, the invention discloses a NOVX nucleic acid molecule that encodes a variant polypeptide, wherein the variant polypeptide has the polypeptide sequence of a naturally occurring polypeptide variant. In another embodiment, the invention discloses a NOVX nucleic acid, wherein the nucleic acid molecule differs by a single nucleotide from a NOVX nucleic acid sequence.

[0019] In another aspect, the invention includes a NOVX nucleic acid, wherein one or more nucleotides in the NOVX nucleotide sequence is changed to a different nucleotide provided that no more than 15% of the nucleotides are so changed. In one embodiment, the invention discloses a nucleic acid fragment of the NOVX nucleotide sequence and a nucleic acid fragment wherein one or more nucleotides in the NOVX nucleotide sequence is changed from that selected from the group consisting of the chosen sequence to a different nucleotide provided that no more than 15% of the nucleotides are so changed. In another embodiment, the invention includes a nucleic acid molecule wherein the nucleic acid molecule hybridizes under stringent conditions to a NOVX nucleotide sequence or a complement of the NOVX nucleotide sequence. In one embodiment, the invention includes a nucleic acid molecule, wherein the sequence is changed such that no more than 15% of the nucleotides in the coding sequence differ from the NOVX nucleotide sequence or a fragment thereof.

[0020] In a further aspect, the invention includes a method for determining the presence or amount of the NOVX nucleic acid in a sample. The method involves the steps of: providing the sample; introducing the sample to a probe that binds to the nucleic acid molecule; and determining the presence or amount of the probe bound to the NOVX nucleic acid molecule, thereby determining the presence or amount of the NOVX nucleic acid molecule in the sample. In one embodiment, the presence or amount of the nucleic acid molecule is used as a marker for cell or tissue type.

[0021] In another aspect, the invention discloses a method for determining the presence of or predisposition to a disease associated with altered levels of the NOVX nucleic acid molecule of in a first mammalian subject. The method involves the steps of: measuring the amount of NOVX nucleic acid in a sample from the first mammalian subject; and comparing the amount of the nucleic acid in the sample of step (a) to the amount of NOVX nucleic acid present in a control sample from a second mammalian subject known not to have or not be predisposed to, the disease; wherein an alteration in the level of the nucleic acid in the first subject as compared to the control sample indicates the presence of or predisposition to the disease.

[0022] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, suitable methods and materials are described below. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety. In the case of conflict, the present specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and not intended to be limiting.

[0023] Other features and advantages of the invention will be apparent from the following detailed description and claims.

DETAILED DESCRIPTION OF THE INVENTION

[0024] The present invention provides novel nucleotides and polypeptides encoded thereby. Included in the invention are the novel nucleic acid sequences, their encoded polypeptides, antibodies, and other related compounds. The sequences are collectively referred to herein as “NOVX nucleic acids” or “NOVX polynucleotides” and the corresponding encoded polypeptides are referred to as “NOVX polypeptides” or “NOVX proteins.” Unless indicated otherwise, “NOVX” is meant to refer to any of the novel sequences disclosed herein. Table A provides a summary of the NOVX nucleic acids and their encoded polypeptides.

TABLE A
Sequences and Corresponding SEQ ID Numbers
NOVX	Internal	SEQ ID NO	SEQ ID NO
Assignment	Identification	(nucleic acid)	(amino acid)	Homology
1a	CG101683-01	1	2	Mitogen-activated protein
				kinase kinase kinase 8
1b	248490507	3	4	Mitogen-activated protein
				kinase kinase kinase 8
1c	253174293	5	6	Mitogen-activated protein
				kinase kinase kinase 8
1d	248490584	7	8	Mitogen-activated protein
				kinase kinase kinase 8
1e	258054391	9	10	Mitogen-activated protein
				kinase kinase kinase 8
1f	248494549	11	12	Mitogen-activated protein
				kinase kinase kinase 8
1g	259741837	13	14	Mitogen-activated protein
				kinase kinase kinase 8
1h	260480803	15	16	Mitogen-activated protein
				kinase kinase kinase 8
1i	209983329	17	18	Mitogen-activated protein
				kinase kinase kinase 8
1j	212779055	19	20	Mitogen-activated protein
				kinase kinase kinase 8
1k	212779063	21	22	Mitogen-activated protein
				kinase kinase kinase 8
1l	CG101683-02	23	24	Mitogen-activated protein
				kinase kinase kinase 8
1m	CG101683-03	25	26	Mitogen-activated protein
				kinase kinase kinase 8
1n	CG101683-04	27	28	Mitogen-activated protein
				kinase kinase kinase 8
1o	CG101683-05	29	30	Mitogen-activated protein
				kinase kinase kinase 8
1p	CG101683-06	31	32	Mitogen-activated protein
				kinase kinase kinase 8
1q	CG101683-07	33	34	Mitogen-activated protein
				kinase kinase kinase 8
1r	CG101683-08	35	36	Mitogen-activated protein
				kinase kinase kinase 8
2a	CG101996-01	37	38	Phosphorylase B kinase
				gamma catalytic chain,
				skeletal muscle isoform
2b	CG101996-04	39	40	Phosphorylase B kinase
				gamma catalytic chain,
				skeletal muscle isoform
2c	CG101996-02	41	42	Phosphorylase B kinase
				gamma catalytic chain,
				skeletal muscle isoform
2d	245245680	43	44	Phosphorylase B kinase
				gamma catalytic chain,
				skeletal muscle isoform
2e	245245707	45	46	Phosphorylase B kinase
				gamma catalytic chain,
				skeletal muscle isoform
2f	248494552	47	48	Phosphorylase B kinase
				gamma catalytic chain,
				skeletal muscle isoform
2g	242435676	49	50	Phosphorylase B kinase
				gamma catalytic chain,
				skeletal muscle isoform
2h	254868664	51	52	Phosphorylase B kinase
				gamma catalytic chain,
				skeletal muscle isoform
2i	249122191	53	54	Phosphorylase B kinase
				gamma catalytic chain,
				skeletal muscle isoform
2j	249122234	55	56	Phosphorylase B kinase
				gamma catalytic chain,
				skeletal muscle isoform
2k	CG101996-03	57	58	Phosphorylase B kinase
				gamma catalytic chain,
				skeletal muscle isoform
2l	CG101996-05	59	60	Phosphorylase B kinase
				gamma catalytic chain,
				skeletal muscle isoform
2m	CG101996-06	61	62	Phosphorylase B kinase
				gamma catalytic chain,
				skeletal muscle isoform
2n	CG101996-07	63	64	Phosphorylase B kinase
				gamma catalytic chain,
				skeletal muscle isoform
2o	CG101996-08	65	66	Phosphorylase B kinase
				gamma catalytic chain,
				skeletal muscle isoform
2p	CG101996-09	67	68	Phosphorylase B kinase
				gamma catalytic chain,
				skeletal muscle isoform
3a	CG102822-01	69	70	glutamate-ammonia
				ligase
3b	CG102822-03	71	72	glutamate-ammonia
				ligase
3c	CG102822-03	73	74	glutamate-5ammonia
				ligase
3d	CG102822-04	75	76	glutamate-ammonia
				ligase
4a	CG103241-01	77	78	Beta-1,4-
				galactosyltransferase 2
4b	CG103241-02	79	80	Beta-1,4-
				galactosyltransferase 2
4c	CG103241-03	81	82	Beta-1,4-
				galactosyltransferase 2
5a	CG106249-01	83	84	KIAA 1590 protein
5b	CG106249-02	85	86	KIAA 1590 protein
6a	CG106824-01	87	88	Tryptase beta-1 precursor
6b	CG106824-04	89	90	Tryptase beta-1 precursor
6c	CG106824-02	91	92	Tryptase beta-1 precursor
6d	CG106824-03	93	94	Tryptase beta-1 precursor
7a	CG114327-01	95	96	Similar to hypothetical
				protein FLJ23469
7b	CG114327-02	97	98	Similar to hypothetical
				protein FLJ23469
8a	CG119418-01	99	100	Farnesyl-diphosphate
				farnesyltransferase
9a	CG120359-01	101	102	Acetyl-coenzyme A
				synthetase, cytoplasmic
9b	277685717	103	104	Acetyl-coenzyme A
				synthetase, cytoplasmic
9c	277686882	105	106	Acetyl-coenzyme A
				synthetase, cytoplasmic
9d	CG120359-02	107	108	Acetyl-coenzyme A
				synthetase, cytoplasmic
10a	CG124907-01	109	110	Ornithine decarboxylase
10b	CG124907-01	111	112	Ornithine decarboxylase
10c	254048022	113	114	Ornithine decarboxylase
10d	258252457	115	116	Ornithine decarboxylase
10e	258280014	117	118	Ornithine decarboxylase
10f	258330318	119	120	Ornithine decarboxylase
10g	258330346	121	122	Ornithine decarboxylase
10h	258330472	123	124	Ornithine decarboxylase
10i	258330611	125	126	Ornithine decarboxylase
10j	260481330	127	128	Ornithine decarboxylase
10k	CG124907-02	129	130	Ornithine decarboxylase
10l	CG124907-03	131	132	Ornithine decarboxylase
10m	CG124907-04	133	134	Ornithine decarboxylase
10n	CG124907-05	135	136	Ornithine decarboxylase
10o	CG124907-06	137	138	Ornithine decarboxylase
11a	CG128347-01	139	140	Hypothetical 96.7 kDa
				protein
11b	CG128347-02	141	142	Hypothetical 96.7 kDa
				protein
12a	CG135823-01	143	144	Tyrosine
				aminotransferase
12b	CG135823-02	145	146	Tyrosine
				aminotransferase
12c	233048273	147	148	Tyrosine
				aminotransferase
12d	233048286	149	150	Tyrosine
				aminotransferase
12e	248490358	151	152	Tyrosine
				aminotransferase
12f	254868693	153	154	Tyrosine
				aminotransferase
12g	255667122	155	156	Tyrosine
				aminotransferase
12h	258252417	157	158	Tyrosine
				aminotransferase
12i	259741773	159	160	Tyrosine
				aminotransferase
12j	260480043	161	162	Tyrosine
				aminotransferase
12k	CG135823-03	163	164	Tyrosine
				aminotransferase
12l	CG135823-04	165	166	Tyrosine
				aminotransferase
13a	CG140122-01	167	168	Polyamine oxidase
				isoform-1 - Homo sapiens
13b	246864043	169	170	Polyamine oxidase
				isoform-1 - Homo sapiens
13c	246864086	171	172	Polyamine oxidase
				isoform-1 - Homo sapiens
13d	258280083	173	174	Polyamine oxidase
				isoform-1 - Homo sapiens
13e	258280066	175	176	Polyamine oxidase
				isoform-1 - Homo sapiens
13f	258329988	177	178	Polyamine oxidase
				isoform-1 - Homo sapiens
13g	254047897	179	180	Polyamine oxidase
				isoform-1 - Homo sapiens
13h	258329988	181	182	Polyamine oxidase
				isoform-1 - Homo sapiens
13i	258280066	183	184	Polyamine oxidase
				isoform-1 - Homosapiens
13j	258280083	185	186	Polyamine oxidase
				isoform-1 - Homo sapiens
13k	CG140122-02	187	188	Polyamine oxidase
				isoform-1 - Homo sapiens
13l	CG140122-03	189	190	Polyamine oxidase
				isoform-1 - Homo sapiens
13m	CG140122-04	191	192	Polyamine oxidase
				isoform-1 - Homo sapiens
13n	CG140122-05	193	194	Polyamine oxidase
				isoform-1 - Homo sapiens
13o	CG140122-06	195	196	Polyamine oxidase
				isoform-1 - Homo sapiens
13p	CG140122-07	197	198	Polyamine oxidase
				isoform-1 - Homo sapiens
13q	CG140122-08	199	200	Polyamine oxidase
				isoform-1 - Homo sapiens
14a	CG140316-01	201	202	NADP-dependent malic
				enzyme
14b	CG140316-01	203	204	NADP-dependent malic
				enzyme
14c	254047949	205	206	NADP-dependent malic
				enzyme
14d	258280122	207	208	NADP-dependent malic
				enzyme
14e	258330149	209	210	NADP-dependent malic
				enzyme
14f	258330422	211	212	NADP-dependent malic
				enzyme
14g	258330562	213	214	NADP-dependent malic
				enzyme
14h	258330639	215	216	NADP-dependent malic
				enzyme
14i	259357792	217	218	NADP-dependent malic
				enzyme
14j	CG140316-02	219	220	NADP-dependent malic
				enzyme
14k	CG140316-03	221	222	NADP-dependent malic
				enzyme
14l	CG140316-04	223	224	NADP-dependent malic
				enzyme
15a	CG142427-01	225	226	ATP-citrate (pro-S—)-lyase
15b	CG142427-01	227	228	ATP-citrate (pro-S—)-lyase
15c	CG142427-04	229	230	ATP-citrate (pro-S—)-lyase
15d	CG142427-02	231	232	ATP-citrate (pro-S—)-lyase
15e	CG142427-03	233	234	ATP-citrate (pro-S—)-lyase
15f	256388552	235	236	ATP-citrate (pro-S—)-lyase
15g	256420210	237	238	ATP-citrate (pro-S—)-lyase
15h	256202925	239	240	ATP-citrate (pro-S—)-lyase
15i	259856081	241	242	ATP-citrate (pro-S—)-lyase
15j	256388552	243	244	ATP-citrate (pro-S—)-lyase
15k	256420210	245	246	ATP-citrate (pro-S—)-lyase
15l	256202925	247	248	ATP-citrate (pro-S—)-lyase
15m	296463359	249	250	ATP-citrate (pro-S—)-lyase
15n	263470992	251	252	ATP-citrate (pro-S—)-lyase
15o	CG142427-05	253	254	ATP-citrate (pro-S—)-lyase
16a	CG142631-01	255	256	L-serine dehydratase
16b	CG142631-01	257	258	L-serine dehydratase
16c	248494617	259	260	L-serine dehydratase
16d	228832711	261	262	L-serine dehydratase
16e	256420310	263	264	L-serine dehydratase
16f	249117058	265	266	L-serine dehydratase
16g	252790334	267	268	L-serine dehydratase
16h	254869149	269	270	L-serine dehydratase
16i	CG142631-02	271	272	L-serine dehydratase
16j	CG142631-03	273	274	L-serine dehydratase
16k	CG142631-04	275	276	L-serine dehydratase
17a	CG151359-01	277	278	L-lactate dehydrogenase
				A-like
18a	CG152227-01	279	280	Similar to 3-
				hydroxyisobutyryl-
				coenzyme A hydrolase
18b	CG152227-02	281	282	Similar to 3-
				hydroxyisobutyryl-
				coenzyme A hydrolase
19a	CG152392-01	283	284	Hypothetical 68.5 kDa
				protein
20a	CG152453-01	285	286	Beta-1,4-
				galactosyltransferase 6
20b	CG152453-03	287	288	Beta-1,4-
				galactosyltransferase 6
20c	CG152453-02	289	290	Beta-1,4-
				galactosyltransferase 6
21a	CG152547-01	291	292	Hypothetical 26.3 kDa
				protein
22a	CG152646-01	293	294	Hypothetical 57.5 kDa
				protein
23a	CG152959-01	295	296	CAAX prenyl protease 2
23b	CG152959-02	297	298	CAAX prenyl protease 2
24a	CG153033-01	299	300	Vesicular glutamate
				transporter 3 - Homo
				sapiens
25a	CG153818-01	301	302	CDNA FLJ37300 fis,
				clone BRAMY2015782,
				moderately similar to
				KINESIN-LIKE
				PROTEIN
26a	CG154435-01	303	304	Dynein beta chain, ciliary
27a	CG154465-01	305	306	Similar to hypothetical
				protein DKFZp434G2226 -
28a	CG154492-01	307	308	High-affinity cGMP-
				specific 3′,5′-cyclic
				phosphodiesterase 9A
28b	CG154492-02	309	310	High-affinity cGMP-
				specific 3′,5′-cyclic
				phosphodiesterase 9A
29a	CG154509-01	311	312	Cytoplasmic dynein
				heavy chain
30a	CG155595-01	313	314	Hypothetical 98.5 kDa
				protein
31a	CG155962-01	315	316	Kinesin-like protein
				KIF1B (Klp)
32a	CG157477-01	317	318	Myosin I
33a	CG157486-01	319	320	EphA2
34a	CG157505-01	321	322	KIAA 1300 protein
35a	CG157629-01	323	324	Serine/threonine protein
				phosphatase with EF-
				hands-1
35b	CG157629-01	325	326	Serine/threonine protein
				phosphatase with EF-
				hands-1
36a	CG157704-01	327	328	Probable mitotic
				centromere associated
				kinesin - Leishmania
				major
37a	CG158218-01	329	330	Kinesin-related protein
				3A
38a	CG158513-01	331	332	Prostatic acid phosphatase
				precursor
38b	CG158513-02	333	334	Prostatic acid phosphatase
				precursor
39a	CG158583-01	335	336	Synaptic vesicle amine
				transporter (Monoamine
				transporter) (Vesicular
				amine transporter 2)
				(VAT2)
39b	CG158583-02	337	338	Synaptic vesicle amine
				transporter (Monoamine
				transporter) (Vesicular
				amine transporter 2)
				(VAT2)
39c	CG158583-04	339	340	Synaptic vesicle amine
				transporter (Monoamine
				transporter) (Vesicular
				amine transporter 2)
				(VAT2)
39d	CG158583-05	341	342	Synaptic vesicle amine
				transporter (Monoamine
				transporter) (Vesicular
				amine transporter 2)
				(VAT2)
39e	CG158583-03	343	345	Synaptic vesicle amine
				transporter (Monoamine
				transporter) (Vesicular
				amine transporter 2)
				(VAT2)
40a	CG158964-01	346	347	PHOSPHATIDIC acid
				phosphatase 2A
40b	CG158964-02	348	349	PHOSPHATIDIC acid
				phosphatase 2A
41a	CG159084-01	349	350	Glutamate decarboxylase
				67
42a	CG159130-01	351	352	Hyperpolarization-
				activated cation channel,
				HAC2
43a	CG159178-01	353	354	Carbonic anhydrase VI
				precursor (EC 4.2.1.1)
				(Carbonate dehydratase
				VI) (CA-VI) (Secreted
				carbonic anhydrase)
				(Salivary carbonic
				anhydrase)
43b	CG159178-02	355	356	Carbonic anhydrase VI
				precursor (EC 4.2.1.1)
				(Carbonate dehydratase
				VI) (CA-VI) (Secreted
				carbonic anhydrase)
				(Salivary carbonic
				anhydrase)
44a	CG160131-01	357	358	Glycerol kinase (EC
				2.7.1.30) (ATP: glycerol
				3-phosphotransferase)
				(Glycerokinase) (GK)
44b	CG160131-04	359	360	Glycerol kinase (EC
				2.7.1.30) (ATP: glycerol
				3-phosphotransferase)
				(Glycerokinase) (GK)
44c	CG160131-02	361	362	Glycerol kinase (EC
				2.7.1.0) (ATP: glycerol
				3-phosphotransferase)
				(Glycerokinase) (GK)
44d	CG160131-03	363	364	Glycerol kinase (EC
				2.7.1.30) (ATP: glycerol
				3-phosphotransferase)
				(Glycerokinase) (GK)
45a	CG166282-01	365	366	Serine/threonine-protein
				kinase Chk1 (EC 2.7.1.-)
46a	CG170739-01	367	368	Pendrin (Sodium-
				independent
				chloride/iodide
				transporter)
47a	CG171632-01	369	370	Gamma-aminobutyric-
				acid receptor rho-1
				subunit precursor
				(GABA(A) receptor)
47b	CG171632-01	371	372	Gamma-aminobutyric-
				acid receptor rho-1
				subunit precursor
				(GABA(A) receptor)
48a	CG173066-01	373	374	Aquaporin 7 (Aquaporin-
				7 like) (Aquaporin
				adipose) (AQPap)
49a	CG173085-01	375	376	Similar to thyroid
				hormone receptor
49b	311531811	377	378	Similar to thyroid
				hormone receptor
50a	CG173095-01	379	380	Ubiquitin-protein ligase
				E3 Mdm2 (EC 6.3.2.-)
				(p53-binding protein
				Mdm2) (Oncoprotein
				Mdm2) (Double minute 2
				protein) (Hdm2)
50b	CG173095-02	381	382	Ubiquitin-protein ligase
				E3 Mdm2 (EC 6.3.2.-)
				(p53-binding protein
				Mdm2) (Oncoprotein
				Mdm2) (Double minute 2
				protein) (Hdm2)
51a	CG173173-01	383	384	Gamma-aminobutyric-
				acid receptor alpha-5
				subunit precursor
				(GABA(A) receptor)
52a	CG51213-01	385	386	Sequence 3 from Patent
				WO0123561
52b	CG51213-07	387	388	Sequence 3 from Patent
				WO0123561
52c	CG51213-02	389	390	Sequence 3 from Patent
				WO0123561
52d	CG51213-03	391	392	Sequence 3 from Patent
				WO0123561
52e	CG51213-04	393	394	Sequence 3 from Patent
				WO0123561
52f	CG51213-05	395	396	Sequence 3 from Patent
				WO0123561
52g	CG51213-06	397	398	Sequence 3 from Patent
				WO0123561
53a	CG56155-01	399	400	Plasma kallikrein
				precursor (EC 3.4.21.34)
				(Plasma prekallikrein)
				(Kininogenin) (Fletcher
				factor)
53b	CG56155-02	401	402	Plasma kallikrein
				precursor (EC 3.4.21.34)
				(Plasma prekallikrein)
				(Kininogenin) (Fletcher
				factor)
53c	CG56155-03	403	404	Plasma kallikrein
				precursor (EC 3.4.21.34)
				(Plasma prekallikrein)
				(Kininogenin) (Fletcher
				factor)
54a	CG57191-01	405	406	Retinal short-chain
				dehydrogenase/reductase
				RETSDR1
54b	CG57191-03	407	408	Retinal short-chain
				dehydrogenase/reductase
				RETSDR1
54c	CG57191-02	409	410	Retinal short-chain
				dehydrogenase/reductase
				RETSDR1
55a	CG59595-01	411	412	Ribonuclease 6 precursor
55b	169728691	413	414	Ribonuclease 6 precursor
55c	169728707	415	416	Ribonuclease 6 precursor
55d	169728746	417	418	Ribonuclease 6 precursor
55e	CG59595-02	419	420	Ribonuclease 6 precursor
55f	CG59595-03	421	422	Ribonuclease 6 precursor
55g	CG59595-04	423	424	Ribonuclease 6 precursor
55h	CG59595-05	425	426	Ribonuclease 6 precursor
56a	CG92142-01	427	428	Glycerol-3-phosphate
				acyltransferase,
				mitochondrial precursor
56b	CG92142-02	429	430	Glycerol-3-phosphate
				acyltransferase,
				mitochondrial precursor
57a	CG95765-01	431	432	Hypothetical protein
57b	CG95765-02	433	434	Hypothetical protein
58a	CG97178-01	435	436	Tryptophan 2,3-
				dioxygenase (EC
				1.13.11.11) (Tryptophan
				pyrrolase)
				(Tryptophanase)
				(Tryptophan oxygenase)
				(Tryptamin 2,3-
				dioxygenase) (TRPO)
58b	275481043	437	438	Tryptophan 2,3-
				dioxygenase (EC
				1.13.11.11) (Tryptophan
				pyrrolase)
				(Tryptophanase)
				(Tryptophan oxygenase)
				(Tryptamin 2,3-
				dioxygenase) (TRPO)
58c	275481043	439	440	Diamine acetyltransferase
				(EC 2.3.1.57)
				(Spermidine/spermine
				N(1)- acetyltransferase)
				(SSAT) (Putrescine
				acetyltransferase)
59a	CG98102-01	441	442	Diamine acetyltransferase
				(EC 2.3.1.57)
				(Spermidine/spermine
				N(1)- acetyltransferase)
				(SSAT) (Putrescine
				acetyltransferase)
59b	CG98102-03	443	444	Diamine acetyltransferase
				(EC 2.3.1.57)
				(Spermidine/spermine
				N(1)- acetyltransferase)
				(SSAT) (Putrescine
				acetyltransferase)
59c	CG98102-02	445	446	Diamine acetyltransferase
				(EC 2.3.1.57)
				(Spermidine/spermine
				N(1)- acetyltransferase)
				(SSAT) (Putrescine
				acetyltransferase)
59d	CG98102-04	447	448	Diamine acetyltransferase
				(EC 2.3.1.57)
				(Spermidine/spermine
				N(1)- acetyltransferase)
				(SSAT) (Putrescine
				acetyltransferase)
59e	CG98102-05	449	450	Diamine acetyltransferase
				(EC 2.3.1.57)
				(Spermidine/spermine
				N(1)- acetyltransferase)
				(SSAT) (Putrescine
				acetyltransferase)
59f	CG98102-06	451	452	Diamine acetyltransferase
				(EC 2.3.1.57)
				(Spermidine/spermine
				N(1)- acetyltransferase)
				(SSAT) (Putrescine
				acetyltransferase)

[0025] Table A indicates the homology of NOVX polypeptides to known protein families. Thus, the nucleic acids and polypeptides, antibodies and related compounds according to the invention corresponding to a NOVX as identified in column 1 of Table A will be useful in therapeutic and diagnostic applications implicated in, for example, pathologies and disorders associated with the known protein families identified in column 5 of Table A.

[0026] Pathologies, diseases, disorders and condition and the like that are associated with NOVX sequences include, but are not limited to: e.g., cardiomyopathy, atherosclerosis, hypertension, congenital heart defects, aortic stenosis, atrial septal defect (ASD), atrioventricular (A-V) canal defect, ductus arteriosus, pulmonary stenosis, subaortic stenosis, ventricular septal defect (VSD), valve diseases, tuberous sclerosis, scleroderma, obesity, metabolic disturbances associated with obesity, transplantation, adrenoleukodystrophy, congenital adrenal hyperplasia, prostate cancer, diabetes, metabolic disorders, neoplasm; adenocarcinoma, lymphoma, uterus cancer, fertility, hemophilia, hypercoagulation, idiopathic thrombocytopenic purpura, immunodeficiencies, graft versus host disease, AIDS, bronchial asthma, Crohn's disease; multiple sclerosis, treatment of Albright Hereditary Ostoeodystrophy, infectious disease, anorexia, cancer-associated cachexia, cancer, neurodegenerative disorders, Alzheimer's Disease, Parkinson's Disorder, immune disorders, hematopoietic disorders, and the various dyslipidemias,] the metabolic syndrome X and wasting disorders associated with chronic diseases and various cancers, as well as conditions such as transplantation and fertility.

[0027] NOVX nucleic acids and their encoded polypeptides are useful in a variety of applications and contexts. The various NOVX nucleic acids and polypeptides according to the invention are useful as novel members of the protein families according to the presence of domains and sequence relatedness to previously described proteins. Additionally, NOVX nucleic acids and polypeptides can also be used to identify proteins that are members of the family to which the NOVX polypeptides belong.

[0028] Consistent with other known members of the family of proteins, identified in column 5 of Table A, the NOVX polypeptides of the present invention show homology to, and contain domains that are characteristic of, other members of such protein families. Details of the sequence relatedness and domain analysis for each NOVX are presented in Example A.

[0029] The NOVX nucleic acids and polypeptides can also be used to screen for molecules, which inhibit or enhance NOVX activity or function. Specifically, the nucleic acids and polypeptides according to the invention may be used as targets for the identification of small molecules that modulate or inhibit diseases associated with the protein families listed in Table A.

[0030] The NOVX nucleic acids and polypeptides are also useful for detecting specific cell types. Details of the expression analysis for each NOVX are presented in Example C. Accordingly, the NOVX nucleic acids, polypeptides, antibodies and related compounds according to the invention will have diagnostic and therapeutic applications in the detection of a variety of diseases with differential expression in normal vs. diseased tissues, e.g. detection of a variety of cancers.

[0031] Additional utilities for NOVX nucleic acids and polypeptides according to the invention are disclosed herein.

[0032] NOVX Clones

[0033] NOVX nucleic acids and their encoded polypeptides are useful in a variety of applications and contexts. The various NOVX nucleic acids and polypeptides according to the invention are useful as novel members of the protein families according to the presence of domains and sequence relatedness to previously described proteins. Additionally, NOVX nucleic acids and polypeptides can also be used to identify proteins that are members of the family to which the NOVX polypeptides belong.

[0034] The NOVX genes and their corresponding encoded proteins are useful for preventing, treating or ameliorating medical conditions, e.g., by protein or gene therapy. Pathological conditions can be diagnosed by determining the amount of the new protein in a sample or by determining the presence of mutations in the new genes. Specific uses are described for each of the NOVX genes, based on the tissues in which they are most highly expressed. Uses include developing products for the diagnosis or treatment of a variety of diseases and disorders.

[0035] The NOVX nucleic acids and proteins of the invention are useful in potential diagnostic and therapeutic applications and as a research tool. These include serving as a specific or selective nucleic acid or protein diagnostic and/or prognostic marker, wherein the presence or amount of the nucleic acid or the protein are to be assessed, as well as potential therapeutic applications such as the following: (i) a protein therapeutic, (ii) a small molecule drug target, (iii) an antibody target (therapeutic, diagnostic, drug targeting/cytotoxic antibody), (iv) a nucleic acid useful in gene therapy (gene delivery/gene ablation), and (v) a composition promoting tissue regeneration in vitro and in vivo (vi) a biological defense weapon.

[0036] In one specific embodiment, the invention includes an isolated polypeptide comprising an amino acid sequence selected from the group consisting of: (a) a mature form of the amino acid sequence selected from the group consisting of SEQ ID NO: 2n, wherein n is an integer between 1 and 226; (b) a variant of a mature form of the amino acid sequence selected from the group consisting of SEQ ID NO: 2n, wherein n is an integer between 1 and 226, wherein any amino acid in the mature form is changed to a different amino acid, provided that no more than 15% of the amino acid residues in the sequence of the mature form are so changed; (c) an amino acid sequence selected from the group consisting of SEQ ID NO: 2n, wherein n is an integer between 1 and 226; (d) a variant of the amino acid sequence selected from the group consisting of SEQ ID NO:2n, wherein n is an integer between 1 and 226 wherein any amino acid specified in the chosen sequence is changed to a different amino acid, provided that no more than 15% of the amino acid residues in the sequence are so changed; and (e) a fragment of any of (a) through (d).

[0037] In another specific embodiment, the invention includes an isolated nucleic acid molecule comprising a nucleic acid sequence encoding a polypeptide comprising an amino acid sequence selected from the group consisting of: (a) a mature form of the amino acid sequence given SEQ ID NO: 2n, wherein n is an integer between 1 and 226; (b) a variant of a mature form of the amino acid sequence selected from the group consisting of SEQ ID NO: 2n, wherein n is an integer between 1 and 226 wherein any amino acid in the mature form of the chosen sequence is changed to a different amino acid, provided that no more than 15% of the amino acid residues in the sequence of the mature form are so changed; (c) the amino acid sequence selected from the group consisting of SEQ ID NO: 2n, wherein n is an integer between 1 and 226; (d) a variant of the amino acid sequence selected from the group consisting of SEQ ID NO: 2n, wherein n is an integer between 1 and 226, in which any amino acid specified in the chosen sequence is changed to a different amino acid, provided that no more than 15% of the amino acid residues in the sequence are so changed; (e) a nucleic acid fragment encoding at least a portion of a polypeptide comprising the amino acid sequence selected from the group consisting of SEQ ID NO: 2n, wherein n is an integer between 1 and 226 or any variant of said polypeptide wherein any amino acid of the chosen sequence is changed to a different amino acid, provided that no more than 10% of the amino acid residues in the sequence are so changed; and (f) the complement of any of said nucleic acid molecules.

[0038] In yet another specific embodiment, the invention includes an isolated nucleic acid molecule, wherein said nucleic acid molecule comprises a nucleotide sequence selected from the group consisting of: (a) the nucleotide sequence selected from the group consisting of SEQ ID NO: 2n−1, wherein n is an integer between 1 and 226; (b) a nucleotide sequence wherein one or more nucleotides in the nucleotide sequence selected from the group consisting of SEQ ID NO: 2n−1, wherein n is an integer between 1 and 226 is changed from that selected from the group consisting of the chosen sequence to a different nucleotide provided that no more than 15% of the nucleotides are so changed; (c) a nucleic acid fragment of the sequence selected from the group consisting of SEQ ID NO: 2n−1, wherein n is an integer between 1 and 226; and (d) a nucleic acid fragment wherein one or more nucleotides in the nucleotide sequence selected from the group consisting of SEQ ID NO: 2n−1, wherein n is an integer between 1 and 226 is changed from that selected from the group consisting of the chosen sequence to a different nucleotide provided that no more than 15% of the nucleotides are so changed.

[0039] NOVX Nucleic Acids and Polypeptides

[0040] One aspect of the invention pertains to isolated nucleic acid molecules that encode NOVX polypeptides or biologically active portions thereof. Also included in the invention are nucleic acid fragments sufficient for use as hybridization probes to identify NOVX-encoding nucleic acids (e.g., NOVX mRNAs) and fragments for use as PCR primers for the amplification and/or mutation of NOVX nucleic acid molecules. As used herein, the term “nucleic acid molecule” is intended to include DNA molecules (e.g., cDNA or genomic DNA), RNA molecules (e.g., mRNA), analogs of the DNA or RNA generated using nucleotide analogs, and derivatives, fragments and homologs thereof. The nucleic acid molecule may be single-stranded or double-stranded, but preferably is comprised double-stranded DNA.

[0041] A NOVX nucleic acid can encode a mature NOVX polypeptide. As used herein, a “mature” form of a polypeptide or protein disclosed in the present invention is the product of a naturally occurring polypeptide or precursor form or proprotein. The naturally occurring polypeptide, precursor or proprotein includes, by way of nonlimiting example, the full-length gene product encoded by the corresponding gene. Alternatively, it may be defined as the polypeptide, precursor or proprotein encoded by an ORF described herein. The product “mature” form arises, by way of nonlimiting example, as a result of one or more naturally occurring processing steps that may take place within the cell (e.g., host cell) in which the gene product arises. Examples of such processing steps leading to a “mature” form of a polypeptide or protein include the cleavage of the N-terminal methionine residue encoded by the initiation codon of an ORF, or the proteolytic cleavage of a signal peptide or leader sequence. Thus a mature form arising from a precursor polypeptide or protein that has residues 1 to N, where residue 1 is the N-terminal methionine, would have residues 2 through N remaining after removal of the N-terminal methionine. Alternatively, a mature form arising from a precursor polypeptide or protein having residues 1 to N, in which an N-terminal signal sequence from residue 1 to residue M is cleaved, would have the residues from residue M+1 to residue N remaining. Further as used herein, a “mature” form of a polypeptide or protein may arise from a step of post-translational modification other than a proteolytic cleavage event. Such additional processes include, by way of non-limiting example, glycosylation, myristylation or phosphorylation. In general, a mature polypeptide or protein may result from the operation of only one of these processes, or a combination of any of them.

[0042] The term “probe”, as utilized herein, refers to nucleic acid sequences of variable length, preferably between at least about 10 nucleotides (nt), about 100 nt, or as many as approximately, e.g., 6,000 nt, depending upon the specific use. Probes are used in the detection of identical, similar, or complementary nucleic acid sequences. Longer length probes are generally obtained from a natural or recombinant source, are highly specific, and much slower to hybridize than shorter-length oligomer probes. Probes may be single-stranded or double-stranded and designed to have specificity in PCR, membrane-based hybridization technologies, or ELISA-like technologies.

[0043] The term “isolated” nucleic acid molecule, as used herein, is a nucleic acid that is separated from other nucleic acid molecules which are present in the natural source of the nucleic acid. Preferably, an “isolated” nucleic acid is free of sequences which naturally flank the nucleic acid (i.e., sequences located at the 5′- and 3′-termini of the nucleic acid) in the genomic DNA of the organism from which the nucleic acid is derived. For example, in various embodiments, the isolated NOVX nucleic acid molecules can contain less than about 5 kb, 4 kb, 3 kb, 2 kb, 1 kb; 0.5 kb or 0.1 kb of nucleotide sequences which naturally flank the nucleic acid molecule in genomic DNA of the cell/tissue from which the nucleic acid is derived (e.g., brain, heart, liver, spleen, etc.). Moreover, an “isolated” nucleic acid molecule, such as a cDNA molecule, can be substantially free of other cellular material, or culture medium, or of chemical precursors or other chemicals.

[0044] A nucleic acid molecule of the invention, e.g., a nucleic acid molecule having the nucleotide sequence of SEQ ID NO:2n−1, wherein n is an integer between 1 and 226, or a complement of this nucleotide sequence, can be isolated using standard molecular biology techniques and the sequence information provided herein. Using all or a portion of the nucleic acid sequence of SEQ ID NO:2n−1, wherein n is an integer between 1 and 226, as a hybridization probe, NOVX molecules can be isolated using standard hybridization and cloning techniques (e.g., as described in Sambrook, et al., (eds.), MOLECULAR CLONING: A LABORATORY MANUAL 2nd Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989; and Ausubel, et al., (eds.), CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, New York, NY, 1993.)

[0045] A nucleic acid of the invention can be amplified using cDNA, mRNA or alternatively, genomic DNA, as a template with appropriate oligonucleotide primers according to standard PCR amplification techniques. The nucleic acid so amplified can be cloned into an appropriate vector and characterized by DNA sequence analysis. Furthermore, oligonucleotides corresponding to NOVX nucleotide sequences can be prepared by standard synthetic techniques, e.g., using an automated DNA synthesizer.

[0046] As used herein, the term “oligonucleotide” refers to a series of linked nucleotide residues. A short oligonucleotide sequence may be based on, or designed from, a genomic or cDNA sequence and is used to amplify, confirm, or reveal the presence of an identical, similar or complementary DNA or RNA in a particular cell or tissue. Oligonucleotides comprise a nucleic acid sequence having about 10 nt, 50 nt, or 100 nt in length, preferably about 15 nt to 30 nt in length. In one embodiment of the invention, an oligonucleotide comprising a nucleic acid molecule less than 100 nt in length would further comprise at least 6 contiguous nucleotides of SEQ ID NO:2n−1, wherein n is an integer between 1 and 226, or a complement thereof. Oligonucleotides may be chemically synthesized and may also be used as probes.

[0047] In another embodiment, an isolated nucleic acid molecule of the invention comprises a nucleic acid molecule that is a complement of the nucleotide sequence shown in SEQ ID NO:2n−1, wherein n is an integer between 1 and 226, or a portion of this nucleotide sequence (e.g., a fragment that can be used as a probe or primer or a fragment encoding a biologically-active portion of a NOVX polypeptide). A nucleic acid molecule that is complementary to the nucleotide sequence of SEQ ID NO:2n−1, wherein n is an integer between 1 and 226, is one that is sufficiently complementary to the nucleotide sequence of SEQ ID NO:2n−1, wherein n is an integer between 1 and 226, that it can hydrogen bond with few or no mismatches to the nucleotide sequence shown in SEQ, ID NO:2n−1, wherein n is an integer between 1 and 226, thereby forming a stable duplex.

[0048] As used herein, the term “complementary” refers to Watson-Crick or Hoogsteen base pairing between nucleotides units of a nucleic acid molecule, and the term “binding” means the physical or chemical interaction between two polypeptides or compounds or associated polypeptides or compounds or combinations thereof. Binding includes ionic, non-ionic, van der Waals, hydrophobic interactions, and the like. A physical interaction can be either direct or indirect. Indirect interactions may be through or due to the effects of another polypeptide or compound. Direct binding refers to interactions that do not take place through, or due to, the effect of another polypeptide or compound, but instead are without other substantial chemical intermediates.

[0049] A “fragment” provided herein is defined as a sequence of at least 6 (contiguous) nucleic acids or at least 4 (contiguous) amino acids, a length sufficient to allow for specific hybridization in the case of nucleic acids or for specific recognition of an epitope in the case of amino acids, and is at most some portion less than a full length sequence. Fragments may be derived from any contiguous portion of a nucleic acid or amino acid sequence of choice.

[0050] A full-length NOVX clone is identified as containing an ATG translation start codon and an in-frame stop codon. Any disclosed NOVX nucleotide sequence lacking an ATG start codon therefore encodes a truncated C-terminal fragment of the respective NOVX polypeptide, and requires that the corresponding full-length cDNA extend in the 5′ direction of the disclosed sequence. Any disclosed NOVX nucleotide sequence lacking an in-frame stop codon similarly encodes a truncated N-terminal fragment of the respective NOVX polypeptide, and requires that the corresponding full-length cDNA extend in the 3′ direction of the disclosed sequence.

[0051] A “derivative” is a nucleic acid sequence or amino acid sequence formed from the native compounds either directly, by modification or partial substitution. An “analog” is a nucleic acid sequence or amino acid sequence that has a structure similar to, but not identical to, the native compound, e.g. they differs from it in respect to certain components or side chains. Analogs may be synthetic or derived from a different evolutionary origin and may have a similar or opposite metabolic activity compared to wild type. A “homolog” is a nucleic acid sequence or amino acid sequence of a particular gene that is derived from different species.

[0052] Derivatives and analogs may be full length or other than full length. Derivatives or analogs of the nucleic acids or proteins of the invention include, but are not limited to, molecules comprising regions that are substantially homologous to the nucleic acids or proteins of the invention, in various embodiments, by at least about 70%, 80%, or 95% identity (with a preferred identity of 80-95%) over a nucleic acid or amino acid sequence of identical size or when compared to an aligned sequence in which the alignment is done by a computer homology program known in the art, or whose encoding nucleic acid is capable of hybridizing to the complement of a sequence encoding the proteins under stringent, moderately stringent, or low stringent conditions. See e.g. Ausubel, et al., CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, New York, N.Y., 1993, and below.

[0053] A “homologous nucleic acid sequence” or “homologous amino acid sequence,” or variations thereof, refer to sequences characterized by a homology at the nucleotide level or amino acid level as discussed above. Homologous nucleotide sequences include those sequences coding for isoforms of NOVX polypeptides. Isoforms can be expressed in different tissues of the same organism as a result of, for example, alternative splicing of RNA. Alternatively, isoforms can be encoded by different genes. In the invention, homologous nucleotide sequences include nucleotide sequences encoding for a NOVX polypeptide of species other than humans, including, but not limited to: vertebrates, and thus can include, e.g., frog, mouse, rat, rabbit, dog, cat cow, horse, and other organisms. Homologous nucleotide sequences also include, but are not limited to, naturally occurring allelic variations and mutations of the nucleotide sequences set forth herein. A homologous nucleotide sequence does not, however, include the exact nucleotide sequence encoding human NOVX protein. Homologous nucleic acid sequences include those nucleic acid sequences that encode conservative amino acid substitutions (see below) in SEQ ID NO:2n−1, wherein n is an integer between 1 and 226, as well as a polypeptide possessing NOVX biological activity. Various biological activities of the NOVX proteins are described below.

[0054] A NOVX polypeptide is encoded by the open reading frame (“ORF”) of a NOVX nucleic acid. An ORF corresponds to a nucleotide sequence that could potentially be translated into a polypeptide. A stretch of nucleic acids comprising an ORF is uninterrupted by a stop codon. An ORF that represents the coding sequence for a full protein begins with an ATG “start” codon and terminates with one of the three “stop” codons, namely, TAA, TAG, or TGA. For the purposes of this invention, an ORF may be any part of a coding sequence, with or without a start codon, a stop codon, or both. For an ORF to be considered as a good candidate for coding for a bona fide cellular protein, a minimum size requirement is often set, e.g., a stretch of DNA that would encode a protein of 50 amino acids or more.

[0055] The nucleotide sequences determined from the cloning of the human NOVX genes allows for the generation of probes and primers designed for use in identifying and/or cloning NOVX homologues in other cell types, e.g. from other tissues, as well as NOVX homologues from other vertebrates. The probe/primer typically comprises substantially purified oligonucleotide. The oligonucleotide typically comprises a region of nucleotide sequence that hybridizes under stringent conditions to at least about 12, 25, 50, 100, 150, 200, 250, 300, 350 or 400 consecutive sense strand nucleotide sequence of SEQ ID NO:2n−1, wherein n is an integer between 1 and 226; or an anti-sense strand nucleotide sequence of SEQ ID NO:2n−1, wherein n is an integer between 1 and 226; or of a naturally occurring mutant of SEQ ID NO:2n−1, wherein n is an integer between 1 and 226.

[0056] Probes based on the human NOVX nucleotide sequences can be used to detect transcripts or genomic sequences encoding the same or homologous proteins. In various embodiments, the probe has a detectable label attached, e.g. the label can be a radioisotope, a fluorescent compound, an enzyme, or an enzyme co-factor. Such probes can be used as a part of a diagnostic test kit for identifying cells or tissues which mis-express a NOVX protein, such as by measuring a level of a NOVX-encoding nucleic acid in a sample of cells from a subject e.g., detecting NOVX mRNA levels or determining whether a genomic NOVX gene has been mutated or deleted.

[0057] “A polypeptide having a biologically-active portion of a NOVX polypeptide” refers to polypeptides exhibiting activity similar, but not necessarily identical to, an activity of a polypeptide of the invention, including mature forms, as measured in a particular biological assay, with or without dose dependency. A nucleic acid fragment encoding a “biologically-active portion of NOVX” can be prepared by isolating a portion of SEQ ID NO:2n−1, wherein n is an integer between 1 and 226, that encodes a polypeptide having a NOVX biological activity (the biological activities of the NOVX proteins are described below), expressing the encoded portion of NOVX protein (e.g., by recombinant expression in vitro) and assessing the activity of the encoded portion of NOVX.

[0058] NOVX Nucleic Acid and Polypeptide Variants

[0059] The invention further encompasses nucleic acid molecules that differ from the nucleotide sequences of SEQ ID NO:2n−1, wherein n is an integer between 1 and 226, due to degeneracy of the genetic code and thus encode the same NOVX proteins as that encoded by the nucleotide sequences of SEQ ID NO:2n−1, wherein n is an integer between 1 and 226. In another embodiment, an isolated nucleic acid molecule of the invention has a nucleotide sequence encoding a protein having an amino acid sequence of SEQ ID NO:2n, wherein n is an integer between I and 226.

[0060] In addition to the human NOVX nucleotide sequences of SEQ ID NO:2n−1, wherein n is an integer between 1 and 226, it will be appreciated by those skilled in the art that DNA sequence polymorphisms that lead to changes in the amino acid sequences of the NOVX polypeptides may exist within a population (e.g., the human population). Such genetic polymorphism in the NOVX genes may exist among individuals within a population due to natural allelic variation. As used herein, the terms “gene” and “recombinant gene” refer to nucleic acid molecules comprising an open reading frame (ORF) encoding a NOVX protein, preferably a vertebrate NOVX protein. Such natural allelic variations can typically result in 1-5% variance in the nucleotide sequence of the NOVX genes. Any and all such nucleotide variations and resulting amino acid polymorphisms in the NOVX polypeptides, which are the result of natural allelic variation and that do not alter the functional activity of the NOVX polypeptides, are intended to be within the scope of the invention.

[0061] Moreover, nucleic acid molecules encoding NOVX proteins from other species, and thus that have a nucleotide sequence that differs from a human SEQ ID NO:2n−1, wherein n is an integer between 1 and 226, are intended to be within the scope of the invention. Nucleic acid molecules corresponding to natural allelic variants and homologues of the NOVX cDNAs of the invention can be isolated based on their homology to the human NOVX nucleic acids disclosed herein using the human cDNAs, or a portion thereof, as a hybridization probe according to standard hybridization techniques under stringent hybridization conditions.

[0062] Accordingly, in another embodiment, an isolated nucleic acid molecule of the invention is at least 6 nucleotides in length and hybridizes under stringent conditions to the nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:2n−1, wherein n is an integer between 1 and 226. In another embodiment, the nucleic acid is at least 10, 25, 50, 100, 250, 500, 750, 1000, 1500, or 2000 or more nucleotides in length. In yet another embodiment, an isolated nucleic acid molecule of the invention hybridizes to the coding region. As used herein, the term “hybridizes under stringent conditions” is intended to describe conditions for hybridization and washing under which nucleotide sequences at least about 65% homologous to each other typically remain hybridized to each other.

[0063] Homologs (i.e., nucleic acids encoding NOVX proteins derived from species other than human) or other related sequences (e.g., paralogs) can be obtained by low, moderate or high stringency hybridization with all or a portion of the particular human sequence as a probe using methods well known in the art for nucleic acid hybridization and cloning.

[0064] As used herein, the phrase “stringent hybridization conditions” refers to conditions under which a probe, primer or oligonucleotide will hybridize to its target sequence, but to no other sequences. Stringent conditions are sequence-dependent and will be different in different circumstances. Longer sequences hybridize specifically at higher temperatures than shorter sequences. Generally, stringent conditions are selected to be about 5° C. lower than the thermal melting point (Tm) for the specific sequence at a defined ionic strength and pH. The Tm is the temperature (under defined ionic strength, pH and nucleic acid concentration) at which 50% of the probes complementary to the target sequence hybridize to the target sequence at equilibrium. Since the target sequences are generally present at excess, at Tm, 50% of the probes are occupied at equilibrium. Typically, stringent conditions will be those in which the salt concentration is less than about 1.0 M sodium ion, typically about 0.01 to 1.0 M sodium ion (or other salts) at pH 7.0 to 8.3 and the temperature is at least about 30° C. for short probes, primers or oligonucleotides (e.g., 10 nt to 50 nt) and at least about 60° C. for longer probes, primers and oligonucleotides. Stringent conditions may also be achieved with the addition of destabilizing agents, such as formamide.

[0065] Stringent conditions are known to those skilled in the art and can be found in Ausubel, et al., (eds.), CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, N.Y. (1989), 6.3.1-6.3.6. Preferably, the conditions are such that sequences at least about 65%, 70%, 75%, 85%, 90%, 95%, 98%, or 99% homologous to each other typically remain hybridized to each other. A non-limiting example of stringent hybridization conditions are hybridization in a high salt buffer comprising 6×SSC, 50 mM Tris-HCl (pH 7.5), 1 mM EDTA, 0.02% PVP, 0.02% Ficoll, 0.02% BSA, and 500 mg/ml denatured salmon sperm DNA at 65° C., followed by one or more washes in 0.2×SSC, 0.01% BSA at 50° C. An isolated nucleic acid molecule of the invention that hybridizes under stringent conditions to a sequence of SEQ ID NO:2n−1, wherein n is an integer between 1 and 226, corresponds to a naturally-occurring nucleic acid molecule. As used herein, a “naturally-occurring” nucleic acid molecule refers to an RNA or DNA molecule having a nucleotide sequence that occurs in nature (e.g., encodes a natural protein).

[0066] In a second embodiment, a nucleic acid sequence that is hybridizable to the nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:2n−1, wherein n is an integer between 1 and 226, or fragments, analogs or derivatives thereof, under conditions of moderate stringency is provided. A non-limiting example of moderate stringency hybridization conditions are hybridization in 6×SSC, 5×Reinhardt's solution, 0.5% SDS and 100 mg/ml denatured salmon sperm DNA at 55° C., followed by one or more washes in 1×SSC, 0.1% SDS at 37° C. Other conditions of moderate stringency that may be used are well-known within the art. See, e.g., Ausubel, et al. (eds.), 1993, CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, NY, and Krieger, 1990; GENE TRANSFER AND EXPRESSION, A LABORATORY MANUAL, Stockton Press, NY.

[0067] In a third embodiment, a nucleic acid that is hybridizable to the nucleic acid molecule comprising the nucleotide sequences of SEQ ID NO:2n−1, wherein n is an integer between 1 and 226, or fragments, analogs or derivatives thereof, under conditions of low stringency, is provided. A non-limiting example of low stringency hybridization conditions are hybridization in 35% formamide, 5×SSC, 50 mM Tris-HCl (pH 7.5), 5 mM EDTA, 0.02% PVP, 0.02% Ficoll, 0.2% BSA, 100 mg/ml denatured salmon sperm DNA, 10% (wt/vol) dextran sulfate at 40° C., followed by one or more washes in 2×SSC, 25 mM Tris-HCl (pH 7.4), 5 mM EDTA, and 0.1% SDS at 50° C. Other conditions of low stringency that may be used are well known in the art (e.g., as employed for cross-species hybridizations). See, e.g., Ausubel, et al. (eds.), 1993, CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, NY, and Kriegler, 1990, GENE TRANSFER AND EXPRESSION, A LABORATORY MANUAL, Stockton Press, NY; Shilo and Weinberg, 1981. Proc Natl Acad Sci USA 78: 6789-6792.

[0068] Conservative Mutations

[0069] In addition to naturally-occurring allelic variants of NOVX sequences that may exist in the population, the skilled artisan will further appreciate that changes can be introduced by mutation into the nucleotide sequences of SEQ ID NO:2n−1, wherein n is an integer between 1 and 226, thereby leading to changes in the amino acid sequences of the encoded NOVX protein, without altering the functional ability of that NOVX protein. For example, nucleotide substitutions leading to amino acid substitutions at “non-essential” amino acid residues can be made in the sequence of SEQ ID NO:2n, wherein n is an integer between 1 and 226. A “non-essential” amino acid residue is a residue that can be altered from the wild-type sequences of the NOVX proteins without altering their biological activity, whereas an “essential” amino acid residue is required for such biological activity. For example, amino acid residues that are conserved among the NOVX proteins of the invention are predicted to be particularly non-amenable to alteration. Amino acids for which conservative substitutions can be made are well-known within the art.

[0070] Another aspect of the invention pertains to nucleic acid molecules encoding NOVX proteins that contain changes in amino acid residues that are not essential for activity. Such NOVX proteins differ in amino acid sequence from SEQ ID NO:2n−1, wherein n is an integer between 1 and 226, yet retain biological activity. In one embodiment, the isolated nucleic acid molecule comprises a nucleotide sequence encoding a protein, wherein the protein comprises an amino acid sequence at least about 40% homologous to the amino acid sequences of SEQ ID NO:2n, wherein n is an integer between 1 and 226. Preferably, the protein encoded by the nucleic acid molecule is at least about 60% homologous to SEQ ID NO:2n, wherein n is an integer between 1 and 226; more preferably at least about 70% homologous to SEQ ID NO:2n, wherein n is an integer between 1 and 226; still more preferably at least about 80% homologous to SEQ ID NO:2n, wherein n is an integer between 1 and 226; even more preferably at least about 90% homologous to SEQ ID NO:2n, wherein n is an integer between 1 and 226; and most preferably at least about 95% homologous to SEQ ID NO:2n, wherein n is an integer between 1 and 226.

[0071] An isolated nucleic acid molecule encoding a NOVX protein homologous to the protein of SEQ ID NO:2n, wherein n is an integer between 1 and 226, can be created by introducing one or more nucleotide substitutions, additions or deletions into the nucleotide sequence of SEQ ID NO:2n−1, wherein n is an integer between 1 and 226, such that one or more amino acid substitutions, additions or deletions are introduced into the encoded protein.

[0072] Mutations can be introduced any one of SEQ ID NO:2n−1, wherein n is an integer between 1 and 226, by standard techniques, such as site-directed mutagenesis and PCR-mediated mutagenesis. Preferably, conservative amino acid substitutions are made at one or more predicted, non-essential amino acid residues. A “conservative amino acid substitution” is one in which the amino acid residue is replaced with an amino acid residue having a similar side chain. Families of amino acid residues having similar side chains have been defined within the art. These families include amino acids with basic side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine), nonpolar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), beta-branched side chains (e.g., threonine, valine, isoleucine) and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine). Thus, a predicted non-essential amino acid residue in the NOVX protein is replaced with another amino acid residue from the same side chain family. Alternatively, in another embodiment, mutations can be introduced randomly along all or part of a NOVX coding sequence, such as by saturation mutagenesis, and the resultant mutants can be screened for NOVX biological activity to identify mutants that retain activity. Following mutagenesis of a nucleic acid of SEQ ID NO:2n−1, wherein n is an integer between 1 and 226, the encoded protein can be expressed by any recombinant technology known in the art and the activity of the protein can be determined.

[0073] The relatedness of amino acid families may also be determined based on side chain interactions. Substituted amino acids may be fully conserved “strong” residues or fully conserved “weak” residues. The “strong” group of conserved amino acid residues may be any one of the following groups: STA, NEQK, NHQK, NDEQ, QHRK, MILV, MILF, HY, FYW, wherein the single letter amino acid codes are grouped by those amino acids that may be substituted for each other. Likewise, the “weak” group of conserved residues may be any one of the following: CSA, ATV, SAG, STNK, STPA, SGND, SNDEQK, NDEQHK, NEQHRK, HFY, wherein the letters within each group represent the single letter amino acid code.

[0074] In one embodiment, a mutant NOVX protein can be assayed for (i) the ability to form protein:protein interactions with other NOVX proteins, other cell-surface proteins, or biologically-active portions thereof, (ii) complex formation between a mutant NOVX protein and a NOVX ligand; or (iii) the ability of a mutant NOVX protein to bind to an intracellular target protein or biologically-active portion thereof; (e.g. avidin proteins).

[0075] In yet another embodiment, a mutant NOVX protein can be assayed for the ability to regulate a specific biological function (e.g., regulation of insulin release).

[0076] Interfering RNA

[0077] In one aspect of the invention, NOVX gene expression can be attenuated by RNA interference. One approach well-known in the art is short interfering RNA (siRNA) mediated gene silencing where expression products of a NOVX gene are targeted by specific double stranded NOVX derived siRNA nucleotide sequences that are complementary to at least a 19-25 nt long segment of the NOVX gene transcript, including the 5′ untranslated (UT) region, the ORF, or the 3′ UT region. See, e.g., PCT applications WO00/44895, WO99/32619, WO01/75164, WO01/92513, WO 01/29058, WO01/89304, WO02/16620, and WO02/29858, each incorporated by reference herein in their entirety. Targeted genes can be a NOVX gene, or an upstream or downstream modulator of the NOVX gene. Nonlimiting examples of upstream or downstream modulators of a NOVX gene include, e.g., a transcription factor that binds the NOVX gene promoter, a kinase or phosphatase that interacts with a NOVX polypeptide, and polypeptides involved in a NOVX regulatory pathway.

[0078] According to the methods of the present invention, NOVX gene expression is silenced using short interfering RNA. A NOVX polynucleotide according to the invention includes a siRNA polynucleotide. Such a NOVX siRNA can be obtained using a NOVX polynucleotide sequence, for example, by processing the NOVX ribopolynucleotide sequence in a cell-free system, such as but not limited to a Drosophila extract, or by transcription of recombinant double stranded NOVX RNA or by chemical synthesis of nucleotide sequences homologous to a NOVX sequence. See, e.g., Tuschl, Zamore, Lehmann, Bartel and Sharp (1999), Genes & Dev. 13: 3191-3197, incorporated herein by reference in its entirety. When synthesized, a typical 0.2 micromolar-scale RNA synthesis provides about 1 milligram of siRNA, which is sufficient for 1000 transfection experiments using a 24-well tissue culture plate format.

[0079] The most efficient silencing is generally observed with siRNA duplexes composed of a 21-nt sense strand and a 21-nt anti sense strand, paired in a manner to have a 2-nt 3′ overhang. The sequence of the 2-nt 3′ overhang makes an additional small contribution to the specificity of siRNA target recognition. The contribution to specificity is localized to the unpaired nucleotide adjacent to the first paired bases. In one embodiment, the nucleotides in the 3′ overhang are ribonucleotides. In an alternative embodiment, the nucleotides in the 3′ overhang are deoxyribonucleotides. Using 2′-deoxyribonucleotides in the 3′ overhangs is as efficient as using ribonucleotides, but deoxyribonucleotides are often cheaper to synthesize and are most likely more nuclease resistant.

[0080] A contemplated recombinant expression vector of the invention comprises a NOVX DNA molecule cloned into an expression vector comprising operatively-linked regulatory sequences flanking the NOVX sequence in a manner that allows for expression (by transcription of the DNA molecule) of both strands. An RNA molecule that is antisense to NOVX mRNA is transcribed by a first promoter (e.g., a promoter sequence 3′ of the cloned DNA) and an RNA molecule that is the sense strand for the NOVX mRNA is transcribed by a second promoter (e.g., a promoter sequence 5′ of the cloned DNA). The sense and antisense strands may hybridize in vivo to generate siRNA constructs for silencing of the NOVX gene. Alternatively, two constructs can be utilized to create the sense and anti-sense strands of a siRNA construct. Finally, cloned DNA can encode a construct having secondary structure, wherein a single transcript has both the sense and complementary antisense sequences from the target gene or genes. In an example of this embodiment, a hairpin RNAi product is homologous to all or a portion of the target gene. In another example, a hairpin RNAi product is a siRNA. The regulatory sequences flanking the NOVX sequence may be identical or may be different, such that their expression may be modulated independently, or in a temporal or spatial manner.

[0081] In a specific embodiment, siRNAs are transcribed intracellularly by cloning the NOVX gene templates into a vector containing, e.g., a RNA pol III transcription unit from the smaller nuclear RNA (snRNA) U6 or the human RNase P RNA H1. One example of a vector system is the GeneSuppressor™ RNA Interference kit (commercially available from Imgenex). The U6 and H1promoters are members of the type III class of Pol III promoters. The +1 nucleotide of the U6-like promoters is always guanosine, whereas the +1 for H1 promoters is adenosine. The termination signal for these promoters is defined by five consecutive thymidines. The transcript is typically cleaved after the second uridine. Cleavage at this position generates a 3′ UU overhang in the expressed siRNA, which is similar to the 3′ overhangs of synthetic siRNAs. Any sequence less than 400 nucleotides in length can be transcribed by these promoter, therefore they are ideally suited for the expression of around 21-nucleotide siRNAs in, e.g., an approximately 50-nucleotide RNA stem-loop transcript.

[0082] A siRNA vector appears to have an advantage over synthetic siRNAs where long term knock-down of expression is desired. Cells transfected with a siRNA expression vector would experience steady, long-term mRNA inhibition. In contrast, cells transfected with exogenous synthetic siRNAs typically recover from mRNA suppression within seven days or ten rounds of cell division. The long-term gene silencing ability of siRNA expression vectors may provide for applications in gene therapy.

[0083] In general, siRNAs are chopped from longer dsRNA by an ATP-dependent ribonuclease called DICER. DICER is a member of the RNase III family of double-stranded RNA-specific endonucleases. The siRNAs assemble with cellular proteins into an endonuclease complex. In vitro studies in Drosophila suggest that the siRNAs/protein complex (siRNP) is then transferred to a second enzyme complex, called an RNA-induced silencing complex (RISC), which contains an endoribonuclease that is distinct from DICER. RISC uses the sequence encoded by the antisense siRNA strand to find and destroy mRNAs of complementary sequence. The siRNA thus acts as a guide, restricting the ribonuclease to cleave only mRNAs complementary to one of the two siRNA strands.

[0084] A NOVX mRNA region to be targeted by siRNA is generally selected from a desired NOVX sequence beginning 50 to 100 nt downstream of the start codon. Alternatively, 5′ or 3′ UTRs and regions nearby the start codon can be used but are generally avoided, as these may be richer in regulatory protein binding sites. UTR-binding proteins and/or translation initiation complexes may interfere with binding of the siRNP or RISC endonuclease complex. An initial BLAST homology search for the selected siRNA sequence is done against an available nucleotide sequence library to ensure that only one gene is targeted. Specificity of target recognition by siRNA duplexes indicate that a single point mutation located in the paired region of an siRNA duplex is sufficient to abolish target mRNA degradation. See, Elbashir et al. 2001 EMBO J. 20(23):6877-88. Hence, consideration should be taken to accommodate SNPs, polymorphisms, allelic variants or species-specific variations when targeting a desired gene.

[0085] In one embodiment, a complete NOVX siRNA experiment includes the proper negative control. A negative control siRNA generally has the same nucleotide composition as the NOVX siRNA but lack significant sequence homology to the genome. Typically, one would scramble the nucleotide sequence of the NOVX siRNA and do a homology search to make sure it lacks homology to any other gene.

[0086] Two independent NOVX siRNA duplexes can be used to knock-down a target NOVX gene. This helps to control for specificity of the silencing effect. In addition, expression of two independent genes can be simultaneously knocked down by using equal concentrations of different NOVX siRNA duplexes, e.g., a NOVX siRNA and an siRNA for a regulator of a NOVX gene or polypeptide. Availability of siRNA-associating proteins is believed to be more limiting than target mRNA accessibility.

[0087] A targeted NOVX region is typically a sequence of two adenines (AA) and two thymidines (TT) divided by a spacer region of nineteen (N 19) residues (e.g., AA(N19)TT). A desirable spacer region has a G/C-content of approximately 30% to 70%, and more preferably of about 50%. If the sequence AA(N19)TT is not present in the target sequence, an alternative target region would be AA(N21). The sequence of the NOVX sense siRNA corresponds to (N19)TT or N21, respectively. In the latter case, conversion of the 3′ end of the sense siRNA to TT can be performed if such a sequence does not naturally occur in the NOVX polynucleotide. The rationale for this sequence conversion is to generate a symmetric duplex with respect to the sequence composition of the sense and antisense 3′ overhangs. Symmetric 3′ overhangs may help to ensure that the siRNPs are formed with approximately equal ratios of sense and antisense target RNA-cleaving siRNPs. See, e.g., Elbashir, Lendeckel and Tuschl (2001). Genes & Dev. 15: 188-200, incorporated by reference herein in its entirely. The modification of the overhang of the sense sequence of the siRNA duplex is not expected to affect targeted mRNA recognition, as the antisense siRNA strand guides target recognition.

[0088] Alternatively, if the NOVX target mRNA does not contain a suitable AA(N21) sequence, one may search for the sequence NA(N21). Further, the sequence of the sense strand and antisense strand may still be synthesized as 5′ (N 19)TT, as it is believed that the sequence of the 3′-most nucleotide of the antisense siRNA does not contribute to specificity. Unlike antisense or ribozyme technology, the secondary structure of the target mRNA does not appear to have a strong effect on silencing. See, Harborth, et al. (2001) J. Cell Science 114: 4557-4565, incorporated by reference in its entirety.

[0089] Transfection of NOVX siRNA duplexes can be achieved using standard nucleic acid transfection methods, for example, OLIGOFECTAMINE Reagent (commercially available from Invitrogen). An assay for NOVX gene silencing is generally performed approximately 2 days after transfection. No NOVX gene silencing has been observed in the absence of transfection reagent, allowing for a comparative analysis of the wild-type and silenced NOVX phenotypes. In a specific embodiment, for one well of a 24-well plate, approximately 0.84 μg of the siRNA duplex is generally sufficient. Cells are typically seeded the previous day, and are transfected at about 50% confluence. The choice of cell culture media and conditions are routine to those of skill in the art, and will vary with the choice of cell type. The efficiency of transfection may depend on the cell type, but also on the passage number and the confluency of the cells. The time and the manner of formation of siRNA-liposome complexes (e.g. inversion versus vortexing) are also critical. Low transfection efficiencies are the most frequent cause of unsuccessful NOVX silencing. The efficiency of transfection needs to be carefully examined for each new cell line to be used. Preferred cell are derived from a mammal, more preferably from a rodent such as a rat or mouse, and most preferably from a human. Where used for therapeutic treatment, the cells are preferentially autologous, although non-autologous cell sources are also contemplated as within the scope of the present invention.

[0090] For a control experiment, transfection of 0.84 μg single-stranded sense NOVX siRNA will have no effect on NOVX silencing, and 0.84 μg antisense siRNA has a weak silencing effect when compared to 0.84 μg of duplex siRNAs. Control experiments again allow for a comparative analysis of the wild-type and silenced NOVX phenotypes. To control for transfection efficiency, targeting of common proteins is typically performed, for example targeting of lamin A/C or transfection of a CMV-driven EGFP-expression plasmid (e.g. commercially available from Clontech). In the above example, a determination of the fraction of lamin A/C knockdown in cells is determined the next day by such techniques as immunofluorescence, Western blot, Northern blot or other similar assays for protein expression or gene expression. Lamin A/C monoclonal antibodies may be obtained from Santa Cruz Biotechnology.

[0091] Depending on the abundance and the half life (or turnover) of the targeted NOVX polynucleotide in a cell, a knock-down phenotype may become apparent after 1 to 3 days, or even later. In cases where no NOVX knock-down phenotype is observed, depletion of the NOVX polynucleotide may be observed by immunofluorescence or Western blotting. If the NOVX polynucleotide is still abundant after 3 days, cells need to be split and transferred to a fresh 24-well plate for re-transfection. If no knock-down of the targeted protein is observed, it may be desirable to analyze whether the target mRNA (NOVX or a NOVX upstream or downstream gene) was effectively destroyed by the transfected siRNA duplex. Two days after transfection, total RNA is prepared, reverse transcribed using a target-specific primer, and PCR-amplified with a primer pair covering at least one exon-exon junction in order to control for amplification of pre-mRNAs. RT/PCR of a non-targeted mRNA is also needed as control. Effective depletion of the mRNA yet undetectable reduction of target protein may indicate that a large reservoir of stable NOVX protein may exist in the cell. Multiple transfection in sufficiently long intervals may be necessary until the target protein is finally depleted to a point where a phenotype may become apparent. If multiple transfection steps are required, cells are split 2 to 3 days after transfection. The cells may be transfected immediately after splitting.

[0092] An inventive therapeutic method of the invention contemplates administering a NOVX siRNA construct as therapy to compensate for increased or aberrant NOVX expression or activity. The NOVX ribopolynucleotide is obtained and processed into siRNA fragments, or a NOVX siRNA is synthesized, as described above. The NOVX siRNA is administered to cells or tissues using known nucleic acid transfection techniques, as described above. A NOVX siRNA specific for a NOVX gene will decrease or knockdown NOVX transcription products, which will lead to reduced NOVX polypeptide production, resulting in reduced NOVX polypeptide activity in the cells or tissues.

[0093] The present invention also encompasses a method of treating a disease or condition associated with the presence of a NOVX protein in an individual comprising administering to the individual an RNAi construct that targets the mRNA of the protein (the mRNA that encodes the protein) for degradation. A specific RNAi construct includes a siRNA or a double stranded gene transcript that is processed into siRNAs. Upon treatment, the target protein is not produced or is not produced to the extent it would be in the absence of the treatment.

[0094] Where the NOVX gene function is not correlated with a known phenotype, a control sample of cells or tissues from healthy individuals provides a reference standard for determining NOVX expression levels. Expression levels are detected using the assays described, e.g., RT-PCR, Northern blotting, Western blotting, ELISA, and the like. A subject sample of cells or tissues is taken from a mammal, preferably a human subject, suffering from a disease state. The NOVX ribopolynucleotide is used to produce siRNA constructs, that are specific for the NOVX gene product. These cells or tissues are treated by administering NOVX siRNA's to the cells or tissues by methods described for the transfection of nucleic acids into a cell or tissue, and a change in NOVX polypeptide or polynucleotide expression is observed in the subject sample relative to the control sample, using the assays described. This NOVX gene knockdown approach provides a rapid method for determination of a NOVX minus (NOVX) phenotype in the treated subject sample. The NOVX- phenotype observed in the treated subject sample thus serves as a marker for monitoring the course of a disease state during treatment.

[0095] In specific embodiments, a NOVX siRNA is used in therapy. Methods for the generation and use of a NOVX siRNA are known to those skilled in the art. Example techniques are provided below.

[0096] Production of RNAs

[0097] Sense RNA (ssRNA) and antisense RNA (asRNA) of NOVX are produced using known methods such as transcription in RNA expression vectors. In the initial experiments, the sense and antisense RNA are about 500 bases in length each. The produced ssRNA and asRNA (0.5 μM) in 10 mM Tris-HCl (pH 7.5) with 20 mM NaCl were heated to 95° C. for 1 min then cooled and annealed at room temperature for 12 to 16 h. The RNAs are precipitated and resuspended in lysis buffer (below). To monitor annealing, RNAs are electrophoresed in a 2% agarose gel in TBE buffer and stained with ethidium bromide. See, e.g., Sambrook et al., Molecular Cloning. Cold Spring Harbor Laboratory Press, Plainview, N.Y. (1989).

[0098] Lysate Preparation

[0099] Untreated rabbit reticulocyte lysate (Ambion) are assembled according to the manufacturer's directions. dsRNA is incubated in the lysate at 30° C. for 10 min prior to the addition of mRNAs. Then NOVX mRNAs are added and the incubation continued for an additional 60 min. The molar ratio of double stranded RNA and mRNA is about 200:1. The NOVX mRNA is radiolabeled (using known techniques) and its stability is monitored by gel electrophoresis.

[0100] In a parallel experiment made with the same conditions, the double stranded RNA is internally radiolabeled with a 32P-ATP. Reactions are stopped by the addition of 2×proteinase K buffer and deproteinized as described previously (Tuschl et al., Genes Dev., 13:3191-3197 (1999)). Products are analyzed by electrophoresis in 15% or 18% polyacrylamide sequencing gels using appropriate RNA standards. By monitoring the gels for radioactivity, the natural production of 10 to 25 nt RNAs from the double stranded RNA can be determined.

[0101] The band of double stranded RNA, about 21-23 bps, is eluded. The efficacy of these 21-23 mers for suppressing NOVX transcription is assayed in vitro using the same rabbit reticulocyte assay described above using 50 nanomolar of double stranded 21-23 mer for each assay. The sequence of these 21-23 mers is then determined using standard nucleic acid sequencing techniques.

[0102] RNA Preparation

[0103] 21 nt RNAs, based on the sequence determined above, are chemically synthesized using Expedite RNA phosphoramidites and thymidine phosphoramidite (Proligo, Germany). Synthetic oligonucleotides are deprotected and gel-purified (Elbashir, Lendeckel, & Tuschl, Genes & Dev. 15, 188-200 (2001)), followed by Sep-Pak C18 cartridge (Waters, Milford, Mass., USA) purification (Tuschl, et al., Biochemistry, 32:11658-11668 (1993)).

[0104] These RNAs (20 μM) single strands are incubated in annealing buffer (100 mM potassium acetate, 30 mM HEPES-KOH at pH 7.4, 2 mM magnesium acetate) for 1 min at 90° C. followed by 1 h at 37° C.

[0105] Cell Culture

[0106] A cell culture known in the art to regularly express NOVX is propagated using standard conditions. 24 hours before transfection, at approx. 80% confluency, the cells are trypsinized and diluted 1:5 with fresh medium without antibiotics (1-3×105 cells/ml) and transferred to 24-well plates (500 ml/well). Transfection is performed using a commercially available lipofection kit and NOVX expression is monitored using standard techniques with positive and negative control. A positive control is cells that naturally express NOVX while a negative control is cells that do not express NOVX. Base-paired 21 and 22 nt siRNAs with overhanging 3′ ends mediate efficient sequence-specific mRNA degradation in lysates and in cell culture. Different concentrations of siRNAs are used. An efficient concentration for suppression in vitro in mammalian culture is between 25 nM to 100 nM final concentration. This indicates that siRNAs are effective at concentrations that are several orders of magnitude below the concentrations applied in conventional antisense or ribozyme gene targeting experiments.

[0107] The above method provides a way both for the deduction of NOVX siRNA sequence and the use of such siRNA for in vitro suppression. In vivo suppression may be performed using the same siRNA using well known in vivo transfection or gene therapy transfection techniques.

[0108] Antisense Nucleic Acids

[0109] Another aspect of the invention pertains to isolated antisense nucleic acid molecules that are hybridizable to or complementary to the nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:2n−1, wherein n is an integer between 1 and 226, or fragments, analogs or derivatives thereof. An “antisense” nucleic acid comprises a nucleotide sequence that is complementary to a “sense” nucleic acid encoding a protein (e.g., complementary to the coding strand of a double-stranded cDNA molecule or complementary to an mRNA sequence). In specific aspects, antisense nucleic acid molecules are provided that comprise a sequence complementary to at least about 10, 25, 50, 100, 250 or 500 nucleotides or an entire NOVX coding strand, or to only a portion thereof. Nucleic acid molecules encoding fragments, homologs, derivatives and analogs of a NOVX protein of SEQ ID NO:2n, wherein n is an integer between 1 and 226, or antisense nucleic acids complementary to a NOVX nucleic acid sequence of SEQ ID NO:2n−1, wherein n is an integer between 1 and 226, are additionally provided.

[0110] In one embodiment, an antisense nucleic acid molecule is antisense to a “coding region” of the coding strand of a nucleotide sequence encoding a NOVX protein. The term “coding region” refers to the region of the nucleotide sequence comprising codons which are translated into amino acid residues. In another embodiment, the antisense nucleic acid molecule is antisense to a “noncoding region” of the coding strand of a nucleotide sequence encoding the NOVX protein. The term “noncoding region” refers to 5′ and 3′ sequences which flank the coding region that are not translated into amino acids (i.e., also referred to as 5′ and 3′ untranslated regions).

[0111] Given the coding strand sequences encoding the NOVX protein disclosed herein, antisense nucleic acids of the invention can be designed according to the rules of Watson and Crick or Hoogsteen base pairing. The antisense nucleic acid molecule can be complementary to the entire coding region of NOVX mRNA, but more preferably is an oligonucleotide that is antisense to only a portion of the coding or noncoding region of NOVX mRNA. For example, the antisense oligonucleotide can be complementary to the region surrounding the translation start site of NOVX mRNA. An antisense oligonucleotide can be, for example, about 5, 10, 15, 20, 25, 30, 35, 40, 45 or 50 nucleotides in length. An antisense nucleic acid of the invention can be constructed using chemical synthesis or enzymatic ligation reactions using procedures known in the art. For example, an antisense nucleic acid (e.g., an antisense oligonucleotide) can be chemically synthesized using naturally-occurring nucleotides or variously modified nucleotides designed to increase the biological stability of the molecules or to increase the physical stability of the duplex formed between the antisense and sense nucleic acids (e.g., phosphorothioate derivatives and acridine substituted nucleotides can be used).

[0112] Examples of modified nucleotides that can be used to generate the antisense nucleic acid include: 5-fluorouracil, 5-bromouracil, 5-chlorouracil, 5-iodouracil, hypoxanthine, xanthine, 4-acetylcytosine, 5-carboxymethylaminomethyl-2-thiouridine, 5-(carboxyhydroxylmethyl)uracil, 5-carboxymethylaminomethyluracil, dihydrouracil, beta-D-galactosylqueosine, inosine, N6-isopentenyladenine, 1-methylguanine, 1-methylinosine, 2,2-dimethylguanine, 2-methyladenine, 2-methylguanine, 5-methoxyuracil, 3-methylcytosine, 5-methylcytosine, N6-adenine, 7-methylguanine, 5-methylaminomethyluracil, 5-methoxyaminomethyl-2-thiouracil, 2-thiouracil, 4-thiouracil, beta-D-mannosylqueosine, 5′-methoxycarboxymethyluracil, 2-methylthio-N6-isopentenyladenine, uracil-5-oxyacetic acid (v), wybutoxosine, pseudouracil, queosine, 2-thiocytosine, 5-methyl-2-thiouracil, 5-methyluracil, uracil-5-oxyacetic acid methylester, uracil-5-oxyacetic acid (v), 5-methyl-2-thiouracil, 3-(3-amino-3-N-2-carboxypropyl)uracil, (acp3)w, and 2,6-diaminopurine. Alternatively, the antisense nucleic acid can be produced biologically using an expression vector into which a nucleic acid has been subcloned in an antisense orientation (i.e., RNA transcribed from the inserted nucleic acid will be of an antisense orientation to a target nucleic acid of interest, described further in the following subsection).

[0113] The antisense nucleic acid molecules of the invention are typically administered to a subject or generated in situ such that they hybridize with or bind to cellular mRNA and/or genomic DNA encoding a NOVX protein to thereby inhibit expression of the protein (e.g., by inhibiting transcription and/or translation). The hybridization can be by conventional nucleotide complementarity to form a stable duplex, or, for example, in the case of an antisense nucleic acid molecule that binds to DNA duplexes, through specific interactions in the major groove of the double helix. An example of a route of administration of antisense nucleic acid molecules of the invention includes direct injection at a tissue site. Alternatively, antisense nucleic acid molecules can be modified to target selected cells and then administered systemically. For example, for systemic administration, antisense molecules can be modified such that they specifically bind to receptors or antigens expressed on a selected cell surface (e.g., by linking the antisense nucleic acid molecules to peptides or antibodies that bind to cell surface receptors or antigens). The antisense nucleic acid molecules can also be delivered to cells using the vectors described herein. To achieve sufficient nucleic acid molecules, vector constructs in which the antisense nucleic acid molecule is placed under the control of a strong pol II or pol III promoter are preferred.

[0114] In yet another embodiment, the antisense nucleic acid molecule of the invention is an α-anomeric nucleic acid molecule. An α-anomeric nucleic acid molecule forms specific double-stranded hybrids with complementary RNA in which, contrary to the usual β-units, the strands run parallel to each other. See, e.g., Gaultier, et al., 1987. Nucl. Acids Res. 15: 6625-6641. The antisense nucleic acid molecule can also comprise a 2′-o-methylribonucleotide (See, e.g., Inoue, et al. 1987. Nucl. Acids Res. 15: 6131-6148) or a chimeric RNA-DNA analogue (See, e.g., Inoue, et al., 1987. FEBS Lett. 215: 327-330.

[0115] Ribozymes and PNA Moieties

[0116] Nucleic acid modifications include, by way of non-limiting example, modified bases, and nucleic acids whose sugar phosphate backbones are modified or derivatized. These modifications are carried out at least in part to enhance the chemical stability of the modified nucleic acid, such that they may be used, for example, as antisense binding nucleic acids in therapeutic applications in a subject.

[0117] In one embodiment, an antisense nucleic acid of the invention is a ribozyme. Ribozymes are catalytic RNA molecules with ribonuclease activity that are capable of cleaving a single-stranded nucleic acid, such as an mRNA, to which they have a complementary region. Thus, ribozymes (e.g., hammerhead ribozymes as described in Haselhoff and Gerlach 1988. Nature 334: 585-591) can be used to catalytically cleave NOVX mRNA transcripts to thereby inhibit translation of NOVX mRNA. A ribozyme having specificity for a NOVX-encoding nucleic acid can be designed based upon the nucleotide sequence of a NOVX cDNA disclosed herein (i.e., SEQ ID NO:2n−1, wherein n is an integer between 1 and 226). For example, a derivative of a Tetrahymena L-19 IVS RNA can be constructed in which the nucleotide sequence of the active site is complementary to the nucleotide sequence to be cleaved in a NOVX-encoding mRNA. See, e.g., U.S. Pat. No. 4,987,071 to Cech, et al. and U.S. Pat. No. 5,116,742 to Cech, et al. NOVX mRNA can also be used to select a catalytic RNA having a specific ribonuclease activity from a pool of RNA molecules. See, e.g., Bartel et al., (1993) Science 261:1411-1418.

[0118] Alternatively, NOVX gene expression can be inhibited by targeting nucleotide sequences complementary to the regulatory region of the NOVX nucleic acid (e.g., the NOVX promoter and/or enhancers) to form triple helical structures that prevent transcription of the NOVX gene in target cells. See, e.g., Helene, 1991. Anticancer Drug Des. 6: 569-84; Helene, et al. 1992. Ann. N.Y Acad. Sci. 660: 27-36; Maher, 1992. Bioassays 14: 807-15.

[0119] In various embodiments, the NOVX nucleic acids can be modified at the base moiety, sugar moiety or phosphate backbone to improve, e.g., the stability, hybridization, or solubility of the molecule. For example, the deoxyribose phosphate backbone of the nucleic acids can be modified to generate peptide nucleic acids. See, e.g., Hyrup, et al., 1996. Bioorg Med Chem 4: 5-23. As used herein, the terms “peptide nucleic acids” or “PNAs” refer to nucleic acid mimics (e.g., DNA mimics) in which the deoxyribose phosphate backbone is replaced by a pseudopeptide backbone and only the four natural nucleotide bases are retained. The neutral backbone of PNAs has been shown to allow for specific hybridization to DNA and RNA under conditions of low ionic strength. The synthesis of PNA oligomer can be performed using standard solid phase peptide synthesis protocols as described in Hyrup, et al., 1996. supra; Perry-O'Keefe, et al., 1996. Proc. Natl. Acad. Sci. USA 93: 14670-14675.

[0120] PNAs of NOVX can be used in therapeutic and diagnostic applications. For example, PNAs can be used as antisense or antigene agents for sequence-specific modulation of gene expression by, e.g., inducing transcription or translation arrest or inhibiting replication. PNAs of NOVX can also be used, for example, in the analysis of single base pair mutations in a gene (e.g., PNA directed PCR clamping; as artificial restriction enzymes when used in combination with other enzymes, e.g., S1 nucleases (See, Hyrup, et al., 1996.supra); or as probes or primers for DNA sequence and hybridization (See, Hyrup, et al., 1996, supra; Perry-O'Keefe, et al., 1996. supra).

[0121] In another embodiment, PNAs of NOVX can be modified, e.g., to enhance their stability or cellular uptake, by attaching lipophilic or other helper groups to PNA, by the formation of PNA-DNA chimeras, or by the use of liposomes or other techniques of drug delivery known in the art. For example, PNA-DNA chimeras of NOVX can be generated that may combine the advantageous properties of PNA and DNA. Such chimeras allow DNA recognition enzymes (e.g., RNase H and DNA polymerases) to interact with the DNA portion while the PNA portion would provide high binding affinity and specificity. PNA-DNA chimeras can be linked using linkers of appropriate lengths selected in terms of base stacking, number of bonds between the nucleotide bases, and orientation (see, Hyrup, et al., 1996. supra). The synthesis of PNA-DNA chimeras can be performed as described in Hyrup, et al., 1996. supra and Finn, et al., 1996. Nucl Acids Res 24: 3357-3363. For example, a DNA chain can be synthesized on a solid support using standard phosphoramidite coupling chemistry, and modified nucleoside analogs, e.g., 5′-(4-methoxytrityl)amino-5′-deoxy-thymidine phosphoramidite, can be used between the PNA and the 5′ end of DNA. See, e.g., Mag, et al., 1989. Nucl Acid Res 17: 5973-5988. PNA monomers are then coupled in a stepwise manner to produce a chimeric molecule with a 5′ PNA segment and a 3′ DNA segment. See, e.g., Finn, et al., 1996. supra. Alternatively, chimeric molecules can be synthesized with a 5′ DNA segment and a 3′ PNA segment. See, e.g., Petersen, et al., 1975. Bioorg. Med. Chem. Lett. 5: 1119-11124.

[0122] In other embodiments, the oligonucleotide may include other appended groups such as peptides (e.g., for targeting host cell receptors in vivo), or agents facilitating transport across the cell membrane (see, e.g., Letsinger, et al., 1989. Proc. Natl. Acad. Sci. U.S.A. 86: 6553-6556; Lemaitre, et al., 1987. Proc. Natl. Acad. Sci. 84: 648-652; PCT Publication No. WO88/09810) or the blood-brain barrier (see, e.g., PCT Publication No. WO 89/10134). In addition, oligonucleotides can be modified with hybridization triggered cleavage agents (see, e.g., Krol, et al., 1988. Bio Techniques 6:958-976) or intercalating agents (see, e.g., Zon, 1988. Pharm. Res. 5: 539-549). To this end, the oligonucleotide may be conjugated to another molecule, e.g., a peptide, a hybridization triggered cross-linking agent, a transport agent, a hybridization-triggered cleavage agent, and the like.

[0123] NOVX Polypeptides

[0124] A polypeptide according to the invention includes a polypeptide including the amino acid sequence of NOVX polypeptides whose sequences are provided in any one of SEQ ID NO:2n, wherein n is an integer between 1 and 226. The invention also includes a mutant or variant protein any of whose residues may be changed from the corresponding residues shown in any one of SEQ ID NO:2n, wherein n is an integer between 1 and 226, while still encoding a protein that maintains its NOVX activities and physiological functions, or a functional fragment thereof.

[0125] In general, a NOVX variant that preserves NOVX-like function includes any variant in which residues at a particular position in the sequence have been substituted by other amino acids, and further include the possibility of inserting an additional residue or residues between two residues of the parent protein as well as the possibility of deleting one or more residues from the parent sequence. Any amino acid substitution, insertion, or deletion is encompassed by the invention. In favorable circumstances, the substitution is a conservative substitution as defined above.

[0126] One aspect of the invention pertains to isolated NOVX proteins, and biologically-active portions thereof, or derivatives, fragments, analogs or homologs thereof. Also provided are polypeptide fragments suitable for use as immunogens to raise anti-NOVX antibodies. In one embodiment, native NOVX proteins can be isolated from cells or tissue sources by an appropriate purification scheme using standard protein purification techniques. In another embodiment, NOVX proteins are produced by recombinant DNA techniques. Alternative to recombinant expression, a NOVX protein or polypeptide can be synthesized chemically using standard peptide synthesis techniques.

[0127] An “isolated” or “purified” polypeptide or protein or biologically-active portion thereof is substantially free of cellular material or other contaminating proteins from the cell or tissue source from which the NOVX protein is derived, or substantially free from chemical precursors or other chemicals when chemically synthesized. The language “substantially free of cellular material” includes preparations of NOVX proteins in which the protein is separated from cellular components of the cells from which it is isolated or recombinantly-produced. In one embodiment, the language “substantially free of cellular material” includes preparations of NOVX proteins having less than about 30% (by dry weight) of non-NOVX proteins (also referred to herein as a “contaminating protein”), more preferably less than about 20% of non-NOVX proteins, still more preferably less than about 10% of non-NOVX proteins, and most preferably less than about 5% of non-NOVX proteins. When the NOVX protein or biologically-active portion thereof is recombinantly-produced, it is also preferably substantially free of culture medium, i.e., culture medium represents less than about 20%, more preferably less than about 10%, and most preferably less than about 5% of the volume of the NOVX protein preparation.

[0128] The language “substantially free of chemical precursors or other chemicals” includes preparations of NOVX proteins in which the protein is separated from chemical precursors or other chemicals that are involved in the synthesis of the protein. In one. embodiment, the language “substantially free of chemical precursors or other chemicals” includes preparations of NOVX proteins having less than about 30% (by dry weight) of chemical precursors or non-NOVX chemicals, more preferably less than about 20% chemical precursors or non-NOVX chemicals, still more preferably less than about 10% chemical precursors or non-NOVX chemicals, and most preferably less than about 5% chemical precursors or non-NOVX chemicals.

[0129] Biologically-active portions of NOVX proteins include peptides comprising amino acid sequences sufficiently homologous to or derived from the amino acid sequences of the NOVX proteins (e.g., the amino acid sequence of SEQ ID NO:2n, wherein n is an integer between 1 and 226) that include fewer amino acids than the full-length NOVX proteins, and exhibit at least one activity of a NOVX protein. Typically, biologically-active portions comprise a domain or motif with at least one activity of the NOVX protein. A biologically-active portion of a NOVX protein can be a polypeptide which is, for example, 10, 25, 50, 100 or more amino acid residues in length.

[0130] Moreover, other biologically-active portions, in which other regions of the protein are deleted, can be prepared by recombinant techniques and evaluated for one or more of the functional activities of a native NOVX protein.

[0131] In an embodiment, the NOVX protein has an amino acid sequence of SEQ ID NO:2n, wherein n is an integer between 1 and 226. In other embodiments, the NOVX protein is substantially homologous to SEQ ID NO:2n, wherein n is an integer between 1 and 226, and retains the functional activity of the protein of SEQ ID NO:2n, wherein n is an integer between 1 and 226, yet differs in amino acid sequence due to natural allelic variation or mutagenesis, as described in detail, below. Accordingly, in another embodiment, the NOVX protein is a protein that comprises an amino acid sequence at least about 45% homologous to the amino acid sequence of SEQ ID NO:2n, wherein n is an integer between 1 and 226, and retains the functional activity of the NOVX proteins of SEQ ID NO:2n, wherein n is an integer between 1 and 226.

[0132] Determining Homology Between Two or More Sequences

[0133] To determine the percent homology of two amino acid sequences or of two nucleic acids, the sequences are aligned for optimal comparison purposes (e.g., gaps can be introduced in the sequence of a first amino acid or nucleic acid sequence for optimal alignment with a second amino or nucleic acid sequence). The amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions are then compared. When a position in the first sequence is occupied by the same amino acid residue or nucleotide as the corresponding position in the second sequence, then the molecules are homologous at that position (i.e., as used herein amino acid or nucleic acid “homology” is equivalent to amino acid or nucleic acid “identity”).

[0134] The nucleic acid sequence homology may be determined as the degree of identity between two sequences. The homology may be determined using computer programs known in the art, such as GAP software provided in the GCG program package. See, Needleman and Wunsch, 1970. J Mol Biol 48: 443-453. Using GCG GAP software with the following settings for nucleic acid sequence comparison: GAP creation penalty of 5.0 and GAP extension penalty of 0.3, the coding region of the analogous nucleic acid sequences referred to above exhibits a degree of identity preferably of at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, or 99%, with the CDS (encoding) part of the DNA sequence of SEQ ID NO:2n−1, wherein n is an integer between 1 and 226.

[0135] The term “sequence identity” refers to the degree to which two polynucleotide or polypeptide sequences are identical on a residue-by-residue basis over a particular region of comparison. The term “percentage of sequence identity” is calculated by comparing two optimally aligned sequences over that region of comparison, determining the number of positions at which the identical nucleic acid base (e.g., A, T, C, G, U, or I, in the case of nucleic acids) occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the region of comparison (i.e., the window size), and multiplying the result by 100 to yield the percentage of sequence identity. The term “substantial identity” as used herein denotes a characteristic of a polynucleotide sequence, wherein the polynucleotide comprises a sequence that has at least 80 percent sequence identity, preferably at least 85 percent identity and often 90 to 95 percent sequence identity, more usually at least 99 percent sequence identity as compared to a reference sequence over a comparison region.

[0136] Chimeric and Fusion Proteins

[0137] The invention also provides NOVX chimeric or fusion proteins. As used herein, a NOVX “chimeric protein” or “fusion protein” comprises a NOVX polypeptide operatively-linked to a non-NOVX polypeptide. An “NOVX polypeptide” refers to a polypeptide having an amino acid sequence corresponding to a NOVX protein of SEQ ID NO:2n, wherein n is an integer between 1 and 226, whereas a “non-NOVX polypeptide” refers to a polypeptide having an amino acid sequence corresponding to a protein that is not substantially homologous to the NOVX protein, e.g., a protein that is different from the NOVX protein and that is derived from the same or a different organism. Within a NOVX fusion protein the NOVX polypeptide can correspond to all or a portion of a NOVX protein. In one embodiment, a NOVX fusion protein comprises at least one biologically-active portion of a NOVX protein. In another embodiment, a NOVX fusion protein comprises at least two biologically-active portions of a NOVX protein. In yet another embodiment, a NOVX fusion protein comprises at least three biologically-active portions of a NOVX protein. Within the fusion protein, the term “operatively-linked” is intended to indicate that the NOVX polypeptide and the non-NOVX polypeptide are fused in-frame with one another. The non-NOVX polypeptide can be fused to the N-terminus or C-terminus of the NOVX polypeptide.

[0138] In one embodiment, the fusion protein is a GST-NOVX fusion protein in which the NOVX sequences are fused to the C-terminus of the GST (glutathione S-transferase) sequences. Such fusion proteins can facilitate the purification of recombinant NOVX polypeptides.

[0139] In another embodiment, the fusion protein is a NOVX protein containing a heterologous signal sequence at its N-terminus. In certain host cells (e.g., mammalian host cells), expression and/or secretion of NOVX can be increased through use of a heterologous signal sequence.

[0140] In yet another embodiment, the fusion protein is a NOVX-immunoglobulin fusion protein in which the NOVX sequences are fused to sequences derived from a member of the immunoglobulin protein family. The NOVX-immunoglobulin fusion proteins of the invention can be incorporated into pharmaceutical compositions and administered to a subject to inhibit an interaction between a NOVX ligand and a NOVX protein on the surface of a cell, to thereby suppress NOVX-mediated signal transduction in vivo. The NOVX-immunoglobulin fusion proteins can be used to affect the bioavailability of a NOVX cognate ligand. Inhibition of the NOVX ligand/NOVX interaction may be useful therapeutically for both the treatment of proliferative and differentiative disorders, as well as modulating (e.g. promoting or inhibiting) cell survival. Moreover, the NOVX-immunoglobulin fusion proteins of the invention can be used as immunogens to produce anti-NOVX antibodies in a subject, to purify NOVX ligands, and in screening assays to identify molecules that inhibit the interaction of NOVX with a NOVX ligand.

[0141] A NOVX chimeric or fusion protein of the invention can be produced by standard recombinant DNA techniques. For example, DNA fragments coding for the different polypeptide sequences are ligated together in-frame in accordance with conventional techniques, e.g., by employing blunt-ended or stagger-ended termini for ligation, restriction enzyme digestion to provide for appropriate termini, filling-in of cohesive ends as appropriate, alkaline phosphatase treatment to avoid undesirable joining, and enzymatic ligation. In another embodiment, the fusion gene can be synthesized by conventional techniques including automated DNA synthesizers. Alternatively, PCR amplification of gene fragments can be carried out using anchor primers that give rise to complementary overhangs between two consecutive gene fragments that can subsequently be annealed and reamplified to generate a chimeric gene sequence (see, e.g., Ausubel, et al. (eds.) CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, 1992). Moreover, many expression vectors are commercially available that already encode a fusion moiety (e.g., a GST polypeptide). A NOVX-encoding nucleic acid can be cloned into such an expression vector such that the fusion moiety is linked in-frame to the NOVX protein.

[0142] NOVX Agonists and Antagonists

[0143] The invention also pertains to variants of the NOVX proteins that function as either NOVX agonists (i.e., mimetics) or as NOVX antagonists. Variants of the NOVX protein can be generated by mutagenesis (e.g., discrete point mutation or truncation of the NOVX protein). An agonist of the NOVX protein can retain substantially the same, or a subset of, the biological activities of the naturally occurring form of the NOVX protein. An antagonist of the NOVX protein can inhibit one or more of the activities of the naturally occurring form of the NOVX protein by, for example, competitively binding to a downstream or upstream member of a cellular signaling cascade which includes the NOVX protein. Thus, specific biological effects can be elicited by treatment with a variant of limited function. In one embodiment, treatment of a subject with a variant having a subset of the biological activities of the naturally occurring form of the protein has fewer side effects in a subject relative to treatment with the naturally occurring form of the NOVX proteins.

[0144] Variants of the NOVX proteins that function as either NOVX agonists (i.e., mimetics) or as NOVX antagonists can be identified by screening combinatorial libraries of mutants (e.g., truncation mutants) of the NOVX proteins for NOVX protein agonist or antagonist activity. In one embodiment, a variegated library of NOVX variants is generated by combinatorial mutagenesis at the nucleic acid level and is encoded by a variegated gene library. A variegated library of NOVX variants can be produced by, for example, enzymatically ligating a mixture of synthetic oligonucleotides into gene sequences such that a degenerate set of potential NOVX sequences is expressible as individual polypeptides, or alternatively, as a set of larger fusion proteins (e.g., for phage display) containing the set of NOVX sequences therein. There are a variety of methods which can be used to produce libraries of potential NOVX variants from a degenerate oligonucleotide sequence. Chemical synthesis of a degenerate gene sequence can be performed in an automatic DNA synthesizer, and the synthetic gene then ligated into an appropriate expression vector. Use of a degenerate set of genes allows for the provision, in one mixture, of all of the sequences encoding the desired set of potential NOVX sequences. Methods for synthesizing degenerate oligonucleotides are well-known within the art. See, e.g., Narang, 1983. Tetrahedron 39: 3; Itakura, et al., 1984. Annu. Rev. Biochem. 53: 323; Itakura, et al., 1984. Science 198: 1056; Ike, et al., 1983. Nucl. Acids Res. 11: 477.

[0145] Polypeptide Libraries

[0146] In addition, libraries of fragments of the NOVX protein coding sequences can be used to generate a variegated population of NOVX fragments for screening and subsequent selection of variants of a NOVX protein. In one embodiment, a library of coding sequence fragments can be generated by treating a double stranded PCR fragment of a NOVX coding sequence with a nuclease under conditions wherein nicking occurs only about once per molecule, denaturing the double stranded DNA, renaturing the DNA to form double-stranded DNA that can include sense/antisense pairs from different nicked products, removing single stranded portions from reformed duplexes by treatment with S1 nuclease, and ligating the resulting fragment library into an expression vector. By this method, expression libraries can be derived which encodes N-terminal and internal fragments of various sizes of the NOVX proteins.

[0147] Various techniques are known in the art for screening gene products of combinatorial libraries made by point mutations or truncation, and for screening cDNA libraries for gene products having a selected property. Such techniques are adaptable for rapid screening of the gene libraries generated by the combinatorial mutagenesis of NOVX proteins. The most widely used techniques, which are amenable to high throughput analysis, for screening large gene libraries typically include cloning the gene library into replicable expression vectors, transforming appropriate cells with the resulting library of vectors, and expressing the combinatorial genes under conditions in which detection of a desired activity facilitates isolation of the vector encoding the gene whose product was detected. Recursive ensemble mutagenesis (REM), a new technique that enhances the frequency of functional mutants in the libraries, can be used in combination with the screening assays to identify NOVX variants. See, e.g., Arkin and Yourvan, 1992. Proc. Natl. Acad. Sci. USA 89: 7811-7815; Delgrave, et al., 1993. Protein Engineering 6:327-331.

[0148] Anti-NOVX Antibodies

[0149] Included in the invention are antibodies to NOVX proteins, or fragments of NOVX proteins. The term “antibody” as used herein refers to immunoglobulin molecules and immunologically active portions of immunoglobulin (Ig) molecules, i.e., molecules that contain an antigen binding site that specifically binds (immunoreacts with) an antigen. Such antibodies include, but are not limited to, polyclonal, monoclonal, chimeric, single chain, Fab, Fab′ and F(ab′)2 fragments, and an Fab expression library. In general, antibody molecules obtained from humans relates to any of the classes IgG, IgM, IgA, IgE and IgD, which differ from one another by the nature of the heavy chain present in the molecule. Certain classes have subclasses as well, such as IgG1, IgG2, and others. Furthermore, in humans, the light chain may be a kappa chain or a lambda chain. Reference herein to antibodies includes a reference to all such classes, subclasses and types of human antibody species.

[0150] An isolated protein of the invention intended to serve as an antigen, or a portion or fragment thereof, can be used as an immunogen to generate antibodies that immunospecifically bind the antigen, using standard techniques for polyclonal and monoclonal antibody preparation. The full-length protein can be used or, alternatively, the invention provides antigenic peptide fragments of the antigen for use as immunogens. An antigenic peptide fragment comprises at least 6 amino acid residues of the amino acid sequence of the full length protein, such as an amino acid sequence of SEQ ID NO:2n, wherein n is an integer between 1 and 226, and encompasses an epitope thereof such that an antibody raised against the peptide forms a specific immune complex with the full length protein or with any fragment that contains the epitope. Preferably, the antigenic peptide comprises at least 10 amino acid residues, or at least 15 amino acid residues, or at least 20 amino acid residues, or at least 30 amino acid residues. Preferred epitopes encompassed by the antigenic peptide are regions of the protein that are located on its surface; commonly these are hydrophilic regions.

[0151] In certain embodiments of the invention, at least one epitope encompassed by the antigenic peptide is a region of NOVX that is located on the surface of the protein, e.g., a hydrophilic region. A hydrophobicity analysis of the human NOVX protein sequence will indicate which regions of a NOVX polypeptide are particularly hydrophilic and, therefore, are likely to encode surface residues useful for targeting antibody production. As a means for targeting antibody production, hydropathy plots showing regions of hydrophilicity and hydrophobicity may be generated by any method well known in the art, including, for example, the Kyte Doolittle or the Hopp Woods methods, either with or without Fourier transformation. See, e.g., Hopp and Woods, 1981, Proc. Nat. Acad. Sci. USA 78: 3824-3828; Kyte and Doolittle 1982, J. Mol. Biol. 157: 105-142, each incorporated herein by reference in their entirety. Antibodies that are specific for one or more domains within an antigenic protein, or derivatives, fragments, analogs or homologs thereof, are also provided herein.

[0152] The term “epitope” includes any protein determinant capable of specific binding to an immunoglobulin or T-cell receptor. Epitopic determinants usually consist of chemically active surface groupings of molecules such as amino acids or sugar side chains and usually have specific three dimensional structural characteristics, as well as specific charge characteristics. A NOVX polypeptide or a fragment thereof comprises at least one antigenic epitope. An anti-NOVX antibody of the present invention is said to specifically bind to antigen NOVX when the equilibrium binding constant (KD) is ≦1 μM, preferably ≦100 nM, more preferably ≦10 nM, and most preferably ≦100 pM to about 1 pM, as measured by assays such as radioligand binding assays or similar assays known to those skilled in the art.

[0153] A protein of the invention, or a derivative, fragment, analog, homolog or ortholog thereof, may be utilized as an immunogen in the generation of antibodies that immunospecifically bind these protein components.

[0154] Various procedures known within the art may be used for the production of polyclonal or monoclonal antibodies directed against a protein of the invention, or against derivatives, fragments, analogs homologs or orthologs thereof (see, for example, Antibodies: A Laboratory Manual, Harlow E, and Lane D, 1988, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., incorporated herein by reference). Some of these antibodies are discussed below.

[0155] Polyclonal Antibodies

[0156] For the production of polyclonal antibodies, various suitable host animals (e.g., rabbit, goat, mouse or other mammal) may be immunized by one or more injections with the native protein, a synthetic variant thereof, or a derivative of the foregoing. An appropriate immunogenic preparation can contain, for example, the naturally occurring immunogenic protein, a chemically synthesized polypeptide representing the immunogenic protein, or a recombinantly expressed immunogenic protein. Furthermore, the protein may be conjugated to a second protein known to be immunogenic in the mammal being immunized. Examples of such immunogenic proteins include but are not limited to keyhole limpet hemocyanin, serum albumin, bovine thyroglobulin, and soybean trypsin inhibitor. The preparation can further include an adjuvant. Various adjuvants used to increase the immunological response include, but are not limited to, Freund's (complete and incomplete), mineral gels (e.g., aluminum hydroxide), surface active substances (e.g., lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, dinitrophenol, etc.), adjuvants usable in humans such as Bacille Calmette-Guerin and Corynebacterium parvum, or similar immunostimulatory agents. Additional examples of adjuvants which can be employed include MPL-TDM adjuvant (monophosphoryl Lipid A, synthetic trehalose dicorynomycolate).

[0157] The polyclonal antibody molecules directed against the immunogenic protein can be isolated from the mammal (e.g., from the blood) and further purified by well known techniques, such as affinity chromatography using protein A or protein G, which provide primarily the IgG fraction of immune serum. Subsequently, or alternatively, the specific antigen which is the target of the immunoglobulin sought, or an epitope thereof, may be immobilized on a column to purify the immune specific antibody by immunoaffinity chromatography. Purification of immunoglobulins is discussed, for example, by D. Wilkinson (The Scientist, published by The Scientist, Inc., Philadelphia Pa., Vol. 14, No. 8 (Apr. 17, 2000), pp. 25-28).

[0158] Monoclonal Antibodies

[0159] The term “monoclonal antibody” (MAb) or “monoclonal antibody composition”, as used herein, refers to a population of antibody molecules that contain only one molecular species of antibody molecule consisting of a unique light chain gene product and a unique heavy chain gene product. In particular, the complementarity determining regions (CDRs) of the monoclonal antibody are identical in all the molecules of the population. MAbs thus contain an antigen binding site capable of immunoreacting with a particular epitope of the antigen characterized by a unique binding affinity for it.

[0160] Monoclonal antibodies can be prepared using hybridoma methods, such as those described by Kohler and Milstein, Nature, 256:495 (1975). In a hybridoma method, a mouse, hamster, or other appropriate host animal, is typically immunized with an immunizing agent to elicit lymphocytes that produce or are capable of producing antibodies that will specifically bind to the immunizing agent. Alternatively, the lymphocytes can be immunized in vitro.

[0161] The immunizing agent will typically include the protein antigen, a fragment thereof or a fusion protein thereof. Generally, either peripheral blood lymphocytes are used if cells of human origin are desired, or spleen cells or lymph node cells are used if non-human mammalian sources are desired. The lymphocytes are then fused with an immortalized cell line using a suitable fusing agent, such as polyethylene glycol, to form a hybridoma cell (Goding, Monoclonal Antibodies: Principles and Practice, Academic Press, (1986) pp. 59-103). Immortalized cell lines are usually transformed mammalian cells, particularly myeloma cells of rodent, bovine and human origin. Usually, rat or mouse myeloma cell lines are employed. The hybridoma cells can be cultured in a suitable culture medium that preferably contains one or more substances that inhibit the growth or survival of the unfused, immortalized cells. For example, if the parental cells lack the enzyme hypoxanthine guanine phosphoribosyl transferase (HGPRT or HPRT), the culture medium for the hybridomas typically will include hypoxanthine, aminopterin, and thymidine (“HAT medium”), which substances prevent the growth of HGPRT-deficient cells.

[0162] Preferred immortalized cell lines are those that fuse efficiently, support stable high level expression of antibody by the selected antibody-producing cells, and are sensitive to a medium such as HAT medium. More preferred immortalized cell lines are murine myeloma lines, which can be obtained, for instance, from the Salk Institute Cell Distribution Center, San Diego, Calif. and the American Type Culture Collection, Manassas, Va. Human myeloma and mouse-human heteromyeloma cell lines also have been described for the production of human monoclonal antibodies (Kozbor, J. Immunol., 133:3001 (1984); Brodeur et al., Monoclonal Antibody Production Techniques and Applications, Marcel Dekker, Inc., New York, (1987) pp. 51-63).

[0163] The culture medium in which the hybridoma cells are cultured can then be assayed for the presence of monoclonal antibodies directed against the antigen. Preferably, the binding specificity of monoclonal antibodies produced by the hybridoma cells is determined by immunoprecipitation or by an in vitro binding assay, such as radioimmunoassay (RIA) or enzyme-linked immunoabsorbent assay (ELISA). Such techniques and assays are known in the art. The binding affinity of the monoclonal antibody can, for example, be determined by the Scatchard analysis of Munson and Pollard, Anal. Biochem., 107:220 (1980). It is an objective, especially important in therapeutic applications of monoclonal antibodies, to identify antibodies having a high degree of specificity and a high binding affinity for the target antigen.

[0164] After the desired hybridoma cells are identified, the clones can be subcloned by limiting dilution procedures and grown by standard methods (Goding, 1986). Suitable culture media for this purpose include, for example, Dulbecco's Modified Eagle's Medium and RPMI-1640 medium. Alternatively, the hybridoma cells can be grown in vivo as ascites in a mammal.

[0165] The monoclonal antibodies secreted by the subclones can be isolated or purified from the culture medium or ascites fluid by conventional immunoglobulin purification procedures such as, for example, protein A-Sepharose, hydroxylapatite chromatography, gel electrophoresis, dialysis, or affinity chromatography.

[0166] The monoclonal antibodies can also be made by recombinant DNA methods, such as those described in U.S. Pat. No. 4,816,567. DNA encoding the monoclonal antibodies of the invention can be readily isolated and sequenced using conventional procedures (e.g., by using oligonucleotide probes that are capable of binding specifically to genes encoding the heavy and light chains of murine antibodies). The hybridoma cells of the invention serve as a preferred source of such DNA. Once isolated, the DNA can be placed into expression vectors, which are then transfected into host cells such as simian COS cells, Chinese hamster ovary (CHO) cells, or myeloma cells that do not otherwise produce immunoglobulin protein, to obtain the synthesis of monoclonal antibodies in the recombinant host cells. The DNA also can be modified, for example, by substituting the coding sequence for human heavy and light chain constant domains in place of the homologous murine sequences (U.S. Pat. No. 4,816,567; Morrison, Nature 368, 812-13 (1994)) or by covalently joining to the immunoglobulin coding sequence all or part of the coding sequence for a non-immunoglobulin polypeptide. Such a non-immunoglobulin polypeptide can be substituted for the constant domains of an antibody of the invention, or can be substituted for the variable domains of one antigen-combining site of an antibody of the invention to create a chimeric bivalent antibody.

[0167] Humanized Antibodies

[0168] The antibodies directed against the protein antigens of the invention can further comprise humanized antibodies or human antibodies. These antibodies are suitable for administration to humans without engendering an immune response by the human against the administered immunoglobulin. Humanized forms of antibodies are chimeric immunoglobulins, immunoglobulin chains or fragments thereof (such as Fv, Fab, Fab′, F(ab′)2 or other antigen-binding subsequences of antibodies) that are principally comprised of the sequence of a human immunoglobulin, and contain minimal sequence derived from a non-human immunoglobulin. Humanization can be performed following the method of Winter and co-workers (Jones et al., Nature, 321:522-525 (1986); Riechmann et al., Nature, 332:323-327 (1988); Verhoeyen et al., Science, 239:1534-1536 (1988)), by substituting rodent CDRs or CDR sequences for the corresponding sequences of a human antibody. (See also U.S. Pat. No. 5,225,539.) In some instances, Fv framework residues of the human immunoglobulin are replaced by corresponding non-human residues. Humanized antibodies can also comprise residues which are found neither in the recipient antibody nor in the imported CDR or framework sequences. In general, the humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the CDR regions correspond to those of a non-human immunoglobulin and all or substantially all of the framework regions are those of a human immunoglobulin consensus sequence. The humanized antibody optimally also will comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin (Jones et al., 1986; Riechmann et al., 1988; and Presta, Curr. Op. Struct. Biol., 2:593-596 (1992)).

[0169] Human Antibodies

[0170] Fully human antibodies essentially relate to antibody molecules in which the entire sequence of both the light chain and the heavy chain, including the CDRs, arise from human genes. Such antibodies are termed “human antibodies”, or “fully human antibodies” herein. Human monoclonal antibodies can be prepared by the trioma technique; the human B-cell hybridoma technique (see Kozbor, et al., 1983 Immunol Today 4: 72) and the EBV hybridoma technique to produce human monoclonal antibodies (see Cole, et al., 1985 In: MONOCLONAL ANTIBODIES AND CANCER THERAPY, Alan R. Liss, Inc., pp. 77-96). Human monoclonal antibodies may be utilized in the practice of the present invention and may be produced by using human hybridomas (see Cote, et al., 1983. Proc Natl Acad Sci USA 80: 2026-2030) or by transforming human B-cells with Epstein Barr Virus in vitro (see Cole, et al., 1985 In: MONOCLONAL ANTIBODIES AND CANCER THERAPY, Alan R. Liss, Inc., pp. 77-96).

[0171] In addition, human antibodies can also be produced using additional techniques, including phage display libraries (Hoogenboom and Winter, J. Mol. Biol., 227:381 (1991); Marks et al., J. Mol. Biol., 222:581 (1991)). Similarly, human antibodies can be made by introducing human immunoglobulin loci into transgenic animals, e.g., mice in which the endogenous immunoglobulin genes have been partially or completely inactivated. Upon challenge, human antibody production is observed, which closely resembles that seen in humans in all respects, including gene rearrangement, assembly, and antibody repertoire. This approach is described, for example, in U.S. Pat. Nos. 5,545,807; 5,545,806; 5,569,825; 5,625,126; 5,633,425; 5,661,016, and in Marks et al. (Bio/Technology 10, 779-783 (1992)); Lonberg et al. (Nature 368 856-859 (1994)); Morrison (Nature 368, 812-13 (1994)); Fishwild et al,(Nature Biotechnology 14, 845-51 (1996)); Neuberger (Nature Biotechnology 14, 826 (1996)); and Lonberg and Huszar (Intern. Rev. Immunol. 13 65-93 (1995)).

[0172] Human antibodies may additionally be produced using transgenic nonhuman animals which are modified so as to produce fully human antibodies rather than the animal's endogenous antibodies in response to challenge by an antigen. (See PCT publication WO94/02602). The endogenous genes encoding the heavy and light immunoglobulin chains in the nonhuman host have been incapacitated, and active loci encoding human heavy and light chain immunoglobulins are inserted into the host's genome. The human genes are incorporated, for example, using yeast artificial chromosomes containing the requisite human DNA segments. An animal which provides all the desired modifications is then obtained as progeny by crossbreeding intermediate transgenic animals containing fewer than the full complement of the modifications. The preferred embodiment of such a nonhuman animal is a mouse, and is termed the Xenomouse™ as disclosed in PCT publications WO 96/33735 and WO 96/34096. This animal produces B cells which secrete fully human immunoglobulins. The antibodies can be obtained directly from the animal after immunization with an immunogen of interest, as, for example, a preparation of a polyclonal antibody, or alternatively from immortalized B cells derived from the animal, such as hybridomas producing monoclonal antibodies. Additionally, the genes encoding the immunoglobulins with human variable regions can be recovered and expressed to obtain the antibodies directly, or can be further modified to obtain analogs of antibodies such as, for example, single chain Fv molecules.

[0173] An example of a method of producing a nonhuman host, exemplified as a mouse, lacking expression of an endogenous immunoglobulin heavy chain is disclosed in U.S. Pat. No. 5,939,598. It can be obtained by a method including deleting the J segment genes from at least one endogenous heavy chain locus in an embryonic stem cell to prevent rearrangement of the locus and to prevent formation of a transcript of a rearranged immunoglobulin heavy chain locus, the deletion being effected by a targeting vector containing a gene encoding a selectable marker; and producing from the embryonic stem cell a transgenic mouse whose somatic and germ cells contain the gene encoding the selectable marker.

[0174] A method for producing an antibody of interest, such as a human antibody, is disclosed in U.S. Pat. No. 5,916,771. It includes introducing an expression vector that contains a nucleotide sequence encoding a heavy chain into one mammalian host cell in culture, introducing an expression vector containing a nucleotide sequence encoding a light chain into another mammalian host cell, and fusing the two cells to form a hybrid cell. The hybrid cell expresses an antibody containing the heavy chain and the light chain.

[0175] In a further improvement on this procedure, a method for identifying a clinically relevant epitope on an immunogen, and a correlative method for selecting an antibody that binds immunospecifically to the relevant epitope with high affinity, are disclosed in PCT publication WO 99/53049.

[0176] Fab Fragments and Single Chain Antibodies

[0177] According to the invention, techniques can be adapted for the production of single-chain antibodies specific to an antigenic protein of the invention (see e.g., U.S. Pat. No. 4,946,778). In addition, methods can be adapted for the construction of Fab expression libraries (see e.g., Huse, et al., 1989 Science 246: 1275-1281) to allow rapid and effective identification of monoclonal Fab fragments with the desired specificity for a protein or derivatives, fragments, analogs or homologs thereof. Antibody fragments that contain the idiotypes to a protein antigen may be produced by techniques known in the art including, but not limited to: (i) an F(ab′)2 fragment produced by pepsin digestion of an antibody molecule; (ii) an Fab fragment generated by reducing the disulfide bridges of an F(ab′)2 fragment; (iii) an Fab fragment generated by the treatment of the antibody molecule with papain and a reducing agent and (iv) Fv fragments.

[0178] Bispecific Antibodies

[0179] Bispecific antibodies are monoclonal, preferably human or humanized, antibodies that have binding specificities for at least two different antigens. In the present case, one of the binding specificities is for an antigenic protein of the invention. The second binding target is any other antigen, and advantageously is a cell-surface protein or receptor or receptor subunit.

[0180] Methods for making bispecific antibodies are known in the art. Traditionally, the recombinant production of bispecific antibodies is based on the co-expression of two immunoglobulin heavy-chain/light-chain pairs, where the two heavy chains have different specificities (Milstein and Cuello, Nature, 305:537-539 (1983)). Because of the random assortment of immunoglobulin heavy and light chains, these hybridomas (quadromas) produce a potential mixture of ten different antibody molecules, of which only one has the correct bispecific structure. The purification of the correct molecule is usually accomplished by affinity chromatography steps. Similar procedures are disclosed in WO 93/08829, published 13 May 1993, and in Traunecker et al., EMBO J., 10:3655-3659 (1991).

[0181] Antibody variable domains with the desired binding specificities (antibody-antigen combining sites) can be fused to immunoglobulin constant domain sequences. The fusion preferably is with an immunoglobulin heavy-chain constant domain, comprising at least part of the hinge, CH2, and CH3 regions. It is preferred to have the first heavy-chain constant region (CH 1) containing the site necessary for light-chain binding present in at least one of the fusions. DNAs encoding the immunoglobulin heavy-chain fusions and, if desired, the immunoglobulin light chain, are inserted into separate expression vectors, and are co-transfected into a suitable host organism. For further details of generating bispecific antibodies see, for example, Suresh et al., Methods in Enzymology, 121:210 (1986).

[0182] According to another approach described in WO 96/27011, the interface between a pair of antibody molecules can be engineered to maximize the percentage of heterodimers which are recovered from recombinant cell culture. The preferred interface comprises at least a part of the CH3 region of an antibody constant domain. In this method, one or more small amino acid side chains from the interface of the first antibody molecule are replaced with larger side chains (e.g. tyrosine or tryptophan). Compensatory “cavities” of identical or similar size to the large side chain(s) are created on the interface of the second antibody molecule by replacing large amino acid side chains with smaller ones (e.g. alanine or threonine). This provides a mechanism for increasing the yield of the heterodimer over other unwanted end-products such as homodimers.

[0183] Bispecific antibodies can be prepared as full length antibodies or antibody fragments (e.g. F(ab′)2 bispecific antibodies). Techniques for generating bispecific antibodies from antibody fragments have been described in the literature. For example, bispecific antibodies can be prepared using chemical linkage. Brennan et al., Science 229:81 (1985) describe a procedure wherein intact antibodies are proteolytically cleaved to generate F(ab′)2 fragments. These fragments are reduced in the presence of the dithiol complexing agent sodium arsenite to stabilize vicinal dithiols and prevent intermolecular disulfide formation. The Fab′ fragments generated are then converted to thionitrobenzoate (TNB) derivatives. One of the Fab′-TNB derivatives is then reconverted to the Fab′-thiol by reduction with mercaptoethylamine and is mixed with an equimolar amount of the other Fab′-TNB derivative to form the bispecific antibody. The bispecific antibodies produced can be used as agents for the selective immobilization of enzymes.

[0184] Additionally, Fab′ fragments can be directly recovered from E. coli and chemically coupled to form bispecific antibodies. Shalaby et al., J. Exp. Med. 175:217-225 (1992) describe the production of a fully humanized bispecific antibody F(ab′)2 molecule. Each Fab′ fragment was separately secreted from E. coli and subjected to directed chemical coupling in vitro to form the bispecific antibody. The bispecific antibody thus formed was able to bind to cells overexpressing the ErbB2 receptor and normal human T cells, as well as trigger the lytic activity of human cytotoxic lymphocytes against human breast tumor targets.

[0185] Various techniques for making and isolating bispecific antibody fragments directly from recombinant cell culture have also been described. For example, bispecific antibodies have been produced using leucine zippers. Kostelny et al., J. Immunol. 148(5): 1547-1553 (1992). The leucine zipper peptides from the Fos and Jun proteins were linked to the Fab′ portions of two different antibodies by gene fusion. The antibody homodimers were reduced at the hinge region to form monomers and then re-oxidized to form the antibody heterodimers. This method can also be utilized for the production of antibody homodimers. The “diabody” technology described by Hollinger et al., Proc. Natl. Acad. Sci. USA 90:6444-6448 (1993) has provided an alternative mechanism for making bispecific antibody fragments. The fragments comprise a heavy-chain variable domain (VH) connected to a light-chain variable domain (VL) by a linker which is too short to allow pairing between the two domains on the same chain. Accordingly, the VH and VL domains of one fragment are forced to pair with the complementary VL and VH domains of another fragment, thereby forming two antigen-binding sites. Another strategy for making bispecific antibody fragments by the use of single-chain Fv (sFv) dimers has also been reported. See, Gruber et al., J. Immunol. 152:5368 (1994).

[0186] Antibodies with more than two valencies are contemplated. For example, trispecific antibodies can be prepared. Tutt et al., J. Immunol. 147:60 (1991).

[0187] Exemplary bispecific antibodies can bind to two different epitopes, at least one of which originates in the protein antigen of the invention. Alternatively, an anti-antigenic arm of an immunoglobulin molecule can be combined with an arm which binds to a triggering molecule on a leukocyte such as a T-cell receptor molecule (e.g. CD2, CD3, CD28, or B7), or Fc receptors for IgG (FcγR), such as FcγRI (CD64), FcγRII (CD32) and FcγRIII (CD16) so as to focus cellular defense mechanisms to the cell expressing the particular antigen. Bispecific antibodies can also be used to direct cytotoxic agents to cells which express a particular antigen. These antibodies possess an antigen-binding arm and an arm which binds a cytotoxic agent or a radionuclide chelator, such as EOTUBE, DPTA, DOTA, or TETA. Another bispecific antibody of interest binds the protein antigen described herein and further binds tissue factor (TF).

[0188] Heteroconjugate Antibodies

[0189] Heteroconjugate antibodies are also within the scope of the present invention. Heteroconjugate antibodies are composed of two covalently joined antibodies. Such antibodies have, for example, been proposed to target immune system cells to unwanted cells (U.S. Pat. No. 4,676,980), and for treatment of HIV infection (WO 91/00360; WO 92/200373; EP 03089). It is contemplated that the antibodies can be prepared in vitro using known methods in synthetic protein chemistry, including those involving crosslinking agents. For example, immunotoxins can be constructed using a disulfide exchange reaction or by forming a thioether bond. Examples of suitable reagents for this purpose include iminothiolate and methyl-4-mercaptobutyrimidate and those disclosed, for example, in U.S. Pat. No. 4,676,980.

[0190] Effector Function Engineering

[0191] It can be desirable to modify the antibody of the invention with respect to effector function, so as to enhance, e.g., the effectiveness of the antibody in treating cancer. For example, cysteine residue(s) can be introduced into the Fc region, thereby allowing interchain disulfide bond formation in this region. The homodimeric antibody thus generated can have improved internalization capability and/or increased complement-mediated cell killing and antibody-dependent cellular cytotoxicity (ADCC). See Caron et al., J. Exp Med., 176: 1191-1195 (1992) and Shopes, J. Immunol., 148: 2918-2922 (1992). Homodimeric antibodies with enhanced anti-tumor activity can also be prepared using heterobifunctional cross-linkers as described in Wolff et al. Cancer Research, 53: 2560-2565 (1993). Alternatively, an antibody can be engineered that has dual Fc regions and can thereby have enhanced complement lysis and ADCC capabilities. See Stevenson et al., Anti-Cancer Drug Design, 3: 219-230 (1989).

[0192] Immunoconjugates

[0193] The invention also pertains to immunoconjugates comprising an antibody conjugated to a cytotoxic agent such as a chemotherapeutic agent, toxin (e.g., an enzymatically active toxin of bacterial, fungal, plant, or animal origin, or fragments thereof), or a radioactive isotope (i.e., a radioconjugate).

[0194] Chemotherapeutic agents useful in the generation of such immunoconjugates have been described above. Enzymatically active toxins and fragments thereof that can be used include diphtheria A chain, nonbinding active fragments of diphtheria toxin, exotoxin A chain (from Pseudomonas aeruginosa), ricin A chain, abrin A chain, modeccin A chain, alpha-sarcin, Aleurites fordii proteins, dianthin proteins, Phytolaca americana proteins (PAPI, PAPII, and PAP-S), momordica charantia inhibitor, curcin, crotin, sapaonaria officinalis inhibitor, gelonin, mitogellin, restrictocin, phenomycin, enomycin, and the tricothecenes. A variety of radionuclides are available for the production of radioconjugated antibodies. Examples include 212Bi, 131I, 131In, 90Y, and 186Re.

[0195] Conjugates of the antibody and cytotoxic agent are made using a variety of bifunctional protein-coupling agents such as N-succinimidyl-3-(2-pyridyldithiol) propionate (SPDP), iminothiolane (IT), bifunctional derivatives of imidoesters (such as dimethyl adipimidate HCL), active esters (such as disuccinimidyl suberate), aldehydes (such as glutareldehyde), bis-azido compounds (such as bis (p-azidobenzoyl) hexanediamine), bis-diazonium derivatives (such as bis-(p-diazoniumbenzoyl)-ethylenediamine), diisocyanates (such as tolyene 2,6-diisocyanate), and bis-active fluorine compounds (such as 1,5-difluoro-2,4-dinitrobenzene). For example, a ricin immunotoxin can be prepared as described in Vitetta et al., Science, 238: 1098 (1987). Carbon-14-labeled 1-isothiocyanatobenzyl-3-methyldiethylene triaminepentaacetic acid (MX-DTPA) is an exemplary chelating agent for conjugation of radionucleotide to the antibody. See WO94/11026.

[0196] In another embodiment, the antibody can be conjugated to a “receptor” (such streptavidin) for utilization in tumor pretargeting wherein the antibody-receptor conjugate is administered to the patient, followed by removal of unbound conjugate from the circulation using a clearing agent and then administration of a “ligand” (e.g., avidin) that is in turn conjugated to a cytotoxic agent.

[0197] Immunoliposomes

[0198] The antibodies disclosed herein can also be formulated as immunoliposomes. Liposomes containing the antibody are prepared by methods known in the art, such as described in Epstein et al., Proc. Natl. Acad. Sci. USA, 82: 3688 (1985); Hwang et al., Proc. Natl Acad. Sci. USA, 77: 4030 (1980); and U.S. Pat. Nos. 4,485,045 and 4,544,545. Liposomes with enhanced circulation time are disclosed in U.S. Pat. No. 5,013,556.

[0199] Particularly useful liposomes can be generated by the reverse-phase evaporation method with a lipid composition comprising phosphatidylcholine, cholesterol, and PEG-derivatized phosphatidylethanolamine (PEG-PE). Liposomes are extruded through filters of defined pore size to yield liposomes with the desired diameter. Fab′ fragments of the antibody of the present invention can be conjugated to the liposomes as described in Martin et al ., J. Biol. Chem., 257: 286-288 (1982) via a disulfide-interchange reaction. A chemotherapeutic agent (such as Doxorubicin) is optionally contained within the liposome. See Gabizon et al., J. National Cancer Inst., 81(19): 1484 (1989).

[0200] Diagnostic Applications of Antibodies Directed Against the Proteins of the Invention

[0201] In one embodiment, methods for the screening of antibodies that possess the desired specificity include, but are not limited to, enzyme linked immunosorbent assay (ELISA) and other immunologically mediated techniques known within the art. In a specific embodiment, selection of antibodies that are specific to a particular domain of an NOVX protein is facilitated by generation of hybridomas that bind to the fragment of an NOVX protein possessing such a domain. Thus, antibodies that are specific for a desired domain within an NOVX protein, or derivatives, fragments, analogs or homologs thereof, are also provided herein.

[0202] Antibodies directed against a NOVX protein of the invention may be used in methods known within the art relating to the localization and/or quantitation of a NOVX protein (e.g., for use in measuring levels of the NOVX protein within appropriate physiological samples, for use in diagnostic methods, for use in imaging the protein, and the like). In a given embodiment, antibodies specific to a NOVX protein, or derivative, fragment, analog or homolog thereof, that contain the antibody derived antigen binding domain, are utilized as pharmacologically active compounds (referred to hereinafter as “Therapeutics”).

[0203] An antibody specific for a NOVX protein of the invention (e.g., a monoclonal antibody or a polyclonal antibody) can be used to isolate a NOVX polypeptide by standard techniques, such as immunoaffinity, chromatography or immunoprecipitation. An antibody to a NOVX polypeptide can facilitate the purification of a natural NOVX antigen from cells, or of a recombinantly produced NOVX antigen expressed in host cells. Moreover, such an anti-NOVX antibody can be used to detect the antigenic NOVX protein (e.g., in a cellular lysate or cell supernatant) in order to evaluate the abundance and pattern of expression of the antigenic NOVX protein. Antibodies directed against a NOVX protein can be used diagnostically to monitor protein levels in tissue as part of a clinical testing procedure, e.g., to, for example, determine the efficacy of a given treatment regimen. Detection can be facilitated by coupling (i.e., physically linking) the antibody to a detectable substance. Examples of detectable substances include various enzymes, prosthetic groups, fluorescent materials, luminescent materials, bioluminescent materials, and radioactive materials. Examples of suitable enzymes include horseradish peroxidase, alkaline phosphatase, β-galactosidase, or acetylcholinesterase; examples of suitable prosthetic group complexes include streptavidin/biotin and avidin/biotin; examples of suitable fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin; an example of a luminescent material includes luminol; examples of bioluminescent materials include luciferase, luciferin, and aequorin, and examples of suitable radioactive material include 125I, 131I, 35S or 3H.

[0204] Antibody Therapeutics

[0205] Antibodies of the invention, including polyclonal, monoclonal, humanized and fully human antibodies, may used as therapeutic agents. Such agents will generally be employed to treat or prevent a disease or pathology in a subject. An antibody preparation, preferably one having high specificity and high affinity for its target antigen, is administered to the subject and will generally have an effect due to its binding with the target. Such an effect may be one of two kinds, depending on the specific nature of the interaction between the given antibody molecule and the target antigen in question. In the first instance, administration of the antibody may abrogate or inhibit the binding of the target with an endogenous ligand to which it naturally binds. In this case, the antibody binds to the target and masks a binding site of the naturally occurring ligand, wherein the ligand serves as an effector molecule. Thus the receptor mediates a signal transduction pathway for which ligand is responsible.

[0206] Alternatively, the effect may be one in which the antibody elicits a physiological result by virtue of binding to an effector binding site on the target molecule. In this case the target, a receptor having an endogenous ligand which may be absent or defective in the disease or pathology, binds the antibody as a surrogate effector ligand, initiating a receptor-based signal transduction event by the receptor.

[0207] A therapeutically effective amount of an antibody of the invention relates generally to the amount needed to achieve a therapeutic objective. As noted above, this may be a binding interaction between the antibody and its target antigen that, in certain cases, interferes with the functioning of the target, and in other cases, promotes a physiological response. The amount required to be administered will furthermore depend on the binding affinity of the antibody for its specific antigen, and will also depend on the rate at which an administered antibody is depleted from the free volume other subject to which it is administered. Common ranges for therapeutically effective dosing of an antibody or antibody fragment of the invention may be, by way of nonlimiting example, from about 0.1 mg/kg body weight to about 50 mg/kg body weight. Common dosing frequencies may range, for example, from twice daily to once a week.

[0208] Pharmaceutical Compositions of Antibodies

[0209] Antibodies specifically binding a protein of the invention, as well as other molecules identified by the screening assays disclosed herein, can be administered for the treatment of various disorders in the form of pharmaceutical compositions. Principles and considerations involved in preparing such compositions, as well as guidance in the choice of components are provided, for example, in Remington: The Science And Practice Of Pharmacy 19th ed. (Alfonso R. Gennaro, et al., editors) Mack Pub. Co., Easton, Pa.: 1995; Drug Absorption Enhancement: Concepts, Possibilities, Limitations, And Trends, Harwood Academic Publishers, Langhorne, Pa., 1994; and Peptide And Protein Drug Delivery (Advances In Parenteral Sciences, Vol. 4), 1991, M. Dekker, New York.

[0210] If the antigenic protein is intracellular and whole antibodies are used as inhibitors, internalizing antibodies are preferred. However, liposomes can also be used to deliver the antibody, or an antibody fragment, into cells. Where antibody fragments are used, the smallest inhibitory fragment that specifically binds to the binding domain of the target protein is preferred. For example, based upon the variable-region sequences of an antibody, peptide molecules can be designed that retain the ability to bind the target protein sequence. Such peptides can be synthesized chemically and/or produced by recombinant DNA technology. See, e.g., Marasco et al., Proc. Natl. Acad. Sci. USA, 90: 7889-7893 (1993). The formulation herein can also contain more than one active compound as necessary for the particular indication being treated, preferably those with complementary activities that do not adversely affect each other. Alternatively, or in addition, the composition can comprise an agent that enhances its function, such as, for example, a cytotoxic agent, cytokine, chemotherapeutic agent, or growth-inhibitory agent. Such molecules are suitably present in combination in amounts that are effective for the purpose intended.

[0211] The active ingredients can also be entrapped in microcapsules prepared, for example, by coacervation techniques or by interfacial polymerization, for example, hydroxymethylcellulose or gelatin-microcapsules and poly-(methylmethacrylate) microcapsules, respectively, in colloidal drug delivery systems (for example, liposomes, albumin microspheres, microemulsions, nano-particles, and nanocapsules) or in macroemulsions.

[0212] The formulations to be used for in vivo administration must be sterile. This is readily accomplished by filtration through sterile filtration membranes.

[0213] Sustained-release preparations can be prepared. Suitable examples of sustained-release preparations include semipermeable matrices of solid hydrophobic polymers containing the antibody, which matrices are in the form of shaped articles, e.g., films, or microcapsules. Examples of sustained-release matrices include polyesters, hydrogels (for example, poly(2-hydroxyethyl-methacrylate), or poly(vinylalcohol)), polylactides (U.S. Pat. No. 3,773,919), copolymers of L-glutamic acid and γ ethyl-L-glutamate, non-degradable ethylene-vinyl acetate, degradable lactic acid-glycolic acid copolymers such as the LUPRON DEPOT ™ (injectable microspheres composed of lactic acid-glycolic acid copolymer and leuprolide acetate), and poly-D-(−)-3-hydroxybutyric acid. While polymers such as ethylene-vinyl acetate and lactic acid-glycolic acid enable release of molecules for over 100 days, certain hydrogels release proteins for shorter time periods.

[0214] ELISA Assay

[0215] An agent for detecting an analyte protein is an antibody capable of binding to an analyte protein, preferably an antibody with a detectable label. Antibodies can be polyclonal, or more preferably, monoclonal. An intact antibody, or a fragment thereof (e.g., Fab or F(ab)2) can be used. The term “labeled”, with regard to the probe or antibody, is intended to encompass direct labeling of the probe or antibody by coupling (i.e., physically linking) a detectable substance to the probe or antibody, as well as indirect labeling of the probe or antibody by reactivity with another reagent that is directly labeled. Examples of indirect labeling include detection of a primary antibody using a fluorescently-labeled secondary antibody and end-labeling of a DNA probe with biotin such that it can be detected with fluorescently-labeled streptavidin. The term “biological sample” is intended to include tissues, cells and biological fluids isolated from a subject, as well as tissues, cells and fluids present within a subject. Included within the usage of the term “biological sample”, therefore, is blood and a fraction or component of blood including blood serum, blood plasma, or lymph. That is, the detection method of the invention can be used to detect an analyte mRNA, protein, or genomic DNA in a biological sample in vitro as well as in vivo. For example, in vitro techniques for detection of an analyte mRNA include Northern hybridizations and in situ hybridizations. In vitro techniques for detection of an analyte protein include enzyme linked immunosorbent assays (ELISAs), Western blots, immunoprecipitations, and immunofluorescence. In vitro techniques for detection of an analyte genomic DNA include Southern hybridizations. Procedures for conducting immunoassays are described, for example in “ELISA: Theory and Practice: Methods in Molecular Biology”, Vol. 42, J. R. Crowther (Ed.) Human Press, Totowa, N.J., 1995; “Immunoassay”, E. Diamandis and T. Christopoulus, Academic Press, Inc., San Diego, Calif., 1996; and “Practice and Thory of Enzyme Immunoassays”, P. Tijssen, Elsevier Science Publishers, Amsterdam, 1985. Furthermore, in vivo techniques for detection of an analyte protein include introducing into a subject a labeled anti-an analyte protein antibody. For example, the antibody can be labeled with a radioactive marker whose presence and location in a subject can be detected by standard imaging techniques.

[0216] NOVX Recombinant Expression Vectors and Host Cells

[0217] Another aspect of the invention pertains to vectors, preferably expression vectors, containing a nucleic acid encoding a NOVX protein, or derivatives, fragments, analogs or homologs thereof. As used herein, the term “vector” refers to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked. One type of vector is a “plasmid”, which refers to a circular double stranded DNA loop into which additional DNA segments can be ligated. Another type of vector is a viral vector, wherein additional DNA segments can be ligated into the viral genome. Certain vectors are capable of autonomous replication in a host cell into which they are introduced (e.g., bacterial vectors having a bacterial origin of replication and episomal mammalian vectors). Other vectors (e.g., non-episomal mammalian vectors) are integrated into the genome of a host cell upon introduction into the host cell, and thereby are replicated along with the host genome. Moreover, certain vectors are capable of directing the expression of genes to which they are operatively-linked. Such vectors are referred to herein as “expression vectors”. In general, expression vectors of utility in recombinant DNA techniques are often in the form of plasmids. In the present specification, “plasmid” and “vector” can be used interchangeably as the plasmid is the most commonly used form of vector. However, the invention is intended to include such other forms of expression vectors, such as viral vectors (e.g., replication defective retroviruses, adenoviruses and adeno-associated viruses), which serve equivalent functions.

[0218] The recombinant expression vectors of the invention comprise a nucleic acid of the invention in a form suitable for expression of the nucleic acid in a host cell, which means that the recombinant expression vectors include one or more regulatory sequences, selected on the basis of the host cells to be used for expression, that is operatively-linked to the nucleic acid sequence to be expressed. Within a recombinant expression vector, “operably-linked” is intended to mean that the nucleotide sequence of interest is linked to the regulatory sequence(s) in a manner that allows for expression of the nucleotide sequence (e.g., in an in vitro transcription/translation system or in a host cell when the vector is introduced into the host cell).

[0219] The term “regulatory sequence” is intended to includes promoters, enhancers and other expression control elements (e.g., polyadenylation signals). Such regulatory sequences are described, for example, in Goeddel, GENE EXPRESSION TECHNOLOGY: METHODS IN ENZYMOLOGY 185, Academic Press, San Diego, Calif. (1990). Regulatory sequences include those that direct constitutive expression of a nucleotide sequence in many types of host cell and those that direct expression of the nucleotide sequence only in certain host cells (e.g., tissue-specific regulatory sequences). It will be appreciated by those skilled in the art that the design of the expression vector can depend on such factors as the choice of the host cell to be transformed, the level of expression of protein desired, etc. The expression vectors of the invention can be introduced into host cells to thereby produce proteins or peptides, including fusion proteins or peptides, encoded by nucleic acids as described herein (e.g., NOVX proteins, mutant forms of NOVX proteins, fusion proteins, etc.).

[0220] The recombinant expression vectors of the invention can be designed for expression of NOVX proteins in prokaryotic or eukaryotic cells. For example, NOVX proteins can be expressed in bacterial cells such as Escherichia coli, insect cells (using baculovirus expression vectors) yeast cells or mammalian cells. Suitable host cells are discussed further in Goeddel, GENE EXPRESSION TECHNOLOGY: METHODS IN ENZYMOLOGY 185, Academic Press, San Diego, Calif. (1990). Alternatively, the recombinant expression vector can be transcribed and translated in vitro, for example using T7 promoter regulatory sequences and T7 polymerase.

[0221] Expression of proteins in prokaryotes is most often carried out in Escherichia coli with vectors containing constitutive or inducible promoters directing the expression of either fusion or non-fusion proteins. Fusion vectors add a number of amino acids to a protein encoded therein, usually to the amino terminus of the recombinant protein. Such fusion vectors typically serve three purposes: (i) to increase expression of recombinant protein; (ii) to increase the solubility of the recombinant protein; and (iii) to aid in the purification of the recombinant protein by acting as a ligand in affinity purification. Often, in fusion expression vectors, a proteolytic cleavage site is introduced at the junction of the fusion moiety and the recombinant protein to enable separation of the recombinant protein from the fusion moiety subsequent to purification of the fusion protein. Such enzymes, and their cognate recognition sequences, include Factor Xa, thrombin and enterokinase. Typical fusion expression vectors include pGEX (Pharmacia Biotech Inc; Smith and Johnson, 1988. Gene 67: 31-40), pMAL (New England Biolabs, Beverly, Mass.) and pRIT5 (Pharmacia, Piscataway, N.J.) that fuse glutathione S-transferase (GST), maltose E binding protein, or protein A, respectively, to the target recombinant protein.

[0222] Examples of suitable inducible non-fusion E. coli expression vectors include pTrc (Amrann et al., (1988) Gene 69:301-315) and pET 1 id (Studier et al., GENE EXPRESSION TECHNOLOGY: METHODS IN ENZYMOLOGY 185, Academic Press, San Diego, Calif. (1990) 60-89).

[0223] One strategy to maximize recombinant protein expression in E. coli is to express the protein in a host bacteria with an impaired capacity to proteolytically cleave the recombinant protein. See, e.g., Gottesman, GENE EXPRESSION TECHNOLOGY: METHODS IN ENZYMOLOGY 185, Academic Press, San Diego, Calif. (1990) 119-128. Another strategy is to alter the nucleic acid sequence of the nucleic acid to be inserted into an expression vector so that the individual codons for each amino acid are those preferentially utilized in E. coli (see, e.g., Wada, et al., 1992. Nucl. Acids Res. 20: 2111-2118). Such alteration of nucleic acid sequences of the invention can be carried out by standard DNA synthesis techniques.

[0224] In another embodiment, the NOVX expression vector is a yeast expression vector. Examples of vectors for expression in yeast Saccharomyces cerivisae include pYepSec 1 (Baldari, et al., 1987. EMBO J. 6: 229-234), pMFa (Kurjan and Herskowitz, 1982. Cell 30: 933-943), pJRY88 (Schultz et al., 1987. Gene 54: 113-123), pYES2 (Invitrogen Corporation, San Diego, Calif.), and picZ (InVitrogen Corp, San Diego, Calif.).

[0225] Alternatively, NOVX can be expressed in insect cells using baculovirus expression vectors. Baculovirus vectors available for expression of proteins in cultured insect cells (e.g., SF9 cells) include the pAc series (Smith, et al., 1983. Mol. Cell. Biol. 3: 2156-2165) and the pVL series (Lucklow and Summers, 1989. Virology 170: 31-39).

[0226] In yet another embodiment, a nucleic acid of the invention is expressed in mammalian cells using a mammalian expression vector. Examples of mammalian expression vectors include pCDM8 (Seed, 1987. Nature 329: 840) and pMT2PC (Kaufman, et al., 1987. EMBO J. 6: 187-195). When used in mammalian cells, the expression vector's control functions are often provided by viral regulatory elements. For example, commonly used promoters are derived from polyoma, adenovirus 2, cytomegalovirus, and simian virus 40. For other suitable expression systems for both prokaryotic and eukaryotic cells see, e.g., Chapters 16 and 17 of Sambrook, et al., MOLECULAR CLONING: A LABORATORY MANUAL. 2nd ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989.

[0227] In another embodiment, the recombinant mammalian expression vector is capable of directing expression of the nucleic acid preferentially in a particular cell type (e.g., tissue-specific regulatory elements are used to express the nucleic acid). Tissue-specific regulatory elements are known in the art. Non-limiting examples of suitable tissue-specific promoters include the albumin promoter (liver-specific; Pinkert, et al., 1987. Genes Dev. 1: 268-277), lymphoid-specific promoters (Calame and Eaton, 1988. Adv. Immunol. 43: 235-275), in particular promoters of T cell receptors (Winoto and Baltimore, 1989. EMBO J. 8: 729-733) and immunoglobulins (Banerji, et al., 1983. Cell 33: 729-740; Queen and Baltimore, 1983. Cell 33: 741-748), neuron-specific promoters (e.g., the neurofilament promoter; Byrne and Ruddle, 1989. Proc. Natl. Acad. Sci. USA 86: 5473-5477), pancreas-specific promoters (Edlund, et al., 1985. Science 230: 912-916), and mammary gland-specific promoters (e.g., milk whey promoter; U.S. Pat. No. 4,873,316 and European Application Publication No. 264,166). Developmentally-regulated promoters are also encompassed, e.g., the murine hox promoters (Kessel and Gruss, 1990. Science 249: 374-379) and the α-fetoprotein promoter (Campes and Tilghman, 1989. Genes Dev. 3: 537-546).

[0228] The invention further provides a recombinant expression vector comprising a DNA molecule of the invention cloned into the expression vector in an antisense orientation. That is, the DNA molecule is operatively-linked to a regulatory sequence in a manner that allows for expression (by transcription of the DNA molecule) of an RNA molecule that is antisense to NOVX mRNA. Regulatory sequences operatively linked to a nucleic acid cloned in the antisense orientation can be chosen that direct the continuous expression of the antisense RNA molecule in a variety of cell types, for instance viral promoters and/or enhancers, or regulatory sequences can be chosen that direct constitutive, tissue specific or cell type specific expression of antisense RNA. The antisense expression vector can be in the form of a recombinant plasmid, phagemid or attenuated virus in which antisense nucleic acids are produced under the control of a high efficiency regulatory region, the activity of which can be determined by the cell type into which the vector is introduced. For a discussion of the regulation of gene expression using antisense genes see, e.g., Weintraub, et al., “Antisense RNA as a molecular tool for genetic analysis,” Reviews-Trends in Genetics, Vol. 1(1) 1986.

[0229] Another aspect of the invention pertains to host cells into which a recombinant expression vector of the invention has been introduced. The terms “host cell” and “recombinant host cell” are used interchangeably herein. It is understood that such terms refer not only to the particular subject cell but also to the progeny or potential progeny of such a cell. Because certain modifications may occur in succeeding generations due to either mutation or environmental influences, such progeny may not, in fact, be identical to the parent cell, but are still included within the scope of the term as used herein.

[0230] A host cell can be any prokaryotic or eukaryotic cell. For example, NOVX protein can be expressed in bacterial cells such as E. coli, insect cells, yeast or mammalian cells (such as Chinese hamster ovary cells (CHO) or COS cells). Other suitable host cells are known to those skilled in the art.

[0231] Vector DNA can be introduced into prokaryotic or eukaryotic cells via conventional transformation or transfection techniques. As used herein, the terms “transformation” and “transfection” are intended to refer to a variety of art-recognized techniques for introducing foreign nucleic acid (e.g., DNA) into a host cell, including calcium phosphate or calcium chloride co-precipitation, DEAE-dextran-mediated transfection, lipofection, or electroporation. Suitable methods for transforming or transfecting host cells can be found in Sambrook, et al. (MOLECULAR CLONING: A LABORATORY MANUAL. 2nd ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989), and other laboratory manuals.

[0232] For stable transfection of mammalian cells, it is known that, depending upon the expression vector and transfection technique used, only a small fraction of cells may integrate the foreign DNA into their genome. In order to identify and select these integrants, a gene that encodes a selectable marker (e.g., resistance to antibiotics) is generally introduced into the host cells along with the gene of interest. Various selectable markers include those that confer resistance to drugs, such as G418, hygromycin and methotrexate. Nucleic acid encoding a selectable marker can be introduced into a host cell on the same vector as that encoding NOVX or can be introduced on a separate vector. Cells stably transfected with the introduced nucleic acid can be identified by drug selection (e.g., cells that have incorporated the selectable marker gene will survive, while the other cells die).

[0233] A host cell of the invention, such as a prokaryotic or eukaryotic host cell in culture, can be used to produce (i.e., express) NOVX protein. Accordingly, the invention further provides methods for producing NOVX protein using the host cells of the invention. In one embodiment, the method comprises culturing the host cell of invention (into which a recombinant expression vector encoding NOVX protein has been introduced) in a suitable medium such that NOVX protein is produced. In another embodiment, the method further comprises isolating NOVX protein from the medium or the host cell.

[0234] Transgenic NOVX Animals

[0235] The host cells of the invention can also be used to produce non-human transgenic animals. For example, in one embodiment, a host cell of the invention is a fertilized oocyte or an embryonic stem cell into which NOVX protein-coding sequences have been introduced. Such host cells can then be used to create non-human transgenic animals in which exogenous NOVX sequences have been introduced into their genome or homologous recombinant animals in which endogenous NOVX sequences have been altered. Such animals are useful for studying the function and/or activity of NOVX protein and for identifying and/or evaluating modulators of NOVX protein activity. As used herein, a “transgenic animal” is a non-human animal, preferably a mammal, more preferably a rodent such as a rat or mouse, in which one or more of the cells of the animal includes a transgene. Other examples of transgenic animals include non-human primates, sheep, dogs, cows, goats, chickens, amphibians, etc. A transgene is exogenous DNA that is integrated into the genome of a cell from which a transgenic animal develops and that remains in the genome of the mature animal, thereby directing the expression of an encoded gene product in one or more cell types or tissues of the transgenic animal. As used herein, a “homologous recombinant animal” is a non-human animal, preferably a mammal, more preferably a mouse, in which an endogenous NOVX gene has been altered by homologous recombination between the endogenous gene and an exogenous DNA molecule introduced into a cell of the animal, e.g., an embryonic cell of the animal, prior to development of the animal.

[0236] A transgenic animal of the invention can be created by introducing NOVX-encoding nucleic acid into the male pronuclei of a fertilized oocyte (e.g., by microinjection, retroviral infection) and allowing the oocyte to develop in a pseudopregnant female foster animal. The human NOVX cDNA sequences, i.e., any one of SEQ ID NO:2n−1, wherein n is an integer between 1 and 226, can be introduced as a transgene into the genome of a non-human animal. Alternatively, a non-human homologue of the human NOVX gene, such as a mouse NOVX gene, can be isolated based on hybridization to the human NOVX cDNA (described further supra) and used as a transgene. Intronic sequences and polyadenylation signals can also be included in the transgene to increase the efficiency of expression of the transgene. A tissue-specific regulatory sequence(s) can be operably-linked to the NOVX transgene to direct expression of NOVX protein to particular cells. Methods for generating transgenic animals via embryo manipulation and microinjection, particularly animals such as mice, have become conventional in the art and are described, for example, in U.S. Pat. Nos. 4,736,866; 4,870,009; and 4,873,191; and Hogan, 1986. In: MANIPULATING THE MOUSE EMBRYO, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. Similar methods are used for production of other transgenic animals. A transgenic founder animal can be identified based upon the presence of the NOVX transgene in its genome and/or expression of NOVX mRNA in tissues or cells of the animals. A transgenic founder animal can then be used to breed additional animals carrying the transgene. Moreover, transgenic animals carrying a transgene-encoding NOVX protein can further be bred to other transgenic animals carrying other transgenes.

[0237] To create a homologous recombinant animal, a vector is prepared which contains at least a portion of a NOVX gene into which a deletion, addition or substitution has been introduced to thereby alter, e.g., functionally disrupt, the NOVX gene. The NOVX gene can be a human gene (e.g., the cDNA of any one of SEQ ID NO:2n−1, wherein n is an integer between 1 and 226), but more preferably, is a non-human homologue of a human NOVX gene. For example, a mouse homologue of human NOVX gene of SEQ ID NO:2n−1, wherein n is an integer between 1 and 226, can be used to construct a homologous recombination vector suitable for altering an endogenous NOVX gene in the mouse genome. In one embodiment, the vector is designed such that, upon homologous recombination, the endogenous NOVX gene is functionally disrupted (i.e., no longer encodes a functional protein; also referred to as a “knock out” vector).

[0238] Alternatively, the vector can be designed such that, upon homologous recombination, the endogenous NOVX gene is mutated or otherwise altered but still encodes functional protein (e.g., the upstream regulatory region can be altered to thereby alter the expression of the endogenous NOVX protein). In the homologous recombination vector, the altered portion of the NOVX gene is flanked at its 5′- and 3′-termini by additional nucleic acid of the NOVX gene to allow for homologous recombination to occur between the exogenous NOVX gene carried by the vector and an endogenous NOVX gene in an embryonic stem cell. The additional flanking NOVX nucleic acid is of sufficient length for successful homologous recombination with the endogenous gene. Typically, several kilobases of flanking DNA (both at the 5′- and 3′-termini) are included in the vector. See, e.g., Thomas, et al., 1987. Cell 51: 503 for a description of homologous recombination vectors. The vector is ten introduced into an embryonic stem cell line (e.g., by electroporation) and cells in which the introduced NOVX gene has homologously-recombined with the endogenous NOVX gene are selected. See, e.g., Li, et al., 1992. Cell 69: 915.

[0239] The selected cells are then injected into a blastocyst of an animal (e.g., a mouse) to form aggregation chimeras. See, e.g., Bradley, 1987. In: TERATOCARCINOMAS AND EMBRYONIC STEM CELLS: A PRACTICAL APPROACH, Robertson, ed. IRL, Oxford, pp. 113-152. A chimeric embryo can then be implanted into a suitable pseudopregnant female foster animal and the embryo brought to term. Progeny harboring the homologously-recombined DNA in their germ cells can be used to breed animals in which all cells of the animal contain the homologously-recombined DNA by germline transmission of the transgene. Methods for constructing homologous recombination vectors and homologous recombinant animals are described further in Bradley, 1991. Curr. Opin. Biotechnol. 2: 823-829; PCT International Publication Nos.: WO 90/11354; WO 91/01140; WO 92/0968; and WO 93/04169.

[0240] In another embodiment, transgenic non-humans animals can be produced that contain selected systems that allow for regulated expression of the transgene. One example of such a system is the cre/loxP recombinase system of bacteriophage P1. For a description of the cre/loxP recombinase system, See, e.g., Lakso, et al., 1992. Proc. Natl. Acad. Sci. USA 89: 6232-6236. Another example of a recombinase system is the FLP recombinase system of Saccharomyces cerevisiae. See, O'Gorman, et al., 1991. Science 251:1351-1355. If a cre/loxP recombinase system is used to regulate expression of the transgene, animals containing transgenes encoding both the Cre recombinase and a selected protein are required. Such animals can be provided through the construction of “double” transgenic animals, e.g., by mating two transgenic animals, one containing a transgene encoding a selected protein and the other containing a transgene encoding a recombinase.

[0241] Clones of the non-human transgenic animals described herein can also be produced according to the methods described in Wilmut, et al., 1997. Nature 385: 810-813. In brief, a cell (e.g., a somatic cell) from the transgenic animal can be isolated and induced to exit the growth cycle and enter G0 phase. The quiescent cell can then be fused, e.g., through the use of electrical pulses, to an enucleated oocyte from an animal of the same species from which the quiescent cell is isolated. The reconstructed oocyte is then cultured such that it develops to morula or blastocyte and then transferred to pseudopregnant female foster animal. The offspring borne of this female foster animal will be a clone of the animal from which the cell (e.g., the somatic cell) is isolated.

[0242] Pharmaceutical Compositions

[0243] The NOVX nucleic acid molecules, NOVX proteins, and anti-NOVX antibodies (also referred to herein as “active compounds”) of the invention, and derivatives, fragments, analogs and homologs thereof, can be incorporated into pharmaceutical compositions suitable for administration. Such compositions typically comprise the nucleic acid molecule, protein, or antibody and a pharmaceutically acceptable carrier. As used herein, “pharmaceutically acceptable carrier” is intended to include any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, compatible with pharmaceutical administration. Suitable carriers are described in the most recent edition of Remington's Pharmaceutical Sciences, a standard reference text in the field, which is incorporated herein by reference. Preferred examples of such carriers or diluents include, but are not limited to, water, saline, finger's solutions, dextrose solution, and 5% human serum albumin. Liposomes and non-aqueous vehicles such as fixed oils may also be used. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active compound, use thereof in the compositions is contemplated. Supplementary active compounds can also be incorporated into the compositions.

[0244] A pharmaceutical composition of the invention is formulated to be compatible with its intended route of administration. Examples of routes of administration include parenteral, e.g., intravenous, intradermal, subcutaneous, oral (e.g., inhalation), transdermal (i.e., topical), transmucosal, and rectal administration. Solutions or suspensions used for parenteral, intradermal, or subcutaneous application can include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid (EDTA); buffers such as acetates, citrates or phosphates, and agents for the adjustment of tonicity such as sodium chloride or dextrose. The pH can be adjusted with acids or bases, such as hydrochloric acid or sodium hydroxide. The parenteral preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.

[0245] Pharmaceutical compositions suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion. For intravenous administration, suitable carriers include physiological saline, bacteriostatic water, Cremophor EL™ (BASF, Parsippany, N.J.) or phosphate buffered saline (PBS). In all cases, the composition must be sterile and should be fluid to the extent that easy syringeability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), and suitable mixtures thereof. The proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars, polyalcohols such as manitol, sorbitol, sodium chloride in the composition. Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent which delays absorption, for example, aluminum monostearate and gelatin.

[0246] Sterile injectable solutions can be prepared by incorporating the active compound (e.g., a NOVX protein or anti-NOVX antibody) in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the active compound into a sterile vehicle that contains a basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, methods of preparation are vacuum drying and freeze-drying that yields a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.

[0247] Oral compositions generally include an inert diluent or an edible carrier. They can be enclosed in gelatin capsules or compressed into tablets. For the purpose of oral therapeutic administration, the active compound can be incorporated with excipients and used in the form of tablets, troches, or capsules. Oral compositions can also be prepared using a fluid carrier for use as a mouthwash, wherein the compound in the fluid carrier is applied orally and swished and expectorated or swallowed. Pharmaceutically compatible binding agents, and/or adjuvant materials can be included as part of the composition. The tablets, pills, capsules, troches and the like can contain any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch; a lubricant such as magnesium stearate or Sterotes; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring.

[0248] For administration by inhalation, the compounds are delivered in the form of an aerosol spray from pressured container or dispenser which contains a suitable propellant, e.g., a gas such as carbon dioxide, or a nebulizer.

[0249] Systemic administration can also be by transmucosal or transdermal means. For transmucosal or transdermal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art, and include, for example, for transmucosal administration, detergents, bile salts, and fusidic acid derivatives. Transmucosal administration can be accomplished through the use of nasal sprays or suppositories. For transdermal administration, the active compounds are formulated into ointments, salves, gels, or creams as generally known in the art.

[0250] The compounds can also be prepared in the form of suppositories (e.g., with conventional suppository bases such as cocoa butter and other glycerides) or retention enemas for rectal delivery.

[0251] In one embodiment, the active compounds are prepared with carriers that will protect the compound against rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems. Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Methods for preparation of such formulations will be apparent to those skilled in the art. The materials can also be obtained commercially from Alza Corporation and Nova Pharmaceuticals, Inc. Liposomal suspensions (including liposomes targeted to infected cells with monoclonal antibodies to viral antigens) can also be used as pharmaceutically acceptable carriers. These can be prepared according to methods known to those skilled in the art, for example, as described in U.S. Pat. No. 4,522,811.

[0252] It is especially advantageous to formulate oral or parenteral compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used herein refers to physically discrete units suited as unitary dosages for the subject to be treated; each unit containing a predetermined quantity of active compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. The specification for the dosage unit forms of the invention are dictated by and directly dependent on the unique characteristics of the active compound and the particular therapeutic effect to be achieved, and the limitations inherent in the art of compounding such an active compound for the treatment of individuals.

[0253] The nucleic acid molecules of the invention can be inserted into vectors and used as gene therapy vectors. Gene therapy vectors can be delivered to a subject by, for example, intravenous injection, local administration (see, e.g., U.S. Pat. No. 5,328,470) or by stereotactic injection (see, e.g., Chen, et al., 1994. Proc. Natl. Acad. Sci. USA 91: 3054-3057). The pharmaceutical preparation of the gene therapy vector can include the gene therapy vector in an acceptable diluent, or can comprise a slow release matrix in which the gene delivery vehicle is imbedded. Alternatively, where the complete gene delivery vector can be produced intact from recombinant cells, e.g., retroviral vectors, the pharmaceutical preparation can include one or more cells that produce the gene delivery system.

[0254] The pharmaceutical compositions can be included in a container, pack, or dispenser together with instructions for administration.

[0255] Screening and Detection Methods

[0256] The isolated nucleic acid molecules of the invention can be used to express NOVX protein (e.g., via a recombinant expression vector in a host cell in gene therapy applications), to detect NOVX mRNA (e.g., in a biological sample) or a genetic lesion in a NOVX gene, and to modulate NOVX activity, as described further, below. In addition, the NOVX proteins can be used to screen drugs or compounds that modulate the NOVX protein activity or expression as well as to treat disorders characterized by insufficient or excessive production of NOVX protein or production of NOVX protein forms that have decreased or aberrant activity compared to NOVX wild-type protein (e.g.; diabetes (regulates insulin release); obesity (binds and transport lipids); metabolic disturbances associated with obesity, the metabolic syndrome X as well as anorexia and wasting disorders associated with chronic diseases and various cancers, and infectious disease(possesses anti microbial activity) and the various dyslipidemias. In addition, the anti-NOVX antibodies of the invention can be used to detect and isolate NOVX proteins and modulate NOVX activity. In yet a further aspect, the invention can be used in methods to influence appetite, absorption of nutrients and the disposition of metabolic substrates in both a positive and negative fashion.

[0257] The invention further pertains to novel agents identified by the screening assays described herein and uses thereof for treatments as described, supra.

[0258] Screening Assays

[0259] The invention provides a method (also referred to herein as a “screening assay”) for identifying modulators, i.e., candidate or test compounds or agents (e.g., peptides, peptidomimetics, small molecules or other drugs) that bind to NOVX proteins or have a stimulatory or inhibitory effect on, e.g. NOVX protein expression or NOVX protein activity. The invention also includes compounds identified in the screening assays described herein.

[0260] In one embodiment, the invention provides assays for screening candidate or test compounds which bind to or modulate the activity of the membrane-bound form of a NOVX protein or polypeptide or biologically-active portion thereof. The test compounds of the invention can be obtained using any of the numerous approaches in combinatorial library methods known in the art, including: biological libraries; spatially addressable parallel solid phase or solution phase libraries; synthetic library methods requiring deconvolution; the “one-bead one-compound” library method; and synthetic library methods using affinity chromatography selection. The biological library approach is limited to peptide libraries, while the other four approaches are applicable to peptide, non-peptide oligomer or small molecule libraries of compounds. See, e.g., Lam, 1997. Anticancer Drug Design 12: 145.

[0261] A “small molecule” as used herein, is meant to refer to a composition that has a molecular weight of less than about 5 kD and most preferably less than about 4 kD. Small molecules can be, e.g., nucleic acids, peptides, polypeptides, peptidomimetics, carbohydrates, lipids or other organic or inorganic molecules. Libraries of chemical and/or biological mixtures, such as fungal, bacterial, or algal extracts, are known in the art and can be screened with any of the assays of the invention.

[0262] Examples of methods for the synthesis of molecular libraries can be found in the art, for example in: DeWitt, et al., 1993. Proc. Natl. Acad. Sci. U.S.A. 90: 6909; Erb, et al., 1994. Proc. Natl. Acad. Sci. U.S.A. 91: 11422; Zuckermann, et al., 1994. J. Med. Chem. 37: 2678; Cho, et al., 1993. Science 261: 1303; Carrell, et al., 1994. Angew. Chem. Int. Ed. Engl. 33: 2059; Carell, et al., 1994. Angew. Chem. Int. Ed. Engl. 33: 2061; and Gallop, et al., 1994. J. Med. Chem. 37: 1233.

[0263] Libraries of compounds may be presented in solution (e.g., Houghten, 1992. Biotechniques 13: 412-421), or on beads (Lam, 1991. Nature 354: 82-84), on chips (Fodor, 1993. Nature 364: 555-556), bacteria (Ladner, U.S. Pat. No. 5,223,409), spores (Ladner, U.S. Pat. No. 5,233,409), plasmids (Cull, et al., 1992. Proc. Natl. Acad. Sci. USA 89: 1865-1869) or on phage (Scott and Smith, 1990. Science 249: 386-390; Devlin, 1990. Science 249: 404-406; Cwirla, et al., 1990. Proc. Natl. Acad. Sci. U.S.A. 87: 6378-6382; Felici, 1991. J. Mol. Biol. 222: 301-310; Ladner, U.S. Pat. No. 5,233,409.).

[0264] In one embodiment, an assay is a cell-based assay in which a cell which expresses a membrane-bound form of NOVX protein, or a biologically-active portion thereof, on the cell surface is contacted with a test compound and the ability of the test compound to bind to a NOVX protein determined. The cell, for example, can of mammalian origin or a yeast cell. Determining the ability of the test compound to bind to the NOVX protein can be accomplished, for example, by coupling the test compound with a radioisotope or enzymatic label such that binding of the test compound to the NOVX protein or biologically-active portion thereof can be determined by detecting the labeled compound in a complex. For example, test compounds can be labeled with 125I, 35S, 14C, or 3H, either directly or indirectly, and the radioisotope detected by direct counting of radioemission or by scintillation counting. Alternatively, test compounds can be enzymatically-labeled with, for example, horseradish peroxidase, alkaline phosphatase, or luciferase, and the enzymatic label detected by determination of conversion of an appropriate substrate to product. In one embodiment, the assay comprises contacting a cell which expresses a membrane-bound form of NOVX protein, or a biologically-active portion thereof, on the cell surface with a known compound which binds NOVX to form an assay mixture, contacting the assay mixture with a test compound, and determining the ability of the test compound to interact with a NOVX protein, wherein determining the ability of the test compound to interact with a NOVX protein comprises determining the ability of the test compound to preferentially bind to NOVX protein or a biologically-active portion thereof as compared to the known compound.

[0265] In another embodiment, an assay is a cell-based assay comprising contacting a cell expressing a membrane-bound form of NOVX protein, or a biologically-active portion thereof, on the cell surface with a test compound and determining the ability of the test compound to modulate (e.g., stimulate or inhibit) the activity of the NOVX protein or biologically-active portion thereof. Determining the ability of the test compound to modulate the activity of NOVX or a biologically-active portion thereof can be accomplished, for example, by determining the ability of the NOVX protein to bind to or interact with a NOVX target molecule. As used herein, a “target molecule” is a molecule with which a NOVX protein binds or interacts in nature, for example, a molecule on the surface of a cell which expresses a NOVX interacting protein, a molecule on the surface of a second cell, a molecule in the extracellular milieu, a molecule associated with the internal surface of a cell membrane or a cytoplasmic molecule. A NOVX target molecule can be a non-NOVX molecule or a NOVX protein or polypeptide of the invention. In one embodiment, a NOVX target molecule is a component of a signal transduction pathway that facilitates transduction of an extracellular signal (e.g. a signal generated by binding of a compound to a membrane-bound NOVX molecule) through the cell membrane and into the cell. The target, for example, can be a second intercellular protein that has catalytic activity or a protein that facilitates the association of downstream signaling molecules with NOVX.

[0266] Determining the ability of the NOVX protein to bind to or interact with a NOVX target molecule can be accomplished by one of the methods described above for determining direct binding. In one embodiment, determining the ability of the NOVX protein to bind to or interact with a NOVX target molecule can be accomplished by determining the activity of the target molecule. For example, the activity of the target molecule can be determined by detecting induction of a cellular second messenger of the target (i.e. intracellular Ca2+, diacylglycerol, IP3, etc.), detecting catalytic/enzymatic activity of the target an appropriate substrate, detecting the induction of a reporter gene (comprising a NOVX-responsive regulatory element operatively linked to a nucleic acid encoding a detectable marker, e.g., luciferase), or detecting a cellular response, for example, cell survival, cellular differentiation, or cell proliferation.

[0267] In yet another embodiment, an assay of the invention is a cell-free assay comprising contacting a NOVX protein or biologically-active portion thereof with a test compound and determining the ability of the test compound to bind to the NOVX protein or biologically-active portion thereof. Binding of the test compound to the NOVX protein can be determined either directly or indirectly as described above. In one such embodiment, the assay comprises contacting the NOVX protein or biologically-active portion thereof with a known compound which binds NOVX to form an assay mixture, contacting the assay mixture with a test compound, and determining the ability of the test compound to interact with a NOVX protein, wherein determining the ability of the test compound to interact with a NOVX protein comprises determining the ability of the test compound to preferentially bind to NOVX or biologically-active portion thereof as compared to the known compound.

[0268] In still another embodiment, an assay is a cell-free assay comprising contacting NOVX protein or biologically-active portion thereof with a test compound and determining the ability of the test compound to modulate (e.g. stimulate or inhibit) the activity of the NOVX protein or biologically-active portion thereof. Determining the ability of the test compound to modulate the activity of NOVX can be accomplished, for example, by determining the ability of the NOVX protein to bind to a NOVX target molecule by one of the methods described above for determining direct binding. In an alternative embodiment, determining the ability of the test compound to modulate the activity of NOVX protein can be accomplished by determining the ability of the NOVX protein further modulate a NOVX target molecule. For example, the catalytic/enzymatic activity of the target molecule on an appropriate substrate can be determined as described, supra.

[0269] In yet another embodiment, the cell-free assay comprises contacting the NOVX protein or biologically-active portion thereof with a known compound which binds NOVX protein to form an assay mixture, contacting the assay mixture with a test compound, and determining the ability of the test compound to interact with a NOVX protein, wherein determining the ability of the test compound to interact with a NOVX protein comprises determining the ability of the NOVX protein to preferentially bind to or modulate the activity of a NOVX target molecule.

[0270] The cell-free assays of the invention are amenable to use of both the soluble form or the membrane-bound form of NOVX protein. In the case of cell-free assays comprising the membrane-bound form of NOVX protein, it may be desirable to utilize a solubilizing agent such that the membrane-bound form of NOVX protein is maintained in solution. Examples of such solubilizing agents include non-ionic detergents such as n-octylglucoside, n-dodecylglucoside, n-dodecylmaltoside, octanoyl-N-methylglucamide, decanoyl-N-methylglucamide, Triton® X-100, Triton® X-114, Thesit®, Isotridecypoly(ethylene glycol ether)n, N-dodecyl--N,N-dimethyl-3-ammonio-1-propane sulfonate, 3-(3-cholamidopropyl) dimethylamminiol-1-propane sulfonate (CHAPS), or 3-(3-cholamidopropyl)dimethylamminiol-2-hydroxy-1-propane sulfonate (CHAPSO).

[0271] In more than one embodiment of the above assay methods of the invention, it may be desirable to immobilize either NOVX protein or its target molecule to facilitate separation of complexed from uncomplexed forms of one or both of the proteins, as well as to accommodate automation of the assay. Binding of a test compound to NOVX protein, or interaction of NOVX protein with a target molecule in the presence and absence of a candidate compound, can be accomplished in any vessel suitable for containing the reactants. Examples of such vessels include microtiter plates, test tubes, and micro-centrifuge tubes. In one embodiment, a fusion protein can be provided that adds a domain that allows one or both of the proteins to be bound to a matrix. For example, GST-NOVX fusion proteins or GST-target fusion proteins can be adsorbed onto glutathione sepharose beads (Sigma Chemical, St. Louis, Mo.) or glutathione derivatized microtiter plates, that are then combined with the test compound or the test compound and either the non-adsorbed target protein or NOVX protein, and the mixture is incubated under conditions conducive to complex formation (e.g., at physiological conditions for salt and pH). Following incubation, the beads or microtiter plate wells are washed to remove any unbound components, the matrix immobilized in the case of beads, complex determined either directly or indirectly, for example, as described, supra. Alternatively, the complexes can be dissociated from the matrix, and the level of NOVX protein binding or activity determined using standard techniques.

[0272] Other techniques for immobilizing proteins on matrices can also be used in the screening assays of the invention. For example, either the NOVX protein or its target molecule can be immobilized utilizing conjugation of biotin and streptavidin. Biotinylated NOVX protein or target molecules can be prepared from biotin-NHS (N-hydroxy-succinimide) using techniques well-known within the art (e.g., biotinylation kit, Pierce Chemicals, Rockford, Ill.), and immobilized in the wells of streptavidin-coated 96 well plates (Pierce Chemical). Alternatively, antibodies reactive with NOVX protein or target molecules, but which do not interfere with binding of the NOVX protein to its target molecule, can be derivatized to the wells of the plate, and unbound target or NOVX protein trapped in the wells by antibody conjugation. Methods for detecting such complexes, in addition to those described above for the GST-immobilized complexes, include immunodetection of complexes using antibodies reactive with the NOVX protein or target molecule, as well as enzyme-linked assays that rely on detecting an enzymatic activity associated with the NOVX protein or target molecule.

[0273] In another embodiment, modulators of NOVX protein expression are identified in a method wherein a cell is contacted with a candidate compound and the expression of NOVX mRNA or protein in the cell is determined. The level of expression of NOVX mRNA or protein in the presence of the candidate compound is compared to the level of expression of NOVX mRNA or protein in the absence of the candidate compound. The candidate compound can then be identified as a modulator of NOVX mRNA or protein expression based upon this comparison. For example, when expression of NOVX mRNA or protein is greater (i.e., statistically significantly greater) in the presence of the candidate compound than in its absence, the candidate compound is identified as a stimulator of NOVX mRNA or protein expression. Alternatively, when expression of NOVX mRNA or protein is less (statistically significantly less) in the presence of the candidate compound than in its absence, the candidate compound is identified as an inhibitor of NOVX mRNA or protein expression. The level of NOVX mRNA or protein expression in the cells can be determined by methods described herein for detecting NOVX mRNA or protein.

[0274] In yet another aspect of the invention, the NOVX proteins can be used as “bait proteins” in a two-hybrid assay or three hybrid assay (see, e.g., U.S. Pat. No. 5,283,317; Zervos, et al., 1993. Cell 72: 223-232; Madura, et al., 1993. J. Biol. Chem. 268: 12046-12054; Bartel, et al., 1993. Biotechniques 14: 920-924; Iwabuchi, et al., 1993. Oncogene 8: 1693-1696; and Brent WO 94/10300), to identify other proteins that bind to or interact with NOVX (“NOVX-binding proteins” or “NOVX-bp”) and modulate NOVX activity. Such NOVX-binding proteins are also involved in the propagation of signals by the NOVX proteins as, for example, upstream or downstream elements of the NOVX pathway.

[0275] The two-hybrid system is based on the modular nature of most transcription factors, which consist of separable DNA-binding and activation domains. Briefly, the assay utilizes two different DNA constructs. In one construct, the gene that codes for NOVX is fused to a gene encoding the DNA binding domain of a known transcription factor (e.g., GAL-4). In the other construct, a DNA sequence, from a library of DNA sequences, that encodes an unidentified protein (“prey” or “sample”) is fused to a gene that codes for the activation domain of the known transcription factor. If the “bait” and the “prey” proteins are able to interact, in vivo, forming a NOVX-dependent complex, the DNA-binding and activation domains of the transcription factor are brought into close proximity. This proximity allows transcription of a reporter gene (e.g., LacZ) that is operably linked to a transcriptional regulatory site responsive to the transcription factor. Expression of the reporter gene can be detected and cell colonies containing the functional transcription factor can be isolated and used to obtain the cloned gene that encodes the protein which interacts with NOVX.

[0276] The invention further pertains to novel agents identified by the aforementioned screening assays and uses thereof for treatments as described herein.

[0277] Detection Assays

[0278] Portions or fragments of the cDNA sequences identified herein (and the corresponding complete gene sequences) can be used in numerous ways as polynucleotide reagents. By way of example, and not of limitation, these sequences can be used to: (i) map their respective genes on a chromosome; and, thus, locate gene regions associated with genetic disease; (ii) identify an individual from a minute biological sample (tissue typing); and (iii) aid in forensic identification of a biological sample. Some of these applications are described in the subsections, below.

[0279] Chromosome Mapping

[0280] Once the sequence (or a portion of the sequence) of a gene has been isolated, this sequence can be used to map the location of the gene on a chromosome. This process is called chromosome mapping. Accordingly, portions or fragments of the NOVX sequences of SEQ ID NO:2n−1, wherein n is an integer between 1 and 226, or fragments or derivatives thereof, can be used to map the location of the NOVX genes, respectively, on a chromosome. The mapping of the NOVX sequences to chromosomes is an important first step in correlating these sequences with genes associated with disease.

[0281] Briefly, NOVX genes can be mapped to chromosomes by preparing PCR primers (preferably 15-25 bp in length) from the NOVX sequences. Computer analysis of the NOVX, sequences can be used to rapidly select primers that do not span more than one exon in the genomic DNA, thus complicating the amplification process. These primers can then be used for PCR screening of somatic cell hybrids containing individual human chromosomes. Only those hybrids containing the human gene corresponding to the NOVX sequences will yield an amplified fragment.

[0282] Somatic cell hybrids are prepared by fusing somatic cells from different mammals (e.g., human and mouse cells). As hybrids of human and mouse cells grow and divide, they gradually lose human chromosomes in random order, but retain the mouse chromosomes. By using media in which mouse cells cannot grow, because they lack a particular enzyme, but in which human cells can, the one human chromosome that contains the gene encoding the needed enzyme will be retained. By using various media, panels of hybrid cell lines can be established. Each cell line in a panel contains either a single human chromosome or a small number of human chromosomes, and a full set of mouse chromosomes, allowing easy mapping of individual genes to specific human chromosomes. See, e.g., D'Eustachio, et al., 1983. Science 220: 919-924. Somatic cell hybrids containing only fragments of human chromosomes can also be produced by using human chromosomes with translocations and deletions.

[0283] PCR mapping of somatic cell hybrids is a rapid procedure for assigning a particular sequence to a particular chromosome. Three or more sequences can be assigned per day using a single thermal cycler. Using the NOVX sequences to design oligonucleotide primers, sub-localization can be achieved with panels of fragments from specific chromosomes.

[0284] Fluorescence in situ hybridization (FISH) of a DNA sequence to a metaphase chromosomal spread can further be used to provide a precise chromosomal location in one step. Chromosome spreads can be made using cells whose division has been blocked in metaphase by a chemical like colcemid that disrupts the mitotic spindle. The chromosomes can be treated briefly with trypsin, and then stained with Giemsa. A pattern of light and dark bands develops on each chromosome, so that the chromosomes can be identified individually. The FISH technique can be used with a DNA sequence as short as 500 or 600 bases. However, clones larger than 1,000 bases have a higher likelihood of binding to a unique chromosomal location with sufficient signal intensity for simple detection. Preferably 1,000 bases, and more preferably 2,000 bases, will suffice to get good results at a reasonable amount of time. For a review of this technique, see, Verma, et al., HUMAN CHROMOSOMES: A MANUAL OF BASIC TECHNIQUES (Pergamon Press, New York 1988).

[0285] Reagents for chromosome mapping can be used individually to mark a single chromosome or a single site on that chromosome, or panels of reagents can be used for marking multiple sites and/or multiple chromosomes. Reagents corresponding to noncoding regions of the genes actually are preferred for mapping purposes. Coding sequences are more likely to be conserved within gene families, thus increasing the chance of cross hybridizations during chromosomal mapping.

[0286] Once a sequence has been mapped to a precise chromosomal location, the physical position of the sequence on the chromosome can be correlated with genetic map data. Such data are found, e.g., in McKusick, MENDELIAN INHERITANCE IN MAN, available on-line through Johns Hopkins University Welch Medical Library). The relationship between genes and disease, mapped to the same chromosomal region, can then be identified through linkage analysis (co-inheritance of physically adjacent genes), described in, e.g., Egeland, et al., 1987. Nature, 325: 783-787.

[0287] Moreover, differences in the DNA sequences between individuals affected and unaffected with a disease associated with the NOVX gene, can be determined. If a mutation is observed in some or all of the affected individuals but not in any unaffected individuals, then the mutation is likely to be the causative agent of the particular disease. Comparison of affected and unaffected individuals generally involves first looking for structural alterations in the chromosomes, such as deletions or translocations that are visible from chromosome spreads or detectable using PCR based on that DNA sequence. Ultimately, complete sequencing of genes from several individuals can be performed to confirm the presence of a mutation and to distinguish mutations from polymorphisms.

[0288] Tissue Typing

[0289] The NOVX sequences of the invention can also be used to identify individuals from minute biological samples. In this technique, an individual's genomic DNA is digested with one or more restriction enzymes, and probed on a Southern blot to yield unique bands for identification. The sequences of the invention are useful as additional DNA markers for RFLP (“restriction fragment length polymorphisms,” described in U.S. Pat. No. 5,272,057).

[0290] Furthermore, the sequences of the invention can be used to provide an alternative technique that determines the actual base-by-base DNA sequence of selected portions of an individual's genome. Thus, the NOVX sequences described herein can be used to prepare two PCR primers from the 5′- and 3′-termini of the sequences. These primers can then be used to amplify an individual's DNA and subsequently sequence it.

[0291] Panels of corresponding DNA sequences from individuals, prepared in this manner, can provide unique individual identifications, as each individual will have a unique set of such DNA sequences due to allelic differences. The sequences of the invention can be used to obtain such identification sequences from individuals and from tissue. The NOVX sequences of the invention uniquely represent portions of the human genome. Allelic variation occurs to some degree in the coding regions of these sequences, and to a greater degree in the noncoding regions. It is estimated that allelic variation between individual humans occurs with a frequency of about once per each 500 bases. Much of the allelic variation is due to single nucleotide polymorphisms (SNPs), which include restriction fragment length polymorphisms (RFLPs).

[0292] Each of the sequences described herein can, to some degree, be used as a standard against which DNA from an individual can be compared for identification purposes. Because greater numbers of polymorphisms occur in the noncoding regions, fewer sequences are necessary to differentiate individuals. The noncoding sequences can comfortably provide positive individual identification with a panel of perhaps 10 to 1,000 primers that each yield a noncoding amplified sequence of 100 bases. If coding sequences, such as those of SEQ ID NO:2n−1, wherein n is an integer between 1 and 226, are used, a more appropriate number of primers for positive individual identification would be 500-2,000.

[0293] Predictive Medicine

[0294] The invention also pertains to the field of predictive medicine in which diagnostic assays, prognostic assays, pharmacogenomics, and monitoring clinical trials are used for prognostic (predictive) purposes to thereby treat an individual prophylactically. Accordingly, one aspect of the invention relates to diagnostic assays for determining NOVX protein and/or nucleic acid expression as well as NOVX activity, in the context of a biological sample (e.g., blood, serum, cells, tissue) to thereby determine whether an individual is afflicted with a disease or disorder, or is at risk of developing a disorder, associated with aberrant NOVX expression or activity. The disorders include metabolic disorders, diabetes, obesity, infectious disease, anorexia, cancer-associated cachexia, cancer, neurodegenerative disorders, Alzheimer's Disease, Parkinson's Disorder, immune disorders, and hematopoietic disorders, and the various dyslipidemias, metabolic disturbances associated with obesity, the metabolic syndrome X and wasting disorders associated with chronic diseases and various cancers. The invention also provides for prognostic (or predictive) assays for determining whether an individual is at risk of developing a disorder associated with NOVX protein, nucleic acid expression or activity. For example, mutations in a NOVX gene can be assayed in a biological sample. Such assays can be used for prognostic or predictive purpose to thereby prophylactically treat an individual prior to the onset of a disorder characterized by or associated with NOVX protein, nucleic acid expression, or biological activity.

[0295] Another aspect of the invention provides methods for determining NOVX protein, nucleic acid expression or activity in an individual to thereby select appropriate therapeutic or prophylactic agents for that individual (referred to herein as “pharmacogenomics”). Pharmacogenomics allows for the selection of agents (e.g., drugs) for therapeutic or prophylactic treatment of an individual based on the genotype of the individual (e.g., the genotype of the individual examined to determine the ability of the individual to respond to a particular agent.)

[0296] Yet another aspect of the invention pertains to monitoring the influence of agents (e.g., drugs, compounds) on the expression or activity of NOVX in clinical trials.

[0297] These and other agents are described in further detail in the following sections.

[0298] Diagnostic Assays

[0299] An exemplary method for detecting the presence or absence of NOVX in a biological sample involves obtaining a biological sample from a test subject and contacting the biological sample with a compound or an agent capable of detecting NOVX protein or nucleic acid (e.g., mRNA, genomic DNA) that encodes NOVX protein such that the presence of NOVX is detected in the biological sample. An agent for detecting NOVX mRNA or genomic DNA is a labeled nucleic acid probe capable of hybridizing to NOVX mRNA or genomic DNA. The nucleic acid probe can be, for example, a full-length NOVX nucleic acid, such as the nucleic acid of SEQ ID NO:2n−1, wherein n is an integer between 1 and 226, or a portion thereof, such as an oligonucleotide of at least 15, 30, 50, 100, 250 or 500 nucleotides in length and sufficient to specifically hybridize under stringent conditions to NOVX mRNA or genomic DNA. Other suitable probes for use in the diagnostic assays of the invention are described herein.

[0300] An agent for detecting NOVX protein is an antibody capable of binding to NOVX protein, preferably an antibody with a detectable label. Antibodies can be polyclonal, or more preferably, monoclonal. An intact antibody, or a fragment thereof (e.g., Fab or F(ab′)2) can be used. The term “labeled”, with regard to the probe or antibody, is intended to encompass direct labeling of the probe or antibody by coupling (i.e., physically linking) a detectable substance to the probe or antibody, as well as indirect labeling of the probe or antibody by reactivity with another reagent that is directly labeled. Examples of indirect labeling include detection of a primary antibody using a fluorescently-labeled secondary antibody and end-labeling of a DNA probe with biotin such that it can be detected with fluorescently-labeled streptavidin. The term “biological sample” is intended to include tissues, cells and biological fluids isolated from a subject, as well as tissues, cells and fluids present within a subject. That is, the detection method of the invention can be used to detect NOVX mRNA, protein, or genomic DNA in a biological sample in vitro as well as in vivo. For example, in vitro techniques for detection of NOVX mRNA include Northern hybridizations and in situ hybridizations. In vitro techniques for detection of NOVX protein include enzyme linked immunosorbent assays (ELISAs), Western blots, immunoprecipitations, and immunofluorescence. In vitro techniques for detection of NOVX genomic DNA include Southern hybridizations. Furthermore, in vivo techniques for detection of NOVX protein include introducing into a subject a labeled anti-NOVX antibody. For example, the antibody can be labeled with a radioactive marker whose presence and location in a subject can be detected by standard imaging techniques.

[0301] In one embodiment, the biological sample contains protein molecules from the test subject. Alternatively, the biological sample can contain mRNA molecules from the test subject or genomic DNA molecules from the test subject. A preferred biological sample is a peripheral blood leukocyte sample isolated by conventional means from a subject.

[0302] In another embodiment, the methods further involve obtaining a control biological sample from a control subject, contacting the control sample with a compound or agent capable of detecting NOVX protein, mRNA, or genomic DNA, such that the presence of NOVX protein, mRNA or genomic DNA is detected in the biological sample, and comparing the presence of NOVX protein, mRNA or genomic DNA in the control sample with the presence of NOVX protein, mRNA or genomic DNA in the test sample.

[0303] The invention also encompasses kits for detecting the presence of NOVX in a biological sample. For example, the kit can comprise: a labeled compound or agent capable of detecting NOVX protein or mRNA in a biological sample; means for determining the amount of NOVX in the sample; and means for comparing the amount of NOVX in the sample with a standard. The compound or agent can be packaged in a suitable container. The kit can further comprise instructions for using the kit to detect NOVX protein or nucleic acid.

[0304] Prognostic Assays

[0305] The diagnostic methods described herein can furthermore be utilized to identify subjects having or at risk of developing a disease or disorder associated with aberrant NOVX expression or activity. For example, the assays described herein, such as the preceding diagnostic assays or the following assays, can be utilized to identify a subject having or at risk of developing a disorder associated with NOVX protein, nucleic acid expression or activity. Alternatively, the prognostic assays can be utilized to identify a subject having or at risk for developing a disease or disorder. Thus, the invention provides a method for identifying a disease or disorder associated with aberrant NOVX expression or activity in which a test sample is obtained from a subject and NOVX protein or nucleic acid (e.g., mRNA, genomic DNA) is detected, wherein the presence of NOVX protein or nucleic acid is diagnostic for a subject having or at risk of developing a disease or disorder associated with aberrant NOVX expression or activity. As used herein, a “test sample” refers to a biological sample obtained from a subject of interest. For example, a test sample can be a biological fluid (e.g., serum), cell sample, or tissue.

[0306] Furthermore, the prognostic assays described herein can be used to determine whether a subject can be administered an agent (e.g., an agonist, antagonist, peptidomimetic, protein, peptide, nucleic acid, small molecule, or other drug candidate) to treat a disease or disorder associated with aberrant NOVX expression or activity. For example, such methods can be used to determine whether a subject can be effectively treated with an agent for a disorder. Thus, the invention provides methods for determining whether a subject can be effectively treated with an agent for a disorder associated with aberrant NOVX expression or activity in which a test sample is obtained and NOVX protein or nucleic acid is detected (e.g., wherein the presence of NOVX protein or nucleic acid is diagnostic for a subject that can be administered the agent to treat a disorder associated with aberrant NOVX expression or activity).

[0307] The methods of the invention can also be used to detect genetic lesions in a NOVX gene, thereby determining if a subject with the lesioned gene is at risk for a disorder characterized by aberrant cell proliferation and/or differentiation. In various embodiments, the methods include detecting, in a sample of cells from the subject, the presence or absence of a genetic lesion characterized by at least one of an alteration affecting the integrity of a gene encoding a NOVX-protein, or the misexpression of the NOVX gene. For example, such genetic lesions can be detected by ascertaining the existence of at least one of: (i) a deletion of one or more nucleotides from a NOVX gene; (ii) an addition of one or more nucleotides to a NOVX gene; (iii) a substitution of one or more nucleotides of a NOVX gene, (iv) a chromosomal rearrangement of a NOVX gene; (v) an alteration in the level of a messenger RNA transcript of a NOVX gene, (vi) aberrant modification of a NOVX gene, such as of the methylation pattern of the genomic DNA, (vii) the presence of a non-wild-type splicing pattern of a messenger RNA transcript of a NOVX gene, (viii) a non-wild-type level of a NOVX protein, (ix) allelic loss of a NOVX gene, and (x) inappropriate post-translational modification of a NOVX protein. As described herein, there are a large number of assay techniques known in the art which can be used for detecting lesions in a NOVX gene. A preferred biological sample is a peripheral blood leukocyte sample isolated by conventional means from a subject. However, any biological sample containing nucleated cells may be used, including, for example, buccal mucosal cells.

[0308] In certain embodiments, detection of the lesion involves the use of a probe/primer in a polymerase chain reaction (PCR) (see, e.g., U.S. Pat. Nos. 4,683,195 and 4,683,202), such as anchor PCR or RACE PCR, or, alternatively, in a ligation chain reaction (LCR) (see, e.g., Landegran, et al., 1988. Science 241: 1077-1080; and Nakazawa, et al., 1994. Proc. Natl. Acad. Sci. USA 91: 360-364), the latter of which can be particularly useful for detecting point mutations in the NOVX-gene (see, Abravaya, et al., 1995. Nucl. Acids Res. 23: 675-682). This method can include the steps of collecting a sample of cells from a patient, isolating nucleic acid (e.g., genomic, mRNA or both) from the cells of the sample, contacting the nucleic acid sample with one or more primers that specifically hybridize to a NOVX gene under conditions such that hybridization and amplification of the NOVX gene (if present) occurs, and detecting the presence or absence of an amplification product, or detecting the size of the amplification product and comparing the length to a control sample. It is anticipated that PCR and/or LCR may be desirable to use as a preliminary amplification step in conjunction with any of the techniques used for detecting mutations described herein.

[0309] Alternative amplification methods include: self sustained sequence replication (see, Guatelli, et al., 1990. Proc. Natl. Acad. Sci. USA 87: 1874-1878), transcriptional amplification system (see, Kwoh, et al., 1989. Proc. Natl. Acad. Sci. USA 86: 1173-1177); Qβ Replicase (see, Lizardi, et al, 1988. BioTechnology 6: 1197), or any other nucleic acid amplification method, followed by the detection of the amplified molecules using techniques well known to those of skill in the art. These detection schemes are especially useful for the detection of nucleic acid molecules if such molecules are present in very low numbers.

[0310] In an alternative embodiment, mutations in a NOVX gene from a sample cell can be identified by alterations in restriction enzyme cleavage patterns. For example, sample and control DNA is isolated, amplified (optionally), digested with one or more restriction endonucleases, and fragment length sizes are determined by gel electrophoresis and compared. Differences in fragment length sizes between sample and control DNA indicates mutations in the sample DNA. Moreover, the use of sequence specific ribozymes (see, e.g., U.S. Pat. No. 5,493,531) can be used to score for the presence of specific mutations by development or loss of a ribozyme cleavage site.

[0311] In other embodiments, genetic mutations in NOVX can be identified by hybridizing a sample and control nucleic acids, e.g., DNA or RNA, to high-density arrays containing hundreds or thousands of oligonucleotides probes. See, e.g., Cronin, et al., 1996. Human Mutation 7: 244-255; Kozal, et al., 1996. Nat. Med. 2: 753-759. For example, genetic mutations in NOVX can be identified in two dimensional arrays containing light-generated DNA probes as described in Cronin, et al., supra. Briefly, a first hybridization array of probes can be used to scan through long stretches of DNA in a sample and control to identify base changes between the sequences by making linear arrays of sequential overlapping probes. This step allows the identification of point mutations. This is followed by a second hybridization array that allows the characterization of specific mutations by using smaller, specialized probe arrays complementary to all variants or mutations detected. Each mutation array is composed of parallel probe sets, one complementary to the wild-type gene and the other complementary to the mutant gene.

[0312] In yet another embodiment, any of a variety of sequencing reactions known in the art can be used to directly sequence the NOVX gene and detect mutations by comparing the sequence of the sample NOVX with the corresponding wild-type (control) sequence. Examples of sequencing reactions include those based on techniques developed by Maxim and Gilbert, 1977. Proc. Natl. Acad. Sci. USA 74: 560 or Sanger, 1977. Proc. Natl. Acad. Sci. USA 74: 5463. It is also contemplated that any of a variety of automated sequencing procedures can be utilized when performing the diagnostic assays (see, e.g., Naeve, et al., 1995. Biotechniques 19: 448), including sequencing by mass spectrometry (see, e.g., PCT International Publication No. WO 94/16101; Cohen, et al., 1996. Adv. Chromatography 36: 127-162; and Griffin, et al., 1993. Appl. Biochem. Biotechnol. 38: 147-159).

[0313] Other methods for detecting mutations in the NOVX gene include methods in which protection from cleavage agents is used to detect mismatched bases in RNA/RNA or RNA/DNA heteroduplexes. See, e.g., Myers, et al., 1985. Science 230: 1242. In general, the art technique of “mismatch cleavage” starts by providing heteroduplexes of formed by hybridizing (labeled) RNA or DNA containing the wild-type NOVX sequence with potentially mutant RNA or DNA obtained from a tissue sample. The double-stranded duplexes are treated with an agent that cleaves single-stranded regions of the duplex such as which will exist due to basepair mismatches between the control and sample strands. For instance, RNA/DNA duplexes can be treated with RNase and DNA/DNA hybrids treated with S1 nuclease to enzymatically digesting the mismatched regions. In other embodiments, either DNA/DNA or RNA/DNA duplexes can be treated with hydroxylamine or osmium tetroxide and with piperidine in order to digest mismatched regions. After digestion of the mismatched regions, the resulting material is then separated by size on denaturing polyacrylamide gels to determine the site of mutation. See, e.g., Cotton, et al., 1988. Proc. Natl. Acad. Sci. USA 85: 4397; Saleeba, et al., 1992. Methods Enzymol. 217: 286-295. In an embodiment, the control DNA or RNA can be labeled for detection.

[0314] In still another embodiment, the mismatch cleavage reaction employs one or more proteins that recognize mismatched base pairs in double-stranded DNA (so called “DNA mismatch repair” enzymes) in defined systems for detecting and mapping point mutations in NOVX cDNAs obtained from samples of cells. For example, the mutY enzyme of E. coli cleaves A at G/A mismatches and the thymidine DNA glycosylase from HeLa cells cleaves T at G/T mismatches. See, e.g., Hsu, et al., 1994. Carcinogenesis 15: 1657-1662. According to an exemplary embodiment, a probe based on a NOVX sequence, e.g., a wild-type NOVX sequence, is hybridized to a cDNA or other DNA product from a test cell(s). The duplex is treated with a DNA mismatch repair enzyme, and the cleavage products, if any, can be detected from electrophoresis protocols or the like. See, e.g., U.S. Pat. No. 5,459,039.

[0315] In other embodiments, alterations in electrophoretic mobility will be used to identify mutations in NOVX genes. For example, single strand conformation polymorphism (SSCP) may be used to detect differences in electrophoretic mobility between mutant and wild type nucleic acids. See, e.g., Orita, et al., 1989. Proc. Natl. Acad. Sci. USA: 86: 2766; Cotton, 1993. Mutat. Res. 285: 125-144; Hayashi, 1992. Genet. Anal. Tech. Appl. 9: 73-79. Single-stranded DNA fragments of sample and control NOVX nucleic acids will be denatured and allowed to renature. The secondary structure of single-stranded nucleic acids varies according to sequence, the resulting alteration in electrophoretic mobility enables the detection of even a single base change. The DNA fragments may be labeled or detected with labeled probes. The sensitivity of the assay may be enhanced by using RNA (rather than DNA), in which the secondary structure is more sensitive to a change in sequence. In one embodiment, the subject method utilizes heteroduplex analysis to separate double stranded heteroduplex molecules on the basis of changes in electrophoretic mobility. See, e.g., Keen, et al., 1991. Trends Genet. 7: 5.

[0316] In yet another embodiment, the movement of mutant or wild-type fragments in polyacrylamide gels containing a gradient of denaturant is assayed using denaturing gradient gel electrophoresis (DGGE). See, e.g., Myers, et al., 1985. Nature 313: 495. When DGGE is used as the method of analysis, DNA will be modified to insure that it does not completely denature, for example by adding a GC clamp of approximately 40 bp of high-melting GC-rich DNA by PCR. In a further embodiment, a temperature gradient is used in place of a denaturing gradient to identify differences in the mobility of control and sample DNA. See, e.g., Rosenbaum and Reissner, 1987. Biophys. Chem. 265: 12753.

[0317] Examples of other techniques for detecting point mutations include, but are not limited to, selective oligonucleotide hybridization, selective amplification, or selective primer extension. For example, oligonucleotide primers may be prepared in which the known mutation is placed centrally and then hybridized to target DNA under conditions that permit hybridization only if a perfect match is found. See, e.g., Saiki, et al., 1986. Nature 324: 163; Saiki, et al., 1989. Proc. Natl. Acad. Sci. USA 86: 6230. Such allele specific oligonucleotides are hybridized to PCR amplified target DNA or a number of different mutations when the oligonucleotides are attached to the hybridizing membrane and hybridized with labeled target DNA.

[0318] Alternatively, allele specific amplification technology that depends on selective PCR amplification may be used in conjunction with the instant invention. Oligonucleotides used as primers for specific amplification may carry the mutation of interest in the center of the molecule (so that amplification depends on differential hybridization; see, e.g., Gibbs, et al., 1989. Nucl. Acids Res. 17: 2437-2448) or at the extreme 3′-terminus of one primer where, under appropriate conditions, mismatch can prevent, or reduce polymerase extension (see, e.g., Prossner, 1993. Tibtech. 11: 238). In addition it may be desirable to introduce a novel restriction site in the region of the mutation to create cleavage-based detection. See, e.g., Gasparini, et al., 1992. Mol. Cell Probes 6: 1. It is anticipated that in certain embodiments amplification may also be performed using Taq ligase for amplification. See, e.g., Barany, 1991. Proc. Natl. Acad. Sci. USA 88: 189. In such cases, ligation will occur only if there is a perfect match at the 3′-terminus of the 5′ sequence, making it possible to detect the presence of a known mutation at a specific site by looking for the presence or absence of amplification.

[0319] The methods described herein may be performed, for example, by utilizing pre-packaged diagnostic kits comprising at least one probe nucleic acid or antibody reagent described herein, which may be conveniently used, e.g., in clinical settings to diagnose patients exhibiting symptoms or family history of a disease or illness involving a NOVX gene.

[0320] Furthermore, any cell type or tissue, preferably peripheral blood leukocytes, in which NOVX is expressed may be utilized in the prognostic assays described herein. However, any biological sample containing nucleated cells may be used, including, for example, buccal mucosal cells.

[0321] Pharmacogenomics

[0322] Agents, or modulators that have a stimulatory or inhibitory effect on NOVX activity (e.g., NOVX gene expression), as identified by a screening assay described herein can be administered to individuals to treat (prophylactically or therapeutically) disorders. The disorders include but are not limited to, e.g., those diseases, disorders and conditions listed above, and more particularly include those diseases, disorders, or conditions associated with homologs of a NOVX protein, such as those summarized in Table A.

[0323] In conjunction with such treatment, the pharmacogenomics (i.e., the study of the relationship between an individual's genotype and that individual's response to a foreign compound or drug) of the individual may be considered. Differences in metabolism of therapeutics can lead to severe toxicity or therapeutic failure by altering the relation between dose and blood concentration of the pharmacologically active drug. Thus, the pharmacogenomics of the individual permits the selection of effective agents (e.g., drugs) for prophylactic or therapeutic treatments based on a consideration of the individual's genotype. Such pharmacogenomics can further be used to determine appropriate dosages and therapeutic regimens. Accordingly, the activity of NOVX protein, expression of NOVX nucleic acid, or mutation content of NOVX genes in an individual can be determined to thereby select appropriate agent(s) for therapeutic or prophylactic treatment of the individual.

[0324] Pharmacogenomics deals with clinically significant hereditary variations in the response to drugs due to altered drug disposition and abnormal action in affected persons. See e.g., Eichelbaum, 1996. Clin. Exp. Pharmacol. Physiol., 23: 983-985; Linder, 1997. Clin. Chem., 43: 254-266. In general, two types of pharmacogenetic conditions can be differentiated. Genetic conditions transmitted as a single factor altering the way drugs act on the body (altered drug action) or genetic conditions transmitted as single factors altering the way the body acts on drugs (altered drug metabolism). These pharmacogenetic conditions can occur either as rare defects or as polymorphisms. For example, glucose-6-phosphate dehydrogenase (G6PD) deficiency is a common inherited enzymopathy in which the main clinical complication is hemolysis after ingestion of oxidant drugs (anti-malarials, sulfonamides, analgesics, nitrofurans) and consumption of fava beans.

[0325] As an illustrative embodiment, the activity of drug metabolizing enzymes is a major determinant of both the intensity and duration of drug action. The discovery of genetic polymorphisms of drug metabolizing enzymes (e.g., N-acetyltransferase 2 (NAT 2) and cytochrome pregnancy zone protein precursor enzymes CYP2D6 and CYP2C19) has provided an explanation as to why some patients do not obtain the expected drug effects or show exaggerated drug response and serious toxicity after taking the standard and safe dose of a drug. These polymorphisms are expressed in two phenotypes in the population, the extensive metabolizer (EM) and poor metabolizer (PM). The prevalence of PM is different among different populations. For example, the gene coding for CYP2D6 is highly polymorphic and several mutations have been identified in PM, which all lead to the absence of functional CYP2D6. Poor metabolizers of CYP2D6 and CYP2C19 quite frequently experience exaggerated drug response and side effects when they receive standard doses. If a metabolite is the active therapeutic moiety, PM show no therapeutic response, as demonstrated for the analgesic effect of codeine mediated by its CYP2D6-formed metabolite morphine. At the other extreme are the so called ultra-rapid metabolizers who do not respond to standard doses. Recently, the molecular basis of ultra-rapid metabolism has been identified to be due to CYP2D6 gene amplification.

[0326] Thus, the activity of NOVX protein, expression of NOVX nucleic acid, or mutation content of NOVX genes in an individual can be determined to thereby select appropriate agent(s) for therapeutic or prophylactic treatment of the individual. In addition, pharmacogenetic studies can be used to apply genotyping of polymorphic alleles encoding drug-metabolizing enzymes to the identification of an individual's drug responsiveness phenotype. This knowledge, when applied to dosing or drug selection, can avoid adverse reactions or therapeutic failure and thus enhance therapeutic or prophylactic efficiency when treating a subject with a NOVX modulator, such as a modulator identified by one of the exemplary screening assays described herein.

[0327] Monitoring of Effects During Clinical Trials

[0328] Monitoring the influence of agents (e.g., drugs, compounds) on the expression or activity of NOVX (e.g., the ability to modulate aberrant cell proliferation and/or differentiation) can be applied not only in basic drug screening, but also in clinical trials. For example, the effectiveness of an agent determined by a screening assay as described herein to increase NOVX gene expression, protein levels, or upregulate NOVX activity, can be monitored in clinical trails of subjects exhibiting decreased NOVX gene expression, protein levels, or downregulated NOVX activity. Alternatively, the effectiveness of an agent determined by a screening assay to decrease NOVX gene expression, protein levels, or downregulate NOVX activity, can be monitored in clinical trails of subjects exhibiting increased NOVX gene expression, protein levels, or upregulated NOVX activity. In such clinical trials, the expression or activity of NOVX and, preferably, other genes that have been implicated in, for example, a cellular proliferation or immune disorder can be used as a “read out” or markers of the immune responsiveness of a particular cell.

[0329] By way of example, and not of limitation, genes, including NOVX, that are modulated in cells by treatment with an agent (e.g., compound, drug or small molecule) that modulates NOVX activity (e.g., identified in a screening assay as described herein) can be identified. Thus, to study the effect of agents on cellular proliferation disorders, for example, in a clinical trial, cells can be isolated and RNA prepared and analyzed for the levels of expression of NOVX and other genes implicated in the disorder. The levels of gene expression (i.e., a gene expression pattern) can be quantified by Northern blot analysis or RT-PCR, as described herein, or alternatively by measuring the amount of protein produced, by one of the methods as described herein, or by measuring the levels of activity of NOVX or other genes. In this manner, the gene expression pattern can serve as a marker, indicative of the physiological response of the cells to the agent. Accordingly, this response state may be determined before, and at various points during, treatment of the individual with the agent.

[0330] In one embodiment, the invention provides a method for monitoring the effectiveness of treatment of a subject with an agent (e.g., an agonist, antagonist, protein, peptide, peptidomimetic, nucleic acid, small molecule, or other drug candidate identified by the screening assays described herein) comprising the steps of (i) obtaining a pre-administration sample from a subject prior to administration of the agent; (ii) detecting the level of expression of a NOVX protein, mRNA, or genomic DNA in the pre-administration sample; (iii) obtaining one or more post-administration samples from the subject; (iv) detecting the level of expression or activity of the NOVX protein, mRNA, or genomic DNA in the post-administration samples; (v) comparing the level of expression or activity of the NOVX protein, mRNA, or genomic DNA in the pre-administration sample with the NOVX protein, mRNA, or genomic DNA in the post administration sample or samples; and (vi) altering the administration of the agent to the subject accordingly. For example, increased administration of the agent may be desirable to increase the expression or activity of NOVX to higher levels than detected, i.e., to increase the effectiveness of the agent. Alternatively, decreased administration of the agent may be desirable to decrease expression or activity of NOVX to lower levels than detected, i.e., to decrease the effectiveness of the agent.

[0331] Methods of Treatment

[0332] The invention provides for both prophylactic and therapeutic methods of treating a subject at risk of (or susceptible to) a disorder or having a disorder associated with aberrant NOVX expression or activity. The disorders include but are not limited to, e.g., those diseases, disorders and conditions listed above, and more particularly include those diseases, disorders, or conditions associated with homologs of a NOVX protein, such as those summarized in Table A.

[0333] These methods of treatment will be discussed more fully, below.

[0334] Diseases and Disorders

[0335] Diseases and disorders that are characterized by increased (relative to a subject not suffering from the disease or disorder) levels or biological activity may be treated with Therapeutics that antagonize (i.e., reduce or inhibit) activity. Therapeutics that antagonize activity may be administered in a therapeutic or prophylactic manner. Therapeutics that may be utilized include, but are not limited to: (i) an aforementioned peptide, or analogs, derivatives, fragments or homologs thereof; (ii) antibodies to an aforementioned peptide; (iii) nucleic acids encoding an aforementioned peptide; (iv) administration of antisense nucleic acid and nucleic acids that are “dysfunctional” (i.e., due to a heterologous insertion within the coding sequences of coding sequences to an aforementioned peptide) that are utilized to “knockout” endogenous function of an aforementioned peptide by homologous recombination (see, e.g., Capecchi, 1989. Science 244: 1288-1292); or (v) modulators (i.e., inhibitors, agonists and antagonists, including additional peptide mimetic of the invention or antibodies specific to a peptide of the invention) that alter the interaction between an aforementioned peptide and its binding partner.

[0336] Diseases and disorders that are characterized by decreased (relative to a subject not suffering from the disease or disorder) levels or biological activity may be treated with Therapeutics that increase (i.e., are agonists to) activity. Therapeutics that upregulate activity may be administered in a therapeutic or prophylactic manner. Therapeutics that may be utilized include, but are not limited to, an aforementioned peptide, or analogs, derivatives, fragments or homologs thereof; or an agonist that increases bioavailability.

[0337] Increased or decreased levels can be readily detected by quantifying peptide and/or RNA, by obtaining a patient tissue sample (e.g., from biopsy tissue) and assaying it in vitro for RNA or peptide levels, structure and/or activity of the expressed peptides (or mRNAs of an aforementioned peptide). Methods that are well-known within the art include, but are not limited to, immunoassays (e.g., by Western blot analysis, immunoprecipitation followed by sodium dodecyl sulfate (SDS) polyacrylamide gel electrophoresis, immunocytochemistry, etc.) and/or hybridization assays to detect expression of mRNAs (e.g., Northern assays, dot blots, in situ hybridization, and the like).

[0338] Prophylactic Methods

[0339] In one aspect, the invention provides a method for preventing, in a subject, a disease or condition associated with an aberrant NOVX expression or activity, by administering to the subject an agent that modulates NOVX expression or at least one NOVX activity. Subjects at risk for a disease that is caused or contributed to by aberrant NOVX expression or activity can be identified by, for example, any or a combination of diagnostic or prognostic assays as described herein. Administration of a prophylactic agent can occur prior to the manifestation of symptoms characteristic of the NOVX aberrancy, such that a disease or disorder is prevented or, alternatively, delayed in its progression. Depending upon the type of NOVX aberrancy, for example, a NOVX agonist or NOVX antagonist agent can be used for treating the subject. The appropriate agent can be determined based on screening assays described herein. The prophylactic methods of the invention are further discussed in the following subsections.

[0340] Therapeutic Methods

[0341] Another aspect of the invention pertains to methods of modulating NOVX expression or activity for therapeutic purposes. The modulatory method of the invention involves contacting a cell with an agent that modulates one or more of the activities of NOVX protein activity associated with the cell. An agent that modulates NOVX protein activity can be an agent as described herein, such as a nucleic acid or a protein, a naturally-occurring cognate ligand of a NOVX protein, a peptide, a NOVX peptidomimetic, or other small molecule. In one embodiment, the agent stimulates one or more NOVX protein activity. Examples of such stimulatory agents include active NOVX protein and a nucleic acid molecule encoding NOVX that has been introduced into the cell. In another embodiment, the agent inhibits one or more NOVX protein activity. Examples of such inhibitory agents include antisense NOVX nucleic acid molecules and anti-NOVX antibodies. These modulatory methods can be performed in vitro (e.g., by culturing the cell with the agent) or, alternatively, in vivo (e.g., by administering the agent to a subject). As such, the invention provides methods of treating an individual afflicted with a disease or disorder characterized by aberrant expression or activity of a NOVX protein or nucleic acid molecule. In one embodiment, the method involves administering an agent (e.g., an agent identified by a screening assay described herein), or combination of agents that modulates (e.g., up-regulates or down-regulates) NOVX expression or activity. In another embodiment, the method involves administering a NOVX protein or nucleic acid molecule as therapy to compensate for reduced or aberrant NOVX expression or activity.

[0342] Stimulation of NOVX activity is desirable in situations in which NOVX is abnormally downregulated and/or in which increased NOVX activity is likely to have a beneficial effect. One example of such a situation is where a subject has a disorder characterized by aberrant cell proliferation and/or differentiation (e.g., cancer or immune associated disorders). Another example of such a situation is where the subject has a gestational disease (e.g., preclampsia).

[0343] Determination of the Biological Effect of the Therapeutic

[0344] In various embodiments of the invention, suitable in vitro or in vivo assays are performed to determine the effect of a specific Therapeutic and whether its administration is indicated for treatment of the affected tissue.

[0345] In various specific embodiments, in vitro assays may be performed with representative cells of the type(s) involved in the patient's disorder, to determine if a given Therapeutic exerts the desired effect upon the cell type(s). Compounds for use in therapy may be tested in suitable animal model systems including, but not limited to rats, mice, chicken, cows, monkeys, rabbits, and the like, prior to testing in human subjects. Similarly, for in vivo testing, any of the animal model system known in the art may be used prior to administration to human subjects.

[0346] Prophylactic and Therapeutic Uses of the Compositions of the Invention

[0347] The NOVX nucleic acids and proteins of the invention are useful in potential prophylactic and therapeutic applications implicated in a variety of disorders. The disorders include but are not limited to, e.g., those diseases, disorders and conditions listed above, and more particularly include those diseases, disorders, or conditions associated with homologs of a NOVX protein, such as those summarized in Table A.

[0348] As an example, a cDNA encoding the NOVX protein of the invention may be useful in gene therapy, and the protein may be useful when administered to a subject in need thereof. By way of non-limiting example, the compositions of the invention will have efficacy for treatment of patients suffering from diseases, disorders, conditions and the like, including but not limited to those listed herein.

[0349] Both the novel nucleic acid encoding the NOVX protein, and the NOVX protein of the invention, or fragments thereof, may also be useful in diagnostic applications, wherein the presence or amount of the nucleic acid or the protein are to be assessed. A further use could be as an anti-bacterial molecule (i.e., some peptides have been found to possess anti-bacterial properties). These materials are further useful in the generation of antibodies, which immunospecifically-bind to the novel substances of the invention for use in therapeutic or diagnostic methods.

[0350] The invention will be further described in the following examples, which do not limit the scope of the invention described in the claims.

EXAMPLES

Example A

[0351] Polynucleotide and Polypeptide Sequences, and Homology Data

[0352] The NOV1 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 1A.

TABLE 1A
NOV1 Sequence Analysis
                 SEQ ID NO: 1           2673 bp
NOV1a,           GGATCCCAGTGGCCCGGCGTGCTCGGCTCCCACAGGCCTGCAGCCAGCATCGCACCGA
CG101683-01
DNA Sequence     ACCTTCGGGGGGCCGCGGCTGGAGCGCTCGGCCGGCGTGGGAGCGCAAGGCCGCAGAT
                 GCAATCTTCTTACCGCGAAGAAGCCAGGGGAATAGGTAGCCACATCTTGTTTGCAGAT
                 AAGAAAGGAAGCTAACGCAGTATCTGCAAAGCCAGGAGTCTGACTCAGTACTTTTCTC
                 ACTCATGCATACAAGCAGCTAAAAATGACACAGCTTATTTACCATGCCCCTGACACTG
                 CACTGAGCACTTTATGAGCTTGAACTCTGTTAATCTCACGACCACCTCATGAGACTCT
                 CCAGAAAGAGCAACAGTAATGGAGTACATGAGCACTGGAAGTGACAATAAAGAAGAGA
                 TTGATTTATTAATTAAACATTTAAATGTGTCTGATGTAATAGACATTATGGAAAATCT
                 TTATGCAAGTGAAGAGCCAGCAGTTTATGAACCCAGTCTAATGACCATGTGTCAAGAC
                 AGTAATCAAAACGATGAGCGTTCTAAGTCTCTGCTGCTTAGTGGCCAAGAGGTACCAT
                 GGTTGTCATCAGTCAGATATGGAACTGTGGAGGATTTGCTTGCTTTTGCAAACCATAT
                 ATCCAACACTGCAAAGCATTTTTATGGACAACGACCACAGGAATCTGGAATTTTATTA
                 AACATGGTCATCACTCCCCAAAATGGACGTTACCAAATAGATTCCGATGTTCTCCTGA
                 TCCCCTGGAAGCTGACTTACAGGAATATTGGTTCTGATTTTATTCCTCGGGGCGCCTT
                 TGGAAAGGTATACTTGGCTCAAGATATAAAGACGAAGAAAAGAATGGCGTGTAAACTG
                 ATCCCAGTAGATCAATTTAAGCCATCTGATGTGGAAATTCAGGCTTGCTTCCGGCACG
                 AGAACATCGCAGAGCTGTATGGCGCAGTCCTGTGGGGTGAAACTGTCCATCTCTTTAT
                 GGAAGCAGGCGAGGGAGGGTCTGTTCTGGAGAAACTGGAGAGCTGTGGACCAATGAGA
                 GAATTTGAAATTATTTGGGTGACAAAGCATGTTCTCAAGGGACTTGATTTTCTACACT
                 CAAAGAAAGTGATCCATCATCATATTAAACCTAGCAACATTGTTTTCATGTCCACAAA
                 AGCTGTTTTGGTGGATTTTGGCCTAAGTGTTCAAATGACCGAAGATGTCTATTTTCCT
                 AAGCACCTCCGAGGAACAGAGATTTACATGAGCCCAGAGGTCATCCTGTGCAGGGGCC
                 ATTCAACCAAAGCAGACATCTACAGCCTGGGGCCCACGCTCATCCACATGCAGACGGG
                 CACCCCACCCTGGGTGAAGCGCTACCCTCGCTCAGCCTATCCCTCCTACCTGTACATA
                 ATCCACAAGCAACCACCTCCACTGGAAGACATTGCAGATGACTCCAGTCCAGGGATGA
                 GAGAGCTGATAGAAGCTTCCCTGGAGAGAAACCCCAATCACCGCCCAAGAGCCGCAGA
                 CCTACTAAAACATGAGGCCCTGAACCCGCCCAGAGAGGATCAGCCACGCTGTACGAGT
                 CTGGACTCTGCCCTCTTGGAGCGCAAGAGGCTGCTGAGTAGGAAGGAGCTGGAACTTC
                 CTGAGAACATTGCTGATTCTTCGTGCACAGGAAGCACCGAGGAATCTGAGATGCTCAA
                 GAGGCAACGCTCTCTCTACATCGACCTCGGCGCTCTGGCTGGCTACTTCAATCTTGTT
                 CGGGGACCACCAACGCTTGAATATGGCTGAAGGATGCCATGTTTGCCTCTAAATTAAG
                 ACAGCATTGATCTCCTGGAGGCTGGTTCTGCTGCCTCTACACAGGGGCCCGTTACAGT
                 GAATGGTGCCATTTTCGAAGGAGCAGTGTGACCTCCTGTGACCCATGAATGTGCCTCC
                 AAGCGGCCCTGTGTGTTTGACATGTGAAGCTATTTGATATGCACCAGGTCTCAAGGTT
                 CTCATTTCTCAGGTGACGTGATTCTAAGGCAGGAATTTGAGAGTTCACAGAAGGATCG
                 TGTCTGCTGACTGTTTCATTCACTGTGCACTTTGCTCAAAATTTTAAAAATACCAATC
                 ACAAGGATAATAGAGTAGCCTAAAATTACTATTCTTGGTTCTTATTTAAGTATGCAAT
                 ATTCATTTTACTCAGAATAGCCTGTTTTGTGTATATTGGTGTATATTATATAACTCTT
                 TGAGCCTTTATTGGTAAATTCTGGTATACATTGAATTCATTATAATTTGGGTGACTAG
                 AACAACTTGAAGATTGTAGCAATAAGCTGGACTAGTGTCCTAAAAATGGCTAACTGAT
                 GAATTAGAACCCATCTGACAGACGGCCACTAGTGACAGTTTCTTTTGTGTTCCTATGG
                 AAACATTTTATACTGTACATGCTATGCTGAAGACATTCAAAACGTGATGTTTTGAATG
                 TGGATAAAACTCTGTAAACCACATAATTTTGTACATCCAAGGATGAGGTGTGACCTTT
                 AAGAAAAATGAAAACTTTTGTAAATTATTGATGATTTTGTAATTCTTATGACTAAATT
                 TTCTTTTAAGCATTTGTATATTAAAATAGCATACTGTGTATGTTTTATATCAAATGCC
                 TTCATGAATCTTTCATACATATATATATTTGTAACATGTAAAGTATGTGAGTAGTCTT
                 ATGTAAAGTATGTTTTTACATTATGCAAATAAAACCCAATACTTTTGTCCAATGTGGT
                 TGGTCAAATCAACTGAATAAATTCAGTATTTTGCCTT
                 ORF Start: ATG at 367                ORF Stop: TGA at 1768
                 SEQ ID NO: 2            467 aa       MW at 52896.9kD
NOV1a,           MEYMSTGSDNKEEIDLLIKHLNVSDVIDIMENLYASEEPAVYEPSLMTMCQDSNQNDE
CG101683-01
Protein Sequence RSKSLLLSGQEVPWLSSVRYGTVEDLLAFANHISNTAKHFYGQRPQESGILLNMVITP
                 QNGRYQIDSDVLLIPWKLTYRNIGSDFIPRGAFGKVYLAQDIKTKKRMACKLIPVDQF
                 KPSDVEIQACFRHENIAELYGAVLWGETVHLFMEAGEGGSVLEKLESCGPMREFEIIW
                 VTKHVLKGLDFLHSKKVIHHDIKPSNIVFMSTKAVLVDFGLSVQMTEDVYFPKDLRGT
                 EIYMSPEVILCRGHSTKADIYSLGATLIHMQTGTPPWVKRYPRSAYPSYLYIIHKQAP
                 PLEDIADDCSPGMRELIEASLERNPNHRPRAADLLKHEALNPPREDQPRCTSLDSALL
                 ERKRLLSRKELELPENIADSSCTGSTEESEMLKRQRSLYIDLGALAGYFNLVRGPPTL
                 SEQ ID NO: 3           1425 bp
NOV1b,           ACCATGGAGTACATGAGCACTGGAAGTGACAATAAAGAAGAGATTGATTTATTAATTA
248490507
DNA Sequence     AACATTTAAATGTGTCTGATGTAATAGACATTATGGAAAATCTTTATGCAAGTGAAGA
                 CCCAGCAGTTTATGAACCCAGTCTAATGACCATGTGTCAAGACAGTAATCAAAACGAT
                 GAGCGTTCTAAGTCTCTGCTGCTTAGTGGCCAAGAGGTACCATGGTTGTCATCAGTCA
                 GATACGGAACTGTGGAGGATTTGCTTGCTTTTGCAAACCATATATCCAACACTGCAAA
                 GCATTTTTATGGACAACGACCACAGGAATCTGGAATTTTATTAAACATGGTCATCACT
                 CCCCAAAATGGACGTTACCAAATAGATTCCGATGTTCTCCTGATCCCCTGGAAGCTGA
                 CTTACAGGAATATTGGTTCTGATTTTATTCCTCGGGGCGCCTTTGGAAAGGTATACTT
                 GGCACAAGATATAAAGACGAAGAAAAGAATGGCGTGTAAACTGATCCCAGTAGATCAA
                 TTTAAGCCATCTGATGTGGAAATCCAGGCTTGCTTCCGGCACGAGAACATCGCAGAGC
                 TGTATGGCGCAGTCCTGTGGGGTGAAACTGTCCATCTCTTTATGGAAGCAGGCGAGGG
                 AGGGTCTGTTCTGGAGAAACTGGAGAGCTGTGCACCAATGAGAGAATTTGAAATTATT
                 TGGGTGACAAAGCATGTTCTCAAGGGACTTGATTTTCTACACTCAAAGAAAGTGATCC
                 ATCATGATATTAAACCTAGCAACATTGTTTTCATGTCCACAAAAGCTGTTTTGGTGGA
                 TTTTGGCCTAAGTGTTCAAATGACCGAAGATGTCTATTTTCCTAAGGACCTCCGAGGA
                 ACAGAGATTTACATGAGCCCAGAGGTCATCCTGTGCAGGGGCCATTCAACCAAAGCAG
                 ACATCTACAGCCTGGGGGCCACGCTCATCCACATGCAGACGCGCACCCCACCCTGGGT
                 GAAGCGCTACCCTCGCTCAGCCTATCCCTCCTACCTGTACATAATCCACAAGCAAGCA
                 CCTCCACTGGAAGACATTGCAGATGACTGCAGTCCAGGGATGAGAGAGCTCATACAAG
                 CTTCCCTGGAGAGAAACCCCAATCACCGCCCAAGAGCCGCAGACCTACTAAAACATGA
                 GGCCCTGAACCCGCCCAGAGAGGATCAGCCACGCTGTCAGAGTCTGGACTCTGCCCTC
                 TTGGAGCGCAAGAGGCTGCTGAGTAGGAAGGAGCTGGAACTTCCTGAGAACATTGCTG
                 ATTCTTCGTCCACAGGAAGCACCGAGGAATCTGAGATGCTCAAGAGGCAACGCTCTCT
                 CTACATCGACCTCGGCGCTCTGGCTGGCTACTTCAATCTTGTTCGGGCACCACCAACG
                 CTTGAATATGGCCATCATCACCACCATCACTGA
                 ORF Start: at 1                      ORF Stop: TGA at 1423
                 SEQ ID NO: 4            474 aa       MW at 53847.9kD
NOV1b,           TMEYMSTGSDNKEEIDLLIKHLNVSDVIDIMENLYASEEPAVYEPSLMTMCQDSNQND
248490507
Protein Sequence ERSKSLLLSGQEVPWLSSVRYGTVEDLLAFANHISNTAKHFYGQRPQESGILLNMVIT
                 PQNGRYQIDSDVLLIPWKLTYRNIGSDFIPRGAFGKVYLAQDIKTKKRMACKLIPVDQ
                 FKPSDVEIQACFRHENIAELYGAVLWGETVHLFMEAGEGGSVLEKLESCGPMREFEII
                 WVTKHVLKGLDFLHSKKVIHHDIKPSNIVFMSTKAVLVDFGLSVQMTEDVYFPKDLRG
                 TEIYNSPEVILCRGHSTKADIYSLGATLIHMQTGTPPWVKRYPRSAYPSYLYIIHKQA
                 PPLEDIADDCSPGMRELIEASLERNPNHRPRAADLLKHEALNPPREDQPRCQSLDSAL
                 LERKRLLSRKELELPENIADSSCTGSTEESEMLKRQRSLYIDLGALAGYFNLVRGPPT
                 LEYGHHHHHH
                 SEQ ID NO: 5           1316 bp
NOV1c,           ACGGGATCCACCATGGAGTACATGAGCACTGGAAGTGACAATAAAGAAGAGATTGATT
253174293
DNA Sequence     TATTAATTAAACATTTAAATGTGTCTGATGTAATAGACATTATGGAAAATCTTTATGC
                 AAGTGAAGAGCCAGCAGTTTATGAACCCAGTCTAATGACCATCTGTCAAGACAGTAAT
                 CAAAACGATGAGCGTTCTAAGTCTCTGCTGCTTAGTGGCCAAGAGGTACCATGGTTGT
                 CATCAGTCAGATACGGAACTGTGGAGGATTTGCTTGCTTTTGCAAACCATATATCCAA
                 CACTGCAAAGCATTTTTATGGACAACGACCACAGGAATCTGGAATTTTATTAAACATG
                 GTCATCACTCCCCAAAATGGACGTTACCAAATAGATTCCGATGTTCTCCTGATCCCCT
                 GGAAGCTGACTTACAGGAATATTGGTTCTGATTTTATTCCTCGGGGCGCCTTTGGAAA
                 GGTATACTTGGCACAAGATATAAAGACGAAGAAAAGAATGGCGTGTAAACTGATCCCA
                 GTAGATCAATTTAAGCCATCTGATGTGGAAATCCAGGCTTGCTTCCGGCACGAGAACA
                 TCGCAGAGCTGTATGGCGCAGTCCTGTGGGGTGAAACTGTCCATCTCTTTATGGAAGC
                 AGGCGAGGGAGGGTCTGTTCTGGAGAAACTGGAGAGCTGTGGACCAATGAGAGAATTT
                 GAAATTATTTGGGTGACAAAGCATGTTCTCAAGGGACTTGATTTTCTACACTCAAAGA
                 AAGTGATCCATCATGATATTAAACCTAGCAACATTGTTTTCATGTCCACAAAAGCTGT
                 TTTGGTGGATTTTGGCCTAAGTGTTCAAATGACCGAAGATGTCTATTTTCCTAAGGAC
                 CTCCGAGGAACAGAGATTTACATGAGCCCAGAGGTCATCCTGTGCAGGGGCCATTCAA
                 CCAAAGCAGACATCTACAGCCTGGGGGCCACGCTCATCCACATGCAGACGGGCACCCC
                 ACCCTGGGTGAAGCGCTACCCTCGCTCAGCCTATCCCTCCTACCTGTACATAATCCAC
                 AAGCAAGCACCTCCACTGGAAGACATTGCAGATGACTGCAGTCCAGGGATGAGAGAGC
                 TGATAGAAGCTTCCCTGGAGAGAAACCCCAATCACCGCCCAAGAGCCGCAGACCTACT
                 AAAACATGAGGCCCTGAACCCGCCCAGAGAGGATCAGCCACGCTGTCAGAGTCTGGAC
                 TCTGCCCTCTTGGAGCGCAAGAGGCTGCTGAGTAGGAAGGAGCTGGAACTTCCTGAGA
                 ACATTGCTCATCATCACCACCATCACTGAGCGGCCGCAAG
                 ORF Start: at 1                      ORF Stop: TGA at 1303
                 SEQ ID NO: 6            434 aa       MW at 49384.9 kD
NOV1c,           TGSTMEYNSTGSDNKEEIDLLIKHLNVSDVIDIMENLYASEEPAVYEPSLMTMCQDSN
253174293
Protein Sequence QNDERSKSLLLSGQEVPWLSSVRYGTVEDLLAFANHISNTAKHFYGQRPQESGILLNM
                 VITPQNGRYQIDSDVLLIPWKLTYRNIGSDFIPRGAFGKVYLAQDIKTKKRMACKLIP
                 VDQFKPSDVEIQACFRHENIAELYGAVLWGETVHLFMEAGEGGSVLEKLESCGPMREF
                 EIIWVTKHVLKGLDFLHSKKVIHHDIKPSNIVFMSTKAVLVDFGLSVQMTEDVYFPKD
                 LRGTEIYMSPEVILCRGHSTKADIYSLGATLIHMQTGTPPWVKRYPRSAYPSYLYIIH
                 KQAPPLEDIADDCSPGMRELIEASLERNPNHRPRAADLLKHEALNPPREDQPRCQSLD
                 SALLERKRLLSRKELELPENIAHHHHHH
                 SEQ ID NO: 7           1407 bp
NOV1d,           ACCATGGAGTACATGAGCACTGGAAGTGACAATAAAGAAGAGATTGATTTATTAATTA
248490584
DNA Sequence     AACATTTAAATGTGTCTGATGTAATAGACATTATGGAAAATCTTTATGCAAGTGAAGA
                 GCCAGCAGTTTATGAACCCAGTCTAATGACCATGTGTCAAGACAGTAATCAAACGAT
                 GAGCGTTCTAAGTCTCTGCTGCTTAGTGGCCAAGAGGTACCATGGTTGTCATCAGTCA
                 GATACGGAACTGTGGAGGATTTGCTTGCTTTTGCAAACCATATATCCAACACTGCAAA
                 GCATTTTTATGGACAACGACCACAGGAATCTGGAATTTTATTAAACATCGTCATCACT
                 CCCCAAAATGGACGTTACCAAATAGATTCCGATGTTCTCCTGATCCCCTGGAAGCTGA
                 CTTACAGGAATATTGGTTCTGATTTTATTCCTCGGGGCGCCTTTGGAAAGGTATACTT
                 GGCACAAGATATAAAGACGAAGAAAAGAATGGCGTGTAAACTGATCCCAGTAGATCAA
                 TTTAAGCCATCTGATGTGGAAATCCAGGCTTGCTTCCGGCACGAGAACATCCCAGAGC
                 TGTATGGCGCAGTCCTGTGGGGTGAAACTGTCCATCTCTTTATGGAAGCAGGCGAGGG
                 AGGGTCTGTTCTGGAGAAACTGGAGAGCTGTGGACCAATGAGAGAATTTGAAATTATT
                 TGGGTGACAAAGCATGTTCTCAAGGGACTTGATTTTCTACACTCAAAGAAAGTGATCC
                 ATCATGATATTAAACCTAGCAACATTGTTTTCATGTCCACAAAAGCTGTTTTGGTGGA
                 TTTTGGCCTAAGTGTTCAAATGACCGAAGATGTCTATTTTCCTAAGGACCTCCGAGGA
                 ACAGAGATTTACATGAGCCCAGAGGTCATCCTGTGCAGGGGCCATTCAACCAAAGCAG
                 ACATCTACAGCCTGGGGGCCACGCTCATCCACATGCAGACGGGCACCCCACCCTGGGT
                 GAAGCGCTACCCTCGCTCAGCCTATCCCTCCTACCTGTACATAATCCACAACCAAGCA
                 CCTCCACTGGAAGACATTGCAGATGACTGCAGTCCAGGGATCAGAGAGCTGATAGAAG
                 CTTCCCTGGAGAGAAACCCCAATCACCGCCCAAGAGCCGCAGACCTACTAAAACATGA
                 GGCCCTGAACCCGCCCAGAGAGGATCAGCCACGCTGTCAGAGTCTGGACTCTGCCCTC
                 TTGGAGCGCAAGAGGCTGCTGAGTAGGAAGGAGCTGGAACTTCCTGAGAACATTGCTG
                 ATTCTTCGTGCACAGGAAGCACCGAGGAATCTGAGATGCTCAAGAGGCAACGCTCTCT
                 CTACATCGACCTCGGCGCTCTGGCTGGCTACTTCAATCTTGTTCGGGGACCACCAACG
                 CTTGAATATGGCTGA
                 ORF Start: at 1                      ORF Stop: TGA at 1405
                 SEQ ID NO: 8            468 aa       MW at 53025.0 kD
NOV1d,           TMEYMSTGSDNKEEIDLLIKHLNVSDVIDIMENLYASEEPAVYEPSLMTMCQDSNQND
248490584
Protein Sequence ERSKSLLLSCQEVPWLSSVRYGTVEDLLAFANHISNTAKHFYGQRPQESGILLNNVIT
                 PQNGRYQIDSDVLLIPWKLTYRNIGSDFIPRGAFGKVYLAQDIKTKKRMACKLIPVDQ
                 FKPSDVEIQACFRHENIAELYGAVLWGETVHLFMEAGEGGSVLEKLESCGPMREFEII
                 WVTKHVLKGLDFLHSKKVIHHDIKPSNIVFMSTKAVLVDFGLSVQMTEDVYFPKDLRG
                 TEIYMSPEVILCRGHSTKADIYSLGATLIHMQTGTPPWVKRYPRSAYPSYLYIIHKQA
                 PPLEDIADDCSPGMRELIEASLERNPNHRPRAADLLKHEALNPPREDQPRCQSLDSAL
                 LERKRLLSRKELELPEMIADSSCTGSTEESEMLKRQRSLYIDLGALAGYFNLVRGPPT
                 LEYG
                 SEQ ID NO: 9           1448 bp
NOV1e,           ACGGGATCCACCATGGGACATCATCACCACCATCACGAGTACATGAGCACTGGAAGTG
258054391
DNA Sequence     ACAATAAAGAAGAGATTGATTTATTAATTAAACATTTAAATGTGTCTGATGTAATAGA
                 CATTATGGAAAATCTTTATGCAAGTGAAGAGCCAGCAGTTTATGAACCCAGTCTAATG
                 ACCATGTGTCAAGACAGTAATCAAAACGATGAGCGTTCTAAGTCTCTGCTGCTTAGTG
                 GCCAAGAGGTACCATGGTTGTCATCAGTCAGATACGGAACTGTGGAGGATTTGCTTGC
                 TTTTGCAAACCATATATCCAACACTGCAAAGCATTTTTATGGACAACGACCACAGGAA
                 TCTGGAATTTTATTAAACATGGTCATCACTCCCCAAAATGGACGTTACCAAATAGATT
                 CCGATGTTCTCCTGATCCCCTGGAAGCTGACTTACAGGAATATTGGTTCTGATTTTAT
                 TCCTCGGGGCGCCTTTGGAAAGGTATACTTGGCACAAGATATAAAGACGAAGAAAAGA
                 ATGGCGTGTAAACTGATCCCAGTAGATCAATTTAAGCCATCTGATGTGGAAATCCAGG
                 CTTGCTTCCGGCACGAGAACATCGCAGAGCTGTATGGCGCAGTCCTGTGGGGTGAAAC
                 TGTCCATCTCTTTATGGAAGCAGGCGAGGGAGGGTCTGTTCTGGAGAAACTGGAGAGC
                 TGTGGACCAATGAGAGAATTTGAAATTATTTGGGTGACAAAGCATGTTCTCAAGGGAC
                 TTGATTTTCTACACTCAAAGAAAGTGATCCATCATGATATTAAACCTAGCAACATTGT
                 TTTCATGTCCACAAAAGCTGTTTTGGTGGATTTTGGCCTAAGTGTTCAAATGACCGAA
                 GATGTCTATTTTCCTAAGGACCTCCGAGGAACAGAGATTTACATGAGCCCAGAGGTCA
                 TCCTGTGCAGGGGCCATTCAACCAAAGCAGACATCTACAGCCTGGGGGCCACGCTCAT
                 CCACATGCAGACGGGCACCCCACCCTGGGTGAAGCGCTACCCTCGCTCAGCCTATCCC
                 TCCTACCTGTACATAATCCACAAGCAAGCACCTCCACTGGAAGACATTGCAGATGACT
                 GCAGTCCAGGGATGAGAGAGCTGATAGAAGCTTCCCTGGAGAGAAACCCCAATCACCG
                 CCCAAGAGCCGCAGACCTACTAAAACATGAGGCCCTGAACCCGCCCAGAGAGGATCAG
                 CCACGCTGTCAGAGTCTGGACTCTGCCCTCTTGGAGCGCAAGAGGCTGCTGAGTAGGA
                 AGGAGCTGGAACTTCCTGAGAACATTGCTGATTCTTCGTGCACAGGAAGCACCGAGGA
                 ATCTGAGATGCTCAAGAGGCAACGCTCTCTCTACATCGACCTCGGCGCTCTGGCTGGC
                 TACTTCAATCTTGTTCGGGGACCACCAACGCTTGAATATGGCTGAGCGGCCGCAAG
                 ORF Start: at 1                      ORF Stop: TGA at 1435
                 SEQ ID NO: 10          1478 aa       MW at 54150.2 kD
NOV1e,           TGSTMGHHHHHHEYMSTGSDNKEEIDLLIKHLNVSDVIDIMENLYASEEPAVYEPSLM
258054391
Protein Sequence TMCQDSNQNDERSKSLLLSGQEVPWLSSVRYGTVEDLLAFANHISNTAKHFYGQRPQE
                 SGILLNMVITPQNGRYQIDSDVLLIPWKLTYRNIGSDFIPRGAFGKVYLAQDIKTKKR
                 MACKLIPVDQFKPSDVEIQACFRHENIAELYGAVLWGETVHLFMEAGEGGSVLEKLES
                 CGPMREFEIIWVTKHVLKGLDFLHSKKVIHHDIKPSNIVFMSTKAVLVDFGLSVQMTE
                 DVYFPKDLRGTEIYMSPEVILCRGHSTKADIYSLGATLIHMQTGTPPWVKRYPRSAYP
                 SYLYIIHKQAPPLEDIADDCSPGMRELIEASLERNPNHRPRAADLLKHEALNPPREDQ
                 PRCQSLDSALLERKRLLSRKELELPENIADSSCTGSTEESEMLKRQRSLYIDLGALAG
                 YFNLVRGPPTLEYG
                 SEQ ID NO: 11          1278 bp
NOV1f,           ACCATGGAGTACATGAGCACTGGAAGTGACAATAAAGAAGAGATTGATTTATTAATTA
248494549
DNA Sequence     AACATTTAAATGTGTCTGATGTAATAGACATTATGGAAAATCTTTATGCAAGTGAAGA
                 GCCAGCAGTTTATGAACCCAGTCTAATGACCATGTGTCAAGACAGTAATCAAAACGAT
                 GAGCGTTCTAAGTCTCTGCTGCTTAGTGGCCAAGAGGTACCATGGTTGTCATCAGTCA
                 GATACGGAACTGTGGAGGATTTGCTTGCTTTTGCAAACCATATATCCAACACTGCAAA
                 GCATTTTTATGGACAACGACCACAGGAATCTGGAATTTTATTAAACATGGTCATCACT
                 CCCCAAAATGGACGTTACCAAATAGATTCCGATGTTCTCCTGATCCCCTGGAAGCTGA
                 CTTACAGGAATATTGGTTCTGATTTTATTCCTCGGGGCGCCTTTGGAAAGGTATACTT
                 GGCACAAGATATAAAGACGAAGAAAAGAATGGCGTGTAAACTGATCCCAGTAGATCAA
                 TTTAAGCCATCTGATGTGGAAATCCAGGCTTGCTTCCGGCACGAGAACATCGCAGAGC
                 TGTATGGCGCAGTCCTGTGGGGTGAAACTGTCCATCTCTTTATGGAAGCAGGCGAGGG
                 AGGGTCTGTTCTGGAGAAACTGGAGAGCTGTGGACCAATGAGAGAATTTGAAATTATT
                 TGGGTGACAAAGCATGTTCTCAAGGGACTTGATTTTCTACACTCAAAGAAAGTGATCC
                 ATCATGATATTAAACCTAGCAACATTGTTTTCATGTCCACAAAAGCTGTTTTGGTGGA
                 TTTTGGCCTAAGTGTTCAAATGACCGAAGATGTCTATTTTCCTAAGGACCTCCGAGGA
                 ACAGAGATTTACATGAGCCCAGAGGTCATCCTGTGCAGGGGCCATTCAACCAAAGCAG
                 ACATCTACAGCCTGGGGGCCACCCTCATCCACATGCAGACGGGCACCCCACCCTGGGT
                 GAAGCGCTACCCTCGCTCAGCCTATCCCTCCTACCTGTACATAATCCACAAGCAAGCA
                 CCTCCACTGGAAGACATTGCAGATGACTGCAGTCCAGGGATGAGAGAGCTGATAGAAG
                 CTTCCCTGGAGAGAAACCCCAATCACCGCCCAAGAGCCGCAGACCTACTAAAACATGA
                 GGCCCTGAACCCGCCCAGAGAGGATCAGCCACGCTGTCAGAGTCTGGACTCTGCCCTC
                 TTGGAGCGCAAGAGGCTGCTGAGTAGGAAGGAGCTGGAACTTCCTGAGAACATTGCTT
                 GA
                 ORF Start: at 1                      ORF Stop: TGA at 1276
                 SEQ ID NO: 12           425 aa       MW at 48316.8 kD
NOV1f            TMEYMSTGSDNKEEIDLLTKHLNVSDVIDIMENLYASEEPAVYEPSLMTMCQDSNQND
248494549
Protein Sequence ERSKSLLLSGQEVPWLSSVRYGTVEDLLAFANHISNTAKHFYGQRPQESGILLNMVIT
                 PQNGRYQIDSDVLLIPWKLTYRNIGSDFIPRGAFGKVYLAQDIKTKKRMACKLIPVDQ
                 FKPSDVEIQACFRHENIAELYGAVLWGETVHLFMEAGEGGSVLEKLESCGPMREFEII
                 WVTKHVLKGLDFLHSKKVIHHDIKPSNIVFMSTKAVLVDFGLSVQMTEDVYFPKDLRG
                 TEIYMSPEVILCRGHSTKADIYSLGATLIHMQTGTPPWVKRYPRSAYPSYLYIIHKQA
                 PPLEDIADDCSPGMRELIEASLERNPNHRPRAADLLKHEALNPPREDQPRCQSLDSAL
                 LERKRLLSRKELELPENIA
                 SEQ ID NO: 13          1327 bp
NOV1g,           CCACCATCGGGCGCGGATCCACCATGGGACATCATCACCACCATCACGAGTACATGAG
259741837
DNA Sequence     CACTGGAAGTGACAATAAAGAAGAGATTGATTTATTAATTAAACATTTAAATGTGTCT
                 GATGTAATAGACATTATGGAAAATCTTTATGCAAGTGAAGAGCCAGCAGTTTATGAAC
                 CCAGTCTAATGACCATGTGTCAAGACAGTAATCAAAACGATGAGCGTTCTAAGTCTCT
                 GCTGCTTAGTGGCCAAGAGGTACCATGGTTGTCATCAGTCAGATACGGAACTGTGGAG
                 GATTTGCTTGCTTTTGCAAACCATATATCCAACACTGCAAAGCATTTTTATGGACAAC
                 GACCACAGGAATCTGGAATTTTATTAAACATGGTCATCACTCCCCAAAATGGACGTTA
                 CCAAATAGATTCCGATGTTCTCCTGATCCCCTGGAAGCTGACTTACAGGAATATTGGT
                 TCTGATTTTATTCCTCGGGGCGCCTTTGGAAAGGTATACTTGGCACAAGATATAAAGA
                 CGAAGAAAAGAATGGCGTGTAAACTGATCCCAGTAGATCAATTTAAGCCATCTGATGT
                 GGAAATCCAGGCTTGCTTCCGGCACGAGAACATCGCAGAGCTGTATGGCGCAGTCCTG
                 TGGGGTGAAACTGTCCATCTCTTTATGGAAGCAGGCGAGGGAGGGTCTGTTCTGGAGA
                 AACTGGAGAGCTGTGGACCAATGAGAGAATTTGAAATTATTTGGGTGACAAAGCATGT
                 TCTCAAGGGACTTGATTTTCTACACTCAAAGAAAGTGATCCATCATGATATTAAACCT
                 AGCAACATTGTTTTCATGTCCACAAAAGCTGTTTTGGTGGATTTTGGCCTAAGTGTTC
                 AAATGACCGAAGATGTCTATTTTCCTAAGGACCTCCGACGAACAGAGATTTACATGAG
                 CCCAGAGGTCATCCTGTGCAGGGGCCATTCAACCAAAGCAGACATCTACAGCCTGGGG
                 GCCACGCTCATCCACATGCAGACGGGCACCCCACCCTGGGTGAAGCGCTACCCTCGCT
                 CAGCCTATCCCTCCTACCTGTACATAATCCACAAGCAAGCACCTCCACTGGAAGACAT
                 TGCAGATCACTGCAGTCCAGGGATGAGAGAGCTGATACAAGCTTCCCTGGAGAGAAAC
                 CCCAATCACCGCCCAAGAGCCGCAGACCTACTAAAACATGAGGCCCTGAACCCGCCCA
                 GAGAGGATCAGCCACGCTGTCAGAGTCTGGACTCTGCCCTCTTGGAGCGCAAGAGGCT
                 GCTGAGTAGGAAGGAGCTGGAACTTCCTGAGAACATTGCTTGAGGCGGCCG
                 ORF Start: at 3                      ORF Stop: TGA at 1317
                 SEQ ID NO: 14           438 aa       MW at 49768.4 kD
NOV1g,           TIGRGSTMGHHHHHHEYMSTGSDNKEEIDLLIKHLNVSDVIDIMENLYASEEPAVYEP
259741837
Protein Sequence SLMTMCQDSNQNDERSKSLLLSGQEVPWLSSVRYGTVEDLLAFANHISNTAKHFYGQR
                 PQESGILLNMVITPQNGRYQIDSDVLLIPWKLTYRNIGSDFIPRGAFGKVYLAQDIKT
                 KKRMACKLIPVDQFKPSDVEIQACFRHENIAELYGAVLWGETVHLFMEAGEGGSVLEK
                 LESCGPMREFEIIWVTKHVLKGLDFLHSKKVIHHDIKPSNIVFMSTKAVLVDFGLSVQ
                 MTEDVYFPKDLRGTEIYMSPEVILCRGHSTKADIYSLGATLIHMQTGTPPWVKRYPRS
                 AYPSYLYIIHKQAPPLEDIADDCSPGMRELIEASLERNPNHRPRAADLLKHEALNPPR
                 EDQPRCQSLDSALLERKRLLSRKELELPENIA
                 SEQ. ID NO: 15         1428 bp
NOV1h,           ACCATGGGACATCATCACCACCATCACGAGTACATGAGCACTGGAAGTGACAATAAAG
260480803
DNA Sequence     AAGAGATTGATTTATTAATTAAACATTTAAATGTGTCTGATGTAATAGACATTATGGA
                 AAATCTTTATGCAAGTGAAGAGCCAGCAGTTTATGAACCCAGTCTAATGACCATGTGT
                 CAAGACAGTAATCAAAACGATGAGCGTTCTAAGTCTCTGCTGCTTAGTGGCCAAGAGG
                 TACCATGGTTGTCATCAGTCAGATACGGAACTGTGGAGGATTTGCTTGCTTTTGCAAA
                 CCATATATCCAACACTGCAAAGCATTTTTATGGACAACGACCACAGGAATCTGGAATT
                 TTATTAAACATGGTCATCACTCCCCAAAATGGACGTTACCAAATAGATTCCGATGTTC
                 TCCTGATCCCCTGGAAGCTGACTTACAGGAATATTGGTTCTGATTTTATTCCTCGGGG
                 CGCCTTTGGAAAGGTATACTTGGCACAAGATATAAAGACGAAGAAAAGAATGGCGTGT
                 AAACTGATCCCAGTAGATCAATTTAAGCCATCTGATGTGGAAATCCAGGCTTGCTTCC
                 GGCACGAGAACATCGCAGAGCTGTATGGCGCAGTCCTGTGGGGTGAAACTGTCCATCT
                 CTTTATGGAAGCAGGCGAGGGAGGGTCTGTTCTGGAGAAACTGGAGAGCTGTGGACCA
                 ATGAGAGAATTTGAAATTATTTGGGTGACAAAGCATGTTCTCAAGGGACTTGATTTTC
                 TACACTCAAAGAAAGTGATCCATCATGATATTAAACCTAGCAACATTGTTTTCATGTC
                 CACAAAAGCTGTTTTGGTGGATTTTGGCCTAAGTGTTCAAATGACCGAAGATGTCTAT
                 TTTCCTAAGGACCTCCGAGGAACAGAGATTTACATGAGCCCAGAGGTCATCCTGTGCA
                 GGGGCCATTCAACCAAAGCACACATCTACAGCCTGGGGGCCACGCTCATCCACATGCA
                 GACGGGCACCCCACCCTGGGTGAAGCGCTACCCTCGCTCAGCCTATCCCTCCTACCTG
                 TACATAATCCACAAGCAAGCACCTCCACTGGAAGACATTGCAGATGACTGCAGTCCAG
                 GGATGAGAGAGCTGATAGAAGCTTCCCTGGAGAGAAACCCCAATCACCGCCCAAGAGC
                 CGCAGACCTACTAAAACATCAGGCCCTGAACCCGCCCAGAGAGGATCAGCCACGCTGT
                 CAGAGTCTGGACTCTGCCCTCTTGGAGCGCAAGAGGCTGCTGAGTAGGAAGGAGCTGG
                 AACTTCCTGAGAACATTGCTGATTCTTCGTCCACAGGAAGCACCGAGGAATCTCAGAT
                 GCTCAAGAGGCAACCCTCTCTCTACATCGACCTCGGCGCTCTGGCTGGCTACTTCAAT
                 CTTGTTCGGGGACCACCAACGCTTGAATATGGCTGA
                 ORF Start: at 1                      ORF Stop: TGA at 1426
                 SEQ ID NO: 16           475 aa       MW at 53904.9kD
NOV1h,           TMGHHHHHHEYMSTGSDNKEEIDLLIKHLNVSDVIDIMENLYASEEPAVYEPSLMTMC
260480803
Protein Sequence QDSNQNDERSKSLLLSCQEVPWLSSVRYGTVEDLLAFANHISNTAKHFYGQRPQESGI
                 LLNMVITPQNGRYQIDSDVLLIPWKLTYRNIGSDFIPRGAFGKVYLAQDIKTKKRMAC
                 KLIPVDQFKPSDVEIQACFRHENIAELYGAVLWGETVHLFMEAGEGGSVLEKLESCGP
                 MREFEIIWVTKHVLKGLDFLHSKKVIHHDIKPSNIVFMSTKAVLVDFGLSVQMTEDVY
                 FPKDLRGTEIYMSPEVILCRGHSTKADIYSLGATLIHMQTGTPPWVKRYPRSAYPSYL
                 YIIHKQAPPLEDIADDCSPGMRELIEASLERNPNHRPRAADLLKHEALNPPREDQPRC
                 QSLDSALLERKRLLSRKELELPENIADSSCTGSTEESEMLKRQRSLYIDLGALAGYFN
                 LVRCPPTLEYG
                 SEQ ID NO: 17          1434 bp
NOV1i,           CGCGGATCCACCATGGAGTACATGAGCACTGGAAGTGACAATAAAGAAGAGATTGATT
209983329
DNA Sequence     TATTAATTAAACATTTAAATGTGTCTGATGTAATAGACATTATGGAAAATCTTTATGC
                 AAGTGAAGAGCCAGCAGTTTATGAACCCAGTCTAATGACCATGTGTCAACACAGTAAT
                 CAAAACGATGAGCGTTCTAAGTCTCTGCTGCTTAGTGGCCAAGACGTACCATGGTTGT
                 CATCACTCAGATACGGAACTGTGGAGGATTTGCTTGCTTTTGCAAACCATATATCCAA
                 CACTGCAAAGCATTTTTATGGACAACGACCACAGGAATCTGGAATTTTATTAAACATG
                 GTCATCACTCCCCAAAATGGACGTTACCAAATAGATTCCGATGTTCTCCTGATCCCCT
                 GGAAGCTGACTTACAGGAATATTGGTTCTGATTTTATTCCTCGGGGCGCCTTTGGAAA
                 GGTATACTTGGCACAAGATATAAAGACGAAGAAAAGAATGGCGTGTAAACTGATCCCA
                 GTAGATCAATTTAAGCCATCTGATGTGGAAATCCAGGCTTGCTTCCGGCACGAGAACA
                 TCGCAGAGCTGTATGGCGCAGTCCTGTGGGGTGAAACTGTCCATCTCTTTATGGAAGC
                 AGGCGAGGGAGGGTCTGTTCTGGAGAAACTGGAGAGCTGTGGACCAATGAGAGAATTT
                 GAAATTATTTGGGTGACAAAGCATGTTCTCAAGGGACTTGATTTTCTACACTCAAAGA
                 AAGTGATCCATCATGATATTAAACCTAGCAACATTGTTTTCATGTCCACAAAAGCTGT
                 TTTGGTGGATTTTGGCCTAAGTGTTCAAATGACCGAAGATGTCTATTTTCCTAAGGAC
                 CTCCGAGGAACAGAGATTTACATGAGCCCAGAGGTCATCCTGTGCAGGGGCCATTCAA
                 CCAAAGCAGACATCTACAGCCTGGGGGCCACGCTCATCCACATGCAGACGGGCACCCC
                 ACCCTGGGTGAAGCGCTACCCTCGCTCAGCCTATCCCTCCTACCTGTACATAATCCAC
                 AAGCAAGCACCTCCACTGGAAGACATTGCAGATGACTGCAGTCCAGGGATGAGAGAGC
                 TGATAGAAGCTTCCCTGGAGAGAAACCCCAATCACCGCCCAAGAGCCGCAGACCTACT
                 AAAACATGAGGCCCTGAACCCGCCCAGAGAGGATCAGCCACGCTGTCAGAGTCTGGAC
                 TCTGCCCTCTTGGACCGCAAGAGGCTGCTGAGTAGGAAGGAGCTGGAACTTCCTGAGA
                 ACATTCCTGATTCTTCGTGCACAGGAAGCACCGAGGAATCTGAGATGCTCAAGAGGCA
                 ACGCTCTCTCTACATCGACCTCGGCGCTCTGGCTGGCTACTTCAATCTTGTTCGGGGA
                 CCACCAACCCTTGAATATGGCTGAGCGGCCGCTTTTTTCCTT
                 ORF Start: at 1                      ORF Stop: TGA at 1414
                 SEQ ID NO: 18           471 aa       MW at 53325.3kD
NOV1i            RGSTMEYMSTGSDNKEEIDLLIKHLNVSDVIDIMENLYASEEPAVYEPSLMTMCQDSN
209983329
Protein Sequence QNDERSKSLLLSGQEVPWLSSVRYGTVEDLLAFANHISNTAKHFYGQRPQESGILLNM
                 VITPQNGRYQIDSDVLLIPWKLTYRNIGSDFIPRGAFGKVYLAQDIKTKKRMACKLIP
                 VDQFKPSDVEIQACFRHENIAELYGAVLWGETVHLFMEAGEGGSVLEKLESCGPMREF
                 EIIWVTKHVLKGLDFLHSKKVIHHDIKPSNIVFMSTKAVLVDFGLSVQMTEDVYFPKD
                 LRGTEIYMSPEVILCRGHSTKADIYSLGATLIHMQTGTPPWVKRYPRSAYPSYLYIIH
                 KQAPPLEDIADDCSPGMRELIEASLERNPNHRPPAADLLKHEALNPPREDQPRCQSLD
                 SALLERKRLLSRKELELPENIADSSCTGSTEESEMLKRQRSLYIDLGALAGYFNLVRG
                 PPTLEYG
                 SEQ ID NO: 19                        1772 bp
NOV1j,           TGTCGTAACAACTCCGCCCCATTGACGCAAATGGGCGGTAGGCGTGTACGGTGGGAGG
212779055
DNA Sequence     TCTATATAAGCAGAGCTCTCTGGCTAACTAGAGAACCCACTGCTTACTGGCTTATCGA
                 AATTAATACGACTCACTATAGGGAGACCCAAGCTGGCTAGCGTTTAAACTTAAGCTTG
                 GTACCGAGCTCGGATCCACCATGGAGTACATGAGCACTGGAAGTGACAATAAAGAAGA
                 GATTGATTTATTAATTAAACATTTAAATGTGTCTGATGTAATACACATTATGGAAAAT
                 CTTTATGCAAGTGAAGAGCCAGCAGTTTATGAACCCAGTCTAATGACCATGTGTCAAG
                 ACAGTAATCAAAACGATGAGCGTTCTAAGTCTCTGCTGCTTAGTGGCCAAGAGGTACC
                 ATGGTTGTCATCAGTCAGATACGGAACTGTGGAGGATTTGCTTGCTTTTGCAAACCAT
                 ATATCCAACACTGCAAAGCATTTTTATGGACAACGACCACAGGAATCTGGAATTTTAT
                 TAAACATGGTCATCACTCCCCAAAATGGACGTTACCAAATAGATTCCGATGTTCTCCT
                 GATCCCCTGGAAGCTGACTTACAGGAATATTGGTTCTGATTTTATTCCTCGGGGCGCC
                 TTTGGAAAGGTATACTTGGCACAAGATATAAAGACGAAGAAAAGAATGGCGTGTAAAC
                 TGATCCCAGTAGATCAATTTAAGCCATCTGATGTGGAAATCCAGGCTTCCTTCCGGCA
                 CGAGAACATCGCAGAGCTGTATGGCGCAGTCCTGTGGGGTGAAACTGTCCATCTCTTT
                 ATGGAAGCAGGCGAGGGAGGGTCTGTTCTGGAGAAACTGGAGAGCTGTGGACCAATGA
                 GAGAATTTGAAATTATTTGGGTGACAAAGCATGTTCTCAAGGGACTTGATTTTCTACA
                 CTCAAAGAAAGTGATCCATCATGATATTAAACCTAGCAACATTGTTTTCATGTCCACA
                 AAAGCTGTTTTGGTGGATTTTGGCCTAAGTGTTCAAATGACCGAAGATGTCTATTTTC
                 CTAAGGACCTCCGAGGAACAGAGATTTACATGAGCCCACAGGTCATCCTGTGCAGGGG
                 CCATTCAACCAAAGCAGACATCTACAGCCTGGGGCCCACGCTCATCCACATGCAGACG
                 GGCACCCCACCCTGGGTGAAGCGCTACCCTCGCTCAGCCTATCCCTCCTACCTGTACA
                 TAATCCACAAGCAAGCACCTCCACTGGAAGACATTGCAGATGACTGCAGTCCAGGGAT
                 GAGAGAGCTGATAGAAGCTTCCCTGGAGAGAAACCCCAATCACCGCCCAAGAGCCGCA
                 GACCTACTAAAACATGAGGCCCTGAACCCGCCCAGAGAGGATCAGCCACGCTGTCAGA
                 GTCTGGACTCTGCCCTCTTGGAGCGCAAGAGGCTGCTGAGTAGGAAGGAGCTGGAACT
                 TCCTGAGAACATTGCTGATTCTTCGTGCACAGGAAGCACCGAGGAATCTGAGATGCTC
                 AAGAGGCAACGCTCTCTCTACATCGACCTCGGCGCTCTGGCTGGCTACTTCAATCTTG
                 TTCGGGGACCACCAACGCTTGAATATGGCTGAGCGGCCGCTCGAGTCTAGAGGGCCCG
                 TTTAAACCCGCTGATCAGCCTCGACTGTGCCTTCTAGTTGCCAGCCATCTGTTGTTTG
                 CCCCTCCCCCGTGCCTTCCTTGACCCTGGAAGGTGCCACTCCCACTGTCCTTTCCTAA
                 TAAAATGAGGAAATTGCATCGCATTGTCTGAG
                 ORF Start: at 138                    ORF Stop: TGA at 1596
                 SEQ ID NO: 20           486 aa       MW at 54926.2 kD
NOV1j,           GDPSWLAFKLKLGTELCSTMEYMSTGSDNKEEIDLLIKHLNVSDVIDIMENLYASEEP
212779055
Protein Sequence AVYEPSLMTMCQDSNQNDERSKSLLLSGQEVPWLSSVRYGTVEDLLAFANHISNTAKH
                 FYGQRPQESGILLNMVITPQNGRYQIDSDVLLIPWKLTYRNIGSDFIPRGAFGKVYLA
                 QDIKTKKRMACKLIPVDQFKPSDVEIQACFRHENIAELYGAVLWGETVHLFMEAGEGG
                 SVLEKLESCGPMREFEIIWVTKHVLKGLDFLHSKKVIHHDIKPSNIVFMSTKAVLVDF
                 GLSVQMTEDVYFPKDLRGTEIYMSPEVILCRGHSTKADIYSLGATLIHMQTGTPPWVK
                 RYPRSAYPSYLYIIHKQAPPLEDIADDCSPGMRELIEASLERNPNHRPRAADLLKHEA
                 LNPPREDQPRCQSLDSALLERKRLLSRKELELPENIADSSCTGSTEESEMLKRQRSLY
                 IDLCALAGYFNLVRGPPTLEYG
                 SEQ ID NO: 21          1770 bp
NOV1k,           TTCGTAACAACTCCGCCCCATTGACGCAAATGGGCGGTAGGCGTGTACGGTGGGAGGT
212779063
DNA Sequence     CTATATAAGCAGAGCTCTCTGGCTAACTAGAGAACCCACTGCTTACTGGCTTATCGAA
                 ATTAATACGACTCACTATAGGGAGACCCAAGCTGGCTAGCGTTTAAACTTAAGCTTGG
                 TACCGAGCTCGGATCCACCATGGAGTACATGAGCACTGGAAGTGACAATAAACAAGAG
                 ATTGATTTATTAATTAAACATTTAAATGTGTCTGATGTAATAGACATTATGGAAAATC
                 TTTATGCAAGTGAAGAGCCAGCAGTTTATGAACCCAGTCTAATCACCATGTGTCAAGA
                 CAGTAATCAAAACGATGAGCGTTCTAAGTCTCTGCTGCTTAGTGGCCAAGAGGTACCA
                 TGGTTGTCATCAGTCAGATATGGAACTGTGGAGGATTTGCTTGCTTTTGCAAACCATA
                 TATCCAACACTGCAAAGCATTTTTATGGACAACGACCACAGGAATCTGGAATTTTATT
                 AAACATGGTCATCACTCCCCAAAATGGACGTTACCAAATAGATTCCGATGTTCTCCTG
                 ATCCCCTGGAAGCTGACTTACAGGAATATTGGTTCTGATTTTATTCCTCGGGGCGCCT
                 TTGGAAAGGTATACTTGGCACAAGATATAAAGACGAAGAAAAGAATGGCGTGTAAACT
                 GATCCCAGTAGATCAATTTAAGCCATCTGATGTGGAAATCCAGGCTTGCTTCCGGCAC
                 GAGAACATCGCAGAGCTGTATGGCGCAGTCCTGTGGGGTGAAACTGTCCATCTCTTTA
                 TGGAAGCAGGCGAGGGAGGGTCTGTTCTGGAGAAACTGGAGAGCTGTGGACCAATGAG
                 AGAATTTGAAATTATTTGGGTGACAAAGCATGTTCTCAAGGGACTTGATTTTCTACAC
                 TCAAAGAAAGTGATCCATCATGATATTAAACCTAGCAACATTGTTTTCATGTCCACAA
                 AAGCTGTTTTGGTGGATTTTGGCCTAAGTGTTCAAATGACCGAAGATGTCTATTTTCC
                 TAAGGACCTCCGAGGAACAGAGATTTACATGAGCCCAGAGGTCATCCTGTGCAGGGGC
                 CATTCAACCAAAGCAGACATCTACAGCCTGGGGGCCACGCTCATCCACATGCAGACGG
                 GCACCCCACCCTCGGTGAAGCGCTACCCTCGCTCAGCCTATCCCTCCTACCTGTACAT
                 AATCCACAAGCAAGCACCTCCACTGGAAGACATTGCAGATGACTGCAGTCCAGGGATC
                 ACAGAGCTGATAGAAGCTTCCCTGGAGAGAAACCCCAATCACCGCCCAAGAGCCGCAG
                 ACCTACTAAAACATGAGCCCCTGAACCCGCCCAGAGAGGATCAGCCACGCTGTCAGAG
                 TCTGGACTCTGCCCTCTTGGAGCGCAAGAGGCTGCTGAGTAGGAAGGAGCTGGAACTT
                 CCTGAGAACATTGCTGATTCTTCGTGCACAGGAAGCACCGAGGAATCTGAGATGCTCA
                 AGAGGCAACGCTCTCTCTACATCGACCTCGGCGCTCTGGCTGGCTACTTCAATCTTGT
                 TCGGGGACCACCAACGCTTGAATATGGCTGAGCGGCCGCTCGAGTCTAGAGGGCCCGT
                 TTAAACCCGCTGATCAGCCTCGACTGTGCCTTCTAGTTGCCAGCCATCTGTTGTTTGC
                 CCCTCCCCCGTGCCTTCCTTGACCCTGGAAGGTGCCACTCCCACTGTCCTTTCCTAAT
                 AAAATCAGGAAATTGCATCGCATTGTCTGA
                 ORF Start: at 137                    ORF Stop: TGA at 1595
                 SEQ ID NO: 22           486 aa       MW at 54926.2kD
NOV1k,           GDPSWLAFKLKLGTELCSTMEYMSTGSDNKEEIDLLIKHLNVSDVIDIMENLYASEEP
212779063
Protein Sequence AVYEPSLMTMCQDSNQNDERSKSLLLSGQEVPWLSSVRYGTVEDLLAFANHISNTAKH
                 FYGQRPQESGILLNMVITPQNGRYQIDSDVLLIPWKLTYRNIGSDFIPRGAFGKVYLA
                 QDIKTKKRMACKLTPVDQFKPSDVEIQACFRHENIAELYGAVLWGETVHLFMEAGEGG
                 SVLEKLESCGPMREFEIIWVTKHVLKGLDFLHSKKVIHHDIKPSNIVFMSTKAVLVDF
                 GLSVQMTEDVYFPKDLRGTEIYMSPEVILCRGHSTKADIYSLGATLIHMQTGTPPWVK
                 RYPRSAYPSYLYIIHKQAPPLEDIADDCSPGMRELIEASLERNPNHRPRAADLLKHEA
                 LNPPREDQPRCQSLDSALLERKRLLSRKELELPENIADSSCTGSTEESEMLKRQRSLY
                 IDLGALAGYFNLVRGPPTLEYG
                 SEQ ID NO: 23          1772 bp
NOV11,           TGTCGTAACAACTCCGCCCCATTGACGCAAATGGGCGGTAGGCGTGTACGGTGGGAGG
CG101683-02
DNA Sequence     TCTATATAAGCAGAGCTCTCTGGCTAACTAGAGAACCCACTGCTTACTGGCTTATCGA
                 AATTAATACGACTCACTATAGGGAGACCCAAGCTGGCTAGCGTTTAAACTTAAGCTTG
                 GTACCGAGCTCGGATCCACCATGGAGTACATGAGCACTGGAAGTGACAATAAAGAAGA
                 GATTGATTTATTAATTAAACATTTAAATGTGTCTGATGTAATAGACATTATGGAAAAT
                 CTTTATGCAAGTGAAGAGCCAGCAGTTTATGAACCCAGTCTAATGACCATGTGTCAAG
                 ACAGTAATCAAAACGATGAGCGTTCTAAGTCTCTGCTGCTTAGTGGCCAAGAGGTACC
                 ATGGTTGTCATCAGTCAGATACGGAACTGTGGAGGATTTGCTTGCTTTTGCAAACCAT
                 ATATCCAACACTGCAAAGCATTTTTATGGACAACGACCACAGGAATCTGGAATTTTAT
                 TAAACATGGTCATCACTCCCCAAAATGGACGTTACCAAATAGATTCCGATGTTCTCCT
                 GATCCCCTGGAAGCTGACTTACAGGAATATTGGTTCTGATTTTATTCCTCGGGGCGCC
                 TTTGGAAAGGTATACTTGGCACAAGATATAAAGACGAAGAAAAGAATGCCGTGTAAAC
                 TGATCCCAGTAGATCAATTTAAGCCATCTGATGTGGAAATCCAGGCTTGCTTCCGGCA
                 CGAGAACATCGCAGAGCTGTATGGCGCAGTCCTGTGGGGTGAAACTGTCCATCTCTTT
                 ATGGAAGCAGGCCAGGGAGGGTCTGTTCTGGAGAAACTGGAGAGCTGTGGACCAATGA
                 GAGAATTTGAAATTATTTGGGTGACAAAGCATGTTCTCAAGGGACTTGATTTTCTACA
                 CTCAAAGAAAGTGATCCATCATGATATTAAACCTAGCAACATTGTTTTCATGTCCACA
                 AAAGCTGTTTTGGTGGATTTTGGCCTAAGTGTTCAAATGACCGAAGATGTCTATTTTC
                 CTAAGGACCTCCGAGGAACAGAGATTTACATGAGCCCAGAGGTCATCCTGTGCAGGGG
                 CCATTCAACCAAAGCAGACATCTACAGCCTGGGGGCCACGCTCATCCACATGCAGACG
                 GGCACCCCACCCTGGGTGAAGCGCTACCCTCGCTCAGCCTATCCCTCCTACCTGTACA
                 TAATCCACAAGCAAGCACCTCCACTGGAAGACATTGCAGATGACTGCAGTCCAGCGAT
                 CAGAGAGCTGATAGAAGCTTCCCTGGAGAGAAACCCCAATCACCGCCCAAGAGCCGCA
                 GACCTACTAAAACATGAGGCCCTGAACCCGCCCAGAGAGGATCAGCCACGCTGTCAGA
                 GTCTGGACTCTGCCCTCTTGGAGCGCAAGAGGCTGCTGAGTAGGAAGGAGCTGGAACT
                 TCCTGAGAACATTGCTGATTCTTCGTGCACAGGAAGCACCGAGGAATCTCAGATGCTC
                 AAGAGGCAACGCTCTCTCTACATCGACCTCGGCGCTCTGGCTGGCTACTTCAATCTTC
                 TTCGGGGACCACCAACGCTTGAATATGGCTGAGCGGCCGCTCGAGTCTAGAGCGCCCG
                 TTTAAACCCGCTGATCAGCCTCGACTGTGCCTTCTAGTTGCCAGCCATCTGTTGTTTG
                 CCCCTCCCCCGTGCCTTCCTTGACCCTGGAAGGTGCCACTCCCACTGTCCTTTCCTAA
                 TAAAATGAGGAAATTGCATCGCATTGTCTGAG
                 ORF Start: ATG at 195                ORF Stop: TGA at 1596
                 SEQ ID NO: 24           467 aa       MW AT 52923.9kD
NOV11,           MEYMSTGSDNKEEIDLLIKHLNVSDVIDIMENLYASEEPAVYEPSLMTMCQDSNQNDE
CG101683-02
Protein Sequence RSKSLLLSGQEVPWLSSVRYGTVEDLLAFANHTSNTAKHFYGQRPQESGILLNMVITP
                 QNGRYQIDSDVLLIPWKLTYRNIGSDFIPRGAFGKVYLAQDIKTKKRMACKLIPVDQF
                 KPSDVEIQACFRHENIAELYGAVLWGETVHLFMEAGEGGSVLEKLESCGPMREFEIIW
                 VTKHVLKGLDFLHSKKVHHDIKPSNIVFMSTKAVLVDFGLSVQMTEDVYFPKDLRGT
                 EIYMSPEVILCRGHSTKADIYSLGATLIHMQTGTPPWVKRYPRSAYPSYLYITHKQAP
                 PLEDTADDCSPGMRELIEASLERNPNHRPRAADLLKHEALNPPREDQPRCQSLDSALL
                 ERKRLLSRKELELPENIADSSCTGSTEESEMLKRQRSLYIDLGALAGYFNLVRGPPTL
                 SEQ ID NO: 25          1425 bp
NOV1m,           ACCATGGAGTACATGAGCACTGGAAGTGACAATAAAGAAGAGATTCATTTATTAATTA
CG101683-03
DNA Sequence     AACATTTAAATGTGTCTGATGTAATAGACATTATGGAAAATCTTTATGCAAGTGAAGA
                 GCCAGCAGTTTATGAACCCAGTCTAATGACCATGTGTCAAGACAGTAATCAAAACGAT
                 GAGCGTTCTAAGTCTCTGCTGCTTAGTGGCCAAGAGGTACCATGGTTGTCATCAGTCA
                 GATACGGAACTGTGGAGGATTTGCTTGCTTTTGCAAACCATATATCCAACACTGCAAA
                 GCATTTTTATGGACAACGACCACAGGAATCTGGAATTTTATTAAACATGGTCATCACT
                 CCCCAAAATGGACGTTACCAAATAGATTCCGATGTTCTCCTGATCCCCTGGAAGCTGA
                 CTTACACGAATATTGGTTCTGATTTTATTCCTCGGGGCGCCTTTGGAAAGGTATACTT
                 GGCACAAGATATAAAGACGAAGAAAAGAATGGCGTGTAAACTGATCCCAGTAGATCAA
                 TTTAAGCCATCTGATGTGGAAATCCAGGCTTGCTTCCGGCACGAGAACATCGCAGAGC
                 TGTATGGCGCAGTCCTGTGGCGTGAAACTGTCCATCTCTTTATGGAAGCAGGCGAGGG
                 AGGGTCTGTTCTGGAGAAACTGGAGAGCTGTGGACCAATCAGAGAATTTGAAATTATT
                 TCGGTGACAAAGCATGTTCTCAAGGGACTTGATTTTCTACACTCAAAGAAAGTGATCC
                 ATCATGATATTAAACCTAGCAACATTGTTTTCATGTCCACAAAAGCTGTTTTGGTGGA
                 TTTTGGCCTAAGTGTTCAAATGACCGAAGATGTCTATTTTCCTAAGGACCTCCGAGGA
                 ACAGAGATTTACATGAGCCCAGAGGTCATCCTGTGCAGGGGCCATTCAACCAAAGCAG
                 ACATCTACAGCCTGGGGGCCACGCTCATCCACATGCAGACGGGCACCCCACCCTGGGT
                 GAAGCGCTACCCTCCCTCAGCCTATCCCTCCTACCTGTACATAATCCACAAGCAAGCA
                 CCTCCACTGGAAGACATTGCAGATGACTGCAGTCCAGGGATGAGAGAGCTGATAGAAG
                 CTTCCCTGGAGAGAAACCCCAATCACCGCCCAAGAGCCGCAGACCTACTAAAACATGA
                 GGCCCTGAACCCGCCCAGAGAGGATCAGCCACGCTGTCAGAGTCTGGACTCTGCCCTC
                 TTGGAGCCCAAGAGGCTGCTGAGTAGGAAGGAGCTGGAACTTCCTGAGAACATTGCTG
                 ATTCTTCGTGCACAGGAAGCACCGAGGAATCTGAGATGCTCAAGAGCCAACGCTCTCT
                 CTACATCGACCTCGGCGCTCTGGCTGGCTACTTCAATCTTGTTCGGGGACCACCAACG
                 CTTGAATATGGCCATCATCACCACCATCACTGA
                 ORF Start: at 1                      ORF Stop: TGA at 1423
                 SEQ ID NO: 26           474 aa       MW at 53847.9kD.
NOV1m,           TMEYMSTGSDNKEEIDLLIKHLNVSDVIDIMENLYASEEPAVYEPSLMTMCQDSNQND
CG101683-03
Protein Sequence ERSKSLLLSGQEVPWLSSVRYGTVEDLLAFANHISNTAKHFYGQRPQESGILLNMVIT
                 PQNGRYQIDSDVLLIPWKLTYRNIGSDFIPRGAFGKVYLAQDIKTKKRMACKLIPVDQ
                 FKPSDVEIQACPRHENIAELYGAVLWGETVHLFMEAGEGGSVLEKLESCGPMREFEII
                 WVTKHVLKGLDFLHSKKVIHHDIKPSNIVFMSTKAVLVDFGLSVQMTEDVYFPKDLRG
                 TEIYMSPEVILCRGHSTKADIYSLGATLIHMQTGTPPWVKRYPRSAYPSYLYIIHKQA
                 PPLEDIADDCSPGMRELIEASLERNPNHRPRAADLLKHEALNPPREDQPRCQSLDSAL
                 LERKRLLSRKELELPENIADSSCTGSTEESEMLKRQRSLYIDLGALAGYFNLVRGPPT
                 LEYGHHHHHH
                 SEQ ID NO: 27          1344 bp
NOV1n,           ACCATGGAGTACATGAGCACTGGAAGTGACAATAAAGAAGAGATTGATTTATTAATTA
CG101683-04
DNA Sequence     AACATTTAAATGTGTCTGATGTAATAGACATTATGGAAAATCTTTATGCAAGTGAAGA
                 GCCAGCAGTTTATGAACCCAGTCTAATGACCATGTGTCAAGACAGTAATCAAAACGAT
                 GAGCGTTCTAAGTCTCTGCTGCTTAGTGGCCAAGAGGTACCATGGTTGTCATCAGTCA
                 GATACGGAACTGTGGAGGATTTGCTTGCTTTTGCAAACCATATATCCAACACTGCAAA
                 GCATTTTTATGGACAACGACCACAGGAATCTGGAATTTTATTAAACATGGTCATCACT
                 CCCCAAAATGGACGTTACCAAATAOATTCCGATGTTCTCCTCATCCCCTGGAAGCTGA
                 CTTACAGGAATATTGGTTCTGATTTTATTCCTCGGGGCGCCTTTGGAAAGGTATACTT
                 GGCACAAGATATAAAGACGAAGAAAAGAATGGCGTGTAAACTGATCCCAGTAGATCAA
                 TTTAAGCCATCTCATGTGGAAATCCAGGCTTGCTTCCGCCACGAGAACATCGCAGAGC
                 TGTATGCCGCAGTCCTGTGGGGTGAAACTGTCCATCTCTTTATGGAAGCAGGCGAGGG
                 AGGGTCTGTTCTGGAGAAACTGGAGAGCTGTGGACCAATGAGAGAATTTCAAATTATT
                 TGGGTGACAAAGCATGTTCTCAAGOGACTTGATTTTCTACACTCAAAGAAAGTGATCC
                 ATCATGATATTAAACCTAGCAACATTGTTTTCATGTCCACAAAAGCTGTTTTGGTGGA
                 TTTTCGCCTAAGTGTTCAAATGACCGAAGATGTCTATTTTCCTAAGGACCTCCGAGGA
                 ACAGAGATTTACATGAGCCCAGAGGTCATCCTGTGCAGGGGCCATTCAACCAAAGCAC
                 ACATCTACAGCCTGGGGGCCACGCTCATCCACATGCAGACGGGCACCCCACCCTGGGT
                 GAAGCGCTACCCTCGCTCAGCCTATCCCTCCTACCTGTACATAATCCACAAGCAACCA
                 CCTCCACTGGAAGACATTGCAGATGACTGCAGTCCAGGGATCAGAGAGCTGATAGAAG
                 CTTCCCTGGACAGAAACCCCAATCACCGCCCAAGAGCCGCAGACCTACTAAAACATGA
                 GGCCCTGAACCCGCCCAGAGAGGATCAGCCACGCTGTCAGAGTCTGGACTCTGCCCTC
                 TTGGAGCGCAAGAGGCTGCTGAGTAGGAAGGAGCTGGAACTTCCTGAGAACATTGCTC
                 ATCATCACCACCATCACTGAGCGGCCCGCTTCCATCTAGAGCTGCAGTCTCGAGCATG
                 CGGTACCAGC
                 ORF Start: at 1                      ORF Stop: TGA at 1294
                 SEQ ID NO: 28           431 aa       MW at 49139.7kD
NOV1n,           TMEYMSTGSDNKEEIDLLIKHLNVSDVIDIMENLYASEEPAVYEPSLMTMCQDSNQND
CG101683-04
Protein Sequence ERSKSLLLSGQEVPWLSSVRYGTVEDLLAFANHISNTAKHFYGQRPQESGILLNMVIT
                 PQNGRYQIDSDVLLIPWKLTYRNIGSDFIPRGAFGKVYLAQDIKTKKRMACKLIPVDQ
                 FKPSDVEIQACFRHENIAELYGAVLWGETVHLFMEAGEGGSVLEKLESCGPMREFEII
                 WVTKHVLKGLDFLHSKKVIHHDIKPSNIVFMSTKAVLVDFGLSVQMTEDVYFPKDLRG
                 TEIYMSPEVILCRGHSTKADIYSLGATLIHMQTGTPPWVKRYPRSAYPSYLYIIHKQA
                 PPLEDIADDCSPGMRELIEASLERNPNHRPRAADLLKHEALNPPREDQPRCQSLDSAL
                 LERKRLLSRKELELPENIAHHHHHH
                 SEQ ID NO: 29          1327 bp
NOV1o,           CCACCATCGGGCGCGGATCCACCATGGGACATCATCACCACCATCACGAGTACATGAG
CG101683-05
DNA Sequence     CACTGGAAGTGACAATAAAGAAGAGATTGATTTATTAATTAAACATTTAAATGTGTCT
                 GATGTAATAGACATTATGGAAAATCTTTATGCAAGTGAAGAGCCAGCAGTTTATGAAC
                 CCAGTCTAATGACCATGTGTCAAGACAGTAATCAAAACGATGAGCGTTCTAAGTCTCT
                 GCTGCTTAGTGGCCAAGAGGTACCATGGTTGTCATCAGTCAGATACGGAACTGTGGAG
                 GATTTGCTTGCTTTTGCAAACCATATATCCAACACTGCAAAGCATTTTTATGGACAAC
                 GACCACAGGAATCTGGAATTTTATTAAACATGGTCATCACTCCCCAAAATGGACGTTA
                 CCAAATAGATTCCGATGTTCTCCTGATCCCCTGGAAGCTGACTTACAGGAATATTGGT
                 TCTGATTTTATTCCTCGGGGCGCCTTTGGAAAGGTATACTTGGCACAAGATATAAAGA
                 CGAAGAAAAGAATGGCGTGTAAACTGATCCCAGTAGATCAATTTAAGCCATCTGATGT
                 GGAAATCCAGGCTTGCTTCCGGCACGAGAACATCGCAGAGCTGTATGGCGCAGTCCTG
                 TGGGGTGAAACTGTCCATCTCTTTATGGAAGCAGGCGAGGGAGGGTCTGTTCTGGAGA
                 AACTGGAGAGCTGTGGACCAATGAGAGAATTTGAAATTATTTGGGTGACAAAGCATGT
                 TCTCAAGGGACTTGATTTTCTACACTCAAACAAAGTGATCCATCATGATATTAAACCT
                 AGCAACATTGTTTTCATGTCCACAAAAGCTGTTTTGGTGGATTTTGGCCTAAGTGTTC
                 AAATGACCGAAGATGTCTATTTTCCTAAGGACCTCCGAGGAACAGAGATTTACATGAG
                 CCCAGAGGTCATCCTGTGCAGGGGCCATTCAACCAAAGCAGACATCTACAGCCTGGGG
                 GCCACGCTCATCCACATGCAGACGGGCACCCCACCCTGGGTGAAGCGCTACCCTCGCT
                 CAGCCTATCCCTCCTACCTGTACATAATCCACAAGCAAGCACCTCCACTGGAAGACAT
                 TGCAGATGACTGCAGTCCAGGGATGAGAGAGCTGATAGAAGCTTCCCTGGAGAGAAAC
                 CCCAATCACCGCCCAAGAGCCGCAGACCTACTAAAACATGAGGCCCTGAACCCGCCCA
                 GAGAGGATCAGCCACGCTGTCAGAGTCTGGACTCTGCCCTCTTGGAGCGCAAGAGGCT
                 GCTGAGTAGGAAGGAGCTGGAACTTCCTGAGAACATTGCTTGAGGCGGCCG
                 ORF Start at 48                      ORF Stop TGA at 1317
                 SEQ ID NO: 30           423 aa       MW at 48084.5 kD
NOV1o,           EYMSTGSDNKEEIDLLIKHLNVSDVIDIMENLYASEEPAVYEPSLMTMCQDSNQNDER
CG101683-05
Protein Sequence SKSLLLSGQEVPWLSSVRYGTVEDLLAFANHISNTAKHFYGQRPQESGILLNMVITPQ
                 NGRYQIDSDVLLIPWKLTYRNIGSDFIPRGAFGKVYLAQDIKTKKRMACKLIPVDQFK
                 PSDVEIQACFRHENIAELYGAVLWGETVHLFMEAGEGGSVLEKLESCGPMREFEIIWV
                 TKHVLKGLDFLHSKKVIHHDIKPSNTVFMSTKAVLVDFGLSVQMTEDVYFPKDLRGTE
                 IYMSPEVILCRGHSTKADIYSLGATLIHMQTGTPPWVKRYPRSAYPSYLYIIHKQAPP
                 LEDIADDCSPGMRELIEASLERNPNHRPRAADLLKHEALNPPREDQPRCQSLDSALLE
                 RKRLLSRKELELPENIA
                 SEQ ID NO: 31          1428 bp
NOV1p,           ACCATGGGACATCATCACCACCATCACGAGTACATGAGCACTGGAAGTGACAATAAAG
CG1 01683-06
DNA Sequence     AAGAGATTGATTTATTAATTAAACATTTAAATGTGTCTGATGTAATAGACATTATGGA
                 AAATCTTTATGCAAGTGAAGAGCCAGCAGTTTATGAACCCAGTCTAATGACCATGTGT
                 CAAGACAGTAATCAAAACGATGAGCGTTCTAAGTCTCTGCTGCTTAGTGGCCAAGAGG
                 TACCATGGTTGTCATCAGTCAGATACGGAACTGTGCAGGATTTGCTTGCTTTTGCAAA
                 CCATATATCCAACACTGCAAAGCATTTTTATGGACAACGACCACAGGAATCTGGAATT
                 TTATTAAACATGGTCATCACTCCCCAAAATGGACGTTACCAAATAGATTCCGATGTTC
                 TCCTGATCCCCTGGAAGCTGACTTACAGGAATATTGGTTCTGATTTTATTCCTCGGGG
                 CGCCTTTGGAAAGGTATACTTGGCACAAGATATAAAGACGAAGAAAAGAATGGCGTGT
                 AAACTGATCCCAGTAGATCAATTTAAGCCATCTGATGTGGAAATCCAGGCTTGCTTCC
                 GGCACGAGAACATCGCAGAGCTGTATGGCGCAGTCCTGTGGGGTGAAACTGTCCATCT
                 CTTTATGGAAGCAGGCGAGGGAGGGTCTGTTCTGGAGAAACTGGAGAGCTGTGGACCA
                 ATGAGAGAATTTGAAATTATTTGGGTGACAAAGCATGTTCTCAAGGGACTTGATTTTC
                 TACACTCAAAGAAAGTGATCCATCATGATATTAAACCTAGCAACATTGTTTTCATGTC
                 CACAAAAGCTGTTTTGGTGGATTTTGGCCTAAGTGTTCAAATGACCGAAGATGTCTAT
                 TTTCCTAAGGACCTCCCAGGAACAGAGATTTACATGAGCCCAGAGGTCATCCTGTCCA
                 GGGGCCATTCAACCAAAGCAGACATCTACAGCCTGGGGGCCACGCTCATCCACATGCA
                 GACGGGCACCCCACCCTGGGTGAAGCGCTACCCTCGCTCAGCCTATCCCTCCTACCTG
                 TACATAATCCACAAGCAAGCACCTCCACTGGAAGACATTGCAGATGACTGCAGTCCAG
                 GGATGAGAGAGCTGATAGAAGCTTCCCTGGAGAGAAACCCCAATCACCGCCCAAGAGC
                 CGCAGACCTACTAAAACATGAGGCCCTGAACCCGCCCAGAGAGGATCAGCCACGCTGT
                 CAGAGTCTGGACTCTGCCCTCTTCGAGCGCAAGAGGCTGCTGAGTAGGAAGGAGCTGG
                 AACTTCCTGAGAACATTGCTGATTCTTCGTGCACAGGAAGCACCGACGAATCTGAGAT
                 GCTCAAGAGGCAACGCTCTCTCTACATCGACCTCGGCGCTCTGGCTGGCTACTTCAAT
                 CTTGTTCGGGGACCACCAACGCTTGAATATGGCTGA
                 ORF Start: at 1                      ORF Stop: TGA at 1426
                 SEQ ID NO: 32           475 aa       MW at 53904.9kD
NOV1p,           TMGHHHHHHEYMSTGSDNKEEIDLLIKHLNVSDVIDIMENLYASEEPAVYEPSLMTMC
CG101683-06
Protein Sequence QDSNQNDERSKSLLLSGQEVPWLSSVRYGTVEDLLAFANHISNTAKHFYGQRPQESGI
                 LLNMVITPQNGRYQIDSDVLLIPWKLTYRNIGSDFIPRGAFGKVYLAQDIKTKKRMAC
                 KLIPVDQFKPSDVEIQACFRHENIAELYGAVLWGETVHLFMEAGEGGSVLEKLESCGP
                 MREFEIIWVTKHVLKGLDFLHSKKVIHHDIKPSNIVFMSTKAVLVDFGLSVQMTEDVY
                 FPKDLRGTEIYMSPEVILCRGHSTKADIYSLGATLIHMQTGTPPWVKRYPRSAYPSYL
                 YIIHKQAPPLEDIADDCSPGMRELIEASLERNPNHRPRAADLLKHEALNPPREDQPRC
                 QSLDSALLERKRLLSRKELELPENIADSSCTGSTEESEMLKRQRSLYIDLGALAGYFN
                 LVRGPPTLEYG
                 SEQ ID NO: 33          1293 bp
NOV1q,           CGGCCCCTGGGATCCACCATGGAGTACATGAGCACTGGAAGTCACAATAAAGAAGAGA
CG1O1683-07
DNA Sequence     TTGATTTATTAATTAAACATTTAAATGTGTCTGATGTAATAGACATTATGGAAAATCT
                 TTATGCAAGTGAAGAGCCAGCAGTTTATGAACCCAGTCTAATGACCATGTGTCAAGAC
                 AGTAATCAAAACGATGAGCGTTCTAAGTCTCTGCTGCTTAGTGGCCAAGAGGTACCAT
                 GGTTGTCATCAGTCAGATACGGAACTGTGGAGGATTTGCTTGCTTTTGCAAACCATAT
                 ATCCAACACTGCAAAGCATTTTTATGGACAACGACCACAGGAATCTGGAATTTTATTA
                 AACATGGTCATCACTCCCCAAAATGGACGTTACCAAATAGATTCCCATGTTCTCCTGA
                 TCCCCTGGAAGCTGACTTACAGGAATATTGGTTCTGATTTTATTCCTCGGGGCGCCTT
                 TGGAAAGGTATACTTGGCACAAGATATAAAGACGAAGAAAAGAATGGCGTGTAAACTG
                 ATCCCAGTAGATCAATTTAAGCCATCTGATGTGGAAATCCAGGCTTGCTTCCGGCACG
                 AGAACATCGCAGAGCTGTATGGCGCAGTCCTGTGGGGTGAAACTGTCCATCTCTTTAT
                 GGAAGCAGGCGAGGGAGGGTCTGTTCTGGAGAAACTGGAGAGCTGTGGACCAATGAGA
                 GAATTTGAAATTATTTGGGTGACAAAGCATGTTCTCAAGGGACTTGATTTTCTACACT
                 CAAAGAAAGTGATCCATCATGATATTAAACCTAGCAACATTGTTTTCATGTCCACAAA
                 AGCTGTTTTGGTGGATTTTGGCCTAAGTGTTCAAATGACCGAAGATGTCTATTTTCCT
                 AAGGACCTCCGAGGAACAGAGATTTACATGACCCCAGAGGTCATCCTGTGCAGGGGCC
                 ATTCAACCAAAGCAGACATCTACAGCCTGGGGGCCACGCTCATCCACATGCAGACGGG
                 CACCCCACCCTGGGTGAAGCGCTACCCTCGCTCAGCCTATCCCTCCTACCTGTACATA
                 ATCCACAAGCAAGCACCTCCACTGGAAGACATTGCAGATGACTGCAGTCCAGGGATGA
                 GAGAGCTGATAGAAGCTTCCCTGCACAGAAACCCCAATCACCGCCCAAGAGCCGCACA
                 CCTACTAAAACATGAGGCCCTGAACCCGCCCAGAGAGGATCAGCCACGCTGTCAGAGT
                 CTCGACTCTGCCCTCTTGGAGCGCAAGAGGCTGCTGAGTAGGAAGGAGCTGGAACTTC
                 CTGAGAACATTGCTTGA
                 ORF Start: ATG at 19                 ORF Stop: TGA at 1291
                 SEQ ID NO: 34           424 aa       MW at 48215.7 kD
NOV1q,           MEYMSTGSDNKEEIDLLIKHLNVSDVIDIMENLYASEEPAVYEPSLMTMCQDSNQNDE
CG101683-07
Protein Sequence RSKSLLLSGQEVPWLSSVRYGTVEDLLAFANHISNTAKHFYGQRPQESGILLNMVITP
                 QNGRYQIDSDVLLIPWKLTYRNIGSDFIPRGAFGKVYLAQDIKTKKRMACKLIPVDQF
                 KPSDVEIQACFRHENIAELYGAVLWGETVHLFMEACEGGSVLEKLESCCPMREFEIIW
                 VTKHVLKGLDFLHSKKVIHHDIKPSNIVFMSTKAVLVDFGLSVQMTEDVYFPKDLRGT
                 EIYMSPEVILCRGHSTKADIYSLGATLIHMQTGTPPWVKRYPRSAYPSYLYIIHKQAP
                 PLEDIADDCSPGMRELIEASLERNPNHRPRAADLLKHEALNPPREDQPRCQSLDSALL
                 ERKRLLSRKELELPENIA
                 SEQ ID NO: 35          1428 bp
NOV1R,           CACCGCGGCCGCACCATGGAGTACATGAGCACTGGAAGTGACAATAAAGAAGAGATTG
CG101683-08
DNA Sequence     ATTTATTAATTAAACATTTAAATGTGTCTGATGTAATAGACATTATGGAAAATCTTTA
                 TGCAAGTGAAGAGCCAGCAGTTTATGAACCCAGTCTAATGACCATGTGTCAAGACAGT
                 AATCAAAACGATGAGCGTTCTAAGTCTCTGCTGCTTAGTGGCCAAGAGGTACCATGGT
                 TGTCATCAGTCAGATACGGAACTGTGGAGGATTTCCTTGCTTTTGCAAACCATATATC
                 CAACACTGCAAAGCATTTTTATGGACAACGACCACAGGAATCTGGAATTTTATTAAAC
                 ATGGTCATCACTCCCCAAAATGGACGTTACCAAATAGATTCCGATGTTCTCCTGATCC
                 CCTGGAAGCTGACTTACAGGAATATTGGTTCTGATTTTATTCCTCGGGGCGCCTTTGG
                 AAAGGTATACTTGGCACAAGATATAAAGACGAAGAAAAGAATGGCGTGTAAACTGATC
                 CCAGTAGATCAATTTAAGCCATCTGATGTGGAAATCCAGGCTTGCTTCCGGCACGAGA
                 ACATCGCAGAGCTGTATGGCGCAGTCCTGTGGGGTGAAACTGTCCATCTCTTTATGGA
                 AGCAGGCGAGGGAGGGTCTGTTCTGGAGAAACTGGAGAGCTGTGGACCAATGAGAGAA
                 TTTGAAATTATTTGGGTGACAAAGCATGTTCTCAAGGGACTTGATTTTCTACACTCAA
                 AGAAAGTGATCCATCATGATATTAAACCTAGCAACATTGTTTTCATGTCCACAAAAGC
                 TGTTTTGGTGGATTTTGGCCTAAGTGTTCAAATGACCGAAGATGTCTATTTTCCTAAG
                 GACCTCCGAGGAACAGAGATTTACATGAGCCCAGAGGTCATCCTGTGCAGGGGCCATT
                 CAACCAAAGCAGACATCTACAGCCTGGGGGCCACGCTCATCCACATGCAGACGGGCAC
                 CCCACCCTGGGTGAAGCGCTACCCTCGCTCAGCCTATCCCTCCTACCTGTACATAATC
                 CACAAGCAAGCACCTCCACTGGAAGACATTGCAGATGACTGCAGTCCAGGGATGAGAG
                 AGCTGATAGAAGCTTCCCTGGAGAGAAACCCCAATCACCGCCCAAGAGCCGCAGACCT
                 ACTAAAACATGAGGCCCTGAACCCGCCCAGAGAGGATCAGCCACGCTGTCAGAGTCTG
                 GACTCTGCCCTCTTGGAGCGCAAGAGGCTGCTGAGTAGGAAGGAGCTGGAACTTCCTG
                 AGAACATTGCTGATTCTTCGTGCACAGGAAGCACCCAGGAATCTGAGATGCTCAAGAG
                 GCAACGCTCTCTCTACATCGACCTCGGCGCTCTGGCTGGCTACTTCAATCTTGTTCGG
                 GGACCACCAACGCTTGAATATGGCTAGGTCGACGGC
                 ORF Start: ATG at 16                 ORF Stop: TAG at 1417
                 SEQ ID NO: 36           467 aa       MW at 52923.9 kD
NOV1r,           MEYMSTGSDNKEEIDLLIKHLNVSDVIDIMENLYASEEPAVYEPSLMTMCQDSNQNDE
CG101683-08
Protein Sequence RSKSLLLSGQEVPWLSSVRYGTVEDLLAFANHISNTAKHFYGQRPQESGILLNMVITP
                 QNGRYQIDSDVLLIPWKLTYRNIGSDFIPRGAFGKVYLAQDIKTKKRMACKLIPVDQF
                 KPSDVEIQACFRHENIAELYGAVLWGETVHLFMEAGEGGSVLEKLESCGPMREFEIIW
                 VTKHVLKGLDFLHSKKVIHHDIKPSNIVFMSTKAVLVDFGLSVQMTEDVYFPKDLRGT
                 EIYMSPEVILCRCHSTKADIYSLGATLIHMQTGTPPWVKRYPRSAYPSYLYIIHKQAP
                 PLEDIADUCSPGMRELIEASLERNPNHRPRAADLLKHEALNPPREDQPRCQSLDSALL
                 ERKRLLSRKELELPENIADSSCTGSTEESEMLKRQRSLYIDLGALAGYFNLVRGPPTL
                 EYG

[0353] Sequence comparison of the above protein sequences yields the following sequence relationships shown in Table 1B.

TABLE 1B
Comparison of NOV1a against NOV1b through NOV1r.
			Identities/
			Similarities for
	Protein	NOV1a Residues/	the Matched
	Sequence	Match Residues	Region
	NOV1b	1 . . . 467	466/467 (99%)
		2 . . . 468	466/467 (99%)
	NOV1c	1 . . . 424	423/424 (99%)
		5 . . . 428	423/424 (99%)
	NOV1d	1 . . . 467	466/467 (99%)
		2 . . . 468	466/467 (99%)
	NOV1e	2 . . . 467	465/466 (99%)
		13 . . . 478	465/466 (99%)
	NOV1f	1 . . . 424	423/424 (99%)
		2 . . . 425	423/424 (99%)
	NOV1g	2 . . . 424	422/423 (99%)
		16 . . . 438	422/423 (99%)
	NOV1h	2 . . . 467	465/466 (99%)
		10 . . . 475	465/466 (99%)
	NOV1i	1 . . . 467	466/467 (99%)
		5 . . . 471	466/467 (99%)
	NOV1j	1 . . . 467	466/467 (99%)
		20 . . . 486	466/467 (99%)
	NOV1k	1 . . . 467	466/467 (99%)
		20 . . . 486	466/467 (99%)
	NOV1l	1 . . . 467	466/467 (99%)
		1 . . . 467	466/467 (99%)
	NOV1m	1 . . . 467	466/467 (99%)
		2 . . . 468	466/467 (99%)
	NOV1n	1 . . . 424	423/424 (99%)
		2 . . . 425	423/424 (99%)
	NOV1o	2 . . . 424	422/423 (99%)
		1 . . . 423	422/423 (99%)
	NOV1p	2 . . . 467	465/466 (99%)
		10 . . . 475	465/466 (99%)
	NOV1q	1 . . . 424	423/424 (99%)
		1 . . . 424	423/424 (99%)
	NOV1r	1 . . . 467	466/467 (99%)
		1 . . . 467	466/467 (99%)

[0354] Further analysis of the NOV1a protein yielded the following properties shown in Table 1C.

TABLE 1C
Protein Sequence Properties NOV1a
PSort     0.6500 probability located in cytoplasm;
analysis: 0.1000 probability located in mitochondrial
          matrix space; 0.1000 probability located in
          lysosome (lumen); 0.0000 probability
          located in endoplasmic reticulum (membrane)
SignalP   No Known Signal Sequence Predicted
analysis:

[0355] A search of the NOV1a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 1D.

TABLE 1D
Geneseq Results for NOV1a
			Identities/
			Similarities for
Geneseq	Protein/Organism/Length	NOV1a Residues/	the Matched	Expect
Identifier	[Patent #, Date]	Match Residues	Region	Value
AAE05951	Human cot oncoprotein encoded by	1 . . . 467	467/467 (100%)	0.0
	D14497 oncogene - Homo sapiens,	1 . . . 467	467/467 (100%)
	467 aa. [US6265216-B1, 24 JUL.
	2001]
AAY79244	Human COT - Homo sapiens, 467	1 . . . 467	467/467(100%)	0.0
	aa. [WO200011191-A2, 02 MAR.	1 . . . 467	467/467(100%)
	2000]
AAE10313	Human Tp12 protein - Homo	1 . . . 467	466/467 (99%)	0.0
	sapiens, 467 aa. [WO200166559-	1 . . . 467	466/467 (99%)
	A1, 13 SEP. 2001]
AAE10314	Rat Tp12 protein - Rattus sp. 467	1 . . . 467	439/467 (94%)	0.0
	aa. [WO200166559-A1, 13 SEP.	1 . . . 467	454/467 (97%)
	2001]
AAY79243	Rat TPL-2 - Rattus norvegicus, 467	1 . . . 467	438/467 (93%)	0.0
	aa. [WO200011191-A2, 02 MAR.	1 . . . 467	453/467 (96%)
	2000]

[0356] In a BLAST search of public sequence datbases, the NOV1a protein was found to have homology to the proteins shown in the BLASTP data in Table 1E.

TABLE 1E
Public BLASTP Results for NOV1a
			Identities/
Protein			Similarities for
Accession		NOV1a Residues/	the Matched	Expect
Number	Protein/Organism/Length	Match Residues	Portion	Value
P41279	Mitogen-activated protein kinase	1 . . . 467	467/467 (100%)	0.0
	kinase kinase 8 (EC 2.7.1.-) (COT	1 . . . 467	467/467 (100%)
	proto-oncogene serine/threonine-
	protein kinase) (C-COT) (Cancer
	Osaka thyroid oncogene) - Homo
	sapiens (Human), 467 aa.
A48713	serine/threonine-specific protein	1 . . . 467	466/467 (99%)	0.0
	kinase cot, 58 K form - human, 467	1 . . . 467	466/467 (99%)
	aa.
Q63562	Mitogen-activated protein kinase	1 . . . 467	438/467 (93%)	0.0
	kinase kinase 8 (EC 2.7.1.-) (Tumor	1 . . . 467	453/467 (96%)
	progression locus 2) (TPL-2) - Rattus
	norvegicus (Rat), 467 aa.
Q07174	Mitogen-activated protein kinase	1 . . . 467	435/467 (93%)	0.0
	kinase kinase 8 (EC 2.7.1.-) (COT	1 . . . 467	454/467 (97%)
	proto-oncogene serine/threonine-
	protein kinase) (C-COT) (Cancer
	Osaka thyroid oncogene) - Mus
	musculus (Mouse), 467 aa.
A41253	kinase-related transforming protein	1 . . . 397	379/397 (95%)	0.0
	(EC 2.7.1.-) - human, 415 aa.	1 . . . 397	379/397 (95%)

[0357] PFam analysis predicts that the NOV1a protein contains the domains shown in the Table 1F.

TABLE 1F
Domain Analysis of NOV1a
			Identities/
			Similarities for
	Pfam	NOV1a	the Matched	Expect
	Domain	Match Region	Region	Value
	pkinase	146 . . . 388	74/279 (27%)	4.7e−54
			187/279 (67%)

Example 2

[0358] The NOV2 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 2A.

TABLE 2A
NOV2 Sequence Analysis
                 SEQ ID NO: 37           917 bp
NOV2a,           GATGAAGAGAGGGGAGCTCTTTGACTACCTCACTGAGAAGGTCACCTTGAGTGAGAAG
CG101996-01
DNA Sequence     GAAACCAGAAACATCATGCGAGCTCTGCTGGAGGTGATCTGCACCTTGCACAAACTCA
                 ACATCGTGCACCCGGACCTGAAGCCCGAGAACATTCTCTTGGATGACAACATGAACAT
                 CAAGCTCACAGACTTTGGCTTTTCCTGCCAGCTGGAGCCGGGACAGAGGCTGCGAGGG
                 TCTGCGGGACCCCCAGTTACCTGGCCCCTGAGATTATCGAGTGCTCCATGAATGACGA
                 CCACCCGGGCTACGGGAAAGAGGTGGACATGTGGAGCACTGGCGTCATCATGTACACG
                 CTGCTGGCCGCTCCCCGCCCTTCTGGCACCGGAAGCAGATGCTGATGCTGAGGATGAT
                 CATGAGCGGCAACTACCAGTTTGGCTCGCCCGAGTGGGATGATTACTCGGACACCGTG
                 AAGGACCTGGTCTCCCGATTCCTGGTGGTGCAACCCCAGAACCCCTACACAGCGCAAG
                 AGGCCTTGGCACACCCCTTCTTCCAGCAGTACTTGGTGGAGGAAGTGCGGCACTTCAG
                 CCCCCGGGGGAAGTTCAAGGTGATCGCTCTGACCGTGCTGGCTTCAGTGCGGATCTAC
                 TACCAGTACCGCCGGGTGAAGCCTGTGACCCGGGAGATCGTCATCCGAGACCCCTATG
                 CCCTCCGGCCTCTGCGCCGGCTCATCGACGCCTACGCTTTCCGAATCTATGGCCACTG
                 GGTGAAGAAGGGGCAGCAGCAGAACCGGGCAGCCCTTTTCCAGAACACACCCAAGGCC
                 GTGCTCCTCTCCCTGCCCGAGGAGGACTACTGAGGGGCTGGCCAGTCAGGGAGGGCTA
                 GGGGGCAGGTGGGGAGGGGAAGCCATGGAAATACAAGTCAAAGGGGT
                 ORF Start: ATG at 387                ORF Stop: TGA at 843
                 SEQ ID NO: 38           152 aa       MW at 18023.7 kD
NOV2a,           MLMLRMIMSGNYQFGSPEWDDYSDTVKDLVSRFLVVQPQNRYTAEEALAHPFFQQYLV
CG101996-01
Protein Sequence EEVRHFSPRGKFKVIALTVLASVRIYYQYRRVKPVTREIVIRDPYALRPLRRLIDAYA
                 FRIYGNWVKKGQQQNRAALFENTPKAVLLSLAEEDY
                 SEQ ID NO: 39          1299 bp
NOV2b,           ATGACCCGGGACGAGGCACTGCCGGACTCTCATTCTGCACAGGACTTCTATGAGAATT
CG101996-04
DNA Sequence     ATGAGCCCAAAGAGATCCTGGGCAGCGGCGTTAGCAGTGTGGTCAGGCGATGCATCCA
                 CAAGCCCACGAGCCAGGAGTACGCCGTGAAGGTCATCGACGTCACCGGTGGAGGCAGC
                 TTCAGCCCGGAGGAGGTGCGGGAGCTGCGAGAAGCCACGCTGAAGGAGGTGGACATCC
                 TGCGCAAGGTCTCAGGGCACCCCAACATCATACAGCTGAAGGACACTTATGAGACCAA
                 CACTTTCTTCTTCTTGGTGTTTGACCTGATGAAGAGAGGGGAGCTCTTTGACTACCTC
                 ACTGAGAAGGTCACCTTGAGTGAGAAGGAAACCAGAAAGATCATGCGAGCTCTGCTGG
                 AGGTGATCTGCACCTTGCACAAACTCAACATCGTGCACCGGGACCTGAAGCCCGAGAA
                 CATTCTCTTGGATGACAACATGAACATCAACCTCACAGACTTTGGCTTTTCCTGCCAG
                 CTGGAGCCGGGAGAGAGGCTGCGAGTAGAGACAGGGTTTCACCATGTTGGTCAGGCTG
                 GTCTCGAACTCCTGACCTTACGATCCGCCCGCCTCGGCCTCCCAAAGTGCTGTGATTA
                 CAGGCGTGAGCCACCATGCCCAGCAGGGCTAGGCATTTCTTCAGAGGTCTGCGGGACC
                 CCCAGTTACCTGCCCCCTGAGATTATCGAGTGCTCCATGAATGAGGACCACCCGGGCT
                 ACGGGAAAGAGGTGGACATGTGGAGCACTGGCGTCATCATGTACACGCTGCTGGCCGG
                 CTCCCCGCCCTTCTGGCACCGGAAGCAGATGCTGATGCTGAGGATGATCATGAGCGGC
                 AACTACCAGTTTGGCTCGCCCGAGTGGGATGATTACTCGGACACCGTGAAGGACCTGG
                 TCTCCCGATTCCTGGTGGTCCAACCCCAGAACCGCTATACAGCGGAAGAGGCCTTGGC
                 ACACCCCTTCTTCCAGCAGTACTTGGTAGAGGAAGTGCGGCACTTCAGCCCCCGGGGG
                 AAGTTCAAGGTGATCGCTCTGACCGTGCTGGCTTCAGTGCGGATCTACTACCACTACC
                 GCCGGGTGAAGCCTGTGACCCGGGAGATCGTCATCCGAGACCCCTATGCCCTCCGGCC
                 TCTGCGCCGGCTCATCGACGCCTACGCTTTCCGAATCTATGGCCACTGGGTGAAGAAC
                 GGGCAGCAGCAGAACCGGGCAGCCCTTTTCGAGAACACACCCAAGGCCGTGCTCCTCT
                 CCCTGGCCGAGGAGGACTACTGA
                 ORF Start: ATG at 1                  ORF Stop: TGA at 1297
                 SEQ ID NO: 40           432 aa       MW at 49811.7 kD
NOV2b,           MTRDEALPDSHSAQDFYENYEPKEILGRGVSSVVRRCIHKPTSQEYAVKVIDVTGGGS
CG101996-04
Protein Sequence FSPEEVRELREATLKEVDILRKVSGHPNIIQLKDTYETNTFFFLVFDLMKRGELFDYL
                 TEKVTLSEKETRKIMRALLEVICTLHKLNIVHRDLKPENILLDDNMNIKLTDFGFSCQ
                 LEPGERLRVETGFHHVGQAGLELLTLRSARLGLPKCCDYRREPPCPAGLGISSEVCGT
                 PSYLAPETIECSMNEDHPGYGKEVDMWSTGVIMYTLLAGSPPFWHRKQMLMLRMIMSG
                 NYQFGSPEWDDYSDTVKDLVSRFLVVQPQNRYTAEEALAHPFFQQYLVEEVRHFSPRG
                 KFKVIALTVLASVRIYYQYRRVKPVTREIVIRDPYALRPLRRLIDAYAFRIYGHWVKK
                 GQQQNRAALFENTPKAVLLSLAEEDY
                 SEQ ID NO: 41          1377 bp
NOV2c,           GGCCTTCAGCCCTCTGTGGTCCCCTCTCCCCGGGGGGCTTTGGGATTCTTGTCAAGCT
CG101996-02
DNA Sequence     CCTTCAAGAGCCTGCAAGCACTTAACCAGCCACCCAGAGTTCCCTCACTGAAGATCTG
                 AGCATGACCCGGGACCAGGCACTGCCGGACTCTCATTCTGCACAGGACTTCTATGAGA
                 ATTATGAGCCCAAAGAGATCCTGGGCAGGGGCGTTAGCAGTGTGGTCAGGCGATGCAT
                 CCACAACCCCACGAGCCAGGAGTACGCCGTGAAGGTCATCGACGTCACCGGTGGAGGC
                 AGCTTCAGCCCGGAGGAGGTGCGGGAGCTGCGAGAAGCCACGCTGAAGGAGGTGGACA
                 TCCTGCGCAAGGTCTCAGGGCACCCCAACATCATACAGCTGAAGGACACTTATGAGAC
                 CAACACTTTCTTCTTCTTGGTGTTTGACCTGATGAAGAGAGCGGAGCTCTTTGACTAC
                 CTCACTGAGAAGGTCACCTTGAGTGAGAAGGAAACCAGAAAGATCATGCGAGCTCTGC
                 TGGAGGTGATCTGCACCTTGCACAAACTCAACATCGTGCACCGGGACCTGAAGCCCGA
                 GAACATTCTCTTGGATGACAACATGAACATCAAGCTCACAGACTTTGGCTTTTCCTGC
                 CAGCTGGAGCCGGGAGAGAGGCTGCGAGAGGTCTGCGGGACCCCCAGTTACCTGCCCC
                 CTGAGATTATCGAGTGCTCCATGAATGAGGACCACCCGGGCTACGGGAAAGAGGTGGA
                 CATGTGGAGCACTCGCGTCATCATGTACACGCTGCTGGCCGGCTCCCCGCCCTTCTGG
                 CACCGGAAGCAGATGCTGATGCTGAGGATGATCATGAGCGGCAACTACCAGTTTGGCT
                 CGCCCGAGTGGGATGATTACTCGGACACCGTGAAGGACCTGGTCTCCCGATTCCTGGT
                 GGTGCAACCCCAGAACCGCTACACAGCGGAAGAGGCCTTGGCACACCCCTTCTTCCAC
                 CAGTACTTGGTGGAGGAAGTGCGGCACTTCAGCCCCCGGGGGAAGTTCAAGGTGATCG
                 CTCTGACCGTCCTGGCTTCAGTGCGGATCTACTACCAGTACCGCCGGGTGAAGCCTGT
                 GACCCGGGAGATCGTCATCCGAGACCCCTATGCCCTCCGGCCTCTGCGCCGGCTCATC
                 GACGCCTACGCTTTCCGAATCTATGGCCACTGGGTGAAGAAGGGGCAGCAGCAGAACC
                 GGGCAGCCCTTTTCGAGAACACACCCAAGGCCGTGCTCCTCTCCCTGGCCGAGGAGGA
                 CTACTGAGGGGCTGGCCAGTCAGGGAGGGCTAGGGGGCAGGTGGGGAGGGGAAGCCAT
                 GCAAATACAAGTCAAAGGGGTAAAAAAAAAAAAAAAAAAAAAA
                 ORF Start:ATG at 120                 ORF Stop: TGA at 1281
                 SEQ ID NO: 42           387 aa       MW at 45023.3 kD
NOV2c,           MTRDEALPDSHSAQDFYENYEPKEILGRGVSSVVRRCIHKPTSQEYAVKVIDVTGGGS
CG101996-02
Protein Sequence FSPEEVRELREATLKEVDILRKVSGHPNIIQLKDTYETNTFFFLVFDLMKRGELFDYL
                 TEKVTLSEKETRKIMRALLEVICTLHKLNIVHRDLKPENILLDDNMNIKLTDFGFSCQ
                 LEPGERLREVCGTPSYLAPEIIECSMNEDHPGYGKEVDMWSTGVIMYTLLAGSPPFWH
                 RKQMLMLRMIMSGNYQFGSPEWDDYSDTVKDLVSRFLVVQPQNRYTAEEALAHPFFQQ
                 YLVEEVRHFSPRGKFKVIALTVLASVRIYYQYRRVKPVTREIVIRDPYALRPLRRLID
                 AYAFRIYGHWVKKGQQQNRAALFENTPKAVLLSLAEEDY
                 SEQ ID NO: 43          1165 bp
NOV2d,           CATGACCCGGGACGAGGCACTGCCGGACTCTCATTCTGCACACGACTTCTATGAGAAT
245245680
DNA Sequence     TATGAGCCCAAAGAGATCCTGGGCAGGGGCGTTAGCAGTGTGGTCAGGCGATGCATCC
                 ACAAGCCCACGAGCCAGGAGTACGCCGTGAAGGTCATCGACGTCACCGGTGGAGGCAG
                 CTTCAGCCCGGAGGAGGTGCGGGAGCTGCGAGAAGCCACGCTGAAGGAGGTGGACATC
                 CTGCGCAAGGTCTCAGGGCACCCCAACATCATACAGCTGAAGGACACTTATGAGACCA
                 ACACTTTCTTCTTCTTGGTGTTTGACCTGATGAAGAGAGGGGAGCTCTTTGACTACCT
                 CACTGAGAAGGTCACCTTGAGTGAGAAGGAAACCAGAAAGATCATGCGAGCTCTGCTG
                 GAGGTGATCTGCACCTTGCACAAACTCAACATCGTGCACCGGGACCTGAAGCCCGAGA
                 ACATTCTCTTGGATGACAACATGAACATCAAGCTCACAGACTTTGGCTTTTCCTGCCA
                 GCTGGAGCCGGGAGAGAGGCTGCGAGAGGTCTGCGGGACCCCCAGTTACCTGGCCCCT
                 GAGATTATCGAGTGCTCCATGAATGAGGACCACCCGGGCTACGGGAAAGAGGTGGACA
                 TGTGGAGCACTGGCGTCATCATGTACACGCTGCTGGCCGGCTCCCCGCCCTTCTGGCA
                 CCGGAAGCAGATGCTGATGCTGAGCATGATCATGAGCGGCAACTACCAGTTTGGCTCG
                 CCCGAGTGGGATGATTACTCGGACACCGTGAAGGACCTGGTCTCCCGATTCCTGGTGG
                 TGCAACCCCAGAACCGCTACACAGCGGAAGAGGCCTTGGCACACCCCTTCTTCCAGCA
                 GTACTTGGTGGAGGAAGTGCGGCACTTCAGCCCCCGGGGGAAGTTCAAGGTGATCGCT
                 CTGACCGTGCTGGCTTCAGTGCGGATCTACTACCAGTACCGCCGGGTGAAGCCTGTGA
                 CCCGGGAGATCGTCATCCGAGACCCCTATGCCCTCCGGCCTCTGCGCCGGCTCATCGA
                 CGCCTACGCTTTCCGAATCTATGGCCACTGGGTGAAGAAGGGGCAGCAGCAGAACCGG
                 GCAGCCCTTTTCGAGAACACACCCAAGGCCGTGCTCCTCTCCCTGGCCGAGGAGGACT
                 ORF Start: ATG at 2                  ORF Stop: TGA at 1163
                 SEQ ID NO: 44           387 aa       MW at 45023.3 kD
NOV2d,           MTRDEALPDSHSAQDFYENYEPKEILGRGVSSVVRRCIHKPTSQEYAVKVIDVTGGGS
245245680
Protein Sequence FSPEEVRELREATLKEVDTLRKVSGHPNIIQLKDTYETNTFFFLVFDLMKRGELFDYL
                 TEKVTLSEKETRKIMRALLEVICTLHKLNTVHRDLKPENILLDDNMNIKLTDFGFSCQ
                 LEPGERLREVCGTPSYLAPEIIECSMNEDHPGYGKEVDMWSTGVIMYTLLAGSPPFWH
                 RKQMLMLRMIMSGNYQFGSPEWDDYSDTVKDLVSRFLVVQPQNRYTAEEALAHPFFQQ
                 YLVEEVRHFSPRGKFKVIALTVLASVRIYYQYRRVKPVTREIVIRDPYALRPLRRLID
                 AYAFRIYGHWVKKGQQQNRAALFENTPKAVLLSLAEEDY
                 SEQ ID NO: 45          1300 bp
NOV2e,           CATGACCCGGGACGAGGCACTGCCGGACTCTCATTCTGCACAGGACTTCTATGAGAAT
245245707
DNA Sequence     TATGAGCCCAAAGAGATCCTGGGCAGGGGCGTTAGCAGTGTGGTCAGGCGATGCATCC
                 ACAAGCCCACGAGCCAGGAGTACGCCGTGAAGGTCATCGACGTCACCGGTGGAGGCAG
                 CTTCAGCCCGGAGGAGGTGCGGGAGCTGCGAGAAGCCACGCTGAAGGAGGTGGACATC
                 CTGCGCAAGGTCTCAGGGCACCCCAACATCATACAGCTGAAGGACACTTATGAGACCA
                 ACACTTTCTTCTTCTTGGTGTTTGACCTGATGAAGAGAGGGGAGCTCTTTGACTACCT
                 CACTCAGAAGGTCACCTTGAGTGACAAGGAAACCAGAAAGATCATGCGAGCTCTGCTG
                 GAGGTGATCTGCACCTTGCACAAACTCAACATCGTGCACCGGGACCTGAAGCCCGAGA
                 ACATTCTCTTGGATGACAACATGAACATCAAGCTCACAGACTTTGGCTTTTCCTGCCA
                 GCTGGAGCCGGGAGAGAGGCTGCGAGTAGAGACAGGGTTTCACCATGTTGGTCAGGCT
                 GGTCTCAAACTCCTGACCTTACGATCCGCCCGCCTCGGCCTCCCAAAGTGCTGTGATT
                 ACAGGCGTGAGCCACCATGCCCAGCAGGGCTAGGCATTTCTTCAGAGGTCTGCGGGAC
                 CCCCAGTTACCTGGCCCCTGAGATTATCGAGTCCTCCATGAATGAGGACCACCCGGGC
                 TACGGGAAAGAGGTGGACATGTGGAGCACTGGCGTCATCATGTACACGCTGCTGGCCG
                 GCTCCCCCCCCTTCTGGCACCGGAAGCAGATGCTGATGCTGAGCATGATCATGAGCGG
                 CAACTACCAGTTTGGCTCGCCCGAGTGGGATGATTACTCGGACACCGTGAAGGACCTG
                 GTCTCCCGATTCCTGGTGGTGCAACCCCAGAACCGCTACACAGCGGAAGAGGCCTTGG
                 CACACCCCTTCTTCCAGCAGTACTTGGTGGAGGAAGTGCGGCACTTCAGCCCCCGGGG
                 GAAGTTCAAGGTGATCGCTCTGACCGTGCTGGCTTCAGTGCGGATCTACTACCAGTAC
                 CGCCGGGTGAAGCCTGTGACCCGGGAGATCGTCATCCGAGACCCCTATGCCCTCCGGC
                 CTCTGCGCCGGCTCATCGACGCCTACGCTTTCCGAATCTATGGCCACTGGGTGAAGAA
                 GGGGCAGCAGCAGAACCGGGCAGCCCTTTTCGAGAACACACCCAAGGCCGTGCTCCTC
                 TCCCTGGCCGAGGAGGACTACTGA
                 ORF Start: ATG at 2                  ORF Stop: TGA at 1298
                 SEQ ID NO: 46           432 aa       MW at 49810.8 kD
NOV2e,           MTRDEALPDSHSAQDFYENYEPKEILGRGVSSVVRRCIHKPTSQEYAVKVIDVTGGGS
245245707
Protein Sequence FSPEEVRELREATLKEVDILRKVSGHPNIIQLKDTYETNTFFFLVFDLMKRGELFDYL
                 TEKVTLSEKETRKIMRALLEVICTLHKLNIVHRDLKPENILLDDNMNIKLTDFGFSCQ
                 LEPGERLRVETGFHHVGQAGLKLLTLRSARLGLPKCCDYRREPPCPAGLGISSEVCGT
                 PSYLAPETIECSMNEDHPGYGKEVDMWSTGVIMYTLLAGSPPFWHRKQMLMLRMIMSG
                 NYQFGSPEWDDYSDTVKDLVSRFLVVQPQNRYTAEEALAHPFFQQYLVEEVRHFSPRG
                 KFKVIALTVLASVRIYYQYRRVKPVTREIVIRDPYALRPLRRLIDAYAFRIYGHWVKK
                 GQQQNRAALFENTPKAVLLSLAEEDY
                 SEQ ID NO: 47           927 bp
NOV2f,           ACCATGGGACATCATCACCACCATCACACCCGGGACGAGGCACTGCCGGACTCTCATT
248494552
DNA Sequence     CTGCACAGGACTTCTATGAGAATTATGAGCCCAAAGAGATCCTGGGCAGGGGCGTTAG
                 CAGTGTGGTCAGGCGATGCATCCACAAGCCCACGAGCCAGGAGTACGCCGTGAAGGTC
                 ATCGACGTCACCGGTGGAGGCAGCTTCAGCCCGGAGGAGGTGCGGGAGCTGCGAGAAG
                 CCACGCTGAAGGAGGTGGACATCCTGCGCAAGGTCTCAGGCCACCCCAACATCATACA
                 GCTGAAGGACACTTATGAGACCAACACTTTCTTCTTCTTGGTGTTTGACCTGATGAAG
                 AGAGGGGAGCTCTTTGACTACCTCACTGAGAAGGTCACCTTGAGTGAGAAGGAAACCA
                 GAAAGATCATGCGAGCTCTGCTGGAGGTGATCTGCACCTTGCACAAACTCAACATCGT
                 GCACCGGGACCTGAAGCCCGAGAACATTCTCTTGGATGACAACATGAACATCAAGCTC
                 ACAGACTTTGGCTTTTCCTGCCAGCTGGAGCCGGGAGAGAGGCTGCGAGAGGTCTGCG
                 GGACCCCCAGTTACCTGGCCCCTGAGATTATCGAGTGCTCCATGAATGAGGACCACCC
                 GGGCTACGGGAAAGAGGTGGACATGTGGAGCACTGGCGTCATCATCTACACGCTGCTG
                 GCCGGCTCCCCGCCCTTCTGGCACCGGAAGCAGATGCTGATGCTGAGGATGATCATGA
                 GCGGCAACTACCAGTTTGGCTCGCCCGAGTGGGATGATTACTCGGACACCGTCAAGGA
                 CCTGGTCTCCCGATTCCTGGTGGTGCAACCCCAGAACCGCTACACAGCGGAAGAGGCC
                 TTGGCACACCCCTTCTTCCAGCAGTACTTGGTGGAGGAAGTGCGGCACTTCAGCTGA
                 ORF Start: at 1                      ORF Stop: TGA at 925
                 SEQ ID NO: 48           308 aa       MW at 35743.4 kD
NOV2f,           TMGHHHHHHTRDEALPDSHSAQDFYENYEPKEILGRGVSSVVRRCIHKPTSQEYAVKV
248494552
Protein Sequence IDVTGGGSFSPEEVRELREATLKEVDILRKVSGHPNIIQLKDTYETNTFFFLVFDLMK
                 RGELFDYLTEKVTLSEKETRKIMRALLEVICTLHKLNIVHRDLKPENILLDDNMNIKL
                 TDFGFSCQLEPGERLREVCGTPSYLAPEIIECSMNEDHPGYGKEVDMWSTGVIMYTLL
                 AGSPPFWHRKQMLMLRMIMSGNYQFGSPEWDDYSDTVKDLVSRFLVVQPQNRYTAEEA
                 LAHPFFQQYLVEEXTRHFS
                 SEQ ID NO: 49          1194 bp
NOV2g,           CGCGGATCCACCATGACCCGGGACGAGGCACTGCCGGACTCTCATTCTGCACAGGACT
242435676
DNA Sequence     TCTATGAGAATTATGAGCCCAAAGAGATCCTGGGCAGGGGCGTTAGCAGTGTGGTCAG
                 GCGATGCATCCACAAGCCCACGAGCCAGGAGTACGCCGTGAAGGTCATCGACGTCACC
                 GGTGGAGGCAGCTTCAGCCCGGAGGAGGTGCGGGAGCTGCGAGAAGCCACGCTGAAGG
                 AGGTGGACATCCTGCGCAAGGTCTCAGGGCACCCCAACATCATACAGCTGAAGGACAC
                 TTATGAGACCAACACTTTCTTCTTCTTGGTGTTTGACCTGATGAAGAGAGGGGAGCTC
                 TTTGACTACCTCACTGAGAAGGTCACCTTGAGTGAGAAGGAAACCAGAAAGATCATGC
                 GAGCTCTGCTGGAGGTGATCTGCACCTTGCACAAACTCAACATCGTGCACCGGGACCT
                 GAAGCCCGAGAACATTCTCTTGGATGACAACATGAACATCAAGCTCACAGACTTTGGC
                 TTTTCCTGCCAGCTGGAGCCGGGAGAGAGGCTGCGAGAGGTCTGCGGGACCCCCAGTT
                 ACCTGGCCCCTGAGATTATCGAGTGCTCCATGAATGAGGACCACCCGGGCTACGGGAA
                 AGAGGTGGACATGTGGAGCACTGGCGTCATCATGTACACGCTGCTGGCCGGCTCCCCG
                 CCCTTCTGGCACCGGAAGCAGATGCTGATGCTGAGGATGATCATGAGCGGCAACTACC
                 AGTTTGGCTCGCCCGAGTGGGATGATTACTCGGACACCGTGAAGGACCTGGTCTCCCG
                 ATTCCTGGTGGTGCAACCCCAGAACCGCTACACAGCGGAAGAGGCCTTGGCACACCCC
                 TTCTTCCAGCAGTACTTGGTGGAGGAAGTGCGGCACTTCAGCCCCCGGGGGAAGTTCA
                 AGGTGATCGCTCTGACCGTGCTGGCTTCAGTGCGGATCTACTACCAGTACCGCCGGGT
                 GAAGCCTGTGACCCGGGAGATCGTCATCCGAGACCCCTATGCCCTCCGGCCTCTGCGC
                 CGGCTCATCGACGCCTACGCTTTCCGAATCTATGGCCACTGGGTGAAGAAGGGGCAGC
                 AGCAGAACCGGGCAGCCCTTTTCGAGAACACACCCAAGGCCGTGCTCCTCTCCCTGGC
                 CGAGGAGGACTACTGAGCGGCCGCTTTTTTCCTT
                 ORF Start: at 1                      ORF Stop: TGA at 1174
                 SEQ ID NO: 50           391 aa       MW at 45424.7 kD
NOV2g,           RGSTMTRDEALPDSHSAQDFYENYEPKEILGRGVSSVVRRCIHKPTSQEYAVKVIDVT
242435676
Protein Sequence GGGSFSPEEVRELREATLKEVDILRKVSGHPNIIQLKDTYETNTFFFLVFDLMKRGEL
                 FDYLTEKVTLSEKETRKIMRALLEVICTLHKLNIVHRDLKPENILLDDNMNIKLTDFG
                 FSCQLEPGERLREVCGTPSYLAPEIIECSMNEDHPGYGKEVDMWSTGVIMYTLLAGSP
                 PFWHRKQMLMLRMIMSGNYQFGSPEWDDYSDTVKDLVSRFLVVQPQNRYTAEEALAHP
                 FFQQYLVEEVRHFSPRGKFKVIALTVLASVRIYYQYRRVKPVTREIVIRDPYALRPLR
                 RLIDAYAFRIYGHWVKKGQQQNRAALFENTPKAVLLSLAEEDY
                 SEQ ID NO: 51           952 bp
NOV2h,           ACATCATCACCACCATCACACCCGGGACGAGGCACTGCCGGACTCTCATTCTGCACAG
254868664
DNA Sequence     GACTTCTATGAGAATTATGAGCCCAAAGAGATCCTGGGCAGGGGCGTTAGCAGTGTGG
                 TCAGGCGATGCATCCACAAGCCCACGAGCCAGGAGTACGCCGTGAAGGTCATCGACGT
                 CACCGGTGGAGGCAGCTTCAGCCCGGAGGAGGTGCGGGAGCTGCGAGAAGCCACGCTG
                 AAGGAGGTGGACATCCTGCGCAAGGTCTCAGGGCACCCCAACATCATACAGCTGAAGG
                 ACACTTATGAGACCAACACTTTCTTCTTCTTGGTGTTTGACCTGATGAAGAGAGGGGA
                 GCTCTTTGACTACCTCACTGAGAAGGTCACCTTGAGTGAGAAGGAAACCAGAAAGATC
                 ATGCGAGCTCTGCTGGAGGTGATCTGCACCTTGCACAAACTCAACATCGTGCACCGGG
                 ACCTGAAGCCCGAGAACATTCTCTTGGATCACAACATGAACATCAAGCTCACAGACTT
                 TGGCTTTTCCTGCCAGCTGGAGCCGGGAGAGAGGCTGCGAGAGGTCTGCGGGACCCCC
                 AGTTACCTGGCCCCTGAGATTATCGAGTGCTCCATGAATGAGGACCACCCGGGCTACG
                 GGAAAGAGGTGGACATGTGGAGCACTGGCGTCATCATGTACACGCTGCTGGCCGGCTC
                 CCCGCCCTTCTGGCACCGGAAGCAGATGCTGATGCTGAGGATGATCATGAGCGGCAAC
                 TACCAGTTTGGCTCGCCCGAGTGGGATGATTACTCGGACACCGTGAAGGACCTGGTCT
                 CCCGATTCCTGGTGGTGCAACCCCAGAACCGCTACACAGCGGAAGAGGCCTTGGCACA
                 CCCCTTCTTCCAGCAGTACTTGGTGGAGGAAGTGCGGCACTTCAGCTGAGCGGCCGCA
                 CTCGAGCACCACCACCACCACCAC
                 ORF Start: at 2                      ORF Stop: TGA at 917
                 SEQ ID NO: 52           305 aa       MW at 35454.0 kD
NOV2h,           HHHHHHTRDEALPDSHSAQDFYENYEPKEILGRGVSSVVRRCIRKPTSQEYAVKVIDV
254868664
Protein Sequence TCGCSFSPEEVRELREATLKEVDILRKVSGHPNITQLKDTYETNTFFFLVFDLMKRGE
                 LFDYLTEKVTLSEKETRKIMRALLEVICTLHKLNIVHRDLKPENILLDDNMNIKLTDF
                 GFSCQLEPGERLREVCCTPSYLAPEIIECSMNEDHPGYGKEVDMWSTGVIMYTLLAGS
                 PPFWHRKQMLMLRMIMSGNYQFGSPEWDDYSDTVKDLVSRFLVVQPQNRYTAEEALAH
                 PFPQQYLVEEVRHFS
                 SEQ ID NO: 53           939 bp
NOV2i,           CATATGACCCGGGACGAGGCACTGCCGGACTCTCATTCTGCACAGGACTTCTATGAGA
249122191
DNA Sequence     ATTATGAGCCCAAAGAGATCCTGGGCAGGGGCGTTAGCAGTGTGGTCAGGCGATGCAT
                 CCACAAGCCCACGAGCCAGGAGTACGCCGTGAAGGTCATCGACGTCACCGGTGGAGGC
                 AGCTTCAGCCCGGAGGAGGTGCGGGAGCTGCGAGAAGCCACGCTGAAGGAGGTGGACA
                 TCCTGCGCAAGGTCTCAGGGCACCCCAACATCATACAGCTGAAGGACACTTATGAGAC
                 CAACACTTTCTTCTTCTTGGTGTTTGACCTGATGAAGAGAGGGGAGCTCTTTGACTAC
                 CTCACTGAGAAGGTCACCTTGAGTGAGAAGGAAACCAGAAAGATCATGCGAGCTCTGC
                 TGGAGGTGATCTGCACCTTGCACAAACTCAACATCGTGCACCGGGACCTGAAGCCCGA
                 GAACATTCTCTTGGATGACAACATGAACATCAAGCTCACAGACTTTGGCTTTTCCTGC
                 CAGCTGGAGCCGGGAGAGAGGCTGCGAGAGGTCTGCGGGACCCCCAGTTACCTGGCCC
                 CTGAGATTATCGAGTGCTCCATGAATGAGGACCACCCGGGCTACGGGAAACAGGTGGA
                 CATGTGGAGCACTGGCGTCATCATGTACACGCTGCTGGCCGGCTCCCCGCCCTTCTGG
                 CACCGGAAGCAGATGCTGATGCTGAGGATGATCATGAGCGGCAACTACCAGTTTGGCT
                 CGCCCGAGTGGGATGATTACTCGGACACCGTGAAGGACCTGGTCTCCCGATTCCTGGT
                 GGTGCAACCCCAGAACCGCTACACAGCGGAAGAGGCCTTGGCACACCCCTTCTTCCAG
                 CAGTACTTGGTGCAGGAAGTGCGGCACTTCAGCTGAGCGGCCGCACTCGAGCACCACC
                 ACCACCACCAC
                 ORF Start: at 1                      ORF Stop: TGA at 904
                 SEQ ID NO: 54           301 aa       MW at 34899.5 kD
NOV21,           HMTRDEALPDSHSAQDFYENYEPKEILGRGVSSVVRRCIHKPTSQEYAVKVIDVTGGG
249122191
Protein Sequence SFSPEEVRELREATLKEVDILRKVSGHPNIIQLKDTYETNTFFFLVFDLMKRGELFDY
                 LTEKVTLSEKETRKIMRALLEVICTLHKLNIVHRDLKPENILLDDNMNIKLTDFGFSC
                 QLEPGERLREVCGTPSYLAPEIIECSMNEDHPGYGKEVDMWSTGVIMYTLLAGSPPFW
                 HRKQMLMLRMIMSGNYQFGSPEWDDYSDTVKDLVSRFLVVQPQNRYTAEEALAHPFFQ
                 QYLVEEVRHFS
                 SEQ ID NO: 55           951 bp
NOV2j,           ACCCGGGACGAGGCACTGCCGGACTCTCATTCTGCACAGGACTTCTATGAGAATTATG
249122234
DNA Sequence     ACCCCAAAGAGATCCTGGGCAGGGGCGTTACCAGTGTGGTCAGGCGATGCATCCACAA
                 GCCCACGAGCCAGGAGTACGCCGTGAAGGTCATCGACGTCACCGGTGGAGGCAGCTTC
                 AGCCCGGAGGAGGTGCGGGAGCTGCGAGAAGCCACGCTGAAGGAGGTGGACATCCTGC
                 GCAAGGTCTCAGGGCACCCCAACATCATACAGCTGAAGGACACTTATGAGACCAACAC
                 TTTCTTCTTCTTGGTGTTTGACCTGATGAAGAGAGGGGAGCTCTTTGACTACCTCACT
                 GAGAAGGTCACCTTGAGTGAGAAGGAAACCAGAAAGATCATGCGAGCTCTGCTGGAGG
                 TGATCTGCACCTTGCACAAACTCAACATCGTGCACCGGGACCTGAAGCCCGAGAACAT
                 TCTCTTCGATGACAACATGAACATCAAGCTCACAGACTTTGGCTTTTCCTGCCAGCTG
                 GAGCCGGGAGAGAGGCTGCGAGAGGTCTGCGGGACCCCCAGTTACCTGGCCCCTGAGA
                 TTATCGAGTGCTCCATGAATGAGGACCACCCGGGCTACGGGAAAGAGGTGGACATGTG
                 GAGCACTGGCGTCATCATGTACACGCTGCTGGCCGGCTCCCCGCCCTTCTGGCACCGG
                 AAGCAGATGCTGATGCTGAGGATGATCATGAGCGGCAACTACCAGTTTGGCTCGCCCG
                 AGTGGGATGATTACTCGGACACCGTCAAGGACCTGGTCTCCCGATTCCTGGTGGTGCA
                 ACCCCAGAACCGCTACACAGCGGAAGAGGCCTTGGCACACCCCTTCTTCCAGCAGTAC
                 TTGGTGGAGGAAGTGCGGCACTTCAGCCATCATCACCACCATCACTGAGCGGCCGCAC
                 TCGAGCACCACCACCACCACCAC
                 ORF Start: at 1                      ORF Stop: TGA at 916
                 SEQ ID NO: 56           305 aa       MW at 35454.0 kD
NOV2j,           TRDEALPDSHSAQDFYENYEPKEILGRGVSSVVRRCIHKPTSQEYAVKVIDVTGGGSF
249122234
Protein Sequence SPEEVRELREATLKEVDILRKVSGHPNIIQLKDTYETNTFFFLVFDLMKRGELFDYLT
                 EKVTLSEKETRKIMRALLEVICTLHKLNIVHRDLKPENILLDDNMNIKLTDFGFSCQL
                 EPGERLREVCGTPSYLAPEIIECSMNEDHPGYGKEVDMWSTGVIMYTLLAGSPPFWHR
                 KQMLMLRMIMSGNYQFGSPEWDDYSDTVKDLVSRFLVVQPQNRYTAEEALAHPFFQQY
                 LVEEVRHFSHHHHHH
                 SEQ ID NO: 57          1252 bp
NOV2k,           CTTTGGGATTCTTGTCAAGCTCCTTCAAGAGCCTGCAAGCACTTAACCAGCCACCCAG
CG101996-03
DNA Sequence     ACTTCCCTCACTGAAGATCTGAGCATGACCCGGGACGAGGCACTGCCGGACTCTCATT
                 CTGCACAGGACTTCTATGAGAATTATGAGCCCAAAGAGATCCTGGGCAGGGGCGTTAG
                 CAGTGTGGTCAGGCGATGCATCCACAAGCCCACGAGCCAGGAGTACGCCGTGAAGGTC
                 ATCGACGTCACCGGTGGAGGCAGCTTCACCCCGGAGGAGGTGCGGGAGCTGCGAGAAG
                 CCACGCTGAAGGAGGTGGACATCCTGCGCAAGGTCTCAGGGCACCCCAACATCATACA
                 GCTGAAGGACACTTATGAGACCAACACTTTCTTCTTCTTGGTGTTTGACCTGATGAAG
                 AGAGGGGAGCTCTTTGACTACCTCACTGAGAAGGTCACCTTGAGTCAGAAGGAAACCA
                 GAAAGATCATGCGAGCTCTGCTGGAGGTGATCTGCACCTTGCACAAACTCAACATCGT
                 GCACCGGGACCTGAAGCCCGAGAACATTCTCTTGGATGACAACATGAACATCAAGCTC
                 ACAGACTTTGGCTTTTCCTGCCAGCTGGAGCCGGGAGAGAGGCTGCGAGAGGTCTGCG
                 GGACCCCCAGTTACCTGGCCCCTGAGATTATCGAGTGCTCCATGAATGACGACCACCC
                 GGGCTACGGGAAAGAGGTGGACATGTGGAGCACTGGCGTCATCATGTACACGCTGCTG
                 GCCGGCTCCCCGCCCTTCTGGCACCGGAAGCAGATCCTGATGCTGAGGATGATCATGA
                 GCGGCAACTACCAGTTTGGCTCGCCCGAGTGGGATGATTACTCGGACACCGTGAAGGA
                 CCTGGTCTCCCGATTCCTGGTGGTGCAACCCCAGAACCGCTACACAGCGGAAGAGGCC
                 TTGGCACACCCCTTCTTCCAGCAGTACTTGGTGGAGGAAGTGCGGCACTTCAGCCCCC
                 GGGGGAAGTTCAAGGTGATCGCTCTGACCGTGCTGGCTTCAGTGCGGATCTACTACCA
                 GTACCGCCGGGTGAAGCCTGTGACCCGGGAGATCGTCATCCGAGACCCCTATGCCCTC
                 CGGCCTCTGCGCCGGCTCATCGACGCCTACGCTTTCCGAATCTATGGCCACTGGGTGA
                 AGAAGGGGCAGCAGCAGAACCGGGCAGCCCTTTTCGAGAACACACCCAAGGCCGTGCT
                 CCTCTCCCTGGCCGAGGAGGACTACTGAGGGGCT
                 ORF Start: ATG at 83                 ORF Stop: TGA at 1244
                 SEQ ID NO: 58           387 aa       MW at 45023.3 kD
NOV2k,           MTRDEALPDSHSAQDFYENYEPKEILGRGVSSVVRRCIHKPTSQEYAVKVIDVTGGGS
CG101996-03
Protein Sequence FSPEEVRELREATLKEVDILRKVSGHPNIIQLKDTYETNTFFFLVFDLMKRGELFDYL
                 TEKVTLSEKETRKIMRALLEVICTLHKLNIVHRDLKPENILLDDNNNIKLTDFGFSCQ
                 LEPGERLREVCGTPSYLAPEIIECSMNEDHPGYGKEVDMWSTGVIMYTLLAGSPPFWH
                 RKQMLMLRMIMSGNYQFGSPEWDDYSDTVKDLVSRFLVVQPQNRYTAEEALAHPFFQQ
                 YLVEEVRHFSPRGKFKVIALTVLASVRIYYQYRRVKPVTREIVIRDPYALRPLRRLID
                 AYAFRIYGHWVKKGQQQNRAALFENTPKAVLLSLAEEDY
                 SEQ ID NO: 59          1194 bp
NOV2l,           CGCGGATCCACCATGACCCGGGACGAGGCACTGCCGGACTCTCATTCTGCACAGGACT
CG101996-05
DNA Sequence     TCTATGAGAATTATGAGCCCAAAGAGATCCTGGGCAGGGGCGTTAGCAGTGTGGTCAG
                 GCGATGCATCCACAAGCCCACGAGCCAGCAGTACGCCGTGAAGGTCATCGACGTCACC
                 GGTGGAGGCAGCTTCAGCCCGGAGGAGGTGCGGGAGCTGCGAGAAGCCACGCTGAAGG
                 AGGTGGACATCCTGCGCAAGGTCTCAGGGCACCCCAACATCATACAGCTGAAGGACAC
                 TTATGAGACCAACACTTTCTTCTTCTTGGTGTTTGACCTGATGAAGAGAGGGGAGCTC
                 TTTGACTACCTCACTGAGAAGGTCACCTTGAGTGAGAAGGAAACCAGAAAGATCATGC
                 GAGCTCTGCTGGAGGTGATCTGCACCTTGCACAAACTCAACATCGTGCACCCGGACCT
                 GAAGCCCGAGAACATTCTCTTGGATGACAACATGAACATCAAGCTCACAGACTTTGGC
                 TTTTCCTGCCAGCTGGAGCCGGGAGAGAGGCTGCGAGAGGTCTGCGGGACCCCCAGTT
                 ACCTGGCCCCTGAGATTATCGAGTGCTCCATGAATGAGGACCACCCGGGCTACGGGAA
                 AGAGGTGGACATGTGGAGCACTGGCGTCATCATGTACACGCTGCTGGCCGGCTCCCCG
                 CCCTTCTGGCACCGGAAGCAGATGCTGATGCTGAGGATGATCATGAGCGGCAACTACC
                 AGTTTGGCTCGCCCGAGTGGGATGATTACTCGGACACCGTGAAGGACCTGGTCTCCCG
                 ATTCCTGGTGGTGCAACCCCAGAACCGCTACACAGCGGAAGAGGCCTTGGCACACCCC
                 TTCTTCCAGCAGTACTTGGTGGAGGAAGTGCGGCACTTCAGCCCCCGGGGGAAGTTCA
                 AGGTGATCGCTCTGACCGTGCTGGCTTCAGTGCGGATCTACTACCAGTACCGCCGGGT
                 GAAGCCTGTGACCCGGGAGATCGTCATCCGAGACCCCTATGCCCTCCGGCCTCTGCGC
                 CGGCTCATCGACGCCTACGCTTTCCGAATCTATGCCCACTGGGTGAAGAAGGGGCAGC
                 AGCAGAACCGGGCACCCCTTTTCGAGAACACACCCAAGGCCGTGCTCCTCTCCCTGGC
                 CGAGGAGGACTACTGAGCGGCCGCTTTTTTCCTT
                 ORF Start at 1                       ORF Stop: TGA at 1174
                 SEQ ID NO: 60           391 aa       MW at 45424.7 kD
NOV21,           RGSTMTRDEALPDSHSAQDFYENYEPKETLGRGVSSVVRRCIHKPTSQEYAVKVIDVT
CG101996-05
Protein Sequence GGGSFSPEEVRELREATLKEVDILRKVSGHPNIIQLKDTYETNTFFFLVFDLMKRGEL
                 FDYLTEKVTLSEKETRKIMRALLEVICTLHKLNIVHRDLKPENILLDDNMNIKLTDFG
                 FSCQLEPGERLREVCGTPSYLAPETIECSMNEDHPGYGKEVDMWSTGVIMYTLLAGSP
                 PFWHRKQMLMLRMIMSGNYQFGSPEWDDYSDTVKDLVSRFLVVQPQNRYTAEEALAIP
                 FFQQYLVEEVRHFSPRGKFKVIALTVLASVRIYYQYRRVKPVTREIVIRDPYALRPLR
                 RLIDAYAFRIYGHWVKKGQQQNRAALFENTPKAVLLSLAEEDY
                 SEQ ID NO: 61          1165 bp
NOV2m,           CATGACCCGGGACGAGGCACTGCCGGACTCTCATTCTGCACAGGACTTCTATGAGAAT
CG101996-06
DNA Sequence     TATGAGCCCAAAGAGATCCTGGGCAGGGGCGTTAGCAGTGTGGTCAGGCGATGCATCC
                 ACAAGCCCACGAGCCAGGAGTACGCCGTGAAGGTCATCGACGTCACCGGTGGAGGCAG
                 CTTCAGCCCGGAGGAGGTGCGGGAGCTGCGAGAAGCCACGCTGAAGGACGTGGACATC
                 CTGCGCAAGGTCTCAGGGCACCCCAACATCATACAGCTGAAGGACACTTATGAGACCA
                 ACACTTTCTTCTTCTTGGTGTTTGACCTGATGAACAGAGGGGAGCTCTTTGACTACCT
                 CACTGAGAAGGTCACCTTGAGTGAGAAGGAAACCAGAAAGATCATGCGAGCTCTGCTG
                 GAGGTGATCTGCACCTTGCACAAACTCAACATCGTGCACCGGGACCTGAAGCCCGACA
                 ACATTCTCTTGGATGACAACATGAACATCAAGCTCACAGACTTTGGCTTTTCCTGCCA
                 GCTGGAGCCGGGAGAGAGGCTGCGAGAGGTCTGCGGGACCCCCAGTTACCTGGCCCCT
                 CAGATTATCGAGTGCTCCATGAATGAGGACCACCCGGGCTACGGGAAAGAGGTGGACA
                 TCTGGAGCACTGGCGTCATCATGTACACGCTGCTGGCCGGCTCCCCGCCCTTCTGGCA
                 CCGGAAGCAGATGCTGATGCTGAGGATGATCATGAGCGGCAACTACCAGTTTGGCTCG
                 CCCGAGTGGGATGATTACTCGGACACCGTGAAGGACCTGGTCTCCCGATTCCTGGTGG
                 TGCAACCCCAGAACCGCTACACAGCGGAAGAGGCCTTGGCACACCCCTTCTTCCAGCA
                 GTACTTGGTGGAGGAAGTGCGGCACTTCAGCCCCCGGGGGAAGTTCAAGGTGATCGCT
                 CTGACCGTGCTGGCTTCAGTGCGGATCTACTACCAGTACCGCCGGGTGAAGCCTGTGA
                 CCCGGGAGATCGTCATCCGAGACCCCTATGCCCTCCGGCCTCTGCGCCGGCTCATCGA
                 CGCCTACGCTTTCCGAATCTATGGCCACTGGGTGAAGAAGGGGCAGCAGCAGAACCGG
                 GCAGCCCTTTTCGAGAACACACCCAAGGCCGTGCTCCTCTCCCTGGCCGAGGAGGACT
                 ACTGA
                 ORF Start: ATG at 2                  ORF Stop: TGA at 1163
                 SEQ ID NO: 62           387 aa       MW at 45023.3 kD
NOV2m,           MTRDEALPDSHSAQDFYENYEPKEILGRGVSSVVRRCIHKPTSQEYAVKVIDVTGGGS
CG101996-06
Protein Sequence FSPEEVRELREATLKEVDILRKVSGHPNIIQLKDTYETNTFFFLVFDLMKRGELFDYL
                 TEKVTLSEKETRKIMRALLEVICTLHKLNIVHRDLKPENILLDDNMNIKLTDFGFSCQ
                 LEPGERLREVCGTPSYLAPEIIECSMNEDHPGYGKEVDMWSTGVIMYTLLAGSPPFWH
                 RKQMLMLRMIMSGNYQFGSPEWDDYSDTVKDLVSRFLVVQPQNRYTAEEALAHPFFQQ
                 YLVEEVRHFSPRGKFKVIALTVLASVRIYYQYRRVKPVTREIVIRDPYALRPLRRLID
                 AYAFRIYGHWVKKGQQQNRAALFENTPKAVLLSLAEEDY
                 SEQ ID NO: 63           927 bp
NOV2n,           ACCATGGGACATCATCACCACCATCACACCCGGGACGAGGCACTGCCGGACTCTCATT
CG101996-07
DNA Sequence     CTGCACAGGACTTCTATGAGAATTATGAGCCCAAAGAGATCCTGGGCAGGGGCGTTAG
                 CAGTGTGGTCAGGCGATGCATCCACAAGCCCACGAGCCAGGAGTACGCCGTGAAGGTC
                 ATCGACGTCACCGGTGGAGGCAGCTTCAGCCCGGAGGAGGTGCGGGAGCTGCGAGAAG
                 CCACGCTGAAGGAGGTGGACATCCTGCGCAAGGTCTCAGGGCACCCCAACATCATACA
                 GCTGAAGGACACTTATGAGACCAACACTTTCTTCTTCTTGGTGTTTGACCTGATGAAG
                 AGAGGGGAGCTCTTTGACTACCTCACTGAGAAGGTCACCTTGAGTGAGAAGGAAACCA
                 GAAAGATCATGCGAGCTCTGCTGGAGGTGATCTGCACCTTGCACAAACTCAACATCGT
                 GCACCGGGACCTGAAGCCCGAGAACATTCTCTTGGATGACAACATGAACATCAAGCTC
                 ACAGACTTTGGCTTTTCCTGCCAGCTGGAGCCGGGAGAGAGGCTGCGAGAGGTCTGCG
                 GGACCCCCAGTTACCTGGCCCCTGAGATTATCGAGTGCTCCATGAATGAGGACCACCC
                 GGGCTACGGGAAAGAGGTGGACATGTGGAGCACTGGCGTCATCATGTACACGCTGCTG
                 GCCGGCTCCCCGCCCTTCTGGCACCGGAAGCAGATGCTGATGCTGAGGATGATCATGA
                 GCGGCAACTACCAGTTTGGCTCGCCCGAGTGGGATGATTACTCGGACACCGTGAAGGA
                 CCTGGTCTCCCGATTCCTGGTGGTGCAACCCCAGAACCGCTACACAGCGGAAGAGGCC
                 TTGGCACACCCCTTCTTCCAGCAGTACTTGGTGGAGGAAGTGCGGCACTTCAGCTGA
                 ORF Start: at 1                      ORF Stop: TGA at 925
                 SEQ ID NO: 64          1308 aa       MW at 35743.4 kD
NOV2n,           TMGHHHHHHTRDEALPDSHSAQDFYENYEPKEILGRGVSSVVRRCIHKPTSQEYAVKV
CG101996-07
Protein Sequence IDVTGGGSFSPEEVRELREATLKEVDILRKVSGHPNIIQLKDTYETNTFFFLVFDLMK
                 RGELFDYLTEKVTLSEKETRKIMRALLEVICTLHKLNIVHRDLKPENILLDDNNNIKL
                 TDFGFSCQLEPGERLREVCGTPSYLAPEIIECSMNEDHPGYGKEVDMWSTGVIMYTLL
                 AGSPPFWHRKQMLMLRMIMSGNYQFGSPEWDDYSDTVKDLVSRFLVVQPQNRYTAEEA
                 LAHPFFQQYLVEEVRHFS
                 SEQ ID NO: 65           924 bp
NOV2o,           ACCATGACCCGGGACGAGGCACTGCCGGACTCTCATTCTGCACAGGACTTCTATGAGA
CG101996-08
DNA Sequence     ATTATGAGCCCAAAGAGATCCTGGGCAGGGGCGTTAGCAGTGTGGTCAGGCGATGCAT
                 CCACAAGCCCACGAGCCAGGAGTACGCCGTGAAGGTCATCGACGTCACCGGTGGAGGC
                 AGCTTCAGCCCGGAGGAGGTGCGGGAGCTGCGAGAAGCCACGCTGAAGGAGGTGGACA
                 TCCTGCGCAAGGTCTCAGGGCACCCCAACATCATACAGCTGAAGGACACTTATGAGAC
                 CAACACTTTCTTCTTCTTGGTGTTTGACCTGATGAAGAGAGGGGAGCTCTTTGACTAC
                 CTCACTGAGAAGGTCACCTTGAGTGAGAAGGAAACCAGAAAGATCATGCGAGCTCTGC
                 TGGAGGTGATCTGCACCTTGCACAAACTCAACATCGTGCACCGGGACCTGAAGCCCGA
                 GAACATTCTCTTGGATGACAACATGAACATCAAGCTCACAGACTTTGGCTTTTCCTGC
                 CAGCTGGAGCCGGGAGAGAGGCTGCGAGAGGTCTGCGGGACCCCCAGTTACCTGGCCC
                 CTGAGATTATCGAGTGCTCCATGAATGAGGACCACCCGGGCTACGGGAAAGAGGTGGA
                 CATGTGGAGCACTGGCGTCATCATGTACACGCTGCTGGCCGGCTCCCCGCCCTTCTGG
                 CACCGGAAGCAGATGCTGATGCTGAGGATGATCATGAGCGGCAACTACCAGTTTGGCT
                 CGCCCGAGTGGGATGATTACTCGGACACCGTGAAGGACCTGGTCTCCCGATTCCTGGT
                 GGTGCAACCCCAGAACCGCTACACAGCGGAAGAGGCCTTGGCACACCCCTTCTTCCAG
                 CAGTACTTGGTGGAGGAAGTGCGGCACTTCAGCCATCATCACCACCATCACTGA
                 ORF Start: at 1                      ORF Stop: TGA at 922
                 SEQ ID NO: 66           307 aa       MW at 35686.3 kD
NOV2o,           TMTRDEALPDSHSAQDFYENYEPKEILGRGVSSVVRRCIHKPTSQEYAVKVIDVTGGG
CG101996-08
Protein Sequence SFSPEEVRELREATLKEVDILRKVSGHPNIIQLKDTYETNTFFFLVFDLMKRGELFDY
                 LTEKVTLSEKETRKIMRALLEVICTLHKLNIVHRDLKPENILLDDNMNIKLTDFGFSC
                 QLEPGERLREVCGTPSYLAPEIIECSMNEDHPGYGKEVDMWSTGVIMYTLLAGSPPFW
                 HRKQMLMLRMIMSGNYQFGSPEWDDYSDTVKDLVSRFLVVQPQNRYTAEEALAHPFFQ
                 QYLVEEVRHFSHHHHHH
                 SEQ ID NO: 67           939 bp
NOV2p,           CATATGACCCGGGACGAGGCACTGCCGGACTCTCATTCTGCACAGGACTTCTATGAGA
CG101996-09
DNA Sequence     ATTATGAGCCCAAAGAGATCCTGGGCAGGGGCGTTAGCAGTGTGGTCAGGCGATGCAT
                 CCACAAGCCCACGAGCCAGGAGTACGCCGTGAAGGTCATCGACGTCACCGGTGGAGGC
                 ACCTTCACCCCCCACCACCTCCCCCACCTCCCACAACCCACCCTCAACCACCTCCACA
                 AGCTTCAGCCCGGAGGAGGTGCGGGAGCTGCGAGAAGCCACGCTGAAGGAGGTGGACA
                 TCCTGCGCAAGGTCTCAGGGCACCCCAACATCATACAGCTGAAGGACACTTATGAGAC
                 CAACACTTTCTTCTTCTTGGTGTTTGACCTGATGAAGAGAGGGGAGCTCTTTGACTAC
                 CTCACTGAGAAGGTCACCTTGAGTGAGAAGGAAACCAGAAAGATCATGCGAGCTCTGC
                 TGGAGGTGATCTGCACCTTGCACAAACTCAACATCGTGCACCGGGACCTGAAGCCCGA
                 GAACATTCTCTTGGATGACAACATGAACATCAAGCTCACAGACTTTGGCTTTTCCTGC
                 CAGCTGGAGCCGGGAGAGAGGCTGCGAGAGGTCTGCGGGACCCCCAGTTACCTGGCCC
                 CTGAGATTATCGAGTGCTCCATGAATGAGGACCACCCGGGCTACGGGAAAGAGGTGGA
                 CATGTGGACCACTGGCGTCATCATGTACACGCTGCTGGCCGGCTCCCCGCCCTTCTGG
                 CACCGGAAGCAGATGCTGATGCTGAGGATGATCATGAGCGGCAACTACCAGTTTGGCT
                 CGCCCGAGTGGGATGATTACTCGGACACCGTGAAGGACCTGGTCTCCCGATTCCTGGT
                 GGTGCAACCCCAGAACCGCTACACAGCGGAAGAGGCCTTGGCACACCCCTTCTTCCAG
                 CAGTACTTGGTGGAGGAAGTGCGGCACTTCAGCTGAGCGGCCGCACTCGAGCACCACC
                 ACCACCACCAC
                 ORF Start: at 1                      ORF Stop: TGA at 904
                 SEQ ID NO: 68           301 aa       MW at 34899.5 kD
NOV2p,           HMTRDEALPDSHSAQDFYENYEPKEILGRGVSSVVRRCIHKPTSQEYAVKVIDVTGGG
CG101996-09
Protein Sequence SFSPEEVRELREATLKEVDILRKVSGHPNIIQLKDTYETNTFFFLVFDLMKRGELFDY
                 LTEKVTLSEKETRKIMRALLEVICTLHKLNIVHRDLKPENILLDDNNNIKLTDFGFSC
                 QLEPGERLREVCGTPSYLAPEIIECSMNEDHPGYGKEVDMWSTGVIMYTLLAGSPPFW
                 HRKQMLMLRMIMSGNYQFGSPEWDDYSDTVKDLVSRFLVVQPQNRYTAEEALAHPFFQ
                 QYLVEEVRHFS

[0359] Sequence comparison of the above protein sequences yields the following sequence relationships shown in Table 2B.

TABLE 2B
Comparison of NOV2a against NOV2b through NOV2p.
	Protein	NOV2a Residues/	Identities/Similarities
	Sequence	Match Residues	for the Matched Region
	NOV2b	1 . . . 152	152/152 (100%)
		281 . . . 432	152/152 (100%)
	NOV2c	1 . . . 152	152/152 (100%)
		236 . . . 387	152/152 (100%)
	NOV2d	1 . . . 152	152/152 (100%)
		236 . . . 387	152/152 (100%)
	NOV2e	1 . . . 152	152/152 (100%)
		281 . . . 432	152/152 (100%)
	NOV2f	1 . . . 65	65/65 (100%)
		244 . . . 308	65/65 (100%)
	NOV2g	1 . . . 152	152/152 (100%)
		240 . . . 391	152/152 (100%)
	NOV2h	1 . . . 65	65/65 (100%)
		241 . . . 305	65/65 (100%)
	NOV2i	1 . . . 65	65/65 (100%)
		237 . . . 301	65/65 (100%)
	NOV2j	1 . . . 65	65/65 (100%)
		235 . . . 299	65/65 (100%)
	NOV2k	1 . . . 152	152/152 (100%)
		236 . . . 387	152/152 (100%)
	NOV2l	1 . . . 152	152/152 (100%)
		240 . . . 391	152/152 (100%)
	NOV2m	1 . . . 152	152/152 (100%)
		236 . . . 387	152/152 (100%)
	NOV2n	1 . . . 65	65/65 (100%)
		244 . . . 308	65/65 (100%)
	NOV2o	1 . . . 65	65/65 (100%)
		237 . . . 301	65/65 (100%)
	NOV2p	1 . . . 65	65/65 (100%)
		237 . . . 301	65/65 (100%)

[0360] Further analysis of the NOV2a protein yielded the following properties shown in Table 2C.

TABLE 2C
Protein Sequence Properties NOV2a
PSort     0.5098 probability located in microbody (peroxisome);
analysis: 0.4500 probability located in cytoplasm; 0.3051
          probability located in lysosome (lumen); 0.1000
          probability located in mitochondrial matrix space
SignalP   No Known Signal Sequence Predicted
analysis:

[0361] A search of the NOV2a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 2D.

TABLE 2D
Geneseq Results for NOV2a
		NOV2a	Identities/
		Residues/	Similarities
Geneseq	Protein/Organism/Length [Patent	Match	for the	Expect
Identifier	#, Date]	Residues	Matched Region	Value
ABB09290	Human phosphorylase kinase	1 . . . 140	82/140 (58%)	5e−43
	gamma 2 (PHKG2) protein SEQ ID	239 . . . 378	105/140 (74%)
	NO: 4 - Homo sapiens, 406 aa.
	[WO200194365-A2, 13 DEC. 2001]
AAY43921	Rabbit protein kinase #3 -	1 . . . 56	55/56 (98%)	2e−26
	Oryctolagus cuniculus, 268 aa.	213 . . . 268	55/56 (98%)
	[US5958784-A, 28 SEP. 1999]
AAY43922	Mouse protein kinase #3 - Mus sp,	1 . . . 56	50/56 (89%)	2e−23
	268 aa. [US5958784-A. 28 SEP.	213 . . . 268	53/56 (94%)
	1999]
ABG10311	Novel human diagnostic protein	44 . . . 140	49/104 (47%)	1e−19
	#10302 - Homo sapiens, 886 aa.	615 . . . 718	69/104 (66%)
	[WO200175067-A2, 11 OCT. 2001]
ABB58577	Drosophila melanogaster	64 . . . 147	43/84 (51%)	4e−17
	polypeptide SEQ ID NO 2523 -	470 . . . 553	57/84 (67%)
	Drosophila melanogaster, 560 aa.
	[WO200171042-A2, 27 SEP. 2001]

[0362] In a BLAST search of public sequence datbases, the NOV2a protein was found to have homology to the proteins shown in the BLASTP data in Table 2E.

TABLE 2E
Public BLASTP Results for NOV2a
		NOV2a	Identities/
Protein		Residues/	Similarities
Accession		Match	for the	Expect
Number	Protein/Organism/Length	Residues	Matched Portion	Value
Q16816	Phosphorylase B kinase gamma	1 . . . 152	152/152 (100%)	5e−84
	catalytic chain, skeletal muscle	235 . . . 386	152/152 (100%)
	isoform (EC 2.7.1.38)
	(Phosphorylase kinase gamma
	subunit 1) - Homo sapiens (Human),
	386 aa.
KIRBFG	phosphorylase kinase (EC 2.7.1.38)	1 . . . 152	147/152 (96%)	1e−81
	catalytic chain, skeletal muscle -	236 . . . 387	149/152 (97%)
	rabbit, 387 aa.
P00518	Phosphorylase B kinase gamma	1 . . . 152	147/152 (96%)	1e−81
	catalytic chain, skeletal muscle	235 . . . 386	149/152 (97%)
	isoform (EC 2.7.1.38)
	(Phosphorylase kinase gamma
	subunit 1) - Oryctolagus cuniculus
	(Rabbit), 386 aa.
S00731	phosphorylase kinase (EC 2.7.1.38)	1 . . . 151	142/151 (94%)	3e−78
	catalytic chain [similarity] - rat, 388	236 . . . 386	147/151 (97%)
	aa.
P13286	Phosphorylase B kinase gamma	1 . . . 151	142/151 (94%)	3e−78
	catalytic chain, skeletal muscle	235 . . . 385	147/151 (97%)
	isoform (EC 2.7.1.38)
	(Phosphorylase kinase gamma
	subunit 1) - Rattus norvegicus (Rat),
	387 aa.

[0363] PFam analysis predicts that the NOV2a protein contains the domains shown in the Table 2F.

TABLE 2F
Domain Analysis of NOV2a
Pfam	NOV2a	Identities/Similarities	Expect
Domain	Match Region	for the Matched Region	Value
pkinase	3 . . . 53	16/54 (30%)	4.4e−09
		43/54 (80%)

Example 3

[0364] The NOV3 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 3A.

TABLE 3A
NOV3 Sequence Analysis
                 SEQ ID NO: 69          2727 bp
NOV3a,           AGAAGAGCGGAGCTGTGAGCAGTACTGCGGCCTCCTCTCCTCTCCTAACCTCGCTCTC
CG102822-01
DNA Sequence     GCGGCCTAGCTTTACCCGCCCGCCTGCTCGGCGACCAGAACACCTTCCACCATGACCA
                 CCTCAGCAAGTTCCCACTTAAATAAAGGCATCAAGCAGGTGTACATGTCCCTGCCTCA
                 GGGTGAGAAAGTCCAGGCCATGTATATCTGGATCGATGGTACTGGAGAAGGACTGCGC
                 TGCAAGACCCGGACCCTGGACAGTGAGCCCAAGTGTGTGGAAGAGTTGCCTGAGTGGA
                 ATTTCGATGGCTCTAGTACTTTACAGTCTGAGGGTTCCAACAGTGACATGTATCTCGT
                 GCCTGCTGCCATGTTTCGGGACCCCTTCCGTAAGGACCCTAACAAGCTGGTGTTATGT
                 GAAGTTTTCAAGTACAATCGAAGGCCTGCAGAGACCAATTTGAGGCACACCTGTAAAC
                 GGATAATGGACATGGTGAGCAACCAGCACCCCTGGTTTGGCATGGAGCAGGAGTATAC
                 CCTCATGGGGACAGATGGGCACCCCTTTCGTTGGCCTTCCAACGGCTTCCCAGGGCCC
                 CAGGGTCCATATTACTGTGGTGTGGGAGCAGACAGAGCCTATGGCAGGGACATCGTGG
                 AGGCCCATTACCGGGCCTGCTTGTATGCTGGAGTCAAGATTGCGGGGACTAATGCCGA
                 GGTCATGCCTGCCCAGTGGGAATTTCAGATTGGACCTTGTGAAGGAATCAGCATGGGA
                 GATCATCTCTGGGTGGCCCGTTTCATCTTCCATCGTGTGTGTGAAGACTTTGGAGTGA
                 TAGCAACCTTTGATCCTAAGCCCATTCCTGGGAACTGGAATGGTGCAGGCTGCCATAC
                 CAACTTCAGCACCAAGGCCATGCGGGAGGAGAATGGTCTGAAGTACATCGAGGAGGCC
                 ATTGAGAAACTAACCAAGCGGCACCAGTACCACATCCGTGCCTATGATCCCAAGGGAG
                 GCCTGGACAATGCCCGACGTCTAACTGGATTCCATGAAACCTCCAACATCAACGACTT
                 TTCTGCTGGTGTAGCCAATCGTAGCGCCAGACTACGCATTCCCCGGACTGTTGGCCAG
                 GAGAAGAAGGGTTACTTTGAAGATCGTCGCCCCTCTGCCAACTGCGAGCCCTTTTCGG
                 TGACAGAAGCCCTCATCCGCACGTGTCTTCTCAATGAAACCGGCGATGAGCCCTTCCA
                 GTACAAAAATTAAGTGGACTAGACCTCCAGCTGTTGAGCCCCTCCTAGTTCTTCATCC
                 CTGACTCCAACTCTTCCCCCTCTCCCAGTTGTCCCGATTGTAACTCAAAGGGTGGAAT
                 ATCAAGGTCGTTTTTTTCATTCCATGTGCCCAGTTAATCTTGCTTTCTTTTGTTTGGC
                 TGGGATAGAGGGGTCAAGTTATTAATTTCTTCACACCTACCCTCCTTTTTTTCCCTAT
                 CACTGAAGCTTTTTAGTGCATTAGTGGGGAGGAGGGTGGGGAGACATAACCACTGCTT
                 CCATTTAATGGGGTGCACCTGTCCAATAGGCGTACGTATCCGGACAGAGCACGTTTGC
                 AGAGGGGTCTCTCTCCAGGTAGCTGAAAGGGAAGACCTGACGTACTCTGGTTAGGTTA
                 GGACTTGCCCTCGTGGTGGAAACTTTTCTTAAAAAGTTATAACCAACTTTTCTATTAA
                 AAGTGGGAATTAGGAGAGAAGGTAGGGGTTGGGAATCAGAGAGAATGGCTTTGGTCTC
                 TTGCTTGTGGGACTAGCCTGGCTTGGGACTAAATGCCCTGCTCTGAACACAAGCTTAG
                 TATAAACTGATGGATATCCCTACCTTGAAAGAAGAAAAGGTTCTTACTGCTTGGTCCT
                 TGATTTATCACACAAAGCAGAATAGTATTTTTATATTTAAATGTAAAGACAAAAAACT
                 ATATGTATGGTTTTGTGGATTATGTGTGTTTTGGCTAAAGGAAAAAACCATCCAGGTC
                 ACGGGGCACCAAATTTGAGACAAATAGTCGGATTAGAAATAAAGCATCTCATTTTGAG
                 TAGAGAGCAAGGAAGTGGTTCTTACATGGTGATCTGGGATTACGCCCTCAAGACCCCT
                 TTTGGGTTTCTGCCCTGCCCACCCTCTGGAGAAGGTGGCACTGATTAGTTAACAGACC
                 AACACCGTTACTAGCAGTCACTGATCTCCGTGGCTTTGGTTTAAAAGACACACTTGTC
                 CACATAGGTTTAGAGATAAGAGTTGGCTGGTCAACTTGAGCATGTTACTGACAGAGGG
                 GGTATTGGGGTTATTTTCTGGTAGGAATAGCATGTCACTAAAGCAGGCCTTTGATATT
                 AAATTTTTTAAAAAGCAAAATTATAGAAGTTTAGATTTTAATCAAATTTGTAGCGTTT
                 CTAGGTATTTACAGATGCTGTTGCTCAACGTCTCCTACCTCTGCTCTGAGAGATGGGA
                 CAGGCTGAGTCAAACACTGTAATTTTGTATCTTGATGTCTTTGTTAAGACTGCTGAAG
                 AATTATTTTTTCTTTTATAATAAGGAATAAACCCCACCTTTATTCCTTCATTTCATCT
                 ACCATTTTCTGGTTCTTGTGTTGGCTGTGGCAGGCCAGCTGTGGTTTTCTTTTGCCAT
                 GACAACTTCTAATTGCCATGTACAGTATGTTCAAAGTCPAATAACTCCTCATTGTAAA
                 CAAACTGTGTAACTGCCCAAAGCAGCACTTATAAATCACCCTAACATAAAAAAAAAAA
                 A
                 ORF Start: at 68                     ORF Stop: TAA at 1229
                 SEQ ID NO: 70           387 aa       MW at 43593.8kD
NOV3a,           LYPPACSATRTPSTMTTSASSHLNKGTKQVYMSLPQGEKVQANYIWIDGTGEGLRCKT
CG102822-01
Protein Sequence RTLDSEPKCVEELPEWNFDGSSTLQSEGSNSDMYLVPAAMFRDPFRKDPNKLVLCEVF
                 KYNRRPAETNLRHTCKRIMDMVSNQHPWFGMEQEYTLMGTDGHPFGWPSNGFPGPQGP
                 YYCGVGADRAYCRDIVEAHYRACLYAGVKIAGTNAEVMPAQWEFQIGPCEGISMGDHL
                 WVARFILHRVCEDFGVIATFDPKPIPGNNNGAGCHTNFSTKAMREENGLKYIEEAIEK
                 LSKRHQYHIRAYDPKGGLDNARRLTGFHETSNINDFSAGVANRSARLRIPRTVGQEKK
                 GYFEDRRPSANCEPFSVTEALIRTCLLNETGDEPFQYKN
                 SEQ ID NO: 71          1366 bp
NOV3b,           CGCGAGAGCAGGTTAGGAGAGGAGAGGAGGCCGCAGTACTGCTCACACGCTCCGCTCT
CG102822-03
DNA Sequence     TCTCCCACTCTCGGCCTACCTTTACCCGCCCGCCTGCTCGGCGACCAGAACACCTTCC
                 ACCATGACCACCTCAGCAAGTTCCCACTTAAATAAAGGCATCAAGCAGGTGTACATGT
                 CCCTGCCTCAGGGTGAGAAAGTCCAGGCCATGTATATCTGGATCGATGGTACTGGAGA
                 AGGACTGCGCTCCAAGACCCGGACCCTGGACAGTGAGCCCAAGTGTGTGGAAGAGTTG
                 CCTGAGTGGAATTTCGATGGCTCCAGTACTTTACAGTCTGAGGGTTCCAACAGTGACA
                 TGTATCTCGTGCCTGCTGCCATGTTTCGGGACCCCTTCCGTAAGGACCCTAACAAGCT
                 GGTGTTATGTGAAGTTTTCAAGTACAATCGAAGGCCTGCAGAGACCAATTTGAGGCAC
                 ACCTGTAAACGGATAATGGACATGGTGAGCAACCAGCACCCCTGGTTTGGCATGGAGC
                 AGGAGTATACCCTCATGGGGACAGATGGGCACCCCTTTGGTTGGCCTTCCAACGGCTT
                 CCCAGCGCCCCAGGGTCCATATTACTGTGGTGTGGGAGCAGACAGAGCCTATGGCAGG
                 GACATCGTGGAGGCCCATTACCGGGCCTGCTTGTATGCTGCAGTCAAGATTGCGGGGA
                 CTAATGCCGAGGTCATGCCTGCCCAGTGGGAATTTCAGATTGGACCTTGTGAAGGAAT
                 CAGCATGGGAGATCATCTCTGGCTGGCCCGTTTCATCTTGCATCGTGTGTGTGAAGAC
                 TTTGGAGTGATAGCAACCTTTGATCCTAAGCCCATTCCTGGGAACTGGAATGGTGCAG
                 CCTGCCATACCAACTTCAGCACCAAGGCCATGCGGGAGGAGAATCGTCTGAAGTACAT
                 CGAGGAGGCCATTGAGAAACTAAGCAAGCGCCACCAGTACCACATCCGTGCCTATGAT
                 CCCAAGGGAGGCCTGGACAATGCCCGACGTCTAACTGGATTCCATGAAACCTCCAACA
                 TCAACGACTTTTCTGGTGGTGTAGCCAATCGTAGCGCCAGCATACGCATTCCCCGGAC
                 TGTTGGCCAGGAGAAGAAGGGTTACTTTGAAGATCGTCGCCCCTCTGCCAACTGCGAC
                 CCCTTTTCGGTGACAGAAGCCCTCATCCGCACGTGTCTTCTCAATGAAACCGGCGATG
                 AGCCCTTCCAGTACAAAAATTAAGTGGACTAGACCTCCAGCTGTTGAGCCCCTCCTAG
                 TTCTTCATCCCACTCCAACTCTTCCCCCTCTCCCAGTTGTCCCGATTGTAACTCAAAG
                 GGTGGAATATCAAGGTCCTTTTTTTTCATTCC
                 ORF Start: ATG at 120                ORF Stop: TAA at 1239
                 SEQ ID NO: 72           373 aa       MW at 42050.0kD
NOV3b,           MTTSASSHLNKGIKQVYMSLPQGEKVQANYIWIDGTGEGLRCKTRTLDSEPKCVEELP
CG102822-03
Protein Sequence EWNFDGSSTLQSEGSNSDMYLVPAANFRDPFRKDPNKLVLCEVFKYNRRPAETNLRHT
                 CKRIMDMVSNQHPWFGMEQEYTLMGTDGHPFGWPSNGFPGPQGPYYCGVGADRAYGRD
                 IVEAHYRACLYAGVKIAGTNAEVMPAQWEFQIGPCEGISMGDHLWVARFILHRVCEDF
                 GVIATFDPKPIPGNWNGAGCHTNFSTKAMREENGLKYIEEAIEKLSKRHQYHIRAYDP
                 KGGLDNARRLTGFHETSNINDFSGGVANRSASIRIPRTVGQEKKGYFEDRRPSANCDP
                 FSVTEALIRTCLLNETGDEPFQYKN
                 SEQ ID NO: 73          2631 bp
NOV3c,           ATGACCACCTCAGCAAGTTCCCACTTAAATAAAGGCATCAAGCAGGTGTACATGTCCC
CG102822-02
DNA Sequence     TGCCTCAGGGTGAGAAAGTCCAGGCCATCTATATCTCGATCGATGGTACTGGAGAAGG
                 ACTGCGCTCCAAGACCCGGACCCTGGACAGTGAGCCCAAGTGTGTGGAAGAGTTGCCT
                 GAGTGGAATTTCGATGGCTCTAGTACTTTACAGTCTGAGGGTTCCAACAGTGACATGT
                 ATCTCGTGCCTGCTGCCATGTTTCGGGACCCCTTCCGTAAGGACCCTAACAAGCTGGT
                 GTTATGTGAAGTTTTCAAGTACAATCGAAGGCCTGCACAGACCAATTTGAGGCACACC
                 TGTAAACGGATAATGGACATGGTGAGCAACCAGCACCCCTGGTTTGGCATGGAGCAGG
                 AGTATACCCTCATGGGGACAGATGGGCACCCCTTTGGTTGGCCTTCCAACGGCTTCCC
                 AGGGCCCCAGGGTCCATATTACTGTGGTGTGGGAGCAGACAGAGCCTATGGCAGGGAC
                 ATCGTGCAGGCCCATTACCGGCCCTGCTTGTATGCTGGAGTCAAGATTGCGGGGACTA
                 ATGCCGAGGTCATGCCTGCCCAGTCGGAATTTCAGATTGGACCTTGTGAAGGAATCAG
                 CATGGGAGATCATCTCTGGGTGGCCCGTTTCATCTTGCATCGTGTGTGTGAAGACTTT
                 GGAGTGATAGCAACCTTTGATCCTAAGCCCATTCCTGGGAACTGGAATGGTGCAGGCT
                 GCCATACCAACTTCAGCACCAAGGCCATGCGGGAGGAGAATGGTCTGAAGTACATCGA
                 GGAGGCCATTGAGAAACTAAGCAAGCGGCACCAGTACCACATCCGTGCCTATCATCCC
                 AAGGGAGGCCTGGACAATGCCCGACGTCTAACTGGATTCCATGAAACCTCCAACATCA
                 ACGACTTTTCTGCTGGTGTAGCCAATCGTAGCGCCAGCATACGCATTCCCCGGACTGT
                 TGGCCAGGAGAAGAAGGGTTACTTTGAAGATCGTCGCCCCTCTGCCAACTGCGACCCC
                 TTTTCGGTGACAGAAGCCCTCATCCGCACGTGTCTTCTCAATGAAACCGGCGATGAGC
                 CCTTCCAGTACAAAAATTAAGTGGACTAGACCTCCAGCTGTTGAGCCCCTCCTAGTTC
                 TTCATCCCACTCCAACTCTTCCCCCTCTCCCAGTTGTCCCGATTGTAACTCAAAGCGT
                 GGAATATCAAGGTCGTTTTTTTCATTCCATGTGCCCAGTTAATCTTGCTTTCTTTGTT
                 TGGCTGGGATAGAGGGGTCAAGTTATTAATTTCTTCACACCTACCCTCCTTTTTTTCC
                 CTATCACTGAAGCTTTTTAGTGCATTAGTGGGGAGGAGGGTGGGGAGACATAACCACT
                 GCTTCCATTTAATGGGGTGCACCTGTCCAATAGGCGTAGCTATCCGGACAGAGCACGT
                 TTGCAGAAGGGGGTCTCTTCTTCCAGGTAGCTGAAAGGGCAAGACCTGACGTACTCTG
                 GTTAGGTTAGGACTTGCCCTCGTGGTGGAAACTTTTCTTAAAAAGTTATAACCAACTT
                 TTCTATTAAAAGTGGGAATTAGGAGAGAAGGTAGGGGTTGGGAATCAGAGAGAATGGC
                 TTTCGTCTCTTGCTTGTGGGACTAGCCTGGCTTGGGACTAAATGCCCTGCTCTGAACA
                 CGAAGCTTAGTATAAACTGATGGATATCCCTACCTTGAAAGAAGAAAAGGTTCTTACT
                 GCTTGGTCCTTGATTTATCACACAAAGCAGAATAGTATTTTTATATTTAAATGTAAAG
                 ACAAAAAACTATATGTATGGTTTTGTGGATTATGTGTGTTTTGCTAAAGGAAAAAACC
                 ATCCAGGTCACGGGGCACCAAATTTGAGACAAATAGTCGGATTAGAAATAAAGCATCT
                 CATTTTGAGTAGAGAGCAAGGGAAGTGGTTCTTAGATGGTGATCTGGGATTAGGCCCT
                 CAAGACCTTTTGGGTTTCTGCCCTGCCCACCCTCTGGAGAAGGTGGGCACTCGATTAG
                 TTAACAGACAACACGTTACTAGCAGTCACTTGATCTCCGTGGCTTTGGTTTAAAAGAC
                 ACACTTCTCCACATAGGTTTAGAGATAAGAGTTGGCTGGTCAACTTGAGCATGTTACT
                 GACAGAGGGGGTATTGGGGTTATTTTCTGGTAGGAATAGCATGTCACTAAAGCAGGCC
                 TTTTGATATTAAATTTTTTAAAAAGCAAAATTATAGAAGTTTAGATTTTAATCAAATT
                 TGATGGGTTTCTAGGTAATTTTTACAGAATTGCTTGTTTGCTTCAACTGTCTCCTACC
                 TCTGCCTCTTGGAGGAGATGGGACAGGGCTGGAGTCAAAACACTTGTAATTTTGTATC
                 TTGATGTCTTTGTTAAGACTGCTGAAGAATTATTTTTTTTCTTTTATAATAAGGAATA
                 AACCCCACCTTTATTCCTTCATTTCATCTACCATTTTCTGGTTCTTGTGTTGGCTGTG
                 GCAGGCCAGCTGTGGTTTTCTTTTGCCATGACAACTTCTAATTGCCATGTACAGTATG
                 TTCAAAGTCAAATAACTCCTCATTGTAAACAAACTGTGTAACTGCCCAAAGCAGCACT
                 TATAAATCAGCCTAACATAAG
                 ORF Start: ATG at 1                  ORF Stop: TAA at 1120
                 SEQ ID NO: 74           373 aa       MW at 42064.0kD
NOV3c,           MTTSASSHLNKGIKQVYMSLPQGEKVQAMYIWIDGTGEGLRCKTRTLDSEPKCVEELP
CG102822-02
Protein Sequence EWNFDGSSTLQSEGSNSDMYLVPAANFRDPFRKDPNKLVLCEVFKYNRRPAETNLRHT
                 CKRIMDMVSNQHPWFGMEQEYTLMGTDGHPFGWPSNGFPGPQGPYYCGVGADRAYGRD
                 IVEAHYRACLYAGVKIAGTNAEVMPAQWEFQIGPCEGISMGDHLWVARFILHRVCEDF
                 GVIATFDPKPIPGNWNGAGCHTNFSTKAMREENGLKYIEEAIEKLSKRHQYHIRAYDP
                 KGGLDNARRLTGFHETSNINDFSAGVANRSASIRIPRTVGQEKKGYFEDRRPSANCDP
                 FSVTEALIRTCLLNETGDEPFQYKN
                 SEQ ID NO: 75          2775 bp
NOV3d,           GGCACGAGGGAAGAGCGGAGCGTGTGAGCAGTACTGCGGCCTCCTCTCCTCTCCTAAC
CG102822-04
DNA Sequence     CTCGCTCTCGCGGCCTACCTTTACCCGCCCGCCTGCTCGGCGACCAGAACACCTTCCA
                 CCATGACCACCTCAGCAAGTTCCCACTTAAATAAAGGCATCAAGCAGGTGTACATGTC
                 CCTGCCTCAGGGTGAGAAAGTCCAGGCCATGTATATCTGGATCGATGGTACTGGAGAA
                 GGACTGCGCTGCAAGACCCGGACCCTGGACAGTGAGCCCAAGTGTGTGGAAGAGTTGC
                 CTGAGTGGAATTTCGATGGCTCCAGTACTTTACAGTCTGAGGGTTCCAACAGTGACAT
                 GTATCTCGTGCCTGCTGCCATGTTTCGGGACCCCTTCCGTAAGGACCCTAACAAGCTG
                 GTGTTATGTGAAGTTTTCAAGTACAATCGAAGGCCTGCAGAGACCAATTTGAGGCACA
                 CCTGTAAACGGATAATGGACATGGTGAGCAACCAGCACCCCTGGTTTGGCATGGAGCA
                 GGAGTATACCCTCATGGGGACAGATGGGCACCCCTTTGGTTGGCCTTCCAACGGCTTC
                 CCAGGGCCCCAGGGTCCATATTACTGTGGTGTGGGAGCAGACAGAGCCTATGGCAGGG
                 ACATCGTGGAGGCCCATTACCGGGCCTGCTTGTATGCTGGAGTCAAGATTGCGGGGAC
                 TAATGCCGAGGTCATGCCTGCCCAGTGGGAATTTCAGATTGGACCTTGTGAAGGAATC
                 AGCATGGGAGATCATCTCTGGGTGGCCCGTTTCATCTTGCATCGTGTGTGTGAAGACT
                 TTGGAGTGATAGCAACCTTTGATCCTAAGCCCATTCCTGGGAACTGGAATGGTGCAGG
                 CTGCCATACCAACTTCAGCACCAAGGCCATGCGGGAGGAGAATGGTCTGAAGTACATC
                 GAGGAGGCCATTGAGAAACTAAGCAAGCGGCACCAGTACCACATCCGTGCCTATGATC
                 CCAAGGGAGGCCTGGACAATGCCCGACGTCTAACTGGATTCCATGAAACCTCCAACAT
                 CAACGACTTTTCTGCTGGTGTAGCCAATCGTAGCGCCAGCATACGCATTCCCCGGACT
                 GTTGGCCAGGAGAAGAAGGGTTACTTTGAAGATCGTCGCCCCTCTGCCAACTGCGACC
                 CCTTTTCGGTGACAGAAGCCCTCATCCGCACGTGTCTTCTCAATGAAACCGGCGATGA
                 GCCCTTCCAGTACAAAAATTAAGTGGACTAGACCTCCAGCTGTTGAGCCCCTCCTAGT
                 TCTTCATCCCACTCCAACTCTTCCCCCTCTCCCAGTTGTCCCGATTGTAACTCAAAGG
                 GTGGAATATCAAGGTCGTTTTTTTCATTCCATGTGCCCAGTTAATCTTGCTTTCTTTG
                 TTTGGCTGGGATAGAGGGGTCAAGTTATTAATTTCTTCACACCTACCCTCCTTTTTTT
                 CCCTATCACTGAAGCTTTTTAGTGCATTAGTGGGGAGGAGGGTGGGGAGACATAACCA
                 CTGCTTCCATTTAATGGGGTGCACCTGTCCAATAGGCGTAGCTATCCGGACACAGCAC
                 GTTTGCAGAAGGGGGACTCTTCTTCCAGGTAGCTGAAAGGGGAAGACCTGACGTACTC
                 TGGTTAGGTTAGGACTTGCCCTCGTGGTGGAAACTTTTCTTAAAAAGTTATAACCAAC
                 TTTTCTATTAAAAGTGGGAATTAGGAGAGAAGGTAGGGGTTGGGAATCAGAGAGAATG
                 GCTTTGGTCTCTTGCTTGTGGGACTAGCCTGGCTTGGGACTAAATGCCCTGCTCTGAA
                 CACGAAGCTTAGTATAAACTGATGGATATCCCTACCTTGAAAGAAGAAAAGGTTCTTA
                 CTGCTTGGTCCTTGATTTATCACACAAAGCAGAATAGTATTTTTATATTTAAATGTAA
                 AGACAAAAAACTATATGTATGGTTTTGTGGATTATGTGTGTTTTGCTAAAGGAAAAAA
                 CCATCCAGGTCACGGGGCACCAAATTTGAGACAAATAGTCGGATTAGAAATAAAGCAT
                 CTCATTTTGAGTAGAGAGCAAGGGAAGTGGTTCTTAGATGGTGATCTGGGATTAGGCC
                 CTCAAGACCCTTTTGGGTTTCTGCCCTGCCCACCCTCTGGAGAAGGTGGGCACTGGAT
                 TAGTTAACAGACGACACGTTACTAGCAGTCACTTGATCTCCGTGGCTTTGGTTTAAAA
                 GACACACTTGTCCACATAGGTTTAGAGATAAGAGTTGGCTGGTCAACTTGAGCATGTT
                 ACTGACAGAGGGGGTATTGGGGTTATTTTCTGGTAGGAATAGCATGTCACTAAAGCAG
                 GCCTTTTGATATTAAATTTTTTAAAAAGCAAAATTATAGAAGTTTAGATTTTAATCAA
                 ATTTGTAGGGTTTCTAGGTAATTTTTACAGAATTGCTTGTTTGCTTCAACTGTCTCCT
                 ACCTCTGCTCTTGGAGGAGATGGGGACAGGGCTGGAGTCAAAACACTTGTAATTTTGT
                 ATCTTGATGTCTTTGTTAAGACTGCTGAAGAATTATTTTTTTCTTTTATAATAAGGAA
                 TAAACCCCACCTTTATTCCTTCATTTCATCTACCATTTTCTGGTTCTTGTGTTGGCTG
                 TGGCAGGCCAGCTGTGGTTTTCTTTTGCCATGACAACTTCTAATTGCCATGTACAGTA
                 TGTTCAAAGTCAAATAACTCCTCATTGTAAACAAACTGTGTAACTGCCCAAAGCAGCA
                 CTTATAATCAGCCTAACATAAGAAAAAAAAAAAAAAAAAAAAAAAAAA
                 ORF Start: ATG at 119                ORF Stop: TAA at 1238
                 SEQ ID NO: 76           373 aa       MW at 42064.0kD
NOV3d,           MTTSASSHLNKGIKQVYMSLPQGEKVQAMYIWIDGTGEGLRCKTRTLDSEPKCVEELP
CG102822-04
Protein Sequence EWNFDGSSTLQSEGSNSDMYLVPAAMFRDPFRKDPNKLVLCEVFKYNRRPAETNLRHT
                 CKRIMDMVSNQHPWFCMEQEYTLMGTDGHPFGWPSNGFPGPQGPYYCGVGADRAYGRD
                 IVEAHYRACLYAGVKIAGTNAEVMPAQWEFQIGPCEGISMGDHLWVARFILHRVCEDF
                 GVIATFDPKPIPGNNNGAGCHTNFSTKAMREENGLKYIEEAIEKLSKRHQYHIRAYDP
                 KGGLDNARRLTGFHETSNINDFSAGVANRSASIRIPRTVGQEKKGYFEDRRPSANCDP
                 FSVTEALIRTCLLNETGDEPFQYKN

[0365] Sequence comparison of the above protein sequences yields the following sequence relationships shown in Table 3B.

TABLE 3B
Comparison of NOV3a against NOV3b through NOV3d.
	Protein	NOV3a Residues/	Identities/Similarities
	Sequence	Match Residues	for the Matched Region
	NOV3b	15 . . . 387	369/373 (98%)
		1 . . . 373	371/373 (98%)
	NOV3c	15 . . . 387	370/373 (99%)
		1 . . . 373	372/373 (99%)
	NOV3d	15 . . . 387	370/373 (99%)
		1 . . . 373	372/373 (99%)

[0366] Further analysis of the NOV3a protein yielded the following properties shown in Table 3C.

TABLE 3C
Protein Sequence Properties NOV3a
PSort     0.5025 probability located in mitochondrial
analysis: matrix space; 0.4633 probability located in
          microbody (peroxisome); 0.2227 probability
          located in mitochondrial inner membrane;
          0.2227 probability located in mitochondrial
          intermembrane space
SignalP   No Known Signal Sequence Predicted
analysis:

[0367] A search of the NOV3a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 3D.

TABLE 3D
Geneseq Results for NOV3a
			Identities/
			Similarities for
Geneseq	Protein/Organism/Length	NOV3a Residues/	the Matched	Expect
Identifier	[Patent #, Date]	Match Residues	Region	Value
AAP70501	Chinese hamster glutamine	15 . . . 387	347/373 (93%)	0.0
	synthetase gene product - Cricetulus	1 . . . 373	361/373 (96%)
	griseus, 373 aa. [WO8704462-A, 30
	JUL. 1987]
ABG08130	Novel human diagnostic protein	15 . . . 333	304/327 (92%)	0.0
	#8121 - Homo sapiens, 338 aa.	1 . . . 320	305/327 (92%)
	[WO200175067-A2, 11 OCT. 2001]
ABB58458	Drosophila melanogaster	18 . . . 377	235/361 (65%)	e−150
	polypeptide SEQ ID NO 2166 -	9 . . . 369	292/361 (80%)
	Drosophila melanogaster, 369 aa.
	[WO200171042-A2, 27 SEP. 2001]
ABB65740	Drosophila melanogaster	15 . . . 377	219/365 (60%)	e−132
	polypeptide SEQ ID NO 24012 -	36 . . . 399	271/365 (74%)
	Drosophila melanogaster, 399 aa.
	[WO200171042-A2, 27 SEP. 2001]

[0368] In a BLAST search of public sequence datbases, the NOV3a protein was found to have homology to the proteins shown in the BLASTP data in Table 3E.

TABLE 3E
Public BLASTP Results for NOV3a
			Identities/
Protein			Similarities for
Accession		NOV3a Residues/	the Matched	Expect
Number	Protein/Organism/Length	Match Residues	Portion	Value
AJHUQ	glutamate--ammonia ligase (EC	15 . . . 387	372/373 (99%)	0.0
	6.3.1.2) - human, 373 aa.	1 . . . 373	373/373 (99%)
P15104	Glutamine synthetase (EC 6.3.1.2)	15 . . . 387	370/373 (99%)	0.0
	(Glutamate--ammonia ligase) -	1 . . . 373	372/373 (99%)
	Homo sapiens (Human), 373 aa.
AAH31964	Similar to glutamine synthetase -	15 . . . 387	368/373 (98%)	0.0
	Homo sapiens (Human), 373 aa.	1 . . . 373	370/373 (98%)
P46410	Glutamine synthetase (EC 6.3.1.2)	15 . . . 387	357/373 (95%)	0.0
	(Glutamate--ammonia ligase) - Sus	1 . . . 373	364/373 (96%)
	scrofa (Pig), 373 aa.
Q91VC6	Glutamine synthetase (EC 6.3.1.2)	15 . . . 387	350/373 (93%)	0.0
	(Hypothetical 42.1 kDa protein) -	1 . . . 373	362/373 (96%)
	Mus musculus (Mouse), 373 aa.

[0369] PFam analysis predicts that the NOV3a protein contains the domains shown in the Table 3F.

TABLE 3F
Domain Analysis of NOV3a
			Identities/
			Similarities for
	Pfam	NOV3a	the Matched	Expect
	Domain	Match Region	Region	Value
	gln-synt	38 . . . 366	133/375 (35%)	3e−198
			298/375 (79%)

Example 4

[0370] The NOV4 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 4A.

TABLE 4A
NOV4 Sequence Analysis
	SEQ ID NO:77	1888 bp
NOV4a,	AGCAGCCGGATGCCCGGGCCCACTGGGCGGGCCAGTGGCCGCTTGCGGGATGAGCAGA
CG103241-01
DNA Sequence	CTGCTGGGGGGGACGCTGGAGCGCGTCTGCAAGGCTGTGCTCCTTCTCTGCCTGCTGC
	ACTTCCTCGTGGCCGTCATCCTCTACTTTGACGTCTACGCCCAGCACCTGGCCTTCTT
	CAGCCGCTTCAGTGCCCGAGGCCCTGCCCATGCCCTCCACCCAGCTGCTAGCAGCAGC
	AGCAGCAGCAGCAACTGCTCCCGGCCCAACGCCACCGCCTCTAGCTCCGGGCTCCCTG
	AGGTCCCCAGTGCCCTGCCCGGTCCCACGGCTCCCACGCTGCCACCCTGTCCTGACAC
	CTCCCCGCCTGGTCTTGTGGGCAGACTGCTGATCGAGTTCACCTCACCCATGCCCCTG
	GAGCGGGTGCAGAGGGAGAACCCAGGCGTGCTCATGGGCGGCCGATACACATCGCCCG
	ACTGCACCCCAGCCCAGACGGTGGCGGTCATCATCCCCTTTAGACACCGGGAACACCA
	CCTGCGCTACTGGCTCCACTATCTACACCCCATCTTGAGGCCGCAGCGGCTGCGCTAC
	TGCGTCTATGTCATCAACCAGCATGGTGAGGACACCTTCAACCGGGCCAAGCTGCTTA
	ACGTGGGCTTCCTAGAGGCGCTGAAGGAGGATGCCGCCTATGACTGCTTCATCTTCAG
	CGATGTGGACCTGGTCCCCATGGATGACCGCAACCTATACCGCTGCGGCGACCAACCC
	CGCCACTTTGCCATTGCCATGGACAAGTTTGGCTTCCGGCTTCCCTATGCTGGCTACT
	TTGGAGGTGTGTCAGGCCTGAGTAAGGCTCAGTTTCTGAGAATCAATGGCTTCCCCAA
	TGAGTACTGGGGCTGGGGTGGCGAGGATGATGACATCTTCAACCGGATCTCCCTGACT
	GGGATGAAGATCTCACGCCCAGACATCCGAATTGGCCGCTACCGCATGATCAAGCACG
	ACCGCGACAACGATAACGAACCTAACCCTCAGAGGTTTACCAAGATTCAAAACACGAA
	GCTGACCATGAAGCGGGACGGCATTGGGTCAGTGCGGTACCAGGTCTTGGAGGTGTCT
	CGCCAACCACTCTTCACCAATATCACAGTGGACATTGGGCGGCCTCCGTCGTGGCCCC
	CTCGGGGCTGACACTAATGGACAGAGGCTCTCGGTGCCGAAGATTGCCTGCCAGAGGA
	CTGACCACAGCCTGGCTGGCAGCTGCTCTGTGGAGGACCTCCAGGACTGAGACTGGGC
	TCTGTTTTCCAAGGGTCTTCACTAGGCCCCCTAGCTATACCTGGAAGTTTCAGAACCC
	ACTTTGGGGGCCTCTCCGTCGGCAGGCTCTTCAAGTGTGGCCCTCTTTGGAGTCAACC
	CTCCTTCCCGACCCCCTCCCCCTAGCCCACCCCCAGTCACTGTCAGGGTCGGCCAGCC
	CCTGCACTGCCTCGCAGAGTGGCCTGGGCTAGGTCACTCCACCTCTCTGTGCCTCAGT
	TTCCCCCCCTTGAGTCCCCTTAGGGCCTGGAAGGGTGGGACGTATGTCTAGGGGGCAA
	GTGTCTCTTCCAGGGGGAATTCTCAGCTCTTGGGAACCCCCTTGCTCCCAGGGGAGGG
	GAAACCTTTTTCATTCAACATTGTACGGGGCAAGCTTTGGTGCGCCCCCTGCTGAGGA
	GCGAGCCCAGGAGGGGACCAGAGGGGATGCTCTGTCCCTGCCTGGGATCTTGGGGTTG
	GCCTTTGCATGGGAGGCAGGTGGGGCTTGGATCAGTAAGTCTGGTTCCCGCCTCCCTG
	TCTGAGAGAGGAGGCAGGANCCCAGGGCCGGCTTGTGTTTGTACATTGCACAGAAACT
	TGTGTGGCTGCTTTACTAAAAAACGTGAATGG
	ORF Start: ATG at 50		ORF Stop: TGA at 1169
	SEQ ID NO:78	373 aa	MW at 42072.7 kD
NOV4a,	MSRLLGGTLERVCKAVLLLCLLHFLVAVILYFDVYAQHLAFFSRFSARGPAHALHPAA
CG103241-01
Protein Sequence	SSSSSSSNCSRPNATASSSGLPEVPSALPGPTAPTLPPCPDTSPPGLVGRLLIEFTSP
	MPLERVQRENPGVLMGGRYTSPDCTPAQTVAVIIPFRHREHHLRYWLHYLHPILRRQR
	LRYCVYVINQHGEDTFNRAKLLNVGFLEALKEDAAYDCFIFSDVDLVPMDDRNLYRCG
	DQPRHFAIAMDKFGFRLPYAGYFGGVSGLSKAQFLRINGFPNEYWGWGGEDDDIFNRI
	SLTGMKISRPDIRIGRYRMIKHDRDNDNEPNPQRFTKIQNTKLTMKRDGIGSVRYQVL
	EVSRQPLFTNITVDIGRPPSWPPRG
	SEQ ID NO:79	1783 bp
NOV4b,	AGCAGCCGGATGCCCGGGCCCACTGGGCGGGCCAGTGGCCGCTTGCGGGATGAGCAGA
CG103241-02
DNA Sequence	CTGCTGGGGGGGACGCTGGAGCGCGTCTGCAAGGCTGTGCTCCTTCTCTGCCTGCTGC
	ACTTCCTCGTGGCCGTCATCCTCTACTTTGACGTCTACGCCCAGCACCTGGCCTTCTT
	CAGCCGCTTCAGTGCCCGAGGCCCTGCCCATGCCCTCCACCCAGCTGCTAGCAGCAGC
	AGCAGCAGCAGCAACTGCTCCCGGCCCAACGCCACCGCCTCTAGCTCCGGGCTCCCTG
	AGGTCCCCAGTGCCCTGCCCGGTCCCACGGCTCCCACGCTGCCACCCTGTCCTGACAC
	CTCCCCGCCTGGTCTTGTGGGCAGACTGCTGATCGAGTTCACCTCACCCATGCCCCTG
	GAGCGGGTGCAGAGGGAGAACCCAGGCGTGCTCATGGGCGGCCGATACACATCGCCCG
	ACTGCACCCCAGCCCAGACGGTGGCGGTCATCATCCCCTTTAGACACCGGGAACACCA
	CCTGCGCTACTGGCTCCACTATCTACACCCCATCTTGAGGCGGCAGCGGCTGCGCTAC
	TGCGTCTATGTCATCAACCAGCATGGTGAGGACACCTTCAACCGGGCCAAGCTGCTTA
	ACGTGGGCTTCCTAGAGGCGCTGAAGGAGGATGCCGCCTATGACTGCTTCATCTTCGG
	CGATGTGGACCTGGTCCCCATGGATGACCGCAACCTATACCGCTGCGGCGACCAACCC
	CGCCACTTTGCCATTGCCATGGACAAGTTTGGCTTCCGGCTTCCCTATGCTGGCTACT
	TTGGAGGTGTGTCAGGCCTGAGTAAGGCTCAGTTTCTGAGAATCAATGGCTTCCCCAA
	TGAGTACTGGGGCTGGGGTGGCGAGGATGATGACATCTTCAACCGGTTTACCAAGATT
	CAAAACACGAAGCTGACCATGAAGCGGGACGACATTGGGTCAGTGCGGTACCAGGTCT
	TGGAGGTGTCTCGGCAACCACTCTTCACCAATATCACAGTGGACATTGGGCGGCCTCC
	GTCGTGGCCCCCTCGGGGCTGACACTAATGGACAGAGGCTCTCGGTGCCGAACATTGC
	CTGCCAGAGGACTGACCACAGCCTGGCTGGCAGCTGCTCTGTGGAGGACCTCCAGGAC
	TGAGACTGGGCTCTGTTTTCCAAGGGTCTTCACTAGGCCCCCTAGCTATACCTGGAAG
	TTTCAGAACCCACTTTGGGGGCCTCTCCGTGGGCAGGCTCTTCAAGTGTGGCCCTCTT
	TGGAGTCAACCCTCCTTCCCGACCCCCTCCCCCTAGCCCAGCCCCAGTCACTGTCAGG
	GTCGGCCAGCCCCTGCACTGCCTCGCAGAGTGGCCTGGGCTAGGTCACTCCACCTCTC
	TGTGCCTCAGTTTCCCCCCCTTGAGTCCCCTTAGGGCCTGGAAGGGTGGGAGGTATGT
	CTAGGGGGCAAGTGTCTCTTCCAGGGGGAATTCTCAGCTCTTGGGAACCCCCTTGCTC
	CCAGGGGAGGGGAAACCTTTTTCATTCAACATTGTAGGGGGCAAGCTTTGGTGCGCCC
	CCTGCTGAGGAGCGAGCCCAGGAGGGGACCAGAGGGGATGCTGTGTCGCTGCCTGGGA
	TCTTGGGGTTGGCCTTTGCATGGCAGGCAGGTGGGGCTTGGATCAGTAAGTCTGGTTC
	CCGCCTCCCTGTCTGAGAGAGGAGGCAGGAACCCAGGGCCGGCTTGTGTTTGTACATT
	GCACAGAAACTTGTGTGGGTGCTTTAGTAAAAAACGTGAATGG
	ORF Start: ATG at 50		ORF Stop: TGA at 1064
	SEQ ID NO:80	338 aa	MW at 37925.0 kD
NOV4b,	MSRLLGGTLERVCKAVLLLCLLHFLVAVILYFDVYAQHLAFFSRFSARGPAHALHPAA
CG103241-02
Protein Sequence	SSSSSSSNCSRPNATASSSGLPEVPSALPGPTAPTLPPCPDTSPPGLVGRLLIEFTSP
	MPLERVQRENPGVLMGGRYTSPDCTPAQTVAVILPFRHREHHLRYWLHYLHPILRRQR
	LRYCVYVINQHGEDTFNRAKLLNVGFLEALKEDAAYDCFIFGDVDLVPMDDRNLYRCG
	DQPRHFAIANDKFGFRLPYAGYFGGVSGLSKAQFLRINGFPNEYWGWGGEDDDIFNRF
	TKIQNTKLTMKRDDIGSVRYQVLEVSRQPLFTNITVDIGRPPSWPPRG
	SEQ ID NO:81	1119 bp
NOV4c,	ATGAGCAGACTGCTGGGGGGGACGCTGGAGCGCGTCTGCAAGGCTGTGCTCCTTCTCT
CG103241-03
DNA Sequence	GCCTGCTGCACTTCCTCGTGGCCGTCATCCTCTACTTTGACGTCTACGCCCAGCACCT
	GGCCTTCTTCAGCCGCTTCAGTGCCCGAGGCCCTGCCCATGCCCTCCACCCAGCTGCT
	AGCAGCAGCAGCAGCAGCAGCAACTGCTCCCGGCCCAACGCCACCGCCTCTAGCTCCG
	GGCTCCCTGAGGTCCCCAGTGCCCTGCCCGGTCCCACGGCTCCCACGCTGCCACCCTG
	TCCTGACTCGCCACCTCGTCTTGTGGGCAGACTGCTGATCGAGTTCACCTCACCCATG
	CCCCTGGAGCGGGTGCACAGGGAGAACCCACGCGTGCTCATGGGCGGCCGATACACAC
	CGCCCGACTGCACCCCAGCCCAGACGGTGGCGGTCATCATCCCCTTTAGACACCGGGA
	ACACCACCTGCGCTACTGGCTCCACTATCTACACCCCATCTTGAGGCGGCAGCGGCTG
	CGCTACGGCGTCTATGTCATCAACCAGCATGGTGAGGACACCTTCAACCGGGCCAAGC
	TGCTTAACGTGGGCTTCCTAGAGGCGCTGAAGGAGGATGCCGCCTATGACTGCTTCAT
	CTTCAGCGATGTGGACCTGGTCCCCATGGATGACCGCAACCTATACCGCTGCGGCGAC
	CAACCCCGCCACTTTGCCATTGCCATGGACAAGTTTGGCTTCCGGCTTCCCTATGCTG
	GCTACTTTGGAGGTGTGTCAGGCCTGAGTAAGGCTCAGTTTCTGAGAATCAATGGCTT
	CCCCAATGAGTACTGGGGCTGGGGTGGCGAGGATGATGACATCTTCAACCGGATCTCC
	CTGACTGGGATGAAGATCTCACGCCCAGACATCCGAATTGGCCGCTACCGCATGATCA
	AGCACGACCGCGACAAGCATAACGAACCTAACCCTCAGAGGTTTACCAAGATTCAAAA
	CACGAAGCTGACCATGAAGCGGGACGGCATTGGGTCAGTGCGGTACCAGGTCTTGGAG
	GTGTCTCGGCAACCACTCTTCACCAATATCACAGTGGACATTGGGCGGCCTCCGTCGT
	GGCCCCCTCGGGGCTGA
	ORF Start: ATG at 1		ORF Stop: TGA at 1117
	SEQ ID NO:82	372 aa	MW at 41980.7 kD
NOV4c,	MSRLLGGTLERVCKAVLLLCLLHFLVAVILYFDVYAQHLAFFSRFSARGPAHALHPAA
CG103241-03
Protein Sequence	SSSSSSSNCSRPNATASSSGLPEVPSALPGPTAPTLPPCPDSPPGLVGRLLIEFTSPM
	PLERVHRENPGVLMGGRYTPPDCTPAQTVAVIIPFRHREHHLRYWLHYLHPILRRQRL
	RYCVYVINQHGEDTFNRAKLLNVGFLEALKEDAAYDCFIFSDVDLVPMDDRNLYRCGD
	QPRHFAIAMDKFGFRLPYAGYFGGVSGLSKAQFLRINGFPNEYWGWGGEDDDIFNRIS
	LTGMKISRPDIRIGRYRMIKHDRDKHNEPNPQRFTKIQNTKLTMKRDGIGSVRYQVLE
	VSRQPLFTNITVDIGRPPSWPPRG

[0371] Sequence comparison of the above protein sequences yields the following sequence relationships shown in Table 4B.

TABLE 4B
Comparison of NOV4a against NOV4b and NOV4c.
			Identities/
			Similarities for
	Protein	NOV4a Residues/	the Matched
	Sequence	Match Residues	Region
	NOV4b	1 . . . 373	336/373 (90%)
		1 . . . 338	336/373 (90%)
	NOV4c	1 . . . 373	367/373 (98%)
		1 . . . 372	367/373 (98%)

[0372] Further analysis of the NOV4a protein yielded the following properties shown in Table 4C.

TABLE 4C
Protein Sequence Properties NOV4a
PSort     0.8650 probability located in lysosome
analysis: (lumen); 0.8200 probability located in
          outside; 0.2030 probability located in
          microbody (peroxisome); 0.1000 probability
          located in endoplasmic reticulum (membrane)
SignalP   Cleavage site between residues 37 and 38
analysis:

[0373] A search of the NOV4a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 4D.

TABLE 4D
Geneseq Results for NOV4a
			Identities/
			Similarities for
Geneseq	Protein/Organism/Length	NOV4a Residues/	the Matched	Expect
Identifier	[Patent #, Date]	Match Residues	Region	Value
AAM93215	Human polypeptide, SEQ ID NO:	117 . . . 373	253/257 (98%)	e−153
	2618 - Homo sapiens, 257 aa.	1 . . . 257	253/257 (98%)
	[EP1130094-A2, 05 SEP. 2001]
AAY17862	Human beta-1,4-galactose	6 . . . 366	204/384 (53%)	e−109
	transferase - Homo sapiens, 398 aa.	16 . . . 397	247/384 (64%)
	[JP11137247-A, 25 MAY 1999]
AAB03647	Beta 1,4 galactose transferase	6 . . . 366	204/384 (53%)	e−109
	protein sequence - Homo sapiens,	3 . . . 384	247/384 (64%)
	385 aa. [WO200034490-A1, 15
	JUN. 2000]
AAR28838	HeLa cell galactosyltransferase	6 . . . 366	204/384 (53%)	e−109
	enzyme - Homo sapiens, 398 aa.	16 . . . 397	247/384 (64%)
	[GB2256197-A, 02 DEC. 1992]
AAR55706	Galactosyltransferase - Homo	6 . . . 366	204/384 (53%)	e−109
	sapiens, 398 aa. [WO9412646-A,	16 . . . 391	247/384 (64%)
	09 JUN. 1994]

[0374] In a BLAST search of public sequence datbases, the NOV4a protein was found to have homology to the proteins shown in the BLASTP data in Table 4E.

TABLE 4E
Public BLASTP Results for NOV4a
			Identities/
Protein			Similarities for
Accession		NOV4a Residues/	the Matched	Expect
Number	Protein/Organism/Length	Match Residues	Portion	Value
O60909	Beta-1,4-galactosyltransferase 2 (EC	1 . . . 373	368/373 (98%)	0.0
	2.4.1.-) (Beta-1,4-GalTase 2)	1 . . . 372	368/373 (98%)
	(Beta4Gal-T2) (b4Gal-T2) (UDP-
	galactose: beta-N-acetylglucosamine
	beta-1,4-galactosyltransferase 2)
	(UDP-Gal: beta-GlcNAc beta-1,4-
	galactosyltransferase 2) [Includes:
	Lactose synthase A protein (EC
	2.4.1.22); N-acetyllactosamine synthase
	(EC 2.4.1.90) (Nal synthetase); Beta-N-
	acetylglucosaminyl-glycopeptidebeta-
	1,4-galactosyltransferase (EC
	2.4.1.38); Beta-N-acetylglucosaminyl-
	glycolipid beta-1,4-
	galactosyltransferase (EC 2.4.1.-)] -
	Homo sapiens (Human), 372 aa.
Q9Z2Y2	Beta-1,4-galactosyltransferase II - Mus	1 . . . 373	338/373 (90%)	0.0
	musculus (Mouse), 369 aa.	1 . . . 369	354/373 (94%)
Q92073	Beta-1,4-galactosyltransferase (EC	4 . . . 373	278/378 (73%)	e−164
	2.4.1.38) - Gallus gallus (Chicken), 373	5 . . . 373	317/378 (83%)
	aa.
T46511	hypothetical protein	150 . . . 373	221/224 (98%)	e−132
	DKFZp586M2424.1 - human, 224 aa	1 . . . 224	221/224 (98%)
	(fragment).
CAA01685	GALACTOSYLTRANSFERASE -	6 . . . 366	204/384 (53%)	e−108
	Homo sapiens (Human), 398 aa.	16 . . . 397	247/384 (64%)

[0375] PFam analysis predicts that the NOV4a protein contains the domains shown in the Table 4F.

TABLE 4F
Domain Analysis of NOV4a
		Identities/
		Similarities for
Pfam	NOV4a	the Matched	Expect
Domain	Match Region	Region	Value
Galactosyl_T_2	97 . . . 367	169/330 (51%)	5.5e−190
		268/330 (81%)

Example 5

[0376] The NOV5 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 5A.

TABLE 5A
NOV5 Sequence Analysis
	SEQ ID NO:83	4215 bp
NOV5a,	CGATGGCATCGGTCAAGGTGGCCGTGAGGGTCCGGCCCATGAATCGCAGGGAAAAGGA
CG106249-01
DNA Sequence	CTTGGAGGCCAAGTTCATTATTCAGATGGAGAAAAGCAAAACGACAATCACAAACTTA
	AAGATACCAGAAGGAGGCACTGGGGACTCAGGAAGAGAACGGACCAAGACCTTCACCT
	ATGACTTTTCTTTTTATTCTCCTGATACAAAAACTACAGACTACGTTTCACAAGAAAT
	GGTTTTCAAAACCCTCCGCACAGATGTCCTGAATTCTGCATTTGAAGTTTATAATGCT
	TGTGTCTTTGCATATGGGCAAACTGGATCTGGAAAGTCCTACGCTATGATGGGAAATT
	CTGGAGATTCTGGCTTAATACCTCGGATCTGTCAAGGACTCTCCATTCGGATTAATGA
	AACCACCAGATCGGATGAAGCTTCTTTCCGAACTGAAGTCAGCTCCTTAAAAATTTAT
	AACGAACGTGTGAGAGATCTACTTCCGCGGAAGTCATCTAAAACCTTCAATTTGAGAG
	TCCGTGAGCATCCCAAAGAAGGCCCTTATGTTGAGGATTTATCCAAACATTTAGTACA
	GAATTATGGTGACGTAGAAGAACTTATGGATGCGGGCAATATCAACCGGACCACCGCA
	GCGACTGGGATGAACGACGTCAGTAGCAGGTCTCATGCCATCTTCACCATCAAGTTCA
	CTCAGGCTAAATTTGATTCTGAAATGCCATGTGAAACCGTCAGTAAGATCCACTTGGT
	TGATCTTGCCGGAAGTGAGCGTGCAGATGCCACCGGAGCCACCGGGGTTAGGCTAAAG
	GAAGGGGGAAATATTAACAAGTCCCTTGTGACTCTGGGGAACGTCATTTCTGCCTTAG
	CTGATTTATCTCAGGATGCTGCAAATACTCTTGCAAAGAAGAAGCAAGTTTTCGTGCC
	TTACAGGGATTCTGTGTTGACTTGGTTGTTAAAAGATAGCCTTGGAGGAAACTCTAAA
	ACTATCATGATTGCCACCATTTCACCTGCTGATGTCAATTATGGAGAAACCCTAAGTA
	CTCTTCGCTATGCAAATAGAGCCAAAAACATCATCAACAAGCCTACCATTAATGAGGA
	TGCCAACGTCAAACTTATCCGTGAGCTGCGAGCTGAAATAGCCAGACTGAAAACGCTG
	CTTGCTCAAGGGAATCAGATTGCCCTCTTAGACTCCCCCACAGCTTTAAGTATGGAGG
	AAAAACTTCAGCAGAATGAAGCAAGAGTTCAAGAATTGACCAAGGAATGGACAAATAA
	GTGGAATGAAACCCAAAATATTTTGAAAOAACAAACTCTAGCCCTCAGGAAAGAAGGG
	ATTGGAGTTGTTTTGGATTCTGAACTGCCTCATTTGATTGGCATCGATGATGACCTTT
	TGAGTACTGGAATCATCTTATATCATTTAAAGGAAGGTCAGACATACGTTGGTAGAGA
	CGATGCTTCCACGGAGCAAGATATTGTTCTTCATGGCCTTGACTTGGACAGTGAGCAT
	TGCATCTTTGAAAATATCGGGGGGACAGTGACTCTGATACCCCTGAGTGGGTCCCAGT
	GCTCTGTGAATGGTGTTCAGATCGTGGAGGCCACACATCTAAATCAAGGTGCTGTGAT
	TCTCTTGGGAAGAACCAATATGTTTCGCTTTAACCATCCAAAGGAAGCCGCCAAGCTC
	AGGGAGAAGAGGAAGAGTGGCCTTCTGTCCTCCTTCAGCTTGTCCATGACCGACCTCT
	CGAAGTCCCGTGAGAACCTGTCTGCAGTCATGTTGTATAACCCCGGACTTGAGTTTGA
	GAGGCAACAGCGTGAAGAACTTGAAAAATTAGAAAGTAAAAGGAAACTCATTGAGGAA
	ATGGAGGAAAAGCAGAAATCGGACAAGGCTGAACTGGAGCGGATGCAGCAGGAGGTGG
	AGACCCAGCGCAAGGAGACAGAAATCGTGCAGCTCCAGATTCGCAAGCAGGAGGAGAG
	CCTCAAACGCCGCAGCTTCCACATCGAGAACAAGCTAAAGGATTTACTTGCGGAGAAG
	GAAAAATTTGAAGAGGAGAGGCTGAGGGAACACCAGGAAATCGAGCTGCAGAAGAAGA
	GACAAGAAGAAGAGACCTTTCTCCGCGTCCAAGAAGAACTCCAACGACTCAAAGAACT
	CAACAACAACGAGAAGGCTGAGAAGTTTCAGATATTTCAAGAACTGGACCAGCTCCAA
	AAGGAAAAAGATGAACAGTATGCCAAGCTTGAACTGGAAAAAAAGAGACTAGAGGAGC
	AGGAGAAGGAGCAGGTCATGCTCGTGGCCCATCTGGAAGAGCAGCTCCGAGAGAAGCA
	GGAGATGATCCAGCTCCTGCGGCGTGGGGAGGTACAGTGGGTGGAAGAGGAGAAGAGG
	GACCTGGAAGGCATTCGGGAATCCCTCCTGCGGGTGAAGGAGGCTCGTGCCGGAGGGG
	ATGAAGATGGCGAGGAGTTAGAAAAGGCTCAACTGCGTTTCTTCGAATTCAAGAGAAG
	GCAGCTTGTCAAGCTAGTGAACTTCGAGAAGGACCTGGTTCAGCAGAAAGACATCCTG
	AAAAAAGAAGTCCAAGAAGAACAGGAGATCCTAGAGTGTTTAAAATGTGAAcATGACA
	AAGAATCTAGATTGTTCGAAAAACATGATGAGACTGTCACAGATGTCACGGAAGTGCC
	TCAAGATTTCGAGAAAATAAAGCCAGTGGAGTACAGGCTGCAATATAAAGAACGCCAG
	CTACAGTACCTCCTGCAGAATCACTTGCCAACTCTGTTGGAAGAAAAGCAGAGAGCAT
	TTGAAATTCTTGACAGAGGCCCTCTCAGCTTAGACAACACTCTTTATCAAGTAGAAAA
	GGAAATGGAAGAAAAAGAAGAACAGCTTGCACAGTACCAGGCCAATGCAAACCAGCTG
	CAAAAGCTCCAAGCCACCTTTGAATTCACTGCCAACATTGCACGTCAGCAGGAAAAAG
	TGAGGAAAAAGGAAAAGGAGATTTTGGAGTCCAGAGAGAAGCAGCAGAGAGAGGCGCT
	GGAGCGGGCCCTGGCCAGGCTGCAGAGGACACATTCTGCGCTGCAGAGGCACTCCACC
	CTGGGCACGGAGATTGAAGAGCAGAGGCAGAAACTTGCCAGTGTGAACAGTGGCAGCA
	GAGAGCAGTCAGGGTTCCAGGCTAGCCTGGAGGCTGAGCAGCAAGCACTAGAGATGTA
	CCATGTAGAAAGGTTAGAATATGAAATCCAGCAGCTGAAACAGAAGATTTATGAGGTC
	GATGGTGTTCAAAAAGATCATCATGGGACCCTGGAAGGGAAGGTGGCTTCTTCCAGCT
	TGCCAGTCAGTGCTGAAAAATCACACCTGGTTCCCCTCATGGATGCCAGGAGGATCAA
	TGCTTACATTGAAGAAGAAGTCCAAAGACGCCTTCAGGATTTGCATCGTGTGATTAGT
	GAAGCCTGCAGTACATCTGCAGACACGATGAAGGATAATGAGAAACTTCACAATGGCA
	CCATTCAACGTAAACTAAAATATGAGCTGTGTCGTGACCTCCTGTGTGTCCTGATGCC
	AGAGCCTGATGCCGCTGCCTGCGCTAATCATCCCTTGCTCCAGCAACATCTGGTTCAG
	CTTTCTCTTGATTGGAAAACAGAAATCCCTGATTTAGTTTTGCCAAATGGAGTTCAGG
	TGTCATCCAAATTCCAGACTACCTTGGTTCACATGATTTACTTTCTTCATGGAAATAT
	GGAAGTCAATGTCCCTTCCCTGGCAGAAGTTCAGTTACTGCTCTACACAACAGTGAAA
	GTCATGGGTGACTCTGGCCATGACCAGTGCCAGTCGCTAGTCCTTCTGAACACCCACA
	TTGCACTGGTGAAGGAAGACTGTGTTTTTTATCCACGCATTCGATCTCGAAACATACC
	TCCTCCGGGTCCACAATTTGATGTGATCAAATGCCATGCTTTAAGTGAATTCAGGTGT
	GTTGTTGTTCCAGAAAAGAAAAATGTGTCAACAGTAGAACTAGTCTTCTTACAGAAAC
	TCAAACCTTCAGTGGGTTCCAGAAATAGTCCACCTGAGCACCTTCAGGAAGCCCCAAA
	TGTCCAGTTGTTCACCACCCCATTGTATCTTCAAGGCAGTCAGAATGTCGCACCTGAG
	GTCTGGAAACTTACTTTCAATTCTCAAGATGAGGCTCTTTGGCTAATCTCACATTTGA
	CAAGACTCTAAGGAGGAGACTTTTAAAGATGCACTACAT
	ORF Start: ATG at 3		ORF Stop: TAA at 4185
	SEQ ID NO:84	1394 aa	MW at 160054.1 kD
NOV5a,	MASVKVAVRVRPMNRREKDLEAKFIIQMEKSKTTITNLKIPEGGTGDSGRERTKTFTY
CG106249-01
Protein Sequence	DFSFYSADTKTTDYVSQEMVFKTLRTDVLNSAFEVYNACVFAYGQTGSGKSYAMMGNS
	GDSGLIPRICEGLSIRINETTRSDEASFRTEVSSLKIYNERVRDLLRRKSSKTFNLRV
	REHPKECPYVEDLSKHLVQNYGDVEELMDACNINRTTAATGMNDVSSRSNAIFTIKFT
	QAKFDSEMPCETVSKIHLVDLAGSERADATGATGVRLKEGGNINKSLVTLGNVISALA
	DLSQDAANTLAKKKQVFVPYRDSVLTWLLKDSLOGNSKTIMIATISPADVNYGETLST
	LRYANRAKNIINKPTINEDANVKLIRELRAEIARLKTLLAQGNQIALLDSPTALSMEE
	KLQQNEARVQELTKEWTNKWNETQNTLKEQTLALRKEGIGVVLDSELPHLIGIDDDLL
	STGIILYHLKEGQTYVGRDDASTEQDIVLHGLDLESEHCIFENIGGTVTLIPLSGSQC
	SVNGVQIVEATHLNQGAVILLCRTNMFRFNHPKEAAKLREKRKSGLLSSFSLSMTDLS
	KSRENLSAVMLYNPGLEFERQQREELEKLESKRKLIEEMEEKQKSDKAELERMQQEVE
	TQRKETEIVQLQIRKQEESLKRRSFHIENKLKDLLAEKEKFEEERLREQQEIELQKKR
	QEEETFLRVQEELQRLKELNNNEKAEKFQIFQELDQLQKEKDEQYAKLELEKKRLEEQ
	EKEQVMLVAHLEEQLREKQEMIQLLRRGEVQWVEEEKRDLEGIRESLLRVKEARAGGD
	EDGEELEKAQLRFFEFKRRQLVKLVNLEKDLVQQKDILKKEVQEEQEILECLKCEHDK
	ESRLLEKHDESVTDVTEVPQDFEKTKPVEYRLQYKERQLQYLLQNHLPTLLEEKQRAF
	EILDRGPLSLDNTLYQVEKEMEEKEEQLAQYQANANQLQKLQATFEFTANIARQEEKV
	RKKEKEILESREKQQREALERALARLERRHSALQRHSTLGTEIEEQRQKLASVNSGSR
	EQSGFQASLEAEQEALEMYHVERLEYEIQQLKQKIYEVDGVQKDHHGTLEGKVASSSL
	PVSAEKSHLVPLMDARRINAYIEEEVQRRLQDLHRVISEGCSTSADTMKDNEKLHNGT
	IQRKLKYELCRDLLCVLMPEPDAAACANHPLLQQDLVQLSLDWKTEIPDLVLPNGVQV
	SSKFQTTLVDMIYFLHGNMEVNVPSLAEVQLLLYTTVKVMGDSGHDQCQSLVLLNTHI
	ALVKEDCVFYPRIRSRNIPPPGAQFDVIKCHALSEFRCVVVPEKKNVSTVELVFLQKL
	KPSVGSRNSPPEHLQEAPNVQLFTTPLYLQGSQNVAPEVWKLTFNSQDEALWLISHLT
	RL
	SEQ ID NO:85	4502 bp
NOV5b,	CGGCACGAGGGGGATGAGCGATGGCATCGGTCAAGGTGGCCGTGAGGGTCCGGCCCAT
CG106249-02
DNA Sequence	GAATCGCAGGGAAAAGGACTTGGAGGCCAAGTTCATTATTCAGATGGAGAAAAGCAAA
	ACGACAATCACAAACTTAAACATACCAGAAGGAGGCACTGGGGACTCAGGAAGAGAAC
	GGACCAAGACCTTCACCTATGACTTTTCTTTTTATTCTGCTGATACAAAAAGCCCAGA
	TTACGTTTCACAAGAAATGGTTTTCAAAACCCTCGGCACAGATGTCGTGAAGTCTGCA
	TTTGAAGGTTATAATGCTTGTGTCTTTGCATATGGGCAAACTGGATCTGGAAAGTCAT
	ACACTATGATGGGAAATTCTGGAGATTCTGGCTTAATACCTCGGATCTGTGAAGGACT
	CTTCAGTCGGATAAATGAAACCACCAGATGGGATGAAGCTTCTTTTCGAACTGAAGTC
	AGCTACTTAGAAATTTATAACGAACGTGTGAGAGATCTACTTCGGCGGAAGTCATCTA
	AAACCTTCAATTTGAGAGTCCGTGAGCATCCCAAAGAAGGCCCTTATGTTGAGGATTT
	ATCCAAACATTTAGTACAGAATTATGGTGACGTAGAAGAACTTATGGATGCGGGCAAT
	ATCAACCGGACCACCGCAGCGACTGGGATGAACGACGTCAGTAGCAGGTCTCATGCCA
	TCTTCACCATCAAGTTCACTCAGGCTAAATTTGATTCTGAAATGCCATGTGAAACCGT
	CAGTAAGATCCACTTGGTTGATCTTGCCGGAAGTGAGCGTGCAGATGCCACCGGAGCC
	ACCGGGGTTAGGCTAAAGGAAGGGGGAAATATTAACAAGTCCCTTGTGACTCTGGGGA
	ACGTCATTTCTGCCTTAGCTGATTTATCTCAGGATGCTGCAAATACTCTTGCAAAGAA
	GAAGCAAGTTTTCGTGCCTTACAGGGATTCTGTGTTGACTTGGTTGTTAAAAGATAGC
	CTTGGAGGAAACTCTAAAACTATCATGATTGCCACCATTTCACCTGCTGATGTCAATT
	ATGGAGAAACCCTAAGTACTCTTCGCTATGCAAATAGAGCCAAAAACATCATCAACAA
	GCCTACCATTAATGAGGATGCCAACGTCAAACTTATCCGTGAGCTGCGAGCTGAAATA
	GCCAGACTGAAAACGCTGCTTGCTCAAGGGAATCAGATTGCCCTCTTAGACTCCCCCA
	CAGCTTTAAGTATGGAGGAAAAACTTCAGCAGAATGAAGCAAGAGTTCAAGAATTGAC
	CAAGGAATGGACAAATAAGTGGAATGAAACCCAAAATATTTTGAAAGAACAAACTCTA
	GCCCTCAGGAAAGAAGGGATTGGAGTTGTTTTGGATTCTGAACTGCCTCATTTGATTG
	GCATCGATGATGACCTTTTGAGTACTGGAATCATCTTATATCATTTAAAGGAAGGTCA
	GACATACGTTGGTAGAGACGATGCTTCCACGGAGCAAGATATTGTTCTTCATGGCCTT
	GACTTGGAGAGTGAGCATTGCATCTTTGAAAATATCGGGGGGACAGTGACTCTGATAC
	CCCTGAGTGGGTCCCAGTGCTCTGTGAATGGTGTTCAGATCGTGGAGGCCACACATCT
	AAATCAAGGTGCTGTGATTCTCTTGGGAAGAACCAATATGTTTCGCTTTAACCATCCA
	AAGGAAGCCGCCAAGCTCAGGGAGAAGAGGAAGAGTGGCCTTCTGTCCTCCTTCAGCT
	TGTCCATGACCGACCTCTCGAAGTCCCGTGAGAACCTGTCTGCAGTCATGTTGTATAA
	CCCCGGACTTGAATTTGAGAGGCAACAGCGTGAAGAACTTGAAAAATTAGAAAGTAAA
	AGGAAACTCATAGAAGAAATGGAGGAAAAGCAGAAATCAGACAAGGCTGAACTGGAGC
	GGATGCAGCAGGAGGTGGAGACCCAGCGCAACGAGACAGAAATCGTGCAGCTCCAGAT
	TCGCAAGCAGGAGGAGAGCCTCAAACGCCGCAGCTTCCACATCGAGAACAAGCTAAAG
	GATTTACTTGCGGAGAAGGAAAAATTTGAAGAGGAGAGGCTGAGGGAACAGCAGGAAA
	TCGAGCTGCAGAAGAAGAGACAAGAAGAAGAGACCTTTCTCCGCGTCCAAGAACAACT
	CCAACGACTCAAAGAACTCAACAACAACGAGAAGGCTGAGAAGTTTCAGATATTTCAA
	GAACTGGACCAGCTCCAAAAGGAAAAAGATGAACAGTATGCCAAGCTTGAACTGGAAA
	AAAAGAGACTAGAGGAGCAGGAGAAGGAGCAGGTCATGCTCGTGGCCCATCTGGAAGA
	GCAGCTCCGAGAGAAGCAGGAGATGATCCAGCTCCTGCCGCGTGGGGAGGTACAGTGG
	GTGGAAGAGGAGAAGAGGGACCTGGAAGGCATTCGGGAATCCCTCCTGCGGGTGAAGG
	AGGCTCGTGCCGGAGGGGATGAAGATGGCGAGGAGTTAGAAAAGGCTCAACTGCGTTT
	CTTCGAATTCAAGAGAAGGCACCTTGTCAAGCTAGTGAACTTGGAGAAGGACCTGGTT
	CAGCAGAAAGACATCCTGAAAAAAGAAGTCCAAGAAGAACAGGAGATCCTAGAGTGTT
	TAAAATGTGAACATGACAAAGAATCTAGATTGTTGGAAAAACATGATGAGAGTGTCAC
	AGATGTCACGGAAGTGCCTCAAGATTTCGAGAAAATAAAGCCAGTGGAGTACAGGCTG
	CAATATAAAGAACGCCAGCTACAGTACCTCCTGCAGAATCACTTGCCAACTCTGTTGG
	AAGAAAAGCAGAGAGCATTTGAAATTCTTGACAGAGGCCCTCTCAGCTTAGACAACAC
	TCTTTATCAAGTAGAAAAGGAAATGGAAGAAAAACAAGAACAGCTTGCACAGTACCAG
	GCCAATGCAAACCAGCTGCAAAAGCTCCAAGCCACCTTTGAATTCACTGCCAACATTG
	CACGTCAGGAGGAAAAAGTGAGGAAAAAGGAAAAGGAGATTTTGGAGTCCAGAGAGAA
	GCAGCAGAGAGAGGCGCTGGAGCGGGCCCTGGCCAGGCTGGAGAGGAGACATTCTGCG
	CTGCAGAGGCACTCCACCCTGGGCACGGAGATTGAAGAGCAGAGGCAGAAACTTGCCA
	GTCTGAACAGTGGCAGCAGAGAGCAGTCAGGGCTCCAGGCTAGCCTGGAGGCTGAGCA
	GGAAGCCCTGGAGAAGGACCAGGAGAGGTTAGAATATGAAATCCAGCAGCTGAAACAG
	AAGATTTATGAGGTCGATGGTGTTCAAAAAGATCATCATGGGACCCTGGAAGGGAAGG
	TGGCTTCTTCCAGCTTGCCAGTCAGTGCTGAAAAATCACACCTGGTTCCCCTCATGGA
	TGCCAGGATCAATGCTTACATTGAAGAAGAACTCCAAAGACGCCTTCAGGATTTGCAT
	CGTGTGATTAGTGAAGGCTGCAGTACATCTGCAGACACGATGAAGGATAATGAGAAAC
	TTCACAATGGCACCATTCAACGTAAACTAAAATATGAGCTGTGTCGTGACCTCCTGTG
	TGTCCTGATGCCAGAGCCTGATGCCGCTGCCTGCGCTAATCATCCCTTGCTCCAGCAA
	GATCTGGTTCAGCTTTCTCTTGATTGGAAAACAGAAATCCCTGATTTAGTTTTGCCAA
	ATGGAGTTCAGCTGTCATCCAAATTCCAGACTACCTTGGTTGACATGATTTACTTTCT
	TCATGGAAATATGGAAGTCAATGTCCCTTCCCTGGCAGAAGTTCAGTTACTGCTCTAC
	ACAACAGTGAAAGTCATGGGTGACTCTGGCCATGACCAGTGCCAGTCGCTAGTCCTTC
	TGAACACCCACATTGCACTGGTGAAGGAAGACTGTGTTTTTTATCCACGCATTCGATC
	TCGAAACATACCTCCTCCGGGTGCACAATTTGATGTGATCAAATGCCATGCTTTAAGT
	GAATTCAGGTGTGTTGTTGTTCCAGAAAAGAAAAATGTGTCAACAGTAGAACTAGTCT
	TCTTACAGAAACTCAAACCTTCAGTGGGTTCCAGAAATAGTCCACCTGAGCACCTTCA
	GGAAGCCCCAAATGTCCAGTTGTTCACCACCCCATTGTATCTTCAAGGCAGTCAGAAT
	GTCGCACCTGAGGTCTGGAAACTTACTTTCAATTCTCAAGATGAGGCTCTTTGGCTAA
	TCTCACATTTGACAAGACTCTAAGGAGGAGACTTTTAAAGATGCACTACATGTTTTTT
	GAGATCATTAATAAAATAAGCATTGTGAAAACAGTCAAGGCAATATGAATATCTCCGT
	GTAGCTAATTGAATTGGAACTGGAAAAATGCAGACCTCTAAAATTGAAAATGTAACTA
	TTTTAAATATCTACAATAAAATAAAAACAGCTAATAGCAGAGCCCCAATGAAATATCT
	TTATCATCACCTTGCTTCATTTTCTTGAAACTCAGGCTTGTAAATTTGTGCCTGCTTC
	ATTATTTGTGAGGTGATTAAAGCATTTCTGATTGTT
	ORF Start: ATG at 21		ORF Stop: TAA at 4197
	SEQ ID NO:86	1392 aa	MW at 159799.8 kD
NOV5b,	MASVKVAVRVRPMNRREKDLEAKFITQMEKSKTTITNLKIPEGGTGDSGRERTKTFTY
CG106249-02
Protein Sequence	DFSFYSADTKSPDYVSQEMVFKTLGTDVVKSAFEGYNACVFAYGQTGSGKSYTMMGNS
	GDSGLIPRICEGLFSRINETTRWDEASFRTEVSYLEIYNERVRDLLRRKSSKTFNLRV
	REHPKEGPYVEDLSKHLVQNYGDVEELMDAGNINRTTAATGMNDVSSRSHAIFTTKFT
	QAKFDSEMPCETVSKIHLVDLAGSERADATGATGVRLKEGGNINKSLVTLGNVISALA
	DLSQDAANTLAKKKQVFVPYRDSVLTWLLKDSLGGNSKTIMIATISPADVNYGETLST
	LRYANRAKNTINKPTTNEDANVKLIRELRAEIARLKTLLAQGNQIALLDSPTALSMEE
	KLQQNEARVQELTKEWTNKNNETQNILKEQTLALRKEGIGVVLDSELPHLIGIDDDLL
	STGIILYHLKEGQTYVGRDDASTEQDIVLHGLDLESEHCIFENIGGTVTLIPLSGSQC
	SVNGVQIVEATHLNQGAVILLGRTNMFRFNHPKEAAKLREKRKSGLLSSFSLSMTDLS
	KSRENLSAVMLYNPGLEFERQQREELEKLESKRKLIEEMEEKQKSDKAELERMQQEVE
	TQRKETEIVQLQTRKQEESLKRRSFHIENKLKDLLAEKEKFEEERLREQQEIELQKKR
	QEEETFLRVQEELQRLKELNNNEKAEKFQIFQELDQLQKEKDEQYAKLELEKKRLEEQ
	EKEQVMLVAHLEEQLREKQEMIQLLRRGEVQWVEEEKRDLEGIRESLLRVKEARAGGD
	EDGEELEKAQLRFFEFKRRQLVKLVNLEKDLVQQKDILKKEVQEEQEILECLKCEHDK
	ESRLLEKHDESVTDVTEVPQDFEKIKPVEYRLQYKERQLQYLLQNHLPTLLEEKQRAF
	EILDRGPLSLDNTLYQVEKEMEEKEEQLAQYQANANQLQKLQATFEFTANIARQEEKV
	RKKEKEILESREKQQREALERALARLERRHSALQRHSTLGTEIEEQRQKLASLNSGSR
	EQSGLQASLEAEQEALEKDQERLEYEIQQLKQKIYEVDGVQKDHHGTLEGKVASSSLP
	VSAEKSHLVPLMDARINAYIEEEVQRRLQDLHRVISEGCSTSADTMKDNEKLHNGTIQ
	RKLKYELCRDLLCVLMPEPDAAACANHPLLQQDLVQLSLDWKTEIPDLVLPMGVQVSS
	KPQTTLVDMIYFLHGNNEVNVPSLAEVQLLLYTTVKVMGDSGHDQCQSLVLLNTHIAL
	VKEDCVFYPRIRSRNIPPPGAQFDVIKCHALSEFRCVVVPEKKNVSTVELVFLQKLKP
SVGSRNSPPEHLQEAPNVQLFTTPLYLQGSQNVAPEVWKLTFNSQDEALWLISHLTRL

[0377] Sequence comparison of the above protein sequences yields the following sequence relationships shown in Table 5B.

TABLE 5B
Comparison of NOV5a against NOV5b.
		Identities/
		Similarities for
Protein	NOV5a Residues/	the Matched
Sequence	Match Residues	Region
NOV5b	1 . . . 1394	1375/1394 (98%)
	1 . . . 1392	1379/1394 (98%)

[0378] Further analysis of the NOV5a protein yielded the following properties shown in Table 5C.

TABLE 5C
Protein Sequence Properties NOV5a
PSort     0.6086 probability located in mitochondrial matrix space;
analysis: 0.3127 probability located in mitochondrial inner membrane;
          0.3127 probability located in mitochondrial intermembrane
          space; 0.3127 probability located in mitochondrial outer
          membrane
SignalP   No Known Signal Sequence Predicted
analysis:

[0379] A search of the NOV5a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 5D.

TABLE 5D
Geneseq Results for NOV5a
		NOV5a	Identities/
		Residues/	Similarities for
Geneseq	Protein/Organism/Length	Match	the Matched	Expect
Identifier	[Patent #, Date]	Residues	Region	Value
ABB79531	Human kinesin motor protein	1 . . . 1394	1358/1394 (97%)	0.0
	HsKif16b - Homo sapiens, 1375	1 . . . 1375	1362/1394 (97%)
	aa. [US6399346-B1, 04 JUN.
	2002]
AAE22525	Human HsKif16b protein - Homo	1 . . . 1394	1358/1394 (97%)	0.0
	sapiens, 1375 aa. [US6355471-B1,	1 . . . 1375	1362/1394 (97%)
	12 MAR. 2002]
ABB79530	Human kinesin motor protein	1 . . . 359	347/359 (96%)	0.0
	HsKif16b motor domain - Homo	1 . . . 359	350/359 (96%)
	sapiens, 359 aa. [US6399346-B1,
	04 JUN. 2002]
AAE22526	Human HsKif16b motor domain	1 . . . 359	347/359 (96%)	0.0
	fragment - Homo sapiens, 359 aa.	1 . . . 359	350/359 (96%)
	[US6355471-B1, 12 MAR. 2002]
ABB61704	Drosophila melanogaster	20 . . . 757	350/776 (45%)	e−161
	polypeptide SEQ ID NO 11904 -	1 . . . 737	476/776 (61%)
	Drosophila melanogaster, 1174 aa.
	[WO200171042-A2, 27 SEP. 2001]

[0380] In a BLAST search of public sequence datbases, the NOV5a protein was found to have homology to the proteins shown in the BLASTP data in Table 5E.

TABLE 5E
Public BLASTP Results for NOV5a
		NOV5a	Identities/
Protein		Residues/	Similarities
Accession		Match	for the	Expect
Number	Protein/Organism/Length	Residues	Matched Portion	Value
Q9HCI2	KIAA1590 protein - Homo sapiens	155 . . . 1394	1233/1240 (99%)	0.0
	(Human), 1238 aa (fragment).	1 . . . 1238	1234/1240 (99%)
Q9BQM0	DJ971B4.1.2 (KIAA1590 (Novel	596 . . . 1394	791/799 (98%)	0.0
	protein similar to KIF1 type and	1 . . . 797	792/799 (98%)
	other kinesin-like proteins)
	(Isoform 2)) - Homo sapiens
	(Human), 797 aa (fragment).
Q9NXN9	CDNA FLJ20135 fis, clone	202 . . . 953	747/752 (99%)	0.0
	COL06818 - Homo sapiens	1 . . . 752	750/752 (99%)
	(Human), 752 aa (fragment).
Q9BQM1	DJ971B4.1.1 (KIAA1590 (Novel	596 . . . 1168	565/573 (98%)	0.0
	protein similar to KIF1 type and	1 . . . 571	566/573 (98%)
	other kinesin-like proteins)
	(Isoform 1)) - Homo sapiens
	(Human), 722 aa (fragment).
Q9BQM5	DJ777L9.1 (KIAA1590 (Novel	37 . . . 434	378/398 (94%)	0.0
	protein similar to KIF1 type and	37 . . . 429	382/398 (95%)
	other kinesin-like proteins)) - Homo
	sapiens (Human), 429 aa
	(fragment).

[0381] PFam analysis predicts that the NOV5a protein contains the domains shown in the Table 5F.

TABLE 5F
Domain Analysis of NOV5a
Pfam	NOV5a	Identities/Similarities	Expect
Domain	Match Region	for the Matched Region	Value
kinesin	9 . . . 387	187/421 (44%)	3.8e−152
		301/421 (71%)
FHA	478 . . . 544	21/80 (26%)	0.025
		45/80 (56%)

Example 6

[0382] The NOV6 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 6A.

TABLE 6A
NOV6 Sequence Analysis
	SEQ ID NO:87	858 bp
NOV6a,	GCCCACGATGCTCCTCCTTGCTCCCCAGATGCTGAATCTGCTGCTGCTGGCGCTGCCC
CG106824-01
DNA Sequence	GTCCTGGCGAGCCGCCCCTACGCGGCCCCTCCAGCCCCAGGCCAGGCCCTGCAGCGAG
	TGGGCATCGTCGGGGGTCAGGAGGCCCCCAGGAGCAAGTGGCCCTGGCAGGTGAGCCT
	GAGAGTCCACGGCCCATACTGGATGCACTTCTGCGGGGGCTCCCTCATCCACCCCCAG
	TGGGTGCTGACCGCAGCGCACTGCGTGGGACCGGACGTCAAGGATCTGGCCGCCCTCA
	GGGTGCAACTGCGGGAGCAGCACCTCTACTACCAGGACCAGCTGCTGCCGGTCAGCAG
	GATCATCGTGCACCCACAGTTCTACACCGCCCAGATCGGAGCGGACATCGCCCTGCTG
	GAGCTGGAGGAGCCGGTGAACGTCTCCAGCCACGTCCACACGGTCACCCTGCCCCCTG
	CCTCAGAGACCTTCCCCCCGGGGATGCCGTGCTGGGTCACTGGCTGGGGCGATGTGCT
	CCCACCGCCATTTCCTCTGAAGCAGGTGAAGGTCCCCATAATGGAAAACCACATTTGT
	GACGCAAAATACCACCTTGGCGCCTACACGGGAGACGACGTCCGCATCGTCCGTGACG
	ACATGCTGTGTGCCGGGAACACCCGGAGGGACTCATGCCAGCAGGGCGACTCCGGAGG
	GCCCCTGGTGTGCAAGGTGAATGGCACCTGGCTGCAGGCGGGCGTGGTCAGCTGGGGC
	GAGGGCTGTGCCCAGCCCAACCGGCCTGGCATCTACACCCGTGTCACCTACTACTTGG
	ACTGGATCCACCACTATGTCCCCAAAAAGCCGTGAGTCAGGCCTGG
	ORF Start: ATG at 8		ORF Stop: TGA at 845
	SEQ ID NO:88	279 aa	MW at 30877.5 kD
NOV6a,	MLLLAPQMLNLLLLALPVLASRAYAAPPAPGQALQRVGIVGGQEAPRSKWPWQVSLRV
CG106824-01
Protein Sequence	HGPYWMHFCGGSLIHPQNVLTAAHCVGPDVKDLAALRVQLREQHLYYQDQLLPVSRII
	VHPQFYTAQIGADIALLELEEPVNVSSHVHTVTLPPASETFPPGMPCWVTGWGDVLPP
	PFPLKQVKVPIMENHICDAKYHLGAYTGDDVRTVRDDMLCAGNTRRDSCQQGDSGGPL
	VCKVNGTWLQAGVVSWGEGCAQPNRPGIYTRVTYYLDWIHHYVPKKP
	SEQ ID NO:89	1828 bp
NOV6b,	ATGCTGAGCCTGCTGCTGCTGGCGCTGCCCGTCCTGGCGAGCCCGGCCTACGTGGCCC
CG106824-04
DNA Sequence	CTGCCCCAGGCCAGGCCCTGCAGCAAACGGGCATTGTTGGGGGGCAGGAGGCCCCCAG
	GAGCAAGTGGCCCTGGCAGGTGAGCCTGAGAGTCCGCGGCCCATACTGGATGCACTTC
	TGCGGGGGCTCCCTCATCCACCCCCAGTGGGTGCTAACCGCGGCGCACTGCGTGGAAC
	CGGACATCAAGGATCTGGCCCCCCTCAGGGTGCAACTGCGGGAGCAGCACCTCTACTA
	CCAGGACCAGCTGCTGCCGGTCAGCAGGATCATCGTGCACCCACAGTTCTACATCATC
	CAGACCGGGGCGGACATCGCCCTGCTGGAGCTGGAGGAGCCCGTGAACATCTCCAGCC
	ACATCCACACGGTCACGCTGCCCCCTGCCTCGGAGACCTTCCCCCCGGGGATGCCGTG
	CTGGGTCACTCGCTGGGGCGACGTGGACAATAATGAGCGCCTCCCACCGCCATTTCCT
	CTGAAGCAGGTGAAGGTCCCCATAATGGAAAACCACATTTGTGACGCAAAATACCACC
	TTGGCCCCTACACGGGAGACGACGTCCGCATCGTCCGTGACGACATGCTGTGTGCCGG
	GAACACCCGGAGGGACTCATGCCAGGGCGACTCCGGAGGGCCCCTGGTGTGCAAGGTG
	AATGGCACCTGGCTGCAGGCGGGCGTGGTCAGCTGGGGCGAGGGCTGTGCCCAGCCCA
	ACCGGCCTGGCATCTACACCCGTGTCACCTACTACTTGGACTGGATCCACCACTATGT
	CCCCAAAAAGCCGTGA
	ORF Start: ATG at 1		ORF Stop: TGA at 826
	SEQ ID NO:90	275 aa	MW at 30605.0 kD
NOV6b,	MLSLLLLALPVLASPAYVAPAPGQALQQTGIVGGQEAPRSKWPWQVSLRVRGPYWMHF
CG106824-04
Protein Sequence	CGGSLIHPQWVLTAAHCVEPDIKDLAALRVQLREQHLYYQDQLLPVSRIIVHPQFYII
	QTGADIALLELEEPVNISSHIHTVTLPPASETFPPGMPCWVTGWGDVDNNERLPPPFP
	LKQVKVPIMENHICDAKYHLGAYTGDDVRIVRDDMLCAGNTRRDSCQGDSGGPLVCKV
	NGTWLQAGVVSWGEGCAQPNRPGIYTRVTYYLDWIHHYVPKKP
	SEQ ID NO:91	828 bp
NOV6c,	ATGCTGAATCTGCTGCTGCTGGCGCTGCCCGTCCTGGCGAGCCGCGCCTACGCGGCCC
CG106824-02
DNA Sequence	CTGCCCCAGGCCAGGCCCTGCAGCGAGTGGGCATCGTCGGGGGTCAGGAGGCCCCCAG
	GAGCAAGTGGCCCTGGCAGGTGAGCCTGAGAGTCCACGGCCCATACTGGATGCACTTC
	TGCGGGGGCTCCCTCATCCACCCCCAGTGGGTGCTGACCGCAGCGCACTGCGTGGGAC
	CGGACGTCAAGGATCTGGCCGCCCTCAGGGTGCAACTGCGGGAGCAGCACCTCTACTA
	CCAGGACCACCTGCTGCCGGTCAGCAGGATCATCGTGCACCCACAGTTCTACACCGCC
	CAGATCGGAGCGGACATCGCCCTGCTGGAGCTGGAGGAGCCGGTGAACGTCTCCAGCC
	ACGTCCACACGGTCACCCTCCCCCCTGCCTCAGAGACCTTCCCCCCGGGGATGCCGTG
	CTGGGTCACTGGCTGGGGCGATGTGGACAATGATGAGCGCCTCCCACCGCCATTTCCT
	CTGAAGCAGGTGAAGGTCCCCATAATGCAAAACCACATTTGTGACGCAAAATACCACC
	TTGGCGCCTACACGGGAGACGACGTCCCCATCGTCCGTGACGACATGCTGTGTGCCGG
	GAACACCCGGAGGGACTCATGCCAGGGCGACTCCGGAGGGCCCCTGGTGTGCAAGGTG
	AATGGCACCTGGCTGCAGGCGGGCGTGGTCAGCTGGGGCGAGGGCTGTGCCCAGCCCA
	ACCGGCCTGGCATCTACACCCGTGTCACCTACTACTTGGACTGGATCCACCACTATGT
	CCCCAAAAAGCCGTGA
	ORF Start: ATG at 1		ORF Stop: TGA at 826
	SEQ ID NO:92	275 aa	MW at 30514.9 kD
NOV6c,	MLNLLLLALPVLASRAYAAPAPGQALQRVGIVGGQEAPRSKWPWQVSLRVHGPYWMHF
CG106824-02
Protein Sequence	CGGSLIHPQWVLTAAHCVGPDVKDLAALRVQLREQHLYYQDQLLPVSRIIVHPQFYTA
	QIGADIALLELEEPVNVSSHVHTVTLPPASETFPPGMPCWVTGWGDVDNDERLPPPFP
	LKQVKVPIMENHICDAKYHLGAYTGDDVRIVRDDMLCAGNTRRDSCQGDSGGPLVCKV
	NGTWLQAGVVSWGEGCAQPNRPGIYTRVTYYLDWIHHYVPKKP
	SEQ ID NO:93	1145 bp
NOV6d,	GGCCAGGATGCTGAATCTGCTGCTGCTGGCGCTGCCCGTCCTGGCGAGCCGCGCCTAC
CG106824-03
DNA Sequence	GCGGCCCCTGCCCCAGGCCAGGCCCTGCAGCGAGTGGGCATCGTTGGGGGTCAGGAGG
	CCCCCAGGAGCAAGTGGCCCTGGCAGGTGAGCCTGAGAGTCCACGGCCCATACTGGAT
	GCACTTCTGCGGGGGCTCCCTCATCCACCCCCAGTGGGTGCTGACCGCAGCGCACTGC
	GTGGGACCGGACGTCAAGGATCTGGCCGCCCTCAGGGTGCAACTGCGGGAGCAGCACC
	TCTACTACCAGGACCAGCTGCTGCCGGTCAGCAGGATCATCGTGCACCCACAGTTCTA
	CACCGCCCAGATCGGAGCGGACATCGCCCTGCTGGAGCTGGAGGAGCCGGTGAAGGTC
	TCCAGCCACGTCCACACGGTCACCCTGCCCCCTGCCTCAGAGACCTTCCCCCCGGGGA
	TGCCGTGCTGGGTCACTGGCTGGGGCGATGTGGACAATGATGAGCGCCTCCCACCGCC
	ATTTCCTCTGAAGCAGGTGAAGGTCCCCATAATGGAAAACCACATTTGTGACGCAAAA
	TACCACCTTGGCGCCTACACGGGAGACGACGTCCGCATCGTCCGTGACGACATGCTGT
	GTGCCGGGAACACCCGGAGGGACTCATGCCAGGGCGACTCCGGAGGGCCCCTGGTGTG
	CAAGGTCAATGGCACCTCGCTGCAGGCGGGCGTGGTCAGCTGGGGCGAGGGCTGTGCC
	CAGCCCAACCGGCCTGGCATCTACACCCGTGTCACCTACTACTTGGACTGGATCCACC
	ACTATGTCCCCAAAAAGCCGTGAGTCAGGCCTGGGTTGGCCACCTGGGTCACTGGAGG
	ACCAACCCCTGCTGTCCAAAACACCACTGCTTCCTACCCAGGTGGCGACTGCCCCCCA
	CACCTTCCCTGCCCCGTCCTGAGTGCCCCTTCCTGTCCTAAGCCCCCTGCTCTCTTCT
	GAGCCCCTTCCCCTGTCCTGAGGACCCTTCCCCATCCTGAGCCCCCTTCCCTGTCCTA
	AGCCTGACGCCTGCACCGGGCCCTCCGGCCCTCCCCTGCCCAGGCAGCTCGTGGTGGG
	CGCTAATCCTCCTGAGTGCTGGACCTCATTAAAGTGCATGGAA
	ORF Start: ATG at 8		ORF Stop: TGA at 833
	SEQ ID NO:94	275 aa	MW at 30528.9 kD
NOV6d,	MLNLLLLALPVLASRAYAAPAPGQALQRVGIVGGQEAPRSKWPWQVSLRVHGPYWMHF
CG106824-03
Protein Sequence	CGGSLIHPQWVLTAAHCVGPDVKDLAALRVQLREQHLYYQDQLLPVSRIIVHPQFYTA
	QIGADIALLELEEPVKVSSHVHTVTLPPASETFPPGMPCWVTGWGDVDNDERLPPPFP
	LKQVKVPIMENHICDAKYHLGAYTGDDVRIVRDDMLCAGNTRRDSCQGDSGGPLVCKV
	NGTWLQAGVVSWGEGCAQPNRPGIYTRVTYYLDWIHHYVPKKP

[0383] Sequence comparison of the above protein sequences yields the following sequence relationships shown in Table 6B.

TABLE 6B
Comparison of NOV6a against NOV6b through NOV6d.
	Protein	NOV6a Residues/	Identities/Similarities
	Sequence	Match Residues	for the Matched Region
	NOV6b	8 . . . 279	257/277 (92%)
		1 . . . 275	262/277 (93%)
	NOV6c	8 . . . 279	270/277 (97%)
		1 . . . 275	270/277 (97%)
	NOV6d	8 . . . 279	269/277 (97%)
		1 . . . 275	269/277 (97%)

[0384] Further analysis of the NOV6a protein yielded the following properties shown in Table 6C.

TABLE 6C
Protein Sequence Properties NOV6a
PSort     0.8650 probability located in lysosome (lumen); 0.6950
analysis: probability located in outside; 0.1333 probability located
          in microbody (peroxisome); 0.1000 probability located in
          endoplasmic reticulum (membrane)
SignalP   Cleavage site between residues 21 and 22
analysis:

[0385] A search of the NOV6a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 6D.

TABLE 6D
Geneseq Results for NOV6a
		NOV6a	Identities/
		Residues/	Similarities
Geneseq	Protein/Organism/Length	Match	for the	Expect
Identifier	[Patent #, Date]	Residues	Matched Region	Value
AAW63174	Human mast cell tryptase I	10 . . . 279	268/275 (97%)	e−161
	polypeptide - Homo sapiens, 273	1 . . . 273	268/275 (97%)
	aa. [WO9833812-A1, 06 AUG.
	1998]
AAW64238	Human mast cell tryptase I - Homo	10 . . . 279	268/275 (97%)	e−161
	sapiens, 273 aa. [WO9824886-A1,	1 . . . 273	268/275 (97%)
	11 JUN. 1998]
AAW63175	Human mast cell tryptase II/beta	9 . . . 279	268/276 (97%)	e−161
	polypeptide - Homo sapiens, 274	1 . . . 274	268/276 (97%)
	aa. [WO9833812-A1, 06 AUG.
	1998]
AAW64240	Human mast cell tryptase II/beta -	9 . . . 279	268/276 (97%)	e−161
	Homo sapiens, 274 aa.	1 . . . 274	268/276 (97%)
	[WO9824886-A1, 11 JUN.
	1998]
AAE14348	Human protease PRTS-13 protein -	1 . . . 279	263/278 (94%)	e−157
	Homo sapiens, 691 aa.	10 . . . 283	264/278 (94%)
	[WO200183775-A2, 08 NOV.
	2001]

[0386] In a BLAST search of public sequence datbases, the NOV6a protein was found to have homology to the proteins shown in the BLASTP data in Table 6E.

TABLE 6E
Public BLASTP Results for NOV6a
		NOV6a	Identities/
Protein		Residues/	Similarities
Accession		Match	for the	Expect
Number	Protein/Organism/Length	Residues	Matched Portion	Value
Q15661	Tryptase beta-1 precursor (EC	8 . . . 279	270/277 (97%)	e−162
	3.4.21.59) (Tryptase 1) (Tryptase	1 . . . 275	270/277 (97%)
	I) - Homo sapiens (Human), 275 aa.
P20231	Tryptase beta-2 precursor (EC	8 . . . 279	269/277 (97%)	e−161
	3.4.21.59) (Tryptase 2) (Tryptase	1 . . . 275	269/277 (97%)
	II) - Homo sapiens (Human), 275
	aa.
C35863	tryptase (EC 3.4.21.59) III	8 . . . 279	267/277 (96%)	e−159
	precursor - human, 275 aa.	1 . . . 275	267/277 (96%)
Q96RZ6	Tryptase I - Homo sapiens	8 . . . 279	266/277 (96%)	e−159
	(Human), 275 aa.	1 . . . 275	267/277 (96%)
P15157	Alpha-tryptase precursor (EC	8 . . . 279	252/277 (90%)	e−150
	3.4.21.59) (Tryptase 1) - Homo	1 . . . 275	258/277 (92%)
	sapiens (Human), 275 aa.

[0387] PFam analysis predicts that the NOV6a protein contains the domains shown in the Table 6F.

TABLE 6F
Domain Analysis of NOV6a
	NOV6a	Identities/Similarities	Expect
Pfam Domain	Match Region	for the Matched Region	Value
trypsin	39 . . . 271	111/264 (42%)	6.4e−89
		191/264 (72%)

Example 7

[0388] The NOV7 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 7A.

TABLE 7A
NOV7 Sequence Analysis
	SEQ ID NO:95	842 bp
NOV7a,	GTGGCCGTCCGAGAGCCGAGAGGTGAGGGTGCCCCCGCCTCACCTGCAGAGGGGCCGT
CG114327-01
DNA Sequence	TCCGGGCTCGAACCCGGCACCTTCCGGAAAATGGCGGCTGCCAGGCCCAGCCTGGGCC
	GAGTCCTCCCAGGATCCTCTGTCCTGTTCCTGTGTGACATGCAGGAGAAGTTCCGCCA
	CAACATCGCCTACTTCCCACAGATCGTCTCAGTGGCTGCCCGCATGCTCAAGAACACG
	ACCCTGGACCTCCTACACCGGGGGCTGCAGGTCCATGTGGTGGTGGACGCCTGCTCCT
	CACGCAGCCAGGTGGACCGGCTGGTGGCTCTGGCCCGCATGAGACAGAGTGGTGCCTT
	CCTCTCCACCAGCGAAGGGCTCATTCTGCAGCTTGTGGGCGATGCCGTCCACCCCCAG
	TTCAAGGAGATCCAGAAACTCATCAAGGAGCCCGCCCCAGACAGCGGACTGCTGGGCC
	TCTTCCAAGGCCAGAACTCCCTCCTCCACTGAACTCCAACCCTGCCTTGAGGGAAGAC
	CACCCTCCTGTCACCCGGACCTCAGTGGAAGCCCGTTCCCCCCATCCCTGGATCCCAA
	GAGTGGTGCGATCCACCAGGAGTGCCGCCCCCTTGTGGGGGGGGGCAGGGTCCTGCCT
	TCCCATTGGACAGCTGCTCCCGGAAATGCAAATGAGACTCCTGGAAACTGGGTGGGAA
	TTGGCTGAGCCAAGATGGAGGCGGGGCTCGGCCCCGGGCCACTTCACGGGGCGGGAAG
	GGGAGGGGAAGAAGAGTCTCAGACTGTGGGACACGGACTCGCAGAATAAACATATATG
	TGGCAAAAAAAAAAAAAAAAAAAAAAAAAA
	ORF Start: ATG at 89		ORF Stop: TGA at 494
	SEQ ID NO:96	135 aa	MW at 14765.0 kD
NOV7a,	MAAARPSLGRVLPGSSVLFLCDMQEKFRHNIAYFPQIVSVAARMLKNTTLDLLDRGLQ
CG114327-01
Protein Sequence	VHVVVDACSSRSQVDRLVALARMRQSGAFLSTSEGLILQLVGDAVHPQFKEIQKLIKE
	PAPDSGLLGLFQGQNSLLH
	SEQ ID NO:97	1091 bp
NOV7b,	GAAACGGTAACCAGCCCTGGGAAGCCCGCAAGAGGCCTCAGCGGTGGCCGTCCGAGCG
CG114327-02
DNA Sequence	CCGAGAGGTGAGGGTGCCCCCGCCTCACCTGCAGAGGGGCCGTTCCGGGCTCGAACCC
	GGCACCTTCCGGAAAATGGCGGCTGCCAGGCCCAGCCTGGGCCGAGTCCTCCCAGGAT
	CCTCTGTCCTGTTCCTCTGTGACATGCAGCAGAAGTTCCGCCACAACATCGCCTACTT
	CCCACAGATCGTCTCAGTGGCTGCCCGCATGCTCAAGGTGGCCCGGCTGCTTGAGGTG
	CCAGTCATGCTGACGGAGCAGTACCCACAAGGCCTGGGCCCCACGGTGCCCGAGCTGG
	GGACTGAGGGCCTTCGGCCGCTGGCCAAGACCTGCTTCAGCATGGTGCCTGCCCTGCA
	GCAGGAGCTGGACAGTCGGCCCCAGCTGCGCTCTGTGCTGCTCTGTGGCATTGAGGCA
	CAGGCCTGCATCTTGAACACGACCCTGGACCTCCTAGACCGGGGGCTGCACGTCCATG
	TGGTGGTGGACGCCTGCTCCTCACGCAGCCAGGTGGACCGGCTGGTGGCTCTGGCCCG
	CATGAGACAGAGTGGTGCCTTCCTCTCCACCAGCGAAGGGCTCATTCTGCAGCTTGTG
	GGCGATGCCGTCCACCCCCAGTTCAAGGACATCCAGAAACTCATCAAGGAGCCCGCCC
	CAGACAGCGGACTGCTGGCCCTCTTCCAAGGCCAGAACTCCCTCCTCCACTGAACTCC
	AACCCTGCCTTGAGGGAAGACCACCCTCCTGTCACCCGGACCTCAGTGGAAGCCCGTT
	CCCCCCATCCCTGGATCCCAAGAGTGGTGCGATCCACCAGGAGTGCCGCCCCCTTGTG
	GGGGGGGGCAGGGTGCTGCCTTCCCATTGGACAGCTCCTCCCGGAAATGCAAATGAGA
	CTCCTGGAAACTGGGTGGGAATTGGCTGACCCAAGATGGACGCGGGGCTCGGCCCCGG
	GCCACTTCACGGGGCGGGAAGGGGAGGGGAAGAAGAGTCTCAGACTGTGGGACACGGA
	CTCGCAGAATAACATATATGTGGCTGTGAAAAAAAAAAAAAAAAAA
	ORF Start: ATG at 132		ORF Stop: TGA at 747
	SEQ ID NO:98	205 aa	MW at 22336.9 kD
NOV7b,	MAAARPSLGRVLPGSSVLFLCDMQEKFRHNIAYFPQIVSVAARMLKVARLLEVPVMLT
CG114327-02
Protein Sequence	EQYPQGLGPTVPELGTEGLRPLAKTCFSMVPALQQELDSRPQLRSVLLCGIEAQACIL
	NTTLDLLDRGLQVHVVVDACSSRSQVDRLVALARMRQSGAFLSTSEGLILQLVGDAVH
	PQFKEIQKLIKEPAPDSGLLGLFQGQNSLLH

[0389] Sequence comparison of the above protein sequences yields the following sequence relationships shown in Table 7B.

TABLE 7B
Comparison of NOV7a against NOV7b.
	Protein	NOV7a Residues/	Identities/Similarities
	Sequence	Match Residues	for the Matched Region
	NOV7b	35 . . . 135	94/107 (87%)
		99 . . . 205	96/107 (88%)

[0390] Further analysis of the NOV7a protein yielded the following properties shown in Table 7C.

TABLE 7C
Protein Sequence Properties NOV7a
PSort     0.5108 probability located in mitochondrial
analysis: matrix space; 0.4500 probability located in
          cytoplasm; 0.2553 probability located in
          lysosome (lumen); 0.2357 probability
          located in mitochondrial inner membrane
SignalP   Cleavage site between residues 24 and 25
analysis:

[0391] A search of the NOV7a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 7D.

TABLE 7D
Geneseq Results for NOV7a
			Identities/
			Similarities for
Geneseq	Protein/Organism/Length	NOV7a Residues/	the Matched	Expect
Identifier	[Patent #, Date]	Match Residues	Region	Value
AAM41577	Human polypeptide SEQ ID NO	1 . . . 135	135/135 (100%)	5e−71
	6508 - Homo sapiens, 173 aa.	39 . . . 173	135/135 (100%)
	[WO200153312-A1, 26 JUL. 2001]
AAM39791	Human polypeptide SEQ ID NO	1 . . . 135	135/135 (100%)	5e−71
	2936 - Homo sapiens, 135 aa.	1 . . . 135	135/135 (100%)
	[WO200153312-A1, 26 JUL. 2001]
AAU23364	Novel human enzyme polypeptide	6 . . . 133	122/128 (95%)	5e−63
	#450 - Homo sapiens, 162 aa.	27 . . . 154	123/128 (95%)
	[WO200155301-A2, 02 AUG.
	2001]
AAB42186	Human ORFX ORF 1950	6 . . . 135	99/136 (72%)	1e−44
	polypeptide sequence SEQ ID	114 . . . 249	105/136 (76%)
	NO: 3900 - Homo sapiens, 249 aa.
	[WO200058473-A2, 05 OCT.
	2000]
AAG89278	Human secreted protein, SEQ ID	35 . . . 135	94/107 (87%)	3e−44
	NO: 398 - Homo sapiens, 205 aa.	99 . . . 205	96/107 (88%)
	[WO200142451-A2, 14 JUN. 2001]

[0392] In a BLAST search of public sequence datbases, the NOV7a protein was found to have homology to the proteins shown in the BLASTP data in Table 7E.

TABLE 7E
Public BLASTP Results for NOV7a
			Identities/
Protein			Similarities for
Accession		NOV7a Residues/	the Matched	Expect
Number	Protein/Organism/Length	Match Residues	Portion	Value
Q96AB3	Similar to hypothetical protein	35 . . . 135	94/107 (87%)	8e−44
	FLJ23469 - Homo sapiens	99 . . . 205	96/107 (88%)
	(Human), 205 aa.
Q9H5G0	CDNA: FLJ23469 fis, clone	46 . . . 135	89/90 (98%)	1e−43
	HSI11914 - Homo sapiens	132 . . . 221	90/90 (99%)
	(Human), 221 aa.
Q9D8T8	0610042E07Rik protein - Mus	47 . . . 134	69/89 (77%)	8e−31
	musculus (Mouse), 131 aa.	38 . . . 126	78/89 (87%)
Q9DCC7	0610042E07Rik protein - Mus	47 . . . 134	69/89 (77%)	8e−31
	musculus (Mouse), 210 aa.	117 . . . 205	78/89 (87%)
Q20062	F35G2.2 protein - Caenorhabditis	48 . . . 126	50/79 (63%)	1e−19
	elegans, 199 aa.	118 . . . 196	59/79 (74%)

[0393] PFam analysis predicts that the NOV7a protein contains the domains shown in the Table 7F.

TABLE 7F
Domain Analysis of NOV7a
		Identities/
		Similarities for
Pfam	NOV7a	the Matched	Expect
Domain	Match Region	Region	Value
Isochorismatase	13 . . . 126	22/213 (10%)	0.61
		86/213 (40%)

Example 8

[0394] The NOV8 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 8A.

TABLE 8A
NOV8 Sequence Analysis
	SEQ ID NO:99	1349 bp
NOV8a,	TGCGCCAGGATGGAGTTCGTGAAATGCCTTGGCCACCCCGAAGAGTTCTACAACCTGG
CG119418-01
DNA Sequence	TGCGCTTCCGGATCGGGGGCAAGCGGAAGGTGATGCCCAAGATGGACCAGGACTCGCT
	CAGCAGCAGCCTGAAAACTTGCTACAAGTATCTCAATCAGACCAGTCGCAGTTTCGCA
	GCTGTTATCCAGGCGCTGGATGGGGAAATGCGCAACGCAGTGTGCATATTTTATCTGG
	TTCTCCGAGCTCTGGACACACTGGAAGATGACATGACCATCAGTGTGGAAAAGAAGGT
	CCCGCTGTTACACAACTTTCACTCTTTCCTTTACCAACCAGACTGGCGGTTCATGGAG
	AGCAAGGAGAAGGATCGCCAGGTGCTGGAGGACTTCCCAACGATCTCCCTTGAGTTTA
	GAAATCTGGCTGAGAAATACCAAACAGTGATTGCCGACATTTGCCGGAGAATGGGCAT
	TGGGATGGCAGAGTTTTTGGATAAGCATGTGACCTCTGAACAGGAGTGGGACAAGTAC
	TGCCACTATGTTGCTGGGCTGGTCGGAATTGGCCTTTCCCGTCTTTTCTCAGCCTCAG
	AGTTTGAAGACCCCTTAGTTGGTGAAGATACAGAACGTGCCAACTCTATGGGCCTGTT
	TCTGCAGAAAACAAACATCATCCGTGACTATCTGGAAGACCAGCAAGGAGGAAGAGAG
	TTCTGGCCTCAAGACGTTTGGAGCAGGTATGTTAAGAAGTTAGGGGATTTTGCTAAGC
	CGGAGAATATTGACTTGGCCGTGCAGTGCCTGAATGAACTTATAACCAATGCACTGCA
	CCACATCCCAGATGTCATCACCTACCTTTCGAGACTCAGAAACCAGAGTGTGTTTAAC
	TTCTGCGCTATTCCACAGGTGATGGCCATTGCCACTTTGGCTGCCTGTTATAATAACC
	AGCAGGTGTTCAAAGGGGCAGTGAAGATTCGGAAAGGGCAAGCAGTGACCCTGATGAT
	GGATGCCACCAATATGCCAGCTGTCAAAGCCATCATATATCAGTATATGGAAGAGATT
	TATCATAGAATCCCCGACTCAGACCCATCTTCTAGCAAAACAAGGCAGATCATCTCCA
	CCATCCGGACGCAGAATCTTCCCAACTGTCAGCTGATTTCCCGAAGCCACTACTCCCC
	CATCTACCTGTCGTTTGTCATGCTTTTGGCTGCCCTGAGCTGGCAGTACCTGACCACT
	CTCTCCCAGGTAACAGAAGACTATGTTCAGACTGGAGAACACTGATCCCAAATTTGTC
	CATAGCTGAAGTCCACCATAAAGTGGATTTACTTTTTTTCTTTAAAAAAAAAAAAAAA
	AAAAAAAAAAAAAAA
	ORF Start: ATG at 10		ORF Stop: TGA at 1261
	SEQ ID NO:100	417 aa	MW at 48114.8 kD
NOV8a,	MEFVKCLGHPEEFYNLVRFRIGGKRKVMPKMDQDSLSSSLKTCYKYLNQTSRSFAAVI
CG119418-01
Protein Sequence	QALDGEMRNAVCIFYLVLRALDTLEDDMTISVEKKVPLLHNFHSFLYQPDWRFMESKE
	KDRQVLEDFPTISLEFRNLAEKYQTVIADICRRMGIGMAEFLDKHVTSEQEWDKYCHY
	VAGLVGIGLSRLFSASEFEDPLVGEDTERANSMGLFLQKTNIIRDYLEDQQGGREFWP
	QEVWSRYVKKLGDFAKPENIDLAVQCLNELITNALHHIPDVITYLSRLRNQSVFNFCA
	IPQVMAIATLAACYNNQQVFKGAVKIRKGQAVTLMMDATNMPAVKAIIYQYMEEIYHR
	IPDSDPSSSKTRQIISTIRTQNLPNCQLISRSHYSPIYLSFVMLLAALSWQYLTTLSQ
	VTEDYVQTGEH

[0395] Further analysis of the NOV8a protein yielded the following properties shown in Table 8B.

TABLE 8B
Protein Sequence Properties NOV8a
PSort     0.4500 probability located in cytoplasm;
analysis: 0.3719 probability located in microbody
          (peroxisome); 0.1000 probability located
          in mitochondrial matrix space; 0.1000
          probability located in lysosome (lumen)
SignalP   No Known Signal Sequence Predicted
analysis:

[0396] A search of the NOV8a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 8C.

TABLE 8C
Geneseq Results for NOV8a
			Identities/
			Similarities for
Geneseq	Protein/Organism/Length	NOV8a Residues/	the Matched	Expect
Identifier	[Patent #, Date]	Match Residues	Region	Value
AAW01739	Human squalene synthetase -	1 . . . 417	417/417 (100%)	0.0
	Homo sapiens, 417 aa.	1 . . . 417	417/417 (100%)
	[US5589372-A, 31 DEC. 1996]
AAR52606	Human squalene synthase - Homo	1 . . . 417	416/417 (99%)	0.0
	sapiens, 417 aa. [GB2272442-A,	1 . . . 417	416/417 (99%)
	18 MAY 1994]
ABB57061	Mouse ischaemic condition related	1 . . . 413	365/413 (88%)	0.0
	protein sequence SEQ ID NO: 118 -	1 . . . 413	395/413 (95%)
	Mus musculus, 416 aa.
	[WO200188188-A2, 22 NOV.
	2001]
AAR94574	Squalene synthetase from Nicotiana	7 . . . 396	177/403 (43%)	2e−89
	benthamiana - Nicotiana	8 . . . 401	257/403 (62%)
	benthamiana. 411 aa.
	[WO9609393-A1, 28 MAR. 1996]
AAG32432	Arabidopsis thaliana protein	7 . . . 401	173/406 (42%)	8e−88
	fragment SEQ ID NO: 39123 -	2 . . . 401	251/406 (61%)
	Arabidopsis thaliana, 404 aa.
	[EP1033405-A2, 06 SEP. 2000]

[0397] In a BLAST search of public sequence datbases, the NOV8a protein was found to have homology to the proteins shown in the BLASTP data in Table 8D.

TABLE 8D
Public BLASTP Results for NOV8a
			Identities/
Protein			Similarities for
Accession		NOV8a Residues/	the Matched	Expect
Number	Protein/Organism/Length	Match Residues	Portion	Value
P37268	Farnesyl-diphosphate	1 . . . 417	417/417 (100%)	0.0
	farnesyltransferase (EC 2.5.1.21)	1 . . . 417	417/417 (100%)
	(Squalene synthetase) (SQS) (SS)
	(FPP: FPP farnesyltransferase) -
	Homo sapiens (Human), 417 aa.
Q96GT0	Farnesyl-diphosphate	1 . . . 417	416/417 (99%)	0.0
	farnesyltransferase 1 - Homo sapiens	1 . . . 417	417/417 (99%)
	(Human), 417 aa.
I38245	farnesyl-diphosphate	1 . . . 417	416/417 (99%)	0.0
	farnesyltransferase (EC 2.5.1.21),	1 . . . 417	416/417 (99%)
	hepatic - human, 417 aa.
I52090	squalene synthase - human, 411 aa.	1 . . . 417	415/417 (99%)	0.0
		1 . . . 417	417/417 (99%)
P53798	Farnesyl-diphosphate	1 . . . 413	365/413 (88%)	0.0
	farnesyltransferase (EC 2.5.1.21)	1 . . . 413	395/413 (95%)
	(Squalene synthetase) (SQS) (SS)
	(FPP: FPP farnesyltransferase) - Mus
	musculus (Mouse), 416 aa.

[0398] PFam analysis predicts that the NOV8a protein contains the domains shown in the Table 8E.

TABLE 8E
Domain Analysis of NOV8a
			Identities/
			Similarities for
	Pfam	NOV8a	the Matched	Expect
	Domain	Match Region	Region	Value
	SQS_PSY	47 . . . 334	115/317 (36%)	6.5e−154
			280/317 (88%)

Example 9

[0399] The NOV9 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 9A.

TABLE 9A
NOV9 Sequence Analysis
	SEQ ID NO:101	2106 bp
NOV9a,	ATGGGGCTTCCTGAGCAGCGGGTCCGGAGCGGCAGCGGGAGCCGGGGCCAGGAGGAAG
CG120359-01
DNA Sequence	CTGGAGCCGGAGGCCGGGCGCGGAGTTGGTCTCCGCCGCCCGAGGTCAGCCGCTCCGC
	GCACGTCCCCTCGCTGCAGCGCTACCGCGAGCTGCACCGGCGCTCCGTGGAGGAGCCG
	CGGGAATTCTGGGGAGACATTGCCAAGGAATTTTACTGGAAGACTCCATGCCCTGGCC
	CATTCCTTCGGTACAACTTTGATGTGACTAAAGGGAAAATCTTCATTCAGTGGATGAA
	AGGAGCAACTACCAACATCTGCTACAATGTACTGGATCGAAATGTCCATGAGAAAAAG
	CTTGGAGATAAAGTTGCTTTTTACTGGGAGGGCAATGAGCCAGGGGAGACCACTCAGA
	TCACATACCATCAGCTTCTGGTCCAAGTGTGTCAGTTCAGCAATGTTCTCCGAAAACA
	GGGCATTCAGAAGGGGGACCGAGTGGCCATCTACATGCCTATGATCCCAGAGCTTGTG
	GTGGCCATGCTGGCATGTGCCCGCATTGGGGCTTTGCACTCCATTGTGTTTGCAGGCT
	TCTCTTCAGAGTCTCTATGTGAACGGATCTTGGATTCCAGCTGCAGTCTTCTCATCAC
	TACAGATGCCTTCTACAGGGGGGAAAAGCTTGTGAACCTGAAGGAGCTGGCTGACGAC
	GCCCTGCAGAAGTGTCAGGAGAAGGGTTTCCCAGTAAGATGCTGCATTGTGGTCAAGC
	ACCTGGGGCGGGCAGAGCTCGGCATGGGTGACTCCACCAGCCAGTCCCCCCCAATTAA
	GAGGTCATGCCCAGATGTGCAGATCTCATGGAACCAAGGGATTGACTTGTGGTGGCAT
	GAGCTCATGCAAGAGGCAGGGGATGAGTGTGAGCCCGAGTGCTGTGATGCCCAGGACC
	CACTCTTCATCCTGTACACCAGTGGCTCCACAGGCAAACCCAAGGGTGTGGTTCACAC
	AGTTGGGGGCTACATGCTCTATGTAGCCACAACCTTCAAGTATGTGTTTGACTTCCAT
	GCAGAGGATGTGTTCTGGTGCACGGCAGACATTGGTTGGATCACTGGTCATTCCTACG
	TCACCTATGGGCCACTGGCCAATGGTGCCACCAGTGTTTTGTTTGAGGCGATTCCCAC
	ATATCCGGACGTGAACCGCCTGTGGAGCATTGTGGACAAATACAAGGTGACCAAGTTC
	TACACAGCACCCACAGCCATCCGTCTGCTCATGAAGTTTGGAGATGAGCCTGTCACCA
	AGCATAGCCGGGCATCCTTGCAGGTGTTAGGCACAGTGGGTGAACCCATCAACCCTGA
	GGCCTGGCTATGGTACCACCGGGTGGTAGGTGCCCAGCGCTGCCCCATCGTGGACACC
	TTCTGGCAAACAGAGACAGGTGGCCACATGTTGACTCCCCTTCCTGGTGCCACACCCA
	TGAAACCCGGTTCTGCTACTTTCCCATTCTTTGGTGTAGCTCCTGCAATCCTGAATGA
	GTCCGGGGAAGAGTTGGAAGGTGAAGCTGAAGGTTATCTGGTGTTCAAGCAGCCCTGG
	CCAGGGATCATGCGCACAGTCTATGGGAACCACGAACGCTTTGAGACAACCTACTTTA
	AGAAGTTTCCTGGATACTATGTTACAGGAGATGGCTGCCAGCGGGACCAGGATGGCTA
	TTACTGGATCACTGGCAGGATTGATGACATGCTCAATGTATCTGGACACCTGCTGAGT
	ACAGCAGACGTGGAGTCAGCACTTGTGGAACATGAGGCTGTTGCAGAGGCAGCTGTGG
	TGGGCCACCCTCATCCTGTGAAGGGTGAATGCCTCTACTGCTTTGTCACCTTGTGTGA
	TGGCCACACCTTCAGCCCCAAGCTCACCGAGGAGCTCAAGAAGCAGATTAGAGAAAAG
	ATTGGCCCCATTGCCACACCAGACTACATCCAGAATGCACCTGGCTTGCCTAAAACCC
	GCTCAGGGAAAATCATGAGGCGAGTGCTTCGGAACATTGCTCAGAATGACCATGACCT
	CGGGGACATGTCTACTGTGGCTGACCCATCTGTCATCAGTCACCTCTTCAGCCACCGC
	TGCCTGACCATCCAGTGA
	ORF Start: ATG at 1		ORF Stop: TGA at 2104
	SEQ ID NO:102	701 aa	MW at 78578.9 kD
NOV9a,	MGLPEERVRSGSGSRGQEEAGAGGRARSWSPPPEVSRSAHVPSLQRYRELHRRSVEEP
CG120359-01
Protein Sequence	REFWGDIAKEFYWKTPCPGPFLRYNFDVTKGKIFIEWMKGATTNICYNVLDRNVHEKK
	LGDKVAFYWEGNEPGETTQITYHQLLVQVCQFSNVLRKQGIQKGDRVAIYMPMIPELV
	VANLACARIGALHSIVFAGFSSESLCERILDSSCSLLITTDAFYRGEKLVNLKELADE
	ALQKCQEKGFPVRCCIVVKHLGRAELGMGDSTSQSPPIKRSCPDVQISWNQGIDLWWH
	ELMQEAGDECEPEWCDAEDPLFILYTSGSTGKPKGVVHTVGGYMLYVATTFKYVFDFH
	AEDVFWCTADIGWITGHSYVTYGPLANGATSVLFEGIPTYPDVNRLWSIVDKYKVTKE
	YTAPTAIRLLMKFGDEPVTKHSRASLQVLGTVGEPINPEAWLWYHRVVGAQRCPIVDT
	FWQTETGGHMLTPLPGATPMKPGSATFPFFGVAPAILNESGEELEGEAEGYLVFKQPW
	PGIMRTVYGNHERFETTYFKKFPGYYVTGDGCQRDQDGYYWITGRIDDMLNVSGHLLS
	TAEVESALVEHEAVAEAAVVGHPHPVKGECLYCFVTLCDCHTFSPKLTEELKKQIREK
	IGPIATPDYIQNAPGLPKTRSGKIMRRVLRKIAQNDHDLGDMSTVADPSVISHLFSHR
	CLTIQ
	SEQ ID NO:103	2125 bp
NOV9b,	CACCGGATCCACCATGGGGCTTCCTGAGGAGCGGGTCCGGAGCGGCAGCGGGAGCCGG
277685717 DNA
Sequence	GGCCAGGAGGAAGCTGGAGCCGGAGGCCGGGCGCGGAGTTGGTCTCCGCCGCCCGAGG
	TCAGCCGCTCCGCGCACGTCCCCTCGCTGCAGCGCTACCGCGAGCTGCACCGGCGCTC
	CGTGGAGGAGCCGCGGGAATTCTGGGGAGACATTGCCAAGGAATTTTACTGGAAGACT
	CCATGCCCTGGCCCATTCCTTCGGTACAACTTTGATGTGACTAAAGGCAAAATCTTTA
	TTGAGTGGATGAAAGGAGCAACTACCAACATCTGCTACAATGTACTGGATCGAAATGT
	CCATGAGAAAAAGCTTGGAGATAAAGTTGCTTTTTACTGGGAGGGCAATGAGCCAGGG
	GAGACCACTCAGATCACATACCATCAGCTTCTGGTCCAAGTGTGTCAGTTCAGCAATG
	TTCTCCGAAAACAGGGCATTCAGAAGGGGGACCGAGTGGCCATCTACATGCCTATGAT
	CCCAGAGCTTGTGGTGGCCATGCTGGCATGTGCCCGCATTGGGGCTTTGCACTCCATT
	GTGTTTGCAGGCTTCTCTTCAGAGTCTCTATGTGAACGGATCTTGGATTCCAGCTGCA
	GTCTTCTCATCACTACAGATGCCTTCTACAGGGGGGAAAAGCTTGTGAACCTGAAGGA
	GCTGGCTGACGAGGCCCTGCAGAAGTGTCAGGACAAGGGTTTCCCAGTAAGATGCTGC
	ATTGTGGTCAAGCACCTGGGGCGGGCAGAGCTCGGCATGGGTGACTCCACCAGCCAGT
	CCCCCCCAATTAAGAGGTCATGCCCAGATGTGCAGATCTCATGGAACCAAGGGATTGA
	CTTCTGGTGGCATGAGCTCATGCAAGAGGCAGGGGATGAGTGTGAGCCCGAGTGGTGT
	GATGCCGAGGACCCACTCTTCATCCTGTACACCAGTGGCTCCACAGGCAAACCCAAGG
	GTGTGGTTCACACAGTTGGGCGCTACATGCTCTATGTAGCCACAACCTTCAAGTATGT
	GTTTGACTTCCATCCAGAGGATGTGTTCTGGTGCACGGCAGACATTGGTTGGATCACT
	GGTCATTCCTACGTCACCTATGGGCCACTGGCCAATGGTGCCACCAGTCTTTTGTTTG
	ACGGGATTCCCACATATCCGGACGTGAACCGCCTGTGGAGCATTGTGGACAAATACAA
	GGTGACCAAGTTCTACACAGCACCCACAGCCATCCGTCTGCTCATGAAGTTTGGAGAT
	GAGCCTGTCACCAAGCATAGCCGGGCATCCTTGCAGGTGTTAGGCACAGTGGGTGAAC
	CCATCAACCCTGAGGCCTGGCTATGGTACCACCGGGTGGTAGGTGCCCAGCGCTGCCC
	CATCGTGGACACCTTCTGGCAAACAGAGACAGGTGGCCACATGTTGACTCCCCTTCCT
	GGTGCCACACCCATGAAACCCGGTTCTGCTACTTTCCCATTCTTTGGTGTAGCTCCTG
	CAATCCTGAATGAGTCCGGGGAAGAGTTGGAAGGTGAAGCTGAAGGTTATCTGGTGTT
	CAAGCAGCCCTGGCCAGGGATCATGCGCACAGTCTATGGGAACCACGAACGCTTTGAG
	ACAACCTACTTTAAGAAGTTTCCTGGATACTATGTTACAGGAGATGGCTGCCAGCGGG
	ACCAGGATGGCTATTACTGGATCACTGGCAGGATTGATGACATGCTCAATGTATCTGG
	ACACCTGCTGAGTACAGCAGAGGTGGAGTCAGCACTTGTGGAACATGAGGCTGTTGCA
	GAGGCAGCTGTGGTGGGCCACCCTCATCCTGTGAAGGGTGAATGCCTCTACTGCTTTG
	TCACCTTGTGTGATGGCCACACCTTCAGCCCCAAGCTCACCGAGGAGCTCAAGAAGCA
	GATTAGAGAAAAGATTGGCCCCATTGCCACACCAGACTACATCCAGAATGCACCTGGC
	TTGCCTAAAACCCGCTCAGGGAAAATCATGAGGCGAGTGCTTCGGAAGATTGCTCAGA
	ATGACCATGACCTCGGGGACATGTCTACTGTGGCTCACCCATCTGTCATCAGTCACCT
	CTTCAGCCACCGCTGCCTGACCATCCAGCTCGAGGGC
	ORF Start: at 2		ORF Stop: end of
			sequence
	SEQ ID NO:104	708 aa	MW at 79224.6 kD
NOV9b,	TGSTMGLPEERVRSGSGSRGQEEAGAGGRARSWSPPPEVSRSAHVPSLQRYRELHRRS
277685717
Protein Sequence	VEEPREFWCDIAKEFYWKTPCPGPFLRYNFDVTKGKIFIEWNKGATTNICYNVLDRNV
	HEKKLCDKVAFYWEGNEPGETTQITYHQLLVQVCQFSNVLRKQGIQKGDRVAIYMPMI
	PELVVAMLACARIGALHSIVFAGFSSESLCERILDSSCSLLITTDAFYRGEKLVMLKE
	LADEALQKCQEKGFPVRCCIVVKHLGRAELGMGDSTSQSPPIKRSCPDVQISWNQGID
	LWWHELMQEAGDECEPEWCDAEDPLFILYTSGSTGKPKGVVHTVGGYMLYVATTFKYV
	FDFHAEDVFWCTADIGWITGHSYVTYGPLANGATSVLFEGIPTYPDVNRLWSIVDKYK
	VTKFYTAPTAIRLLMKFGDEPVTKHSRASLQVLGTVGEPINPEAWLWYHRVVGAQRCP
	IVDTFWQTETGGHMLTPLPGATPMKPGSATFPFFGVAPAILNESGEELEGEAEGYLVF
	KQPWPGIMRTVYGNHERFETTYFKKFPGYYVTGDGCQRDQDGYYWITGRIDDMLNVSG
	HLLSTAEVESALVEHEAVAEAAVVGHPHPVKGECLYCFVTLCDGHTFSPKLTEELKKQ
	IREKIGPIATPDYIQNAPGLPKTRSGKIMRRVLRKIAQNDHDLGDMSTVADPSVISHL
	FSHRCLTIQLEG
	SEQ ID NO:105	1408 bp
NOV9c,	CACCGGATCCACATACCATCAGCTTCTGGTCCAAGTGTGTCAGTTCAGCAATGTTCTC
277686882 DNA
Sequence	CGAAAACAGGGCATTCAGAAGGGGGACCGAGTGGCCATCTACATGCCTATGATCCCAG
	AGCTTGTGGTGGCCATGCTGGCATGTGCCCGCATTGGGGCTTTGCACTCCATTGTGTT
	TGCAGGCTTCTCTTCAGAGTCTCTATGTGAACGGATCTTGCATTCCAGCTGCAGTCTT
	CTCATCACTACAGATGCCTTCTACAGGGGGGAAAAGCTTGTGAACCTGAAGGAGCTGG
	CTGACGAGGCCCTGCAGAAGTGTCAGGAGAAGGGTTTCCCAGTAAGATGCTGCATTGT
	GGTCAAGCACCTGGGGCGGGCAGAGCTCGGCATGGGTGACTCCACCAGCCAGTCCCCC
	CCAATTAAGAGGTCATGCCCAGATGTGCAGATCTCATGGAACCAAGGGATTGACTTGT
	GGTGGCATGACCTCATGCAAGAGGCAGGGGATGAGTGTGAGCCCGAGTGGTGTGATGC
	CGAGGACCCACTCTTCATCCTGTACACCAGTGGCTCCACAGGCAAACCCAAGGGTGTG
	GTTCACACAGTTGGGGGCTACATGCTCTATGTAGCCACAACCTTCAAGTATGTGTTTG
	ACTTCCATGCAGAGGATGTGTTCTGGTGCACGGCAGACATTGGTTGGATCACTGGTCA
	TTCCTACGTCACCTATGGGCCACTGGCCAATGGTGCCACCAGTGTTTTGTTTGAGGGG
	ATTCCCACATATCCGGACGTGAACCGCCTGTGGAGCATTGTGGACAAATACAAGGTGA
	CCAAGTTCTACACAGCACCCACAGCCATCCGTCTGCTCATGAAGTTTGGAGATGAGCC
	TGTCACCAAGCATAGCCGGGCATCCTTGCAGGTGTTAGGCACAGTGGGTGAACCCATC
	AACCCTGAGGCCTGGCTATGGTACCACCGGGTGGTAGGTGCCCAGCGCTGCCCCATCG
	TGGACACCTTCTGGCAAACAGAGACAGGTGGCCACATGTTGACTCCCCTTCCTGGTGC
	CACACCCATGAAACCCGGTTCTGCTACTTTCCCATTCTTTGGTGTAGCTCCTGCAATC
	CTGAATGAGTCCGGGGAAGAGTTGGAAGGTGAAGCTGAAGGTTATCTGGTGTTCAAGC
	AGCCCTGGCCAGGGATCATGCGCACAGTCTATGGGAACCACGAACGCTTTGAGACAAC
	CTACTTTAAGAAGTTTCCTGGATACTATGTTACAGGAGATGGCTGCCAGCGGGACCAG
	GATCGCTATTACTGGATCACTGGCAGGATTGATGACATGCTCAATGTATCTGGACACC
	TGCTGAGTACAGCAGAGGTGGAGTCAGCACTTGTGGAACATGAGGCTGTTGCAGAGGC
	AGCTGTGCTCGAGGGC
	ORF Start: at 2		ORF Stop: end of
			sequence
	SEQ ID NO:106	469 aa	MW at 52125.0 kD
NOV9c,	TGSTYHQLLVQVCQFSNVLRKQGIQKGDRVAIYMPMTPELVVAMLACARIGALHSIVF
277686882
Protein Sequence	AGFSSESLCERILDSSCSLLITTDAFYRGEKLVNLKELADEALQKCQEKGPPVRCCIV
	VKHLGRAELGMGDSTSQSPPTKRSCPDVQISNNQGIDLWWHELMQEAGDECEPEWCDA
	EDPLFILYTSGSTGKPKGVVHTVGGYMLYVATTFKYVFDFHAEDVFWCTADIGWITGH
	SYVTYGPLANGATSVLFEGIPTYPDVNRLWSIVDKYKVTKFYTAPTAIRLLMKFGDEP
	VTKHSRASLQVLGTVGEPINPEAWLWYHRVVGAQRCPIVDTFWQTETGGHMLTPLPGA
	TPMKPGSATFPFFGVAPAILNESGEELEGEAEGYLVFKQPWPGIMRTVYGNHERFETT
	YFKKFPGYYVTGDGCQRDQDGYYWITGRIDDMLNVSGHLLSTAEVESALVEHEAVAEA
	AVLEG
	SEQ ID NO:107	2164 bp
NOV9d,	CACCGGATCCACCATGGGGCTTCCTGAGCAGCGCGTCCGGAGCGGCAGCGGGAGCCGG
CG120359-02
DNA Sequence	GGCCAGGAGGAAGCTGGAGCCGGAGGCCGGGCGCGGAGTTGGTCTCCGCCGCCCGAGG
	TCAGCCGCTCCGCGCACGTCCCCTCGCTGCAGCGCTACCGCGAGCTGCACCGGCGCTC
	CGTGGAGGAGCCGCGGGAATTCTGGGGAGACATTGCCAAGGAATTTTACTGGAAGACT
	CCATGCCCTGGCCCATTCCTTCGGTACAACTTTGATGTGACTAAAGGGAAAATCTTCA
	TTGAGTGGATGAAAGGAGCAACTACCAACATCTGCTACAATGTACTGGATCGAAATGT
	CCATGAGAAAAAGCTTGGAGATAAAGTTGCTTTTTACTGGTCCACTTCTGGTAATTCA
	TCCTACAGATATACTTGCAGGGAGGGCAATGAGCCAGGGGAGACCACTCAGATCACAT
	ACCATCAGCTTCTGGTCCAAGTGTGTCAGTTCAGCAATGTTCTCCGAAAACAGGGCAT
	TCAGAAGGGGGACCGAGTGGCCATCTACATGCCTATGATCCCAGAGCTTGTGGTGGCC
	ATCCTGGCATGTGCCCGCATTGGGGCTTTGCACTCCATTGTGTTTGCAGGCTTCTCTT
	CAGAGTCTCTATGTGAACGGATCTTCGATTCCAGCTGCAGTCTTCTCATCACTACAGA
	TGCCTTCTACAGGGGGGAAAAGCTTGTGAACCTGAAGGAGCTGGCTGACGAGGCCCTG
	CAGAAGTGTCAGGAGAAGGGTTTCCCAGTAAGATGCTGCATTGTGGTCAAGCACCTGG
	GGCGGGCAGAGCTCGGCATGGGTGACTCCACCAGCCAGTCCCCCCCAATTAAGAGGTC
	ATGCCCAGATGTGCAGATCTCATGGAACCAAGGGATTGACTTGTGGTGGCATGAGCTC
	ATGCAAGAGGCAGGGGATGAGTGTGAGCCCGAGTGGTGTGATGCCGAGGACCCACTCT
	TCATCCTGTACACCAGTGGCTCCACAGGCAAACCCAAGGGTGTGGTTCACACAGTTGG
	GGGCTACATGCTCTATCTAGCCACAACCTTCAAGTATGTGTTTGACTTCCATGCAGAG
	GATGTGTTCTGGTGCACGGCAGACATTGGTTGGATCACTGGTCATTCCTACGTCACCT
	ATGGGCCACTGGCCAATGGTGCCACCAGTGTTTTGTTTGAGGGGATTCCCACATATCC
	GGACGTGAACCGCCTGTGGAGCATTGTGGACAAATACAAGGTGACCAAGTTCTACACA
	GCACCCACAGCCATCCGTCTGCTCATGAAGTTTGGAGATGAGCCTGTCACCAAGCATA
	GCCGGGCATCCTTCCAGGTGTTAGGCACAGTGGGTGAACCCATCAACCCTGAGGCCTG
	GCTATGGTACCACCGGGTGGTAGGTGCCCAGCGCTGCCCCATCGTGGACACCTTCTGG
	CAAACAGAGACAGGTGGCCACATGTTGACTCCCCTTCCTGGTGCCACACCCATGAAAC
	CCGGTTCTGCTACTTTCCCATTCTTTGGTGTAGCTCCTGCAATCCTGAATGAGTCCGG
	GGAAGAGTTGGAAGGTGAAGCTGAAGGTTATCTGGTGTTCAAGCAGCCCTGGCCAGGG
	ATCATGCGCACAGTCTATGGGAACCACGAACGCTTTGAGACAACCTACTTTAAGAAGT
	TTCCTGGATACTATGTTACAGGAGATGGCTGCCAGCGGCACCAGGATGGCTATTACTG
	GATCACTGGCAGGATTGATGACATGCTCAATGTATCTGGACACCTGCTGAGTACAGCA
	GAGGTGGAGTCAGCACTTGTGGAACATGAGGCTGTTGCAGAGGCAGCTGTGGTGGGCC
	ACCCTCATCCTGTGAAGGGTGAATGCCTCTACTGCTTTGTCACCTTGTGTGATGGCCA
	CACCTTCAGCCCCAAGCTCACCGAGGAGCTCAAGAAGCAGATTAGAGAAAAGATTGGC
	CCCATTGCCACACCAGACTACATCCAGAATGCACCTGGCTTGCCTAAAACCCGCTCAG
	GGAAAATCATGAGGCGAGTGCTTCGGAAGATTGCTCAGAATGACCATGACCTCGGGGA
	CATGTCTACTGTGGCTGACCCATCTGTCATCAGTCACCTCTTCAGCCACCGCTGCCTG
	ACCATCCAGCTCGAGGGC
	ORF Start: ATG at 14		ORF Stop: at 2156
	SEQ ID NO:108	714 aa	MW at 80042.4 kD
NOV9d,	MGLPEERVRSGSGSRGQEEAGAGGRARSWSPPPEVSRSAHVPSLQRYRELHRRSVEEP
CG120359-02
Protein Sequence	REFWGDIAKEFYWKTPCPGPFLRYNFDVTKGKIFIEWMKGATTNICYNVLDRNVHEKK
	LGDKVAFYWSTSGNSSYRYTCREGNEPGETTQITYHQLLVQVCQFSNVLRKQGIQKGD
	RVAIYMPMIPELVVAMLACARIGALHSIVFAGFSSESLCERILDSSCSLLITTDAFYR
	GEKLVNLKELADEALQKCQEKGFPVRCCIVVKHLGRAELGMGDSTSQSPPIKRSCPDV
	QISWNQGIDLWWHELMQEAGDECEPEWCDAEDPLFILYTSGSTGKPKGVVHTVGGYML
	YVATTFKYVFDFHAEDVFWCTADIGWITGHSYVTYGPLANGATSVLFEGIPTYPDVNR
	LWSIVDKYKVTKFYTAPTAIRLLMKFGDEPVTKHSRASLQVLGTVGEPINPEAWLWYH
	RVVGAQRCPIVDTFWQTETGGHMLTPLPGATPMKPGSATFPFFGVAPAILNESGEELE
	GEAEGYLVFKQPWPGIMRTVYGNHERFETTYFKKFPGYYVTGDCCQRDQDGYYWITGR
	IDDMLNVSGHLLSTAEVESALVEHEAVAEAAVVGHPHPVKGECLYCFVTLCDGHTFSP
	KLTEELKKQIREKIGPIATPDYIQNAPGLPKTRSGKIMRRVLRKIAQNDHDLGDMSTV
	ADPSVISHLFSHRCLTIQ

[0400] Sequence comparison of the above protein sequences yields the following sequence relationships shown in Table 9B.

TABLE 9B
Comparison of NOV9a against NOV9b through NOV9d.
			Identities/
			Similarities for
	Protein	NOV9a Residues/	the Matched
	Sequence	Match Residues	Region
	NOV9b	1 . . . 701	701/701 (100%)
		5 . . . 705	701/701 (100%)
	NOV9c	134 . . . 600	464/467 (99%)
		1 . . . 467	465/467 (99%)
	NOV9d	1 . . . 701	701/714 (98%)
		1 . . . 714	701/714 (98%)

[0401] Further analysis of the NOV9a protein yielded the following properties shown in Table 9C.

TABLE 9C
Protein Sequence Properties NOV9a
PSort     0.9000 probability located in Golgi body;
analysis: 0.7900 probability located in plasma
          membrane; 0.7166 probability located in
          microbody (peroxisome); 0.2000 probability
          located in endoplasmic reticulum (membrane)
SignalP   No Known Signal Sequence Predicted
analysis:

[0402] A search of the NOV9a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 9D.

TABLE 9D
Geneseq Results for NOV9a
		NOV9a	Identities/
		Residues/	Similarities
Geneseq	Protein/Organism/Length [Patent	Match	for the Matched	Expect
Identifier	#, Date]	Residues	Region	Value
AAM41491	Human polypeptide SEQ ID NO	59 . . . 701	641/643 (99%)	0.0
	6422 - Homo sapiens, 651 aa.	9 . . . 651	642/643 (99%)
	[WO200153312-A1, 26 JUL. 2001]
AAM39705	Human polypeptide SEQ ID NO	60 . . . 701	641/642 (99%)	0.0
	2850 - Homo sapiens, 666 aa.	25 . . . 666	641/642 (99%)
	[WO200153312-A1, 26 JUL. 2001]
AAB42913	Human ORFX ORF2677	96 . . . 701	593/606 (97%)	0.0
	polypeptide sequence SEQ ID	1 . . . 605	594/606 (97%)
	NO:5354 - Homo sapiens, 605 aa.
	[WO200058473-A2, 05 OCT. 2000]
AAB94113	Human protein sequence SEQ ID	260 . . . 701	441/442 (99%)	0.0
	NO: 14352 - Homo sapiens, 442 aa.	1 . . . 442	442/442 (99%)
	[EP1074617-A2, 07 FEB. 2001]
ABB71619	Drosophila melanogaster	29 . . . 696	420/670 (62%)	0.0
	polypeptide SEQ ID NO 41649 -	8 . . . 665	522/670 (77%)
	Drosophila melanogaster, 670 aa.
	[WO200171042-A2, 27 SEP. 2001]

[0403] In a BLAST search of public sequence datbases, the NOV9a protein was found to have homology to the proteins shown in the BLASTP data in Table 9E.

TABLE 9E
Public BLASTP Results for NOV9a
		NOV9a	Identities/
Protein		Residues/	Similarities
Accession		Match	for the	Expect
Number	Protein/Organism/Length	Residues	Matched Portion	Value
Q9NR19	Acetyl-coenzyme A synthetase,	1 . . . 701	701/701 (100%)	0.0
	cytoplasmic (EC. 6.2.1.1)(Acetate--	1 . . . 701	701/701 (100%)
	CoA ligase) (Acyl-activating
	enzyme) (Acetyl-CoA synthetase)
	(ACS) (AceCS) - Homo sapiens
	(Human), 701 aa.
BAC03849	CDNA FLJ34962 fis, clone	1 . . . 701	699/714 (97%)	0.0
	NTONG2003897, highly similar to	1 . . . 714	700/714 (97%)
	Homo sapiens acetyl-CoA
	synthetase mRNA - Homo sapiens
	(Human), 714 aa.
BAC04235	CDNA fis, clone TRACH2001275,	1 . . . 701	653/701 (93%)	0.0
	highly similar to Mus musculus	1 . . . 701	676/701 (96%)
	acetyl-CoA synthetase mRNA - Mus
	musculus (Mouse), 701 aa.
Q9QXG4	Acetyl-coenzyme A synthetase,	1 . . . 701	651/701 (92%)	0.0
	cytoplasmic (EC 6.2.1.1) (Acetate-	1 . . . 701	673/701 (95%)
	CoA ligase) (Acyl-activating
	enzyme) (Acetyl-CoA synthetase)
	(ACS) (AceCS) - Mus musculus
	(Mouse), 701 aa.
Q96FY7	Unknown (protein for MGC: 19474) -	260 . . . 701	442/442 (100%)	0.0
	Homo sapiens (Human), 442 aa.	1 . . . 442	442/442 (100%)

[0404] PFam analysis predicts that the NOV9a protein contains the domains shown in the Table 9F.

TABLE 9F
Domain Analysis of NOV9a
	NOV9a	Identities/Similarities	Expect
Pfam Domain	Match Region	for the Matched Region	Value
AMP-binding	137 . . . 599	125/465 (27%)	2.4e−127
		354/465 (76%)

Example 10

[0405] The NOV10 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 10A.

TABLE 10A
NOV10 Sequence Analysis
	SEQ ID NO:109	1958 bp
NOV10a,	GCAGGCCAGCCCCATGGGGAAGCGCAGACGCCGGNGCCTGGGCGCTCTGAGATTGTCA
CG124907-01
DNA Sequence	CTGCTGTTCCAAGGGCACACGCAGAGGGATTTGGAATTCCTGGAGAGTTGCCTTTGTG
	AGAAGCTGGAAATATTTCTTTCAATTCCATCTCTTAGTTTTCCATAGGAACATCAAGA
	AATCATGAACAACTTTGGTAATGAAGAGTTTGACTGCCACTTCCTCGATGAAGGTTTT
	ACTGCCAAGGACATTCTGGACCAGAAAATTAATGAAGTTTCTTCTTCTGATGATAAGG
	ATGCCTTCTATGTGGCAGACCTGGGAGACATTCTAAAGAAACATCTGAGGTGGTTAAA
	AGCTCTCCCTCGTGTCACCCCCTTTTATGCAGTCAAATGTAATGATAGCAAAGCCATC
	GTGAAGACCCTTGCTGCTACCGGGACAGGATTTGACTGTGCTAGCAAGACTGAAATAC
	AGTTGGTGCAGAGTCTGGGGGTGCCTCCAGAGAGGATTATCTATGCAAATCCTTGTAA
	ACAAGTATCTCAAATTAAGTATGCTGCTAATAATGGAGTCCAGATGATGACTTTTGAT
	AGTGAAGTTGAGTTGATGAAAGTTGCCAGAGCACATCCCAAAGCAAAGTTGGTTTTGC
	GGATTGCCACTGATGATTCCAAAGCAGTCTGTCGTCTCAGTGTCAAATTCGGTGccAc
	GCTCAGAACCAGCAGGCTCCTTTTGGAACGGGCGAAAGAGCTAAATATCGATGTTGTT
	GGTGTCAGCTTCCATGTAGGAAGCGGCTGTACCGATCCTGAGACCTTCGTGCAGGCAA
	TCTCTGATGCCCGCTGTGTTTTTGACATGGGGGCTGAGGTTGGTTTCAGCATGTACT
	GCTTGATATTGGCCGTGGCTTTCCTGGATCTGAGGATGTGAAACTTAAATTTGAAGAG
	ATCACCGGCGTAATCAACCCAGCGTTGGACAAATACTTTCCGTCAGACTCTGGAGTGA
	GAATCATAGCTGAGCCCGGCAGATACTATGTTGCATCAGCTTTCACGCTTGCAGTTAA
	TATCATTGCCAAGAAAATTGTATTAAAGGAACAGACGGGCTCTGATGACGAAGATGAG
	TCGAGTGAGCAGACCTTTATGTATTATGTGAATGATGGCGTCTATGGATCATTTAATT
	GCATACTCTATGACCACGCACATGTAAAGCCCCTTCTGCAAAAGAGACCTAAACCAGA
	TGAGAAGTATTATTCATCCAGCATATGGGGACCAACATGTGATGGCCTCGATCGGATT
	GTTGAGCGCTGTCACCTGCCTGAAATGCATGTGGGTGATTGGATGCTCTTTGAAAACA
	TGGGCGCTTACACTGTTGCTGCTGCCTCTACGTTCAATGGCTTCCAGAGGCCGACGAT
	CTACTATGTGATGTCAGGGCCTGCGTGGCAACTCATGCAGCAATTCCAGAACCCCGAC
	TTCCCACCCGAAGTAGAGGAACAGGATGCCAGCACCCTGCCTGTGTCTTGTGCCTGGG
	AGAGTGGGATGAAACGCCACAGAGCAGCCTGTGCTTCGGCTAGTATTAATGTGTAGAT
	AGCACTCTGGTAGCTGTTAACTGCAAGTTTAGCTTGAATTAAGGGATTTGGGGGGACC
	ATGTAACTTAATTACTGCTAGTTTTGAAATGTCTTTGTAAGAGTAGGGTCGCCATGAT
	GCAGCCATATGGAAGACTAGGATATGGGTCACACTTATCTGTGTTCCTATGCAAACTA
	TTTGAATATTTGTTTTATATGGATTTTTATTCACTCTTCAGACACGCTACTCAAGAGT
	GCCCCTCAGCTGCTGAACAAGCATTTGTAGCTTGTACAATGGCAGAATGGGCCAAAAG
	CTTAGTGTTGTGACCTGTTTTTAAAATAAAGTATCTTGAAATAAACAAAAAAAAAAAA
	GGGGGGCCGCCCTAGGGGTTCCCAAGTTTACGTACGCTGCATGG
	ORF Start: ATG at 179		ORF Stop: TAG at 1562
	SEQ ID NO:110	461 aa	MW at 51147.6 kD
NOV10a,	MNNFGNEEFDCHFLDEGFTAKDILDQKINEVSSSDDKDAFYVADLGDILKKHLRWLKA
CG124907-01
Protein Sequence	LPRVTPFYAVKCNDSKAIVKTLAATGTGFDCASKTEIQLVQSLGVPPERIIYANPCKQ
	VSQIKYAANNGVQMMTFDSEVELMKVARAHPKAKLVLRIATDDSKAVCRLSVKFGATL
	RTSRLLLERAKELNIDVVGVSFHVGSGCTDPETFVQAISDARCVFDMGAEVGFSMYLL
	DTGGGFPGSEDVKLKFEEITGVINPALDKYFPSDSGVRIIAEPGRYYVASAFTLAVNI
	IAKKIVLKEQTGSDDEDESSEQTFMYYVNDGVYGSFNCILYDHAHVKPLLQKRPKPDE
	KYYSSSIWGPTCDGLDRIVERCDLPEMHVGDWMLFENMGAYTVAAASTFNGFQRPTIY
	YVMSGPAWQLMQQFQNPDFPPEVEEQDASTLPVSCAWESGMKRHRAACASASINV
	SEQ ID NO:111	1958 bp
NOV10b,	GCAGGCCAGCCCCATGGGGAAGCGCAGACGCCGGNGCCTGGGCGCTCTGAGATTGTCA
CG124907-01
DNA Sequence	CTGCTGTTCCAAGGGCACACGCAGAGGGATTTGGAATTCCTGGAGAGTTGCCTTTGTG
	AGAAGCTGGAAATATTTCTTTCAATTCCATCTCTTAGTTTTCCATAGGAACATCAAGA
	AATCEE ATGAACAACTTTGGTAATGAAGAGTTTGACTGCCACTTCCTCGATGAAGGTTTT
	ACTGCCAAGGACATTCTGGACCAGAAAATTAATGAAGTTTCTTCTTCTGATGATAAGG
	ATGCCTTCTATGTGGCAGACCTGGGAGACATTCTAAAGAAACATCTGAGGTGGTTAAA
	AGCTCTCCCTCGTGTCACCCCCTTTTATGCAGTCAAATGTAATGATAGCAAAGCCATC
	GTGAAGACCCTTGCTGCTACCGGGACAGGATTTGACTGTGCTAGCAAGACTGAAATAC
	AGTTGGTGCACAGTCTGGGGGTGCCTCCAGAGAGGATTATCTATGCAAATCCTTGTAA
	ACAAGTATCTCAAATTAAGTATGCTGCTAATAATGGAGTCCAGATGATGACTTTTGAT
	AGTGAAGTTGAGTTGATGAAAGTTGCCAGAGCACATCCCAAAGCAAAGTTGGTTTTGC
	CGATTGCCACTGATGATTCCAAAGCAGTCTGTCGTCTCAGTGTGAAATTCGGTGCCAC
	GCTCAGAACCAGCAGCCTCCTTTTGGAACGGGCGAAAGAGCTAAATATCGATGTTGTT
	GGTGTCAGCTTCCATGTAGGAAGCGGCTGTACCGATCCTGAGACCTTCGTGCAGGCAA
	TCTCTGATGCCCGCTGTGTTTTTGACATGGGGGCTGAGGTTGGTTTCAGCATGTATCT
	GCTTGATATTGGCGGTGGCTTTCCTCGATCTGAGGATGTGAAACTTAAATTTGAAGAG
	ATCACCGGCGTAATCAACCCAGCGTTGGACAAATACTTTCCGTCAGACTCTGGAGTGA
	GAATCATAGCTGACCCCGGCAGATACTATGTTGCATCAGCTTTCACGCTTGCAGTTAA
	TATCATTGCCAAGAAAATTGTATTAAAGGAACAGACGGGCTCTGATGACGAAGATGAG
	TCGAGTGAGCAGACCTTTATGTATTATGTGAATGATGGCGTCTATGGATCATTTAATT
	GCATACTCTATGACCACGCACATGTAAAGCCCCTTCTGCAAAAGAGACCTAAACCAGA
	TGAGAAGTATTATTCATCCAGCATATGGGGACCAACATGTGATGGCCTCGATCGGATT
	GTTGAGCGCTGTGACCTGCCTGAAATGCATGTGGGTGATTGGATGCTCTTTGAAAACA
	TGGGCGCTTACACTGTTGCTGCTGCCTCTACGTTCAATGGCTTCCAGAGGCCGACGAT
	CTACTATGTGATGTCAGGGCCTGCGTGGCAACTCATGCAGCAATTCCAGAACCCCGAC
	TTCCCACCCGAAGTAGACGAACAGGATGCCAGCACCCTGCCTGTGTCTTGTGCCTGGG
	AGAGTGGGATGAAACGCCACAGAGCAGCCTGTGCTTCGGCTAGTATTAATGTGTAGAT
	AGCACTCTGGTAGCTGTTAACTGCAAGTTTAGCTTGAATTAAGGGATTTGGGGGGACC
	ATGTAACTTAATTACTGCTAGTTTTGAAATGTCTTTGTAAGAGTAGGGTCGCCATGAT
	GCAGCCATATGGAAGACTAGGATATGGGTCACACTTATCTGTGTTCCTATGGAAACTA
	TTTGAATATTTGTTTTATATGGATTTTTATTCACTCTTCAGACACGCTACTCAAGAGT
	GCCCCTCAGCTGCTGAACAAGCATTTGTAGCTTGTACAATGGCAGAATGGGCCAAAAG
	CTTAGTGTTGTGACCTGTTTTTAAAATAAAGTATCTTGAAATAACAAAAAAAAAAAAA
	GGGGGGCCGCCCTAGGGGTTCCCAAGTTTACGTACGCTGCATGG
	ORF Start: ATG at 179		ORF Stop: TAG at 1562
	SEQ ID NO:112	461 aa	MW at 51147.6 kD
NOV10b,	MNNFGNEEFDCHFLDEGFTAKDILDQKINEVSSSDDKDAFYVADLGDILKKHLRWLKA
CG124907-01
Protein Sequence	LPRVTPFYAVKCNDSKAIVKTLAATGTGFDCASKTEIQLVQSLGVPPERIIYANPCKQ
	VSQTKYAANNGVQMMTFDSEVELMKVARAHPKAKLVLRIATDDSKAVCRLSVKFGATL
	RTSRLLLERAKELNIDVVGVSFHVGSGCTDPETFVQAISDARCVFDMGAEVGFSMYLL
	DIGGGFPGSEDVKLKFEEITGVINPALDKYFPSDSGVRIIAEPGRYYVASAFTLAVNI
	IAKKIVLKEQTGSDDEDESSEQTFMYYVNDGVYGSFNCILYDHAHVKPLLQKRPKPDE
	KYYSSSTWGPTCDGLDRIVERCDLPEMHVGDWMLFEMMGAYTVAAASTFNGFQRPTIY
	YVMSGPAWQLMQQFQNPDFPPEVEEQDASTLPVSCAWESGMKRHRAACASASINV
	SEQ ID NO:113	1416 bp
NOV10c,	CGCGGATCCACCATGAACAACTTTGGTAATGAAGAGTTTGACTGCCACTTCCTCGATG
254048022 DNA
Sequence	AAGGTTTTACTCCCAAGGACATTCTGGACCAGAAAATTAATGAAGTTTCTTCTTCTGA
	TGATAAGGATGCCTTCTATGTGGCAGACCTGGGAGACATTCTAAAGAAACATCTGAGG
	TGGTTAAAAGCTCTCCCTCGTGTCACCCCCTTTTATGCAGTCAAATGTAATGATAGCA
	AAGCCATCGTGAAGACCCTTGCTGCTACCGGGACAGGATTTGACTGTGCTAGCAAGAC
	TGAAATACAGTTGGTGCAGAGTCTGGGGGTGCCTCCAGAGAGGATTATCTATGCAAAT
	CCTTGTAAACAAGTATCTCAAATTAAGTATGCTGCTAATAATGGAGTCCAGATGATGA
	CTTTTGATAGTGAAGTTGAGTTGATGAAAGTTGCCAGAGCACATCCCAAAGCAAAGTT
	GGTTTTGCGGATTGCCACTGATGATTCCAAAGCAGTCTGTCGTCTCAGTGTGAAATTC
	GGTGCCACGCTCAGAACCAGCAGGCTCCTTTTGGAACGGGCGAAAGAGCTAAATATCG
	ATGTTGTTGGTGTCAGCTTCCATGTAGGAAGCGGCTGTACCGATCCTGAGACCTTCGT
	GCAGGCAATCTCTGATGCCCGCTGTGTTTTTGACATGGGGGCTGAGGTTGGTTTCAGC
	ATGTATCTGCTTGATATTGGCGGTGGCTTTCCTGGATCTGAGGATGTGAAACTTAAAT
	TTGAAGAGATCACCGGCGTAATCAACCCAGCGTTGGACAAATACTTTCCGTCAGACTC
	TGGAGTGAGAATCATAGCTGAGCCCGGCAGATACTATGTTGCATCAGCTTTCACGCTT
	GCAGTTAATATCATTGCCAAGAAAATTGTATTAAAGGAACAGACGGGCTCTGATGACG
	AAGATGAGTCGAGTGAGCAGACCTTTATGTATTATGTGAATGATGGCGTCTATGGATC
	ATTTAATTGCATACTCTATGACCACGCACATGTAAAGCCCCTTCTGCAAAAGAGACCT
	AAACCAGATGAGAAGTATTATTCATCCAGCATATGGGGACCAACATGTGATGGCCTCG
	ATCGGATTGTTGAGCGCTGTGACCTGCCTGAAATGCATGTGGGTCATTGGATGCTCTT
	TGAAAACATGGGCGCTTACACTGTTGCTCCTGCCTCTACGTTCAATGGCTTCCAGAGG
	CCGACGATCTACTATGTGATGTCAGCGCCTGCGTGGCAACTCATGCAGCAATTCCAGA
	ACCCTGACTTCCCACCCGAAGTAGAGCAACAGGATGCCAGCACCCTGCCTGTGTCTTG
	TGCCTGGGAGAGTGGGATGAAACGCCACAGAGCAGCCTGTGCTTCGGCTAGTATTAAT
	GTGTAGGCGGCCGCTTTTTTCCTT
	ORF Start: at 1		ORF Stop: TAG at 1396
	SEQ ID NO:114	465 aa	MW at 51549.0 kD
NOV10c,	RGSTMNNFGNEEFDCHFLDEGFTAKDILDQKINEVSSSDDKDAFYVADLGDILKKHLR
254048022
Protein Sequence	WLKALPRVTPFYAVKCNDSKAIVKTLAATGTGFDCASKTEIQLVQSLGVPPERIIYAN
	PCKQVSQIKYAANNGVQMMTFDSEVELMKVARAHPKAKLVLRIATDDSKAVCRLSVKF
	GATLRTSRLLLERAKELNIDVVGVSFHVGSGCTDPETFVQAISDARCVFDMGAEVGFS
	MYLLDIGGGFPGSEDVKLKFEEITGVINPALDKYFPSDSGVRIIAEPCRYYVASAFTL
	AVNIIAKKIVLKEQTGSDDEDESSEQTFMYYVNDGVYGSFNCILYDHAHVKPLLQKRP
	KPDEKYYSSSIWGPTCDGLDRIVERCDLPEMHVGDWMLFENNGAYTVAAASTFNGFQR
	PTIYYVMSGPAWQLMQQFQNPDFPPEVEEQDASTLPVSCAWESGMKRHRAACASASIN
V
	SEQ ID NO:115	1410 bp
NOV10d,	ACCATGGGCCACCATCACCACCATCACAACAACTTTGGTAATGAAGAGTTTGACTGCC
258252457 DNA
Sequence	ACTTCCTCGATGAAGGTTTTACTGCCAAGGACATTCTGGACCAGAAAATTAATGAAGT
	TTCTTCTTCTGATGATAAGGATGCCTTCTATGTGGCAGACCTGGGAGACATTCTAAAG
	AAACATCTGAGGTGGTTAAAAGCTCTCCCTCGTGTCACCCCCTTTTATGCAGTCAAAT
	GTAATGATAGCAAAGCCATCGTGAAGACCCTTGCTGCTACCGGGACAGGATTTGACTG
	TGCTAGCAAGACTGAAATACAGTTGGTGCAGAGTCTGGGGGTGCCTCCAGAGAGGATT
	ATCTATGCAAATCCTTGTAAACAAGTATCTCAAATTAAGTATGCTGCTAATAATGGAG
	TCCAGATGATGACTTTTGATAGTGAAGTTGAGTTGATGAAAGTTGCCAGAGCACATCC
	CAAAGCAAAGTTGGTTTTGCGGATTGCCACTGATGATTCCAAAGCAGTCTGTCGTCTC
	AGTGTGAAATTCGGTGCCACGCTCAGAACCAGCAGGCTCCTTTTGGAACGGGCGAAAG
	AGCTAAATATCGATGTTGTTGGTGTCAGCTTCCATGTAGGAAGCGGCTGTACCGATCC
	TGAGACCTTCGTGCAGGCAATCTCTGATGCCCGCTGTGTTTTTGACATGGGGGCTGAG
	GTTGGTTTCAGCATGTATCTGCTTGATATTGGCGGTGGCTTTCCTGGATCTGAGGATG
	TGAAACTTAAATTTGAAGAGATCACCGGCGTAATCAACCCAGCGTTGGACAAATACTT
	TCCGTCAGACTCTGGAGTGAGAATCATAGCTGAGCCCGGCAGATACTATGTTGCATCA
	GCTTTCACGCTTGCAGTTAATATCATTGCCAAGAAAATTGTATTAAAGGAACAGACGG
	GCTCTGATGACGAAGATGAGTCGAGTGAGCAGACCTTTATGTATTATGTGAATGATGG
	CGTCTATGGATCATTTAATTGCATACTCTATGACCACGCACATGTAAAGCCCCTTCTG
	CAAAAGAGACCTAAACCAGATGAGAAGTATTATTCATCCAGCATATGGGGACCAACAT
	GTGATGGCCTCGATCGGATTGTTGAGCGCTGTGACCTGCCTGAAATGCATGTGGGTGA
	TTGGATGCTCTTTGAAAACATGGGCGCTTACACTGTTGCTGCTGCCTCTACGTTCAAT
	GGCTTCCAGAGGCCGACGATCTACTATGTGATGTCAGGGCCTGCGTGGCAACTCATGC
	ACCAATTCCAGAACCCTGACTTCCCACCCGAAGTAGAGGAACAGGATGCCACCACCCT
	GCCTGTGTCTTGTGCCTGGGAGAGTGGGATGAAACGCCACAGAGCAGCCTGTGCTTCG
	GCTAGTATTAATGTGTAG
	ORF Start: at 1		ORF Stop: TAG at 1408
	SEQ ID NO:116	469 aa	MW at 52128.6 kD
NOV10d,	TMGHHHHHHNNFGNEEFDCHFLDEGFTAKDILDQKINEVSSSDDKDAFYVADLGDILK
258252457
Protein Sequence	KHLRWLKALPRVTPFYAVKCNDSKAIVKTLAATGTGFDCASKTEIQLVQSLGVPPERI
	IYANPCKQVSQIKYAANNGVQMMTFDSEVELMKVARAHPKAKLVLRIATDDSKAVCRL
	SVKFGATLRTSRLLLERAKELNIDVVGVSFHVGSGCTDPETFVQAISDARCVFDMGAE
	VGFSMYLLDIGGGFPGSEDVKLKFEEITGVINPALDKYFPSDSGVRIIAEPGRYYVAS
	AFTLAVNIIAKKIVLKEQTGSDDEDESSEQTFMYYVNDGVYGSFNCILYDHAHVKPLL
	QKRPKPDEKYYSSSIWGPTCDGLDRIVERCDLPEMHVGDWMLFENMGAYTVAAASTFN
	GFQRPTIYYVMSGPAWQLMQQFQNPDFPPEVEEQDASTLPVSCAWESGMKRHRAACAS
	ASINV
	SEQ ID NO:117	1407 bp
NOV10e,	ACCATGAACAACTTTGGTAATGAAGAGTTTGACTGCCACTTCCTCCATGAAGGTTTTA
258280014 DNA
Sequence	CTGCCAAGGACATTCTGGACCAGAAAATTAATGAAGTTTCTTCTTCTGATGATAAGGA
	TGCCTTCTATGTGGCAGACCTGGGAGACATTCTAAAGAAACATCTGACGTGGTTAAAA
	GCTCTCCCTCGTGTCACCCCCTTTTATGCAGTCAAATGTAATGATAGCAAAGCCATCG
	TGAAGACCCTTGCTGCTACCGGGACAGGATTTGACTGTGCTAGCAAGACTGAAATACA
	GTTGGTGCAGAGTCTGGGGGTGCCTCCAGAGAGGATTATCTATGCAAATCCTTGTAAA
	CAAGTATCTCAAATTAAGTATGCTGCTAATAATGGAGTCCAGATGATGACTTTTGATA
	GTGAAGTTGAGTTGATGAAAGTTGCCAGAGCACATCCCAAAGCAAAGTTGGTTTTGCG
	GATTGCCACTGATGATTCCAAAGCAGTCTGTCGTCTCAGTGTGAAATTCGGTGCCACG
	CTCAGAACCAGCAGGCTCCTTTTGGAACGGGCGAAAGAGCTAAATATCGATGTTGTTG
	GTGTCAGCTTCCATGTAGGAACCGGCTGTACCGATCCTGAGACCTTCGTGCAGGCAAT
	CTCTGATGCCCGCTGTGTTTTTGACATGGGGGCTGAGGTTGGTTTCAGCATGTATCTG
	CTTGATATTGGCGGTGGCTTTCCTGGATCTGAGGATGTGAAACTTAAATTTGAAGAGA
	TCACCGGCGTAATCAACCCAGCGTTGGACAAATACTTTCCGTCAGACTCTGGAGTGAG
	AATCATAGCTGAGCCCGGCAGATACTATGTTGCATCAGCTTTCACGCTTGCAGTTAAT
	ATCATTGCCAAGAAAATTGTATTAAAGGAACAGACGGGCTCTGATGACCAAGATGAGT
	CGAGTGAGCAGACCTTTATGTATTATGTGAATGATGGCGTCTATGGATCATTTAATTG
	CATACTCTATGACCACGCACATGTAAAGCCCCTTCTGCAAAAGAGACCTAAACCAGAT
	GAGAAGTATTATTCATCCAGCATATGGGGACCAACATGTGATGGCCTCGATCGGATTG
	TTGAGCGCTGTGACCTGCCTGAAATGCATGTGGGTGATTGGATGCTCTTTGAAAACAT
	GGGCGCTTACACTGTTGCTGCTGCCTCTACGTTCAATGGCTTCCAGAGGCCGACGATC
	TACTATGTGATGTCAGGGCCTGCGTGGCAACTCATGCAGCAATTCCAGAACCCTGACT
	TCCCACCCGAAGTAGAGGAACAGGATGCCAGCACCCTGCCTGTGTCTTGTGCCTGGGA
	GAGTGGGATGAAACGCCACAGAGCAGCCTGTGCTTCGGCTAGTATTAATGTGCACCAT
	CACCACCATCACTGA
	ORF Start: at 1		ORF Stop: TGA at 1405
	SEQ ID NO:118	468 aa	MW at 5207l.6 kD
NOV10e,	TMNNFGNEEFDCHFLDEGFTAKDILDQKINEVSSSDDKDAFYVADLGDILKKHLRWLK
258280014
Protein Sequence	ALPRVTPFYAVKCNDSKAIVKTLAATGTGFDCASKTEIQLVQSLGVPPERIIYANPCK
	QVSQIKYAANNGVQMMTFDSEVELMKVARAHPKAKLVLRIATDDSKAVCRLSVKFGAT
	LRTSRLLLERAKELNIDVVGVSFHVGSGCTDPETFVQAISDARCVFDMGAEVGFSMYL
	LDIGGGFPGSEDVKLKFEEITGVINPALDKYFPSDSGVRIIAEPGRYYVASAFTLAVN
	IIAKKIVLKEQTGSDDEDESSEQTFMYYVNDGVYGSFNCILYDHAHVKPLLQKRPKPD
	EKYYSSSIWGPTCDGLDRIVERCDLPEMHVGDWMLFENMGAYTVAAASTFNGFQRPTI
	YYVMSGPAWQLMQQFQNPDFPPEVEEQDASTLPVSCAWESGMKRHRAACASASINVHH
	HHHH
	SEQ ID NO:119	1434 bp
NOV10f,	CACCATCACCACCATCACAACAACTTTGGTAATGAAGAGTTTGACTGCCACTTCCTCG
258330318 DNA
Sequence	ATGAAGGTTTTACTGCCAAGGACATTCTGGACCAGAAAATTAATGAAGTTTCTTCTTC
	TGATGATAAGGATGCCTTCTATGTGGCAGACCTGGGAGACATTCTAAAGAAACATCTG
	AGGTGGTTAAAAGCTCTCCCTCGTGTCACCCCCTTTTATGCAGTCAAATGTAATGATA
	GCAAAGCCATCGTCAAGACCCTTGCTGCTACCGGGACAGGATTTGACTGTGCTAGCAA
	GACTGAAATACAGTTGGTGCAGAGTCTGGGGGTGCCTCCAGAGAGGATTATCTATGCA
	AATCCTTCTAAACAAGTATCTCAAATTAAGTATGCTGCTAATAATGGAGTCCAGATGA
	TGACTTTTGATAGTGAAGTTGAGTTGATGAAAGTTGCCAGAGCACATCCCAAAGCAAA
	GTTGGTTTTGCGGATTGCCACTGATGATTCCAAAGCAGTCTGTCGTCTCAGTGTGAAA
	TTCGGTGCCACGCTCAGAACCAGCAGGCTCCTTTTGGAACGGGCGPAAGAGCTAAATA
	TCGATGTTGTTGGTGTCAGCTTCCATGTAGGAAGCGGCTGTACCGATCCTGAGACCTT
	CGTGCAGGCAATCTCTGATGCCCGCTGTGTTTTTGACATGGCGGCTGAGGTTGGTTTC
	AGCATGTATCTGCTTGATATTGGCGGTGGCTTTCCTGGATCTGAGGATGTGAAACTTA
	AATTTGAAGAGATCACCGGCGTAATCAACCCAGCGTTGGACAAATACTTTCCGTCAGA
	CTCTGGAGTGAGAATCATAGCTGAGCCCGGCAGATACTATGTTGCATCAGCTTTCACG
	CTTGCAGTTAATATCATTGCCAAGAAAATTGTATTAAAGGAACAGACGGGCTCTGATG
	ACGAAGATGAGTCGAGTGAGCAGACCTTTATGTATTATGTGAATGATGGCGTCTATGG
	ATCATTTAATTGCATACTCTATGACCACGCACATGTAAAGCCCCTTCTGCAAAAGAGA
	CCTAAACCAGATGAGAAGTATTATTCATCCAGCATATGGGGACCAACATGTGATGGCC
	TCGATCGGATTGTTGAGCGCTGTGACCTGCCTGAAATGCATGTGGGTGATTGGATGCT
	CTTTGAAAACATGGGCGCTTACACTGTTGCTGCTGCCTCTACGTTCAATGGCTTCCAG
	AGGCCGACGATCTACTATGTGATGTCAGGGCCTGCGTGGCAACTCATGCAGCAATTCC
	AGAACCCTGACTTCCCACCCGAAGTAGAGGAACAGGATGCCAGCACCCTGCCTGTGTC
	TTGTGCCTGGGAGAGTGGGATGAAACGCCACAGAGCAGCCTGTGCTTCGGCTAGTATT
	AATGTGTAGGCGCCCGCACTCGAGCACCACCACCACCACCAC
	ORF Start: at 1		ORF Stop: TAG at 1399
	SEQ ID NO:120	466 aa	MW at 51839.3 kD
NOV10f	HHHHNHNNFGNEEFDCHFLDEGFTAKDILDQKINEVSSSDDKDAFYVADLGDILKKHL
258330318
Protein Sequence	RWLKALPRVTPFYAVKCNDSKAIVKTLAATGTGFDCASKTEIQLVQSLGVPPERIIYA
	NPCKQVSQTKYAANNGVQMMTFDSEVELMKVARAHPKAKLVLRIATDDSKAVCRLSVK
	FGATLRTSRLLLERAKELNIDVVGVSFHVGSGCTDPETFVQAISDARCVFDMGAEVGF
	SMYLLDIGGGFPGSEDVKLKFEEITGVINPALDKYFPSDSGVRIIAEPGRYYVASAFT
	LAVNIIAKKIVLKEQTGSDDEDESSEQTFMYYVNDGVYGSFNCILYDHAHVKPLLQKR
	PKPDEKYYSSSIWGPTCDGLDRIVERCDLPEMHVGDWMLFENMGAYTVAAASTFNGFQ
	RPTIYYVMSGPAWQLMQQFQNPDFPPEVEEQDASTLPVSCAWESGMKRHRAACASASI
	NV
	SEQ ID NO:121	1305 bp
NOV10g,	ACATCATCACCACCATCAAACAACTTTGGTAATGAAGAGTTTCACTGCCACTTCCTCG
258330346 DNA
Sequence	ATGAAGGTTTTACTGCCAACGACATTCTGGACCAGAAAATTAATGAAGTTTCTTCTTC
	TGATGATAAGGATGCCTTCTATGTGGCAGACCTGGGAGACATTCTAAAGAAACATCTG
	AGGTGGTTAAAAGCTCTCCCTCGTGTCACCCCCTTTTATGCAGTCAAATGTAATGATA
	GCAAAGCCATCGTGAAGACCCTTGCTGCTACCGGGACAGGATTTGACTGTGCTAGCAA
	GACTGAAATACAGTTGGTGCAGAGTCTGGGGGTGCCTCCAGAGAGGATTATCTATGCA
	AATCCTTGTAAACAAGTATCTCAAATTAAGTATGCTGCTAATAATGGAGTCCAGATGA
	TGACTTTTGATAGTGAAGTTGAGTTGATGAAAGTTGCCAGAGCACATCCCAAAGCAAA
	GTTGGTTTTGCGGATTGCCACTGATGATTCCAAAGCAGTCTGTCGTCTCAGTGTGAAA
	TTCGGTGCCACGCTCAGAACCAGCAGGCTCCTTTTGGAACGGGCGAAAGAGCTAAATA
	TCGATGTTGTTGGTGTCAGCTTCCATGTAGGAAGCGGCTGTACCGATCCTGAGACCTT
	CGTGCAGGCAATCTCTGATGCCCGCTGTGTTTTTGACATGGGGGCTGAGGTTGGTTTC
	AGCATGTATCTGCTTGATATTGGCGGTGGCTTTCCTGGATCTGAGGATGTGAAACTTA
	AATTTGAAGAGATCACCGGCGTAATCAACCCAGCGTTGGACAAATACTTTCCGTCAGA
	CTCTGGAGTGAGAATCATAGCTGAGCCCGGCAGATACTATGTTGCATCAGCTTTCACG
	CTTGCAGTTAATATCATTGCCAAGAAAATTGTATTAAAGGAACAGACGGGCTCTGATG
	ACGAAGATGAGTCGAGTGAGCAGACCTTTATGTATTATGTGAATGATGGCGTCTATGG
	ATCATTTAATTGCATACTCTATGACCACGCACATGTAAAGCCCCTTCTGCAAAAGAGA
	CCTAAACCAGATGAGAAGTATTATTCATCCAGCATATGGGGACCAACATGTGATGGCC
	TCGATCGGATTGTTGAGCGCTGTGACCTGCCTGAAATGCATGTGGGTGATTGGATGCT
	CTTTGAAAACATGGGCGCTTACACTGTTGCTGCTGCCTCTACGTTCAATGGCTTCCAG
	AGGCCGACGATCTACTATGTGATGTCAGGGCCTGCGTGGCAACTCATGCAGTAGGCGG
	CCGCACTCGAGCACCACCACCACCACCAC
	ORF Start: at 1		ORF Stop: TAG at 1270
	SEQ ID NO:122	423 aa	MW at 46885.9 kD
NOV10g,	TSSPPSNNFGNEEFDCHFLDEGFTAKDILDQKIMEVSSSDDKDAFYVADLGDILKKHL
258330346
Protein Sequence	RWLKALPRVTPFYAVKCNDSKAIVKThAATGTGFDCASKTEIQLVQSLGVPPERIIYA
	NPCKQVSQIKYAANNGVQMMTFDSEVELMKVARAHPKAKLVLRIATDDSKAVCRLSVK
	FGATLRTSRLLLERAKELNIDVVGVSFHVGSGCTDPETFVQAISDARCVFDMGAEVGF
	SMYLLDIGGGFPGSEDVKLKFEEITGVINPALDKYFPSDSGVRIIAEPGRYYVASAFT
	LAVNIIAKKIVLKEQTGSDDEDESSEQTFMYYVNDGVYGSFNCILYDHAHVKPLLQKR
	PKPDEKYYSSSIWGPTCDGLDRIVERCDLPEMHVGDWMLFENMGAYTVAAASTFNGFQ
	RPTIYYVMSGPAWQLMQ
	SEQ ID NO:123	1389 bp
NOV10h,	ACCATGAACAACTTTGGTAATGAAGAGTTTGACTGCCACTTCCTCGATGAAGGTTTTA
258330472 DNA
Sequence	CTGCCAAGGACATTCTGGACCAGAAAATTAATGAAGTTTCTTCTTCTGATGATAAGGA
	TGCCTTCTATGTGGCAGACCTGGGAGACATTCTAAAGAAACATCTGAGGTGGTTAAAA
	GCTCTCCCTCGTGTCACCCCCTTTTATGCAGTCAAATGTAATGATAGCAAAGCCATCG
	TGAAGACCCTTGCTGCTACCGGGACAGGATTTGACTGTGCTAGCAAGACTGAAATACA
	GTTGGTGCAGAGTCTGGGGGTGCCTCCAGAGAGGATTATCTATGCAAATCCTTGTAAA
	CAAGTATCTCAAATTAAGTATGCTGCTAATAATGGAGTCCAGATGATGACTTTTGATA
	GTGAAGTTGAGTTGATGAAAGTTGCCAGAGCACATCCCAAAGCAAAGTTGGTTTTGCG
	GATTGCCACTGATGATTCCAAAGCAGTCTGTCGTCTCAGTGTGAAATTCGGTGCCACG
	CTCAGAACCAGCAGGCTCCTTTTGCAACGGGCGAAAGAGCTAAATATCGATGTTGTTG
	GTGTCAGCTTCCATGTAGGAAGCGGCTGTACCGATCCTGAGACCTTCGTGCAGGCAAT
	CTCTGATGCCCGCTGTGTTTTTGACATGGGGGCTGAGGTTGGTTTCAGCATGTATCTG
	CTTGATATTGGCGGTGGCTTTCCTGGATCTGAGGATGTGAAACTTAAATTTGAAGAGA
	TCACCGGCGTAATCAACCCAGCGTTGGACAAATACTTTCCGTCAGACTCTGGAGTGAG
	AATCATAGCTGAGCCCGGCAGATACTATGTTGCATCAGCTTTCACGCTTGCAGTTAAT
	ATCATTGCCAAGAAAATTGTATTAAAGGAACAGACGGGCTCTCATGACGAAGATGAGT
	CGAGTGAGCAGACCTTTATGTATTATGTGAATGATGGCGTCTATGGATCATTTAATTG
	CATACTCTATGACCACGCACATGTAAAGCCCCTTCTGCAAAAGAGACCTAAACCAGAT
	GAGAAGTATTATTCATCCAGCATATGGGGACCAACATGTGATGGCCTCGATCGGATTG
	TTGAGCGCTGTGACCTGCCTGAAATGCATGTGGGTGATTGGATCCTCTTTGAAAACAT
	GGGCGCTTACACTGTTGCTGCTGCCTCTACGTTCAATGGCTTCCAGAGGCCGACGATC
	TACTATGTGATGTCAGGGCCTGCGTGGCAACTCATGCAGCAATTCCAGAACCCTGACT
	TCCCACCCGAAGTAGAGGAACAGGATGCCAGCACCCTGCCTGTGTCTTGTGCCTGGGA
	GAGTGGGATGAAACGCCACAGAGCAGCCTGTGCTTCGGCTAGTATTAATGTGTAG
	ORF Start: at 1		ORF Stop: TAG at 1387
	SEQ ID NO:124	462 aa	MW at 51248.7 kD
NOV10h,	TMNNFGNEEFDCHFLDEGFTAKDILDQKINEVSSSDDKDAFYVADLGDILKKHLRWLK
258330472
Protein Sequence	ALPRVTPFYAVKCNDSKAIVKTLAATGTGFDCASKTEIQLVQSLGVPPERIIYANPCK
	QVSQIKYAANNGVQMMTFDSEVELMKVARAHPKAKLVLRIATDDSKAVCRLSVKFGAT
	LRTSRLLLERAKELNIDVVGVSFHVGSGCTDPETFVQAISDARCVFDMGAEVGFSMYL
	LDIGCGFPGSEDVKLKFEEITGVINPALDKYFPSDSGVRIIAEPGRYYVASAFTLAVN
	IIAKKIVLKEQTGSDDEDESSEQTFMYYVNDGVYGSFNCILYDHAHVKPLLQKRPKPD
	KYYSSSIWGPTCDGLDRIVERCDLPEMHVGDWMLFENMGAYTVAAASTFNGFQRPTIY
	YYVMSGPAWQLMQQFQNPDFPPEVEEQDASTLPVSCAWESGMKRHRAACASASINV
	SEQ ID NO:125	1386 bp
NOV10i	CATGAACAACTTTGGTAATGAAGAGTTTGACTGCCACTTCCTCGATGAAGGTTTTACT
258330611 DNA
Sequence	GCCAAGGACATTCTGGACCAGAAAATTAATGAAGTTTCTTCTTCTGATGATAAGGATG
	CCTTCTATGTGGCAGACCTGGGAGACATTCTAAAGAAACATCTGAGGTGGTTAAAAGC
	TCTCCCTCGTGTCACCCCCTTTTATGCAGTCAAATGTAATGATAGCAAAGCCATCGTG
	AAGACCCTTGCTGCTACCGGGACAGGATTTGACTGTGCTAGCAAGACTGAAATACAGT
	TGGTGCAGAGTCTCGGGGTGCCTCCAGAGAGGATTATCTATGCAAATCCTTGTAAACA
	AGTATCTCAAATTAAGTATGCTGCTAATAATGGAGTCCAGATGATGACTTTTGATAGT
	GAAGTTGAGTTGATGAAAGTTGCCAGAGCACATCCCAAAGCAAAGTTGGTTTTGCGGA
	TTGCCACTGATGATTCCAAAGCAGTCTGTCGTCTCAGTGTGAAATTCGGTGCCACGCT
	CAGAACCAGCAGGCTCCTTTTGGAACGGGCGAAAGAGCTAAATATCGATGTTGTTGGT
	GTCAGCTTCCATGTAGGAAGCGGCTGTACCCATCCTGAGACCTTCGTGCAGGCAATCT
	CTGATGCCCGCTGTGTTTTTGACATGGGGGCTGAGGTTGGTTTCAGCATGTATCTGCT
	TGATATTGGCGGTGGCTTTCCTGGATCTGAGGATGTGAAACTTAAATTTGAAGAGATC
	ACCGGCGTAATCAACCCAGCGTTGGACAAATACTTTCCGTCAGACTCTGGAGTGAGAA
	TCATAGCTGAGCCCGGCAGATACTATGTTCCATCAGCTTTCACGCTTCCAGTTAATAT
	CATTCCCAAGAAAATTGTATTAAAGGAACAGACGGGCTCTGATGACGAAGATGAGTCG
	AGTGAGCAGACCTTTATGTATTATGTGAATGATGGCGTCTATGGATCATTTAATTGCA
	TACTCTATGACCACGCACATGTAAAGCCCCTTCTGCAAAAGAGACCTAAACCAGATGA
	GAAGTATTATTCATCCAGCATATGGGGACCAACATGTGATGGCCTCGATCGGATTGTT
	GAGCGCTGTGACCTGCCTGAAATGCATGTGGGTGATTGGATGCTCTTTGAAAACATGG
	GCGCTTACACTGTTGCTGCTGCCTCTACGTTCAATGGCTTCCAGAGGCCGACGATCTA
	CTATGTGATGTCAGGGCCTGCGTGGCAACTCATGCAGCAATTCCAGAACCCTGACTTC
	CCACCCGAAGTAGAGGAACAGGATGCCAGCACCCTGCCTGTGTCTTGTGCCTGGGAGA
	GTGGGATGAAACGCCACAGAGCAGCCTGTGCTTCGGCTAGTATTAATGTGTA
	ORF Start: ATG at 2		ORF Stop: end of
			sequence
	SEQ ID NO:126	1462 aa	MW at 51147.6 kD
NOV10I,	MNNFGNEEFDCHFLDEGFTAKDILDQKINEVSSSDDKDAFYVADLGDILKKHLRWLKA
258330611
Protein Sequence	LPRVTPFYAVKCNDSKAIVKTLAATGTGFDCASKTEIQLVQSLGVPPERIIYANPCKQ
	VSQIKYAANNGVQMMTFDSEVELMKVARAHPKAKLVLRIATDDSKAVCRLSVKFGATL
	RTSRLLLERAKELNIDVVGVSFHVGSGCTDPETFVQAISDARCVFDMGAEVGFSMYLL
	DIGGGFPGSEDVKLKFEEITGVINPALDKYFPSDSGVRIIAEPGRYYVASAFTLAVNI
	IAKKIVLKEQTGSDDEDESSEQTFMYYVNDGVYGSFNCILYDHAHVKPLLQKRPKPDE
	KYYSSSIWGPTCDGLDRIVERCDLPEMHVGDWMLFENMGAYTVAAASTFNGFQRPTIY
	YVMSGPAWQLMQQFQNPDFPPEVEEQDASTLPVSCAWESGMKRHPAACASASINVX
	SEQ ID NO:127	1305 bp
NOV10j,	CACCATCACCACCATCACAACAACTTTGGTAATGAAGAGTTTGACTGCCACTTCCTCG
260481330 DNA
Sequence	ATGAAGGTTTTACTGCCAAGGACATTCTGGACCAGAAAATTAATGAAGTTTCTTCTTC
	TGATGATAAGGATGCCTTCTATGTGGCAGACCTGGGAGACATTCTAAAGAAACATCTG
	AGGTGGTTAAAAGCTCTCCCTCGTGTCACCCCCTTTTATGCAGTCAAATGTAATGATA
	GCAAAGCCATCGTGAAGACCCTTCCTGCTACCGGGACAGGATTTGACTGTGCTAGCAA
	GACTGAAATACAGTTGGTGCAGAGTCTGGGGGTGCCTCCAGAGAGGATTATCTATGCA
	AATCCTTGTAAACAAGTATCTCAAATTAAGTATGCTGCTAATAATGGAGTCCAGATGA
	TGACTTTTGATAGTGAAGTTGAGTTGATGAAAGTTGCCAGAGCACATCCCAAAGCAAA
	GTTGGTTTTGCGGATTGCCACTGATGATTCCAAAGCAGTCTGTCGTCTCAGTGTGAAA
	TTCGGTGCCACGCTCAGAACCAGCAGGCTCCTTTTGGAACGGGCGAAAGAGCTAAATA
	TCGATGTTGTTGGTGTCAGCTTCCATGTAGCAAGCGGCTGTACCGATCCTGAGACCTT
	CGTGCAGGCAATCTCTGATGCCCGCTGTGTTTTTGACATGGGGGCTGAGGTTGGTTTC
	AGCATGTATCTGCTTGATATTGGCGGTGGCTTTCCTGGATCTGAGGATGTGAAACTTA
	AATTTGAAGAGATCACCGGCGTAATCAACCCAGCGTTGGACAAATACTTTCCGTCAGA
	CTCTGGAGTGAGAATCATAGCTGAGCCCGGCAGATACTATGTTGCATCAGCTTTCACG
	CTTGCAGTTAATATCATTGCCAAGAAAATTGTATTAAAGGAACAGACGGGCTCTGATG
	ACGAAGATGAGTCGAGTGAGCAGACCTTTATGTATTATGTGAATGATGGCGTCTATGG
	ATCATTTAATTGCATACTCTATGACCACGCACATGTAAAGCCCCTTCTGCAAAAGAGA
	CCTAAACCAGATGAGAAGTATTATTCATCCAGCATATGGGGACCAACATGTGATGGCC
	TCGATCGGATTGTTGAGCGCTGTGACCTGCCTGAAATGCATGTGGGTGATTGGATGCT
	CTTTGAAAACATGGGCGCTTACACTGTTGCTGCTGCCTCTACGTTCAATGGCTTCCAG
	AGGCCGACGATCTACTATGTGATGTCAGGGCCTCCGTGGCAACTCATGCAGTAGGCGG
	CCGCACTCGAGCACCACCACCACCACCAC
	ORF Start: at 1		ORF Stop: TAG at 1270
	SEQ ID NO:128	423 aa	MW at 47152.2 kD
NOV10j,	HHHHHHNNFGNEEFDCHFLDEGFTAKDILDQKINEVSSSDDKDAFYVADLGDILKKHL
260481330
Protein Sequence	RWLKALPRVTPFYAVKCNDSKAIVKTLAATGTGFDCASKTEIQLVQSLGVPPERIIYA
	NPCKQVSQIKYAANNGVQMMTFDSEVELMKVARAHPKAKLVLRIATDDSKAVCRLSVK
	FGATLRTSRLLLERAKELNIDVVGVSFHVGSGCTDPETFVQAISDARCVFDMGAEVGF
	SMYLLDIGGGFPGSEDVKLKFEEITGVINPALDKYFPSDSGVRIIAEPGRYYVASAFT
	LAVNIIAKKIVLKEQTGSDDEDESSEQTFMYYVNDGVYGSFNCILYDHAHVKPLLQKR
	PKPDEKYYSSSIWGPTCDGLDRIVERCDLPEMHVGDWMLFENMGAYTVAAASTFNGFQ
	RPTIYYVMSGPAWQLMQ
	SEQ ID NO:129	1416 bp
NOV10k,	CGCGGATCCACCATGAACAACTTTGGTAATGAAGAGTTTGACTGCCACTTCCTCGATG
CG124907-02
DNA Sequence	AAGGTTTTACTGCCAAGGACATTCTGGACCAGAAAATTAATGAAGTTTCTTCTTCTGA
	TGATAAGGATGCCTTCTATGTGGCAGACCTGGGAGACATTCTAAACAAACATCTGAGG
	TGGTTAAAAGCTCTCCCTCGTGTCACCCCCTTTTATGCAGTCAAATGTAATGATAGCA
	AAGCCATCGTGAAGACCCTTGCTGCTACCGGGACAGGATTTGACTGTGCTAGCAAGAC
	TGAAATACAGTTGGTGCAGAGTCTGGGGGTGCCTCCAGAGAGGATTATCTATGCAAAT
	CCTTGTAAACAAGTATCTCAAATTAAGTATGCTGCTAATAATGGAGTCCAGATGATGA
	CTTTTGATAGTGAAGTTGAGTTGATGAAAGTTGCCAGAGCACATCCCAAAGCAAAGTT
	GGTTTTGCGGATTGCCACTGATGATTCCAAAGCAGTCTGTCGTCTCAGTGTGAAATTC
	GGTGCCACGCTCAGAACCAGCAGGCTCCTTTTGGAACGGGCGAAAGAGCTAAATATCG
	ATGTTGTTGGTGTCAGCTTCCATGTAGGAAGCGGCTGTACCGATCCTGAGACCTTCGT
	GCAGGCAATCTCTGATGCCCGCTGTGTTTTTGACATGGGGGCTGAGGTTGGTTTCAGC
	ATGTATCTGCTTGATATTGGCGGTGGCTTTCCTGGATCTGAGGATGTGAAACTTAAAT
	TTGAAGAGATCACCGGCGTAATCAACCCACCGTTGGACAAATACTTTCCGTCAGACTC
	TGGAGTGAGAATCATAGCTGAGCCCGGCAGATACTATGTTGCATCAGCTTTCACGCTT
	GCAGTTAATATCATTGCCAAGAAAATTGTATTAAAGGAACAGACGGGCTCTGATGACG
	AAGATGAGTCGAGTGAGCAGACCTTTATGTATTATGTGAATGATGGCGTCTATGGATC
	ATTTAATTGCATACTCTATGACCACGCACATGTAAAGCCCCTTCTGCAAAAGACACCT
	AAACCAGATGAGAAGTATTATTCATCCAGCATATGGGGACCAACATGTGATGGCCTCG
	ATCGGATTGTTGAGCGCTGTGACCTGCCTGAAATGCATGTGGGTGATTGGATGCTCTT
	TGAAAACATGGGCGCTTACACTGTTGCTGCTGCCTCTACGTTCAATGGCTTCCAGAGG
	CCGACGATCTACTATGTGATGTCAGGGCCTGCGTGGCAACTCATGCAGCAATTCCAGA
	ACCCTGACTTCCCACCCGAAGTAGAGGAACAGGATGCCAGCACCCTGCCTGTGTCTTG
	TGCCTGGGAGAGTGGGATGAAACGCCACAGAGCAGCCTGTGCTTCGGCTAGTATTAAT
	GTGTAGGCGGCCGCTTTTTTCCTT
	ORF Start: ATG at 13		ORF Stop: TAG at 1396
	SEQ ID NO:130	461 aa	MW at 51147.6 kD
NOV10k	MNNFGNEEFDCHFLDEGFTAKDILDQKINEVSSSDDKDAFYVADLGDILKKHLRWLKA
CG124907-02
Protein Sequence	LPRVTPFYAVKCNDSKAIVKTLAATCTGFDCASKTEIQLVQSLGVPPERIIYANPCKQ
	VSQIKYAANNGVQMMTFDSEVELMKVAPAHPKAKLVLRIATDDSKAVCRLSVKFGATL
	RTSRLLLERAKELNIDVVGVSFHVGSGCTDPETFVQAISDARCVFDMGAEVGFSMYLL
	DIGGGFPGSEDVKLKFEEITGVINPALDKYFPSDSGVRIIAEPGRYYVASAFTLAVNI
	IAKKIVLKEQTGSDDEDESSEQTFMYYVNDGVYGSFNCILYDHAHVKPLLQKRPKPDE
	KYYSSSIWGPTCDGLDRIVERCDLPEMHVGDWNLFENMGAYTVAAASTFNGFQRPTIY
	YVMSGPAWQLMQQFQNPDFPPEVEEQDASTLPVSCAWESGMKRHRAACASASINV
	SEQ ID NO:131	1410 bp
NOV10l,	ACCATGGGCCACCATCACCACCATCACAACAACTTTGGTAATGAAGAGTTTGACTGCC
CG124907-03
DNA Sequence	ACTTCCTCGATGAAGGTTTTACTGCCAAGGACATTCTGGACCAGAAAATTAATGAAGT
	TTCTTCTTCTGATGATAAGGATGCCTTCTATGTGGCAGACCTGGGAGACATTCTAAAG
	AAACATCTGAGGTGGTTAAAAGCTCTCCCTCGTGTCACCCCCTTTTATGCAGTCAAAT
	GTAATGATAGCAAAGCCATCGTGAAGACCCTTGCTGCTACCGGGACAGGATTTGACTG
	TGCTAGCAAGACTGAAATACAGTTGGTGCAGAGTCTGGGGGTGCCTCCAGAGAGGATT
	ATCTATGCAAATCCTTGTAAACAAGTATCTCAAATTAAGTATGCTGCTAATAATGGAG
	TCCAGATGATGACTTTTGATAGTGAAGTTGAGTTGATGAAAGTTGCCAGAGCACATCC
	CAAAGCAAAGTTGGTTTTGCGGATTGCCACTGATGATTCCAAAGCAGTCTGTCGTCTC
	AGTGTGAAATTCGGTGCCACGCTCAGAACCAGCAGGCTCCTTTTGGAACGGGCGAAAG
	AGCTAAATATCGATGTTGTTGGTGTCAGCTTCCATGTAGGAAGCGGCTGTACCGATCC
	TGAGACCTTCGTGCAGGCAATCTCTGATGCCCGCTGTGTTTTTGACATGGGGGCTGAG
	GTTGGTTTCAGCATGTATCTGCTTGATATTGGCGGTGGCTTTCCTGGATCTGAGGATG
	TGAAACTTAAATTTGAAGAGATCACCGGCGTAATCAACCCAGCGTTGGACAAATACTT
	TCCGTCAGACTCTGGAGTGAGAATCATAGCTGAGCCCGGCAGATACTATGTTGCATCA
	GCTTTCACGCTTGCAGTTAATATCATTGCCAAGAAAATTGTATTAAAGGAACAGACGG
	GCTCTGATGACGAAGATGAGTCGAGTGAGCAGACCTTTATGTATTATGTGAATGATCG
	CGTCTATGGATCATTTAATTGCATACTCTATGACCACGCACATGTAAAGCCCCTTCTG
	CAAAAGAGACCTAAACCAGATGAGAAGTATTATTCATCCAGCATATGGGGACCAACAT
	GTGATGGCCTCGATCGGATTGTTGAGCGCTGTGACCTGCCTGAAATGCATGTGGGTGA
	TTGGATGCTCTTTGAAAACATGGGCGCTTACACTGTTGCTGCTGCCTCTACGTTCAAT
	GGCTTCCAGAGGCCGACGATCTACTATGTGATGTCAGCGCCTGCGTGCCAACTCATGC
	AGCAATTCCAGAACCCTGACTTCCCACCCGAAGTAGAGGAACAGGATGCCAGCACCCT
	GCCTGTGTCTTGTGCCTGGGAGAGTGGGATGAAACGCCACAGAGCAGCCTGTGCTTCG
	GCTAGTATTAATGTGTAG
	ORF Start: at 1		ORF Stop: TAG at 1408
	SEQ ID NO:132	469 aa	MW at 52128.6 kD
NOV10l,	TMGHHHHHHNNFGNEEFDCHFLDEGFTAKDILDQKINEVSSSDDKDAFYVADLGDILK
CG124907-03
Protein Sequence	KHLRWLKALPRVTPFYAVKCNDSKAIVKTLAATGTGFDCASKTEIQLVQSLGVPPERI
	IYANPCKQVSQIKYAANNGVQMMTFDSEVELMKVARAHPKAKLVLRIATDDSKAVCRL
	SVKFGATLRTSRLLLERAKELNIDVVGVSFHVGSGCTDPETFVQAISDARCVFDMGAE
	VGFSMYLLDIGGGFPGSEDVKLKFEEITGVINPALDKYFPSDSGVRIIAEPGRYYVAS
	AFTLAVNIIAKKIVLKEQTGSDDEDESSEQTFMYYVNDGVYGSFNCILYDHAHVKPLL
	QKRPKPDEKYYSSSIWGPTCDGLDRIVERCDLPEMHVGDWMLFENMGAYTVAAASTFN
	GFQRPTIYYVMSGPAWQLMQQFQNPDFPPEVEEQDASTLPVSCAWESGMKRHRAACAS
	ASINV
	SEQ ID NO:133	1407 bp
NOV10m,	ACCATGAACAACTTTGGTAATGAAGAGTTTGACTGCCACTTCCTCGATGAAGGTTTTA
CG124907-04
DNA Sequence	CTGCCAAGGACATTCTGGACCAGAAAATTAATGAAGTTTCTTCTTCTGATGATAAGGA
	TGCCTTCTATGTGGCAGACCTGGGAGACATTCTAAAGAAACATCTGAGGTGGTTAAAA
	GCTCTCCCTCGTGTCACCCCCTTTTATGCAGTCAAATGTAATGATAGCAAAGCCATCG
	TGAAGACCCTTGCTGCTACCGGGACAGGATTTGACTGTGCTAGCAAGACTGAAATACA
	GTTGGTGCAGAGTCTGGGGGTGCCTCCAGAGAGGATTATCTATGCAAATCCTTGTAAA
	CAAGTATCTCAAATTAACTATGCTGCTAATAATGGAGTCCAGATGATGACTTTTGATA
	GTGAAGTTGAGTTGATGAAAGTTGCCAGAGCACATCCCAAAGCAAAGTTGGTTTTGCG
	GATTGCCACTGATGATTCCAAAGCAGTCTGTCGTCTCAGTGTGAAATTCGGTGCCACG
	CTCAGAACCAGCAGGCTCCTTTTGGAACGGGCGAAAGAGCTAAATATCGATGTTGTTG
	GTGTCAGCTTCCATGTAGGAAGCGGCTGTACCGATCCTGAGACCTTCGTGCAGGCAAT
	CTCTGATGCCCGCTGTGTTTTTGACATGGGGGCTGAGGTTGGTTTCAGCATGTATCTG
	CTTGATATTGGCGGTGGCTTTCCTGGATCTCAGGATGTGAAACTTAAATTTGAAGAGA
	TCACCGGCGTAATCAACCCAGCGTTGGACAAATACTTTCCGTCAGACTCTGGAGTGAG
	AATCATAGCTGAGCCCGGCAGATACTATGTTGCATCAGCTTTCACGCTTGCAGTTAAT
	ATCATTGCCAAGAAAATTGTATTAAAGGAACAGACGGGCTCTGATGACGAAGATGAGT
	CGAGTGAGCAGACCTTTATGTATTATGTGAATGATGGCGTCTATGGATCATTTAATTG
	CATACTCTATGACCACGCACATGTAAAGCCCCTTCTGCAAAAGAGACCTAAACCAGAT
	GAGAAGTATTATTCATCCAGCATATGGGGACCAACATGTGATGGCCTCGATCGGATTG
	TTGAGCGCTGTGACCTGCCTGAAATGCATGTGGGTGATTGGATGCTCTTTGAAAACAT
	GGGCGCTTACACTGTTGCTGCTGCCTCTACGTTCAATGGCTTCCAGAGGCCGACGATC
	TACTATGTGATGTCAGGGCCTGCGTGGCAACTCATGCAGCAATTCCAGAACCCTGACT
	TCCCACCCGAAGTAGAGGAACAGGATGCCAGCACCCTGCCTGTGTCTTGTGCCTGGGA
	GAGTGGGATGAAACGCCACAGAGCAGCCTGTGCTTCGGCTAGTATTAATGTGCACCAT
	CACCACCATCACTGA
	ORF Start: at 1		ORF Stop: TGA at 1405
	SEQ ID NO:134	468 aa	MW at 52071.6 kD
NOV10m,	TMNNFGNEEFDCHFLDEGFTAKDILDQKINEVSSSDDKDAFYVADLGDILKKHLRWLK
CG124907-04
Protein Sequence	ALPRVTPFYAVKCNDSKAIVKTLAATGTGFDCASKTEIQLVQSLGVPPERIIYANPCK
	QVSQIKYAANNGVQMMTFDSEVELMKVARAHPKAKLVLRIATDDSKAVCRLSVKFGAT
	LRTSRLLLERAKELNIDVVGVSFHVGSGCTDPETFVQAISDARCVFDMGAEVGFSMYL
	LDIGGGFPGSEDVKLKFEEITGVINPALDKYFPSDSGVRIIAEPGRYYVASAFTLAVN
	IIAKKTVLKEQTGSDDEDESSEQTFMYYVNDGVYGSFNCILYDHAHVKPLLQKRPKPD
	EKYYSSSIWGPTCDGLDRIVERCDLPEMHVGDWMLFENMGAYTVAAASTFNGFQRPTI
	YYVMSGPAWQLMQQFQNPDFPPEVEEQDASTLPVSCAWESGMKRHRAACASASINVHH
	HHHH
	SEQ ID NO:135	1305 bp
NOV10n,	ACATCATCACCACCATCAAACAACTTTGGTAATGAAGAGTTTGACTGCCACTTCCTCG
CG124907-05
DNA Sequence	ATGAAGGTTTTACTGCCAAGGACATTCTGGACCAGAAAATTAATGAAGTTTCTTCTTC
	TGATGATAAGGATGCCTTCTATGTGGCAGACCTGGGAGACATTCTAAAGAAACATCTG
	AGGTGGTTAAAAGCTCTCCCTCGTGTCACCCCCTTTTATGCAGTCAAATGTAATGATA
	GCAAAGCCATCGTGAAGACCCTTGCTGCTACCGGGACAGGATTTGACTGTGCTAGCAA
	GACTGAAATACAGTTGGTGCAGAGTCTGGGGGTGCCTCCAGAGAGGATTATCTATGCA
	AATCCTTGTAAACAAGTATCTCAAATTAAGTATGCTGCTAATAATGGAGTCCACATCA
	TGACTTTTGATAGTGAAGTTGAGTTGATGAAAGTTGCCAGAGCACATCCCAAAGCAAA
	GTTGGTTTTGCGGATTGCCACTGATGATTCCAAAGCAGTCTGTCGTCTCAGTGTGAAA
	TTCGGTGCCACGCTCAGAACCAGCAGGCTCCTTTTGGAACGGGCGAAAGAGCTAAATA
	TCGATGTTGTTGGTGTCAGCTTCCATGTAGGAAGCGGCTGTACCGATCCTGAGACCTT
	CGTGCAGGCAATCTCTGATGCCCGCTGTGTTTTTGACATGGGGGCTGAGGTTGGTTTC
	AGCATGTATCTGCTTGATATTGGCGGTGGCTTTCCTGGATCTGAGGATGTGAAACTTA
	AATTTGAAGACATCACCGGCGTAATCAACCCAGCGTTGGACAAATACTTTCCGTCAGA
	CTCTGGAGTGAGAATCATAGCTGAGCCCGGCAGATACTATGTTGCATCAGCTTTCACG
	CTTGCAGTTAATATCATTGCCAAGAAAATTGTATTAAAGGAACAGACGGGCTCTGATG
	ACGAAGATGAGTCGAGTGAGCAGACCTTTATGTATTATGTGAATGATGGCGTCTATGG
	ATCATTTAATTGCATACTCTATGACCACGCACATGTAAAGCCCCTTCTGCAAAAGAGA
	CCTAAACCAGATGAGAAGTATTATTCATCCAGCATATGGGGACCAACATGTGATGGCC
	TCGATCGGATTGTTGAGCGCTGTGACCTGCCTGAAATGCATGTGGGTGATTGGATGCT
	CTTTGAAAACATCGGCGCTTACACTGTTGCTGCTGCCTCTACGTTCAATGGCTTCCAG
	AGGCCGACGATCTACTATGTGATGTCAGGGCCTGCGTGGCAACTCATGCAGTAGGCGG
	CCGCACTCGAGCACCACCACCACCACCAC
	ORF Start: at 1		ORF Stop: TAG at 1270
	SEQID NO:136	423 aa	MW at 46885.9 kD
NOV10n,	TSSPPSNNFGNEEFDCHFLDEGFTAKDILDQKINEVSSSDDKDAFYVADLGDILKKHL
CG124907-05
Protein Sequence	RWLKALPRVTPFYAVKCNDSKAIVKTLAATGTGFDCASKTEIQLVQSLGVPPERIIYA
	NPCKQVSQIKYAANNGVQMMTFDSEVELMKVARAHPKAKLVLRIATDDSKAVCRLSVK
	FGATLRTSRLLLERAKELNIDVVGVSFHVGSGCTDPETFVQAISDARCVFDMGAEVGF
	SMYLLDIGGGFPGSEDVKLKFEEITGVINPALDKYFPSDSGVRIIAEPGRYYVASAFT
	LAVNIIAKKIVLKEQTGSDDEDESSEQTFMYYVNDGVYGSFNCILYDHAHVKPLLQKR
	PKPDEKYYSSSIWGPTCDGLDRIVERCDLPEMHVGDWMLFENMGAYTVAAASTFNGFQ
	RPTIYYVMSGPAWQLMQ
	SEQ ID NO:137	1305 bp
NOV10o,	CACCATCACCACCATCACAACAACTTTGGTAATGAAGAGTTTGACTGCCACTTCCTCG
CG124907-06
DNA Sequence	ATGAAGGTTTTACTGCCAAGGACATTCTGGACCAGAAAATTAATGAAGTTTCTTCTTC
	TGATGATAAGGATGCCTTCTATGTGGCAGACCTGCGAGACATTCTAAAGAAACATCTG
	AGGTGGTTAAAAGCTCTCCCTCGTGTCACCCCCTTTTATGCAGTCAAATGTAATGATA
	GCAAAGCCATCGTGAAGACCCTTGCTGCTACCGGGACAGGATTTGACTGTGCTAGCAA
	GACTGAAATACAGTTGGTGCAGAGTCTGGGGGTGCCTCCAGAGAGGATTATCTATGCA
	AATCCTTGTAAACAAGTATCTCAAATTAAGTATGCTGCTAATAATGGAGTCCAGATGA
	TGACTTTTGATAGTGAAGTTGAGTTGATGAAAGTTGCCAGAGCACATCCCAAAGCAAA
	GTTGGTTTTGCGGATTGCCACTGATGATTCCAAAGCAGTCTGTCGTCTCAGTGTGAAA
	TTCGGTGCCACGCTCAGAACCAGCAGGCTCCTTTTGGAACGGGCGAAAGAGCTAAATA
	TCGATGTTGTTGGTGTCAGCTTCCATGTAGGAAGCGGCTGTACCGATCCTGAGACCTT
	CGTGCAGGCAATCTCTGATGCCCGCTGTGTTTTTGACATGGGGGCTGAGGTTGGTTTC
	AGCATGTATCTGCTTGATATTGGCGGTGGCTTTCCTGGATCTGAGGATGTGAAACTTA
	AATTTGAAGAGATCACCGGCGTAATCAACCCAGCGTTGGACAAATACTTTCCGTCAGA
	CTCTGGAGTGAGAATCATAGCTGAGCCCGGCAGATACTATGTTGCATCAGCTTTCACG
	CTTGCAGTTAATATCATTGCCAAGAAAATTGTATTAAAGGAACAGACGGGCTCTGATG
	ACGAAGATGAGTCGAGTGAGCAGACCTTTATGTATTATGTGAATGATGGCGTCTATGG
	ATCATTTAATTGCATACTCTATGACCACGCACATGTAAAGCCCCTTCTGCAAAAGAGA
	CCTAAACCAGATGAGAAGTATTATTCATCCAGCATATGGGGACCAACATGTGATGGCC
	TCGATCGGATTGTTGAGCGCTGTGACCTGCCTGAAATGCATGTGGGTGATTGGATGCT
	CTTTGAAAACATGGGCGCTTACACTGTTGCTGCTGCCTCTACGTTCAATGGCTTCCAG
	AGGCCGACGATCTACTATGTGATGTCAGGGCCTGCGTGGCAACTCATGCAGTAGGCGG
	CCGCACTCGAGCACCACCACCACCACCAC
	ORF Start: at 19		ORF Stop: TAG at 1270
	SEQ ID NO:138	417 aa	MW at 46329.3 kD
NOV10o,	NNFGNEEFDCHFLDEGFTAKDILDQKINEVSSSDDKDAFYVADLGDILKKHLRWLKAL
CG124907-06
Protein Sequence	PRVTPFYAVKCNDSKAIVKTLAATGTGFDCASKTEIQLVQSLGVPPERIIYANPCKQV
	SQIKYAANNGVQMMTFDSEVELMKVARAHPKAKLVLRIATDDSKAVCRLSVKFGATLR
	TSRLLLERAKELNIDVVGVSFHVGSGCTDPETFVQAISDARCVFDMGAEVGFSMYLLD
	IGGGFPGSEDVKLKFEEITGVINPALDKYFPSDSGVRIIAEPGRYYVASAFTLAVNII
	AKKIVLKEQTGSDDEDESSEQTFMYYVNDGVYGSFNCILYDHAHVKPLLQKRPKPDEK
YYSSSIWGPTCDGLDRIVERCDLPEMHVGDWMLFENMGAYTVAAASTFNGFQRPTIYY
	VMSGPAWQLMQ

[0406] Sequence comparison of the above protein sequences yields the following sequence relationships shown in Table 10B.

TABLE 10B
Comparison of NOV10a against NOV10b through NOV10o.
		NOV10a	Identities/
		Residues/	Similarities
		Match	for the
	Protein Sequence	Residues	Matched Region
	NOV10b	1 . . . 461	461/461 (100%)
		1 . . . 461	461/461 (100%)
	NOV10c	1 . . . 461	461/461 (100%)
		5 . . . 465	461/461 (100%)
	NOV10d	2 . . . 461	460/460 (100%)
		10 . . . 469	460/460 (100%)
	NOV10e	1 . . . 461	461/461 (100%)
		2 . . . 462	461/461 (100%)
	NOV10f	2 . . . 461	460/460 (100%)
		7 . . . 466	460/460 (100%)
	NOV10g	2 . . . 418	417/417 (100%)
		7 . . . 423	417/417 (100%)
	NOV10h	1 . . . 461	461/461 (100%)
		2 . . . 462	461/461 (100%)
	NOV10i	1 . . . 461	461/461 (100%)
		1 . . . 461	461/461 (100%)
	NOV10j	2 . . . 418	417/417 (100%)
		7 . . . 423	417/417 (100%)
	NOV10k	1 . . . 461	461/461 (100%)
		1 . . . 461	461/461 (100%)
	NOV10l	2 . . . 461	460/460 (100%)
		10 . . . 469	460/460 (100%)
	NOV10m	1 . . . 461	461/461 (100%)
		2 . . . 462	461/461 (100%)
	NOV10n	2 . . . 418	417/417 (100%)
		7 . . . 423	417/417 (100%)
	NOV10o	2 . . . 418	417/417 (100%)
		1 . . . 417	417/417 (100%)

[0407] Further analysis of the NOV10a protein yielded the following properties shown in Table 10C.

TABLE 10C
Protein Sequence Properties NOV10a
PSort     0.6000 probability located in nucleus;
analysis: 0.3922 probability located in microbody
          (peroxisome); 0.1000 probability located
          in mitochondrial matrix space; 0.1000
          probability located in lysosome (lumen)
SignalP   No Known Signal Sequence Predicted
analysis:

[0408] A search of the NOV10a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 10D.

TABLE 10D
Geneseq Results for NOV10a
		NOV10a	Identities/
		Residues/	Similarities for
Geneseq	Protein/Organism/Length	Match	the Matched	Expect
Identifier	[Patent #, Date]	Residues	Region	Value
AAG73867	Human colon cancer antigen	1 . . . 461	461/461 (100%)	0.0
	protein SEQ ID NO: 4631 - Homo	6 . . . 466	461/461 (100%)
	sapiens, 466 aa. [WO200122920-
	A2, 05 APR. 2001]
AAB58391	Lung cancer associated polypeptide	1 . . . 461	461/461 (100%)	0.0
	sequence SEQ ID 729 - Homo	6 . . . 466	461/461 (100%)
	sapiens, 466 aa. [WO200055180-
	A2, 21 SEP. 2000]
AAR37270	ODC - Synthetic, 461 aa.	1 . . . 461	460/461 (99%)	0.0
	[EP542287-A, 19 MAY 1993]	1 . . . 461	461/461 (99%)
AAB52181	Human secreted protein BLAST	17 . . . 444	427/428 (99%)	0.0
	search protein SEQ ID NO: 137 -	1 . . . 428	428/428 (99%)
	Homo sapiens, 428 aa.
	[WO200061624-A1, 19 OCT.
	2000]
AAW76000	Ornithine decarboxylase amino	1 . . . 461	417/461 (90%)	0.0
	acid sequence - Mus sp, 461 aa.	1 . . . 461	434/461 (93%)
	[US5811634-A, 22 SEP. 1998]

[0409] In a BLAST search of public sequence datbases, the NOV10a protein was found to have homology to the proteins shown in the BLASTP data in Table 10E.

TABLE 10E
Public BLASTP Results for NOV10a
			Identities/
Protein			Similarities for
Accession		NOV10a Residues/	the Matched	Expect
Number	Protein/Organism/Length	Match Residues	Portion	Value
P11926	Ornithine decarboxylase (EC	1 . . . 461	461/461 (100%)	0.0
	4.1.1.17) (ODC) - Homo sapiens	1 . . . 461	461/461 (100%)
	(Human), 461 aa.
P27117	Ornithine decarboxylase (EC	1 . . . 461	431/461 (93%)	0.0
	4.1.1.17) (ODC) - Bos taurus	1 . . . 461	444/461 (95%)
	(Bovine), 461 aa.
P09057	Ornithine decarboxylase (EC	1 . . . 461	422/461 (91%)	0.0
	4.1.1.17) (ODC) - Rattus	1 . . . 461	434/461 (93%)
	norvegicus (Rat), 461 aa.
P27119	Ornithine decarboxylase (EC	1 . . . 461	421/461 (91%)	0.0
	4.1.1.17) (ODC) - Mus pahari	1 . . . 461	436/461 (94%)
	(Shrew mouse), 461 aa.
P00860	Ornithine decarboxylase (EC	1 . . . 461	417/461 (90%)	0.0
	4.1.1.17) (ODC) - Mus musculus	1 . . . 461	434/461 (93%)
	(Mouse), 461 aa.

[0410] PFam analysis predicts that the NOV10a protein contains the domains shown in the Table 10F.

TABLE 10F
Domain Analysis of NOV10a
		Identities/
	NOV10a	Similarities
	Match	for the	Expect
Pfam Domain	Region	Matched Region	Value
Orn_Arg_deC_N	44 . . . 282	131/289 (45%)	7.8e−132
		225/289 (78%)
Orn_DAP_Arg_deC	285 . . . 409	68/199 (34%)	5.6e−62
		119/199 (60%)

Example 11

[0411] The NOV11 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 11A.

TABLE 11A
NOV11 Sequence Analysis
                 SEQ ID NO: 139          994 bp
NOV11a,          CACACAAGTCCGCCTATGTACTCTCTGGATCGAATATTTGCTGGATTTCGAACACGAA
CG128347-01
DNA Sequence     GTCAGATGCTGTTGGGTCACATAGAAGAACAAGATAAGGTCCTCCACTGCCAATTTTC
                 TGATAACAGTGATGATGAAGAATCAGAAGGCCAAGAGAAATCTGGAACTAGGTGTAGA
                 AGTCGTTCATGGATTCAGAAGCCAGACTCTGTTTGTTCCCTTGTTGAATTGAGTGATA
                 CTCAGGATGAAACACAAAAGTCAGATTTGGAGAATGAAGATTTAAAGATTGATTGTCT
                 CCAGGAGAGTCAAGAATTGAATTTGCAAAAATTAAAGAATTCAGAACGCATACTTACT
                 GAAGCTAAACAAAAAATGAGAGAACTTACAATTAACATCAAGATGAAGGAAGATCTGA
                 TTAAAGAATTAATAAAAACAGGTAATGATGCCAAGTCTGTAAGCAAGCAGTATTCTTT
                 GAAAGTAACAAAGCTAGAGCATGATGCAGAACAGGCAAAAGTCGAACTAACTGAAACA
                 CAAAAGCAGCTACAGGAGCTGGAAAACAAAGATCTTTCTGATGTTGCAATGAACGTAA
                 AATTACAGAAAGAGTTTCGTAAAAAGATGGATGCTGCAAAGCTGAGAGTTCAGGTCTT
                 ACAGAAGAAGCAACAAGATAGTAAGAAACTGGCATCACTGTCAATCCAAAATGAGAAA
                 CGTGCTAATGAACTAGAGCAGAGTGTAGATCACATGAAATATCAAAAGATACAGCTAC
                 AAAGAAAACTACAAGAAGAAAATGAAAAAAGGAAGCAACTGGATGCAGTAATTAAGCG
                 GGACCAGCAAAAAATCAAAGTAATATTGTCATACATTCCTGCTAAGTATAATATGAAA
                 TGTTAAACGGCTCAGAGCTAACGAATCCATGGTCTTCATTCAGTTGGCTTGTGAAGTA
                 TCTATCCTTGACTTGCCCTTCACTGCTGTCCTTATTCACTTTAAAGCTTTGTTCATCT
                 ACATAGTA
                 ORF Start: ATG at 16                 ORF Stop: TAA at 874
                 SEQ ID NO: 140          286 aa       MW at 33507.0kD
NOV11a,          MYSLDRIFAGFRTRSQMLLGHIEEQDKVLHCQFSDNSDDEESEGQEKSGTRCRSRSWI
CG128347-01
Protein Sequence QKPDSVCSLVELSDTQDETQKSDLENEDLKIDCLQESQELNLQKLKNSERILTEAKQK
                 MRELTINIKNKEDLIKELIKTGNDAKSVSKQYSLKVTKLEHDAEQAKVELTETQKQLQ
                 ELENKDLSDVAMKVKLQKEFRKKNDAAKLRVQVLQKKQQDSKKLASLSIQNEKRANEL
                 EQSVDHMKYQKIQLQRKLQEENEKRKQLDAVIKRDQQKIKVILSYIPAKYNMKC
                 SEQ ID NO: 141         4622 bp
NOV11b,          AGGAGTCCAGCGCTCGCCGACAGGGGCCTGGGCTGTCCCGAGCCGGAATCCAGATCTT
CG128347-02
DNA Sequence     ACATAAGATGGAAGTCTCTCACACTAGATACTGAACATTAAATAGAAAATCTATTTAG
                 TAAAATCTAAGTTGCCATGGAAGAAATACCAGTAAAAGTTGCTGTAAGAATTAGACCT
                 CTGCTTTGCAAAGAAGCTCTTCATAATCATCAAGTTTGTGTGAGAGTTATTCCAAACA
                 GCCAGCAAGTTATCATTGGGAGAGATAGAGTCTTCACTTTTGATTTTGTTTTTGGCAA
                 AAATTCCACTCAAGATGAAGTTTATAACACATGTATAAAGCCCCTAGTGTTGTCACTC
                 ATTGAGGGCTATAATGCAACTGTTTTTGCCTATGGACAAACTGGATCTGGGAAGAcAT
                 ACACCATTGGAGGGGGCCATATTGCTTCAGTTGTGGAGGGCCAAAAGGGTATCATTCC
                 TCGAGCTATTCAAGAAATATTTCAAAGCATCTCTGAACATCCTAGCATTGACTTTAAT
                 GTAAAAGTATCTTATATAGAAGTGTACAAGGAAGACCTAAGAGATCTTCTAGAATTGG
                 AGACATCCATGAACGATCTTCACATCCGAGAAGATGAAAAAGGAAACACAGTGATTGT
                 TGGGGCCAAGGAATGCCATGTGGAGAGTGCACGTGAAGTGATGAGTCTTTTGGAGATG
                 GGGAATGCAGCCAGACATACAGGTACCACTCAAATGAATGAGCACTCCAGCAGATCAC
                 ATGCAATTTTTACAATCAGCATTTGTCAAGTTCATAAAAATATGGAGGCAGCTGAAGA
                 TGGATCATGGTATTCCCCTCGGCATATTGTCTCAAAGTTCCACTTTGTGGATTTGGCA
                 GGATCAGAAAGAGTAACCAAAACGGGGAATACTGGTGAACGGTTCAAAGAATCCATTC
                 AAATCAATAGTGGATTGCTGGCTTTAGGAAATGTAATAAGCGCTCTTGGGGACCCACG
                 CAGGAAGAGTTCACATATTCCATATAGGGATGCTAAAATTACCCGGCTTCTGAAAGAT
                 TCTCTGGGAGGCAGTGCTAAGACTGTCATGATCACATGTGTCAGCCCCTCCTCCTCGA
                 ATTTTGATGAGTCCTTAAATTCTCTCAAATATGCCAACAGAGCACGGAACATTAGAAA
                 CAAACCCACTGTAAACTTCAGCCCCGAGTCAGACCGTATAGATGAAATGGAATTTGAG
                 ATTAAATTGCTTCGAGAAGCTTTGCAAAGCCAGCAGGCTGGTGTCAGCCAAACTACCC
                 AGATCAATCGAGAAGGGAGTCCTGATACAAATAGGATTCATTCTCTTGAGGAGCAAGT
                 AGCTCAGCTTCAAGGAGAATGTCTGGGTTACCAGTGTTGTGTAGAAGAAGCCTTTACC
                 TTCCTGGTTGACCTAAAAGATACTGTCAGACTAAACGAAAAGCAGCAACACAAACTGC
                 AGGAGTGGTTTAACATGATCCAAGAGGTCAGGAAGGCTGTCCTCACCTCATTTCGAGG
                 AATCGGAGGCACTGCAAGTCTGGAAGAAGGACCACAGCATGTTACAGTTCTCCAGCTG
                 AACAGAGAGCTTAAGAAATGCCAGTGTGTGCTTGCTGCTGATGAAGTAGTATTTAATC
                 AGAAGGAACTGGAGGTGAAGGAACTGAAGAATCAAGTGCAGATGATGGTACAGGAAAA
                 CAAAGGGCATGCTGTATCTTTGAAAGAAGCGCAAAAAGTGAATAGACTGCAGAATGAA
                 AAAATAATAGAACAACAACTTCTTGTGGATCAACTGAGTGAAGAACTAACAAAACTTA
                 ACCTGTCAGTGACTTCTTCAGCTAAAGAAAATTGTGGAGATGGGCCAGATGCCAGGAT
                 CCCTGAAAGGAGACCATATACTGTACCATTTGATACTCATTTGGGGCATTATATTTAT
                 ATCCCATCAAGACAAGATTCCAGGAAGGTCCACACAAGTCCGCCTATGTACTCTCTGG
                 ATCGAATATTTGCTGGATTTCGAACACGAAGTCAGATGCTGTTGGGTCACATAGAAGA
                 ACAAGATAAGGTCCTCCACTGCCAATTTTCTGATAACAGTGATGATGAAGAATCAGAA
                 GGCCAAGACAAATCTGGAACTAGATGTAGAAGTCGTTCATGGATTCAGAAGCCAGACT
                 CTGTTTGTTCCCTTGTTGAATTGAGTGATACTCAGGATGAAACACAAAACTCAGATTT
                 GGAGAATGAAGATTTAAGATTGATTGTCTCCAGGAGAGTCAAGAATTGAATTTGCAA
                 AAATTAAAGAATTCAGAACGCATACTTACTGAAGCTAAACAAAAAATGAGAGAACTTA
                 CAATTAACATCAACATGAAGGAAGATCTGATTAAAGAATTAATAAAAACAGGTAATGA
                 TGCCAAGTCTGTAAGCAACCAGTATTCTTTGAAAGTAACAAAGCTAGAGCATGATGCA
                 GAACAGGCAAAAGTCGAACTGATTGAAACACAAAAGCAGCTACAGGAGCTGGAAAACA
                 AAGATCTTTCTGATGTTGCAATGAAGGTAAAATTACAGAAAGAGTTTCGTAAAAAGAT
                 GGATGCTGCAAAGCTGAGAGTTCAGGTCTTGCAGAAGAAGCAACAAGATAGTAAGAAA
                 CTGGCATCACTGTCAATCCAAAATGAGAAACGTGCTAATGAGCTAGAGCAGAGTGTAG
                 ATCACATGAAATATCAAAAGATACAGCTACAAAGAAAACTACGAGAAGAAAATGAAAA
                 AAGGAAGCAACTGGATGCAGTAATTAAGCGGGACCAGCAAAAAATCAAAGTAATACAA
                 TTAAAAACAGGACAGGAAGAAGGTCTAAAACCGAAAGCTGAGGACCTTGATGCATGTA
                 ACTTGAAAAGCAGAAAAGGTTCGTTTGGAAGTATAGACCATCTCCAGAAATTGGATGA
                 GCAAAAGAAATGGTTAGATGAAGAAGTAGAGAAAGTTCTGAACCAACGCCAAGAATTA
                 GAGGAGCTGGAAGCAGACTTAAAGAAACGGGAGGCCATAGTTTCTAAGAAGGAGGCTC
                 TGTTACAGGAGAAGAGTCACCTGGAAATAAGAAATTGAGATCTAGTCAGGCCTTAAA
                 CACAGATAGTTTGAAAATATCAACTCGCCTGAACTTACTGGAACAAGAGTTGTCTGAA
                 AAGAATGTGCAGCTCCAGACCAGTACAGCTGAGGAGAAAACAAAGATTTCAGAACAAG
                 TTGAAGTCCTCCAGAAAGAAAAGGATCAGCTCCAGAAACGCAGACACGATGTGGATGA
                 AAAACTTAAAAATGGTAGAGTGTTATCACCTGAAGAAGAACATGTTCTTTTCCAACTT
                 GAAGAAGGGATAGAAGCTTTGGAAGCTGCAATTGAATACAGGAATGAAAGTATCCAGA
                 ATCGCCAGAAGTCACTTAGAGCATCATTCCATAACCTCTCTCGTGGTGAAGCAAATGT
                 CTTGGAAAAGCTAGCTTGCCTGAGTCCTGTTGAGATTACAACTATTCTTTTCAGATAT
                 TTCAATAAGGTGGTGAATTTGCGAGAAGCTGAACGGAACAACAGTTATATAATGAAG
                 AAATGAAAATGAAAGTTCTGGAACGGGATAATATGGTTCGTGAATTACAATCTGCACT
                 GGACCATCTAAAATTGCAGTGTGACCGGAGACTGACCCTCCAGCAAAAGGAACACGAA
                 CAAAAGATGCAGTTGCTATTACATCATTTCAAAGAACAAGATGGAGAAGGCATTATGG
                 AAACTTTCAAAACATATGAAGATAAAATCCAGCAGTTGGAAAAAGATCTTTATTTCTA
                 TAAGAAAACCAGCCGGGATCATAAGAAGAAACTTAAGGAACTGGTAGGGGAAGCAATT
                 CGGCGGCAACTAGCATCATCAGAGTATCAAGAGGCTGGAGATGGAGTCCTGAAGCCAG
                 AAGGAGGAGGCATGCTTTCAGAAGAATTAAAATGGGCATCCAGACCTGAAAGTATGAA
                 ATTAAGTGGAAGAGAAAGAGAATGGACAGTTCAGCAAGCAGCTTAAGAACACAGCCA
                 AATCCTCAAAAGCTCTGGGAAGATATCCCAGAATTACCTCCAATTCATAGTTCTTTAG
                 CACCCCCCAGTGGGCATATGTTAGGTAATGAGAATAAAACAGAAACAGATGATAATCA
                 GTTTACAAAATCTCACAGTCGACTGTCATCCCAAATTCAGGTTGTGGGAAATGTGGGA
                 CGACTTCATGGTGTCACACCTGTAAAACTGTGTCGAAAAGAATTACGTCAAATTTCCG
                 CCTTGGAACTATCATTGCGACGTTCCAGTCTTGGAGTTGGCATTGGATCAATGGCTGC
                 TGATTCCATCGAAGTATCTAGGAAACCAAGGGACTTAAAAACTTAGACATTGAATAAT
                 AGAACTTTTAGTAGATATGTAAAAAGATTCCTTTTTCTAACCTGTTAAAAACTAAAGC
                 TCAAGTTCACTACCTCTTTCCTCAGAATAAAGGAAGAAGGGGAGCAAGGAATCCCTAA
                 TTCTTTTATATGCTATAGATGTGTACATCTTCTATATATATTTGCGGAGTTTTAGTTT
                 ATATTCCCATAGTAATCAAACATGTTTTCCAATACTTGATAACATTTAAATATTTATA
                 AATACGCTTAAATGTTTTTCCAGGCATATTTGAAGATTAA
                 ORF Start: ATG at 133                ORF Stop: TAG at 4336
                 SEQ ID NO: 142         1401 aa       MW at 16O242.6kD
NOV11b,          MEEIPVKVAVRIRPLLCKEALHNHQVCVRVIPNSQQVTIGRDRVFTFDFVFGKNSTQD
CG128347-02
Protein Sequence EVYNTCIKPLVLSLIEGYNATVFAYGQTGSGKTYTIGGGHIASVVEGQKGTIPRAIQE
                 IFQSISEHPSIDFNVKVSYIEVYKEDLRDLLELETSMKDLHIREDEKGNTVIVGAKEC
                 HVESAGEVMSLLEMGNAARHTGTTQMNEHSSRSHAIFTISICQVHKNMEAAEDGSWYS
                 PRHIVSKFHFVDLAGSERVTKTGNTGERFKESIQIMSCLLALGNVISALCDPRRKSSH
                 IPYRDAKITRLLKDSLGGSAKTVMITCVSPSSSNFDESLNSLKYANRARNIRNKPTVN
                 FSPESDRIDEMEFEIKLLREALQSQQAGVSQTTQINREGSPDTNRIHSLEEQVAQLQG
                 ECLGYQCCVEEAFTFLVDLKDTVRLNEKQQHKLQEWFNMIQEVRKAVLTSFRGIGGTA
                 SLEEGPQHVTVLQLKRELKKCQCVLAADEVVFNQKELEVKELKNQVQMMVQENKGHAV
                 SLKEAQKVNRLQNEKTIEQQLLVDQLSEELTKLNLSVTSSAKENCGDGPDARIPERRP
                 YTVPFDTHLGHYIYIPSRQDSRKVHTSPPMYSLDRIFAGFRTRSQMLLGHIEEQDKVL
                 HCQFSDNSDDEESEGQEKSGTRCRSRSWIQKPDSVCSLVELSDTQDETQKSDLENEDL
                 KIDCLQESQELNLQKLKNSERILTEAKQKMRELTINJKMKEDLIKELIKTGNDAKSVS
                 KQYSLKVTKLEHDAEQAKVELIETQKQLQELENKDLSDVAMKVKLQKEFRKKMDAAKL
                 RVQVLQKKQQDSKKLASLSIQNEKRANELEQSVDHMKYQKIQLQRTCIJREENEKRKQLD
                 AVIKRDQQKIKVIQLKTGQEEGLKPKAEDLDACNLKRRKGSFGSIDHLQKLDEQKKWL
                 DEEVEKVLNQRQELEELEADLKKREAIVSKKEALLQEKSHLENKKLRSSQALNTDSLK
                 ISTRLNLLEQELSEKNVQLQTSTAEEKTKISEQVEVLQKEKDQLQKRRHDVDEKLKNG
                 RVLSPEEEHVLFQLEEGIEALEAAIEYRNESIQNRQKSLRASFHNLSRGEANVLEKLA
                 CLSPVEIRTILFRYFNKVVNLREAERKQQLYNEEMKMKVLERDNMVRELESALDHLKL
                 QCDRRLTLQQKEHEQKMQLLLHHFKEQDGEGIMETFKTYEDKIQQLEKDLYFYKKTSR
                 DHKKKLKELVGEAIRRQLASSEYQEAGDGVLKPEGGGMLSEELKWASRPESMKLSGRE
                 REMDSSASSLRTQPNPQKLWEDIPELPPIHSSLAPPSGHMLGNENKTETDDNQFTKSH
                 SRLSSQIQVVGNVGRLHGVTPVKLCRKELRQISALELSLRRSSLGVGIGSMAADSIEV
                 SRKPRDLKT

[0412] Sequence comparison of the above protein sequences yields the following sequence relationships shown in Table 11B.

TABLE 11B
Comparison of NOV11a against NOV11b.
	NOV11a	Identities/
	Residues/	Similarities
Protein	Match	for the
Sequence	Residues	Matched Region
NOV11b	1 . . . 274	272/274 (99%)
	610 . . . 883	273/274 (99%)

[0413] Further analysis of the NOV11a protein yielded the following properties shown in Table 11C.

TABLE 11C
Protein Sequence Properties NOVlla
PSort     0.5517 probability located in mitochondrial
analysis: matrix space: 0.3000 probability located in
          microbody (peroxisome); 0.2717 probability
          located in mitochondrial inner membrane;
          0.2717 probability located in mitochondrial
          intermembrane space
SignalP   No Known Signal Sequence Predicted
analysis:

[0414] A search of the NOV11a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 11D.

TABLE 11D
Geneseq Results for NOV11a
		NOV11a	Identities/
		Residues/	Similarities for
Geneseq	Protein/Organism/Length [Patent	Match	the Matched	Expect
Identifier	#, Date]	Residues	Region	Value
AAB42353	Human ORFX ORF2117	1 . . . 274	270/274 (98%)	e−150
	polypeptide sequence SEQ ID	42 . . . 315	274/274 (99%)
	NO: 4234 - Homo sapiens, 833 aa.
	[WO200058473-A2, 05 OCT. 2000]
ABB80078	Human kinesin motor protein	1 . . . 274	271/274 (98%)	e−149
	(HsKrp5) amino acid sequence -	488 . . . 761	272/274 (98%)
	Homo sapiens, 1279 aa.
	[US6379941-B1, 30 APR. 2002]
AAM40604	Human polypeptide SEQ ID NO	55 . . . 286	219/232 (94%)	e−118
	5535 - Homo sapiens, 232 aa.	1 . . . 232	226/232 (97%)
	[WO200153312-A1, 26 JUL. 2001]
AAM38818	Human polypeptide SEQ ID NO	64 . . . 286	218/223 (97%)	e−118
	1963 - Homo sapiens, 229 aa.	7 . . . 229	222/223 (98%)
	[WO200153312-A1, 26 JUL. 2001]
AAY41675	Human channel-related molecule	64 . . . 286	218/223 (97%)	e−118
	HCRM-3 - Homo sapiens, 229 aa.	7 . . . 229	222/223 (98%)
	[WO9943807-A2, 02 SEP. 1999]

[0415] In a BLAST search of public sequence datbases, the NOV11a protein was found to have homology to the proteins shown in the BLASTP data in Table 11E.

TABLE 11E
Public BLASTP Results for NOV11a
		NOVlla	Identities/
Protein		Residues/	Similarities for
Accession		Match	the Matched	Expect
Number	Protein/Organism/Length	Residues	Portion	Value
Q9UF54	Hypothetical 96.7 kDa protein -	1 . . . 274	265/274 (96%)	e−146
	Homo sapiens (Human), 833 aa	42 . . . 315	269/274 (97%)
	(fragment).
Q95LL1	Hypothetical 98.5 kDa protein -	1 . . . 256	245/256 (95%)	e−135
	Macaca fascicularis (Crab eating	610 . . . 865	254/256 (98%)
	macaque) (Cynomolgus monkey),
	865 aa (fragment).
Q95JP3	Hypothetical 49.3 kDa protein -	1 . . . 248	242/248 (97%)	e−132
	Macaca fascicularis (Crab eating	166 . . . 413	247/248 (99%)
	macaque) (Cynomolgus monkey),
	428 aa.
Q9QXL2	Kif21a - Mus musculus (Mouse),	23 . . . 270	68/255 (26%)	2e−16
	1573 aa.	551 . . . 793	129/255 (49%)
Q64075	Nucleoporin p62 homolog protein -	90 . . . 239	55/151 (36%)	6e−13
	Rattus sp, 215 aa (fragment).	12 . . . 151	86/151 (56%)

[0416] PFam analysis predicts that the NOV11a protein contains the domains shown in the Table 11F.

TABLE 11F
Domain Analysis of NOV11a
			Identities/
		NOV11a	Similarities
	Pfam	Match	for the	Expect
	Domain	Region	Matched Region	Value
No Significant Matches Found

Example 12

[0417] The NOV12 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 12A.

TABLE 12A
NOV12 Sequence Analysis
                 SEQ ID NO: 143         2754 bp
NOV12a,          ATTGCCCCTGTAACCTGTCAAAGAAGAGCTAAGGGAGCTTTCGGGGTTGGCTTCTTGG
CG135823-01
DNA Sequence     AGGCTGCTTTCTCCTTTACTTGGAAGGCTTCGCTACTGATGGACCCATACATGATTCA
                 GATGAGCAGCAAAGGCAACCTCCCCTCAATTCTGGACGTGCATGTCAACGTTGGTGGG
                 AGAAGCTCTGTGCCGGGAAAAATGAAAGGCAGAAAGGCCAGGTGGTCTGTGAGGCCCT
                 CAGACATGGCCAAGAAAACTTTCAACCCCATCCGAGCCATTGTGGACAACATGAAGGT
                 GAAACCAAATCCAAACAAAACCATGATTTCCCTGTCCATTGGGGACCCTACTGTGTTT
                 GGAAACCTGCCTACAGACCCTGAAGTTACCCAGGCAATGAAAGATGCCCTGGACTCGG
                 GCAAATATAATGGCTATCCCCCATCCATCGGCTTCCTATCCAGTCGGGAGGAGATTGC
                 TTCTTATTACCACTGTCCTGAGGCACCCCTAGAAGCTAAGGACGTCATTCTGACAAGT
                 GGCTGCAGCCAAGCTATTGACCTTTGTTTAGCTGTGTTGGCCAACCCAGGGCAGAACA
                 TCCTGGTTCCAAGACCTGGTTTCTCTCTCTACAAGACTCTGGCTGAGTCTATGGGAAT
                 TGAGGTCAAACTCTACAATTTGTTGCCAGAGAAATCTTGGGAAATTGACCTGAAACAA
                 CTGGAATATCTAATTGATGAAAAGACAGCTTGTCTCATTGTCAATAATCCATCAAACC
                 CCTGTGGGTCAGTGTTCAGCAAACGTCATCTTCAGAAGATTCTGGCAGTGGCTGCACG
                 GCAGTGTGTCCCCATCTTAGCTGATGAGATCTATGGAGACATGGTGTTTTCGGATTGC
                 AAATATGAACCACTGGCCACCCTCAGCACCGATGTCCCCATCCTGTCCTGTGGAGGGC
                 TGGCCAAGCGCTGGCTGGTTCCTGGCTGGAGGTTGGGCTGGATCCTCATTCATGACCG
                 AAGAGACATTTTTGGCAATGAGATCCGAGATGGGCTGGTGAAGCTGAGTCAGCGCATT
                 TTGGGACCCTGTACCATTGTCCAGGGACCTCTGAAAAGCATCCTATGTCGCACCCCGG
                 GAGAGTTTTACCACAACACTCTGAGCTTCCTCAAGTCCAATGCTGATCTCTGTTATGG
                 GGCGTTGGCTGCCATCCCTGGACTCCGGCCAGTCCGCCCTTCTGGGGCTATGTACCTC
                 ATGGTTGGAATTGAGATGGAACATTTCCCAGAATTTGAGAACGATGTGGAGTTCACGG
                 AGCGGTTAGTTGCTGAGCAGTCTGTCCACTGCCTCCCAGCAACGTCCTTTGAGTACCC
                 GAATTTCATCCGAGTGGTCATCACAGTCCCCGAGGTGATGATGCTGGAGGCGTGCAGC
                 CGGATCCAGGAGTTCTGTGAGCAGCACTACCATTGTGCTGAAGGCAGCCAGGAGGAGT
                 GTGATAAATAGGCCTGCATCCATTCTCCTGAGGATGTGTCCCATCTAGGGAAGGCTGG
                 ACTAGGCCTTGCGGCTCCTCAGGGACTCAGGTGGCCCTACTGGGAGAGGGGCCTCAAA
                 TGCACCATGTCAAGGGTTCAAGATTGTTCCTGCTTTTCCCCAAGTACAACCACACCCA
                 CACTCAGATCCTCCTCATTCACATCGCAGATTACTCCCTTGCTCTGCGCTGCTAGAGT
                 GACTCACTAATTCATTAATCTGCCTCCCTCTCGTAAGATTTCCTTCTTTTTTTTCTTG
                 AAAGTACCAGGTGAACAAAGTTTACCAGAAAGCAGTTGAGACAAGAAAATAAGAGCTC
                 AGGATGAGGGAAAAGAAAAAGATTGAGAGAATTTGTGCCCCCAACCATTTCCTCAGAC
                 TCTAAGAAAGAACACGCTCTCTCCAGGCAGGTCTGAAGCTCAACTCTCTTATTGCCTC
                 ACTTCAGGTATACCTCACTTTACACAATAGAATTATAACTGGAAAGAAGTTGGGGACA
                 CATGTATTTGGTGATTACATTTTAAACACATTAGGAAAAGTTGCTATTTGAACTTTTT
                 ATTGATTTTTGGGGGGAGTAAAGAATTATTTTGGATGCAAATAAATATCCTTTAATTG
                 ATCGACTTGCCAAATTTAGATTTGTGTGCATCAGGCTTTCTTTTTTTTCTTTTTTTAG
                 AGAAGTTCAATATAAGCTTTTCTTTTCTTTGTTTCTTTCTTTCTTTATTTTGAGATGG
                 AGTCTTGCTCTGTCGCCCATGCTGGAGTGCAGTGGCGCGATCTCGGCTCACTGCAACC
                 TCCACCTCCTGGGTTCAAGCGATTCTCTTGCCTCAACCTCCCAAGCAGTTGGGACTAC
                 AGGCGTGAGCCACCATGCCCCGCTAATTTTTGTATTTTTAGTAGAGACAGGGTTTCAC
                 CATGTTAGCCAGGCTGGTCTCAAACTCCTGACCTCAGGCAATCTGCCCGCCTGGGTCT
                 CCTAAAGTACTGGGATTACAGGCGTGAGCCACCTCGCCCAGCGGCATCAGGCTTTCTT
                 AAAGTGAGACCACGCCTGTACTAGAGCAAGCAGGAATCAGAGACCTTCCAGAAATACT
                 ACTGTGTAAGGGCCAGAAATATCTTCACTTGTCATTGTTATATAATCATTATTACTTT
                 TGCTGTATGTTAATATTGATTTATTAATATATATTATCTTTTCATACATTTTCTAAG
                 AAACATTTATATTGATAAGATCTTTTATTTTGCAAGGGCATAAATTATTGTTTTTCTT
                 TTTTTTTTTTTAATAAATTTCACCAAGT
                 ORF Start: ATG at 97                 ORF Stop: TAG at 1459
                 SEQ ID NO: 144          454 aa       MW at 50398.8kD
NOV12a,          MDPYMIQMSSKGNLPSILDVHVNVGGRSSVPGKMKGRKARWSVRPSDMAKKTFNPIRA
CG135823-01
Protein Sequence IVDNMKVKPNPNKTMISLSIGDPTVFGNLPTDPEVTQANKDALDSGKYNGYAPSIGFL
                 SSREEIASYYHCPEAPLEAKDVILTSGCSQAIDLCLAVLANPGQMILVPRPGFSLYKT
                 LAESMGIEVKLYNLLPEKSWEIDLKQLEYLIDEKTACLIVNNPSNPCGSVFSKRHLQK
                 ILAVAARQCVPILADEIYGDMVFSDCKYEPLATLSTDVPILSCGGLAKRWLVPGWRLG
                 WILIHDRRDIFGNEIRDGLVKLSQRILGPCTIVQGALKSILCRTPGEFYHNTLSFLKS
                 NADLCYGALAAIPGLRPVRPSGAMYLMVGIEMEHFPEFENDVEFTERLVAEQSVHCLP
                 ATCFEYPNFIRVVITVPEVMMLEACSRIQEFCEQHYHCAEGSQEECDK
                 SEQ ID NO: 145         1400 bp
NOV12b,          CCAGAATTCCACCATGGACCCATACATGATTCAGATGAGCAGCAAAGGCAACCTCCCC
CG135823-02
DNA Sequence     TCAATTCTGGACGTGCATGTCAACGTTGGTGGGAGAAGCTCTGTGCCGGGAAAAATGA
                 AAGGCAGAAAGGCCAGGTGGTCTGTGAGGCCCTCAGACATGGCCAAGAAAACTTTCAA
                 CCCCATCCGAGCCATTGTGGACAACATGAAGGTGAAACCAAATCCAAACAAAACCATG
                 ATTTCCCTGTCCATTGGGGACCCTACTGTGTTTGGAAACCTGCCTACAGACCCTGAAG
                 TTACCCAGGCAATGAAAGATGCCCTGGACTCGGGCAAATATAATGGCTATGCCCCATC
                 CATCGGCTTCCTATCCAGTCGGGAGGAGATTGCTTCTTATTACCACTGTCCTGAGGCA
                 CCCCTAGAACCTAAGGACGTCATTCTGACAAGTGGCTGCAGCCAAGCTATTGACCTTT
                 GTTTAGCTGTGTTGGCCAACCCAGGGCAAAACATCCTGGTTCCAAGACCTGGTTTCTC
                 TCTCTACAAGACTCTGGCTGAGTCTATGGGAATTGAGGTCAAACTCTACAATTTGTTG
                 CCAGAGAAATCTTGGGAAATTGACCTGAAACAACTGGAATATCTAATTGATGAAAAGA
                 CAGCTTGTCTCATTGTCAATAATCCATCAAACCCCTGTGGGTCAGTGTTCAGCAAACG
                 TCATCTTCAGAAGATTCTGGCAGTGGCTGCACGGCAGTGTGTCCCCATCTTAGCTGAT
                 GAGATCTATGGAGACATGGTGTTTTCGGATTGCAA2ATATGAACCACTGGCCACCCTCA
                 GCACCGATGTCCCCATCCTGTCCTGTGGAGGGCTGGCCAAGCGCTGGCTGGTTCCTGG
                 CTGGAGGTTGGGCTGGATCCTCATTCATGACCGAAGAGACATTTTTGGCAATGAGATC
                 CGAGATGGGCTGGTGAAGCTGAGTCAGCGCATTTTGGGACCCTGTACCATTGTCCAGG
                 GAGCTCTGAAAAGCATCCTATGTCGCACCCCGGGAGAGTTTTACCACAACACTCTGAG
                 CTTCCTCAAGTCCAATGCTGATCTCTGTTATGGGGCGTTGGCTGCCATCCCTGGACTC
                 CGGCCAGTCCGCCCTTCTGGGGCTATGTACCTCATGGTTGGAATTGAGATGGAACATT
                 TCCCAGAATTTGAGAACGATGTGGAGTTCACGGAGCGGTTAGTTGCTGAGCAGTCTGT
                 CCACTGCCTCCCAGCAACGTGCTTTGAGTACCCGAATTTCATCCGAGTGGTCATCACA
                 GTCCCCGAGGTGATGATGCTGGAGGCGTGCAGCCGGATCCAGGAGTTCTGTGAGCAGC
                 ACTACCATTGTGCTGAAGGCAGCCAGGAGGAGTGTGATAAATAGGGTGGCGGCCGCTT
                 TTTTCCTT
                 ORF Start: ATG at 14                 ORF Stop: TAG at 1376
                 SEQ ID NO: 146          454 aa       MW at 50398.8kD
NOV12b,          MDPYMIQMSSKGNLPSTLDVHVNVGGRSSVPGKMKGRKARWSVRPSDMAKKTFNPIRA
CG135823-02
Protein Sequence IVDNNKVKPNPNKTMISLSIGDPTVFGNLPTDPEVTQAIVTKDALDSGKYNGYAPSIGFL
                 SSREEIASYYHCPEAPLEAKDVILTSGCSQAIDLCLAVLANPGQNILVPRPGFSLYKT
                 LAESMGIEVKLYNLLPEKSWEIDLKQLEYLIDEKTACLIVNNPSNPCGSVFSKRHLQK
                 ILAVAARQCVPILADEIYGDMVFSDCKYEPLATLSTDVPILSCGGLAKRWLVPGWRLG
                 WILIHDRRDIFGNEIRDGLVKLSQRILGPCTIVQGALKSILCRTPGEFYHNTLSFLKS
                 NADLCYGALAAIPGLRPVRPSGANYLMVGIEMEHFPEFENDVEFTERLVAEQSVHCLP
                 ATCFEYPNFIRVVITVPEVMNLEACSRIQEFCEQHYHCAEGSQEECDK
                 SEQ ID NO: 147         1400 bp
NOV12c,          CCAGAATTCCACCATGGACCCATACATGATTCAGATGAGCAGCAAAGGCAACCTCCCC
233048273
DNA Sequence     TCAATTCTGGACGTGCATGTCAACGTTGGTGGGAGAAGCTCTGTGCCGGGAAAAATGA
                 AAGGCAGAAAGGCCAGGTGGTCTGTGAGGCCCTCAGACATGGCCAAGAAAACTTTCAA
                 CCCCATCCGAGCCATTGTGGACAACATGAAGGTGAAACCAAATCCAAACAAAACCATG
                 ATTTCCCTGTCCATTGGGGACCCTACTGTGTTTGGAAACCTGCCTACAGACCCTGAAG
                 TTACCCAGGCAATGAAAGATGCCCTGGACTCGGGCAAATATAATGGCTATGCCCCATC
                 CATCGGCTTCCTATCCAGTCGGGAGGAGATTGCTTCTTATTACCACTGTCCTGAGGCA
                 CCCCTAGAAGCTAAGGACGTCATTCTGACAAGTGGCTGCAGCCAAGCTATTGACCTTT
                 CTTTAGCTGTGTTGGCCAACCCAGGGCAAAACATCCTGGTTCCAAGACCTGGTTTCTC
                 TCTCTACAAGACTCTGGCTGAGTCTATGGGAATTGAGGTCAAACTCTACAATTTGTTG
                 CCAGAGAAATCTTGGGAAATTGACCTGAAACAACTGGAATATCTAATTGATGAAAAGA
                 CAGCTTGTCTCATTGTCAATAATCCATCAAACCCCTGTGGGTCAGTGTTCAGCAAACG
                 TCATCTTCAGAAGATTCTGGCAGTGGCTGCACGGCAGTGTGTCCCCATCTTAGCTGAT
                 GAGATCTATGGAGACATGGTGTTTTCGGATTGCAAATATGAACCACTGGCCACCCTCA
                 GCACCGATGTCCCCATCCTGTCCTGTGGAGGGCTGGCCAAGCGCTGGCTGGTTCCTGG
                 CTGGAGGTTGGGCTGGATCCTCATTCATGACCGAAGAGACATTTTTGGCAATGAGATC
                 CGAGATGCGCTGGTGAAGCTGAGTCAGCGCATTTTGGGACCCTGTACCATTGTCCAGG
                 GACCTCTGAAAAGCATCCTATGTCGCACCCCGGGAGAGTTTTACCACAACACTCTGAG
                 CTTCCTCAAGTCCAATGCTGATCTCTGTTATGGGGCGTTGGCTGCCATCCCTGGACTC
                 CGGCCAGTCCGCCCTTCTGGGGCTATGTACCTCATGGTTGGAATTGAGATGGAACATT
                 TCCCAGAATTTGAGAACGATGTGGAGTTCACGGAGCGGTTAGTTGCTGAGCAGTCTGT
                 CCACTGCCTCCCAGCAACGTGCTTTGAGTACCCGAATTTCATCCGAGTGGTCATCACA
                 GTCCCCGAGGTGATGATGCTGGAGGCGTGCAGCCGGATCCAGGAGTTCTGTGAGCAGC
                 ACTACCATTGTGCTGAAGGCAGCCAGGAGGAGTGTGATAAATAGGGTGGCGGCCGCTT
                 TTTTCCTT
                 ORF Start: at 2                      ORF Stop: TAG at 1376
                 SEQ ID NO: 148          458 aa       MW at 50829.2kD
NOV12c,          QNSTMDPYMIQMSSKGNLPSILDVHVNVGGRSSVPGKMKGRKARWSVRPSDMAKKTFN
233048273
Protein Sequence PIRAIVDNMKVKPNPNKTMISLSIGDPTVFGNLPTDPEVTQAMKDALDSGKYNGYAPS
                 IGFLSSREEIASYYHCPEAPLEAKDVILTSGCSQAIDLCLAVLANPGQNILVPRPGFS
                 LYKTLAESMGIEVKLYNLLPEKSWEIDLKQLEYLIDEKTACLIVNNPSNPCGSVFSKR
                 HLQKILAVAARQCVPILADEIYGDMVFSDCKYEPLATLSTDVPILSCGGLAKRWLVPG
                 WRLGWILIHDRRDIFCNEIRDGLVKLSQRILGPCTTVQGALKSILCRTPGEFYHNTLS
                 FLKSNADLCYGALAAIPGLRPVRPSGAMYLMVGIEMEHFPEFENDVEFTERLVAEQSV
                 HCLPATCFEYPNFIRVVITVPEVMMLEACSRIQEFCEQHYHCAEGSQEECDK
                 SEQ ID NO: 149         1271 bp
NOV12d,          CCAGAATTCCACCATGGACCCATACATGATTCAGATGAGCAGCAAAGGCAACCTCCCC
233048286
DNA Sequence     TCAATTCTGGACGTGCATGTCAACGTTGGTGGGAGAAGCTCTGTGCCGGGAAAAATGA
                 AAGGCAGAAAGGCcAGGTGGTCTGTGAGGCCCTCAGACATGGCCAAGAAAACTTTCAA
                 CCCCATCCGAGCCATTGTGGACAACATGAAGGTGAAACCAAATCCAAACAAAACCATG
                 ATTTCCCTGTCCATTGGGGACCCTACTGTGTTTGGAAACCTGCCTACAGACCCTGAAG
                 TTACCCAGGCAATGAAAGATGCCCTGGACTCGGGCAAATATAATGGCTATGCCCCATC
                 CATCGGCTTCCTATCCAGTCGGGAGGAGATTGCTTCTTATTACCACTGTCCTGAGGCA
                 CCCCTAGAAGCTAAGGACGTCATTCTGACAAGTGGCTGCAGCCAAGCTATTGACCTTT
                 GTTTAGCTGTGTTGGCCAACCCAGGGCAAAACATCCTGGTTCCAAGACCTGGTTTCTC
                 TCTCTACAAGACTCTGGCTGAGTCTATGGGAATTGAGGTCAAACTCTACAATTTGTTG
                 CCAGAGAAATCTTGGGAAATTGACCTGAAACAACTGGAATATCTAATTGATGAAAAGA
                 CAGCTTGTCTCATTGTCAATAATCCATCAAACCCCTGTGGGTCAGTGTTCAGCAAACG
                 TCATCTTCAGAAGATTCTGGCAGTGGCTGCACGGCAGTGTGTCCCCATCTTAGCTCAT
                 GAGATCTATGGAGACATGGTGTTTTCGGATTGCAAATATGAACCACTGGCCACCCTCA
                 GCACCGATGTCCCCATCCTGTCCTGTGGAGGGCTGGCCAAGCGCTGGCTGGTTCCTGG
                 CTGGAGGTTGGGCTGGATCCTCATTCATGACCGAAGAGACATTTTTGGCAATGAGTCC
                 AATGCTGATCTCTGTTATGGGGCGTTGGCTGCCATCCCTGGACTCCGGCCAGTCCGCC
                 CTTCTGGGGCTATGTACCTCATGGTTGGAATTGAGATGGAACATTTCCCAGAATTTGA
                 GAACGATGTGGAGTTCACGGAGCGGTTAGTTGCTGAGCAGTCTGTCCACTGCCTCCCA
                 GCAACGTGCTTTGAGTACCCGAATTTCATCCGAGTCGTCATCACAGTCCCCGAGGTGA
                 TGATGCTGGAGGCGTGCAGCCGGATCCAGGAGTTCTGTGAGCAGCACTACCATTGTGC
                 TGAAGGCAGCCAGGAGGAGTGTGATAAATAGGGTGGCGGCCGCTTTTTTCCTT
                 ORF Start: at 2                      ORF Stop: TAG at 1247
                 SEQ ID NO: 150          415 aa       MW at 46059.6kD
NOV12d,          QNSTMDPYMIQMSSKGNLPSILDVHVNVGGRSSVPGKMKGRKARWSVRPSDMAKKTFN
233048286
Protein Sequence PIRAIVDNMKVKPNPNKTMISLSIGDPTVFGMLPTDPEVTQANKDALDSGKYNGYAPS
                 IGFLSSREEIASYYHCPEAPLEAKDVILTSGCSQAIDLCLAVLANPGQNILVPRPGFS
                 LYKTLAESMGIEVKLYNLLPEKSWEIDLKQLEYLIDEKTACLIVNNPSNPCGSVFSKR
                 HLQKILAVAARQCVPILADEIYGDMVFSDCKYEPLATLSTDVPILSCGGLAKRWLVPG
                 WRLGWILIHDRRDIFGNESNADLCYGALAAIPGLRPVRPSGAMYLMVGIEMEHFPEFE
                 NDVEFTERLVAEQSVHCLPATCFEYPNFIRVVITVPEVMMLEACSRIQEFCEQHYHCA
                 EGSQEECDK
                 SEQ ID NO: 151         1372 bp
NOV12e,          ACCATGGACCCATACATGATTCAGATGACCAGCAAAGGCAACCTCCCCTCAATTCTGG
248490358
DNA Sequence     ACGTGCATGTCAACGTTGGTGGGAGAAGCTCTGTGCCGGGAAAAATGAAAGGCAGAAA
                 GGCCAGGTGGTCTGTGAGGCCCTCAGACATGGCCAAGAAAACTTTCAACCCCATCCGA
                 GCCATTGTGGACAACATGAAGGTGAAACCAAATCCAAACAAAACCATGATTTCCCTGT
                 CCATTGGGGACCCTACTGTGTTTGGAAACCTGCCTACAGACCCTGAAGTTACCCACGC
                 AATGAAAGATGCCCTGGACTCGGGCAAATATAATGGCTATGCCCCATCCATCGGCTTC
                 CTATCCAGTCGGGAGGAGATTGCTTCTTATTACCACTGTCCTGAGGCACCCCTAGAAG
                 CTAAGGACGTCATTCTGACAAGTGGCTGCAGCCAAGCTATTGACCTTTGTTTAGCTGT
                 GTTGCCCAACCCAGGGCAAAACATCCTGGTTCCAAGACCTGGTTTCTCTCTCTACAAG
                 ACTCTGGCTGAGTCTATGGGAATTGAGGTCAAACTCTACAATTTGTTGCCAGAGAAAT
                 CTTGGGAAATTGACCTGAAACAACTGGAATATCTAATTGATGAAAAGACAGCTTGTCT
                 CATTGTCAATAATCCATCAAACCCCTGTGGGTCAGTGTTCACCAAACGTCATCTTCAG
                 AAGATTCTGGCAGTGGCTGCACGGCAGTGTGTCCCCATCTTAGCTGATGAGATCTATG
                 GAGACATGGTGTTTTCGGATTGCAAATATGAACCACTGGCCACCCTCAGCACCGATGT
                 CCCCATCCTGTCCTGTGGAGGGCTGGCCAAGCGCTGGCTGGTTCCTGGCTGGAGGTTG
                 GGCTGGATCCTCATTCATGACCGAAGAGACATTTTTGGCAATGAGATCCGAGATGGGC
                 TGGTGAAGCTGAGTCAGCGCATTTTGGGACCCTGTACCATTGTCCAGGGAGCTCTGAA
                 AAGCATCCTATGTCGCACCCCGGGAGAGTTTTACCACAACACTCTGAGCTTCCTCAAG
                 TCCAATGCTGATCTCTGTTATGGGGCGTTGGCTGCCATCCCTGGACTCCGGCCAGTCC
                 GCCCTTCTGGGGCTATGTACCTCATGGTTGGAATTGAGATGGAACATTTCCCAGAATT
                 TGAGAACGATGTGGAGTTCACGGAGCGGTTAGTTGCTGAGCAGTCTGTCCACTGCCTC
                 CCAGCAACGTGCTTTGAGTACCCGAATTTCATCCGAGTGGTCATCACACTCCCCGAGG
                 TGATGATGCTGGAGGCGTGCAGCCGGATCCAGGAGTTCTGTGAGCAGCACTACCATTG
                 TGCTGAAGGCAGCCAGGAGGAGTGTGATAAATAGGGTG
                 ORF Start: at 1                      ORF Stop: TAG at 1366
                 SEQ ID NO: 152          455 aa       MW at 50499.9kD
NOV12e,          TMDPYMIQMSSKGNLPSILDVHVNVGGRSSVPGKMKGRKARWSVRPSDMAKKTFNPIR
248490358
Protein Sequence AIVDNMKVKPNPNKTMISLSIGDPTVFGNLPTDPEVTQAMKDALDSGKYNGYAPSIGF
                 LSSREEIASYYHCPEAPLEAKDVILTSGCSQAIDLCLAVLANPGQNILVPRPGFSLYK
                 TLAESMGIEVKLYNLLPEKSWEIDLKQLEYLIDEKTACLIVNNPSNPCGSVFSKRHLQ
                 KILAVAARQCVPILADEIYGDMVFSDCKYEPLATLSTDVPTLSCGGLAKRWLVPGWRL
                 GWILIHDRRDIFGNEIRDGLVKLSQRILGPCTIVQGALKSILCRTPGEFYHNTLSFLK
                 SNADLCYGALAAIPGLRPVRPSGANYLMVGIEMEHFPEFENDVEFTERLVAEQSVNCL
                 PATCFEYPNFIRVVITVPEVMNLEACSRIQEFCEQHYHCAEGSQEECDK
                 SEQ ID NO: 153         1398 bp
NOV12f,          ACCCATACATGATTCAGATGAGCAGCAAAGGCAACCTCCCCTCAATTCTGGACGTGCA
254868693
DNA Sequence     TGTCAACGTTGGTGGGAGAAGCTCTGTGCCGGGAAAAATGAAAGGCAGAAAGGCCAGG
                 TGGTCTGTGAGGCCCTCAGACATGGCCAAGAAAACTTTCAACCCCATCCGAGCCATTG
                 TGGACAACATGAAGGTGAAACCAAATCCAAACAAAACCATGATTTCCCTGTCCATTGG
                 GGACCCTACTGTGTTTGGAAACCTGCCTACAGACCCTGAAGTTACCCAGGCAATGAAA
                 GATGCCCTGGACTCGGGCAAATATAATGGCTATGCCCCATCCATCGGCTTCCTATCCA
                 GTCGGGAGGAGATTGCTTCTTATTACCACTGTCCTGAGGCACCCCTAGAAGCTAAGGA
                 CGTCATTCTGACAAGTGGCTGCAGCCAAGCTATTGACCTTTGTTTAGCTGTGTTGGCC
                 AACCCAGGGCAAAACATCCTGGTTCCAAGACCTGGTTTCTCTCTCTACAAGACTCTGG
                 CTGAGTCTATGGGAATTGAGGTCAAACTCTACAATTTGTTGCCAGAGAAATCTTGGGA
                 AATTGACCTGAAACAACTGGAATATCTAATTGATGAAAAGACAGCTTGTCTCATTGTC
                 AATAATCCATCAAACCCCTGTGGGTCAGTGTTCAGCAAACGTCATCTTCAGAAGATTC
                 TGGCAGTGGCTGCACGGCAGTGTGTCCCCATCTTAGCTGATGAGATCTATGGAGACAT
                 GGTGTTTTCGGATTGCAAATATGAACCACTGGCCACCCTCACCACCGATGTCCCCATC
                 CTGTCCTGTGGAGGGCTGGCCAAGCOCTCGCTGGTTCCTGGCTGGAGGTTGGGCTGGA
                 TCCTCATTCATGACCGAAGAGACATTTTTGGCAATGAGATCCGAGATGGGCTGGTGAA
                 GCTGAGTCAGCGCATTTTGGGACCCTGTACCATTGTCCAGGGAGCTCTGAAAAGCATC
                 CTATGTCGCACCCCGGGAGAGTTTTACCACAACACTCTGAGCTTCCTCAAGTCCAATG
                 CTGATCTCTGTTATGGGGCGTTGGCTGCCATCCCTGGACTCCGGCCAGTCCGCCCTTC
                 TGGGCTATGTACCTCATGGTTGGAATTGAGATGGAACATTTCCCAGAATTTGAGAAC
                 GATGTGGAGTTCACGGAGCGGTTAGTTGCTGAGCAGTCTGTCCACTGCCTCCCAGCAA
                 CGTGCTTTGAGTACCCGAATTTCATCCGAGTGGTCATCACAGTCCCCGAGGTGATGAT
                 GCTGGAGGCGTGCAGCCGGATCCAGGAGTTCTGTGAGCAGCACTACCATTGTGCTGAA
                 GGCAGCCAGGAGGAGTGTGATAAATAGGGTGGCGGCCGCACTCGAGCACCACCACCAC
                 CACCAC
                 ORF Start: at 3                      ORF Stop: TAG at 1359
                 SEQ ID NO: 154          452 aa       MW at 50152.5kD
NOV12f,          PYMIQMSSKGNLPSILDVHVNVGGRSSVPGKMKGRKARWSVRPSDMAKKTFNPIRAIV
254868693
Protein Sequence DNMKVKPNPNKTMISLSIGDPTVFGNLPTDPEVTQAMKDALDSGKYNGYAPSIGFLSS
                 REEIASYYHCPEAPLEAKDVILTSGCSQAIDLCLAVLANPGQNILVPRPCFSLYKTLA
                 ESMGIEVKLYNLLPEKSWEIDLKQLEYLIDEKTACLIVNNPSNPCGSVFSKRHLQKIL
                 AVAARQCVPILADEIYGDMVFSDCKYEPLATLSTDVPILSCGGLAKRWLVPGWRLGWI
                 LIHDRRDIFGNEIRDGLVKLSQRILGPCTIVQGALKSILCRTPGEFYHNTLSFLKSNA
                 DLCYGALAAIPGLRPVRPSGANYLMVGIEMEHFPEFENDVEFTERLVAEQSVHCLPAT
                 CFEYPNFIRVVITVPEVMMLEACSRIQEFCEQHYHCAEGSQEECDK
                 SEQ ID NO: 155         1414 bp
NOV12g,          ACATCATCACCACCATCACGACCCATACATGATTCAGATGAGCAGCAAAGGCAACCTC
255667122
DNA Sequence     CCCTCAATTCTGGACGTGCATGTCAACGTTGGTGGGAGAAGCTCTGTGCCCOGAAAAA
                 TGAAAGGCAGAAAGGCCAGGTGGTCTGTGAGGCCCTCAGACATGGCCAAGAAAACTTT
                 CAACCCCATCCGAGCCATTGTGGACAACATGAAGGTGAAACCAAATCCAAACAAAACC
                 ATGATTTCCCTGTCCATTGGGGACCCTACTGTGTTTGGAAACCTGCCTACAGACCCTG
                 AAGTTACCCAGGCAATGAAAGATGCCCTGGACTCGGGCAAATATAATGGCTATGCCCC
                 ATCCATCGGCTTCCTATCCAGTCGGGAGGAGATTGCTTCTTATTACCACTGTCCTGAG
                 GCACCCCTAGAAGCTAAGGACGTCATTCTGACAAGTGGCTGCAGCCAAGCTATTGACC
                 TTTGTTTAGCTGTGTTGCCCAACCCAGGGCAAAACATCCTGGTTCCAAGACCTGGTTT
                 CTCTCTCTACAAGACTCTGCCTGAGTCTATGGGAATTGAGGTCAAACTCTACAATTTG
                 TTGCCAGAGAAATCTTGGGAAATTGACCTGAAACAACTGGAATATCTAATTGATGAAA
                 AGACAGCTTGTCTCATTGTCAATAATCCATCAAACCCCTGTGGGTCAGTGTTCAGCAA
                 ACGTCATCTTCAGAAGATTCTGGCAGTGGCTGCACGGCAGTGTGTCCCCATCTTAGCT
                 GATGAGATCTATGGAGACATGGTGTTTTCGGATTGCAAATATGAACCACTGGCCACCC
                 TCAGCACCGATGTCCCCATCCTGTCCTGTGGAGGGCTGGCCAAGCGCTGGCTGGTTCC
                 TGGCTGGAGGTTGGGCTGGATCCTCATTCATGACCGAAGAGACATTTTTGGCAATGAG
                 ATCCGAGATGGGCTGGTGAAGCTGAGTCAGCGCATTTTGGGACCCTGTACCATTGTCC
                 AGGGAGCTCTGAAAAGCATCCTATGTCGCACCCCGGGAGAGTTTTACCACAACACTCT
                 GAGCTTCCTCAAGTCCAATGCTGATCTCTGTTATGGGGCGTTGGCTGCCATCCCTGGA
                 CTCCGGCCAGTCCGCCCTTCTGGGGCTATGTACCTCATGGTTGGAATTGAGATGGAAC
                 ATTTCCCAGAATTTGAGAACGATGTGGAGTTCACGGAGCGGTTAGTTGCTGAGCAGTC
                 TGTCCACTGCCTCCCAGCAACGTGCTTTGAGTACCCGAATTTCATCCGAGTGGTCATC
                 ACAGTCCCCGAGGTGATGATGCTGGAGGCGTGCAGCCGGATCCAGGAGTTCTGTGAGC
                 AGCACTACCATTGTGCTGAAGGCAGCCAGGAGGAGTGTGATAAATAGGCGGCCGCACT
                 CGAGCACCACCACCACCACCAC
                 ORF Start: at 2                      ORF Stop: TAG at 1379
                 SEQ ID NO: 156          459 aa       MW at 51090.4kD
NOV12g,          HHHHHHDPYMIQMSSKGNLPSILDVHVNVGGRSSVPGKMKGRKARWSVRPSDMAKKTF
255667122
Protein Sequence NPIRAIVDNMKVKPNPNKTMISLSTGDPTVFGNLPTDPEVTQAMKDALDSGKYNGYAP
                 SIGFLSSREETASYYHCPEAPLEAKDVILTSGCSQAIDLCLAVLANPGQNILVPRPGF
                 SLYKTLAESMGIEVKLYNLLPEKSWEIDLKQLEYLIDEKTACLIVNNPSNPCGSVFSK
                 RHLQKILAVAARQCVPILADEIYGDMVFSDCKYEPLATLSTDVPILSCGGLAKRWLVP
                 GWRLGWILIHDRRDIFGNEIRDGLVKLSQRILGPCTIVQGALKSILCRTPGEFYHNTL
                 SFLKSNADLCYGALAAILPGLRPVRPSGAI4YLMVGIEMEHFPEFENDVEFTERLVAEQS
                 VHCLPATCFEYPNFIRVVITVPEVMMLEACSRIQEFCEQHYHCAEGSQEECDK
                 SEQ ID NO: 157         1412 bp
NOV12h,          ACCCATACATGATTCAGATGAGCAGCAAAGGCAACCTCCCCTCAATTCTGGACGTGCA
258252417
DNA Sequence     TGTCAACGTTGGTGGGAGAAGCTCTGTGCCGGGAAAAATGAAAGGCAGAAAGGCCAGG
                 TGGTCTGTGAGGCCCTCAGACATGGCCAAGAAAACTTTCAACCCCATCCGAGCCATTG
                 TGGACAACATGAAGGTGAAACCAAATCCAAACAAAACCATGATTTCCCTGTCCATTGG
                 GGACCCTACTGTGTTTGGAAACCTGCCTACAGACCCTGAAGTTACCCAGGCAATGAAA
                 GATGCCCTGGACTCGGGCAAATATAATGGCTATGCCCCATCCATCGGCTTCCTATCCA
                 GTCGGGAGGAGATTGCTTCTTATTACCACTGTCCTGAGGCACCCCTAGAAGCTAAGGA
                 CGTCATTCTGACAAGTGGCTGCAGCCAAGCTATTGACCTTTGTTTAGCTGTGTTAACC
                 AACCCAGGGCAAAACATCCTCGTTCCAAGACCTGGTTTCTCTCTCTACAAGACTCTGG
                 CTGAGTCTATGGGAATTGAGGTCAAACTCTACAATTTGTTGCCAGAGAAATCTTGCGA
                 AATTGACCTGAAACAACTGGAATATCTAATTGATGAAAAGACAGCTTGTCTCATTGTC
                 AATAATCCATCAAACCCCTGTGGGTCAGTGTTCAGCAAACGTCATCTTCAGAAGATTC
                 TGGCAGTGGCTGCACGGCAGTGTGTCCCCATCTTAGCTGATGAGATCTATGGAGACAT
                 GGTGTTTTCGGATTGCAAATATGAACCACTGGCCACCCTCAGCACCGATGTCCCCATC
                 CTGTCCTGTGGAGGGCTGGCCAAGCGCTGGCTGGTTCCTGGCTGGAGGTTGGGCTGGA
                 TCCTCATTCATGACCGAAGAGACATTTTTGGCAATGAGATCCGAGATGGGCTGGTGAA
                 GCTGAGTCAGCGCATTTTGGGACCCTGTACCATTGTCCAGGGAGCTCTGAAAAGCATC
                 CTATGTCGCACCCCGGGAGAGTTTTACCACAACACTCTGAGCTTCCTCAAGTCCAATG
                 CTGATCTCTGTTATGGGGCGTTGGCTGCCATCCCTGGACTCCGGCCAGTCCGCCCTTC
                 TGGGGCTATGTACCTCATGGTTGGAATTGAGATGGAACATTTCCCAGAATTTGAGAAC
                 GATGTGGAGTTCACGGAGCGGTTAGTTGCTGAGCAGTCTGTCCACTGCCTCCCAGCAA
                 CGTGCTTTGAGTACCCGAATTTCATCCGAGTGGTCATCACAGTCCCCGAGGTGATGAT
                 GCTGGAGGCGTGCAGCCGGATCCAGGAGTTCTGTGAGCAGCACTACCATTGTGCTGAA
                 GGCAGCCAGGAGGAGTGTGATAAACATCATCACCACCATCACTAGGCGGCCGCACTCG
                 AGCACCACCACCACCACCAC
                 ORF Start: at 3                      ORF Stop: TAG at 1377
                 SEQ ID NO: 158          458 aa       MW at 50975.4kD
NOV12h,          PYMIQMSSKGNLPSILDVHVNVGGRSSVPGKMKGRKARWSVRPSDMAKKTFNPIRAIV
258252417
Protein Sequence DNNKVKPNPNKTMISLSIGDPTVFGNLPTDPEVTQANKDALDSGKYNGYAPSIGFLSS
                 REEIASYYHCPEAPLEAKDVILTSGCSQAIDLCLAVLANPGQNILVPRPGFSLYKTLA
                 ESMGIEVKLYNLLPEKSWEIDLKQLEYLIDEKTACLIVNNPSNPCGSVFSKRHLQKIL
                 AVAARQCVPILADEIYGDMVFSDCKYEPLATLSTDVPILSCGGLAKRWLVPGWRLGWI
                 LIHDRRDIFGNEIRDGLVKLSQRILGPCTIVQGALKSILCRTPGEFYHNTLSFLKSNA
                 DLCYGALAAIPGLRPVRPSGAMYLMVGIEMEHFPEFENDVEFTERLVAEQSVHCLPAT
                 CFEYPNFIRVVITVPEVMIVILEACSRIQEFCEQHYHCAEGSQEECDKHHHHHH
                 SEQ ID NO: 159         1385 bp
NOV12i,          CCATGGACCCATACATGATTCAGATGAGCAGCAAAGGCAACCTCCCCTCAATTCTGGA
259741773
DNA Sequence     CGTGCATGTCAACGTTGGTGGGAGAAGCTCTGTGCCGGGAAAAATGAAAGGCAGAAAG
                 GCCAGGTGGTCTGTGAGGCCCTCAGACATGGCCAAGAAAACTTTCAACCCCATCCGAG
                 CCATTGTGGACAACATGAAGGTGAAACCAAATCCAAACAAAACCATGATTTCCCTGTC
                 CATTGGGGACCCTACTGTGTTTGGAAACCTGCCTACAGACCCTGAAGTTACCCAGGCA
                 ATGAAAGATGCCCTGGACTCAGGCAAATATAATGGCTATGCCCCATCCATCGGCTTCC
                 TATCCAGTCGGGAGGAGATTGCTTCTTATTACCACTGTCCTGAGGCACCCCTAGAAGC
                 TAAGGACGTCATTCTCACAAGTGGCTGCAGCCAAGCTATTGACCTTTGTTTAGCTGTG
                 TTGGCCAACCCAGGGCAAAACATCCTGGTTCCAAGACCTGGTTTCTCTCTCTACAAGA
                 CTCTGGCTGAGTCTATGGGAATTGAGGTCAAACTCTACAATTTGTTGCCAGAGAAATC
                 TTGGGAAATTGACCTGAAACAACTGGAATATCTAATTGATGAAAAGACAGCTTGTCTC
                 ATTGTCAATAATCCATCAAACCCCTGTGGGTCAGTGTTCAGCAAACGTCATCTTCAGA
                 AGATTCTGGCAGTGGCTGCACGGCAGTGTGTCCCCATCTTAGCTGATGAGATCTATGG
                 AGACATGGTGTTTTCGGATTGCAAATATGAACCACTGGCCACCCTCAGCACCGATGTC
                 CCCATCCTGTCCTGTGGAGGGCTGGCCAAGCGCTGGCTGGTTCCTGGCTGGAGGTTGG
                 GCTGGATCCTCATTCATGACCGAAGAGACATTTTTGGCAATGAGATCCGAGATGGGCT
                 GGTGAAGCTGAGTCACCGCATTTTGGGACCCTGTACCATTGTCCAGGGAGCTCTGAAA
                 AGCATCCTATGTCGCACCCCGGGAGAGTTTTACCACAACACTCTGAGCTTCCTCAAGT
                 CCAATGCTGATCTCTGTTATGGGGCGTTGGCTGCCATCCCTGGACTCCGGCCAGTCCG
                 CCCTTCTGGGGCTATGTACCTCATGGTTGGAATTGAGATGGAACATTTCCCAGAATTT
                 GAGAACGATGTGGAGTTCACGGAGCGGTTAGTTGCTGAGCAGTCTGTCCACTGCCTCC
                 CAGCAACGTGCTTTCAGTACCCGAATTTCATCCGAGTGGTCATCACAGTCCCCGAGGT
                 GATGATGCTGGAGGCGTGCAGCCGGATCCAGGAGTTCTGTGAGCAGCACTACCATTGT
                 GCTGAAGGCAGCCAGGAGGAGTGTGATAAACATCATCACCACCATCACTAG
                 ORF Start: ATG at 3                  ORF Stop: TAG at 1383
                 SEQ ID NO: 160          460 aa       MW at 51221.6kD
NOV12i,          MDPYMIQMSSKGMLPSILDVHVNVGGRSSVPGKMKGRKARWSVRPSDMAKKTFNPIRA
259741773
Protein Sequence IVDNMKVKPNPNKTMISLSIGDPTVFGNLPTDPEVTQAMKDALDSGKYNGYAPSIGFL
                 SSREEIASYYHCPEAPLEAKDVILTSGCSQAIDLCLAVLANPGQNILVPRPGFSLYKT
                 LAESMGIEVKLYNLLPEKSWEIDLKQLEYLIDEKTACLIVNNPSNPCGSVFSKRHLQK
                 ILAVAARQCVPILADEIYGDMVFSDCKYEPLATLSTDVPILSCGGLAKRWLVPGWRLG
                 WILIHDRRDIFGNEIRDGLVKLSQRILGPCTIVQGALKSILCRTPGEFYHNTLSFLKS
                 NADLCYGALAAIPGLRPVRPSGAMYLMVGIEMEHFPEFENDVEFTERLVAEQSVHCLP
                 ATCFEYPNFIRVVITVPEVMMLEACSRIQEFCEQHYHCAEGSQEECDKHHHHHH
                 SEQ ID NO: 161         1370 bp
NOV12j,          CACCATGGACCCATACATGATTCAGATGAGCAGCAAAGGCAACCTCCCCTCAATTCTG
260480043
DNA Sequence     GACGTGCATGTCAACGTTGGTGGGAGAAGCTCTGTGCCGGGAAAAATGAAAGGCAGAA
                 AGGCCAGGTGGTCTGTGAGGCCCTCAGACATGGCCAAGAAAACTTTCAACCCCATCCG
                 AGCCATTGTGGACAACATGAAGCTGAAACCAAATCCAAACAAAACCATGATTTCCCTG
                 TCCATTGGGGACCCTACTGTGTTTGGAAACCTGCCTACAGACCCTGAAGTTACCCAGG
                 CAATGAAAGATGCCCTGGACTCGGGCAAATATAATGGCTATGCCCCATCCATCGGCTT
                 CCTATCCAGTCGGGAGGAGATTGCTTCTTATTACCACTGTCCTGAGGCACCCCTAGAA
                 GCTAAGGACGTCATTCTGACAAGTGGCTGCAGCCAAGCTATTGACCTTTGTTTAGCTG
                 TGTTGGCCAACCCAGGGCAAAACATCCTGGTTCCAAGACCTGGTTTCTCTCTCTACAA
                 GACTCTGGCTGAGTCTATGGGAATTGAGGTCAAACTCTACAATTTGTTGCCAGAGAAA
                 TCTTGGGAAATTGACCTGAAACAACTGCAATATCTAATTGATGAAAAGACAGCTTGTC
                 TCATTGTCAATAATCCATCAAACCCCTGTGGGTCAGTGTTCAGCAAACGTCATCTTCA
                 GAAGATTCTGGCAGTGGCTGCACGGCAGTGTGTCCCCATCTTAGCTGATGAGATCTAT
                 GGAGACATGGTGTTTTCGGATTGCAAATATGAACCACTGGCCACCCTCAGCACCGATG
                 TCCCCATCCTGTCCTGTGGAGGGCTGGCCAAGCGCTGGCTGGTTCCTGGCTGGAGGTT
                 GGGCTGGATCCTCATTCATGACCGAAGAGACATTTTTGGCAATGAGATCCGAGATGGG
                 CTGGTGAAGCTGAGTCAGCGCATTTTGGGACCCTGTACCATTGTCCAGGGAGCTCTGA
                 AAAGCATCCTATGTCGCACCCCGGGAGAGTTTTACCACAACACTCTGAGCTTCCTCAA
                 GTCCAATGCTGATCTCTGTTATGGGGCGTTGGCTGCCATCCCTGGACTCCGGCCAGTC
                 CGCCCTTCTGGGGCTATGTACCTCATGGTTGGAATTGAGATGGAACATTTCCCAGAAT
                 TTGAGAACGATGTGGAGTTCACGGAGCGGTTAGTTGCTGAGCAGTCTGTCCACTGCCT
                 CCCAGCAACGTGCTTTGAGTACCCGAATTTCATCCGAGTGGTCATCACAGTCCCCGAG
                 GTGATGATGCTGGAGGCGTGCAGCCGGATCCAGGAGTTCTGTGAGCAGCACTACCATT
                 GTGCTGAAGGCAGCCAGGAGGAGTGTGATAAATAGG
                 ORF Start: at 2                      ORF Stop: TAG at 1367
                 SEQ ID NO: 162          455 aa       MW at 50499.9kD
NOV12j,          TMDPYMIQMSSKGNLPSILDVHVNVGGRSSVPGKMKGRKARWSVRPSDMAKKTFNPIR
260480043
Protein Sequence AIVDNMKVKPNPNKTMISLSIGDPTVFGNLPTDPEVTQAMKDALDSGKYNGYAPSIGF
                 LSSREEIASYYHCPEAPLEAKDVILTSGCSQAIDLCLAVLANPGQNILVPRPGFSLYK
                 TLAESMGIEVKLYNLLPEKSWEIDLKQLEYLTDEKTACLIVNNPSNPCGSVFSKRHLQ
                 KILAVAARQCVPILADEIYGDMVFSDCKYEPLATLSTDVPILSCGGLAKRWLVPGWRL
                 GWILIHDRRDIFGNEIRDGLVKLSQRILGPCTIVQGALKSILCRTPGEFYHNTLSFLK
                 SNADLCYGALAAIPGLRPVRPSGAMYLMVGIEMEHFPEFENDVEFTERLVAEQSVHCL
                 PATCFEYPNFIRVVITVPEVMMLEACSRIQEFCEQHYHCAEGSQEECDK
                 SEQ ID NO: 163         1414 bp
NOVi2k,          ACATCATCACCACCATCACGACCCATACATGATTCAGATGAGCAGCAAAGGCAACCTC
CG135823-03
DNA Sequence     CCCTCAATTCTGGACGTGCATGTCAACGTTGGTGGGAGAAGCTCTGTGCCGGGAAAAA
                 TGAAAGGCAGAAAGGCCAGGTGGTCTGTGAGGCCCTCAGACATGGCCAAGAAAACTTT
                 CAACCCCATCCGAGCCATTGTGGACAACATGAAGGTGAAACCAAATCCAAACAAAACC
                 ATGATTTCCCTGTCCATTGGGGACCCTACTGTGTTTGGAAACCTGCCTACAGACCCTG
                 AAGTTACCCAGGCAATGAAAGATGCCCTGGACTCGGGCAAATATAATGGCTATGCCCC
                 ATCCATCGGCTTCCTATCCAGTCGGGAGGAGATTGCTTCTTATTACCACTGTCCTGAG
                 GCACCCCTAGAAGCTAAGGACGTCATTCTGACAAGTGGCTGCAGCCAAGCTATTGACC
                 TTTGTTTAGCTGTGTTGGCCAACCCAGGGCAAAACATCCTGGTTCCAAGACCTGGTTT
                 CTCTCTCTACAAGACTCTGGCTGAGTCTATGGGAATTGAGGTCAAACTCTACAATTTG
                 TTGCCAGAGAAATCTTGGGAAATTGACCTGAAACAACTGGAATATCTAATTGATGAAA
                 AGACAGCTTGTCTCATTGTCAATAATCCATCAAACCCCTGTGGGTCAGTGTTCAGCAA
                 ACGTCATCTTCAGAAGATTCTGGCACTGGCTGCACGGCAGTGTGTCCCCATCTTAGCT
                 GATGAGATCTATGGACACATGGTGTTTTCGGATTGCAAATATGAACCACTCGCCACCC
                 TCAGCACCGATGTCCCCATCCTGTCCTGTGGAGCGCTGGCCAAGCGCTGGCTGGTTCC
                 TGGCTGGAGGTTGGGCTGGATCCTCATTCATGACCGAAGAGACATTTTTGGCAATGAG
                 ATCCGAGATGGGCTGGTGAAGCTGAGTCAGCGCATTTTGGGACCCTGTACCATTGTCC
                 AGGGAGCTCTGAAAAGCATCCTATGTCGCACCCCGGGAGAGTTTTACCACAACACTCT
                 GAGCTTCCTCAAGTCCAATGCTGATCTCTGTTATGGGGCGTTGGCTGCCATCCCTGGA
                 CTCCGGCCAGTCCGCCCTTCTGGGGCTATGTACCTCATGGTTGGAATTGAGATGGAAC
                 ATTTCCCAGAATTTGAGAACGATGTGGAGTTCACGGAGCGGTTAGTTGCTGAGCAGTC
                 TGTCCACTGCCTCCCAGCAACGTGCTTTGAGTACCCGAATTTCATCCGAGTGGTCATC
                 ACAGTCCCCGAGGTGATGATGCTGGAGGCGTGCAGCCGGATCCAGGAGTTCTGTCAGC
                 AGCACTACCATTGTGCTGAAGGCAGCCAGGAGGAGTGTGATAAATAGGCGGCCGCACT
                 CGAGCACCACCACCACCACCAC
                 ORF Start: at 2                      ORF Stop: TAG at 1379
                 SEQ ID NO: 164          459 aa       MW at 51090.4kD
NOV12k,          HHHHHHDPYMTQMSSKGNLPSILDVHVNVGGRSSVPGKMKGRKARWSVRPSDMAKKTF
CG135823-03
Protein Sequence NPIRAIVDNNKVKPNPNKTMISLSIGDPTVFGNLPTDPEVTQAMKDALDSGKYNGYAP
                 SIGFLSSREEIASYYHCPEAPLEAKDVILTSGCSQAIDLCLAVLANPGQNILVPRPGF
                 SLYKTLAESMGIEVKLYNLLPEKSWEIDLKQLEYLIDEKTACLIVNNPSNPCGSVFSK
                 RHLQKILAVAARQCVPILADEIYGDMVFSDCKYEPLATLSTDVPILSCGGLAKRWLVP
                 GWRLGWILIHDRRDIFGNEIRDGLVKLSQRILGPCTIVQGALKSILCRTPGEFYHNTL
                 SFLKSNADLCYGALAAIPGLRPVRPSCANYLMVGIEMEHFPEFENDVEFTERLVAEQS
                 VHCLPATCFEYPNFIRVVITVPEVMNLEACSRIQEFCEQHYHCAEGSQEECDK
                 SEQ ID NO: 165         1412 bp
NOV12l,          ACCCATACATGATTCAGATGAGCAGCAAAGGCAACCTCCCCTCAATTCTGGACGTCCA
CG135823-04
DNA Sequence     TGTCAACGTTGGTCGGAGAAGCTCTGTGCCGGGAAAAATGAAAGGCAGAAAGGCCAGG
                 TGGTCTGTGAGGCCCTCAGACATGGCCAAGAAAACTTTCAACCCCATCCGAGCCATTG
                 TGGACAACATGAAGGTGAAACCAAATCCAAACAAAACCATGATTTCCCTGTCCATTGG
                 GGACCCTACTGTGTTTGGAAACCTGCCTACAGACCCTGAAGTTACCCAGGCAATGAAA
                 GATGCCCTGGACTCGGGCAAATATAATGGCTATGCCCCATCCATCGGCTTCCTATCCA
                 GTCGGGAGGAGATTGCTTCTTATTACCACTGTCCTGAGGCACCCCTAGAAGCTAAGGA
                 CGTCATTCTGACAAGTGGCTGCAGCCAAGCTATTGACCTTTGTTTAGCTGTGTTGGCC
                 AACCCAGGGCAAAACATCCTGGTTCCAAGACCTGGTTTCTCTCTCTACAAGACTCTGG
                 CTGAGTCTATGGGAATTGAGGTCAAACTCTACAATTTGTTGCCAGAGAAATCTTGGGA
                 AATTGACCTGAAACAACTGGAATATCTAATTGATGAAAAGACAGCTTGTCTCATTGTC
                 AATAATCCATCAAACCCCTGTGGGTCAGTGTTCAGCAAACGTCATCTTCAGAAGATTC
                 TGGCAGTGGCTGCACCGCAGTGTGTCCCCATCTTAGCTGATGAGATCTATGGAGACAT
                 GGTGTTTTCGGATTGCAAATATGAACCACTGGCCACCCTCAGCACCGATGTCCCCATC
                 CTGTCCTGTGGAGGGCTGGCCAAGCGCTGGCTGGTTCCTGGCTGGAGGTTGGGCTGGA
                 TCCTCATTCATGACCGAAGAGACATTTTTGGCAATCAGATCCGAGATGGGCTCGTGAA
                 GCTGAGTCAGCGCATTTTGGGACCCTGTACCATTGTCCAGGGAGCTCTGAAAAGCATC
                 CTATGTCGCACCCCGGGAGAGTTTTACCACAACACTCTGAGCTTCCTCAAGTCCAATG
                 CTGATCTCTGTTATGGGGCGTTGGCTGCCATCCCTGGACTCCGGCCAGTCCGCCCTTC
                 TGGGGCTATGTACCTCATGGTTGGAATTGAGATGGAACATTTCCCAGAATTTGAGAAC
                 GATGTGGAGTTCACGGAGCGGTTAGTTGCTGAGCAGTCTGTCCACTGCCTCCCAGCAA
                 CGTGCTTTGAGTACCCGAATTTCATCCGAGTGGTCATCACAGTCCCCGAGGTGATGAT
                 GCTGGAGGCGTGCAGCCGGATCCAGGAGTTCTGTGAGCAGCACTACCATTGTGCTGAA
                 GGCAGCCAGGAGGAGTGTGATAAACATCATCACCACCATCACTAGGCGCCCGCACTCG
                 AGGACCACCACCACCACCAC
                 ORF Start: ATG at 9                  ORF Stop: TAG at 1377
                 SEQ ID NO: 166          456 aa       MW at 50715.lkD
NOV12l,          MIQMSSKGNLPSILDVHVNVGGRSSVPGKMKGRKARWSVRPSDMAKKTFNPIRAIVDN
CG135823-04
Protein Sequence MKVKPNPNKTMISLSIGDPTVFGNLPTDPEVTQAMKDALDSGKYNGYAPSIGFLSSRE
                 EIASYYHCPEAPLEAKDVILTSGCSQAIDLCLAVLANPGQNILVPRPGFSLYKTLAES
                 MGIEVKLYNLLPEKSWEIDLKQLEYLIDEKTACLIVNNPSNPCGSVFSKRHLQKILAV
                 AARQCVPILADEIYGDMVFSDCKYEPLATLSTDVPILSCGGLAKRWLVPGWRLGWILI
                 HDRRDIFGNEIRDGLVKLSQRILGPCTIVQGALKSILCRTPGEFYHNTLSFLKSNADL
                 CYGALAAIPGLRPVRPSGAMYLMVGIEMEHFPEFENDVEFTERLVAEQSVHCLPATCF
                 EYPNFIRVVITVPEVMMLEACSRIQEFCEQHYHCAEGSQEECDKHNHHHH

[0418] Sequence comparison of the above protein sequences yields the following sequence relationships shown in Table 12B.

TABLE 12B
Comparison of NOV12a against NOV12b through NOV121.
			Identities/
			Similarities
	Protein	NOV12a Residues/	for the
	Sequence	Match Residues	Matched Region
	NOV12b	1 . . . 454	454/454 (100%)
		1 . . . 454	454/454 (100%)
	NOV12c	1 . . . 454	454/454 (100%)
		5 . . . 458	454/454 (100%)
	NOV12d	1 . . . 454	411/454 (90%)
		5 . . . 415	411/454 (90%)
	NOV12e	1 . . . 454	454/454 (100%)
		2 . . . 454	454/454 (100%)
	NOV12f	3 . . . 454	452/452 (100%)
		1 . . . 452	452/452 (100%)
	NOV12g	2 . . . 454	453/453 (100%)
		7 . . . 459	453/453 (100%)
	NOV12h	3 . . . 454	452/452 (100%)
		1 . . . 452	452/452 (100%)
	NOV12i	1 . . . 454	454/454 (100%)
		1 . . . 454	454/454 (100%)
	NOV12j	1 . . . 454	454/454 (100%)
		2 . . . 455	454/454 (100%)
	NOV12k	2 . . . 454	453/453 (100%)
		7 . . . 459	453/453 (100%)
	NOV12l	5 . . . 454	450/450 (100%)
		1 . . . 450	450/450 (100%)

[0419] Further analysis of the NOV12a protein yielded the following properties shown in Table 12C.

TABLE 12C
Protein Sequence Properties NOV12a
PSort analysis:   0.6500 probability located in cytoplasm;
                  0.1000 probability located in mitochondrial
                  matrix space; 0.1000 probability located in
                  lysosome (lumen); 0.0000 probability located
                  in endoplasmic reticulum (membrane)
SignalP analysis: No Known Signal Sequence Predicted

[0420] A search of the NOV12a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 12D.

TABLE 12D
Geneseq Results for NOV12a
			Identities/
			Similarities
Geneseq	Protein/Organism/	NOV12a Residues/	for the	Expect
Identifier	Length [Patent #, Date]	Match Residues	Matched Region	Value
ABB58136	Drosophila melanogaster	37 . . . 442	212/411 (51%)	e−128
	polypeptide SEQ ID NO 1200 -	75 . . . 481	296/411 (71%)
	Drosophila melanogaster, 501 aa.
	[WO200171042-A2, 27 SEP. 2001]
AAG10932	Arabidopsis thaliana protein	68 . . . 441	136/382 (35%)	3e−67
	fragment SEQ ID NO: 9454 -	8 . . . 385	220/382 (56%)
	Arabidopsis thaliana, 407 aa.
	[EP1033405-A2, 06 SEP. 2000]
AAG10931	Arabidopsis thaliana protein	68 . . . 441	136/382 (35%)	3e−67
	fragment SEQ ID NO: 9453 -	46 . . . 423	220/382 (56%)
	Arabidonsis thaliana. 445 aa.
	[EP1033405-A2, 06 SEP. 2000]
AAG10930	Arabidopsis thaliana protein	68 . . . 441	136/382 (35%)	3e−67
	fragment SEQ ID NO: 9452 -	67 . . . 444	220/382 (56%)
	Arabidopsis thaliana, 466 aa.
	[EP1033405-A2, 06 SEP. 2000]
AAG39068	Arabidopsis thaliana protein	68 . . . 441	135/382 (35%)	3e−66
	fragment SEQ ID NO: 48288 -	8 . . . 385	219/382 (56%)
	Arabidopsis thaliana, 407 aa.
	[EP1033405-A2, 06 SEP. 2000]

[0421] In a BLAST search of public sequence datbases, the NOV12a protein was found to have homology to the proteins shown in the BLASTP data in Table 12E.

TABLE 12E
Public BLASTP Results for NOV12a
			Identities/
Protein			Similarities
Accession		NOV12a Residues/	for the	Expect
Number	Protein/Organism/Length	Match Residues	Matched Portion	Value
P17735	Tyrosine aminotransferase (EC	1 . . . 454	454/454 (100%)	0.0
	2.6.1.5) (L-tyrosine: 2-oxoglutarate	1 . . . 454	454/454 (100%)
	aminotransferase) (TAT) - Homo
	sapiens (Human), 454 aa.
Q8QZR1	Similar to tyrosine aminotransferase	1 . . . 454	418/454 (92%)	0.0
	(Hypothetical 50.6 kDa protein) -	1 . . . 454	439/454 (96%)
	Mus musculus (Mouse), 454 aa.
P04694	Tyrosine aminotransferase (EC	1 . . . 454	416/454 (91%)	0.0
	2.6.1.5) (L-tyrosine: 2-oxoglutarate	1 . . . 454	436/454 (95%)
	aminotransferase) (TAT) - Rattus
	norvegicus (Rat), 454 aa.
Q9XSW4	Tyrosine aminotransferase -	1 . . . 454	417/454 (91%)	0.0
	Mustela vison (American mink),	1 . . . 454	438/454 (95%)
	454 aa.
Q9QWS4	Tyrosine aminotransferase -	1 . . . 454	415/454 (91%)	0.0
	Rattus norvegicus (Rat), 454 aa.	1 . . . 454	435/454 (95%)

[0422] PFam analysis predicts that the NOV12a protein contains the domains shown in the Table 12F.

TABLE 12F
Domain Analysis of NOV12a
		Identities/
		Similarities
	NOV12a Match	for the	Expect
Pfam Domain	Region	Matched Region	Value
aminotran_1_2	113 . . . 438	72/356 (20%)	2.1e−76
		262/356 (74%)

Example 13

[0423] The NOV13 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 13A.

TABLE 13A
NOV13 Sequence Analysis
                 SEQ ID NO: 167         1894 bp
NOV13a,          CGCCGCTCGCCCCAGACTTACTTCCCCGGCTCACCAGGGAAAGGTTCCTAGAAGGTGA
CG140122-01
DNA Sequence     GCGCGGACGGTATGCAAAGTTGTGAATCCAGTGGTGACAGTGCGGATGACCCTCTCAG
                 TCGCGGCCTACGGAGAAGGGGACAGCCTCGTGTGGTGGTGATCGGCGCCGGCTTGGCT
                 GGCCTGGCTGCAGCCAAAGCACTTCTTGAGCAGGGTTTCACGGATGTCACTGTGCTTG
                 AGGCTTCCAGCCACATCGGAGGCCGTGTGCAGAGTGTGAAACTTGGACACGCCACCTT
                 TGAGCTGCGAGCCACCTGGATCCATGGCTCCCATGGGAACCCTATCTATCATCTAGCA
                 GAAGCCAACGAACCTCCTGGAAGAGACAACCGATGGGGAACGCAGCGTGGGCCGCATCA
                 GCCTCTATTCCAAGAATGGCGTGGCCTGCTACCTTACCAACCACGGCCGCAGGATCCC
                 CAAGGACGTGGTTGAGGAATTCAGCGATTTATACAACGAGGTCTATAACTTGACCCAG
                 GAGTTCTTCCGGCACGATAAACCAGTCAATGCTGAAAGTCAAAATAGCGTGGGGGTGT
                 TCACCCGAGAGGACGTGCGTAACCGCATCAGGAATGACCCTGACGACCCAGAGGCTAC
                 CAAGCGCCTGAAGCTCGCCATGATCCAGCAGTACCTGAAGGTGGAGAGCTGTGAGAGC
                 AGCTCACACAGCATGGACGAGGTGTCCCTGAGCGCCTTCGGGGAGTGGACCGAGATCC
                 CCGGCGCTCACCACATCATCCCCTCGGGCTTCATGCGGGTTGTGGAGCTGCTGGCGGA
                 GGGCATCCCTGCCCACGTCATCCAGCTAGGGAAACCTGTCCGCTGCATTCACTGGGAC
                 CAGGCCTCAGCCCGCCCCAGAGGCCCTGAGATTGAGCCCCGGGGTGAGGGCGACCACA
                 ATCACGACACTGGGGAGGGTGGCCAGGGTGGAGAGGAGCCCCCGGGGGGCAGGTGGGA
                 TGAGGATGAGCAGTGGTCGGTGGTGGTGGAGTGCGAGGACCGTGAGCTGATCCCGGCG
                 GACCATGTGATTGTGACCGTGTCGCTAGGTGTGCTAAAGAGGCAGTACACCAGTTTCT
                 TCCGCCCAGGCCTGCCCACAGAGAAGGTGGCTGCCATCCACCCCCTGGGCATTGGCAC
                 CACCGACAAGATCTTTCTGGAATTCGAGGAGCCCTTCTGGGGCCCTGAGTGCAACAGC
                 CTACAGTTTGTGTGGGAGGACGAAGCGGAGAGCCACACCCTCACCTACCCACCTGAGC
                 TCTGGTACCGCAAGATCTGCGGCTTTGATGTCCTCTACCCGCCTGAGCGCTACGGCCA
                 TGTGCTGAGCGGCTGGATCTGCGGGGAGGAGGCCCTCGTCATGGAGAAGTGTGATGAC
                 GAGGCAGTGGCCGAGATCTGCACGGAGATGCTGCGTCAGTTCACAGGGAACCCCAACA
                 TTCCAAAACCTCGGCGAATCTTGCGCTCGGCCTGGGGCAGCAACCCTTACTTCCGTGG
                 CTCCTATTCATACACGCAGGTGGGCTCCAGCGGGGCGGATGTGGAGAAGCTGGCCAAG
                 CCCCTGCCGTACACGGAGAGCTCAAAGACAGCGCCCATGCAGGTGCTGTTTTCCGGTG
                 AGGCCACCCACCGCAAGTACTATTCCACCACCCACGGTGCTCTGCTGTCCGGCCAGCG
                 TGAGGCTGCCCGCCTCATTGAGATGTACCGAGACCTCTTCCAGCAGGGGACCTGAGGG
                 CTGTCCTCGCTGCTGAGAAGAGCCACTAACTCGTGACCTCCAGCCTGCCCCTTGCTGC
                 CGTGTGCTCCTGCCTTCCTGATCCTCTGTAGAAAGGATTTTTATCTTCTGTAGAGCTA
                 GCCGCCCTGACTGCCTTCAGACCTGGCCCTGTAGCTTT
                 ORF Start: ATG at 70                 ORF Stop: TGA at 1735
                 SEQ ID NO: 168          555 aa       MW at 61871.7kD
NOV13a,          MQSCESSGDSADDPLSRGLRRRGQPRVVVIGAGLAGLAAAKALLEQGFTDVTVLEASS
CG140122-01
Protein Sequence HIGGRVQSVKLGHATFELGATWIHGSHGNPIYHLAEANGLLEETTDGERSVGRISLYS
                 KNGVACYLTNHGRRIPKDVVEEFSDLYNEVYNLTQEFFRHDKPVNAESQNSVGVFTRE
                 EVRNRIRNDPDDPEATKRLKLANIQQYLKVESCESSSHSMDEVSLSAFGEWTEIPGAII
                 HIIPSGFMRVVELLAEGIPAHVIQLGKPVRCIHWDQASARPRGPEIEPRGEGDHNHDT
                 GEGGQGGEEPRGGRWDEDEQWSVVVECEDRELIPADHVIVTVSLGXTLKRQYTSFFRPG
                 LPTEKVAAIHRLGIGTTDKIFLEFEEPFWGPECNSLQFVWEDEAESHTLTYPPELWYR
                 KICGFDVLYPPERYGHVLSGWICGEEALVMEKCDDEAVAEICTEMLRQFTGNPNIPKP
                 RRILRSAWGSNPYFRGSYSYTQVGSSGADVEKLAKPLPYTESSKTAPMQVLFSGEATH
                 RKYYSTTNGALLSGQREAARLIEMYRDLFQQGT
                 SEQ ID NO: 169         1012 bp
NOV13b,          CACCATGCAAAGTTGTGAATCCAGTGGTGACAGTGCGGATGACCCTCTCAGTCGCGGC
246864043
DNA Sequence     CTACGGAGAAGGGGACAGCCTCGTGTGGTGGTGATCGGCGCCGGCTTGGCTGGCCTGG
                 CTGCAGCCAAAGCACTTCTTGAGCAGGGTTTCACGGATGTCACTGTGCTTGAGGCTTC
                 CAGCCACATCGGAGGCCGTGTGCAGAGTGTGAAACTTGGACACGCCACCTTTGAGCTG
                 GGAGCCACCTGGATCCATGGCTCCCATGGGAACCCTATCTATCATCTAGCAGAAGCCA
                 ACGGCCTCCTGGAAGAGACAACCGATGGGGAACGCAGCGTGGGCCGCATCAGCCTCTA
                 TTCCAAGAATGGCGTGGCCTGCTACCTTACCAACCACGGCCGCAGGATCCCCAAGGAC
                 GTGGTTGAGGAATTCAGCGATTTATACAACGAGGTCTATAACTTGACCCAGGAGTTCT
                 TCCGGCACGATAAACCAGTCAATGCTGAAAGTCAAAATAGCGTGGGGGTGTTCACCCG
                 AGAGGAGGTGCGTAACCGCATCAGGAATGACCCTGACGACCCAGAGGCTACCAAGCGC
                 CTGAAGCTCGCCATGATCCAGCAGTACCTGAAGGTGGAGAGCTGTGAGAGCAGCTCAC
                 ACAGCATGGACGAGGTGTCCCTGAGCGCCTTCGGGGAGTGGACCGAGATCCCCGGCGC
                 TCACCACATCATCCCCTCGGGCTTCATGCGGGTTGTGGAGCTGCTGGCGGAGGGCATC
                 CCTGCCCACGTCATCCAGCTAGGGAAACCTGTCCGCTGCATTCACTGGGACCAGGCCT
                 CAGCCCGCCCCAGAGGCCCTGAGATTGAGCCCCTGCCGTACACAGAGAGCTCAAAGAC
                 AGCGCCCATGCAGGTGCTGTTTTCCGGTGAGGCCACCCACCGCAAGTACTATTCCACC
                 ACCCACGGTGCTCTGCTGTCCGGCCAGCGTGAGGCTGCCCGCCTCATTGAGATGTACC
                 GAGACCTCTTCCAGCAGGGGACCTGA
                 ORF Start: at 2                      ORF Stop: TGA at 1010
                 SEQ ID NO: 170          336 aa       MW at 37093.2kD
NOV13b,          TMQSCESSGDSADDPLSRGLRRRGQPRVVVIGAGLAGLAAAKALLEQGFTDVTVLEAS
246864043
Protein Sequence SHIGGRVQSVKLGHATFELGATWIHGSHGNPIYHLAEANGLLEETTDGERSVGRISLY
                 SKNGVACYLTNHGRRIPKDVVEEFSDLYNEVYNLTQEFFRHDKPVNAESQNSVGVFTR
                 EEVRNRIRNDPDDPEATKRLKLAMIQQYLKVESCESSSHSMDEVSLSAFGEWTEIPGA
                 HHIIPSGFMRVVELLAEGIPAHVIQLGKPVRCIHWDQASARPRGPEJIEPLPYTESSKT
                 APMQVLFSGEATHRKYYSTTHGALLSGQREAARLIEMYRDLFQQGT
                 SEQ ID NO: 171         1603 bp
NOV13c,          CACCATGCAAAGTTGTGAATCCAGTGGTGACAGTGCGGATGACCCTCTCAGTCGCGGC
246864086
DNA Sequence     CTACGGAGAAGGGGACAGCCTCGTGTGGTGGTGATCGGCGCCGGCTTGGCTGGCCTCG
                 CTGCAGCCAAAGCACTTCTTGAGCAGGGTTTCACGGATGTCACTGTGCTTGAGGCTTC
                 CAGCCACATCGGAGGCCGTGTGCAGAGTGTGAAACTTGGACACGCCACCTTTGAGCTG
                 GGAGCCACCTGGATCCATGGCTCCCATGCGAACCCTATCTATCATCTAGCAGAAGCCA
                 ACGGCCTCCTGGAAGAGACAACCGATGGCGAACGCAGCGTGGGCCGCATCAGCCTCTA
                 TTCCAAGAATGGCGTGGCCTGCTACCTTACCAACCACGGCCGCAGGATCCCCAAGGAC
                 GTGGTTGAGGAATTCAGCGATTTATACAACGAGGTCTATAACTTGACCCAGGAGTTCT
                 TCCGGCACGATAAACCAGTCAATGCTGAAAGTCAAAATAGCGTGGGGGTGTTCACCCG
                 AGAGGAGGTGCGTAACCGCATCAGGAATGACCCTGACGACCCAGAGGCTACCAAGCGC
                 CTGAAGCTCGCCATGATCCAGCAGTACCTGAAGGTGCACAGCTGTGAGAGCAGCTCAC
                 ACAGCATGGACGAGGTGTCCCTCAGCGCCTTCGGGGAGTGGACCGAGATCCCCGGCGC
                 TCACCACATCATCCCCTCGGGCTTCATGCGGGTTGTGGAGCTGCTGGCGGAGGGCATC
                 CCTGCCCACGTCATCCAGCTAGGGAAACCTGTCCGCTGCATTCACTGGGACCAGGCCT
                 CAGCCCGCCCCAGAGGCCCTGAGATTGAGCCCCGGGGTGTGCTAAAGAGGCAGTACAC
                 CAGTTTCTTCCGGCCAGGCCTGCCCACAGAGAAGGTGGCTGCCATCCACCGCCTGGGC
                 ATTGGCACCACCGACAAGATCTTTCTGGAATTCGAGGAGCCCTTCTGGGGCCCTGAGT
                 GCAACAGCCTACAGTTTGTGTGGGAGGACGAAGCGGACAGCCACACCCTCACCTACCC
                 ACCTGAGCTCTGGTACCGCAAGATCTGCGGCTTTGATGTCCTCTACCCGCCTGAGCGC
                 TACGGCCATGTGCTGAGCGGCTGGATCTGCGGGGAGGAGGCCCTCGTCATGGAGAAGT
                 GTGATGACGAGGCAGTGGCCGAGATCTGCACGGAGATGCTGCGTCAGTTCACAGOGAA
                 CCCCAACATTCCAAAACCTCGGCGAATCTTGCGCTCGGCCTGGGGCAGCAACCCTTAC
                 TTCCGCGGCTCCTATTCATACACGCAGGTGGGCTCCAGCGGGGCGGATGTGGAGAAGC
                 TGGCCAAGCCCCTGCCGTACACGGAGAGCTCAAAGACAGCGCATGGAAGCTCCACAAA
                 GCAGCAGCCTGGTCACCTTTTCTCTTCCAAGTGCCCAGAACAGCCCCTGGATGCTAAC
                 AGGGGCGCCGTAAAGCCCATGCAGGTGCTGTTTTCCGGTGAGGCCACCCACCGCAAGT
                 ACTATTCCACCACCCACGGTGCTCTGCTGTCCGGCCAGCGTGAGGCTGCCCGCCTCAT
                 TGAGATGTACCGAGACCTCTTCCAGCAGGGGACCTGA
                 ORF Start: at 2                      ORF Stop: TGA at 1601
                 SEQ ID NO: 172          533 aa       MW at 59379.2kD
NOV13c,          TMQSCESSGDSADDPLSRGLRRRGQPRVVVIGAGLAGLAAAKALLEQGFTDVTVLEAS
246864086
Protein Sequence SHIGGRVQSVKLGHATFELGATWIHGSHGNPIYHLAEANGLLEETTDGERSVGRISLY
                 SKNGVACYLTNhGRRIPKDVVEEFSDLYNEVYNLTQEFFRhDKPVNAESQNSVGVFTR
                 EEVRNRIRNDPDDPEATKRLKLAMIQQYLKVESCESSSHSMDEVSLSAFGEWTEIPGA
                 HHIIPSGFMRVVELLAEGIPAHVIQLGKPVRCIHWDQASARPRGPEIEPRGVLKRQYT
                 SFFRPGLPTEKVAAIHRLGIGTTDKIFLEFEEPFWGPECNSLQFVWEDEAESHTLTYP
                 PELWYRKICGFDVLYPPERYGHVLSGWICGEEALVMEKCDDEAVAEICTEMLRQFTGN
                 PNIPKPRRILRSAWGSNPYFRGSYSYTQVGSSGADVEKLAKPLPYTESSKTAHGSSTK
                 QQPGHLFSSKCPEQPLDANRGAVKPMQVLFSGEATHRKYYSTTHGALLSGQREAARLI
                 EMYRDLFQQGT
                 SEQ ID NO: 173         1693 bp
NOV13d,          CACCATGGGACATCATCACCACCATCACCAAAGTTGTGAATCCAGTGGTGACAGTGCG
258280083
DNA Sequence     GATGACCCTCTCAGTCGCGGCCTACGGAGAAGGGGACAGCCTCGTGTGGTGGTGATCG
                 GCGCCGGCTTGGCTGGCCTGGCTGCAGCCAAAGCACTTCTTGAGCAGGGTTTCACGCA
                 TGTCACTGTGCTTGAGGCTTCCAGCCACATCGGAGGCCGTGTGCAGAGTGTGAAACTT
                 GGACACGCCACCTTTGAGCTGGGAGCCACCTGGATCCATGGCTCCCATGGGAACCCTA
                 TCTATCATCTAGCAGAAGCCAACGGCCTCCTGGAAGAGACAACCGATGGGGAACGCAG
                 CGTGGGCCGCATCAGCCTCTATTCCAAGAATGGCGTGGCCTGCTACCTTACCAACCAC
                 GGCCGCAGGATCCCCAAGGACGTGGTTGAGGAATTCAGCGATTTATACAACGAGGTCT
                 ATAACTTGACCCAGGAGTTCTTCCGGCACGATAAACCAGTCAATGCTGAAAGTCAAAA
                 TAGCGTGGGGGTGTTCACCCGACAGGAGGTGCGTAACCGCATCAGGAATGACCCTGAC
                 GACCCAGAGGCTACCAAGCGCCTGAAGCTCGCCATGATCCAGCAGTACCTGAAGGTGG
                 AGAGCTGTGAGAGCAGCTCACACAGCATGGACGAGGTGTCCCTGAGCGCCTTCGGGGA
                 GTGGACCGAGATCCCCGGCGCTCACCACATCATCCCCTCGGGCTTCATGCGGGTTGTG
                 GAGCTGCTGGCGGAGGGCATCCCTGCCCACGTCATCCAGCTAGGGAAACCTGTCCGCT
                 GCATTCACTGGGACCAGGCCTCAGCCCGCCCCAGAGGCCCTGAGATTGAGCCCCGGGG
                 TGAGGGCGACCACAATCACGACACTGGGGAGGGTGGCCAGGGTGCAGAGGAGCCCCGG
                 GGGGGCAGGTGGGATGAGGATGAGCAGTGGTCGGTGGTGGTGGAGTGCGAGGACTGTG
                 AGCTGATCCCGGCGGACCATGTGATTGTGACCGTGTCGCTAGGTGTGCTAAAGAGGCA
                 GTACACCAGTTTCTTCCGGCCAGGCCTGCCCACAGAGAAGGTGGCTGCCATCCACCGC
                 CTGGGCATTGGCACCACCGACAAGATCTTTCTGGAATTCGAGGACCCCTTCTGGGGCC
                 CTGAGTGCAACAGCCTACAGTTTGTGTGGGAGGACGAAGCAGAGAGCCACACCCTCAC
                 CTACCCACCTGAGCTCTGGTACCGCAAGATCTGCGGCTTTGATGTCCTCTACCCGCCT
                 GAGCGCTACGGCCATGTGCTGAGCGGCTGGATCTGCGGGGAGGAGGCCCTCGTCATGG
                 AGAAGTGTGATGACGACGCAGTGGCCGAGATCTGCACGGAGATGCTGCGTCAGTTCAC
                 AGGGAACCCCAACATTCCAAAACCTCGGCGAATCTTGCGCTCGGCCTGGGGCAGCAAC
                 CCTTACTTCCGCGGCTCCTATTCATACACGCAGGTGGGCTCCAGCGGGGCGGATGTGG
                 AGAAGCTGGCCAAGCCCCTGCCGTACACGGAGAGCTCAAAGACAGCGCCCATGCAGGT
                 GCTGTTTTCCGGTGAGGCCACCCACCGCAAGTACTATTCCACCACCCACGGTGCTCTG
                 CTGTCCGGCCAGCGTGAGGCTGCCCGCCTCATTGAGATGTACCGAGACCTCTTCCAGC
                 AGGGGACCTGA
                 ORF Start: at 2                      ORF Stop: TGA at 1691
                 SEQ ID NO: 174          563 aa       MW at 62799.6kD
NOV13d,          TMGHHHHHHQSCESSGDSADDPLSRGLRRRGQPRVVVIGAGLAGLAAAKALLEQGFTD
258280083
Protein Sequence VTVLEASSHIGGRVQSVKLGHATFELGATWIHGSHGNPIYHLAEANGLLEETTDGERS
                 VGRISLYSKNGVACYLTNHGRRIPKDVVEEFSDLYNEVYNLTQEFFRHDKPVNAESQN
                 SVGVFTREEVRNRIRNDPDDPEATKRLKLANIQQYLKVESCESSSHSMDEVSLSAFGE
                 WTEIPGAHHIIPSGFMRVVELLAEGIPAHVIQLGKPVRCIHWDQASARPRGPEIEPRG
                 EGDHNHDTGEGGQGGEEPRGGRWDEDEQWSVVVECEDCELIPADHVIVTVSLGVLKRQ
                 YTSFFRPGLPTEKVAAIHRLGIGTTDKIFLEFEEPFWGPECNSLQFVWEDEAESHTLT
                 YPPELWYRKICGFDVLYPPERYGHVLSGWICGEEALVMEKCDDEAVAEICTEMLRQFT
                 GNPNIPKPRRILRSAWGSNPYFRGSYSYTQVGSSGADVEKLAKPLPYTESSKTAPMQV
                 LFSGEATHRKYYSTTHGALLSGQREAARLIEMYRDLFQQGT
                 SEQ ID NO: 175         1672 bp
NOV13e,          CACCATGCAAAGTTGTGAATCCAGTGGTGACAGTGCGGATGACCCTCTCAGTCGCGGC
258280066
DNA Sequence     CTACGGAGAAGGGGACAGCCTCGTGTGGTGGTGATCGGCGCCGGCTTGGCTGCCCTGG
                 CTGCAGCCAAAGCACTTCTTGAGCAGGGTTTCACGGATGTCACTGTGCTTGAGGCTTC
                 CAGCCACATCGGAGGCCGTGTGCAGAGTGTGAAACTTGGACACGCCACCTTTGAGCTG
                 GGAGCCACCTGGATCCATGGCTCCCATGGGAACCCTATCTATCATCTAGCAGAAGCCA
                 ACGGCCTCCTGGAAGAGACAACCGATGGGGAACGCAGCGTGGGCCGCATCAGCCTCTA
                 TTCCAAGAATGGCGTGGcCTGCTACCTTACCAACCACGGCCGCAGGATCCCCAAGGAc
                 GTGGTTGAGGAATTCAGCGATTTATACAACGAGGTCTATAACTTGACCCAGGAGTTCT
                 TCCGGCACGATAAACCAGTCAATGCTGAAAGTCAAAATAGCGTGGGGGTGTTCACCCG
                 AGAGGAGGTGCGTAACCGCATCAGGAATGACCCTGACGACCCAGAGGCTACCAAGCGC
                 CTGAAGCTCGCCATGATCCAGCAGTACCTGAAGGTGGAGAGCTGTGAGAGCAGCTCAC
                 ACAGCATGGACGAGGTGTCCCTGAGCGCCTTCGGGGAGTGGACCGAGATCCCCGGCGC
                 TCACCACATCATCCCCTCGGGCTTCATGCGGGTTGTGGAGCTGCTGGCGGAGGGCATC
                 CCTGCCCACGTCATCCAGCTAGGGAAACCTGTCCGCTGCATTCACTGGGACCAGGCCT
                 CAGCCCGCCCCAGAGGCCCTGAGATTGAGCCCCGGGGTGAGGGCGACCACAATCACGA
                 CACTGGGGAGGGTGGCCAGGGTGGAGAGGAGCCCCGGGGGGGCAGGTGGGATGAGGAT
                 GAGCAGTGGTCGGTGGTGGTGGAGTGCGAGGACTGTGAGCTGATCCCGGCGGACCATG
                 TGATTGTGACCGTGTCGCTAGGTGTGCTAAAGAGGCAGTACACCAGTTTCTTCCGGCC
                 AGGCCTGCCCACAGAGAAGGTGGCTGCCATCCACCGCCTGGGCATTGGCACCACCGAC
                 AAGATCTTTCTGCAATTCGAGGAGCCCTTCTGGGGCCCTGAGTGCAACAGCCTACAGT
                 TTGTGTGGGAGGACGAAGCAGAGAGCCACACCCTCACCTACCCACCTGAGCTCTGGTA
                 CCGCAAGATCTGCGGCTTTGATGTCCTCTACCCGCCTGAGCGCTACGGCCATGTGCTG
                 AGCGGCTGGATCTGCGGGGAGGAGGCCCTCGTCATGGAGAAGTGTGATGACGAGGCAG
                 TGGCCGACATCTGCACGGAGATGCTGCGTCAGTTCACAGGGAACCCCAACATTCCAAA
                 ACCTCGGCGAATCTTGCGCTCGGCCTGGGGCAGCAACCCTTACTTCCGCGGCTCCTAT
                 TCATACACGCAGGTGGGCTCCAGCGGGGCGGATGTGGAGAAGCTGGCCAAGCCCCTGC
                 CGTACACGGAGAGCTCAAAGACAGCGCCCATGCAGGTGCTGTTTTCCGGTGAGGCCAC
                 CCACCGCAAGTACTATTCCACCACCCACGGTGCTCTGCTGTCCGGCCAGCGTGAGGCT
                 GCCCGCCTCATTGAGATGTACCGAGACCTCTTCCAGCAGGGGACCTGA
                 ORF Start: at 2                      ORF Stop: TGA at 1670
                 SEQ ID NO: 176          556 aa       MW at 61919.7kD
NOV13e,          TMQSCESSGDSADDPLSRGLRRRGQPRVVVIGAGLAGLAAAKALLEQGFTDVTVLEAS
258280066
Protein Sequence SHIGGRVQSVKLGHATFELGATWIHGSHGNPIYHLAEANGLLEETTDGERSVGRISLY
                 SKNGVACYLTNHGRRIPKDVVEEFSDLYNEVYNLTQEFFRHDKPVNAESQNSVGVFTR
                 EEVRNRIRNDPDDPEATKRLKLANIQQYLKVESCESSSHSMDEVSLSAFGEWTEIPGA
                 HHITPSGFMRVVELLAEGIPAHVIQLGKPVRCIHWDQASARPRGPEIEPRGEGDHNHD
                 TGEGGQGGEEPRGGRWDEDEQWSVVVECEDCELIPADHVIVTVSLGVLKRQYTSFFRP
                 CLPTEKVAAIHRLGIGTTDKIFLEFEEPFWGPECNSLQFVWEDEAESHTLTYPPELWY
                 RKICGFDVLYPPERYGHVLSGWICGEEALVMEKCDDEAVAEICTEMLRQFTGIJPNT PK
                 PRRILRSAWGSNPYFRGSYSYTQVGSSGADVEKLAKPLPYTESSKTAPMQVLFSGEAT
                 HRKYYSTTHGALLSGQREAARLIEMYRDLFQQGT
                 SEQ ID NO: 177         1690 bp
NOV13f           CACCATGCAAAGTTGTGAATCCAGTGGTGACAGTGCGGATGACCCTCTCAGTCGCGGC
258329988
DNA Sequence     CTACGGAGAAGGGGACAGCCTCGTGTGGTGGTGATCGGCGCCGGCTTGGCTGGCCTGG
                 CTGCAGCCAAAGCACTTCTTGAGCAGGGTTTCACGGATGTCACTGTGCTTGAGGCTTC
                 CAGCCACATCGGAGGCCGTGTGCAGAGTGTGAAACTTOGACACGCCACCTTTGAGCTG
                 GGAGCCACCTGGATCCATGGCTCCCATGGGAACCCTATCTATCATCTAGCAGAAGCCA
                 ACGGCCTCCTGGAAGAGACAACCGATCGGGAACGCAGCGTGGGCCGCATCAGCCTCTA
                 TTCCAAGAATGGCGTGGCCTGCTACCTTACCAACCACGGCCGCAGGATCCCCAAGGAC
                 GTGGTTGAGGAATTCAGCGATTTATACAACGAGGTCTATAACTTGACCCAGGAGTTCT
                 TCCGGCACGATAAACCAGTCAATGCTGAAAGTCAAAATAGCGTGGGGGTGTTCACCCG
                 AGAGGAGGTGCGTAACCGCATCAGGAATGACCCTGACGACCCAGAGGCTACCAAGCGC
                 CTGAAGCTCGCCATGATCCAGCAGTACCTGAAGGTGGAGAGCTGTGAGAGCAGCTCAC
                 ACAGCATGGACGAGGTGTCCCTGAGCGCCTTCGGGGAGTGGACCGAGATCCCCGGCGC
                 TCACCACATCATCCCCTCGGGCTTCATGCGGGTTGTGGAGCTGCTGGCGGAGGGCATC
                 CCTGCCCACGTCATCCAGCTAGGGAAACCTGTCCGCTGCATTCACTGGGACCAGGCCT
                 CAGCCCGCCCCAGAGGCCCTGAGATTGAGCCCCGGGGTGAGGGCGACCACAATCACGA
                 CACTGGGGAGGGTGGCCAGGGTCGAGAGGAGCCCCGGGGGGGCAGGTGGGATGAGGAT
                 GAGCAGTGGTCGGTGGTGGTGGAGTGCGAGGACTGTGAGCTGATCCCGGCGGACCATG
                 TGATTGTGACCGTGTCGCTAGGTGTGCTAAAGAGGCAGTACACCAGTTTCTTCCGGCC
                 AGGCCTGCCCACAGAGAAGGTGGCTGCCATCCACCGCCTGGGCATTGGCACCACCGAC
                 AAGATCTTTCTGGAATTCGAGGAGCCCTTCTGGGGCCCTCAGTGCAACAGCCTACAGT
                 TTGTGTGGGAGGACGAAGCAGAGAGCCACACCCTCACCTACCCACCTGAGCTCTGGTA
                 CCGCAAGATCTGCGGCTTTGATGTCCTCTACCCGCCTGAGCGCTACGGCCATGTGCTG
                 AGCGGCTGGATCTGCGGGGAGGAGGCCCTCGTCATGGAGAAGTGTGATGACGAGGCAG
                 TGGCCGAGATCTGCACGGAGATGCTGCGTCAGTTCACAGGGAACCCCAACATTCCAAA
                 ACCTCGGCGAATCTTGCGCTCGGCCTGGGGCAGCAACCCTTACTTCCGCGGCTCCTAT
                 TCATACACGCAGGTGGGCTCCAGCGGGGCGGATGTGGAGAAGCTGGCCAAGCCCCTGC
                 CGTACACGGAGAGCTCAAAGACAGCGCCCATGCAGGTGCTGTTTTCCGGTGAGGCCAC
                 CCACCGCAAGTACTATTCCACCACCCACGGTGCTCTGCTGTCCGGCCAGCGTGAGGCT
                 GCCCGCCTCATTGAGATGTACCGAGACCTCTTCCAGCAGGGGACCCATCATCACCACC
                 ATCACTGA
                 ORF Start: at 2                      ORF Stop: TGA at 1688
                 SEQ ID NO: 178          562 aa       MW at 62742.6kD
NOV13f           TMQSCESSGDSADDPLSRGLRRRGQPRVVVIGAGLAGLAAAKALLEQGFTDVTVLEAS
258329988
Protein Sequence SHIGGRVQSVKLGHATFELGATWIHGSHGNPIYHLAEANGLLEETTDGERSVGRISLY
                 SKNGVACYLTNHGRRIPKDVVEEFSDLYNEVYNLTQEFFRHDKPVNAESQNSVGVFTR
                 EEVRNRIRNDPDDPEATKRLKLAMIQQYLKVESCESSSNSMDEVSLSAFGEWTEIPGA
                 HHIIPSGFMRVVELLAEGIPAHVIQLGKPVRCIHWDQASARPRGPEIEPRGEGDHNHD
                 TGEGGQGGEEPRGGRWDEDEQWSVVVECEDCELIPADHVIVTVSLGVLKRQYTSFFRP
                 GLPTEKVAAIHRLGTGTTDKIFLEFEEPFWGPECNSLQFVWEDEAESHTLTYPPELWY
                 RKICGFDVLYPPERYGHVLSGWICGEEALVMEKCDDEAVAEICTEMLRQFTGNPNI PK
                 PRRILRSAWGSNPYFRGSYSYTQVGSSGADVEKLAKPLPYTESSKTAPMQVLFSGEAT
                 HRKYYSTTHGALLSGQREAARLIEMYRDLFQQGTHHHHHH
                 SEQ ID NO: 179         1700 bp
NOV13g, AAGGAAAAAAGCGGCCGCCACCATGCAAAGTTGTGAATCCAGTGGTGACAGTGCGGAT
254047897
DNA Sequence     GACCCTCTCAGTCGCGGCCTACGGAGAAGGGGACAGCCTCGTGTGGTGGTGATCGGCG
                 CCGGCTTGGCTGGCCTGGCTGCAGCCAAAGCACTTCTTGAGCAGGGTTTCACGGATGT
                 CACTGTGCTTGAGGCTTCCAGCCACATCGGAGGCCGTGTGCAGAGTGTGAAACTTGGA
                 CACGCCACCTTTGAGCTGGGAGCCACCTGGATCCATGGCTCCCATGGGAACCCTATCT
                 ATCATCTAGCAGAAGCCAACGGCCTCCTGGAAGAGACAACCGATGGGGAACGCAGCGT
                 GGGCCGCATCAGCCTCTATTCCAAGAATGGCGTGGCCTGCTACCTTACCAACCACGGC
                 CGCAGGATCCCCAAGGACGTGGTTGAGGAATTCAGCGATTTATACAACGAGGTCTATA
                 ACTTGACCCAGGAGTTCTTCCGGCACGATAAACCAGTCAATGCTGAAAGTCAAAATAG
                 CGTGGGGGTGTTCACCCGAGAGGAGGTGCGTAACCGCATCAGGAATGACCCTGACGAC
                 CCAGAGGCTACCAAGCGCCTGAAGCTCGCCATGATCCAGCAGTACCTGAAGGTGGAGA
                 GCTGTGAGAGCAGCTCACACAGCATGGACGAGGTGTCCCTGAGCGCCTTCGGGGAGTG
                 GACCGAGATCCCCGGCGCTCACCACATCATCCCCTCGGGCTTCATGCGGGTTGTGGAG
                 CTGCTGGCGGAGGGCATCCCTGCCCACGTCATCCAGCTAGGGAAACCTGTCCGCTGCA
                 TTCACTGGGACCAGGCCTCAGCCCGCCCCAGAGGCCCTGAGATTGAGCCCCGGGGTGA
                 GGGCGACCACAATCACGACACTGGGGAGGGTGGCCAGGGTGGAGAGGAGCCCCGGGGG
                 GGCAGGTGGGATGAGGATGAGCAGTGGTCGGTGGTGGTGGAGTGCGAGGACTGTGAGC
                 TGATCCCGGCGGACCATGTGATTGTGACCGTGTCGCTAGGTGTGCTAAAGAGGCAGTA
                 CACCAGTTTCTTCCGGCCAGGCCTGCCCACAGAGAAGGTGGCTGCCATCCACCGCCTG
                 GGCATTGGCACCACCGACAAGATCTTTCTGGAATTCGAGGAGCCCTTCTGGGGCCCTG
                 AGTGCAACAGCCTACAGTTTGTGTGGGAGGACGAAGCAGAGAGCCACACCCTCACCTA
                 CCCACCTGAGCTCTGGTACCGCAAGATCTGCGGCTTTGATGTCCTCTACCCGCCTGAG
                 CGCTACGGCCATGTGCTGAGCGGCTGGATCTGCGGGGAGGAGGCCCTCGTCATGGAGA
                 AGTGTGATGACGAGGCAGTGGCCGAGATCTGCACGGAGATGCTGCGTCAGTTCACAGG
                 GAACCCCAACATTCCAAAACCTCGGCGAATCTTGCGCTCGGCCTGGGGCAGCAACCCT
                 TACTTCCGCGGCTCCTATTCATACACGCAGGTGGGCTCCAGCGGGGCGGATGTGGAGA
                 AGCTGGCCAAGCCCCTGCCGTACACGGAGAGCTCAAAGACAGCGCCCATGCAGGTGCT
                 GTTTTCCGGTGAGGCCACCCACCGCAAGTACTATTCCACCACCCACGGTGCTCTGCTG
                 TCCGGCCAGCGTGAGGCTGCCCGCCTCATTGAGATGTACCGAGACCTCTTCCAGCAGG
                 GGACCTGATCTAGACTAG
                 ORF Start: at 2                      ORF Stop: TGA at 1688
                 SEQ ID NO: 180          562 aa       MW at 62545.5kD
NOV13g,          RKKAAATMQSCESSGDSADDPLSRGLRRRGQPRVVVIGAGLAGTJAAAKALLEQGFTDV
254047897
Protein Sequence TVLEASSHIGGRVQSVKLGHATFELGATWIIIGSHGMPIYHLAEANGLLEETTDGERSV
                 GRISLYSKNGVACYLTNHGRRIPKDVVEEFSDLYNEVYNLTQEFFRHDKPVNAESQNS
                 VGVFTREEVRNRIRNDPDDPEATKRLKLANIQQYLKVESCESSSHSMDEVSLSAFGEW
                 TEIPGANHIIPSGFMRVVELLAEGIPAHVIQLGKPVRCIHWDQASARPRGPEIEPRGE
                 GDHNHDTGEGCQGGEEPRGGRWDEDEQWSVVVECEDCELIPADHVIVTVSLGVLKRQY
                 TSFFRPGLPTEKVAAIHRLGIGTTDKIFLEFEEPFWGPECNSLQFVWEDEAESHTLTY
                 PPELWYRKICGFDVLYPPERYGHVLSGWICGEEALVMEKCDDEAVAEICTEMLRQFTG
                 NPNIPKPRRILRSAWGSNPYFRGSYSYTQVGSSGADVEKLAKPLPYTESSKTAPMQVL
                 FSGEATHRKYYSTTHGALLSGQREAARLIEMYRDLFQQGT
                 SEQ ID NO: 181         1690 bp
NOV13h,          CACCATGCAAAGTTGTGAATCCAGTGGTGACAGTGCGGATGACCCTCTCAGTCGCGGC
258329988
DNA Sequence     CTACGGAGAAGGGGACAGCCTCGTGTGGTGGTGATCGGCGCCGGCTTGCCTGGCCTGG
                 CTGCAGCCAAAGCACTTCTTGAGCAGGGTTTCACGGATGTCACTGTGCTTGAGGCTTC
                 CAGCCACATCGGAGGCCGTGTGCAGAGTGTGAAACTTGGACACGCCACCTTTGAGCTG
                 GGAGCCACCTGGATCCATGGCTCCCATGGGAACCCTATCTATCATCTAGCAGAAGCCA
                 ACGGCCTCCTGGAAGAGACAACCGATGGGGAACGCAGCGTGGGCCGCATCAGCCTCTA
                 TTCCAAGAATGGCGTGGCCTGCTACCTTACCAACCACGGCCGCAGGATCCCCAAGGAC
                 GTGGTTGAGGAATTCAGCGATTTATACAACGAGGTCTATAACTTGACCCAGGAGTTCT
                 TCCGGCACGATAAACCAGTCAATGCTGAAAGTCAAAATAGCGTGGGGGTGTTCACCCG
                 AGAGGAGGTGCGTAACCGCATCAGGAATGACCCTGACGACCCAGAGGCTACCAAGCGC
                 CTGAAGCTCGCCATGATCCAGCAGTACCTGAAGGTGGAGAGCTGTGAGAGCAGCTCAC
                 ACAGCATGGACGAGGTGTCCCTGAGCGCCTTCGGGGAGTGGACCGAGATCCCCGGCGC
                 TCACCACATCATCCCCTCGGGCTTCATGCGGGTTGTGGAGCTGCTGGCGGAGGGCATC
                 CCTGCCCACGTCATCCAGCTAGGGAAACCTGTCCGCTGCATTCACTGGGACCAGGCCT
                 CAGCCCGCCCCAGAGGCCCTGAGATTGAGCCCCGGGGTGAGGGCGACCACAATCACGA
                 CACTGGGGAGGGTGGCCAGGGTGGAGAGGAGCCCCGGGGGGGCACGTGGGATGAGGAT
                 GAGCAGTGGTCGGTGGTGGTGGAGTGCGAGGACTGTGAGCTGATCCCGGCGGACCATG
                 TGATTGTGACCGTGTCGCTAGGTGTGCTAAAGAGGCAGTACACCAGTTTCTTCCGGCC
                 AGGCCTGCCCACAGAGAAGGTGGCTGCCATCCACCGCCTGGGCATTGGCACCACCGAC
                 AAGATCTTTCTGGAATTCGAGGAGCCCTTCTGGGGCCCTGAGTGCAACAGCCTACAGT
                 TTGTGTGGGAGGACGAAGCAGAGAGCCACACCCTCACCTACCCACCTGAGCTCTGGTA
                 CCCCAAGATCTGCGCCTTTGATGTCCTCTACCCGCCTGAGCGCTACGGCCATGTGCTG
                 AGCGGCTGGATCTGCGGGGAGGAGGCCCTCGTCATGGAGAAGTGTGATGACGAGGCAG
                 TGGCCGAGATCTGCACGGAGATGCTGCGTCAGTTCACAGGGAACCCCAACATTCCAAA
                 ACCTCGGCGAATCTTGCGCTCGGCCTGGGGCAGCAACCCTTACTTCCGCGGCTCCTAT
                 TCATACACGCAGGTGGGCTCCAGCGGGGCGGATGTGGAGAAGCTGGCCAAGCCCCTGC
                 CGTACACCGAGAGCTCAAAGACAGCGCCCATGCAGGTGCTGTTTTCCGGTGAGGCCAC
                 CCACCGCAAGTACTATTCCACCACCCACGGTGCTCTGCTGTCCGGCCAGCGTGAGGCT
                 GCCCGCCTCATTGAGATGTACCGAGACCTCTTCCAGCAGGGGACCCATCATCACCACC
                 ATCACTGA
                 ORF Start: at 2                      ORF Stop: TGA at 1688
                 SEQ ID NO: 182          562 aa       MW at 62742.6kD
NOV13h,          TMQSCESSGDSADDPLSRGLRRRGQPRVVVIGAGLAGLAAAKALLEQGFTDVTVLEAS
258329988
Protein Sequence SHIGGRVQSVKLGHATFELGATWIHGSHGNPIYHLAEANGLLEETTDGERSVGRISLY
                 SKNGVACYLTNHGRRIPKDVVEEFSDLYNEVYNLTQEFFRHDKPVNAESQNSVGVFTR
                 EEVRNRIRNDPDDPEATKRLKLANIQQYLKVESCESSSHSMDEVSLSAFGEWTEIPGA
                 HHIIPSGFMRVVELLAEGIPAHVIQLGKPVRCIHWDQASARPRGPEIEPRGEGDHNHD
                 TGEGGQGGEEPRGGRWDEDEQWSVVVECEDCELIPADHVIVTVSLGVLKRQYTSFFRP
                 GLPTEKVAAIHRLGIGTTDKIFLEFEEPFWGPECNSLQFVWEDEAESHTLTYPPELWY
                 RKICGFDVLYPPERYGHVLSGWICGEEALVMEKCDDEAVAEICTEMLRQPTGNPNIPK
                 PRRILRSAWGSNPYFRGSYSYTQVGSSGADVEKLAKPLPYTESSKTAPMQVLFSGEAT
                 HRKYYSTTHGALLSGQREAARLIEMYRDLFQQGTHHHHHH
                 SEQ ID NO: 183         1672 bp
NOV13j,          CACCATGCAAAGTTGTGAATCCAGTGGTGACAGTGCGGATGACCCTCTCAGTCGCGGC
258280066
DNA Sequence     CTACGGAGAAGGGGACAGCCTCGTGTGGTGGTGATCGGCGCCGGCTTGGCTGGCCTGG
                 CTGCAGCCAAAGCACTTCTTGAGCAGGGTTTCACGGATGTCACTGTGCTTGAGCCTTC
                 CAGCCACATCGGAGGCCGTGTGCAGAGTGTGAAACTTGGACACGCCACCTTTGAGCTG
                 GGAGCCACCTGGATCCATGGCTCCCATGGGAACCCTATCTATCATCTAGCAGAAGCCA
                 ACGGCCTCCTGGAAGAGACAACCGATGGGGAACGCAGCGTGGGCCGCATCAGCCTCTA
                 TTCCAAGAATGGCGTGGCCTGCTACCTTACCAACCACGGCCGCAGGATCCCCAAGGAC
                 GTGGTTGAGGAATTCAGCGATTTATACAACGAGGTCTATAACTTGACCCAGGAGTTCT
                 TCCGGCACGATAAACCAGTCAATGCTGAAAGTCAAAATAGCGTGGGGGTGTTCACCCG
                 AGAGGAGGTGCGTAACCGCATCAGGAATGACCCTGACGACCCAGAGGCTACCAAGCGC
                 CTGAAGCTCGCCATGATCCAGCAGTACCTGAAGGTGGAGAGCTGTGAGAGCAGCTCAC
                 ACAGCATGGACGAGGTGTCCCTGAGCGCCTTCGGGGAGTGGACCGAGATCCCCGGCGC
                 TCACCACATCATCCCCTCGCGCTTCATGCGGGTTGTGGAGCTGCTGGCGGAGGGCATC
                 CCTGCCCACGTCATCCAGCTAGGGAAACCTGTCCGCTGCATTCACTGGGACCAGGCCT
                 CAGCCCGCCCCAGAGGCCCTGAGATTGAGCCCCGGGGTGAGGGCGACCACAATCACGA
                 CACTGCGGAGGGTGGCCAGGGTGGAGAGGAGCCCCGGGGGGGCAGGTGGGATGAGGAT
                 GAGCAGTGGTCGGTGGTGGTGGAGTGCGAGGACTGTGAGCTGATCCCGGCGGACCATG
                 TGATTGTGACCGTGTCGCTAGGTGTGCTAAAGAGGCAGTACACCAGTTTCTTCCGGCC
                 AGGCCTGCCCACAGAGAAGGTGGCTGCCATCCACCGCCTGGGCATTGGCACCACCGAC
                 AAGATCTTTCTGGAATTCGAGGAGCCCTTCTGGGGCCCTGAGTGCAACAGCCTACAGT
                 TTGTGTGGGAGGACGAAGCAGAGAGCCACACCCTCACCTACCCACCTGAGCTCTGGTA
                 CCGCAAGATCTGCGGCTTTGATGTCCTCTACCCGCCTGAGCGCTACGGCCATGTGCTG
                 AGCGGCTGGATCTGCGGGGAGGAGGCCCTCGTCATGGAGAAGTGTGATGACGAGGCAG
                 TGGCCGAGATCTGCACGGAGATGCTGCGTCAGTTCACAGGGAACCCCAACATTCCAAA
                 ACCTCGGCGAATCTTGCGCTCGGCCTGGGGCAGCAACCCTTACTTCCGCGGCTCCTAT
                 TCATACACGCAGGTGGGCTCCAGCGGGGCGGATGTGGAGAAGCTGGCCAAGCCCCTGC
                 CGTACACGGAGAGCTCAAAGACAGCGCCCATGCAGGTGCTGTTTTCCGGTGAGGCCAC
                 CCACCGCAAGTACTATTCCACCACCCACGGTGCTCTGCTGTCCGGCCAGCGTGAGGCT
                 GCCCGCCTCATTGAGATGTACCGAGACCTCTTCCAGCAGGGGACCTGA
                 ORF Start: at 2                      ORF Stop: TGA at 1670
                 SEQ ID NO: 184          556 aa       MW at 61919.7kD
NOV13j,          TMQSCESSGDSADDPLSRGLRRRGQPRVVVIGAGLAGLAAAKALLEQGFTDVTVLEAS
258280066
Protein Sequence SHIGGRVQSVKLGHATFELGATWIHGSHGNPIYHLAEANGLLEETTDGERSVGRISLY
                 SKNGVACYLTNHGRRIPKDVVEEFSDLYNEVYNLTQEFFRHDKPVNAESQNSVGVFTR
                 EEVRNRIRNDPDDPEATKRLKLAMIQQYLKVESCESSSHSMDEVSLSAFGEWTEIPGA
                 HHIIPSGFMRVVELLAEGIPAHVIQLGKPVRCIHWDQASARPRGPEIEPRGEGDHNHD
                 TGEGGQGGEEPRGGRWDEDEQWSVVVECEDCELIPADHVIVTVSLGVLKRQYTSFFRP
                 GLPTEKVAAIHRLGIGTTDKIFLEFEEPFWGPECNSLQFVWEDEAESHTLTYPPELWY
                 RKICGFDVLYPPERYGHVLSGWICGEEALVMEKCDDEAVAEICTEMLRQFTGNPNIPK
                 PRRILRSAWGSNPYFRGSYSYTQVGSSGADVEKLAKPLPYTESSKTAPMQVLFSGEAT
                 HRKYYSTTHGALLSGQREAARLIEMYRDLFQQGT
                 SEQ ID NO: 185         1693 bp
NOV13j,          CACCATGGGACATCATCACCACCATCACCAAAGTTGTGAATCCAGTGGTGACAGTGCG
258280083
DNA Sequence     GATGACCCTCTCAGTCGCGGCCTACGGAGAAGGGGACAGCCTCGTGTGGTGGTGATCG
                 GCGCCGGCTTGGCTGGCCTGGCTGCAGCCAAAGCACTTCTTGAGCAGGGTTTCACGGA
                 TGTCACTGTCCTTGAGGCTTCCAGCCACATCGGAGGCCGTGTGCAGAGTGTGAAACTT
                 GGACACGCCACCTTTGAGCTGGGAGCCACCTGGATCCATGGCTCCCATGGCAACCCTA
                 TCTATCATCTAGCAGAAGCCAACGGCCTCCTGGAAGAGACAACCGATGGGGAACGCAG
                 CGTGGGCCGCATCAGCCTCTATTCCAAGAATGGCGTGGCCTGCTACCTTACCAACCAC
                 GGCCGCAGGATCCCCAAGGACGTGGTTGAGGAATTCAGCGATTTATACAACGACGTCT
                 ATAACTTGACCCAGGAGTTCTTCCGGCACGATAAACCAGTCAATGCTGAAAGTCAAAA
                 TAGCGTGGGGGTGTTCACCCGAGACGAGGTGCGTAACCGCATCAGGAATGACCCTGAC
                 GACCCAGAGGCTACCAAGCGCCTGAACCTCGCCATGATCCAGCAGTACCTGAAGGTGG
                 AGAGCTGTGAGAGCAGCTCACACAGCATGGACGAGGTGTCCCTGAGCGCCTTCGGGGA
                 GTGGACCGAGATCCCCGGCGCTCACCACATCATCCCCTCGGGCTTCATGCGGGTTGTG
                 GAGCTGCTGGCGGAGGGCATCCCTCCCCACGTCATCCAGCTAGGGAAACCTGTCCGCT
                 GCATTCACTGGGACCAGGCCTCAGCCCGCCCCAGAGGCCCTGAGATTGAGCCCCGGGG
                 TGAGGGCGACCACAATCACGACACTGGGGAGGGTGGCCAGGGTGGAGAGGAGCCCCGG
                 GGCGGCAGGTGGGATGAGGATGAGCAGTGGTCGGTCGTGGTGGAGTGCGAGGACTGTG
                 AGCTGATCCCGGCGGACCATGTGATTGTGACCGTGTCGCTAGGTGTGCTAAAGAGGCA
                 GTACACCAGTTTCTTCCGGCCAGGCCTGCCCACAGAGAAGGTGGCTGCCATCCACCGC
                 CTGGGCATTGGCACCACCGACAAGATCTTTCTGGAATTCGAGGAGCCCTTCTGGGGCC
                 CTGAGTGCAACAGCCTACAGTTTGTGTGGGAGGACGAAGCAGAGAGCCACACCCTCAC
                 CTACCCACCTGAGCTCTGGTACCGCAAGATCTGCGGCTTTGATGTCCTCTACCCGCCT
                 GAGCGCTACGGCCATGTGCTGAGCGGCTGGATCTGCGGGGAGGAGGCCCTCGTCATGG
                 AGAAGTGTGATGACGAGGCAGTGGCCGAGATCTGCACGGAGATGCTGCGTCAGTTCAC
                 AGGGAACCCCAACATTCCAAAACCTCGGCGAATCTTGCGCTCGGCCTGGGGCACCAAC
                 CCTTACTTCCGCGGCTCCTATTCATACACGCAGGTGGGCTCCAGCGGGGCGGATGTGG
                 AGAAGCTGGCCAAGCCCCTGCCGTACACGGAGAGCTCAAAGACAGCGCCCATGCAGGT
                 GCTGTTTTCCGGTGAGGCCACCCACCGCAAGTACTATTCCACCACCCACGGTGCTCTG
                 CTGTCCGGCCAGCGTGAGGCTGCCCGCCTCATTCAGATGTAcCGAGACCTCTTCCAGC
                 AGGGGACCTGA
                 ORF Start: at 2                      ORF Stop: TGA at 1691
                 SEQ ID NO: 186          563 aa       MW at 62799.6kD
NOV13j,          TMGHHHHHHQSCESSGDSADDPLSRGLRRRGQPRVVVIGAGLAGLAAAKALLEQGFTD
258280083
Protein Sequence VTVLEASSHIGGRVQSVKLGHATFELGATWIHGSHGNPIYHLAEANGLLEETTDGERS
                 VGRISLYSKNGVACYLTNHGRRIPKDVVEEFSDLYNEVYNLTQEFFRHDKPVNAESQN
                 SVGVFTREEVRNRIRNDPDDPEATKRLKLAMIQQYLKVESCESSSHSMDEVSLSAFGE
                 WTEIPGAHHIISGFMRVVELLAEGIPAHVIQLGKPVRCIHWDQASARPRGPEIEPRG
                 EGDHNHDTGEGGQGGEEPRGGRWDEDEQWSVVVECEDCELIPADHVIVTVSLGVLKRQ
                 YTSFFRPGLPTEKVAAIHRLGIGTTDKIFLEFEEPFWGPECNSLQFVWEDEAESHTLT
                 YPPELWYRKICGFDVLYPPERYGHVLSGWICGEEALVMEKCDDEAVAEICTEMLRQFT
                 GNPNIPKPRRILRSAWGSNPYFRGSYSYTQVGSSGADVEKLAKPLPYTESSKTAPMQV
                 LFSGEATHRKYYSTTHGALLSGQREAARLIEMYRDLFQQGT
                 SEQ ID NO: 187         1993 bp
NOV13k           GGCACGAGGGTCCCGGCGGCGGCTGGAGGAGGAAGCCAGGCGGCTGGCGGAGGAGGAG
CG140122-02
DNA Sequence     AGACGGAGGAGGCCGAGACCGGAGCGCCGCTCGCCGCAGACTTACTTCCCCGGCTCAG
                 CAGGGAAAGGTTCCTAGAAGGTGAGCGCGGACGGTATGCAAAGTTGTGAATCCAGTGG
                 TGACAGTGCGGATGACCCTCTCAGTCGCGGCCTACGGAGAAGCGGACAGCCTCGTGTG
                 GTGGTGATCGGCGCCGGCTTGGCTGGCCTGGCTGCAGCCAAAGCACTTCTTGACCAGG
                 GTTTCACGGATGTCACTGTCCTTGAGGCTTCCAGCCACATCGGAGGCCGTGTGCAGAG
                 TGTGAAACTTGGACACGCCACCTTTGACCTGGGAGCCACCTGGATCCATGGCTCCCAT
                 GGGAACCCTATCTATCATCTAGCAGAGCCAACGGCCTCCTGGAAGAGACAACCGATG
                 GGGAACGCAGCGTGGGCCGCATCAGCCTCTATTCCAAGAATGGCGTGGCCTGCTACCT
                 TACCAACCACGGCCGCAGCATCCCCAAGGACGTGGTTGAGGAATTCAGCGATTTATAC
                 AACGAGGTCTATAACTTGACCCAGGAGTTCTTCCGGCACGATAAACCAGTCAATGCTG
                 AAAGTCAAAATAGCGTGGGGGTGTTCACCCGAGAGGAGGTGCGTAACCGCATCAGGAA
                 TGACCCTGACGACCCAGAGGCTACCAAGCGCCTGAAGCTCGCCATGATCCAGCAGTAc
                 CTGAAGGTGGAGAGCTGTGAGAGCAGCTCACACAGCATGGACGAGGTGTCCCTGAGCG
                 CCTTCGGGGAGTGGACCGAGATCCCCGGCGCTCACCACATCATCCCCTCGGGCTTCAT
                 GCGGGTTGTGGAGCTGCTGGCGGAGGGCATCCCTGCCCACGTCATCCAGCTAGGGAAA
                 CCTGTCCGCTGCATTCACTGGGACCAGGCCTCAGCCCGCCCCAGAGGCCCTGAGATTG
                 AGCCCCGGGGTGTGCTAAAGAGGCAGTACACCAGTTTCTTCCGGCCAGGCCTGCCCAC
                 AGAGAAGGTGGCTGCCATCCACCGCCTGGGCATTGGCACCACCGACAAGATCTTTCTG
                 GAATTCGAGGAGCCCTTCTGGGGCCCTGAGTGCAACAGCCTACAGTTTGTGTGGGAGG
                 ACGAAGCGGAGAGCCACACCCTCACCTACCCACCTGAGCTCTGGTACCGCAAGATCTG
                 CGGCTTTGATGTCCTCTACCCGCCTGAGCGCTACGGCCATGTGCTGAGCGGCTGGATC
                 TGCGGGGAGGAGGCCCTCGTCATGGAGAAGTGTGATGACGAGGCAGTGGCCGAGATCT
                 GCACGGAGATGCTGCGTCAGTTCACAGGGAACCCCAACATTCCAAAACCTCGGCGAAT
                 CTTGCGCTCGGCCTGGGGCAGCAACCCTTACTTCCGCGGCTCCTATTCATACACGCAG
                 GTGGGCTCCAGCGGGGCGGATGTGGAGAAGCTGGCCAAGCCCCTGCCGTACACGGAGA
                 GCTCAAAGACAGCGCCCATGCAGGTGCTGTTTTCCGGTGAGGCCACCCACCGCAAGTA
                 CTATTCCACCACCCACGGTGCTCTGCTGTCCGGCCAGCGTGAGGCTGCCCGCCTCATT
                 GAGATGTACCGAGACCTCTTCCAGCAGGGGACCTGAGGGCTGTCCTCGCTGCTGAGAA
                 UGAGCCACTAACTCGTGACCTCCAGCCTGCCCCTTGCTGCCGTGTGCTCCTGCCTTCCT
                 GATCCTCTGTAGAAAGGATTTTTATCTTCTGTAGAGCTAGCCGCCCTGACTGCCTTCA
                 GACCTGGCCCTGTAGCTTTTCTTTTTCTCCAGGCTGGGCCGTGAGCAGGTGGGCCGTT
                 GAGTTACCTCTGTGCTGGATCCCGTGCCCCCACTTGCCTACCCTCTGTCCTCCCTTGT
                 TATTGTAAGTGCCTTCAATACTTTGCATTTTGGGATAATAAAAAAGGCTCCCTCCCCT
                 GCAAAAAAAAAAAAAAAAAAA
                 ORF Start: ATG at 152                ORF Stop: TGA at 1658
                 SEQ ID NO: 188          502 aa       MW at 56090.6kD
NOV13k,          MQSCESSGDSADDPLSRGLRRRGQPRVVVIGAGLAGLAAAKALLEQGFTDVTVLEASS
CG140122-02
Protein Sequence HIGGRVQSVKLGHATFELGATWIHGSHGNPIYHLAEANGLLEETTDGERSVGRISLYS
                 KNGVACYLTNHGRRIPKDVVEEFSDLYNEVYNLTQEFFRHDKPVNAESQNSVGVFTRE
                 EVRNRIRNDPDDPEATKRLKLAMIQQYLKVESCESSSHSMDEVSLSAFGEWTEIPGAH
                 HIIPSGFMRVVELLAEGIPAHVIQLCKPVRCIHWDQASARPRGPEIEPRGVLKRQYTS
                 FFRPGLPTEKVAAIHRLGIGTTDKIFLEFEEPFWGPECNSLQFVWEDEAESHTLTYPP
                 ELWYRKICGFDVLYPPERYGHVLSGWICGEEALVMEKCDDEAVAEICTEMLRQFTGNP
                 NIPKPRRILRSAWGSNPYFRGSYSYTQVGSSGADVEKLAKPLPYTESSKTAPMQVLFS
                 CEATHRKYYSTTHGALLSGQREAARLIEMYRDLFQQGT
                 SEQ ID NO: 189         1012 bp
NOV13l,          CACCATGCAAAGTTGTGAATCCAGTGGTGACAGTGCGGATGACCCTCTCAGTCGCGGC
CG140122-03
DNA Sequence     CTACGGAGAAGGGCACAGCCTCGTGTGGTGGTGATCGGCGCCGGCTTGGCTGGCCTGG
                 CTGCAGCCAAAGCACTTCTTGAGCAGGGTTTCACGGATGTCACTGTGCTTGAGGCTTC
                 CAGCCACATCGGAGGCCGTGTGCAGAGTGTGAAACTTGGACACGCCACCTTTGAGCTG
                 GGAGCCACCTGGATCCATGGCTCCCATGGGAACCCTATCTATCATCTAGCAGAAGCCA
                 ACGGCCTCCTGCAAGAGACAACCGATCGGGAACGCAGCGTGGGCCGCATCAGCCTCTA
                 TTCCAAGAATGGCGTGGCCTGCTACCTTACCAACCACCGCCGCAGCATCCCCAAGGAC
                 GTGGTTGAGGAATTCAGCGATTTATACAACGAGGTCTATAACTTGACCCAGGAGTTCT
                 TCCGGCACGATAAACCAGTCAATGCTGAAAGTCAAAATAGCGTGGGGGTGTTCACCCG
                 AGAGGAGGTGCGTAACCGCATCAGGAATGACCCTGACGACCCAGAGGCTACCAAGCGC
                 CTGAAGCTCGCCATGATCCAGCAGTACCTGAAGGTGGAGAGCTGTGAGAGCAGCTCAC
                 ACAGCATGGACGAGGTGTCCCTGAGCGCCTTCGGGGAGTGGACCGAGATCCCCGGcGC
                 TCACCACATCATCCCCTCGGGCTTCATGCGGGTTGTGGAGCTGCTGGCGGAGGGCATC
                 CCTGCCCACGTCATCCAGCTAGGGAAACCTGTCCGCTGCATTCACTGGGACCAGGCCT
                 CAGCCCGCCCCAGAGGCCCTGAGATTGAGCCCCTGCCGTACACAGAGAGCTCAAAGAC
                 AGCGCCCATGCAGGTGCTGTTTTCCGGTGAGCCCACCCACCGCAAGTACTATTCCACC
                 ACCCACGGTGCTCTCCTGTCCGGCCAGCGTGAGGCTGCCCGCCTCATTGAGATGTACC
                 GACACCTCTTCCAGCAGGGGACCTGA
                 ORF Start: at 2                      ORF Stop: TGA at 1010
                 SEQ ID NO: 190          336 aa       MW at 37093.2kD
NOV13L,          TMQSCESSGDSADDPLSRGLRRRGQPRVVVIGAGLAGLAAAKALLEQGFTDVTVLEAS
CG140122-03
Protein Sequence SHIGGRVQSVKLGHATFELGATWIHGSHGNPIYHLAEANGLLEETTDGERSVGRISLY
                 SKNGVACYLTNHGRRIPKDVVEEFSDLYNEVYNLTQEFFRHDKPVNAESQNSVGVFTR
                 EEVRNRIRNDPDDPEATKRLKLAMIQQYLKVESCESSSHSMDEVSLSAFGEWTEIPGA
                 RHIIPSGFMRVVELLAEGIPAHXTIQLGKPVRCIHWDQASARPRGPEIEPLPYTESSKT
                 APMQVLFSGEATHRKYYSTTHGALLSGQREAARLIEMYRDLFQQGT
                 SEQ ID NO: 191         1603 bp
NOV13m,          CACCATGCAAAGTTGTGAATCCAGTGGTGACAGTGCGGATGACCCTCTCAGTCGCGGC
CG140122-04
DNA Sequence     CTACGGAGAAGGGGACAGCCTCGTGTGGTGGTGATCGGCGCCGGCTTGGCTGGCCTGG
                 CTGCAGCCAAAGCACTTCTTGAGCAGGGTTTCACGGATGTCACTGTGCTTGAGGCTTC
                 CAGCCACATCGGAGGCCGTGTGCAGAGTGTGAAACTTGGACACGCCACCTTTGAGCTG
                 GGAGCCACCTGGATCCATGGCTCCCATGGGAACCCTATCTATCATCTAGCAGAAQCCA
                 ACGGCCTCCTGGAAGAGACAACCGATGGGGAACGCAGCGTGGGCCGCATCAGCCTCTA
                 TTCCAAGAATGGCGTGGCCTGCTACCTTACCAACCACGGCCGCAGGATCCCCAAGGAC
                 GTGGTTGAGGAATTCAGCGATTTATACAACGAGGTCTATAACTTGACCCAGGAGTTCT
                 TCCGGCACGATAAACCAGTCAATGCTGAAAGTCAAAATAGCGTGGGGGTGTTCACCCG
                 AGAGGAGGTGCGTAACCGCATCAGGAATGACCCTGACGACCCAGAGGCTACCAAGCGC
                 CTGAAGCTCGCCATGATCCAGCAGTACCTGAAGGTGGAGAGCTGTGAGAGCAGCTCAC
                 ACAGCATGGACGAGGTGTCCCTGAGCGCCTTCGGGGAGTGGACCGAGATCCCCGGCGC
                 TCACCACATCATCCCCTCGGGCTTCATGCGGGTTGTGGAGCTGCTGGCGGAGGGCATC
                 CCTGCCCACGTCATCCAGCTAGGGAAACCTGTCCGCTGCATTCACTGGGACCAGGCCT
                 CAGCCCGCCCCAGAGGCCCTGAGATTGAGCCCCGGGGTGTGCTAAAGAGGCAGTACAC
                 CAGTTTCTTCCGGCCAGGCCTGCCCACAGAGAAGGTGGCTGCCATCCACCGCCTGGGC
                 ATTGGCACCACCGACAAGATCTTTCTGGAATTCGAGGAGCCCTTCTGGGGCCCTGAGT
                 GCAACAGCCTACAGTTTGTGTGGGAGGACGAAGCGGAGAGCCACACCCTCACCTACCC
                 ACCTGAGCTCTGGTACCGCAAGATCTGCGGCTTTGATGTCCTCTACCCGCCTGAGCGC
                 TACGGCCATGTGCTGAGCGGCTGGATCTGCGGGGAGGAGGCCCTCGTCATGGAGAAGT
                 GTGATGACGAGGCAGTGGCCGAGATCTGCACGGAGATGCTGCGTCAGTTCACAGGGAA
                 CCCCAACATTCCAAAACCTCGGCGAATCTTGCGCTCGGCCTGGGGCAGCAACCCTTAC
                 TTCCGCGGCTCCTATTCATACACGCAGGTGGGCTCCAGCGGGGCGGATGTGGAGAAGC
                 TGGCCAAGCCCCTGCCGTACACGGAGAGCTCAAAGACAGCGCATGGAAGCTCCACAAA
                 GCAGCAGCCTGGTCACCTTTTCTCTTCCAAGTGCCCAGAACAGCCCCTGGATGCTAAC
                 AGGGGCGCCGTAAAGCCCATGCAGGTGCTGTTTTCCGGTGAGGCCACCCACCGCAAGT
                 ACTATTCCACCACCCACGGTGCTCTGCTGTCCGGCCAGCGTGAGGCTGCCCGCCTCAT
                 TGAGATGTACCGAGACCTCTTCCAGCAGGGGACCTGA
                 ORF Start: at 2                      ORF Stop: TGA at 1601
                 SEQ ID NO: 192          533 aa       MW at 59379.2kD
NOV13m,          TMQSCESSGDSADDPLSRGLRRRGQPRVVVIGAGLAGLAAAAKALLEQGFTDVTVLEAS
CG140122-04
Protein Sequence SHIGGRVQSVKLGHATFELGATWIHGSHGNPIYHLAEANGLLEETTDGERSVGRISLY
                 SKNGVACYLTNHGRRIPKDVVEEFSDLYNEVYNLTQEFFRHDKPVNAESQNSVGVFTR
                 EEVRNRIRNDPDDPEATKRLKLAMIQQYLKVESCESSSHSMDEVSLSAFGEWTEIPGA
                 HHIIPSGFMRVVELLAEGIPAHVIQLGKPVRCIHWDQASARPRGPEIEPRGVLKRQYT
                 SFFRPGLPTEKVAAIHRLGIGTTDKIFLEFEEPFWGPECNSLQFVWEDEAESHTLTYP
                 PELWYRKICGFDVLYPPERYGHVLSGWICGEEALVMEKCDDEAVAEICTEMLRQFTGN
                 PNIPKPRRILRSAWGSNPYFRGSYSYTQVGSSGADVEKLAKPLPYTESSKTAHGSSTK
                 QQPGHLFSSKCPEQPLDANRGAVKPMQVLFSGEATHRKYYSTTHGALLSGQREAARLT
                 EMYRDLFQQGT
                 SEQ ID NO: 193         1513 bp
NOV13n,          CACCATGCAAAGTTGTGAATCCAGTGGTGACAGTGCGGATGACCCTCTCAGTCGCGGC
CG140122-05
DNA Sequence     CTACGGAGAAGGGGACAGCCTCGTGTGGTGGTGATCGGCGCCGGCTTGGCTGGCCTGG
                 CTGCAGCCAAAGCACTTCTTGAGCAGGGTTTCACGGATGTCACTGTGCTTGAGGCTTC
                 CAGCCACATCGGAGGCCGTGTGCAGAGTGTGAAACTTGGACACGCCACCTTTGAGCTG
                 GGAGCCACCTGGATCCATGGCTCCCATGGGAACCCTATCTATCATCTAGCAGAAGCCA
                 ACGGCCTCCTGGAAGAGACAACCGATGGGGAACGCAGCCTGGGCCGCATCAGCCTCTA
                 TTCCAAGAATGGCGTGGCCTGCTACCTTACCAACCACGGCCGCAGGATCCCCAAGGAC
                 GTGGTTGAGGAATTCAGCGATTTATACAACGAGGTCTATAACTTGACCCAGGAGTTCT
                 TCCGGCACGATAAACCAGTCAATGCTGAAAGTCAAAATAGCGTGGGGGTGTTCACCCG
                 AGAGGAGGTGCGTAACCGCATCAGGAATGACCCTGACGACCCAGAGGCTACCAAGCGC
                 CTGAAGCTCGCCATGATCCAGCAGTACCTGAAGGTGGAGAGCTGTGAGAGCAGCTCAC
                 ACAGCATGGACGAGGTGTCCCTGAGCGCCTTCGGGGAGTGGACCGAGATCCCCGGCGC
                 TCACCACATCATCCCCTCGGGCTTCATGCGGGTTGTGGAGCTGCTGGCGGAGGGCATC
                 CCTGCCCACGTCATCCAGCTAGGGAAACCTGTCCGCTGCATTCACTGGGACCAGGCCT
                 CAGCCCGCCCCAGAGGCCCTGAGATTGAGCCCCGGGGTGTGCTAAAGAGGCAGTACAC
                 CAGTTTCTTCCGGCCAGGCCTGCCCACAGAGAAGGTGGCTGCCATCCACCGCCTGGGC
                 ATTGGCACCACCGACAAGATCTTTCTGGAATTCGAGGAGCCCTTCTGGGGCCCTGAGT
                 GCAACAGCCTACAGTTTGTGTGGGAGGACGAAGCGGAGAGCCACACCCTCACCTACCC
                 ACCTGAGCTCTGGTACCGCAAGATCTGCGGCTTTGATGTCCTCTACCCGCCTGAGCGC
                 TACGOCCATGTGCTGAGCGGCTGGATCTGCGGGGAGGAGGCCCTCGTCATGGAGAAGT
                 GTGATGACGAGGCAGTGGCCGAGATCTGCACGGAGATGCTGCGTCAGTTCACAGGGAA
                 CCCCAACATTCCAAAACCTCGGCGAATCTTGCGCTCGGCCTGGGGCAGCAACCCTTAC
                 TTCCGCGGCTCCTATTCATACACGCAGGTGGGCTCCAGCGGGGCGGATGTGGAGAAGC
                 TGGCCAAGCCCCTGCCGTACACGGAGAGCTCAAAGACAGCGCCCATGCAGGTGCTGTT
                 TTCCGGTGAGGCCACCCACCGCAAGTACTATTCCACCACCCACGGTGCTCTGCTGTCC
                 GGCCAGCGTGAGGCTGCCCGCCTCATTGAGATGTACCGAGACCTCTTCCAGCAGGGGA
                 CCTGA
                 ORF Start: at 2                      ORF Stop: TGA at 1511
                 SEQ ID NO: 194          503 aa       MW at 56191.7kD
NOV13n,          TMQSCESSGDSADDPLSRGLRRRGQPRVVVIGAGLAGLAAAKALLEQGFTDVTVLEAS
CG14O122-05
Protein Sequence SHIGGRVQSVKLGHATFELGATWIHGSHGNPIYHLAEANGLLEETTDGERSVGRISLY
                 SKNGVACYLTNHGRRIPKDVVEEFSDLYNEVYNLTQEFFRHDKPVNAESQNSVGVFTR
                 EEVRNRIRNDPDDPEATKRLKLAMIQQYLKVESCESSSHSMDEVSLSAFGEWTEIPGA
                 HHIIPSGFMRVVELLAEGIPAHVIQLGKPVRCIHWDQASARPRGPEIEPRGVLKRQYT
                 SFFRPGLPTEKVAAIHRLGIGTTDKIFLEFEEPFWGPECNSLQFVWEDEAESHTLTYP
                 PELWYRKICGFDVLYPPERYGHVLSGWICGEEALVMEKCDDEAVAEICTEMLRQFTGN
                 PNIPKPRRILRSAWGSNPYFRGSYSYTQVGSSGADVEKLAKPLPYTESSKTAPMQVLF
                 SGEATHRKYYSTTHGALLSGQREAARLIEMYRDLFQQGT
                 SEQ ID NO: 195         1693 bp
NOV13o,          CACCATGGGACATCATCACCACCATCACCAAAGTTGTGAATCCAGTGGTGACAGTGCG
CG140122-06
DNA Sequence     GATGACCCTCTCAGTCGCGGCCTACGGAGAAGGGGACAGCCTCGTGTGGTGGTGATCG
                 CCGCCGGCTTGGCTGGCCTGGCTGCAGCCAAAGCACTTCTTGAGCAGGGTTTCACGGA
                 TGTCACTGTGCTTGAGGCTTCCAGCCACATCGGAGGCCGTGTGCACAGTGTGAAACTT
                 GGACACGCCACCTTTGAGCTGGGAGCCACCTGGATCCATGGCTCCCATGGGAACCCTA
                 TCTATCATCTAGCAGAAGCCAACGGCCTCCTGGAAGAGACAACCGATGGGGAACGCAG
                 CGTGGGCCGCATCAGCCTCTATTCCAAGAATGGCGTGGCCTGCTACCTTACCAACCAC
                 GGCCGCAGGATCCCCAAGGACGTGGTTGAGGAATTCAGCGATTTATACAACGAGGTCT
                 ATAACTTGACCCAGGAGTTCTTCCGGCACGATAAACCAGTCAATGCTGAAAGTCAAAA
                 TAGCGTGGGGGTGTTCACCCGAGAGGAGGTGCGTAACCGCATCAGGAATGACCCTGAC
                 GACCCAGAGGCTACCAAGCGCCTGAAGCTCGCCATGATCCAGCAGTACCTGAAGGTGG
                 AGAGCTGTGAGAGCAGCTCACACAGCATGGACGAGGTGTCCCTGAGCGCCTTCGGGGA
                 GTGGACCGAGATCCCCGGCGCTCACCACATCATCCCCTCGGGCTTCATGCGGGTTGTG
                 GAGCTGCTGGCGGAGGGCATCCCTGCCCACGTCATCCAGCTAGGGAAACCTGTCCGCT
                 GCATTCACTGGGACCAGGCCTCAGCCCGCCCCAGAGGCCCTGAGATTGAGCCCCGGGG
                 TGAGGGCGACCACAATCACGACACTGGGGAGGGTGGCCAGGGTGGAGAGGAGCCCCGG
                 GGGGGCAGGTGGGATGAGGATGAGCAGTGGTCGGTGGTGGTGGAGTGCGAGGACTGTG
                 AGCTGATCCCGGCGGACCATGTGATTGTGACCGTGTCGCTAGGTGTGCTAAAGAGGCA
                 GTACACCAGTTTCTTCCGGCCAGGCCTGCCCACAGAGAAGGTGGCTGCCATCCACCGC
                 CTGGGCATTGGCACCACCGACAAGATCTTTCTGGAATTCGAGGAGCCCTTCTGGGGCC
                 CTGAGTGCAACAGCCTACAGTTTGTGTGGGAGGACGAAGCAGAGAGCCACACCCTCAC
                 CTACCCACCTGACCTCTGGTACCGCAAGATCTGCGGCTTTGATGTCCTCTACCCGCCT
                 GAGCGCTACGGCCATGTGCTGAGCGGCTGGATCTGCGGGGAGGAGGCCCTCGTCATGG
                 AGAAGTGTGATGACGAGGCAGTGGCCGAGATCTGCACGGAGATGCTGCGTCAGTTCAC
                 AGGGAACCCCAACATTCCAAAACCTCGGCGAATCTTGCGCTCGGCCTGGGGCAGCAAC
                 CCTTACTTCCGCGGCTCCTATTCATACACGCAGGTGGGCTCCAGCGGGGCGGATGTGG
                 AGAAGCTGGCCAAGCCCCTGCCGTACACGGAGAGCTCAAAGACAGCGCCCATGCAGGT
                 GCTGTTTTCCGGTGAGGCCACCCACCGCAAGTACTATTCCACCACCCACGGTGCTCTG
                 CTGTCCGGCCAGCGTGAGGCTGCCCGCCTCATTGAGATGTACCGAGACCTCTTCCACC
                 AGGGGACCTGA
                 ORF Start: at 29                     ORF Stop: TGA at 1691
                 SEQ ID NO: 196          554 aa       MW at 61687.4kD
NOV13o,          QSCESSGDSADDPLSRGLRRRGQPRVVVIGAGLAGLAAAKALLEQGFTDVTVLEASSH
CG140122-06
Protein Sequence IGGRVQSVKLGHATFELGATWIHGSNGNPIYHLAEANGLLEETTDGERSVGRISLYSK
                 NGVACYLTNHGRRIPKDVVEEFSDLYNEVYNLTQEFFRHDKPVNAESQNSVGVFTREE
                 VRNRIRNDPDDPEATKRLKLANIQQYLKVESCESSSHSMDEVSLSAFGEWTEIPGAHH
                 IIPSGFMRVVELLAEGIPAHVIQLGKPVRCIHWDQASARPRGPEIEPRGEGDHNHDTG
                 EGGQGGEEPRGGRWDEDEQWSVVVECEDCELIPADHVIVTVSLGVLKRQYTSFFRPGL
                 PTEKVAAIHRLGIGTTDKIFLEFEEPFWGPECNSLQFVWEDEAESHTLTYPPELWYRK
                 ICGFDVLYPPERYGHVLSGWICGEEALVNEKCDDEAVAEICTEMLRQFTGNPNIPKPR
                 RILRSAWGSNPYFRGSYSYTQVGSSGADVEKLAKPLPYTESSKTAPMQVLFSGEATHR
                 KYYSTTHGALLSGQREAARLIEMYRDLFQQGT
                 SEQ ID NO: 197         1690 bp
NOV13p,          CACCATGCAAAGTTGTGAATCCAGTGGTGACAGTGCGGATGACCCTCTCAGTCGCGGC
CG140122-07
DNA Sequence     CTACGGAGAAGGCGACAGCCTCGTGTGGTGGTGATCGGCGCCGGCTTGGCTGGCCTGG
                 CTGCAGCCAAAGCACTTCTTGAGCAGGGTTTCACGGATGTCACTGTGCTTGAGGCTTC
                 CAGCCACATCGGAGGCCGTGTGCAGAGTGTGAAACTTGGACACGCCACCTTTGAGCTG
                 GGAGCCACCTGGATCCATGGCTCCCATGGGAACCCTATCTATCATCTAGCAGAAGCCA
                 ACGGCCTCCTGGAAGAGACAACCGATGGGGAACGCAGCGTGGGCCGCATCAGCCTCTA
                 TTCCAAGAATGGCGTGGCCTGCTACCTTACCAACCACGGCCGCAGGATCCCCAAGGAC
                 GTGGTTGAGGAATTCAGCGATTTATACAACGAGGTCTATAACTTGACCCAGGAGTTCT
                 TCCGGCACGATAAACCAGTCAATGCTGAAAGTCAAAATAGCGTGGGGGTGTTCACCCG
                 AGAGGAGGTGCGTAACCGCATCAGGAATGACCCTGACGACCCAGAGGCTACCAAGCGC
                 CTCAAGCTCGCCATGATCCAGCAGTACCTGAAGGTGGAGAGCTGTGAGAGCAGCTCAC
                 ACAGCATGGACGAGGTGTCCCTGAGCGCCTTCGGGGAGTGGACCGAGATCCCCGGCGC
                 TCACCACATCATCCCCTCGGGCTTCATGCGGGTTGTGGAGCTGCTGGCGGAGGGCATC
                 CCTGCCCACGTCATCCAGCTAGGGAAACCTGTCCGCTGCATTCACTGGGACCAGGCCT
                 CAGCCCGCCCCAGAGGCCCTGAGATTGAGCCCCGGGGTGAGGGCGACCACAATCACGA
                 CACTGGGGAGGGTGGCCAGGGTGGAGAGGAGCCCCGGGGGGGCAGGTGGGATGAGGAT
                 GAGCAGTGGTCGGTGGTGGTGGAGTGCGAGGACTGTGAGCTGATCCCGGCGGACCATG
                 TGATTGTGACCGTGTCGCTAGGTGTGCTAAAGAGGCAGTACACCAGTTTCTTCCGGCC
                 ACGCCTGCCCACAGAGAAGGTGGCTGCCATCCACCGCCTGGGCATTGGCACCACCGAC
                 AAGATCTTTCTGGAATTCGAGGAGCCCTTCTGGGGCCCTGAGTGCAACAGCCTACAGT
                 TTGTGTGGGAGGACGAAGCAGAGAGCCACACCCTCACCTACCCACCTGAGCTCTGGTA
                 CCGCAAGATCTGCGGCTTTGATGTCCTCTACCCGCCTGAGCGCTACGGCCATGTGCTG
                 AGCGGCTGGATCTGCGGGGAGGAGGCCCTCGTCATGGAGAAGTGTGATGACGAGGCAG
                 TGGCCGAGATCTGCACGGAGATGCTGCGTCAGTTCACAGGGAACCCCAACATTCCAAA
                 ACCTCGGCGAATCTTGCCCTCGGCCTGGGGCAGCAACCCTTACTTCCGCGGCTCCTAT
                 TCATACACGCAGGTGGGCTCCAGCGGGGCGGATGTGGAGAAGCTGGCCAAGCCCCTGC
                 CGTACACGGAGAGCTCAAAGACAGCGCCCATGCAGGTGCTGTTTTCCGGTGAGGCCAC
                 CCACCGCAAGTACTATTCCACCACCCACGGTGCTCTGCTGTCCGGCCAGCGTGAGGCT
                 GCCCCCCTCATTGAGATGTACCGAGACCTCTTCCAGCAGGGGACCCATCATCACCACC
                 ATCACTGA
                 ORF Start: at 29                     ORF Stop: TGA at 1691
                 SEQ ID NO: 196          554 aa       MW at 61687.4kD
NOV13p           TMQSCESSGDSADDPLSRGLRRRCQPRVVVIGAGLAGLAAAKALLEQGFTDVTVLEAS
CG140122-07
Protein Sequence SHIGGRVQSVKLGHATFELGATWIHGSHGNPIYHLAEANGLLEETTDGERSVGRISLY
                 SKNGVACYLTNHGRRIPKDVVEEFSDLYNEVYNLTQEFFRHDKPVNAESQNSVGVFTR
                 EEVRNRIRNDPDDPEATKRLKLANIQQYLKVESCESSSHSMDEVSLSAFGEWTEIPGA
                 HHIIPSGFMRVVELLAEGIPAHVIQLGKPVRCIHWDQASARPRGPEIEPRGEGDHNHD
                 TGEGGQGGEEPRGGRWDEDEQWSVVVECEDCELIPADHVIVTVSLGVLKRQYTSFFRP
                 GLPTEKVAAIHRLGIGTTDKIFLEFEEPFWGPECNSLQFVWEDEAESHTLTYPPELWY
                 RKICGFDVLYPPERYGHVLSGWICGEEALVMEKCDDEAVAEICTEMLRQFTGNPNIPK
                 PRRILRSAWGSNPYFRGSYSYTQVGSSGADVEKLAKPLPYTESSKTAPMQVLFSGEAT
                 HRKYYSTTHGALLSGQREAARLIEMYRDLFQQGTHHHHHH
                 SEQ ID NO: 199         1680 bp
NOV13q,          TCCACCATGCAAAGTTGTGAATCCAGTGGTGACAGTGCGGATGACCCTCTCAGTCGCG
CG140122-08
DNA Sequence     GCCTACGGAGAAGGGGACAGCCTCGTGTGGTGGTGATCGGCGCCGGCTTGGCTGGCCT
                 GGCTGCAGCCAAAGCACTTCTTGAGCAGGGTTTCACGGATGTCACTGTGCTTGAGGCT
                 TCCAGCCACATCGGAGGCCGTGTGCAGAGTGTGAAACTTGGACACGCCACCTTTGAGC
                 TGGGAGCCACCTGGATCCATGGCTCCCATGGGAACCCTATCTATCATCTAGCAGAAGC
                 CAACGGCCTCCTGGAAGAGACAACCGATGGGGAACGCAGCGTGGGCCGCATCAGCCTC
                 TATTCCAAGAATGGCGTGGCCTGCTACCTTACCAACCACGGCCGCAGGATCCCCAAGG
                 ACGTGGTTGAGGAATTCAGCGATTTATACAACGAGGTCTATAACTTGACCCAGGAGTT
                 CTTCCGGCACGATAAACCAGTCAATGCTGAAAGTCAAAATAGCGTGGGGGTGTTCACC
                 CGAGAGGAGGTGCGTAACCGCATCAGGAATGACCCTGACGACCCAGAGGCTACCAAGC
                 GCCTGAAGCTCGCCATGATCCAGCAGTACCTGAAGGTGGAGAGCTGTGAGAGCAGCTC
                 ACACAGCATGGACGAGGTGTCCCTGAGCGCCTTCGGGGAGTGGACCGAGATCCCCGGC
                 GCTCACCACATCATCCCCTCGGGCTTCATGCGGGTTGTGGAGCTGCTGGCGGAGGGCA
                 TCCCTGCCCACGTCATCCAGCTAGGGAAACCTGTCCGCTGCATTCACTGGGACCAGGC
                 CTCAGCCCGCCCCAGAGGCCCTGAGATTGAGCCCCGGGGTGAGGGCGACCACAATCAC
                 GACACTGGGGAGGGTGGCCAGGGTGGAGAGGAGCCCCGGGGGGGCAGGTGGGATGAGG
                 ATGAGCAGTGGTCGGTGGTGGTGGAGTGCGAGGACTGTGAGCTGATCCCGGCGGACCA
                 TGTGATTGTGACCGTGTCGCTAGGTGTGCTAAAGAGGCAGTACACCAGTTTCTTCCGG
                 CCAGGCCTGCCCACAGAGAAGGTGGCTGCCATCCACCGCCTGGGCATTGGCACCACCG
                 ACAAGATCTTTCTGGAATTCGAGGAGCCCTTCTGGGGCCCTGAGTGCAACAGCCTACA
                 GTTTGTGTGGGAGGACGAAGCAGAGAGCCACACCCTCACCTACCCACCTGAGCTCTGG
                 TACCGCAAGATCTCCGGCTTTGATGTCCTCTACCCGCCTGAGCGCTACGGCCATGTGC
                 TGAGCGGCTGGATCTGCGGGGAGGAGGCCCTCGTCATGGAGAAGTGTGATGACGAGGC
                 AGTGGCCGAGATCTGCACGGAGATGCTGCGTCAGTTCACAGGGAACCCCAACATTCCA
                 AAACCTCGGCGAATCTTGCGCTCGGCCTGGGGCAGCAACCCTTACTTCCGCGGCTCCT
                 ATTCATACACGCAGGTGGGCTCCAGCGGGGCGGATGTGGAGAAGCTGGCCAAGCCCCT
                 GCCGTACACGGAGAGCTCAAAGACAGCGCCCATGCAGGTGCTGTTTTCCGGTGAGGCC
                 ACCCACCGCAAGTACTATTCCACCACCCACGGTGCTCTGCTGTCCGGCCAGCGTGAGG
                 CTGCCCGCCTCATTGAGATGTACCGAGACCTCTTCCAGCAGGGGACCTGAAAGCTT
                 ORF Start: at 1                      ORF Stop: TGA at 1672
                 SEQ ID NO: 200          557 aa       MW at 62006.8kD
NOV13q,          STMQSCESSGDSADDPLSRGLRRRGQPRVVVIGAGLAGLAAAKALLEQGFTDVTVLEA
CG140122-08
Protein Sequence SSHIGGRVQSVKLGHATFELGATWIHGSHGNPIYHLAEANGLLEETTDGERSVGRISL
                 YSKNGVACYLTNHGRRIPKDVVEEFSDLYMEVYNLTQEFFRHDKPVNAESQNSVGVFT
                 REEVRNRIRNDPDDPEATKRLKLAMIQQYLKVESCESSSHSMDEVSLSAFGEWTEIPG
                 AHHIIPSGFMRVVELLAEGIPAHVIQLGKPVRCIHWDQASARPRGPEIEPRGEGDHNH
                 DTGEGGQGGEEPRGGRWDEDEQWSVVVECEDCELIPADHVIVTVSLGVLKRQYTSFFR
                 PGLPTEKVAAIHRLGIGTTDKIFLEFEEPFWGPECNSLQFVWEDEAESHTLTYPPELW
                 YRKICGFDVLYPPERYGHVLSGWICGEEALVMEKCDDEAVAEICTEMLRQFTGNPNIP
                 KPRRILRSAWGSNPYFRGSYSYTQVGSSGADVEKLAKPLPYTESSKTAPMQVLFSGEA
                 THRKYYSTTHGALLSGQREAARLIEMYRDLFQQGT

[0424] Sequence comparison of the above protein sequences yields the following sequence relationships shown in Table 13B.

TABLE 13B
Comparison of NOV13a against NOV13b through NOV13q.
			Identities/
			Similarities
	Protein	NOV13a Residues/	for the
	Sequence	Match Residues	Matched Region
	NOV13b	1 . . . 280	280/280 (100%)
		2 . . . 281	280/280 (100%)
	NOV13c	1 . . . 555	502/585 (85%)
		2 . . . 533	502/585 (85%)
	NOV13d	2 . . . 555	553/554 (99%)
		10 . . . 563	553/554 (99%)
	NOV13e	1 . . . 555	554/555 (99%)
		2 . . . 556	554/555 (99%)
	NOV13f	1 . . . 555	554/555 (99%)
		2 . . . 556	554/555 (99%)
	NOV13g	1 . . . 555	554/555 (99%)
		8 . . . 562	554/555 (99%)
	NOV13h	1 . . . 555	554/555 (99%)
		2 . . . 556	554/555 (99%)
	NOV13i	1 . . . 555	554/555 (99%)
		2 . . . 556	554/555 (99%)
	NOV13j	2 . . . 555	553/554 (99%)
		10 . . . 563	553/554 (99%)
	NOV13k	1 . . . 555	502/555 (90%)
		1 . . . 502	502/555 (90%)
	NOV13l	1 . . . 280	280/280 (100%)
		2 . . . 281	280/280 (100%)
	NOV13m	1 . . . 555	502/585 (85%)
		2 . . . 533	502/585 (85%)
	NOV13n	1 . . . 555	502/555 (90%)
		2 . . . 503	502/555 (90%)
	NOV13o	2 . . . 555	553/554 (99%)
		1 . . . 554	553/554 (99%)
	NOV13p	1 . . . 555	554/555 (99%)
		2 . . . 556	554/555 (99%)
	NOV13q	1 . . . 555	554/555 (99%)
		3 . . . 557	554/555 (99%

[0425] Further analysis of the NOV13a protein yielded the following properties shown in Table 13C.

TABLE 13C
Protein Sequence Properties NOV13a
PSort analysis:   0.7900 probability located in plasma membrane;
                  0.4802 probability located in microbody
                  (peroxisome); 0.3000 probability located in
                  Golgi body; 0.2000 probability located in
                  endoplasmic reticulum (membrane)
SignalP analysis: Cleavage site between residues 41 and 42

[0426] A search of the NOV13a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 13D.

TABLE 13D
Geneseq Results for NOV13a
			Identities/
			Similarities
Geneseq	Protein/Organism/	NOV13a Residues/	for the	Expect
Identifier	Length [Patent #, Date]	Match Residues	Matched Region	Value
AAB73670	Human oxidoreductase protein	1 . . . 555	554/555 (99%)	0.0
	ORP-3 - Homo sapiens, 555 aa.	1 . . . 555	554/555 (99%)
	[WO200144448-A2, 21 JUN. 2001]
AAB12164	Hydrophobic domain protein from	1 . . . 555	554/555 (99%)	0.0
	clone HP10673 isolated from	1 . . . 555	554/555 (99%)
	Thymus cells - Homo sapiens,
	555 aa. [WO200029448-A2, 25 MAY
	2000]
AAM79546	Human protein SEQ ID NO 3192 -	1 . . . 510	508/510(99%)	0.0
	Homo sapiens, 518 aa.	7 . . . 516	508/510(99%)
	[WO200157190-A2, 09 AUG. 2001]
AAM78562	Human protein SEQ ID NO 1224 -	1 . . . 510	501/511(98%)	0.0
	Homo sapiens, 513 aa.	1 . . . 511	501/511(98%)
	[WO200157190-A2, 09 AUG. 2001]
AAU21643	Novel human neoplastic disease	273 . . . 555	282/283 (99%)	e−171
	associated polypeptide #76 - Homo	53 . . . 335	282/283 (99%)
	sapiens, 335 aa. [WO200155163-
	A1, 02 AUG. 2001]

[0427] In a BLAST search of public sequence datbases, the NOV13a protein was found to have homology to the proteins shown in the BLASTP data in Table 13E.

TABLE 13E
Public BLASTP Results for NOV13a
			Identities/
Protein			Similarities
Accession		NOV13a Residues/	for the	Expect
Number	Protein/Organism/Length	Match Residues	Matched Portion	Value
Q96QT3	Polyamine oxidase isoform-1 -	1 . . . 555	555/555 (100%)	0.0
	Homo sapiens (Human), 555 aa.	1 . . . 555	555/555 (100%)
Q9NWMO	CDNA FLJ20746 fis, clone	1 . . . 555	554/555 (99%)	0.0
	HEP06040 - Homo sapiens	1 . . . 555	554/555 (99%)
	(Human), 555 aa.
Q99K82	Similar to hypothetical protein -	1 . . . 554	528/554 (95%)	0.0
	Mus musculus (Mouse), 555 aa.	1 . . . 554	537/554 (96%)
Q9NP51	DJ779E11.1.5 (Novel flavin	144 . . . 555	411/412 (99%)	0.0
	containing amine oxidase	1 . . . 412	411/412 (99%)
	(Translation of cDNA
	DFKZp761P0724 (Em: AL162058))
	(Isoform 5)) - Homo sapiens
	(Human), 412 aa (fragment).
Q9H6H1	CDNA: FLJ22285 fis, clone	197 . . . 555	357/389 (91%)	0.0
	HRC03956 - Homo sapiens	1 . . . 389	357/389 (91%)
	(Human), 389 aa.

[0428] PFam analysis predicts that the NOV13a protein contains the domains shown in the Table 13F.

TABLE 13F
Domain Analysis of NOV13a
		Identities/
		Similarities
	NOV13a Match	for the	Expect
Pfam Domain	Region	Matched Region	Value
FAD_binding_3	27 . . . 141	24/142 (17%)	0.31
		74/142 (52%)
Amino_oxidase	34 . . . 544	124/574 (22%)	1.8e−28
		366/574 (64%)

[0429] The NOV14 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 14A.

TABLE 14A
NOV14 Sequence Analysis
	SEQ ID NO: 201         2058 bp
NOV14a,	ATGGAGCCCGAAGCCCCCCGTCGCCGCCACACCCATCAGCGCGGCTACCTGCTGACAC
CG140316-01
DNA Sequence	GGAACCCTCACCTCAACAACGACTTGGCCTTTACCCTGGAAGAGAGACAGCAATTGAA
	CATTCATGGATTGTTGCCACCTTCCTTCAACAGTCAGGAGATCCAGGTTCTTAGAGTA
	GTAAAAAATTTCGAGCATCTGAACTCTGACTTTGACAGGTATCTTCTCTTAATGGATC
	TCCAAGATAGAAATGAAAAACTCTTTTATAGAGTGCTGACATCTGACATTGAGAAATT
	CATGCCTATTGTTTATACTCCCACTGTGGGTCTGGCTTGCCAACAATATAGTTTGGTG
	TTTCGGAAGCCAAGAGGTCTCTTTATTACTATCCACGATCGAGGGCATATTGCTTCAG
	TTCTCAATGCATGGCCAGAAGATGTCATCAAGGCCATTGTGGTGACTGATGGAGAGCG
	TATTCTTGGCTTGGGAGACCTTGGCTGTAATGGAATGGGCATCCCTGTGGGTAAATTG
	GCTCTATATACAGCTTGCGGAGGGATGAATCCTCAAGAATGTCTGCCTGTCATTCTGG
	ATGTGGGAACCGAAAATGAGGAGTTACTTAAAGATCCACTCTACATTGGACTACGGCA
	GAGAAGAGTAAGAGGTTCTGAATATGATGATTTTTTGGACGAATTCATGGAGGCAGTT
	TCTTCCAAGTATGGCATGAATTGCCTTATTCAGTTTGAAGATTTTGCCAATGTGAATG
	CATTTCGTCTCCTGAACAAGTATCGAAACCAGTATTGCACATTCAATGATGATATTCA
	AGGAACAGCATCTGTTGCAGTTGCAGGTCTCCTTGCAGCTCTTCGAATAACCAAGAAC
	AAACTGTCTGATCAAACAATACTATTCCAAGGAGCTGGAGAGGCTGCCCTAGGGATTG
	CACACCTGATTGTGATGGCCTTGGAAAAAGAAGGTTTACCAAAAGAGAAAGCCATCAA
	AAAGATATGGCTGGTTGATTCAAAAGGATTAATAGTTAAGGGACGTGCTTCCTTAACA
	CAAGAGAAAGAGAAGTTTGCCCATGAACATGAAGAAATGAAGAACCTAGAAGCCATTG
	TTCAAGAAATAAAACCAACTGCCCTCATAGGAGTTGCTGCAATTGGTGGTGCATTCTC
	AGAACAAATTCTCAAAGATATGGCTGCCTTCAATGAACGGCCTATTATTTTTGCTTTG
	AGTAATCCAACTAGCAAAGCAGAATGTTCTGCAGAGCAGTGCTACAAAATAACCAAGG
	GACGTGCAATTTTTGCCAGTGGCAGTCCTTTTGATCCAGTCACTCTTCCAAATGGACA
	GACCCTATATCCTGGCCAAGGCAACAATTCCTACGTGTTCCCTGGAGTTGCTCTTGGT
	GTTGTGGCGTGTGGATTGAGGCAGATCACAGATAATATTTTCCTCACTACTGCTGAGG
	TTATAGCTCAGCAAGTGTCAGATAAACACTTGGAAGAGGGTCGGCTTTATCCTCCTTT
	GAATACCATTAGAGATGTTTCTCTGAAAATTGCAGAAAAGATTGTGAAAGATGCATAC
	CAAGAAAAGACAGCCACAGTTTATCCTGAACCGCAAAACAAAGAAGCATTTGTCCGCT
	CCCAGATGTATAGTACTGATTATGACCAGATTCTACCTGATTGTTATTCTTGGCCTGA
	AGAGGTGCAGAAAATACAGACCAAAGTTGACCAGTAGGATAATAGCAAACATTTCTAA
	CTCTATTAATGAGGTCTTTAAACCTTTCATAATTTTTAAAGGTTGGAATCTTTTATAA
	TGATTCATAAGACACTTAGATTAAGATTTTACTTTAACAGTCTAAAAATTGATAGAAG
	AATATCGATATAAATTGGGATAAACATCACATGAGACAATTTTGCTTCACTTTGCCTT
	CTGGTTATTTATGGTTTCTGTCTGAATTATTCTGCCTACGTTCTCTTTAAAAGCTGTT
	GTACGTACTACGGAGAAACTCATCATTTTTATACAGGACACTAATGGGAAGACCAAAA
	TTACTAATAAATTGAAATAACCAACATT
	ORF Start: ATG at 1                  ORF Stop: TAG at 1717
	SEQ ID NO: 202         1572 aa       MW at 64148.9kD
NOV 14a,	MEPEAPRRRHTHQRGYLLTRNPHLNKDLAFTLEERQQLNIHGLLPPSFNSQEIQVLRV
CG140316-01
Protein Sequence	VKNFEHLNSDFDRYLLLMDLQDRNEKLFYRVLTSDIEKFMPIVYTPTVGLACQQYSLV
	FRKPRGLFITIHDRGHIASVLNAWPEDVIKAIVVTDGERILGLGDLGCNGMGIPVGKL
	ALYTACGGMNPQECLPVILDVGTENEELLKDPLYIGLRQRRVRGSEYDDFLDEFMEAV
	SSKYGMNCLIQFEDFANVNAFRLLNKYRNQYCTFNDDIQGTASVAVAGLLAALRITKN
	KLSDQTILFQGAGEAALGIAHLIVMALEKEGLPKEKAIKKIWLVDSKGLIVKGRASLT
	QEKEKFAHEHEEMKNLEAIVQEIKPTALIGVAAIGGAFSEQILKDMAAFNERPIIFAL
	SNPTSKAECSAEQCYKITKGPAIFASGSPFDPVTLPNGQTLYPGQGNNSYVFPGVALG
	VVACGLRQITDNIFLTTAEVIAQQVSDKHLEEGRLYPPLNTIRDVSLKIAEKIVKDAY
	QEKTATVYPEPQNKEAFVRSQMYSTDYDQILPDCYSWPEEVQKIQTKVDQ
	SEQ ID NO: 203         2058 bp
NOV14b,	ATGGAGCCCGAAGCCCCCCGTCGCCGCCACACCCATCAGCGCGGCTACCTGCTGACAC
CG140316-01
DNA Sequence	GGAACCCTCACCTCAACAAGGACTTGGCCTTTACCCTGGAAGAGAGACAGCAATTGAA
	CATTCATGGATTGTTGCCACCTTCCTTCAACAGTCAGGAGATCCAGGTTCTTAGAGTA
	CTAAAAAATTTCGAGCATCTGAACTCTGACTTTGACAGGTATCTTCTCTTAATGGATC
	TCCAAGATAGAAATGAAAAACTCTTTTATAGAGTGCTGACATCTGACATTGAGAAATT
	CATGCCTATTGTTTATACTCCCACTGTGGGTCTGGCTTGCCAACAATATAGTTTGGTG
	TTTCGGAAGCCAAGAGGTCTCTTTATTACTATCCACGATCGAGGGCATATTGCTTCAG
	TTCTCAATCCATGGCCAGAAGATGTCATCAAGGCCATTGTGGTGACTGATGGAGAGCG
	TATTCTTGGCTTGGGAGACCTTGGCTGTAATGGAATGGGCATCCCTGTGGGTAAATTG
	CCTCTATATACAGCTTGCGGAGGGATGAATCCTCAAGAATGTCTGCCTGTCATTCTGG
	ATGTGGGAACCGAAAATGAGGAGTTACTTAAAGATCCACTCTACATTGGACTACGGCA
	GAGAAGAGTAAGACGTTCTGAATATGATGATTTTTTGGACGAATTCATGGAGGCAGTT
	TCTTCCAAGTATGGCATCAATTGCCTTATTCAGTTTGAAGATTTTGCCAATGTGAATG
	CATTTCGTCTCCTGAACAAGTATCGAAACCAGTATTGCACATTCAATGATGATATTCA
	AGGAACAGCATCTGTTGCAGTTGCAGGTCTCCTTGCAGCTCTTCGAATAACCAAGAAC
	AAACTGTCTGATCAAACAATACTATTCCAAGGAGCTGGAGAGGCTGCCCTAGGGATTG
	CACACCTGATTGTGATGGCCTTGGAAAAAGAAGGTTTACCAAAAGAGAAAGCCATCAA
	AAAGATATGGCTGGTTGATTCAAAAGGATTAATAGTTAAGGGACCTGCTTCCTTAACA
	CAAGAGAAAGAGAAGTTTGCCCATGAACATCAAGAAATGAAGAACCTAGAAGCCATTG
	TTCAAGAAATAAAACCAACTGCCCTCATAGGAGTTGCTGCAATTGGTGGTGCATTCTC
	AGAACAAATTCTCAAAGATATGGCTGCCTTCAATGAACGGCCTATTATTTTTGCTTTG
	AGTAATCCAACTAGCAAACCAGAATGTTCTGCAGAGCAGTGCTACAAAATAACCAAGG
	GACGTGCAATTTTTGCCAGTGGCAGTCCTTTTGATCCAGTCACTCTTCCAAATGGACA
	GACCCTATATCCTGGCCAAGGCAACAATTCCTACGTGTTCCCTGGAGTTGCTCTTGGT
	GTTGTGGCGTGTGGATTGAGGCACATCACAGATAATATTTTCCTCACTACTGCTGAGG
	TTATAGCTCAGCAAGTGTCAGATAAACACTTGGAAGAGGGTCGGCTTTATCCTCCTTT
	GAATACCATTAGAGATGTTTCTCTGAAAATTGCAGAAAAGATTGTGAAAGATGCATAC
	CAAGAAAAGACAGCCACAGTTTATCCTGAACCGCAAAACAAAGAAGCATTTGTCCGCT
	CCCAGATGTATAGTACTGATTATGACCAGATTCTACCTGATTGTTATTCTTGGCCTGA
	AGAGGTGCAGAAAATACAGACCAAAGTTGACCAGTAGGATAATAGCAAACATTTCTAA
	CTCTATTAATGAGGTCTTTAAACCTTTCATAATTTTTAAAGGTTGGAATCTTTTATAA
	TGATTCATAAGACACTTAGATTAAGATTTTACTTTAACAGTCTAAAAATTGATAGAAG
	AATATCGATATAAATTGGGATAAACATCACATGAGACAATTTTGCTTCACTTTGCCTT
	CTGGTTATTTATGGTTTCTGTCTGAATTATTCTGCCTACGTTCTCTTTAAAAGCTGTT
	CTACGTACTACGGAGAAACTCATCATTTTTATACAGGACACTAATGGGAAGACCAAAA
	TTACTAATAAATTGAAATAACCAACATT
	ORF Start: ATG at 1                  ORF Stop: TAG at 1717
	SEQ ID NO: 202          572 aa       MW at 64148.9kD
NOV14b,	MEPEAPRRRHTHQRGYLLTRNPHLNKDLAFTLEERQQLNIHGLLPPSFNSQEIQVLRV
CG140316-01
Protein Sequence	VKNFEHLNSDFDRYLLLMDLQDRNEKLFYRVLTSDIEKFMPIVYTPTVGLACQQYSLV
	FRKPRGLFITIHDRGHIASVLNAWPEDVIKAIVVTDGERILGLGDLGCNGMGIPVGKL
	ALYTACGGMNPQECLPVILDVGTENEELLKDPLYIGLRQRRVRGSEYDDFLDEFMEAV
	SSKYGMNCLIQFEDFANVNAFRLLNKYRNQYCTFNDDIQGTASVAVAGLLAALRITKN
	KLSDQTILFQGAGEAALGIAHLIVMALEKEGLPKEKAIKKIWLVDSKGLIVKGRASLT
	QEKEKFAHEHEEMKNLEAIVQEIKPTALIGVAAIGGAFSEQILKDMAAFNERPIIPAL
	SNPTSKAECSAEQCYKITKGRATFASGSPFDPVTLPNGQTLYPGQGNNSYVFPGVALG
	VVACGLRQITDNIFLTTAEVIAQQVSDKHLEEGRLYPPLNTIRDVSLKIAEKIVKDAY
	QEKTATVYPEPQNKEAFVRSQMYSTDYDQILPDCYSWPEEVQKIQTKVDQ
	SEQ ID NO: 205         1750 bp
NOV14c,	CGCGGATCCATGGAGCCCGAAGCCCCCCGTCGCCGCCACACCCATCAGCGCGGCTACC
254047949
DNA Sequence	TGCTGACACGGAACCCTCACCTCAACAAGGACTTGGCCTTTACCCTGGAAGAGAGACA
	GCAATTGAACATTCATGGATTGTTGCCACCTTCCTTCAACAGTCAGGAGATCCAGGTT
	CTTAGAGTAGTAAAAAATTTCGAGCATCTGAACTCTGACTTTGACAGGTATCTTCTCT
	TAATGGATCTCCAAGATAGAAATGAAAAACTCTTTTATAGAGTGCTGACATCTGACAT
	TGAGAAATTCATGCCTATTGTTTATACTCCCACTGTGGGTCTGGCTTGCCAACAATAT
	AGTTTGGTGTTTCGGAAGCCAAGAGGTCTCTTTATTACTATCCACGATCGAGGGCATA
	TTGCTTCAGTTCTCAATGCATGGCCAGAAGATGTCATCAAGGCCATTGTGGTGACTGA
	TGGAGAGCGTATTCTTGGCTTGGGAGACCTTGGCTGTAATGGAATGGGCATCCCTGTG
	GGTAAATTGGCTCTATATACAGCTTQCGGAGGGATGAATCCTCAAGAATGTCTGCCTG
	TCATTCTGGATGTGGGAACCGAAAATGAGGAGTTACTTAAAGATCCACTCTACATTGG
	ACTACGGCAGAGAAGAGTAAGAGGTTCTGAATATGATGATTTTTTGGACGAATTCATG
	GAGGCAGTTTCTTCCAAGTATGGCATGAATTGCCTTATTCAGTTTGAAGATTTTGCCA
	ATGTGAATGCATTTCGTCTCCTGAACAAGTATCGAAACCAGTATTGCACATTCAATGA
	TGATATTCAAGGAACAGCATCTGTTGCAGTTGCAGGTCTCCTTGCAGCTCTTCGAATA
	ACCAACAACAAACTGTCTGATCAAACAATACTATTCCAAGGAGCTCGGGAGGCTGCCC
	TAGGGATTGCACACCTGATTGTGATGGCCTTGGAAAAAGAAGGTTTACCAAAAGAGAA
	AGCCATCAAAAAGATATGGCTGGTTGATTCAAAAGGATTAATAGTTAAGGGACGTGCT
	TCCTTAACACAAGAGAAAGAGAAGTTTGCCCATGAACATGAAGAAATGAAGAACCTAG
	AAGCCATTGTTCAAGAAATAAAACCAACTGCCCTCATAGGAGTTGCTGCAATTGGTGG
	TGCATTCTCAGAACAAATTCTCAAAGATATGGCTGCCTTCAATGAACGGCCTATTATT
	TTTGCTTTGAGTAATCCAACTAGCAAACCAGAATGTTCTGCAGAGCAGTGCTACAAAA
	TAACCAAGGGACGTGCAATTTTTGCCAGTGGCAGTCCTTTTGATCCAGTCACTCTTCC
	AAATGGACAGACCCTATATCCTGGCCAAGGCAACAATTCCTATGTGTTCCCTGGAGTT
	GCTCTTGGTGTTGTGGCGTGTGGATTGAGGCAGATCACAGATAATATTTTCCTCACTA
	CTGCTGAGGTTATAGCTCAGCAAGTGTCAGATAAACACTTGGAAGAGGGTCGGCTTTA
	TCCTCCTTTGAATACCATTAGAGATGTTTCTCTGAAAATTGCAGAAAAGATTGTGAAA
	GATGCATACCAAGAAAAGACAGCCACAGTTTATCCTGAACCGCAAAACAAAGAAGCAT
	TTGTCCGCTCCCAGATGTATAGTACTGATTATGACCAGATTCTACCTGATTGTTATTC
	TTGGCCTGAAGAGGTGCAGAAAATACAGACCAAAGTTGACCAGTAGGGTGGCGGCCGC
	TTTTTTCCYYTT
	ORF Start: at 1                      ORF Stop: TAG at 1726
	SEQ ID NO: 206          575 aa       MW at 64449.2kD
NOV14c,	RGSMEPEAPRRRHTHQRGYLLTRNPHLNKDLAFTLEERQQLNIHGLLPPSFNSQEIQV
254047949
Protein Sequence	LRVVKNFEHLNSDFDRYLLLMDLQDRNEKLFYRVLTSDIEKFMPIVYTPTVGLACQQY
	SLVFRKPRGLFITIHDRGHIASVLNAWPEDVIKAIVVTDGERILGLGDLGCNGMGIPV
	GKLALYTACGGMNPQECLPVILDVGTENEELLKDPLYIGLRQRRVRGSEYDDFLDEFM
	EAVSSKYGMNCLIQFEDFANVNAFRLLNKYRNQYCTFNDDIQGTASVAVAGLLAALRI
	TKNKLSDQTILFQGAGEAALGIAHLIVMALEKEGLPKEKAIKKIWLVDSKGLIVKGRA
	SLTQEKEKFAHEHEEMKNLEAIVQEIKPTALIGVAAIGGAFSEQILKDMAAFNERPII
	FALSNPTSKAECSAEQCYKITKGRAIFASGSPFDPVTLPNGQTLYPGQGNNSYVFPGV
	ALGVVACGLRQITDNIFLTTAEVIAQQVSDKHLEEGRLYPPLNTIRDVSLKIAEKIVK
	DAYQEKTATVYPEPQNKEAFVRSQMYSTDYDQILPDCYSWPEEVQKIQTKVDQ
	SEQ ID NO: 207         1752 bp
NOV14d,	AGCCCGAAGCCCCCCGTCGCCGCCACACCCATCAGCGCCGCTACCTGCTGACACGGAA
258280122
DNA Sequence	CCCTCACCTCAACAAGGACTTGGCCTTTACCCTGGAAGAGAGACAGCAATTGAACATT
	CATGGATTGTTGCCACCTTCCTTCAACAGTCAGGAGATCCAGGTTCTTAGAGTAGTAA
	AAAATTTCGAGCATCTGAACTCTGACTTTGACAGGTATCTTCTCTTAATGGATCTCCA
	AGATAGAAATGAAAAACTCTTTTATAGAGTGCTGACATCTGACATTGAGAAATTCATG
	CCTATTGTTTATACTCCCACTGTGGGTCTGGCTTGCCAACAATATAGTTTGGTGTTTC
	GGAAGCCAAGAGGTCTCTTTATTACTATCCACGATCGAGGGCATATTGCTTCAGTTCT
	CAATGCATGGCCAGAAGATGTCATCAAGGCCATTGTGGTGACTGATGGAGAGCGTATT
	CTTGGCTTGGGAGACCTTGGCTGTAATCGAATGGGCATCCCTGTGGGTAAATTGGCTC
	TATATACAGCTTGCGGAGGGATGAATCCTCAAGAATGTCTGCCTGTCATTCTGGATGT
	GGGAACCGAAAATGAGGAGTTACTTAAAGATCCACTCTACATTGGACTACGGCAGAGA
	AGAGTAAGAGGTTCTGAATATGATGATTTTTTGGACGAATTCATGGAGGCAGTTTCTT
	CCAAGTATGGCATGAATTGCCTTATTCAGTTTGAAGATTTTGCCAATGTGAATGCATT
	TCGTCTCCTGAACAAGTATCGAAACCAGTATTGCACATTCAATGATGATATTCAAGGA
	ACAGCATCTGTTGCAGTTGCAGGTCTCCTTGCAGCTCTTCGAATAACCAAGAACAAAC
	TGTCTGATCAAACAATACTATTCCAAGGAGCTGGGGAGGCTGCCCTAGGGATTGCACA
	CCTGATTGTGATGGCCTTGGAAAAAGAAGGTTTACCAAAAGAGAAAGCCATCAAAAAG
	ATATGGCTGGTTGATTCAAAAGGATTAATAGTTAAGGGACGTGCTTCCTTAACACAAG
	AGAAAGAGAAGTTTGCCCATGAACATGAAGAAATGAAGAACCTAGAAGCCATTGTTCA
	AGAAATAAAACCAACTGCCCTCATAGGAGTTGCTGCAATTGGTGGTGCATTCTCAGAA
	CAAATTCTCAAAGATATGGCTGCCTTCAATGAACGGCCTATTATTTTTGCTTTGAGTA
	ATCCAACTAGCAAAGCAGAATGTTCTGCAGAGCAGTGCTACAAAATAACCAAGGGACG
	TGCAATTTTTGCCAGTGGCAGTCCTTTTGATCCAGTCACTCTTCCAAATGGACAGACC
	CTATATCCTGGCCAAGGCAACAATTCCTATGTGTTCCCTGGAGTTGCTCTTGGTGTTG
	TGGCGTGTGGATTGAGGCAGATCACAGATAATATTTTCCTCACTACTGCTGAGGTTAT
	AGCTCAGCAAGTGTCAGATAAACACTTGGAAGACGGTCGGCTTTATCCTCCTTTGAAT
	ACCATTAGAGATGTTTCTCTGAAAATTGCAGAAAAGATTGTGAAAGATGCATACCAAG
	AAAAGACAGCCACAGTTTATCCTGAACCGCAAAACAAAGAAGCATTTGTCCGCTCCCA
	GATGTATAGTACTGATTATGACCAGATTCTACCTGATTGTTATTCTTGGCCTGAAGAG
	GTGCAGAAAATACAGACCAAAGTTGACCAGTAGGGTGGCGGCCGCACTCGAGCACCAC
	CACCACCACCAC
	ORF Start: at 3                      ORF Stop: TAG at 1713
	SEQ ID NO: 208          570 aa       MW at 63888.6kD
NOV14d,	PEAPRRRHTHQRGYLLTRNPHLNKDLAFTLEERQQLNIHGLLPPSFNSQEIQVLRVVK
258280122
Protein Sequence	NFEHLNSDFDRYLLLMDLQDRNEKLFYRVLTSDIEKFMPIVYTPTVGLACQQYSLVFR
	KPRGLFITIHDRGHIASVLNAWPEDVIKAIVVTDGERILGLGDLGCNGMGIPVGKLAL
	YTACGGMNPQECLPVILDVGTENEELLKDPLYIGLRQRRVRGSEYDDFLDEFMEAVSS
	KYGMNCLIQFEDFANVNAFRLLNKYRNQYCTFNDDIQGTASVAVAGLLAALRITKNKL
	SDQTILFQGAGEAALGIAHLIVMALEKEGLPKEKAIKKIWLVDSKGLIVKGRASLTQE
	KEKFAHEHEEMKNLEAIVQEIKPTALIGVAAIGGAFSEQILKDMAAFNERPIIFALSN
	PTSKAECSAEQCYKITKGRAIFASGSPFDPVTLPNGQTLYPGQGNNSYVFPGVALGVV
	ACGLRQITDNIFLTTAEVTAQQVSDKHLEEGRLYPPLNTIRDVSLKIAEKIVKDAYQE
	KTATVYPEPQNKEAFVRSQMYSTDYDQILPDCYSWPEEVQKIQTKVDQ
	SEQ ID NO: 209         1743 bp
NOV14e,	ACCATGGGCCACCATCACCACCATCACGAGCCCGAAGCCCCCCGTCGCCGCCACACCC
258330149
DNA Sequence	ATCAGCGCGGCTACCTGCTGACACGGAACCCTCACCTCAACAAGGACTTGGCCTTTAC
	CCTGGAAGAGAGACAGCAATTGAACATTCATGCATTGTTGCCACCTTCCTTCAACAGT
	CAGGAGATCCAGGTTCTTAGAGTAGTAAAAAATTTCGAGCATCTGAACTCTGACTTTG
	ACAGGTATCTTCTCTTAATGGATCTCCAAGATAGAAATGAAAAACTCTTTTATAGAGT
	GCTGACATCTGACATTGACAAATTCATGCCTATTGTTTATACTCCCACTGTGGGTCTG
	GCTTGCCAACAATATAGTTTGGTGTTTCGGAAGCCAAGAGGTCTCTTTATTACTATCC
	ACGATCGAGGGCATATTGCTTCAGTTCTCAATGCATGGCCAGAAGATGTCATCAAGGC
	CATTGTGGTGACTGATGCAGAGCGTATTCTTGGCTTGGGAGACCTTGGCTCTAATGGA
	ATGGGCATCCCTGTGGGTAAATTGGCTCTATATACAGCTTGCGGAGGGATGAATCCTC
	AAGAATGTCTGCCTGTCATTCTGGATGTGGGAACCGAAAATGAGGAGTTACTTAAAGA
	TCCACTCTACATTGGACTACGGCAGAGAAGAGTAAGAGGTTCTGAATATGATGATTTT
	TTGGACGAATTCATGGAGGCAGTTTCTTCCAAGTATGGCATGAATTGCCTTATTCAGT
	TTGAAGATTTTGCCAATGTGAATGCATTTCGTCTCCTGAACAAGTATCGAAACCAGTA
	TTGCACATTCAATGATGATATTCAAGGAACAGCATCTGTTGCAGTTGCAGGTCTCCTT
	GCAGCTCTTCGAATAACCAAGAACAAACTGTCTGATCAAACAATACTATTCCAAGGAG
	CTGGGGAGGCTGCCCTAGGGATTGCACACCTGATTGTGATGGCCTTGGAAAAAGAAGG
	TTTACCAAAAGAGAAAGCCATCAAAAAGATATGGCTGGTTGATTCAAAAGGATTAATA
	GTTAAGGGACGTGCTTCCTTAACACAAGAGAAAGAGAAGTTTGCCCATGAACATGAAG
	AAATGAAGAACCTAGAAGCCATTGTTCAAGAAATAAAACCAACTGCCCTCATAGGAGT
	TGCTGCAATTGGTGGTGCATTCTCAGAACAAATTCTCAAAGATATGGCTGCCTTCAAT
	GAACGGCCTATTATTTTTGCTTTGAGTAATCCAACTAGCAAAGCAGAATGTTCTGCAG
	AGCAGTGCTACAAAATAACCAAGGGACGTGCAATTTTTGCCAGTGGCAGTCCTTTTGA
	TCCAGTCACTCTTCCAAATGGACAGACCCTATATCCTGGCCAAGGCAACAATTCCTAT
	GTGTTCCCTGGAGTTGCTCTTGGTGTTGTGGCGTGTGGATTGAGGCAGATCACAGATA
	ATATTTTCCTCACTACTGCTGAGGTTATAGCTCAGCAAGTGTCAGATAAACACTTGGA
	AGAGGGTCGGCTTTATCCTCCTTTGAATACCATTAGAGATGTTTCTCTGAAAATTGCA
	GAAAAGATTGTGAAAGATGCATACCAAGAAAAGACAGCCACAGTTTATCCTGAACCGC
	AAAACAAAGAACCATTTGTCCGCTCCCAGATGTATAGTACTGATTATGACCAGATTCT
	ACCTGATTGTTATTCTTGGCCTGAAGAGGTGCAGAAAATACAGACCAAAGTTGACCAG
	TAG
	ORF Start: at 1		ORF Stop: TAG at 1741
	SEQ ID NO: 210	580 aa	MW at 65129.9kD
NOV14e,	TMGHHHHHHEPEAPRRRHTHQRGYLLTRNPHLNKDLAFTLEERQQLNIHGLLPPSFNS
258330149
Protein Sequence	QEIQVLRVVKNFEHLNSDFDRYLLLMDLQDRNEKLFYRVLTSDIEKFMPIVYTPTVGL
	ACQQYSLVFRKPRGLFITIHDRGHIASVLNAWPEDVIKAIVVTDGERILGLGDLGCNG
	MGIPVGKLALYTACCGMNPQECLPVILDVGTENEELLKDPLYIGLRQRRVRGSEYDDF
	LDEFMEAVSSKYGMNCLIQFEDFANVNAFRLLNKYRNQYCTFNDDIQGTASVAVAGLL
	AALRITKNKLSDQTILFQGAGEAALGIAHLIVMALEKEGLPKEKAIKKIWLVDSKGLI
	VKGRASLTQEKEKFAHEHEEMKNLEAIVQEIKPTALIGVAAIGGAFSEQILKDMAAFN
	ERPIIFALSNPTSKAECSAEQCYKITKGRAIFASGSPFDPVTLPNGQTLYPGQGNNSY
	VFPGVALGVVACGLRQITDNIFLTTAEVIAQQVSDKHLEEGRLYPPLNTIRDVSLKIA
	EKIVKDAYQEKTATVYPEPQNKEAFVRSQMYSTDYDQTLPDCYSWPEEVQKIQTKVDQ
	SEQ ID NO: 211         1767 bp
NOV14f	CACCATCACCACCATCACGAGCCCGAAGCCCCCCGTCGCCGCCACACCCATCAGCGCG
258330422
DNA Sequence	GCTACCTGCTGACACGGAACCCTCACCTCAACAAGGACTTGGCCTTTACCCTGGAAGA
	GAGACAGCAATTGAACATTCATGGATTGTTGCCACCTTCCTTCAACAGTCAGGAGATC
	CAGGTTCTTAGAGTAGTAAAAAATTTCGAGCATCTGAACTCTGACTTTGACAGGTATC
	TTCTCTTAATGGATCTCCAAGATAGAAATGAAAAACTCTTTTATAGAGTGCTGACATC
	TGACATTGAGAAATTCATGCCTATTGTTTATACTCCCACTGTGGGTCTGGCTTGCCAA
	CAATATAGTTTGGTGTTTCGGAAGCCAAGAGGTCTCTTTATTACTATCCACGATCGAG
	GGCATATTGCTTCAGTTCTCAATCCATGCCCAGAAGATGTCATCAAGGCCATTGTGGT
	GACTGATGGAGAGCGTATTCTTGGCTTGGGAGACCTTGGCTGTAATGGAATGGGCATC
	CCTGTGGGTAAATTGGCTCTATATACAGCTTGCGGAGGGATGAATCCTCAAGAATGTC
	TGCCTGTCATTCTGGATGTGGGAACCGAAAATCAGGAGTTACTTAAAGATCCACTCTA
	CATTGGACTACGGCAGAGAAGAGTAAGAGGTTCTGAATATGATGATTTTTTGGACGAA
	TTCATGGAGGCAGTTTCTTCCAAGTATGGCATGAATTGCCTTATTCAGTTTGAAGATT
	TTGCCAATGTGAATGCATTTCGTCTCCTGAACAAGTATCGAAACCAGTATTGCACATT
	CAATGATCATATTCAAGGAACAGCATCTGTTGCAGTTGCAGGTCTCCTTGCACCTCTT
	CGAATAACCAAGAACAAACTGTCTGATCAAACAATACTATTCCAAGGAGCTGGGGAGG
	CTGCCCTAGGGATTGCACACCTGATTGTGATGGCCTTGGAAAAAGAAGGTTTACCAAA
	AGAGAAAGCCATCAAAAAGATATGGCTGGTTGATTCAAAAGGATTAATAGTTAAGGGA
	CGTGCTTCCTTAACACAAGAGAAAGAGAAGTTTGCCCATGAACATGAAGAAATGAAGA
	ACCTAGAAGCCATTGTTCAAGAAATAAAACCAACTGCCCTCATAGGAGTTGCTGCAAT
	TGGTGGTGCATTCTCAGAACAAATTCTCAAAGATATGGCTGCCTTCAATGAACGGCCT
	ATTATTTTTGCTTTGAGTAATCCAACTAGCAAAGCAGAATGTTCTGCAGAGCAGTGCT
	ACAAAATAACCAAGGGACGTGCAATTTTTGCCAGTGGCAGTCCTTTTGATCCAGTCAC
	TCTTCCAAATGGACAGACCCTATATCCTGGCCAAGGCAACAATTCCTATGTGTTCCCT
	GGAGTTGCTCTTGGTGTTGTGGCGTGTGGATTGAGGCAGATCACAGATAATATTTTCC
	TCACTACTGCTGAGGTTATAGCTCAGCAAGTGTCAGATAAACACTTGGAAGAGGGTCG
	GCTTTATCCTCCTTTGAATACCATTAGAGATGTTTCTCTGAAAATTGCAGAAAAGATT
	GTGAAAGATGCATACCAAGAAAAGACAGCCACAGTTTATCCTGAACCGCAAAACAAAG
	AAGCATTTGTCCGCTCCCAGATGTATAGTACTGATTATGACCAGATTCTACCTGATTG
	TTATTCTTGGCCTGAAGAGGTGCAGAAAATACAGACCAAAGTTGACCAGTAGGCGGCC
	GCACTCGAGCACCACCACCACCACCAC
	ORF Start: at 1                      ORF Stop: TAG at 1732
	SEQ ID NO: 212          577 aa       MW at 64840.6kD
NOV14f,	HHHHHHEPEAPRRRHTHQRGYLLTRNPHLNKDLAFTLEERQQLNIHGLLPPSFNSQEI
258330422
Protein Sequence	QVLRVVKNFEHLNSDFDRYLLLMDLQDRNEKLFYRVLTSDIEKFMPIVYTPTVCLACQ
	QYSLVFRKPRGLFITIHDRGHIASVLNAWPEDVIKAIVVTDGERILGLGDLGCNGMGI
	PVGKLALYTACGGMNPQECLPVILDVGTENEELLKDPLYIGLRQRRVRGSEYDDFLDE
	FMEAVSSKYGMNCLIQFEDFANVNAFRLLNKYRNQYCTFNDDIQGTASVAVAGLLAAL
	RITKNKLSDQTILFQGAGEAALGIAHLIVMALEKEGLPKEKAIKKIWLVDSKGLIVKG
	RASLTQEKEKFAHEHEEMKNLEAIVQEIKPTALIGVAAIGGAFSEQILKDMAAFNERP
	IIFALSNPTSKAECSAEQCYKITKGRAIFASGSPFDPVTLPNGQTLYPGQGNNSYVFP
	GVALGVVACGLRQITDNIFLTTAEVIAQQVSDKHLEEGRLYPPLNTIRDVSLKIAEKI
	KDAYQEKTATVYPEPQNKEAFVRSQMYSTDYDQILPDCYSWPEEVQKIQTKVDQ
	SEQ ID NO: 213         1722 bp
NOV14g,	ACCATGGAGCCCGAAGCCCCCCGTCGCCGCCACACCCATCAGCGCGGCTACCTGCTGA
258330562
DNA Sequence	CACGGAACCCTCACCTCAACAAGGACTTGGCCTTTACCCTGGAAGAGAGACAGCAATT
	GAACATTCATGGATTGTTGCCACCTTCCTTCAACAGTCAGGAGATCCAGGTTCTTAGA
	GTAGTAAAAAATTTCGAGCATCTGAACTCTGACTTTGACAGGTATCTTCTCTTAATGG
	ATCTCCAAGATAGAAATGAAAAACTCTTTTATAGAGTGCTGACATCTGACATTGAGAA
	ATTCATGCCTATTGTTTATACTCCCACTGTGGGTCTGGCTTGCCAACAATATAGTTTG
	GTGTTTCGGAAGCCAAGAGGTCTCTTTATTACTATCCACGATCGAGGGCATATTGCTT
	CAGTTCTCAATGCATGGCCAGAAGATGTCATCAAGGCCATTGTGGTGACTGATGGAGA
	GCGTATTCTTGGCTTGGGAGACCTTGGCTGTAATGGAATGGGCATCCCTGTGGGTAAA
	TTGGCTCTATATACAGCTTGCGGAGGGATGAATCCTCAAGAATGTCTGCCTGTCATTC
	TGGATGTGGGAACCGAAAATGAGGAGTTACTTAAAGATCCACTCTACATTGGACTACG
	GCAGAGAAGAGTAAGAGGTTCTCAATATGATGATTTTTTGGACGAATTCATGGAGGCA
	GTTTCTTCCAAGTATGGCATGAATTGCCTTATTCAGTTTGAAGATTTTGCCAATGTGA
	ATGCATTTCGTCTCCTGAACAAGTATCGAAACCAGTATTGCACATTCAATGATGATAT
	TCAAGGAACAGCATCTGTTGCAGTTGCAGGTCTCCTTGCAGCTCTTCGAATAACCAAG
	AACAAACTGTCTGATCAAACAATACTATTCCAAGGAGCTGGAGAGGCTGCCCTAGGGA
	TTGCACACCTGATTGTGATGGCCTTGGAAAAAGAAGGTTTACCAAAAGAGAAAGCCAT
	CAAAAAGATATGGCTGGTTGATTCAAAAGGATTAATAGTTAAGGGACGTGCTTCCTTA
	ACACAAGAGAAAGAGAAGTTTGCCCATGAACATGAAGAAATGAAGAACCTAGAAGCCA
	TTGTTCAAGAAATAAAACCAACTCCCCTCATAGGAGTTGCTGCAATTGGTGGTGCATT
	CTCAGAACAAATTCTCAAAGATATGGCTGCCTTCAATGAACGGCCTATTATTTTTGCT
	TTGAGTAATCCAACTAGCAAAGCAGAATGTTCTGCAGAGCAGTGCTACAAAATAACCA
	ACGGACGTGCAATTTTTGCCAGTGGCAGTCCTTTTGATCCAGTCACTCTTCCAAATGG
	ACAGACCCTATATCCTGGCCAAGGCAACAATTCCTATGTGTTCCCTGGAGTTGCTCTT
	GGTGTTGTGGCGTGTGGATTGAGGCAGATCACAGATAATATTTTCCTCACTACTGCTG
	AGGTTATAGCTCAGCAAGTGTCAGATAAACACTTGGAAGAGGGTCGGCTTTATCCTCC
	TTTGAATACCATTAGAGATGTTTCTCTGAAAATTGCAGAAAAGATTGTGAAAGATGCA
	TACCAAGAAAAGACAGCCACAGTTTATCCTGAACCGCAAAACAAAGAAGCATTTGTCC
	GCTCCCAGATGTATAGTACTGATTATGACCAGATTCTACCTGATTGTTATTCTTGGCC
	TGAAGAGGTGCAGAAAATACAGACCAAAGTTGACCAGTAG
	ORF Start: at 1                      ORF Stop: TAG at 1720
	SEQ ID NO: 214          573 aa       MW at 64250.0kD
NOV14g,	TMEPEAPRRRHTHQRGYLLTRNPHLNKDLAFTLEERQQLNIHGLLPPSFNSQEIQVLR
258330562
Protein Sequence	VVKNFEHLMSDFDRYLLLMDLQDRNEKLFYRVLTSDIEKFMPIVYTPTVGLACQQYSL
	VFRKPRGLFITIHDRGHIASVLNAWPEDVIKAIVVTDGERILGLGDLGCNGMGIPVGK
	LALYTACGGMNPQECLPVILDVGTENEELLKDPLYIGLRQRRVRGSEYDDFLDEFMEA
	VSSKYGMNCLIQFEDFANVNAFRLLNKYRNQYCTFNDDIQGTASVAVAGLLAALRITK
	NKLSDQTILFQGAGEAALGIAHLIVMALEKEGLPKEKAIKKIWLVDSKGLIVKGRASL
	TQEKEKFAHEHEEMKNLEAIVQEIKPTALIGVAAIGGAFSEQILKDMAAFNERPIIFA
	LSNPTSKAECSAEQCYKITKGRAIFASGSPFDPVTLPNGQTLYPGQGNNSYVFPGVAL
	GVVACGLRQITDNTFLTTAEVIAQQVSDKHLEEGRLYPPLNTIRDVSLKIAEKIVKDA
	YQEKTATVYPEPQNKEAFVRSQMYSTDYDQILPDCYSWPEEVQKIQTKVDQ
	SEQ ID NO: 215         1719 bp
NOV14h,	TGGAGCCCGAAGCCCCCCGTCGCCGCCACACCCATCAGCGCGGCTACCTGCTGACACG
258330639
DNA Sequence	GAACCCTCACCTCAACAAGGACTTGGCCTTTACCCTGGAAGAGAGACAGCAATTGAAC
	ATTCATGGATTGTTGCCACCTTCCTTCAACAGTCAGGAGATCCAGGTTCTTAGAGTAG
	TAAAAAATTTCGAGCATCTGAACTCTGACTTTGACAGGTATCTTCTCTTAATGGATCT
	CCAAGATAGAAATGAAAAACTCTTTTATAGAGTGCTGACATCTGACATTGAGAAATTC
	ATGCCTATTGTTTATACTCCCACTGTGGGTCTGGCTTGCCAACAATATAGTTTGGTGT
	TTCGGAAGCCAAGAGGTCTCTTTATTACTATCCACGATCGAGGGCATATTGCTTCAGT
	TCTCAATGCATGGCCAGAAGATGTCATCAAGGCCATTGTGGTGACTGATGGAGAGCGT
	ATTCTTGGCTTGGGAGACCTTGGCTGTAATGGAATGGGCATCCCTGTGGGTAAATTGG
	CTCTATATACAGCTTGCGGAGGGATGAATCCTCAAGAATGTCTGCCTGTCATTCTGGA
	TGTGGGAACCGAAAATGAGGAGTTACTTAAAGATCCACTCTACATTGGACTACGGCAG
	AGAAGAGTAAGAGGTTCTGAATATGATGATTTTTTGGACGAATTCATGGAGGCAGTTT
	CTTCCAAGTATGGCATGAATTGCCTTATTCAGTTTGAAGATTTTGCCAATGTGAATGC
	ATTTCGTCTCCTGAACAAGTATCGAAACCAGTATTGCACATTCAATGATGATATTCAA
	GGAACAGCATCTGTTGCAGTTGCAGGTCTCCTTGCAGCTCTTCGAATAACCAAGAACA
	AACTGTCTGATCAAACAATACTATTCCAAGGAGCTGGGGAGGCTGCCCTAGGGATTGC
	ACACCTGATTGTGATGGCCTTGGAAAAAGAAGGTTTACCAAAAGAGAAAGCCATCAAA
	AAGATATGGCTGGTTGATTCAAAAGGATTAATAGTTAAGGGACGTGCTTCCTTAACAC
	AAGAGAAAGAGAAGTTTGCCCATGAACATGAAGAAATGAAGAACCTAGAAGCCATTGT
	TCAAGAAATAAAACCAACTGCCCTCATAGGAGTTGCTGCAATTGGTGGTGCATTCTCA
	GAACAAATTCTCAAAGATATGGCTGCCTTCAATGAACGGCCTATTATTTTTGCTTTGA
	GTAATCCAACTAGCAAAGCAGAATGTTCTGCAGAGCAGTGCTACAAAATAACCAAGGG
	ACGTGCAATTTTTGCCAGTGGCAGTCCTTTTGATCCAGTCACTCTTCCAAATGGACAG
	ACCCTATATCCTGGCCAAGGCAACAATTCCTATGTGTTCCCTGGAGTTGCTCTTGGTG
	TTGTGGCGTGTGGATTGAGGCAGATCACAGATAATATTTTCCTCACTACTGCTGAGGT
	TATAGCTCAGCAAGTGTCAGATAAACACTTGGAAGAGGGTCGGCTTTATCCTCCTTTG
	AATACCATTAGAGATGTTTCTCTGAAAATTGCAGAAAAGATTGTGAAAGATGCATACC
	AAGAAAAGACAGCCACAGTTTATCCTGAACCGCAAAACAAAGAAGCATTTGTCCGCTC
	CCAGATGTATAGTACTGATTATGACCAGATTCTACCTGATTGTTATTCTTGGCCTGAA
	GAGGTGCAGAAAATACAGACCAAAGTTGACCAGTAGG
	ORF Start: at 3                      ORF Stop: TAG at 1716
	SEQ ID NO: 216          571 aa       MW at 64017.7kD
NOV14h,	EPEAPRRRHTHQRGYLLTRNPHLNKDLAFTLEERQQLNIHGLLPPSFNSQEIQVLRVV
258330639
Protein Sequence	KNFEHLNSDFDRYLLLMDLQDRNEKLFYRVLTSDIEKFMPIVYTPTVGLACQQYSLVF
	RKPRGLFITIHDRGHIASVLNAWPEDVIKAIVVTDGERILGLGDLGCNGMGIPVGKLA
	LYTACGGMNPQECLPVILDVGTENEELLKDPLYIGLRQRRVRGSEYDDFLDEFMEAVS
	SKYGMNCLIQFEDFANVNAFRLLNKYRNQYCTFNDDIQGTASVAVAGLLAALRITKNK
	LSDQTILFQGAGEAALGTAHLIVMALEKEGLPKEKAIKKIWLVDSKGLIVKGRASLTQ
	EKEKFAHEHEEMKNLEAIVQEIKPTALIGVAAIGGAFSEQILKDMAAFNERPIIFALS
	NPTSKAECSAEQCYKITKGRAIFASGSPFDPVTLPNGQTLYPGQGNNSYVFPGVALGV
	VACGLRQITDNIFLTTAEVIAQQVSDKHLEEGRLYPPLNTIRDVSLKIAEKIVKDAYQ
	EKTATVYPEPQNKEAFVRSQMYSTDYDQILPDCYSWPEEVQKIQTKVDQ
	SEQ ID NO: 217         1732 bp
NOV14i,	ACCATGGAGCCCGAAGCCCCCCGTCGCCGCCACACCCATCAGCGCGGCTACCTGCTGA
259357792
DNA Sequence	CACGGAACCCTCACCTCAACAAGGACTTGGCCTTTACCCTGGAAGAGAGACAGCAATT
	GAACATTCATGGATTGTTGCCACCTTCCTTCAACAGTCAGGAGATCCAGGTTCTTAGA
	GTAGTAAAAAATTTCGAGCATCTGAACTCTGACTTTGACAGGTATCTTCTCTTAATGG
	ATCTCCAAGATAGAAATGAAAAACTCTTTTATAGAGTGCTGACATCTGACATTGAGAA
	ATTCATGCCTATTCTTTATACTCCCACTGTGGGTCTGGCTTGCCAACAATATAGTTTG
	GTGTTTCGGAAGCCAAGAGGTCTCTTTATTACTATCCACGATCGAGGGCATATTGCTT
	CAGTTCTCAATGCATGGCCAGAAGATGTCATCAAGGCCATTGTGGTGACTGATGGAGA
	GCGTATTCTTCGCTTGGGAGACCTTGGCTGTAATGGAATGGGCATCCCTGTGGGTAAA
	TTGGCTCTATATACAGCTTGCGGAGGGATGAATCCTCAAGAATGTCTGCCTGTCATTC
	TGGATGTGGGAACCGAAAATGAGGAGTTACTTAAAGATCCACTCTACATTGGACTACG
	GCAGAGAAGAGTAAGAGGTTCTGAATATGATGATTTTTTGGACGAATTCATGGAGGCA
	GTTTCTTCCAAGTATGCCATGAATTGCCTTATTCAGTTTGAAGATTTTGCCAATGTGA
	ATGCATTTCGTCTCCTGAACAAGTATCGAAACCAGTATTGCACATTCAATGATGATAT
	TCAAGGAACAGCATCTGTTGCAGTTGCAGGTCTCCTTGCAGCTCTTCGAATAACCAAG
	AACAAACTGTCTGATCAAACAATACTATTCCAAGGAGCTGGGGAGGCTGCCCTAGGGA
	TTGCACACCTGATTGTGATGGCCTTGGAAAAAGAAGGTTTACCAAAAGAGAAAGCCAT
	CAAAAAGATATGGCTGGTTGATTCAAAAGGATTAATAGTTAAGGGACGTGCTTCCTTA
	ACACAAGAGAAAGAGAAGTTTGCCCATGAACATGAAGAAATGAAGAACCTAGAAGCCA
	TTGTTCAAGAAATAAAACCAACTGCCCTCATAGGAGTTGCTGCAATTGGTGGTGCATT
	CTCAGAACAAATTCTCAAAGATATGGCTGCCTTCAATGAACGGCCTATTATTTTTGCT
	TTGAGTAATCCAACTAGCAAAGCAGAATGTTCTGCAGAGCAGTGCTACAAAATAACCA
	AGGGACGTGCAATTTTTGCCAGTGGCAGTCCTTTTGATCCAGTCACTCTTCCAAATGG
	ACAGACCCTATATCCTGGCCAAGGCAACAATTCCTATGTGTTCCCTGGAGTTGCTCTT
	GGTGTTGTGGCGTGTGGATTGAGGCAGATCACAGATAATATTTTCCTCACTACTGCTG
	AGGTTATAGCTCAGCAAGTGTCAGATAAACACTTGGAAGAGGGTCGGCTTTATCCTCC
	TTTGAATACCATTAGAGATGTTTCTCTGAAAATTGCAGAAAAGATTGTGAAAGATGCA
	TACCAAGAAAAGACAGCCACAGTTTATCCTGAACCGCAAAACAAAGAAGCATTTGTCC
	GCTCCCAGATGTATAGTACTGATTATGACCAGATTCTACCTGATTGTTATTCTTGGCC
	TGAAGAGGTGCAGAAAATACAGACCAAAGTTGACCAGTAGGCGGCCGCTT
	ORF Start: at 1                      ORF Stop: TAG at 1720
	SEQ ID NO: 218          573 aa       MW at 64250.0kD
NOV14i,	TMEPEAPRRRHTHQRGYLLTRNPHLNKDLAFTLEERQQLNIHGLLPPSFNSQEIQVLR
259357792
Protein Sequence	VVKNFEHLNSDFDRYLLLMDLQDRNEKLFYRVLTSDIEKFMPIVYTPTVGLACQQYSL
	VFRKPRGLFITIHDRGHIASVLNAWPEDVIKATVVTDGERILGLGDLGCNGMGIPVGK
	LALYTACGGMNPQECLPVILDVGTENEELLKDPLYIGLRQRRVRGSEYDDFLDEFMEA
	VSSKYGMNCLIQFEDFANVNAFRLLNKYRNQYCTFNDDIQGTASVAVAGLLAALRITK
	NKLSDQTILFQGAGEAALGIAHLIVMALEKEGLPKEKAIKKIWLVDSKGLIVKGRASL
	TQEKEKFAHEHEEMKNLEAIVQEIKPTALIGVAAIGGAFSEQILKDMAAFNERPIIFA
	LSNPTSKAECSAEQCYKITKGRAIFASGSPFDPVTLPNGQTLYPGQGNNSYVFPGVAL
	GVVACGLRQITDNIFLTTAEVIAQQVSDKHLEEGRLYPPLNTIRDVSLKIAEKIVKDA
	YQEKTATVYPEPQNKEAFVRSQMYSTDYDQILPDCYSWPEEVQKIQTKVDQ
	SEQ ID NO: 219         1838 bp
NOV14j,	CCGGCGCCAGCCATGGAGCCCGAAGCCCCCCGTCGCCGCCACACCCATCAGCGCCGCT
CG140316-02
DNA Sequence	ACCTGCTGACACGGAACCCTCACCTCAACAAGGACTTGGCCTTTACCCTGGAAGAGAG
	ACAGCAATTGAACATTCATGGATTGTTGCCACCTTCCTTCAACAGTCAGGAGATCCAG
	GTTCTTAGAGTAGTAAAAAATTTCGAGCATCTGAACTCTGACTTTGACAGGTATCTTC
	TCTTAATGGATCTCCAAGATAGAAATGAAAAACTCTTTTATAGAGTGCTGACATCTGA
	CATTGAGAAATTCATGCCTATTGTTTATACTCCCACTGTGGGTCTGGCTTGCCAACAA
	TATAGTTTGGTGTTTCGGAAGCCAAGAGGTCTCTTTATTACTATCCACCATCGAGGGC
	ATATTGCTTCAGTTCTCAATGCATGGCCAGAAGATGTCATCAAGGCCATTGTGGTGAC
	TGATGGAGAGCGTATTCTTGGCTTGGGAGACCTTGGCTGTAATGGAATGGGCATCCCT
	GTGGGTAAATTGGCTCTATATACAGCTTGCGGAGGGATGAATCCTCAAGAATGTCTGC
	CTGTCATTCTGGATGTGGGAACCGAAAATGAGGAGTTACTTAAAGATCCACTCTACAT
	TGGACTACGGCAGAGAAGAGTAAGAGGTTCTGAATATGATGATTTTTTGGACGAATTC
	ATGGAGGCAGTTTCTTCCAAGTATGGCATGAATTGCCTTATTCAGTTTGAAGATTTTG
	CCAATGTGAATGCATTTCGTCTCCTGAACAAGTATCGAAACCAGTATTGCACATTCAA
	TGATGATATTCAAGGAACAGCATCTGTTGCAGTTGCAGGTCTCCTTGCAGCTCTTCGA
	ATAACCAAGAACAAACTGTCTGATCAAACAATACTATTCCAAGGAGCTGGAGAGGCTG
	CCCTAGGGATTGCACACCTGATTGTGATGGCCTTGGAAAAAGAAGGTTTACCAAAGGA
	GAAAGCCATCAAAAAGATATGGCTGGTTGATTCAAAAGGATTAATAGTTAAGGGACGT
	GCTTCCTTAACACAAGAGAAAGAGAAGTTTGCCCATGAACATGAAGAAATGAAGAACC
	TAGAAGCCATTGTTCAAGAAATAAAACCAACTGCCCTCATAGGAGTTGCTGCAATTGG
	TGGTGCATTCTCAGAACAAATTCTCAAAGATATGGCTGCCTTCAATGAACGGCCTATT
	ATTTTTGCTTTGAGTAATCCAACTAGCAAAGCAGAATGTTCTGCAGAGCAGTGCTACA
	AAATAACCAAGGGACGTGCAATTTTTGCCAGTGGCAGTCCTTTTGATCCAGTCACTCT
	CCCAGATGGACGGACTCTGTTTCCTGGCCAAGGCAACAATTCCTACGTGTTCCCTGGA
	GTTGCTCTTGGGGTGGTGGCCTGCGGACTGAGACACATCGATGATAAGGTCTTCCTCA
	CCACTGCTGAGGTCATATCTCAGCAAGTGTCAGATAAACACCTGCAAGAAGGCCGGCT
	CTATCCTCCTTTGAATACCATTCGAGACGTTTCGTTGAAAATTGCAGTAAAGATTGTG
	CAAGATGCATACAAAGAAAAGATGGCCACTGTTTATCCTGAACCCCAAAACAAAGAAG
	AATTTGTCTCCTCCCAGATGTACAGCACTAATTATGACCAGATCCTACCTGATTGTTA
	TCCGTGGCCTGCAGAAGTCCAGAAAATACAGACCAAAGTCAACCAGTAACGCAACAGC
	TAGGATTTTTAACTTTATTAGTAAAATCTTGAAGTTTTCATGATCTTTAAGGGTCAGA
	ATCTTTTATGATGATTCATAGTATGCTTAGAATAAGGTGC
	ORF Start: ATG at 13                 ORF Stop: TAA at 1729
	SEQ ID NO: 220          572 aa       MW at 64139.1kD
NOV14j,	MEPEAPRRRHTHQRGYLLTRNPHLNKDLAFTLEERQQLNIHGLLPPSFNSQEIQVLRV
CG140316-02
Protein Sequence	VKNFEHLNSDFDRYLLLMDLQDRNEKLFYRVLTSDIEKFMPIVYTPTVGLACQQYSLV
	FRKPRGLFITIHDRGHIASVLNAWPEDVIKATVVTDGERILGLGDLGCNGMGIPVGKL
	ALYTACGGMNPQECLPVILDVGTENEELLKDPLYIGLRQRRVRGSEYDDFLDEFMEAV
	SSKYGMNCLIQFEDFANVNAFRLLNKYRNQYCTFNDDIQGTASVAVAGLLAALRITKN
	KLSDQTILFQGAGEAALGIAHLIVMALEKEGLPKEKAIKKIWLVDSKGLIVKGRASLT
	QEKEKFAHEHEEMKNLEAIVQEIKPTALIGVAAIGGAFSEQILKDMAAFNERPIIFAL
	SNPTSKAECSAEQCYKITKGRAIFASGSPFDPVTLPDGRTLFPGQGNNSYVFPGVALG
	VVACGLRHIDDKVFLTTAEVTSQQVSDKHLQEGRLYPPLNTIRDVSLKIAVKIVQDAY
	KEKMATVYPEPQNKEEFVSSQMYSTNYDQILPDCYPWPAEVQKIQTKVNQ
	SEQ ID NO: 221         1750 bp
NOV 14k,	CGCGGATCCATGGAGCCCGAAGCCCCCCGTCGCCGCCACACCCATCAGCGCGGCTACC
CG140316-03
DNA Sequence	TGCTGACACGGAACCCTCACCTCAACAAGGACTTGGCCTTTACCCTGGAAGAGAGACA
	GCAATTGAACATTCATGGATTGTTGCCACCTTCCTTCAACAGTCAGGAGATCCAGGTT
	CTTAGAGTAGTAAAAAATTTCGAGCATCTGAACTCTGACTTTGACAGGTATCTTCTCT
	TAATGGATCTCCAAGATAGAAATGAAAAACTCTTTTATAGAGTGCTGACATCTGACAT
	TGAGAAATTCATGCCTATTGTTTATACTCCCACTGTGGGTCTGGCTTGCCAACAATAT
	AGTTTGGTGTTTCGGAAGCCAAGAGGTCTCTTTATTACTATCCACGATCGAGGGCATA
	TTGCTTCAGTTCTCAATGCATGGCCAGAAGATGTCATCAAGGCCATTGTGGTGACTGA
	TGGAGAGCGTATTCTTGGCTTGGGAGACCTTGGCTGTAATGGAATGGGCATCCCTGTG
	GGTAAATTGGCTCTATATACAGCTTGCGGAGGGATGAATCCTCAAGAATGTCTGCCTG
	TCATTCTGGATGTGGGAACCGAAAATGAGGAGTTACTTAAAGATCCACTCTACATTGG
	ACTACGGCAGAGAAGAGTAAGAGGTTCTGAATATGATGATTTTTTGGACGAATTCATG
	GAGGCAGTTTCTTCCAAGTATGGCATGAATTGCCTTATTCAGTTTGAAGATTTTGCCA
	ATGTGAATGCATTTCGTCTCCTGAACAAGTATCGAAACCAGTATTGCACATTCAATGA
	TGATATTCAAGGAACAGCATCTGTTGCAGTTGCAGGTCTCCTTGCAGCTCTTCGAATA
	ACCAAGAACAAACTGTCTGATCAAACAATACTATTCCAAGGAGCTGGGGAGGCTGCCC
	TAGGGATTGCACACCTGATTGTGATGGCCTTGGAAAAAGAAGGTTTACCAAAAGAGAA
	AGCCATCAAAAAGATATGGCTGGTTGATTCAAAAGGATTAATAGTTAACGGACGTGCT
	TCCTTAACACAAGAGAAAGAGAAGTTTGCCCATGAACATGAAGAAATGAAGAACCTAG
	AAGCCATTGTTCAAGAAATAAAACCAACTGCCCTCATAGGAGTTGCTGCAATTGGTGG
	TGCATTCTCAGAACAAATTCTCAAAGATATGGCTGCCTTCAATGAACGGCCTATTATT
	TTTGCTTTGAGTAATCCAACTAGCAAAGCAGAATGTTCTGCAGAGCAGTGCTACAAAA
	TAACCAAGGGACGTGCAATTTTTGCCAGTGGCAGTCCTTTTGATCCAGTCACTCTTCC
	AAATGGACACACCCTATATCCTGGCCAAGGCAACAATTCCTATGTGTTCCCTGGAGTT
	GCTCTTGGTGTTGTGGCGTGTGGATTGAGGCAGATCACAGATAATATTTTCCTCACTA
	CTGCTGAGGTTATAGCTCAGCAAGTGTCAGATAAACACTTGGAAGAGGGTCGGCTTTA
	TCCTCCTTTGAATACCATTAGAGATGTTTCTCTGAAAATTGCAGAAAAGATTGTGAAA
	GATGCATACCAAGAAAAGACAGCCACAGTTTATCCTGAACCGCAAAACAAAGAAGCAT
	TTGTCCGCTCCCAGATGTATAGTACTGATTATGACCAGATTCTACCTGATTGTTATTC
	TTGGCCTGAAGAGGTGCAGAAAATACAGACCAAAGTTGACCAGTAGGGTGCCGGCCGC
	TTTTTTCCTT
	ORF Start: ATG at 10                 ORF Stop: TAG at 1726
	SEQ ID NO: 222          572 aa       MW at 64148.9kD
NOV14k,	MEPEAPRRRHTHQRGYLLTRNPHLNKDLAFTLEERQQLNIHGLLPPSFNSQEIQVLRV
CG140316-03
Protein Sequence	VKNFEHLNSDFDRYLLLMDLQDRNEKLFYRVLTSDIEKFMPIVYTPTVGLACQQYSLV
	FRKPRGLFITIHDRGHIASVLNAWPEDVIKAIVVTDGERILGLGDLGCNGMGIPVGKL
	ALYTACGGMNPQECLPVILDVGTENEELLKDPLYIGLRQRRVRGSEYDDFLDEFMEAV
	SSKYGMNCLIQFEDFANVNAFRLLNKYRNQYCTFNDDIQGTASVAVAGLLAALRITKN
	KLSDQTILFQGAGEAALGIAHLIVMALEKEGLPKEKAIKKIWLVDSKGLIVKGRASLT
	QEKEKFAHEHEEMKNLEAIVQEIKPTALIGVAAIGGAFSEQILKDMAAFNERPIIFAL
	SNPTSKAECSAEQCYKITKGRAIFASGSPFDPVTLPNGQTLYPGQGNNSYVFPGVALG
	VVACGLRQITDNIFLTTAEVIAQQVSDKHLEEGRLYPPLNTIRDVSLKIAEKIVKDAY
	QEKTATVYPEPQNKEAFVRSQMYSTDYDQILPDCYSWPEEVQKIQTKVDQ
	SEQ ID NO: 223         1767 bp
NOV14l,	CACCATCACCACCATCACGAGCCCGAAGCCCCCCGTCGCCGCCACACCCATCAGCGCG
CG140316-04
DNA Sequence	GCTACCTGCTGACACGGAACCCTCACCTCAACAAGGACTTGGCCTTTACCCTGGAAGA
	GAGACAGCAATTGAACATTCATGGATTGTTGCCACCTTCCTTCAACAGTCAGGAGATC
	CAGGTTCTTAGAGTAGTAAAAAATTTCGAGCATCTGAACTCTGACTTTGACAGGTATC
	TTCTCTTAATGGATCTCCAAGATAGAAATGAAAAACTCTTTTATAGAGTGCTGACATC
	TGACATTGAGAAATTCATGCCTATTGTTTATACTCCCACTGTGGGTCTGGCTTGCCAA
	CAATATAGTTTGGTGTTTCGGAAGCCAAGAGGTCTCTTTATTACTATCCACGATCGAG
	GGCATATTGCTTCAGTTCTCAATGCATGGCCAGAAGATGTCATCAAGGCCATTGTGGT
	GACTGATGGAGAGCGTATTCTTGGCTTGGGAGACCTTCGCTCTAATOGAATGGCCATC
	CCTGTGGGTAAATTGGCTCTATATACAGCTTGCGGAGGGATGAATCCTCAAGAATGTC
	TGCCTGTCATTCTGGATGTGGGAACCGAAAATGAGGAGTTACTTAAAGATCCACTCTA
	CATTGGACTACGGCAGAGAAGAGTAAGAGGTTCTGAATATGATGATTTTTTGGACGAA
	TTCATGGAGGCAGTTTCTTCCAAGTATGGCATGAATTGCCTTATTCAGTTTGAAGATT
	TTGCCAATGTGAATGCATTTCGTCTCCTGAACAAGTATCGAAACCAGTATTGCACATT
	CAATGATGATATTCAAGGAACAGCATCTGTTGCAGTTGCAGGTCTCCTTGCAGCTCTT
	CGAATAACCAAGAACAAACTGTCTGATCAAACAATACTATTCCAAGGAGCTGGGGAGG
	CTGCCCTAGGGATTGCACACCTGATTGTGATGGCCTTGGAAAAAGAAGGTTTACCAAA
	AGAGAAAGCCATCAAAAAGATATGGCTGGTTGATTCAAAAGGATTAATAGTTAAGGGA
	CGTGCTTCCTTAACACAAGAGAAAGAGAAGTTTGCCCATGAACATGAAGAAATGAAGA
	ACCTAGAAGCCATTGTTCAAGAAATAAAACCAACTGCCCTCATAGGAGTTGCTGCAAT
	TGGTGGTGCATTCTCAGAACAAATTCTCAAAGATATGGCTGCCTTCAATGAACGGCCT
	ATTATTTTTGCTTTGAGTAATCCAACTAGCAAAGCAGAATGTTCTGCAGAGCAGTGCT
	ACAAAATAACCAAGGGACGTGCAATTTTTGCCAGTGGCAGTCCTTTTGATCCAGTCAC
	TCTTCCAAATGGACAGACCCTATATCCTGGCCAAGGCAACAATTCCTATGTGTTCCCT
	GGAGTTGCTCTTGGTGTTGTGGCGTGTGGATTGAGGCAGATCACAGATAATATTTTCC
	TCACTACTGCTGAGGTTATAGCTCAGCAAGTGTCAGATAAACACTTCGAAGAGGGTCG
	GCTTTATCCTCCTTTGAATACCATTAGAGATGTTTCTCTGAAAATTGCAGAAAAGATT
	GTGAAAGATGCATACCAAGAAAAGACAGCCACAGTTTATCCTGAACCGCAAAACAAAG
	AAGCATTTGTCCGCTCCCAGATGTATAGTACTGATTATGACCAGATTCTACCTGATTC
	TTATTCTTGGCCTGAAGAGGTGCAGAAAATACAGACCAAAGTTGACCAGTAGGCGGCC
	CCACTCGAGCACCACCACCACCACCAC
NOV14l,	HHHHHHEPEAPRRRHTHQRGYLLTRNPHLNKDLAFTLEERQQLNIHGLLPPSFNSQEI
CG140316-04
Protein Sequence	QVLRVVKNFEHLNSDFDRYLLLMDLQDRNEKLFYRVLTSDIEKFMPIVYTPTVGLACQ
	QYSLVFRKPRGLFITIHDRGHIASVLNAWPEDVIKAIVVTDGERILGLGDLGCNGMGI
	PVGKLALYTACGGMNPQECLPVILDVGTENEELLKDPLYIGLRQRRVRGSEYDDFLDE
	FMEAVSSKYGMNCLIQFEDFANVNAFRLLNKYRNQYCTFNDDIQGTASVAVAGLLAAL
	RITKNKLSDQTILFQGAGEAALGIAHLIVMALEKEGLPKEKAIKKIWLVDSKGLIVKG
	RASLTQEKEKFAHEHEEMKNLEAIVQEIKPTALIGVAAIGGAFSEQILKDMAAFNERP
	IIFALSNPTSKAECSAEQCYKITKGRAIFASGSPFDPVTLPNGQTLYPGQGNNSYVFP
	GVALGVVACGLRQITDNIFLTTAEVIAQQVSDKHLEEGRLYPPLNTIRDVSLKIAEKI
	VKDAYQEKTATVYPEPQNKEAFVRSQMYSTDYDQILPDCYSWPEEVQKIQTKVDQ

[0430] Sequence comparison of the above protein sequences yields the following sequence relationships shown in Table 14B.

TABLE 14B
Comparison of NOV14a against NOV14b through NOV14l.
			Identities/
			Similarities for
	Protein	NOV14a Residues/	the Matched
	Sequence	Match Residues	Region
	NOV14b	1 . . . 572	572/572	(100%)
		1 . . . 572	572/572	(100%)
	NOV14c	1 . . . 572	572/572	(100%)
		4 . . . 575	572/572	(100%)
	NOV14d	3 . . . 572	570/570	(100%)
		1 . . . 570	570/570	(100%)
	NOV14e	2 . . . 572	571/571	(100%)
		10 . . . 580	571/571	(100%)
	NOV14f	2 . . . 572	571/571	(100%)
		7 . . . 577	571/571	(100%)
	NOV14g	1 . . . 572	572/572	(100%)
		2 . . . 573	572/572	(100%)
	NOV14h	2 . . . 572	571/571	(100%)
		1 . . . 571	571/571	(100%)
	NOV14i	1 . . . 572	572/572	(100%)
		2 . . . 573	572/572	(100%)
	NOV14j	1 . . . 572	553/572	(96%)
		1 . . . 572	563/572	(97%)
	NOV14k	1 . . . 572	572/572	(100%)
		1 . . . 572	572/572	(100%)
	NOV14l	2 . . . 572	571/571	(100%)
		7 . . . 577	571/571	(100%)

[0431] Further analysis of the NOV14a protein yielded the following properties shown in Table 14C.

TABLE 14C
Protein Sequence Properties NOV14a
PSort     0.7000 probability located in nucleus; 0.3000
analysis: probability located in microbody (peroxisome);
          0.1771 probability located in lysosome (lumen);
          0.1000 probability located in mitochondrial
          matrix space
SignalP   No Known Signal Sequence Predicted
analysis:

[0432] A search of the NOV14a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 14D.

TABLE 14D
Geneseq Results for NOV14a
			Identities/
			Similarities for
Geneseq	Protein/Organism/Length	NOV14a Residues/	the Matched	Expect
Identifier	[Patent #, Date]	Match Residues	Region	Value
AAR52605	Human cytoplasmic NADP+-	1 . . . 572	572/572	(100%)	0.0
	dependent malate enzyme ME1 -	1 . . . 572	572/572	(100%)
	Homo sapiens, 572 aa. [EP595241-
	A, 04 MAY 1994]
AAM40228	Human polypeptide SEQ ID NO	13 . . . 568	404/556	(72%)	0.0
	3373 - Homo sapiens, 604 aa.	48 . . . 603	485/556	(86%)
	[WO200153312-A1, 26 JUL.
	2001]
AAU33270	Novel human secreted protein	13 . . . 568	380/563	(67%)	0.0
	#3761 - Homo sapiens. 621 aa.	58 . . . 620	464/563	(81%)
	[WO200179449-A2, 25 OCT.
	2001]
AAM42014	Human polypeptide SEQ ID NO	13 . . . 568	376/566	(66%)	0.0
	6945 - Homo sapiens, 624 aa.	58 . . . 623	458/566	(80%)
	[WO200153312-A1, 26 JUL.
	2001]
ABG21889	Novel human diagnostic protein	13 . . . 568	372/567	(65%)	0.0
	#21880 - Homo sapiens, 625 aa.	58 . . . 624	455/567	(79%)
	[WO200175067-A2, 11 OCT.
	2001]

[0433] In a BLAST search of public sequence datbases, the NOV14a protein was found to have homology to the proteins shown in the BLASTP data in Table 14E.

TABLE 14E
Public BLASTP Results for NOV14a
			Identities/
Protein			Similarities for
Accession		NOV14a Residues/	the Matched	Expect
Number	Protein/Organism/Length	Match Residues	Portion	Value
P48163	NADP-dependent malic enzyme	1 . . . 572	572/572	(100%)	0.0
	(EC 1.1.1.40) (NADP-ME) (Malic	1 . . . 572	572/572	(100%)
	enzyme 1) - Homo sapiens
	(Human), 572 aa.
Q16797	NADP-dependent malic enzyme	1 . . . 572	553/572	(96%)	0.0
	(EC 1.1.1.40) - Homo sapiens	1 . . . 572	563/572	(97%)
	(Human), 572 aa.
JC4160	malate dehydrogenase	1 . . . 572	552/572	(96%)	0.0
	(oxaloacetate-decarboxylating)	1 . . . 572	562/572	(97%)
	(NADP+) (EC 1.1.1.40) - human,
	572 aa.
P13697	NADP-dependent malic enzyme	1 . . . 572	517/572	(90%)	0.0
	(EC 1.1.1.40) (NADP-ME) (Malic	1 . . . 572	549/572	(95%)
	enzyme 1) - Rattus norvegicus
	(Rat), 572 aa.
Q921S3	Malic enzyme, supernatant - Mus	1 . . . 572	516/572	(90%)	0.0
	musculus (Mouse), 572 aa.	1 . . . 572	545/572	(95%)

[0434] PFam analysis predicts that the NOV14a protein contains the domains shown in the Table 14F.

TABLE 14F
Domain Analysis of NOV14a
			Identities/
			Similarities for
Pfam	NOV14a		the Matched	Expect
Domain	Match Region		Region	Value
Paramyx_ncap	278 . . . 314	14/37	(38%)	0.77
		24/37	(65%)
malic	15 . . . 553	356/580	(61%)	0
		515/580	(89%)

Example 15

[0435] The NOV15 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 15A.

TABLE 15A
NOV15 Sequence Analysis
                 SEQ ID NO: 225      4427 bp
NOV15a,          GGCACGAGGCCGGGACAAAAGCCGGATCCCGGGAAGCTACCGGCTGCTGGGGTGCTCC
CG142427-01
DNA Sequence     GGATTTTGCGGGGTTCGTCGGGCCTGTGGAAGAAGCGCCGCGCACGGACTTCGGCAGA
                 GGTAGAGCAGGTCTCTCTGCAGCCATGTCGGCCAAGGCAATTTCAGAGCAGACGGGCA
                 AACAACTCCTTTACAAGTTCATCTGTACCACCTCAGCCATCCAGAATCGGTTCAAGTA
                 TGCTCGGGTCACTCCTGACACAGACTGGGCCCGCTTGCTGCAGGACCACCCCTGGCTG
                 CTCAGCCAGAACTTGGTAGTCAAGCCAGACCAGCTGATCAAACGTCGTGGAAAACTTG
                 GTCTCGTTGGGGTCAACCTCACTCTCGATGGGGTCAAGTCCTGGCTGAAGCCACGGCT
                 GGGACAGGAAGCCACAGTTGGCAAGGCCACAGGCTTCCTCAAGAACTTTCTGATCGAG
                 CCCTTCGTCCCCCACAGTCAGGCTGAGGAGTTCTATGTCTGCATCTATCCCACCCGAG
                 AAGGGGACTACGTCCTGTTCCACCACGAGGGGGGTGTGGACGTCGGTGATGTGGACGC
                 CAAGGCCCAGAAGCTGCTTGTTGCCGTGGATGAGAAACTGAATCCTGAGGACATCAAA
                 AAACACCTGTTGGTCCACGCCCCTGAAGACAAGAAAGAAATTCTGGCCAGTTTTATCT
                 CCCGCCTCTTCAATTTCTACGAGGACTTGTACTTCACCTACCTCGAGATCAATCCCCT
                 TGTAGTGACCAAAGATGGAGTCTATGTCCTTGACTTGGCGGCCAAGGTGGACGCCACT
                 GCCGACTACATCTGCAAAGTGAAGTGGGGTGACATCGAGTTCCCTCCCCCCTTCGGGC
                 GGGAGGCATATCCAGAGGAAGCCTACATTGCAGACCTCGATGCCAAAAGTGGGGCAAG
                 CCTGAAGCTGACCTTGCTGAACCCCAAAGGGAGGATCTGGACCATGGTGGCCGGGGGT
                 GGCGCCTCTGTCGTGTACAGCGATACCATCTGTGATCTAGGGGGTGTCAACGAGCTGG
                 CAAACTATGGGGAGTACTCAGGCGCCCCCAGCGAGCAGCAGACCTATGACTATGCCAA
                 GACTATCCTCTCCCTCATGACCCGAGAGAAGCACCCAGATGGCAAGATCCTCATCATT
                 GGAGGCACCATCGCAAACTTCACCAACGTGGCTGCCACGTTCAAGGGCATCGTGAGAG
                 CAATTCGAGATTACCAGGGCCCCCTGAAGGAGCACGAAGTCACAATCTTTGTCCGAAG
                 AGGTGGCCCCAACTATCAGGAGGGCTTACGGGTGATGGGAGAAGTCGGGAAGACCACT
                 GGGATCCCCATCCATGTCTTTGGCACAGAGACTCACATGACGGCCATTGTGGGCATGG
                 CCCTGGGCCACCGGCCCATCCCCAACCAGCCACCCACAGCGGCCCACACTGCAAACTT
                 CCTCCTCAACGCCAGCGGGAGCACATCGACCCCAGCCCCCAGCAGGACAGCATCTTTT
                 TCTGAGTCCAGGGCCGATGAGGTGGCGCCTGCAAAGAAGGCCAAGCCTGCCATGCCAC
                 AAGATTCAGTCCCAAGTCCAAGATCCCTGCAAGGAAAGAGCACCACCCTCTTCAGCCG
                 CCACACCAAGGCCATTGTGTGGGGCATGCAGACCCGGGCCGTGCAAGGCATGCTGGAC
                 TTTGACTATGTCTGCTCCCGAGACGAGCCCTCAGTGGCTGCCATGGTCTACCCTTTCA
                 CTGGGGACCACAAGCAGAAGTTTTACTGGGGGCACAAAGAGATCCTGATCCCTGTCTT
                 CAAGAACATGGCTGATGCCATGAGGAAGCATCCGGAGGTAGATGTGCTCATCAACTTT
                 GCCTCTCTCCGCTCTGCCTATGACAGCACCATGGAGACCATCAACTATGCCCAGATCC
                 GGACCATCGCCATCATAGCTGAAGGCATCCCTGAGGCCCTCACGAGAAAGCTGATCAA
                 GAAGGCGGACCAGAAGGCAGTGACCATCATCGGACCTGCCACTGTTGGAGGCATCAAG
                 CCTGGGTGCTTTAAGATTGGCAACACAGGTGGGATGCTGGACAACATCCTGGCCTCCA
                 AACTGTACCGCCCAGGCAGCGTGGCCTATGTCTCACGTTCCGGAGGCATGTCCAACGA
                 GCTCAACAATATCATCTCTCGGACCACGGATGGCGTCTATGAGGGCGTGGCCATTGGT
                 GGGGACAGGTACCCGGGCTCCACATTCATGGATCATGTGTTACGCTATCAGGACACTC
                 CAGGAGTCAAAATGATTGTGGTTCTTGGAGAGATTGGGGGCACTGAGGAATATAAGAT
                 TTGCCGGGGCATCAAGGACGGCCGCCTCACTAAGCCCATCGTCTGCTGGTGCATCGGG
                 ACGTGTGCCACCATGTTCTCCTCTGAGGTCCAGTTTGGCCATGCTGGAGCTTGTGCCA
                 ACCAGGCTTCTGAAACTGCAGTAGCCAAGAACCAGGCTTTGAAGGAAGCAGGAGTGTT
                 TGTGCCCCGGAGCTTTGATGAGCTTGGAGAGATCATCCAGTCTGTATACGAAGATCTC
                 GTGGCCAATGGAGTCATTGTACCTGCCCAGGAGGTGCCGCCCCCAACCGTGCCCATGG
                 ACTACTCCTGGGCCAGGGAGCTTGGTTTGATCCGCAAACCTGCCTCGTTCATGACCAG
                 CATCTGCGATGAGCGAGGACAGGAGCTCATCTACGCGGGCATGCCCATCACTGAGGTC
                 TTCAAGGAAGAGATGGGCATTGGCGGGGTCCTCGGCCTCCTCTGGTTCCAGAAAAGGT
                 TGCCTAAGTACTCTTGCCAGTTCATTGACATGTGTCTGATGGTGACAGCTGATCACGG
                 GCCAGCCGTCTCTGGAGCCCACAACACCATCATTTGTGCGCGAGCTGGGAAAGACCTG
                 GTCTCCAGCCTCACCTCGGGGCTGCTCACCATCGGGGATCGGTTTGGGGGTGCCTTGG
                 ATGCAGCAGCCAAGATGTTCAGTAAAGCCTTTGACAGTGGCATTATCCCCATGGAGTT
                 TGTGAACAAGATGAAGAAGGAAGGGAAGCTGATCATGGGCATTGGTCACCGAGTGAAG
                 TCCATAAACAACCCAGACATGCGAGTGCAGATCCTCAAAGATTACGTCAGGCAGCACT
                 TCCCTGCCACTCCTCTGCTCGATTATGCACTGGAAGTAGAGAAGATTACCACCTCGAA
                 GAAGCCAAATCTTATCCTGAATGTAGATGGTCTCATCGGAGTCGCATTTGTAGACATG
                 CTTAGAAACTGTGGGTCCTTTACTCGGGAGGAAGCTGATGAATATATTGACATTGGAG
                 CCCTCAATGGCATCTTTGTGCTGGGAAGGAGTATGGGGTTCATTGGACACTATCTTGA
                 TCAGAAGAGGCTGAAGCAGGGGCTGTATCGTCATCCGTGGGATGATATTTCATATGTT
                 CTTCCGGAACACATGAGCATGTAACAGAGCCAGGAACCCTACTGCAGTAAACTGAACA
                 CAAGATCTCTTCCCCCAAGAAAAAGTGTACAGACAGCTGGCAGTGGAGCCTGCTTTAT
                 TTAGCAGGGGCCTGGAATGTAAACAGCCACTGGGGTACAGGCACCGAAGACCAACATC
                 CACAGGCTAACACCCCTTCAGTCCACACAAAGAACCTTCATATTTTTTTTATAAGCAT
                 AGAAATAAAAACCAAGCCAATATTTGTGACTTTGCTCTGCTACCTGCTGTATTTATTA
                 TATGGAAGCATCTAAGTACTGTCAGGATGGGGTCTTCCTCATTGTAGGGCGTTAGGAT
                 GTTGCTTTCTTTTTCCATTAGTTAAACATTTTTTTCTCCTTTGGAGGAAGGGAATGAA
                 ACATTTATGGCCTCAAGATACTATACATTTAAAGCACCCCAATGTCTCTCTTTTTTTT
                 TTTTTACTTCCCTTTCTTCTTCCTTATATAACATGAAGAACATTGTATTAATCTGATT
                 TTTAAAGATCTTTTTGTATGTTACGTGTTAAGGGCTTGTTTGGTATCCCACTGAAATG
                 TTCTGTGTTGCAGACCAGAGTCTGTTTATGTCAGGGGGATGGGGCCATTGCATCCTTA
                 GCCATTGTCACAAAATATGTGGAGTAGTAACTTAATATGTAAAGTTGTAACATACATA
                 CATTTAAAATGGAAATGCAGAAAGCTGTGAAATGTCTTGTGTCTTATGTTCTCTGTAT
                 TTATGCAGCTGATTTGTCTGTCTGTAACTGAAGTGTGGGTCCAAGGACTCCTAACTAC
                 TTTGCATCTGTAATCCACAAAGATTCTGGGCAGCTGCCACCTCAGTCTCTTCTCTGTA
                 TTATCATAGTCTGGTTTAAATAACTATATAGTAACAAAAAAAAAAAAAAAAAAAAAA
                 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
                 AAAAAAAAAAAAAAAAAAA
                 ORF Start: ATG at 141            ORF Stop: TAA at 3444
                 SEQ ID NO: 226      1101 aa      MW at 120838.0kD
NOV15a,          MSAKAISEQTGKELLYKFICTTSAIQNRFKYARVTPDTDWARLLQDHPWLLSQNLVVK
CG142427-01
Protein Sequence PDQLIKRRGKLGLVGVNLTLDGVKSWLKPRLGQEATVGKATGFLKNFLIEPFVPHSQA
                 EEFYVCIYATREGDYVLFHHEGGVDVGDVDAKAQKLLVGVDEKLNPEDIKKHLLVHAP
                 EDKKEILASFISGLFNFYEDLYFTYLEINPLVVTKDGVYVLDLAAKVDATADYICKVK
                 WGDIEFPPPFGREAYPEEAYIADLDAKSGASLKLTLLNPKGRIWTMVAGGGASVVYSD
                 TICDLGGVNELANYGEYSGAPSEQQTYDYAKTILSLMTREKHPDGKILIIGGSIANFT
                 NVAATFKGIVRAIRDYQGPLKEHEVTIFVRRGGPNYQEGLRVMGEVGKTTGIPIHVFG
                 TETHMTAIVGMALGHRPIPNQPPTAAHTANFLLNASGSTSTPAPSRTASFSESRADEV
                 APAKKAKPAMPQDSVPSPRSLQGKSTTLFSRHTKAIVWGMQTRAVQGMLDFDYVCSRD
                 EPSVAAMVYPFTGDHKQKFYWGHKEILIPVFKNMADAMRKHPEVDVLINFASLRSAYD
                 STMETMNYAQIRTIAIIAEGIPEALTRKLIKKADQKGVTIIGPATVGGIKPGCFKIGN
                 TGGMLDNILASKLYRPGSVAYVSRSGGMSNELNNIISRTTDGVYEGVAIGGDRYPGST
                 FMDHVLRYQDTPGVKMIVVLGEIGGTEEYKICRGIKEGRLTKPIVCWCIGTCATMFSS
                 EVQFGHAGACANQASETAVAKNQALKEAGVFVPRSFDELGEIIQSVYEDLVANGVIVP
                 AQEVPPPTVPMDYSWARELGLIRKPASFMTSICDERGQELIYAGMPITEVFKEEMGIG
                 GVLGLLWFQKRLPKYSCQFIEMCLMVTADHGPAVSGAHNTIICARAGKDLVSSLTSGL
                 LTIGDRFGGALDAAAKNFSKAFDSGIIPMEFXTNKMKKEGKLIMGIGHRVKSINNPDMR
                 VQILKDYVRQHFPATPLLDYALEVEKITTSKKPNLILNVDGLIGVAFVDMLRNCGSFT
                 REEADEYIDIGALNGIFVLGRSMGFIGHYLDQKRLKQGLYRHPWDDISYVLPEHMSM
                 SEQ ID NO: 227      4427 bp
NOV15b,          GGCACGAGGCCGGGACAAAAGCCGGATCCCGGGAAGCTACCGGCTGCTGGGGTGCTCC
CG142427-01
DNA Sequence     GGATTTTGCGGGGTTCGTCGGGCCTGTGGAAGAAGCGCCGCGCACGGACTTCGGCAGA
                 GGTAGAGCAGGTCTCTCTGCAGCCATGTCGGCCAAGGCAATTTCAGAGCAGACGGGCA
                 AAGAACTCCTTTACAAGTTCATCTGTACCACCTCAGCCATCCAGAATCGGTTCAAGTA
                 TGCTCGGGTCACTCCTGACACAGACTGGGCCCGCTTGCTGCAGGACCACCCCTGGCTG
                 CTCAGCCAGAACTTGGTAGTCAAGCCAGACCAGCTGATCAAACGTCGTGGAAAACTTG
                 GTCTCGTTGGGGTCAACCTCACTCTGGATGGGGTCAAGTCCTGGCTGAAGCCACGGCT
                 GGGACAGGAAGCCACAGTTGGCAAGGCCACAGGCTTCCTCAAGAACTTTCTGATCGAG
                 CCCTTCGTCCCCCACAGTCAGGCTGAGGAGTTCTATGTCTGCATCTATGCCACCCGAG
                 AAGGGGACTACGTCCTGTTCCACCACGAGGGGGGTGTGGACGTGGGTGATGTGGACGC
                 CAAGGCCCAGAAGCTGCTTGTTGGCGTGGATGAGAAACTGAATCCTGAGGACATCAAA
                 AAACACCTGTTGGTCCACGCCCCTGAAGACAAGAAAGAAATTCTGGCCAGTTTTATCT
                 CCGGCCTCTTCAATTTCTACGAGGACTTGTACTTCACCTACCTCGAGATCAATCCCCT
                 TGTAGTGACCAAAGATGGAGTCTATGTCCTTGACTTGGCGGCCAAGGTGGACGCCACT
                 GCCGACTACATCTGCAAAGTGAAGTGGGGTGACATCGAGTTCCCTCCCCCCTTCGGGC
                 GGGAGGCATATCCAGAGGAAGCCTACATTGCAGACCTCGATGCCAAAAGTGGGGCAAG
                 CCTGAAGCTGACCTTGCTGAACCCCAAAGGGAGGATCTGGACCATGGTGGCCGGGGGT
                 GGCGCCTCTGTCGTGTACAGCGATACCATCTGTGATCTAGGGGGTGTCAACGAGCTGG
                 CAAACTATGGGGAGTACTCAGGCGCCCCCAGCGAGCAGCAGACCTATGACTATGCCAA
                 GACTATCCTCTCCCTCATGACCCGAGAGAAGCACCCAGATGGCAAGATCCTCATCATT
                 GGAGGCAGCATCGCAAACTTCACCAACGTGGCTGCCACGTTCAAGGGCATCGTGAGAG
                 CAATTCGAGATTACCAGGGCCCCCTGAAGGAGCACGAAGTCACAATCTTTGTCCGAAG
                 AGGTGGCCCCAACTATCAGGAGGGCTTACGGGTGATGGGAGAAGTCGGGAAGACCACT
                 GGGATCCCCATCCATGTCTTTGGCACAGAGACTCACATGACGGCCATTGTGGGCATGG
                 CCCTGGGCCACCGGCCCATCCCCAACCAGCCACCCACAGCGGCCCACACTGCAAACTT
                 CCTCCTCAACGCCAGCGGGAGCACATCGACGCCAGCCCCCAGCAGGACAGCATCTTTT
                 TCTGAGTCCAGGGCCGATGAGGTGGCGCCTGCAAAGAAGGCCAAGCCTGCCATGCCAC
                 AACATTCAGTCCCAAGTCCAAGATCCCTGCAAGGAAAGAGCACCACCCTCTTCAGCCG
                 CCACACCAAGGCCATTGTGTGGGGCATGCAGACCCGGGCCGTGCAAGGCATGCTGGAC
                 TTTGACTATGTCTGCTCCCGAGACGAGCCCTCAGTGGCTGCCATGGTCTACCCTTTCA
                 CTGGGGACCACAAGCAGAAGTTTTACTGGGGGCACAAAGAGATCCTGATCCCTGTCTT
                 CAAGAACATGGCTGATGCCATGAGGAAGCATCCGGAGGTAGATGTGCTCATCAACTTT
                 GCCTCTCTCCGCTCTGCCTATGACAGCACCATGGAGACCATGAACTATGCCCAGATCC
                 GGACCATCGCCATCATAGCTGAAGGCATCCCTGAGGCCCTCACGAGAAAGCTGATCAA
                 GAAGGCGGACCAGAAGCGAGTGACCATCATCGGACCTGCCACTGTTGGAGGCATCAAG
                 CCTGGGTGCTTTAAGATTGGCAACACAGGTGGGATGCTGGACAACATCCTGGCCTCCA
                 AACTGTACCGCCCAGGCAGCGTGGCCTATGTCTCACGTTCCGGAGGCATGTCCAACGA
                 GCTCAACAATATCATCTCTCGGACCACGGATGGCGTCTATGAGGGCGTGGCCATTGGT
                 GGGGACAGGTACCCGGGCTCCACATTCATGGATCATGTGTTACGCTATCAGGACACTC
                 CAGGAGTCAAAATGATTGTGGTTCTTGGAGAGATTGGGGGCACTGAGGAATATAAGAT
                 TTGCCGGGGCATCAAGGAGGGCCGCCTCACTAAGCCCATCGTCTGCTGGTGCATCGGG
                 ACGTGTGCCACCATGTTCTCCTCTGAGGTCCAGTTTGGCCATGCTGGAGCTTGTGCCA
                 ACCACGCTTCTGAAACTGCAGTAGCCAAGAACCAGGCTTTGAAGGAAGCAGGAGTGTT
                 TGTGCCCCGGAGCTTTGATGAGCTTGGAGAGATCATCCAGTCTGTATACGAAGATCTC
                 GTGGCCAATGGAGTCATTGTACCTGCCCAGGAGGTGCCGCCCCCAACCGTGCCCATGG
                 ACTACTCCTGGGCCAGGGAGCTTGGTTTGATCCGCAA~ACCTGCCTCGTTCATGACCAG
                 CATCTGCGATGAGCGAGGACAGGAGCTCATCTACGCGGGCATGCCCATCACTGAGGTC
                 TTCAAGGAAGAGATGGGCATTGGCGGGGTCCTCGGCCTCCTCTGGTTCCAGAAAAGGT
                 TGCCTAAGTACTCTTGCCAGTTCATTGAGATGTGTCTGATGGTGACAGCTGATCACGG
                 GCCAGCCGTCTCTGGAGCCCACAACACCATCATTTGTGCGCGAGCTGGGAAAGACCTG
                 GTCTCCAGCCTCACCTCGGGGCTGCTCACCATCGGGGATCGGTTTGGGGGTGCCTTOG
                 ATGCAGCAGCCAAGATGTTCAGTAAAGCCTTTGACAGTGGCATTATCCCCATGGAGTT
                 TGTGAACAAGATGAAGAAGGAAGGGAAGCTGATCATGGGCATTGGTCACCGAGTGAAG
                 TCGATAAACAACCCAGACATCCGAGTGCAGATCCTCAAAGATTACGTCAGGCAGCACT
                 TCCCTGCCACTCCTCTGCTCGATTATGCACTGGAAGTAGAGAAGATTACCACCTCGAA
                 GAAGCCAAATCTTATCCTGAATGTAGATGGTCTCATCGGAGTCGCATTTGTAGACATG
                 CTTAGAAACTGTGGGTCCTTTACTCGGGAGGAAGCTGATGAATATATTGACATTGGAG
                 CCCTCAATGGCATCTTTGTGCTGGGAAGGAGTATGGCGTTCATTGGACACTATCTTGA
                 TCAGAAGAGGCTGAAGCAGGGGCTGTATCGTCATCCGTGGGATGATATTTCATATGTT
                 CTTCCGGAACACATGAGCATGTAACAGAGCCAGGAACCCTACTGCAGTAAACTGAAGA
                 CAAGATCTCTTCCCCCAAGAAAAAGTGTACAGACAGCTGGCAGTGGAGCCTGCTTTAT
                 TTAGCAGGGGCCTGGAATGTAAACAGCCACTGGGGTACAGGCACCGAAGACCAACATC
                 CACAGGCTAACACCCCTTCAGTCCACACAAAGAAGCTTCATATTTTTTTTATAAGCAT
                 AGAAATAAAAACCAAGCCAATATTTGTGACTTTGCTCTGCTACCTGCTGTATTTATTA
                 TATGGAAGCATCTAAGTACTGTCAGGATGGGGTCTTCCTCATTGTAGGGCGTTAGGAT
                 GTTGCTTTCTTTTTCCATTAGTTAAACATTTTTTTCTCCTTTGGAGGAAGGGAATGAA
                 ACATTTATGGCCTCAAGATACTATACATTTAAAGCACCCCAATCTCTCTCTTTTTTTT
                 TTTTTACTTCCCTTTCTTCTTCCTTATATAACATGAAGAACATTGTATTAATCTGATT
                 TTTAAAGATCTTTTTGTATGTTACGTGTTAAGGGCTTGTTTGGTATCCCACTGAAATG
                 TTCTGTGTTGCAGACCAGAGTCTGTTTATGTCAGGGGGATGGGGCCATTGCATCCTTA
                 GCCATTGTCACAAAATATGTGGAGTACTAACTTAATATGTAAAGTTGTAACATACATA
                 CATTTAAAATGGAAATGCAGAAAGCTGTGAAATGTCTTGTGTCTTATGTTCTCTGTAT
                 TTATGCAGCTGATTTGTCTGTCTGTAACTGAAGTGTGGGTCCAAGGACTCCTAACTAC
                 TTTGCATCTGTAATCCACAAAGATTCTGGGCAGCTGCCACCTCAGTCTCTTCTCTGTA
                 TTATCATAGTCTGGTTTAATAAACTATATAGTAACAAAAAAAAAAAAAAAAAAAAAA
                 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
                 AAAAAAAAAAAAAAAAAAA
                 ORF Start: ATG at 141            ORF Stop: TAA at 3444
                 SEQ ID NO: 228      1101 aa      MW at 120838.0kD
NOV15b,          MSAKAISEQTGKELLYKFICTTSAIQNRFKYARVTPDTDWARLLQDHPWLLSQNLVVK
CG142427-01
Protein Sequence PDQLIKRRGKLGLVGVNLTLDGVKSWLKPRLGQEATVGKATGFLKNFLIEPFVPHSQA
                 EEFYVCIYATREGDYVLFHHEGGVDVGDVDAKAQKLLVGVDEKLNPEDIKKHLLVHAP
                 EDKKEILASFISGLFNFYEDLYFTYLEINPLVVTKDGVYVLDLAAKVDATADYICKVK
                 WGDIEFPPPFGREAYPEEAYIADLDAKSGASLKLTLLNPKGRIWTMVAGGGASVVYSD
                 TICDLGGVNELANYGEYSGAPSEQQTYDYAKTILSLMTREKHPDGKILIIGGSIANFT
                 NVAATFKGIVRAIRDYQGPLKEHEVTIFVRRGGPNYQEGLRVMGEVGKTTGIPIHVFG
                 TETHMTAIVGMALGHRPIPNQPPTAAHTANFLLNASGSTSTPAPSRTASFSESRADEV
                 APAKKAKPAMPQDSVPSPRSLQGKSTTLFSRHTKAIVWGMQTRAVQGMLDFDYVCSRD
                 EPSVAAMVYPFTGDHKQKFYWGHKEILIPVFKNMADAMRKHPEVDVLINFASLRSAYD
                 STMETMNYAQIRTIAIIAEGIPEALTRKLIKKADQKGVTIIGPATVGGIKPGCFKIGN
                 TGGMLDNILASKLYRPGSVAYVSRSGGMSNELNNIISRTTDGVYEGVAIGGDRYPGST
                 FMDHVLRYQDTPGVKMIVVLGEIGGTEEYKICRGIKEGRLTKPIVCWCIGTCATMFSS
                 EVQFGHAGACANQASETAVAKNQALKEAGVFVPRSFDELGEIIQSVYEDLVANGVIVP
                 AQEVPPPTVPMDYSWARELGLIRKPASFMTSICDERGQELIYAGMPITEVFKEEMGIG
                 GVLGLLWFQKRLPKYSCQFIEMCLMVTADHGPAVSGAHNTIICARAGKDLVSSLTSGL
                 LTIGDRFGGALDAAAKMFSKAFDSGIIPMEFVNKMKKEGKLIMGIGHRVKSINNPDMR
                 VQILKDYVRQHFPATPLLDYALEVEKITTSKKPNLILNVDGLIGVAFVDMLRNCGSFT
                 REEADEYIDIGALNGIFVLGRSMGFIGHYLDQKRLKQGLYRHPWDDISYVLPEHMSM
                 SEQ ID NO: 229      3238 bp
NOV15c,          CCAGAATTCCACCATGTCGGCCAACGCAATTTCAGAGCAGACGGGCAAAGAACTCCTT
CG142427-04
DNA Sequence     TACAAGTTCATCTGTACCACCTCAGCCATCCAGAATCGGTTCAAGTATGCTCGGGTCA
                 CTCCTGACACAGACTGGGCCCGCTTGCTCCAGGACCACCCCTGGCTGCTCAGCCAGAA
                 CTTGGTAGTCAAGCCACACCAGCTGATCAAACGTCGTGGAAAACTTGGTCTCGTTGGG
                 GTCAACCTCACTCTGGATGGGGTCAAGTCCTGGCTGAAGCCACGGCTGGGACAGGAAG
                 CCACAGTTGGCAAGGCCACAGGCTTCCTCAAGAACTTTCTGATCGAGCCCTTCGTCCC
                 CCACAGTCAGGCTGAGGAGTTCTATGTCTGCATCTATGCCACCCGAGAAGGGGACTAC
                 GTCCTGTTCCACCACGAGGGGGGTGTGGACGTGGGTCATGTGGACGCCAAGGCCCAGA
                 AGCTGCTTGTTGGCGTGGATGAGAAACTGAATCCTGAGGACATCAAAAAACACCTGTT
                 GGTCCACGCCCCTGAAGACAAGAAAGAAATTCTGGCCAGTTTTATCTCCGGCCTCTTC
                 AATTTCTACGAGGACTTGTACTTCACCTACCTCGAGATCAATCCCCTTGTAGTGACCA
                 AAGATGGAGTCTATGTCCTTGACTTGGCGGCCAAGGTGGACGCCACTGCCGACTACAT
                 CTGCAAAGTGAAGTGGGGTGACATCGAGTTCCCTCCCCCCTTCGGGCGGGAGGCATAT
                 CCAGAGGAAGCCTACATTGCAGGCCTCGATGCCAAAAGTGGGGCAAGCCTGAAGCTGA
                 CCTTGCTGAACCCCAAAGGGAGGATCTGGACCATGGTGGCCGGGGGTGGCGCCTCTGT
                 CGTGTACAGCGATACCATCTGTGATCTAGGGGGTGTCAACGAGCTGGCAAACTATGGG
                 GAGTACTCAGGCGCCCCCAGCGAGCAGCAGACCTATGACTATGCCAAGACTATCCTCT
                 CCCTCATGACCCGAGAGAAGCACCCAGATGGCAAGATCCTCATCATTGGAGGCAGCAT
                 CGCAAACTTCACCAACGTGGCTGCCACGTTCAAGGGCATCGTGAGAGCAATTCGAGAT
                 TACCAGGGCCCCCTGAAGGAGCACGAAGTCACAATCTTTGTCCGAAGAGGTGGCCCCA
                 ACTATCAGGAGGGCTTACGGGTGATGGGAGAAGTCGGGAAGACCACTGGGATCCCCAT
                 CCATGTCTTTGGCACAGAGACCCACACTGCAAACTTCCTCCTCAACGCCAGCGGGAGC
                 ACATCGACGCCAGCCCCCAGCAGGACAGCATCTTTTTCTGAGTCCAGGGCCGATGAGG
                 TGGCGCCTGCAAAGAAGGCCAAGCCTGCCATGCCACAAGGAAAGAGCACCACCCTCTT
                 CAGCCGCCACACCAAGGCCATTGTGTGGGGCATGCAGACCCGGGCCGTGCAAGGCATG
                 CTGGACTTTGACTATGTCTGCTCCCGAGACGAGCCCTCAGTGGCTGCCATGGTCTACC
                 CTTTCACTGGGGACCACAAGCAGAAGTTTTACTGGGGGCACAAAGAGATCCTGATCCC
                 TGTCTTCAAGAACATGGCTGATGCCATGAGGAAGCATCCGGAGGTAGATGTGCTCATC
                 AACTTTGCCTCTCTCCGCTCTGCCTATGACAGCACCATGGAGACCACGAACTATGCCC
                 AGATCCGGACCATCGCCATCATAGCTGAAGGCATTCCTGAGGCCCTCACGAGAAAGCT
                 GATCAAGAAGGCGGACCAGAAGGGAGTGACCATCATCGGACCTGCCACTGTTGGAGGC
                 ATCAAGCCTGGGTGCTTTAAGATTGGCAACACAGGTGGGATGCTGGACAACATCCTGG
                 CCTCCAAACTGTACCGCCCAGGCAGCGTGGCCTATGCCTCACGTTCCCGAGGCATGTC
                 CAACGAGCTCAACAATATCATCTCTCGGACCACGGATGGCGTCTATGAGGGCGTGGCC
                 ATTGGTGGGGACAGGTACCCGGGCTCCACATTCATGGATCATGTGTTACGCTATCAGG
                 ACACTCCAGGAGTCAAAATGATTGTGGTTCTTGGAGAGATTGGGGGCACTGAGGAATA
                 TAAGATTTGCCGGGGCATCAAGGAGGGCCGCCTCACTAAGCCCATCGTCTGCTGGTGC
                 ATCCGGACGTGTGCCACCATGTTCTCCTCTGAGGTCCAGTTTGGCCATGCTGGAGCTT
                 CTGCCAACCAGGCTTCTGAAACTGCAGTAGCCAAGAACCAGGCTTTGAAGGAACCAGC
                 AGTGTTTGTGCCCCGGAGCTTTGATGAGCTTGGAGAGATCATCCAGTCTGTATACGAA
                 GATCTCGTGGCCAATGGAGTCATTGTACCTGCCCAGGAGGTGCCGCCCCCAACCGTGC
                 CCATGGACTACTCCTGGGCCAGGGAGCTTGGTTTGATCCGCAAACCTGCCTCGTTCAT
                 GACCAGCATCTGCGATGAGCGAGGACAGGAGCTCATCTACGCGGGCATGCCCATCACT
                 GAGGTCTTCAAGGAAGAGATGGGCATTGGCGGGGTCCTCGGCCTCCTCTGGTTCCAGA
                 AAAGGTTGCCTAAGTACTCTTGCCAGTTCATTGAGATGTGTCTGATGGTGACAGCTGA
                 TCACGGGCCAGCCGTCTCTGCAGCCCACAACACCATCATTTGTGCGCGAGCTGGGAAA
                 GACCTGGTCTCCAGCCTCACCTCGGGGCTGCTCACCATCGGGGATCGGTTTGGGGGTG
                 CCTTGGATGCAGCAGCCAAGATGTTCAGTAAAGCCTTTGACAGTGGCATTATCCCCAT
                 GGAGTTTGTGAACAAGATGAAGAAGGAAGGGAAGCTGATCATGGGCATTGGTCACCGA
                 GTGAAGTCGATAAACAACCCAGACATGCGAGTGCAGATCCTCAAAGATTACGTCAGGC
                 AGCACTTCCCTGCCACTCCTCTGCTCGATTATGCACTGGAAGTAGAGAAGATTACCAC
                 CTCGAAGAAGCCAAATCTTATCCTGAATGTAGATGGTCTCATCGGAGTCGCATTTGTA
                 GACATGCTTACAAACTGTGGGTCCTTTACTCGGGAGGAAGCTGATGAATATATTGACA
                 TTGGAGCCCTCAATGGCATCTTTGTGCTGGGAACGAGTATGGGGTTCATTGGACACTA
                 TCTTGATCAGAAGAGGCTGAAGCAGGGGCTGTATCGTCATCCGTGGGATGATATTTCA
                 TATGTTCTTCCGGAACACATGAGCATGTAAGCGGCCGCTTTTTTCCTT
                 ORF Start: at 2                  ORF Stop: TAA at 3218
                 SEQ ID NO: 230      1072 aa      MW at 117722.3kD
NOV15c,          QNSTMSAKAISEQTGKELLYKFICTTSAIQNRFKYARVTPDTDWARLLQDHPWLLSQN
CG142427-04
Protein Sequence LVVKPDQLIKRRGKLGLVGVNLTLDGVKSWLKPRLGQEATVGKATGFLKNFLIEPFVP
                 HSQAEEFYVCIYATREGDYVLFHHEGGVDVGDVDAKAQKLLVGVDEKLNPEDIKKHLL
                 VHAPEDKKEILASFISGLFNFYEDLYFTYLEINPLVVTKDGVYVLDLAAKVDATADYI
                 CKVKWGDIEFPPPFGREAYPEEAYIAGLDAKSGASLKLTLLNPKGRIWTMVAGGGASV
                 VYSDTICDLGGVNELANYGEYSGAPSEQQTYDYAKTILSLMTREKHPDGKILIIGGSI
                 ANFTNVAATFKGIVRAIRDYQGPLKEHEVTIFVRRGGPNYQEGLRVMGEVGKTTGIPT
                 HVFGTETHTANFLLNASGSTSTPAPSRTASFSESRADEVAPAKKAKPANPQGKSTTLF
                 SRHTKAIVWGMQTRAVQGMLDFDYVCSRDEPSVAANVYPFTGDHKQKFYWGHKEILIP
                 VFKNMADAMRKHPEVDVLINFASLRSAYDSTMETTNYAQIRTIAIIAEGIPEALTRKL
                 IKKADQKGVTIIGPATVGGIKPGCFKIGNTGGMLDNILASKLYRPGSVAYASRSGGMS
                 NELNNIISRTTDGVYEGVAIGGDRYPGSTFMDHVLRYQDTPGVKMIVVLGEIGGTEEY
                 KICRGIKEGRLTKPIVCWCIGTCATMFSSEVQFGHAGACANQASETAVAKNQALKEAG
                 VFVPRSFDELGEIIQSVYEDLVANGVIVPAQEVPPPTVPMDYSWARELGLIRKPASFM
                 TSICDERGQELIYAGMPITEVFKEEMGIGGVLGLLWFQKRLPKYSCQFIEMCLMVTAD
                 HGPAVSGAHNTICARAGKDLVSSLTSGLLTIGDRFGGALDAAAKMFSKAFDSGIIPM
                 EFVNKMKKEGKLIMGIGHRVKSINNPDMRVQILKDYVRQHFPATPLLDYALEVEKITT
                 SKKPNLILNVDGLIGVAFVDMLRNCGSFTREEADEYIDIGALNGIFVLGRSMGFIGHY
                 LDQKRLKQGLYRHPWDDISYVLPEIIMSM
                 SEQ ID NO: 231      3307 bp
NOV15d,          CCAGAATTCCACCATGTCGGCCAAGGCAATTTCAGAGCAGACGGGCAAAGAACTCCTT
CG142427-02
DNA Sequence     TACAAGTTCATCTGTACCACCTCAGCCATCCAGAATCGGTTCAAGTATGCTCGGGTCA
                 CTCCTGACACAGACTGGGCCCGCTTGCTGCAGGACCACCCCTGGCTGCTCAGCCAGAA
                 CTTGGTAGTCAAGCCAGACCAGCTGATCAAACGTCCTGGAAAACTTGGTCTCGTTGGG
                 GTCAACCTCACTCTGGATGGGGTCAAGTCCTGGCTGAAGCCACGGCTGGGACAGGAAG
                 CCACAGTTGGCAAGGCCACAGGCTTCCTCAAGAACTTTCTGATCGAGCCCTTCGTCCC
                 CCACAGTCAGGCTGAGGAGTTCTATGTCTGCATCTATGCCACCCGAGAAGGGGACTAC
                 GTCCTGTTCCACCACGAGGGGGGTGTGGACGTGGGTGATGTGGACGCCAAGGCCCAGA
                 AGCTGCTTGTTGGCGTGGATGAGAAACTGAATCCTGAGGACATCAAAAAACACCTGTT
                 GGTCCACGCCCCTGAAGACAAGAAAGAAATTCTGGCCAGTTTTATCTCCGGCCTCTTC
                 AATTTCTACGAGGACTTGTACTTCACCTACCTCGAGATCAATCCCCTTGTAGTGACCA
                 AAGATGGAGTCTATGTCCTTGACTTGGCGGCCAAGGTGGACGCCACTGCCGACTACAT
                 CTGCAAAGTGAAGTGGGGTGACATCGAGTTCCCTCCCCCCTTCGGGCGGGAGGCATAT
                 CCAGAGGAAGCCTACATTGCAGACCTCGATGCCAAAAGTGGGGCAAGCCTGAAGCTGA
                 CCTTGCTGAACCCCAAAGGGAGGATCTGGACCATGGTGGCCGGGGGTGGCGCCTCTGT
                 CGTGTACAGCGATACCATCTGTGATCTAGGGGGTGTCAACGAGCTGGCAAACTATGGG
                 GAGTACTCAGGCGCCCCCAGCGAGCAGCAGACCTATGACTATGCCAAGACTATCCTCT
                 CCCTCATGACCCGAGAGAAGCACCCAGATGGCAAGATCCTCATCATTGGAGGCAGCAT
                 CGCAAACTTCACCAACGTGGCTGCCACGTTCAAGGGCATCGTGAGAGCAATTCGAGAT
                 TACCAGGGCCCCCTGAAGGAGCACGAAGTCACAATCTTTGTCCGAAGAGGTGGCCCCA
                 ACTATCAGGAGGGCTTACGGGTGATGGGAGAAGTCGGGAAGACCACTGGGATCCCCAT
                 CCATGTCTTTGGCACAGAGACTCACATGACGGCCATTGTGGGCATGGCCCTGGGCCAC
                 CGGCCCATCCCCAACCAGCCACCCACAGCGGCCCACACTGCAAACTTCCTCCTCAACG
                 CCAGCGGGAGCACATCGACGCCAGCCCCCAGCAGGACAGCATCTTTTTCTGAGTCCAG
                 GGCCGATGAGGTGGCGCCTGCAAAGAAGGCCAAGCCTGCCATGCCACAAGGAAAGAGC
                 ACCACCCTCTTCAGCCGCCACACCAAGGCCATTGTGTGGGGCATGCAGACCCGGGCCG
                 TGCAAGGCATGCTGGACTTTGACTATGTCTGCTCCCGAGACGAGCCCTCAGTGGCTGC
                 CATGGTCTACCCTTTCACTGGGGACCACAAGCAGAAGTTTTACTGOGGGCACAAAGAG
                 ATCCTGATCCCTGTCTTCAAGAACATGGCTGATGCCATGAGGAAGCACCCGGAGGTAG
                 ATGTGCTCATCAACTTTGCCTCTCTCCGCTCTGCCTATGACAGCACCATGGAGACCAT
                 GAACTATGCCCAGATCCGGACCATCGCCATCATAGCTGAAGGCATCCCTGAGGCCCTC
                 ACGAGAAAGCTGATCAAGAAGGCGGACCAGAAGGGAGTGACCATCATCGGACCTCCCA
                 CTGTTGGAGGCATCAAGCCTGGGTGCTTTAAGATTGGCAACACAGGTGGGATGCTGGA
                 CAACATCCTGGCCTCCAAACTGTACCGCCCAGGCAGCGTGGCCTATGTCTCACGTTCC
                 GGAGGCATGTCCAACGAGCTCAACAATATCATCTCTCGGACCACGGATGGCGTCTATG
                 AGGGCGTGGCCATTGGTGGGGACAGGTACCCGGGCTCCACATTCATGGATCATGTGTT
                 ACGCTATCAGGACACTCCAGGAGTCAAAATGATTGTGGTTCTTGGAGAGATTGGGGGC
                 ACTGAGGAATATAAGATTTGCCGGGGCATCAAGGAGGGCCGCCTCACTAAGCCCATCG
                 TCTGCTGGTGCATCCGGACGTGTGCCACCATGTTCTCCTCTGAGGTCCAGTTTGGCCA
                 TGCTGGAGCTTGTGCCAACCAGGCTTCTGAAACTGCAGTAGCCAAGAACCAGGCTTTG
                 AAGGAAGCAGGAGTGTTTGTGCCCCGGAGCTTTGATGAGCTTGGAGAGATCATCCAGT
                 CTGTATACGAAGATCTCGTGGCCAATGGAGTCATTGTACCTGCCCAGGAGGTGCCGCC
                 CCCAACCGTGCCCATGGACTACTCCTGGGCCAGGGAGCTTGGTTTGATCCGCAAACCT
                 GCCTCGTTCATGACCAGCATCTGCGATGAGCGAGGACAGGAGCTCATCTACGCGGGCA
                 TGCCCATCACTGAGGTCTTCAAGGAAGAGATGGGCATTGGCGGGGTCCTCGGCCTCCT
                 CTGGTTCCAGAAAAGGTTGCCTAAGTACTCTTGCCAGTTCATTGAGATGTGTCTGATG
                 GTGACAGCTGATCACGGGCCAGCCGTCTCTGGAGCCCACAACACCATCATTTGTGCGC
                 GAGCTGGGAAAGACCTGGTCTCCAGCCTCACCTCGGGGCTGCTCACCATCGGGGATCG
                 GTTTGCGGGTGCCTTGGATGCAGCAGCCAAGATGTTCAGTAAAGCCTTTGACAGTGGC
                 ATTATCCCCATGGAGTTTGTGAACAAGATGAAGAAGGAAGGGAAGCTGATCATGGGCA
                 TTGGTCACCGAGTGAAGTCGATAAACAACCCAGACATGCGAGTGCAGATCCTCAAAGA
                 TTACGTCAGGCAGCACTTCCCTGCCACTCCTCTGCTCGATTATGCACTGGAAGTAGAG
                 AAGATTACCACCTCGAAGAAGCCAAATCTTATCCTGAATGTAGATGGTCTCATCGGAG
                 TCGCATTTGTAGACATGCTTAGAAACTGTGGGTCCTTTACTCGGGAGGAAGCTGATGA
                 ATATATTGACATTGGAGCCCTCAATGGCATCTTTGTGCTGGGAAGGAGTATGGGGTTC
                 ATTGGACACTATCTTGATCAGAAGAGGCTGAAGCAGGGGCTGTATCGTCATCCGTGGG
                 ATGATATTTCATATGTTCTTCCGGAACACATGAGCATGTAAGCGGCCGCTTTTTTCCT
                 T
                 ORF Start: at 2                  ORF Stop: TAA at 3287
                 SEQ ID NO: 232      1095 aa      MW at 120201.2kD
NOV15d,          QNSTMSAKAISEQTGKELLYKFICTTSAIQNRFKYARVTPDTDWARLLQDHPWLLSQN
CG142427-02
Protein Sequence LVVKPDQLIKRRGKLGLVGVNLTLDGVKSWLKPRLGQEATVGKATGFLKNFLIEPFVP
                 HSQAEEFYVCIYATREGDYVLFHHEGGVDVGDVDAKAQKLLVGVDEKLNPEDIKKHLL
                 VHAPEDKKEILASFISGLFNFYEDLYFTYLEINPLVVTKDGVYVLDLAAKVDATADYI
                 CKVKWGDIEFPPPFGREAYPEEAYIADLDAKSGASLKLTLLNPKGRIWTMVAGGGASV
                 VYSDTICDLGGVNELANYGEYSGAPSEQQTYDYAKTILSLMTREKHPDGKILIIGGSI
                 ANFTNVAATFKGIVRAIRDYQGPLKEHEVTIFVRRGGPNYQEGLRVMGEVGKTTGIPT
                 HVFGTETHMTATVGMALGHRPIPNQPPTAAHTANFLLNASGSTSTPAPSRTASFSESR
                 ADEVAPAKKAKPAMPQGKSTTLFSRHTKAIVWGMQTRAVQGMLDFDYVCSRDEPSVAA
                 MVYPFTGDHKQKFYWGHKEILIPVFKNMADAMRKHPEVDVLINFASLRSAYDSTMETM
                 NYAQIRTIATIAEGIPEALTRKLIKKADQKGVTIIGPATVGGIKPGCFKIGNTGGMLD
                 NILASKLYRPGSVAYVSRSGGMSNELNNIISRTTDGVYEGVAIGGDRYPGSTFMDHVL
                 RYQDTPGVKMIVVLGEIGGTEEYKICRGIKEGRLTKPIVCWCIGTCATMFSSEVQFGH
                 AGACANQASETAVAKNQALKEAGVFVPRSFDELGEIIQSVYEDLVANGVIVPAQEVPP
                 PTVPMDYSWARELGLIRKPASFMTSICDRRGQELIYAGMPITEVFKEEMGIGGVLGLL
                 WFQKRLPKYSCQFIEMCLMVTADHGPAVSGAHNTIICARAGKDLVSSLTSGLLTIGDR
                 FGGALDAAAKMFSKAFDSGIIPMEFVNKMKKEGKLIMGIGHRVKSINNPDMRVQILKD
                 YVRQHFPATPLLDYALEVEKITTSKKPNLILNVDGLIGVAFVDMLRNCGSFTREEADE
                 YIDIGALNGIFVLGRSMGFTGHYLDQKRLKQGLYRHPWDDISYVLPEHMSM
                 SEQ ID NO: 233      2290 bp
NOV 15e,         CCAGAATTCCACCATGTCGGCCAAGGCAATTTCAGAGCAGACGGGCAAAGAACTCCTT
CG142427-03
DNA Sequence     TACAAGTTCATCTGTACCACCTCAGCCATCCAGAATCGGTTCAAGTATGCTCGGGTCA
                 CTCCTGACACAGACTGGGCCCGCTTGCTGCAGGACCACCCCTGGCTGCTCAGCCAGAA
                 CTTGGTAGTCAAGCCAGACCAGCTGATCAAACGTCCTGGAAAACTTGGTCTCGTTGGG
                 GTCAACCTCACTCTGGATGGGGTCAAGTCCTGGCTGAAGCCACGGCTGGGACAGGAAG
                 CCACAGTGAGTGGCATGGGGTCAAGATGAACGTGTGTGGTAACAGAAGCAAATATGG
                 TCACCTTCAGGTTGGCAAGGCCACAGGCTTCCTCAAGAACTTTCTGATCGAGCCCTTC
                 GTCCCCCACAGTCAGGCTGAGGAGTTCTATGTCTGCATCTATGCCACCCGAGAAGGGG
                 ACTACGTCCTGTTCCACCACGAGGGGGGTGTGGACGTGGGTGATGTGGACGCCAAGGC
                 CCAGAAGCTGCTTGTTGGCGTGGATGAGAAACTGAATCCTGAGGACATCAAAAAACAC
                 CTGTTGGTCCACGCCCCTGAAGACAAGAAAGAAATTCTGGCCAGTTTTATCTCCGGCC
                 TCTTCAATTTCTACGAGGACTTGTACTTCACCTACCTCGAGATCAATCCCCTTGTAGT
                 GACCAAAGATGGAGTCTATGTCCTTGACTTGGCGGCCAAGGTGGACGCCACTGCCGAC
                 TACATCTGCAAAGTGAAGTGGGGTGACATCGAGTTCCCTCCCCCCTTCGGGCGGGAGG
                 CATATCCAGAGGAAGCCTACATTGCAGACCTCGACGCCAAAAGTGGGGCAAGCCTGAA
                 GCTGACCTTGCTGAACCCCAAAGGGAGGATCTGGACCATGGTGGCCGGGGGTGGCGCC
                 TCTGTCGTGTACAGCGATACCATCTGTGATCTAGGGGGTGTCAACGAGCTGGCAAACT
                 ATGGGGAGTACTCAGGCGCCCCCAGCGAGCAGCACACCTATGACTATGCCAAGACTAT
                 CCTCTCCCTCATGACCCGAGAGAAGCACCCAGATGGCAAGATCCTCATCATTGGAGGC
                 AGCATCGCAAACTTCACCAACGTGGCTGCCACGTTCAAGGGCATCGTGAGAGCAATTC
                 GAGATTACCAGGGCCCCCTGAAGGAGCACGAAGTCACAATCTTTGTCCGAAGAGGTGG
                 CCCCAACTATCAGGAGGGCTTACGGGTGATGGGAGAAGTCGGGAAGACCACTGGGATC
                 CCCATCCATGTCTTTGGCACAGAGACTCACATCACGGCCATTGTGGGCATGGCCCTGG
                 GCCACCGGCCCATCCCCAACCAGCCACCCACACCGGCCCACACTGCAAACTTCCTCCT
                 CAACGCCAGCGGGAGCACATCGACGCCAGCCCCCAGCAGGACAGCATCTTTTTCTGAG
                 TCCAGGGCCGATGAGGTGGCGCCTGCAAAGAAGGCCAAGCCTGCCATGCCACAAGGAA
                 AGAGCACCACCCTCTTCAGCCGCCACACCAAGGCCATTGTGTGGGGCATGCAGACCCG
                 GGCCGTGCAAGGCATGCTGGACTTTGACTATGTCTGCTCCCGAGACGAGCCCTCAGTG
                 GCTGCCATGGTCTACCCTTTCACTGGGGACCACAAGCAGAAGTTTTACTGGGGGCACA
                 AAGAGATCCTGATCCCTGTCTTCAAGAACATGGCTGATGCCATGAGGAAGCACCCGGA
                 GGTAGATGTGCTCATCAACTTTGCTTCTCTCCGCTCTGCCTTGGATGCAGCAGCCAAG
                 ATGTTCAGTAAAGCCTTTGACAGTGGCATTATCCCCATGGAGTTTGTGAACAAGATGA
                 AGAAGGAAGGGAAGCTGATCATGGGCATTGGTCACCGAGTGAAGTCGATAAACAACCC
                 AGACATGCGAGTGCGGATCCTCAAAGATTACGTCAGGCAGCACTTCCCTGCCACTCCT
                 CTGCTCGATTATGCACTGGAAGTAGAGAAGATTACCACCTCGAAGAAGCCAAATCTTA
                 TCCTGAATGTAGATGGTCTCATCGGAGTCGCATTTGTAGACATGCTTAGAAACTGTGG
                 GTCCTTTACTCGGGAGGAAGCTGATGAATATATTGACATTGGAGCCCTCAATGGCATC
                 TTTGTGCTGGGAAGGAGTATGGGGTTCATTGGACACTATCTTGATCAGAAGAGGCTGA
                 AGCAGGGGCTGTATCGTCATCCGTGGGATGATATTTCATATGTTCTTCCGGAACACAT
                 GAGCATGTAAGCGGCCGCTTTTTTCCTT
                 ORF Start: at 2                  ORF Start: TAA at 2270
                 SEQ ID NO: 234       756 aa      MW at 83890.7kD
NOV15e,          QNSTMSAKAISEQTGKELLYKFICTTSAIQNRFKYARVTPDTDWARLLQDHPWLLSQN
CG142427-03
Protein Sequence LVVKPDQLIKRRGKJLGLVGVNLTLDGVKSWLKPRLGQEATVSGHGVKMNVCGNRSKYG
                 HLQVGKATGFLKNFLIEPFVPHSQAEEFYVCIYATREGDYVLFHHEGGVDVGDVDAKA
                 QKLLVGVDEKLNPEDIKKHLLVHAPEDKKEILASFISGLFNFYEDLYFTYLEINPLVV
                 TKDGVYVLDLAAKVDATADYICKVKWGDIEFPPPFGREAYPEEAYIADLDAKSGASLK
                 LTLLNPKGRIWTMVAGGGASXTVYSDTICDLGGVNELANYGEYSGAPSEQQTYDYAKTI
                 LSLMTREKHPDGKTLIIGGSIANFThVAATFKGIVRAIRDYQGPLKEHEVTIFVRRGG
                 PNYQEGLRVMGEVGKTTGIPIHVFGTETHMTAIVGMALGHRPIPNQPPTAAHTANFLL
                 NASGSTSTPAPSRTASFSESRADEVAPAKKAKPANPQGKSTTLFSRHTKAIVWGMQTR
                 AVQGMLDFDYVCSRDEPSVAAMVYPFTGDHKQKFYWGHKEILIPVFKNMADAMRKHPE
                 VDVLINFASLRSALDAAAKMFSKAFDSGIIPMEFVNKMKKEGKLIMGIGHRVKSINNP
                 DMRVRILKDYVRQHFPATPLLDYALEVEKITTSKKPNLILNVDGLTGVAFVDMLRNCC
                 SFTREEADEYIDIGALNGIFVLGRSMGFIGHYLDQKRLKQGLYRHPWDDISYVLPEHM
                 SEQ ID NO: 235      3317 bp
NOV15f           CCAGAATTCCACCATGTCGGCCAAGGCAATTTCAGAGCAGACGGGCAAAGAACTCCTT
256388552
DNA Sequence     TACAAGTTCATCTGTACCACCTCAGCCATCCAGAATCGGTTCAAGTATGCTCGGGTCA
                 CTCCTGACACAGACTGGGCCCGCTTGCTGCAGGACCACCCCTGGCTGCTCAGCCAGAA
                 CTTGGTAGTCAAGCCAGACCAGCTGATCAAACGTCGTGGAAAACTTGGTCTCGTTGGG
                 GTCAACCTCACTCTGGATGGGGTCAAGTCCTGGCTGAAGCCACGGCTGGGACAGGAAG
                 CCACAGTTGGCAAGGCCACAGGCTTCCTCAAGAACTTTCTGATCGAGCCCTTCGTCCC
                 CCACAGTCAGGCTGAGGAGTTCTATGTCTGCATCTATGCCACCCGAGAAGGGGACTAC
                 GTCCTGTTCCACCACGAGGGGGGTGTGGACGTGGGTGATGTGGACGCCAAGGCCCAGA
                 AGCTGCTTGTTGGCGTGGATGAGAAACTGAATCCTGAGGACATCAAAAAACACCTGTT
                 GGTCCACGCCCCTGAAGACAAGAAAGAAATTCTGGCCAGTTTTATCTCCGGCCTCTTC
                 AATTTCTACGAGGACTTGTACTTCACCTACCTCGAGATCAATCCCCTTGTAGTGACCA
                 AAGATGGAGTCTATGTCCTTGACTTGGCGGCCAAGGTGGACGCCACTGCCGACTACAT
                 CTGCAAAGTGAAGTGGGGTGACATCGAGTTCCCTCCCCCCTTCGGGCGGGAGGCATAT
                 CCAGAGGAAGCCTACATTGCAGACCTCGATGCCAAAAGTGGGGCAAGCCTGAAGCTGA
                 CCTTGCTGAACCCCAAAGGGAGGATCTGGACCATGGTGGCCGGGGGTGGCGCCTCTGT
                 CGTGTACAGCGATACCATCTGTGATCTAGGGGGTGTCAACGAGCTGGCAAACTATGGG
                 GAGTACTCAGGCGCCCCCAGCGAGCAGCAGACCTATGATTATGCCAAGACTATCCTCT
                 CCCTCATGACCCGAGAGAAGCACCCAGATGGCAAGATCCTCATCATTGGAGGCAGCAT
                 CGCAAACTTCACCAACGTGGCTGCCACGTTCAAGGGCATCGTGAGAGCAATTCGAGAT
                 TACCAGGGCCCCCTGAAGGAGCACGAAGTCACAATCTTTGTCCGAAGAGGTGGCCCCA
                 ACTATCAGGAGGGCTTACGGGTGATGGGAGAAGTCGGGAAGACCACTGGGATCCCCAT
                 CCATGTCTTTGGCACAGAGACTCACATGACGGCCATTGTGGGCATGGCCCTGGGCCAC
                 CGGCCCATCCCCAACCAGCCACCCACAGCGGCCCACACTGCAAACTTCCTCCTCAACG
                 CCAGCGGGAGCACATCGACGCCAGCCCCCAGCAGGACAGCATCTTTTTCTGAGTCCAG
                 GGCCGATGAGGTGGCGCCTGCAAAGAAGGCCAAGCCTGCCATGCCACAAGATTCAGTC
                 CCAAGTCCAAGATCCCTGCAAGGAAAGAGCACCACCCTCTTCAGCCGCCACACCAAGG
                 CCATTGTGTGGGGCATGCAGACCCGGGCCGTGCAAGGCATGCTGGACTTTGACTATGT
                 CTGCTCCCGAGACGAGCCCTCAGTGGCTGCCATGGTCTACCCTTTCACTGGGGACCAC
                 AAGCAGAAGTTTTACTGGGGGCACAAAGAGATCCTGATCCCTGTCTTCAAGAACATGG
                 CTGATGCCATGAGGAAGCACCCGGAGGTAGATGTGCTCATCAACTTTGCCTCTCTCCG
                 CTCTGCCTATGACAGCACCATGGAGACCATGAACTATGCCCAGATCCGGACCATCGCC
                 ATCATAGCTGAAGGCATCCCTGAGGCCCTCACGAGAAAGCTGATCAAGAAGGCGGACC
                 AGAAGGGAGTGACCATCATCGGACCTGCCACTGTTGGAGGCATCAAGCCTGGGTGCTT
                 TAAGATTGGCAACACAGGTGGGATGCTGGACAACATCCTGGCCTCCAAACTGTACCGC
                 CCAGGCAGCGTGGCCTATGTCTCACGTTCCGGAGGCATGTCCAACGAGCTCAACAATA
                 TCATCTCTCGGACCACGGATGGCGTCTATGAGGGCGTGGCCATTGGTGGGGACAGGTA
                 CCCGGGCTCCACATTCATGGATCATGTGTTACGCTATCAGGACACTCCAGGAGTCAAA
                 ATGATTGTGGTTCTTGGAGAGATTGGGGGCACTGAGGAATATAAGATTTGCCGGGGCA
                 TCAAGGACGGCCGCCTCACTAAGCCCATCGTCTGCTGGTGCATCGGGACGTGTGCCAC
                 CATGTTCTCCTCTGAGGTCCAGTTTGGCCATGCTGGAGCTTGTGCCAACCAGGCTTCT
                 GAAACTGCAGTAGCCAAGAACCAGGCTTTGAAGGAAGCAGGAGTGTTTGTGCCCCGGA
                 GCTTTGATGAGCTTGGAGAGATCATCCAGTCTGTATACGAAGATCTCGTGGCCAATGG
                 AGTCATTGTACCTGCCCAGGAGGTGCCGCCCCCAACCGTGCCCATGGACTACTCCTGG
                 GCCAGGGAGCTTGGTTTGATCCGCAAACCTGCCTCGTTCATGACCAGCATCTGCGATG
                 AGCGAGGACAGGAGCTCATCTACGCGGGCATGCCCATCACTGAGGTCTTCAAGGAAGA
                 GATGGGCATTGGCCGGGTCCTCGGCCTCCTCTGGTTCCAGAAAAGGTTGCCTAAGTAC
                 TCTTGCCAGTTCATTGAGATGTGTCTGATGGTGACAGCTGATCACGGGCCAGCCGTCT
                 CTGGAGCCCACAACACCATCATTTGTGCGCGAGCTGGGAAAGACCTGGTCTCCAGCCT
                 CACCTCGGGGCTGCTCACCATCGGGGATCGGTTTGGGGGTGCCTTGGATGCAGCAGCC
                 AAGATGTTCAGTAAAGCCTTTGACAGTGGCATTATCCCCATGGAGTTTGTGAACAAGA
                 TGAAGAAGGAAGGGAAGCTGATCATGGGCATTGGTCACCGAGTGAAGTCGATAAACAA
                 CCCAGACATGCGAGTGCAGATCCTCAAAGATTACGTCAGGCAGCACTTCCCTGCCACT
                 CCTCTGCTCGATTATGCACTGGAAGTAGAGAAGATTACCACCTCGAAGAAGCCAAATC
                 TTATCCTGAATGTAGATGGTCTCATCGGAGTCGCATTTGTAGACATGCTTAGAAACTG
                 TGGGTCCTTTACTCGGGAGGAAGCTGATGAATATATTGACATTGGAGCCCTCAATGGC
                 ATCTTTGTGCTGGGAAGGAGTATGGGGTTCATTGGACACTATCTTGATCAGAAGAGGC
                 TGAAGCAGGGGCTGTATCGTCATCCGTGGGATGATATTTCATATGTTCTTCCGGAACA
                 CATGAGCATGT
                 ORF Start: at 2                  ORF Stop: end of sequence
                 SEQ ID NO: 236      1106 aa      MW at 121268.4kD
NOV15f,          QNSTMSAKAISEQTGKELLYKFICTTSAILQNRFKYARVTPDTDWARLLQDHPWLLSQN
256388552
Protein Sequence LVVKPDQLIKRRGKLGLVGVNLTLDGVKSWLKPRLGQEATVGKATGFLKNFLIEPFVP
                 HSQAEEFYVCIYATREGDYVLFHHEGGVDVGDVDAKAQKLLVGVDEKLNPEDIKKHLL
                 VHAPEDKKETLASFISGLFNFYEDLYFTYLEINPLVVTKDGVYVLDLAAKVDATADYI
                 CKVKWGDIEFPPPFGREAYPEEAYIADLDAKSGASLKLTLLNPKCRIWTMVAGGGASV
                 VYSDTICDLGGVNELANYGEYSGAPSEQQTYDYAKTILSLMTREKHPDGKILIIGGSI
                 ANFTNVAATFKGIVRAIRDYQGPLKEHEVTIFVRRGGPNYQEGLRVMGEVGKTTGIPT
                 HVFGTETHMTAIVGMALGHRPIPNQPPTAAHTANFLLNASGSTSTPAPSRTASFSESR
                 ADEVAPAKKAKPAMPQDSVPSPRSLQGKSTTLFSRHTKAIVWGMQTRAVQGMLDFDYV
                 CSRDEPSVAAMVYPFTGDHKQKFYWGHKEILIPVFKNMADAMRKHPEVDVLINFASLR
                 SAYDSTMETMNYAQIRTIAIIAEGIPEALTRKLIKKADQKGVTIIGPATVGGIKPGCF
                 KIGNTGGMLDNILASKLYRPGSVAYVSRSGGMSNELNNIISRTTDGVYEGVAIGGDRY
                 PGSTFMDHVLRYQDTPGVKMIVVLGEIGGTEEYKICRGIKEGRLTKPIVCWCIGTCAT
                 MFSSEVQFGHAGACANQASETAVAKNQALKEAGVFVPRSFDELGEIIQSVYEDLVANG
                 VIVPAQEVPPPTVPMDYSWARELGLIRKPASFMTSICDERGQELIYAGMPITEVFKEE
                 MGIGGVLGLLWFQKRLPKYSCQFIEMCLMVTADHGPAVSGAHNTIICARAGKDLVSSL
                 TSGLLTIGDRFGGALDAAAKMFSKAFDSGIIPMEFVNKMKKEGKLIMGIGHRVKSINN
                 PDMRVQILKDYVRQHFPATPLLDYALEVEKITTSKKPNLILNVDGLIGVAFVDMLRNC
                 GSFTREEADEYIDIGALNGIFVLGRSMGFIGHYLDQKRLKQGLYRHPWDDISYVLPEH
                 SEQ ID NO: 237      3307 bp
NOV15g,          CCAGAATTCCACCATGTCGGCCAAGGCAATTTCAGAGCAGACGGGCAAAGAACTCCTT
256420210
DNA Sequence     TACAAGTTCATCTGTACCACCTCAGCCATCCAGAATCGGTTCAAGTATGCTCGGGTCA
                 CTCCTGACACAGACTGGGCCCGCTTGCTGCAGGACCACCCCTGGCTGCTCAGCCAGAA
                 CTTGGTAGTCAAGCCAGACCAGCTGATCAAACGTCGTGGAAAACTTGGTCTCGTTGGG
                 GTCAACCTCACTCTGGATGGGGTCAAGTCCTGGCTGAAGCCACGGCTGGGACAGGAAG
                 CCACAGTTGGCAAGGCCACAGGCTTCCTCAAGAACTTTCTGATCGAGCCCTTCGTCCC
                 CCACAGTCAGGCTGAGGAGTTCTATGTCTGCATCTATGCCACCCGAGAAGGGGACTAC
                 GTCCTGTTCCACCACGAGGGGGGTGTGGACGTGGGTGATGTGGACGCCAAGGCCCAGA
                 AGCTGCTTGTTGGCGTGGATGAGAAACTGAATCCTGAGGACATCAAAAAACACCTGTT
                 GGTCCACGCCCCTGAAGACAAGAAAGAAATTCTGGCCAGTTTTATCTCCGGCCTCTTC
                 AATTTCTACGAGGACTTGTACTTCACCTACCTCGAGATCAATCCCCTTGTAGTGACCA
                 AAGATGGAGTCTATGTCCTTGACTTGGCGGCCAAGGTGGACGCCACTGCCGACTACAT
                 CTGCAAAGTGAAGTGGGGTGACATCGAGTTCCCTCCCCCCTTCGGCCGGGAGGCATAT
                 CCAGAGGAAGCCTACATTGCAGACCTCGATGCCAAAAGTGGGGCAAGCCTGAAGCTGA
                 CCTTCCTGAACCCCAAAGGGAGGATCTGGACCATGGTGGCCGGGGGTGGCGCCTCTCT
                 CGTGTACAGCGATACCATCTGTGATCTAGGGGGTGTCAACGAGCTGGCAAACTATGGG
                 GAGTACTCAGGCGCCCCCAGCGAGCAGCAGACCTATGACTATGCCAAGACTATCCTCT
                 CCCTCATGACCCGAGAGAAGCACCCAGATGGCAAGATCCTCATCATTGGAGGCAGCAT
                 CGCAAACTTCACCAACGTGGCTGCCACGTTCAAGGGCATCGTGAGAGCAATTCGAGAT
                 TACCAGGGCCCCCTGAAGGAGCACGAAGTCACAATCTTTGTCCGAAGAGGTGGCCCCA
                 ACTATCAGGAGGGCTTACGGGTGATGGGAGAAGTCGGGAAGACCACTGGGATCCCCAT
                 CCATGTCTTTGGCACAGAGACTCACATGACGGCCATTGTGGGCATGGCCCTGGGCCAC
                 CGGCCCATCCCCAACCAGCCACCCACAGCGGCCCACACTGCAAACTTCCTCCTCAACG
                 CCAGCGGGAGCACATCGACGCCAGCCCCCAGCAGGACAGCATCTTTTTCTGAGTCCAG
                 GGCCGATGAGGTGGCGCCTGCAAAGAAGGCCAAGCCTGCCATGCCACAAGGAAAGAGC
                 ACCACCCTCTTCAGCCGCCACACCAAGGCCATTGTGTGGGGCATGCAGACCCGGGCCG
                 TGCAAGGCATGCTGGACTTTGACTATGTCTGCTCCCGAGACGAGCCCTCAGTGGCTGC
                 CATGGTCTACCCTTTCACTGGGGACCACAAGCAGAAGTTTTACTGGGGGCACAAAGAG
                 ATCCTGATCCCTGTCTTCAAGAACATGGCTGATGCCATGAGGAAGCACCCGGAGGTAG
                 ATGTGCTCATCAACTTTGCCTCTCTCCGCTCTGCCTATGACAGCACCATGGAGACCAT
                 GAACTATGCCCAGATCCGGACCATCGCCATCATAGCTGAAGGCATCCCTGAGGCCCTC
                 ACGAGAAAGCTGATCAAGAAGGCGGACCAGAAGGGAGTGACCATCATCGGACCTGCCA
                 CTGTTGAGGCATCAAGCCTGGGTGCTTTAAGATTGGCAACACAGGTGGGATGCTGGA
                 CAACATCCTGGCCTCCAAACTGTACCGCCCAGGCAGCGTGGCCTATGTCTCACGTTCC
                 GGAGGCATGTCCAACGAGCTCAACAATATCATCTCTCGGACCACGGATGGCGTCTATG
                 AGGGCGTGGCCATTGGTGGGGACAGGTACCCGGGCTCCACATTCATGCATCATGTGTT
                 ACGCTATCAGGACACTCCACGAGTCAAAATGATTGTGGTTCTTGGAGAGATTGGGGGO
                 ACTGAGGAATATAAGATTTCCCGGGGCATCAAGGAGGGCCGCCTCACTAAGCCCATCG
                 TCTGCTGGTGCATCGGGACGTGTGCCACCATGTTCTCCTCTGAGGTCCAGTTTGGCCA
                 TGCTGGAGCTTGTGCCAACCAGGCTTCTGAAACTGCAGTAGCCAAGAACCAGGCTTTG
                 AAGGAAGCAGGAGTGTTTGTGCCCCGGAGCTTTGATGAGCTTGGAGAGATCATCCAGT
                 CTGTATACGAAGATCTCGTGGCCAATGGAGTCATTGTACCTGCCCAGGAGGTGCCGCC
                 CCCAACCGTGCCCATGGACTACTCCTGGGCCAGGGAGCTTGGTTTGATCCGCAAACCT
                 GCCTCGTTCATGACCAGCATCTGCGATGAGCGAGGACAGGAGCTCATCTACGCGGGCA
                 TGCCCATCACTGAGGTCTTCAAGGAAGAGATGGGCATTGGCGGGGTCCTCGGCCTCCT
                 CTGGTTCCAGAAAAGGTTGCCTAAGTACTCTTCCCAGTTCATTGAGATGTGTCTGATG
                 GTGACAGCTGATCACGGGCCAGCCGTCTCTGGAGCCCACAACACCATCATTTGTGCGC
                 GAGCTGGGAAAGACCTGGTCTCCAGCCTCACCTCGGGGCTGCTCACCATCGGGGATCG
                 GTTTGGGGGTGCCTTGGATGCAGCAGCCAAGATGTTCAGTAAAGCCTTTGACAGTGGC
                 ATTATCCCCATGGAGTTTGTGAACAAGATCAACAAGGAAGCGAAGCTGATCATGGGCA
                 TTGGTCACCGAGTGAAGTCGATAAACAACCCAGACATGCGAGTGCAGATCCTCAAAGA
                 TTACGTCAGGCAGCACTTCCCTGCCACTCCTCTGCTCGATTATGCACTGGAAGTAGAG
                 AAGATTACCACCTCGAAGAAGCCAAATCTTATCCTGAATGTAGATGGTCTCATCGGAG
                 TCGCATTTGTAGACATGCTTAGAAACTGTGGGTCCTTTACTCGGGAGGAAGCTGATGA
                 ATATATTGACATTGGAGCCCTCAATGGCATCTTTGTGCTGGGAAGGAGTATGGGGTTC
                 ATTGGACACTATCTTGATCAGAAGAGGCTGAAGCAGGGGCTGTATCGTCATCCGTGGG
                 ATGATATTTCATATGTTCTTCCGGAACACATGAGCATGTAAGCGGCCGCTTTTTTCCT
                 ORF Start: at 2                  ORF Stop: TAA at 3287
                 SEQ ID NO: 238      1095 aa      MW at 120201.2kD
NOV15g,          QNSTMSAKAISEQTGKELLYKFICTTSAIQNRFKYARVTPDTDWARLLQDNPWLLSQN
256420210
Protein Sequence LVVKPDQLIKRRGKLGLVGVNLTLDGVKSWLKPRLGQEATVGKATGFLKNFLIEPFVP
                 HSQAEEFYVCIYATREGDYVLFHHEGGVDVGDVDAKAQKLLVGVDEKLNPEDIKKHLL
                 VHAPEDKKEILASFISGLFNFYEDLYFTYLEINPLVVTKDGVYVLDLAAKVDATADYI
                 CKVKWGDIEFPPPFGREAYPEEAYIADLDAKSGASLKLTLLNPKGRIWTMVAGGGASV
                 VYSDTICDLGGVNELANYGEYSGAPSEQQTYDYAKTILSLMTREKHPDGKILIIGGSI
                 ANFTNVAATFKGIVPAIRDYQGPLKEHEVTIFVRRGGPNYQEGLRVMGEVGKTTGIPI
                 HVFGTETHMTAIVGMALGHRPIPNQPPTAAHTANFLLNASGSTSTPAPSRTASFSESR
                 ADEVAPAKKAKPAMPQGKSTTLFSRHTKAIVWGMQTRAVQGMLDFDYVCSRDEPSVAA
                 MVYPFTGDHKQKFYWGHKEILIPVFKNMADAMRKHPEVDVLINFASLRSAYDSTMETM
                 NYAQIRTIAIIAEGIPEALTRKLIKKADQKGVTIIGPATVGGIKPGCFKIGNTGGMLD
                 NILASKLYRPGSVAYVSRSGGMSNELNNIISRTTDGVYEGVAIGGDRYPGSTFMDHVL
                 RYQDTPGVKMIVVLGEIGGTEEYKICRGIKEGRLTKPIVCWCIGTCATMFSSEVQFCH
                 AGACANQASETAVAKNQALKEAGVFVPRSFDELGEIIQSVYEDLVANGVIVPAQEVPP
                 PTVPMDYSWARELGLIRKPASFMTSICDERGQELIYAGMPITEVFKEEMGIGGVLGLL
                 WFQKRLPKYSCQFIEMCLMVTADHGPAVSGAHNTIICARAGKDLVSSLTSGLLTIGDR
                 FGGALDAAAKMFSKAFDSGIIPMEFVNKMKKEGKLIMGIGHRVKSINNPDMRVQILKD
                 YVRQHFPATPLLDYALEvEKITTSKKPNLILNVDGLIGVAFVDMLRNCGSFTREEADE
                 YIDIGALNGIFVLGRSMCFIGHYLDQKRLKQGLYRHPWDDISYVLPEHMSM
                 SEQ ID NO: 239      2290 bp
NOV15h,          CCAGAATTCCACCATGTCGGCCAAGGCAATTTCAGAGCAGACGGGCAAAGAACTCCTT
256202925
DNA Sequence     TACAAGTTCATCTGTACCACCTCAGCCATCCAGAATCGGTTCAAGTATGCTCGGGTCA
                 CTCCTGACACAGACTGGGCCCGCTTGCTGCAGGACCACCCCTGGCTGCTCAGCCAGAA
                 CTTGGTAGTCAAGCCAGACCAGCTGATCAAACGTCGTGGAAAACTTGGTCTCGTTGGG
                 GTCAACCTCACTCTGGATGGGGTCAAGTCCTGGCTGAAGCCACGGCTGGGACAGGAAG
                 CCACAGTGAGTGGGCATGGGGTCAAGATGAACGTGTGTGGTAACAGAAGCAAATATGG
                 TCACCTTCAGGTTGGCAAGGCCACAGGCTTCCTCAAGAACTTTCTGATCGAGCCCTTC
                 GTCCCCCACAGTCAGGCTGAGGAGTTCTATGTCTGCATCTATGCCACCCGAGAAGGGG
                 ACTACGTCCTGTTCCACCACGAGGGGGGTGTGGACGTGGGTGATGTGGACGCCAAGGC
                 CCAGAAGCTGCTTGTTGGCGTGGATGAGAAACTGAATCCTGAGGACATCAAAAAACAC
                 CTGTTGGTCCACGCCCCTGAAGACAAGAAAGAAATTCTGGCCAGTTTTATCTCCGGCC
                 TCTTCAATTTCTACGAGGACTTGTACTTCACCTACCTCGAGATCAATCCCCTTGTAGT
                 GACCAAAGATGGAGTCTATGTCCTTGACTTGGCGGCCAAGGTGGACGCCACTGCCGAC
                 TACATCTGCAAAGTGAAGTGGGGTGACATCGAGTTCCCTCCCCCCTTCGGGCGGGAGG
                 CATATCCAGAGGAAGCCTACATTGCAGACCTCGACGCCAAAAGTGGGGCAAGCCTGAA
                 GCTGACCTTGCTGAACCCCAAAGGGAGGATCTGGACCATGGTGGCCGGGGGTGGCGCC
                 TCTGTCGTGTACAGCGATACCATCTGTGATCTAGGGGGTGTCAACGAGCTGGCAAACT
                 ATGGGGAGTACTCAGGCGCCCCCAGCGAGCAGCAGACCTATGACTATGCCAAGACTAT
                 CCTCTCCCTCATGACCCGAGAGAAGCACCCAGATGGCAAGATCCTCATCATTGGAGGC
                 AGCATCGCAAACTTCACCAACGTGGCTGCCACGTTCAAGGGCATCGTGAGAGCAATTC
                 GAGATTACCAGGGCCCCCTGAAGGAGCACGAAGTCACAATCTTTGTCCGAAGAGGTGG
                 CCCCAACTATCAGGAGGGCTTACGGGTGATGGGAGAAGTCGGGAAGACCACTGGGATC
                 CCCATCCATGTCTTTGGCACAGAGACTCACATGACGGCCATTGTGGGCATGGCCCTGG
                 GCCACCGGCCCATCCCCAACCAGCCACCCACAGCGGCCCACACTGCAAACTTCCTCCT
                 CAACGCCAGCGGGAGCACATCGACGCCAGCCCCCAGCAGGACAGCATCTTTTTCTGAG
                 TCCAGGGCCGATCAGGTGGCGCCTGCAAAGAAGGCCAAGCCTGCCATGCCACAAGGAA
                 AGAGCACCACCCTCTTCAGCCGCCACACCAAGGCCATTGTGTGGGGCATGCAGACCCG
                 GGCCGTGCAAGGCATGCTGGACTTTGACTATGTCTGCTCCCGAGACGAGCCCTCAGTG
                 GCTGCCATGGTCTACCCTTTCACTGGGGACCACAAGCAGAAGTTTTACTGGGGGCACA
                 AAGAGATCCTGATCCCTGTCTTCAAGAACATGGCTGATGCCATGAGGAAGCACCCGGA
                 GGTAGATGTGCTCATCAACTTTGCTTCTCTCCGCTCTGCCTTGGATGCAGCAGCCAAG
                 ATGTTCAGTAAAGCCTTTGACAGTGGCATTATCCCCATGGAGTTTGTGAACAAGATGA
                 AGAAGGAAGGGAAGCTGATCATGGGCATTGGTCACCGAGTGAAGTCGATAAACAACCC
                 AGACATGCGAGTGCGGATCCTCAAAGATTACGTCAGGCAGCACTTCCCTGCCACTCCT
                 CTGCTCGATTATGCACTGGAAGTAGAGAACATTACCACCTCGAAGAAGCCAAATCTTA
                 TCCTGAATGTAGATGGTCTCATCGGAGTCGCATTTGTAGACATGCTTAGAAACTGTGG
                 GTCCTTTACTCGGGAGGAAGCTGATGAATATATTGACATTGGAGCCCTCAATGGCATC
                 TTTGTGCTGGGAAGGAGTATGGGGTTCATTGGACACTATCTTGATCAGAAGAGGCTGA
                 AGCAGGGGCTGTATCGTCATCCGTGGGATGATATTTCATATGTTCTTCCGGAACACAT
                 GAGCATGTAAGCGGCCGCTTTTTTCCTT
                 ORF Start: at 2                  ORF Stop: TAA at 2270
                 SEQ ID NO: 240       756 aa      MW at 83890.7kD
NOV15h,          QNSTMSAKAISEQTGKELLYKFICTTSAIQNRFKYARVTPDTDWARLLQDHPWLLSQN
256202925
Protein Sequence LVVKPDQLIKRRGKLGLVGVNLTLDGVKSWLKPRLGQEATVSGHGVKMNVCGNRSKYG
                 HLQVGKATGFLKNFLIEPFVPHSQAEEFYVCIYATREGDYVLFHHEGGVDVGDVDAKA
                 QKLLVGVDEKLNPEDIKKHLLVHAPEDKKEILASFISGLFNFYEDLYFTYLEINPLVV
                 TKDGVYVLDLAAKVDATADYICKVKWGDIEFPPPFGREAYPEEAYIADLDAKSGASLK
                 LTLLNPKGRIWTMVAGGGASVVYSDTICDLGGVNELANYGEYSGAPSEQQTYDYAKTI
                 LSLMTREKHPDGKILIIGGSIANFTNVAATFKGIVRAIRDYQGPLKEHEVTIFVRRGG
                 PNYQEGLRVMGEVGKTTGIPIHVFGTETHMTAIVGMALGHRPIPNQPPTAAHTANFLL
                 NASGSTSTPAPSRTASFSESRADEVAPAKKAKPAIVTPQGKSTTLFSRHTKAIVWGMQTR
                 AVQGMLDFDYVCSRDEPSVAAMVYPFTGDHKQKFYWGHKEILIPVFKNMADANRKHPE
                 VDVLINFASLRSALDAAAKMFSKAFDSGIIPMEFVNKMKKEGKLIMGIGHRVKSINNP
                 DMRVRILKDYVRQHFPATPLLDyALEVEKITTSKKPNLILNVDGLIGVAFVDMLRNCG
                 SFTREEADEYIDIGALNGIFVLGRSMGFIGHYLDQKRLKQGLYRHPWDDISYXTLPEHM
                 SM
                 SEQ ID NO: 241      3310 bp
NOV5j,           CACCATGTCGGCCAAGGCAATTTCAGAGCAGACGGGCAAAGAACTCCTTTACAAGTTC
259856081
DNA Sequence     ATCTGTACCACCTCAGCCATCCAGAATCGGTTCAAGTATGCTCGGGTCACTCCTGACA
                 CAGACTGGGCCCGCTTGCTGCAGGACCACCCCTGGCTGCTCAGCCAGAACTTGGTAGT
                 CAAGCCAGACCAGCTGATCAAACGTCGTGGAAAACTTGGTCTCGTTGGGGTCAACCTC
                 ACTCTGGATGGGGTCAAGTCCTGGCTGAAGCCACGGCTGGGACAGGAAGCCACAGTTG
                 GCAAGGCCACAGGCTTCCTCAAGAACTTTCTGATCGAGCCCTTCGTCCCCCACAGTCA
                 GGCTGAGGAGTTCTATGTCTGCATCTATGCCACCCGAGAAGGGGACTACGTCCTGTTC
                 CACCACGAGGGGGGTGTGGACGTGGGTGATGTGGACGCCAAGGCCCAGAAGCTGCTTG
                 TTGGCGTGGATGAGAAACTGAATCCTGAGGACATCAAAAAACACCTGTTGGTCCACGC
                 CCCTGAAGACAAGAAAGAAATTCTGGCCAGTTTTATCTCCGGCCTCTTCAATTTCTAC
                 GAGGACTTGTACTTCACCTACCTCGAGATCAATCCCCTTGTAGTGACCAAAGATGGAG
                 TCTATGTCCTTGACTTGGCGGCCAAGGTGGACGCCACTGCCGACTACATCTGCAAAGT
                 GAAGTCGGGTGACATCGAGTTCCCTCCCCCCTTCGGGCGGGAGGCATATCCAGAGGAA
                 GCCTACATTGCAGACCTCGATGCCAAAAGTGGGGCAAGCCTGAAGCTGACCTTGCTGA
                 ACCCCAAAGGGAGGATCTGGACCATGGTGGCCGGGGGTGGCGCCTCTGTCGTGTACAG
                 CGATACCATCTGTGATCTAGGGGGTGTCAACGAGCTGGCAAACTATGGGGAGTACTCA
                 GGCGCCCCCAGCGAGCAGCAGACCTATGATTATGCCAAGACTATCCTCTCCCTCATGA
                 CCCGAGAGAAGCACCCAGATGGCAAGATCCTCATCATTGGAGCCAGCATCGCAAACTT
                 CACCAACGTGGCTGCCACGTTCAAGGGCATCGTGAGAGCAATTCGAGATTACCAGGGC
                 CCCCTGAAGGAGCACGAAGTCACAATCTTTGTCCGAAGAGGTGGCCCCAACTATCAGG
                 AGGGCTTACGGGTGATGGGAGAAGTCGGGAAGACCACTGGGATCCCCATCCATGTCTT
                 TGGCACAGAGACTCACATGACGGCCATTGTGGGCATGGCCCTGGGCCACCGGCCCATC
                 CCCAACCAGCCACCCACAGCGGCCCACACTGCAAACTTCCTCCTCAACGCCAGCGGGA
                 GCACATCGACGCCAGCCCCCAGCAGGACAGCATCTTTTTCTGAGTCCAGGGCCGATGA
                 GGTGGCGCCTGCAAAGAAGGCCAAGCCTGCCATGCCACAAGATTCAGTCCCAAGTCCA
                 AGATCCCTGCAAGGAAAGAGCACCACCCTCTTCAGCCGCCACACCAAGGCCATTGTGT
                 GGGGCATGCAGACCCCGGCCCTGCAAGGCATGCTGGACTTTGACTATGTCTGCTCCCC
                 AGACGAGCCCTCAGTGGCTGCCATGGTCTACCCTTTCACTGGGGACCACAAGCAGAAG
                 TTTTACTGGGGGCACAAAGAGATCCTGATCCCTGTCTTCAAGAACATGGCTGATGCCA
                 TGAGGAAGCACCCGGAGGTAGATGTGCTCATCAACTTTGCCTCTCTCCGCTCTGCCTA
                 TGACAGCACCATGGAGACCATGAACTATGCCCAGATCCCGACCATCGCCATCATAGCT
                 GAAGGCATCCCTGAGGCCCTCACCAGAAAGCTGATCAAGAAGCCGGACCAGAAGGGAG
                 TGACCATCATCGGACCTGCCACTGTTGGAGGCATCAAGCCTGGGTGCTTTAAGATTGG
                 CAACACAGGTGGGATGCTGGACAACATCCTGGCCTCCAAACTGTACCGCCCAGGCAGC
                 GTGGCCTATGTCTCACGTTCCGGAGGCATGTCCAACGAGCTCAACAATATCATCTCTC
                 GGACCACGGATGGCGTCTATCAGGGCGTGGCCATTGGTGGGGACAGGTACCCCGGCTC
                 CACATTCATGGATCATGTGTTACGCTATCAGGACACTCCAGGAGTCAAAATGATTGTG
                 GTTCTTGGAGAGATTGGGGGCACTGAGGAATATAAGATTTGCCGCGGCATCAAGGAGG
                 GCCGCCTCACTAAGCCCATCGTCTGCTGGTGCATCGGGACGTGTGCCACCATGTTCTC
                 CTCTGAGGTCCAGTTTGGCCATGCTGGAGCTTGTGCCAACCAGGCTTCTGAAACTGCA
                 GTAGCCAAGAACCAGGCTTTGAAGGAAGCAGGAGTGTTTGTGCCCCGGAGCTTTGATG
                 AGCTTGGAGAGATCATCCAGTCTGTATACGAAGATCTCGTGGCCAATGGAGTCATTGT
                 ACCTGCCCAGGAGGTGCCGCCCCCAACCGTGCCCATGGACTACTCCTGGGCCAGGGAG
                 CTTGGTTTGATCCGCAAACCTGCCTCGTTCATGACCAGCATCTGCGATGAGCGAGGAC
                 AGGAGCTCATCTACGCGGGCATGCCCATCACTGAGGTCTTCAAGGAAGAGATGGGCAT
                 TGGCGGGGTCCTCGGCCTCCTCTGGTTCCAGAAAAGGTTGCCTAAGTACTCTTGCCAG
                 TTCATTGAGATGTGTCTGATGGTGACAGCTGATCACGGGCCAGCCGTCTCTGGAGCCC
                 ACAACACCATCATTTGTGCGCGAGCTGGGAAAGACCTGGTCTCCAGCCTCACCTCGGG
                 GCTGCTCACCATCGGGGATCGGTTTGGGGGTGCCTTGGATGCAGCAGCCAAGATGTTC
                 AGTAAAGCCTTTGACAGTGGCATTATCCCCATGGAGTTTGTGAACAAGATGAAGAAGG
                 AAGGGAAGCTGATCATGGGCATTGGTCACCGAGTGAAGTCGATAAACAACCCAGACAT
                 GCGAGTGCAGATCCTCAAAGATTACGTCAGGCAGCACTTCCCTGCCACTCCTCTGCTC
                 GATTATGCACTGGAAGTAGAGAAGATTACCACCTCGAAGAAGCCAAATCTTATCCTGA
                 ATGTAGATGGTCTCATCGGAGTCCCATTTGTAGACATGCTTAGAAACTGTGGGTCCTT
                 TACTCGGGAGGAAGCTGATGAATATATTGACATTGGAGCCCTCAATGGCATCTTTGTG
                 CTGGGAAGGAGTATGGGGTTCATTGGACACTATCTTGATCAGAAGAGGCTGAAGCAGG
                 CGCTGTATCGTCATCCGTGCGATGATATTTCATATGTTCTTCCGGAACACATGACCAT
                 GTAA
                 ORF Start: at 2                  ORF Stop: TAA at 3308
NOV15i,          TMSAKAISEQTGKELLYKFICTTSAIQNRFKYARVTPDTDWARLLQDHPWLLSQNLVV
259856081
Protein Sequence KPDQLIKRRGKLGLVGVNLTLDGVKSWLKPRLGQEATVGKATGFLKNFLIEPFVPHSQ
                 AEEFYVCIYATREGDYVLFNHEGGVDVGDVDAKAQKLLVGVDEKLNPEDIKKHLLVHA
                 PEDKKEILASFISGLFNFYEDLYFTYLEINPLVVTKDGVYVLDLAAKVDATADYICKV
                 KWGDIEFPPPFGREAYPEEAYIADLDAKSGASLKLTLLNPKGRIWTMVAGGGASVVYS
                 DTICDLGGVNELANYGEYSGAPSEQQTYDYAKTILSLMTREKHPDGKILIIGGSIANF
                 TNVAATFKGIVRAIRDYQGPLKEHEVTIFVRRGGPNYQEGLRVMGEVGKTTGIPIHVF
                 GTETHMTAIVGMALGHRPIPNQPPTAAHTANFLLNASGSTSTPAPSRTASFSESRADE
                 VAPAKKAKPAMPQDSVPSPRSLQGKSTTLFSRHTKAIVWGMQTRAVQGMLDFDYVCSR
                 DEPSVAAMVYPFTGDHKQKFYWGHKEILIPVFKNMADAMRKHPEVDVLINFASLRSAY
                 DSTMETMNYAQIRTIAIIAEGIPEALTRKLIKKADQKGVTIIGPATVGGIKPGCFKIG
                 NTGGMLDNILASKLYRPGSVAYVSRSGGMSNELNNIISRTTDGVYEGVAIGGDRYPGS
                 TFMDHVLRYQDTPGVKMIXTVLGEIGGTEEYKICRGIKEGRLTKPIVCWCIGTCATMFS
                 SEVQFGHAGACANQASETAVAKNQALKEAGVFVPRSFDELGEIIQSVYEDLVANGVIV
                 PAQEVPPPTVPMDYSWARELGLIRKPASFMTSICDERGQELIYAGMPITEVFKEEMGI
                 GGVLGLLWFQKRLPKYSCQFIEMCLMVTADHGPAVSGAHNTIICARAGKDLVSSLTSG
                 LLTIGDRFGGALDAAAKNFSKAFDSGIIPMEFVNKMKKEGKLIMGIGHRVKSINNPDM
                 RVQILKDYVRQHFPATPLLDYALEVEKITTSKKPNLILNVDGLIGVAFVDMLRNCGSF
                 TREEADEYTDIGALNGIFVLGRSMGFIGHYLDQKRLKQGLYRHPWDDISYVLPEHMSM
                 SEQ ID NO: 243      3317 bp
NOV15j,          CCAGAATTCCACCATGTCGGCCAAGGCAATTTCAGAGCAGACGGGCAAAGAACTCCTT
256388552
DNA Sequence     TACAAGTTCATCTGTACCACCTCAGCCATCCAGAATCGGTTCAAGTATGCTCGGGTCA
                 CTCCTGACACAGACTGGGCCCGCTTGCTGCAGGACCACCCCTGGCTGCTCAGCCAGAA
                 CTTGGTAGTCAAGCCAGACCAGCTGATCAAACGTCGTGGAAAACTTGGTCTCGTTGGG
                 GTCAACCTCACTCTGGATGGGGTCAAGTCCTGGCTGAAGCCACGGCTGGGACAGGAAG
                 CCACAGTTGGCAAGGCCACAGGCTTCCTCAAGAACTTTCTGATCGAGCCCTTCGTCCC
                 CCACAGTCAGGCTGAGGAGTTCTATGTCTGCATCTATGCCACCCGAGAAGGGGACTAC
                 GTCCTGTTCCACCACGAGGCGGGTGTGGACGTGGGTGATGTGGACGCCAACGCCCAGA
                 AGCTGCTTGTTGGCGTGGATGAGAAACTGAATCCTGAGGACATCAAAAAACACCTGTT
                 GGTCCACGCCCCTGAAGACAAGAAAGAAATTCTGGCCAGTTTTATCTCCGGCCTCTTC
                 AATTTCTACGAGGACTTGTACTTCACCTACCTCGAGATCAATCCCCTTGTAGTGACCA
                 AAGATGGAGTCTATGTCCTTGACTTGGCGGCCAAGGTGGACGCCACTGCCGACTACAT
                 CTGCAAAGTGAAGTGGGGTGACATCGAGTTCCCTCCCCCCTTCGGGCGGGAGGCATAT
                 CCAGAGGAAGCCTACATTGCAGACCTCGATGCCAAAAGTGGGGCAAGCCTGAAGCTGA
                 CCTTGCTGAACCCCAAAGGGAGGATCTGGACCATGCTGGCCGGGGGTGGCGCCTCTGT
                 CGTGTACAGCGATACCATCTGTGATCTAGGGGGTGTCAACGAGCTGGCAAACTATGGG
                 GAGTACTCAGGCGCCCCCAGCGAGCAGCAGACCTATGATTATGCCAAGACTATCCTCT
                 CCCTCATGACCCGAGAGAAGCACCCAGATGGCAAGATCCTCATCATTGGAGGCAGCAT
                 CGCAAACTTCACCAACGTGGCTGCCACGTTCAAGGGCATCGTGAGAGCAATTCGAGAT
                 TACCAGGGCCCCCTGAAGGAGCACGAAGTCACAATCTTTGTCCGAAGAGGTGGCCCCA
                 ACTATCAGGAGGGCTTACGGGTGATGGGAGAAGTCGGGAAGACCACTGGGATCCCCAT
                 CCATGTCTTTGGCACAGAGACTCACATGACGGCCATTGTGGGCATGGCCCTGGGCCAC
                 CGGCCCATCCCCAACCAGCCACCCACAGCGGCCCACACTGCAAACTTCCTCCTCAACG
                 CCAGCGGGAGCACATCGACGCCAGCCCCCAGCAGGACAGCATCTTTTTCTGAGTCCAG
                 GGCCGATGAGGTGGCGCCTGCAAAGAAGGCCAAGCCTGCCATGCCACAAGATTCAGTC
                 CCAAGTCCAAGATCCCTGCAAGGAAAGAGCACCACCCTCTTCAGCCGCCACACCAAGG
                 CCATTGTGTGGGCCATGCAGACCCGGGCCGTGCAAGGCATGCTGGACTTTGACTATGT
                 CTGCTCCCGAGACGAGCCCTCAGTGGCTGCCATGGTCTACCCTTTCACTGGGGACCAC
                 AAGCAGAAGTTTTACTGGGGGCACAAAGAGATCCTGATCCCTGTCTTCAAGAACATGG
                 CTGATGCCATGAGGAAGCACCCGGAGGTAGATGTGCTCATCAACTTTGCCTCTCTCCG
                 CTCTGCCTATGACAGCACCATGGAGACCATGAACTATGCCCAGATCCGGACCATCGCC
                 ATCATAGCTGAAGGCATCCCTGAGGCCCTCACGAGA~AGCTGATCAAGAAGGCGGACC
                 AGAAGGGAGTGACCATCATCGGACCTGCCACTGTTGGAGGCATCAAGCCTGGGTGCTT
                 TAAGATTGGCAACACAGGTGGGATGCTGGACAACATCCTGGCCTCCAAACTGTACCGC
                 CCAGGCAGCGTCGCCTATGTCTCACGTTCCGGAGGCATGTCCAACGAGCTCAACAATA
                 TCATCTCTCGGACCACGGATGGCGTCTATGAGGGCGTGGCCATTGGTGGGGACAGGTA
                 CCCGGGCTCCACATTCATGGATCATGTGTTACGCTATCAGGACACTCCAGGAGTCAAA
                 ATGATTGTGGTTCTTGGAGAGATTGGGGGCACTGAGGAATATAAGATTTGCCGGGGCA
                 TCAAGGAGGGCCGCCTCACTAAGCCCATCGTCTGCTGGTCCATCGGGACGTGTGCCAC
                 CATGTTCTCCTCTGAGGTCCAGTTTGGCCATGCTGGAGCTTGTGCCAACCAGGCTTCT
                 GAAACTGCAGTAGCCAAGAACCAGGCTTTGAAGGAAGCAGGAGTGTTTGTGCCCCGGA
                 GCTTTGATGAGCTTGGAGAGATCATCCAGTCTGTATACGAAGATCTCGTGGCCAATGG
                 AGTCATTGTACCTGCCCAGGAGGTCCCGCCCCCAACCGTGCCCATGGACTACTCCTGG
                 GCCAGGGAGCTTGGTTTGATCCGCAAACCTGCCTCGTTCATGACCAGCATCTGCGATG
                 AGCGAGGACAGGAGCTCATCTACGCGGGCATGCCCATCACTGAGGTCTTCAAGGAAGA
                 GATGGGCATTGGCGGGGTCCTCGGCCTCCTCTGGTTCCAGAAAACGTTGCCTAAGTAC
                 TCTTGCCAGTTCATTGAGATGTGTCTGATGGTGACAGCTGATCACGGGCCAGCCGTCT
                 CTGGAGCCCACAACACCATCATTTGTGCGCGAGCTGGGAAAGACCTGGTCTCCAGCCT
                 CACCTCGGGGCTGCTCACCATCGGGGATCGGTTTGGGGGTGCCTTGGATGCAGCAGCC
                 AAGATGTTCAGTAAAGCCTTTGACAGTGGCATTATCCCCATGGAGTTTGTGAACAAGA
                 TGAAGAAGGAAGGGAAGCTGATCATGGGCATTGGTCACCGAGTGAAGTCGATAAACAA
                 CCCAGACATGCGAGTGCAGATCCTCAAAGATTACGTCAGGCAGCACTTCCCTGCCACT
                 CCTCTGCTCGATTATGCACTGGAAGTAGAGAAGATTACCACCTCGAAGAAGCCAAATC
                 TTATCCTGAATGTAGATGGTCTCATCGGAGTCGCATTTGTAGACATGCTTAGAAACTG
                 TGGGTCCTTTACTCGGGAGGAAGCTGATGAATATATTCACATTGGAGCCCTCAATGGC
                 ATCTTTGTGCTGGGAAGGAGTATGGGGTTCATTGGACACTATCTTGATCAGAAGAGGC
                 TGAAGCAGGGGCTGTATCGTCATCCGTGGGATGATATTTCATATGTTCTTCCGGAACA
                 CATGAGCATGT
                 ORF Start: at 2                  ORF Stop: end of sequence
                 SEQ ID NO: 244      1106 aa      MW at 121268.4kD
NOV15j,          QNSTMSAKAISEQTGKELLYKFICTTSAIQNRFKYARVTPDTDWARLLQDHPWLLSQN
256388552
Protein Sequence LVVKPDQLIKRRGKLGLVGVNLTLDGVKSWLKPRLGQEATVGKATGFLKNFLIEPFVP
                 HSQAEEFYVCIYATREGDYVLFHHEGGVDVGDVDAKAQKLLVGVDEKLNPEDIKKHLL
                 VHAPEDKKEILASFISGLFNFYEDLYFTYLEINPLVVTKDGVYVLDLAAKVDATADYI
                 CKVKWGDIEFPPPFGREAYPEEAYIADLDAKSGASLKLTLLNPKCRIWTMVAGGGASV
                 VYSDTICDLGGVNELANYGEYSGAPSEQQTYDYAKTILSLMTREKHPDGKILIIGGSI
                 ANFTNVAATFKGIVRAIRDYQGPLKEHEVTIFVRRGGPMYQEGLRVMGEVGKTTGIPI
                 HVFGTETHMTAIVGMALGHRPIPNQPPTAAHTANFLLNASGSTSTPAPSRTASFSESR
                 ADEVAPAKKAKPAMPQDSVPSPRSLQGKSTTLFSRHTKAIVWGMQTRAVQGMLDFDYV
                 CSRDEPSVAAMVYPFTGDHKQKFYWGHKEILIPVFKNMADAMRKHPEVDVLINFASLR
                 SAYDSTMETMNYAQIRTIAIIAEGIPEALTRKLIKKADQKGVTIIGPATVGGIKPGCF
                 KIGNTGGMLDNILASKLYRPGSVAYVSRSGGMSNELNNIISRTTDGVYEGVAIGCDRY
                 PGSTFMDHVLRYQDTPGVKMIVVLGEIGGTEEYKICRGIKEGRLTKPIVCWCIGTCAT
                 MFSSEVQFGHAGACANQASETAVAKNQALKEAGVFVPRSFDELGEIIQSVYEDLVANG
                 VIVPAQEVPPPTVPMDYSWARELGLIRKPASFMTSICDERGQELIYAGMPTTEVFKEE
                 MGIGGVLGLLWFQKRLPKYSCQFIEMCLMVTADHGPAVSGAHNTIICARAGKDLVSSL
                 TSGLLTIGDRFGGALDAAAKMFSKAFDSGIIPMEFVNKMKKEGKLIMGIGHRVKSINN
                 PDMRVQILKDYVRQHFPATPLLDYALEVEKITTSKKPNLILNVDGLIGVAFVDMLRNC
                 CSFTREEADEYIDIGALNGIFVLGRSMGFIGHYLDQKRLKQGLYRHPWDDISYVLPEH
                 SEQ ID NO: 245      3307 bp
NOV15k,          CCAGAATTCCACCATGTCCGCCAAGGCAATTTCAGAGCAGACGGGCAAAGAACTCCTT
256420210
DNA Sequence     TACAAGTTCATCTGTACCACCTCAGCCATCCAGAATCGGTTCAAGTATGCTCGGGTCA
                 CTCCTGACACAGACTGGGCCCGCTTGCTGCAGGACCACCCCTGGCTGCTCAGCCAGAA
                 CTTGGTAGTCAAGCCAGACCAGCTGATCAAACGTCGTGGAAAACTTGGTCTCGTTGGG
                 GTCAACCTCACTCTGGATGGGGTCAAGTCCTGGCTGAAGCCACGGCTGGGACAGCAAG
                 CCACAGTTGGCAAGGCCACAGGCTTCCTCAAGAACTTTCTGATCGAGCCCTTCGTCCC
                 CCACAGTCAGGCTGAGGAGTTCTATGTCTGCATCTATGCCACCCGAGAAGGGGACTAC
                 GTCCTGTTCCACCACGAGGGGGGTGTGGACGTGGGTGATGTGGACGCCAAGGCCCAGA
                 AGCTGCTTGTTGGCGTGGATGAGAAACTGAATCCTGAGGACATCAAAAAACACCTGTT
                 GGTCCACGCCCCTGAAGACAAGAAAGAAATTCTGGCCAGTTTTATCTCCGCCCTCTTC
                 AATTTCTACGAGGACTTGTACTTCACCTACCTCGAGATCAATCCCCTTGTAGTCACCA
                 AAGATGGAGTCTATGTCCTTGACTTGGCGGCCAAGGTGGACGCCACTGCCGACTACAT
                 CTGCAAAGTGAAGTGGGGTGACATCGAGTTCCCTCCCCCCTTCGGGCGGGAGGCATAT
                 CCAGAGGAAGCCTACATTGCAGACCTCGATGCCAAAAGTGGGGCAAGCCTGAAGCTGA
                 CCTTGCTGAACCCCAAAGGGAGGATCTGGACCATGGTGGCCGGGGGTGGCGCCTCTGT
                 CGTGTACAGCGATACCATCTGTGATCTAGGGGGTGTCAACGAGCTGGCAAACTATGGG
                 GAGTACTCAGGCGCCCCCAGCGAGCAGCAGACCTATGACTATGCCAAGACTATCCTCT
                 CCCTCATGACCCGAGAGAAGCACCCAGATGGCAAGATCCTCATCATTGGAGGCAGCAT
                 CGCAAACTTCACCAACGTGGCTGCCACGTTCAAGGGCATCGTGAGAGCAATTCGAGAT
                 TACCAGGGCCCCCTGAAGGAGCACGAAGTCACAATCTTTGTCCGAAGAGGTGGCCCCA
                 ACTATCAGGAGGGCTTACGGGTGATGGGAGAAGTCGGGAAGACCACTGGGATCCCCAT
                 CCATGTCTTTGGCACAGAGACTCACATGACGGCCATTGTGGGCATGGCCCTGGGCCAC
                 CGGCCCATCCCCAACCAGCCACCCACAGCGGCCCACACTGCAAACTTCCTCCTCAACG
                 CCAGCGGGAGCACATCGACGCCAGCCCCCAGCAGGACAGCATCTTTTTCTGAGTCCAG
                 GGCCGATGAGGTGGCGCCTGCAAAGAAGGCCAAGCCTGCCATGCCACAAGGAAAGAGC
                 ACCACCCTCTTCAGCCGCCACACCAACGCCATTGTGTGGGGCATGCAGACCCGGGCCG
                 TGCAAGGCATGCTGGACTTTCACTATGTCTGCTCCCGAGACGAGCCCTCAGTGGCTGC
                 CATGGTCTACCCTTTCACTGGGGACCACAAGCAGAAGTTTTACTGGGGGCACAAAGAG
                 ATCCTGATCCCTGTCTTCAAGAACATGGCTGATGCCATGAGGAAGCACCCGGAGGTAG
                 ATGTGCTCATCAACTTTGCCTCTCTCCGCTCTGCCTATGACAGCACCATGGAGACCAT
                 GAACTATGCCCAGATCCGGACCATCGCCATCATAGCTGAAGGCATCCCTGAGGCCCTC
                 ACGAGAAAGCTGATCAAGAAGGCGGACCAGAAGGGAGTGACCATCATCGGACCTGCCA
                 CTGTTGGAGGCATCAAGCCTGGGTGCTTTAAGATTGGCAACACAGGTGGGATGCTGGA
                 CAACATCCTGGCCTCCAAACTGTACCGCCCAGGCAGCGTGGCCTATGTCTCACGTTCC
                 GGAGGCATGTCCAACGAGCTCAACAATATCATCTCTCGGACCACGGATGGCGTCTATG
                 AGGGCGTGGCCATTGGTGGGGACAGGTACCCGGGCTCCACATTCATGGATCATGTGTT
                 ACGCTATCAGGACACTCCAGGAGTCAAAATGATTGTGGTTCTTGGAGAGATTGGGGGC
                 ACTGAGGAATATAAGATTTGCCGGGGCATCAAGGAGGGCCGCCTCACTAAGCCCATCG
                 TCTGCTGGTGCATCGGGACGTGTGCCACCATGTTCTCCTCTGAGGTCCAGTTTGGCCA
                 TGCTGGAGCTTGTGCCAACCAGGCTTCTGAAACTGCAGTAGCCAAGAACCAGGCTTTG
                 AAGGAAGCAGGAGTGTTTGTGCCCCGGAGCTTTGATGAGCTTGGAGAGATCATCCAGT
                 CTGTATACGAAGATCTCGTGGCCAATGGAGTCATTGTACCTGCCCAGGAGGTGCCGCC
                 CCCAACCGTGCCCATGGACTACTCCTGGGCCAGGGAGCTTGGTTTGATCCGCAAACCT
                 GCCTCGTTCATGACCAGCATCTGCGATGAGCGAGGACAGGAGCTCATCTACGCGGGCA
                 TGCCCATCACTGAGGTCTTCAAGGAAGAGATGGGCATTGGCGGGGTCCTCGGCCTCCT
                 CTGGTTCCAGAAAAGGTTGCCTAAGTACTCTTGCCAGTTCATTGAGATGTGTCTGATG
                 GTGACAGCTGATCACGGGCCAGCCGTCTCTGGAGCCCACAACACCATCATTTGTGCGC
                 GAGCTGGGAAAGACCTGGTCTCCAGCCTCACCTCGGGGCTGCTCACCATCGGGGATCG
                 GTTTGGCGGTGCCTTGGATGCAGCAGCCAACATGTTCAGTAAAGCCTTTGACAGTGGC
                 ATTATCCCCATGGAGTTTGTGAACAAGATGAAGAAGGAAGGGAAGCTGATCATGGGCA
                 TTGGTCACCCAGTGAAGTCGATAAACAACCCAGACATGCGAGTGCAGATCCTCAAAGA
                 TTACGTCAGGCAGCACTTCCCTGCCACTCCTCTGCTCGATTATGCACTGGAAGTAGAG
                 AAGATTACCACCTCGAAGAAGCCAAATCTTATCCTGAATGTAGATGGTCTCATCGGAG
                 TCGCATTTGTAGACATGCTTAGAAACTGTGGGTCCTTTACTCGGGAGGAAGCTGATGA
                 ATATATTGACATTGGAGCCCTCAATGGCATCTTTGTGCTGGGAAGGAGTATGGGGTTC
                 ATTGGACACTATCTTGATCAGAAGAGGCTGAAGCAGGGGCTGTATCGTCATCCGTGGG
                 ATGATATTTCATATGTTCTTCCGGAACACATGAGCATGTAAGCGGCCGCTTTTTTCCT
                 T
                 ORF Start: at 2                  ORF Stop: TAA at 3287
                 SEQ ID NO: 246      1095 aa      MW at 120201.2kD
NOV15k,          QNSTMSAKAISEQTGKELLYKFICTTSAIQNRFKYARVTPDTDWARLLQDHPWLLSQN
256420210
Protein Sequence LVVKPDQLIKRRGKLGLVGVNLTLDGVKSWLKPRLGQEATVGKATGFLKNFLIEPFVP
                 HSQAEEFYVCIYATREGDYVLFHHEGGVDVGDVDAKAQKLLVGVDEKLNPEDIKKHLL
                 VHAPEDKKEILASFISGLFNFYEDLYFTYLEINPLVVTKDGVYVLDLAAKVDATADYI
                 CKVKWGDIEFPPPFGREAYPEEAYIADLDAKSGASLKLTLLNPKGRIWTMVAGGGASV
                 VYSDTICDLGGVNELANYGEYSGAPSFQQTYDYAKTILSLMTREKHPDGKILIIGGSI
                 ANFTNXTAATFKGIVRAIRDYQGPLKEHEVTIFVRRGGPNYQEGLRVMGEVGKTTGIPT
                 HVFGTETHMTAIVGMALGHRPIPNQPPTAAHTANFLLNASGSTSTPAPSRTASFSESR
                 ADEVAPAKKAKPAMPQGKSTTLFSRHTKAIVWGMQTRAVQGMLDFDYVCSRDEPSVAA
                 MVYPFTGDHKQKFYWGHKEILIPVFKNMADAMRKHPEVDVLINFASLRSAYDSTMETM
                 NYAQIRTIATIAEGIPEALTRKLIKKADQKGVTIIGPATVGGIKPGCFKIGNTGGMLD
                 NILASKLYRPCSVAYVSRSGGMSNELNNIISRTTDGVYEGVAIGGDRYPGSTFMDHVL
                 RYQDTPGVKMIVVLGEIGGTEEYKICRGIKEGRLTKPIVCWCIGTCATMFSSEVQFGH
                 AGACANQASETAVAKNQALKEAGVFVPRSFDELGEIIQSVYEDLVANGVIVPAQEVPP
                 PTVPMDYSWARELGLIRKPASFMTSICDERGQELIYAGMPITEVFKEEMGIGGVLGLL
                 WFQKRLPKYSCQFIEMCLMVTADHGPAVSGAHNTIICARAGKDLVSSLTSGLLTIGDR
                 FGGALDAAAKMFSKAFDSGIIPMEFVNKIVIKKEGKLIMGIGHRVKSINNPDMRVQILKD
                 YVRQHFPATPLLDYALEVEKITTSKKPNLILNVDGLIGVAFVDMLRNCGSFTREEADE
                 YIDIGALNGIFVLGRSMGFIGHYLDQKRLKQGLYRHPWDDISYVLPEHMSM
                 SEQ ID NO: 247      2290 bp
NOV15l,          CCAGAATTCCACCATGTCGGCCAAGGCAATTTCAGAGCAGACGGGCAAAGAACTCCTT
256202925
DNA Sequence     TACAAGTTCATCTGTACCACCTCAGCCATCCAGAATCGGTTCAAGTATGCTCGCGTCA
                 CTCCTGACACAGACTGGGCCCGCTTGCTGCAGGACCACCCCTGGCTGCTCAGCCAGAA
                 CTTGGTAGTCAAGCCAGACCAGCTGATCAAACGTCGTGGAAAACTTGGTCTCGTTGGG
                 GTCAACCTCACTCTGGATGGGGTCAAGTCCTGGCTGAAGCCACGGCTGGGACAGGAAG
                 CCACAGTGAGTGGGCATGGGGTCAAGATGAACGTGTGTGGTAACAGAAGCAAATATGG
                 TCACCTTCAGGTTGGCAAGGCCACAGGCTTCCTCAAGAACTTTCTGATCGAGCCCTTC
                 GTCCCCCACAGTCAGGCTGAGGAGTTCTATGTCTGCATCTATGCCACCCGAGAAGGGG
                 ACTACGTCCTGTTCCACCACGAGGGGGGTGTGGACGTGGGTGATGTGGACGCCAAGGC
                 CCAGAAGCTGCTTGTTGGCGTGGATCAGAAACTGAATCCTGAGGACATCAAAAAACAC
                 CTGTTGCTCCACGCCCCTGAAGACAAGAAAGAAATTCTGGCCAGTTTTATCTCCGGCC
                 TCTTCAATTTCTACGAGGACTTGTACTTCACCTACCTCGAGATCAATCCCCTTGTAGT
                 GACCAAAGATGGAGTCTATGTCCTTGACTTGGCGGCCAAGGTGGACGCCACTGCCGAC
                 TACATCTGCAAAGTGAAGTGGGGTGACATCGAGTTCCCTCCCCCCTTCGGGCGGGAGG
                 CATATCCAGAGGAAGCCTACATTGCAGACCTCGACGCCAAAAGTGGGGCAAGCCTGAA
                 GCTGACCTTGCTGAACCCCAAAGGGAGGATCTGGACCATGGTGGCCGGGGGTGGCGCC
                 TCTGTCGTGTACAGCGATACCATCTGTGATCTAGGGGGTGTCAACGAGCTGGCAAACT
                 ATGGGGAGTACTCAGGCGCCCCCAGCGAGCAGCAGACCTATGACTATGCCAAGACTAT
                 CCTCTCCCTCATGACCCGAGAGAAGCACCCAGATGGCAAGATCCTCATCATTGGAGGC
                 AGCATCGCAAACTTCACCAACGTGGCTGCCACGTTCAAGGGCATCGTGAGAGCAATTC
                 GAGATTACCAGGGCCCCCTGAAGGAGCACGAAGTCACAATCTTTGTCCGAAGAGGTGG
                 CCCCAACTATCAGGAGGGCTTACGGGTGATGGGAGAAGTCGGGAAGACCACTGGGATC
                 CCCATCCATGTCTTTGGCACAGAGACTCACATGACGGCCATTGTGGGCATGGCCCTGG
                 GCCACCGGCCCATCCCCAACCAGCCACCCACAGCGGCCCACACTGCAAACTTCCTCCT
                 CAACGCCAGCGGGAGCACATCGACGCCAGCCCCCAGCAGGACAGCATCTTTTTCTGAG
                 TCCAGGGCCGATGAGGTGGCGCCTGCAAAGAAGGCCAAGCCTGCCATGCCACAAGGAA
                 AGAGCACCACCCTCTTCAGCCGCCACACCAAGGCCATTGTGTGGGGCATGCAGACCCG
                 GGCCGTGCAAGGCATGCTGGACTTTGACTATGTCTGCTCCCGAGACGAGCCCTCAGTG
                 GCTGCCATGGTCTACCCTTTCACTGGGGACCACAAGCAGAAGTTTTACTGGGGGCACA
                 AAGAGATCCTGATCCCTGTCTTCAAGAACATGGCTGATGCCATGAGGAAGCACCCGGA
                 GGTAGATGTGCTCATCAACTTTGCTTCTCTCCGCTCTGCCTTGGATGCAGCAGCCAAG
                 ATGTTCAGTAAAGCCTTTGACAGTGGCATTATCCCCATGGAGTTTGTGAACAAGATGA
                 AGAAGGAAGGGAAGCTGATCATGGGCATTGGTCACCGAGTGAAGTCGATAAACAACCC
                 AGACATGCGAGTGCGGATCCTCAAAGATTACGTCAGGCAGCACTTCCCTGCCACTCCT
                 CTGCTCGATTATGCACTGGAAGTAGAGAAGATTACCACCTCGAAGAAGCCAAATCTTA
                 TCCTGAATGTAGATGGTCTCATCGGAGTCGCATTTGTAGACATGCTTAGAAACTGTCG
                 GTCCTTTACTCGGGAGGAAGCTGATGAATATATTGACATTGGAGCCCTCAATGGCATC
                 TTTGTGCTGGGAAGGAGTATGGGGTTCATTGGACACTATCTTGATCAGAAGAGGCTGA
                 AGCAGGGGCTGTATCGTCATCCGTGGGATGATATTTCATATGTTCTTCCGGAACACAT
                 GAGCATGTAAGCGGCCGCTTTTTTCCTT
                 ORF Start:at 2                   ORF Stop: TAA at 2270
                 SEQ ID NO: 248       756 aa      MW at 83890.7kD
NOV15l,          QNSTMSAKAISEQTGKELLYKFICTTSAIQNRFKYARVTPDTDWARLLQDHPWLLSQN
256202925
Protein Sequence LVVKPDQLIKRRGKLGLVGVNLTLDGVKSWLKPRLGQEATVSGHGVKMNVCGNRSKYG
                 HLQVGKATGFLKNFLIEPFVPHSQAEEFYVCIYATREGDYVLFHHEGGVDVGDVDAKA
                 QKLLVGVDEKLNPEDIKKHLLVHAPEDKKEILASFISGLFNFYEDLYFTYLEINPLVV
                 TKDGVYVLDLAAKVDATADYICKVKWGDIEFPPPFGREAYPEEAYIADLDAKSGASLK
                 LTLLNPKGRIWTMVAGGGASVVYSDTICDLGGVNELANYGEYSGAPSEQQTYDYAKTI
                 LSLMTREKHPDGKILIIGGSIANFTNVAATFKGIVRAIRDYQGPLKEHEVTIFVRRGG
                 PNYQEGLRVMGEVGKTTGIPIHVFGTETHMTAIVGMALGHRPIPNQPPTAAHTANFLL
                 NASGSTSTPAPSRTASFSESRADEVAPAKKAKPAMPQGKSTTLFSRHTKAIVWGMQTR
                 AVQGMLDFDYVCSRDEPSVAAIVIVYPFTGDHKQKFYWGHKEILIPVFKNMADAMRKHPE
                 VDVLINFASLRSALDAAAKNFSKAFDSGIIPMEFVMKMKKEGKLIMGIGHRVKSINNP
                 DMRVRILKDYVRQHFPATPLLDYALEVEKITTSKKPNLILNVDGLIGVAFVDMLRNCG
                 SFTREEADEYIDIGALNGIFVLGRSMGFIGHYLDQKRLKQGLYRHPWDDISYVLPEHM
                 SM
                 SEQ ID NO: 249      3368 bp
NOV15m,          CCCGGTCCGAAGCGCGCGGATTCCACCATGTCGGCCAAGGCAATTTCAGAGCAGACGG
296463359
DNA Sequence     GCAAAGAACTCCTTTACAAGTTCATCTGTACCACCTCAGCCATCCAGAATCGGTTCAA
                 GTATGCTCGGGTCACTCCTGACACAGACTGGGCCCGCTTGCTGCAGGACCACCCCTGG
                 CTGCTCAGCCAGAACTTGGTAGTCAAGCCAGACCAGCTGATCAAACGTCGTGGAAAAC
                 TTGGTCTCGTTGGGGTCAACCTCACTCTGGATGGGGTCAAGTCCTGGCTGAAGCCACG
                 GCTGGGACAGGAAGCCACAGTTGGCAAGGCCACAGGCTTCCTCAAGAACTTTCTGATC
                 GAGCCCTTCGTCCCCCACAGTCAGGCTGAGGAGTTCTATGTCTGCATCTATCCCACCC
                 GAGAAGGGGACTACGTCCTGTTCCACCACGAGGGGGGTGTGGACGTGGGTGATGTGGA
                 CGCCAAGGCCCAGAAGCTGCTTGTTGGCGTGGATGAGAAACTGAATCCTGAGGACATC
                 AAAAAACACCTGTTGGTCCACGCCCCTGAAGACAAGAAAGAAATTCTGGCCAGTTTTA
                 TCTCCGGCCTCTTCAATTTCTACGAGGACTTGTACTTCACCTACCTCGAGATCAATCC
                 CCTTGTAGTGACCAAAGATGGAGTCTATGTCCTTGACTTGGCGGCCAAGGTGGACGCC
                 ACTGCCGACTACATCTGCAAAGTGAAGTGGGCTGACATCGAGTTCCCTCCCCCCTTCG
                 GGCGGGAGGCATATCCAGAGGAAGCCTACATTGCAGACCTCGATGCCAAAAGTGGGGC
                 AAGCCTGAAGCTGACCTTGCTGAACCCCAAAGGGAGGATCTGGACCATGGTGGCCGGG
                 GGTGGCGCCTCTGTCGTGTACAGCGATACCATCTGTGATCTAGGGGGTGTCAACGAGC
                 TGGCAAACTATGGGGAGTACTCAGGCGCCCCCAGCGAGCAGCAGACCTATGATTATGC
                 CAAGACTATCCTCTCCCTCATGACCCGAGAGAAGCACCCAGATGGCAAGATCCTCATC
                 ATTGGACGCAGCATCGCAAACTTCACCAACGTGGCTGCCACGTTCAAGGGCATCGTGA
                 GACCAATTCGAGATTACCAGGGCCCCCTGAAGGAGCACGAAGTCACAATCTTTGTCCG
                 AAGAGGTGGCCCCAACTATCAGGAGGGCTTACGGGTGATGGGAGAAGTCGGGAACACC
                 ACTGGGATCCCCATCCATGTCTTTGGCACAGAGACTCACATGACGGCCATTGTGGGCA
                 TGGCCCTGGGCCACCGGCCCATCCCCAACCAGCCACCCACAGCGGCCCACACTGCAAA
                 CTTCCTCCTCAACGCCAGCGGGAGCACATCGACGCCAGCCCCCAGCAGGACAGCATCT
                 TTTTCTGAGTCCAGGGCCGATGAGGTGGCGCCTGCAAAGAAGGCCAAGCCTGCCATGC
                 CACAAGATTCAGTCCCAAGTCCAAGATCCCTGCAAGGAAAGAGCACCACCCTCTTCAG
                 CCGCCACACCAAGGCCATTGTGTGGGGCATGCAGACCCGGGCCGTGCAAGGCATGCTG
                 GACTTTGACTATGTCTGCTCCCGAGACGAGCCCTCAGTGGCTGCCATGGTCTACCCTT
                 TCACTGGGGACCACAAGCAGAAGTTTTACTGGGGGCACAAAGAGATCCTGATCCCTGT
                 CTTCAAGAACATGGCTGATGCCATGAGGAAGCACCCGGAGGTAGATGTGCTCATCAAC
                 TTTGCCTCTCTCCGCTCTGCCTATGACAGCACCATGGAGACCATCAACTATGCCCAGA
                 TCCGGACCATCGCCATCATAGCTGAAGCCATCCCTGAGGCCCTCACGAGAAAGCTGAT
                 CAAGAAGGCGGACCAGAAGGGAGTGACCATCATCGGACCTGCCACTGTTGGAGGCATC
                 AAGCCTGGGTGCTTTAAGATTGGCAACACAGGTGGGATGCTGGACAACATCCTGGCCT
                 CCAAACTGTACCGCCCAGGCAGCGTGGCCTATGTCTCACGTTCCGGAGGCATGTCCAA
                 CGAGCTCAACAATATCATCTCTCGGACCACGGATGGCGTCTATGAGGGCGTGGCCATT
                 CGTGGGGACAGGTACCCGGGCTCCACATTCATGGATCATGTGTTACGCTATCAGGACA
                 CTCCAGGAGTCAAAATGATTGTGGTTCTTGGAGAGATTGGGGGCACTGAGGAATATAA
                 GATTTGCCCGGGCATCAAGGAGGGCCGCCTCACTAAGCCCATCGTCTGCTGGTGCATC
                 GGGACGTGTGCCACCATGTTCTCCTCTGAGGTCCAGTTTGGCCATGCTGGAGCTTGTG
                 CCAACCAGGCTTCTGAAACTGCAGTAGCCAAGAACCAGGCTTTGAAGGAAGCAGGAGT
                 GTTTGTGCCCCGGAGCTTTGATGAGCTTGGAGAGATCATCCAGTCTGTATACGAAGAT
                 CTCGTGGCCAATGGAGTCATTGTACCTGCCCAGGAGGTGCCGCCCCCAACCGTGCCCA
                 TGGACTACTCCTGGGCCAGGGAGCTTGGTTTGATCCGCAAACCTGCCTCGTTCATGAC
                 CAGCATCTGCGATGAGCGAGGACAGGAGCTCATCTACGCGGGCATGCCCATCACTGAG
                 GTCTTCAAGGAAGAGATGGGCATTGGCGGGGTCCTCGGCCTCCTCTGGTTCCAGAAAA
                 GGTTGCCTAAGTACTCTTGCCAGTTCATTGAGATGTGTCTGATGGTGACAGCTGATCA
                 CGGGCCAGCCGTCTCTGGAGCCCACAACACCATCATTTGTGCGCGAGCTGGGAAAGAC
                 CTGGTCTCCAGCCTCACCTCGGGGCTGCTCACCATCGGGGATCGGTTTGGGGGTGCCT
                 TGGATGCAGCAGCCAAGATGTTCAGTAAAGCCTTTGACAGTGGCATTATCCCCATGGA
                 GTTTGTGAACAAGATGAAGAAGGAAGGGAAGCTGATCATGGGCATTGGTCACCGAGTG
                 AAGTCGATAAACAACCCAGACATGCGAGTGCAGATCCTCAAAGATTACGTCAGGCAGC
                 ACTTCCCTGCCACTCCTCTGCTCGATTATGCACTGGAAGTAGAGAAGATTACCACCTC
                 GAAGAAGCCAAATCTTATCCTGAATGTAGATGGTCTCATCGGAGTCGCATTTGTAGAC
                 ATGCTTAGAAACTGTGGGTCCTTTACTCGGGAGGAAGCTGATGAATATATTGACATTG
                 GAGCCCTCAATGGCATCTTTGTGCTGGGAAGGAGTATGGGGTTCATTGGACACTATCT
                 TGATCAGAAGAGGCTGAAGCAGGGGCTGTATCGTCATCCGTGGGATGATATTTCATAT
                 GTTCTTCCGGAACACATGAGCATGCATCATCACCACCATCACTAAGCGCCCGCTTTCG
                 AATC
                 ORF Start: at 1                  ORF Stop: TAA at 3349
                 SEQ ID NO: 250      1116 aa      MW at 122570.8kD
NOV15m,          PGPKRADSTMSAKAISEQTGKELLYKFICTTSAIQNRFKYARVTPDTDWARLLQDHPW
296463359
Protein Sequence LLSQNLVVKPDQLIKRRGKLGLVGVNLTLDGVKSWLKPRLGQEATVGKATGFLKNFLI
                 EPFVPHSQAEEFYVCIYATREGDYVLFHHEGGVDVGDVDAKAQKLLVGVDEKLNPEDI
                 KKHLLVHAPEDKKEILASFISGLFNFYEDLYFTYLEINPLVVTKDGVYVLDLAAKVDA
                 TADYICKVKWGDIEFPPPFGREAYPEEAYIADLDAKSGASLKLTLLNPKGRIWTMVAG
                 GGASVVYSDTICDLGGVNELANYGEYSGAPSEQQTYDYAKTILSLMTREKHPDGKILI
                 IGGSIANFTNVAATFKGIVRAIRDYQGPLKEHEVTIFVRRGGPNYQEGLRVMGEVGKT
                 TGIPIHVFGTETHMTAIVGMALGHRPIPNQPPTAAHTANFLLNASGSTSTPAPSRTAS
                 FSESRADEVAPAKKAKPAMPQDSVPSPRSLQGKSTTLFSRHTKAIVWGMQTRAVQGML
                 DFDYVCSRDEPSVAAMVYPFTGDHKQKFYWGHKEILIPVFKNMADAMRKHPEVDVLIN
                 FASLRSAYDSTMETMNYAQIRTIAIIAEGIPEALTRKLIKKADQKGVTIIGPATVGGI
                 KPGCFKIGNTGGMLDNILASKLYRPCSVAYVSRSGGMSNELNNIISRTTDGVYEGVAI
                 GGDRYPGSTFMDHVLRYQDTPGVKMIVVLGEIGGTEEYKICRGIKEGRLTKPIVCWCT
                 GTCATMFSSEVQFGHAGACANQASETAVAKNQALKEAGVFVPRSFDELGEIIQSVYED
                 LVANGVIVPAQEVPPPTVPMDYSWARELGLIRKPASFMTSICDERGQELIYAGMPITE
                 VFKEEMGIGGVLGLLWFQKRLPKYSCQFIEMCLMVTADHGPAVSGAHNTIICARAGKD
                 LVSSLTSGLLTIGDRFGGALDAAAKMFSKAFDSGIIPMEFVNKMKKEGKLIMGIGHRV
                 KSINNPDMRVQILKDYVRQHFPATPLLDYALEVEKITTSKKPNLILNVDGLIGVAFVD
                 MLRNCGSFTREEADEYIDIGALNGIFVLGRSMGFIGHYLDQKRLKQGLYRHPWDDISY
                 VLPEHMSMHHHHHH
                 SEQ ID NO: 251      3313 bp
NOV15n,          TTCCACCATGTCCGCCAAGGCAATTTCAGAGCAGACGGGCAAAGAACTCCTTTACAAG
263470992
DNA Sequence     TTCATCTGTACCACCTCAGCCATCCAGAATCGGTTCAAGTATGCTCGGGTCACTCCTG
                 ACACAGACTGGGCCCGCTTGCTGCAGGACCACCCCTGGCTGCTCAGCCAGAACTTGGT
                 AGTCAAGCCAGACCAGCTGATCAAACGTCGTGGAAAACTTGGTCTCGTTGGGGTCAAC
                 CTCACTCTGGATGGGGTCAAGTCCTGGCTGAAGCCACGGCTGGGACAGGAAGCCACAG
                 TTGGCAAGGCCACAGGCTTCCTCAAGAACTTTCTGATCGAGCCCTTCGTCCCCCACAG
                 TCAGGCTGAGGAGTTCTATGTCTGCATCTATGCCACCCGAGAAGGGGACTACGTCCTG
                 TTCCACCACGAGGGGGGTGTGGACGTGGGTGATGTGGACGCCAAGGCCCAGAAGCTGC
                 TTGTTGGCGTGGATGAGAAACTGAATCCTGAGGACATCAAAAAACACCTGTTGGTCCA
                 CCCCCCTGAAGACAAGAAAGAAATTCTGGCCAGTTTTATCTCCGGCCTCTTCAATTTC
                 TACGAGGACTTGTACTTCACCTACCTCGAGATCAATCCCCTTGTAGTGACCAAAGATG
                 GAGTCTATGTCCTTGACTTGGCGGCCAAGGTGGACGCCACTGCCGACTACATCTGCAA
                 AGTGAAGTGGGGTGACATCGAGTTCCCTCCCCCCTTCGGGCGGGAGGCATATCCAGAG
                 GAAGCCTACATTGCAGACCTCGATGCCAAAAGTGGGGCAAGCCTGAAGCTGACCTTGC
                 TGAACCCCAAAGGGAGGATCTGGACCATGGTGGCCGGGGGTGGCGCCTCTGTCGTGTA
                 CAGCGATACCATCTGTGATCTAGGGGGTGTCAACGAGCTGGCAAACTATGGGGAGTAC
                 TCAGGCGCCCCCAGCGAGCAGCAGACCTATGATTATGCCAAGACTATCCTCTCCCTCA
                 TGACCCGAGAGAAGCACCCAGATGGCAAGATCCTCATCATTGGAGGCAGCATCGCAAA
                 CTTCACCAACGTGGCTGCCACGTTCAAGGGCATCGTGAGAGCAATTCGAGATTACCAG
                 GGCCCCCTGAAGGAGCACGAAGTCACAATCTTTGTCCGAAGAGGTGGCCCCAACTATC
                 AGGAGGGCTTACGGGTGATGGGAGAAGTCGGGAAGACCACTGGGATCCCCATCCATGT
                 CTTTGGCACAGAGACTCACATGACGGCCATTGTGGGCATGGCCCTGGGCCACCGGCCC
                 ATCCCCAACCAGCCACCCACAGCGGCCCACACTGCAAACTTCCTCCTCAACGCCAGCG
                 GGAGCACATCGACGCCAGCCCCCAGCAGGACAGCATCTTTTTCTGAGTCCAGGGCCGA
                 TGAGGTGGCGCCTGCAAAGAAGGCCAAGCCTGCCATGCCACAAGATTCAGTCCCAAGT
                 CCAAGATCCCTGCAAGGAAAGAGCACCACCCTCTTCAGCCGCCACACCAAGGCCATTG
                 TGTGGGGCATGCAGACCCGGGCCGTGCAAGGCATGCTGGACTTTGACTATGTCTGCTC
                 CCGAGACGAGCCCTCAGTGGCTGCCATGGTCTACCCTTTCACTGGGGACCACAAGCAG
                 AAGTTTTACTGGGGGCACAAAGAGATCCTGATCCCTGTCTTCAAGAACATGGCTGATG
                 CCATGAGGAAGCACCCGGAGGTAGATGTGCTCATCAACTTTGCCTCTCTCCGCTCTGC
                 CTATGACAGCACCATCGAGACCATGAACTATGCCCAGATCCGGACCATCGCCATCATA
                 GCTGAAGGCATCCCTGAGGCCCTCACGAGAAAGCTGATCAAGAAGGCGGACCAGAAGG
                 GAGTGACCATCATCGGACCTGCCACTGTTGGAGGCATCAAGCCTGGGTGCTTTAAGAT
                 TGGCAACACAGGTGGGATGCTGGACAACATCCTGGCCTCCAAACTGTACCGCCCAGGC
                 AGCGTGGCCTATGTCTCACGTTCCGGAGGCATGTCCAACGAGCTCAACAATATCATCT
                 CTCGGACCACGGATGGCGTCTATGAGGGCGTGGCCATTGGTGGGGACAGGTACCCGGG
                 CTCCACATTCATGGATCATGTGTTACGCTATCAGGACACTCCAGGAGTCAAAATGATT
                 GTGGTTCTTGGAGAGATTGGGGGCACTGAGGAATATAAGATTTGCCGGGGCATCAAGG
                 AGGGCCGCCTCACTAAGCCCATCGTCTGCTGGTGCATCGGGACGTGTGCCACCATGTT
                 CTCCTCTGAGGTCCAGTTTGGCCATGCTGGAGCTTGTGCCAACCAGGCTTCTGAAACT
                 GCAGTAGCCAAGAACCAGGCTTTGAAGGAAGCAGGAGTGTTTGTGCCCCGGAGCTTTG
                 ATGAGCTTGGAGAGATCATCCAGTCTGTATACGAAGATCTCGTGGCCAATGGAGTCAT
                 TGTACCTGCCCAGGAGGTGCCGCCCCCAACCGTGCCCATGGACTACTCCTGGGCCAGG
                 GAGCTTGGTTTGATCCGCAAACCTGCCTCGTTCATGACCAGCATCTGCGATGAGCGAG
                 GACAGGAGCTCATCTACGCGGGCATGCCCATCACTGAGGTCTTCAAGGAAGAGATGGG
                 CATTGGCGGGGTCCTCGGCCTCCTCTGGTTCCAGAAAAGGTTGCCTAAGTACTCTTGC
                 CAGTTCATTGAGATGTGTCTGATGGTGACAGCTGATCACGGGCCAGCCGTCTCTGGAG
                 CCCACAACACCATCATTTGTGCGCGAGCTGGGAAAGACCTGGTCTCCAGCCTCACCTC
                 GGGGCTGCTCACCATCGGGGATCGGTTTGGGGGTGCCTTGGATGCAGCAGCCAAGATG
                 TTCAGTAAAGCCTTTGACAGTGGCATTATCCCCATGGAGTTTGTGAACAAGATGAAGA
                 AGGAAGGGAAGCTGATCATGGGCATTGGTCACCGAGTGAAGTCGATAAACAACCCAGA
                 CATGCGAGTGCAGATCCTCAAAGATTACGTCAGGCAGCACTTCCCTGCCACTCCTCTG
                 CTCGATTATGCACTGGAAGTAGAGAAGATTACCACCTCGAAGAAGCCAAATCTTATCC
                 TGAATGTAGATGGTCTCATCGGAGTCGCATTTGTAGACATGCTTAGAAACTGTGGGTC
                 CTTTACTCGGGAGGAAGCTGATGAATATATTGACATTGGAGCCCTCAATGGCATCTTT
                 GTGCTGGGAAGGAGTATGGGGTTCATTGGACACTATCTTGATCAGAAGAGGCTGAAGC
                 AGGGGCTGTATCGTCATCCGTGGGATGATATTTCATATGTTCTTCCGGAACACATGAG
                 CATGTAA
                 ORF Start: at 2                  ORF Stop: TAA at 3311
                 SEQ ID NO: 252      1103 aa      MW at 121026.1kD
NOV15n,          STMSAKAISEQTGKELLYKFICTTSAIQNRFKYARVTPDTDWARLLQDHPWLLSQNLV
263470992
Protein Sequence VKPDQLIKRRGKLGLVGVNLTLDGVKSWLKPRLGQEATVGKATGFLKNFLIEPFVPHS
                 QAEEFYVCIYATREGDYVLFHHEGGVDVGDVDAKAQKLLVGVDEKLNPEDIKKHLLVH
                 APEDKKEILASFISGLFNFYEDLYFTYLEINPLVVTKDGVYVLDLAAKVDATADYICK
                 VKWGDIEFPPPFGREAYPEEAYIADLDAKSGASLKLTLLNPKGRIWTMVAGGGASVVY
                 SDTICDLGGVNELANYGEYSGAPSEQQTYDYAKTILSLMTREKHPDGKILIIGGSIAN
                 FTNVAATFKGIVRAIRDYQGPLKEHEVTIFVRRGGPNYQEGLRVMGEVGKTTGIPIIW
                 FGTETHMTAIVGMALGHRPIPNQPPTAAHTANFLLNASGSTSTPAPSRTASFSESRAD
                 EVAPAKKAKPAMPQDSVPSPRSLQGKSTTLFSRHTKAIVWGMQTRAVQGMLDFDYVCS
                 RDEPSVAAMVYPFTGDHKQKFYWGHKEILIPVFKNMADAMRKHPEVDVLINFASLRSA
                 YDSTMETMNYAQIRTIAIIAEGIPEALTRKLIKKADQKGVTIIGPATVGGIKPGCFKI
                 GNTGGMLDNILASKLYRPGSVAYVSRSGGMSNELNNIISRTTDGVYEGVAIGGDRYPG
                 STFMDHVLRYQDTPGVKMIVVLGEIGGTEEYKICRGIKEGRLTKPIVCWCIGTCATMF
                 SSEVQFGHAGACANQASETAVAKNQALKEAGVFVPRSFDELGEIIQSVYEDLVANGVI
                 VPAQEVPPPTVPMDYSWARELGLIRKPASFMTSICDERGQELIYAGMPITEVFKEEMG
                 IGGVLGLLWFQKRLPKYSCQFIEMCLMVTADHGPAVSGAHNTIICARAGKDLVSSLTS
                 GLLTIGDRFGGALDAAAKMFSKAFDSGIIPMEFVNKMKKEGKLIMGIGHRVKSINNPD
                 MRVQILKDYVRQHFPATPLLDYALEVEKITTSKKPNLILNVDGLIGVAFVDMLRNCGS
                 FTREEADEYIDIGALNGIFVLGRSMGFIGHYLDQKRLKQGLYRHPWDDISYVLPEHMS
                 SEQ ID NO: 253      3368 bp
NOV15o,          CCCGGTCCGAAGCGCGCGGATTCCACCATGTCGGCCAAGGCAATTTCAGAGCAGACGG
CG142427-05
DNA Sequence     GCAAAGAACTCCTTTACAAGTTCATCTGTACCACCTCAGCCATCCAGAATCGGTTCAA
                 GTATGCTCGGGTCACTCCTGACACAGACTGGGCCCGCTTGCTGCAGGACCACCCCTGG
                 CTGCTCAGCCAGAACTTGGTAGTCAAGCCAGACCAGCTGATCAAACGTCGTGGAAAAC
                 TTGGTCTCGTTGGGGTCAACCTCACTCTGGATGGGGTCAAGTCCTGGCTCAAGCCACG
                 CCTGGGACAGGAAGCCACAGTTGGCAAGGCCACAGGCTTCCTCAAGAACTTTCTGATC
                 GAGCCCTTCGTCCCCCACAGTCAGGCTGAGGAGTTCTATGTCTGCATCTATGCCACCC
                 GAGAAGGGGACTACGTCCTGTTCCACCACGAGGGGGGTGTGGACGTGGGTGATGTGGA
                 CGCCAAGGCCCAGAAGCTGCTTGTTGGCGTGGATGAGAAACTGAATCCTGAGGACATC
                 AAAAAACACCTGTTGGTCCACGCCCCTGAAGACAAGAAAGAAATTCTGGCCAGTTTTA
                 TCTCCGGCCTCTTCAATTTCTACGAGGACTTGTACTTCACCTACCTCGAGATCAATCC
                 CCTTGTAGTGACCAAAGATGGAGTCTATGTCCTTGACTTGGCGGCCAAGGTGGACGCC
                 ACTGCCGACTACATCTGCAAAGTGAAGTGGGGTGACATCGAGTTCCCTCCCCCCTTCG
                 GGCGGGAGGCATATCCAGAGGAAGCCTACATTGCAGACCTCGATGCCAAAAGTGGGGC
                 AAGCCTGAAGCTGACCTTGCTGAACCCCAAAGGGAGGATCTGGACCATGGTGGCCGGG
                 GGTGGCGCCTCTGTCGTGTACAGCGATACCATCTGTGATCTAGGGGGTGTCAACGAGC
                 TGGCAAACTATGGGGAGTACTCAGGCGCCCCCAGCGAGCAGCAGACCTATGATTATGC
                 CAAGACTATCCTCTCCCTCATGACCCGAGAGAAGCACCCAGATGGCAAGATCCTCATC
                 ATTGGAGGCAGCATCGCAAACTTCACCAACGTGGCTGCCACGTTCAAGGGCATCGTGA
                 GAGCAATTCGAGATTACCAGGGCCCCCTGAAGGAGCACGAAGTCACAATCTTTGTCCG
                 AAGAGGTGGCCCCAACTATCAGGAGGGCTTACGGGTGATGGGAGAAGTCGGGAAGACC
                 ACTGGGATCCCCATCCATGTCTTTGGCACAGAGACTCACATGACGGCCATTGTGGGCA
                 TGGCCCTGGGCCACCGGCCCATCCCCAACCAGCCACCCACAGCGGCCCACACTGCAAA
                 CTTCCTCCTCAACGCCAGCGGGAGCACATCGACGCCAGCCCCCAGCAGGACAGCATCT
                 TTTTCTGAGTCCAGGGCCGATCAGGTGGCGCCTGCAAAAGAAGGCCAAGCCTGCCATGC
                 CACAAGATTCAGTCCCAAGTCCAAGATCCCTGCAAGGAAAGAGCACCACCCTCTTCAG
                 CCGCCACACCAAGGCCATTGTGTGGGGCATGCAGACCCGGGCCGTGCAAGGCATGCTG
                 GACTTTGACTATGTCTGCTCCCGAGACGAGCCCTCAGTGGCTGCCATGGTCTACCCTT
                 TCACTGGGGACCACAAGCAGAAGTTTTACTGGGGGCACAAAGAGATCCTGATCCCTGT
                 CTTCAAGAACATGGCTGATGCCATGAGGAAGCACCCGGAGGTAGATGTGCTCATCAAC
                 TTTGCCTCTCTCCGCTCTGCCTATGACAGCACCATGGAGACCATGAACTATGCCCAGA
                 TCCGGACCATCGCCATCATAGCTGAAGGCATCCCTGAGGCCCTCACGAGAAAGCTGAT
                 CAAGAAGGCGGACCAGAAGGGAGTGACCATCATCGGACCTGCCACTGTTGGAGGCATC
                 AAGCCTGGGTGCTTTAAGATTGGCAACACAGGTGGGATGCTGGACAACATCCTGGCCT
                 CCAAACTGTACCGCCCAGGCAGCGTGGCCTATGTCTCACGTTCCCGAGGCATGTCCAA
                 CGAGCTCAACAATATCATCTCTCGGACCACGGATGGCGTCTATGAGGGCGTGGCCATT
                 GGTGGGGACAGGTACCCGGGCTCCACATTCATGGATCATGTGTTACGCTATCAGGACA
                 CTCCAGGAGTCAAAATGATTGTGGTTCTTGGAGAGATTGGGGGCACTGAGGAATATAA
                 GATTTGCCGGGGCATCAAGGAGGGCCGCCTCACTAAGCCCATCGTCTGCTGGTGCATC
                 GGGACGTGTGCCACCATGTTCTCCTCTGAGGTCCAGTTTGGCCATGCTGGAGCTTGTG
                 CCAACCAGGCTTCTGAAACTGCAGTAGCCAAGAACCAGGCTTTGAAGGAAGCAGGAGT
                 GTTTGTGCCCCGGAGCTTTGATGAGCTTGGAGAGATCATCCAGTCTGTATACGAAGAT
                 CTCGTGGCCAATGGACTCATTGTACCTGCCCAGGAGGTGCCGCCCCCAACCGTGCCCA
                 TGGACTACTCCTGGCCCAGGGAGCTTGGTTTGATCCGCAAACCTGCCTCGTTCATGAC
                 CAGCATCTGCGATGAGCGAGGACAGGAGCTCATCTACGCGGGCATGCCCATCACTGAG
                 GTCTTCAAGGAAGAGATGGGCATTGGCGGGGTCCTCGGCCTCCTCTGGTTCCAGAAAA
                 GGTTGCCTAAGTACTCTTGCCAGTTCATTGAGATGTGTCTGATGGTGACAGCTGATCA
                 CGGCCCAGCCGTCTCTGGAGCCCACAACACCATCATTTGTGCGCGAGCTGGGAAAGAC
                 CTCGTCTCCAGCCTCACCTCGGGGCTGCTCACCATCGGGGATCGGTTTGGGGGTGCCT
                 TGGATGCAGCAGCCAAGATGTTCAGTAAAGCCTTTGACAGTGGCATTATCCCCATGGA
                 GTTTGTGAACAAGATGAAGAAGGAAGGGAAGCTGATCATGGGCATTGGTCACCGAGTG
                 AAGTCGATAAACAACCCAGACATGCGAGTGCAGATCCTCAAAGATTACGTCAGGCAGC
                 ACTTCCCTGCCACTCCTCTGCTCGATTATGCACTGGAAGTAGAGAAGATTACCACCTC
                 GAAGAAGCCAAATCTTATCCTGAATGTAGATGGTCTCATCGGAGTCGCATTTGTAGAC
                 ATGCTTAGAAACTGTGGGTCCTTTACTCGGGAGGAAGCTGATGAATATATTGACATTG
                 GAGCCCTCAATGGCATCTTTGTGCTGGGAAGGAGTATGGGGTTCATTGGACACTATCT
                 TGATCAGAAGAGGCTGAACCAGGGGCTGTATCGTCATCCGTGGGATGATATTTCATAT
                 GTTCTTCCGGAACACATGAGCATGCATCATCACCACCATCACTAAGCGGCCGCTTTCG
                 ORF Start: ATG at 28             ORF Stop: at 3331
                 SEQ ID NO: 254      1101 aa      MW at 120838.0kD
NOV15o,          MSAKAISEQTGKELLYKFICTTSAIQNRFKYARVTPDTDWARLLQDHPWLLSQNLVVK
CG142427-05
Protein Sequence PDQLIKRRGKLGLVGVNLTLDGVKSWLKPRLGQEATVGKATGFLKNFLIEPFVPHSQA
                 EEFVCIYATREGDYVLFHHEGGVDVGDVDAKAQKLLVGVDEKLNPEDIKKHLLVHAP
                 EDKKEILASFISGLFNFYEDLYFTYLEINPLVVTKDGVYVLDLAAKVDATADYI CKVK
                 WGDIEFPPPFGREAYPEEAYIADLDAKSGASLKLTLLMPKCRIWTNVAGGCASVVYSD
                 TICDLGGVNELANYGEYSGAPSEQQTYDYAKTILSLMTREKHPDGKILIIGGSIANFT
                 NVAATFKGIVRAIRDYQGPLKEHEVTIPVRRGGPNYQEGLRVMGEVGKTTGIPIHVFG
                 TETHMTAIVGMALGHRPIPNQPPTAAHTANFLLNASGSTSTPAPSRTASFSESRADEV
                 APAKKAKPANPQDSVPSPRSLQGKSTTLFSRHTKAIVWGMQTRAVQGMLDFDYVCSRD
                 EPSVAAIVIVYPFTCDHKQKFYWGHKEILIPVFKNMADANRKHPEVDVLINFASLRSAYD
                 STMETMNYAQIRTIAIIAEGIPEALTRKLIKKADQKGVTIIGPATVGGIKPGCFKIGN
                 TGGMLDNILASKLYRPGSVAYVSRSGGMSNELNNIISRTTDGVYEGVAIGGDRYPGST
                 FMDHVLRYQDTPGVKMIVVLGEIGGTEEYKICRGIKEGRLTKPIVCWCIGTCATMFSS
                 EVQFGHAGACANQASETAVAKNQALKEAGVFVPRSFDELGEIIQSVYEDLVANGVIVP
                 AQEVPPPTVPMDYSWARELGLIRKPASFMTSICDERGQELIYAGMPITEVFKEEMGIG
                 GVLGLLWFQKRLPKYSCQFIEMCLMVTADHGPAVSGAHNTIICARAGKDLVSSLTSGL
                 LTIGDRFGGALDAAAKMFSKAFDSGIIPMEFVNKMKKEGKLIMGIGHRVKSINNPDMR
                 VQILKDYVRQHFPATPLLDYALEVEKITTSKKPNLILNVDGLIGVAFVDMLRNCGSFT
                 REEADEYIDIGALNGIFVLGRSMGFIGHYLDQKRLKQGLYRHPWDDISYVLPEHMSM

[0436] Sequence comparison of the above protein sequences yields the following sequence relationships shown in Table 15B.

TABLE 15B
Comparison of NOV15a against NOV15b through NOV15o.
			Identities/
			Similarities for
	Protein	NOV15a Residues/	the Matched
	Sequence	Match Residues	Region
	NOV15b	1 . . . 1101	1101/1101	(100%)
		1 . . . 1101	1101/1101	(100%)
	NOV15c	1 . . . 1101	1065/1101	(96%)
		5 . . . 1072	1065/1101	(96%)
	NOV15d	1 . . . 1101	1091/1101	(99%)
		5 . . . 1095	1091/1101	(99%)
	NOV15e	1 . . . 589	570/610	(93%)
		5 . . . 604	573/610	(93%)
	NOV15f	1 . . . 1101	1101/1101	(100%)
		5 . . . 1105	1101/1101	(100%)
	NOV15g	1 . . . 1101	1091/1101	(99%)
		5 . . . 1095	1091/1101	(99%)
	NOV15h	1 . . . 589	570/610	(93%)
		5 . . . 604	573/610	(93%)
	NOV15i	1 . . . 1101	1101/1101	(100%)
		2 . . . 1102	1101/1101	(100%)
	NOV15j	1 . . . 1101	1101/1101	(100%)
		5 . . . 1105	1101/1101	(100%)
	NOV15k	1 . . . 1101	1091/1101	(99%)
		5 . . . 1095	1091/1101	(99%)
	NOV15l	1 . . . 589	570/610	(93%)
		5 . . . 604	573/610	(93%)
	NOV15m	1 . . . 1101	1101/1101	(100%)
		10 . . . 1110	1101/1101	(100%)
	NOV15n	1 . . . 1101	1101/1101	(100%)
		3 . . . 1103	1101/1101	(100%)
	NOV15o	1 . . . 1101	1101/1101	(100%)
		1 . . . 1101	1101/1101	(100%)

[0437] Further analysis of the NOV15a protein yielded the following properties shown in Table 15C.

TABLE 15C
Protein Sequence Properties NOV15a
PSort     0.8500 probability located in endoplasmic
analysis: reticulum (membrane); 0.4450 probability
          located in microbody (peroxisome); 0.4400
          probability located in plasma membrane;
          0.1000 probability located in mitochondrial
          inner membrane
SignalP   No Known Signal Sequence Predicted
analysis:

[0438] A search of the NOV15a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 15D.

TABLE 15D
Geneseq Results for NOV15a
			Identities/
			Similarities for
Geneseq	Protein/Organism/Length	NOV15a Residues/	the Matched	Expect
Identifier	[Patent #, Date]	Match Residues	Region	Value
ABB61832	Drosophila melanogaster	1 . . . 1097	762/1099	(69%)	0.0
	polypeptide SEQ ID NO 12288 -	1 . . . 1083	895/1099	(81%)
	Drosophila melanogaster, 1086 aa.
	[WO200171042-A2, 27 SEP. 2001]
AAB56952	Human prostate cancer antigen	753 . . . 1101	347/349	(99%)	0.0
	protein sequence SEQ ID NO:	15 . . . 363	347/349	(99%)
	1530 - Homo sapiens, 363 aa.
	[WO200055174-A1, 21 SEP. 2000]
AAY67408	Arabidopsis ATP citrate lyase	492 . . . 1093	321/602	(53%)	0.0
	(ACL) B-2 subunit - Arabidopsis	6 . . . 606	429/602	(70%)
	sp, 608 aa. [WO200000619-A2, 06
	JAN. 2000]
AAG36247	Arabidopsis thaliana protein	492 . . . 1093	321/602	(53%)	0.0
	fragment SEQ ID NO: 44394 -	6 . . . 606	429/602	(70%)
	Arabidopsis thaliana, 681 aa.
	[EP1033405-A2, 06 SEP. 2000]
AAG36248	Arabidopsis thaliana protein	512 . . . 1093	313/582	(53%)	0.0
	fragment SEQ ID NO: 44395 -	1 . . . 581	417/582	(70%)
	Arabidopsis thaliana, 656 aa.
	[EP1033405-A2, 06 SEP. 2000]

[0439] In a BLAST search of public sequence datbases, the NOV15a protein was found to have homology to the proteins shown in the BLASTP data in Table 15E.

TABLE 15E
Public BLASTP Results for NOV15a
			Identities/
Protein			Similarities for
Accession		NOV15a Residues/	the Matched	Expect
Number	Protein/Organism/Length	Match Residues	Portion	Value
P53396	ATP-citrate (pro-S-)-lyase (EC	1 . . . 1101	1100/1101	(99%)	0.0
	4.1.3.8) (Citrate cleavage	1 . . . 1101	1101/1101	(99%)
	enzyme) - Homo sapiens (Human),
	1101 aa.
P16638	ATP-citrate (pro-S-)-lyase (EC	1 . . . 1101	1074/1101	(97%)	0.0
	4.1.3.8) (Citrate cleavage	1 . . . 1100	1086/1101	(98%)
	enzyme) - Rattus norvegicus
	(Rat), 1100 aa.
Q91V92	ATP-citrate (pro-S-)-lyase (EC	1 . . . 1101	1070/1101	(97%)	0.0
	4.1.3.8) (Citrate cleavage enzyme) -	1 . . . 1091	1083/1101	(98%)
	Mus musculus (Mouse), 1091 aa.
S21173	ATP citrate (pro-S)-lyase -	1 . . . 1101	1078/1106	(97%)	0.0
	human, 1105 aa.	1 . . . 1105	1082/1106	(97%)
Q8VIQ1	ATP-citrate lyase - Rattus	250 . . . 1101	835/852	(98%)	0.0
	norvegicus (Rat), 851 aa	1 . . . 851	842/852	(98%)
	(fragment).

[0440] PFam analysis predicts that the NOV15a protein contains the domains shown in the Table 15F.

TABLE 15F
Domain Analysis of NOV15a
			Identities/
			Similarities for
Pfam	NOV15a		the Matched	Expect
Domain	Match Region		Region	Value
CoA_binding	492 . . . 616	33/126	(26%)	1.5e−19
		88/126	(70%)
ligase-CoA	642 . . . 793	49/156	(31%)	3.9e−53
		126/156	(81%)

Example 16

[0441] The NOV16 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 16A.

TABLE 16A
NOV16 Sequence Analysis
                 SEQ ID NO: 255           1393 bp
NOV16a,          CCTTCTCTTCGTGGGCTATCTACTCAGTTGATCCCTCCCTCGCTGGCTTGGCTCTGAC
CG142631-01
DNA Sequence     TCCTGCTCAGACCCATCACCTTTGCCGGGGAATGATGTCTGGAGAACCCCTGCACGTG
                 AAGACCCCCATCCGTGACAGCATGGCCCTGTCCAAAATGGCCGGCACCAGCGTCTACC
                 TCAAGATGGACAGTGCCCAGCCCTCCGGCTCCTTCAAGATCCGGGGCATTGGGCACTT
                 CTGCAAGAGGTGGCCCAAGCAAGGCTGTGCACATTTTGTCTGCTCCTCGGCGGGCAAC
                 GCAGGCATGGCGGCTGCATATGCGGCCAGGCAACTCGGCGTCCCCGCCACCATCGTAG
                 TGCCCGGCACCACACCTGCTCTCACCATTGAGCGCCTCAAGAATGAAGGTGCCACATG
                 CAAGGTGGTGGGTGAGTTATTGGATGAAGCCTTCGACCTGGCCAAGGCCCTAGCGAAG
                 AACAACCCGGGTTGGGTCTACATTCCCCCCTTTGATGACCCCCTCATCTGGGAAGGCC
                 ACGCTTCCATCGTGAAAGAGCTGAAGGAGACACTGTGGGAAAAGCCGGGGGCCATCGC
                 GCTGTCAGTGGGCGGCCGCGGCCTGCTGTGTGGAGTGGTCCAGGGGCTGCAGGAGTGT
                 GGCTGGGGGGACGTGCCTGTCATCGCCATGGAGACTTTTGGTGCCCACAGCTTCCACG
                 CTGCCACCACCGCAGGCAAACTTGTCTCCCTGCCCAAGATCACCAGTGTTGCCAAGGC
                 CCTGGGCGTGAAGACTGTGGGGTCTCAGGCCCTGAAGCTGTTTCAGGAACACCCCATT
                 TTCTCTGAAGTTATCTCCGACCAGGAGGCTGTGGCCGCCATTGAGAAGTTCGTGGATG
                 ATGAGAAGATCCTGGTGGAGCCCGCCTGGGGCGCAGCCCTGGCCGCTGTCTATAGCCA
                 CGTGATCCAGAAGCTCCAACTGGAGGGGAATCTCCGAACCCCGCTGCCATCCCTCGTG
                 GTCATCGTCTGCGGGGGCAGCAACATCAGCCTGGCCCAGCTGCGGGCGCTCAAGGAAC
                 AGCTGGGCATGACAAATAGGTTGCCCAAGTGAGGACGGACCCCTTACCGATCTGTGCT
                 CTCCTAGCCCAAGAGACCCCTGGAGGGGCTGGAGTTTATCCAGCGCCTCGTCGTATGT
                 TTGGCTGAGCACCTGTGGCCCTGGGTGCAGGTTAACTTCTTGTTATCAGGAGCCCACT
                 ATGCAGAGGCCAAAGGTCGGCAGCCAGCGAGGCTATGAATTGGACCTTTTTGGTATCT
                 GTGTGACTGCTCTGTGCCCATCCTTAGCCAACTTGCTGGCGTGACAAGTGCCCACAAG
                 TAACACACCAGGTACCCAGAGCAGGGTGGACAGGAGAGACCTGAATCACAGCAGTGAG
                 G
                 ORF Start: ATG at 90                 ORF Stop: TGA at 1074
                 SEQ ID NO: 256            328 aa     MW at 34702.1kD
NOV16a,          MMSGEPLHVKTPIRDSMALSKMAGTSVYLKMDSAQPSGSFKIRGIGHFCKRWAKQGCA
CG142631-01
Protein Sequence HFVCSSAGNAGMAAAYAARQLGVPATIVVPGTTPALTIERLKNEGATCKVVGELLDEA
                 FELAKALAKNNPGWVYIPPFDDPLIWEGHASIVKELKETLWEKPGAIALSVGGGGLLC
                 GVVQGLQECGWGDVPVIANETPGAHSFHAATTAGKLVSLPKITSVAKALGVKTVGSQA
                 LKLFQEHPIFSEVISDQEAVAAIEKFVDDEKILVEPAWGAALAAVYSHVIQKLQLEGN
                 LRTPLPSLVVIVCGGSNISLAQLRALKEQLGMTNRLPK
                 SEQ ID NO: 257           1393 bp
NOV16b,          CCTTCTCTTCGTGGGCTATCTACTCAGTTGATCCCTCCCTCGCTGGCTTGGCTCTGAC
CG142631-01
DNA Sequence     TCCTGCTCAGACCCATCACCTTTGCCGGGGAATGATGTCTGGAGAACCCCTGCACGTG
                 AAGACCCCCATCCGTGACAGCATGGCCCTGTCCAAAATGGCCGGCACCAGCGTCTACC
                 TCAAGATGGACAGTGCCCAGCCCTCCGGCTCCTTCAAGATCCGGGGCATTGGGCACTT
                 CTGCAAGAGGTGGGCCAAGCAAGGCTGTGCACATTTTGTCTGCTCCTCGGCGGGCAAC
                 GCAGGCATGGCGGCTGCATATGCGGCCAGGCAACTCGGCGTCCCCGCCACCATCGTAG
                 TGCCCGGCACCACACCTGCTCTCACCATTGAGCGCCTCAAGAATGAAGGTGCCACATG
                 CAAGGTGGTGGGTGAGTTATTGGATGAAGCCTTCGAGCTGGCCAAGGCCCTAGCGAAG
                 AACAACCCGGGTTGGGTCTACATTCCCCCCTTTGATGACCCCCTCATCTGGGAAGGCC
                 ACGCTTCCATCGTCAAAGAGCTGAAGGAGACACTGTGGGAAAAGCCGGGGGCCATCGC
                 GCTGTCAGTGGGCGGCGGGGGCCTGCTGTGTGGAGTGGTCCAGGGGCTGCAGGAGTGT
                 GGCTCGGGGGACGTGCCTGTCATCGCCATGGAGACTTTTGGTGCCCACAGCTTCCACG
                 CTGCCACCACCGCAGGCAAACTTGTCTCCCTGCCCAAGATCACCAGTGTTGCCAAGGC
                 CCTGGGCGTGAAGACTGTGGGGTCTCAGGCCCTGAAGCTGTTTCAGGAACACCCCATT
                 TTCTCTGAAGTTATCTCGGACCAGGAGGCTGTGCCCCCCATTGAGAAGTTCGTGGATG
                 ATGAGAAGATCCTGGTGGAGCCCGCCTGGGGCGCAGCCCTGGCCGCTGTCTATAGCCA
                 CGTGATCCACAAGCTCCAACTGGAGGGGAATCTCCGAACCCCGCTGCCATCCCTCGTG
                 GTCATCGTCTGCGGGGGCAGCAACATCAGCCTGGCCCAGCTGCGGGCGCTCAAGGAAC
                 AGCTGGGCATGACAAATAGGTTGCCCAAGTGAGGACGGACCCCTTACCGATCTGTGCT
                 CTCCTAGCCCAAGAGACCCCTGGAGGGGCTGGAGTTTATCCAGCGCCTCGTCGTATGT
                 TTGGCTGAGCACCTGTGGCCCTGGGTGCAGGTTAACTTCTTGTTATCAGGAGCCCACT
                 ATGCAGAGGCCAAAGGTCGGCAGCCAGCGAGGCTATGAATTGGACCTTTTTGGTATCT
                 GTGTGACTGCTCTGTGCCCATCCTTAGCCAACTTGCTGGCGTGACAAGTGCCCACAAG
                 TAACACACCAGGTACCCAGAGCAGGGTGGACAGGAGAGACCTGAATCACAGCAGTGAG
                 C
                 ORF Start: ATG at 90                 ORF Stop: TGA at 1074
                 SEQ ID NO: 258            328 aa     MW at 34702.1kD
NOV16b,          MMSGEPLHVKTPIRDSMALSKMAGTSVYLKMDSAQPSGSFKIRGIGHFCKRWAKQGCA
CG142631-01
Protein Sequence HFVCSSAGNAGMAAAYAARQLGVPATIVVPGTTPALTIERLKNEGATCKVVGELLDEA
                 FELAKALAKNNPGWVYIPPFDDPLIWEGHASIVKELKETLWEKPGAIALSVGGGGLLC
                 GVVQCLQECGWGDVPVIAMETFGAHSFHAATTAGKLVSLPKITSVAKALGVKTVGSQA
                 LKLFQEHPIFSEVISDQEAVAAIEKFVDDEKILVEPAWGAALAAVYSHVIQKLQLEGN
                 LRTPLPSLVVIVCGGSNISLAQLRALKEQLGMTNRLPK
                 SEQ ID NO: 259           1008 bp
NOV16c,          ACCATGATGTCTGGAGAACCCCTGCACGTGAAGACCCCCATCCGTGACAGCATGGCCC
248494617
DNA Sequence     TGTCCAAAATGGCCGGCACCAGCGTCTACCTCAAGATGGACAGTGCCCAGCCCTCCGG
                 CTCCTTCAAGATCCGGGGCATTGGGCACTTCTGCAAGAGGTGCGCCAAGCAAGGCTGT
                 GCACATTTTGTCTGCTCCTCGGCGGGCAACGCAGGCATGGCGGCTGCATATGCGGCCA
                 GGCAACTCGGCGTCCCCGCCACCATCGTGGTCCCCAGCACCACACCTGCTCTCACCAT
                 TGAGCGCCTCAAGAATGAAGGTGCCACAGTCAAGGTGGTGGGTGAGTTATTGGATGAA
                 GCCTTCGAGCTGGCCAAGGCCCTAGCGAAGAACAACCCGGGTTGGGTCTACATTCCCC
                 CCTTTGATGACCCCCTCATCTGGGAAGGCCACGCTTCCATCGTGAAAGAGCTGAAGGA
                 GACACTGTGGGAAAAGCCGGGGGCCATCGCGCTGTCAGTGGGCGGCGGGGGCCTGCTG
                 TGTGGAGTCGTCCAGGGGCTGCAGGAGGTGGGCTGGGGGGACGTGCCTGTCATCGCCA
                 TGGAGACTTTTGGTGCCCACAGCTTCCACGCTGCCACCACCGCAGGCAAACTTGTCTC
                 CCTGCCCAAGATCACCAGTGTTGCCAAGGCCCTGGGCGTGAAGACTGTGGGGGCTCAG
                 GCCCTGAAGCTGTTTCAGGAACACCCCATTTTCTCTGAAGTTATCTCGGACCAGGAGG
                 CTGTGGCCGCCATTGAGAAGTTCGTGCATGATGAGAACATCCTGGTGGAGCCCGCCTG
                 CGGGGCAGCCCTGGCCGCTCTCTATAGCCACGTGATCCAGAAGCTCCAACTGGAGGGG
                 AATCTCCGAACCCCGCTGCCATCCCTCGTGGTCATCGTCTGCCGGGGCAGCAACATCA
                 GCCTGGCCCAGCTGCGGGCGCTCAAGGAACAGCTGGGCATGACAAATAGGTTGCCCAA
                 GCATCATCACCACCATCACTGA
                 ORF Start: at 1                      ORF Stop: TGA at 1006
                 SEQ ID NO: 260            335 aa     MW at 35549.0kD
NOV16c,          TMMSGEPLHVKTPIRDSMALSKMAGTSVYLKMDSAQPSGSFKIRGIGHFCKRWAKQGC
248494617
Protein Sequence AHFVCSSAGNAGMAAAYAARQLGVPATIVVPSTTPALTIERLKNEGATVKVVGELLDE
                 AFELAKALAKNNPGWVYIPPFDDPLIWEGHASIVKELKETLWEKPGAIALSVGGGGLL
                 CGVVQGLQEVGWGDVPVIANETFCAHSFHAATTAGKLVSLPKITSVAKALGVKTVGAQ
                 ALKLFQEHPIFSEVISDQEAVAAIEKFVDDEKILVEPACGAALAAVYSHVIQKLQLEG
                 NLRTPLPSLVVIVCGGSNISLAQLRALKEQLGMTNRLPKHHHHHH
                 SEQ ID NO: 261            988 bp
NOV16d,          CATGATGTCTGGAGAACCCCTGCACGTGAAGACCCCCATCCGTGACAGCATGGCCCTG
228832711
DNA Sequence     TCCAAAATGGCCGGCACCAGCGTCTACCTCAAGATGGACAGTGCCCAGCCCTCCGGCT
                 CCTTCAAGATCCGGGGCATTGGGCACTTCTGCAAGAGGTGGGCCAAGCAAGGCTGTGC
                 ACATTTTGTCTGCTCCTCGGCGGGCAACGCAGGCATGGCGGCTGCATATGCGGCCAGG
                 CAACTCGGCGTCCCCGCCACCATCGTGGTGCCCAGCACCACACCTGCTCTCACCATTG
                 AGCGCCTCAAGAATGAAGGTGCCACAGTCAAGGTGGTGGGTGAGTTATTGGATGAAGC
                 CTTCGAGCTGGCCAAGGCCCTAGCGAAGAACAACCCGGGTTGGGTCTACATTCCCCCC
                 TTTGATGACCCCCTCATCTGGGAAGGCCACGCTTCCATCGTGAAAGACCTGAAGGAGA
                 CACTGTGGGAAAAGCCGGGGGCCATCGCGCTGTCAGTGGGCGGCGGGGGCCTGCTGTG
                 TGGAGTGGTCCAGGGGCTGCAGGAGGTGGGCTGGGCGGACGTGCCTGTCATCGCCATG
                 GAGACTTTTGGTGCCCACAGCTTCCACCCTGCCACCACCGCAGGCAAACTTGTCTCCC
                 TGCCCAAGATCACCAGTGTTGCCAAGGCCCTGGGCGTGAAGACTGTGGGGGCTCAGGC
                 CCTGAAGCTGTTTCAGGAACACCCCATTTTCTCTGAAGTTATCTCGGACCAGGAGGCT
                 GTGGCCGCCATTGAGAAGTTCGTGGATGATGAGAAGATCCTGGTGGAGCCCGCCTGCG
                 GGGCAGCCCTGGCCGCTGTCTATAGCCACGTGATCCAGAAGCTCCAACTGGAGGGGAA
                 TCTCCGAACCCCGCTGCCATCCCTCGTGGTCATCGTCTGCGGGGGCAGCAACATCAGC
                 CTGGCCCAGCTGCGGGCGCTCAAGGAACAGCTGGGCATGACAAATAGGTTGCCCAAGT
                 GA
                 ORF Start: ATG at 2                  ORF Stop: TGA at 986
                 SEQ ID NO: 262            328 aa     MW at 34625.0kD
NOV16d,          MMSGEPLHVKTPIRDSMALSKMAGTSVYLKMDSAQPSGSFKIRGIGHFCKRwAKQGCA
228832711
Protein Sequence HFVCSSAGNAGMAAAYAARQLGVPATIVVPSTTPALTIERLKNEGATVKVVGELLDEA
                 FELAKALAKNNPGWVYIPPPDDPLIWEGHASIVKELKETLWEKPGAIALSVGGGGLLC
                 GVVQGLQEVGWGDVPVIAMETFGAHSFHAATTAGKLVSLPKITSVAKALGVKTVGAQA
                 LKLFQEHPIFSEVISDQEAVAAIEKFVDDEKILVEPACGAALAAVYSHVIQKLQLEGN
                 LRTPLPSLVVIVCGGSNISLAQLRALKEQLGMTNRLPK
                 SEQ ID NO: 263           1035 bp
NOV16e,          ATGTCTGGAGAACCCCTGCACGTGAAGACCCCCATCCGTGACAGCATGGCCCTGTCCA
256420310
DNA Sequence     AAATGGCCGGCACCAGCGTCTACCTCAAGATGGACAGTGCCCAGCCCTCCGGCTCCTT
                 CAAGATCCGGGGCATTGGGCACTTCTGCAAGAGGTGGGCCAAGCAAGGCTGTGCACAT
                 TTTGTCTGCTCCTCGGCGGGCAACGCAGGCATGGCGGCTGCATATGCGGCCAGGCAAC
                 TCGGCGTCCCCGCCACCATCGTGGTGCCCAGCACCACACCTGCTCTCACCATTGAGCG
                 CCTCAAGAATGAAGGTGCCACAGTCAAGGTGGTGGGTGAGTTATTGGATGAAGCCTTC
                 GAGCTGGCCAAGGCCCTAGCGAAGAACAACCCGGGTTGGGTCTACATTCCCCCCTTTG
                 ATGACCCCCTCATCTGCGAAGGCCACGCTTCCATCGTGAAAGAGCTGAAGGAGACACT
                 GTGGGAAAAGCCGGGGGCCATCGCGCTGTCAGTGGGCGCCGGCGGCCTGCTCTGTGGA
                 GTGGTCCAGGGGCTGCAGGAGGTGGGCTGGGGGGACGTGCCTGTCATCGCCATGGAGA
                 CTTTTGGTGCCCACAGCTTCCACGCTGCCACCACCGCAGGCAAACTTGTCTCCCTGCC
                 CAAGATCACCAGTGTTGCCAAGGCCCTGGGCGTGAAGACTGTGGGGGCTCAGGCCCTG
                 AAGCTGTTTCAGGAACACCCCATTTTCTCTGAAGTTATCTCGGACCAGGAGGCTGTGG
                 CCGCCATTGAGAAGTTCGTGGATGATGAGAAGATCCTGGTGGAGCCCGCCTGCGGGGC
                 AGCCCTGGCCGCTGTCTATAGCCACGTGATCCAGAAGCTCCAACTGGAGGGGAATCTC
                 CGAACCCCGCTGCCATCCCTCGTGGTCATCGTCTGCGGGGGCAGCAACATCAGCCTGG
                 CCCAGCTGCGGGCGCTCAAGGAACAGCTGGGCATGACAAATAGGTTGCCCAAGCATCA
                 TCACCACCATCACTGAGCGGCCGCACTCGAGCACCACCACCACCACCAC
                 ORF Start: ATG at 1                  ORF Stop: TGA at 1000
                 SEQ ID NO: 264            333 aa     MW at 35316.7kD
NOV16e,          MSGEPLHVKTPIRDSMALSKMAGTSVYLKMDSAQPSGSFKIRGIGHFCKRWAKQGCAH
256420310
Protein Sequence FVCSSAGNAGMAAAYAARQLGVPATIVVPSTTPALTIERLKNEGATVKVVGELLDEAF
                 ELAKALAKNNPGWVYIPPFDDPLIWEGHASIVKELKETLWEKPGAIALSVGGGGLLCG
                 VVQGLQEVGWGDVPVIAMETFGAHSFHAATTAGKLVSLPKITSVAKALGVKTVGAQAL
                 KLFQEHPIFSEVISDQEAVAAIEKFVDDEKILVEPACGAALAAVYSHVIQKLQLEGNL
                 RTPLPSLVVIVCGGSNISLAQLRALKEQLGMTMRLPKHHHHHH
                 SEQ ID NO: 265           1017 bp
NOV16f,          ATGTCTGGAGAACCCCTGCACGTGAAGACCCCCATCCGTGACAGCATGGCCCTGTCCA
249117058
DNA Sequence     AAATGGCCGGCACCAGCGTCTACCTCAAGATGGACAGTGCCCAGCCCTCCGGCTCCTT
                 CAAGATCCGGGGCATTGGGCACTTCTGCAAGAGGTGGGCCAAGCAAGGCTGTGCACAT
                 TTTGTCTGCTCCTCGGCGGGCAACGCAGGCATGGCGGCTGCATATCCGGCCAGGCAAC
                 TCGGCGTCCCCGCCACCATCGTGGTGCCCAGCACCACACCTCCTCTCACCATTGAGCG
                 CCTCAAGAATGAAGGTGCCACAGTCAAGGTGGTGGGTGAGTTATTGGATGAAGCCTTC
                 GAGCTGGCCAAGGCCCTAGCGAAGAACAACCCGGGTTGCGTCTACATTCCCCCCTTTG
                 ATGACCCCCTCATCTGGGAAGGCCACGCTTCCATCGTGAAAGAGCTGAAGGAGACACT
                 GTGGGAAAAGCCGGGGGCCATCGCGCTGTCAGTGGGCGGCGGGGGCCTGCTGTGTGGA
                 GTGGTCCAGGGGCTGCAGGAGGTGGGCTGGGGGGACGTGCCTGTCATCGCCATGGAGA
                 CTTTTGGTGCCCACAGCTTCCACGCTGCCACCACCGCAGGCAAACTTGTCTCCCTGCC
                 CAAGATCACCAGTGTTGCCAAGGCCCTGGGCGTGAAGACTGTGGGGGCTCAGGCCCTG
                 AAGCTGTTTCAGGAACACCCCATTTTCTCTGAAGTTATCTCGGACCAGGAGGCTGTGG
                 CCGCCATTGAGAAGTTCGTGGATGATGAGAAGATCCTGGTGGAGCCCGCCTGCGGGGC
                 AGCCCTGGCCGCTGTCTATAGCCACGTGATCCAGAAGCTCCAACTGGAGGGGAATCTC
                 CGAACCCCGCTGCCATCCCTCGTGGTCATCGTCTGCGGGGGCAGCAACATCAGCCTGG
                 CCCAGCTGCGGGCGCTCAAGGAACAGCTGGGCATGACAAATAGGTTGCCCAAGTGAGC
                 GGCCGCACTCGAGCACCACCACCACCACCAC
                 ORF Start: ATG at 1                  ORF Stop: TGA at 982
                 SEQ ID NO: 266            327 aa     MW at 34493.8kD
NOV16f,          MSGEPLHVKTPIRDSMALSKMAGTSVYLKMDSAQPSGSFKIRGIGHFCKRWAKQGCAH
249117058
Protein Sequence FVCSSAGNAGMAAAYAARQLGVPATIVVPSTTPALTIERLKNEGATVKVVGELLDEAF
                 ELAKALAKNNPGWVYIPPFDDPLIWEGHASIVKELKETLWEKPGAIALSVGGGGLLCG
                 VVQGLQEVGWGDVPVIAMETFCAHSFHAATTAGKLVSLPKITSVAKALGVKTVGAQAL
                 KLFQEHPIFSEVISDQEAVAAIEKFVDDEKILVEPACGAALAAVYSHVIQKLQLEGNL
                 RTPLPSLVVIVCGGSNISLAQLRALKEQLGMTNRLPK
                 SEQ ID NO: 267           1031 bp
NOV16g,          CACCCGTCTCACATGGGACATCATCACCACCATCACATGTCTGGAGAACCCCTGCACG
252790334
DNA Sequence     TGAAGACCCCCATCCGTGACAGCATGGCCCTGTCCAAAATGGCCGGCACCAGCGTCTA
                 CCTCAAGATGGACAGTGCCCAGCCCTCCGGCTCCTTCAAGATCCGGGGCATTGGGCAC
                 TTCTGCAAGAGGTGGGCCAAGCAAGGCTGTGCACATTTTGTCTGCTCCTCGGCGGGCA
                 ACGCAGGCATGGCGGCTGCATATGCGGCCAGGCAACTCGGCGTCCCCGCCACCATCGT
                 GGTGCCCAGCACCACACCTGCTCTCACCATTGAGCGCCTCAAGAATGAAGGTGCCACA
                 GTCAAGGTGGTGGGTGAGTTATTGGATGAAGCCTTCGAGCTGGCCAAAGCCCTAGCGA
                 AGAACAACCCGGGTTGGGTCTACATTCCCCCCTTTGATGACCCCCTCATCTGGGAAGG
                 CCACGCTTCCATCGTGAAAGAGCTGAAGGAGACACTGTGGGAAAAGCCGGGGGCCATC
                 GCGCTGTCAGTGGGCGGCGGGGGCCTGCTGTGTGGAGTGGTCCAGGGGCTGCAGGAGG
                 TGGGCTGGGGGGACGTGCCTGTCATCGCCATGGAGACTTTTGGTGCCCACAGCTTCCA
                 CGCTGCCACCACCGCAGGCAAACTTGTCTCCCTGCCCAAGATCACCAGTGTTGCCAAG
                 GCCCTGGGCGTGAAGACTGTGGGGGCTCAGGCCCTGAAGCTGTTTCAGGAACACCCCA
                 TTTTCTCTGAAGTTATCTCGGACCAGGAGGCTGTGGCCGCCATTGAGAAGTTCGTGGA
                 TGATGAGAAGATCCTGGTGGAGCCCGCCTGCGGGGCAGCCCTGGCCGCTGTCTATAGC
                 CACGTGATCCAGAAGCTCCAACTGGAGGGGAATCTCCGAACCCCGCTGCCATCCCTCG
                 TGGTCATCGTCTGCGGGCGCAGCAACATCAGCCTGGCCCAGCTGCGGGCGCTCAAGGA
                 ACAGCTGGGCATGACAAATAGGTTGCCCAAGTGAGCGGCCGCAAG
                 ORF Start: at 1                      ORF Stop: TGA at 1018
                 SEQ ID NO: 268            339 aa     MW at 35963.4kD
NOV16g,          HPSHMGHHHHHHMSGEPLHVKTPIRDSMALSKMAGTSVYLKMDSAQPSGSFKIRGIGH
252790334
Protein Sequence FCKRWAKQGCAHFVCSSAGNAGMAAAYAARQLGVPATIVVPSTTPALTIERLKNEGAT
                 VKVVGELLDEAFELAKALAKNNPGWVYIPPFDDPLIWEGHASIVKELKETLWEKPGAI
                 ALSVGGGGLLCGVVQGLQEVGWGDVPVIAMETFGAHSFHAATTAGKLVSLPKITSVAK
                 ALGVKTVGAQALKLFQEHPIFSEVISDQEAVAAIEKFVDDEKILVEPACGAALAAVYS
                 HVIQKLQLEGNLRTPLPSLVVIVCGGSNISLAQLRALKEQLGMTNRLPK
                 SEQ ID NO: 269           1036 bp
NOV16h,          ACATCATCACCACCATCACATGTCTGGAGAACCCCTGCACGTGAAGACCCCCATCCGT
254869149
DNA Sequence     GACAGCATGGCCCTGTCCAAAATGGCCGGCACCAGCGTCTACCTCAAGATGGACAGTG
                 CCCAGCCCTCCGGCTCCTTCAAGATCCGGGGCATTGGCCACTTCTGCAAGAGGTGGGC
                 CAAGCAAGGCTGTGCACATTTTGTCTGCTCCTCGGCGGGCAACGCAGGCATGGCGGCT
                 GCATATGCGGCCAGGCAACTCGGCGTCCCCGCCACCATCGTGGTGCCCAGCACCACAC
                 CTGCTCTCACCATTGAGCGCCTCAAGAATGAAGGTGCCACAGTCAAGGTGGTGGGTGA
                 GTTATTGGATGAAGCCTTCGAGCTGGCCAAGGCCCTAGCGAAGAACAACCCGGGTTGG
                 GTCTACATTCCCCCCTTTGATGACCCCCTCATCTGGGAAGGCCACGCTTCCATCGTGA
                 AAGAGCTGAAGGAGACACTGTGGGAAAAGCCGGGGGCCATCGCGCTGTCAGTGGGCGG
                 CGGGGGCCTGCTGTGTGGAGTGGTCCAGGGGCTGCAGGAGGTGGGCTGGGGGGACGTG
                 CCTGTCATCGCCATGGAGACTTTTGGTGCCCACAGCTTCCACGCTGCCACCACCGCAG
                 GCAAACTTGTCTCCCTGCCCAAGATCACCAGTGTTGCCAAGGCCCTGGGCGTGAAGAC
                 TGTGGGGGCTCAGGCCCTGAAGCTGTTTCAGGAACACCCCATTTTCTCTGAAGTTATC
                 TCGGACCAGGAGGCTGTGCCCGCCATTGAGAAGTTCGTGGATGATGAGAAGATCCTGG
                 TGGAGCCCGCCTGCGGGGCAGCCCTGGCCGCTGTCTATAGCCACGTGATCCAGAAGCT
                 CCAACTGGAGGGGAATCTCCGAACCCCGCTGCCATCCCTCGTGGTCATCGTCTGCGGG
                 GGCAGCAACATCAGCCTGGCCCAGCTGCGGGCGCTCAAGGAACAGCTGGGCATGACAA
                 ATAGGTTGCCCAAGTGAGCGGCCGCACTCGAGCACCACCACCACCACCAC
                 ORF Start: at 2                      ORF Stop: TGA at 1001
                 SEQ ID NO: 270            333 aa     MW at 35316.7kD
NOV16h,          HHHHHHMSGEPLHVKTPIRDSMALSKMAGTSVYLKMDSAQPSGSFKIRGIGHFCKRWA
254869149
Protein Sequence KQGCAHFVCSSAGNAGMAAAYAARQLGVPATIVVPSTTPALTIERLKNEGATXIKWGE
                 LLDEAFELAKALAKNNPGWVYIPPFDDPLIWEGHASIVKELKETLWEKPGAIALSVGG
                 GGLLCGVVQGLQEVGWGDVPVIANETFGAHSFHAATTAGKLVSLPKITSVAKALGVKT
                 VGAQALKLFQEHPIFSEVISDQEAVAAIEKFVDDEKILVEPACGAALAAVYSHVIQKL
                 QLEGNLRTPLPSLVVIVCGGSNISLAQLPALKEQLGMTNRLPK
                 SEQ ID NO: 271            988 bp
NOV16i,          CATGATGTCTGGAGAACCCCTGCACGTGAAGACCCCCATCCGTGACAGCATGGCCCTG
CG142631-02
DNA Sequence     TCCAAAATGGCCGGCACCAGCGTCTACCTCAAGATGGACAGTGCCCAGCCCTCCGGCT
                 CCTTCAAGATCCGGGGCATTGGGCACTTCTGCAAGAGGTGGGCCAAGCAACGCTGTGC
                 ACATTTTGTCTGCTCCTCGGCGGGCAACGCAGGCATGGCGGCTGCATATGCGGCCAGG
                 CAACTCGGCGTCCCCGCCACCATCGTGGTGCCCAGCACCACACCTGCTCTCACCATTG
                 AGCGCCTCAAGAATGAAGGTGCCACAGTCAAGGTGGTGGGTGAGTTATTGCATGAAGC
                 CTTCGAGCTGGCCAACGCCCTAGCGAAGAACAACCCGGGTTGGGTCTACATTCCCCCC
                 TTTGATGACCCCCTCATCTGGGAAGGCCACGCTTCCATCGTGAAAGAGCTGAAGGAGA
                 CACTGTGGGAAAAGCCGGGGGCCATCGCGCTGTCAGTGGGCGGCGGGGGCCTGCTGTG
                 TGGAGTGGTCCAGGCGCTGCAGGAGGTGGGCTGGGGGGACGTGCCTGTCATCGCCATG
                 GAGACTTTTGGTGCCCACAGCTTCCACGCTGCCACCACCGCAGGCAAACTTGTCTCCC
                 TGCCCAAGATCACCAGTGTTGCCAAGGCCCTGGGCGTGAAGACTGTGGGGGCTCAGGC
                 CCTGAAGCTGTTTCAGGAACACCCCATTTTCTCTGAAGTTATCTCGGACCAGGAGGCT
                 GTGGCCGCCATTGAGAAGTTCGTGGATGATGAGAAGATCCTGGTGGAGCCCGCCTGCG
                 GGGCAGCCCTGGCCGCTGTCTATAGCCACGTGATCCAGAAGCTCCAACTCGAGGGGAA
                 TCTCCGAACCCCGCTGCCATCCCTCGTGGTCATCGTCTGCGGGGGCAGCAACATCAGC
                 CTGGCCCAGCTGCGGGCGCTCAAGGAACAGCTGGGCATGACAAATAGGTTGCCCAAGT
                 GA
                 ORF Start: ATG at 2                  ORF Stop: TGA at 986
                 SEQ ID NO: 272            328 aa     MW at 34625.0kD
NOV161,          MMSGEPLHVKTPIRDSMALSKMAGTSVYLKMDSAQPSGSFKIRGIGHFCKRWAKQCCA
CG142631-02
Protein Sequence HFVCSSAGNAGMAAAYAARQLGVPATIVVPSTTPALTIERLKNEGATVKVVGELLDEA
                 FELAKALAKNNPGWVYIPPFDDPLIWEGHASIVKELKETLWEKPGAIALSVGGGGLLC
                 GVVQGLQEVGWGDVPVIAMETFGAHSFHAATTAGKLVSLPKITSVAKALGVKTVGAQA
                 LKLFQEHPIFSEVISDQEAVAAIEKFVDDEKILVEPACGAALAAVTSHVIQKLQLEGN
                 LRTPLPSLVVIVCGGSNISLAQLRALKEQLGMTNRLPK
                 SEQ ID NO: 273           1011 bp
NOV16j,          ACCATGGGACATCATCACCACCATCACATGTCTGGAGAACCCCTGCACGTGAAGACCC
CG142631-03
DNA Sequence     CCATCCGTGACAGCATGGCCCTGTCCAAAATGGCCGGCACCAGCGTCTACCTCAAGAT
                 GGACAGTGCCCAGCCCTCCGGCTCCTTCAAGATCCGGGGCATTGGGCACTTCTGCAAG
                 AGGTGGGCCAAGCAAGGCTGTGCACATTTTGTCTGCTCCTCGGCGGGCAACGCAGGCA
                 TGGCGGCTGCATATGCGGCCAGGCAACTCGGCGTCCCCGCCACCATCGTGGTGCCCAG
                 CACCACACCTGCTCTCACCATTGAGCGCCTCAAGAATGAAGGTGCCACAGTCAAGGTG
                 GTGGGTGAGTTATTGGATGAAGCCTTCGAGCTGGCCAAGGCCCTAGCGAAGAACAACC
                 CGGGTTGGGTCTACATTCCCCCCTTTGATGACCCCCTCATCTGGGAAGGCCACGCTTC
                 CATCGTGAAAGAGCTGAAGGAGACACTGTGGGAAAAGCCGGGGGCCATCGCGCTGTCA
                 GTGGGCGGCGGGGGCCTGCTGTGTGGAGTGGTCCAGGGGCTGCAGGAGGTGGGCTGGG
                 GGGACGTGCCTGTCATCGCCATGGAGACTTTTGGTGCCCACAGCTTCCACGCTGCCAC
                 CACCGCAGGCAAACTTGTCTCCCTGCCCAAGATCACCAGTGTTGCCAAGGCCCTGGGC
                 GTGAAGACTGTGGGCGCTCAGGCCCTGAAGCTGTTTCAGCAACACCCCATTTTCTCTG
                 AAGTTATCTCGGACCAGGAGGCTGTGGCCGCCATTGAGAAGTTCGTGGATGATGAGAA
                 GATCCTGGTGGAGCCCGCCTGCGGGGCAGCCCTGGCCGCTGTCTATAGCCACGTGATC
                 CAGAAGCTCCAACTGGAGGGGAATCTCCGAACCCCGCTGCCATCCCTCGTGGTCATCG
                 TCTGCGGGGGCAGCAACATCAGCCTGGCCCAGCTGCGGGCGCTCAAGGAACAGCTGGG
                 CATGACAAATAGGTTGCCCAAGTGA
                 ORF Start: at 1                      ORF Stop: TGA at 1009
                 SEQ ID NO: 274            336 aa     MW at 35606.0kD
NOV16j,          TMGHHHHHHMSGEPLHVKTPIRDSMALSKMAGTSVYLKMDSAQPSGSFKIRGIGHFCK
CG142631-03
Protein Sequence RWAKQGCAHFVCSSAGNAGMAAAYAARQLGVPATIVVPSTTPALTIERLKNEGATVKV
                 VGELLDEAFELAKALAKNNPGWVYIPPFDDPLIWEGHASIVKELKETLWEKPGAIALS
                 VGGGGLLCGVVQGLQEVGWGDVPVIAMETFGAHSFHAATTAGKLVSLPKITSVAKALG
                 VKTVGAQALKLFQEHPIFSEVISDQEAVAAIEKFVDDEKILVEPACGAALAAVYSHVI
                 QKLQLEGNLRTPLPSLVVIVCGGSNISLAQLRALKEQLGMTNRLPK
                 SEQ ID NO: 275           1008 bp
NOV16k,          ACCATGATGTCTGGAGAACCCCTCCACGTGAAGACCCCCATCCGTGACAGCATGGCCC
CG142631-04
DNA Sequence     TGTCCAAAATGGCCGGCACCAGCGTCTACCTCAAGATGGACAGTGCCCAGCCCTCCGG
                 CTCCTTCAAGATCCGGGGCATTGGGCACTTCTGCAAGAGCTGGGCCAAGCAAGGCTGT
                 GCACATTTTGTCTGCTCCTCGGCGGGCAACGCAGGCATGGCGGCTGCATATGCGGCCA
                 GGCAACTCGGCGTCCCCGCCACCATCGTGGTGCCCAGCACCACACCTGCTCTCACCAT
                 TGAGCGCCTCAAGAATGAAGGTGCCACAGTCAAGGTGGTGGGTGAGTTATTGGATGAA
                 GCCTTCGAGCTGGCCAAGGCCCTAGCGAAGAACAACCCGGGTTGGGTCTACATTCCCC
                 CCTTTGATGACCCCCTCATCTGGGAAGGCCACGCTTCCATCGTGAAAGAGCTGAAGGA
                 GACACTGTGGGAAAAGCCCGGGGCCATCGCGCTGTCAGTGGGCGGCGGGGGCCTGCTG
                 TGTGGAGTGGTCCAGGGGCTGCAGGAGGTGGGCTGGGGGGACGTGCCTGTCATCGCCA
                 TGGAGACTTTTGGTGCCCACAGCTTCCACGCTGCCACCACCGCAGGCAAACTTGTCTC
                 CCTGCCCAAGATCACCAGTGTTGCCAAGGCCCTGGGCGTGAAGACTGTGGGGGCTCAG
                 GCCCTGAAGCTGTTTCAGGAACACCCCATTTTCTCTGAAGTTATCTCGGACCAGGAGC
                 CTGTGGCCGCCATTGAGAAGTTCGTGGATGATGAGAAGATCCTGGTGGAGCCCGCCTG
                 CGGGGCAGCCCTGGCCGCTGTCTATAGCCACGTGATCCAGAAGCTCCAACTGGAGGGG
                 AATCTCCGAACCCCGCTGCCATCCCTCGTGGTCATCGTCTGCGGGGGCAGCAACATCA
                 GCCTGGCCCAGCTGCGGGCGCTCAAGGAACAGCTGGGCATGACAAATAGGTTGCCCAA
                 GCATCATCACCACCATCACTGA
                 ORF Start: at 1                      ORF Stop: TGA at 1006
                 SEQ ID NO: 276            335 aa     MW at 35549.0kD
NOV16k,          TMMSGEPLHVKTPIRDSMALSKMAGTSVYLKMDSAQPSGSFKIRGIGHFCKRWAKQGC
CG142631-04
Protein Sequence AHFVCSSAGNAGMAAAYAARQLGVPATIVVPSTTPALTIERLKNEGATVKVVGELLDE
                 AFFLAKALAKNNPGWVYIPPFDDPLIWEGHASIVKELKETLWEKPGAIALSVGGGGLL
                 CGVVQGLQEVGWGDVPVIAMETFGAHSFHAATTAGKLVSLPKITSVAKALGVKTVGAQ
                 ALKLFQEHPIFSEVISDQEAVAAIEKFVDDEKTLVEPACGAALAAVYSHTIQKLQLEG
                 NLRTPLPSLVVIVCGGSNISLAQLRALKEQLGMTNRLPKHHHHHH

[0442] Sequence comparison of the above protein sequences yields the following sequence relationships shown in Table 16B.

TABLE 16B
Comparison of NOV16a against NOV16b through NOV16k.
			Identities/
			Similarities for
	Protein	NOV16a Residues/	the Matched
	Sequence	Match Residues	Region
	NOV16b	1 . . . 328	328/328 (100%)
		1 . . . 328	328/328 (100%)
	NOV16c	1 . . . 328	323/328 (98%)
		2 . . . 329	324/328 (98%)
	NOV16d	1 . . . 328	323/328 (98%)
		1 . . . 328	324/328 (98%)
	NOV16e	2 . . . 328	322/327 (98%)
		1 . . . 327	323/327 (98%)
	NOV16f	2 . . . 328	322/327 (98%)
		1 . . . 327	323/327 (98%)
	NOV16g	2 . . . 328	322/327 (98%)
		13 . . . 339	323/327 (98%)
	NOV16h	2 . . . 328	322/327 (98%)
		7 . . . 333	323/327 (98%)
	NOV16i	1 . . . 328	323/328 (98%)
		1 . . . 328	324/328 (98%)
	NOV16j	2 . . . 328	322/327 (98%)
		10 . . . 336	323/327 (98%)
	NOV16k	1 . . . 328	323/328 (98%)
		2 . . . 329	324/328 (98%)

[0443] Further analysis of the NOV16a protein yielded the following properties shown in Table 16C.

TABLE 16C
Protein Sequence Properties NOV16a
PSort     0.8500 probability located in endoplasmic
analysis: reticulum (membrane); 0.4400 probability
          located in plasma membrane; 0.1000 probability
          located in mitochondrial inner membrane;
          0.1000 probability located in Golgi body
SignalP   No Known Signal Sequence Predicted
analysis:

[0444] A search of the NOV16a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 16D.

TABLE 16D
Geneseq Results for NOV16a
			Identities/
			Similarities for
Geneseq	Protein/Organism/Length	NOV16a Residues/	the Matched	Expect
Identifier	[Patent #, Date]	Match Residues	Region	Value
AAU23764	Novel human enzyme polypeptide	5 . . . 321	192/317 (60%)	e−106
	#850 - Homo sapiens, 340 aa.	23 . . . 338	246/317 (77%)
	[WO200155301-A2, 02 AUG.
	2001]
ABB89752	Human polypeptide SEQ ID NO	5 . . . 321	192/317 (60%)	e−106
	2128 - Homo sapiens, 329 aa.	12 . . . 327	246/317 (77%)
	[WO200190304-A2, 29 NOV.
	2001]
AAM40622	Human polypeptide SEQ ID NO	5 . . . 321	192/317 (60%)	e−106
	5553 - Homo sapiens, 340 aa.	23 . . . 338	246/317 (77%)
	[WO200153312-A1, 26 JUL. 2001]
AAM38836	Human polypeptide SEQ ID NO	5 . . . 321	192/317 (60%)	e−106
	1981 - Homo sapiens, 329 aa.	12 . . . 327	246/317 (77%)
	[WO200153312-A1, 26 JUL. 2001]
AAU23238	Novel human enzyme polypeptide	5 . . . 321	192/317 (60%)	e−106
	#324 - Homo sapiens, 340 aa.	23 . . . 338	246/317 (77%)
	[WO200155301-A2, 02 AUG.
	2001]

[0445] In a BLAST search of public sequence datbases, the NOV16a protein was found to have homology to the proteins shown in the BLASTP data in Table 16E.

TABLE 16E
Public BLASTP Results for NOV16a
			Identities/
Protein			Similarities for
Accession		NOV16a Residues/	the Matched	Expect
Number	Protein/Organism/Length	Match Residues	Portion	Value
P20132	L-serine dehydratase (EC	1 . . . 328	328/328 (100%)	0.0
	4.2.1.13) (L-serine deaminase) -	1 . . . 328	328/328 (100%)
	Homo sapiens (Human), 328 aa.
Q8VBT2	Similar to serine dehydratase -	1 . . . 328	270/328 (82%)	e−151
	Mus musculus (Mouse), 327 aa.	1 . . . 327	294/328 (89%)
DWRTT	L-serine dehydratase (EC	1 . . . 326	269/326 (82%)	e−151
	4.2.1.13) - rat, 327 aa.	1 . . . 326	289/326 (88%)
Q91X68	Similar to serine dehydratase -	1 . . . 313	260/313 (83%)	e−147
	Mus musculus (Mouse), 313 aa.	1 . . . 313	281/313 (89%)
Q8WW81	Hypothetical 23.0 kDa protein -	1 . . . 217	214/217 (98%)	e−122
	Homo sapiens (Human), 218 aa.	1 . . . 217	214/217 (98%)

[0446] PFam analysis predicts that the NOV16a protein contains the domains shown in the Table 16F.

TABLE 16F
Domain Analysis of NOV16a
			Identities/
			Similarities for
	Pfam	NOV16a	the Matched	Expect
	Domain	Match Region	Region	Value
	PALP	4 . . . 298	97/378 (26%)	3.8e−64
			221/378 (58%)

Example 17

[0447] The NOV17 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 17A.

TABLE 17A
NOV17 Sequence Analysis
                 SEQ ID NO: 277         1146 bp
NOV17a,          ATGAGTTGGACTGTACCTGTTGTGTGGGCCAGCCAGAGAGTGAGCTCGGCAGGAGCGA
CG151359-01
DNA Sequence     ATTTTCTGTGCCTGGGGATGGCCCTGTGTCCCCGTCAGGCAGCGTGCATGCCACTCAT
                 GGGCACCTGGCTCTTCACCTCCGTGAGCAAGATGGCGACTGTGAAGAGTGAGCTTATT
                 GAGTGCTTCACTTCCGAGGAGCCCTTTCATCACAGAAAGGTCTCCATCACAGGAACTG
                 GATCAGTGGGCATGGCCTGCGCTACCAGCATCTTATTAAAAGGCTTGAGTGATGAACT
                 TGCCTTTGTGGATCTTGATGAAGGCAAACTGAAAGGTGAGACAATGGATCTTCAACAT
                 GACAGCCCTTTCATGAAAATGTCAAATATTGTTTGTAGCAAAGATTACCTTGTCACAG
                 CAAACCCCCATCTAGTGATTATCACAGCAGGTGCACGCCGAGAAAAGGGAGAAATGCG
                 CTTTAATTTAGTCCGGCAAAATGTGGCCATCTTCAAGTTAATGATTTCCAGTATTGTC
                 CAGCAGAGCCCCCTCTGCAAACTAATTATTGTTTCCAATCCAGTAGATATCTTAACTT
                 ACGTAGCCTGGAAGTTGAGTGCATTTCCCAAAAACCGTGTTATTGGAAGCGGCTGTAA
                 TCTGGATACTGTTCGTTTTCAATTCTTCATTGGACAAAAGCTTGGTATCCACTCTGAA
                 AGCTGCCGTGGATGGATCCTCGGAGAGCATGGAGACTCAAGTGTTCCTGTGTGGAGTG
                 GAATGAACATAGCTGGTGTCCTTTTGAAGGATCTGAACTCTGATATAGGAACTGATAA
                 AGATCCTGAGAAATGGAAAAATGTCCACAAAGAAGTGATTGCTAGTGCCTATGAGATT
                 ATTGAAATGAAAAGTTCTACTTCGTGGGCCATTGGCCTATCTGGAGCTGATTTAACAG
                 AAAGTATTTTGAAGAATCTTAGGAGAAAACATCCAGTTTCCACCATAATTAAGGGCCT
                 CTACGGAATAAATGAAGAAGTCTTCCTCAGTATTCCTTCTTTGTTTGGAGAGAAGGGT
                 ATTACCAACCTTATAAAGAGAAAGCTGACCCCTCAAGAGGAGGCCCATCTGAAAAAGA
                 GTGCAAAAACACTTTGGGAAATTCAGAAGGAGCTTGAGACTTAA
                 ORF Start: ATG at 1                  ORF Stop: TAA at 1144
                 SEQ ID NO: 278          381 aa       MW at 42104.6kD
NOV17a,          MSWTVPVVWASQRVSSAGANFLCLGMALCPRQAACMPLMGTWLFTSVSKMATVKSELI
CG151359-O1
Protein Sequence ECFTSEEPFHHRKVSITGTGSVGMACATSILLKGLSDELAFVDLDEGKLKGETMDLQH
                 DSPFMKMSNIVCSKDYLVTANPHLVIITAGARREKGEMRFNLVRQNVAIFKLMISSIV
                 QQSPLCKLIIVSNPVDILTYVAWKLSAFPKNRVIGSGCNLDTVRFQFFIGQKLGIHSE
                 SCRGWILGEHGDSSVPVWSGMNIAGVLLKDLNSDIGTDKDPEKWKNVHKEVIASAYEI
                 IEMKSSTSWAIGLSGADLTESILKNLRRKHPVSTIIKGLYGINEEVFLSIPSLFGEKG
                 ITNLIKRKLTPEEEAHLKKSAKTLWEIQKELET

[0448] Further analysis of the NOV17a protein yielded the following properties shown in Table 17B.

TABLE 17B
Protein Sequence Properties NOV17a
PSort     0.6736 probability located in nucleus;
analysis: 0.5701 probability located in mitochondrial
          matrix space; 0.3952 probability located in
          microbody (peroxisome); 0.2847 probability
          located in mitochondrial inner membrane
SignalP   Cleavage site between residues 49 and 50
analysis:

[0449] A search of the NOV17a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 17C.

TABLE 17C
Geneseq Results for NOV17a
			Identities/
			Similarities for
Geneseq	Protein/Organism/Length	NOV17a Residues/	the Matched	Expect
Identifier	[Patent #, Date]	Match Residues	Region	Value
AAU11432	Human testicular lactate	1 . . . 380	328/380 (86%)	0.0
	dehydrogenase A - Homo sapiens,	1 . . . 380	344/380 (90%)
	381 aa. [CN1313342-A, 19 SEP.
	2001]
AAG89135	Human secreted protein, SEQ ID	1 . . . 380	328/380 (86%)	0.0
	NO: 255 - Homo sapiens, 381 aa.	1 . . . 380	344/380 (90%)
	[WO200142451-A2, 14 JUN. 2001]
AAY36058	Extended human secreted protein	1 . . . 380	321/380 (84%)	0.0
	sequence, SEQ ID NO. 443 - Homo	1 . . . 380	336/380 (87%)
	sapiens, 381 aa. [WO9931236-A2,
	24 JUN. 1999]
AAM42058	Human polypeptide SEQ ID NO	44 . . . 380	221/337 (65%)	e−128
	6989 - Homo sapiens, 372 aa.	35 . . . 371	271/337 (79%)
	[WO200153312-A1, 26 JUL. 2001]
AAM40272	Human polypeptide SEQ ID NO	50 . . . 380	218/331 (65%)	e−127
	3417 - Homo sapiens, 332 aa.	1 . . . 331	268/331 (80%)
	[WO200153312-A1, 26 JUL. 2001]

[0450] In a BLAST search of public sequence datbases, the NOV17a protein was found to have homology to the proteins shown in the BLASTP data in Table 17D.

TABLE 17D
Public BLASTP Results for NOV17a
			Identities/
Protein			Similarities for
Accession		NOV17a Residues/	the Matched	Expect
Number	Protein/Organism/Length	Match Residues	Portion	Value
Q9BYZ2	L-lactate dehydrogenase A-like (EC	1 . . . 380	328/380 (86%)	0.0
	1.1.1.27) - Homo sapiens (Human),	1 . . . 380	344/380 (90%)
	381 aa.
Q96LI2	CDNA FLJ25463 fis, clone	1 . . . 380	325/380 (85%)	0.0
	TST09242 (Lactate dehydrogenase	1 . . . 380	342/380 (89%)
	A-like) - Homo sapiens (Human),
	381 aa.
DEMSLM	L-lactate dehydrogenase (EC	50 . . . 380	220/331 (66%)	e−129
	1.1.1.27) chain M - mouse, 332 aa.	1 . . . 331	271/331 (81%)
P06151	L-lactate dehydrogenase A chain (EC	51 . . . 380	219/330 (66%)	e−128
	1.1.1.27) (LDH-A) (LDH muscle	1 . . . 330	270/330 (81%)
	subunit) (LDH-M) - Mus musculus
	(Mouse), 331 aa.
Q9XT87	L-lactate dehydrogenase A chain (EC	52 . . . 380	219/329 (66%)	e−127
	1.1.1.27) (LDH-A) (LDH muscle	2 . . . 330	269/329 (81%)
	subunit) (LDH-M) - Monodelphis
	domestica (Short-tailed grey
	opossum), 331 aa.

[0451] PFam analysis predicts that the NOV17a protein contains the domains shown in the Table 17E.

TABLE 17E
Domain Analysis of NOV17a
			Identities/
			Similarities for
	Pfam	NOV17a	the Matched	Expect
	Domain	Match Region	Region	Value
	ldh	67 . . . 210	63/156 (40%)	9.1e−55
			120/156 (77%)
	ldh_C	212 . . . 380	68/179 (38%)	4.4e−67
			148/179 (83%)

Example 18

[0452] The NOV18 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 18A.

TABLE 18A
NOV18 Sequence Analysis
                 SEQ ID NO: 279         1015 bp
NOV18a,          CTCTGCTGCTTTAGTTTCGGAGTGTTTGGCGACGGGGCAGCGCGAGATGTGGAGGCTC
CG152227-01
DNA Sequence     ATGTCGAGGTTTAATGCATTCAAAAGGACTAATACCATACTGCACCATTTGAGAATGT
                 CCAAGCACACAGATGCAGCAGAAGAGGTGCTATTGGAAAAAAAAGGTTGCGCGGGAGT
                 CATAACACTAAACAGACCAAAGTTCCTCAATGCACTGACTCTTAATATGATTCGGCAG
                 ATTTATCCACAGCTAAAGAAGTGCGAACAAGATCCTGAAACTTTCCTGATCATTATAA
                 AGGGAGCAGGAGGAAAGGCTTTCTGTGCCGGGGGTGATATCAGAGTGATCTCGGAAGC
                 TGAAAAGGCAAAACAGAAOATAGCTCCAGTTTTCTTCAGAGAAGAATATATGCTGAAT
                 AATGCTGTTGGTTCTTGCCAGAAACCTTATGTTGCACTTATTCATGGAATTACAATGG
                 GTGGGGGAGTTGGTCTCTCAGTCCATGGGCAATTTCGAGTGGCTACAGAAAAGTGTCT
                 TTTTGCTATGCCAGAAACTGCAATAGGACTGTTCCCTGATGTGGGTGGAGGTTATTTC
                 TTGCCACGACTCCAAGGAAAACTTGGTTACTTCCTTGCATTAACAGGATTCAGACTAA
                 AAGGAAGAGATGTGTACAGAGCAGGAATTGCTACACACTTTGTAGATTCTGAAAAGTT
                 GGCCATGTTAGAGGAAGATTTGTTAGCCTTGAAATCTCCTTCAAAAGAAAATATTGCA
                 TCTGTCTTAGAAAATTACCATACAGAGTCTAAGATTGATCGAGACAAGTCTTTTATAC
                 TTGAAGACCAGAGTCCAAAATGGAAACCAGCTGATCTAAAAGAAGCTACTGAGGAAGA
                 TTTGAATAATCACTTTAAGTCTTTGGGAAGCAGTGATTTGAAATTTTGAGGTGACAGG
                 CTTTTAAGGTATATTTTGTAGCATGGGTTGGCAATCTACAGCATGTGGGCCAAATCCA
                 GCCTGCTGCCTGTTTTTATATACCCTGTA
                 ORF Start: ATG at 47                 ORF Stop: TGA at 917
                 SEQ ID NO: 280          290 aa       MW at 32497.3kD
NOV18a,          MWRLMSRFNAFKRTNTILHHLRMSKHTDAAEEVLLEKKGCAGVITLNRPKFLNALTLN
CG152227-01
Protein Sequence MIRQIYPQLKKWEQDPETFLIIIKGAGGKAFCAGGDIRVISEAEKAKQKIAPVFFREE
                 YMLNNAVGSCQKPYVALIHGITMGGGVGLSVHGQFRVATEKCLFANPETAIGLFPDVG
                 GGYFLPRLQGKLGYFLALTGFRLKGRDVYRAGIATHFVDSEKLAMLEEDLLALKSPSK
                 ENIASVLENYHTESKIDRDKSFILEDQSPKWKPADLKEATEEDLNNHFKSLGSSDLKF
                 SEQ ID NO: 281         1311 bp
NOV18b,          AGTCCGGGAGATTCTCCCTCTGCTGCTTTAGTTTCGGAGTGTTTGGCGACGGGGCAGC
CG152227-02
DNA Sequence     GCGAGATGTGGAGGCTCATGTCGAGGTTTAATGCATTCAAAAGGACTAATACCATACT
                 GCACCATTTGAGAATGTCCAAGCACACAGATGCAGCAGAAGAGGTGCTATTGGAAAAA
                 AAAGGTTGCGCGGGAGTCATAACACTAAACAGACCAAAGTTCCTCAATGCACTGACTC
                 TTAATATGATTCGGCAGATTTATCCACAGCTAAAGAAGTGGGAACAAGATCCTGAAAC
                 TTTCGTGATCATTATAAAGGGAGCAGGAGGAAAGGCTTTCTGTGCCGGGGGTGATATC
                 AGAGTGATCTCGGAAGCTGAAAAGGCAAAACAGAAGATAGCTCCAGTTTTCTTCAGAG
                 AAGAATATATGCTGAATAATGCTGTTGGTTCTTGCCAGAAACCTTATGTTGCACTTAT
                 TCATGGAATTACAATGGGTGGGGGAGTTGGTCTCTCAGTCCATGGGCAATTTCGAGTG
                 GCTACAGAAAAGTGTCTTTTTGCTATGCCAGAAACTGCAATAGGACTGTTCCCTGATG
                 TGGGTGGAGGTTATTTCTTTGCCACGACTCCAAGGAAAACTTGGTTACTTCCTTGCAT
                 TAACGGATTCAGACTAAAAGGAAGAGATGTGTACAGAGCAGGAATTGCTACACACTTT
                 GTAGATTCTGAAAAGTTGGCCATGTTAGAGGAAGATTTGTTAGCCTTGAAATCTCCTT
                 CAAAAGAAAATATTGCATCTGTCTTAGAAAATTACCATACAGAGTCTAAGATTGATCG
                 AGACAAGTCTTTTATACTTGAGGAACACATGGACAAAATAAACAGTTGTTTTTCAGCC
                 AATACTGTGGAAGAAATTATTGAAAACTTACAGCAAGATGGTTCATCTTTTGCCCTAG
                 AGCAATTGAAGGTAATTAATAAAATGTCTCCAACATCTCTAAAGATCACACTAAGGCA
                 ACTCATGGAGGGGTCTTCAAAGACCTTGCAAGAAGTACTAACTATGGAGTATCGGCTA
                 AGTCAAGCTTGTATGAGAGGTCATGACTTTCATGAACGCGTTAGAGCTGTTTTAATTG
                 ATAAAGACCAGAGTCCAAAATGGAAACCAGCTGATCTAAAAGAAGTTACTGAGGAAGA
                 TTTGAATAATCACTTTAAGTCTTTGGGAAGCAGTGATTTGAAATTTTGAGGTGACAGG
                 CTTTTAAGGTATATTTTGTAGCATGGGTTGGCAATCTACAGCATGTGGGCCAAATCCA
                 GCCTGCTGCCTGTTTTTATATACCCTGTAAGCAAG
                 ORF Start: ATG at 64                 ORF Stop: TGA at 1207
                 SEQ ID NO: 282          381 aa       MW at 42907.1kD
NOV18b,          MWRLMSRFNAFKRTNTILHHLRMSKHTDAAEEVLLEKKGCAGVITLNRPKFLNALTLN
CG152227-02
Protein Sequence MIRQIYPQLKKWEQDPETFVIIIKGAGGKAFCAGGDIRVISEAEKAKQKIAPVFFREE
                 YMLNNAVGSCQKPYVALIHGITMGGGVGLSVHGQFRVATEKCLFAMPETAIGLFPDVG
                 GGYFFATTPRKTWLLPCINGFRLKGRDVYRAGIATHFVDSEKLANLEEDLLALKSPSK
                 ENIASVLENYHTESKIDRDKSFILEEHMDKINSCFSANTVEEIIENLQQDGSSFALEQ
                 LKVINKNSPTSLKITLRQLMEGSSKTLQEVLTMEYRLSQACMRGHDFHEGVRAVLIDK
                 DQSPKWKPADLKEVTEEDLNNHFKSLGSSDLKF

[0453] Sequence comparison of the above protein sequences yields the following sequence relationships shown in Table 18B.

TABLE 18B
Comparison of NOV18a against NOV18b.
		Identities/
		Similarities for
Protein	NOV18a Residues/	the Matched
Sequence	Match Residues	Region
NOV18b	1 . . . 278	246/278 (88%)
	1 . . . 278	250/278 (89%)

[0454] Further analysis of the NOV18a protein yielded the following properties shown in Table 18C.

TABLE 18C
Protein Sequence Properties NOV18a
PSort     0.6784 probability located in mitochondrial matrix space;
analysis: 0.3893 probability located in microbody (peroxisome);
          0.3672 probability located in mitochondrial inner
          membrane; 0.3672 probability located in mitochondrial
          intermembrane space
SignalP   No Known Signal Sequence Predicted
analysis:

[0455] A search of the NOV18a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 18D.

TABLE 18D
Geneseq Results for NOV18a
			Identities/
			Similarities for
Geneseq	Protein/Organism/Length	NOV18a Residues/	the Matched	Expect
Identifier	[Patent #, Date]	Match Residues	Region	Value
AAW81135	Human 3-hydroxyisobutyryl-	1 . . . 278	259/278 (93%)	e−147
	coenzyme A hydrolase - Homo	1 . . . 278	261/278 (93%)
	sapiens, 381 aa. [WO9851782-A2,
	19 NOV. 1998]
AAG75795	Human colon cancer antigen protein	2 . . . 176	158/175 (90%)	1e−86
	SEQ ID NO: 6559 - Homo sapiens,	1 . . . 175	159/175 (90%)
	178 aa. [WO200122920-A2, 05
	APR. 2001]
ABB61217	Drosophila melanogaster	29 . . . 278	131/253 (51%)	2e−63
	polypeptide SEQ ID NO 10443 -	8 . . . 250	171/253 (66%)
	Drosophila melanogaster, 351 aa.
	[WO200171042-A2, 27 SEP. 2001]
AAG23865	Arabidopsis thaliana protein	23 . . . 254	98/233 (42%)	9e−50
	fragment SEQ ID NO: 27329 -	1 . . . 232	148/233 (63%)
	Arabidopsis thaliana, 378 aa.
	[EP1033405-A2, 06 SEP. 2000]
AAG23866	Arabidopsis thaliana protein	32 . . . 254	97/224 (43%)	1e−49
	fragment SEQ ID NO: 27330 -	6 . . . 228	145/224 (64%)
	Arabidopsis thaliana, 374 aa.
	[EP1033405-A2, 06 SEP. 2000]

[0456] In a BLAST search of public sequence datbases, the NOV18a protein was found to have homology to the proteins shown in the BLASTP data in Table 18E.

TABLE 18E
Public BLASTP Results for NOV18a
			Identities/
Protein			Similarities for
Accession		NOV18a Residues/	the Matched	Expect
Number	Protein/Organism/Length	Match Residues	Portion	Value
Q9BS94	Similar to 3-hydroxyisobutyryl-	1 . . . 278	261/278 (93%)	e−148
	coenzyme A hydrolase - Homo	1 . . . 278	263/278 (93%)
	sapiens (Human), 333 aa.
Q92931	3-hydroxyisobutyryl-coenzyme A	1 . . . 278	246/278 (88%)	e−138
	hydrolase - Homo sapiens	1 . . . 278	250/278 (89%)
	(Human), 381 aa.
Q8QZS1	Similar to 3-hydroxyisobutyryl-	2 . . . 278	207/277 (74%)	e−118
	coenzyme A hydrolase - Mus	7 . . . 282	238/277 (85%)
	musculus (Mouse), 385 aa.
Q9VF79	CG5044 protein - Drosophila	29 . . . 278	131/253 (51%)	6e−63
	melanogaster (Fruit fly), 351 aa.	8 . . . 250	171/253 (66%)
Q960K8	LD47223p - Drosophila	29 . . . 278	131/253 (51%)	6e−63
	melanogaster (Fruit fly), 385 aa.	42 . . . 284	171/253 (66%)

[0457] PFam analysis predicts that the NOV18a protein contains the domains shown in the Table 18F.

TABLE 18F
Domain Analysis of NOV18a
			Identities/
			Similarities for
	Pfam	NOV18a	the Matched	Expect
	Domain	Match Region	Region	Value
	ECH	42 . . . 213	54/176 (31%)	2.3e−17
			112/176 (64%)

Example 19

[0458] The NOV19 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 19A.

TABLE 19A
NOV19 Sequence Analysis
                 SEQ ID NO: 283         1935 bp
NOV19a,          GTGCTGGCTTGCCCTGCAAATTGTGTCTGCAGCAAGACTGAGATCAATTGCCGGCGGC
CG152392-01
DNA Sequence     CGCACGATGCCAACCTCTTCCCCCTCCTGGAAGGGCAGGATTCAGGGAACAGCAATGG
                 GAACGCCAGTATCAACATCACGGACATCTCAAGGAATATCACTTCCATACACATAGAG
                 AACTGGCGCAGTCTTCACACGCTCAACGCCGTGGACATGCAGCTCTACACCGGACTTC
                 AAAAGCTGACCATCAAGAACTCAGGACTTCGGAGCATTCAGCCCAGAGCCTTTGCCAA
                 GAACCCCCATTTGCGTTATATAAACCTGTCAAGTAACCGGCTCACCACACTCTCGTGG
                 CAGCTCTTCCAGACGCTCAGTCTTCGGGAATTGCAGTTGGAGCAGAACTTTTTCAACT
                 GCAGCTGTGACATCCGCTCGATGCAGCTCTGGCAGGAGCAGGGGGAGGCCAAGCTCAA
                 CAGCCAGAACCTCTACTGCATCAATGCTGATGCCTCCCAGCTTCCTCTCTTCCGCATG
                 AACATCAGTCAGTGTGACCTTCCTGAGATCAGCGTGAGCCACGTCAACCTGACCGTAC
                 GAGAGGGTGACAATGCTGTTATCACTTGCAATGGCTCTGGATCACCCCTTCCTGATGT
                 GGACTGGATAGTCACTGGGCTGCAGTCCATCAACACTCACCAGACCAATCTGAACTGG
                 ACCAATCTTCATGCCATCAACTTGACGCTGGTGAATGTGACGAGTGAGGACAATGGCT
                 TCACCCTGACGTGCATTGCAGAGAACGTGGTGGGCATGAGCAATGCCAGTGTTGCCCT
                 CACTGTCTACTATCCCCCACGTGTGGTGAGCCTGGAGGAGCCTGAGCTGCGCCTGGAG
                 CACTGCATCGAGTTTGTCGTGCGTGGCAACCCCCCACCAACGCTGCACTGGCTGCACA
                 ATGGGCAGCCTCTGCGGGAGTCCAAGATCATCCATGTGGAATACTACCAAGAGGGAGA
                 GATTTCCGAGGGCTGCCTGCTCTTCAACAAGCCCACCCACTACAACAATGGCAACTAT
                 ACCCTCATTGCCAAAAACCCACTGGGCACAGCCAACCAGACCATCAATGGCCACTTCC
                 TCAAGGAGCCCTTTCCAGTTGACGAAGTGAGTCCCACACCTCCTATCACTGTGACCCA
                 CAAACCAGAAGAAGACACTTTTGGGGTATCCATAGCAGTTGGACTTGCTGCTTTTGCC
                 TGTGTCCTGTTGGTGGTTGTCTTCGTCATGATCAACAAATATGGTCGACGGTCCAAAT
                 TTGCAATGAACGGTCCCGTGGCTGTCATCAGTGGTGAGGAGGACTCAGCCAGCCCACT
                 GCACCACATCAACCACGGCATCACCACGCCCTCGTCACTGGATGCGGGGCCCGACACT
                 GTGGTCATTGGCATGACTCGCATCCCTGTCATTGAGAACCCCCAGTACTTCCGTCAGG
                 GACACAACTGCCACAAGCCGGACACGTGGGTCTTTTCAAACATAGACAATCATGGGAT
                 ATTAAACTTGAAGGACAATAGAGATCATCTAGTCCCATCAACTCACTATATATATGAG
                 GAACCTGAGGTCCAGAGTGGGGAAGTGTCTTACCCAAGGTCACATGGTTTCAGAGAAA
                 TTATGTTGAATCCAATAAGCCTTCCCGGACATTCCAAGCCTCTTAACCATGGCATCTA
                 TGTTGAGGATGTCAATGTTTATTTCAGCAAAGGACGTCATGGCTTTTAAAAACTCCTT
                 TTAAGCCTCCTTGTTTTGATGTCACCTTGGTAGGCTGGGCCCTCTGAGAGGTTGGAAG
                 CTCTAGGCATTGTTCTCTTTGGATCCAGGGATGCTAAGTAGAAACTGCATGAGCCACC
                 AGTGCCCCGGCACCCTTTAACACCACCAGATGGGTGTTTTCCCCCATCCACCACTGGC
                 AGGGCTTGCCAGGAGTAAGAG
                 ORF Start: at 1                      ORF Stop: TAA at 1729
                 SEQ ID NO: 284          576 aa       MW at 64294.1kD
NOV19a,          VLACPANCVCSKTEINCRRPDDGNLFPLLEGQDSGNSMGNASINITDISRNITSIHIE
CG152392-01
Protein Sequence NWRSLHTLNAVDMELYTGLQKITIKNSGLRSIQPRAFAKNPHLRYINLSSNRLTTLSW
                 QLFQTLSLRELQLEQNFFNCSCDIRWMQLWQEQGEAKLNSQNLYCINADGSQLPLFRN
                 NISQCDLPETSVSHVNLTVREGDNAVITCNGSGSPLPDVDWIVTGLQSINTHQTNLNW
                 TNVHAINLTLVNVTSEDMGFTLTCIAENVVGMSNASVALTVYYPPRVVSLEEPELRLE
                 HCIEFVVRGNPPPTLHWLHNGQPLRESKIIHVEYYQEGEISEGCLLFNKPTHYNNGNY
                 TLIAKNPLGTANQTINGHFLKEPFPVDEVSPTPPITVTHKPEEDTFGVSIAVGLAAFA
                 CVLLVVVFVMINKYGRRSKFGMKGPVAVISGEEDSASPLHHINHGITTPSSLDAGPDT
                 VVIGMTRIPVIENPQYFRQGHNCHKPDTWVFSNIDNHGILNLKDNRDHLVPSTHYIYE
                 EPEVQSGEVSYPRSHGFREIMLNPISLPGHSKPLNHGIYVEDVNVYFSKGRHGF

[0459] Further analysis of the NOV19a protein yielded the following properties shown in Table 19B.

TABLE 19B
Protein Sequence Properties NOV19a
PSort     0.8357 probability located in mitochondrial inner membrane;
analysis: 0.8200 probability located in plasma membrane; 0.3000
          probability located in microbody (peroxisome); 0.2000
          probability located in endoplasmic reticulum (membrane)
SignalP   No Known Signal Sequence Predicted
analysis:

[0460] A search of the NOV19a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 19C.

TABLE 19C
Geneseq Results for NOV19a
			Identities/
			Similarities for
Geneseq	Protein/Organism/Length	NOV19a Residues/	the Matched	Expect
Identifier	[Patent #, Date]	Match Residues	Region	Value
AAY51602	Human truncated trkC receptor	1 . . . 576	573/584 (98%)	0.0
	protein - Homo sapiens, 612 aa.	29 . . . 612	575/584 (98%)
	[US6027927-A, 22 FEB. 2000]
AAR81627	Human trkC receptor protein	1 . . . 494	490/494 (99%)	0.0
	mutant - Homo sapiens, 830 aa.	29 . . . 521	493/494 (99%)
	[WO9525795-A1, 28 SEP. 1995]
AAY06595	Neurotrophin-3 receptor TrkC -	1 . . . 494	491/502 (97%)	0.0
	Homo sapiens, 825 aa.	29 . . . 530	493/502 (97%)
	[WO9940103-A1, 12 AUG. 1999]
AAM50853	Human receptor tyrosine kinase	1 . . . 494	490/502 (97%)	0.0
	TrkC - Homo sapiens, 839 aa.	29 . . . 530	493/502 (97%)
	[WO200203071-A2, 10 JAN.
	2002]
AAY51601	Human trkC receptor protein -	1 . . . 494	490/502 (97%)	0.0
	Homo sapiens, 839 aa.	29 . . . 530	493/502 (97%)
	[US6027927-A, 22 FEB. 2000]

[0461] In a BLAST search of public sequence datbases, the NOV19a protein was found to have homology to the proteins shown in the BLASTP data in Table 19D.

TABLE 19D
Public BLASTP Results for NOV19a
			Identities/
Protein			Similarities for
Accession		NOV19a Residues/	the Matched	Expect
Number	Protein/Organism/Length	Match Residues	Portion	Value
Q96CY4	Hypothetical 68.5 kDa protein -	1 . . . 576	574/584 (98%)	0.0
	Homo sapiens (Human), 612 aa.	29 . . . 612	575/584 (98%)
I73633	gene trkC protein - human, 612 aa.	1 . . . 576	573/584 (98%)	0.0
		29 . . . 612	575/584 (98%)
Q9Z2P9	Neurotrophin-3 receptor non-	1 . . . 576	553/584 (94%)	0.0
	catalytic isoform 2 - Mus	29 . . . 612	568/584 (96%)
	musculus (Mouse), 612 aa.
A55178	neurotrophin receptor trkC	1 . . . 494	491/502 (97%)	0.0
	precursor - human, 825 aa.	29 . . . 530	493/502 (97%)
O75682	TRKC protein - Homo sapiens	1 . . . 494	491/502 (97%)	0.0
	(Human), 839 aa.	29 . . . 530	493/502 (97%)

[0462] PFam analysis predicts that the NOV19a protein contains the domains shown in the Table 19E.

TABLE 19E
Domain Analysis of NOV19a
			Identities/
			Similarities for
	Pfam	NOV19a	the Matched	Expect
	Domain	Match Region	Region	Value
	LRRNT	3 . . . 30	9/31 (29%)	0.00013
			23/31 (74%)
	LRR	100 . . . 123	8/25 (32%)	0.0043
			22/25 (88%)
	LRRCT	132 . . . 180	13/54 (24%)	2.4e−10
			40/54 (74%)
	ig	196 . . . 258	20/65 (31%)	4.8e−07
			43/65 (66%)

Example 20

[0463] The NOV20 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 20A.

TABLE 20A
NOV20 Sequence Analysis
                 SEQ ID NO: 285         1201 bp
NOV2Oa,          GCCCTTCTGGCAGGAAGAGGAAGATGTCTGTGCTCAGGCGGATGATGCCGGTTTCCAA
CG152453-01
DNA Sequence     TCGCTCTCTCCTCGCCTTCATCTTCTTCTTCTCCCTCTCTTCGTCCTGTCTGTACTTC
                 ATCTATGTGGCCCCAGGCATCGCCAACACATATCTCTTTATGGTACAAGCTCGAGGTA
                 TAATGTTGAGAGAAAATGTGAAAACAATAGGTCATATGATCAGGCTGTACACAAATAA
                 AAACAGTACGCTCAACGGTACAGATTATCCCGAAGGCAATAATTCAAGTGATTATCTT
                 GTTCAAACAACAACGTATCTCCCGGAAAACTTCACATACTCACCATACCTCCCCTGTC
                 CAGAAAAGCTGCCTTATATGCGAGGATTCCTCAATGTCAATGTAACCGAAGTCAGTTT
                 TGATGAAATTCATCAACTCTTCTCCAACOATTTAGATATTGAGCCAGGGGGTCATTGG
                 AGGCCAAAAGACTGTAAACCCAGATGGAAGGTGGCAGTTCTCATTCCTTTCCGTAATC
                 GCCATGAACATCTTCCAATTTTTTTCTTACATCTGATTCCAATGCTCCAGAAGCAGCG
                 GCTGGAATTTGCGTTTTATGTCATTGAACAGACTGGCACACAACCTTTTAACCGTGCG
                 ATGCTTTTCAATGTGGGCTTCAAAGAGCCCATGAAACACAGTGTCTGGGACTGTGTAA
                 TCTTCCACCATGTGGATCATCTACCTCAAAATGACCGGAACTATTACGGATGTGGAGA
                 AATGCCACGTCATTTTGCTGCAAAGCTGGATAAATACATGTATATTCTTCCATATAAA
                 GAATTTTTTGGTGGTGTAAGTGGGCTGACAGTGGAACAATTTAGAAAGATCAATGGTT
                 TTCCTAATGCCTTCTGGGGATGGGGAGGAGAAGATGATGACCTTTGGAACAGAGTTCA
                 CTATGCTGGATATAATGTAACCAGACCAGAGGGAGACTTAGGAAAATACAAGTCAATT
                 CCTCATCACCATAGAGGTGAAGTCCAGTTTTTAGGACGGTATAAATTACTAAGGTATT
                 CCAAGGAGCGTCAGTACATCGATGGACTGAACAATTTAATATATAGGCCAAAAATACT
                 GGTTGATAGGTTGTATACAAACATATCTGTAAACCTCATGCCAGAGTTAGCTCCAATC
                 GAAGACTATTAAAAGAAGTGGCTGTCGTGGCAAGGTAGACC
                 ORF Start: ATG at 24                 ORF Stop: TAA at 1170
                 SEQ ID NO: 286          382 aa       MW at 44913.2kD
NOV20a,          MSVLRRMMRVSNRSLLAFIFFFSLSSSCLYFIYVAPGIANTYLFMVQARGIMLRENVK
CG152453-01
Protein Sequence TIGHMIRLYTNKNSTLNGTDYPEGNNSSDYLVQTTTYLPENFTYSPYLPCPEKLPYMR
                 GFLNVNVSEVSFDEIHQLFSKDLDIEPGGHWRPKDCKPRWKVAVLIPFRNRHEHLPIF
                 FLHLIPMLQKQRLEFAFYVIEQTGTQPFNRAMLFNVGFKEAMKDSVWDCVIFHDVDHL
                 PENDRNYYGCGEMPRHFAAKLDKYMYILPYKEFFGGVSGLTVEQFRKINGFPNAFWGW
                 GGEDDDLWNRVHYAGYNVTRPEGDLGKYKSIPHHHRGEVQFLGRYKLLRYSKERQYID
                 GLNNLIYRPKILVDRLYTNISVNLMPELAPIEDY
                 SEQ ID NO: 287         1062 bp
NOV20b,          GATGTCTGTGCTCAGGCGGATGATGCGGGTTTCCAATCGCTCTCTCCTCGCCTTCATC
CG152453-03
DNA Sequence     TTCTTCTTCTCCCTCTCTTCGTCCTGTCTGTACTTCATCTATGTGGCCCCAGGCATCG
                 ATTATCCCGAAGGCAATAATTCAAGTGATTATCTTGTTCAAACAACAACGTATCTCCC
                 GGAAAACTTCACATACTCACCATACCTCCCCTGTCCAGAAAAGCTGCCTTATATGCGA
                 GGATTCCTCAATGTCAATGTAAGCGAAGTCAGTTTTGATGAAATTCATCAACTCTTCT
                 CCAAGGATTTAGATATTGAGCCAGGGGGTCATTGGAGGCCAAAAGACTGTAAACCCAG
                 ATGGAAGGTGGCAGTTCTCATTCCTTTCCGTAATCGCCATGAACATCTTCCAATTTTT
                 TTCTTACATCTGATTCCAATGCTCCAGAAGCAGCGGCTGGAATTTGCGTTTTATGTCA
                 TTGAACAGACTGGCACACAACCTTTTAACCGTGCGATGCTTTTCAATGTGGGCTTCAA
                 AGAGGCCATGAAAGACAGTGTCTGGGACTGTGTAATCTTCCACGATGTGGATCATCTA
                 CCTGAAAATGACCGGAACTATTACGGATGTGGAGAAATGCCACGTCATTTTGCTGCAA
                 AGCTGGATAAATACATGTATATTCTTCCATATAAAGAATTTTTTGGTGGTGTAAGTGG
                 GCTGACAGTGGAACAATTTAGAAAGATCAATGGTTTTCCTAATGCCTTCTGGGGATCG
                 GGAGGAGAAGATGATGACCTTTCGAACAGAGTTCACTATGCTGGATATAATGTAACCA
                 GACCAGAGGGAGACTTAGGAAAATACAAGTCAATTCCTCATCACCATAGAGGTGAAGT
                 CCAGTTTTTAGGACGGTATAAATTACTAAGGTATTCCAAGGAGCGTCAGTACATCGAT
                 GGACTGAACAATTTAATATATAGGCCAAAAATACTGGTTGATAGGTTGTATACAAACA
                 TATCTGTAAACCTCATGCCAGAGTTAGCTCCAATCGAAGACTATTAAAAGAAGTGGCT
                 GTCGTGGCAAGGTAGACC
                 ORF Start: ATG at 2                  ORF Stop: TAA at 1031
                 SEQ ID NO: 288          343 aa       MW at 40460.0kD
NOV20b,          MSVLRRMMRVSNRSLLAFIFFFSLSSSCLYFIYVAPGIDYPEGNNSSDYLVQTTTYLP
CG152453-03
Protein Sequence ENFTYSPYLPCPEKLPYMRGFLNVNXTSEVSFDEIHQLFSKDLDIEPGGHWRPKDCKPR
                 WKVAVLIPFRNRHEHLPIFFLHLIPMLQKQRLEFAFYVIEQTGTQPFNRAMLFNVGFK
                 EAMKDSVWDCVIFHDVDHLPENDRNYYGCGEMPRHFAAKLDKYMYILPYKEFFGGVSC
                 LTVEQFRKINGFPNAFWGWGGEDDDLWNRVHYAGYNVTRPEGDLGKYKSIPHHHRGEV
                 QFLGRYKLLRYSKERQYIDGLNNLIYRPKILVDRLYTNISVNLMPELAPIEDY
                 SEQ ID NO: 289         1100 bp
NOV20c,          ATGTCTGTGCTCAGGCGGATGATGCGGGTTTCCAATCGCTCTCTCCTCGCCTTCATCT
CG152453-02
DNA Sequence     TCTTCTTCTCCCTCTCTTCGTCCTGTCTGTACTTCATCTATGTGGCCCCAGGCATCGC
                 CAACACACATCTCTTTATGGTACAAGCTCGAGGTATAATGTTGAGAGAAAATGTGAAA
                 ACAATAGGTCATATGATCAGGCTGTACACAAATAAAAACAGTACGCTCAACGGTACAG
                 ATTATCCCGAAGGCAATAATTCAAGTGATTATCTTGTTCAAACAACAACGTATCTCCC
                 GGAAAACTTCACATACTCACCATACCTCCCCTGTCCAGAAAAGCTGCCTTATATGCGA
                 GGATTCCTCAATGTCAATGTAAGCGAAGTCAGTTTTGATGAAATTCATCAACTCTTCT
                 CCAAGGATTTAGATATTGAGCCAGGGGGTCATTGGAGGCCAAAAGACTGTAAACCCAG
                 ATGGAAGAAGCAGCGGCTGGAATTTGCGTTTTATGTCATTGAACAGACTGGCACACAA
                 CCTTTTAACCGTGCGATGCTTTTCAATGTGGGCTTCAAACAGGCCATGAAAGACAGTG
                 TCTGGGACTGTGTAATCTTCCACGATGTGGATCATCTACCTGAAAATGACCGGAACTA
                 TTACGGATGTGGAGAAATGCCACGTCATTTTGCTGCAAAGCTGGATAAATACATGTAT
                 ATTCTTCCATATAAAGAATTTTTTGGTGGTGTAAGTGGGCTGACAGTGGAACAATTTA
                 GAAAGATCAATGGTTTTCCTAATGCCTTCTGGGGATGGGCAGGAGAAGATGATGACCT
                 TTGGAACAGAGTTCACTATGCTGGATATAATGTAACCAGACCAGAGGGAGACTTAGGA
                 AAATACAAGTCAATTCCTCATCACCATAGAGGTGAAGTCCAGTTTTTAGGACGGTATA
                 AATTACTAAGGTATTCCAAGGAGCGTCAGTACATCGATGGACTGAACAATTTAATATA
                 TAGGCCAAAAATACTGGTTGATAGGTTGTATACAAACATATCTGTAAACCTCATGCCA
                 GAGTTAGCTCCAATCGAAGACTATTAAAAGAAGTGGCTGTCGTGGCAAGGTAGACC
                 ORF Start: ATG at 1                  ORF Stop: TAA at 1069
                 SEQ ID NO: 290          356 aa       MW at 41753.4kD
NOV20c,          MSVLRRMNRVSNRSLLAFIFFFSLSSSCLYFIYVAPGIANTHLFMVQARGIMLRENVK
CG152453-02
Protein Sequence TIGHMIRLYTNKNSTLNGTDYPEGNNSSDYLVQTTTYLPENFTYSPYLPCPEKLPYMR
                 GFLNVNVSEVSFDEIHQLFSKDLDIEPGGHWRPKDCKPRWKKQRLEFAFYVIEQTGTQ
                 PFNRAMLFNVGFKEANKDSVWDCVIFHDVDHLPENDRNYYGCGEMPRHFAAKLDKYMY
                 ILPYKEFFGGVSCLTVEQFRKINGFPNAFWGWGGEDDDLWNRVHYAGYNVTRPEGDLG
                 KYKSIPHHHRGEVQFLGRYKLLRYSKERQYIDGLNNLIYRPKILVDRLYTNISVNLMP
                 ELAPIEDY

[0464] Sequence comparison of the above protein sequences yields the following sequence relationships shown in Table 20B.

TABLE 20B
Comparison of NOV20a against NOV20b and NOV20c.
			Identities/
			Similarities for
	Protein	NOV20a Residues/	the Matched
	Sequence	Match Residues	Region
	NOV20b	1 . . . 382	343/382 (89%)
		1 . . . 343	343/382 (89%)
	NOV20c	1 . . . 382	355/382 (92%)
		1 . . . 356	356/382 (92%)

[0465] Further analysis of the NOV20a protein yielded the following properties shown in Table 20C.

TABLE 20C
Protein Sequence Properties NOV20a
PSort     0.8541 probability located in lysosome (lumen); 0.7189
analysis: probability located in outside; 0.2757 probability
          located in microbody (peroxisome); 0.1000 probability
          located in endoplasmic reticulum (membrane)
SignalP   Cleavage site between residues 28 and 29
analysis:

[0466] A search of the NOV20a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 20D.

TABLE 20D
Geneseq Results for NOV20a
			Identities/
			Similarities for
Geneseq	Protein/Organism/Length	NOV20a Residues/	the Matched	Expect
Identifier	[Patent #, Date]	Match Residues	Region	Value
AAW81569	Human lactosyl ceramide synthase -	1 . . . 382	382/382 (100%)	0.0
	Homo sapiens, 382 aa.	1 . . . 382	382/382 (100%)
	[JP10295371-A, 10 NOV. 1998]
ABG23077	Novel human diagnostic protein	1 . . . 382	381/382 (99%)	0.0
	#23068 - Homo sapiens, 404 aa.	23 . . . 404	382/382 (99%)
	[WO200175067-A2, 11 OCT. 2001]
AAW81567	Rat lactosyl ceramide synthase -	1 . . . 382	360/382 (94%)	0.0
	Rattus sp, 382 aa. [JP10295371-A,	1 . . . 382	376/382 (98%)
	10 NOV. 1998]
AAW81568	Mouse lactosyl ceramide synthase -	1 . . . 382	362/382 (94%)	0.0
	Mus sp, 382 aa. [JP10295371-A,	1 . . . 382	374/382 (97%)
	10 NOV. 1998]
AAB26791	Human galactoside transferase	1 . . . 382	342/382 (89%)	0.0
	I-type homologous protein - Homo	1 . . . 343	343/382 (89%)
	sapiens, 343 aa. [CN1257925-A,
	28 JUN. 2000]

[0467] In a BLAST search of public sequence datbases, the NOV20a protein was found to have homology to the proteins shown in the BLASTP data in Table 20E.

TABLE 20E
Public BLASTP Results for NOV20a
			Identities/
Protein			Similarities for
Accession		NOV20a Residues/	the Matched	Expect
Number	Protein/Organism/Length	Match Residues	Portion	Value
Q9UBX8	Beta-1,4-galactosyltransferase 6 (EC	1 . . . 382	382/382 (100%)	0.0
	2.4.1.-) (Beta-1,4-GalTase 6)	1 . . . 382	382/382 (100%)
	(Beta4Gal-T6) (b4Gal-T6) (UDP-
	galactose: beta-N-acetylglucosamine
	beta- 1,4-galactosyltransferase 6)
	(UDP-Gal: beta-GlcNAc beta-1,4-
	galactosyltransferase 6) [Includes:
	Lactosylceramide synthase (EC 2.4.1.-)
	(LacCer synthase) (UDP-
	Gal: glucosylceramide beta-1,4-
	galactosyltransferase)] - Homo sapiens
	(Human), 382 aa.
O88419	Beta-1,4-galactosyltransferase 6 (EC	1 . . . 382	360/382 (94%)	0.0
	2.4.1.-) (Beta-1,4-GalTase 6)	1 . . . 382	376/382 (98%)
	(Beta4Gal-T6) (b4Gal-T6) (UDP-
	galactose: beta-N-acetylglucosamine
	beta- 1,4-galactosyltransferase 6)
	(UDP-Gal: beta-GlcNAc beta-1,4-
	galactosyltransferase 6) [Includes:
	Lactosylceramide synthase (EC 2.4.1.-)
	(LacCer synthase) (UDP-
	Gal: glucosylceramide beta-1,4-
	galactosyltransferase)] - Rattus
	norvegicus (Rat), 382 aa.
Q9WVK5	Beta-1,4-galactosyltransferase 6	1 . . . 382	362/382 (94%)	0.0
	(EC 2.4.1.-) (Beta-1,4-GalTase 6)	1 . . . 382	374/382 (97%)
	(Beta4Gal-T6) (b4Gal-T6) (UDP-
	galactose: beta-N-acetylglucosamine
	beta- 1,4-galactosyltransferase 6)
	(UDP-Gal: beta-GlcNAc beta-1,4-
	galactosyltransferase 6) [Includes:
	Lactosylceramide synthase (EC 2.4.1.-)
	(LacCer synthase) (UDP-
	Gal: glucosylceramide beta-1,4-
	galactosyltransferase)] - Mus musculus
	(Mouse), 382 aa.
Q8WZ95	Beta-1,4-galactosyltransferase - Homo	1 . . . 382	342/382 (89%)	0.0
	sapiens (Human), 343 aa.	1 . . . 343	343/382 (89%)
O43286	Beta-1,4-galactosyltransferase 5	1 . . . 382	273/388 (70%)	e−169
	(EC 2.4.1.-) (Beta-1,4-GalTase 5)	1 . . . 388	321/388 (82%)
	(Beta4Gal-T5) (b4Gal-T5) (UDP-
	galactose: beta-N-acetylglucosamine
	beta- 1,4-galactosyltransferase 5)
	(UDP-Gal: beta-GlcNAc beta-1,4-
	galactosyltransferase 5) (EC 2.4.1.-)
	(Beta-1,4-GalT II) - Homo sapiens
	(Human), 388 aa.

[0468] PFam analysis predicts that the NOV20a protein contains the domains shown in the Table 20F.

TABLE 20F
Domain Analysis of NOV20a
		Identities/
		Similarities for
Pfam	NOV20a	the Matched	Expect
Domain	Match Region	Region	Value
Galactosyl_T_2	108 . . . 375	157/329 (48%)	3.2e−187
		266/329 (81%)

Example 21

[0469] The NOV21 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 21A.

TABLE 21A
NOV21 Sequence Analysis
                 SEQ ID NO: 291         1327 bp
NOV21a,          ATGGGCCGCTACTCTGGCAAGACGTGCCGGCTGCTCTTCATGCTGGTGCTCACCGTCG
CG152547-01
DNA Sequence     CCTTCTTCGTGGCGGAGCTGGTCTCCGGCTACCTGGGCAACTCCATCGCGCTGCTCTC
                 CGACTCCTTCAACATGCTCTCCGACCTGATCTCGCTGTGCGTGGGCCTGAGCGCCGGC
                 TACATCGCCCGGCGCCCCACCCGGGGCTTCAGCGCCACCTACGGCTACGCCCGCGCCG
                 AGGTGGTGGGCGCGCTGAGCAACGCGGTCTTCCTCACCGCGCTCTGCTTCACCATCTT
                 CGTGGAGGCCGTGCTGCGCCTGGCCCGGCCCGAGCGCATCGATGACCCCGAGCTGGTG
                 CTCATCGTCGGCGTCCTGGGGCTGTTGGTCAACGTGGTGGGGCTGCTCATCTTCCATC
                 ACCAATCCCTAATCTCAAGTAATCAGGGACACAAACACTGCGGAAGGCCGCAGGGTCC
                 TCTGCCTAGGAAAACCAGAAACACCCAGAATGAGCCAGAAGACATGATGAAAAAAGAG
                 AAAAAGTCTGAAGCTCTGAATATCAGAGGTGTACTTTTGCATGTGATGGGAGATGCCC
                 TGGGGTCCGTGGTTGTGGTCATCACGGCCATCATATTCTATGTGCTTCCCCTGAAGAG
                 TGAGGACCCGTGTAACTGGCAGTGTTACATTGACCCCAGCCTGACTGTCCTCATGGTC
                 ATCATCATTTTGTCATCTGCCTTCCCGCTTATCAAGGAGACCGCTGCCATTCTGCTAC
                 AGATGGTCCCAAAAGGAGTCAACATGGAAGAGCTGATGAGTAAACTCTCTGCTGTGCC
                 TGGAATTAGCAGTGTACATGAAGTGCACATCTGGCAACTTGTAAGTGGAAAGATTATT
                 GCCACCCTGCACATCAAGTATCCTAAGGACAGGGGATATCAAGATGCCAGCACAAAAA
                 TTCGAGAAATCTTCCACCATGCGGGAATCCACAATGTGACCATCCAGTTTGAAAATGT
                 GGACTTGAAGGAACCCCTGGAGCAGAAGGACTTACTGTTGCTCTGCAACTCACCCTGC
                 ATCTCCAAGGGCTGTGCTAAGCAGCTGTGTTGTCCCCCCGGGGCACTGCCTCTGGCTC
                 ACGTCAATGGCTGTGCTGAGCACAATGGTGGGCCCTCTCTAGACACATACGGAAGTGA
                 TGGCCTCAGTAGAAGAGACGCAAGAGAAGTGGCTATTGAAGTGTCTTTGGATAGCTGT
                 CTGAGTGACCACGGACAATGTCTTAACAAAACTCAGGAGGACCAATGTTATGTCAACA
                 GAACGCATTTTTAATCTGGTACTCACATAATCAGACCATATAGACGAGAAG
                 ORF Start: ATG at 1                  ORF Stop: TAA at 1288
                 SEQ ID NO: 292          429 aa       MW at 46990.2kD
NOV21a,          MGRYSGKTCRLLFMLVLTVAFFVAELVSGYLGNSIALLSDSFNMLSDLISLCVGLSAG
CG152547-01
Protein Sequence YIARRPTRGFSATYGYARAEVVGALSNAVFLTALCFTIFVEAVLRLARPERIDDPELV
                 LIVGVLGLLVNVVGLLIFHHQSLISSNQGHKHCGRPQGPLPRKTRNTQNEPEDMMKKE
                 KKSEALNIRGVLLHVMGDALGSVVVVITAIIFYVLPLKSEDPCNWQCYIDPSLTVLMV
                 IIILSSAFPLIKETAAILLQMXTPKGVNMEELMSKLSAVPGISSVHEVHIWELVSGKII
                 ATLHIKYPKDRGYQDASTKIREIFHAGIHNVTIQFENVDLKEPLEQKDLLLLCNSPC
                 ISKGCAKQLCCPPGALPLAHVNGCAEHNGGPSLDTYGSDGLSRRDAREVAIEVSLDSC
                 LSDHCQCLNKTQEDQCYVNRTHF

[0470] Further analysis of the NOV21a protein yielded the following properties shown in Table 21B.

TABLE 21B
Protein Sequence Properties NOV21a
PSort     0.6400 probability located in plasma membrane;
analysis: 0.4600 probability located in Golgi body;
          0.3700 probability located in endoplasmic
          reticulum (membrane); 0.1000 probability
          located in endoplasmic reticulum (lumen)
SignalP   Cleavage site between residues 30 and 31
analysis:

[0471] A search of the NOV21a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 21C.

TABLE 21C
Geneseq Results for NOV21a
			Identities/
			Similarities for
Geneseq	Protein/Organism/Length	NOV21a Residues/	the Matched	Expect
Identifier	[Patent #, Date]	Match Residues	Region	Value
ABP51303	Human MDDT SEQ ID NO 325 -	1 . . . 429	410/485 (84%)	0.0
	Homo sapiens, 520 aa.	36 . . . 520	413/485 (84%)
	[WO200240715-A2, 23 MAY 2002]
AAU99906	Human 83378 metal transporter	1 . . . 429	408/485 (84%)	0.0
	protein - Homo sapiens, 485 aa.	1 . . . 485	411/485 (84%)
	[WO200240656-A2, 23 MAY 2002]
AAM52621	Human zinc ion transport protein	190 . . . 429	238/240 (99%)	e−138
	26 - Homo sapiens, 240 aa.	1 . . . 240	238/240 (99%)
	[WO200181539-A2, 01 NOV. 2001]
AAG66785	Zinc transporter homologue ZnT-1-	231 . . . 429	197/199 (98%)	e−112
	22 - Homo sapiens, 199 aa.	1 . . . 199	197/199 (98%)
	[WO200171000-A1, 27 SEP. 2001]
AAU69449	Human purified secretory	1 . . . 290	240/346 (69%)	e−111
	polypeptide #18 - Homo sapiens,	36 . . . 349	243/346 (69%)
	349 aa. [WO200162918-A2,
	30 AUG. 2001]

[0472] In a BLAST search of public sequence datbases, the NOV21a protein was found to have homology to the proteins shown in the BLASTP data in Table 21D.

TABLE 21D
Public BLASTP Results for NOV21a
			Identities/
Protein			Similarities for
Accession		NOV21a Residues/	the Matched	Expect
Number	Protein/Organism/Length	Match Residues	Portion	Value
Q9NPW0	Hypothetical 26.3 kDa protein -	190 . . . 429	239/240 (99%)	e−138
	Homo sapiens (Human), 240 aa.	1 . . . 240	239/240 (99%)
Q9Y6M5	Zinc transporter 1 (ZnT-1) - Homo	1 . . . 398	181/493 (36%)	2e−72
	sapiens (Human), 507 aa.	1 . . . 485	249/493 (49%)
Q9VZR4	CG17723 protein (LD22804P) -	1 . . . 359	148/390 (37%)	5e−68
	Drosophila melanogaster (Fruit	1 . . . 378	228/390 (57%)
	fly), 449 aa.
Q06808	Oxidative stress resistance -	5 . . . 351	143/402 (35%)	6e−61
	Saccharomyces cerevisiae (Baker's	3 . . . 398	222/402 (54%)
	yeast), 429 aa.
P20107	Zinc/cadmium resistance protein -	5 . . . 351	143/402 (35%)	6e−61
	Saccharomyces cerevisiae (Baker's	3 . . . 398	222/402 (54%)
	yeast), 442 aa.

[0473] PFam analysis predicts that the NOV21a protein contains the domains shown in the Table 21E.

TABLE 21E
Domain Analysis of NOV21a
			Identities/
			Similarities for
	Pfam	NOV21a	the Matched	Expect
	Domain	Match Region	Region	Value
	Cation_efflux	11 . . . 333	101/358 (28%)	2.2e−68
			259/358 (72%)

Example 22

[0474] The NOV22 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 22A.

TABLE 22A
NOV22 Sequence Analysis
                 SEQ ID NO: 293         1047 bp
NOV22a,          AGGCTGGGCACGAGGACCATGCTGGGCCGGAGCCTCCGAGAAGTTTCTGCGGCACTGA
CG152646-01
DNA Sequence     AACAAGGCCAAATTACACCAACAGAGCTCTGTCAAAAATGTCTCTCTCTTATCAAGAA
                 GACCAAGTTTCTAAATGCCTACATTACTGTGTCAGAAGAGGTGGCCTTAAAACAAGCT
                 GAAGAATCAGAAAAGAGATATAAGAATGGACAGTCACTTGGGGATTTAGATGGAATTC
                 CTATTGCAGTAAAAGACAATTTCAGCACTTCTGGCATTGAGACAACATGTGCATCAAA
                 TATGCTGAAAGGTTATATACCACCTTATAATGCTACAGTAGTTCAGAAGTTGTTGGAT
                 CAGGGAGCTCTACTAATGGGAAAAACAAATTTAGATGAGTTTGCTATGGGATCTGGGA
                 GCACAGATGGTGTATTTGGACCAGTTAPAAACCCCTGGAGTTATTCAAAACAATATGG
                 TCACAGATGTGACATTGATTTGTCCACTGAAGCCATGTATGCTGCAACCAGACGAGAA
                 GGGTTTAATGATGTGGTGAGAGGAAGAATTCTCTCAGGAAACTTTTTCTTATTAAAAG
                 AAAACTATGAAAATTATTTTGTCAAAGCACAGAAAGTGAGACGCCTCATTGCTAATGA
                 CTTTGTAAATGCTTTTAACTCTGGAGTAGATGTCTTGCTAACTCCCACCACCTTGAGT
                 GAGGCAGTACCATACTTGGAGTTCATCAAAGAGGACAACAGAACCCGAAGTGCCCAGG
                 ATGATATTTTTACACAAGCTGTAAATATGGCAGGATTGCCAGCAGTGAGTATCCCTGT
                 TGCACTCTCAAACCAGGGGTTGCCAATAGGACTGCAGTTTATTGGACGTGCGTTTTGT
                 GACCAGCAGCTTCTTACAGTAGCCAAATGGTTTGAAAAACAAGTACAGTTTCCTGTTA
                 TTCAACTTCAAGAACTCATGGATGATTGTTCAGCAGTCCTTGAAAATGAAAAGTTAGC
                 CTCTGTCTCTCTAAAACAGTAAACATATCTTACAAATTAAAATGACTTTTAGGCTGGG
                 TGC
                 ORF Start: ATG at 19                 ORF Stop: TAA at 1006
                 SEQ ID NO: 294          329 aa       MW at 36411.3kD
NOV22a,          MLGRSLREVSAALKQGQITPTELCQKCLSLIKKTKFLNAYITVSEEVALKQAEESEKR
CG152646-01
Protein Sequence YKNGQSLGDLDGIPIAVKDNFSTSGTETTCASNMLKGYIPPYNATVVQKLLDQGALLM
                 GKTNLDEFAMGSGSTDGVFGPVKNPWSYSKQYGHRCDIDLSTEANYAATRREGFNDVV
                 RGRILSGNFFLLKENYENYFVKAQKVRRLIANDFVNAFNSGVDVLLTPTTLSEAVPYL
                 EFIKEDNRTRSAQDDIFTQAVNMAGLPAVSIPVALSNQGLPIGLQFIGRAFCDQQLLT
                 VAKWFEKQVQFPVIQLQELMDDCSAVLENEKLASVSLKQ

[0475] Further analysis of the NOV22a protein yielded the following properties shown in Table 22B.

TABLE 22B
Protein Sequence Properties NOV22a
PSort     0.6500 probability located in cytoplasm;
analysis: 0.1000 probability located in mitochondrial
          matrix space; 0.1000 probability located in
          lysosome (lumen); 0.0000 probability located
          in endoplasmic reticulum (membrane)
SignalP   No Known Signal Sequence Predicted
analysis:

[0476] A search of the NOV22a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 22C.

TABLE 22C
Geneseq Results for NOV22a
			Identities/
			Similarities for
Geneseq	Protein/Organism/Length	NOV22a Residues/	the Matched	Expect
Identifier	[Patent #, Date]	Match Residues	Region	Value
ABP41274	Human ovarian antigen HOSED43,	147 . . . 329	182/183 (99%)	e−100
	SEQ ID NO: 2406 - Homo sapiens,	81 . . . 263	183/183 (99%)
	263 aa. [WO200200677-A1,
	03 JAN. 2002]
ABB05695	Human nucleic acid management	147 . . . 329	182/183 (99%)	e−100
	protein clone fbr2_78c12 - Homo	346 . . . 528	183/183 (99%)
	sapiens, 528 aa. [WO200198454-
	A2, 27 DEC. 2001]
AAE18112	Human glutamyl-tRNA (Gln)	147 . . . 329	182/183 (99%)	e−100
	amidotransferase−like enzyme -	346 . . . 528	183/183 (99%)
	Homo sapiens, 528 aa.
	[WO200200703-A2, 03 JAN. 2002]
AAU19422	Human diagnostic and therapeutic	147 . . . 329	182/183 (99%)	e−100
	polypeptide (DITHP) #8 - Homo	367 . . . 549	183/183 (99%)
	sapiens, 549 aa. [WO200162927-
	A2, 30 AUG. 2001]
AAB94654	Human protein sequence SEQ ID	147 . . . 329	182/183 (99%)	e−100
	NO: 15566 - Homo sapiens, 528 aa.	346 . . . 528	183/183 (99%)
	[EP1074617-A2, 07 FEB. 2001]

[0477] In a BLAST search of public sequence datbases, the NOV22a protein was found to have homology to the proteins shown in the BLASTP data in Table 22D.

TABLE 22D
Public BLASTP Results for NOV22a
			Identities/
Protein			Similarities for
Accession		NOV22a Residues/	the Matched	Expect
Number	Protein/Organism/Length	Match Residues	Portion	Value
Q9NV19	Hypothetical 57.5 kDa protein	147 . . . 329	182/183 (99%)	e−100
	(Similar to hypothetical protein	346 . . . 528	183/183 (99%)
	FLJ10989) - Homo sapiens
	(Human), 528 aa.
Q9H0R6	Hypothetical 57.5 kDa protein -	147 . . . 329	182/183 (99%)	e−100
	Homo sapiens (Human), 528 aa.	346 . . . 528	183/183 (99%)
Q9CZN8	2700038P16Rik protein - Mus	147 . . . 329	163/183 (89%)	6e−88
	musculus (Mouse), 525 aa.	342 . . . 524	169/183 (92%)
Q9HA60	CDNA FLJ12189 fis, clone	1 . . . 148	148/148 (100%)	4e−80
	MAMMA1000841, moderately	1 . . . 148	148/148 (100%)
	similar to putative amidase (EC
	3.5.1.4) - Homo sapiens (Human),
	303 aa.
Q9VE09	GATA protein - Drosophila	147 . . . 305	89/164 (54%)	6e−43
	melanogaster (Fruit fly), 508 aa.	336 . . . 499	114/164 (69%)

[0478] PFam analysis predicts that the NOV22a protein contains the domains shown in the Table 22E.

TABLE 22E
Domain Analysis of NOV22a
		Identities/
	NOV22a	Similarities for the
Pfam Domain	Match Region	Matched Region	Expect Value
Amidase	22 . . . 142	58/126 (46%)	1.5e-41
		98/126 (78%)
Amidase	148 . . . 289	62/170 (36%)	7.6e-35
		114/170 (67%)

Example 23

[0479] The NOV23 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 23A.

TABLE 23A
NOV23 Sequence Analysis
                 SEQ ID NO: 295         1935 bp
NOV23a,          AGAGGCTCAAGAGGGGCAGCCCCCGCATAGAGGAGATGCGAGCTCTGCGCTCTGCCAG
CG152959-01
DNA Sequence     GGCCCCGAGCCCGTCAGAGGCCGCCCCGCGCCGCCCGGAAGCCACCGCGGCCCCCCTC
                 ACTCCTAGAGGAAGGGAGCACCGCGAGGCTCACGGCAGGGCCCTGGCGCCGGGCAGGG
                 CGAGCCTCGGAAGCCGCCTGGAGGACGTCCTGTGGCTGCAGGAGGTCTCCAACCTGTC
                 AGAGTGGCTGAGTCCCAGCCCTGGGCCCTGAGCCGGGTCCCCTTCCGCAAGCGCCCAC
                 CGATCCGGAGGCTGCGGGCAGCCGTTATCCCGTGGTTTAATAAAGCTGCCGCGCGCTC
                 ACCAAGTCCTCTTCCGCGTCTGCTTCCGCGTCGGGCCCGGGCGGGGCGGGGCGGGGCG
                 TGGAGCCGCGCCGCGGCCTGACGTCACCCACACCTCCCTGGGACTGCGTCACTGGTCC
                 GCGCCGCGGGTCAGGGCGCAATGGCGGCGCTGGGCGGGGATGGGCTGCGACTGCTGTC
                 GGTGTCGCGGCCGGAGCGGCCGCCCGAGTCGGCGGCGCTGGGCGGCCTGGGCCCCGGG
                 CTGTGCTGCTGGGTGTCAGTGTTCTCCTGCCTCAGCCTCGCCTGCTCCTACATGGGCA
                 GCCTCTACGTCTGGAAGAGCGAACTGCCCAGGGACCATCCCGCGGTCATCAAGCGACG
                 CTTCACCAGCGTCCTGGTGGTGTCCAGTCTCTCACCCCTGTGCGTGCTGCTCTGGAGG
                 GAACTCACAGGCATCCAGGCACATCCCTGCTCACCCTGATGGGCTTCAGGCTGGAGGG
                 CATTTTCCCAGCGGCGCTGCTGCCCCTGTTGCTGACCATGATTCTTTTCCTGGGCCCA
                 CTGATGCAGCTCTCTATGGATTGCCCTTGTGACCTGGCAGATGGGCTGAAGGTTGTCC
                 TGGCCCCCCGCTCCTGGGCCCGCTGCCTCACAGACATGCGTTGGCTGCGGAACCAAGT
                 GATCGCCCCGCTGACAGAGGAGCTGGTGTTCCGGGCCTGTATGCTGCCCATGTTAGCA
                 CCGTGCATGGGCCTGGGCCCTGCTGTGTTCACCTGCCCGCTCTTTTTTGGAGTTGCCC
                 ATTTTCACCATATTATTGAGCAGCTGCGTTTCCGCCAGAGCAGCGTGGGGAACATCTT
                 CTTGTCTGCTGCGTTCCAGTTCCCCTACACAGCTGTCTTCGGTGCCTACACTGCTTTC
                 CTCTTCATCCGCACAGGACACCTGATTGGGCCGGTTCTCTGCCATTCCTTCTGCAATT
                 ACATGGGTTTCCCAGCTGTTTGCGCGGCCTTGGAGCACCCACAGAGGCGGCCCCTGCT
                 GGCAGGCTATGCCCTGGGTGTGGGACTCTTCCTGCTTCTGCTCCAGCCCCTCACGGAC
                 CCCAAGCTCTACGGCAGCCTTCCCCTTTGTGTGCTTTTGGAGCGGGCAGGGGACTCAG
                 AGGCTCCCCTGTGCTCCTGACCTATGCTCCTGGATACGCTATGAACTCTCACCGGCTC
                 CCCAGCCCTCCCCACCAAGGGGTACTGCAGGGGAAGGGCTGGCTGGGGTCCCCGAGAT
                 CTCAGGAATTTTTGTAGGGGATTGAAGCCAGAGCTAGTTGCGTCCCAGGGACCAAGAG
                 AAAGAAGCAGATATCCAAAGGGTGCAGCCCCTTTTGAAAGGGGTGTTTACGAGCAGCT
                 GTGAGTGAGGGGACAAGGGGCACGTCCCAGGAGCCACACACTCCCTTCCTCACTTTGG
                 ACTGCTGCTTCTCTTAGCTCCTCTGCCTCTGAAAAGCTGCTCGGGGTTTTTTATTTAT
                 AAAACCTCTCCCCACCCCCCACCCCCCAACTTCCTGGGTTTTCTCATTGTCTTTTTGC
                 ATCAGTACTTTGTATTGGGATATTAAAGAGATTTAACTTGGGTAAAAAAAAAAAAAAA
                 AAAAAAAAAAAAAAAAAAAAA
                 ORF Start: ATG at 475                ORF Stop: TGA at 791
                 SEQ ID NO: 296          102 aa       MW at 10925.7kD
NOV 23a,         MAALGGDGLRLLSVSRPERPPESAALGGLGPGLCCWVSVFSCLSLACSYMGSLYVWKS
CG152959-01
Protein Sequence ELPRDHPAVIKRRFTSVLVVSSLSPLCVLLWRELTGIQAHPCSP
                 SEQ ID NO: 297         1472 bp
NOV23b,          GTCACTGGTGCGCGCCGCGGGTCAGGGCGCAATGGCGGCGCTGGGCGGGGATGGGCTG
CG152959-02
DNA Sequence     CGACTGCTGTCGGTGTCGCGGCCGGAGCGGCCGCCCCAGTCGGCGGCGCTGGGCGGCC
                 TGGGCCCCGGGCTGTGCTGCTGGGTGTCAGTGTTCTCCTGCCTCAGCCTCGCCTGCTC
                 CTACGTGGGCAGCCTCTACGTCTGGAAGAGCGAACTGCCCAGGGACCATCCCGCGGTC
                 ATCAAGCGACGCTTCACCAGCGTCCTGGTGGTGTCCAGTCTCTCACCCCTGTGCGTGC
                 TGCTCTGGAGGGAACTCACAGGCATCCAGCCAGGCACATCCCTGCTCACCCTGATGGG
                 CTTCAGGCTGGAGGGCATTTTCCCAGCGGCGCTGCTGCCCCTGTTGCTGACCATGATT
                 CTTTTCCTGGGCCCACTGATGCAGCTCTCTATGGATTGCCCTTGTGACCTGGCAGATG
                 GGCTGAAGGTTGTCCTGGCCCCCCGCTCCTGGGCCCGCTGCCTCACAGACATGCGTTG
                 GCTGCGGAACCAAGTGATCGCCCCGCTGACAGAGGAGCTGGTGTTCCGGGCCTGTATG
                 CTGCCCATGTTAGCACCGTGCATGGGCCTGGGCCCTGCTGTGTTCACCTGCCCGCTCT
                 TTTTTGGAGTTGCCCATTTTCACCATATTATTGAGCAGCTGCGTTTCCGCCAGAGCAG
                 CGTGGGGAACATCTTCTTGTCTGCTGCGTTCCAGTTCTCCTACACAGCTGTCTTCGGT
                 CCCTACACTGCTTTCCTCTTCATCCGCACAGGACACCTGATTGGGCCGGTTCTCTGCC
                 ATTCCTTCTGCAATTACATGGGTTTCCCAGCTGTTTGCGCGGCCTTGGAGCACCCACA
                 GAGGCGGCCCCTGCTGGCAGGCTATGCCCTGGGTGTGGGACTCTTCCTGCTTCTGCTC
                 CAGCCCCTCACGGACCCCAAGCTCTACGGCAGCCTTCCCCTTTGTGTGCTTTTGGAGC
                 GGGCAGGGGACTCAGAGGCTCCCCTGTGCTCCTGACCTATGCTCCTGGATACGCTATG
                 AACTCTCACCGGCTCCCCAGCCCTCCCCACCAAGGGGTACTGCAGGGGAAGGGCTGGC
                 TGGGGTCCCCGAGATCTCAGGAATTTTTGTAGGGGATTGAAGCCAGAGCTAGTTGCGT
                 CCCAGGGACCAAGAGAAAGAAGCAGATATCCAAAGGGTGCAGCCCCTTTTGAAAGGGG
                 TGTTTACGAGCAGCTGTGAGTGAGGGGACAAGGGGCAGGTCCCAGGAGCCACACACTC
                 CCTTCCTCACTTTGGACTGCTGCTTCTCTTAGCTCCTCTGCCTCTGAAAAGCTGCTCG
                 GGGTTTTTTATTTATAAAACCTCTCCCCACCCCCCACCCCCCAAACTTCCTGGGTTTT
                 CTCATTGTCTTTTTGCATCAGTACTTTGTATTGGGATATTAAAGAGATTTAACTTGGG
                 TAAAAAAAAAAAAAAAAAAAA
                 ORF Start: ATG at 32                 ORE Stop: TGA at 1019
                 SEQ ID NO: 298          329 aa       MW at 35832.2kD
NOV23b,          MAALGGDGLRLLSVSRPERPPESAALGGLGPGLCCWVSVFSCLSLACSYVGSLYVWKS
CG152959-02
Protein Sequence ELPRDHPAVIKRRFTSVLVVSSLSPLCVLLWRELTGIQPGTSLLTLMGFRLEGIFPAA
                 LLPLLLTMILFLGPLMQLSMDCPCDLADGLKVVLAPRSWARCLTDMRWLRNQVIAPLT
                 EELVFRACMLPMLAPCMGLGPAVFTCPLFFGVAHFHHIIEQLRFRQSSVGNIFLSAAF
                 QFSYTAVFGAYTAFLFIRTGHLIGPVLCHSFCNYMGFPAVCAALEHPQRRPLLAGYAL
                 GVGLFLLLLQPLTDPKLYGSLPLCVLLERAGDSEAPLCS

[0480] Sequence comparison of the above protein sequences yields the following sequence relationships shown in Table 23B.

TABLE 23B
Comparison of NOV23a against NOV23b.
	NOV23a Residues/	Identities/Similarities
Protein Sequence	Match Residues	for the Matched Region
NOV23b	1 . . . 96	95/96 (98%)
	1 . . . 96	96/96 (99%)

[0481] Further analysis of the NOV23a protein yielded the following properties shown in Table 23C.

TABLE 23C
Protein Sequence Properties NOV23a
PSort     0.7000 probability located in plasma membrane; 0.2000
analysis: probability located in endoplasmic reticulum (membrane);
          0.1000 probability located in mitochondrial inner membrane;
          0.0000 probability located in endoplasmic reticulum (lumen)
SignalP   Cleavage site between residues 49 and 50
analysis:

[0482] A search of the NOV23a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 23D.

TABLE 23D
Geneseq Results for NOV23a
			Identities/
		NOV23a	Similarities
	Protein/Organism/	Residues/	for the
Geneseq	Length [Patent	Match	Matched	Expect
Identifier	#, Date]	Residues	Region	Value
AAY55809	Human RCE1	1 . . . 96	95/96 (98%)	5e-51
	(farnesyl-directed	1 . . . 96	96/96 (99%)
	endopeptidase) se-
	quence - Homo
	sapiens, 329 aa.
	[WO9961628-A2,
	02-DEC-1999]
AAW89181	Human RCE1	1 . . . 96	95/96 (98%)	5e-51
	(hRCE1) polypep-	1 . . . 96	96/96 (99%)
	tide - Homo sapiens,
	329 aa. [EP887415-
	A2, 30-DEC-1998]
AAW98105	Guman ras carboxy-	1 . . . 96	95/96 (98%)	5e-51
	terminal processing	10 . . . 105	96/96 (99%)
	protein - Homo
	sapiens, 338 aa.
	[WO9914343-A1,
	25-MAR-1999]
AAY26897	Human farnesyla-	1 . . . 96	95/96 (98%)	5e-51
	ted--protein convert-	1 . . . 96	96/96 (99%)
	ing enzyme 2 pro-
	tein - Homo sapiens,
	329 aa.
	[WO9935275-A1,
	15-JUL-1999]
AAU03600	Human ras convert-	1 . . . 96	94/96 (97%)	1e-50
	ing endoprotease	1 . . . 96	96/96 (99%)
	(RCE) - Homo sa-
	piens, 329 aa.
	[US6261793-B1,
	17-JUL-2001]

[0483] In a BLAST search of public sequence datbases, the NOV23a protein was found to have homology to the proteins shown in the BLASTP data in Table 23E.

TABLE 23E
Public BLASTP Results for NOV23a
			Identities/
		NOV23a	Similarities
Protein		Residues/	for the
Accession	Protein/Organism/	Match	Matched	Expect
Number	Length	Residues	Portion	Value
Q9Y256	CAAX prenyl pro-	1 . . . 96	95/96 (98%)	1e-50
	tease 2 (EC	1 . . . 96	96/96 (99%)
	3.4.22.-) (Prenyl
	protein-specific en-
	doprotease 2)
	(Farnesylated-pro-
	teins converting
	enzyme 2) (FACE-
	2) (hRCE1) - Homo
	sapiens (Human),
	329 aa.
P57791	CAAX prenyl pro-	1 . . . 96	89/96 (92%)	8e-46
	tease 2 (EC	1 . . . 96	90/96 (93%)
	3.4.22.-) (Prenyl
	protein-specific en-
	doprotease 2)
	(Farnesylated-pro-
	teins converting
	enzyme 2) (FACE-
	2) - Mus musculus
	(Mouse), 329 aa.
Q9CSF8	Ras and a-factor-	28 . . . 96	63/69 (91%)	2e-31
	converting enzyme	13 . . . 81	65/69 (93%)
	1 homolog (S.
	cerevisiae) - Mus
	musculus (Mouse),
	314 aa (fragment).
Q8SZZ3	LD46418p -	38 . . . 86	24/49 (48%)	2e-06
	Drosophila	30 . . . 78	31/49 (62%)
	melanogaster (Fruit
	fly), 302 aa.
Q9U1H8	CAAX prenyl pro-	38 . . . 86	24/49 (48%)	2e-06
	tease 2 (EC	18 . . . 66	31/49 (62%)
	3.4.22.-) (Prenyl
	protein-specific en-
	doprotease 2)
	(Farnesylated-pro-
	teins converting
	enzyme 2) (FACE-
	2) (Severas pro-
	tein) -
	Drosophila
	melanogaster (Fruit
	fly), 290 aa.

[0484] PFam analysis predicts that the NOV23a protein contains the domains shown in the Table 23F.

TABLE 23F
Domain Analysis of NOV23a
		Identities/
Pfam	NOV23a	Similarities
Domain	Match Region	for the Matched Region	Expect Value
No Significant Matches Found

Example 24

[0485] The NOV24 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 24A.

TABLE 24A
NOV24 Sequence Analysis
                 SEQ ID NO: 299         1710 bp
NOV24a,          ATGGCTGGACCAGGCAAAGAGGGTGTGGTGTGGTGGGAAGAAAAATCGATGGGACAAC
CG153033-01
DNA Sequence     TGAGGGAAGAAGATAACATTGAGCTGAATGAAGAAGGAAGGCCGGTGCAGACGTCCAG
                 GCCAAGCCCCCCACTCTGCGACTGCCACTGCTGCGGCCTCCCCAAGCGTTACATCATT
                 GCTATCATGAGTGGGCTGGGATTCTGCATTTCCTTTGGGATCCGGTGCAATCTTGGAG
                 TTGCCATTGTGGAAATGGTCAACAATAGCACCGTATATGTTGATGGAAAACAGACAGC
                 ACAGTTTAACTGGGATCCAGAAACAGTGGGCCTTATCCATGGATCTTTTTTCTGGGGC
                 TATATTATGACACAAATTCCAGGTGGTTTCATTTCAAACAAGTTTGCTGCTAACAGGG
                 TCTTTGGAGCTGCCATCTTCTTAACATCGACTCTGAACATGTTTATTCCCTCTGCAGC
                 CAGAGTGCATTACGGATGCGTCATGTGTGTCAGAATTCTGCAAGGTTTAGTGGGTGTG
                 ACCTACCCAGCCTGCCATGGGATGTGGAGTAAGTGGGCACCACCTTTGGAGAGAAGCC
                 GACTGGCCACAACCTCTTTTTGTGGTTCCTATGCAGGGGCAGTGGTTGCCATGCCCCT
                 GGCTGGGGTGTTGGTGCAGTACATTGGATGGTCCTCTGTCTTTTATATTTATGGTATG
                 TTTGGGATTATTTGGTACATGTTTTGGCTGTTGCAGGCCTATGAGTGCCCAGCAGCTC
                 ATCCAACAATATCCAATGAGGAGAAGACCTATATAGAGACAAGCATAGGAGAGGGGGC
                 CAACGTGGTTAGTCTAAGTGTAAAATTTAGTACCCCATGGAAAAGATTTTTCACATCT
                 TTGCCGGTTTATGCAATCATTGTGGCAAATTTTTGCAGAAGCTGGACCTTTTATTTGC
                 TCCTCATAAGTCAGCCTGCTTATTTTGAAGAGGTCTTTGGATTTGCAATAAGTAAGGT
                 AGGTCTCTTGTCAGCAGTCCCACACATGGTTATGACAATCGTTGTACCTATTGGAGGA
                 CAATTGGCTGATTATTTAAGAAGCAGACAAATTTTAACCACAACTGCTGTCAGAAAAA
                 TCATGAACTGTGGAGGTTTTGGCATGGAGGCAACCTTACTCCTGGTGGTTGGCTTTTC
                 GCATACCAAAGGGGTGGCTATCTCCTTTCTGGTACTTGCTGTAGGATTTAGTGCCTTC
                 GCTATTTCAGGTTTTAATGTCAACCACCTGGACATTGCCCCACGCTATGCCAGCATTC
                 TCATGGGGATCTCAAACGGACTGGGAACCCTCTCTGGAATGGTCTGTCCCCTCATTGT
                 CGGTGCAATGACCAGGCACAAGACCCGTGAAGAATGGCAGAATGTGTTCCTCATAGCT
                 GCCCTGGTGCATTACAGTGGTGTGATCTTCTATGGGGTCTTTGCTTCTGGGGAGAAAC
                 AGGAGTGGGCTGACCCAGAGAATCTCTCTGAGGAGAAATGTGGAATCATTGACCAGGA
                 CGAATTAGCTGAGGAGATAGAACTCAACCATGAGAGTTTTGCGAGTCCCAAAAAGAAG
                 ATGTCTTATGGAGCCACCTCCCAGAATTGTGAAGTCCAGAAGAAGGAATGGAAAGGAC
                 AGAGAGGAGCGACCCTTGATGAGGAAGAGCTGACATCCTACCAGAATGAAGAGAGAAA
                 CTTCTCAACTATATCCTAA
                 ORF Start: ATG at 1                  ORF Stop: TAA at 1699
                 SEQ ID NO: 300          566 aa       MW at 62488.6kD
NOV24a,          MAGPGKEGVVWWEEKSMGQLREEDNIELNEEGRPVQTSRPSPPLCDCHCCGLPKRYII
CG153033-01
Protein Sequence AIMSGLGFCISFGIRCNLGVAIVEMVNNSTVYVDGKQTAQFNWDPETVGLIHGSFFWG
                 YIMTQIPGGFISNKFAANRVFGAAIFLTSTLNMFIPSAARVHYGCVMCVRILQGLVGV
                 TYPACHGMWSKWAPPLERSRLATTSFCGSYAGAWAMPLAGVLVQYIGWSSVFYIYGM
                 FGIIWYMFWLLQAYECPAAHPTISNEEKTYIETSIGEGANVVSLSVKFSTPWKRFFTS
                 LPVYAIIVANFCRSWTFYLLLISQPAYFEEVFGFAISKVGLLSAVPHMVMTIVVPIGG
                 QLADYLRSRQILTTTAVRKIMNCGGFGMEATLLLVVGFSHTKGVAISFLVLAVGFSGF
                 AISGFNVNHLDIAPRYASILMGISNGVGTLSGMVCPLIVGANTRHKTREEWQNVFLIA
                 ALVHYSGVIFYGVFASGEKQEWADPENLSEEKCGIIDQDELAEEIELNHESFASPKKK
                 MSYGATSQNCEVQKKEWKGQRGATLDEEELTSYQNEERNFSTIS

[0486] Further analysis of the NOV24a protein yielded the following properties shown in Table 24B.

TABLE 24B
Protein Sequence Properties NOV24a
PSort     0.6000 probability located in plasma membrane; 0.4000
analysis: probability located in Golgi body; 0.3000 probability located
          in endoplasmic reticulum (membrane); 0.3000 probability
          located in microbody (peroxisome)
SignalP   No Known Signal Sequence Predicted
analysis:

[0487] A search of the NOV24a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 24C.

TABLE 24C
Geneseq Results for NOV24a
		NOV24a	Identities/
		Residues/	Similarities
Geneseq	Protein/Organism/Length	Match	for the	Expect
Identifier	[Patent #, Date]	Residues	Matched Region	Value
AAU99329	Human transporter protein - Homo	4 . . . 566	553/575 (96%)	0.0
	sapiens, 589 aa. [US2002082190-	16 . . . 589	555/575 (96%)
	A1, 27 JUN. 2002]
ABB07689	Rat glutamate transporter VGLUT3	4 . . . 566	509/580 (87%)	0.0
	amino acid sequence - Rattus sp,	24 . . . 601	532/580 (90%)
	860 aa. [WO200208384-A2, 31
	JAN. 2002]
AAM79273	Human protein SEQ ID NO 1935 -	4 . . . 530	413/542 (76%)	0.0
	Homo sapiens, 582 aa.	11 . . . 549	473/542 (87%)
	[WO200157190-A2, 09 AUG.
	2001]
AAO13870	Human polypeptide SEQ ID NO	24 . . . 528	404/514 (78%)	0.0
	27762 - Homo sapiens, 567 aa.	38 . . . 551	450/514 (86%)
	[WO200164835-A2, 07 SEP. 2001]
AAW70500	Human sodium-lithium	24 . . . 528	403/514 (78%)	0.0
	countertransporter BNPI - Homo	31 . . . 544	449/514 (86%)
	sapiens, 560 aa. [WO9838203-A1,
	03 SEP. 1998]

[0488] In a BLAST search of public sequence datbases, the NOV24a protein was found to have homology to the proteins shown in the BLASTP data in Table 24D.

TABLE 24D
Public BLASTP Results for NOV24a
		NOV24a	Identities/
Protein		Residues/	Similarities
Accession		Match	for the	Expect
Number	Protein/Organism/Length	Residues	Matched Portion	Value
CAD30553	Vesicular glutamate transporter 3 -	4 . . . 566	553/575 (96%)	0.0
	Homo sapiens (Human), 589 aa.	16 . . . 589	555/575 (96%)
CAD37138	Vesicular glutamate transporter 3 -	4 . . . 566	510/575 (88%)	0.0
	Rattus norvegicus (Rat), 588 aa.	16 . . . 588	533/575 (92%)
Q9JI12	Differentation-associated Na-	4 . . . 561	421/573 (73%)	0.0
	dependent inorganic phosphate	11 . . . 579	487/573 (84%)
	cotransporter - Rattus norvegicus
	(Rat), 582 aa.
Q920B7	Vesicular glutamate transporter 2 -	4 . . . 530	417/542 (76%)	0.0
	Mus musculus (Mouse), 582 aa.	11 . . . 549	475/542 (86%)
CAD52142	SI: PACKT73.2 (novel protein similar	2 . . . 530	418/545 (76%)	0.0
	to solute carrier family 17 (sodium-	8 . . . 550	472/545 (85%)
	dependent inorganic phosphate
	cotransporter), member 6
	(SLC17A6)) - Brachydanio rerio
	(Zebrafish) (Danio rerio), 584 aa.

[0489] PFam analysis predicts that the NOV24a protein contains the domains shown in the Table 24E.

TABLE 24E
Domain Analysis of NOV24a
			Identities/
		NOV24a	Similarities
		Match	for the	Expect
	Pfam Domain	Region	Matched Region	Value
	sugar_tr	64 . . . 488	72/506 (14%)	0.04
			262/506 (52%)

Example 25

[0490] The NOV25 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 25A.

TABLE 25A
NOV25 Sequence Analysis
	SEQ ID NO:301	3374 bp
NOV25a,	GCAATCATGAAGGACAGCGGGGACTCCAAGGACCAGCAACTCATGGTGGCGCTTCGGG
GG153818-01
DNA Sequence	TCCGGCCCATCAGCGTGGCAGAGCTGCAGCAAGGAGCTACCCTCATCGCCCATAAAGT
	GGATGAGCAGCATTTACCTGCTGCCACCCCCCTCTGCTCCCGGGGTGCTGTAGAGCCA
	GGCTCAAAGCTGCAAAGGGCCACTGGAGCAGTTCCCTCACAGCCCTCTCAGCTGCGAG
	TGGAGATCCCCAAGCCCAGCGTGCTGACCTCATCCCTCACCCAGCTGCCTGTGCCTCT
	TTGCTCTGTCCCAGGCTCTGCCCTGGAGGCGGCCCGGGGTTCCCAGGTGACCGTGGGC
	CTCCCTCTGGGGACCTTGCAGATGGTGGTTCTCATGGACCCAATGGAGGATCCCGACG
	ACATCCTGCGGGCGCATCGCTCCCGGCAGAAGTCCTACCTGTTCGACGTGGCCTTTGA
	CTTCACCGCCACCCAGGAGATGGTGTATCAGGCCACCACCAAGAGCCTCATCGAGGGC
	GTCATCTCAGGCTACAATGCCACTGTCTTTGCCTATGGCCCACAGGTAAGGGGAATGC
	CAGACTTGTGCGAGACAGCAATGATCTGCTGTCGGAAAACCTACACCATGCTGGGCAC
	AGACCAGGAGCCTGGCATCTATGTTCAGACCCTCAACGACCTCTTCCGTCCCATCGAG
	GAGACCAGCAATGACATGGAGTATGAGGTCTCCATGTCCTACCTGGAGATCTACAATG
	AGATGATCCGCGACCTGCTGAACCCCTCCCTGGGCTACCTGGAGCTGCGGGAGGACTC
	TAAGGGGGTGATCCAGGTGGCCGGCATCACCGAAGTCTCCACCATCAATGCCAAGGAG
	ATCATGCAGCTGCTGATGAAGGGGAACCGGCAGAGGACCCAGGAGCCCACGGCCGCCA
	ACCAGACGTCCTCCCGCTCCCACGCGGTACTGCAGGTGACCGTGCGCCAGCGCAGCCG
	GGTCAAGAACATCTTGCAGGAGGCGCAGGGCCGCCTGTTCATGATCGACCTGGCTGGC
	TCAGAGCGCGCCTCGCAGACACAGAATCGTGGGCAGCGTATGAAGGAGGGGGCCCACA
	TCAACCGCTCACTGCTGCCACTGGGCAACTGCATCAACGCCCTGAGCGACAAGGGTAG
	CAACAAGTACATCAACTATCGCGACAGCAAGCTCACCCGGCTCCTGAAGGACTCTCTG
	GGAGGAAACAGCCGCACAGTCATGATCGCTCACATCAGTCCTGCGAGCAGTGCCTTCG
	AGGAGTCCCGGAACACCCTGACCTACGCCGGCCGGGCCAAGAACATTAAGACTAGGGT
	GAAGCAGAACCTCCTGAACGTCTCCTACCACATCGCCCAGTACACCAGCATCATCGCT
	GACCTGCGGGGCGAGATCCAGCGACTCAAGCGCAAGATTGATGAGCAGACTGGGCGGG
	GCCAGGCCCGGGGCCGGCAGGATCGGGGTGACATCCGCCACATCCAAGCTGAGGTCCA
	GCTGCACAGCGGGCAGGGTGAGAAGGCTGGCATGGGACAGCTTCGGGAGCAGCTCGCC
	AGCGCCTTCCAGGAGCAGATGGATGTGCGGAGGCGCCTGCTGGAGCTGGAGAACCGCG
	CCATGGAGGTCCAGATTGACACCTCCCGACACCTGCTCACCATCGCCGGCTGGAAGCA
	TGAGAAGTCCCGCCGGGCCCTCAAATGGCGGGAGGAGCAGCGAAAGGAGTGCTACGCT
	AAGGACGACAGCGAGAAGGACTCAGACACAGGTGATGACCAACCAGACATCCTGGAGC
	CACCCGAGGTGGCCGCAGCCCGGGAGAGCATTGCAGCCCTGGTGGACGAGCAGAAGCA
	ACTGCGCAAGCAGAAGGTGTCCAGGGTTTGGGGGGACAAGGAGAGTGGGTTTAGGGGA
	CAGGATGCTGACCTGCGCCTCCTGCAGCTGGCGCTGGAGCAGCGCTGCCGGGAGCTGC
	GCGCGCGGGGCCGGCGCCTGGAGGAGACGCTGCCGCGGCGCATCGGCTCCGAGGAGCA
	GCGCGAGGTGCTCAGCCTGCTGTGCCGCGTGCACGAGCTCGAGGTGGAGAACACCGAG
	ATGCAGTCGCACGCGCTGCTCCGCGACGGTGCGCTCCGCCACCGCCACGAGGCCGTGC
	GCCGCCTGGAGCAGCACCGCAGTCTCTGCGACGAGATTATCCAGGGCCAGCGGCAGAT
	CATCGACGCAGACTACAACCTGGCCGTCCCGCAGCGCCTGGAAGAGCTCTACGAAGTG
	TACCTGCGGGAGCTGGAGGAGGGCAGCCTGGAGCAGGCCACCATCATGGACCAAGTGG
	CCTCCAGGGCCCTGCAGGACAGCTCCTTGCCCAAAATTACCCCAGCAGGAACCTCACT
	GACCCCAGATTCTGACCTGGAGAGTGTGAAGACATTGAGCTCTGATGCCCAGCACCTG
	CAGAACAGCGCCCTCCCTCCCCTCAGCACAGAGAGTGAAGGCCACCACGTGTTCAAGG
	CTGGTACTGGGGCCTGGCAGGCAAPAAGCTCCTCTGTGCCCACCCCACCTCCCATCCA
	GCTCGGCAGCCTGGTGACGCAGGAGGCCCCGGCTCAGGACAGCCTGGGCAGCTGGATC
	AACTCTTCCCCTGACAGCAGTGAGAACCTGTCGGAGATCCCCTTGTCCCACAAAGAGA
	GGAAGGAGATCCTGACTGGCACCAAGTGCATCTGGGTGAAGGCCGCCCGGCGGCGCTC
	GCGGGCCCTGGGAACCGAGGGGCGACACCTGCTGGCACCCGCGACAGAGCGCAGCAGC
	CTGTCCCTGCACTCACTGAGCGAGCCCGACGATGCGCGGCCACCAGGCCCACTGGCCT
	GCAACCGGCCGCCCAGCCCCACACTACAGCATGCTGCCAGTGAGGACAACCTGTCCAG
	CAGCACGGGCGAGGCCCCGTCCCGGGCAGTCGGACATCATGGGGACGGCCCCAGGCCC
	TGGCTGCGTGGCCAGAAGAAAAGCCTGGGCAAGAAAAGGGAGGAGTCGCTGGAGGCAA
	AGAGAAGGAAGCGGAGGTCCCGATCCTTCGAGGTCACCGGGCAAGGGCTCTCCCACCC
	CAAGACACACCTCCTGGGGCCCCATCAGGCGGAGCGCATCTCGGACCACAGGATGCCA
	GTGTGCAGGCACCCAGCCCCTGGTATCCGGCATCTGGGAAAGGTCACGCTACCTTTGG
	CCAAAGTCAAACTCCCTCCAAGCCAGAACACGGGCCCGGGGGACTCCTCACCCCTGGC
	TGTTCCCCCCAACCCAGGTGGTGGTTCTCGACGGGCTACCCGTGGGCCCCGCCTGCCC
	CATGGCACAAGCACCCATGGCAAAGATGGATGCTCCCGGCATAACTGAGGGGGCCTGC
	CTGGAACTGG
	ORF Start: ATG at 7		ORF Stop: TGA at 3352
	SEQ ID NO:302	1115 aa	MW at 123442.0 kD
NOV25a,	MKDSGDSKDQQLMVALRVRPISVAELEEGATLIAHKVDEQHLPAATPLCSRGAVEPGS
CG153818-01
Protein Sequence	KLQRATGAVPSQPSQLRVEIPKPSVLTSSLTQLPVALCSVPGSALEGARGSQVTVGLP
	LGTLQMVVLMDPMEDPDDILRAHRSREKSYLFDVAFDFTATQEMVYQATTKSLIEGVI
	SGYNATVFAYGPQVRGMPDLCETAMICCGKTYTMLGTDQEPGIYVQTLNDLFRAIEET
	SNDMEYEVSMSYLEIYNEMIRDLLNPSLGYLELREDSKGVIQVAGITEVSTINAKEIM
	QLLMKGNRQRTQEPTAANQTSSRSHAVLQVTVRQRSRVKNILQEAQGRLFMIDLAGSE
	RASQTQNRGQRMKEGAHINRSLLALGNCINALSDKGSNKYINYRDSKLTRLLKDSLGG
	NSRTVMIAHISPASSAFEESRNTLTYAGRAKNIKTRVKQNLLNVSYHIAQYTSIIADL
	RGEIQRLKRKIDEQTGRGQARGRQDRGDIRHIQAEVQLHSGQGEKAGMGQLREQLASA
	FQEQMDVRRRLLELEMRANEVQIDTSRHLLTIAGWKHEKSRRALKwREEQRKECYAKD
	DSEKDSDTGDDQPDILEPPEVAAARESIAALVDEQKQLRKQKVSRVWGDKESGFRGQD
	ADLRLLQLALEQRCRELRARGRRLEETLPRRIGSEEQREVLSLLCRVHELEVENTEMQ
	SHALLRDGALRHRHEAVRRLEQHRSLCDEIIQGQRQIIDADYNLAVPQRLEELYEVYL
	RELEEGSLEQATIMDQVASRALQDSSLPKITPAGTSLTPDSDLESVKTLSSDAQHLQN
	SALPPLSTESEGHHVFKAGTGAWQAKSSSVPTPPPIQLGSLVTQEAPAQDSLGSWINS
	SPDSSENLSEIPLSHKERKEILTGTKCIWVKAARRRSRALGTEGRHLLAPATERSSLS
	LHSLSEGDDARPPGPLACKRPPSPTLQHAASEDNLSSSTGEAPSRAVGHHGDGPRPWL
	RGQKKSLGKKREESLEAKRRKRRSRSFEVTGQGLSHPKTHLLGPHQAERISDHRMPVC
	RHPAPGIRHLGKVTLPLAKVKLPPSQNTGPGDSSPLAVPPNPGGGSRRATRGPRLPHG
	TSTHGKDGCSRHN

[0491] Further analysis of the NOV25a protein yielded the following properties shown in Table 25B.

TABLE 25B
Protein Sequence Properties NOV25a
PSort     0.9800 probability located in nucleus; 0.3000
analysis: probability located in microbody (peroxisome);
          0.1000 probability located in mitochondrial matrix
          space; 0.1000 probability located in lysosome (lumen)
SignalP   No Known Signal Sequence Predicted
analysis:

[0492] A search of the NOV25a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 25C.

TABLE 25C
Geneseq Results for NOV25a
		NOV25a	Identities/
		Residues/	Similarities
Geneseq	Protein/Organism/Length	Match	forthe	Expect
Identifier	[Patent #, Date]	Residues	Matched Region	Value
AAO21658	Protein fragment of the motor	111 . . . 442	289/332 (87%)	e−155
	domain HsKip3b - Homo sapiens,	1 . . . 299	289/332 (87%)
	299 aa. [US6368841-B1, 09 APR.
	2002]
AAM50137	Human kinesin motor protein	111 . . . 442	289/332 (87%)	e−155
	HsKip3b motor domain - Homo	1 . . . 299	289/332 (87%)
	sapiens, 299 aa. [US6294371-B1,
	25 SEP. 2001]
ABB64748	Drosophila melanogaster	140 . . . 816	259/692 (37%)	e−106
	polypeptide SEQ ID NO 21036 -	68 . . . 684	379/692 (54%)
	Drosophila melanogaster, 728 aa.
	[WO200171042-A2, 27 SEP. 2001]
ABB07410	Human kinesin motor protein,	140 . . . 483	161/346 (46%)	3e−81
	HsKip3A - Homo sapiens, 864 aa.	64 . . . 395	229/346 (65%)
	[WO200196593-A2, 20 DEC. 2001]
AAU76957	Novel human kinesin motor protein,	140 . . . 537	171/400 (42%)	3e−79
	HsKip3d - Homo sapiens, 898 aa.	68 . . . 444	254/400 (62%)
	[WO200212268-A1, 14 FEB. 2002]

[0493] In a BLAST search of public sequence datbases, the NOV25a protein was found to have homology to the proteins shown in the BLASTP data in Table 25D.

TABLE 25D
Public BLASTP Results for NOV25a
		NOV25a	Identities/
Protein		Residues/	Similarities
Accession		Match	for the	Expect
Number	Protein/Organism/Length	Residues	Matched Portion	Value
BAC04386	CDNA FLJ37300 fis, clone	90 . . . 637	510/549 (92%)	0.0
	BRAMY2015782, moderately	11 . . . 544	512/549 (92%)
	similar to KINESIN-LIKE
	PROTEIN - Homo sapiens
	(Human), 548 aa.
Q9VFN0	CG9913 protein - Drosophila	140 . . . 816	259/692 (37%)	e−105
	melanogaster (Fruit fly), 728 aa.	68 . . . 684	379/692 (54%)
CAD49067	Kinesin, putative - Plasmodium	121 . . . 478	191/363 (52%)	4e−95
	falciparum, 1669 aa.	955 . . . 1304	252/363 (68%)
O14343	Kinesin-like protein 5 -	7 . . . 486	195/485 (40%)	1e−83
	Schizosaccharomyces pombe	2 . . . 437	276/485 (56%)
	(Fission yeast), 883 aa.
Q9SCJ4	Kinesin-like protein - Arabidopsis	89 . . . 716	217/631 (34%)	4e−83
	thaliana (Mouse-ear cress), 813 aa.	13 . . . 548	338/631 (53%)

[0494] PFam analysis predicts that the NOV25a protein contains the domains shown in the Table 25E.

TABLE 25E
Domain Analysis of NOV25a
			Identities/
		NOV25a	Similarities
		Match	for the	Expect
	Pfam Domain	Region	Matched Region	Value
	kinesin	140 . . . 186	22/54 (41%)	2.1e−10
			38/54 (70%)
	kinesin	203 . . . 468	126/319 (39%)	2.3e−89
			212/319 (66%)

Example 26

[0495] The NOV26 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 26A.

TABLE 26A
NOV26 Sequence Analysis
	SEQ ID NO:303	13734 bp
NOV26a,	GTTTCTTGCACTCTTAACAGATACACAGTGTAAGGAAAGGCCAAGATGACAATGGCCC
CG154435-01
DNA Sequence	CGGACGTCAGACTAGAGTATCTGGAGGAAGTTGCCTCCATCGTCCTGAAGTTCAAGCC
	GGACAAGTGGAGCAAGCTGATAGGCGCCGAGGAGAACGTGGCCCTGTTCACAGAGTTC
	TTTGAAAAGCCCGACGTCCAGGTGCTGGTGCTGACGCTCAATGCAGCCGGCATGATCA
	TACCCTGCCTGGGCTTCCCCCAGTCCCTCAAGTCCAAAGGGGTTTACTTCATCAAGAC
	AAAGTCCGAGAACATCAACAAGGACAACTACAGGGCCCGGCTCCTTTACGGCGACATC
	AGCCCCACACCCGTGGACCAGCTGATCGCGGTGGTGGAGGAGGTCCTCTCTTCTCTGT
	TAAACCAAAGTGAGAACATGGCTGGATGGCCCCAGGTGGTCTCGGAAGACATCGTGAA
	GCAGGTCCACAGGCTGAAGAATGAAATGTTTGTGATGAGTGGCAAGATCAAAGGCAAA
	ACCTTGCTGCCTATTCCGGAGCACCTGGGCAGCCTGGATGGCACGCTGGAGTCCATGG
	AGAGGATCCCCTCTTCACTGGACAACTTGCTCCTOCACGCCATTGAAACCACCATCAT
	CGACTGGTCCCACCAGATCCGGGATGTGCTGAGCAAAGACTCAGCCCAGGCGCTGCTG
	GATGGGCTGCACCCCCTGCCCCAAGTGGAGTTCGAGTTCTGGGACACTCGGCTGCTGA
	ACCTCAAGTGCATCCATGAACAGCTAAACAGACCCAAAGTGAACAAGATTGTTGAGAT
	CCTAGAGAAAGCCAAAAGCTGCTACTGGCCAGCCCTGCAPAACGTTTACACCAACGTC
	ACTGAAGGGCTGAAGGAAGCCAACGACATCGTGCTCTATTTGAAGCCCCTACGGATCC
	TGCTGGAGGAGATGGAACAAGCCGACTTCACGATGCTCCCCACCTTCATTGCCAAGGT
	GCTGGACACCATCTGCTTCATCTGGGCCACCTCTGAGTACTATAACACACCTGCCAGG
	ATCATCGTCATCCTGCAGGAGTTCTGCAACCAAATCATCGAGATGACACGAACCTTCC
	TGAGCCCGGAAGAGGTGCTGAAGGGCCTGCAAGGTGAAATCGAGGAAGTCCTGAGTGG
	CATCTCCCTGGCTGTAAATGTGCTGAAGGAGCTCTACCAGACGTACGACTTCTGCTGC
	GTGAACATGAAGCTTTTCTTTAAGGACAAAGAGCCCGTGCCTTGGGAATTCCCTTCTT
	CTCTTGCCTTTTCCAGGATAAATTCCTTCTTCCAGCGCATCCAGACCATTGAGGAACT
	CTATAAAACAGCAATTGAGTTTCTGAAGCTGGAGAAAATCGAGCTTGGGGGCGTGCGT
	GGGAACCTCCTCGGGAGCCTGGTGACCCGTATCTATGATGAGGTCTTTGAGCTGGTGA
	AGGTTTTTGCCGACTGCAAATATGATCCCTTGGACCCTGGAGACTCGAATTTTGACCG
	TGATTATGCTGATTTTGAGATCAAAATCCAAGACCTGGATAGGAGGCTGGCCACGATC
	TTTTGCCAAGGATTTGATGACTGCAGCTGTATCAAGTCCTCCGCAAAGCTCCTGTACA
	TGTGTGGGGGCCTCATGGAGCGGCCCCTGATTCTTGCCGAGGTGGCGCCCAGGTATTC
	AGTCATGCTGGAGCTGTTTGACGCTGAGCTAGACAATGCTAAGATCTTGTACGATGCC
	CAGATGGCGGCCTCCGAGGAGCGGAACATCCCCCTGATCCACAAAAACATGCCTCCCG
	TGGCCGGGCAGCTCAAATGGACCCTGGAGCTGCAGGAGAGGCTAGAGGTGTCCATGAA
	ACACCTGAAGCACGTCGAACACCCGGTCATGTCTGGAGCAGAGGCCAAGCTGACCTAT
	CAGAAGTATGACGAGATGATGGAGCTGCTGAGGTGCCACCGCGAGAAGATCTACCAGC
	AGTGGGTGGCGGGCGTGGACCAGGACTGCCACTTTAACCTGGGGCAGCCGCTGATTCT
	GCGGGACGCCGCTAGCAACCTCATCCACGTCAACTTCAGCAAAGCGTTGGTGGCAGTT
	CTGAGAGAAGTCAAGTATTTGAATTTCCAGCAACAGAAAGAGATTCCAGACAGTGCGG
	AGAGTCTGTTCTCAGAGAACGAAACTTTCCGGAAGTTTGTGGGCAACCTGGAGCTCAT
	CGTTGGCTGGTATAATGAGATAAAGACTATAGTGAAGGCAGTAGAATTTCTACTAATA
	AAGTCAGAACTGGAAGCAATTGATGTCAAGTTATTGAGCGCTGAAACGACATTATTCT
	GGAATGGCGAAGGTGTGTTTCAGTACATTCAAGAGGTGCGAGAAATTCTGCACAACTT
	GCAGAACAGGATGCAAAAGGCAAAACAAAATATAGAAGGAATTTCCCAGGCTATGAAG
	GACTGGTCGGCCAACCCGCTGTTTGAAAGAAAGGACAATAAGAAAGAGGCCCTGTTAG
	ACTTGGATGGAAGAATTGCCAACCTCAACAAGCGCTACGCAGCAGTCAGGGATGCTGG
	AGTGAAGATCCAACCCATGGAAAACGCAGAACTATTCAGGGCAGACACACTGAGCCTG
	CCCTGGAAGGATTATGTCATCTACATTGACGACATGGTCTTAGATGAATTTGACCAGT
	TCATTCGCAAATCTCTGAGTTTCCTAATGGACAACATGGTTATAGATGAGAGTATCGC
	TCCCCTGTTTGAGATCCGCATGGAGCTGGACGAGGATGGGCTGACCTTCAACCCGACC
	CTGGAGGTGCGCTCAGATCGCGGCTTCCTGGCACTGATCGAGGGCCTGGTCAACGACA
	TCTACAACGTAGCCAGGCTCATCCCTCGGCTGGCCAAGGACAGGATGAACTACAAGAT
	GGACCTGGAAGATAACACAGACCTCATAGAGATGAGGGAGGAGGTGTCCAGCCTGGTC
	ATCAATGCCATGAAGGAGGCCGAGGAGTACCAGGATTCCTTTGAGAGGTACTCCTACC
	TCTGGACGGACAACCTGCAGGAGTTTATGAAGAATTTCCTGATATATGGGTGTGCAGT
	CACTGCGGAGGACTTGGACACCTGGACAGATGACACCATCCCCAAGACACCGCCCACC
	CTGGCTCAGTTCCAGGAGCAGATCGACTCCTACGAGAAGCTGTATGAGGAGGTGTCCA
	AGTGCGAGAACACCAAGGTGTTCCACGGCTGGCTGCAGTGCGACTGCCGCCCCTTCAA
	GCAGGCCCTGCTCAGCACAATCCGGCGCTGGGGCTTCATGTTCAAGCGGCACCTGAGC
	AACCACGTCACCAACAGCCTGGCTGACCTGGAAGCCTTCATGAAAGTCGCCAGAATGG
	GCTTGACCAAGCCCCTCAAGGAGGGGGACTATGATGGGCTTGTGGAGGTGATGGGGCA
	CCTGATGAAAGTCAAGGAGAGGCAAGCAGCCACCGACAACATGTTTGAGCCCCTGAAG
	CAAACCATCGAGCTGCTCAAGACCTACGGGGAGGAGATGCCAGAGGAGATCCACTTGA
	AGCTGCAGGAGCTGCCGGAGCACTGGGCAAATACCAAGAAACTGGCCATTCACGTGAA
	GCTGACCGTGGCACCACTCCAGGCCAACGAGGTCAGCATCCTGCGGCGGAAATGCCAG
	CAATTCGACCTCAAGCAACATGAGTTCAGGGAGAGGTTCAGGCGCGAGGCCCCGTTCT
	CCTTCAGCGACCCCAACCCCTACAAGTCCCTGAATAAGCAACAAAAGAGCATCTCCGC
	CATGGAAGGCATCATGGAGGCGCTGTCCAAGTCCGGGGGCCTGTTCGAGGTCCCCGTC
	CCAGACTACAAGCAGCTCAAGGCCTGCCACCGGGAGGTCCGCCTACTGAAGGAGCTCT
	GGGACATCGTTGTTGTGGTAAATACCAGCATCGAGGACTGGAAGACCACCAAGTGGAA
	AGATATCAACGTTGAGCAGATGGACATAGATTGTAAGAAGTTTGCCAAGGACATGAGG
	TCTTTGGACAAGGAGATGAAAACCTGGGATGCCTTCGTGGGGCTCGACAACACCGTGA
	AAAACGTGATCACGTCCCTGCGTGCCGTGAGCGAGCTGCAGAACCCTGCCATTCGGGA
	ACGCCACTGGCAGCAGCTCATGCAGGCCACCCAGGTGAAATTTAAAATGTCAGAAGAG
	ACGACCCTGGCAGATTTACTCCAGCTGAACCTCCACAGTTACGAGGATGACGTCCGCA
	ACATCGTGGACAAGGCCGTGAAGGAGTCGGGCATGGAAAAGGTGCTGAAAGCCCTGGA
	CAGTACCTGGAGCATGATGGAATTCCAGCACGAGCCGCACCCGCGGACAGGCACCATG
	ATGCTCAAGTCCAGCGAGGTGCTGGTGGAGACGCTGGAGGACAACCAGGTGCAGCTGC
	AGAACCTGATGATGTCCAAGTACCTGGCCCACTTCCTGAAGGAGGTGACAAGCTGGCA
	GCAGAAGCTGTCCACGGCGGACTCCGTCATCTCCATCTGGTTTGAGGTCCAGCGAACC
	TGGAGCCACCTGGAGAGCATCTTCATCGGCTCCGAAGACATCCGCACCCAGCTCCCGG
	GGGACTCCCAGCGCTTTGACGACATCAACCAGGAATTCAAGGCCTTGATGGAAGATGC
	AGTGAAAACACCCAACGTGGTGGAAGCCACCAGCAAACCCGGCCTCTACAATAAACTG
	GAGGCCCTGAAGAAGAGCTTGGCCATCTGTGAAAAGGCTTTGGCAGAGTATTTAGAGA
	CGAAAAGACTGGCTTTCCCCCGGTTCTATTTTGTCTCCTCGGCTGACCTCCTGGACAT
	TCTCTCCAATGGCAATGACCCCGTGGAGGTGAGCCGCCACCTGTCCAAACTCTTCGAT
	AGCCTGTGTAAACTGAAGTTCCGGCTCGATGCCAGTGACAAACCTCTCAAGGTGGGCC
	TGGGAATGTACAGCAAGGAGGACGAGTACATGGTTTTTGATCAGGAATGCGACCTCTC
	GGGGCAGGTGGAAGTGTGGCTGAATCGAGTGCTGGACCGAATGTGCTCTACCCTCCGG
	CACGAAATCCCAGAGGCCGTGGTGACCTACGAAGAGAAGCCGAGGGAGCAGTGCATCC
	TGGACTACCCAGCCCAGGTGGCCCTGACTTGCACCCAGATCTGGTGGACGACCGAGGT
	GGGCCTGGCATTTGCCAGGCTGGAGGAAGGCTATGAAAACGCTATCAGAGATTATAAC
	AAAAAGCAGATTAGCCAGCTGAACGTACTCATCACCCTGCTCATGGGGAACCTCAACG
	CTGGCGACAGGATGAAGATCATCACCATCTGCACCATCGATGTGCACGCACGGGACGT
	GGTGGCCAAAATGATCGTGGCCAAGGTGGAGAGTTCTCAGGCCTTCACCTGGCAGGCC
	CAGCTCCGGCATCGCTGGGACGAAGAGAAGCGACACTGCTTTGCCAACATCTGCGATG
	CCCAAATCCAGTATTCCTATGAGTATCTGGGCAACACGCCGCGGCTGGTCATCACCCC
	ACTCACTGACAGGTGCTATATCACCCTGACCCAGTCCCTCCATCTCATCATGGGTGGA
	GCCCCTGCCGGCCCCGCTGGGACCGGCAAGACTGAGACGACCAAGGACCTGGGCAGAG
	CCCTGGGCACCATGGTCTACGTCTTCAACTGCTCCGAGCAGATGGACTACAAGTCCTG
	TGGAAATATCTACAAGGGCCTGGCCCAGACGGGAGCCTGGGGCTGCTTTGACGAGTTT
	AATCGCATCTCAGTGGAAGTCTTGTCTGTGATTGCCGTGCAGGTAAAATGTGTCCAGG
	ATGCAATTCGGGCCAAGAAAAAAGCATTCAATTTCCTGGGAGAGATCATAGGCCTCAT
	TCCCACCGTCGGTATCTTCATCACCATGAACCCTGGGTACGCCGGACGCGCGGACCTG
	CCTGAGAACCTAAAAGCCTTATTCAGGCCCTGTGCCATGGTCGTCCCCGACTTCGAAC
	TGATATGTGAGATCATGCTCATGGCCGAGGGCTTTCTGGAAGCCCGCCTTCTGGCCAG
	GAAGTTCATCACCCTGTACACCTTGTGCAAGGAGCTGCTCTCGAAGCAGGATCATTAC
	GACTGGGGCCTGAGAGCCATCAAGTCTGTGCTGGTGGTGGCCGGCTCCCTGAAGAGGG
	GCGACCCCAGCCGGGCAGAGGACCAGGTGCTCATGCGGGCGCTGAGAGACTTCAACAT
	CCCCAAGATTGTGACAGACGACCTGCCCGTATTCATGGGACTGATCGGGGACCTCTTC
	CCGGCTCTGGACGTGCCTCGGAAACGGGACCTGAATTTTGAAAAGATCATCAAGCAGA
	GCATCGTGGAGCTCAAGCTGCAGGCGGAGGACAGCTTCGTGCTGAAGGTGGTGCAGCT
	GGAGGAGCTGCTGCAGGTCCGCCACTCCGTGTTCATCGTCGGGAATGCGGGCAGCGGC
	AAATCTCAGGTCCTCAAATCCCTCAACAAGACCTATCAGAACCTGAAGAGGAAGCCGG
	TCGCCGTGGACCTGGACCCCAAGGCCGTCACCTGCGACGAGCTCTTTGGCATCATCAA
	CCCAGTGACCAGGGAATGGAAAGATGGCCTGTTCTCCACCATCATGCGAGACCTGGCC
	AACATCACCCATGACGGCCCCAAGTGGATCATCCTTGACGGAGACATAGACCCCATGT
	GGATCGAGTCTCTCAACACAGTCATGGATGACAACAAGGTCCTCACCCTGCCCAGCAA
	CGAGCGGATCCCCCTGAACCGCACCATGAGGCTGGTGTTCGAAATCAGCCACCTGAGG
	ACGGCCACCCCAGCCACCGTTTCCAGAGCCGGCATCCTCTACATCAACCCAGCCGACC
	TGGGATGGAACCCGGTGGTGAGCAGCTGGATCGAGAGGCGCAAGGTGCAGTCGGAGAA
	GGCCAACCTGATGATCCTCTTTGACAAGTACCTGCCCACGTGCCTGGACAAGTTGCGC
	TTTGGGTTCAAGAAGATCACGCCAGTGCCGGAGATCACGGTGATCCAAACGATTCTGT
	ACCTGCTGGAGTGCCTGCTCACGGAGAAGACCGTGCCCCCCGACTCCCCCAGGGAGCT
	GTACGAGCTGTACTTCGTGTTCACCTGCTTCTGGGCCTTCGGTGGCGCCATGTTCCAG
	GACCAGCTTGTGGATTATCGAGTGGAGTTCAGTAAATGGTGGATCAACGAATTCAAGA
	CTATCAAGTTCCCCTCGCAGGGAACGATTTTTGACTACTACATTGATCCTGACACAAA
	AAAGTTCCTGCCCTGGACAGATAAAGTGCCCTCCTTTGAGCTCGATCCCGATGTCCCA
	CTGCAGGCCTCTTTGGTCCACACCACGGAAACCATCCGCATCCGCTACTTCATGGACC
	TGCTCATGGAGAAGTCCTGGCCGGTGATGCTGGTGGGGAACGCGGGGACGGGCAAGTC
	GGTGCTGATGGGGGACAAGCTGGAAAGCCTGAACACGGACAACTACCTGGTGCAGGCT
	GTGCCCTTCAACTTCTACACGACCTCAGCCATGCTGCAGGGGGTGCTGGAGAAGCCGC
	TGGAGAAGAAATCGGGGAGGAACTACGGGCCGCCAGGCACTAAGAAGCTCGTCTACTT
	CATCGACGACATGAACATGCCCGAGGTGGACAAGTATGGGACGGTGGCCCCGCACACC
	CTCATCCGGCAGCACATGGACCACCGGCACTGGTATGACAGACATAAGCTGACGTTAA
	AAGATATCCATAATTGTCAGTACGTGGCCTGCATGAACCCCACTTCCGGATCCTTCAC
	CATCGACTCCAGGCTTCAGCGCCATTTCTGCGTGTTTGCTGTGAGCTTCCCCGGCCAG
	GAGGCCCTCACCACCATCTACAACACAATCCTGACGCAGCACCTGGCCTTCCGCTCGG
	TCTCCATGGCTATCCAGAGGATAAGCAGCCAGCTGGTGGCCGCGGCCCTGGCTTTGCA
	TCAGAAAATCACGGCAACATTTCTTCCCACGGCCATTAAGTTTCATTATGTCTTCAAC
	CTCAGGGACCTCTCCAATATTTTCCAGGGACTCTTATTTTCCACAGCAGAAGTTCTGA
	AAACCCCACTGGACCTCGTCCGCCTTTGGCTACATGAGACTGAACGAGTGTATGGTGA
	CAAAATGGTTGACGAAAAAGACCAGGAAACATTGCATACAGTCACCATGGCCTCCACC
	AAGAAGTTCTTTGATGATCTTGGTGATGAACTCTTATTTGCCAAGCCAAATATCTTCT
	GCCACTTTGCTCAACGGATTGGCGATCCCAAATATGTTCCTGTAACCGACATGGCTCC
	TCTGAACAAGCTCCTCGTGGACGTCCTGGACAGCTACAATGAAGTTAATGCAGTCATG
	AATTTCGTGCTGTTTGAGGACGCCGTGGCTCACATCTGCAGGATTAATCGCATCCTGG
	AGTCTCCCCGGGGGAATGCCCTGCTGGTGGGGGTGGGCGGCAGTGGCAAACAGAGCCT
	CTCCCGCCTGGCAGCGTACATCAGCGGGCTTGACGTGTTTCAGATCACCCTCAAGAAG
	GGCTACGGGATCCCCGACCTCAAGATTGACCTCGCTCCTCAGTACATAAAGGCTGCCG
	TGAAGAACGTTCCCTCGGTGTTCCTGATGACAGACTCCCAGGTGGCCGAGGAGCAGTT
	TCTGGTGCTGATCAATGACCTGCTGGCCTCAGGAGAGATCCCTGGGCTGTTTATGGAG
	GACGAGGTGGAGAACATCATCTCCTCCATGCGACCCCAAGTCAAGTCCCTTGGCATGA
	ATGACACTCGGGAAACATGTTGGAAGTTCTTCATCGAAAAAGTGCGCAGACAGCTCAA
	GGTGATCCTGTGTTTCTCCCCTGTGGGCTCCGTGCTCCGGGTACGAGCCAGAAAGTTC
	CCAGCTGTGGTCAACTGCACGGCCATCGACTGGTTCCACGAGTGGCCGGAAGATGCGC
	TGGTGTCCGTCAGCGCCCGCTTCCTGGAGGAGACTGAGGGGATTCCGTGGGAAGTCAA
	GGCCTCCATCAGCTTCTTCATGTCCTACGTGCACACCACCGTCAACGAGATGTCCAGG
	GTATACCTGGCTACTGAGAGGCGCTACAACTACACCACACCCAAAACCTTTCTGGAGC
	AGATCAAACTGTACCAGAACCTGCTGGCCAAGAACAGAACGGAACTTGTTGCCAAAAT
	CGAGAGGCTGGAGAACGGCCTGATGAAGCTGCAGAGCACGGCTTCCCAGGTGGATGAT
	TTGAAAGCCAAGTTCGCGATTCAGGAGGCTGAGCTCAAGCAGAAGAATGAGAGCCCAG
	ACCAACTGATCCAGGTGGTCGGCATCGAGGCCGAGAAGGTCACCAAAGAGAAGGCCAT
	TGCTGACCAGGAAGAAGTCAAGGTCGAGGTCATCAATAAGAACGTCACTGAGAAGCAA
	AAGGCCTGTGAAACAGACCTGGCCAAAGCAGAACCGGCCCTGCTGGCAGCCCAGGAGG
	CTCTGGACACTCTGAATAAGAACAACCTGACAGAGCTGAAGTCCTTTGGGTCCCCGCC
	GGATGCTGTGGTCAACGTCACCGCCGCCGTCATGATTCTGACCGCACCTCGGGGCAAG
	ATCCCCAAGGACAAGAGCTGGAAGGCGGCCAAGATCATGATGGGCAAGGTGGACACCT
	TCCTAGACTCCCTGAAGAAGTTCGACAAGGAGCACATCCCTGAGGCCTGCCTGAAGGC
	CTTCAAGCCCTACCAAGGCAACCCGACGTTCGACCCCGAGTTCATCCGCTCCAAGTCC
	ACGGCCGCCGCCGGCCTGTGCTCCTGGTGCATCAACATCGTCCGCTTCTACGAGGTCT
	ACTGCGACGTGGCGCCCAAGAGGCAGGCACTGGAGGAGGCTAATGCAGAGCTGGCAGA
	GGCACAAGAGAAGCTGTCCCGGATCAAAAACAAGATTGCCGAACTTAACGCCAACCTG
	AGCAACCTAACCTCAGCGTTTGAAAAAGCAACAGCTGAGAAAATCAAGTGTCAGCAAG
	AGGCCGATGCCACGAACAGGGTGATCTTACTGGCGAACAGGCTGGTCGGGGGATTAGC
	ATCGGAAAACATCCCCTGGGCTGAGTCTGTGGAGAACTTCAGGAGCCAGGGGGTCACG
	CTGTGTGGGGACGTCCTGCTCATCTCTGCCTTCGTGTCCTACGTGGGCTACTTCACCA
	AGAAATACCGGAATGAGCTGATGGAGAAATTCTGCATCCCTTACATACATAACTTAAA
	GGTCCCCATCCCGATCACGAATGGCCTGGATCCCTTGAGCCTGCTGACAGATGACGCG
	GACGTGGCCACCTGGAACAACCAGGGCCTCCCCAGCGACCGCATGTCCACCGAGAATG
	CCACCATCCTGGGCAACACCGAGCGGTGGCCGCTGATCGTGGACGCCCAGCTCCAAGG
	AATCAAGTGGATCAAAAACAAATACAGGAGTGAACTGAAAGCCATCCGCCTGGGACAG
	AAGAGCTACCTGGATGTCATCGAGCAGGCCATCTCGGAAGGGGACACCTTGCTCATTG
	AGAACATCGGCGAAACCGTGGACCCCGTGCTGGACCCTCTACTGGGCAGGAACACGAT
	TAAAAAGGGAAAGTACATTAAGATCGGTGACAAGGAGGTGGAGTACCACCCCAAGTTC
	CGCCTGATCCTACACACCAAGTACTTCAACCCACACTACAACCCAGAGATGCAGGCTC
	AGTGCACCCTCATCAACTTCCTGGTCACCAGGGATGGACTCGAGGACCAACTCTTGGC
	CGCTGTGGTGGCCAAAGAGCGCCCAGATCTGGAACAGCTGAAGGCAAACCTCACCAAG
	TCTCAAAACGAATTTAAGATTGTTCTGAAAGAGCTGGAAGATTCGCTCCTGGCCCGTC
	TGTCGGCTGCGTCGGGGAACTTTCTGGGAGACACGGCCTTGGTGGAGAATCTGGAGAC
	CACCAAGCACACAGCCAGCGAGATCGAGGAGAAGGTGGTGGAGGCAAAAATCACAGAA
	GTTAAAATCAACGAAGCGAGAGAGAACTACCGCCCGGCTGCGGAGAGGGCATCTCTGC
	TCTACTTCATACTGAACGATCTCAACAAAATCAACCCCGTCTACCAGTTCTCCCTCAA
	GGCCTTCAACGTGGTGTTTGAGAAAGCCATCCAGAGGACCACCCCTGCCAACGAGGTG
	AAGCAGCGGGTGATCAACCTGACGGACGAGATCACCTACTCCGTCTACATGTACACGG
	CCCGGGGACTCTTCGAGAGGGACAAACTCATTTTCCTGGCACAAGTTACGTTTCAGGT
	CCTGTCCATGAAGAAGGAGCTGAACCCAGTGGAGCTGGATTTCCTCCTGCGGTTCCCT
	TTTAAGGCCGGAGTGGTCTCACCAGTGGACTTCCTCCAGCATCAAGGCTGGGGCGGGA
	TCAAGGCCCTCTCCGAGATGGATGAGTTCAAAAATCTGGACAGTGACATCGAAGGATC
	TGCCAAGCGCTGGAAAAAGCTGGTGGAGTCGGAAGCCCCCGAGAAGGAGATCTTCCCC
	AAGGAGTGGAAGAACAAGACGGCCCTGCAGAAGCTGTGCATGGTGCGCTGCCTGCGGC
	CAGATCGCATGACCTACGCTATCAAGAACTTCGTGGAGGAAAAGATGGGCAGCAAGTT
	CGTGGAAGGCCGGAGTGTTGAGTTTTCTAAGTCCTACGAGGAGAGCAGCCCCTCCACG
	TCAATCTTCTTCATCCTCTCCCCGGGGGTTGACCCCTTGAAAGACGTGGAAGCCCTGG
	GAAAAAAACTAGGGTTTACCATAGACAATGGAAAACTCCATAATGTGTCCCTGGGGCA
	GGGACAAGAGGTGGTGGCTGAGAACGCCCTGGACGTGGCTGCAGAGAAAGGACACTGG
	GTCATTCTGCAGAATATCCACCTGGTGGCCCGGTGGCTGGGAACACTGGACAAGAAGC
	TGGAGTGCTACAGCACGGGCAGCCATGAGGACTACCGCGTGTTCATCAGCGCGGAGCC
	TGCCCCCAGCCCCGAGACCCACATCATCCCCCAGGGCATTCTGGAGAACGCCATCAAG
	ATCACCAACGAGCCCCCCACGGGCATGCACGCCAACTTGCACAAGGCCCTGGACCTGT
	TCACCCAGGACACCCTGGAGATGTGCACCAAGGAGATGGAGTTCAAGTGCATGCTCTT
	CGCCCTGTGCTACTTCCACGCTGTGGTGGCAGAGAGGCGCAAGTTCGGCGCCCAGGGC
	TGGAACCGGTCGTACCCCTTCAACAACGGGGACCTCACCATCTCCATCAACGTGCTCT
	ACAACTACCTGGAGGCCAACCCCAAGGTGCCCTGGGACGATCTCCGCTACCTTTTTGG
	TGAAATCATGTATGGCGGCCACATCACAGATGACTGGGACCGTCGGCTGTCCAGGACC
	TACCTGGCTGAATACATCCGGACGGAGATGCTGGAGGGAGACGTCCTGCTGGCCCCCG
	GCTTTCAGATCCCCCCCAACCTGGACTACAAGGGTTACCACGAATACATCGATGAGAA
	CCTGCCCCCTGAGAGTCCCTATCTGTATGGCCTGCACCCCAACGCAGAGATTGGCTTT
	CTGACGGTCACCTCAGAGAAGCTGTTCCGCACTGTCCTGGAAATGCAGCCAAAAGAGA
	CGGACTCGGGGGCAGGCACGGGACTGTCCCGCGAGGAGAAGGTGAAGGCCGTGCTGGA
	CGACATCCTGCAGAAGATTCCGGAGACTTTCAACATGGCTGAGATCATGGCAAAGGCA
	GCGGAAAAGACCCCCTACGTGGTAGTCGCCTTTCAAGAATGTGAAAGAATGAACATCC
	TGACCAACGAAATGCGCCGTTCGCTCAAGGAGCTGAACCTGGGGCTGAAGGGAGAACT
	GACCATCACGACCGACGTGGAAGATCTGTCCACGGCTCTCTTCTATGACACCGTGCCT
	GATACGTGGGTGGCCCGGGCCTACCCCTCCATGATGGGCCTGGCGGCCTGGTACGCAG
	ACCTGCTGCTCCGCATCAGGGAACTCGAGGCCTGGACGACAGACTTTGCCCTGCCCAC
	CACCGTGTGGCTGGCCGGCTTCTTCAACCCCCAGTCGTTCCTCACGGCCATCATGCAG
	TCCATGGCCAGGAAGAACGAGTGGCCCCTGGACAAGATGTGTCTGTCTGTCGAGGTGA
	CCAAGAAAAACCGAGAGGACATGACCGCTCCTCCGCGAGAGGGCTCCTACGTGTACGG
	ACTCTTCATGGAAGGGGCTCGCTGGGACACCCAGACTGGAGTCATCGCTGAAGCGCGG
	CTGAAAGAGCTGACCCCGGCCATGCCTGTCATCTTCATCAAGGCCATTCCTGTGGACC
	GCATGGAGACCAAGAACATCTATGAGTGTCCCGTGTACAAAACACGCATCCGCGGCCC
	CACCTATGTCTGGACCTTTAACTTGAAGACCAAAGAGAACGCAGCGAAGTGGATCCTG
	GCAGCCGTGGCGCTGCTCCTACAGGTTTAGCTCGCTCCTGCCTCACAGCCCACACTCC
	CTGGGGCTCOACCACAACTCAGCCCTTCACCTGTGCACCTGTGACTTATTCTTTACAG
	GAACTGGTGGTGGTTTTTCGTTCTCTTAAATAATCAGGTGCTTTGTAACCAAGCACAT
	CGGAACCAGAGGGTGGAGGTTGGTGTGGAAGAGGTGGGGCAGATTAAAGCCAGTGGAG
	CCACTCAGCTGTGCCCATCCATTCTGTGCCTGATGGCCACTGTGAGGCCTGGTTCAGG
	CTTTGGGGAAACGCCCCAATTCCCAGCAGCCAGAGGCAAGCATTCC
	ORF Start: at 61		ORF Stop: TAG at 13426
	SEQ ID NO:304	4455 aa	MW at 508571.2 kD
NOV26a,	DVRLEYLEEVASIVLKFKPDKWSKLIGAEENVALFTEFFEKPDVQVLVLTLNAAGMII
CG54435-01
Protein Sequence	PCLGFPQSLKSKGVYFIKTKSENINKDNYPARLLYGDISPTPVDQLIAVVEEVLSSLL
	NQSENMAGWPQVVSEDIVKQVHRLKNEMFVMSGKIKGKTLLPIPEHLGSLDGTLESME
	RIPSSLDNLLLHAIETTIIDWSHQIRDVLSKDSAQALLDGLHPLPQVEFEFWDTRLLN
	LKCIHEQLNRPKVNKIVEILEKAKSCYWPALQNVYTNVTEGLKEANDIVLYLKPLRIL
	LEEMEQADFTMLPTFIAKVLDTICFIWATSEYYNTPARIIVILQEFCNQIIEMTRTFL
	SPEEVLKGLQGEIEEVLSGISLAVNVLKELYQTYDFCCVNMKLFFKDKEPVPWEFPSS
	LAFSRINSFFQRIQTIEELYKTAIEFLKLEKIELGGVRGNLLGSLVTRIYDEVFELVK
	VFADCKYDPLDPGDSNFDRDYADFEIKIQDLDRRLATIFCQCFDDCSCIKSSAKLLYM
	CGGLMERPLILAEVAPRYSVMLELFDAELDNAKILYDAQMAASEEGNIPLIHKNNPPV
	ACQLKWSLELQERLEVSMKHLKHVEHPVMSGAEAKLTYQKYDEMMELLRCHREKIYQQ
	WVAGVDQDCHFNLGQPLILRDAASNLIHVNFSKALVAVLREVKYLNFQQQKEIPDSAE
	SLFSENETFRKFVGNLELIVGWYNEIKTIVKAVEFLLIKSELEAIDVKLLSAETTLFW
	NGEGVFQYIQEVREILHNLQNRMQKAKQNIEGISQAMKDWSANPLFERKDNKKEALLD
	LDGRIANLNKRYAAVRDAGVKIQAMENAELFRADTLSLPWKDYVIYIDDMVLDEFDQF
	IRKSLSFLMDNMVIDESIAPLFEIRMELDEDGLTFNPTLEVGSDRGFLALIEGLVNDI
	YNVARLIPRLAKDRMNYKMDLEDNTDLIEMREEVSSLVINAMKEAEEYQDSFERYSYL
	WTDNLQEFMKNFLIYGCAVTAEDLDTWTDDTIPKTPPTLAQFQEQIDSYEKLYEEVSK
	CENTKVFHGWLQCDCRPFKQALLSTIRRWGFMFKRHLSNHVTNSLADLEAFMKVARMG
	LTKPLKEGDYDGLVEVMGHLMKVKERQAATDNNFEPLKQTIELLKTYGEEMPEEIHLK
	LQELPEHWANTKKLAIQVKLTVAPLQANEVSILRRKCQQFELKQHEFRERFRREAPFS
	FSDPNPYKSLNKQQKSISAMEGIMEALSKSGGLFEVPVPDYKQLKACHREVRLLKELW
	DMVVVVNTSIEDWKTTKWKDINVEQMDIDCKKFAKDMRSLDKEMKTWDAFVGLDNTVK
	NVITSLPAVSELQNPAIRERHWQQLMQATQVKFKMSEETTLADLLQLNLHSYEDEVRN
	IVDKAVKESGMEKVLKALDSTWSMNEFQHEPHPRTGTMMLKSSEVLVETLEDNQVQLQ
	NLMNSKYLAHFLKEVTSWQQKLSTADSVISIWFEVQRTWSHLESIFIGSEDIRTQLPG
	DSQRFDDTNQEFKALMEDAVKTPNVVEATSKPGLYNKLEALKKSLAICEKALAEYLET
	KRLAFPRFYFVSSADLLDILSNGNDPVEVSRHLSKLPDSLCKLKFRLDASDKPLKVGL
	GMYSKEDEYMVFDQECDLSGQVEVWLNRVLDRMCSTLRHEIPEAVVTYEEKPREQWIL
	DYPAQVALTCTQIWWTTEVGLAFARLEEGYENAIRDYNKKQISQLNVLITLLMGNLNA
	GDRMKIMTICTIDVHARDVVAKMIVAKVESSQAFTWQAQLRHRWDEEKRHCFANICDA
	QIQYSYEYLGNTPRLVITPLTDRCYITLTQSLHLIMGGAFAGPAGTGKTETTKDLGRA
	LGTMVYVFNCSEQMDYKSCCNIYKGLAQTGAWCCFDEFNRISVEVLSVIAVQVKCVQD
	AIRAKKKAFNFLGEIIGLIPTVGIFITMNPGYAGRAELPENLKALFRPCAMVVPDFEL
	ICEIMLMAEGFLEARLLARKFITLYTLCKELLSKQDHYDWGLRAIKSVLVVAGSLKRG
	DPSRAEDQVLMRALRDFNIPKIVTDDLPVFMGLIGDLFPALDVPRKRDLNFEKIIKQS
	IVELKLQAEDSFVLKVVQLEELLQVRHSVFIVGNAGSGKSQVLKSLNKTYQNLKRKPV
	AVDLDPKAVTCDELFGIINPVTREWKDGLFSTIMRDLANITHDGPKWIILDGDIDPMW
	IESLNTVMDDNKVLTLASNERIPLNRTMRLVFEISHLRTATPATVSRAGILYINTADL
	GWNPVVSSWIERRKVQSEKANLMILFDKYLPTCLDKLRFGFKKITPVPEITVIQTILY
	LLECLLTEKTVPPDSPRELYELYFVFTCFWAFGGAMFQDQLVDYRVEFSKWWINEFKT
	IKFPSQGTIFDYYIDPDTKKFLPWTDKVPSFELDPDVPLQASLVHTTETIRIRYFMDL
	LMEKSWPVMLVGNAGTGKSVLMGDKLESLNTDNYLVQAVPFNFYTTSAMLQGVLEKPL
	EKKSGRNYGPPGTKKLVYFIDDMNMPEVDKYGTVAPHTLIRQHMDHRHWYDRHKLTLK
	DIHNCQYVACMNPTSGSFTIDSRLQRHFCVFAVSFPGQEALTTIYNTILTQHLAFRSV
	SMAIQRISSQLVAAALALHQKITATFLPTAIKFHYVFNLRDLSNIFQGLLFSTAEVLK
	TPLDLVRLWLHETERVYGDKMVDEKDQETLHRVTMASTKKFFDDLGDELLFAKPNIFC
	HFAQGIGDPKYVPVTDMAPLNKLLVDVLDSYNEVNAVMNLVLFEDAVAHICRINRILE
	SPRGNALLVGVGGSGKQSLSRLAAYISGLDVFQITLKKGYGIPDLKIDLAAQYIKAAV
	KNVPSVFLMTDSQVAEEQFLVLIMDLLASGEIPGLFMEDEVENIISSMRPQVKSLGMN
	DTRETCWKFFIEKVRRQLKVILCFSPVGSVLRVRARKFPAVVNCTAIDWFHEWPEDAL
	VSVSARFLEETEGIPWEVKASISFFMSYVHTTVNEMSRVYLATERRYNYTTPKTFLEQ
	IKLYQNLLAKKRTELVAKIERLENGLMKLQSTASQVDDLKAKLAIQEAELKQKNESAD
	QLIQVVGIEAEKVSKEKAIADQEEVKVEVINKNVTEKQKACETDLAKAEPALLAAQEA
	LDTLNKNNLTELKSFGSPPDAVVNVTAAVMILTAPGGKIPKDKSWKAAKIMMGKVDTF
	LDSLKKFDKEHIPEACLKAFKPYQGNPTFDPEFIRSKSTAAAGLCSWCINIVRFYEVY
	CDVAPKRQALEEANAELAEAQEKLSRIKNKIAELNANLSNLTSAFEKATAEKIKCQQE
	ADATNRVILLANRLVGGLASENIRWAESVENFRSQGVTLCGDVLLISAFVSYVGYFTK
	KYRNELMEKFWIPYIHNLKVPIPITNGLDPLSLLTDDADVATNNNQGLPSDRMSTENA
	TILGNTERWPLIVDAQLQGIKWIKNKYRSELKAIRLGQKSYLDVIEQAISEGDTLLIE
	NIGETVDPVLDPLLGRNTIKKGKYIKIGDKEVEYHPKFRLILHTKYFNPHYKPEMQAQ
	CTLINTLVTRDGLEDQLLAAVVAKERPDLEQLKANLTKSQNEFKIVLKELEDSLLARL
	SAASGNFLGDTALVENLETTKHTASEIEEKVVEAKITEVKINEARENYRPAAERASLL
	YFILNDLNKINPVYQFSLKAFNVVFEKAIQRTTPANEVKQRVINLTDEITYSVYNYTA
	RGLFERDKLIFLAQVTFQVLSMKKELNPVELDFLLRFPFKAGVVSPVDFLQHQGWGGI
	KALSEMDEFKNLDSDIEGSAKRWKKLVESEAPEKEIFPKEWKNKTALQKLCMVRCLRP
	DRMTYAIKNFVEEKMGSKFVEGRSVEFSKSYEESSPSTSIFFILSPGVDPLKDVEALG
	KKLGFTIDNGKLHNVSLGQGQEVVAENALDVAAEKGHWVILQNIHLVARWLGTLDKKL
	ECYSTGSHEDYRVFISAEPAPSPETHIIPQGILENAIKITNEPPTGMHANLHKALDLF
	TQDTLEMCTKEMEFKCMLFALCYFHAVVAERRKFGAQGWNRSYPFNNGDLTISINVLY
	NYLEANPKVPWDDLRYLFGEIMYGGHITDDWDRRLCRTYLAEYIRTEMLEGDVLLAPG
	FQIPPNLDYKGYHEYIDENLPPESPYLYGLHPNAEIGFLTVTSEKLFRTVLEMQPKET
	DSGAGTGVSREEKVKAVLDDILEKIPETFNMAEIMAKAAEKTPYVVVAFQECERMNIL
	TNEMRRSLKELNLGLKGELTITTDVEDLSTALFYDTVPDTWVARAYPSMMGLAAWYAD
	LLLRIRELEAWTTDFALPTTVWLAGFFNPQSFLTATMQSMARKNEWPLDKMCLSVEVT
	KKNREDMTAPPREGSYVYGLFMEGARWDTOTGVIAEARLKELTPANPVIFIKAIPVDR
	METKNTYECPVYKTRIRGPTYVWTFNLKTKEKAAKWILAAVALLLQV

[0496] Further analysis of the NOV26a protein yielded the following properties shown in Table 26B.

TABLE 26B
Protein Sequence Properties NOV26a
PSort     0.6000 probability located in plasma membrane;
analysis: 0.4000 probability located in Golgi body; 0.3000
          probability located in endoplasmic reticulum (membrane);
          0.3000 probability located in microbody (peroxisome)
SignalP   No Known Signal Sequence Predicted
analysis:

[0497] A search of the NOV26a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 26C.

TABLE 26C
Geneseq Results for NOV26a
		NOV26a	Identities/
		Residues/	Similarities
Geneseq	Protein/Organism/Length	Match	forthe	Expect
Identifier	[Patent #, Date]	Residues	Matched Region	Value
ABB60101	Drosophila melanogaster	1 . . . 4454	2669/4492 (59%)	0.0
	polypeptide SEQ ID NO 7095 -	19 . . . 4471	3378/4492 (74%)
	Drosophila melanogaster, 4472
	aa. [WO200171042-A2, 27 SEP.
	2001]
AAM78879	Human protein SEQ ID NO 1541 -	2314 . . . 4455	1504/2143 (70%)	0.0
	Homo sapiens, 2143 aa.	1 . . . 2143	1804/2143 (83%)
	[WO200157190-A2, 09 AUG.
	2001]
AAM79863	Human protein SEQ ID NO 3509 -	2254 . . . 3929	1160/1677 (69%)	0.0
	Homo sapiens, 2127 aa.	1 . . . 1677	1397/1677 (83%)
	[WO200157190-A2, 09 AUG.
	2001]
AAM79862	Human protein SEQ ID NO 3508 -	2254 . . . 3929	1160/1677 (69%)	0.0
	Homo sapiens, 2127 aa.	1 . . . 1677	1397/1677 (83%)
	[WO200157190-A2, 09 AUG.
	2001]
AAU74335	Human cytoskeleton-associated	3279 . . . 4455	1173/1177 (99%)	0.0
	protein (CYSKP) #6 - Homo	14 . . . 1190	1175/1177 (99%)
	sapiens, 1190 aa.
	[WO200185942-A2, 15 NOV.
	2001]

[0498] In a BLAST search of public sequence datbases, the NOV26a protein was found to have homology to the proteins shown in the BLASTP data in Table 26D.

TABLE 26D
Public BLASTP Results for NOV26a
		NOV26a	Identities/
Protein		Residues/	Similarities
Accession		Match	for the	Expect
Number	Protein/Organism/Length	Residues	Matched Portion	Value
P23098	Dynein beta chain, ciliary -	1 . . . 4455	3040/4467 (68%)	0.0
	Tripneustes gratilla (Hawaian sea	6 . . . 4466	3658/4467 (81%)
	urchin), 4466 aa.
P39057	Dynein beta chain, ciliary -	1 . . . 4455	3039/4467 (68%)	0.0
	Anthocidaris crassispina (Sea	6 . . . 4466	3657/4467 (81%)
	urchin), 4466 aa.
Q9NYC9	Ciliary dynein heavy chain 9	1 . . . 4455	2812/4469 (62%)	0.0
	(Axonemal beta dynein heavy	22 . . . 4486	3518/4469 (77%)
	chain 9) - Homo sapiens
	(Human), 4486 aa.
AAF55834	CG3723-PA - Drosophila	1 . . . 4454	2683/4482 (59%)	0.0
	melanogaster (Fruit fly), 4496 aa.	19 . . . 4495	3400/4482 (74%)
Q9VDG0	DHC93AB protein - Drosophila	1 . . . 4454	2669/4492 (59%)	0.0
	melanogaster (Fruit fly), 4472 aa.	19 . . . 4471	3378/4492 (74%)

[0499] PFam analysis predicts that the NOV26a protein contains the domains shown in the Table 26E.

TABLE 26E
Domain Analysis of NOV26a
		Identities/
	NOV26a	Similarities
	Match	for the	Expect
Pfam Domain	Region	Matched Region	Value
Luteo_ORF3	1022 . . . 1055	9/35 (26%)	0.41
		21/35 (60%)
Dynein_heavy	3751 . . . 4454	434/777 (56%)	0
		674/777 (87%)

Example 27

[0500] The NOV27 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 27A.

TABLE 27A
NOV27 Sequence Analysis
	SEQ ID NO:305	2675 bp
NOV27a,	CTGTCTGTGGTGTGGCTGTGGGACCCGTGAGCAAGCAGCGACGCCAGCGGCGGAGAAC
CG154465-01
DNA Sequence	CGACGAAAGGTGTCACCACAGTGATGGCAGTGGAGGACAGCACGCTGCAAGTAGTGGT
	ACGGGTGCGGCCCCCCACCCCTCGGGAGCTGGACAGTCAGCGGCGGCCAGTGGTTCAG
	GTGGTGGACGAGCGGGTGCTGGTGTTTAACCCTGAGGAGCCCGATGGAGGGTTCCCTG
	GCCTGAAATGGGGTGGCACCCATGATGGCCCCAAGAAGAAGGGCAAAGACCTGACGTT
	TGTCTTTGACCGGGTCTTTGGCGAGGCGGCCACCCAACAGGACGTGTTCCAGCACACC
	ACGCACAGCGTCCTGGACAGCTTCCTCCAGGGCTACAACTGCTCAGTGTTTGCCTACG
	GGGCCACCGGGGCTGGGAAGACACACACCATGCTGGGAAGGGAGGGGGACCCCGGCAT
	CATGTACCTGACCACCGTGGAACTGTACAGGCGCCTGGAGGCCCGCCAGCAGGAGAAG
	CACTTCGAGGTGCTCATCAGCTACCAGGAGGTCTATAATGAACAGATCCATGACCTCC
	TGGAGCCCAAGGGGCCCCTTGCCATCCGCGAGGACCCCGACAAGGGGGTGGTGGTGCA
	AGGACTTTCTTTCCACCAGCCAGCCTCAGCCGAGCAGCTGCTGGAGATACTGACCAGG
	GGGAACCGTAACCGCACGCAGCACCCCACTGATGCCAACGCGACTTCCTCCCGCTCCC
	ATGCCATCTTCCAGATCTTTGTGAAGCAGCAGGACCGGGTTCCAGGACTGACCCAGGC
	TGTCCAGGTGGCCAAGATGAGCCTGATTGACCTGGCTGGCTCAGAGCGGGCATCCAGC
	ACCCATGCGAAGGGGGAGCGGCTGCGGGAGGGGGCCAACATCAACCGCTCTCTCCTGG
	CGCTCATCAACGTCCTCAATGCCTTGGCCGATGCAAAGGTAGGCCGCAAGACCCATGT
	GCCCTACCGGGACAGCAAACTGACCCGCCTGCTCAAAGACTCCCTCGGGGGCAACTGC
	CGCACAGTGATGATCGCTGCCATCAGCCCCTCCAGCCTGACCTACGAGGACACGTACA
	ACACCCTCAAATATGCCGACCGCGCCAAGGAGATCAGGCTCTCGCTGAAGAGCAATGT
	GACCAGCCTGGACTGTCACATCAGCCAGTATGCTACCATCTGCCAACAGCTCCAGGCT
	GAGGTAGCCGCTCTGAGGAAGAAGCTCCAAGTGTATGAGGGGGGAGGCCAGCCCCCAC
	CACAGGACCTCCCAGGATCTCCCAAGTCGGGACCACCACCAGAACACCTTCCCAGCTC
	CCCCTTGCCACCCCACCCTCCCAGCCAGCCCTGCACCCCAGAGCTCCCTGCAGGGCCT
	AGAGCCCTTCAAGAGGAGAGTCTGGGGATGGAGGCCCAGGTGGAGAGGGCCATGGAAG
	GGAACTCTTCAGACCAGGAGCAGTCCCCAGAGGATGAGGATGAAGGCCCACCTGAGGA
	GGTTCCAACCCAGATGCCAGAGCAGAACCCCACACATGCACTGCCAGAGTCCCCTCGC
	CTGACCCTGCAGCCCAAGCCAGTCGTGGGCCACTTCTCAGCACGGGAACTGGATGGGG
	ACCGTTCTAAGCAGTTGGCCCTAAAGGTGCTGTGCGTTGCCCAGCGGCAGTACTCCCT
	GCTCCAAGCAGCCAACCTCCTGACGCCCGACATGATCACAGAGTTTGAGACCCTACAG
	CAGCTGGTGCAAGAGGAAAAAATTGAGCCTGGGGCAGAGGCCTTGAGGACTTCAGGCC
	TGGCCAGGGGGGCACCTCTGGCTCAGGAGCTGTGTTCAGAGTCAATCCCTGTGCCGTC
	TCCTCTCTGCCCAGAGCCTCCAGGATACACTGGCCCTGTGACCCGGACTATGGCGAGG
	CGACTGAGTGGCCCCCTGCACACCCTGGGAATCCCGCCTGGACCCAACTGCACCCCAG
	CCCAGGGGTCCCCATGGCCCATGGAGAAGAAGAGGAGGAGACCAAGCGCCTTGGAGGC
	AGACAGTCCCATGGCCCCAAAGCGGGGCACCAAGCGCCAGCGCCAGTCCTTCCTGCCC
	TGCCTAAGGAGAGGGTCTCTGCCTGACACCCAACCTTCACAGGGGCCCAGCACCCCCA
	AAGGAGAAAGGGCCTCCTCCCCCTGCCATTCCCCTCGCGTTTGCCCAGCCACAGTCAT
	CAAAAGCCGGGTGCCCCTGGGCCCTTCCGCCATGCAGAACTGCTCCACCCCGCTGGCT
	CTGCCCACTCGAGACCTCAATGCCACCTTTGATCTCTCTGAGGAGCCTCCCTCAAAGC
	CCAGTTTCCATGAATGCATTGGCTGGGACAAAATACCCCAGGAGCTGAGCAGGCTGGA
	CCAGCCCTTCATCCCCAGGGCACCTGTGCCCCTGTTCACCATGAAGGGCCCCAAGCCA
	ACATCTTCCCTCCCTGGGACCTCTGCCTCCAAGAAGAAGCGCGTTGCGAGTTCCTCAG
	TCTCCCATGGCCGCAGCCGCATCGCCCGCCTCCCCAGCAGCACTTTGAAGAGGCCAGC
	TGGGCCCCTTGTACTCCCAGGTGACTGGCACTAGGGACACGGATAGCCTGGGCCATGG
	AGGCCGATGAAGACAAGAAGGAGGAGGGGACGGGGAGCTGAGACCCAGAAGAAAGGAG
	GGCCTAG
	ORF Start: ATG at 82		ORF Stop: TAG at 2584
	SEQ ID NO:306	834 aa	MW at 91153.5 kD
NOV27a,	MAVEDSTLQVVVRVRPPTPRELDSQRRPVVQVVDERVLVFNPEEPDGGFPGLKWGGTH
CG154465-01
Protein Sequence	DGPKKKGKDLTFVFDRVFGEAATQQDVPQHTTHSVLDSFLQGYNCSVFAYGATGAGKT
	HTMLCREGDPGIMYLTTVELYRRLEARQQEKHFEVLISYQEVYNEQIHDLLEPKGPLA
	IREDPDKGVVVQGLSFHQPASAEQLLEILTRGNRNRTQHPTDANATSSRSHAIFQIFV
	KQQDRVPGLTQAVQVAKMSLIDLAGSERASSTHAKGERLREGANINRSLLALINVLNA
	LADAKVGRKTHVPYRDSKLTRLLKDSLGGNCRTVMIAAISPSSLTYEDTYNTLKYADR
	AKEIRLSLKSNVTSLDCHISQYATICQQLQAEVAALRKKLQVYEGGGQPPPQDLPGSP
	KSGPPPEHLPSSPLPPHPPSQPCTPELPAGPRALQEESLGMEAQVERAMEGNSSDQEQ
	SPEDEDEGPAEEVPTQMPEQNPTHALPESPRLTLQPKPVVGHFSARELDGDRSKQLAL
	KVLCVAQRQYSLLQAANLLTPDMITEFETLQQLVQEEKIEPGAEALRTSGLARGAPLA
	QELCSESIPVPSPLCPEPPGYTGPVTRTMARRLSGPLHTLGIPPGPNCTPAQGSRWPM
	EKKRRRPSALEADSPMAPKRGTKRQRQSFLPCLRRGSLPDTQPSQGPSTPKGERASSP
	CHSPRVCPATVIKSRVPLGPSANQNCSTPLALPTRDLNATFDLSEEPPSKPSFHECIG
	WDKIPQELSRLDQPFIPRAPVPLFTMKGPKPTSSLPGTSACKKKRVASSSVSHGRSRI
	ARLPSSTLKRPAGPLVLPGDWH

[0501] Further analysis of the NOV27a protein yielded the following properties shown in Table 27B.

TABLE 27B
Protein Sequence Properties NOV27a
PSort     0.7000 probability located in nucleus; 0.4267
analysis: probability located in mitochondrial matrix space;
          0.3000 probability located in microbody (peroxisome);
          0.1042 probability located in mitochondrial inner
          membrane
SignalP   No Known Signal Sequence Predicted
analysis:

[0502] A search of the NOV27a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 27C.

TABLE 27C
Geneseq Results for NOV27a
		NOV27a	Identities/
		Residues/	Similarities
Geneseq	Protein/Organism/Length	Match	for the	Expect
Identifier	[Patent #, Date]	Residues	Matched Region	Value
ABB07410	Human kinesin motor protein,	1 . . . 830	828/830 (99%)	0.0
	HsKip3A - Homo sapiens, 864 aa.	1 . . . 829	828/830 (99%)
	[WO200196593-A2, 20 DEC. 2001]
ABB07412	Amino acid sequence of Kip3A	1 . . . 360	354/360 (98%)	0.0
	fragment used in ATPase assay -	1 . . . 359	355/360 (98%)
	Homo sapiens, 383 aa.
	[WO200196593-A2, 20 DEC. 2001]
ABB07411	Human HsKip3A motor domain	5 . . . 343	338/339 (99%)	0.0
	fragment - Homo sapiens, 338 aa.	1 . . . 338	338/339 (99%)
	[WO200196593-A2, 20 DEC. 2001]
AAU76967	Novel human kinesin motor protein,	8 . . . 392	231/391 (59%)	e−130
	HsKip3d insertion mutant - Homo	12 . . . 402	298/391 (76%)
	sapiens, 905 aa. [WO200212268-A1,
	14 FEB. 2002]
AAU76957	Novel human kinesin motor protein,	8 . . . 392	231/385 (60%)	e−130
	HsKip3d - Homo sapiens, 898 aa.	12 . . . 395	297/385 (77%)
	[WO200212268-A1, 14 FEB. 2002]

[0503] In a BLAST search of public sequence datbases, the NOV27a protein was found to have homology to the proteins shown in the BLASTP data in Table 27D.

TABLE 27D
Public BLASTP Results for NOV27a
		NOV27a	Identities/
Protein		Residues/	Similarities
Accession		Match	for the	Expect
Number	Protein/Organism/Length	Residues	Matched Portion	Value
Q91WD7	Similar to hypothetical protein	8 . . . 392	233/385 (60%)	e−131
	DKFZp434G2226 - Mus	12 . . . 395	296/385 (76%)
	musculus (Mouse), 886 aa.
BAB93508	OK/SW-CL.108 - Homo sapiens	8 . . . 392	231/385 (60%)	e−129
	(Human), 898 aa.	12 . . . 395	297/385 (77%)
Q9H0F3	Hypothetical 102.3 kDa protein -	8 . . . 392	231/385 (60%)	e−129
	Homo sapiens (Human), 898 aa.	12 . . . 395	297/385 (77%)
Q9VSW5	KLP67A protein (RE52076p) -	4 . . . 452	213/451 (47%)	3e−99
	Drosophila melanogaster (Fruit	5 . . . 434	283/451 (62%)
	fly), 814 aa.
P91945	Kinesin like protein 67A -	4 . . . 452	213/451 (47%)	3e−99
	Drosophila melanogaster (Fruit	5 . . . 434	283/451 (62%)
	fly), 814 aa.

[0504] PFam analysis predicts that the NOV27a protein contains the domains shown in the Table 27E.

TABLE 27E
Domain Analysis of NOV27a
		Identities/
	NOV27a	Similarities
	Match	for the	Expect
Pfam Domain	Region	Matched Region	Value
kinesin	13 . . . 388	158/435 (36%)	2.3e−114
		281/435 (65%)

Example 28

[0505] The NOV28 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 28A.

TABLE 28A
NOV28 Sequence Analysis
	SEQ ID NO:307	1872 bp
NOV28a,	CGCGGCGGCTGGCGTCGGGAAAGTACAGTAAAAAGTCCGAGTGCAGCCGCCGGGCGCA
CG154492-01
DNA Sequence	GGATGGGATCCGGCTCCTCCAGCTACCGGCCCAAGGCCATCTACCTGGACATCGATGG
	ACGCATTCAGAAGGTAATCTTCAGCAAGTACTGCAACTCCAGCGACATCATGGACCTG
	TTCTGCATCGCCACCGGCCTGCCTCGGAACACGACCATCTCCCTGCTGACCACCGACG
	ACGCCATGGTCTCCATCGACCCCACCATGCCCGCGAATTCAGAACGCACTCCGTACAA
	AGTGAGACCTGTGGCCATCAAGCAACTCTCCGCTGGTGTCGAGGACAAGAGAACCACA
	AGCCGTGGCCAGTCTGCTGAGAGACCACTCAGGGACAGACGGGTTGTGGGCCTGGAGC
	AGCCCCGGAGGGAAGGAGCATTTGAAAGTGGACAGGTAGAGCCCAGGCCCAGAGAGCC
	CCAGGGCTGCTACCAGGAAGGCCAGCGCATCCCTCCACAGAGAGAAGAATTAATCCAG
	AGCGTGCTGGCGCAGGTTGCAGAGCAGTTCTCAAGAGCATTCAAAATCAATGAACTGA
	AAGCTGAAGTTGCAAATCACTTGGCTGTCCTAGAGAAACGCGTGGAATTGGAAGGACT
	AAAAGTGGTGGAGATTGAGAAATGCAAGAGTGACATTAAGAAGATGAGGGAGGAGCTG
	GCGGCCAGAAGCAGCAGGACCAACTGCCCCTGTAAGTACAGTTTTTTGGATAACCACA
	AGAAGTTGACTCCTCGACGCGATGTTCCCACTTACCCCAAGTACCTGCTCTCTCCAGA
	GACCATCGAGGCCCTGCGGAAGCCGACCTTTGACGTCTGGCTTTGGGAGCCCAATGAG
	ATGCTGAGCTGCCTGGAGCACATGTACCACGACCTCGGGCTGGTCAGGGACTTCAGCA
	TCAACCCTGTCACCCTCAGGAGGTGGCTGTTCTGTGTCCACGACAACTACAGAAACAA
	CCCCTTCCACAACTTCCGGCACTGCTTCTGCGTGGCCCAGATGATGTACAGCATGGTC
	TGGCTCTGCAGTCTCCAGGAGAAGTTCTCACAAACGGATATCCTGATCCTAATGACAG
	CGGCCATCTGCCACGATCTGGACCATCCCGGCTACAACAACACGTACCAGATCAATGC
	CCGCACAGAGCTGGCGGTCCGCTACAATGACATCTCACCGCTGGAGAACCACCACTGC
	GCCGTGGCCTTCCAGATCCTCGCCGAGCCTGAGTGCAACATCTTCTCCAACATCCCAC
	CTGATGGGTTCAAGCAGATCCGACAGGGAATGATCACATTAATCTTGGCCACTGACAT
	GGCAAGACATGCAGAAATTATGGATTCTTTCAAAGAGAAAATGGAGAATTTTGACTAC
	AGCAACGAGGAGCACATGACCCTCAGCGACCGTGAGAAGTCAGAAGGCCTTCCTGTGG
	CACCGTTCATGGACCGAGACAAAGTGACCAAGGCCACAGCCCAGATTGGGTTCATCAA
	GTTTGTCCTGATCCCAATGTTTGAAACAGTGACCAAGCTCTTCCCCATGGTTGAGGAG
	ATCATGCTGCAGCCACTTTGGGAATCCCGAGATCGCTACGAGGAGCTGAAGCGGATAG
	ATGACGCCATGAAAGAGTTACAGAAGAAGACTGACAGCTTGACGTCTGGGGCCACCGA
	GAAGTCCAGAGAGAGAAGCAGAGATGTGAAAAACAGTGAAGGAGACTGTGCCTGAGGA
	AAGCGGGGGGCGTGGCTGCAGTTCTGGACGGGCTGGCCGAGCTGCGCGGGATCCTTGT
	GCAGGGAAGAGCTGCCCTGGGCACCTGGCACCACAAGACCATGTTTTCTAAGAACCAT
	TTTGTTCACTGATACA
	ORF Start: ATG at 61		ORF Stop: TGA at 1735
	SEQ ID NO:308	558 aa	MW at 64319.9 kD
NOV28a,	MGSGSSSYRPKAIYLDIDGRIQKVIFSKYCNSSDIMDLFCIATGLPRNTTISLLTTDD
CG154492-01
Protein Sequence	AMVSIDPTMPANSERTPYKVRPVAIKQLSAGVEDKRTTSRGQSAERPLRDRRVVGLEQ
	PRREGAFESGQVEPRPREPQGCYQEGQRIPPEREELIQSVLAQVAEQFSRAFKINELK
	AEVANHLAVLEKRVELEGLKVVEIEKCKSDIKKMREELAARSSRTNCPCKYSFLDNHK
	KLTPRRDVPTYPKYLLSPETIEALRKPTFDVWLWEPNEMLSCLEHMYHDLGLVRDFSI
	NPVTLRRWLFCVHDNYRNNPFHNFRHCFCVAQMMYSMVWLCSLQEKFSQTDILILMTA
	AICHDLDHPGYNNTYQINARTELAVRYNDISPLENHHCAVAFQILAEPECNIFSNIPP
	DGFKQIRQGMITLILATDMARHAEIMDSFKEKMENFDYSNEEHMTLSDREKSEGLPVA
	PFMDRDKVTKATAQIGFIKFVLIPMFETVTKLFPMVEEIMLQPLWESRDRYEELKRID
	DAMKELQKKTDSLTSGATEKSRERSRDVKNSEGDCA
	SEQ ID NO:309	1653 bp
NOV28b,	CGGGAAAGTACAGTAAAAAGTCCGAGTGCAGCCACCGGGCGCAGGATGGCGTCCGGCT
CG154492-02
DNA Sequence	CCTCCGGCTACCGGCCCAAGGCCATCTACCTGGACATCGATGGACGCATTCAGAAGGT
	AATCTTCAGCAAGTACTGCAACTCCAGCGACATCATGGACCTGTTCTGCATCGCCACC
	GGCCTGCCTCGGAACACGACCATCTCCCTGCTGACCACCGACGACGCCATGGTCTCCA
	TCGACCCCACCATGCCCGCGAATTCAGAACGCACTCCGTACAAAGTGAGACCTGTGGC
	CATCAAGCAACTCTCCGAGAGAGAAGAATTAATCCAGAGCGTGCTGGCGCAGGTTGCA
	GAGCAGTTCTCAAGAGCATTCAAAATCAATGAACTGAAAGCTGAAGTTGCAAATCACT
	TGGCTGTCCTACACAAACGCGTGGAATTGGAAGGACTAAAAGTGGTGGAGATTGAGAA
	ATGCAAGAGTGACATTAAGAAGATGAGGGAGGAGCTGGCGGCCAGAAGCAGCAGGACC
	AACTGCCCCTGTAAGTACAGTTTTTTGGATAACCACAAGAAGTTGACTCCTCGACGCG
	ATGTTCCCACTTACCCCAAGTACCTGCTCTCTCCAGAGACCATCGAGGCCCTGCGGAA
	GCCGACCTTTGACGTCTGGCTTTGGGAGCCCAATGAGATGCTGAGCTGCCTGGAGCAC
	ATGTACCACGACCTCGGGCTGGTCAGGGACTTCAGCATCAACCCTGTCACCCTCAGGA
	GGTGGCTGTTCTGTGTCCACGACAACTACAGAAACAACCCCTTCCACAACTTCCGGCA
	CTGCTTCTGCGTGGCCCAGATGATGTACAGCATGGTCTGGCTCTGCAGTCTCCAGGAG
	AAGTTCTCACAAACGGATATCCTGATCCTAATGACAGCGGCCATCTGCCACGATCTGG
	ACCATCCCGGCTACAACAACACGTACCAGATCAATGCCCGCACAGAGCTGGCGGTCCG
	CTACAATGACATCTCACCGCTGGAGAACCACCACTGCGCCGTGGCCTTCCAGATCCTC
	GCCGAGCCTGAGTGCAACATCTTCTCCAACATCCCACCTGATGGGTTCAAGCAGATCC
	GACAGGGAATCATCACATTAATCTTGGCCACTGACATGGCAAGACATGCAGAAATTAT
	GGATTCTTTCAAAGGGAAAATGGAGAATTTTGACTACAGCAACGAGGAGCACATGACC
	CTGCTGAAGATGATTTTGATAAAATGCTGTGATATCTCTAACGAGGTCCGTCCAATGG
	AAGTCGCAGAGCCTTGGGTGGACTGTTTATTAGAGGAATATTTTATGCAGAGCGACCG
	TGAGAAGTCAGAAGGCCTTCCTGTGGCACCGTTCATGGACCGAGACAAAGTGACCAAG
	GCCACAGCCCAGATTGGGTTCATCAAGTTTGTCCTGATCCCAATGTTTGAAACAGTGA
	CCAAGCTCTTCCCCATGGTTGAGGAGATCATGCTGCAGCCACTTTGGGAATCCCGAGA
	TCGCTACGAGGAGCTGAAGCGGATAGATGACGCCATGAAAGAGTTACAGAAGAAGACT
	GACAGCTTGACGTCTGGCGCCACCGAGAAGTCCAGAGAGAGAAGCAGAGATGTGAAAA
	ACAGTGAAGGAGACTGTGCCTGAGGAAAG
	ORF Start: ATG at 46		ORF Stop: TGA at 1645
	SEQ ID NO:310	533 aa	MW at 61606.3 kD
NOV28b,	MGSGSSGYRPKAIYLDIDGRIQKVIFSKYCNSSDIMDLFCIATGLPRNTTISLLTTDD
CG154492-02
Protein Sequence	ANVSIDPTMPANSERTPYKVRPVAIKQLSEREELIQSVLAQVAEQFSRAFKINELKAE
	VANHLAVLEKRVELEGLKVVEIEKCKSDIKKMREELAARSSRTNCPCKYSFLDNHKKL
	TPRRDVPTYPKYLLSPETIEALRKPTFDVWLWEPNEMLSCLEHMYHDLGLVRDFSINP
	VTLRRWLFCVHDNYRNNPFHNFRHCFCVAQMMYSMVWLCSLQEKFSQTDILILMTAAI
	CHDLDHPCYNNTYQINARTELAVRYNDISPLENHHCAVAFQILAEPECNIFSNIPPDG
	FKQIRQGMITLILATDMARHAEIMDSFKGKMENFDYSNEEHMTLLKMILIKCCDISNE
	VRPMEVAEPWVDCLLEEYFMQSDREKSEGLPVAPFMDRDKVTKATAQIGFIKFVLIPM
	FETVTKLFPMVEEIMLQPLWESRDRYEELKRIDDAMKELQKKTDSLTSGATEKSRERS
	RDVKNSEGDCA

[0506] Sequence comparison of the above protein sequences yields the following sequence relationships shown in Table 28B.

TABLE 28B
Comparison of NOV28a against NOV28b.
			Identities/
			Similarities for
	Protein	NOV28a Residues/	the Matched
	Sequence	Match Residues	Region
	NOV28b	1 . . . 558	461/593 (77%)
		1 . . . 533	470/593 (78%)

[0507] Further analysis of the NOV28a protein yielded the following properties shown in Table 28C.

TABLE 28C
Protein Sequence Properties NOV28a
PSort     0.7600 probability located in nucleus; 0.1000 probability
analysis: located in mitochondrial matrix space; 0.1000 probability
          located in lysosome (lumen); 0.1000 probability located
          in plasma membrane
SignalP   No Known Signal Sequence Predicted
analysis:

[0508] A search of the NOV28a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 28D.

TABLE 28D
Geneseq Results for NOV28a
			Identities/
			Similarities for
Geneseq	Protein/Organism/Length	NOV28a Residues/	the Matched	Expect
Identifier	[Patent #, Date]	Match Residues	Region	Value
ABG61846	Prostate cancer-associated protein	1 . . . 558	558/593 (94%)	0.0
	#47 - Mammalia, 593 aa.	1 . . . 593	558/593 (94%)
	[WO200230268-A2, 18 APR. 2002]
AAY28561	Cyclic-GMP specific phosphodiesterase	1 . . . 558	558/593 (94%)	0.0
	(PDE9A) - Homo sapiens, 593 aa.	1 . . . 593	558/593 (94%)
	[WO9929873-A1, 17 JUN. 1999]
AAY39285	Phosphodiesterase 10 (PDE10) clone	14 . . . 558	544/580 (93%)	0.0
	FB68.2 - Homo sapiens, 580 aa.	1 . . . 580	544/580 (93%)
	[WO9942596-A2, 26 AUG. 1999]
AAY39284	Phosphodiesterase 10 (PDE10) clone	1 . . . 558	463/593 (78%)	0.0
	FB76.2 - Homo sapiens, 533 aa.	1 . . . 533	472/593 (79%)
	[WO9942596-A2, 26 AUG. 1999]
AAB92673	Human protein sequence SEQ ID NO:	148 . . . 558	411/446 (92%)	0.0
	11043 - Homo sapiens, 474 aa.	29 . . . 474	411/446 (92%)
	[EP1074617-A2, 07 FEB. 2001]

[0509] In a BLAST search of public sequence datbases, the NOV28a protein was found to have homology to the proteins shown in the BLASTP data in Table 28E.

TABLE 28E
Public BLASTP Results for NOV28a
			Identities/
Protein			Similarities for
Accession		NOV28a Residues/	the Matched	Expect
Number	Protein/Organism/Length	Match Residues	Portion	Value
O76083	High-affinity cGMP-specific 3′,5′-	1 . . . 558	558/593 (94%)	0.0
	cyclic phosphodiesterase 9A	1 . . . 593	558/593 (94%)
	(EC 3.1.4.17) - Homo sapiens
	(Human), 593 aa.
AAH09047	Similar to phosphodiesterase 9A -	1 . . . 558	463/593 (78%)	0.0
	Homo sapiens (Human), 533 aa.	1 . . . 533	472/593 (79%)
O70628	High-affinity cGMP-specific 3′,5′-	1 . . . 555	423/590 (71%)	0.0
	cyclic phosphodiesterase 9A	1 . . . 529	456/590 (76%)
	(EC 3.1.4.17) - Mus musculus
	(Mouse), 534 aa.
Q8QZV1	cGMP phosphodiesterase - Rattus	1 . . . 554	420/589 (71%)	0.0
	norvegicus (Rat), 534 aa.	1 . . . 528	457/589 (77%)
AAF48205	CG32648-PA - Drosophila	249 . . . 549	152/336 (45%)	4e−78
	melanogaster (Fruit fly), 963 aa.	48 . . . 380	199/336 (58%)

[0510] PFam analysis predicts that the NOV28a protein contains the domains shown in the Table 28F.

TABLE 28F
Domain Analysis of NOV28a
			Identities/
			Similarities for
	Pfam	NOV28a	the Matched	Expect
	Domain	Match Region	Region	Value
	PDEase	311 . . . 440	55/133 (41%)	9.8e−52
			90/133 (68%)
	PDEase	454 . . . 498	14/47 (30%)	1.1e−08
			33/47 (70%)

Example 29

[0511] The NOV29 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 29A.

TABLE 29A
NOV29 Sequence Analysis
	SEQ ID NO:311	13332 bp
NOV29a,	CTCCGGACTGGTTTCTTCTTCCTTCCCCCTTCCCCCAACTTCCCTCCACCCCTTCCAA
CG154509-01
DNA Sequence	TCATGCCGAACGGGACTGCGGACGTTCGGAAGCTCTTCATCTTCACTACTACCCAGAA
	TTACTTCGGGTTGATGTCTGAACTCTGGGATCAGCCACTGTTGTGCAACTGTCTTGAA
	ATCAACAACTTCTTGGATGACGGCAACCAGATGCTCCTCAGGGTGCAGCGATCCGACG
	CAGGAATCTCCTTTTCCAACACGATTGAGTTTGGTGACACAAAAGATAAAGTGCTGGT
	GTTTTTCAAGCTGCGACCTGAAGTAATTACTGATGAGAATCTACATGATAACATTCTT
	GTTTCATCTATGTTAGAGTCACCTATTAGTTCTCTTTACCAAGCAGTACGGCAAGTAT
	TCGCACCAATGTTGTTAAAGGATCAGGAATGGAGCAGAAACTTTGATCCCAAACTTCA
	GAATCTTTTGAGTGAACTAGAAGCTGGGTTGGGTATAGTTCTACGAAGATCAGACACT
	AACTTAACAAAATTGAAATTTAAGGAAGATGACACACGAGGTATCCTTACACCAAGCG
	ATGAGTTCCAGTTTTGGATAGAACAAGCTCACCGTGGAAATAAACAGATTAGTAAAGA
	AAGAGCCAATTATTTTAAAGAATTATTTGAAACAATTGCAACAGAGTTTTATAACTTG
	GACAGTCTATCCTTACTAGAAGTTGTTGACTTGGTGGAGACTACTCAGGATGTTGTAG
	ATGATGTGTGGAGACAAACAGAACATGATCATTATCCTGAGTCACGAATGTTGCATCT
	CTTAGACATCATAGGTCGTTCATTTGGAAGGTTTGTTCAGAAAAAGTTGGGAACTTTG
	AACCTGTGGGAAGATCCTTATTATCTTGTGAAAGAAAGTCTGAAAGCTGGTATTTCAA
	TTTGTGAACAGTGGGTGATAGTCTGTAATCATCTAACAGGTCAGGTGTGGCAGCGCTA
	TGTTCCTCATCCATGGAAAAATGAAAAATATTTTCCAGAAACACTTGACAAACTTGGC
	AAACGCCTTGAAGAGGTCTTGGCTATTAGAACAATTCATGAGAAGTTTCTCTATTTTC
	TACCTGCCAGTGAAGAGAAAATCATATGCCTCACTCGAGTATTTGAACCTTTTACTGG
	CCTGAATCCTGTGCAATATAATCCATATACTGAGCCCTTGTGGAAAGCTGCGGTGTCT
	CAATATGAAAAGATTATTGCACCTGCGGAACAAAAAATAGCAGGAAAATTGAAAAATT
	ATATTTCAGAAATTCAAGACAGTCCACAGCAGCTTCTTCAAGCATTCCTGAAATATAA
	AGAGTTGGTAAAGCGTCCAACTATAAGCAAAGAATTGATGTTAGAAAGAGAAACTTTA
	CTGGCAAGACTTGTGGACTCAATTAAAGATTTTCGATTAGACTTTGAGAATCGGTGCC
	GAGGAATTCCTGGTGATGCATCTGGACCACTTTCTGGCAAAAATCTTTCAGAAGTTGT
	CAACAGTATAGTTTGGGTTCGCCAGTTGGAATTGAAGGTAGATGATACTATCAAGACT
	GCAGAGGCTCTTTTATCTGACTTGCCAGGATTTCGATGTTTCCATCAAAGTGCCAAAG
	ATCTCTTAGACCAGCTTAAACTATATGAACAGGAACAATTTGATGATTGGTCCAGGGA
	TATTCAATCAGGTTTATCTGATTCCAGATCTGCTTTGTGTATTGAGGCTAGTAGTCGA
	ATTATGGAATTGGATTCTAATGATGGATTACTAAAAGTGCATTATTCAGATCGTTTGG
	TGATTCTTCTGAGAGAAGTTCGTCAGCTCTCTGCACTTGGCTTTGTTATTCCTGCCAA
	AATACAGCAAGTTGCAAACATTGCACAGAAATTCTGCAAGCAAGCAATTATTCTTAAA
	CAAGTCGCACATTTTTATAATTCTATTGATCAACAAATGATTCAAAGTCAGAGGCCAA
	TGATGTTACAATCTGCCTTAGCATTTGAACAGATAATTAAGAATTCAAAAGCAGGAAG
	TGGAGGGAAATCACAGATAACTTGGGATAATCCTAAAGAATTAGAAGGCTATATCCAA
	AAACTCCAAAATGCTGCTGAACGGCTTGCCACTGAAAATAGAAAACTGAGAAAATGGC
	ACACTACATTTTGTGAAAAGGTGGTTGTTCTTATGAATATTGATCTGCTTCGGCAGCA
	ACAGCGCTGGAAAGATGGATTACAAGAATTGAGAACTGGCTTAGCAACTGTAGAAGCA
	CAGGGATTCCAAGCAAGTGACATGCATGCATGGAAACAACACTGGAATCATCAACTGT
	ACAAAGCTCTGGAGCATCAGTACCAGATGGGCTTAGAAGCACTTAATGAGAATTTGCC
	AGAAATAAATATAGACTTAACTTACAAACAGGGACGATTACAATTCAGGCCCCCTTTT
	GAAGAAATCCGGGCTAAATATTATAGAGAAATGAAGAGATTCATCGGCATTCCAAATC
	AGTTTAAGGGAGTGGGTGAGGCCAGGAGCATTAATTCTATTTTTTCTATTATGATTGA
	TAGAAATGCAAGTGGATTTTTGACGATTTTCAGCAAAGCTGAACATCTGTTTAGAAGA
	TTGTCAGCTGTTTTACACCAACATAAGGAATGGATTGTAATTGGGCAAGTTGATATGG
	AAGCTCTGGTGGAAAAGCATCTTTTTACTGTACATGATTGGGAGAAAAATTTTAAAGC
	ATTAAAAATAAAGGGGAAAGAAGTAGAACGACTTCCAAGTGCTGTCAAGGTAGATTGT
	TTAAATATTAATTGCAACCCTGTGAAGACTGTGATTGATGATCTCATCCAGAAGTTAT
	TTGATCTGCTTGTTCTTTCTTTGAAGAAGTCCATACAGGCTCATTTACATGAAATTGA
	TACATTTGTTACTGAGGCTATGGAAGTCTTAACAATTATGCCCCAGTCTGTGGAAGAA
	ATTGGTGATGCAAATCTACAATATAGTAAGTTACAAGAACGGAAGCCAGAGATTTTGC
	CCTTATTTCAAGAAGCTGAAGACAAAAACAGACTTTTACGAACTGTGGCTGGTGGAGG
	TTTAGAAACAATTAGTAATTTGAAAGCCAAGTGGGATAAATTTGAGTTAATGATGGAA
	AGTCACCAACTTATGATTAAAGACCAGATTGAAGTGATGAAAGGAAATGTGAAATCAC
	GTCTTCAGATCTATTATCAAGAACTGGAAAAATTTAAAGCTCGTTGGGACCAACTAAA
	GCCTGGTGATGATGTTATTGAAACTGGCCAACATAATACTCTTGATAAAAGTGCAAAG
	TTAATAAAAGAGAAAAAAATTGAGTTTGATGATCTTGAAGTCACAAGAAAAAAGCTGG
	TTGATGATTGCCATCATTTTAGACTGGAAGAGCCTAATTTCTCCCTGGCAAGTAGTAT
	CTCTAAAGATATCGAGAGCTGTGCCCAAATTTGGGCCTTTTATGAAGACTTTCAACAA
	GGATTTCAGGAAATGGCCAATGAAGACTGGATCACTTTTCGGACTAAGACATACCTGT
	TTGAGGAATTTTTGATGAACTCGCATGACAGATTAAGGAAGGTTGAAGAACATTCAGT
	GATGACAGTGAAATTACAATCAGAGGTTGACAAATATAAAATCGTAATTCCTATCTTG
	AAATATGTGAGAGGGGAGCATCTTTCTCCAGATCACTGGCTTGACCTTTTTCGTCTCC
	TTGGACTTCCTAGGGGGACTAGTCTAGAGAAACTACTGTTTGGTGATTTGCTCAGAGT
	AGCTGATACAATTGTAGCCAAAGCTGCCGACCTTAAAGATTTAAATAGTCGGGCACAA
	GGTGAAGTTACAATCACAGAAGCTTTACGTGAACTTGATCTTTGGGGAGTTGGAGCAG
	TGTTTACATTAATTGATTATGAAGACAGCCAAAGTCGAACTATGAAGCTGATTAAAGA
	CTGGAAAGATATAGTAAATCAGGTTGGACATAATAGATGCCTTCTCCAATCCTTAAAG
	GATTCTCCTTATTATAAAGGATTTGAAGATAAAGTATCAATTTGGGAAAGAAAACTTG
	CAGAGTTAGATGAATACCTGCAGAATTTAAATCATATTCACAGAAAGTGGGTGTATTT
	GGAACCCATTTTCGGCCGTGGAGCATTGCCAAAAGAACAGACACGCTTCAACAGAGTT
	GATGAAGATTTTAGATCAATAATGACTGATATCAAGAAAGACAATAGAGTCACAACAT
	TAACTACTCATGCTGGAATAAGAAATTCTCTACTAACAATACTTGATCAGCTTCAAAG
	ATGTCAGAGATCATTAAATGAATTTTTGGAGGAAAAACGCTCAGCATTCCCAAGATTT
	TATTTTATTGGTGATGATGACTTATTAGAAATATTGGGCCAGTCTACCAACCCATCAG
	TGATTCAGTCTCACCTGAAGAAGCTTTTTGCTGGTATTAACAGTGTTTGCTTTGATGA
	GAAATCAAAACATATAACTGCAATGAAATCTTTAGAGGGAGAAGTTGTACCTTTTAAA
	AATAAAGTTCCTCTATCAAATAATGTAGAGACATGGTTGAATGATTTGGCCTTAGAAA
	TGAAGAAAACTTTGGAACAGTTGTTGAAGGAATGTGTTACTACTGGGCGAAGTTCTCA
	AGGTGCAGTTGACCCATCTCTGTTCCCTTCACAGATTTTATGCTTGGCGGAGCAGATT
	AAATTCACTGAAGATGTAGAAAATGCTATTAAAGATCATAGTCTTCATCAGATTGAAA
	CACAACTGGTGAATAAGTTAGAGCAATATACTAACATTGATACAAGTTCTGAGGATCC
	AGGGAATACTGAATCGGGCATCCTGGAGCTTAAACTTAAAGCCCTAATTCTTGACATT
	ATCCATAATATTGATGTGGTAAAGCAGTTAAACCAAATTCAGGTTCATACAACTGAAG
	ACTGGGCTTGGAAAAAACAACTTAGATTCTATATGAAAAGTGATCATACATGTTGTGT
	TCAAATGGTGGATTCTGAATTTCAGTATACTTATGAATATCAGGGTAATGCTTCCAAA
	CTGGTTTATACTCCACTGACAGACAAGTGCTACTTAACTCTCACTCAAGCCATGAAGA
	TGGGACTTGGAGGAAATCCTTATGGACCAGCTGGAACTGGGAAAACGGAATCAGTAAA
	GGCTTTAGGTGGACTTCTTGGAAGACAAGTTTTAGTCTTTAATTGTGATGAGGGCATC
	GATGTGAAGTCAATGGGACGAATATTTGTTGGTTTGGTGAAGTGTGGGGCCTGGGGTT
	GTTTTGATGAATTTAATAGGCTGGAAGAATCTGTACTGTCAGCAGTTTCTATGCAAAT
	CCAGACAATTCAAGATGCTTTGAAGAATCATAGAACTGTATGTGAACTGCTTGGCAAG
	GAGGTAGAAGTAAATTCTAATTCTGGAATTTTTATCACTATGAATCCTGCTGGAAAAG
	GTTATGGAGGAAGACAAAAACTCCCTGATAATCTTAAACAGCTTTTCAGGCCCGTAGC
	TATGTCTCATCCAGACAATGAGCTTATTGCAGAAGTTATTCTCTATTCGGAAGGCTTT
	AAAGACGCTAAAGTATTGAGCAGAAAATTGGTAGCTATTTTCAATCTATCTAGGGAAC
	TTTTGACACCTCAGCAACATTATGATTGGGGTTTGAGAGCTTTGAAGACAGTTCTGAG
	AGGAAGTGGAAATCTCCTTAGACAGCTAAACAAAAGTGGCACTACACAGAATGCTAAT
	GAAAGTCATATTGTGGTACAAGCACTGAGGCTTAATACAATGTCAAAGTTTACGTTTA
	CTGATTGCACCCGGTTTGATGCACTGATAAAAGATGTCTTTCCGGGAATTGAATTGAA
	AGAAGTGGAATATGATGAACTAAGTGCTGCATTAAAGCAGGTCTTTGAAGAGGCCAAT
	TATGAAATTATACCCAATCAGATCAAAAAGGCTTTAGAATTGTATGAACAGTTATGCC
	AGAGGATGGGAGTTGTTATTGTTGGTCCAAGTGGTGCTGGAAAATCAACGCTTTGGAG
	AATGTTAAGGGCTGCGCTTTGTAAAACTGGCAAAGTAGTGAAACAATATACTATGAAT
	CCCAAAGCTATCCCTCGATATCAATTATTAGGCCATATTGACATGGACACAAGAGAAT
	GGTCTGATGGTGTTTTGACAAATAGTGCTCGTCAAGTGGTTCGGGAACCTCAAGATGT
	CAGCTCATGGATAATCTGTGATGGTGATATTGACCCTGAATGGATAGAATCTCTGAAT
	TCTGTTCTGGATGATAATCGACTGCTGACTATGCCCAGTGGAGAAAGGATTCAGTTTG
	GCCCAAATGTTAACTTTGTATTTGAAACTCATGATTTAAGTTGTGCATCACCAGCCAC
	AATATCTAGAATGGGAATGATCTTTCTTAGTGATGAAGAGACAGATCTTAATTCTCTG
	ATAAAATCTTGGTTGAGGAATCAGCCTGCTGAATATAGAAATAATCTTGAAAATTGGA
	TTGGAGATTATTTTGAAAAGGCTTTACAATGGGTTCTAAAGCAGAATGACTATGTGGT
	AGAAACAAGTTTGGTTGGGACTGTGATGAATGGTTTGTCACATCTACATGGTTGCAGA
	GATCATGACGAATTCATTATTAATCTCATAAGGGGACTTGGTGGAAATCTGAATATGA
	AGTCACGTTTGGAATTTACCAAAGAGGTTTTTCATTGGGCACGAGAATCTCCTCCAGA
	CTTTCACAAACCTATGGATACCTACTATGACTCTACTAGGGGTCGATTAGCAACATAT
	GTGCTTAAGAAGCCAGAAGACTTGACTGCTGATGATTTCAGTAACGGCTTAACTCTTC
	CAGTCATTCAGACTCCTGACATGCAACGAGGTCTAGATTATTTCAAACCATGGTTAAG
	TTCTGATACTAAACAGCCCTTTATTCTCGTAGGACCAGAAGGATGTGGCAAAGGGATG
	CTGCTCAGGTACGCATTTTCACAACTCCGGTCCACTCAAATTGCTACAGTTCACTGTA
	GTGCACAAACCACTTCTCGACATCTCCTGCAGAAACTGAGCCAGACTTGCATGGTAAT
	CAGTACTAATACTGGTCGTGTATACAGACCAAAAGACTGTGAAAGACTTGTTCTGTAC
	TTAAAAGATATCAACCTACCTAAACTTGATAAATGGGGGACCAGTACTTTGGTAGCAT
	TCCTACAACAGGTATTGACGTATCAAGGATTTTATGATGAAAATTTGGAATGGGTTGG
	TCTAGAAAATATTCAAATTGTGGCTTCTATGTCAGCTGGAGGAAGACTGGGAAGACAT
	AAACTTACTACCAGATTTACTTCCATCGTTCGTCTTTGTTCTATAGATTACCCAGAAA
	GAGAGCAGTTACAAACGATTTATGGAGCATATTTGGAACCAGTTCTACATAAAAATCT
	GAAGAATCATTCTATTTGGGGTTCTTCATCAAAAATTTATCTTTTAGCAGGATCTATG
	GTACAAGTGTATCAACAGGTAGATATGCATCAGGTGCGAGCCAAATTTACAGTTGATG
	ATTATAGTCACTATTTCTTTACTCCTTGCATTCTTACCCAATGGGTTCTTGGCTTATT
	TAGATATGATTTAGAAGGAGGATCCTCAAACCATCCACTAGATTATGTGTTAGAAATT
	GTAGCATATGAGGCACGGCGCTTATTTCGTGACAAAATTGTTGGTGCAAAGGAACTTC
	ATTTATTTGACATCATTTTAACATCAGTGTTTCAAGGAGATTGGGGCTCAGACATATT
	AGACAATATGTCAGATAGTTTCTACGTTACATGGGGAGCTCGGCATAATTCAGGAGCA
	AGGGCAGCCCCAGGACAACCATTACCTCCACATGGAAAACCACTTGGAAAACTAAACT
	CTACTGATCTCAAGGATGTTATTAAAAAGGGTCTTATTCATTATGGACGAGATAACCA
	GAATTTAGACATTTTACTTTTCCACGAAGTCTTGGAGTATATGTCTAGGATAGATAGA
	GTGCTGAGTTTCCCTGCACGTTCACTTCTATTAGCAGGACGCAGTGGTGTAGGTCGTC
	GGACCATCACTTCTTTAGTCAGTCACATGCATGGAGCGGTCCTGTTTTCTCCAAAGAT
	TTCCAGAGGATATGAACTGAAGCAGTTCAAAAATGATCTCAAACATGTGCTGCAACTT
	GCAGGAATTGAAGCACAACAGGTAGTTTTACTTCTTGAGGATTACCAGTTTGTACATC
	CTACATTTTTGGAGATGATCAATAGCCTTTTGTCTTCAGGTGAAGTTCCTGGACTCTA
	TACTCTTGAAGAATTAGAGCCCTTGCTGTTACCACTTAAGGATCAAGCTTCACAAGAT
	GGTTTTTTTGGACCAGTCTTCAATTACTTCACATATAGAATTCAGCAAAACTTGCATA
	TTGTCTTGATAATGGATTCTGCAAATTCAAACTTCATGATAAACTGTGAGAGTAATCC
	AGCTTTGCATAAGAAATGCCAGCTGTTGTGGATGGAGGGTTGGTCCAATAGCAGTATG
	AAGAAAATACCTGAAATGTTATTCAGTGAAACAGGTGGTGGAGAAAAATACAATGATA
	AAAAACGAAAAGAAGAAAAGAAAAAAAATTCAGTTGATCCTGATTTTCTAAAATCATT
	TTTATTAATCCATCAATCTTGTAAAGCATATGGTGCTACACCAAGCCGATACATGACC
	TTTTTACATGTGTATTCTGCCATTAGTAGTAGCAAGAAAAAGGAATTATTAAAAAGAC
	AAAGTCATTTGCAGGCTGGTGTATCTAAACTAAATGAAGCTAAAGCTCTTGTGGATGA
	ACTGAACAGAAAAGCTGGAGAACAAAGTGTGTTACTTAAAACGAAGCAAGATGAAGCA
	GATGCTGCCCTTCAAATGATCACAGTGTCAATGCAGGATGCTAGTGAGCAAAAAACAG
	AACTTGAAAGACTGAAGCACAGAATAGCAGAAGAAGTTGTTAAAATTGAAGAAAGAAA
	AAATAAAATTGATGATGAATTAAAAGAAGTACAACCTTTAGTCAATGAAGCTAAACTA
	GCAGTTGGAAACATTAAGCCCGAATCACTTTCAGAAATTCGCTCACTACGCATGCCAC
	CTGATGTAATTAGAGATATTCTTGAAGGAGTTTTAAGGTTGATGGGTATCTTTGATAC
	ATCTTGGGTGAGCATGAAAAGTTTCCTTGCAAAAAGAGGTGTAAGACAAGACATAGCA
	ACCTTTGATGCCCGAAATATTTCAAAGGAAATAAGAGAGAGTGTTGAAGAACTTCTTT
	TTAAAAATAAAGGCTCTTTTGATCCAAAGAATGCTAAGCGTGCCAGTACTGCAGCTGC
	ACCTTTGGCTGCCTGGGTGAAAGCCAATATTCAGTATTCCCATGTCTTGGAACGAATT
	CATCCTTTGGAAACTGAACAGGCAGGATTAGAATCGAATCTGAAGAAAACTGAAGACA
	GAAAAAGGAAACTAGAGGAGCTTCTTAATTCTGTTGGTCAAAAGGTATCAGAACTCAA
	AGAAAAATTTCAGAGCAGGACTTCAGAAGCTGCCAAACTTGAGGCTGAAGTAAGCAAG
	GCACAAGAAACAATCAAAGCTGCAGAAGTCTTAATTAATCAGCTTGACAGAGAACATA
	AGAGATGGAATGCACAGGTTGTAGAGATAACAGAGGAATTAGCTACTCTTCCTAAAAG
	AGCTCAACTTGCTGCTGCATTTATTACATATCTTTCTGCTGCTCCTGAATCTCTGAGA
	AAAACCTGTTTGGAAGAATGGACCAAGTCAGCTGGTCTTGAGAAATTTGATCTGAGGA
	GATTTCTTTGTACTGAAAGTGAGCAGTTAATTTGGAAAAGTGAAGGCCTACCATCAGA
	TGACCTTTCCATAGAAAATGCTCTTGTAATATTACAGAGTCGAGTGTGCCCATTTCTT
	ATAGATCCTTCTTCCCAAGCTACAGAGTGGTTAAAAACACATTTGAAAGACTCACGTT
	TAGAAGTTATCAATCAGCAGGATAGTAACTTTATCACAGCTCTTGAATTAGCAGTACG
	TTTTGGGAAAACCCTTATTATACAAGAGATGGATGGTGTAGAACCTGTTCTTTATCCA
	TTATTGAGACGAGATCTGGTTGCTCAAGGACCACGTTATGTGGTACAAATAGGTGACA
	AAATTATTGACTACAATGAAGAATTCCGCCTCTTTTTGTCAACAAGAAACCCAAATCC
	TTTTATTCCACCGGATGCAGCTTCCATTGTTACTGAGGTTAACTTTACTACAACAAGA
	AGTGGATTACGAGGGCAGCTTTTAGCTTTAACCATTCAGCATGAGAAACCTGATTTAG
	AAGAACAGAAAACAAAACTATTACAACAGGAAGAAGATAAGAAAATACAGCTAGCCAA
	GCTCGAAGAATCTCTTCTAGAGACACTTGCCACATCTCAAGGCAATATTTTGGAAAAT
	AAGGATTTGATTGAGTCTTTGAATCAGACAAAAGCAAGCAGTGCACTTATTCAAGAGT
	CACTTAAAGAATCTTACAAACTCCAAATTTCCCTTGATCAAGAACGGGATGCCTATCT
	CCCCCTGGCTGAGAGTGCCAGCAAGATGTACTTCATTATTTCTGATTTGTCCAAAATT
	AATAACATGTACCGTTTTAGTTTGGCTGCTTTTCTCCGACTTTTCCAACGAGCTCTAC
	AAAACAAACAGGATTCTGAAAATACAGAACAGAGAATCCAGTCACTTATCAGCTCATT
	ACAACATATGGTATATGAATATATATGTCGTTGTCTATTTAAGGCTGATCAGTTGATG
	TTCGCTTTGCATTTTGTTCGAGGCATGCATCCTGAACTTTTTCAAGAAAATGAATGGG
	ATACGTTTACAGGTGTGGTTGTTGCAGACATGTTACGGAAAGCTGACTCTCAACAAAA
	AATACGTGATCAGCTTCCGTCTTGGATAGATCAGGAACGAAGCTGGGCCGTGGCAACA
	TTAAAGATTGCTCTCCCCAGTCTTTATCAGACCCTCTGCTTTGAAGATGCAGCTCTGT
	GGCGTACTTATTATAATAATTCAATGTGTGAGCAAGAGTTTCCATCTATCCTTGCAAA
	GAAAGTTTCCTTATTTCAGCAGATTCTTGTAGTACAGGCGCTAAGACCGGACAGATTG
	CAAAGTGCCATGGCTCTTTTTGCATGTAAAACTCTGGGACTGAAAGAGGTGTCCCCAC
	TGCCTCTAAATCTCAAACGTTTATACAAAGAGACACTGGAAATTGAACCCATCTTGAT
	AATTATTTCTCCGGGTGCTGATCCTTCTCAGGAACTTCAAGAACTAGCTAATGCTGAA
	AGAAGCGGAGAGTGTTATCACCAGGTTGCCATGGGTCAAGGTCAAGCTGATTTAGCAA
	TTCAAATGCTAAAAGAATGTGCCCGCAATGGAGACTGGCTCTGTTTGAAGAACTTACA
	TCTTGTGGTATCTTGGCTCCCAGTTCTGGAAAAGGAATTGAATACTCTTCAACCTAAA
	GATACCTTTCGTCTTTGGCTCACTGCAGAAGTTCATCCCAACTTTACTCCTATTTTAC
	TACAGTCAAGTCTGAAGATAACATATGAGTCACCTCCAGGTTTAGAGAACAATTTAAT
	GCGTACTTATGAGTCTTGGACTCCTGAGCAAATTAGCAAAAAAGATAATACACATCGA
	GCTCATGCTCTCTTCAGTCTTGCATGGTTTCATGCTGCATGTCAAGAAAGAAGAAACT
	ATATTCCTCAGGGTTGGACAAAGTTTTATGAATTTTCTTTATCAGATCTTCGGGCTGG
	GTACAACATTATTGACAGACTTTTTGATGGTGCCAAAGATGTACAATGGGAATTTGTA
	CATGGTTTACTTGAAAATGCTATTTATGGAGGACGTATAGACAACTATTTTGACCTTA
	GAGTTCTTCAGTCATACCTGAAGCAGTTTTTTAATTCTTCAGTTATTGATGTATTCAA
	CCAAAGGAACAAGAAAAGCATTTTTCCATATTCCGTATCTCTACCACAATCCTGCAGC
	ATTTTGGACTATCGTGCTGTCATTGAGAAAATTCCAGAGGACGACAAACCTAGTTTCT
	TTGGTCTGCCTGCCAATATCGCTCGCTCATCTCAGCGCATGATCAGTTCTCAGGTTAT
	TTCACAGTTGAGGATTTTGGGCAGATCCATAACAGCTGGTTCCAAATTTGATAGAGAA
	ATCTGGTCTAATGAACTTTCTCCTGTCCTCAATCTCTGGAAGAAACTAAACCAGAATT
	CAAACCTAATACATCAGAAAGTGCCTCCTCCTAACGATCGACAAGGATCTCCAATACT
	GTCATTCATCATTCTTGAACAATTTAATGCTATTCGTTTAGTACAAAGTGTCCACCAG
	TCTCTTGCTGCTCTCAGCAAAGTCATCAGAGGAACTACTTTACTGAGTTCAGAAGTAC
	AAAAATTGGCAAGTGCTTTATTAAACCAAAAGTGTCCTCTCGCATGGCAGAGCAAGTG
	GGAAGGCCCAGAAGATCCCTTACAATACCTGAGAGGTCTTGTTGCCCGTGCCCTTGCA
	ATACAGAACTGGGTAGATAAAGCTGAAAAACAGGCTCTTCTCTCTGAAACACTTGACC
	TATCAGAACTTTTCCATCCAGACACATTTCTTAATGCTCTTCGCCAGGAAACTGCAAG
	GGCAGTGGGTCGTTCTCTGGATAGCCTTAAATTTGTAGCCTCATGGAAAGGTCGACTG
	CAAGAAGCAAAGCTACAAATTAAGATCAGTGGCTTGTTACTAGAAGGATGTAGTTTTG
	ATGGAAATCAACTTTCTGAAAATCAGCTTGATTCTCCCAGCGTGTCATCAGTGCTCCC
	TTGTTTTATGGGCTGGATTCCACAGGATGCATGTGGTCCATATTCTCCGGATGAGTGC
	ATCTCTTTGCCTGTTTACACAAGTGCTGAAAGGGATCGTGTGGTTACCAATATTGATG
	TTCCATGTGGGGGCAACCAAGACCAGTGGATTCAGTGTGGAGCAGCTCTATTCCTAAA
	AAATCAGTAGAATCTAATGACAACAAAAGCCATCTTCACAAAAGGGAACATTGATTCT
	TTAAGCTTTAAATCAAACATGTGGTCAGTCTACATTTGAAATGTTAGTTCAAAATATT
	AACATATAGTTATGTTGTTGATGTCACTGAAATTTTAATGTGTAAAAGCAGCACTGTG
	CATCTTTTAAAGTAATAAATTAATGGAGTTATTGTTAAAACAGAGTATTCTTTTGACA
	ACATTAAATATTTCTGTGAGAAAGTTCACTTTTCCAGTGGCTCAAAAATTTGTTTTAG
	GTCAGAGATTTTAAGTGGTATATTAACCAATAATAAATATTTTGGCTGTC
	ORF Start: ATG at 61		ORF Stop: TAG at 13000
	SEQ ID NO:312	4313 aa	MW at 493435.2 kD
NOV29a,	MANGTADVRKLFIFTTTQNYFGLMSELWDQPLLCNCLEINNFLDDGNQMLLRVQRSDA
CG154509-01
Protein Sequence	GISFSNTIEFGDTKDKVLVFFKLRPEVITDENLHDNILVSSMLESPISSLYQAVRQVF
	APMLLKDQEWSRNFDPKLQNLLSELEAGLGTVLRRSDTNLTKLKFKEDDTRGILTPSD
	EFQFWIEQAHRGNKQISKERANYFKELFETTAREFYNLDSLSLLEVVDLVETTQDVVD
	DVWRQTEHDHYPESRMLHLLDIIGGSFGRFVQKKLGTLNLWEDPYYLVKESLKAGISI
	CEQWVIVCNHLTGQVWQRYVPHPWKNEKYFPETLDKLGKRLEEVLAIRTIHEKFLYFL
	PASEEKIICLTRVFEPFTGLNPVQYNPYTEPLWKAAVSQYEKTIAPAEQKIAGKLKNY
	ISEIQDSPQQLLQAFLKYKELVKRPTISKELMLERETLLARLVDSTKDFRLDFENRCR
	GIPGDASGPLSGKNLSEVVNSIVWVRQLELKVDDTIKTAEALLSDLPGFRCFHQSAKD
	LLDQLKLYEQEQFDDWSRDIQSGLSDSRSGLCIEASSRIMELDSNDGLLKVHYSDRLV
	ILLREVRQLSALGFVIPAKIQQVANIAQKFCKQAIILKQVAHFYNSIDQQMIQSQRPM
	MLQSALAFEQIIKNSKAGSGGKSQITWDNPKELEGYIQKLQNAAERLATENRKLRKWH
	TTFCEKVVVLMNIDLLRQQQRWKDGLQELRTGLATVEAQGFQASDMHAWKQHWNHQLY
	KALEHQYQMGLEALNENLPEINIDLTYKQGRLQFRPPFEEIRAKYYREMKRFIGIPNQ
	FKGVGEARSINSIFSIMIDRNASGFLTIFSKAEHLFRRLSAVLHQHKEWTVIGQVDME
	ALVEKHLFTVHDWEKNFKALKIKGKEVERLPSAVKVDCLNINCNPVKTVTDDLIQKLF
	DLLVLSLKKSIQAHLHEIDTFVTEAMEVLTIMPQSVEEIGDANLQYSKLQERKPEILP
	LFQEAEDKNRLLRTVAGGGLETISNLKAKWDKFELMMESHQLMIKDQIEVMKGNVKSR
	LQTYYQELEKFKARWDQLKPGDDVIETGQHNTLDKSAKLIKEKKIEFDDLEVTRKKLV
	DDCHHFRLEEPNFSLASSISKDIESCAQIWAFYEEFQQGFQEMANEDWITFRTKTYLF
	EEFLMNWHDRLRKVEEHSVMTVKLQSEVDKYKIVIPILKYVRGEHLSPDHWLDLFRLL
	GLPRGTSLEKLLFGDLLRVADTIVAKAADLKDLNSRAQGEVTIREALRELDLWGVGAV
	FTLIDYEDSQSRTMKLIKDWKDIVNQVGDNRCLLQSLKDSPYYKGFEDKVSIWERKLA
	ELDEYLQNLNHIQRKWVYLEPIFGRGALPKEQTRFNRVDEDFRSIMTDIKKDMRVTTL
	TTHAGIRNSLLTILDQLQRCQRSLNEFLEEKRSAFPRFYFIGDDDLLEILGQSTNPSV
	IQSHLKKLFAGINSVCFDEKSKHITANKSLEGEVVPFKNKVPLSNNVETWLNDLALEM
	KKTLEQLLKECVTTGRSSQGAVDPSLFPSQILCLAEQIKETEDVENAIKDHSLHQIET
	QLVNKLEQYTNIDTSSEDPGNTESGILELKLKALILDIIHNIDVVKQLNQIQVHTTED
	WAWKKQLRFYMKSDHTCCVQMVDSEFQYTYEYQGNASKLVYTPLTDKCYLTLTQAMKM
	GLGGNPYGPAGTGKTESVKALGGLLGRQVLVFNCDEGIDVKSMGRIFVGLVKCGAWGC
	FDEFNRLEESVLSAVSMQIQTIQDALKNHRTVCELLGKEVEVNSNSGIFITMNPAGKG
	YGGRQKLPDNLKQLFRPVAMSHPDNELIAEVILYSEGFKDAKVLSRKLVAIFNLSREL
	LTPQQHYDWGLRALKTVLRGSGNLLRQLNKSGTTQNANESHIVVQALRLNTMSKFTFT
	DCTRFDALIKDVFPGIELKEVEYDELSAALKQVFEEANYEIIPNQIKKALELYEQLCQ
	RMGVVIVGPSGAGKSTLWRMLPAALCKTGKVVKQYTMNPKANPRYQLLGHIDMDTREW
	SDGVLTNSARQVVREPQDVSSWIICDGDIDPEWIESLNSVLDDNRLLTMPSGERIQFG
	PNVNFVFETHDLSCASPATISRMGMIFLSDEETDLNSLIKSWLRNQPAEYRNNLENWI
	GDYFEKALQWVLKQNDYVVETSLVGTVMNGLSHLHGCRDHDEFIINLIRGLCGNLNNK
	SRLEFTKEVFHWARESPPDFHKPMDTYYDSTRGRLATYVLKKPEDLTADDFSNGLTLP
	VIQTPDMQRCLDYFKPWLSSDTKQPFILVGPEGCGKCMLLRYAFSQLRSTQIATVHCS
	AQTTSRHLLQKLSQTCMVISTNTGRVYRPKDCERLVLYLKDINLPKLDKWGTSTLVAF
	LQQVLTYQGFYDENLEWVGLENIQIVASMSAGGRLGRHKLTTRFTSIVRLCSIDYPER
	EQLQTIYGAYLEPVLHKNLKNHSIWGSSSKIYLLAGSMVQVYEQVDMHQVRAKFTVDD
	YSHYFFTPCILTQWVLGLFRYDLEGGSSNHPLDYVLEIVAYEARRLFRDKIVGAKELH
	LFDIILTSVFQGDWGSDILDNMSDSFYVTWGARHNSGARAAPGQPLPPHGKPLGKLNS
	TDLKDVIKKGLIHYGRDNQNLDILLFHEVLEYMSRIDRVLSFPGGSLLLAGRSGVGRR
	TTTSLVSHMHGAVLFSPKISRGYELKQFKNDLKHVLQLAGIEAQQVVLLLEDYQFVHP
	TFLEMINSLLSSGEVPGLYTLEELEPLLLPLKDQASQDGFFGPVFNYFTYRIQQNLHI
	VLIMDSANSNFMINCESNPALHKKCQVLWMEGWSNSSMKKIPEMLFSETGGGEKYNDK
	KRKEEKKKNSVDPDFLKSFLLIHESCKAYGATPSRYMTFLHVYSAISSSKKKELLKRQ
	SHLQAGVSKLNEAKALVDELNRKAGEQSVLLKTKQDEADAALQMITVSMQDASEQKTE
	LERLKHRIAEEVVKIEERKNKIDDELKEVQPLVNEAKLAVGNIKFESLSEIRSLRMPP
	DVIRDILEGVLRLMGIFDTSWVSMKSFLAKRGVREDIATFDARNISKEIRESVEELLF
	KNKGSFDPKNAKRASTAAAPLAANVKANIQYSHVLERIHPLETEQAGLESNLKKTEDR
	KRKLEELLNSVGQKVSELKEKFQSRTSEAAKLEAEVSKAQETIKAAEVLINQLDREHK
	RWNAQVVEITEELATLPKRAQLAAAFITYLSAAPESLRKTCLEEWTKSAGLEKFDLRR
	FLCTESEQLIWKSEGLPSDDLSIENALVILQSRVCPFLIDPSSQATEWLKTHLKDSRL
	EVINQQDSNFITALELAVRFGKTLIIQEMDGVEPVLYPLLRRDLVAQGPRYVVQIGDK
	IIDYNEEFRLFLSTRNPNPFIPPDAASIVTEVNFTTTRSGLRGQLLALTIQHEKPDLE
	EQKTKLLQQEEDKKIQLAKLEESLLETLATSQGNILENKDLIESLNQTKASSALIQES
	LKESYKLQISLDQERDAYLPLAESASKMYFIISDLSKINNMYRFSLAAFLRLFQRALQ
	NKQDSENTEQRIQSLISSLQHMVYEYICRCLFKADQLMFALHFVRGMHPELFQENEWD
	TFTGVVVGDMLRKADSQQKIRDQLPSWIDQERSWAVATLKIALPSLYQTLCFEDAALW
	RTYYNNSMCEQEFPSILAKKVSLFQQILVVQALRPDRLQSAMALFACKTLGLKEVSPL
	PLNLKRLYKETLEIEPILIIISPGADPSQELQELANAERSGECYHQVAMGQGQADLAI
	QMLKECARNGDWLCLKNLHLVVSWLPVLEKELNTLQPKDTFRLWLTAEVHPNFTPILL
	QSSLKITYESPPGLEKNLMRTYESWTPEQISKKDNTHRAHALFSLAWFHAACQERRNY
	IPQCWTKFYEFSLSDLRAGYNIIDRLFDGAKDVQWEFVHGLLENAIYGGRIDNYFDLR
	VLQSYLKQFFNSSVIDVFNQRNKKSIFPYSVSLPQSCSILDYRAVIEKIPEDDKPSFF
	GLPANIARSSQRMISSQVISQLRILGRSITAGSKFDREIWSNELSPVLNLWKKLNQNS
	NLIHQKVPPPNDRQGSPILSFIILEQFNAIRLVQSVHQSLAALSKVIRGTTLLSSEVQ
	KLASALLNQKCPLAWQSKWEGPEDPLQYLRGLVARALAIQNWVDKAEKQALLSETLDL
	SELFHPDTFLNALRQETARAVGRSVDSLKFVASWKGRLQEAKLQIKISGLLLEGCSFD
	GNQLSENQLDSPSVSSVLPCFMGWIPQDACGPYSPDECISLPVYTSAERDRVVTNIDV
	PCGGNQDQWIQCGAALFLKNQ

[0512] Further analysis of the NOV29a protein yielded the following properties shown in Table 29B.

TABLE 29B
Protein Sequence Properties NOV29a
PSort     0.6000 probability located in nucleus; 0.3600 probability
analysis: located in mitochondrial matrix space; 0.3249 probability
          located in microbody (peroxisome); 0.1000 probability
          located in lysosome (lumen)
SignalP   No Known Signal Sequence Predicted
analysis:

[0513] A search of the NOV29a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 29C.

TABLE 29C
Geneseq Results for NOV29a
			Identities/
			Similarities for
Geneseq	Protein/Organism/Length	NOV29a Residues/	the Matched	Expect
Identifier	[Patent #, Date]	Match Residues	Region	Value
ABB70206	Drosophila melanogasterpolypeptide	55 . . . 2085	708/2074 (34%)	0.0
	SEQ ID NO 37410 - Drosophila	20 . . . 2015	1159/2074 (55%)
	melanogaster, 2055 aa. [WO200171042-A2,
	27 SEP. 2001]
ABB60101	Drosophila melanogaster polypeptide	896 . . . 4311	959/3550 (27%)	0.0
	SEQ ID NO 7095 - Drosophila	1081 . . . 4471	1674/3550 (47%)
	melanogaster, 4472 aa. [WO200171042-A2,
	27 SEP. 2001]
AAB93815	Human protein sequence SEQ ID NO:	3761 . . . 4313	551/553 (99%)	0.0
	13606 - Homo sapiens, 553 aa.	1 . . . 553	552/553 (99%)
	[EP1074617-A2, 07 FEB. 2001]
AAM79140	Human protein SEQ ID NO 1802 -	2193 . . . 4299	612/2209 (27%)	0.0
	Homo sapiens, 2166 aa.	14 . . . 2151	1078/2209 (48%)
	[WO200157190-A2, 09 AUG. 2001]
AAM80124	Human protein SEQ ID NO 3770 -	2263 . . . 4299	596/2135 (27%)	0.0
	Homo sapiens, 2088 aa.	9 . . . 2073	1048/2135 (48%)
	[WO200157190-A2, 09 AUG. 2001]

[0514] In a BLAST search of public sequence datbases, the NOV29a protein was found to have homology to the proteins shown in the BLASTP data in Table 29D.

TABLE 29D
Public BLASTP Results for NOV29a
			Identities/
Protein			Similarities for
Accession		NOV29a Residues/	the Matched	Expect
Number	Protein/Organism/Length	Match Residues	Portion	Value
Q9JJ79	Cytoplasmic dynein heavy chain -	1 . . . 4313	4004/4313 (92%)	0.0
	Rattus norvegicus (Rat), 4306 aa.	1 . . . 4306	4175/4313 (95%)
Q27802	Dynein heavy chain isotype 1B	7 . . . 4313	2677/4338 (61%)	0.0
	(EC 3.6.1.3) - Tripneustes gratilla	5 . . . 4318	3354/4338 (76%)
	(Hawaian sea urchin), 4318 aa.
Q19542	F18C12.1 protein - Caenorhabditis	1 . . . 4311	1719/4328 (39%)	0.0
	elegans, 4131 aa.	1 . . . 4131	2570/4328 (58%)
BAC02706	KIAA1997 protein - Homo sapiens	3120 . . . 4313	1192/1194 (99%)	0.0
	(Human), 1194 aa (fragment).	1 . . . 1194	1193/1194 (99%)
Q9SMH5	Cytoplasmic dynein heavy chain	39 . . . 3064	1249/3133 (39%)	0.0
	1b - Chlamydomonas reinhardtii,	39 . . . 3074	1833/3133 (57%)
	3074 aa (fragment).

[0515] PFam analysis predicts that the NOV29a protein contains the domains shown in the Table 29E.

TABLE 29E
Domain Analysis of NOV29a
		Identities/
		Similarities for
Pfam	NOV29a	the Matched	Expect
Domain	Match Region	Region	Value
PRK	1976 . . . 2002	9/28 (32%)	0.69
		20/28 (71%)
DUF164	3099 . . . 3307	52/239 (22%)	0.15
		112/239 (47%)
Dynein_heavy	3613 . . . 4311	218/790 (28%)	9.9e−129
		513/790 (65%)

Example 30

[0516] The NOV30 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 30A.

TABLE 30A
NOV30 Sequence Analysis
	SEQ ID NO:313	4292 bp
NOV30a,	GTCAGGAGCTGCAGGATCTGGCTCGAGTCCCCTGCAGGGGCCCAGAGCAGTCCTCCCT
CG155595-01
DNA Sequence	CGGCATGGGGCTGGAGGCTCAGAGGCTGCCAGGGGCTGAGGAGGCCCCAGTGCGGGTT
	GCCCTGCGAGTTCGACCACTGCTGCCCAAGGAGCTGCTGCACGGGCATCAGAGCTGCC
	TGCAGGTGGAGCCAGGGCTTGGCCGCGTCACTCTGGGCCGTGACCGACACTTTGGCTT
	CCACGTGGTGCTGGCCGAGGATGCGGGGCAGGAGGCCGTGTACCAGGCCTGCGTTCAG
	CCCCTCCTTGAGGCCTTCTTCGAGGGCTTCAATGCCACTGTCTTTGCCTATGGTCAGA
	CGGGCTCAGGGAAGACATACACCATGGGGGAGGCCAGTGTGCCCTCCCTCCTTGAGGA
	TGAGCAGGGCATTGTCCCGAGGGCCATGGCCGAGGCCTTCAAGCTCATCGATGAGAAC
	GACCTGCTTGACTGTCTGGTACATGTGTCCTACCTGGAAGTGTACAAGGAGGAGTTCC
	GAGACCTGCTCGAGGTGGGCACTGCCAGCCGTGACATCCAGCTCCGGGAAGATGAGCG
	CGGGAATGTTGTGCTGTGCGGGGTGAAGGAGGTCGACGTGGAGGGCCTGGATGAGGTG
	CTGAGCCTCCTGGAGATGGGCAACGCGGCGCGGCACACGCGAGCCACGCACCTCAACC
	ACCTGTCTAGCCGCTCACACACGGTCTTCACCGTGACCCTGGAGCAGCGGGGGCGCGC
	CCCCAGCCGCCTACCCCGCCCCGCCCCGGGCCAGCTGCTCGTCTCCAAGTTCCACTTC
	GTGGACCTGGCGGGCTCAGAGAGGGTGCTCAAGACGGGCAGCACCGGCGAGCGGCTCA
	AGGAGAGCATCCAGATCAACAGCAGCCTCCTGGCGCTGGGCAACGTCATCAGCGCCCT
	GGGGGACCCTCAGCGCCGGGGCAGCCACATACCCTACCGCGACTCCAAGATCACCCGG
	ATCCTCAAAGACTCGCTGGGCGGGAACGCCAAGACGGTGATGATCGCCTGCGTCAGCC
	CTTCCTCCTCCGACTTCGACGAGACCCTCAACACCCTCAACTACGCCAGCCGCGCCCA
	GAACATCCGCAACCGCGCCACGGTCAACTGGCGGCCCGAGGCCGAGCGGCCACCCGAA
	GAGACGGCGAGCGGCGCGCGGGGTCCGCCACGGCACCGCTCCGAGACCCGCATCATCC
	ACCGCGGCCGGCGCGCCCCAGGCCCAGCCACCGCCTCCGCGGCGGCCGCCATGCGCCT
	GGGCGCCGAGTGCGCGCGCTACCGGGCCTGCACCGACGCCGCCTACAGCCTCTTGCGC
	GAGCTGCAGGCCGAGCCCGGGCTGCCCGGCGCCGCCGCCCGCAAGGTGCGCGACTGGC
	TGTGCGCCGTCGAGGGCGACCGCAGCGCCCTGAGCTCCGCCTCCGGGCCCGATAGCGG
	CATCGAGAGCGCCTCCGTCGAGGACCAGGCGGCGCAGGGGGCCCGCGGCCGAAAGGTG
	GCCGAGGGACAGGAGGATGAGGGGGCGCAGCAGCTGCTGACCCTGCAGAACCAGGTGG
	CGCGGCTGGAGGAGGAGAACCGAGACTTTCTGGCTGCGCTGGAGGACGCCATGGAGCA
	GTACAAACTGCAGAGCGACCGGCTGCGTGAGCAGCAGGAGGAGATGGTGGAACTGCGG
	CTGCGGTTAGAGCTGGTGCGGCCAGGCTGGGGCGGCCCGCGGCTCCTGAATGGCCTGC
	CTCCCGGGTCCTTTGTGCCTCGACCTCATACAGCCCCCCTGGGGGGTGCCCACGCCCA
	TGTGCTGGGCATGGTGCCGCCTGCCTGCCTCCCTGGAGATGAAGTTGGCTCTGAGCAG
	AGGGGACAGGTGACAAATGGCAGGGAGGCTGGAGCTGAGTTGCTGACTGAGGTGAACA
	GGCTGGGAAGTGGCTCTTCAGCTGCTTCAGAGGAGGAAGAGGAGGAGGAGGAGCCGCC
	CAGGCGGACCTTACACCTGCGCAGTTGGGGCAGCAACCTTGACAGGCTGCCTGTTGCA
	GCAGTTGGTGGGAGCAAGGCCCGAGTTCAGGCCCGCCAGGTCCCCCCTGCCACAGCCT
	CAGAGTGGCGGCTGGCCCAGGCCCAGCAGAAGATCCGGGAGCTGGCTATCAACATCCG
	CATGAAGGAGGAGCTTATTGGCGAGCTGGTCCGCACAGGAAAGGCAGCTCAGGCCCTG
	AACCGCCAGCACAGCCAGCGTATCCGGGACCTGCAGCAGGAGGCAGAGCAGGTGCGGG
	CCGAGCTGAGTGAAGGCCAGAGGCAGCTGCGGGAGCTCGAGGGCAAGGAGCTCCAGGA
	TGCTGGCGAGCGGTCTCGGCTCCAGGAGTTCCGCACGAGGGTCGCTGCGGCCCAGAGC
	CAGGTGCAGGTGCTGAAGGAGAAGAAGCAGGCTACGGAGCGGCTGGTGTCACTGTCGG
	CCCAGAGTGAGAAGCGACTGCAGGAGCTCGAGCGGAACGTGCAGCTCATGCGGCAGCA
	GCAGGGACAGCTGCAGAGGCGGCTTCGCGAGGAGACGGAGCAGAAGCGGCGCCTGGAG
	GCAGAAATGAGCAAGCGGCAGCACCGCGTCAAGGAGCTGGAGCTGAAGCATGAGCAAC
	AGCAGAAGATCCTGAAGATTAAGACGGAAGAGATCGCGGCATTCCAGAGGAAGAGGCG
	CAGTGGCAGCAACGGCTCTGTGGTCAGCCTGGAACAGCAGCAGGTGGGGCCAGGCTGT
	GTCCGCACCCAGGGCTCCCCTGGGGGCTGGCTGGTGGGTGCACCTTTCTCCCCAGTGA
	ACCTCGAGTGGCCGCTGACACACCCAGAGAAGATTGAGGAGCAGAAGAAGTGGCTGGA
	CCAGGAGATGGAGAAGGTGCTACAGCAGCGGCGGGCGCTGGAGGAGCTGGGGGAGGAG
	CTCCACAAGCGGGAGGCCATCCTGGCCAAGAAGGAGGCCCTGATGCAGGAGAAGACGG
	GGCTGGAGAGCAAGCGCCTGAGATCCAGCCAGGCCCTCAACGAGGACATCGTGCGAGT
	GTCCAGCCGGCTCGAGCACCTGGAGAAGGAGCTGTCCGAGAAGAGCGGGCAGCTGCGG
	CAGGGCAGCGCCCAGAGCCAGCAGCAGATCCGCGGGGAGATCGACAGCCTGCGCCAGG
	AGAAGGACTCGCTGCTCAAGCAGCGCCTGGAGATCGACGGCAAGCTGAGGCAGGGGAG
	TCTGCTGTCCCCCGAGGAGGAGCGGACGCTGTTCCAGTTGGATGAGGCCATCGAGGCC
	CTGGATGCTGCCATTGAGTATAAGAATGAGGCCATCACATGCCGCCAGCGCGTGCTTC
	GGGCCTCAGCCTCGTTGCTGTCCCAGTGCGAGATGAACCTCATGCCCAAGCTCAGCTA
	CCTCTCATCCTCAGAGACCAGAGCCCTCCTCTGCAAGTATTTTGACAAGGTGGTGACG
	CTCCGAGAGGAGCAGCACCAGCAGCAGATTGCCTTCTCGGAACTGGAGATGCAGCTGG
	AGGAGCAGCAGAGGCTGGTGTACTGGCTGGAGGTGGCCCTGGAGCGGCAGCGCCTGGA
	GATGGACCGCCAGCTGACCCTGCAGCAGAAGGAGCACGAGCAGAACATGCAGCTGCTC
	CTGCAGCAGAGTCGAGACCACCTCGGTGAAGGGTTAGCAGACAGCAGGAGGCAGTATG
	AGGCCCGGATTCAAGCTCTGGAGAAGGAACTGGGCCGTTACATGTGGATAAACCAGGA
	ACTGAAACAGAAGCTCGGCGGTGTGAACGCTGTAGGCCACAGCAGGGGTGGGGAGAAG
	AGGAGCCTGTGCTCGGAGGGCAGACAGGCTCCTGGAAATGAAGATGAGCTCCACCTGG
	CACCCGAGCTTCTCTGGCTGTCCCCCCTCACTGAGGGGGCCCCCCGCACCCGGGAGGA
	GACGCGGGACTTGGTCCACGCTCCGTTACCCTTGACCTGGAAACGCTCGAGCCTGTGT
	GGGGACTCTTCAACAACACCAATATCAGGACCAGGATCAGAGGACCTCGAGGAACCAC
	ATGCACAAGGATTATTCCATACCACTTGTAATTAACACTTATTAAGGAGACAGGCAGC
	TTCTCACTTAACAAGATCACAAAGATCACAGGGTCTGATAACACCAGTGCTGCTATTC
	TGAAATGTGGTACCTTTGTTCTTCTTGAAGTTGTCAAGTTTATCCTCTAGACCATCCA
	CAGCTGACACAGAATGGCTTCTAGGCAACCCCCGCTTTAGTGATCTCTTTGAAGGGGA
	AAGCAATTCCTGGTTGAAAAGATTTCTTCGAACTTTGGTCACTTCTAAAAGCATCAAA
	ORF Start: ATG at 63		ORF Stop: TAA at 4035
	SEQ ID NO:314	1324 aa	MW at 148066.3 kD
NOV30a,	MGLEAQRLPGAEEAPVRVALRVRPLLPKELLHGHQSCLQVEPGLGRVTLGRDRHFGFH
CG155595-01
Protein Sequence	VVLAEDAGQEAVYQACVQPLLEAFFEGFNATVFAYGQTGSGKTYTMGEASVASLLEDE
	QGIVPRAMAEAFKLIDENDLLDCLVHVSYLEVYKEEFRDLLEVGTASRDIQLREDERG
	NVVLCGVKEVDVEGLDEVLSLLEMGNAARHTGATHLNHLSSRSHTVFTVTLEQRGRAP
	SRLPRPAPGQLLVSKFHFVDLAGSERVLKTGSTGERLKESIQINSSLLALGNVISALG
	DPQRRGSHIPYRDSKITRILKDSLGGNAKTVMIACVSPSSSDFDETLNTLNYASRAQN
	IRNRATVNWRPEAERPPEETASGARGPPRHRSETRIIHRGRRAPGPATASAAAANRLG
	AECARYRACTDAAYSLLRELQAEPGLPGAAARKVRDWLCAVEGERSALSSASGPDSGI
	ESASVEDQAAQGAGGRKVAEGQEDEGAQQLLTLQNQVARLEEENRDFLAALEDAMEQY
	KLQSDRLREQQEEMVELRLRLELVRPGWGGPRLLNGLPPGSFVPRPHTAPLGGAHAHV
	LGMVPPACLPGDEVGSEQRGEVTNGREAGAELLTEVNRLGSGSSAASEEEEEEEEPPR
	RTLHLRSWGSNLDRLPVAAVGGSKARVQARQVPPATASEWRLAQAQQKIRELAINIRM
	KEELIGELVRTGKAAQALNRQHSQRIRELEQEAEQVRAELSEGQRQLRELEGKELQDA
	GERSRLQEFRRRVAAAQSQVQVLKEKKQATERLVSLSAQSEKRLQELERNVQLMRQQQ
	GQLQRRLREETEQKRRLEAEMSKRQHRVKELELKHEQQQKILKIKTEEIAAFQRKRRS
	GSNGSVVSLEQQQVGPGCVRTQGSPGGWLVGAPFSPVNLEWRLTQPEKIEEQKKWLDQ
	EMEKVLQQRRALEELGEELHKREAILAKKEALMQEKTGLESKRLRSSQALNEDIVRVS
	SRLEHLEKELSEKSGQLRQGSAQSQQQIRGEIDSLRQEKDSLLKQRLEIDGKLRQGSL
	LSPEEERTLFQLDEAIEALDAAIEYKNEAITCRQRVLRASASLLSQCEMNLMAKLSYL
	SSSETRALLCKYFDKVVTLREEQHQQQIAFSELEMQLEEQQRLVYWLEVALERQRLEM
	DRQLTLQQKEHEQNMQLLLQQSRDHLGEGLADSRRQYEARIQALEKELGRYMWINQEL
	KQKLGGVNAVGNSRGGEKRSLCSEGRQAPGNEDELHLAPELLWLSPLTEGAPRTREET
	RDLVHAPLPLTWKRSSLCGDSSTTPISGPGSEDLEEPHAQGLFHTTCN

[0517] Further analysis of the NOV30a protein yielded the following properties shown in Table 30B.

TABLE 30B
Protein Sequence Properties NOV30a
PSort     0.8800 probability located in nucleus; 0.3000 probability
analysis: located in microbody (peroxisome); 0.1000 probability
          located in mitochondrial matrix space; 0.1000 probability
          located in lysosome (lumen)
SignalP   No Known Signal Sequence Predicted
analysis:

[0518] A search of the NOV30a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 30C.

TABLE 30C
Geneseq Results for NOV30a
			Identities/
			Similarities for
Geneseq	Protein/Organism/Length	NOV30a Residues/	the Matched	Expect
Identifier	[Patent #, Date]	Match Residues	Region	Value
AAU86160	Human PRO539 polypeptide - Homo sapiens,	519 . . . 1301	734/811 (90%)	0.0
	830 aa. [WO200153486-A1, 26 JUL. 2001]	1 . . . 777	737/811 (90%)
AAY96730	PRO539, a Costal-2 homologue - Homo	519 . . . 1301	734/811 (90%)	0.0
	sapiens, 830 aa. [WO200036102-A2,	1 . . . 777	737/811 (90%)
	22 JUN. 2000]
ABB81633	Human kinesin motor protein HsKif7	11 . . . 354	341/344 (99%)	0.0
	fragment SEQ ID NO: 2 - Homo sapiens,	1 . . . 342	342/344 (99%)
	342 aa. [US6395527-B1, 28 MAY 2002]
ABB81634	Human kinesin motor protein HsKif7	12 . . . 350	336/339 (99%)	0.0
	fragment SEQ ID NO: 4 - Homo sapiens,	1 . . . 337	337/339 (99%)
	337 aa. [US6395527-B1, 28 MAY 2002]
ABB80078	Human kinesin motor protein (HsKrp5)	676 . . . 1222	259/548 (47%)	e−131
	amino acid sequence - Homo sapiens,	593 . . . 1102	386/548 (70%)
	1279 aa. [US6379941-B1, 30 APR. 2002]

[0519] In a BLAST search of public sequence datbases, the NOV30a protein was found to have homology to the proteins shown in the BLASTP data in Table 30D.

TABLE 30D
Public BLASTP Results for NOV30a
			Identities/
Protein			Similarities for
Accession		NOV30a Residues/	the Matched	Expect
Number	Protein/Organism/Length	Match Residues	Portion	Value
Q95LL1	Hypothetical 98.5 kDa protein -	12 . . . 825	359/877 (40%)	e−166
	Macaca fascicularis (Crab eating	2 . . . 865	527/877 (59%)
	macaque) (Cynomolgus monkey),
	865 aa (fragment).
Q9UF54	Hypothetical 96.7 kDa protein -	676 . . . 1222	256/548 (46%)	e−129
	Homo sapiens (Human), 833 aa	147 . . . 656	384/548 (69%)
	(fragment).
Q9QXL2	Kif21a - Mus musculus (Mouse),	8 . . . 356	178/377 (47%)	2e−88
	1573 aa.	2 . . . 378	236/377 (62%)
Q9CTY0	Kinesin family member 21A -	5 . . . 356	178/380 (46%)	1e−87
	Mus musculus (Mouse), 647 aa	82 . . . 461	236/380 (61%)
	(fragment).
Q9NXU4	CDNA FLJ20052 fis, clone	8 . . . 356	175/377 (46%)	8e−87
	COL00777 - Homo sapiens	2 . . . 378	237/377 (62%)
	(Human), 576 aa (fragment).

[0520] PFam analysis predicts that the NOV30a protein contains the domains shown in the Table 30E.

TABLE 30E
Domain Analysis of NOV30a
			Identities/
			Similarities for
	Pfam	NOV30a	the Matched	Expect
	Domain	Match Region	Region	Value
	kinesin	21 . . . 364	168/404 (42%)	1.3e−125
			260/404 (64%)
	DUF164	681 . . . 913	55/251 (22%)	0.015
			132/251 (53%)

Example 31

[0521] The NOV31 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 31A.

TABLE 31A
NOV31 Sequence Analysis
	SEQ ID NO:315	5460 bp
NOV31a,	ATGTCGGGAGCCTCAGTGAAGGTGGCTGTCCGGGTAAGGCCCTTCAATTCTCGAGAGA
CG155962-01
DNA Sequence	CCAGCAAGGAATCCAAATGCATCATTCAGATGCAAGGCAACTCGACCAGTATTATTAA
	CCCAAAGAATCCAAAGGAAGCTCCAAAGTCCTTCAGCTTCGACTATTCCTACTGGTCT
	CATACCTCACCCGAAGATCCCTGTTTTGCATCTCAAAACCGTGTGTACAATGACATTG
	GCAAGGAAATGCTCTTACACGCCTTTGAGGGATATAATGTCTGTATTTTTGCCTATGG
	GCAGACTGGTGCTGGAAAATCTTATACAATGATGGGTAAACAAGAACAAAGCCAGGCT
	GGCATCATTCCACAGTTATGTGAAGAACTTTTTGAGAAAATCAATGACAACTGTAATG
	AAGAAATGTCTTACTCTGTAGAGGTGAGTTACATGGAAATTTACTGTGAAAGAGTACG
	AGATTTGCTGAATCCAAAAAACAAGGGTAATTTGCGTGTGCGTGAACACCCACTTCTT
	GGACCCTATGTGGAGGATCTGTCCAAGTTGGCAGTTACTTCCTACACAGACATTGCTG
	ACCTCATGGATGCTGGGAACAAAGCCACGACAGTGGCAGCTACAAACATGAATGAAAC
	AAGTAGCCGTTCCCACGCTGTGTTTACGATTGTTTTCACCCAGAAGAAACACGATAAT
	GAGACCAACCTTTCCACTGAGAAGGTAGTCAGTAAAATCAGCTTGGTGGATCTAGCAG
	GAAGTGAACGAGCTGATTCAACTGGTGCCAAAGGGACTCGATTAAAGGAAGGAGCAAA
	TATTAATAAGTCTCTTACAACTTTGGGCAAAGTCATTTCAGCCTTGCCCGAGGTGAGT
	AAAAAGAAGAAGAAAACAGATTTTATTCCCTACAGGGATTCTGTACTTACTTGGCTCC
	TTCGAGAAAATTTAGGTGGCAATTCTCGGACTGCAATCGTTGCTGCTCTGAGCCCCGC
	GGATATCAACTACGATGAGACTTTGAGCACTCTGAGGTACGCAGATCGTGCAAAACAA
	ATTAAATGCAATGCTGTTATCAATGAGGACCCCAATGCCAAACTGGTTCGTGAATTAA
	AGGAGGAGGTGACACGGCTGAAGGACCTTCTTCGTGCTCAGGGCCTGGCAGATATTAT
	TGATGTTGATCCATTGATCGATGATTACTCTGGAAGTGGAAGCAAACTGAAAGATTTT
	CAGAACAATAAGCATAGATACTTGCTAGCCTCTGAGAATCAACGCCCTGGCCATTTTT
	CCACAGCATCCATGGGGTCCCTCACTTCATCCCCATCTTCCTGCTCACTCAGTAGTCA
	GGTGGGCTTGACGTCTGTGACCAGTATTCAACAGAGGATCATGTCTACACCTGGAGGA
	GAGGAAGCTATTGAACGTTTAAAGGAATCAGAGAAGATCATTGCTGAGTTGAATGAAA
	CTTGGGAAGAGAAGCTTCGTAAAACAGAGGCCATCAGAATGGAGAGGGAGGCTTTGTT
	GGCTGAGATGGGAGTTGCCATTCGGGAAGATGGAGGAACCCTAGGGGTTTTCTCACCT
	AAAAAGACCCCACATCTTGTTAACCTCAATGAAGACCCACTAATGTCTGAGTGCCTAC
	TTTATTACATCAAAGATGGAATTACAAGGGTTGGCCAAGCAGATGCTGAGCGGCGCCA
	GGACATAGTGCTGAGCGGGGCTCACATTAAAGAAGAGCATTGTATCTTCCGGAGTGAG
	AGAAGCAACAGCGGGGAAGTTATCGTGACCTTAGAGCCCTGTGAGCGCTCAGAAACCT
	ACGTAAATGGCAAGAGGGTGTCCCAGCCTGTTCAGCTGCGCTCAGGTAACCGTATCAT
	CATGGGTAAAAACCATGTTTTCCGCTTTAACCACCCGGAACAAGCACGAGCTGAGCGA
	GAGAAGACTCCTTCTGCTGAGACCCCCTCTGAGCCTGTGGACTGGACATTTGCCCAGA
	GGGAGCTTCTGGAAAAACAAGGAATTGATATGAAACAAGAGATGGAGAAAAGGCTACA
	GGAAATGGAGATCTTATACAAAAAGGACAAGGAAGAAGCAGATCTTCTTTTGGAGCAG
	CAGAGACTGGACTATGAGAGTAAATTGCAGGCCTTGCAGAAGCAGGTTGAAACCCGAT
	CTCTGGCTGCAGAAACAACTGAAGAGGAGGAAGAAGAGGAAGAAGTTCCTTGGACACA
	GCATGAATTTGAGTTGGCCCAATGGGCCTTCCGGAAATGGAAGTCTCATCAGTTTACT
	TCATTACGGGACTTACTCTGGGGCAATGCCGTGTACCTAAAGGAGGCCAATGCCATCA
	GTGTGGAACTGAAAAAGAAGGTACAGTTTCAGTTTGTTCTGCTGACTGACACACTGTA
	CTCCCCTTTGCCTCCTGAATTACTTCCCACTGAGATGGAAAAAACTCATGAGGACAGG
	CCTTTCCCTCGCACAGTGGTAGCAGTAGAAGTCCAGGATTTGAAGAATGGAGCAACAC
	ACTATTGGTCTTTGGAGAAACTCAAGCAGAGGCTGGATTTGATGCGAGAGATGTATGA
	TAGGGCAGGGGAGATGGCCTCCAGTGCCCAAGACGAAAGCGAAACCACTGTGACTGGC
	AGCGATCCCTTCTATGATCGGTTCCACTGGTTCAAACTTGTGGGGAGCTCCCCCATTT
	TCCACGGCTGTGTGAACGAGCGCCTTGCCGACCGCACACCCTCCCCCACTTTTTCCAC
	GGCCGATTCCGACATCACTGAGCTGGCTGACGAGCAGCAAGATGAGATGGAGGATTTT
	GATGATGAGGCATTCGTGGATGACGCCGGCTCTGACGCAGGGACGGAGGAGGGATCAG
	ATCTCTTCAGTGACGGGCATGACCCGTTTTACGACCGATCCCCTTGGTTCATTTTAGT
	GGGAAGGGCATTTGTTTACCTGAGCAATCTGCTGTATCCCGTGCCCCTGATCCACAGG
	GTGGCCATCGTCAGTGAGAAAGGTGAAGTGCGGGGATTTCTGCGTGTGGCTGTACAGG
	CCATCGCAGATGAAGAAGCTCCTGATTATGGCTCTGGAATTCGACAGTCAGGAACAGC
	TAAAATATCTTTTGATAATGAATACTTTAATCAGAGTGACTTTTCGTCTGTTGCAATG
	ACTCGTTCTGGTCTGTCCTTGGAGGAGTTGAGGATTGTGGAAGGACAGGGTCAGAGTT
	CTGAGGTCATCACTCCTCCAGAAGAAATCAGTCGAATTAATGACTTGTTAGATTTGAA
	GTCAAGCACTTTGCTGGATGGTAAGATGGTAATGGAAGGGTTTTCTGAAGAGATTGGC
	AACCACCTGAAACTGGGCAGTGCCTTCACTTTCCGAGTAACAGTGTTGCAGGCCAGTG
	GAATCCTCCCAGAGTATGCAGATATCTTCTGTCAGTTCAGCTTTTTGCATCGCCATGA
	TGAAGCATTCTCCACGGAGCCCCTCAAAAACAATGGCAGAGGAAGTCCCCTGGCCTTT
	TATCATGTGCAGAATATTGCAGTGGAGATCACTGAATCATTTGTGGATTACATCAAAA
	CCAAGCCTATTGTATTTGAAGTCTTTGGGCATTATCAGCAGCACCCACTTCATCTGCA
	AGGACAGGAGCTTAACAGTCCGCCTCAGCCGTGCCGCCGATTCTTCCCTCCACCCATG
	CCACTGTCCAAGCCAGTTCCAGCCACCAAGTTAAACACGATGAGCAAAACCAGCCTTG
	GCCAGAGCATGAGCAAGTATGACCTCCTGGTTTGGTTTGAGATCAGTGAACTGGAGCC
	TACAGGAGAGTATATCCCAGCTGTGGTTGACCACACAGCAGGCTTGCCTTGCCAGGGG
	ACATTTTTGCTTCATCAGGGCATCCAGCGAAGGATCACAGTGACCATTATCCATGAGA
	AGGGGAGCGAGCTCCATTGGAAAGATGTTCGTGAACTGGTGGTAGGTGGTCGTATTCG
	GAATAACCCTGAGGTGGATGAAGCTGCAGTTGATGCCATCCTCTCCCTAAATATTATT
	TCTGCCAAGTACCTGAAGTCTTCCCACAACTCTAGCAGGACCTTCTACCGCTTTGAGG
	CTGTGTGGGATAGCTCTCTGCATAACTCCCTTCTTCTGAACCGAGTGACACCCTATGG
	AGAAAAGATCTACATGACCTTGTCGGCCTACCTAGAGCTGGATCATTGCATCCAGCCG
	GCTGTCATCACCAAGGATGTGTGCATGGTCTTCTACTCCCGAGATGCCAAGATCTCAC
	CACCACGCTCTCTGCGTAGCCTCTTTGGCAGCGGCTACTCAAAGTCACCAGATTCGAA
	TCGAGTCACTGGCATTTACGAACTCAGCTTATGCAAAATGTCAGACACAGGTAGTCCA
	GGTAAGATGCAGAGAAGGAGAAGAAAAATCTTAGATACGTCAGTGGCATATGTGCGGG
	GAGAAGAGAACTTAGCAGGCTGGCGGCCCCGTGGAGACAGCCTCATCCTTGAGCACCA
	GTGGGAGCTGGAGAAGCTGGAAAAAACCCGCCACTTTTTGCTGCTGCGTGAGAGACTT
	GGTGACAGCATCCCCAAATCCCTGAGCGACTCGTTATCCCCCAGCCTCAGCAGTGGGA
	CCCTCAGCACCTCCACCACTATCTCCTCTCAGATCTCAACCACTACCTTTGAAAGCGC
	CATCACACCTAGCGAGAGCAGTGGCTATGATTCAGGAGACATCGAAAGCCTGGTGGAC
	CGAGAGAAAGAGCTGGCTACCAAGTGCCTGCAACTTCTCACCCACACTTTCAACAGAG
	AATTCAGCCAGGTGCACGGCAGCGTCACTGACTGTAAGGTGAGCGATATCTCTCCAAT
	TGGACGGGATCCCTCTGAGTCCAGTTTCAGCAGTGCCACCCTCACTCCCTCCTCCACC
	TGTCCCTCTCTGGTAGACTCTAGGAGCAACTCTCTGGATCAGAAGACCCCAGAAGCCA
	ATTCCCGGGCCTCTAGTCCCTGCCCAGAATTTGAACAGTTTCAGATTGTCCCAGCTGT
	GGAAACACCATATTTGGCCCGAGCAGGAAAAAACGAATTTCTCAATCTTGTTCCAGAT
	ATTGAAGAAATTAGATCAGTGGTCTCTAAGAAAGGATACCTTCATTTCAAGGAGCCTC
	TTTACAGTAACTGGGCTAAACATTTTGTTGTCGTCCGTCGGCCTTATGTCTTCATCTA
	TAACAGTGACAAAGACCCTGTGGAGCGTGGAATCATTAACCTGTCCACAGCACAGGTG
	GAGTACAGTGAGGACCAGCAGGCCATGGTGAAGACACCAAACACCTTTGCTGTCTGCA
	CAAAGCACCGTGGGGTCCTTTTGCAGGCCCTCAATGACAAAGACATGAACGACTGGTT
	GTATCCCTTCAACCCACTTCTAGCTGGCACAATACGGAGGTCAAAGCTTTCCCGCAGA
	TGCCCGAGCCAGTCGAAATACTAAGTGACTCTGCCGAGTGCCCTCACTCGCCTTCGAG
	AGATAAAG
	ORF Start: ATG at 1		ORF Stop: TAA at 5416
	SEQ ID NO:316	1805 aa	MW at 203184.5 kD
NOV31a,	MSGASVKVAVRVRPFMSRETSKESKCIIQMQGNSTSIINPKWPKEAPKSFSFDYSYWS
CG155962-01
Protein Sequence	HTSPEDPCFASQNRVYNDIGKEMLLHAFEGYNVCIFAYGQTGAGKSYTMMGKQEESQA
	GIIPQLCEELFEKINDNCNEEMSYSVEVSYMEIYCERVRDLLNPKNKGNLRVREHPLL
	GPYVEDLSKLAVTSYTDIADLMDAGNKARTVAATNMNETSSRSHAVFTIVFTQKKHDN
	ETNLSTEKVVSKISLVDLAGSERADSTGAKGTRLKEGANINKSLTTLGKVISALAEVS
	KKKKKTDFIPYRDSVLTWLLRENLGGNSRTANVAALSPADINYDETLSTLRYADRAKQ
	IKCNAVINEDPNAKLVRELKEEVTRLKDLLRAQGLGDIIDVDPLIDDYSGSGSKLKDF
	QNNKHRYLLASENQRPGHFSTASMGSLTSSPSSCSLSSQVGLTSVTSIQERIMSTPGG
	EEAIERLKESEKIIAELNETWEEKLRKTEAIRMEREALLAEMGVAIREDGGTLGVFSP
	KKTPHLVNLNEDPLMSECLLYYIKDGITRVGQADAERRQDIVLSGAHIKEEHCIFRSE
	RSNSGEVIVTLEPCERSETYVNGKRVSQPVQLRSGNRIIMGKNHVFRFNHPEQARAER
	EKTPSAETPSEPVDWTFAQRELLEKQGIDMKQEMEKRLQEMEILYKKEKEEADLLLEQ
	QRLDYESKLQALQKQVETRSLAAETTEEEEEEEEVPWTQHEFELAQWAFRKWKSHQFT
	SLRDLLWGNAVYLKEANAISVELKKKVQFQFVLLTDTLYSPLPPELLPTEMEKTHEDR
	PFPRTVVAVEVQDLKNGATHYWSLEKLKQRLDLMREMYDRAGEMASSAQDESETTVTG
	SDPFYDRFHWFKLVGSSPIFHGCVNERLADRTPSPTFSTADSDITELADEQQDEMEDF
	DDEAFVDDAGSDAGTEEGSDLFSDGHDPFYDRSPWFILVGRAFVYLSNLLYPVPLIHR
	VAIVSEKGEVRGFLRVAVQAIADEEAPDYGSGIRQSGTAKISFDNEYFNQSDFSSVAM
	TRSGLSLEELRIVEGQGQSSEVITPPEEISRIMDLLDLKSSTLLDGKMVMEGFSEEIG
	NHLKLGSAFTFRVTVLQASGILPEYADIFCQFSFLHRHDEAFSTEPLKNNGRGSPLAF
	YHVQNIAVEITESFVDYIKTKPIVFEVFGHYQQHPLHLQGQELNSPPQPCRRFFPPPM
	PLSKPVPATKLNTMSKTSLGQSMSKYDLLVWFEISELEPTGEYIPAVVDHTAGLPCQG
	TFLLHQGIQRRITVTIIHEKGSELHWKDVRELVVGGRIRNKPEVDEAAVDAILSLNII
	SAKYLKSSHNSSRTFYRFEAVWDSSLHNSLLLNRVTPYGEKIYMTLSAYLELDHCIQP
	AVITKDVCMVFYSRDAKISPPRSLRSLFGSGYSKSPDSNRVTGIYELSLCKMSDTGSP
	GKMQRRRRKILDTSVAYVRGEENLAGWRPRGDSLILEHQWELEKLEKTRHFLLLRERL
	GDSIPKSLSDSLSPSLSSGTLSTSTSISSQISTTTFESAITPSESSGYDSGDIESLVD
	REKELATKCLQLLTHTFNREFSQVHGSVSDCKVSDISPIGRDPSESSFSSATLTPSST
	CPSLVDSRSNSLDQKTPEANSRASSPCPEFEQFQIVPAVETPYLARAGKNEFLNLVPD
	IEEIRSVVSKKGYLHFKEPLYSNWAKHFVVVRRPYVFIYNSDKDPVERGIINLSTAQV
	EYSEDQQAMVKTPNTFAVCTKHRCVLLQALNDKDMNDWLYAFNPLLAGTIRRSKLSRR
	CPSQSKY

[0522] Further analysis of the NOV31a protein yielded the following properties shown in Table 31B.

TABLE 31B
Protein Sequence Properties NOV31a
PSort     0.5985 probability located in mitochondrial matrix space;
analysis: 0.4900 probability located in nucleus; 0.3052 probability
          located in mitochondrial inner membrane; 0.3052 probability
          located in mitochondrial intermembrane space
SignalP   No Known Signal Sequence Predicted
analysis:

[0523] A search of the NOV31a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 31C.

TABLE 31C
Geneseq Results for NOV31a
			Identities/
			Similarities for
Geneseq	Protein/Organism/Length	NOV31a Residues/	the Matched	Expect
Identifier	[Patent #, Date]	Match Residues	Region	Value
AAB36227	Human kinesin-like protein HKLP SEQ ID	1 . . . 1805	1797/1821 (98%)	0.0
	NO: 4 - Homo sapiens, 1816 aa.	1 . . . 1816	1800/1821 (98%)
	[WO200063375-A1, 26 OCT. 2000]
ABB07867	Human kinesin-associated protein	1 . . . 1804	1785/1820 (98%)	0.0
	having motor domain - Homo sapiens,	1 . . . 1816	1790/1820 (98%)
	1823 aa. [WO200226965-A1, 04 APR. 2002]
ABB07866	Human kinesin-associated protein	430 . . . 1805	1370/1385 (98%)	0.0
	lacking motor domain - Homo sapiens,	1 . . . 1381	1372/1385 (98%)
	1381 aa. [WO200226965-A1, 04 APR. 2002]
AAU28137	Novel human secretory protein, Seq ID	430 . . . 1805	1370/1385 (98%)	0.0
	No 306 - Homo sapiens, 1381 aa.	1 . . . 1381	1372/1385 (98%)
	[WO200166689-A2, 13 SEP. 2001]
AAU28325	Novel human secretory protein, Seq ID	439 . . . 1805	1355/1376 (98%)	0.0
	No 682 - Homo sapiens, 1374 aa.	3 . . . 1374	1360/1376 (98%)
	[WO200166689-A2, 13 SEP. 2001]

[0524] In a BLAST search of public sequence datbases, the NOV31a protein was found to have homology to the proteins shown in the BLASTP data in Table 31D.

TABLE 31D
Public BLASTP Results for NOV31a
		NOV31a	Identities/
Protein		Residues/	Similarities
Accession		Match	for the	Expect
Number	Protein/Organism/Length	Residues	Matched Portion	Value
O60333	Kinesin-like protein KIF1B	1 . . . 1805	1783/1821 (97%)	0.0
	(Klp) - Homo sapiens (Human),	1 . . . 1816	1791/1821 (97%)
	1816 aa.
Q60575	Kinesin-like protein KIF1B -	1 . . . 1805	1745/1821 (95%)	0.0
	Mus musculus (Mouse), 1816	1 . . . 1816	1783/1821 (97%)
	aa.
Q8R524	Kinesin-family protein 1Bp204 -	1 . . . 1805	1741/1821 (95%)	0.0
	Rattus norvegicus (Rat), 1816	1 . . . 1816	1779/1821 (97%)
	aa.
Q96Q94	Kinesin-related protein - Homo	430 . . . 1804	1359/1384 (98%)	0.0
	sapiens (Human), 1388 aa.	1 . . . 1381	1363/1384 (98%)
O88658	Kinesin-like protein KIF1B -	1 . . . 700	657/704 (93%)	0.0
	Rattus norvegicus (Rat), 689 aa	1 . . . 689	668/704 (94%)
	(fragment).

[0525] PFam analysis predicts that the NOV31a protein contains the domains shown in the Table 31E.

TABLE 31E
Domain Analysis of NOV31a
			Identities/
			Similarities
	Pfam	NOV31a	for the	Expect
	Domain	Match Region	Matched Region	Value
	kinesin	11 . . . 378	183/418 (44%)	6.7e−188
			323/418 (77%)
	FHA	550 . . . 621	22/85 (26%)	1.6e−14
			55/85 (65%)
	PH	1690 . . . 1787	28/98 (29%)	4.6e−18
			78/98 (80%)

Example 32

[0526] The NOV32 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 32A.

TABLE 32A
NOV32 Sequence Analysis
	SEQ ID:317	3120 bp
NOV32a,	GGAGGCCCGAGCGGCGCCCACCTGAGCCCCCGCGCTGGCGCCATGGCGGAGCAGGAGA
CG157477-01
DNA Sequence	GCCTGGAATTCGGCAAGGCAGACTTCGTGCTGATGGACACCGTCTCCATCCCCGAGTT
	CATGGCCAACCTCAGGCTCAGATTTGAAAAAGGGCGCATCTATACGTTCATTGGAGAA
	GTCGTCGTTTCTGTGAACCCTTACAAGTTGTTGAACATCTATGGAAGAGACACAATTG
	AGCAGTATAAAGGCCGTGAGCTGTATGAGAGACCGCCTCACCTTTTTGCTATTGCGGA
	TGCTGCTTACAAGGCTATGAAGAGGCGATCAAAAGACACTTGTATTGTGATATCAGGG
	GAAAGTGGAGCTGGTAAAACGGAAGCCAGTAAGTACATTATGCAGTATATTGCGGCCA
	TCACCAACCCCAGTCAGAGAGCAGAGGTTGAAAGAGTGAAGAATATGTTGCTTAAGTC
	CAACTGTGTTTTGGAAGCTTTTGGAAATGCCAAAACCAACCGTAATGACAACTCAAGC
	AGGTTTGGAAAATACATGGATATCAACTTTGACTTCAAGGGTGACCCTATTGGTGGGC
	ATATCAATAACTACTTACTAGAAAAGTCTCGAGTGATTGTGCAACAGCCAGGAGAAAG
	AAGCTTTCATTCTTTCTATCAGCTACTCCAAGGAGGTTCAGAACAAATGCTACGCTCT
	CTACATCTCCAGAAATCCCTTTCATCCTACAACTATATTCATGTGGGAGCTCAATTAA
	AGTCTTCTATCAATGATGCTGCCGAATTCAGAGTTGTTGCTGATGCCATGAAAGTCAT
	TGGCTTCAAACCTGAGGAGATCCAAACAGTGTATAAGATTTTGGCTGCTATTCTGCAC
	TTGGGAAATTTAAAATTTGTAGTACATGGTGACACGCCTCTTATTGAGAATGGCAAAG
	TAGTATCTATCATAGCAGAATTGCTCTCTACTAAGACAGATATGGTTGAGAAAGCCCT
	TCTTTACCGGACTGTGGCCACAGGCCGTGACATCATTGACAAGCAGCACACAGAACAA
	GAGGCCAGCTACGGCAGAGACGCCTTTGCCAAGGCAATATATGAGCGCCTTTTTTGTT
	GGATCGTTACTCGCATCAATGATATTATTGAGGTCAAGAACTATGACACCACAATCCA
	TGGGAACAACACTGTTATTGGTGTCTTGGATATCTATGGCTTTGAAATCTTTGACAAC
	AACAGTTTTGAACAATTCTGTATCAATTACTGCAATGAGAAACTGCAGCAGCTATTTA
	TTCAGCTGGTTCTGAAGCAAGAACAAGAGGAATACCAGCGGGAAGGGATCCCCTGGAA
	ACATATTGACTACTTCAACAATCAGATCATTGTTGACCTCGTGGAGCAACAGCACAAA
	GGGATCATTGCAATCCTTGATGATGCTTGCATGAATGTCGGCAAAGTCACCGATGAAA
	TGTTTCTTCAAGCACTTAACAGTAAATTGGGCAAACACGCCCATTTTTCCAGCCGAAA
	GCTCTGTGCCTCAGACAAAATTCTGGAGTTTGATCGAGATTTTCGAATTCGACATTAT
	GCAGGCGATGTAGTCTATTCTGTCATTGGTTTTATTGACAAAAATAAAGATACTTTAT
	TTCAAGATTTCAAGCGCCTTATGTATAACAGTTCAAATCCTGTGCTCAAGAATATGTG
	GCCTGAAGGCAAACTGAGCATTACAGAGGTGACCAAGCGACCTCTGACTGCTGCTACC
	TTGTTTAAGAATTCTATGATTGCTCTAGTAGACAACCTTGCATCAAAGGAACCATATT
	ACGTTCGTTGCATCAAACCCAATGACAAGAAATCTCCACAGATATTTGATGATGAACG
	CTGCCGGCACCAAGTAGAATATCTTGGACTACTGGAAAATGTGAGAGTGCGTCGGGCA
	GGATTTGCCTTCCGCCAGACATACGAGAAGTTTCTTCACAGGTATAAGATGATCTCTG
	AATTCACCTGGCCCAACCATGACCTTCCTTCAGACAAAGAGGCTGTCAAGAAACTAAT
	TGAACGGTGTGGTTTTCAGGATGATGTAGCTTATGGGAAGACCAAAATTTTCATTCGA
	ACACCCCGAACATTGTTTACCTTGGAAGAACTCCGTGCCCAGATGCTCATAAGGATTG
	TCCTCTTTCTACAAAAGGTGTGGCGGGGCACCCTGGCCCGCATGCGGTACAAAAGAAC
	CAAGGCAGCTCTGACAATAATCAGGTACTACCGGCGCTACAAAGTGAAGTCGTACATC
	CACGAGGTGGCCAGACGCTTCCATGGCGTCAAGACCATGCGAGACTACGGGAAGCACG
	TGAAGTGGCCAAGCCCTCCTAAAGTTCTTCGCCGTTTTGAGGAGGCCCTGCAGACGAT
	TTTCAATAGATGGAGAGCATCCCAGCTCATCAAGAGCATTCCGGCCTCAGACCTGCCC
	CAGGTCAGGGCAAAGGTTGCAGCCGTGGAAATGTTGAAGGGTCAAAGGGCTGACCTCG
	GGCTCCAGAGGGCCTGGGAGGGCAACTATCTTGCTTCAAAGCCAGATACACCTCAGAC
	CTCAGGCACTTTTGTCCCTGTTGCTAATGAATTGAAACGGAAGGACAAATACATGAAT
	GTCCTCTTTTCCTGTCACGTCCGTAAGGTAAATCGATTTAGTAAGGTGGTGGACAGAG
	CAATTTTTGTCACTGACCGTCACCTGTATAAAATGGATCCCACTAAACAGTACAAGGT
	GATGAAGACTATCCCTCTATACAATTTGACTGGTCTGAGTGTCTCCAATGGAAAGGAC
	CAACTTGTAGTGTTCCATACGAAAGACAACAAAGACCTCATTGTCTGCCTCTTCAGCA
	AACAGCCAACCCATGAGAGTCGAATTGGAGAACTTGTTGGAGTGCTGGTGAATCATTT
	CAAGAGTGAGAAGCGCCACCTTCAAGTGAACGTCACCAACCCAGTACAGTGCAGCCTG
	CACGGGAAGAAGTGCACCGTCTCCGTGGAGACGCGGCTCAACCAGCCCCAGCCCGACT
	TCACCAAGAATCGCTCGGGCTTCATCCTCAGCGTGCCCGGGAACTGACGCCCCGCGGA
	GGCCTGGCCCGGAGCCCGGCCACACTCCGAGTCCTGGGTCCCAGTC
	ORF Start: ATG at 43		ORF Stop: TGA at 3061
	SEQ ID NO:318	1006 aa	MW at 116201.0 kD
NOV32a,	MAEQESLEFGKADFVLMDTVSMPEFMANLRLRFEKGRIYTFIGEVVVSVNPYKLLNIY
CG157477-01
Protein Sequence	GRDTIEQYKGRELYERPPHLFATADAAYKAMKRRSKDTCIVISGESGAGKTEASKYIM
	QYIAAITNPSQRAEVERVKNMLLKSNCVLEAFGNAKTNRNDNSSRFGKYMDINFDFKG
	DPIGGHINNYLLEKSRVIVQQPGERSFHSFYQLLQGGSEQMLRSLHLQKSLSSYNYIH
	VGAQLKSSINDAAEFRVVADAMKVIGFKPEEIQTVYKILAAILHLGNLKFVVDGDTPL
	IENGKVVSIIAELLSTKTDMVEKALLYRTVATGRDIIDKQHTEQEASYGRDAFAKAIY
	ERLFCWIVTRINDIIEVKNYDTTIHGKNTVIGVLDIYGFEIFDNNSFEQFCINYCNEK
	LQQLFIQLVLKQEQEEYQREGIPWKHIDYFNNQIIVDLVEQQHKGIIAILDDACMNVG
	KVTDEMFLEALNSKLGKHAHFSSRKLCASDKILEFDRDFRIRHYAGDVVYSVIGFIDK
	NKDTLFQDFKRLMYNSSNPVLKNMWPEGKLSITEVTKRPLTAATLFKMSMIALVDNLA
	SKEPYYVRCIKPNDKKSPQIFDDERCRHQVEYLGLLENVRVRRAGFAFRQTYEKFLHR
	YKMISEFTWPNHDLPSDKEAVKKLIERCGFQDDVAYGKTKIFIRTPRTLFTLEELRAQ
	MLIRIVLFLQKVWRGTLARMRYKRTKAALTIIRYYRRYKVKSYIHEVARRFHCVKTMR
	DYGKHVKWPSPPKVLRRFEEALQTIFNRWRASQLIKSIPASDLPQVRAKVAAVEMLKG
	QRADLGLQRAWEGNYLASKPDTPQTSGTFVPVANELKRKDKYMNVLFSCHVRKVNRFS
	KVEDPAIFVTDRHLYKMDPTKQYKVMKTIPLYNLTGLSVSNGKDQLVVFHTKDNKDLI
	VCLFSKQPTHESRIGELVGVLVNHFKSEKRHLQVNVTNPVQCSLHGKKCTVSVETRLN
	QPQPDFTKNRSGFILSVPGN

[0527] Further analysis of the NOV32a protein yielded the following properties shown in Table 32B.

TABLE 32B
Protein Sequence Properties NOV32a
PSort     0.7600 probability located in nucleus; 0.3760 probability
analysis: located in microbody (peroxisome); 0.1000 probability
          located in mitochondrial matrix space; 0.1000 probability
          located in lysosome (lumen)
SignalP   No Known Signal Sequence Predicted
analysis:

[0528] A search of the NOV32a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 32C.

TABLE 32C
Geneseq Results for NOV32a
		NOV32a	Identities/
		Residues/	Similarities
Geneseq	Protein/Organism/Length	Match	for the	Expect
Identifier	[Patent #, Date]	Residues	Matched Region	Value
AAM80123	Human protein SEQ ID NO 3769 -	243 . . . 1006	764/764 (100%)	0.0
	Homo sapiens, 764 aa.	1 . . . 764	764/764 (100%)
	[WO200157190-A2, 09 AUG.
	2001]
AAM79139	Human protein SEQ ID NO 1801 -	254 . . . 1006	752/753 (99%)	0.0
	Homo sapiens, 753 aa.	1 . . . 753	752/753 (99%)
	[WO200157190-A2, 09 AUG.
	2001]
ABG16605	Novel human diagnostic protein	333 . . . 1006	670/674 (99%)	0.0
	#16596 - Homo sapiens, 674 aa.	1 . . . 674	671/674 (99%)
	[WO200175067-A2, 11 OCT.
	2001]
AAU23125	Novel human enzyme polypeptide	1 . . . 1004	611/1016 (60%)	0.0
	#211 - Homo sapiens, 1026 aa.	9 . . . 1024	784/1016 (77%)
	[WO200155301-A2, 02 AUG.
	2001]
AAU23128	Novel human enzyme polypeptide	1 . . . 841	532/853 (62%)	0.0
	#214 - Homo sapiens, 909 aa.	9 . . . 861	676/853 (78%)
	[WO200155301-A2, 02 AUG.
	2001]

[0529] In a BLAST search of public sequence datbases, the NOV32a protein was found to have homology to the proteins shown in the BLASTP data in Table 32D.

TABLE 32D
Public BLASTP Results for NOV32a
		NOV32a	Identities/
Protein		Residues/	Similarities
Accession		Match	for the	Expect
Number	Protein/Organism/Length	Residues	Matched Portion	Value
Q63357	Myosin I - Rattus norvegicus	1 . . . 1006	985/1006 (97%)	0.0
	(Rat), 1006 aa.	1 . . . 1006	998/1006 (98%)
A53933	myosin I myr 4 - rat, 1006 aa.	1 . . . 1006	983/1006 (97%)	0.0
		1 . . . 1006	996/1006 (98%)
O94832	KIAA0727 protein - Homo sapiens	333 . . . 1006	674/674 (100%)	0.0
	(Human), 674 aa (fragment).	1 . . . 674	674/674 (100%)
Q23978	Myosin IA (MIA) (Brush border	8 . . . 1004	542/1004 (53%)	0.0
	myosin IA) (BBMIA) - Drosophila	6 . . . 1006	706/1004 (69%)
	melanogaster (Fruit fly), 1011 aa.
S45573	myosin IA - fruit fly (Drosophila	8 . . . 1004	541/1004 (53%)	0.0
	melanogaster), 1011 aa.	6 . . . 1006	704/1004 (69%)

[0530] PFam analysis predicts that the NOV32a protein contains the domains shown in the Table 32E.

TABLE 32E
Domain Analysis of NOV32a
		Identities/
		Similarities
Pfam	NOV32a	for the	Expect
Domain	Match Region	Matched Region	Value
myosin_head	13 . . . 682	314/743 (42%)	0
		544/743 (73%)
IQ	699 . . . 719	10/21 (48%)	0.0053
		16/21 (76%)

Example 33

[0531] The NOV33 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 33A.

TABLE 33A
NOV33 Sequence Analysis
	SEQ ID NO:319	3921 bp
NOV33a,	CAGAAGTTGCGCGCAGGCCGGCGGGCGGGAGCGGACACCGAGGCCGGCGTGCAGGCGT
CG157486-01
DNA Sequence	GCGGGTGTGCGGGAGCCGGGCTCGGGGGGATCGGACCGAGAGCGAGAAGCGCGGCATG
	GAGCTCCAGGCAGCCCGCGCCTGCTTCGCCCTGCTGTGGGGCTGTGCGCTGGCCGCGG
	CCGCGGCGGCGCAGGGCAAGGAAGTGGTACTGCTGGACTTTGCTGCAGCTGGAGGGGA
	GCTCGGCTGGCTCACACACCCGTATGGCAAAGGGTGGGACCTGATGCAGAACATCATG
	AATGACATGCCGATCTACATGTACTCCGTGTGCAACGTGATGTCTGGCGACCAGGACA
	ACTGGCTCCGCACCAACTGGGTGTACCGAGGAGAGGCTGAGCGTATCTTCATTGAGCT
	CAAGTTTACTGTACGTGACTGCAACAGCTTCCCTGGTGCCGCCAGCTCCTGCAAGGAG
	ACTTTCAACCTCTACTATGCCGAGTCGGACCTGGACTACGGCACCAACTTCCAGAAGC
	GCCTGTTCACCAAGATTGACACCATTGCGCCCGATGAGATCACCGTCAGCAGCGACTT
	CGAGGCACGCCACGTGAAGCTGAACGTGGAGGAGCGCTCCGTGGGGCCGCTCACCCGC
	AAAGGCTTCTACCTGGCCTTCCAGGATATCGGTGCCTGTGTGGCGCTGCTCTCCGTCC
	GTGTCTACTACAAGAAGTGCCCCGAGCTGCTGCAGGGCCTGGCCCACTTCCCTGAGAC
	CATCGCCGGCTCTGATGCACCTTCCCTGGCCACTGTGGCCGGCACCTGTGTGGACCAT
	GCCGTGGTGCCACCGGCGGGTGAAGAGCCCCGTATGCACTGTGCAGTGGATGGCGAGT
	GGCTGGTGCCCATTGGGCAGTGCCTGTGCCAGGCAGGCTACGAGAAGGTGGAGGATGC
	CTGCCAGGCCTGCTCGCCTGGATTTTTTAAGTTTGAGGCATCTGAGAGCCCCTGCTTG
	GAGTGCCCTGAGCACACGCTGCCATCCCCTGAGGGTGCCACCTCCTGCGAGTGTGAGG
	AAGGCTTCTTCCGGGCACCTCAGGACCCAGCGTCGATGCCTTGCACACGACCCCCCTC
	CGCCCCACACTACCTCACAGCCGTGGGCATGGGTGCCAAGGTGGAGCTGCGCTGGACG
	CCCCCTCAGGACAGCGGGGGCCGCGAGGACATTGTCTACAGCGTCACCTGCGAACAGT
	GCTGGCCCGAGTCTGGGGAATGCGGGCCGTGTGAGGCCAGTGTGCGCTACTCGGAGCC
	TCCTCACGCACTGACCCGCACCAGTGTGACAGTGAGCGACCTGGAGCCCCACATGAAC
	TACACCTTCACCGTGGAGGCCCGCAATGGCGTCTCAGGCCTGGTAACCAGCCGCAGCT
	TCCGTACTGCCAGTGTCAGCATCAACCAGACAGAGCCCCCCAAGGTGAGGCTGGAGGG
	CCGCAGCACCACCTCGCTTAGCGTCTCCTGGAGCATCCCCCCGCCGCAGCAGAGCCGA
	GTGTGGAAGTACGAGGTCACTTACCGCAAGAAGGGAGACTCCAACAGCTACAATGTGC
	GCCGCACCGAGGGTTTCTCCGTGACCCTGGACGACCTGGCCCCAGACACCACCTACCT
	GGTCCAGGTGCAGGCACTGACGCAGGAGGGCCAGGGGGCCGGCAGCAAGGTGCACGAA
	TTCCAGACGCTGTCCCCGGAGGGATCTGGCAACTTGGCGGTGATTGGCGGCGTGGCTG
	TCGGTGTGGTCCTGCTTCTGGTGCTGGCAGGAGTTGGCTTCTTTATCCACCCCAGGAG
	GAAGAACCAGCGTGCCCGCCAGTCCCCGGAGGACGTTTACTTCTCCAAGTCAGAACAA
	CTGAAGCCCCTGAAGACATACGTGGACCCCCACACATATGAGGACCCCAACCAGGCTG
	TGTTGAAGTTCACTACCGAGATCCATCCATCCTGTGTCACTCGGCAGAAGGTGATCGG
	AGCAGGAGAGTTTGGGGAGGTGTACAAGGGCATGCTGAAGACATCCTCGGGGAAGAAG
	GAGGTGCCGGTGGCCATCAAGACGCTGAAAGCCGGCTACACAGAGAAGCAGCGAGTGG
	ACTTCCTCGGCGAGGCCGGCATCATGGGCCAGTTCAGCCACCACAACATCATCCGCCT
	AGAGGGCGTCATCTCCAAATACAAGCCCATGATGATCATCACTGAGTACATGGAGAAT
	GGGGCCCTGGACAAGTTCCTTCGGGAGAAGGATGGCGAGTTCAGCGTGCTGCAGCTGG
	TGGGCATGCTGCGGGGCATCGCAGCTGGCATGAAGTACCTGGCCAACATGAACTATGT
	GCACCGTGACCTGGCTGCCCGCAACATCCTCGTCAACAGCAACCTGGTCTGCAAGGTG
	TCTGACTTTGGCCTGTCCCGCGTGCTGGAGGACGACCCCGAGGCCACCTACACCACCA
	GTGGCGGCAAGATCCCCATCCGCTGGACCGCCCCGGAGGCCATTTCCTACCGGAAGTT
	CACCTCTGCCAGCGACGTGTGGAGCTTTGGCATTGTCATGTGGGAGGTGATGACCTAT
	GGCGAGCGGCCCTACTGGGAGTTGTCCAACCACGAGGTGATGAAAGCCATCAATGATG
	GCTTCCGGCTCCCCACACCCATGGACTGCCCCTCCGCCATCTACCAGCTCATGATGCA
	GTGCTGGCAGCAGGAGCGTGCCCGCCGCCCCAAGTTCGCTGACATCGTCAGCATCCTG
	GACAAGCTCATTCGTGCCCCTGACTCCCTCAAGACCCTGGCTGACTTTGACCCCCGCG
	TGTCTATCCGGCTCCCCAGCACGAGCGGCTCGGAGGGGGTGCCCTTCCGCACGGTGTC
	CGAGTGGCTGGAGTCCATCAAGATGCAGCAGTATACGGAGCACTTCATGGCGGCCGGC
	TACACTGCCATCGAGAAGGTGGTGCAGATGACCAACGACGACATCAAGAGGATTGGGG
	TGCGGCTGCCCGGCCACCAGAAGCGCATCGCCTACAGCCTGCTGGGACTCAAGGACCA
	GGTGAACACTGTGGGGATCCCCATCTGAGCCTCGACAGGGCCTGGAGCCCCATCGGCC
	AAGAATACTTGAAGAAACAGAGTGGCCTCCCTGCTGTGCCATGCTGGGCCACTGGGGA
	CTTTATTTATTTCTAGTTCTTTCCTCCCCCTGCAACTTCCGCTGAGGGGTCTCGGATG
	ACACCCTGGCCTGAACTGAGGAGATGACCAGGGATGCTGGGCTGGGCCCTCTTTCCCT
	GCGAGACGCACACAGCTGAGCACTTAGCAGGCACCGCCACGTCCCAGCATCCCTGGAG
	CAGGAGCCCCGCCACAGCCTTCGGACAGACATATGGGATATTCCCAAGCCGACCTTCC
	CTCCGCCTTCTCCCACATGAGGCCATCTCAGGAGATGGAGGGCTTGGCCCAGCGCCAA
	GTAAACAGGGTACCTCAAGCCCCATTTCCTCACACTAAGAGGGCAGACTGTGAACTTG
	ACTGGGTGAGACCCAAAGCGGTCCCTGTCCCTCTAGTGCCTTCTTTAGACCCTCGGGC
	CCCATCCTCATCCCTGACTGGCCAAACCCTTGCTTTCCTGGGCCTTTGCAAGATGCTT
	GGTTGTGTTGAGGTTTTTAAATATATATTTTGTACTTTGTGGAGAGAATGTGTGTGTG
	TGGCAGGGGGCCCCGCCAGGGCTGGGGACAGAGGGTGTCAAACATTCGTGAGCTGGGG
	ACTCAGGGACCGGTGCTGCAGGAGTGTCCTGCCCATGCCCCAGTCGGCCCCATCTCTC
	ATCCTTTTGGATAAGTTTCTATTCTGTCAGTGTTAAAGATTTTGTTTTGTTGGACATT
	TTTTTCGAATCTTAATTTATTATTTTTTTTATATTTATTGTTAGAAAATGACTTATTT
	CTGCTCTGGAATAAAGTTGCAGATGATTCAAACCG
	ORF Start: ATG at 114		ORF Stop: TGA at 3042
	SEQ ID NO:320	976 aa	MW at 108265.3 kD
NOV33a,	MELQAARACFALLWGCALAAAAAAQGKEVVLLDFAAAGGELGWLTHPYGKGWDLMQNI
CG157486-01
Protein Sequence	MNDMPIYMYSVCNVMSGDQDNWLRTNWVYRGEAERIFIELKFTVRDCNSFPGGASSCK
	ETFNLYYAESDLDYGTNFQKRLFTKIDTIAPDEITVSSDFEARHVKLNVEERSVGPLT
	RKGFYLAFQDIGACVALLSVRVYYKKCPELLQGLAHFPETIAGSDAPSLATVAGTCVD
	HAVVPPGGEEPRNHCAVDGEWLVPIGQCLCQAGYEKVEDACQACSPGFFKFEASESPC
	LECPEHTLPSPEGATSCECEEGFFRAPQDPASMPCTRPPSAPHYLTAVGMGAKVELRW
	TPPQDSGGREDIVYSVTCEQCWPESGECGPCEASVRYSEPPHGLTRTSVTVSDLEPHM
	NYTFTVEARNGVSGLVTSRSFRTASVSINQTEPPKVRLEGRSTTSLSVSWSIPPPQQS
	RVWKYEVTYRKKGDSNSYNVRRTEGFSVTLDDLAPDTTYLVQVQALTQEGQGAGSKVH
	EFQTLSPEGSGNLAVIGGVAVGVVLLLVLAGVGFFIHRRRKNQRARQSPEDVYFSKSE
	QLKPLKTYVDPHTYEDPNQAVLKFTTEIHPSCVTRQKVIGAGEFGEVYKGMLKTSSGK
	KEVPVAIKTLKAGYTEKQRVDFLGEAGIMGQFSHHNIIRLEGVISKYKPMMIITEYME
	NGALDKFLREKDGEFSVLQLVGMLRGIAAGMKYLANMNYVHRDLAARNILVNSNLVCK
	VSDFGLSRVLEDDPEATYTTSGGKIPIRWTAPEAISYRKFTSASDVWSFGIVMWEVMT
	YGERPYWELSNHEVMKAINDGFRLPTPMDCPSAIYQLMMQCWQQERARRPKFADIVSI
	LDKLIRAPDSLKTLADFDPRVSIRLPSTSGSEGVPFRTVSEWLESIKMQQYTEHFMAA
	GYTAIEKVVQMTNDDIKRIGVRLPGHQKRIAYSLLGLKDQVNTVGIPI

[0532] Further analysis of the NOV33a protein yielded the following properties shown in Table 33B.

TABLE 33B
Protein Sequence Properties NOV33a
PSort     0.4600 probability located in plasma membrane; 0.1000
analysis: probability located in endoplasmic reticulum (membrane);
          0.1000 probability located in endoplasmic reticulum
          (lumen); 0.1000 probability located in outside
SignalP   Cleavage site between residues 24 and 25
analysis:

[0533] A search of the NOV33a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 33C.

TABLE 33C
Geneseq Results for NOV33a
		NOV33a	Identities/
		Residues/	Similarities
Geneseq	Protein/Organism/Length	Match	for the	Expect
Identifier	[Patent #, Date]	Residues	Matched Region	Value
AAR85090	EPH-like receptor protein tyrosine	11 . . . 976	524/984 (53%)	0.0
	kinase HEK7 - Homo sapiens, 991	14 . . . 991	680/984 (68%)
	aa. [WO9528484-A1, 26 OCT.
	1995]
AAR85092	EPH-like receptor protein tyrosine	13 . . . 969	504/979 (51%)	0.0
	kinase HEK11 - Homo sapiens, 998	16 . . . 988	659/979 (66%)
	aa. [WO9528484-A1, 26 OCT.
	1995]
AAW03421	Mouse developmental kinase 1 -	9 . . . 969	505/982 (51%)	0.0
	Mus sp, 998 aa. [WO9621013-A1,	14 . . . 988	660/982 (66%)
	11 JUL. 1996]
AAW83147	Rat receptor tyrosine kinase Ehk-1 -	13 . . . 940	503/969 (51%)	0.0
	Rattus sp, 1005 aa. [US5843749-A,	42 . . . 1003	654/969 (66%)
	01 DEC. 1998]
AAB08665	Amino acid sequence of a human	28 . . . 976	499/964 (51%)	0.0
	EphA3 HLA class II-binding	29 . . . 983	652/964 (66%)
	peptide - Homo sapiens, 983 aa.
	[WO200050589-A1, 31 AUG.
	2000]

[0534] In a BLAST search of public sequence datbases, the NOV33a protein was found to have homology to the proteins shown in the BLASTP data in Table 33D.

TABLE 33D
Public BLASTP Results for NOV33a
		NOV33a	Identities/
Protein		Residues/	Similarities
Accession		Match	for the	Expect
Number	Protein/Organism/Length	Residues	Matched Portion	Value
AAH37166	EphA2 - Homo sapiens (Human),	1 . . . 976	976/976 (100%)	0.0
	976 aa.	1 . . . 976	976/976 (100%)
P29317	Ephrin type-A receptor 2 precursor	1 . . . 976	972/976 (99%)	0.0
	(EC 2.7.1.112) (Tyrosine-protein	1 . . . 976	972/976 (99%)
	kinase receptor ECK) (Epithelial
	cell kinase) - Homo sapiens
	(Human), 976 aa.
Q03145	Ephrin type-A receptor 2 precursor	1 . . . 976	905/978 (92%)	0.0
	(EC 2.7.1.112) (Tyrosine-protein	1 . . . 977	931/978 (94%)
	kinase receptor ECK) (Epithelial
	cell kinase) (MPK-5) (SEK-2) -
	Mus musculus (Mouse), 977 aa.
I48974	receptor-protein tyrosine kinase -	1 . . . 976	886/978 (90%)	0.0
	mouse, 975 aa.	1 . . . 975	916/978 (93%)
Q9PWR5	Eph receptor tyrosine kinase	25 . . . 976	690/957 (72%)	0.0
	precursor - Xenopus laevis (African	24 . . . 977	798/957 (83%)
	clawed frog), 977 aa.

[0535] PFam analysis predicts that the NOV33a protein contains the domains shown in the Table 33E.

TABLE 33E
Domain Analysis of NOV33a
			Identities/
			Similarities
	Pfam	NOV33a	for the	Expect
	Domain	Match Region	Matched Region	Value
	EPH_lbd	28 . . . 201	103/178 (58%)	2.4e−126
			167/178 (94%)
	fn3	329 . . . 424	29/98 (30%)	4.1e−12
			72/98 (73%)
	fn3	436 . . . 519	32/87 (37%)	2.3e−20
			67/87 (77%)
	pkinase	613 . . . 868	82/292 (28%)	1.7e−75
			204/292 (70%)
	SAM	902 . . . 966	30/68 (44%)	7.1e−26
			58/68 (85%)

Example 34

[0536] The NOV34 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 34A.

TABLE 34A
NOV34 Sequence Analysis
	SEQ ID NO:321	14399 bp
NOV34a,	ATGGCGAACGTGCAGGTCGCCGTGCGGGTCCGGCCGCTCAGCAAGAGGGAGACCAAAG
CG157505-01
DNA Sequence	AAGGGGGAAGAATTATTGTGGAAGTTGATGGCAAAGTGGCAAAAATCAGGAATTTAAA
	GGTAGACAATCGACCAGATGGCTTTGGGGACTCCCGGGAGAAGGTTATGGCATTTGGC
	TTTGATTACTGCTACTGGTCAGTCAACCCAGAGCATCCCCAGTATGCATCTCAAGATG
	TGGTATTCCAGGATTTAGGGATGGAAGTACTGTCTGGAGTTGCCAAAGGCTATAACAT
	ATGCCTTTTTGCTTATGGACAGACAGGCTCTGGGAAGACATATACCATGCTGGGGACC
	CCAGCCTCTGTTGGGTTGACACCACGGATATGTGAGGGTCTCTTCGTCAGGGAGAAAG
	ACTGTGCCTCACTGCCTTCCTCCTGTAGGATAAAAGTAAGTTTTCTAGAAATCTATAA
	TGAACGGGTGCGGGATCTGTTGAAGCAATCTGGTCAAAAAAAGTCCTATACCCTGCGG
	GTCAGGGAGCATCCAGAGATGGGGCCCTATGTACAAGGTTTATCTCAACATGTAGTTA
	CCAATTATAAGCAAGTAATCCAACTCTTGGAGGAGGGAATTGCAAACAGGATCACAGC
	AGCCACCCATGTTCATGAGGCCAGCAGCAGATCCCACGCCATTTTCACGATCCACTAC
	ACGCAGGCAATCCTGGAGAACAACCTCCCTTCTGAAATGGCTAGCAAGATCAACCTTG
	TGGACCTAGCAGGCAGCGAAAGAGCAGATCCCAGTTACTGTAAGGACCGCATTGCTGA
	AGGAGCCAATATCAACAAGTCCCTTGTGACTCTAGGAATTGTCATCTCCACCTTAGCC
	CAGAACTCCCAAGTTTTCAGCAGCTGCCAGAGCCTCAACAGCTCAGTCAGCAATGGTG
	GTGACAGTGGGATCCTTAGCTCTCCTTCTGGGACCAGCAGTGGAGGGGCACCCTCCCG
	AAGGCAGTCTTATATCCCATACCGAGACTCTGTGTTGACCTGGCTGCTGAAGGACAGC
	CTTGGACGCAACTCTAAAACCATCATGGTTGCCAGTGTGTCTCCTGCACACACTAGCT
	ACAGTGAGACCATGAGCACACTGAGATATGCATCCAGTGCCAAAAACATTATCAACAA
	GCCACGAGTAAATGAGGATGCAAACTTAAAACTGATTAGAGAACTCAGAGAAGAGATT
	GAAAGACTGAAAGCCCTGCTGCTGAGCTTTGAACTGAGAAACTTCAGTTCATTGAGTG
	ATGAAAACCTGAAGGAGCTGGTTCTCCAAAATGAATTGAAGATAGACCAGCTGACTAA
	AGACTGGACCCAGAAGTGGAATGATTGGCAGGCCCTCATGGAGCATTACAGTGTGGAC
	ATCAACAGGAGGAGGGCTCGGGTGGTCATCGACTCCAGCCTGCCACACTTGATGGCCT
	TGGAGGATGATGTGCTCAGCACAGGTGTTCTGCTCTATCATCTCAAGGAAGGGACAAC
	AAAAATAGGAAGGATTGACTCAGACCAGGAACAGGACATTGTCCTGCAGGGTCAGTGG
	ATTGAGAGAGACCACTGCACTATCACCAGTGCCTGTGGTGTAGTTGTTCTACGACCTG
	CCCGTGGGGCCCGCTGTACAGTCAATGGCCGGGAGGTCACTGCCTCCTGCCGTCTGAC
	TCAAGGAGCTGTCATAACCCTGGGGAAGGCACAGAAGTTCCGATTCAACCACCCAGCA
	GAGGCTGCTGTCCTGCGGCAGCGAAGGCAGGTTGGAGAGGCTGCTGCTGGTCGTGGCT
	CGTTGGAGTGGCTGGATTTGGATGGAGATCTCGCTGCCTCCCGGCTGGGTCTCTCCCC
	TTTGCTTTGGAAGGAAAGGAGAGCGCTTGAAGAGCAATGTGACGAGGACCATCAGACA
	CCGAGGGATGGAGAGACATCCCACAGGGCCCAGATTCAGCAGCAGCAGAGCTACGTAG
	AGGATTTGAGGCATCAAATCCTAGCAGAAGAGATTCGAGCTGCGAAGGAACTGGAATT
	TGACCAAGCTTGGATTAGCCAGCAGATTAAAGAAAACCAGCAGTGTCTGCTCAGAGAA
	GAGACCTGCCTGGCCAGCTTGCAACAGCAGCAGCAAGAAGACCAGGTAGCAGAGAAAG
	AACTTGAGGCATCTGTGGCACTTGATGCTTGGCTTCAGACAGATCCTGAGATTCAGCC
	ATCCCCATTTGTCCAAAGTCAGAAAAGGGTGGTGCACCTGCAGCTCCTGCGGAGACAC
	ACTCTTCGGGCAGCAGAGCGGAATGTCCGGCGGAAAAAGGTCTCATTCCAGCTAGAGA
	GAATCATCAAAAAGCAGAGGCTGCTGGAGGCCCAGAAGAGACTGGAGAAGCTCACGAC
	ATTGTGCTGGCTCCAGGATGACAGCACCCAGGAGCCCCCATACCAGGTCCTCAGCCCT
	GATGCCACAGTCCCACGGCCTCCATGTAGAAGCAAATTGACGAGTTGCAGTTCTTTGA
	GCCCCCAAAGACTCTGCAGCAAGCACATGCCCCAGCTACACAGCATTTTCCTAAGTTG
	GGATCCCTCTACCACATTGCCACCTAGGCCTGACCCTACACACCAAACATCAGAGAAA
	ACATCATCAGAAGAGCATTTGCCACAGGCTGCTTCCTACCCTGCAAGGACAGGGTGCC
	TCCGCAAGAACGGCCTGCATTCCTCAGGTCATGGGCAGCCCTGCACAGCCAGAGCAGC
	CTTGGCCAGGAAGGCAGCCTCAGCTCCAGACCCTTGCCTCACCATGAGTCCCAACTCT
	GTTGGCATCCAGGAAATGGAGATGGGGGTTAAGCAGCCCCATCAGATGGTGAGCCAGG
	GCTTAGCATCTCTGAGGAAATCAGCTAACAAACTAAAGCCAAGGCATGAGCCAAAGAT
	CTTCACCTCTACTACCCAGACCAGAGGGGCGAAGGGACTAGCAGACCCTAGCCACACA
	CAAGCTGGGTGGCGAAAAGAAGGGAACCTTGGGACCCACAAGGCTGCTAAGGGAGCCA
	GTTGCAATTCCTTGTATCCTCATGGACCCAGGCAGACTGCTGGGCACGGAAAGGCAGT
	CAAGACTTTTTGGACAGAATACAAACCACCTTCTCCAAGCAGGGCATCAAAAAGGCAT
	CAGAGGGTTCTGGCAACTAGGGTCAGAAATATTACCAAAAAGTCCTCTCACTTGCCTC
	TTGGCAGTCCTTTGAAGAGACAACAAAATACAAGGGACCCAGACACCATGGTCCCACT
	CACAGATTTCACCCCAGTAATGGATCATTCAAGAGAAAAAGACAATGATTTATCTGAC
	ACAGATAGCAACTACTCATTGGATTCTCTCTCATGTGTCTATGCCAAAGCCCTGATAG
	AGCCACTGAAGCCAGAGGAGAGGAAATGGGATTTCCCAGAGCCAGAGAACTCTGAAAG
	TGATGACAGCCAACTATCTGAGGACTCACTGGCTGAGAAGAGGTACCAAAGCCCCAAA
	AACAGGCTAGGGGGCAATCGTCCCACCAACAACCGTGGCCAACCCAGGACCAGAACTA
	GAGCTTCTGTGAGGGGCTTCACTGCAGCCTCAGACAGTGACCTACTTGCTCAAACTCA
	TAGGAGCTTCTCCTTGGATAGCCTGATTGATGCAGAGGAAGAACTGGGGGAAGATCAG
	CAAGAAGAACCTTTCCCTGGTTCAGCTGACGAGATACCCACAGAGACTTTTTGGCACC
	TGGAGGACTCTAGTCTGCCTGTAATGGACCAAGAGGCAATATGCAGGCTTGGTCCCAT
	CAACTACAGAACAGCAGCTAGGCTGGATGCCGTCCTGCCAATGAGCAGTTCGTTTTAC
	CTTGATCCTCAGTTCCAACCCCATTGTGAGCTCCAACCCCATTGTGAGCTCCAACCCC
	ATTGTGAGCTCCAGCCCCATTGTGAGCAGGCTGAATCACAGGTAGAGCCAAGCTACTC
	TGAACAAGCCGACTCTCTCCAAGGCATGCAGCTTTCAAGAGAGAGCCCACTGATGTCC
	ATGGATTCCTGGTTTTCCTGTGACTCTAAGATCAACCCCAGCAGCCCCCCAGGAATAG
	TGGGTTCTTTATGTCCAAGTCCTGATATGCAGGAATTTCACTCCTGTAAGGGGGAGAG
	GCCTGGATACTGGCCAAATACTGAGGAACTAAAGCCATCAGATGCAGAAACGGTTCTG
	CCATATAGCTCCAAACTGCACCAAGGCAGTACTGAGCTCCTCTGCAGTGCAAGAGATG
	AGCACACAGCCTCTGCTGCTGATACGTCTAGGCTGTCTCTCTGGGGAATTCAAAGGCT
	TATTCAACCAGGAGCTGATGGCACCTTTCAGGGCAGATGTATCCCTGACATGACCCAG
	CAGGGCAGCTCTGAAGCATCCCACAATTCTAGCGTATCAAACGTGCTGGCTGCCTCTG
	CCACCACCTTGACTCATGTAGGCAGCACCCATGAAAGGGATTGGTCTGCCCTTCAGCA
	GAAGTACCTCCTTGAACTCTCTTGTCCTGTTTTGGAGGCCATAGGAGCACCCAAGCCA
	GCTTACCCCTACCTTGAGGAAGACTCTGGTTCCCTGGCCCAACCTTCTAGCAAAGGAG
	GAGATACTCTATTGCCAGTTGGCCCTAGGGTATCTAGCAATCTGAATCTCAACAACTT
	TCCAGTCCATCTGTCCAGAATCAGGCGTTTGAGGGCAGAGAAAGAACAGCACAGTTTA
	AATGCCAAATTAGAAGGTGTTTCAGATTTCTTTAGCACTAGTGAGAAAGAGGCGAGTT
	ATGACGAAACTTATTCGGCAGACTTAGAATCATTGTCTGCTTCTCGATCTACAAATGC
	ACAGGTCTTTGCAACAGAGAACGCGATACCAGATTCCATGACAGAAGCATGTGAAGTC
	AAGCAGAACAACTTGGAAGAATGCCTTCAGAGTTGCAGGAAACCTGGACTGATGACTT
	CCTCTGATGAGGATTTTTTCCAGAAGAACGCTTGTCACAGTAATGTCACTACAGCCAC
	CAAAGCAGACCATTGGTCCCAAGGCTGGGCTCCTCTCAGGAAAAATAGTGCAGTCCAG
	CCAGGGCAATTAAGTCCCGACAGCCACTACCCACTAGAGGAAGAGAAGACAGATTGCC
	AGGAGAGCTCTAAGGAAGCAGTTAGAACACACATAAATGTTTCCTTTGCCCTTCCTTC
	AGGTCCAGAGCTATACCTTCACTCTGCTCCCTGGAATCCATTGTCATCTTCCCTGCAG
	CCCCCACTCTTGGAAACATTCTATGTGACCAAAAGCAGGGATGCCCTGACAGAAACTG
	CCTTAGAGATTCCAGCTTGCAGAGAAGTAAGGGTACCCTCCCCACCCCCCAGGGAAGC
	CTGGGGCTTTGGTCACAACCACCAAGCTCTCCAAGGTGCTTATTTGAAGAATAATTTG
	CCAGTGCTGTTACAAAACCAGAATTCTAAGATTGCCTCATCTCAGCAGGTCACAGCTG
	AGATACCAGTTGATCTGAATACCAGGGAAGTCATCAGAGAATCAGGTAAATGCCCTGG
	AAATATTACAGAAGAAAGCCATGATTCAGTTTATTCTTCTGTTACTCAGAACAGACAT
	TTTCTCCCCTCTACCAGCACAAAAGTATGTGAATTTGAAAACCAAGTTGTAATTTTAA
	ATAAAAAACACAGTTTTCCAGCACTTGAGGGAGGAGAGGTCACTGCTCAGTCCTGTTG
	CGGTGCTTCCTCAGACAGCACTGAGTCTGGGAAGTCTCTCCTCTTTCGTGAATCTGAG
	GCACGAGAGGAAGAAGAGCTGGATCAGAATACGGTTCTGAGGCAGACCATCAATGTAA
	GCCTTGAGAAAGACATGCCAGGGGAAAGTGCTGTTTCTTTGAAATCCAGATCAGTAGA
	TCGTAGAGTAAGCAGCCCAGTGATGGTGGCCCAGGGTGGTGGCCCAACCCCTAAGTGG
	GAAGGGAAAAATGAAACTGGGCTTCTTGAAAAAGGTCTTCGTCCCAAAGATAGCTCAG
	AAGAGTTTAAGCTTCCAGGTACAAAGCCTGCATATGAAAGGTTCCAGTTAGTTGCATG
	CCCTCAGGAAAGAAACCCCAGTGAATGCAAGTCACAAGAAATGTTAAATCCCAACAGA
	GAACCTTCTGGAAAGAAACAGAATAAAAGAGTTAATAATACTGATGAAATGGCTAGGC
	TAATTAGGAGTGTAATGCAGCTGGAAAATGGCATCTTAGAAATTGAATCTAAGCAGAA
	TAAGCAGGTTCATGCTTCCCACACACCAGGAACCGATAAGGAGTTGGTGTTCCAGGAC
	CAGAAGGAGCAGGAGAAGACTGACCATGCCTTTAGGCCAGACAGCTCTGGAAACCCTT
	TGCCCTCTAAGGATCAGCCATCTTCTCCAAGACAGACAGATGATACTGTCTTTAGGGA
	TAGTGAAGCTCGAGCGATGGAGGTTAACAGCATTGGGAACCATCCCCAGOTCCAGAAA
	ATCACCCCAAACCCCTTCAGGTCAAGGGAAGGTGTACGAGAGAGTGAACCTGTGAGAG
	AGCACACCCACCCAGCTGGATCGGACAGACCTGCCAGGGATATTTGTGATTCTTTAGG
	GAAACACACAACTTGCAGAGAGTTCACCAACACTTCTCTTCACCCACAGAGAATGAAA
	GCATTGGCTAGAGCTCTGCCATTGCAACCCAGGCTAGAGAGGTCTTCTAAGAATAATG
	GCCAGTTTGTAAAAGCATCAGCAAGTCTCAAAGGGCAGCCTTGGGGCTTAGGAAGTCT
	TGAGGAATTGGAGACTGTGAAAGGTTTTCAGGAAAGCCAAGTAGCTGAACACGTAAGT
	AGTTCCAACCAAGAAGAGCCAAAAGCTCAAGGTAAAGTTGAAGAAATGCCTATGCAAA
	GGGGAGGCAGCCTTCAGGAAGAAAATAAAGTGACTCAGAAATTTCCTAGTCTCAGCCA
	GCTTTGTAGGGACACGTTTTTCAGGCAGGAAACTGTCAGCCCATTACTAAGCCGGACA
	GAATTCTGTACAGCTCCTCTTCACCAAGACCTGAGTAATACCTTGCCCTTGAATTCTC
	CAAGGTGGCCAAGAAGGTGTCTTCATGTACCTGTTGCTCTAGGCATCTCTTCACTTGA
	CTGTGTGCTGGATCTCACAATGTTGAAAATTCATAACAGTCCCTTGGTAACTGGAGTA
	GAGCATCAGGACCAGAGTACGGAGACCAGAAGCCACAGCCCCGAAGGAAATGTTAGAG
	GGCGTTCCTCTGAGGCACACACTGCCTGGTGTGGGTCTGTGCGATCCATGGCCATGGG
	ATCTCATAGTCAATCTGGTGTACCAGAGAGCATTCCTCTGGGGACAGAGGACAGGATC
	TCAGCAAGCACCAGCCCCCAAGACCATGGAAAGGACCTCAGAATCACCTTGCTGGGTT
	TCAGTACCAGTGAAGATTTTGCTTCTGAAGCCGAGGTGGCTGTACAAAAAGAAATAAG
	AGTCAGTTCACTGAACAAGGTCTCTAGCCAGCCTGAAAAGAGGGTCAGCTTCTCCTTG
	GAAGACGATAGTGACCAAGCCAGCAAGCCAAGGCAGAAGGCAGAGAAGGAGACTGAGG
	ACGTCGGACTGACCAGCGGTGTTTCCTTAGCACCTGTTTCCCTGCCGAGGGTGCCCAG
	TCCAGAGCCTAGGCTGTTGGAGCCCTCTGACCATGCATCCATGTGCCTGGCCATCTTG
	GAGGAGATCAGACAGGCAAAGGCCCAGAGAAAGCAGCTTCATGACTTTGTGGCCAGGG
	GCACAGTCCTTTCTTACTGTGAAACTTTACTAGAACCCGAATGTTCTTCAAGGGTTGC
	TGGCACGCCTCAGTGTAAACAAATAGACCAGTCATCATCAGACCAGACCAGGAATGAG
	GGTGAAGCACCGGGATTTCATGTGGCATCTCTATCTGCTGAAGCAGGGCAGATAGATC
	TGTTACCTGATGAGAGGAAAGTCCAGGCCACATCTCTGTCTGCAGACAGCTTTGAATC
	TCTGCCCAATACGGAAACTGACAGAGAGCCATGGGATCCTGTGCAGGCTTTCTCCCAT
	GCTGCTCCTGCTCAAGACAGGAAACGTCGTACTGGAGAACTGAGGCAGTTCGCGGGAG
	CAAGTGAACCATTTATATGTCACTCTAGTTCTTCTGAAATCATAGAGAAAAAGAAAGA
	TGCAACCAGAACACCTTCCTCAGCTGATCCTTTGGCCCCAGACAGTCCTCGTTCTTCA
	GCACCTGTGGAGGAGGTCAGGAGGGTAGTATCAAAGAAGGTAGTGGCTGCCTTACCTT
	CTCAGGCCCCTTATGATGATCCTAGAGTGACTCTGCATGAGCTAAGTCAGTCAGTTCC
	GCAGGAGACTGCAGAGGGCATACCCCCTGGCAGTCAGGACAGCAGCCCAGAGCATCAG
	GAACCCAGAACTCTAGACACCACATATGGAGAAGTTTCAGATAATTTGTTAGTGACTG
	CACAGGGAGAAAAAACAGCCCATTTTGAAAGTCAGTCTGTGACCTGTGATGTTCAGAA
	TTCTACAAGTGCCTCAGGGCCTAAGCAAGACCATGTCCAATGCCCTGAGGCTTCTACT
	GGCTTTGAAGAAGGTAGGGCAAGTCCCAAACAAGATACCATTCTGCCTGGAGCTCTGA
	CAAGGGTTGCACTGGAAGCTCCCACACAGCAGTGTGTGCAGTGTAAGGAGAGTGTTGG
	GTCTGGGTTGACAGAAGTCTGCAGGGCTGGCAGCAAACATTCCAGGCCAATTCCACTG
	CCAGATCAAAGACCAAGCGCAAATCCTGGGGGAATTGGGGAGGAAGCCCCATGTAGAC
	ACCCAAGGGAAGCTTTAGATGGCCCTGTCTTCTCAAGGAACCCTGAAGGCAGCAGGAC
	TCTCAGCCCGTCTAGAGGGAAAGAGAGCAGAACTCTTCCTTGCCGACAGCCATGCAGT
	TCTCAACCTGTTGCTACTCATGCTTATTCCTCCCATTCCTCTACTTTACTGTGTTTTA
	GAGATGGTGACCTAGGGAAGGAGCCTTTCAAGCCTGCCCCACATACTATCCACCCACC
	CTGTGTAGTACCTTCCAGGGCCTATGAAATGGATGAGACAGGAGAGATCTCTAGGGGA
	CCTGATGTGCACTTGACACATGGCCTTGAGCCCAAAGATGTTAACAGGGAATTTAGGC
	TAACAGAGAGCAGCACTTGTGAGCCTTCTACTGTGGCTGCTGTCCTATCTCGAGCTCA
	AGGCTGCAGATCCCCTTCTGCTCCTGACGTGAGGACAGGTTCCTTCAGCCACTCAGCT
	ACTGATGGAAGCGTGGGGTTAATAGGGGTTCCTGAGAAAAAGGTTGCTGAGAAGCAAG
	CAAGCACAGAACTTGAGGCTGCCTCTTTCCCTGCAGGCATGTACTCTGAGCCCCTGAG
	GCAGTTTAGGGACAGCTCTGTAGGTGACCAGAATGCACAGGTGTGTCAAACCAATCCA
	GAACCACCTGCAACAACTCAGGGACCACACACCCTGGATTTAAGTGAAGGGTCTGCTG
	AGAGCAAGTTGGTGGTAGAGCCACAGCATGAATGTTTAGAAAATACCACTAGATGTTT
	TTTGGAAAAGCCACAATTTTCCACTGAGTTGAGGGATCACAATCGCTTGGATTCCCAA
	GCCAAGTTTGTAGCAAGGTTAAAACATACCTGCAGCCCCCAGGAAGACAGTCCCTGGC
	AGGAAGAAGAGCAGCACAGAGACCAGGCTTCACGTGGTGGAGAAGGCTTCGCCCAGGG
	TGTGAATCCCCTTCCTGATGAAGATGGCTTAGATGGCTGTCAGATTTTAGATGCTGGG
	AGAGAGGAGGTGGCTGTGGCCAAGCCTCCTGTGTCCAAGATTTTATCACAGGGCTTCA
	AAGACCCAGCCACTGTGTCCTTGAGGCAAAATGAAACACCGCAGCCTGCTGCTCAGAG
	GAGTGGCCACCTCTACACTGGCAGAGAGCAGCCAGCACCCAACCACAGGGGCTCACTT
	CCTGTGACTACAATCTTCTCTGGCCCCAAACACTCCAGGTCCTCCCCCACACCACAGT
	TCTCAGTTGTCGGCTCTTCTCGTTCTCTTCAGGAGCTGAACTTGAGTGTGGAGCCTCC
	TTCCCCTACAGACGAAGATACACAGGGGCCTAACAGATTGTGGAACCCACATCTCAGG
	CGCTATTCCTCAGGAAAGTCAGTGGCAAGAACATCTCTCCAGGCTGAGGACAGCGATC
	AGAAAGCCTCATCTCGCTTGGATGATGGGACTACCGATCACAGGCACCTGAAGCCTGC
	CACCCCTCCTTATCCAATGCCTTCCACTCTCTCACACATGCCAACCCCTGATTTCACG
	ACCAGCTGGATGTCTGGTACTTTGGAACAAGCCCAACAGGGAAAGCGAGAGAAACTGG
	GTGTCCAGGTTAGGCCAGAAAATTGGTGCTCTCAGATGGACAAAGGAATGCTGCACTT
	TGGCTCCAGTGACATCAGTCCCTATGCGCTGCCGTGGCGTCCCGAGGAGCCTGCACGT
	ATCAGCTGGAAGCAGTATATGTCTGGCAGTGCAGTCGATGTTTCCTGCAGCCAGAAGC
	CCCAGGGGCTGACACTATCAAATGTGGCCCGGTGCTCCAGCATGGACAATGGCCTAGA
	AGACCAGAACTCCCCTTTCCACTCCCACCTCAGCACTTACGCCAATATTTGTGATCTG
	TCAACCACACACAGCAGCACTGAGAATGCCCAGGGTTCAAATGAGGCCTGGGAAGTAT
	TCCGAGGGAGTTCTTCAATTGCCTTAGGAGACCCCCACATCCCGACGAGCCCTGAAGG
	AGTAGCCCCCACTTCGGGTCATGACAGAAGGCCTCAGTTCAGGGGCCCTTCTGGTGAA
	GCAGACTGTCTGAGGAGTAAGCCCCCCTTGGCCAAAGGAAGTGCTGCAGGTCCAGTGG
	ATGAGATTATGCTGCTGTATCCATCAGAGGCAGGCTGCCCTGTGGGACAGACCAGGAC
	GAACACATTCGAACAGGGCACACAGACCCTCGGCAGCAGGCGCCACTGGAGCAGCACT
	GACATCTCCTTTGCTCAGCCTGAAGCCAGTGCAGTATCAGCCTTTGATCTGGCCTCAT
	GGACCAGCATGCACAATCTGTCTCTCCACCTCTCACAGCTCCTGCACAGTACCTCAGA
	GCTGCTTGGGAGTCTCTCCCAGCCAGATGTGGCCAGAAGGGAGCAGAACACCAAGAGG
	GACATCCCAGATAAAGCCCCACAGGCCCTGATGATGGATGGCTCTACTCAGACCACTG
	TGGATGAGGGCAGCCAGACTGACCTCACCTTACCCACCCTGTGCCTCCAGACTTCAGA
	GGCTGAACCTCAGGGAGCCAATGTGATCCTTGAAGGGCTAGGCTCAGATACCTCGACT
	GTGTCTCAAGAAGAGGGAGATGTGCCAGGGGTACCTCAGAAGAGAGAGGCAGAGGAAA
	CAGCACAGAAAATGGCTCAGCTCCTCTATCTTCAGGAAGAAAGCACTCCCTACAAGCC
	CCAGAGCCCTTCAATACCCTCATCCCACTTGAGGTTTCAGAAAGCCCCCGTTGGGCAG
	CATCTTCCTTCTGTGAGCCCCTCAGTTTCTGATGCTTTCCTGCCTCCCACCTCCCAGC
	CAGAGGAGTCATATTGCTTAGTTGTCAGCAGTCCCAGTCCCAGCTCCCCTCATTCCCC
	AGGGCTCTTTCCCACTACTTCCGAGTATCCTGGGGACTCCAGGGTCCAGAAGAAGCTG
	GGCCCCACAAGTGCTTTGTTCGTGGACAGGGCCTCCTCCCCAATCCTCACTCTTAGTG
	CCAGCACCCAAGAGCCGGGTCTTTCCCCAGGCTCTTTGACCCTCTCAGCCCCTTCAAC
	TCACCCTGTTGAAGGCCACCAGAAGCTTGACTCCAGCCCAGACCCTGTTGATGCCCCA
	AGGACTCCAATGGATAATTATTCCCAAACCACTGACGAGTTAGGTGGCTCCCAGAGAG
	GTAGAAGTTCCTTACAAAGGAGTAATGGGAGATCCTTCCTTGAGTTGCACTCCCCACA
	CAGCCCACAGCAGAGTCCAAAACTCCAATTTAGTTTCTTAGGGCAGCACCCTCAGCAG
	CTTCAGCCCAGGACAACTATCGGGGTCCAAAGCAGACTGCTGCCACCACCACTGAGGC
	ACAGGAGCCAAAGGCTGGGCAACAGCTTTGTGCCTGAGAAGGTGGCTTCCCCGGAGCA
	TTGCCCACTGAGCGGTAGGGAGCCAAGTCAGTGGCAGAGCAGGACAGAAAATGGAGGT
	GAGAGTTCAGCATCTCCAGGGGAACCACAACGCACTCTGGACCGACCTTCTTCATGGG
	GAGGCCTCCAGCACCTCAGCCCCTGCCCTGTCTCTGAGTTGACTGATACTGCAGGGCT
	CCGAGGTTCTGCCTTGGGCCTCCCTCAGGCCTGCCAACCTGAGGAGTTACTGTGCTTC
	AGTTGCCAGATGTGCATGGCCCCTGAGCACCAGCACCACAGTCTGAGGGACCTCCCGG
	TGCATAACAAATTTAGTAACTGGTGTGGGGTTCAGAAGGGCTCACCTGGGGGGTTGGA
	CATGACTGAGGAGGAGCTGGGGGCCAGCGGTGATCTCAGCTCTGAAAAGCAGGAACAG
	AGTCCCCCACAACCTCCTAATGACCACAGCCAGGATTCTGAGTGGTCCAAGAGGGAGC
	AGATCCCCCTGCAAGTTGGGGCCCAGAACCTCTCACTCAGCGTGGAACTCACAGAAGC
	GAAACTGCACCATGGCTTTGGGGAGGCCGATGCCCTGCTCCAGGTGCTGCAGAGTGGG
	ACAGGGGAGGCGCTTGCTGCTGATGAACCTGTGACATCCACCTGGAAGGAGCTCTATG
	CACGGCAAAAAAAGGCCATTGAGACCCTCAGGAGAGAGCGGGCTGAGCGACTTGGGAA
	CTTCTGCCGGACGCGAAGCCTTAGCCCTCAGAAACAACTGAGCCTCCTGCCCAACAAA
	GATCTCTTCATCTGGGATCTTGACTTGCCCAGCAGACGCCGAGAATACCTGCAGCAAC
	TGAGGAAGGATGTTGTGGAGACCACCAGGAGCCCAGAGTCAGTGTCAAGGTCAGCTCA
	CACACCCTCTGACATAGAGTTGATGCTGCAAGACTACCAGCAGGCCCATGAGGAGGCC
	AAGGTGGAGATTGCCCGGGCCCGAGACCAACTGCGGGAGCGGACTGAACAAGAGAAGC
	TGAGAATCCACCAGAAGATCATTTCCCAGCTATTGAAGGAAGAGGATAAACTACATAC
	CTTGGCCAATTCCAGCTCCCTGTGCACCAGCTCTAATGGAAGCCTCTCGTCTGGCATG
	ACCTCTGGCTATAATAGCAGCCCAGCCTTGTCAGGCCAGCTCCAGTTCCCAGAGAATA
	TGGGGCATACAAACTTGCCTGATTCCAGGGATGTATGGATAGGGGATGAGCGAGGAGG
	CCATTCTGCAGTGAGGAAGAACTCTGCCTACAGCCACAGAGCCTCCCTGGGCAGTTGC
	TGCTGTTCACCATCCAGTCTGTCCAGCTTGGGGACCTGCTTTTCCTCCTCCTACCAGG
	ATTTGGCCAAGCATGTCGTGGACACTTCTATGGCTGATGTAATGGCTGCTTGTTCGGA
	TAATTTGCACAACCTCTTCAGCTGCCAGGCAACTGCTGGCTGGAACTATCAGGGTGAG
	GAGCAGGCGGTGCAGCTTTACTACAAGGTGTTTTCTCCCACTCGGCATGGCTTCCTGG
	GGGCAGGTGTGGTGTCCCAGCCGCTGTCTCGTGTGTGGGCGGCTGTCAGTGACCCCAC
	TGTGTGGCCCCTGTATTACAAGCCCATCCAGACAGCAAGGCTGCATCAGCGAGTGACC
	AACAGCATCAGCCTGGTGTACTTGGTGTGCAACACCACCCTGTGCGCACTGAAGCAGC
	CACGGGATTTCTGTTGTGTCTGCGTGGAAGCCAAAGAGGGTCACCTGTCTGTCATGGC
	AGCCCAGTCTCTGTATGATACATCCATGCCAAGACCCAGCAGAAAAATGGTTCACGGG
	GAGATCCTGCCCAGTGCCTGGATCTTGCAGCCCATCACTGTGGAAGGGAAGGAAGTCA
	CCAGAGTCATCTACTTGGCCCAGGTGGAACTTGGTGCTCCAGGCTTCCCACCTCAGCT
	CCTGAGCTCTTTCATCAAACGGCACCCACTGGTTATAGCCAGACTGGCTTCCTTCCTT
	GTGCAGGAAAAGCTGATGCTACCTGCTGTGGCCGATTGGGGCAGACAGCACTGGCCCA
	GGGATGCTAGCAAAGCCCAGTCAGTACTTGGTCACAGCTGGCACCAGTGCAGAGCAAA
	CGGCCTGAGCTCCTGGCCCAGACTATCCAGAGTGAATGCAGCTCTGCTCACCTTTTGG
	ATTTCTCACCTTTCTTTCCTGTTTCTGGGACTCTGCGGCAGACAGGACACTTAAGGAC
	CAGGACTGGCCACAGCCAGCAGAGCCGGGGACTGCAGTGCTTTGGCAAGGTGCTTCCG
	CAGGCTGGTAGGGAA
	ORF Start: ATG at 1		ORF Stop: TAA at 14320
	SEQ ID NO:322	4773 aa	MW at 524614.9 kD
NOV34a,	MANVQVAVRVRPLSKRETKEGGRIIVEVDGKVAKIRNLKVDNRPDGFGDSREKVMAFG
CG157505-01
Protein Sequence	FDYCYWSVNPEDPQYASQDVVFQDLGMEVLSGVAKGYNICLFAYGQTGSGKTYTMLGT
	PASVGLTPRICEGLFVREKDCASLPSSCRIKVSFLETYNERVRDLLKQSGQKKSYTLR
	VREHPEMGPYVQGLSQHVVTNYKQVIQLLEEGIANRITAATHVHEASSRSHAIFTIHY
	TQAILENNLPSEMASKINLVDLAGSERADPSYCKDRIAEGANINKSLVTLGTVISTLA
	QNSQVFSSCQSLNSSVSNGGDSGILSSPSGTSSGGAPSRRQSYIPYRDSVLTWLLKDS
	LGGNSKTIMVASVSPAHTSYSETMSTLRYASSAKNIINKPRVNEDANLKLIRELREEI
	ERLKALLLSFELRNFSSLSDENLKELVLQNELKTDQLTKDWTQKWNDWQALMEHYSVD
	INRRRAGVVIDSSLPHLMALEDDVLSTGVVLYHLKEGTTKIGRIDSDQEQDIVLQGQW
	IERDHCTTTSACGVVVLRPARGARCTVNGREVTASCRLTQGAVITLGKAQKFRFNHPA
	EAAVLRQRRQVGEAAAGRGSLEWLDLDGDLAASRLGLSPLLWKERRALEEQCDEDHQT
	PRDGETSHRAQIQQQQSYVEDLRHQILAEEIRAAKELEFDQAWISQQIKENQQCLLRE
	ETWLASLQQQQQEDQVAEKELEASVALDAWLQTDPEIQPSPFVQSQKRVVHLQLLRRH
	TLRAAERNVRRKKVSFQLERIIKKQRLLEAQKRLEKLTTLCWLQDDSTQEPPYQVLSP
	DATVPRPPCRSKLTSCSSLSPQRLCSKHMPQLHSIFLSWDPSTTLPPRPDPTHQTSEK
	TSSEEHLPQAASYPARTGCLRKNGLHSSGHGQPCTARAALARKGASAPDACLTMSPNS
	VGIQEMEMGVKQPHQMVSQGLASLRKSANKLKPRHEPKIFTSTTQTRGAKGLADPSHT
	QAGWRKEGNLGTHKAAKCASCNSLYPHGPRQTAGHGKAVKTFWTEYKPPSPSRASKRH
	QRVLATRVRNITKKSSHLPLGSPLKRQQNTRDPDTMVPLTDFSPVMDHSREKDNDLSD
	TDSNYSLDSLSCVYAKALIEPLKPEERKWDFPEPENSESDDSQLSEDSLAEKRYQSPK
	NRLGGNRPTNNRGQPRTRTRASVRGFTAASDSDLLAQTHRSFSLDSLIDAEEELGEDQ
	QEEPFPGSADEIPTETFWHLEDSSLPVMDQEAICRLGPINYRTAARLDAVLPMSSSFY
	LDPQFQPHCELQPHCELQPHCELQPHCEQAESQVEPSYSEQADSLQGMQLSRESPLMS
	MDSWFSCDSKINPSSPPGIVGSLCPSPDMQEFHSCKGERPGYWPNTEELKPSDAETVL
	PYSSKLHQGSTELLCSARDEHTASAADTSRLSLWGIQRLIQPGADGTFQGRCIPDMTQ
	QGSSEASHNSSVSNVLAASATTLTHVGSTHERDWSALQQKYLLELSCPVLEAIGAPKP
	AYPYLEEDSGSLAQASSKGGDTLLPVGPRVSSNLNLNNFPVHLSRIRRLRAEKEQDSL
	NAKLEGVSDFFSTSEKEASYDETYSADLESLSASRSTNAQVFATENAIPDSMTEACEV
	KQNNLEECLQSCRKPGLMTSSDEDFFQKNACHSNVTTATKADHWSQGWAPLRKNSAVQ
	PGQLSPDSHYPLEEEKTDCQESSKEAVRRHINVSFALPSGPELYLHSAPWNPLSSSLQ
	PPLLETFYVTKSRDALTETALEIPACREVRVPSPPPREAWGFGHNHQALQGAYLKNNL
	PVLLQNQNSKIASSQQVTAEIPVDLNTREVIRESGKCPGNITEESHDSVYSSVTQNRH
	FLPSTSTKVCEFENQVVILNKKHSFPALEGGEVTAQSCCGASSDSTESGKSLLFRESE
	AREEEELDQNTVLRQTINVSLEKDMPGESAVSLKSRSVDRRVSSPVMVAQCGGPTPKW
	EGKNETGLLEKGLRPKDSSEEFKLPGTKPAYERFQLVACPQERNPSECKSQEMLNPNR
	EPSGKKQNKRVNNTDEMARLIRSVMQLENGILEIESKQNKQVHASHTPGTDKELVFQD
	QKEQEKTDHAFRPDSSGNPLPSKDQPSSPRQTDDTVFRDSEAGAMEVNSIGNHPQVQK
	ITPNTFRSREGVRESEPVREHTHPAGSDRPARDICDSLGKHTTCREFTNTSLHPQRMK
	ALARALPLQPRLERSSKNNCQFVKASASLKGQPWGLGSLEELETVKGFQESQVAEHVS
	SSNQEEPKAQGKVEEMPMQRGGSLQEENKVTQKFPSLSQLCRDTFFRQETVSPLLSRT
	EFCTAPLHQDLSNTLPLNSPRWPRRCLHVPVALGISSLDCVLDLTMLKIHNSPLVTGV
	EHQDQSTETRSHSPECNVRGRSSEAHTAWCGSVRSMANGSHSQSGVPESIPLGTEDRI
	SASTSPQDHGKDLRITLLCFSTSEDFASEAEVAVQKEIRVSSLNKVSSQPEKRVSFSL
	EEDSDQASKPRQKAEKETEDVGLTSGVSLAPVSLPRVPSPEPRLLEPSDHASMCLAIL
	EEIRQAKAQRKQLHDFVARGTVLSYCETLLEPECSSRVAGRPQCKQIDQSSSDQTRNE
	GEAPGFHVASLSAEAGQIDLLPDERKVQATSLSADSFESLPNTETDREPWDPVQAFSH
	AAPAQDRKRRTGELRQFAGASEPFICHSSSSEIIEKKKDATRTPSSADPLAPDSPRSS
	APVEEVRRVVSKKVVAALPSQAPYDDPRVTLHELSQSVPQETAEGIPPGSQDSSPEHQ
	EPRTLDTTYGEVSDNLLVTAQGEKTAHFESQSVTCDVQNSTSASGPKQDHVQCPEAST
	GFEEGRASPKQDTILPGALTRVALEAPTQQCVQCKESVGSGLTEVCRAGSKHSRPIPL
	PDQRPSANPGGICEEAPCRHPREALDGPVFSRNPEGSRTLSPSRGKESRTLPCRQPCS
	SQPVATHAYSSHSSTLLCFRDGDLGKEPFKAAPHTIHPPCVVPSRAYEMDETGEISRG
	PDVHLTHGLEPKDVNREFRLTESSTCEPSTVAAVLSRAQCCRSPSAPDVRTGSFSHSA
	TDGSVGLIGVPEKKVAEKQASTELEAASFPAGMYSEPLRQFRDSSVGDQNAQVCQTNP
	EPPATTQGPHTLDLSEGSAESKLVVEPQHECLENTTRCFLEKPQFSTELRDHNRLDSQ
	AKFVARLKHTCSPQEDSPWQEEEQHRDQASGGGEGFAQGVNPLPDEDGLDGCQILDAG
	REEVAVAKPPVSKILSQCFKDPATVSLRQNETPQPAAQRSGHLYTGREQPAPNHRGSL
	PVTTIFSGPKHSRSSPTPQFSVVGSSRSLQELNLSVEPPSPTDEDTQGPNRLWNPHLR
	GYSSGKSVARTSLQAEDSDQKASSRLDDGTTDHRHLKPATPPYPMPSTLSHMPTPDFT
	TSWMSGTLEQAQQGKREKLGVQVRPENWCSQMDKGMLHFGSSDISPYALPWRPEEPAR
	ISWKQYMSGSAVDVSCSQKPQGLTLSNVARCSSMDNGLEDQNSPFHSHLSTYANICDL
	STTHSSTENAQGSNEAWEVFRGSSSIALGDPHIPTSPEGVAPTSGHDRRPQFRGPSGE
	ADCLRSKPPLAKCSAAGPVDEIMLLYPSEAGCPVGQTRTNTFEQGTQTLGSRRHWSST
	DISFAQPEASAVSAFDLASWTSMHNLSLHLSQLLHSTSELLGSLSQPDVARREQNTKR
	DIPDKAPQALMMDGSTQTTVDEGSQTDLTLPTLCLQTSEAEPQGANVILEGLGSDTST
	VSQEEGDVPGVPQKREAEETAQKMAQLLYLQEESTPYKPQSPSIPSSHLRFQKAPVGQ
	HLPSVSPSVSDAFLPPSSQPEESYCLVVSSPSPSSPHSPGLFPSTSEYPGDSRVQKKL
	GPTSALFVDRASSPILTLSASTQEPGLSPGSLTLSAPSTHPVEGHQKLDSSPDPVDAP
	RTPMDNYSQTTDELGGSQRGRSSLQRSNGRSFLELHSPHSPQQSPKLQFSFLGQHPQQ
	LQPRTTIGVQSRLLPPPLRHRSQRLGNSFVPEKVASPEHCPLSGREPSQWQSRTENGG
	ESSASPGEPQRTLDRPSSWGGLQHLSPCPVSELTDTAGLRGSALGLPQACQPEELLCF
	SCQMCMAPEHQHHSLRDLPVHNKFSNWCGVQKGSPGGLDMTEEELGASGDLSSEKQEQ
	SPPQPPNDHSQDSEWSKREQIPLQVGAQNLSLSVELTEAKLHHGFGEADALLQVLQSG
	TGEALAADEPVTSTWKELYARQKKAIETLRRERAERLGNFCRTRSLSPQKQLSLLPNK
	DLFIWDLDLPSRRREYLQQLRKDVVETTRSPESVSRSAHTPSDIELMLQDYQQAHEEA
	KVEIARARDQLRERTEQEKLRIHQKIHSQLLKEEDKLHTLANSSSLCTSSNGSLSSGM
	TSGYNSSPALSGQLQFPENMGHTNLFDSRDVWIGDERGGHSAVRKNSAYSHRASLGSC
	CCSPSSLSSLGTCFSSSYQDLAKHVVDTSMADVMAACSDNLHNLFSCQATAGWNYQGE
	EQAVQLYYKVFSPTRHGFLGAGVVSQPLSRVWAAVSDPTVWPLYYKPIQTARLHQRVT
	NSISLVYLVCNTTLCALKQPRDFCCVCVEAKEGHLSVMAAQSVYDTSMPRPSRKMVHG
	EILPSAWILQPITVEGKEVTRVIYLAQVELGAPGFPPQLLSSFIKRQPLVIARLASFL
	VQEKLMLPAVADWGRQHWPRDASKAQSVLGNSWHQCRANGLSSWPRLSRVNAALLTFW
	ISHLSFLFLGLCGRQDT

[0537] Further analysis of the NOV34a protein yielded the following properties shown in Table 34B.

TABLE 34B
Protein Sequence Properties NOV34a
PSort     0.9000 probability located in nucleus; 0.6640 probability
analysis: located in plasma membrane; 0.3694 probability located
          in mitochondrial inner membrane; 0.3000 probability
          located in microbody (peroxisome)
SignalP   No Known Signal Sequence Predicted
analysis:

[0538] A search of the NOV34a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 34C.

TABLE 34C
Geneseq Results for NOV34a
		NOV34a	Identities/
		Residues/	Similarities
Geneseq	Protein/Organism/Length	Match	for the	Expect
Identifier	[Patent #, Date]	Residues	Matched Region	Value
AAU74557	Human kinesin motor protein	1 . . . 590	518/591 (87%)	0.0
	HsKif16a - Homo sapiens, 563 aa.	1 . . . 563	519/591 (87%)
	[US6333184-B1, 25 DEC. 2001]
AAU74558	Human kinesin motor protein	1 . . . 385	334/385 (86%)	0.0
	HsKif16a motor domain - Homo	1 . . . 357	335/385 (86%)
	sapiens, 357 aa. [US6333184-B1,
	25 DEC. 2001]
ABB61704	Drosophila melanogaster	23 . . . 784	306/782 (39%)	e−132
	polypeptide SEQ ID NO 11904 -	4 . . . 707	439/782 (56%)
	Drosophila melanogaster, 1174 aa.
	[WO200171042-A2, 27 SEP. 2001]
AAM40034	Human polypeptide SEQ ID NO	2 . . . 737	295/804 (36%)	e−117
	3179 - Homo sapiens, 893 aa.	4 . . . 763	416/804 (51%)
	[WO200153312-A1, 26 JUL. 2001]
ABP51294	Human MDDT SEQ ID NO 316 -	2 . . . 609	248/619 (40%)	e−114
	Homo sapiens, 757 aa.	19 . . . 591	355/619 (57%)
	[WO200240715-A2, 23 MAY
	2002]

[0539] In a BLAST search of public sequence datbases, the NOV34a protein was found to have homology to the proteins shown in the BLASTP data in Table 34D.

TABLE 34D
Public BLASTP Results for NOV34a
		NOV34a	Identities/
Protein		Residues/	Similarities
Accession		Match	for the	Expect
Number	Protein/Organism/Length	Residues	Matched Portion	Value
Q9P2P6	KIAA1300 protein - Homo	2881 . . . 4698	1818/1818 (100%)	0.0
	sapiens (Human), 1820 aa	1 . . . 1818	1818/1818 (100%)
	(fragment).
Q9H6S2	CDNA: FLJ21936 fis, clone	1080 . . . 1883	802/804 (99%)	0.0
	HEP04408 - Homo sapiens	1 . . . 804	802/804 (99%)
	(Human), 818 aa (fragment).
Q9DDA6	Kinesin-like protein - Xenopus	1 . . . 1285	617/1321 (46%)	0.0
	laevis (African clawed frog),	1 . . . 1269	825/1321 (61%)
	1499 aa (fragment).
Q15885	Partial cDNA sequence, clone	1428 . . . 1807	378/380 (99%)	0.0
	x529, unknown open reading	1 . . . 380	378/380 (99%)
	frame - Homo sapiens (Human),
	380 aa (fragment).
AAH32885	Hypothetical protein - Mus	4340 . . . 4698	284/370 (76%)	e−158
	musculus (Mouse), 371 aa	1 . . . 369	315/370 (84%)
	(fragment).

[0540] PFam analysis predicts that the NOV34a protein contains the domains shown in the Table 34E.

TABLE 34E
Domain Analysis of NOV34a
Pfam	NOV34a	Identities/Similarities	Expect
Domain	Match Region	for the Matched Region	Value
kinesin	9 . . . 295	122/340 (36%)	3.1e−85
		219/340 (64%)
kinesin	332 . . . 413	52/83 (63%)	7e−41
		72/83 (87%)
FHA	503 . . . 569	24/80 (30%)	0.0059
		46/80 (58%)
REV	4268 . . . 4335	16/69 (23%)	0.52
		43/69 (62%)
START	4496 . . . 4704	45/254 (18%)	0.012
		138/254 (54%)

Example 35

[0541] The NOV35 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 35A.

TABLE 35A
NOV35 Sequence Analysis
	SEQ ID NO:323	2039 bp
NOV35a,	CTAAGAGTGGTTCCTCGCAGCTTAAAGGGAGGCACTTTTCACACTCTGTCTTAAAATC
CG157629-01
DNA Sequence	AGAAGTTGAATTCATGAACACATATGATTTAGATAGAAGTCATGGGATGCAGCAGTTC
	TTCAACGAAAACCAGGAGATCTGACACATCACTGAGAGCTGCGTTGATCATCCAGAAC
	TGGTACCGAGGTTACAAAGCTCGACTGAAGGCCAGACAACACTATGCCCTCACCATCT
	TCCAGTCCATCGAATATGCTGATGAACAAGGCCAAATGCAGTTATCCACCTTCTTTTC
	CTTCATGTTGGAAAACTACACACATATACATAAGGAAGAGCTAGAATTAAGAAATCAG
	TCTCTTGAAAGCGAACAGGACATGAGGGATAGATGGGATTATGTGGACTCGATAGATG
	TCCCAGACTCCTATAATGGTCCTCGGCTACAATTTCCTCTCACTTGTACGGATATTGA
	TTTACTTCTTGAGGCCTTCAAGGAACAACAGATACTTCATGCCCATTATGTCTTAGAG
	GTGCTATTTGAAACCAAGAAAGTCCTGAAGCAAATGCCGAATTTCACTCACATACAAA
	CTTCTCCCTCCAAAGAGGTAACAATCTGTGGTGATTTGCATGGGAAACTGGATGATCT
	TTTTTTGATCTTCTACAAGAATGGTCTCCCCTCAGAGAGGAACCCGTATGTTTTTAAT
	GGTGACTTTGTAGATCGAGGAAAGAATTCCATAGAGATCCTAATGATCCTGTGTGTGA
	GTTTTCTTGTCTACCCCAATGACCTGCACTTGAACAGAGGGAACCACGAAGATTTTAT
	GATGAATCTGAGGTATGGCTTCACGAAAGAAATTTTGCATAAATATAAGCTACATGGA
	AAAAGAATCTTACAAATCTTCGAAGAATTCTATGCCTGGCTCCCAACGGAAACAAACA
	GAGACCATGGCACTGACTCGAAGCACAATAAAGTAGGTGTGACTTTTAATGCACATGG
	AAGAATCAAAACAAATGGATCTCCTACTGAACACTTAACAGAGCATGAATGGGAACAG
	ATTATTGATATTCTGTGGAGTGATCCCAGAGGCAAAAATGGCTGTTTTCCAAATACGT
	GCCGAGGAGGGGGCTGCTATTTTGGACCAGATGTTACTTCCAAGATTCTTAATAAATA
	CCAGTTGAAGATGCTCATCAGGTCTCATGAATGTAAGCCCGAAGGGTATGAAATCTGT
	CATGATGGGAAGGTGGTGACTATATTTTCTGCTTCTAATTATTATGAAGAAGGCAGCA
	ATCGAGGAGCTTACATCAAACTATGTTCTGGTACAACTCCTCGATTTTTCCAGTACCA
	AGTAACTAAAGCAACGTGCTTTCAGCCTCTTCGCCAAAGAGTGGATACTATGGAAAAC
	AGCGCCATCAAGATATTAAGAGAGAGAGTGATTTCACGAAAAAGTGACCTTACTCGTG
	CTTTCCAACTTCAAGACCACAGAAAATCAGGAAAACTTTCTGTGAGCCAGTGGGCTTT
	TTGCATGGAGAACATTTTGGGGCTGAACTTACCATGGAGATCCCTCAGTTCGAATCTG
	GTAAACATAGACCAAAATGGAAACGTTGAATACATGTCCAGCTTCCAGAATATCCGCA
	TTGAAAAACCTGTACAAGAGGCTCATTCTACTCTAGTTGAAACTCTGTACAGATACAG
	ATCTGACCTGGAAATCATATTTAATGCCATTGACACTGATCACTCAGGCCTGATCTCC
	GTGGAAGAATTTCGTGCCATGTGGAAACTTTTTAGTTCTCACTACAATGTTCACATTG
	ATGATTCCCAAGTCAATAAGCTTGCCAACATAATGGACTTGAACAAAGATGGAAGCAT
	TGACTTTAATGAGTTTTTAAAGGCTTTCTATGTAGTGCATAGATATGAAGACTTGATG
	AAACCTGATGTCACCAACCTTGGCTAAACACAAATGAGAGCTTCCCTCAGGCTCCCTG
	AAACAGCTAGGCCCAAATCACAAGTACAGTCCTTTCCAACACCCCTGAAATTCATAGT
	CAGTAGCAG
	ORF Start: ATG at 100		ORF Stop: TAA at 1939
	SEQ ID NO:324	613 aa	MW at 71315.2 kD
NOV35a,	MGCSSSSTKTRRSDTSLRAALIIQNWYRGYKARLKARQHYALTIFQSIEYADEQGQMQ
CG157629-01
Protein Sequence	LSTFFSFMLENYTHIHKEELELRNQSLESEQDMRDRWDYVDSIDVPDSYNGPRLQFPL
	TCTDIDLLLEAFKEQQILHAHYVLEVLFETKKVLKQMPNFTHIQTSPSKEVTICGDLH
	GKLDDLFLTFYKNGLPSERNPYVFNGDFVDRGKNSIEILMILCVSFLVYPNDLHLNRG
	NHEDFMMNLRYGFTKEILHKYKLHGKRILQILEEFYAWLPTETNRDHGTDSKHNKVGV
	TFNAHGRIKTNGSPTEHLTEHEWEQIIDILWSDPRGKNGCFPNTCRGGGCYFGPDVTS
	KILNKYQLKMLIRSHECKPECYEICHDGKVVTIFSASNYYEEGSNRCAYIKLCSGTTP
	RFFQYQVTKATCFQPLRQRVDTMENSAIKILRERVISRKSDLTRAFQLQDHRKSGKLS
	VSQWAFCMENILGLNLPWRSLSSNLVNIDQNGNVEYMSSFQNIRIEKPVQEAHSTLVE
	TLYRYRSDLEIIFNAIDTDHSGLISVEEFRAMWKLFSSHYNVHIDDSQVNKLANIMDL
	NKDGSIDFNEFLKAFYVVHRYEDLMKPDVTNLG
	SEQ ID NO:325	2039 bp
NOV35b,	CTAAGAGTGGTTCCTCGCACCTTAAAGGGAGGCACTTTTCACACTCTGTCTTAAAATC
CG157629-01
DNA Sequence	AGAAGTTGAATTCATGAACACATATGATTTAGATAGAAGTCATGGGATGCAGCAGTTC
	TTCAACGAAAACCAGGAGATCTGACACATCACTGAGAGCTGCGTTGATCATCCAGAAC
	TGGTACCGAGGTTACAAAGCTCGACTGAAGGCCAGACAACACTATGCCCTCACCATCT
	TCCAGTCCATCGAATATGCTGATGAACAAGGCCAAATGCAGTTATCCACCTTCTTTTC
	CTTCATGTTGGAAAACTACACACATATACATAAGGAAGAGCTAGAATTAAGAAATCAG
	TCTCTTGAAAGCGAACAGGACATGAGGGATAGATGGGATTATGTGGACTCGATAGATG
	TCCCAGACTCCTATAATGGTCCTCGGCTACAATTTCCTCTCACTTGTACGGATATTGA
	TTTACTTCTTGAGGCCTTCAAGGAACAACAGATACTTCATGCCCATTATGTCTTAGAG
	GTGCTATTTGAAACCAAGAAAGTCCTGAAGCAAATGCCGAATTTCACTCACATACAAA
	CTTCTCCCTCCAAAGAGGTAACAATCTGTGGTGATTTGCATGGGAAACTGGATGATCT
	TTTTTTGATCTTCTACAAGAATGGTCTCCCCTCAGAGAGGAACCCGTATGTTTTTAAT
	GGTGACTTTGTAGATCGAGGAAAGAATTCCATAGAGATCCTAATGATCCTGTGTGTGA
	GTTTTCTTGTCTACCCCAATGACCTGCACTTGAACAGAGGGAACCACGAAGATTTTAT
	GATGAATCTGAGGTATGGCTTCACGAAAGAAATTTTGCATAAATATAAGCTACATGGA
	AAAAGAATCTTACAAATCTTGGAAGAATTCTATGCCTGGCTCCCAACGCAAACAAACA
	GAGACCATGGCACTGACTCGAAGCACAATAAAGTAGGTGTGACTTTTAATGCACATGG
	AAGAATCAAAACAAATGGATCTCCTACTGAACACTTAACAGAGCATGAATGGGAACAG
	ATTATTGATATTCTGTGGAGTGATCCCAGAGGCAAAAATGGCTGTTTTCCAAATACGT
	GCCGAGGAGGGGGCTGCTATTTTGGACCAGATGTTACTTCCAAGATTCTTAATAAATA
	CCAGTTGAAGATGCTCATCAGGTCTCATGAATGTAAGCCCGAAGGGTATGAAATCTGT
	CATGATGGGAAGGTGGTGACTATATTTTCTGCTTCTAATTATTATGAAGAAGGCAGCA
	ATCGAGGAGCTTACATCAAACTATCTTCTGGTACAACTCCTCGATTTTTCCAGTACCA
	AGTAACTAAAGCAACGTGCTTTCAGCCTCTTCGCCAAAGAGTGGATACTATGGAAAAC
	AGCGCCATCAAGATATTAAGAGAGAGAGTGATTTCACGAAAAAGTGACCTTACTCGTG
	CTTTCCAACTTCAAGACCACAGAAAATCAGGAAAACTTTCTGTGAGCCAGTGGGCTTT
	TTGCATGGAGAACATTTTGGGGCTGAACTTACCATGGAGATCCCTCAGTTCGAATCTG
	GTAAACATAGACCAAAATGGAAACGTTGAATACATGTCCAGCTTCCAGAATATCCGCA
	TTGAAAAACCTGTACAAGAGGCTCATTCTACTCTAGTTGAAACTCTGTACAGATACAG
	ATCTGACCTGGAAATCATATTTAATGCCATTGACACTGATCACTCAGGCCTGATCTCC
	GTGGAAGAATTTCGTGCCATGTGGAAACTTTTTAGTTCTCACTACAATGTTCACATTG
	ATGATTCCCAAGTCAATAAGCTTGCCAACATAATGGACTTGAACAAAGATGGAAGCAT
	TGACTTTAATGAGTTTTTAAAGGCTTTCTATGTAGTGCATAGATATGAAGACTTGATG
	AAACCTGATGTCACCAACCTTGGCTAAACACAAATGAGAGCTTCCCTCAGGCTCCCTG
	AAACAGCTAGGCCCAAATCACAAGTACAGTCCTTTCCAACACCCCTGAAATTCATAGT
	CAGTAGCAG
	ORF Start: ATG at 100		ORF Stop: TAA at 1939
	SEQ ID NO:326	613 aa	MW at 71315.2 kD
NOV35b,	MGCSSSSTKTRRSDTSLRAALIIQNWYRGYKARLKARQHYALTIFQSIEYADEQOQMQ
CG157629-01
Protein Sequence	LSTFFSFMLENYTHIHKEELELRNQSLESEQDMRDRWDYVDSIDVPDSYNGPRLQFPL
	TCTDIDLLLEAFKEQQILHAHYVLEVLFETKKVLKQMPNFTHIQTSPSKEVTICGDLH
	GKLDDLFLIFYKNGLPSERNPYVFNGDFVDRGKNSIEILMILCVSFLVYPNDLHLNRG
	NHEDFMMNLRYGFTKEILHKYKLHGKRILQILEEFYAWLPTETNRDHGTDSKHNKVGV
	TFNAHGRIKTNGSPTEHLTEHEWEQIIDILWSDPRGKNGCFPNTCRGGGCYFGPDVTS
	KILNKYQLKMLIRSHECKPEGYEICHDGKVVTIFSASNYYEEGSNRGAYIKLCSGTTP
	RFFQYQVTKATCFQPLRQRVDTMENSAIKILRERVISRKSDLTNAFQLQDHRKSGKLS
	VSQWAFCMENILGLNLPWRSLSSNLVMIDQNGNVEYMSSFQNIRIEKPVQEAHSTLVE
	TLYRYRSDLEIIFNAIDTDHSGLISVEEFRAMWKLFSSHYNVHIDDSQVNKLANIMDL
	NKDGSIDFNEFLKAFYVVHRYEDLMKPDVTNLG

[0542] Sequence comparison of the above protein sequences yields the following sequence relationships shown in Table 35B.

TABLE 35B
Comparison of NOV35a against NOV35b.
			Identities/
			Similarities for
	Protein	NOV35a Residues/	the Matched
	Sequence	Match Residues	Region
	NOV35b	1 . . . 613	613/613 (100%)
		1 . . . 613	613/613 (100%)

[0543] Further analysis of the NOV35a protein yielded the following properties shown in Table 35C.

TABLE 35C
Protein Sequence Properties NOV35a
PSort     0.8171 probability located in mitochondrial matrix space;
analysis: 0.4962 probability located in mitochondrial inner membrane;
          0.4962 probability located in mitochondrial intermembrane
          space; 0.4962 probability located in mitochondrial outer
          membrane
SignalP   No Known Signal Sequence Predicted
analysis:

[0544] A search of the NOV35a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 35D.

TABLE 35D
Geneseq Results for NOV35a
			Identities/
			Similarities for
Geneseq	Protein/Organism/Length	NOV35a Residues/	the Matched	Expect
Identifier	[Patent #, Date]	Match Residues	Region	Value
AAB47250	Human PP7 - Homo sapiens, 653 aa.	1 . . . 613	612/653 (93%)	0.0
	[WO200130830-A2, 03 MAY	1 . . . 653	612/653 (93%)
	2001]
ABB71489	Drosophila melanogaster	44 . . . 602	231/578 (39%)	e−117
	polypeptide SEQ ID NO 41259 -	9 . . . 580	341/578 (58%)
	Drosophila melanogaster, 637 aa.
	[WO200171042-A2, 27 SEP. 2001]
AAE09722	Novel cell cycle protein, protein	86 . . . 422	126/343 (36%)	3e−57
	phosphatase type 5 (PP5) -	156 . . . 487	194/343 (55%)
	Unidentified, 499 aa.
	[WO200164913-A2, 07 SEP. 2001]
AAE09733	Protein phosphatase type 5 (PP5)	86 . . . 422	125/343 (36%)	2e−56
	variant, N303A - Unidentified, 499	156 . . . 487	193/343 (55%)
	aa. [WO200164913-A2, 07 SEP.
	2001]
ABG09989	Novel human diagnostic protein	86 . . . 422	125/343 (36%)	3e−56
	#9980 - Homo sapiens, 500 aa.	160 . . . 491	193/343 (55%)
	[WO200175067-A2, 11 OCT. 2001]

[0545] In a BLAST search of public sequence datbases, the NOV35a protein was found to have homology to the proteins shown in the BLASTP data in Table 35E.

TABLE 35E
Public BLASTP Results for NOV35a
			Identities/
Protein			Similarities for
Accession		NOV35a Residues/	the Matched	Expect
Number	Protein/Organism/Length	Match Residues	Portion	Value
O14829	Serine/threonine protein phosphatase	1 . . . 613	612/653 (93%)	0.0
	with EF-hands-1 (EC 3.1.3.16)	1 . . . 653	612/653 (93%)
	(PPEF-1) (Protein phosphatase with
	EF calcium-binding domain) (PPEF)
	(Serine/threonine protein phosphatase
	7) (PP7) - Homo sapiens (Human),
	653 aa.
O01921	Hypothetical 80.3 kDa protein	6 . . . 600	258/637 (40%)	e−131
	(Protein phosphatase with EF-hands) -	67 . . . 703	375/637 (58%)
	Caenorhabditis elegans, 707 aa.
T34072	hypothetical protein F23H11.8 -	15 . . . 600	252/629 (40%)	e−130
	Caenorhabditis elegans, 722 aa.	90 . . . 718	368/629 (58%)
P40421	Serine/threonine protein phosphatase	14 . . . 602	241/608 (39%)	e−123
	rdgC (EC 3.1.3.16) (Retinal	3 . . . 604	360/608 (58%)
	degeneration C protein) - Drosophila
	melanogaster (Fruit fly), 661 aa.
AAM22065	C. elegans PEF-1 protein	100 . . . 600	224/520 (43%)	e−121
	(corresponding sequence F23H11.8b) -	49 . . . 568	319/520 (61%)
	Caenorhabditis elegans, 572 aa.

[0546] PFam analysis predicts that the NOV35a protein contains the domains shown in the Table 35F.

TABLE 35F
Domain Analysis of NOV35a
		Identities/
		Similarities for
Pfam	NOV35a	the Matched	Expect
Domain	Match Region	Region	Value
IQ	17 . . . 37	9/21 (43%)	0.0022
		17/21 (81%)
STphosphatase	121 . . . 272	53/159 (33%)	7.9e−46
		115/159 (72%)
STphosphatase	315 . . . 416	37/104 (36%)	1.5e−34
		83/104 (80%)
efhand	530 . . . 558	12/29 (41%)	3.4e−06
		25/29 (86%)
efhand	570 . . . 598	8/29 (28%)	0.0011
		24/29 (83%)

Example 36

[0547] The NOV36 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 36A.

TABLE 36A
NOV36 Sequence Analysis
	SEQ ID NO:327	4037 bp
NOV36a,	TTCACCAAAATGGCATCCTGGTTATATGAATGTCTTTGTGAAGCTGAACTTGCACAGT
CG157704-01
DNA Sequence	ATTATTCTCATTTCACTGCCCTTGGCCTTCAGAAAATAGATGAATTAGCCAAGATTAC
	AATGAAGGACTACTCCAAATTAGGAGTCCATGACATGAACGACCGCAAACGTCTCTTC
	CAACTTATCAAAATTATTAAGATTATGCAAGAAGAAGATAAAGCAGTCAGTATCCCAG
	AGCGTCATCTTCAGACAAGCAGCCTGCGCATCAAATCTCAGGAATTAAGATCTGGCCC
	TCGCAGACAGCTGAATTTTGATTCTCCTGCTGACAATAAAGACAGAAATGCCAGCAAT
	GATGGGTTTGAAATGTGCAGTTTATCAGATTTCTCTGCAAATGAACAGAAGTCCACTT
	ACCTAAAAGTGCTAGAACACATGCTACCAGATGATTCCCAGTACCATACAAAAACAGG
	AATTCTGAATGCCACAGCTGGTGATTCCTATGTGCAAACAGAAATCAGCACTTCACTC
	TTTTCACCAAATTACCTTTCTGCAATACTGGGGGATTGTGATATTCCCATTATTCAAA
	GAATCTCTCATGTTTCAGGGTATAACTATGGAATCCCTCATTCTTGTATCAGACAGAA
	CACTTCAGAGAAACAGAATCCTTGGACTGAGATGGAGAAAATCAGAGTTTGTGTTCGA
	AAACGCCCCCTGGGCATGAGGGAGGTACGTCGTGGAGAAATTAATATTATTACTGTAG
	AAGACAAAGAAACTCTACTTGTGCATGAGAAGAAAGAAGCAGTTGACCTCACTCAATA
	TATTCTGCAGCATGTTTTTTATTTTGATGAAGTCTTTGGTGAGGCGTGCACCAATCAG
	GATGTATACATGAAGACTACTCACCCACTTATTCAGCATATTTTCAATGGAGGCAATG
	CCACTTGCTTTGCTTATGGACAGACAGGTGCTGGAAAGACCTACACCATGATAGGAAC
	TCATGAGAACCCAGGATTGTATGCTCTAGCTGCCAAAGATATCTTCAGGCAACTAGAA
	GTGTCCCAGCCAAGAAAGCACCTCTTTGTGTGGATCAGCTTCTATGAAATTTACTGTG
	GACAGCTTTATGACCTCCTAAATAGAAGAAAAAGGCTCTTTGCAAGAGAAGATAGCAA
	GCACATGGTGCAGATAGTGGGACTGCAAGAGCTTCAGGTGGACAGTGTGGAGCTCCTC
	TTACAGGTGATCTTAAAGGGCAGCAAGGAGCGCAGCACTGGGGCCACTGGAGTTAATG
	CAGACTCCTCCCGCTCCCATGCCGTCATCCAAATTCAGATCAAAGATTCAGCCAAGAG
	GACATTTGGCAGGATCTCTTTTATTGACTTGGCTGGCAGTGAAAGAGCAGCAGATGCA
	AGGGACTCAGATAGACAGACAAAGATGGAAGGTGCAGAAATAAATCAGAGTCTACTGG
	CTCTGAAGGAATGTATCCGAGCACTGGATCAGGAACACACCCATACTCCCTTCAGGCA
	AAGCAAACTAACTCAGGTCCTGAAGGACTCTTTCATCGGCAATGCCAAAACCTGCATG
	ATCGCCAACATCTCACCAAGCCACGTGGCCACTGAACACACTCTCAACACCTTGCGCT
	ATGCTGACCGGGTCAAAGAACTAAAGAAAGGCATTAAGTGTTGCACTTCAGTTACCAG
	TCGAAATCGGACATCTGGAAACTCCTCTCCAAAACGAATTCAGAGCTCCCCTGGGGCT
	TTGTCAGAGGACAAATGTTCTCCCAAAAAAGTCAAGCTGGGATTTCAGCAGTCACTCA
	CAGTGGCAGCCCCTGGTTCCACGAGAGGGAAGGTCCATCCTCTGACCAGCCACCCACC
	CAACATTCCTTTTACTTCTGCACCTAAGGTCTCTGGTAAAAGGGGTGGCTCCAGAGGG
	AGTCCTTCACAAGAGTGGGTCATTCATGCTAGCCCTGTGAAAGGAACTGTGCGCTCTG
	GACATGTGGCCAAAAAAAAGCCAGAAGAGTCAGCACCATTGTGCTCTGAGAAAAATCG
	AATGGGCAACAAAACTGTCCTTGGGTGGGAAAGCAGCGCCTCAGGCCCAGGAGAAGGC
	CTAGTGCGTGGTAAGCTGTCCACCAAGTGCAAGAAAGTGCAGACAGTGCAGCCAGTAC
	AGAAGCAGCTTGTGTCTCGAGTTGAGCTCTCCTTTGGCAACGCCCACCACAGGGCTGA
	GTACAGTCAAGACAGCCAGAGGGGCACCCCTGCTAGGCCTGCCTCTGAAGCTTGGACA
	AACATCCCGCCACATCAGAAGGAGAGGGAGGAACATCTGCGTTTCTATCACCAGCAGT
	TCCAACAGCCACCTCTCCTCCAACAGAAGTTAAAATACCAACCACTGAAAAGGTCTTT
	ACGCCAGTACAGGCCCCCAGAGGGTCAGCTCACGAATGAGACTCCGCCTCTGTTCCAC
	TCTTACTCTGAAAACCATGATGGAGCCCAAGTAGAGGAACTTGATGACAGTGATTTCA
	GTGAAGATTCTTTTTCACACATCTCTAGTCAGAGGGCCACAAAGCAAAGGAACACCCT
	GGAGAATAGCGAAGACTCATTCTTCCTGCACCAGACGTGGGGACAGGGTCCTGAGAAG
	CAGGTGGCAGAAAGACAGCAGAGTCTGTTTTCTAGCCCCAGGACAGGTGACAAGAAAG
	ATCTAACTAAAAGCTGGGTGGACTCCAGGGACCCCATAAACCACAGAAGAGCAGCACT
	CGATCACAGCTGCAGCCCAAGTAAGGGGCCCGTGGACTGGAGCAGAGAGAACTCTACT
	TCCTCAGGGCCTTCTCCCAGAGACAGCCTGGCAGAGAACCCATACTGTTCACAGGTAG
	ATTTCATATATAGACAGGAAAGAGGTGGAGGCTCTTCCTTTGATCTCAGAAAGGATGC
	CTCCCAAAGTGAGGTTTCTGGGGAGAATGAGGGCAACTTGCCATCCCCAGAGGAAGAT
	GGTTTCACTATCTCATTGTCCCACGTTGCAGTTCCTGGATCCCCAGACCAAAGAGACA
	CAGTCACCACACCTCTGAGAGAAGTCAGTGCAGACGGCCCAATCCAGGTGACCAGCAC
	TGTGAAAAACGGTCATGCTGTCCCAGGAGAGGATCCTAGGGGGCAGTTAGGCACGCAT
	GCTGAATATGCTTCTGGACTCATGTCTCCCCTCACCATGTCCCTCCTGGAGAACCCAG
	ACAACGAAGGGTCTCCTCCCTCGGAGCAGCTGGTCCAGGATGGGGCTACGCACAGTCT
	AGTGGCAGAGAGCACAGGGGGCCCAGTTGTGAGCCACACAGTGCCATCTGGTGATCAA
	GAGGCAGCCTTGCCAGTGTCTTCAGCAACTAGGCACCTGTGGCTGTCCTCATCTCCCC
	CTGATAATAAGCCTGGTGGTGATCTTCCAGCTCTGTCCCCATCACCCATCCGTCAGCA
	CCCAGCTGACAAGCTGCCCAGCAGGGAGGCAGACCTAGGAGAGGCCTGCCAGAGCAGA
	GAGACTGTACTTTTCTCCCACGAACACATGGGTAGTGAGCAGTATGATGCTGATGCAG
	AGGAGACGGGGCTGGATGGCTCCTGGGGTTTCCCAGGAAAGCCCTTCACCACCATACA
	TATGGGGGTACCCCATTCTGGACCTACACTCACCCCACGAACAGGAAGTAGTGATGTG
	GCTGACCAGCTCTGGGCCCAGGAGAGAAAACATCCTACAAGGCTTGGTTGGCAGGAGT
	TTGGTTTGTCCACAGACCCCATCAAGTTGCCCTGCAACAGTGAAAATGTCACATGGCT
	CAAACCCAGGCCGATCTCAAGGCAGGTGGTCATCCGAGCACACCAGGAACAGCTGGAT
	GAAATGGCTGAGCTCGGCTTCAAGGAGGAGACGCTGATGAGCCAGCTGGCTTCTAATG
	ATTTTGAAGATTTTGTGACCCAGCTGGATGAAATCATGGTTCTGAAATCCAAGTGTAT
	CCAGAGTCTGAGGAGCCAGCTGCAGCTCTATCTCACCTGCCACGGGCCCACCGCAGCC
	CCTGAGGGAACAGTGCCGTCTTAGAGCCAGACCCT
	ORF Start: ATG at 10		ORF Stop: TAG at 4024
	SEQ ID NO:328	1338 aa	MW at 148781.1 kD
NOV36a,	MASWLYECLCEAELAQYYSHFTALGLQKIDELAKITMKDYSKLGVHDMNDRKRLFQLI
CG157704-01
Protein Sequence	KIIKIMQEEDKAVSIPERHLQTSSLRIKSQELRSGPRRQLNFDSPADNKDRNASNDGF
	EMCSLSDFSANEQKSTYLKVLEHMLPDDSQYHTKTGILNATAGDSYVQTEISTSLFSP
	NYLSAILGDCDIPIIQRISHVSGYNYGIPHSCIRQNTSEKQNPWTEMEKIRVCVRKRP
	LGMREVRRGEINIITVEDKETLLVHEKKEAVDLTQYILQHVFYFDEVFGEACTNQDVY
	MKTTHPLIQHIFNGGNATCFAYGQTGAGKTYTMIGTHENPGLYALAAKDIFRQLEVSQ
	PRKHLFVWISFYEIYCGQLYDLLNRRKRLFAREDSKHMVQIVGLQELQVDSVELLLQV
	ILKGSKERSTGATGVNADSSRSHAVIQIQIKDSAKRTFGRISFIDLAGSERAADARDS
	DRQTKMEGAEINQSLLALKECIRALDQEHTHTPFRQSKLTQVLKDSPIGNAKTCMIAN
	ISPSHVATEHTLNTLRYADRVKELKKGIKCCTSVTSRNRTSGNSSPKRIQSSPGALSE
	DKCSPKKVKLGFQQSLTVAAPGSTRGKVHPLTSHPPNIPFTSAPKVSGKRGGSRGSPS
	QEWVIHASPVKGTVRSGHVAKKKPEESAPLCSEKNRMGNKTVLGWESRASGPGEGLVR
	GKLSTKCKKVQTVQPVQKQLVSRVELSFGNAHHRAEYSQDSQRGTPARPASEAWTNIP
	PHQKEREEHLRFYHQQFQQPPLLQQKLKYQPLKRSLRQYRPPEGQLTNETPPLFHSYS
	ENNDGAQVEELDDSDFSEDSFSHISSQRATKQRNTLENSEDSFFLHQTWGQGPEKQVA
	ERQQSLFSSPRTGDKKDLTKSWVDSRDPINHRRAALDHSCSPSKGPVDWSRENSTSSG
	PSPRDSLAEKPYCSQVDFIYRQERGGGSSFDLRKDASQSEVSGENEGNLPSPEEDGFT
	ISLSHVAVPGSPDQRDTVTTPLREVSADGPIQVTSTVKNGHAVPGEDPRGQLGTHAEY
	ASGLMSPLTMSLLENPDNEGSPPSEQLVQDGATHSLVAESTGGPVVSHTVPSGDQEAA
	LPVSSATRHLWLSSSPPDNKPGGDLPALSPSPIRQHPADKLPSREADLGEACQSRETV
	LFSHEHMGSEQYDADAEETGLDGSWGFPGKPFTTIHMGVPHSGPTLTPRTGSSDVADQ
	LWAQERKHPTRLGWQEFGLSTDPIKLPCNSENVTWLKPRPISRQVVIRAHQEQLDEMA
	ELGFKEETLMSQLASNDFEDFVTQLDEIMVLKSKCIQSLRSQLQLYLTCHGPTAAPEG
	TVPS

[0548] Further analysis of the NOV36a protein yielded the following properties shown in Table 36B.

TABLE 36B
Protein Sequence Properties NOV36a
PSort     0.8200 probability located in nucleus; 0.3000 probability
analysis: located in microbody (peroxisome); 0.1000 probability
          located in mitochondrial matrix space; 0.1000 probability
          located in lysosome (lumen)
SignalP   No Known Signal Sequence Predicted
analysis:

[0549] A search of the NOV36a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 36C.

TABLE 36C
Geneseq Results for NOV36a
			Identities/
			Similarities for
Geneseq	Protein/Organism/Length	NOV36a Residues/	the Matched	Expect
Identifier	[Patent #, Date]	Match Residues	Region	Value
AAU77182	Human kinesin motor protein	1 . . . 1338	1337/1368 (97%)	0.0
	KinI-3 - Homo sapiens, 1368 aa.	1 . . . 1368	1338/1368 (97%)
	[WO200226929-A2, 04 APR.
	2002]
AAU77184	Human KinI-3 DNA fragment	195 . . . 566	371/372 (99%)	0.0
	with flanking vector sequences #2 -	2 . . . 373	372/372 (99%)
	Homo sapiens, 381 aa.
	[WO200226929-A2, 04 APR.
	2002]
AAU77183	Human KinI-3 DNA fragment	183 . . . 546	363/364 (99%)	0.0
	with flanking vector sequences #1 -	2 . . . 365	364/364 (99%)
	Homo sapiens, 373 aa.
	[WO200226929-A2, 04 APR.
	2002]
AAU77186	Human KinI-3 DNA fragment	213 . . . 566	353/354 (99%)	0.0
	with flanking vector sequences #4 -	2 . . . 355	354/354 (99%)
	Homo sapiens, 363 aa.
	[WO200226929-A2, 04 APR.
	2002]
AAU77185	Human KinI-3 DNA fragment	213 . . . 546	333/334 (99%)	0.0
	with flanking vector sequences #3 -	2 . . . 335	334/334 (99%)
	Homo sapiens, 343 aa.
	[WO200226929-A2, 04 APR.
	2002]

[0550] In a BLAST search of public sequence datbases, the NOV36a protein was found to have homology to the proteins shown in the BLASTP data in Table 36D.

TABLE 36D
Public BLASTP Results for NOV36a
			Identities/
Protein			Similarities for
Accession		NOV36a Residues/	the Matched	Expect
Number	Protein/Organism/Length	Match Residues	Portion	Value
Q9GYC7	Probable mitotic centromere	1 . . . 548	222/551 (40%)	e−101
	associated kinesin - Leishmania	1 . . . 519	317/551 (57%)
	major, 728 aa.
Q9NV43	OVARC1000605 protein - Homo	37 . . . 208	172/172 (100%)	5e−95
	sapiens (Human), 172 aa.	1 . . . 172	172/172 (100%)
Q94GW1	Kinesin-like protein - Oryza	208 . . . 574	192/368 (52%)	3e−94
	sativa (Rice), 800 aa.	188 . . . 539	251/368 (68%)
P28740	Kinesin-like protein KIF2 - Mus	223 . . . 617	196/407 (48%)	2e−93
	musculus (Mouse), 716 aa.	195 . . . 582	259/407 (63%)
Q9VZ28	CG1453 protein - Drosophila	223 . . . 546	182/333 (54%)	5e−93
	melanogaster (Fruit fly), 803 aa.	276 . . . 608	236/333 (70%)

[0551] PFam analysis predicts that the NOV36a protein contains the domains shown in the Table 36E.

TABLE 36E
Domain Analysis of NOV36a
			Identities/
			Similarities for
	Pfam	NOV36a	the Matched	Expect
	Domain	Match Region	Region	Value
	SAM	2 . . . 62	19/68 (28%)	0.42
			41/68 (60%)
	kinesin	229 . . . 547	129/388 (33%)	3.7e−89
			236/388 (61%)

Example 37

[0552] The NOV37 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 37A.

TABLE 37A
NOV37 Sequence Analysis
	SEQ ID NO:329	2770 bp
NOV37a,	TTATGGGACCATGATGTTGAGAGTTAGTGTGAAGTGGACCATTGAAAAAGCCAGCCAA
CG158218-01
DNA Sequence	AGTAGCATCTTCATCCGTTTCCAGGCCATGCCCTTTCATTATAACCAGAAGGCCCCAT
	GTTCTGAGTGCCATGATCTGATGTGTAGGAATGTCAATTCCACCCCGCAGATCATTGC
	AACTTTAGTGGACATACCTATACATGCCAAAAGCATCCTGCCTCCAGGGTCTGCACCT
	CTCTCTGCCCAACGGCTTTCTCTGAATGTCAGGGCACACAGGATTTATTCCATAGATG
	AAGATGAAAAATTAATACCTAGCTTGGAAATCATCTTACCACGTGATTTGGCAGATGG
	GTTTGTGAATAATAAGCGAGAAAGCTACAAATTTAAATTTCAAAGAATTTTTGATCAG
	GATGCAAACCAAGAGACCGTTTTTGAAAACATTGCCAAACCAGTTGCTGGGAGGTATC
	TCACCCCTGGTGGTAAGGATGTCCTGGCAGGTTACAATGGTACCATCTTTGCATATGG
	GCAAACAGGCAGCGGGAAGACATTCACTATCACAGGGGGTGCAGAGCGTTACAGTGAC
	ACAGGCATTATCCCAAGGACACTGTCATACATTTTTGAACAGTTACAAAAGGACAGCA
	GCAAAATATATACAACACACATTTCCTATTTGGAAATCTACAATGAATGTGGTTATGA
	TCTTTTGGATCCAAGACATGAAGCCTCCAGTTTGGAAGATTTGCCGAAAGTGACAATA
	CTGGAGGATCCTGATCAGAACATTCACCTGAAAAACTTGACTCTCCATCAGGCAACCA
	CAGAGGAAGAAGCTCTGAATTTGCTTTTTTTAGGAGACACCAACCGAATGATTGCAGA
	GACTCCTATGAACCAAGCTTCAACCCGTTCCCACTGCATTTTCACCATTCATTTGTCA
	AGCAAGGAACCAGGATCTGCAACTGTACGACATGCCAAACTCCATCTGGTTGACCTGG
	CTGGTTCAGAGCGAGTTGCAAAGACTGGAGTAGGGGGCCATCTTCTAACAGAGGCCAA
	GTATATCAACTTGTCACTACATTACTTAGAACAGGTTATCATTGCCCTTTCAGAAAAG
	CACCGTTCGCACATTCCTTATAGAAACTCCATCATGACCAGTGTCCTAAGAGACAGTT
	TGGGAGGGAACTGCATGACAACTATGATTGCAACACTCTCCTTGGAGAAAAGGAATCT
	TGATGAGTCTATATCAACCTGCAGATTTGCACAGCGAGTGGCACTCATAAAGAATGAA
	GCTGTTCTTAATGAAGAAATTAACCCCAGATTAGTGATTAAACGCCTACAAAAGGAAA
	TCCAGGAACTGAAGGATGAACTGGCCATGGTCACTGGGGAGCAGAGGACAGAGGCACT
	CACAGAAGCAGAGCTCCTTCAGCTGGAAAAACTAATAACATCCTTTTTGGAAGACCAG
	GATTCAGACAGTAGATTAGAGGTTGGCGCGGATATGCGTAAAGTTCATCACTGTTTTC
	ATCATTTAAAGAAACTATTGAATGACAAGAAGATCCTTGAAAACAATACAGTCTCCTC
	TGAAAGCAAAGACCAAGATTGTCAAGAACCATTAAAAGAAGAAGAATATAGAAAGCTA
	CGAGATATTCTGAAACAGAGAGATAACGAAATCAATATCCTGGTCAACATGTTAAAAA
	AAGAAAAGAAGAAAGCTCAGGAGGCTCTCCACTTGGCTGGCATGGATAGACGTGAATT
	CAGACAGTCCCAGAGCCCACCCTTCCGCCTAGGAAACCCAGAAGAAGGTCAAAGAATG
	CGACTATCCTCAGCTCCCTCACAGGCCCAGGACTTCAGCATTTTGGGGAAAAGATCCA
	GTTTGCTCCACAAGAAAATAGGAATGAGAGAGGAAATGTCATTAGGATGCCAGGAGGC
	TTTTGAAATCTTCAAGACGGACCACGCTGACAGCGTTACCATCGATGACAACAAACAG
	ATTCTGAAACAGAGATTTTCTGAAGCCAAGGCCCTGGGAGAAAGTATAAATGAAGCAA
	GAAGTAAAATTGGTCACCTGAAGGAAGAAATCACCCAGCGGCATATACAGCAAGTAGC
	CCTAGGAATCTCGGAAAACATGGCCGTGCCTCTGATGCCAGACCAGCAGGAGGAGAAG
	CTGCGATCACAACTGGAGGAAGAAAAGAGAAGGTATAAAACAATGTTCACTCGCCTGA
	AAGCCCTGAAGGTGGAGATCGAGCACTTGCAGCTGCTCATGGACAAAGCCAAGGTGAA
	GCTACAGAAAGAGTTTGAAGTCTGGTGGGCAGAGGAGGCCACCAACCTGCAGGTAAAT
	TCTCCAGCAGTGAATTCACTCGATCACACGAAGCCATTTCTCCAGACATCTGACTCCC
	AGCATGAATGGTCCCAACTCCTCTCTAACAAAAGTTCTGCAGGCTGGGAAGTCCAAGA
	TCAAGGCACTGGCAGATTCGATGTCTGTGATGTGAATGCCAGGAAAATCCTGCCCTCG
	CCTTGCCCCAGTCCACACACCCAGAAACAGAGCAGCACCAGCACCCCACTGGAAGACA
	GCATCCCCAAGAGGCCAGTGTCGTCCATCCCTCTCACCGGAGACAGCCAGACGGACTC
	GGACATCATCGCCTTCATCAAGGCCAGACAGAGCATTCTGCAGAAGCAATATCTTCAG
	CTCCTTTGTTCTCTGTTCCCAAAGTCAGCTGTCTCCTCTGCTCAGGCTTCTACAAACA
	GGAAGGGGCTGAGTGATGTTTTGGTAACTCGTTGAACCCCTGGC
	ORF Start: ATG at 11		ORF Stop: TGA at 2759
	SEQ ID NO:330	916 aa	MW at 103840.1 kD
NOV37a,	MMLRVSVKWTIEKASQSSIFIRFQAMPFHYNQKAPCSECHDLMCRNVNSTPQIIATLV
CG158218-01
Protein Sequence	DIPIHAKSILPPGSAPLSAQRLSLNVRAHRIYSIDEDEKLIPSLEIILPRDLADGFVN
	NKRESYKFKFQRIFDQDANQETVFENIAKPVAGRYLTPGGKDVLAGYNGTIFAYGQTG
	SGKTFTITGGAERYSDRGIIPRTLSYIFEQLQKDSSKIYTTHISYLEIYNECGYDLLD
	PRHEASSLEDLPKVTILEDPDQNIHLKNLTLHQATTEEEALNLLFLGDTNRMIAETPM
	NQASTRSHCIFTIHLSSKEPGSATVRHAKLHLVDLAGSERVAKTGVGGHLLTEAKYIN
	LSLHYLEQVIIALSEKHRSHIPYRNSMMTSVLRDSLGGNCMTTMIATLSLEKRNLDES
	ISTCRFAQRVALIKNEAVLNEEINPRLVIKRLQKEIQELKDELAMVTGEQRTEALTEA
	ELLQLEKLITSFLEDQDSDSRLEVGADMRKVHHCFHHLKKLLNDKKTLENNTVSSESK
	DQDCQEPLKEEEYRKLRDTLKQRDNEINILVNMLKKEKKKAQEALHLAGMDRREPRQS
	QSPPFRLGNPEEGQRMRLSSAPSQAQDFSILGKRSSLLHKKIGMREEMSLGCQEAFEI
	FKRDHADSVTIDDNKQILKQRFSEAKALCESINEARSKIGHLKEEITQRHIQQVALGI
	SENMAVPLMPDQQEEKLRSQLEEEKRRYKTMFTRLKALKVEIEHLQLLMDKAKVKLQK
	EFEVWWAEEATNLQVNSPAVNSLDHTKPFLQTSDSQHEWSQLLSNKSSGGWEVQDQGT
	GRFDVCDVNARKILPSPCPSPHSQKQSSTSTPLEDSIPKRPVSSIPLTGDSQTDSDII
	AFIKARQSILQKQYLQLLCSLFPKSAVSSAQASTNRKGLSDVLVTR

[0553] Further analysis of the NOV37a protein yielded the following properties shown in Table 37B.

TABLE 37B
Protein Sequence Properties NOV37a
PSort     0.6863 probability located in mitochondrial matrix space;
analysis: 0.3737 probability located in mitochondrial inner membrane;
          0.3737 probability located in mitochondrial intermembrane
          space; 0.3737 probability located in mitochondrial outer
          membrane
SignalP   No Known Signal Sequence Predicted
analysis:

[0554] A search of the NOV37a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 37C.

TABLE 37C
Geneseq Results for NOV37a
			Identities/
			Similarities for
Geneseq	Protein/Organism/Length	NOV37a Residues/	the Matched	Expect
Identifier	[Patent #, Date]	Match Residues	Region	Value
AAU75177	Human kinesin protein 9 - Homo	86 . . . 762	220/685 (32%)	3e−91
	sapiens, 725 aa. [CN1319665-A,	20 . . . 643	363/685 (52%)
	31 OCT. 2001]
AAE14609	Human microtubule motor protein	159 . . . 322	164/164 (100%)	3e−91
	HsKif6 motor domain - Homo	28 . . . 191	164/164 (100%)
	sapiens, 205 aa. [US6346410-B1,
	12 FEB. 2002]
AAU75800	Human ortholog of mouse kinesin	86 . . . 762	217/739 (29%)	8e−81
	Kif9, HsKif9 - Homo sapiens, 790	20 . . . 708	362/739 (48%)
	aa. [US6331430-B1, 18 DEC.
	2001]
ABB80741	Human kinesin motor protein,	86 . . . 762	217/739 (29%)	8e−81
	HsKif9 sequence - Homo sapiens,	20 . . . 708	362/739 (48%)
	790 aa. [US6355447-B1, 12 MAR.
	2002]
AAB94768	Human protein sequence SEQ ID	86 . . . 510	162/432 (37%)	1e−77
	NO: 15849 - Homo sapiens, 664 aa.	20 . . . 433	258/432 (59%)
	[EP1074617-A2, 07 FEB. 2001]

[0555] In a BLAST search of public sequence datbases, the NOV37a protein was found to have homology to the proteins shown in the BLASTP data in Table 37D.

TABLE 37D
Public BLASTP Results for NOV37a
			Identities/
Protein			Similarities for
Accession		NOV37a Residues/	the Matched	Expect
Number	Protein/Organism/Length	Match Residues	Portion	Value
054720	Kinesin-related protein 3A -	81 . . . 560	416/480 (86%)	0.0
	Rattus norvegicus (Rat), 486 aa	15 . . . 486	442/480 (91%)
	(fragment).
Q8R471	Kinesin-related protein 3B -	81 . . . 507	376/427 (88%)	0.0
	Rattus norvegicus (Rat), 452 aa	14 . . . 432	396/427 (92%)
	(fragment).
Q8WTV4	Hypothetical 30.1 kDa protein -	624 . . . 885	261/262 (99%)	e−147
	Homo sapiens (Human), 265 aa.	1 . . . 262	261/262 (99%)
Q9UJR0	DJ1043E3.1 (Novel protein) -	434 . . . 622	189/189 (100%)	e−102
	Homo sapiens (Human), 189 aa	1 . . . 189	189/189 (100%)
	(fragment).
O35067	Motor domain of KIF6 - Mus	167 . . . 329	155/165 (93%)	2e−84
	musculus (Mouse), 165 aa	1 . . . 165	158/165 (94%)
	(fragment).

[0556] PFam analysis predicts that the NOV37a protein contains the domains shown in the Table 37E.

TABLE 37E
Domain Analysis of NOV37a
			Identities/
			Similarities for
	Pfam	NOV37a	the Matched	Expect
	Domain	Match Region	Region	Value
	kinesin	124 . . . 449	153/375 (41%)	6.5e−119
			255/375 (68%)

Example 38

[0557] The NOV38 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 38A.

TABLE 38A
NOV38 Sequence Analysis
	SEQ ID NO:331	1184 bp
NOV38a,	AGTTCCTCCTAACTCCTGCCAGAAACAGCTCTCCTCAACATGAGAGCTGCACCCCTCC
CG158513-01
DNA Sequence	TCCTGGCCAGGGCAGCAAGCCTTAGCCTTGGCTTCTTGTTTCTGCTTTTTTTCTGGCT
	AGACCGAAGTGTACTAGCCAAGGAGTTGAAGTTTGTGACTTTGGTGTTTCGGCATGGA
	GACCGAAGTCCCATTGACACCTTTCCCACTGACCCCATAAAGGAATCCTCATGGCCAC
	AAGGATTTGGCCAACTCACCCAGCTGGGCATGGAGCAGCATTATGAACTTGGAGAGTA
	TATAAGAAAGAGATATAGAAAATTCTTGAATGAGTCCTATAAACATGAACAGGTTTAT
	ATTCGAAGCACAGACGTTGACCGGACTTTGATGAGTGCTATGACAAACCTGGCAGCCC
	TGTTTCCCCCAGAAGGTGTCAGCATCTGGAATCCTATCCTACTCTGGCAGCCCATCCC
	GGTGCACACAGTTCCTCTTTCTGAAGATCAGGATTTTATAGCTACCTTGGGAAAACTT
	TCAGGATTACATGGCCAGGACCTTTTTGGAATTTGGAGTAAAGTCTACGACCCTTTAT
	ATTGTGAGAGTGTTCACAATTTCACTTTACCCTCCTGGGCCACTGAGGACACCATGAC
	TAAGTTGAGAGAATTGTCAGAATTGTCCCTCCTGTCCCTCTATGGAATTCACAAGCAG
	AAAGAGAAATCTAGGCTCCAAGGGGGTGTCCTGGTCAATGAAATCCTCAATCACATGA
	AGAGAGCAACTCAGATACCAAGCTACAAAAAACTCATCATGTATTCTGCGCATGACAC
	TACTGTGAGTGGCCTACAGATGGCGCTAGATGTTTACAACGGACTCCTTCCTCCCTAT
	GCTTCTTGCCACTTGACGGAATTGTACTTTGAGAAGGGGGAGTACTTTGTGGAGATGT
	ACTATCGGAATGAGACGCAGCACGAGCCGTATCCCCTCATGCTACCTGGCTGCAGCCC
	CAGCTGTCCTCTGGAGAGGTTTGCTGAGCTGGTTGGCCCTGTGATCCCTCAAGACTGG
	TCCACGGAGTGTATGACCACAAACAGCCATCAAGGTACTGAGGACAGTACAGATTAGT
	GTGCACAGAGATCTCTGTAGAAAGAGTAGCTGCCCTTTCTCAGGGCAGATGATGCTTT
	GAGAACATACTTTGGCCATTACCC
	ORF Start: ATG at 40		ORF Stop: TAG at 1099
	SEQ ID NO:332	353 aa	MW at 404492.9 kD
NOV38a,	MRAAPLLLARAASLSLGFLFLLFFWLDRSVLAKELKFVTLVFRHGDRSPIDTFPTDPI
CG158513-01
Protein Sequence	KESSWPQGFGQLTQLGMEQHYELGEYIRKRYRKFLNESYKHEQVYIRSTDVDRTLMSA
	MTNLAALFPPEGVSIWNPILLWQPIPVHTVPLSEDQDFIATLGKLSGLHGQDLFGIWS
	KVYDPLYCESVHNFTLPSWATEDTMTKLRELSELSLLSLYGIHKQKEKSRLQGGVLVN
	EILNHMKRATQIPSYKKLIMYSAHDTTVSCLQMALDVYNGLLPPYASCHLTELYFEKG
	EYFVEMYYRNETQHEPYPLMLPGCSPSCPLERFAELVGPVIPQDWSTECMTTNSHQGT
	EDSTD
	SEQ ID NO:333	1184 bp
NOV38b,	AGTTCCTCCTAACTCCTGCCAGAAACAGCTCTCCTCAACATGAGAGCTGCACCCCTCC
CG158513-02
DNA Sequence	TCCTGGCCAGGGCAGCAAGCCTTAGCCTTGGCTTCTTGTTTCTGCTTTTTTTCTGGCT
	AGACCGAAGTGTACTAGCCAAGGAGTTGAAGTTTGTGACTTTGGTGTTTCGGCATGGA
	GACCGAAGTCCCATTGACACCTTTCCCACTGACCCCATAAAGGAATCCTCATGGCCAC
	AAGGATTTCGCCAACTCACCCAGCTGGGCATGGAGCAGCATTATGAACTTGGAGAGTA
	TATAAGAAAGAGATATAGAAAATTCTTGAATGAGTCCTATAAACATGAACAGGTTTAT
	ATTCGAAGCACAGACGTTGACCGGACTTTGATGAGTGCTATGACAAACCTGGCAGCCC
	TGTTTCCCCCAGAAGGTGTCAGCATCTGGAATCCTATCCTACTCTGGCAGCCCATCCC
	GGTGCACACAGTTCCTCTTTCTGAAGATCAGGATTTTATAGCTACCTTGGGAAAACTT
	TCAGGATTACATGGCCAGGACCTTTTTGGAATTTGGAGTAAAGTCTACGACCCTTTAT
	ATTGTGAGAGTGTTCACAATTTCACTTTACCCTCCTGGGCCACTGAGGACACCATGAC
	TAAGTTGAGAGAATTGTCAGAATTGTCCCTCCTGTCCCTCTATGGAATTCACAAGCAG
	AAAGAGAAATCTAGGCTCCAAGGGGGTGTCCTGGTCAATGAAATCCTCAATCACATGA
	AGAGAGCAACTCAGATACCAAGCTACAAAAAACTTATCATGTATTCTGCGCATGACAC
	TACTGTGAGTGGTCTACAGATGGCGCTAGATGTTTACAACGGACTCCTTCCTCCCTAT
	GCTTCTTGCCACTTGACGGAATTGTACTTTGAGAAGGGGGAGTACTTTGTGGAGATGT
	ACTACCGGAATGAGACGCAGCACGAGCCGTATCCCCTCATGCTACCTGGCTGCAGCCC
	CAGCTGTCCTCTGGAGAGGTTTGCTGAGCTGGTTGGCCCTGTGATCCCTCAAGACTGG
	TCCACGGAGTGTATGACCACAAACAGCCATCAAGGTACTGAGGACAGTACAGATTAGT
	GTGCACAGAGATCTCTGTAGAAAGAGTAGCTGCCCTTTCTCAGGGCAGATGATGCTTT
	GAGAACATACTTTGGCCATTACCC
	ORF Start: ATG at 40		ORF Stop: TAG at 1099
	SEQ ID NO:334	353 aa	MW at 40442.9 kD
NOV38b,	MRAAPLLLARAASLSLGFLFLLFFWLDRSVLAKELKFVTLVFRHGDRSPIDTFPTDPI
CG158513-02
Protein Sequence	KESSWPQGFGQLTQLGMEQHYELGEYIRKRYRKFLNESYKHEQVYIRSTDVDRTLMSA
	MTNLAALFPPEGVSIWNPILLWQPIPVHTVPLSEDQDFIATLGKLSGLHGQDLFGIWS
	KVYDPLYCESVHNFTLPSWATEDTMTKLRELSELSLLSLYGIHKQKEKSRLQGGVLVN
	EILNHMKRATQIPSYKKLIMYSAHDTTVSGLQMALDVYNGLLPPYASCHLTELYFEKG
	EYFVEMYYRNETQHEPYPLMLPGCSPSCPLERFAELVGPVIPQDWSTECMTTNSHQGT
	EDSTD

[0558] Sequence comparison of the above protein sequences yields the following sequence relationships shown in Table 38B.

TABLE 38B
Comparison of NOV38a against NOV38b.
			Identities/
			Similarities for
	Protein	NOV38a Residues/	the Matched
	Sequence	Match Residues	Region
	NOV38b	1 . . . 353	353/353 (100%)
		1 . . . 353	353/353 (100%)

[0559] Further analysis of the NOV38a protein yielded the following properties shown in Table 38C.

TABLE 38C
Protein Sequence Properties NOV38a
PSort     0.4600 probability located in plasma membrane; 0.2083
analysis: probability located in microbody (peroxisome); 0.1000
          probability located in endoplasmic reticulum (membrane);
          0.1000 probability located in endoplasmic reticulum (lumen)
SignalP   Cleavage site between residues 33 and 34
analysis:

[0560] A search of the NOV38a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 38D.

TABLE 38D
Geneseq Results for NOV38a
			Identities/
			Similarities for
Geneseq	Protein/Organism/Length	NOV38a Residues/	the Matched	Expect
Identifier	[Patent #, Date]	Match Residues	Region	Value
AAB74820	Prostate tumour antigen amino acid	1 . . . 353	353/386 (91%)	0.0
	sequence for PAP - Homo sapiens,	1 . . . 386	353/386 (91%)
	386 aa. [WO200125272-A2, 12
	APR. 2001]
AAG62145	Human prostatic acid phosphatase	1 . . . 353	353/386 (91%)	0.0
	SEQ ID NO: 328 - Homo sapiens,	1 . . . 386	353/386 (91%)
	386 aa. [WO200125273-A2, 12
	APR. 2001]
AAU02172	Biomarker UC band 47 (PAP), used	1 . . . 353	353/386 (91%)	0.0
	in diagnosis and prognosis of	1 . . . 386	353/386 (91%)
	cancer - Homo sapiens, 386 aa.
	[US6218529-B1, 17 APR. 2001]
AAU06277	Prostatic Acid Phosphatase (PAP)	1 . . . 353	353/386 (91%)	0.0
	polypeptide - Homo sapiens, 386 aa.	1 . . . 386	353/386 (91%)
	[WO200145728-A2, 28 JUN. 2001]
AAY59293	Prostatic acid phosphatase marker	1 . . . 353	353/386 (91%)	0.0
	UC Band #47 amino acid sequence -	1 . . . 386	353/386 (91%)
	Homo sapiens, 386 aa.
	[WO9964631-A1, 16 DEC. 1999]

[0561] In a BLAST search of public sequence datbases, the NOV38a protein was found to have homology to the proteins shown in the BLASTP data in Table 38E.

TABLE 38E
Public BLASTP Results for NOV38a
			Identities/
Protein			Similarities for
Accession		NOV38a Residues/	the Matched	Expect
Number	Protein/Organism/Length	Match Residues	Portion	Value
P15309	Prostatic acid phosphatase	1 . . . 353	353/386 (91%)	0.0
	precursor (EC 3.1.3.2) - Homo	1 . . . 386	353/386 (91%)
	sapiens (Human), 386 aa.
Q96KY0	Acid phosphatase, prostate -	1 . . . 353	352/386 (91%)	0.0
	Homo sapiens (Human), 386 aa.	1 . . . 386	353/386 (91%)
Q96QK9	Acid phosphatase, prostate -	1 . . . 353	350/386 (90%)	0.0
	Homo sapiens (Human), 386 aa.	1 . . . 386	351/386 (90%)
Q96QM0	Acid phosphatase, prostate -	1 . . . 346	345/379 (91%)	0.0
	Homo sapiens (Human), 418 aa.	1 . . . 379	345/379 (91%)
Q9QXH7	Prostatic acid phosphatase -	1 . . . 347	281/380 (73%)	e−162
	Mus musculus (Mouse), 381 aa.	1 . . . 379	307/380 (79%)

[0562] PFam analysis predicts that the NOV38a protein contains the domains shown in the Table 38F.

TABLE 38F
Domain Analysis of NOV38a
		Identities/
		Similarities for
Pfam	NOV38a	the Matched	Expect
Domain	Match Region	Region	Value
Acid_phosphat	33 . . . 340	128/436 (29%)	2.7e−126
		300/436 (69%)

Example 39

[0563] The NOV39 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 39A.

TABLE 39A
NOV39 Sequence Analysis
	SEQ ID NO:335	1967 bp
NOV39a,	GGAGCCATGGCCCTGAGCGAGCTGGCGCTGGTCCGCTGGCTGCAGGAGAGCCGCCGCT
CG158583-01
DNA Sequence	CGCGGAAGCTCATCCTGTTCATCGTGTTCCTGGCGCTGCTGCTGGACAACATGCTGCT
	CACTGTCGTGGTAGAGAGAGGGTTTCTCCATGTTGGCCAGCCTGGTCTCGAACTCCTG
	ACCTCAGGTGATCCACCTGCCTCAGCTTCCCAAAGTCCTGGAATTACAGTCCCCATCA
	TCCCAAGTTATCTGTACAGCATTAAGCATGAGAAGAATGCTACAGAAATCCAGACGGC
	CAGGCCAGTGCACACTGCCTCCATCTCAGACAGCTTCCAGAGCATCTTCTCCTATTAT
	GATAACTCGACTATGGTCACCGGGAATGCTACCAGAGACCTGACACTTCATCAGACCG
	CCACACAGCACATGGTGACCAACGCGTCCGCTGTTCCTTCCGACTGTCCCAGTGAAGA
	CAAAGACCTCCTGAATGAAAACGTGCAAGTTGGTCTGTTGTTTGCCTCGAAAGCCACC
	GTCCAGCTCATCACCAACCCTTTCATAGGACTACTGACCAACAGAATTGGCTATCCAA
	TTCCCATATTTGCGGGATTCTGCATCATGTTTGTCTCAACAATTATGTTTGCCTTCTC
	CAGCAGCTATGCCTTCCTGCTGATTGCCAGGTCGCTGCAGGGCATCGGCTCGTCCTGC
	TCCTCTGTGGCTGGGATGGGCATGCTTGCCAGTGTCTACACAGATGATGAAGAGAGAG
	GCAACGTCATGGGAATCGCCTTGGGAGGCCTGGCCATGGGGGTCTTAGTGGCCCCCCC
	CTTCGGGAGTGTGCTCTATGAGTTTGTGGGGAAGACGGCTCCGTTCCTGGTGCTGGCC
	GCCCTCGTACTCTTGGATGGAGCTATTCAGCTCTTTGTGCTCCAGCCGTCCCGGGTGC
	AGCCAGAGAGTCAGAAGGGGACACCCCTAACCACGCTGCTGAAGGACCCGTACATCCT
	CATTGCTGCAGGCTCCATCTGCTTTGCAAACATGGGCATCGCCATGCTGGAGCCAGCC
	CTGCCCATCTCGATCATGGAGACCATGTGTTCCCGAAAGTGGCAGCTGGGCGTTGCCT
	TCTTGCCAGCTAGTATCTCTTATCTCATTGGAACCAATATTTTTGGGATACTTGCACA
	CAAAATGGGGAGGTGGCTTTGTGCTCTTCTGGGAATGATAATTGTTGGAGTCAGCATT
	TTATGTATTCCATTTGCAAAAAACATTTATGGACTCATAGCTCCGAACTTTGGAGTTG
	GTTTTGCAATTGGAATGGTGGATTCGTCAATGATGCCTATCATGGGCTACCTCGTAGA
	CCTGCGGCACGTGTCCGTCTATGGGAGTGTGTACGCCATTGCGGATGTGGCATTTTGT
	ATGGGGTATGCTATAGGTCCTTCTGCTGGTGGTGCTATTGCAAAGGCAATTGGATTTC
	CATGGCTCATGACAATTATTGGGATAATTGATATTCTTTTTGCCCCTCTCTGCTTTTT
	TCTTCGAAGTCCACCTGCCAAAGAAGAAAAAATGGCTATTCTCATGGATCACAACTGC
	CCTATTAAAACAAAAATGTACACTCAGAATAATATCCAGTCATATCCGATAGGTGAAG
	ATGAAGAATCTGAAAGTGACTGAGATGAGATCCTCAAAATCATCAAAGTGTTTAATT
	GTATAAAACAGTGTTTCCAGTGACACAACTCATCCAGAACTGTCTTAGTCATACCATC
	CATCCCTGGTGAAAGAGTAAAACCAAAGGTTATTATTTCCTTTCCATGGTTATGGTCG
	ATTGCCAACAGCCTTATAAACAAAAAGAAGCTTTTCTAGGGGTTTGTATAAATAGTGT
	TGAAACTTTATTTTATGTATTTAATTTTATTAAATATCATACAATATATTTTGATGAA
	ATAGGTATTGTGTAAATCTATAAATATTTGAATCCAAACCAAATATAATTTCC
	ORF Start: ATG at 7		ORF Stop: TGA at 1645
	SEQ ID NO:336	546 aa	MW at 58912.5 kD
NOV39a,	MALSELALVRWLQESRRSRKLILFIVFLALLLDNMLLTVVVERGFLHVGQPGLELLTS
CG158583-01
Protein Sequence	GDPPASASQSPGITVPIIPSYLYSIKHEKNATEIQTARPVHTASISDSFQSIFSYYDN
	STMVTGNATRDLTLHQTATQHMVTNASAVPSDCPSEDKDLLNENVQVGLLFASKATVQ
	LITNPFIGLLTNRIGYPIPIFAGFCIMFVSTIMFAFSSSYAFLLIARSLQGIGSSCSS
	VAGMGMLASVYTDDEERGNVMGIALGGLAMGVLVGPPFGSVLYEFVGKTAPFLVLAAL
	VLLDGAIQLFVLQPSRVQPESQKGTPLTTLLKDPYILIAAGSICFANMGIAMLEPALP
	IWMMETMCSRKWQLGVAFLPASISYLIGTNIFGILAHKMGRWLCALLGMIIVGVSILC
	IPFAKNIYGLIAPNFGVGFAIGMVDSSMMPIMGYLVDLRHVSVYGSVYAIADVAFCMG
	YAIGPSAGGAIAKAIGFPWLMTIIGIIDILFAPLCFFLRSPPAKEEKMAILMDHNCPI
	KTKMYTQNNIQSYPIGEDEESESD
	SEQ ID NO:337	1952 bp
NOV39b,	GCAGGCATCGCAAGCGACCCCGAGCGGAGCCCCGGAGCCATGGCCCTGAGCGAGCTGG
CG158583-02
DNA Sequence	CGCTGGTCCGCTGGCTGCAGGAGAGCCGCCGCTCGCGGAAGCTCATCCTGTTCATCGT
	GTTCCTGGCGCTGCTGCTGGACAACATGCTGCTCACTGTCGTGGGTTCAAGCGATCCT
	CCTTTCTCAGCCTCCAAAGGACCTGGGATTACAGTCCCCATCATCCCAAGTTATCTGT
	ACAGCATTAAGCATGAGAAGAATGCTACAGAAATCCAGACGGCCAGGCCAGTGCACAC
	TGCCTCCATCTCAGACAGCTTCCAGAGCATCTTCTCCTATTATGATAACTCGACTATG
	GTCACCGGGAATGCTACCAGAGACCTGACACTTCATCAGACCGCCACACAGCACATGG
	TGACCAACGCGTCCGCTGTTCCTTCCGACTGTCCCAGTGAAGACAAAGACCTCCTGAA
	TGAAAACGTGCAAGTTGGTCTGTTGTTTGCCTCGAAAGCCACCGTCCAGCTCATCACC
	AACCCTTTCATAGGACTACTGACCAACAGAATTGGCTATCCAATTCCCATATTTGCGG
	GATTCTGCATACATGTTGTCTCAACAATTATGTTTGCCTTCTCCAGCAGCTATGCCTT
	CCTGCTGATTGCCAGGTCGCTGCAGGCCATCGGCTCGTCCTGCTCCTCTGTGGCTGGG
	ATGGGCATGCTTGCCAGTGTCTACACAGATGATGAAGAGAGAGGCAACGTCATGGGAA
	TCGCCTTGGGAGGCCTGGCCATGGGGGTCTTAGTGGGCCCCCCCTTCGGGAGTGTGCT
	CTATGAGTTTGTGGGGAAGACGGCTCCGTTCCTGGTGCTGGCCGCCCTGGTACTCTTG
	GATGGAGCTATTCAGCTCTTTGTGCTCCAGCCGTCCCGGGTGCAGCCAGAGAGTCAGA
	AGGGGACACCCCTAACCACGCTGCTGAAGGACCCGTACATCCTCATTGCTGCAGGCTC
	CATCTGCTTTGCAAACATGGGCATCGCCATGCTGGAGCCACCCCTGCCCATCTGGATG
	ATGGAGACCATGTGTTCCCGAAAGTGGCAGCTGGGCGTTGCCTTCTTGCCAGCTAGTA
	TCTCTTATCTCATTGGAACCAATATTTTTGGGATACTTGCACACAAAATGGGGAGGTG
	GCTTTGTGCTCTTCTGGGAATGATAATTGTTGGAGTCAGCATTTTATGTATTCCATTT
	GCAAAAAACATTTATGGACTCATAGCTCCGAACTTTGGAGTTGGTTTTGCAATTGGAA
	TGGTGGATTCGTCAATGATGCCTATCATGGGCTACCTCGTAGACCTGCGGCACGTGTC
	CGTCTATGGGAGTGTGTACGCCATTGCGGATGTGGCATTTTGTATGGGGTATGCTATA
	GGTCCTTCTGCTGGTGGTGCTATTGCAAAGGCAATTGGATTTCCATGGCTCATGACAA
	TTATTGGGATAATTGATATTCTTTTTCCCCCTCTCTGCTTTTTTCTTCGAAGTCCACC
	TGCCAAAGAAGAAAAAATGGCTATTCTCATGGATCACAACTGCCCTATTAAAACAAAA
	ATGTACACTCAGAATAATATCCAGTCATATCCGATAGGTGAAGATGAAGAATCTGAAA
	GTGACTGAGATGAGATCCTCAAAAATCATCAAAGTGTTTAATTGTATAAAACAGTGTT
	TCCAGTGACACAACTCATCCAGAACTGTCTTAGTCATACCATCCATCCCTGGTGAAAG
	AGTAAAACCAAAGGTTATTATTTCCTTTCCATGGTTATGGTCGATTGCCAACAGCCTT
	ATAAAGAAAAAGAAGCTTTTCTAGGGGTTTGTATAAATAGTGTTGAAACTTTATTTTA
	TGTATTTAATTTTATTAAATATCATACAATATATTTTGATGAAATAGGTATTGTGTAA
	ATCTATAAATATTTGAATCCAAACCAAATATAATTTCC
	ORF Start: ATG at 40		ORF Stop: TGA at 1630
	SEQ ID NO:338	530 aa	MW at 57130.4 kD
NOV39b,	MALSELALVRWLQESRRSRKLILFIVFLALLLDNMLLTVVGSSDPPFSASKGAGITVP
CG158583-02
Protein Sequence	IIPSYLYSIKHEKNATEIQTARPVHTASISDSFQSIFSYYDNSTMVTGNATRDLTLHQ
	TATQHMVTNASAVPSDCPSEDKDLLNENVQVGLLFASKATVQLITNPFIGLLTNRIGY
	PIPIFAGFCIHVVSTIMFAFSSSYAFLLIARSLQGIGSSCSSVAGMGMLASVYTDDEE
	RGNVMGIALGGLAMGVLVGPPFGSVLYEFVGKTAPFLVLAALVLLDGAIQLFVLQPSR
	VQPESQKGTPLTTLLKDPYILIAAGSICFANMGIAMLEPALPIWMMETMCSRKWQLGV
	AFLPASISYLIGTNIFGILAHKMGRWLCALLGMIIVGVSILCIPFAKNIYGLIAPNFG
	VGFAIGMVDSSMMPIMGYLVDLRHVSVYGSVYAIADVAFCMGYAIGPSAGGAIAKAIG
	FPWLMTIIGIIDILFAPLCFFLRSPPAKEEKMAILMDHNCPIKTKMYTQNNIQSYPIG
	EDEESESD
	SEQ ID NO:339	1647 bp
NOV39c,	GGAGCCATGGCCCTGAGCGAGCTGGCGCTGGTCCGCTGGCTGCAGGACAGCCGCCGCT
CG158583-04
DNA Sequence	CGCGGAAGCTCATCCTGTTCATCGTGTTCCTGGCGCTGCTGCTGGACAACATGCTGCT
	CACTGTCGTGGTAGAGAGAGGGTTTCTCCATGTTGGCCAGCCTGGTCTCGAACTCCTG
	ACCTCAGGTGATCCACCTGCCTCAGCTTCCCAAAGTCCTGGAATTACAGTCCCCATCA
	TCCCAAGTTATCTGTACAGCATTAAGCATGAGAAGAATGCTACAGAAATCCAGACGGC
	CAGGCCAGTGCACACTGCCTCCATCTCAGACAGCTTCCAGAGCATCTTCTCCTATTAT
	GATAACTCGACTATGGTCACCGGGAATGCTACCAGAGACCTGACACTTCATCAGACCG
	CCACACAGCACATGGTGACCAACGCGTCCGCTGTTCCTTCCGACTGTCCCAGTGAAGA
	CAAAGACCTCCTGAATGAAAACGTGCAAGTTGGTCTGTTGTTTGCCTCGAAAGCCACC
	GTCCAGCTCATCACCAACCCTTTCATAGGACTACTGACCAACAGAATTGCCTATCCAA
	TTCCCATATTTGCGGGATTCTGCATCATGTTTGTCTCAACAATTATGTTTGCCTTCTC
	CAGCAGCTATGCCTTCCTGCTGATTGCCAGGTCGCTGCAGGGCATCGGCTCGTCCTGC
	TCCTCTGTGGCTGGGATGGGCATGCTTGCCAGTGTCTACACAGATGATGAAGAGAGAG
	GCAACGTCATGGGAATCGCCTTGGGAGGCCTGGCCATGGGGGTCTTAGTGGGCCCCCC
	CTTCGGGAGTGTGCTCTATGAGTTTGTGGGGAAGACGGCTCCGTTCCTGGTGCTGGCC
	GCCCTGGTACTCTTGGATGGAGCTATTCAGCTCTTTGTGCTCCAGCCGTCCCGGGTGC
	AGCCAGAGAGTCAGAAGGGGACACCCCTAACCACGCTGCTGAAGGACCCGTACATCCT
	CATTCCTGCAGGCTCCATCTGCTTTGCAAACATGGGCATCGCCATGCTGGAGCCAGCC
	CTGCCCATCTGGATGATCGAGACCATGTGTTCCCGAAAGTGGCAGCTGGGCGTTGCCT
	TCTTGCCAGCTAGTATCTCTTATCTCATTGGAACCAATATTTTTGGGATACTTGCACA
	CAAAATGGGGAGGTGGCTTTGTGCTCTTCTGGGAATGATAATTGTTGGAGTCAGCACT
	TTATGTATTCCATTTGCAAAAAACATTTATGGACTCATACCTCCGAACTTTGGAGTTG
	GTTTTGCAATTGGAATGGTGGATTCGTCAATGATGCCTATCATGGGCTACCTCGTAGA
	CCTGCGGCACGTGTCCGTCTATGGGAGTGTGTACGCCATTGCGGATGTGGCATTTTGT
	ATGGGGTATGCTATAGGTCCTTCTGCTGGTGGTGCTATTGCAAAGGCAATTGGATTTC
	CATGGCTCATGACAATTATTGGGATAATTGATATTCTTTTTGCCCCTCTCTGCTTTTT
	TCTTCGAAGTCCACCTACCAAAGAAGAAAAAATGGCTATTCTCATGGATCACAACTGC
	CCTATTAAAACAAAAATGTACACTCAGAATAGTATCCAGTCATATCCGATAGGTGAAG
	ATGAAGAATCTGAAAGTGACTGA
	ORF Start: ATG at 7		ORF Stop: TGA at 1645
	SEQ ID NO:340	546 aa	MW at 58903.4 kD
NOV39c,	MALSELALVRWLQESRRSRKLILFIVFLALLLDNMLLTVVVERGFLHVGQPGLELLTS
CG158583-04
Protein Sequence	GDPPASASQSPGITVPIIPSYLYSIKHEKNATEIQTARPVHTASISDSPQSIFSYYDN
	STMVTGNATRDLTLHQTATQHMVTNASAVPSDCPSEDKDLLNENVQVGLLFASKATVQ
	LITNPFIGLLTNRIGYPIPIFAGFCIMFVSTIMFAFSSSYAFLLIARSLQGIGSSCSS
	VAGMGMLASVYTDDEERGNVMGIALGGLAMGVLVGPPFGSVLYEFVGKTAPFLVLAAL
	VLLDGAIQLFVLQPSRVQPESQKGTPLTTLLKDPYILIAAGSICFANMGIAMLEPALP
	IWMMETMCSRKWQLGVAFLPASISYLIGTNIFGILAHKMGRWLCALLGMITVGVSTLC
	IPFAKNIYGLIAPNFGVGFAIGMVDSSMMPIMGYLVDLRHVSVYGSVYAIADVAFCMG
	YAIGPSAGGAIAKAIGFPWLMTIIGIIDILFAPLCFFLRSPPTKEEKMAILMDHNCPI
	KTKMYTQNSIQSYPIGEDEESESD
	SEQ ID NO:341	1666 bp
NOV39d,	GCAGGCATCGCAAGCGACCCCGAGCGGAGCCCCGGAGCCATGGCCCTGAGCGACCTGG
CG158583-05
DNA Sequence	CGCTGGTCCGCTGGCTGCAGGAGAGCCGCCGCTCGCGGAAGCTCATCCTGTTCATCGT
	GTTCCTGGCGCTGCTGCTGGACAACATGCTGCTCACTGTCGTGGGTTCAAGCGATCCT
	CCTTTCTCAGCCTCCAAAGGAGCTGGGATTACAGTCCCCATCATCCCAAGTTATCTGT
	ACAGCATTAAGCATGAGAAGAATGCTACAGAAATCCAGACGGCCAGGCCAGTGCACAC
	TGCCTCCATCTCAGACAGCTTCCAGGGCATCTTCTCCTATTATGATAACTCGACTATG
	GTCACCGGGAATGCTACCAGAGACCTGACACTTCATCAGACCGCCACACAGCACATGG
	TGACCAACGCGTCCGCTGTTCCTTCCGACTGTCCCAGTGAAGACAAAGACCTCCTGAA
	TGAAAACGTGCAAGTTGGTCTGTTGTTTGCCTCGAAAGCCACCGTCCAGCTCATCACC
	AACCCTTTCATAGGACTACTGACCAACAGAATTGGCTATCCAATTCCCATATTTGCGG
	GATTCTGCATCATGTTTGTCTCAACAATTATGTTTGCCTTCTCCAGCAGCTATGCCTT
	CCTGCTGATTGCCAGGTCGCTGCAGGGCATCGGCTCGTCCTGCTCCTCTGTGGCTGGG
	ATGGGCATGCTTGCCAGTGTCTACACAGATGATGAAGAGAGAGGCAACGTCATGGGAA
	TCGCCTTGGGAGGCCTGGCCATGGGGGTCTTAGTGGGCCCCCCCTTCGGGAGTGTGCT
	CTATGAGTTTGTGGGGAAGACGGCTCCGTTCCTGGTGCTGGCTGCCCTGGTACTCTTG
	GATGGAGCTATTCAGCTCTTTCTGCTCCAGCCGTCCCGGGTGCAGCCAGAGAGTCAGA
	AGGGGACACCCCTAACCACGCTGCTGAAGGACCCGTACATCCTCATTGCTGCAGGCTC
	CATCTGCTTTGCAAACATGGGCATCGCCATGCTGCAGCCAGCCCTGCCCATCTGGATG
	ATGGAGACCATGTGTTCCCGAAAGTGGCAGCTGGGCGTTGCCTTCTTGCCAGCTAGTA
	TCTCTTATCTCATTGGAACCAATATTTTTGGGATACTTGCACACAAAATGGGGAGGTG
	GCTTTGTGCTCTTCTGGGAATGATAATTGTTGGAGTCAGCATTTTATGTATTCCATTT
	GCAAAAAACATTTATGGACTCATAGCTCCGAACTTTGGAGTTGGTTTTGCAATTGGAA
	TGGTGGATTCGTCAATGATGCCTATCATGGGCTACCTCGTAGACCTGCGGCACGTGTC
	CGTCTATGGGAGTGTGTACGCCATTGCGGATGTGGCATTTTGTATGGGGTATGCTATA
	GGTCCTTCTGCTGGTGGTGCTATTGCAAAGGCAATTGGATTTCCATGGCTCATGACAA
	TTATTGGGATAATTGATATTCTTTTTGCCCCTCTCTGCTTTTTTCTTCGAAGTCCACC
	TGCCAAAGAAGAAAAAATGGCTATTCTCATGGATCACAACTGCCCTATTAAAACAAAA
	ATGTACACTCAGAATAATATCCAGTCATATCCGATAGGTGAAGATGAAGAATCTGAAA
	GTGACTGAGATGAGATCCTCAAAAATCATCAAAGTGTAAGGG
	ORF Start: ATG at 40		ORF Stop: TGA at 1630
	SEQ ID NO:342	530 aa	MW at 57142.5 kD
NOV39d,	MALSELALVRWLQESRRSRKLILFIVFLALLLDNMLLTVVGSSDPPFSASKGAGITVP
CG158583-05
Protein Sequence	IIPSYLYSIKHEKNATEIQTARPVHTASISDSFQGIFSYYDNSTMVTGNATRDLTLHQ
	TATQHMVTNASAVPSDCPSEDKDLLNENVQVGLLFASKATVQLITNPFIGLLTNRIGY
	PIPIFAGFCIMFVSTIMFAFSSSYAFLLIARSLQGIGSSCSSVAGMGMLASVYTDDEE
	RGNVMGIALGGLAMGVLVGPPFGSVLYEFVGKTAPFLVLAALVLLDGAIQLFVLQPSR
	VQPESQKGTPLTTLLKDPYILIAAGSICFANMGIANLEPALPIWMMETMCSRKWQLGV
	AFLPASISYLIGTNTFGILAHKMGRWLCALLGMIIVGVSILCIPFAKNIYGLIAPNFG
	VGFAIGMVDSSMNPIMGYLVDLRHVSVYGSVYAIADVAFCMGYAIGPSAGGAIAKAIG
	FPWLMTIIGIIDILFAPLCFFLRSPPAKEEKMAILMDHNCPIKTKMYTQNNIQSYPIG
	EDEESESD
	SEQ ID NO:343	1618 bp
NOV39e,	GCAGGCATCGCAAGCGACCCCGAGCGGAGCCCCGGAGCCATGGCCCTGAGCGAGCTGG
CG158583.03
DNA Sequence	CGCTGGTCCGCTGGCTGCAGGAGAGCCGCCGCTCGCGGAAGCTCATCCTGTTCATCGT
	GTTCCTGGCGCTGCTGCTGGACAACATGCTGCTCACTGTCGTGGTCCCCATCATCCCA
	AGTTATCTGTACAGCATTAAGCATGAGAAGAATGCTACAGAAATCCAGACGGCCAGGC
	CAGTGCACACTGCCTCCATCTCAGACAGCTTCCAGAGCATCTTCTCCTATTATGATAA
	CTCGACTATGGTCACCGGGAATGCTACCAGAGACCTGACACTTCATCAGACCGCCACA
	CAGCACATGGTGACCAACGCGTCCGCTGTTCCTTCCGACTGTCCCAGTGAAGACAAAG
	ACCTCCTGAATGAAAACGTGCAAGTTGGTCTGTTGTTTGCCTCGAAAGCCACCGTCCA
	GCTCATCACCAACCCTTTCATAGGACTACTGACCAACAGAATTGGCTATCCAATTCCC
	ATATTTGCGGGATTCTGCATCATGTTTGTCTCAACAATTATGTTTGCCTTCTCCAGCA
	GCTATGCCTTCCTGCTGATTGCCAGGTCGCTGCAGGGCATCGGCTCGTCCTGCTCCTC
	TGTGGCTGGGATGGGCATGCTTGCCAGTGTCTACACAGATGATGAAGAGAGAGGCAAC
	GTCATGGGAATCGCCTTGGGAGGCCTGGCCATGGGGGTCTTAGTGGGCCCCCCCTTCG
	GGAGTGTGCTCTATGAGTTTGTGGGGAAGACGGCTCCGTTCCTGGTGCTGGCCGCCCT
	GGTACTCTTGGATGGAGCTATTCAGCTCTTTGTGCTCCAGCCGTCCCGGGTGCAGCCA
	GAGAGTCAGAAGGGGACACCCCTAACCACGCTGCTGAAGGACCCGTACATCCTCATTG
	CTGCAGGCTCCATCTGCTTTGCAAACATGGGCATCGCCATGCTGGAGCCAGCCCTGCC
	CATCTGGATGATGGAGACCATGTGTTCCCGAAAGTGGCAGCTGGGCGTTGCCTTCTTG
	CCAGCTAGTATCTCTTATCTCATTGGAACCAATATTTTTGGGATACTTGCACACAAAA
	TGGGGAGGTGGCTTTGTGCTCTTCTGGGAATGATAATTGTTGGAGTCAGCACTTTATG
	TATTCCATTTGCAAAAAACATTTATGGACTCATAGCTCCGAACTTTGGAGTTGGTTTT
	GCAATTGGAATGGTGGATTCGTCAATGATGCCTATCATGGGCTACCTCGTAGACCTGC
	GGCACGTGTCCGTCTATGGGAGTGTGTACGCCATTGCGGATGTGGCATTTTGTATGGG
	GTATGCTATAGGTCCTTCTGCTGGTGGTGCTATTGCAAAGGCAATTGGATTTCCATGG
	CTCATGACAATTATTGGGATAATTGATATTCTTTTTGCCCCTCTCTGCTTTTTTCTTC
	GAAGTCCACCTGCCAAAGAAGAAAAAATGGCTATTCTCATGGATCACAACTGCCCTAT
	TAAAACAAAAATGTACACTCAGAATAGTATCCAGTCATATCCGATAGGTGAAGATGAA
	GAATCTGAAAGTGACTGAGATGAGATCCTCAAAAATCATCAAAGTGTAAGGG
	ORF Start: ATG at 40		ORF Stop: TGA at 1582
	SEQ ID NO:344	514 aa	MW at 55672.9 kD
NOV39e,	MALSELALVRWLQESRRSRKLILFIVFLALLLDNMLLTVVVPIIPSYLYSIKHEKNAT
CG158583-03
Protein Sequence	EIQTARPVHTASISDSFQSIFSYYDNSTMVTGNATRDLTLHQTATQHMVTNASAVPSD
	CPSEDKDLLNENVQVGLLFASKATVQLITNPFIGLLTNRIGYPIPIFAGFCIMFVSTI
	MFAFSSSYAFLLIARSLQGIGSSCSSVAGMGMLASVYTDDEERGNVMGIALGGLAMGV
	LVGPPFGSVLYEFVGKTAPFLVLAALVLLDGAIQLFVLQPSRVQPESQKGTPLTTLLK
	DPYILIAAGSICFANMGIAMLEPALPIWMMETMCSRKWQLGVAFLPASISYLIGTNIF
	GILAHKMGRWLCALLGMIIVGVSTLCIPFAKNIYGLIAPNFGVGFAIGMVDSSMMPIM
	GYLVDLRHVSVYGSVYAIADVAFCMGYAIGPSAGGAIAKAIGFPWLMTIIGIIDILFA
	PLCFFLRSPPAKEEKMAILMDHNCPIKTKMYTQNSIQSYPIGEDEESESD

[0564] Sequence comparison of the above protein sequences yields the following sequence relationships shown in Table 39B.

TABLE 39B
Comparison of NOV39a against NOV39b through NOV39e.
			Identities/
			Similarities for
	Protein	NOV39a Residues/	the Matched
	Sequence	Match Residues	Region
	NOV39b	1 . . . 546	522/546 (95%)
		1 . . . 530	523/546 (95%)
	NOV39c	1 . . . 546	543/546 (99%)
		1 . . . 546	544/546 (99%)
	NOV39d	1 . . . 546	523/546 (95%)
		1 . . . 530	524/546 (95%)
	NOV39e	1 . . . 546	512/546 (93%)
		1 . . . 514	513/546 (93%)

[0565] Further analysis of the NOV39a protein yielded the following properties shown in Table 39C.

TABLE 39C
Protein Sequence Properties NOV39a
PSort     0.6400 probability located in plasma membrane; 0.4600
analysis: probability located in Golgi body; 0.3700 probability
          located in endoplasmic reticulum (membrane); 0.1000
          probability located in endoplasmic reticulum (lumen)
SignalP   Cleavage site between residues 38 and 39
analysis:

[0566] A search of the NOV39a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 39D.

TABLE 39D
Geneseq Results for NOV39a
			Identities/
			Similarities for
Geneseq	Protein/Organism/Length	NOV39a Residues/	the Matched	Expect
Identifier	[Patent #, Date]	Match Residues	Region	Value
ABB09288	Human solute carrier family 18	1 . . . 546	514/546 (94%)	0.0
	member 2 (SLC18A2) protein SEQ	1 . . . 514	514/546 (94%)
	ID NO: 3 - Homo sapiens, 514 aa.
	[WO200222652-A2, 21 MAR.
	2002]
AAW38286	Human synaptic vesicle amine	1 . . . 546	514/546 (94%)	0.0
	transporter protein - Homo sapiens,	1 . . . 514	514/546 (94%)
	514 aa. [US5688936-A, 18 NOV.
	1997]
AAR47342	Mammalian synaptic vesicle amine	1 . . . 546	514/546 (94%)	0.0
	transporter protein - Homo sapiens,	1 . . . 514	514/546 (94%)
	514 aa. [WO9325699-A, 23 DEC.
	1993]
AAW38285	Rat synaptic vesicle amine	1 . . . 546	470/551 (85%)	0.0
	transporter protein - Rattus rattus,	1 . . . 515	490/551 (88%)
	515 aa. [US5688936-A, 18 NOV.
	1997]
AAR47335	Mammalian synaptic vesicle amine	1 . . . 546	470/551 (85%)	0.0
	transporter protein - Rattus rattus,	1 . . . 515	490/551 (88%)
	515 aa. [WO9325699-A, 23 DEC.
	1993]

[0567] In a BLAST search of public sequence datbases, the NOV39a protein was found to have homology to the proteins shown in the BLASTP data in Table 39E.

TABLE 39E
Public BLASTP Results for NOV39a
			Identities/
Protein			Similarities for
Accession		NOV39a Residues/	the Matched	Expect
Number	Protein/Organism/Length	Match Residues	Portion	Value
Q05940	Synaptic vesicle amine transporter	1 . . . 546	514/546 (94%)	0.0
	(Monoamine transporter) (Vesicular	1 . . . 514	514/546 (94%)
	amine transporter 2) (VAT2) - Homo
	sapiens (Human), 514 aa.
Q9H3P6	Synaptic vesicle monoamine	4 . . . 546	511/543 (94%)	0.0
	transporter - Homo sapiens	12 . . . 522	511/543 (94%)
	(Human), 522 aa.
S29810	monoamine transport protein -	1 . . . 546	510/546 (93%)	0.0
	human, 514 aa.	1 . . . 514	510/546 (93%)
Q27963	Synaptic vesicle amine transporter	1 . . . 546	471/549 (85%)	0.0
	(Monoamine transporter) (Vesicular	1 . . . 517	492/549 (88%)
	amine transporter 2) (VAT2) - Bos
	taurus (Bovine), 517 aa.
A46374	resernine-sensitive vesicular	1 . . . 546	472/551 (85%)	0.0
	monoamine transporter - rat, 515 aa.	1 . . . 515	492/551 (88%)

[0568] PFam analysis predicts that the NOV39a protein contains the domains shown in the Table 39F.

TABLE 39F
Domain Analysis of NOV39a
			Identities/
			Similarities for
	Pfam	NOV39a	the Matched	Expect
	Domain	Match Region	Region	Value
	sugar_tr	98 . . . 516	66/523 (13%)	0.019
			268/523 (51%)

Example 40

[0569] The NOV40 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 40A.

TABLE 40A
NOV40 Sequence Analysis
                 SEQ ID NO: 345             1096 bp
NOV40a, GCAACCGGGGCAGGCCGTGCCGGCTGAGGAGGTCCTGAGGCTACAGAGCTGCCGCGGC
CG158964-01
DNA Sequence     TGGCACACGAGCGCCTCGGCACTAACCGAGTGTTCGCCGGGGCTGTGAGGGGAGGGCC
                 CCGGGCGCCATTGCTGGCGGTGGGAGCGCCGCCCCGTCTCAGCCCGCCCTCGGCTGCT
                 CTCCTCCTCCGGCTGGGAGGGGCCGTAGCTCGGGGCCGTCGCCAGCCCCGGCCCGGGC
                 TCGAGAATCAAGGGCCTCGGCCGCCGTCCCGCAGCTCAGTCCATCGCCCTTGCCGGGC
                 AGCCCGGGCAGAGACCATGTTTGACAAGACGCGGCTGCCGTACGTGGCCCTCGATGTG
                 CTCTGCGTGTTGCTGGATTATTCTTGGAGAAACCCTGTCTGTTTACTGTAACCTTTTG
                 CACTCAAATTCCTTTATCAGGAATAACTACATAGCCACTATTTACAAAGCCATTGGAA
                 CCTTTTTATTTGGTGCAGCTGCTAGTCAGTCCCTGACTGACATTGCCAAGTATTCAAT
                 AGGCAGACTGCGGCCTCACTTCTTGGATGTTTGTGATCCAGATTGGTCAAAAATCAAC
                 TGCAGCGATGGTTACATTGAATACTACATATGTCGAGGGAATGCAGAAAGAGTTAAGG
                 AAGGCAGGTTGTCCTTCTATTCAGGCCACTCTTCGTTTTCCATGTACTGCATGCTGTT
                 TGTGGCACTTTATCTTCAAGCCAGGATGAAGGGAGACTGGGCAAGACTCTTACGCCCC
                 ACACTGCAATTTGGTCTTGTTGCCGTATCCATTTATGTGGGCCTTTCTCGAGTTTCTG
                 ATTATAAACACCACTGGAGCGATGTGTTGACTGGACTCATTCAGGGAGCTCTGGTTGC
                 AATATTAGTTGCTGTATATGTATCGGATTTCTTCAAAGAAAGAACTTCTTTTAAAGAA
                 AGAAAAGAGGAGGACTCTCATACAACTCTGCATGAAACACCAACAACTGGGAATCACT
                 ATCCGAGCAATCACCAGCCTTGAAAGGCAGCAGGGTGCCCAGGTGAAGCTGGCCTGTT
                 TTCTAAAGGAAAATGATTGCCACAAGGCAAGAGGATGCATCTTTCTTCCTGG
                 ORF Start: ATG at 344                ORF Stop: TGA at 1007
                 SEQ ID NO: 346            221 aa     MW at 25083.4kD
NOV40a,          MCSACCWIILGETLSVYCNLLHSNSFIRNNYIATIYKAIGTFLFGAAASQSLTDIAKY
CG158964-01
Protein Sequence SIGRLRPHFLDVCDPDWSKINCSDGYIEYYICRGNAERVKEGRLSFYSGHSSFSMYCM
                 LFVALYLQARMKGDWARLLRPTLQFGLVAVSIYVGLSRVSDYKHHWSDVLTGLIQGAL
                 VAILVAVYVSDFFKERTSFKERKEEDSHTTLHETPTTGNHYPSNHQP
                 SEQ ID NO: 347           1388 bp
NOV40b,          CGGCCGCGTCGACGCAACCGGGGCAGGCCGTGCCGGCTGAGGAGGTCCTGAGGCTACA
CG158964-02
DNA Sequence     GAGCTGCCGCGGCTGGCACACGAGCGCCTCGGCACTAACCGAGTGTTCGCGGGGGCTG
                 TGAGGGGAGGGCCCCGGGCGCCATTGCTGGCGGTGGGAGCGCCGCCCGGTCTCAGCCC
                 GCCCTCGGCTGCTCTCCTCCTCCGGCTGGGAGGGGCCGTAGCTCGGGGCCGTCGCCAG
                 CCCCGGCCCGGGCTCGAGAATCAAGGGCCTCGGCCGCCGTCCCGCAGCTCAGTCCATC
                 GCCCTTGCCGGGCAGCCCGGGCAGAGACCATGTTTGACAAGACGCGGCTGCCGTACGT
                 GGCCCTCGATGTGCTCTGCGTGTTGCTGGATTATTCTTGGAGAAACCCTGTCTGTTTA
                 CTGTAACCTTTTGCACTCAAATTCCTTTATCAGGAATAACTACATAGCCACTATTTAC
                 AAAGCCATTGGAACCTTTTTATTTGGTGCAGCTGCTAGTCAGTCCCTGACTGACATTG
                 CCAAGTATTCAATAGGCAGACTCCGGCCTCACTTCTTGGATGTTTGTGATCCAGATTG
                 GTCAAAAATCAACTGCAGCGATGGTTACATTGAATACTACATATGTCGAGGGAATGCA
                 GAAAGAGTTAAGGAAGGCAGGTTGTCCTTCTATTCAGGCCACTCTTCGTTTTCCATGT
                 ACTGCATGCTGTTTGTGGCACTTTATCTTCAAGCCAGGATGAAGGGAGACTGGGCAAG
                 ACTCTTACGCCCCACACTGCAATTTGGTCTTGTTGCCGTATCCATTTATGTGGGCCTT
                 TCTCGAGTTTCTGATTATAAACACCACTGGAGCGATGTGTTGACTGGACTCATTCAGG
                 GAGCTCTGGTTGCAATATTAGTTGCTGTATATGTATCGGATTTCTTCAAAGAAAGAAC
                 TTCTTTTAAAGAAAGAAAAGAGGAGGACTCTCATACAACTCTGCATGAAACACCAACA
                 ACTGGGAATCACTATCCGAGCAATCACCAGCCTTGAAAGGCAGCAGGGTGCCCAGGTG
                 AAGCTGGCCTGTTTTCTAAAGGAAAATGATTGCCACAAGGCAAGAGGATGCATCTTTC
                 TTCCTGGTGTACAAGCCTTTAAAGACTTCTGCTGCTGCTATGCCTCTTGGATGCACAC
                 TTTGTGTGTACATAGTTACCTTTAACTCAGTGGTTATCTAATAGCTCTAAACTCATTA
                 AAAAAACTCCAAGCCTTCCACCAAAACAGTGCCCCACCTGTATACATTTTTATTAAAA
                 AAATGTAATGCTTATGTATAAACATGTATGTAATATGCTTTCTATGAATGATGTTTGA
                 TTTAAATATAATACATATTAAAATGTATGGGAGAACCAAAAAAAAAAAAAAAAA
                 ORF Start: ATG at 357                ORR Stop: TGA at 1020
                 SEQ ID NO: 348            221 aa     MW at 25083.4kD
NOV40b,          MCSACCWIILGETLSVYCNLLHSNSFIRNNYIATIYKAIGTFLFGAAASQSLTDIAKY
CG158964-02
Protein Sequence SIGRLRPHFLDVCDPDWSKTNCSDGYIEYYICRGNAERVKEGRLSFYSGHSSFSMYCM
                 LFVALYLQARMKGDWARLLRPTLQFGLVAVSIYVGLSRVSDYKHHWSDVLTGLIQGAL
                 VATLVAVYVSDFFKERTSFKERKEEDSHTTLHETPTTGNNYPSNHQP

[0570] Sequence comparison of the above protein sequences yields the following sequence relationships shown in Table 40B.

TABLE 40B
Comparison of NOV40a against NOV40b.
			Identities/
			Similarities for
	Protein	NOV40a Residues/	the Matched
	Sequence	Match Residues	Region
	NOV40b	1 . . . 221	221/221 (100%)
		1 . . . 221	221/221 (100%)

[0571] Further analysis of the NOV40a protein yielded the following properties shown in Table 40C.

TABLE 40C
Protein Sequence Properties NOV40a
PSort     0.6400 probability located in endoplasmic reticulum
analysis: (membrane); 0.4960 probability located in plasma
          membrane; 0.3776 probability located in microbody
          (peroxisome); 0.1900 probability located in Golgi body
SignalP   Cleavage site between residues 49 and 50
analysis:

[0572] A search of the NOV40a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 40D.

TABLE 40D
Geneseq Results for NOV40a
			Identities/
			Similarities for
Geneseq	Protein/Organism/Length	NOV40a Residues/	the Matched	Expect
Identifier	[Patent #, Date]	Match Residues	Region	Value
AAY24916	Human phosphatase HPA-1 -	8 . . . 221	214/214 (100%)	e−125
	Homo sapiens, 285 aa.	72 . . . 285	214/214 (100%)
	[WO9931225-A2, 24 JUN. 1999]
AAW79284	Human phosphatidic acid	8 . . . 221	214/214 (100%)	e−125
	phosphatase alpha 1 - Homo	71 . . . 284	214/214 (100%)
	sapiens, 284 aa. [WO9846730-A1,
	22 OCT. 1998]
AAW79285	Human phosphatidic acid	8 . . . 221	213/214 (99%)	e−124
	phosphatase alpha 2 - Homo	72 . . . 285	213/214 (99%)
	sapiens, 285 aa. [WO9846730-A1,
	22 OCT. 1998]
AAW79287	Human phosphatidic acid	11 . . . 200	123/190 (64%)	2e−66
	phosphatase gamma - Homo	72 . . . 260	145/190 (75%)
	sapiens, 276 aa. [WO9846730-A1,
	22 OCT. 1998]
AAW79286	Human phosphatidic acid	8 . . . 192	113/185 (61%)	5e−59
	phosphatase beta - Homo sapiens,	100 . . . 283	138/185 (74%)
	311 aa. [WO9846730-A1, 22
	OCT. 1998]

[0573] In a BLAST search of public sequence datbases, the NOV40a protein was found to have homology to the proteins shown in the BLASTP data in Table 40E.

TABLE 40E
Public BLASTP Results for NOV40a
			Identities/
Protein			Similarities for
Accession		NOV40a Residues/	the Matched	Expect
Number	Protein/Organism/Length	Match Residues	Portion	Value
O14494	PHOSPHATIDIC acid	8 . . . 221	214/214 (100%)	e−124
	phosphatase 2A (EC 3.1.3.4) -	71 . . . 284	214/214 (100%)
	Homo sapiens (Human), 284 aa.
O60463	Type-2 phosphatidic acid	8 . . . 221	214/214 (100%)	e−124
	phosphohydrolase - Homo sapiens	76 . . . 289	214/214 (100%)
	(Human), 289 aa.
O60457	Type-2 phosphatidic acid	8 . . . 221	213/214 (99%)	e−123
	phosphatase alpha-2 (EC 3.1.3.4) -	72 . . . 285	213/214 (99%)
	Homo sapiens (Human), 285 aa.
O88957	Phosphatidic acid phosphatase 2a2 -	8 . . . 221	199/215 (92%)	e−116
	Cavia porcellus (Guinea pig),	72 . . . 286	208/215 (96%)
	286 aa.
O88956	Phosphatidic acid phosphatase 2a -	8 . . . 221	198/215 (92%)	e−116
	Cavia porcellus (Guinea pig), 285	71 . . . 285	208/215 (96%)
	aa.

[0574] PFam analysis predicts that the NOV40a protein contains the domains shown in the Table 40F.

TABLE 40F
Domain Analysis of NOV40a
			Identities/
			Similarities for
	Pfam	NOV40a	the Matched	Expect
	Domain	Match Region	Region	Value
	PAP2	37 . . . 188	62/174 (36%)	1.5e−50
			133/174 (76%)

Example 41

[0575] The NOV41 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 41A.

TABLE 41A
NOV41 Sequence Analysis
	SEQ ID NO:349	1524 bp
NOV41a,	AACCAGATGGGAAAAATGTCTATCTGTACTTTTCAATCAACTGAGAAAGACGAGAAAA
CG15908-01
DNA Sequence	AAGAAGCTCACACTGGGAATGTAATGACTAATTTATCAAATGCTTATGCTTCAGATTT
	GTTGCTATGCAAAGATGACAAAGACTTAACAAAATATTTTCTGCTGCAAGTGGTAGAT
	ATTCTTCTACAGTATGCAAAAAACACCTTTGATGGTAAGAGTGAAATATTGGACTTCC
	ATCATCCTCATCAACTACTTGAAGGTTTGGTTGGGTTTACCTTAGAACTGCCTGACCA
	CCCTGAATCTCTGGAACAGTTACTTGCTGATTGCACAGATACCTTAAAATACAGTGTT
	AAAACAGGTCATCCTCGCTATTTTAACCAGCTGTCCAGTGGGTTAGATATGACTGGAC
	TTGCAGGGGAATGGTTGACAGCCACTGCAAATACCAACCTGTTTACATATGAAATAGC
	CCCAGTTTTTACTGTCATGGAGACAATTCTTCTCAAGAAAATGTATGAAATTATTGGC
	TGGGGGAAGAAACAAGCAGATGGAATATTTTCACCTGGTGGCAGTATATCAAGCCTTT
	ATGGTATTTTAGTAGCTCACTATAAACAATATCCAGAGATAAAAACAAAAGGCATGAC
	TGCACTTCCATGCATTGTATTATTTGTTTCTGAGCAAGGTCATTACTCAATAAAAATA
	GCTGCAACAATTTTGGGTATTGGAATTGATAATGTAATTGAAGTAAAGTGTGATGAAA
	GGGGAAAGATGATTCCAGCTGAGTTAGAGAAAAATATATTACAAGCTAAAAAAAAAGG
	TCAAACTCCATTCTGTGTCTGTGCCACAGCCGGAAGCACAGTGTACGGAGCCTTCGAC
	CCTCTCCCTGACATCGCTGATATTTGTGAGAAGCACAAACTCTGGATGCATGTGGATG
	CAGCTTCGGGAGGTGGACTGCTGCTATCCAGAAACTATTCCTATAAACTCAGTGGTAT
	TGAAAGGGCCAAGTCTGTGACCTGGAATCCACACAAACTAATGGGTGTCCCTCTTCAG
	TGCTCTGCTATCTTGATCCGGGAAAAAGGCCTTCTAGATGCATGTAATCAGATGCAAG
	CTGAATATCTTTTCCAGTCAGGTAAACTCTACAATGTTGACTTTGACACGGCGGATAA
	AACTATTCAGTGTGGCCGACATGTTGATATCTTCAAGCAGTGGTTAATGTGGAAAGCA
	AAGGGAACCCTTGGCTTTGAGGAACAAATCAACAAATATATGGAACTTGCAAAATACT
	TCTATAAGGTTTTAAAGAAAAAAGATAACTTTAAGCTTGTGTTTGATGCAGAGCCTGA
	GTTCACTAATGTCTGCTTCTGGTATTTCCCAGCAAGGCTTAAACATATTCCAAAAGGT
	TTTGAAAGAGATCAAGAACTCCGAAAGGTAGCTCCAAAGATTAAAGCACAGATGATGA
	TGGAAGGCACAATCATGATAAGCTACCAGCCATGTGGAGACAAAGTAAATATTTTGCG
	AATGGTTTTTTTCTAA
	ORF Start: ATG at 7		ORF Stop: TAA at 1522
	SEQ ID NO:350	505 aa	MW at 57169.9 kD
NOV41a,	MGKMSICTFQSTEKDEKKEAHTGNVMTNLSNAYASDLLLCKDDKDLTKYFLLQVVDIL
CG159084-01
Protein Sequence	LQYAKNTFDGKSEILDFHHPHQLLEGLVGFTLELPDHPESLEQLLADCTDTLKYSVKT
	GHPRYFNQLSSGLDMTGLAGEWLTATANTNLFTYEIAPVFTVMETILLKKMYEIIGWG
	KKQADGIFSPGGSISSLYGILVAHYKQYPEIKTKGMTALPCIVLFVSEQGHYSIKIAA
	TILGIGIDNVIEVKCDERGKMIPAELEKNILQAKKKGQTPFCVCATAGSTVYGAFDPL
	PDIADICEKHKLWMHVDAAWGGGLLLSRNYSYKLSGIERAKSVTWNPHKLMGVPLQCS
	AILIREKGLLDACNQMQAEYLFQSGKLYNVDFDTADKTIQCGRHVDIFKQWLMWKAKG
	TLGFEEQINKYMELAKYFYKVLKKKDNFKLVFDAEPEFTNVCFWYFPARLKHIPKGFE
	RDQELRKVAPKIKAQMMMEGTIMISYQPCGDKVNILRNVFF

[0576] Further analysis of the NOV41a protein yielded the following properties shown in Table 41B.

TABLE 41B
Protein Sequence Properties NOV41a
PSort     0.5819 probability located in microbody (peroxisome);
analysis: 0.1000 probability located in mitochondrial matrix space;
          0.1000 probability located in lysosome (lumen); 0.0000
          probability located in endoplasmic reticulum (membrane)
SignalP   No Known Signal Sequence Predicted
analysis:

[0577] A search of the NOV41a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 41C.

TABLE 41C
Geneseq Results for NOV41a
			Identities/
			Similarities for
Geneseq	Protein/Organism/Length	NOV41a Residues/	the Matched	Expect
Identifier	[Patent #, Date]	Match Residues	Region	Value
AAY57064	Glutamate decarboxylase 67 (GAD-	14 . . . 503	319/490 (65%)	0.0
	67) amino acid sequence - Homo	80 . . . 569	387/490 (78%)
	sapiens, 594 aa. [WO9956763-A1,
	11 NOV. 1999]
AAR27221	Full length brain GAD - Homo	14 . . . 503	319/490 (65%)	0.0
	sapiens, 594 aa. [WO9214485-A, 03	80 . . . 569	387/490 (78%)
	SEP. 1992]
AAR27220	Brain GAD #2 - Mus musculus, 593	27 . . . 503	317/477 (66%)	0.0
	aa. [WO9214485-A, 03 SEP. 1992]	92 . . . 568	378/477 (78%)
AAB03072	Chimeric human GAD67/rat GAD65	14 . . . 503	310/490 (63%)	0.0
	glutamic acid decarboxylase, SEQ	80 . . . 569	388/490 (78%)
	ID NO: 4 - Chimeric - Homo sapiens,
	594 aa. [US6060593-A, 09 MAY
	2000]
AAY33656	Chimeric rat GAD65/human GAD67	14 . . . 503	310/490 (63%)	0.0
	fusion protein 2 - Synthetic, 594 aa.	80 . . . 569	388/490 (78%)
	[US5968757-A, 19 OCT. 1999]

[0578] In a BLAST search of public sequence datbases, the NOV41a protein was found to have homology to the proteins shown in the BLASTP data in Table 41D.

TABLE 41D
Public BLASTP Results for NOV41a
			Identities/
Protein			Similarities for
Accession		NOV41a Residues/	the Matched	Expect
Number	Protein/Organism/Length	Match Residues	Portion	Value
Q9YI58	Glutamate decarboxylase 67 - Gallus	14 . . . 503	322/490 (65%)	0.0
	gallus (Chicken), 590 aa.	76 . . . 565	388/490 (78%)
B41935	glutamate decarboxylase (EC	14 . . . 503	319/490 (65%)	0.0
	4.1.1.15) 1 - human, 594 aa.	80 . . . 569	387/490 (78%)
Q99259	Glutamate decarboxylase, 67 kDa	14 . . . 503	319/490 (65%)	0.0
	isoform (EC 4.1.1.15) (GAD-67) (67	80 . . . 569	387/490 (78%)
	kDa glutamic acid decarboxylase) -
	Homo sapiens (Human), 594 aa.
S48135	glutamate decarboxylase (EC	14 . . . 503	318/490 (64%)	0.0
	4.1.1.15) - human, 593 aa.	79 . . . 568	387/490 (78%)
S51776	glutamate decarboxylase (EC	14 . . . 503	318/490 (64%)	0.0
	4.1.1.15) - human, 593 aa.	79 . . . 568	387/490 (78%)

[0579] PFam analysis predicts that the NOV41a protein contains the domains shown in the Table 41E.

TABLE 41E
Domain Analysis of NOV41a
		Identities/
		Similarities for
Pfam	NOV41a	the Matched	Expect
Domain	Match Region	Region	Value
pyridoxal_deC	78 . . . 452	136/401 (34%)	6.9e−154
		322/401 (80%)

Example 42

[0580] The NOV42 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 42A.

TABLE 42A
NOV42 Sequence Analysis
	SEQ ID NO:351	2990 bp
NOV42a,	CCGGCGCCGGGCGGCCGGCGAGTCTGGAGCCCGCCCCGTCGCCGGCCGCGTCCTCCGG
CG159130-01
DNA Sequence	GCATGGAAGGAGGCGGCAAGCCCAACTCTTCGTCTAACAGCCGGGACGATGGCAACAG
	CGTCTTCCCCGCCAAGGCGTCCGCGCCGGGCGCGGGGCCGGCCGCGGCCGAGAAGCGC
	CTGGGCACCCCGCCGGGGGGCGGCGGGGCCGGCGCGAAGGAGCACGGCAACTCCGTGT
	GCTTCAAGGTGGACGGCGGTGGCGGCGGTGGCGGCGGCGGCGGCGGCGGCGAGGAGCC
	GGCGGGGGGCTTCGAAGACGCCGAGGGGCCCCGGCGGCAGTACGGCTTCATGCAGAGG
	CAGTTCACCTCCATGCTGCAGCCCGGGGTCAACAAATTCTCCCTCCGCATGTTTGGGA
	GCCAGAAGGCGGTGGAAAAGGAGCAGGAAAGGGTTAAAACTGCAGGCTTCTGGATTAT
	CCACCCTTACAGTGATTTCAGGTTTTACTGGGATTTAATAATGCTTATAATGATGGTT
	GGAAATCTAGTCATCATACCAGTTGGAATCACATTCTTTACAGAGCAAACAACAACAC
	CATGGATTATTTTCAATGTGGCATCAGATACAGTTTTCCTATTGGACCTGATCATGAA
	TTTTAGGACTGGGACTGTCAATGAAGACAGTTCTGAAATCATCCTGGACCCCAAAGTG
	ATCAAGATGAATTATTTAAAAAGCTGGTTTGTGGTTGACTTCATCTCATCCATCCCAG
	TGGATTATATCTTTCTTATTGTAGAAAAAGGAATGGATTCTGAAGTTTACAAGACAGC
	CAGGGCACTTCGCATTGTGAGGTTTACAAAAATTCTCAGTCTCTTGCGTTTATTACGA
	CTTTCAAGGTTAATTAGATACATACATCAATGGGAAGAGATATTCCACATGACATATG
	ATCTCGCCAGTGCAGTGGTGAGAATTTTTAATCTCATCGGCATGATGCTGCTCCTGTG
	CCACTGGGATGGTTGTCTTCAGTTCTTAGTACCACTACTGCAGGACTTCCCACCAGAT
	TGCTGGGTGTCTTTAAATGAAATGGTTAATGATTCTTGGGGAAAGCAGTATTCATACG
	CACTCTTCAAAGCTATGAGTCACATGCTGTGCATTGGGTATGGAGCCCAAGCCCCAGT
	CAGCATGTCTGACCTCTGGATTACCATGCTGAGCATGATCGTCGGGGCCACCTGCTAT
	GCCATGTTTGTCGGCCATGCCACCGCTTTAATCCAGTCTCTGGATTCTTCGAGGCGGC
	AGTATCAAGAGAAGTATAAGCAAGTGGAACAATACATGTCATTCCATAAGTTACCAGC
	TGATATGCGTCAGAAGATACATGATTACTATGAACACAGATACCAAGGCAAAATCTTT
	GATGAGGAAAATATTCTCAATGAACTCAATGATCCTCTGAGAGAGGAGATAGTCAACT
	TCAACTGTCGGAAACTGGTGGCTACAATGCCTTTATTTGCTAATGCGGATCCTAATTT
	TGTGACTGCCATGCTGAGCAAGTTGAGATTTGAGGTGTTTCAACCTGCAGATTATATC
	ATACGAGAAGGAGCCGTGGGTAAAAAAATGTATTTCATTCAACACGGTGTTGCTGGTG
	TCATTACAAAATCCAGTAAAGAAATGAAGCTGACAGATGGCTCTTACTTTGGGGAGAT
	TTGCCTGCTGACCAAAGGACGTCGTACTGCCAGTGTTCGAGCTGATACATATTGTCGT
	CTTTACTCACTTTCCCTGGACAATTTCAACGAGGTCCTGGAGGAATATCCAATGATGA
	GGAGAGCCTTTGAGACAGTTGCCATTGACCGACTAGATCGAATAGGAAAGAAAAATTC
	AATTCTTCTGCAAAAGTTCCAGAAGGATCTGAACACTGGTGTTTTCAACAATCAGGAG
	AACGAAATCCTCAAGCAGATTGTGAAACATGACAGGGAGATGGTGCAGGCAATCGCTC
	CCATCAATTATCCTCAAATGACAACCCTGAATTCCACATCGTCTACTACGACCCCGAC
	CTCCCGCATGAGGACACAATCTCCACCGGTGTACACAGCGACCAGCCTCTCTCACAGC
	AACCTGCACTCCCCCAGTCCCAGCACACAGACCCCCCAGCCATCAGCCATCCTGTCAC
	CCTGCTCCTACACCACCGCGGTCTGCAGCCCTCCTGTACAGAGCCCTCTGGCCGCTCG
	AACTTTCCACTATGCCTCCCCCACCGCCTCCCAGCTGTCACTCATGCAACAGCAGCCG
	CAGCAGCAGGTACAGCAGTCCCAGCCGCCGCAGACTCAGCCACAGCAGCCGTCCCCGC
	AGCCACAGACACCTGGCAGCTCCACGCCGAAAAATGAAGTGCACAAGAGCACGCAGGC
	GCTTCACAACACCAACCTGACCCGGGAAGTCAGGCCACTCTCCGCCTCGCAGCCCTCG
	CTGCCCCATGAGGTGTCCACTCTGATTTCCAGACCTCATCCCACTGTGGGCGAGTCCC
	TGGCCTCCATCCCTCAACCCGTGACGGCGGTCCCCGGAACGGGCCTTCAGGCAGGGGG
	CAGGAGCACTGTCCCGCAGCGCGTCACCCTCTTCCGACAGATGTCGTCGGGAGCCATC
	CCCCCGAACCGAGGAGTCCCTCCAGCACCCCCTCCACCAGCAGCTGCTCTTCCAAGAG
	AATCTTCCTCAGTCTTAAACACAGACCCAGACGCAGAAAAGCCACGATTTGCTTCAAA
	TTTATGATCCCTGCTGATTGTCAAAGCAGAAAGAAATACTCTCATAAACTGAGACTAT
	ACTCAGATCTTATTTTATTCTATCTCCTGATAGATCCCTCTAGCCTACTATGAAGAGA
	TATTTTAGACAGCTGTGGCCTACACGTGAAATGTAAAAATATATATACATATACTATA
	AAATATATATCTAAATTCCCAAGAGAGGGTCAAAAGACCTGTTTAGCATTCAGTGTTA
	TATGTCTTCCTTTCTTTAAATCATTAAAGGAT
	ORF Start: ATG at 61		ORF Stop: TGA at 2731
	SEQ ID NO:352	890 aa	MW at 98791.0 kD
NOV42a,	MEGGGKPNSSSNSRDDGNSVFPAKASAPGAGPAAAEKRLGTPPGGGGAGAKEHGNSVC
CG159130-01
Protein Sequence	FKVDGGGGGGGGGGGGEEPAGGFEDAEGPRRQYGFMQRQFTSMLQPGVNKFSLRMFGS
	QKAVEKEQERVKTAGFWIIHPYSDFRFYWDLIMLIMMVGNLVIIPVGITFFTEQTTTP
	WIIFNVASDTVFLLDLIMNFRTGTVNEDSSEIILDPKVIKMNYLKSWFVVDFISSIPV
	DYIFLIVEKGMDSEVYKTARALRIVRFTKILSLLRLLRLSRLIRYIHQWEEIFHMTYD
	LASAVVRIFNLIGMMLLLCHWDGCLQFLVPLLQDFPPDCWVSLNEMVNDSWGKQYSYA
	LFKAMSHMLCIGYGAQAPVSMSDLWITMLSMIVGATCYAMFVGHATALIQSLDSSRRQ
	YQEKYKQVEQYMSFHKLPADMRQKIHDYYEHRYQGKIFDEENILNELNDPLREEIVNF
	NCRKLVATMPLFANADPNFVTAMLSKLRFEVFQPGDYIIREGAVGKKMYFIQHGVAGV
	ITKSSKEMKLTDGSYFGEICLLTKGRRTASVRADTYCRLYSLSVDNFNEVLEEYPMMR
	RAFETVAIDRLDRIGKKNSILLQKFQKDLNTGVFNNQENEILKQIVKHDREMVQAIAP
	INYPQMTTLNSTSSTTTPTSRMRTQSPPVYTATSLSHSNLHSPSPSTQTPQPSAILSP
	CSYTTAVCSPPVQSPLAARTFHYASPTASQLSLMQQQPQQQVQQSQPPQTQPQQPSPQ
	PQTPGSSTPKNEVHKSTQALHNTNLTREVRPLSASQPSLPHEVSTLISRPHPTVGESL
	ASIPQPVTAVPGTGLQAGGRSTVPQRVTLFRQMSSGAIPPNRGVPPAPPPPAAALPRE
	SSSVLNTDPDAEKPRFASNL

[0581] Further analysis of the NOV42a protein yielded the following properties shown in Table 42B.

TABLE 42B
Protein Sequence Properties NOV42a
PSort     0.6000 probability located in plasma membrane; 0.4000
analysis: probability located in Golgi body; 0.3000 probability
          located in endoplasmic reticulum (membrane);
          0.3000 probability located in microbody (peroxisome)
SignalP   No Known Signal Sequence Predicted
analysis:

[0582] A search of the NOV42a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 42C.

TABLE 42C
Geneseq Results for NOV42a
			Identities/
			Similarities for
Geneseq	Protein/Organism/Length	NOV42a Residues/	the Matched	Expect
Identifier	[Patent #, Date]	Match Residues	Region	Value
AAU11712	Human HCN1 channel subunit full	1 . . . 890	890/890 (100%)	0.0
	length sequence from splice variant	1 . . . 890	890/890 (100%)
	#1 - Homo sapiens, 890 aa.
	[WO200190142-A2, 29 NOV.
	2001]
AAU11714	Human full length HCN1 channel	1 . . . 890	888/890 (99%)	0.0
	subunit variant 2 - Homo sapiens,	1 . . . 890	888/890 (99%)
	890 aa. [WO200190142-A2, 29
	NOV. 2001]
AAE18675	Human hyperpolarisation-activated	1 . . . 890	885/890 (99%)	0.0
	cyclic nucleotide-gated channel 1 -	1 . . . 890	885/890 (99%)
	Homo sapiens, 890 aa.
	[WO200202630-A2, 10 JAN. 2002]
AAE21167	Human TRICH-11 protein - Homo	1 . . . 890	882/890 (99%)	0.0
	sapiens, 882 aa. [WO200212340-	1 . . . 882	882/890 (99%)
	A2, 14 FEB. 2002]
AAY22191	Mouse brain CNG-1 protein sequence -	1 . . . 890	845/922 (91%)	0.0
	Mus sp, 910 aa. [WO9932615-A1,	1 . . . 910	852/922 (91%)
	01 JUL. 1999]

[0583] In a BLAST search of public sequence datbases, the NOV42a protein was found to have homology to the proteins shown in the BLASTP data in Table 42D.

TABLE 42D
Public BLASTP Results for NOV42a
			Identities/
Protein			Similarities for
Accession		NOV42a Residues/	the Matched	Expect
Number	Protein/Organism/Length	Match Residues	Portion	Value
O88704	Hyperpolarization-activated cation	1 . . . 890	846/922 (91%)	0.0
	channel, HAC2 - Mus musculus	1 . . . 910	853/922 (91%)
	(Mouse), 910 aa.
Q9JKB0	Hyperpolarization-activated, cyclic	1 . . . 890	847/922 (91%)	0.0
	nucleotide-gated potassium channel	1 . . . 910	856/922 (91%)
	1 - Rattus norvegicus (Rat), 910 aa.
O54899	Brain cyclic nucleotide gated 1 -	1 . . . 890	845/922 (91%)	0.0
	Mus musculus (Mouse), 910 aa.	1 . . . 910	852/922 (91%)
Q9MZS1	Hyperpolarization-activated cyclic	78 . . . 890	786/813 (96%)	0.0
	nucleotide-gated channel 1 -	14 . . . 822	792/813 (96%)
	Oryctolagus cuniculus (Rabbit),
	822 aa.
O60741	Ion channel BCNG-1 - Homo	122 . . . 870	737/749 (98%)	0.0
	sapiens (Human), 749 aa	1 . . . 749	739/749 (98%)
	(fragment).

[0584] PFam analysis predicts that the NOV42a protein contains the domains shown in the Table 42E.

TABLE 42E
Domain Analysis of NOV42a
		Identities/
		Similarities for
Pfam	NOV42a	the Matched	Expect
Domain	Match Region	Region	Value
ion_trans	174 . . . 393	50/244 (20%)	1.6e−22
		160/244 (66%)
cNMP_binding	490 . . . 578	31/120 (26%)	2e−28
		71/120 (59%)
Transthyretin	692 . . . 709	12/19 (63%)	0.82
		14/19 (74%)

Example 43

[0585] The NOV43 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 43A.

TABLE 43A
NOV43 Sequence Analysis
	SEQ ID NO:353	1136 bp
NOV43a,	AACACCATGAGGGCCCTGGTGCTTCTGCTGTCCCTGTTCCTGCTGGGTGGCCAGGCCC
CG159178-01
DNA Sequence	AGCATGTGTCTGACTGGACCTACTCAGTGCAGATCGGCCTGCCCTCCACCATGCGCAT
	GACAGTGGCTGACGGCACTGTATACGTAGCCCAGCAGATGCACTTTCACTGGGGAGGT
	GCGTCCTCGGAGATCAGCGGCTCTGAGCACACCGTGGACGGGATCAGACATGTGATCG
	AGATTCACATTGTTCACTACAATTCTAAATACAAGAGCTATGATATAGCCCAAGATGC
	GCCGGATGGTTTGGCTGTACTGGCAGCCTTCGTTGAGGTGAAGAATTACCCTGAAAAC
	ACTTATTACAGCAACTTCATTTCTCATCTGGCCAACATCAAGTACCCAGGACAAAGAA
	CAACCCTGACTGGCCTTGACGTTCAGGACATGCTGCCCAGGAACCTCCAGCACTACTA
	CACCTACCATGGCTCACTCACCACGCCTCCCTGCACTGAGAACGTCCACTGGTTTGTG
	CTGGCAGATTTTGTCAAGCTCTCCAGGACACAGGTTTGGAAGCTGGAGAATTCCTTAC
	TGGATCACCGCAATAAGACCATCCACAACGATTACCGCAGGACCCAGCCCCTGAAACA
	CAGAGTGGTGGAATCCAACTTCCCGAATCAGGAATACACTCTAGGCTCTGAATTCCAG
	TTTTACCTACATAAGATTGAGGAAATTCTTGACTACTTAAGAAGAGCATTGAACTGAG
	GAAAGCTAAGAGGAAGATTCAATAATATTAACTAGCTTGAAGCCTGACCTAGCCAGAA
	GTGCCTGTCCGCTGCAGCCGCACCCTACCTTGTCTAAGAAACCATGTGTGTCTGGAAC
	ACGCTGCTCCCCTGGGCAGCTGTTGGGATTCTGATTAAAGAGGGGAAACGATCATCCT
	GGACAGGAAGTGAGATGGCTTCAGTTCATGAGACGGGATCTGAGTTAGACATCACCAG
	TGGAAATTGATTGGAATAGAAACTTAAAGGAAATGGAACCCTAACTATTCTCCCATCA
	AATCATATATGTTGACCTGTCTGAATTATAAACCAGCCTGACCTTTCCTTTAGCATTA
	GATGTAATAAAATAACTTTGGAAATTTGTCATTT
	ORF Start: ATG at 7		ORF Stop: TGA at 751
	SEQ ID NO:354	248 aa	MW at 28657.2 kD
NOV43a,	MRALVLLLSLFLLGGQAQHVSDWTYSVQIGLPSTMRMTVADGTVYVAQQMHFHWGGAS
CG159178-01
Protein Sequence	SEISGSEHTVDGIRHVIEIEIVHYNSKYKSYDIAQDAPDGLAVLAAFVEVKNYPENTY
	YSNFISHLANIKYPGQRTTLTGLDVQDMLPRNLQHYYTYHGSLTTPPCTENVHWFVLA
	DFVKLSRTQVWKLENSLLDHRNKTIHNDYRRTQPLKHRVVESNFPNQEYTLGSEFQFY
	LHKIEEILDYLRRALN
	SEQ ID NO:355	1006 bp
NOV43b,	AACACCATGAGGGCCCTGGTGCTTCTGCTGTCCCTGTTCCTGCTGGGTGGCCAGGCCC
CG159178-02
DNA Sequence	AGCATGTGTCTGACTGGACCTACTCAGAAGGGGCACTGGACGAAGCGCACTGGCCACA
	GCACTACCCCGCCTGTGGGGGCCAGAGACAGTCGCCTATCAACCTACAGAGGACGAAG
	GTGCGGTACAACCCCTCCTTGAAGGGGCTCAATATGACAGGCTATGAGACCCAGGCAG
	GGGAGTTCCCCATGGTCAACAATGGCCACACAGTGCACATCGGCCTGCCCTCCACCAT
	GCGCATGACAGTGGCTGACGGCACTGTATACATAGCCCAGCAGATGCACTTTCACTGG
	GGAGGTGCGTCCTCGGAGATCAGCGGCTCTGAGCACACCGTGGACGGGATCAGACATG
	TGATCGAGATTCACATTGTTCACTACAATTCTAAATACAAGAGCTATGATATAGCCCA
	AGATGCGCCGGATGGTTTGGCTGTACTGGCAGCCTTCGTTGAGGTGAAGAATTACCCT
	GAAAACACTTATTACAGCAACTTCATTTCTCATCTGGCCAACATCAAGTACCCAGGAC
	AAAGAACAACCCTCACTGGCCTTGACGTTCAGGACATGCTGCCCAGGAACCTCCAGCA
	CTACTACACCTACCATGGCTCACTCACCACGCCTCCCTGCACTGAGAACGTCCACTGG
	TTTGTGCTGGCAGATTTTGTCAAGCTCTCCAGGACACAGGTTTGGAAGCTGGAGAATT
	CCTTACTGGATCACCGCAATAAGACCATCCACAACGATTACCGCAGGACCCAGCCCCT
	GAACCACAGAGTGGTGGAATCCAACTTCCCGAATCAGGAATACACTCTAGGCTCTGAA
	TTCCAGTTTTACCTACATAAGATTGAGGAAATTCTTGACTACTTAAGAAGAGCATTGA
	ACTGAGGAAAGCTAAGAGGAAGATTCAATATTAACTAGCTTGAAGCCTGACCTAGCCA
	AGGGCGATTCCACACACTCC
	ORF Start: ATG at 7		ORF Stop: TGA at 931
	SEQ ID NO:356	308 aa	MW at 35336.5 kD
NOV43b,	MRALVLLLSLFLLGGQAQHVSDWTYSEGALDEAHWPQHYPACGGQRQSPINLQRTKVR
CG159178-02
Protein Sequence	YNPSLKGLNMTGYETQAGEFPMVNNGHTVQIGLPSTMRMTVADGTVYIAQQMHFHWGG
	ASSEISGSEHTVDGIRHVIEIHIVHYNSKYKSYDIAQDAPDGLAVLAAFVEVKNYPEN
	TYYSNFISHLANIKYPGQRTTLTGLDVQDMLPRNLQHYYTYHGSLTTPPCTENVHWFV
	LADFVKLSRTQVWKLENSLLDHRNKTIHNDYRRTQPLNHRVVESMFPNQEYTLGSEFQ
	FYLHKIEEILDYLRRALN

[0586] Sequence comparison of the above protein sequences yields the following sequence relationships shown in Table 43B.

TABLE 43B
Comparison of NOV43a against NOV43b.
			Identities/
			Similarities for
	Protein	NOV43a Residues/	the Matched
	Sequence	Match Residues	Region
	NOV43b	25 . . . 248	220/224 (98%)
		85 . . . 308	223/224 (99%)

[0587] Further analysis of the NOV43a protein yielded the following properties shown in Table 43C.

TABLE 43C
Protein Sequence Properties NOV43a
PSort     0.4132 probability located in outside; 0.2473 probability
analysis: located in microbody (peroxisome); 0.1000 probability
          located in endoplasmic reticulum (membrane); 0.1000
          probability located in endoplasmic reticulum (lumen)
SignalP   Cleavage site between residues 18 and 19
analysis:

[0588] A search of the NOV43a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 43D.

TABLE 43D
Geneseq Results for NOV43a
			Identities/
			Similarities for
Geneseq	Protein/Organism/Length	NOV43a Residues/	the Matched	Expect
Identifier	[Patent #, Date]	Match Residues	Region	Value
AAB59592	Human carbonic anhydrase isoform	25 . . . 219	189/195 (96%)	e−112
	#5 - Homo sapiens, 262 aa.	68 . . . 262	193/195 (98%)
	[US6160090-A, 12 DEC. 2000]
AAE17175	Human RCC-associated antigen,	25 . . . 219	82/195 (42%)	3e−37
	G250 protein - Homo sapiens, 459	200 . . . 391	112/195 (57%)
	aa. [WO200198363-A2, 27 DEC.
	2001]
AAB82848	Kidney cancer specific antigen	25 . . . 219	82/195 (42%)	3e−37
	G250-GM-CSF fusion protein -	345 . . . 536	112/195 (57%)
	Homo sapiens, 610 aa.
	[WO200160317-A2, 23 AUG. 2001]
AAY53245	MN protein extracellular domain	25 . . . 219	82/195 (42%)	3e−37
	SEQ ID NO: 87 - Homo sapiens, 377	163 . . . 354	112/195 (57%)
	aa. [US6027887-A, 22 FEB. 2000]
AAY53241	MN protein carbonic anhydrase	25 . . . 219	82/195 (42%)	3e−37
	domain SEQ ID NO: 51 - Homo	66 . . . 257	112/195 (57%)
	sapiens, 257 aa. [US6027887-A, 22
	FEB. 2000]

[0589] In a BLAST search of public sequence datbases, the NOV43a protein was found to have homology to the proteins shown in the BLASTP data in Table 43E.

TABLE 43E
Public BLASTP Results for NOV43a
			Identities/
Protein			Similarities for
Accession		NOV43a Residues/	the Matched	Expect
Number	Protein/Organism/Length	Match Residues	Portion	Value
P23280	Carbonic anhydrase VI precursor (EC	25 . . . 248	220/224 (98%)	e−131
	4.2.1.1) (Carbonate dehydratase VI)	85 . . . 308	224/224 (99%)
	(CA-VI) (Secreted carbonic
	anhydrase) (Salivary carbonic
	anhydrase) - Homo sapiens (Human),
	308 aa.
Q96QX8	DJ477M7.5 (carbonic anhydrase VI) -	25 . . . 248	219/224 (97%)	e−130
	Homo sapiens (Human), 308 aa.	85 . . . 308	222/224 (98%)
CRHU6	carbonate dehydratase (EC 4.2.1.1)	25 . . . 248	218/224 (97%)	e−129
	VI precursor - human, 308 aa.	85 . . . 308	222/224 (98%)
A29993	carbonate dehydratase (EC 4.2.1.1)	25 . . . 245	164/224 (73%)	1e−94
	VI - sheep, 307 aa.	68 . . . 291	193/224 (85%)
E966553	SYNTHETIC OVINE CARBONIC	25 . . . 245	164/224 (73%)	1e−94
	ANHYDRASE VI PROTEIN -	68 . . . 291	193/224 (85%)
	vectors, 307 aa.

[0590] PFam analysis predicts that the NOV43a protein contains the domains shown in the Table 43F.

TABLE 43F
Domain Analysis of NOV43a
		Identities/
		Similarities for
Pfam	NOV43a	the Matched	Expect
Domain	Match Region	Region	Value
Carb_anhydrase	25 . . . 218	86/210 (41%)	1.6e−118
		191/210 (91%)

Example 44

[0591] The NOV44 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 44A.

TABLE 44A
NOV44 Sequence Analysis
	SEQ ID NO:357	1704 bp
NOV44a,	GGTTTCATGGCAGCCTCAAAGAAGGCAGTTTTGGGGCCATTGGTGGGGGCGGTGGACC
CG160131-01
DNA Sequence	AGGGCACCAGTTCGACGCGCTTTTTGGTTTTCAATTCAAAAACAGCTGAACTACTTAG
	TCATCATCAAGTAGAAATAAAACAAGAGTTCCCAAGAGAAGGATGGGTGGAACAGGAC
	CCTAAGGAAATTCTACATTCTGTCTATGAGTGTATAGAGAAAACATGTGAGAAACTTG
	GACAGCTCAATATTGATATTTCCAACATAAAAGCTATTGGTGTCAGCAACCAGAGGGA
	AACCACTGTAGTCTGGGACAAGATAACTGGAGAGCCTCTCTACAATGCTGTGGCTGCT
	CCAGTTTCTCCTGGCCCTTCAGTTCCAGTTGCCGTTGTTCCCTCTGGCTCTTCAGTTC
	CAGCTCCTGGTACTTCCTCAGTGTGGCTTGATCTAAGAACCCAGTCTACCGTTGAGAG
	TCTTAGTAAAAGAATTCCAGGAAATAATAACTTTGTCAAGTCCAAGACAGGCCTTCCA
	CTTAGCACTTACTTCAGTGCAGTGAAACTTCGTTGGCTCCTTGACAATGTGAGAAAAG
	TTCAAAAGGCCGTTGAAGAAAAACGAGCTCTTTTTGGGACTATTGATTCATGGCTTAT
	TTGGAGTTTGACAGGAGGAGTCAATGGAGGTGTCCACTGTACAGATGTAACAAATGCA
	AGTAGGACTATGCTTTTCAACATTCATTCTTTGGAATGGGATAAACAACTCTGCGAAT
	TTTTTGGAATTCCAATGGAAATTCTTCCAAATGTCCGGAGTTCTTCTGAGATCTATGG
	CCTAATGAAAGCTGGGGCCTTGGAAGGTGTGCCAATATCTGGGTGTTTAGGGGACCAG
	TCTGCTGCATTGGTGGGACAAATGTGCTTCCAGATTGGACAAGCCAAAAATACGTATG
	GAACAGGATGTTTCTTACTATGTAATACAGGCCATAAGTGTGTATTTTCTGATCATGG
	CCTTCTCACCACAGTGGCTTACAAACTTGGCAGAGACAAACCAGTATATTATGCTTTG
	GAAGGTTCTGTAGCTATAGCTGGTGCTGTTATTCGCTGGCTAAGAGACAATCTTGGAA
	TTATAAAGACCTCAGAAGAAATTGAAAAACTTGCTAAAGAAGTAGGTACTTCTTATGG
	CTGCTACTTCGTCCCAGCATTTTCGGGGTTATATGCACCTTATTGGGAGCCCAGCGCA
	AGAGGGATAATCTGTGGACTCACTCAGTTCACCAATAAATGCCATATTGCTTTTGCTG
	CATTAGAAGCTGTTTGTTTCCAAACTCGAGAGATTTTGGATGCCATGAATCGAGACTG
	TGGAATTCCACTCAGTCATTTGCAGGTAGATGGAGGAATGACCAGCAACAAAATTCTT
	ATGCAGCTACAAGCAGACATTCTGTATATACCAGTAGTGAAGCCCTCAATGCCCGAAA
	CCACTGCACTGGGTGCGGCTATGGCGGCAGGGGCTGCAGAAGGAGTCGGCGTATGGAG
	TCTCGAACCCGAGGATTTGTCTGCCGTCACGATGGAGCGGTTTGAACCTCAGATTAAT
	GCGGAGGAAAGTGAAATTCGTTATTCTACATGGAAGAAAGCTGTGATGAAGTCAATGG
	GTTGGGTTACAACTCAATCTCCAGAAAGTGGTATTCCATAAAACCTACCAACTCATGG
	ATTCCCAAGATGTGAGCTTTTT
	ORF Start: ATG at 7		ORF Stop: TAA at 1663
	SEQ ID NO:358	552 aa	MW at 59929.2 kD
NOV44a,	MAASKKAVLGPLVGAVDQGTSSTRFLVFNSKTAELLSNHQVEIKQEFPREGWVEQDPK
CG160131-01
Protein Sequence	EILHSVYECIEKTCEKLGQLNIDISNIKAIGVSNQRETTVVWDKITGEPLYNAVAAPV
	SPGPSVPVAVVPSGSSVPAPGTSSVWLDLRTQSTVESLSKRIPGNNNFVKSKTGLPLS
	TYFSAVKLRWLLDNVRKVQKAVEEKRALFGTIDSWLIWSLTGGVNGGVHCTDVTNASR
	TMLFNIHSLEWDKQLCEFFGIPMEILPNVRSSSEIYGLMKAGALEGVPISGCLGDQSA
	ALVGQMCFQIGQAKNTYGTGCFLLCNTGHKCVFSDHGLLTTVAYKLGRDKPVYYALEG
	SVAIAGAVIRWLRDNLGIIKTSEEIEKIAKEVGTSYGCYFVPAFSGLYAPYWEPSARG
	IICGLTQFTNKCHIAFAALEAVCFQTREILDAMNRDCGIPLSHLQVDGGMTSNKILMQ
	LQADILYIPVVKPSMPETTALGAAMAAGAAEGVGVWSLEPEDLSAVTMERFEPQINAE
	ESEIRYSTWKKAVMKSMGWVTTQSPESGIP
	SEQ ID NO:359	1609 bp
NOV44b,	CACCGGATCCATGGCAGCCTCAAAGAAGGCAGTTTTGGGGCCATTGGTGGGGGCGGTG
CG160131-04
DNA Sequence	GACCAGGGCACCAGTTCGACGCGCTTTTTGGTTTTCAATTCAAAAACAGCTGAACTAC
	TTAGTCATCATCAAGTAGAAATAAAACAAGAGTTCCCAAGAGAAGGATGGGTGGAACA
	GGACCCTAAGGAAATTCTACATTCTGTCTATGAGTGTATAGAGAAAACATGTGAGAAA
	CTTGGACAGCTCAATATTGATATTTCCAACATAAAAGCTATTGGTGTCAGCAACCAGA
	GGGAAACCACTGTAGTCTGGGACAAGATAACTGGAGAGCCTCTCTACAATGCTGTGGT
	GTGGCTTGATCTAAGAACCCAGTCTACCGTTGAGAGTCTTAGTAAAAGAATTCCAGGA
	AATAATAACTTTGTCAAGTCCAAGACAGGCCTTCCACTTAGCACTTACTTCAGTGCAG
	TGAAACTTCGTTGGCTCCTTGACAATGTGAGAAAAGTTCAAAAGGCCGTTGAAGAAAA
	ACGAGCTCTTTTTGGGACTATTGATTCATGGCTTATTTGGAGTTTGACAGGAGGAGTC
	AATGGAGGTGTCCACTGTACAGATGTAACAAATGCAAGTAGGACTATGCTTTTCAACA
	TTCATTCTTTGGAATGGGATAAACAACTCTGCGAATTTTTTGGAATTCCAATGGAAAT
	TCTTCCAAATGTCCGGAGTTCTTCTGAGATCTATGGCCTAATGAAAATCTCTCATAGC
	GTGAAAGCTGGGGCCTTGGAAGGTGTGCCAATATCTGGGTGTTTAGGGGACCAGTCTG
	CTGCATTGGTGGGACAAATGTGCTTCCAGATTGGACAAGCCAAAAATACGTATGGAAC
	AGGATGTTTCTTACTATGTAATACAGGCCATAAGTGTGTATTTTCTGATCATGGCCTT
	CTCACCACAGTGGCTTACAAAAACTTGGCAGAGACAAACCAGTATATTATGCTTTGGG
	GTTCTGTAGCTATAGCTGGTGCTGTTATTCGCTGGCTAAGAGACAATCTTGGAATTAT
	AAAGACCTCAGAAGAAATTGAAAAACTTGCTAAAGAAGTAGGTACTTCTTATGGCTGC
	TACTTCGTCCCAGCATTTTCGGGGTTATATGCACCTTATTGGGAGCCCAGCGCAAGAG
	GGATAATCTGTGGACTCACTCAGTTCACCAATAAATGCCATATTGCTTTTGCTGCATT
	AGAAGCTGTTTGTTTCCAAACTCGAGAGATTTTGGATGCCATGAATCGAGACTGTGGA
	ATTCCACTCAGTCATTTGCAGGTAGATGGAGGAATGACCAGCAACAAAATTCTTATGC
	AGCTACAAGCAGACATTCTGTATATACCAGTAGTGAAGCCCTCAATGCCCGAAACCAC
	TGCACTGGGTGCGGCTATGGCGGCAGGGGCTGCAGAAGGAGTCGGCGTATGGAGTCTC
	GAACCCGAGGATTTGTCTGCCGTCACGATGGAGCGGTTTGAACCTCAGATTAATGCGG
	AGGAAAGTGAAATTCGTTATTCTACATGGAAGAAAGCTGTGATGAAGTCAATGGGTTG
	GGTTACAACTCAATCTCCAGAAAGTGGTATTCCAGTCGACGGC
	ORF Start: at 2		ORF Stop: end of
			sequence
	SEQ ID NO:360	536 aa	MW at 58656.8 kD
NOV44b,	TGSMAASKKAVLGPLVGAVDQGTSSTRFLVFNSKTAELLSHHQVEIKQEFPREGWVEQ
CG160131-04
Protein Sequence	DPKEILHSVYECIEKTCEKLGQLNIDISNIKAIGVSNQRETTVVWDKITGEPLYNAVV
	WLDLRTQSTVESLSKRIPGNNNFVKSKTGLPLSTYFSAVKLRWLLDNVRKVQKAVEEK
	RALFGTIDSWLIWSLTGGVNGGVHCTDVTNASRTMLFNIHSLEWDKQLCEFFGIPMEI
	LPNVRSSSEIYGLMKISHSVKAGALEGVPISGCLGDQSAALVGQMCFQIGQAKNTYGT
	GCFLLCNTGHKCVFSDHGLLTTVAYKLGRDKPVYYALEGSVAIAGAVIRWLRDNLGII
	KTSEEIEKLAKEVGTSYGCYFVPAFSGLYAPYWEPSARGIICGLTQFTNKCNTAFAAL
	EAVCFQTREILDAMNRDCGIPLSHLQVDGGMTSNKILMQLQADILYTPVVKPSMPETT
	ALGAAMAAGAAEGVGVWSLEPEDLSAVTMERFEPQINAEESEIRYSTWKKAVMKSMGW
	VTTQSPESGIPVDG
	SEQ ID NO:361	1581 bp
NOV44c,	GGTTTCATGGCAGCCTCAAAGAAGGCAGTTTTGGGGCCATTGGTGGGGGCGGTGGACC
CG160131-02
DNA Sequence	AGGGCACCAGTTCGACGCGCTTTTTGGTTTTCAATTCAAAAACAGCTGAACTACTTAG
	TCATCATCAAGTAGAAATAAAACAAGAGTTCCCAAGAGAAGGATGGGTGGAACAGGAC
	CCTAAGGAAATTCTACATTCTGTCTATGAGTGTATAGAGAAAACATGTGAGAAACTTG
	GACAGCTCAATATTGATATTTCCAACATAAAAGCTATTGGTGTCAGCAACCAGAGGGA
	AACCACTGTAGTCTGGGACAAGATAACTGGAGAGCCTCTCTACAATGCTGTGGTGTGG
	CTTGATCTAAGAACCCAGTCTACCGTTGAGAGTCTTAGTAAAAGAATTCCAGGAAATA
	ATAACTTTGTCAAGTCCAAGACAGGCCTTCCACTTAGCACTTACTTCAGTGCAGTGAA
	ACTTCGTTGGCTCCTTGACAATGTGAGAAAAGTTCAAAAGGCCGTTGAAGAAAAACGA
	GCTCTTTTTGGGACTATTGATTCATGGCTTATTTGGAGTTTGACAGGAGGAGTCAATG
	GAGGTGTCCACTGTACAGATGTAACAAATGCAAGTAGGACTATGCTTTTCAACATTCA
	TTCTTTGGAATGGGATAAACAACTCTGCGAATTTTTTGGAATTCCAATGGAAATTCTT
	CCAAATGTCCGGAGTTCTTCTGAGATCTATGGCCTAATGAAAGCTGGGGCCTTGGAAG
	GTGTGCCAATATCTGGGTGTTTAGGGGACCAGTCTGCTGCATTGGTGGGACAAATGTG
	CTTCCAGATTGGACAAGCCAAAAATACGTATGGAACAGGATGTTTCTTACTATGTAAT
	ACAGGCCATAAGTGTGTATTTTCTGATCATGGCCTTCTCACCACAGTGGCTTACAAAC
	TTGGCAGAGACAAACCAGTATATTATGCTTTGGAAGGTTCTGTAGCTATAGCTGGTGC
	TGTTATTCGCTGGCTAAGAGACAATCTTGGAATTATAAAGACCTCAGAAGAAATTGAA
	AAACTTGCTAAAGAAGTAGGTACTTCTTATGGCTGCTACTTCGTCCCAGCATTTTCGG
	GGTTATATGCACCTTATTGGGAGCCCAGCGCAAGAGGGATAATCTGTGGACTCACTCA
	GTTCACCAATAAATGCCATATTGCTTTTGCTGCATTAGAAGCTGTTTGTTTCCAAACT
	CGAGAGATTTTGGATGCCATGAATCGAGACTGTGGAATTCCACTCAGTCATTTGCAGG
	TAGATGGAGGAATQACCAGCAACAAAATTCTTATGCAGCTACAAGCAGACATTCTGTA
	TATACCAGTAGTGAAGCCCTCAATGCCCGAAACCACTGCACTGGGTGCGGCTATGGCG
	GCAGGGGCTGCAGAAGGAGTCGGCGTATGGAGTCTCGAACCCGAGGATTTGTCTGCCG
	TCACGATGGAGCGGTTTGAACCTCAGATTAATGCGGACGAAAGTGAAATTCGTTATTC
	TACATGGAAGAAAGCTGTGATGAAGTCAATGGGTTGGGTTACAACTCAATCTCCAGAA
	AGTGGTATTCCATAA
	ORF Start: ATG at 7		ORF Stop: TAA at 1579
	SEQ ID NO:362	524 aa	MW at 57488.5 kD
NOV44c,	MAASKKAVLGPLVGAVDQGTSSTRFLVFNSKTAELLSHHQVEIKQEFPREGWVEQDPK
CG160131-02
Protein Sequence	EILHSVYECIEKTCEKLGQLNIDISNIKAIGVSNQRETTVVWDKITGEPLYNAVVWLD
	LRTQSTVESLSKRIPGNNNFVKSKTGLPLSTYFSAVKLRWLLDNVRKVQKAVEEKRAL
	FGTIDSWLIWSLTGGVNGGVHCTDVTNASRTMLFNIHSLEWDKQLCEFFGIPMEILPN
	VRSSSEIYGLMKAGALEGVPISGCLGDQSAALVGQMCFQIGQAKNTYGTGCFLLCNTG
	HKCVFSDHGLLTTVAYKLGRDKPVYYALEGSVAIAGAVIRWLRDNLGIIKTSEEIEKL
	AKEVGTSYGCYFVPAFSGLYAPYWEPSARGIICGLTQFTNKCHIAFAALEAVCFQTRE
	ILDANNRDCGIPLSHLQVDGGMTSNKILMQLQADILYIPVVKPSMPETTALGAAMAAG
	AAEGVGVWSLEPEDLSAVTMERFEPQINAEESEIRYSTWKKAVMKSMGWVTTQSPESG
	IP
	SEQ ID NO:363	1625 bp
NOV44d,	TCGCCCTTTTGACTGTATCGCCGGAATTCATGGCAGCCTCAAAGAAGGCAGTTTTGGG
CG160131-03
DNA Sequence	GCCATTGGTGGGGGCGGTGGACCAGGCCACCAGTTCGACGCGCTTTTTGGTTTTCAAT
	TCAAAAACAGCTGAACTACTTAGTCATCATCAAGTAGAAATAAAACAAGAGTTCCCAA
	GAGAAGGATGGGTGGAACAGGACCCTAAGGAAATTCTACATTCTGTCTATGAGTGTAT
	AGAGAAAACATGTGAGAAACTTGGACAGCTCAATATTGATATTTCCAACATAAAAGCT
	ATTGGTGTCAGCAACCAGAGGGAAACCACTGTAGTCTGGGACAAGATAACTGGAGAGC
	CTCTCTACAATGCTGTGGTGTGGCTTGATCTAAGAACCCAGTCTACCGTTGAGAGTCT
	TAGTAAAAGAATTCCAGGAAATAATAACTTTGTCAAGTCCAAGACAGGCCTTCCACTT
	AGCACTTACTTCAGTGCAGTGAAACTTCGTTGGCTCCTTGACAATGTGAGAAAAGTTC
	AAAAGGCCGTTGAAGAAAAACGAGCTCTTTTTGGGACTATTGACTCATGGCTTATTTG
	GAGTTTGACAGGAGGAGTCAATGGAGGTGTCCACTGTACAGATGTAACAAATGCAAGT
	AGGACTATGCTTTTCAACATTCATTCTTTGGAATGGGATAAACAACTCTGCGAATTTT
	TTGGAATTCCAATGGAAATTCTTCCAAATGTCCGGAGTTCTTCTGAGATCTATGGCCT
	AATGAAAGCTGGGGCCTTGGAAGGTGTGCCAATATCTGGGTGTTTAGGGGACCAGTCT
	GCTGCATTGGTGGGACAAATGTGCTTCCAGATTGGACAAGCCAAAAATACGTATGGAA
	CAGGATGTTTCTTACTATGTAATACAGGCCATAAGTGCGTATTTTCTGATCATGGCCT
	TCTCACCACAGTGGCTTACAAACTTGGCAGAGACAAACCAGTATATTATGCTTTGGAA
	GGTTCTGTAGCTATAGCTGGTGCTGTTATTCGCTGGCTAAGAGACAATCTTGGAATTA
	TAAAGACCTCAGAAGAAATTGAAAAACTTGCTAAAGAAGTAGGTACTTCTTATGGCTG
	CTACTTCGTCCCAGCATTTTCGGGGTTATATGCACCTTATTGGGAGCCCAGCGCAAGA
	GGGATAATCTGTGGACTCACTCAGTTCACCAATAAATGCCATATTGCTTTTGCTGCAT
	TAGAAGCTGTTTGTTTCCAAACTCGAGAGATTTTGGATGCCATGAATCGAGACTGTGG
	AATTCCACTCAGTCATTTGCAGGTAGATGGAGGAATGACCAGCAACAAAATTCTTATG
	CAGCTACAAGCAGACATTCTGTATATACCAGTAGTGAAGCCCTCAATGCCCGAAACCA
	CTGCACTGGGTGCGGCTATGGCGGCAGGGGCTGCAGAAGGAGTCGGCGTATGGAGTCT
	CGAACCCGAGGATCTGTCTGCCGTCACGATGGAGCGGTTTGAACCTCAGATTAATGCG
	GAGGAAAGTGAAATTCGTTATTCTACATGGAAGAAAGCTGTGATGAAGTCAATGGGTT
	GGGTTACAACTCAATCTCCAGAAAGTGGTATTCCATGACTGCAGCCAACCTAATTCCG
	ORF Start: ATG at 30		ORF Stop: TGA at 1602
	SEQ ID NO:364	524 aa	MW at 57502.5 kD
NOV44d,	MAASKKAVLGPLVGAVDQATSSTRFLVFNSKTAELLSHHQVEIKQEFPREGWVEQDPK
CG160131-03
Protein Sequence	EILHSVYECIEKTCEKLGQLNIDISNIKAIGVSNQRETTVVWDKITGEPLYNAVVWLD
	LRTQSTVESLSKRIPGNNNFVKSKTGLPLSTYFSAVKLRWLLDNVRKVQKAVEEKRAL
	FGTIDSWLIWSLTGGVNGGVHCTDVTNASRTMLFNIHSLEWDKQLCEFFGIPMEILPN
	VRSSSEIYGLMKAGALEGVPISGCLGDQSAALVGQMCFQIGQAKNTYGTGCFLLCNTG
	HKCVFSDHGLLTTVAYKLGRDKPVYYALEGSVAIAGAVIRWLRDNLGIIKTSEEIEKL
	AKEVGTSYGCYFVPAFSGLYAPYWEPSARGIICGLTQFTNKCHIAFAALEAVCFQTRE
	ILDAMNRDCGIPLSHLQVDGGMTSNKILMQLQADILYIPVVKPSMPETTALGAAMAAG
	AAEGVGVWSLEPEDLSAVTMERFEPQINAEESEIRYSTWKKAVMKSMGWVTTQSPESG
	IP

[0592] Sequence comparison of the above protein sequences yields the following sequence relationships shown in Table 44B.

TABLE 44B
Comparison of NOV44a against NOV44b through NOV44d.
			Identities/
			Similarities for
	Protein	NOV44a Residues/	the Matched
	Sequence	Match Residues	Region
	NOV44b	1 . . . 552	524/558 (93%)
		4 . . . 533	524/558 (93%)
	NOV44c	1 . . . 552	524/552 (94%)
		1 . . . 524	524/552 (94%)
	NOV44d	1 . . . 552	523/552 (94%)
		1 . . . 524	523/552 (94%)

[0593] Further analysis of the NOV44a protein yielded the following properties shown in Table 44C.

TABLE 44C
Protein Sequence Properties NOV44a
PSort     0.4500 probability located in cytoplasm; 0.3731 probability
analysis: located in microbody (peroxisome); 0.1000 probability
          located in mitochondrial matrix space; 0.1000 probability
          located in lysosome (lumen)
SignalP   No Known Signal Sequence Predicted
analysis:

[0594] A search of the NOV44a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 44D.

TABLE 44D
Geneseq Results for NOV44a
			Identities/
			Similarities for
Geneseq	Protein/Organism/Length	NOV44a Residues/	the Matched	Expect
Identifier	[Patent #, Date]	Match Residues	Region	Value
ABB66928	Drosophila melanogaster	10 . . . 548	277/542 (51%)	e−155
	polypeptide SEQ ID NO 27576 -	17 . . . 529	362/542 (66%)
	Drosophila melanogaster, 538 aa.
	[WO200171042-A2, 27 SEP. 2001]
AAU60271	Propionibacterium acnes	15 . . . 542	266/530 (50%)	e−144
	immunogenic protein #21167 -	28 . . . 520	348/530 (65%)
	Propionibacterium acnes, 526 aa.
	[WO200181581-A2, 01 NOV. 2001]
ABB57950	Drosophila melanogaster	12 . . . 545	251/538 (46%)	e−143
	polypeptide SEQ ID NO 642 -	32 . . . 537	356/538 (65%)
	Drosophila melanogaster, 576 aa.
	[WO200171042-A2, 27 SEP. 2001]
ABB57948	Drosophila melanogaster	12 . . . 545	251/538 (46%)	e−143
	polypeptide SEQ ID NO 636 -	34 . . . 539	356/538 (65%)
	Drosophila melanogaster, 578 aa.
	[WO200171042-A2, 27 SEP. 2001]
ABB57846	Drosophila melanogaster	12 . . . 545	251/538 (46%)	e−143
	polypeptide SEQ ID NO 330 -	32 . . . 537	356/538 (65%)
	Drosophila melanogaster, 576 aa.
	[WO200171042-A2, 27 SEP. 2001]

[0595] In a BLAST search of public sequence datbases, the NOV44a protein was found to have homology to the proteins shown in the BLASTP data in Table 44E.

TABLE 44E
Public BLASTP Results for NOV44a
			Identities/
Protein			Similarities for
Accession		NOV44a Residues/	the Matched	Expect
Number	Protein/Organism/Length	Match Residues	Portion	Value
P32189	Glycerol kinase (EC 2.7.1.30)	1 . . . 552	524/552 (94%)	0.0
	(ATP: glycerol 3-phosphotransferase)	1 . . . 524	524/552 (94%)
	(Glycerokinase) (GK) - Homo sapiens
	(Human), 524 aa.
Q14409	Glycerol kinase, testis specific 1 (EC	1 . . . 552	516/552 (93%)	0.0
	2.7.1.30) (ATP: glycerol 3-	1 . . . 524	518/552 (93%)
	phosphotransferase) (Glycerokinase)
	(GK) - Homo sapiens (Human), 553
	aa.
Q64516	Glycerol kinase (EC 2.7.1.30)	1 . . . 552	510/552 (92%)	0.0
	(ATP: glycerol 3-phosphotransferase)	1 . . . 524	521/552 (93%)
	(Glycerokinase) (GK) - Mus musculus
	(Mouse), 524 aa.
Q63060	Glycerol kinase (EC 2.7.1.30)	1 . . . 552	510/552 (92%)	0.0
	(ATP: glycerol 3-phosphotransferase)	1 . . . 524	519/552 (93%)
	(Glycerokinase) (GK) (ATP-
	stimulated glucocorticoid-receptor
	translocation promoter) (ASTP) -
	Rattus norvegicus (Rat), 524 aa.
Q14410	Glycerol kinase, testis specific 2 (EC	1 . . . 552	461/552 (83%)	0.0
	2.7.1.30) (ATP: glycerol 3-	1 . . . 524	495/552 (89%)
	phosphotransferase) (Glycerokinase)
	(GK) - Homo sapiens (Human), 553
	aa.

[0596] PFam analysis predicts that the NOV44a protein contains the domains shown in the Table 44F.

TABLE 44F
Domain Analysis of NOV44a
		Identities/
		Similarities
		for the Matched	Expect
Pfam Domain	NOV44a Match Region	Region	Value
FGGY	12 . . . 294	99/293 (34%)	2.9e−126
		266/293 (91%)
FGGY_C	297 . . . 525	101/235 (43%)	5.4e−110
		222/235 (94%)

Example 45

[0597] The NOV45 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 45A.

TABLE 45A
NOV45 Sequence Analysis
	SEQ ID NO:365	1719 bp
NOV45a,	GGCCGGACAGTCCGCCGAGGTGCTCGGTGGAGTCATGGCAGTGCCCTTTGTGGAAGAC
CG166282-01
DNA Sequence	TGGGACTTGGTGCAAACCCTGGGAGAAGGTGCCTATGGAGAAGTTCAACTTGCTGTGA
	ATAGAGTAACTGAAGAAGCAGTCGCAGTGAAGATTGTAGATATGAAGCGTGCCGTAGA
	CTGTCCAGAAAATATTAAGAAAGAGATCTGTATCAATAAAATGCTAAATCATGAAAAT
	GTAGTAAAATTCTATGGTCACAGGAGAGAAGGCAATATCCAATATTTATTTCTGGAGT
	ACTGTAGTGGAGGAGAGCTTTTTGACAGAATAGAGCCAGACATAGGCATGCCTGAACC
	AGATGCTCAGAGATTCTTCCATCAACTCATGGCAGGGGTGGTTTATCTGCATGGTATT
	GGAATAACTCACAGGGATATTAAACCAGAAAATCTTCTGTTGGATGAAAGGGATAACC
	TCAAAATCTCAGACTTTGGCTTGGCAACAGTATTTCGGTATAATAATCGTGAGCGTTT
	GTTGAACAAGATGTGTGGTACTTTACCATATGTTGCTCCAGAACTTCTGAAGAGAAGA
	GAATTTCATGCAGAACCAGTTGATGTTTGGTCCTGTGGAATAGTACTTACTGCAATGC
	TCGCTGGAGAATTGCCATGGGACCAACCCAGTGACAGCTGTCAGGAGTATTCTGACTG
	GAAAGAAAAAAAAACATACCTCAACCCTTGGAAAAAAATCGATTCTGCTCCTCTAGCT
	CTGCTGCATAAAATCTTAGTTGAGAATCCATCAGCAAGAATTACCATTCCAGACATCA
	AAAAAGATAGATGGTACAACAAACCCCTCAAGAAAGGGGCAAAAAGGCCCCGAGTCAC
	TTCAGGTGGTGTGTCAGAGTCTCCCAGTGGATTTTCTAAGCACATTCAATCCAATTTG
	GACTTCTCTCCAGTAAACAGTGCTTCTAGTGAAGAAAATGTGAAGTACTCCAGTTCTC
	AGCCAGAACCCCGCACAGGTCTTTCCTTATGGGATACCAGCCCCTCATACATTGATAA
	ATTGGTACAAGGGATCAGCTTTTCCCAGCCCACATGTCCTGATCATATGCTTTTGAAT
	AGTCAGTTACTTGGCACCCCAGGATCCTCACAGAACCCCTGGCAGCGGTTGGTCAAAA
	GAATGACACGATTTTTTACCAAATTGGATGCAGACAAATCTTATCAATGCCTGAAAGA
	GACTTGTGAGAAGTTGGGCTATCAATGGAAGAAAAGTTGTATGAATCAGGGTGATGGA
	TTGGAGTTCAAGAGACACTTCCTGAAGATTAAAGGGAAGCTGATTGATATTGTGAGCA
	GCCAGAAGGTTTGGCTTCCTGCCACATGATCGGACCATCGGCTCTGGGGAATCCTGGT
	GAATATAGTGCTGCTATGTTGACATTATTCTTCCTAGAGAAGATTATCCTGTCCTGCA
	AACTGCAAATAGTAGTTCCTGAAGTGTTCACTTCCCTGTTTATCCAAACATCTTCCAA
	TTTATTTTGTTTGTTCGGCATACAAATAATACCTATATCTTAATTGTAAGCAAAACTT
	TGGGGAAAGGATGAATAGAATTCATTTGATTATTTCTTCATGTGTGTTTAGTATCTGA
	ATTTGAAACTCATCTGGTGGAAACCAAGTTTCAGGGGACATGAGTTTTCCAGCTTTTA
	TACACACGTATCTCATTTTTATCAAAACATTTTGTTT
	ORF Start: ATG at 35		ORF Stop: TGA at 1361
	SEQ ID NO:366	422 aa	MW at 50400.3 kD
NOV45a,	MAVPFVEDWDLVQTLGEGAYGEVQLAVNRVTEEAVAVKIVDMKRAVDCPENIKKEICI
CG166282-01
Protein Sequence	NKMLNHENVVKFYGHRREGNIQYLFLEYCSGGELFDRIEPDIGMPEPDAQRFFHQLMA
	CVVYLHGIGITHRDIKPENLLLDERDNLKISDFGLATVFRYNNRERLLNKMCGTLPYV
	APELLKRREFHAEPVDVWSCGIVLTAMLAGELPWDQPSDSCQEYSDWKEKKTYLNPWK
	KIDSAPLALLHKILVENPSARITIPDIKKDRWYNKPLKKGAKRPRVTSGGVSESPSGF
	SKHIQSNLDFSPVNSASSEENVKYSSSQPEPRTGLSLWDTSPSYIDKLVQGISFSQPT
	CPDHMLLNSQLLGTPGSSQNPWQRLVKRMTRFFTKLDADKSYQCLKETCEKLGYQWKK
	SCMNQGDGLEFKRHFLKIKGKLIDIVSSQKVWLPAT

[0598] Further analysis of the NOV45a protein yielded the following properties shown in Table 45B.

TABLE 45B
Protein Sequence Properties NOV45a
PSort     0.3000 probability located in nucleus; 0.1000 probability
analysis: located in mitochondrial matrix space; 0.1000 probability
          located in lysosome (lumen); 0.0423 probability located in
          microbody (peroxisome)
SignalP   No Known Signal Sequence Predicted
analysis:

[0599] A search of the NOV45a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 45C.

TABLE 45C
Geneseq Results for NOV45a
			Identi-
			ties/Simi-
		NOV45a	larities
		Residues/	for the	Ex-
Geneseq	Protein/Organism/Length	Match	Matched	pect
Identifier	[Patent #, Date]	Residues	Region	Value
AAU10752	Human checkpoint protein	1 . . . 442	442/476	0.0
	chk1 - Homo sapiens,		(92%)
	476 aa.	1 . . . 476	442/476
	[US6307015-B1,		(92%)
	OCT. 23, 2001]
AAE00662	Human cell cycle check-	1 . . . 442	442/476	0.0
	point protein, hchk1,		(92%)
	alternative version #1 -	1 . . . 476	442/476
	Homo sapiens, 476 aa.		(92%)
	[US6218109-B1,
	APR. 17, 2001]
AAG68374	Human Chk1 kinase protein	1 . . . 442	442/476	0.0
	sequence - Homo sapiens,		(92%)
	476 aa.	1 . . . 476	442/476
	[WO200121771-A2,		(92%)
	MAR. 29, 2001]
AAE01155	Human Chk1 protein -	1 . . . 442	442/476	0.0
	Homo sapiens, 476 aa.		(92%)
	[US6211164-B1,	1 . . . 476	442/476
	APR. 03, 2001]		(92%)
AAY54452	A human checkpoint kinase	1 . . . 442	442/476	0.0
	(hChk1) polypeptide -		(92%)
	Homo sapiens, 476 aa.	1 . . . 476	442/476
	[WO200003005-A2,		(92%)
	JAN. 20, 2000]

[0600] In a BLAST search of public sequence datbases, the NOV45a protein was found to have homology to the proteins shown in the BLASTP data in Table 45D.

TABLE 45D
Public BLASTP Results for NOV45a
			Identi-
			ties/Simi-
		NOV45a	larities
Protein		Residues/	for the	Ex-
Accession		Match	Matched	pect
Number	Protein/Organism/Length	Residues	Portion	Value
O14757	Serine/threonine-protein	1 . . . 442	442/476	0.0
	kinase Chk1 (EC 2.7.1.-) -		(92%)
	Homo sapiens (Human),	1 . . . 476	442/476
	476 aa.		(92%)
Q91ZN7	Checkpoint kinase 1 (Cell	1 . . . 442	420/476	0.0
	cycle checkpoint protein		(88%)
	kinase) - Rattus norvegicus	1 . . . 476	430/476
	(Rat), 476 aa.		(90%)
Q9D0N2	Checkpoint kinase 1 homo-	1 . . . 442	414/476	0.0
	log (S. pombe) - Mus		(86%)
	musculus (Mouse), 476 aa.	1 . . . 476	428/476
			(88%)
O35280	Serine/threonine-protein	1 . . . 442	411/476	0.0
	kinase Chk1 (EC 2.7.1.-) -		(86%)
	Mus musculus (Mouse),	1 . . . 476	427/476
	476 aa.		(89%)
AAN33019	Checkpoint 1 protein -	1 . . . 440	371/474	0.0
	Gallus gallus (Chicken),		(78%)
	476 aa.	1 . . . 474	403/474
			(84%)

[0601] PFam analysis predicts that the NOV45a protein contains the domains shown in the Table 45E.

TABLE 45E
Domain Analysis of NOV45a
		Identities/
		Similarities
		for the Matched	Expect
Pfam Domain	NOV45a Match Region	Region	Value
pkinase	9 . . . 265	93/294 (32%)	1.2e−75
		201/294 (68%)

Example 46

[0602] The NOV46 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 46A.

TABLE 46A
NOV46 Sequence Analysis
	SEQ ID NO:367	2264 bp
NOV46a,	TTGACTGTATCGCCGGAATTCATGGCAGCGCCAGGCGGCAGGTCGGAGCCGCCGCAGC
CG170739-01
DNA Sequence	TCCCCGAGTACAGCTGCAGCTACATGGTGTCGCGGCCGGTCTACAGCGAGCTCGCTTT
	CCAGCAACAGCACGAGCGGCGCCTGCAGGAGCGCAAGACGCTGCGGGAGAGCCTGGCC
	AAGTGCTGCAGTTGTTCAAGAAAGAGAGCCTTTGGTGTGCTAAAGACTCTAGTGCCCA
	TCTTGGAGTGGCTCCCCAAATACCGAGTCAAGGAATCGCTGCTTAGTGACGTCATTTC
	GGGAGTTAGTACTGGGCTAGTGGCCACGCTGCAAGGACCTTTTCCAGTGGTGAGTTTA
	ATGGTGGGATCTGTTGTTCTGAGCATGGCCCCCGACGAACACTTTCTCGTATCCAGCA
	GCAATGGAACTGTATTAAATACTACTATGATAGACACTGCAGCTAGAGATACAGCCAG
	AGTCCTGATTGCCAGTGCCCTGACTCTGCTGGTTGGAATTATACAGTTGATATTTGGT
	GGCTTGCAGATTGGATTCATAGTGAGGCACTTGGCAGATCCTTTGGTTGGTGGCTTCA
	CAACAGCTGCTGCCTTCCAAGTGCTGGTCTCACAGCTAAAGATTGTCCTCAATGTTTC
	AACCAAAAACTACAATGGAGTTCTCTCTATTATCTATACGCTGGTTGAGATTTTTCAA
	AATATTGGTGATACCAATCTTGCTGATTTCACTGCTGGATTGCTCACCATTGTCGTCT
	GTATGGCAGTTAAGGAATTAAATGATCGGTTTAGACACAAAATCCCAGTCCCTATTCC
	TATAGAAGTAATTGTGACGATAATTGCTACTGCCATTTCATATGGAGCCAACCTGGAA
	AAAAATTACAATGCTGGCATTGTTAAATCCATCCCAAGGGGGTTTTTGCCTCCTGAAC
	TTCCACCTGTGAGCTTGTTCTCGGAGATGCTGGCTGCATCATTTTCCATCGCTGTGGT
	GGCTTATGCTATTGCAGTGTCAGTAGGAAAAGTATATGCCACCAAGTATGATTACACC
	ATCGATGGGAACCAGGAATTCATTGCCTTTGGGATCAGCAACATCTTCTCAGGATTCT
	TCTCTTGTTTTGTGGCCACCACTGCTCTTTCCCGCACGGCCGTCCAGGAGAGCACTGG
	AGGAAAGACACAGGTTGCTGGCATCATCTCTCCTGCGATTGTGATGATCGCCATTCTT
	GCCCTGGGGAAGCTTCTGGAACCCTTGCAGAAGTCGGTCTTGGCAGCTGTTGTAATTG
	CCAACCTGAAAGGGATGTTTATGCAGCTGTGTGACATTCCTCGTCTGTGGAGACAGAA
	TAAGATTGATGCTGTTATCTGGGTGTTTACGTGTATAGTGTCCATCATTCTGGGGCTG
	GATCTCGGTTTACTAGCTGGCCTTATATTTGGACTGTTGACTGTGGTCCTGAGAGTTC
	AGTTTCCTTCTTGGAATGGCCTTGGAAGCATCCCTAGCACAGATATCTACAAAAGTAC
	CAAGAATTACAAAAACATTGAAGAACCTCAAGGAGTGAAGATTCTTAGATTTTCCAGT
	CCTATTTTCTATGGCAATGTCGATGGTTTTAAAAAATGTATCAAGTCCACAGTTGGAT
	TTGATGCCATTAGAGTATATAATAAGAGGCTGAAAGCGCTGAGGAAAATACAGAAACT
	AATAAAAAGTGGACAATTAAGAGCAACGAAGAATGGCATCATAAGTGATGCTGTTTCA
	ACAAATAATGCTTTTGAGCCCGATGAGGATATTGAAGATCTGGAGGAACTTGATATCC
	CAACCAAGGAAATAGAGATTCAAGTGGATTGGAACTCTGAGCTTCCAGTCAAAGTGAA
	CGTTCCCAAAGTGCCAATCCATAGCCTTGTGCTTGACTGTGGAGCTATATCTTTCCTG
	GACGTTGTTGGAGTGAGATCACTGCGGGTGATTGTCAAAGAATTCCAAAGAATTGATG
	TGAATGTGTATTTTGCATCACTTCAAGATTATGTGATAGAAAAGCTGGAGCAATGCGG
	GTTCTTTGACGACAACATTAGAAAGGACACATTCTTTTTGACGGTCCATGATGCTATA
	CTCTATCTACAGAACCAAGTGAAATCTCAAGAGGGTCAAGGTTCCATTTTAGAAACGA
	TCACTCTCATTCAGGATTGTAAAGATACCCTTGAATTAGTAGAAACAGAGCTGACGGA
	AGAAGAACTTGATGTCCAGGATGAGGCTATGCGTACACTTGCATCCTGACTGCAGCCA
	ORF Start: ATG at 22		ORF Stop: TGA at 2251
	SEQ ID NO:368	743 aa	MW at 81685.2 kD
NOV46a,	MAAPGGRSEPPQLPEYSCSYMVSRPVYSELAFQQQHERRLQERKTLRESLAKCCSCSR
CG170739-01
Protein Sequence	KRAFGVLKTLVPILEWLPKYRVKEWLLSDVISGVSTGLVATLQGPFPVVSLMVGSVVL
	SMAPDEHFLVSSSNGTVLNTTMIDTAARDTARVLIASALTLLVGIIQLIFGGLQIGFI
	VRHLADPLVGGFTTAAAFQVLVSQLKIVLNVSTKNYNGVLSIIYTLVEIFQNIGDTNL
	ADFTAGLLTIVVCMAVKELNDRFRHKIPVPIPIEVIVTIIATAISYGANLEKNYNAGI
	VKSIPRGFLPPELPPVSLFSEMLAASPSIAVVAYAIAVSVGKVYATKYDYTIDGNQEF
	IAFGISNIFSGFFSCFVATTALSRTAVQESTGGKTQVAGIISAAIVMIAILALGKLLE
	PLQKSVLAAVVIANLKGMFMQLCDIPRLWRQNKIDAVIWVFTCIVSIILGLDLGLLAG
	LIFGLLTVVLRVQFPSWNGLGSIPSTDIYKSTKNYKNIEEPQGVKILRFSSPIFYGNV
	DGFKKCIKSTVGFDAIRVYNKRLKALRKIQKLIKSGQLRATKNGIISDAVSTNNAFEP
	DEDIEDLEELDIPTKEIEIQVDWNSELPVKVNVPKVPIHSLVLDCGAISFLDVVGVRS
	LRVIVKEFQRIDVNVYFASLQDYVIEKLEQCGFFDDNIRKDTFFLTVHDAILYLQNQV
	KSQEGQGSILETITLIQDCKDTLELVETELTEEELDVQDEAMRTLAS

[0603] Further analysis of the NOV46a protein yielded the following properties shown in Table 46B.

TABLE 46B
Protein Sequence Properties NOV46a
PSort     0.8000 probability located in plasma membrane; 0.4000 prob-
analysis: ability located in Golgi body; 0.3000 probability located in
          endoplasmic reticulum (membrane); 0.0300 probability lo-
          cated in mitochondrial inner membrane
SignalP   No Known Signal Sequence Predicted
analysis:

[0604] A search of the NOV46a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 46C.

TABLE 46C
Geneseq Results for NOV46a
		NOV46a	Identities/
		Residues/	Similarities for
Geneseq	Protein/Organism/Length [Patent	Match	the Matched	Expect
Identifier	#, Date]	Residues	Region	Value
ABG61914	Prostate cancer-associated protein	1 . . . 743	741/780 (95%)	0.0
	#115 - Mammalia, 790 aa.	1 . . . 780	743/780 (95%)
	[WO200230268-A2, 18 APR. 2002]
AAM51696	Human pendrin SEQ ID NO 2 -	1 . . . 743	741/780 (95%)	0.0
	Homo sapiens, 780 aa.	1 . . . 780	743/780 (95%)
	[JP2001228146-A, 24 AUG. 2001]
AAM51695	Mouse pendrin SEQ ID NO 1 - Mus	1 . . . 743	648/780 (83%)	0.0
	sp, 780 aa. [JP2001228146-A, 24	1 . . . 780	701/780 (89%)
	AUG. 2001]
AAR60568	Down-regulated in adenoma DRA	20 . . . 692	322/716 (44%)	e−176
	tumor suppressor - Homo sapiens,	9 . . . 720	448/716 (61%)
	764 aa. [WO9420616-A, 15 SEP.
	1994]
AAG67162	Amino acid sequence of a human	56 . . . 691	257/689 (37%)	e−132
	32613 transporter polypeptide -	62 . . . 733	401/689 (57%)
	Homo sapiens, 751 aa.
	[WO200164875-A2, 07 SEP. 2001]

[0605] In a BLAST search of public sequence datbases, the NOV46a protein was found to have homology to the proteins shown in the BLASTP data in Table 46D.

TABLE 46D
Public BLASTP Results for NOV46a
		NOV46a	Identities/
Protein		Residues/	Similarities for
Accession		Match	the Matched	Expect
Number	Protein/Organism/Length	Residues	Portion	Value
O43511	Pendrin (Sodium-independent	1 . . . 743	741/780 (95%)	0.0
	chloride/iodide transporter) - Homo	1 . . . 780	743/780 (95%)
	sapiens (Human), 780 aa.
Q9R154	Pendrin (Sodium-independent	1 . . . 743	656/780 (84%)	0.0
	chloride/iodide transporter) - Rattus	1 . . . 780	700/780 (89%)
	norvegicus (Rat), 780 aa.
Q9R155	Pendrin (Sodium-independent	1 . . . 743	648/780 (83%)	0.0
	chloride/iodide transporter) - Mus	1 . . . 780	701/780 (89%)
	musculus (Mouse), 780 aa.
Q924C9	Chloride anion exchanger (DRA	20 . . . 692	330/715 (46%)	0.0
	protein) (Down-regulated in	9 . . . 713	470/715 (65%)
	adenoma) - Rattus norvegicus
	(Rat), 757 aa.
Q9WVC8	Chloride anion exchanger (DRA	20 . . . 692	328/715 (45%)	0.0
	protein) (Down-regulated in	9 . . . 713	463/715 (63%)
	adenoma) - Mus musculus (Mouse),
	757 aa.

[0606] PFam analysis predicts that the NOV46a protein contains the domains shown in the Table 46E.

TABLE 46E
Domain Analysis of NOV46a
		Identities/
	NOV46a	Similarities
	Match	for the	Expect
Pfam Domain	Region	Matched Region	Value
7tm_3	171 . . . 410	48/293 (16%)	0.46
		137/293 (47%)
Xan_ur_permease	85 . . . 465	67/468 (14%)	0.56
		234/468 (50%)
Sulfate_transp	166 . . . 476	110/328 (34%)	1.8e−97
		265/328 (81%)
STAS	499 . . . 688	32/192 (17%)	1.6e−30
		147/192 (77%)

Example 47

[0607] The NOV47 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 47A.

TABLE 47A
NOV47 Sequence Analysis
	SEQ ID NO:369	1337 bp
NOV47a,	ATGAGATTTGGCATCTTTCTTTTGTGGTGGGGATGGGTTTTGGCCACTGAAAGCAGAA
CG171632-01
DNA Sequence	TGCGCTGGCCCGGAAGAGAAGTCCACGAGATGTCTAAGAAAGGCAGTAGGCCCCAAAG
	ACAAACACGAGAAGTACATGAAGATGCCCACAAGCAAGTCAGCCCAATTCTGAGACGA
	AGTCCTGCCATTCCTGTTGGTGTGGATGTGCAGGTGGAGAGTTTGCATAGCATCTCAG
	AGGTTGACATGGACTTTACGATGACCCTCTACCTGAGGCACTACTGGAAGGACGAGAG
	GCTGTCTTTTCCAAGCACCAACAACCTCAGCATGACGTTTGATGGCCGGCTGGTCAAG
	AAGATCTGGGTCCCTGACATGTTTTTCGTGCACTCCAAACGCTCCTTCATCCACGACA
	CCACCACAGACAACGTCATGTTGCGGGTCCAGCCTGATGGGAAAGTGCTCTATAGTCT
	CAGGGTTACAGTAACTGCAATGTGCAACATGGACTTCAGCCGATTTCCCTTGGACACA
	CAAACGTGCTCTCTTGAAATTGAAAGCTATGCCTATACAGAAGATGACCTCATGCTGT
	ACTGGAAAAAGGGCAATGACTCCTTAAAGACAGATGAACGGATCTCACTCTCCCAGTT
	CCTCATTCAGGAATTCCACACCACCACCAAACTGGCTTTCTACAGCAGCACAGGCTGG
	TACAACCGTCTCTACATTAATTTCACGTTGCGTCGCCACATCTTCTTCTTCTTGCCCC
	AAACTTATTTCCCCGCTACCCTGGTGGTCATGCTGTCCTGGGTGTCCTTCTGGATCGA
	CCGCAGAGCCGTGCCTGCCAGAGTCCCCTTAGGTATCACAACGCTCCTGACCATGTCC
	ACCATCATCACGGGCGTGAATGCCTCCATGCCGCGCGTCTCCTACATCAAGGCCGTGG
	ACATCTACCTCTGGGTCAGCTTTGTGTTCGTGTTCCTCTCGGTGCTGGAGTATGCGGC
	CGTCAACTACCTGACCACTGTGCAGGAGAGGAAGGAACAGAAGCTGCGGGAGAAGCTT
	CCCTGCACCAGCGGATTACCTCCGCCCAACACTGCGATGCTGGACGGCAACTACAGTC
	ATGGGGAGGTGAATGACCTGGACAACTACATGCCAGAGAATGGAGAGAAGCCCGACAG
	GATGATGGTGCAGCTGACCCTGGCCTCAGAGAGGAGCTCCCCACAGAGGAAAAGTCAG
	AGAAGCAGCTATGTGAGCATGAGAATCGACACCCACGCCATTGATAAATACTCCAGGA
	TCATCTTTCCAGCAGCATACATTTTATTCAATTTAATATACTGGTCTATTTTCTCCTA
	GAT
	ORF Start: ATG at 1		ORF Stop: TAG at 1333
	SEQ ID NO:370	444 aa	MW at 51932.2 kD
NOV47a,	MRFGIFLLWWGWVLATESRMRWPGREVHEMSKKGSRPQRQRREVHEDAHKQVSPILRR
CG171632-01
Protein Sequence	SPAIPVGVDVQVESLDSISEVDMDFTMTLYLRHYWKDERLSFPSTNNLSMTFDGRLVK
	KIWVPDMFFVHSKRSFIHDTTTDNVMLRVQPDGKVLYSLRVTVTAMCNMDFSRFPLDT
	QTCSLEIESYAYTEDDLMLYWKKGNDSLKTDERISLSQFLIQEFHTTTKLAFYSSTGW
	YNRLYINFTLRRHIFFFLPQTYFPATLVVMLSWVSFWIDRRAVPARVPLGITTVLTMS
	TIITGVNASMPRVSYIKAVDIYLWVSFVFVFLSVLEYAAVNYLTTVQERKEQKLREKL
	PCTSGLPPPNTAMLDGNYSDGEVNDLDNYMPENGEKPDRMMVQLTLASERSSPQRKSQ
	RSSYVSMRIDTHAIDKYSRTIFPAAYILFNLIYWSIFS
	SEQ ID NO:371	1337 bp
NOV47b,	ATGAGATTTGGCATCTTTCTTTTGTGGTGGGGATGGGTTTTGGCCACTGAAAGCAGAA
CG171632-01
DNA Sequence	TGCGCTGGCCCGGAAGAGAAGTCCACGAGATGTCTAAGAAAGGCAGTAGGCCCCAAAG
	ACAAAGACGAGAAGTACATGAAGATGCCCACAAGCAAGTCAGCCCAATTCTGAGACGA
	AGTCCTGCCATTCCTGTTGGTGTGGATGTGCAGGTAAAGAGTTTGGATAGCATCTCAG
	AGGTTGACATGGACTTTACGATGACCCTCTACCTGACCCACTACTGGAAGGACGAGAG
	GCTGTCTTTTCCAAGCACCAACAACCTCAGCATGACGTTTGATGGCCGGCTGGTCAAG
	AAGATCTGGGTCCCTGACATGTTTTTCGTGCACTCCAAACGCTCCTTCATCCACGACA
	CCACCACAGACAACGTCATGTTGCGGGTCCAGCCTGATGGGAAAGTGCTCTATAGTCT
	CAGGGTTACAGTAACTGCAATGTGCAACATGGACTTCAGCCGATTTCCCTTGGACACA
	CAAACGTGCTCTCTTGAAATTGAAAGCTATGCCTATACAGAAGATGACCTCATGCTGT
	ACTGGAAAAAGGGCAATGACTCCTTAAAGACAGATGAACGGATCTCACTCTCCCAGTT
	CCTCATTCAGGAATTCCACACCACCACCAAACTGGCTTTCTACAGCAGCACAGGCTGG
	TACAACCGTCTCTACATTAATTTCACGTTGCGTCGCCACATCTTCTTCTTCTTGCCCC
	AAACTTATTTCCCCGCTACCCTGGTGGTCATGCTGTCCTGGGTGTCCTTCTGGATCGA
	CCGCAGAGCCGTGCCTGCCAGAGTCCCCTTAGGTATCACAACGGTGCTGACCATGTCC
	ACCATCATCACGGGCGTGAATGCCTCCATGCCGCGCGTCTCCTACATCAAGGCCGTGG
	ACATCTACCTCTGGGTCAGCTTTGTGTTCGTGTTCCTCTCGGTGCTGGAGTATGCGGC
	CGTCAACTACCTGACCACTGTGCAGGAGAGGAAGGAACAGAAGCTGCGGGAGAAGCTT
	CCCTGCACCAGCGGATTACCTCCGCCCAACACTGCGATGCTGGACGGCAACTACAGTG
	ATGGGGAGGTGAATGACCTGGACAACTACATGCCAGAGAATGGACAGAAGCCCGACAG
	GATGATGGTGCAGCTGACCCTGGCCTCAGAGAGGAGCTCCCCACAGAGGAAAAGTCAG
	AGAAGCAGCTATGTGAGCATGAGAATCGACACCCACGCCATTGATAAATACTCCAGGA
	TCATCTTTCCAGCAGCATACATTTTATTCAATTTAATATACTGGTCTATTTTCTCCTA
	GAT
	ORF Start: ATG at 1		ORF Stop: TAG at 1333
	SEQ ID NO:372	444 aa	MW at 51932.2 kD
NOV47b,	MRFGIFLLWWGWVLATESRMRWPGREVHEMSKKGSRPQRQRREVHEDAHKQVSPTLRR
CG171632-01
Protein Sequence	SPAIPVGVDVQVESLDSISEVDMDFTMTLYLRHYWKDERLSFPSTNNLSMTFDGRLVK
	KINVPDMFFVHSKRSFIHDTTTDNVMLRVQPDGKVLYSLRVTVTAMCNMDFSRFPLDT
	QTCSLEIESYAYTEDDLMLYWKKGNDSLKTDERISLSQFLIQEFHTTTKLAFYSSTGW
	YNRLYINFTLRRHIFFFLPQTYFPATLVVMLSWVSFWIDRRAVPARVPLCITTVLTMS
	TIITGVNASMPRVSYIKAVDIYLWVSFVFVFLSVLEYAAVNYLTTVQERKEQKLREKL
	PCTSGLPPPNTANLDGNYSDGEVNDLDNYMPENGEKPDRMMVQLTLASERSSPQRKSQ
	RSSYVSMRIDTHAIDKYSRIIFPAAYTLFNLIYWSIFS

[0608] Sequence comparison of the above protein sequences yields the following sequence relationships shown in Table 47B.

TABLE 47B
Comparison of NOV47a against NOV47b.
	NOV47a Residues/	Identities/Similarities
Protein Sequence	Match Residues	for the Matched Region
NOV47b	1 . . . 444	444/444 (100%)
	1 . . . 444	444/444 (100%)

[0609] Further analysis of the NOV47a protein yielded the following properties shown in Table 47C.

TABLE 47C
Protein Sequence Properties NOV47a
PSort     0.4600 probability located in plasma membrane; 0.1692
analysis: probability located inmicrobody (peroxisome);
          0.1000 probability located in endoplasmic reticulum
          (membrane); 0.1000 probability located in
          endoplasmic reticulum (lumen)
SignalP   Cleavage site between residues 16 and 17
analysis:

[0610] A search of the NOV47a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 47D.

TABLE 47D
Geneseq Results for NOV47a
		NOV47a	Identities/
		Residues/	Similarities
Geneseq	Protein/Organism/Length	Match	for the	Expect
Identifier	[Patent #, Date]	Residues	Matched Region	Value
AAE21956	Human transporter protein - Homo	18 . . . 443	268/432 (62%)	e−149
	sapiens, 467 aa. [US2002028773-	36 . . . 466	320/432 (74%)
	A1, 07 MAR. 2002]
AAU04467	Human gamma-amino butyric acid	18 . . . 443	268/432 (62%)	e−149
	(GABA) receptor protein #1 - Homo	36 . . . 466	320/432 (74%)
	sapiens, 467 aa. [WO200153489-
	A1, 26 JUL. 2001]
AAU04470	Human gamma-amino butyric acid	35 . . . 443	263/412 (63%)	e−149
	(GABA) receptor protein #4 - Homo	9 . . . 419	313/412 (75%)
	sapiens, 420 aa. [WO200153489-
	A1, 26 JUL. 2001]
AAG68256	Human POLY3 protein sequence	18 . . . 443	266/433 (61%)	e−146
	SEQ ID NO: 6 - Homo sapiens, 468	36 . . . 467	318/433 (73%)
	aa. [WO200179294-A2, 25 OCT.
	2001]
AAO14188	Human transporter and ion channel	18 . . . 443	264/432 (61%)	e−146
	TRICH-5 - Homo sapiens, 467 aa.	36 . . . 466	317/432 (73%)
	[WO200204520-A2, 17 JAN. 2002]

[0611] In a BLAST search of public sequence datbases, the NOV47a protein was found to have homology to the proteins shown in the BLASTP data in Table 47E.

TABLE 47E
Public BLASTP Results for NOV47a
		NOV47a	Identities/
Protein		Residues/	Similarities
Accession		Match	for the	Expect
Number	Protein/Organism/Length	Residues	Matched Portion	Value
P24046	Gamma-aminobutyric-acid receptor	1 . . . 444	439/474 (92%)	0.0
	rho-1 subunit precursor (GABA(A)	1 . . . 473	440/474 (92%)
	receptor) - Homo sapiens (Human),
	473 aa.
P50572	Gamma-aminobutyric-acid receptor	1 . . . 444	416/474 (87%)	0.0
	rho-1 subunit precursor (GABA(A)	1 . . . 474	425/474 (88%)
	receptor) - Rattus norvegicus (Rat),
	474 aa.
P56475	Gamma-aminobutyric-acid receptor	1 . . . 444	413/474 (87%)	0.0
	rho-1 subunit precursor (GABA(A)	1 . . . 474	423/474 (89%)
	receptor) - Mus musculus (Mouse),
	474 aa.
Q8UW04	GABA receptor rho-1 subunit -	23 . . . 443	325/427 (76%)	0.0
	Fugu rubripes (Japanese pufferfish)	54 . . . 479	361/427 (84%)
	(Takifugu rubripes), 480 aa.
Q9YGQ4	Gamma-aminobutyric-acid receptor	60 . . . 444	317/389 (81%)	0.0
	rho-1A subunit - Morone americana	89 . . . 476	345/389 (88%)
	(White perch), 476 aa.

[0612] PFam analysis predicts that the NOV47a protein contains the domains shown in the Table 47F.

TABLE 47F
Domain Analysis of NOV47a
		Identities/
		Similarities
	NOV47a	for the	Expect
Pfam Domain	Match Region	Matched Region	Value
Neur_chan_LBD	59 . . . 246	64/242 (26%)	8.3e−71
		168/242 (69%)
Neur_chan_memb	253 . . . 440	40/291 (14%)	2.6e−52
		154/291 (53%)

Example 48

[0613] The NOV48 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 48A.

TABLE 48A
NOV48 Sequence Analysis
	SEQ ID NO:373	1118 bp
NOV48a,	GCCCTTAGATCAAGATGCGCTGTAACTGAGAAGCCCCCAAGGCGGAGGCTGAGAATCA
CG173066-01
DNA Sequence	GAGACATTTCAGCAGACATCTACAAATCCGAAAGACAAAACATGGTTCAAGCATCCGG
	GCACAGGCGGTCCACCCGTGGCTCCAAAATGGTCTCCTGGTCCGTGATAGCAAAGATC
	CAGGAAATACTGCAGAGGAAGATGGTGCGAGAGTTCCTGGCCGAGTTCATGAGCACAT
	ATGTCATGATGGTATTCGGCCTTGGTTCCGTGGCCCATATGGTTCTAAATAAAAAATA
	TGGGAGCTACCTTGGTGTCAACTTGGGTTTTGGCTTCGGAGTCACCATGGGAGTGCAC
	GTGGCAGGCCGCATCTCTGGAGCCCACATGAACGCAGCTGTGACCTTTGCTAACTGTG
	CGCTGGGCCGCGTGCCCTGGAGGAAGTTTCCGGTCTATGTGCTGGGGCAGTTCCTGGG
	CTCCTTCCTGGCGGCTGCCACCATCTACAGTCTCTTCTACACGGCCATTCTCCACTTT
	TCGGGTGGACAGCTGATGGTGACCGGTCCCGTCGCTACAGCTGGCATTTTTGCCACCT
	ACCTTCCTGATCACATGACATTGTGGCGGGGCTTCCTGAATGAGGCGTGGCTGACCGG
	GATGCTCCAGCTGTGCCTCTTCGCCATCACGGACCAGGAGAACAACCCAGCACTGCCA
	GGAACAGAGGCGCTGGTGATAGGCATCCTCGTGGTCATCATCGGGGTGTCCCTTGGCA
	TGAACACAGGATATGCCATCAACCCGTCCCGGGACCTGCCCCCCCGCATCTTCACCTT
	CATTGCTGGTTGGGGCAAACAGGTCTTCAGGTGGCATCATCTACCTGGTCTTCATTGG
	CTCCACCATCCCACGGGAGCCCCTGAAATTGGAGGATTCTGTGGCGTATGAAGACCAC
	GGGATAACCGTATTGCCCAAGATGGGATCTCATGAACCCACGATCTCTCCCCTCACCC
	CCGTCTCTGTGAGCCCTGCCAACAGATCTTCAGTCCACCCTGCCCCACCCTTACATGA
	ATCCATAGCCCTAGAGCACTTCTAAGCAGAGATTATTTGTGATCCCATCCATTCCCCA
	ATAAAGCAAGGCTTGT
	ORF Start: ATG at 100		ORF Stop: TGA at 919
	SEQ ID NO:374	273 aa	MW at 29820.8 kD
NOV48a,	MVQASGHRRSTRGSKMVSWSVIAKIQEILQRKMVREFLAEFMSTYVMMVFGLGSVAHM
CG173066-01
Protein Sequence	VLNKKYGSYLGVNLGFGFGVTMGVHVAGRISGAHMNAAVTFANCALGRVPWRKFPVYV
	LGQFLGSFLAAATIYSLFYTAILHFSGGQLMVTGPVATAGIFATYLPDHMTLWRGFLN
	EAWLTGMLQLCLFAITDQENNPALPGTEALVIGILVVIIGVSLGMNTGYAINPSRDLP
	PRIFTFIAGWGKQVFRWHHLPGLHWLHHPTGAPEIGGFCGV

[0614] Further analysis of the NOV48a protein yielded the following properties shown in Table 48B.

TABLE 48B
Protein Sequence Properties NOV48a
PSort     0.8586 probability located in mitochondrial
analysis: inner membrane; 0.7000 probability located in
          plasma membrane; 0.6400 probability located in
          microbody (peroxisome); 0.3568 probability
          located in mitochondrial intermembrane space
SignalP   No Known Signal Sequence Predicted
analysis:

[0615] A search of the NOV48a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 48C.

TABLE 48C
Geneseq Results for NOV48a
		NOV48a	Identities/
		Residues/	Similarities
Geneseq	Protein/Organism/Length	Match	for the	Expect
Identifier	[Patent #, Date]	Residues	Matched Region	Value
AAW87644	A protein with water channel	1 . . . 272	253/272 (93%)	e−143
	activity - Homo sapiens, 342 aa.	1 . . . 268	256/272 (94%)
	[WO9843997-A1, 08 OCT. 1998]
AAY70455	Human membrane channel protein-	5 . . . 272	249/269 (92%)	e−140
	5 (MECHP-5) - Homo sapiens, 341	3 . . . 267	252/269 (93%)
	aa. [WO200012711-A2, 09 MAR.
	2000]
AAE13275	Human transporters and ion	1 . . . 272	236/276 (85%)	e−130
	channels (TRICH)-2 - Homo	1 . . . 272	243/276 (87%)
	sapiens, 346 aa. [WO200177174-
	A2, 18 OCT. 2001]
ABG27139	Novel human diagnostic protein	49 . . . 273	217/225 (96%)	e−130
	#27130 - Homo sapiens, 225 aa.	1 . . . 225	221/225 (97%)
	[WO200175067-A2, 11 OCT. 2001]
ABB57440	Human secreted protein encoding	29 . . . 273	116/246 (47%)	3e−64
	polypeptide SEQ ID NO 86 - Homo	17 . . . 258	165/246 (66%)
	sapiens, 292 aa. [WO200183510-
	A1, 08 NOV. 2001]

[0616] In a BLAST search of public sequence datbases, the NOV48a protein was found to have homology to the proteins shown in the BLASTP data in Table 48D.

TABLE 48D
Public BLASTP Results for NOV48a
		NOV48a	Identities/
Protein		Residues/	Similarities
Accession		Match	for the	Expect
Number	Protein/Organism/Length	Residues	Matched Portion	Value
O14520	Aquaporin 7 (Aquaporin-7 like)	1 . . . 272	254/272 (93%)	e−143
	(Aquaporin adipose) (AQPap) -	1 . . . 268	257/272 (94%)
	Homo sapiens (Human), 342 aa.
BAC05693	Aquaporin adipose - Homo	1 . . . 272	253/272 (93%)	e−142
	sapiens (Human), 342 aa.	1 . . . 268	256/272 (94%)
Q8WX69	BA251O17.3 (similar to aquaporin	1 . . . 272	237/276 (85%)	e−130
	7) - Homo sapiens (Human), 346	1 . . . 272	243/276 (87%)
	aa.
O54794	Aquaporin 7 - Mus musculus	16 . . . 272	193/257 (75%)	e−108
	(Mouse), 303 aa.	1 . . . 253	218/257 (84%)
AAM81581	Aquaporin 7 variant - Rattus	20 . . . 272	184/253 (72%)	e−106
	norvegicus (Rat), 269 aa.	4 . . . 252	216/253 (84%)

[0617] PFam analysis predicts that the NOV48a protein contains the domains shown in the Table 48E.

TABLE 48E
Domain Analysis of NOV48a
		Identities/
		Similarities
	NOV48a	for the	Expect
Pfam Domain	Match Region	Matched Region	Value
MIP	27 . . . 251	71/247 (29%)	1.5e−56
		168/247 (68%)

Example 49

[0618] The NOV49 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 49A.

TABLE 49A
NOV49 Sequence Analysis
	SEQ ID NO:375	1461 bp
NOV49a,	GAATTGAAGTGAATGGAACAGAAGCCAAGCAAGGTGGAGTGTGGGTCAGACCCAGAGG
CG173085-01
DNA Sequence	AGAACAGTGCCAGGTCACCAGATGGAAACCGAAAAAGAAAGAACGGCCAATGTTCCCT
	GAAAACCAGCATGTCAGGGTATATCCCTAGTTACCTGGACAAAGACGAGCAGTGTGTC
	GTGTGTGGGGACAAGGCAACTGGTTATCACTACCGCTGTATCACTTGTGAGGGCTGCA
	AGGGCTTCTTTCGCCGCACAATCCAGAAGAACCTCCATCCCACCTATTCCTGCAAATA
	TGACAGCTGCTGTGTCATTGACAAGATCACCCGCAATCAGTGCCAGCTGTGCCGCTTC
	AAGAAGTGCATCGCCGTGGGCATGGCCATGGACTTGGTTCTAGATGACTCGAAGCGGG
	TGGCCAAGCGTAAGCTGATTGAGCAGAACCGGGAGCGGCGGCGGAAGGAGGAGATGAT
	CCGATCACTGCAGCAGCGACCAGAGCCCACTCCTGAAGAGTGGGATCTGATCCACATT
	GCCACAGAGGCCCATCGCAGCACCAATGCCCAGGGCAGCCATTGGAAACAGAGGCGGA
	AATTCCTGCCCGATGACATTGGCCAGTCACCCATTGTCTCCATGCCGGACGGAGACAA
	GGTGGACCTGGAAGCCTTCAGCGAGTTTACCAAGATCATCACCCCGGCCATCACCCGT
	GTGGTGGACTTTGCCAAAAAACTGCCCATGTTCTCCGAGCTGCCTTGCGAAGACCAGA
	TCATCCTCCTGAAGGGGTGCTGCATGGAGATCATGTCCCTGCGGGCGGCTGTCCGCTA
	CGACCCTGAGAGCGACACCCTGACGCTGAGTGGGGAGATGGCTGTCAAGCGGGAGCAG
	CTCAAGAATGGCGGCCTGGGCGTAGTCTCCGACGCCATCTTTGAACTGGGCAAGTCAC
	TCTCTGCCTTTAACCTGGATGACACGGAAGTGGCTCTGCTGCAGGCTGTGCTGCTAAT
	GTCAACAGACCGCTCGGGCCTGCTGTGTGTGGACAAGATCGAGAAGAGTCAGGAGGCG
	TACCTGCTGGCGTTCGAGCACGACGTCAACCACCGCAAACACAACATTCCGCACTTCT
	GGCCCAAGCTGCTGATGAAGGGTCCGCAGGTCCGGCAGCTTGAGCAGCAGCTTGGTGA
	AGCGGGAAGTCTCCAAGGGCCGGTTCTTCAGCACCAGAGCCCGAAGAGCCCGCAGCAG
	CGTCTCCTGGAGCTGCTCCACCGAAGCGGAATTCTCCATGCCCGAGCGGTCTGTGGGG
	AAGACGACAGCAGTGAGGCGGACTCCCCGAGCTCCTCTGAGGAGGAACCGGAGGTCTG
	CGGGGACCTCGCAGGCAATGCAGCCTCTCCCTGAACCCCCCCAGAAGGCCGATGGGGA
	AGGAGAAGGAGTGCCATACCTTCTCCCAGGCCTCTGCCCCAAGAGCAGGAGGTGCCTG
	AAAGCTGGGAG
	ORF Start: ATG at 13		ORF Stop: TGA at 1366
	SEQ ID NO:376	451 aa	MW at 506l2.1 kD
NOV49a,	MEQKPSKVECGSDPEENSARSPDGNRKRKNGQCSLKTSMSGYIPSYLDKDEQCVVCGD
CG173085-01
Protein Sequence	KATGYHYRCITCEGCKGFFRRTIQKNLHPTYSCKYDSCCVIDKITRNQCQLCRFKKCI
	AVGMAMDLVLDDSKRVAKRKLIEQNRERRRKEEMIRSLQQRPEPTPEEWDLIHIATEA
	HRSTNAQGSHWKQRRKFLPDDIGQSPIVSMPDGDKVDLEAFSEFTKIITPAITRVVDF
	AKKLPMFSELPCEDQIILLKGCCMEIMSLRAAVRYDPESDTLTLSGEMAVKREQLKNG
	GLGVVSDAIFELGKSLSAFNLDDTEVALLQAVLLMSTDRSGLLCVDKIEKSQEAYLLA
	FEHDVNHRKHNIPHFWPKLLMKGPQVRQLEQQLGEAGSLQGPVLQHQSPKSPQQRLLE
	LLHRSGILHARAVCGEDDSSEADSPSSSEEEPEVCGDLAGNAASP
	SEQ ID NO:377	1375 bp
NOV49b,	CACCGGATCCACCATGGAACAGAAGCCAAGCAAGGTGGAGTGTGGGTCAGACCCAGAG
311531811 DNA
Sequence	GAGAACACTGCCAGGTCACCAGATGGAAAGCGAAAAAGAAAGAACGGCCAATGTTCCC
	TGAAAACCAGCATGTCAGGGTATATCCCTAGTTACCTGGACAAAGACGAGCAGTGTGT
	CGTGTGTGGGGACAAGGCAACTGGTTATCACTACCGCTGTATCACTTGTGAGGGCTGC
	AAGGGCTTCTTTCGCCGCACAATCCAGAAGAACCTCCATCCCACCTATTCCTGCAAAT
	ATGACAGCTGCTGTGTCATTGACAAGATCACCCGCAATCAGTGCCAGCTGTGCCGCTT
	CAAGAAGTGCATCGCCGTGGGCATGGCCATGGACTTGGTTCTAGATGACTCGAAGCGG
	GTGGCCAAGCGTAAGCTGATTGAGCAGAACCGGGAGCGGCGGCGGAAGGAGGAGATGA
	TCCGATCACTCCAGCAGCGACCAGAGCCCACTCCTGAAGAGTGGGATCTGATCCACAT
	TGCCACAGAGGCCCATCGCAGCACCAATGCCCAGGGCAGCCATTGGAAACAGAGGCGG
	AAATTCCTGCCCGATGACATTGGCCAGTCACCCATTGTCTCCATGCCGGACGGAGACA
	AGGTGGACCTGGAAGCCTTCAGCGAGTTTACCAAGATCATCACCCCGGCCATCACCCG
	TGTGGTGGACTTTGCCAAAAAACTGCCCATGTTCTCCGAGCTGCCTTGCGAAGACCAG
	ATCATCCTCCTGAAGGGGTGCTGCATGGAGATCATGTCCCTGCGGGCGGCTGTCCGCT
	ACGACCCTGAGAGCGACACCCTGACGCTGAGTGGGGAGATGGCTGTCAAGCGGGAGCA
	GCTCAAGAATGGCGGCCTGGGCGTAGTCTCCGACCCCATCTTTGAACTGGGCAAGTCA
	CTCTCTGCCTTTAACCTGGATGACACGGAAGTGGCTCTGCTGCAGGCTGTGCTGCTAA
	TGTCAACAGACCGCTCGGGCCTGCTGTGTGTGGACAAGATCGAGAAGAGTCAGGAGGC
	GTACCTGCTGGCGTTCGAGCACTACGTCAACCACCGCAAACACAACATTCCGCACTTC
	TGGCCCAAGCTGCTGATGAAGGGTCCGCAGGTCCGGCAGCTTGAGCAGCAGCTTGGTG
	AAGCGGGAAGTCTCCAAGGGCCGGTTCTTCAGCACCAGAGCCCGAAGAGCCCGCAGCA
	GCGTCTCCTGGAGCTGCTCCACCGAGCGGAATTCTCCATGCCCGAGCGGTCTTTGGTG
	GAAGACGACAGCAGTGAGGCGGACTCCCCGAGCTCCTCTGAGGAGGAACCGGAGGTCT
	GCGAGGACCTGGCAGGCAATGCAGCCTCTCCCGTCGACGGC
	ORF Start: at 2		ORF Stop: end of
			sequence
	SEQ ID NO:378	458 aa	MW at 51408.0 kD
NOV49b,	TGSTMEQKPSKVECGSDPEENSARSPDGKRKRKNGQCSLKTSMSGYIPSYLDKDEQCV
311531811
Protein Sequence	VCGDKATGYHYRCITCEGCKGFFRRTIQKNLHPTYSCKYDSCCVIDKITRNQCQLCRF
	KKCIAVGMAMDLVLDDSKRVAKRKLIEQNRERRRKEEMIRSLQQRPEPTPEEWDLIHI
	ATEAHRSTNAQGSHWKQRRKFLPDDIGQSPIVSMPDGDKVDLEAFSEFTKIITPAITR
	VVDFAKKLPMFSELPCEDQIILLKGCCMEIMSLRAAVRYDPESDTLTLSGEMAVKREQ
	LKNGGLGVVSDAIFELGKSLSAFNLDDTEVALLQAVLLMSTDRSGLLCVDKIEKSQEA
	YLLAFEHYVNHRKHNIPHFWPKLLMKGPQVRQLEQQLGEAGSLQGPVLQHQSPKSPQQ
	RLLELLHRSGILHARAVFGEDDSSEADSPSSSEEEPEVCEDLAGNAASPVDG

[0619] Sequence comparison of the above protein sequences yields the following sequence relationships shown in Table 49B.

TABLE 49B
Comparison of NOV49a against NOV49b.
			Identities/
			Similarities
		NOV49a Residues/	for the
	Protein Sequence	Match Residues	Matched Region
	NOV49b	1 . . . 451	447/451 (99%)
		5 . . . 455	447/451 (99%)

[0620] Further analysis of the NOV49a protein yielded the following properties shown in Table 49C.

TABLE 49C
Protein Sequence Properties NOV49a
PSort     0.9700 probability located in nucleus; 0.1000
analysis: probability located in mitochondrial matrix space;
          0.1000 probability located in lysosome (lumen);
          0.0000 probability located in endoplasmic reticulum
          (membrane)
SignalP   No Known Signal Sequence Predicted
analysis:

[0621] A search of the NOV49a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 49D.

TABLE 49D
Geneseq Results for NOV49a
		NOV49a	Identities/
		Residues/	Similarities
Geneseq	Protein/Organism/Length	Match	for the	Expect
Identifier	[Patent #, Date]	Residues	Matched Region	Value
AAP80926	Sequence of the human thyroid	1 . . . 451	448/490 (91%)	0.0
	receptor hERBA 8.7 - Homo	1 . . . 490	448/490 (91%)
	sapiens, 490 aa. [WO8803168-A,
	05 MAY 1988]
AAR26899	HerbA-T sequence - Homo sapiens,	1 . . . 451	446/490 (91%)	0.0
	490 aa. [US5144007-A, 01 SEP.	1 . . . 490	447/490 (91%)
	1992]
AAY21630	Ligand binding domain of nuclear	1 . . . 377	369/377 (97%)	0.0
	receptor hTRalpha - Homo sapiens,	1 . . . 377	371/377 (97%)
	410 aa. [WO9926966-A2, 03 JUN.
	1999]
AAR78318	Human thyroid hormone receptor	1 . . . 377	369/377 (97%)	0.0
	alpha-1 - Homo sapiens, 410 aa.	1 . . . 377	371/377 (97%)
	[US5438126-A, 01 AUG. 1995]
AAY21629	Ligand binding domain of nuclear	1 . . . 377	364/377 (96%)	0.0
	receptor rTRalpha - Rattus sp, 410	1 . . . 377	369/377 (97%)
	aa. [WO9926966-A2, 03 JUN.
	1999]

[0622] In a BLAST search of public sequence datbases, the NOV49a protein was found to have homology to the proteins shown in the BLASTP data in Table 49E.

TABLE 49E
Public BLASTP Results for NOV49a
		NOV49a	Identities/
Protein		Residues/	Similarities
Accession		Match	for the	Expect
Number	Protein/Organism/Length	Residues	Matched Portion	Value
AAH35137	Similar to thyroid hormone	1 . . . 451	448/451 (99%)	0.0
	receptor - Homo sapiens (Human),	1 . . . 451	448/451 (99%)
	451 aa.
P10827	Thyroid hormone receptor alpha	1 . . . 451	448/490 (91%)	0.0
	(C-erbA-alpha) (c-erbA-1) (EAR-	1 . . . 490	448/490 (91%)
	7) (EAR7) - Homo sapiens
	(Human), 490 aa.
O97716	Thyroid hormone receptor alpha	1 . . . 445	434/484 (89%)	0.0
	(C-erbA-alpha) (c-erbA-1) - Sus	1 . . . 484	439/484 (90%)
	scrofa (Pig), 506 aa.
I57696	c-erbA-alpha-2-related protein -	1 . . . 451	435/492 (88%)	0.0
	rat, 492 aa.	1 . . . 492	441/492 (89%)
S14418	thyroid hormone receptor alpha-3 -	1 . . . 413	407/413 (98%)	0.0
	mouse, 413 aa (fragment).	1 . . . 413	410/413 (98%)

[0623] PFam analysis predicts that the NOV49a protein contains the domains shown in the Table 49F.

TABLE 49F
Domain Analysis of NOV49a
		Identities/
		Similarities
	NOV49a	for the
Pfam Domain	Match Region	Matched Region	Expect Value
zf-C4	51 . . . 128	50/78 (64%)	2e−52
		71/78 (91%)
hormone_rec	223 . . . 408	58/212 (27%)	7.2e−34
		136/212 (64%)

Example 50

[0624] The NOV50 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 50A.

TABLE 50A
NOV50 Sequence Analysis
	SEQ ID NO:379	2174 bp
NOV50a,	GCCCTTTATCGCCGGAATTCATGTGCAATACCAACATGTCTGTACCTACTGATGGTGC
CG173095-01
DNA Sequence	TGTAACCACCTCACAGATTCCAGCTTCGGAACAAGAGACCCTGGTTAGACCAAAGCCA
	TTGCTTTTGAAGTTATTAAAGTCTGTTGGTGCACAAAAAGACACTTATACTATGAAAG
	AGAGATGGAGTTTCACTATGTTGCCCAGGCTGGTCTGGAACTCCTGGGCTCAAGGGAT
	CTGCTTACCTCGGCCTCCTAAAGTGCTAGATTTACAGGTTCTTTTTTATCTTGGCCAG
	TATATTATGACTAAACGATTATATGATGAGAAGCAACAACATATTGTATATTGTTCAA
	ATGATCTTCTAGGAGATTTGTTTGGCGTGCCAAGCTTCTCTGTGAAAGAGCACAGGAA
	AATATATACCATGATCTACAGGAACTTGGTAGTAGTCAATCAGCAGGAATCATCGGAC
	TCAGGTACATCTGTGAGTGAGAACAGGTGTCACCTTGAAGGTGGGAGTGATCAAAAGG
	ACCTTGTACAAGAGCTTCAGGAAGAGAAACCTTCATCTTCACATTTGGTTTCTAGACC
	ATCTACCTCATCTAGAAAGAGAGCAATTAGTGAGACAGAAGAAAATTCAGATGAATTA
	TCTGGTGAACGACAAAGAAAACGCCACAAATCTGATAGTATTTCCCTTTCCTTTGATG
	AAAGCCTGGCTCTGTGTGTAATAAGGGAGATATGTTGTGAAAGAAGCAGTAGCAGTGA
	ATCTACAGGGACGCCATCGAATCCGGATCTTGATGCTGGTGTAAGTGAACATTCAGGT
	GATTGGTTGGATCAGGATTCAGTTTCAGATCAGTTTAGTGTAGAATTTGAAGTTGAAT
	CTCTCGACTCAGAAGATTATAGCCTTAGTGAAGAAGGACAAGAACTCTCAGATGAAGA
	TGATGAGGTATATCAAGTTACTGTGTATCAGGCAGGGGAGAGTGATACAGATTCATTT
	GAAGAAGATCCTGAAATTTCCTTAGCTGACTATTGGAAATGCACTTCATGCAATGAAA
	TGAATCCCCCCCTTCCATCACATTGCAACAGATGTTGGGCCCTTCGTGAGAATTGGCT
	TCCTGAAGATAAAGGGAAAGATAAAGGGGAAATCTCTGAGAAAGCCAAACTGGAAAAC
	TCAACACAAGCTGAAGACGGCTTTGATGTTCCTGATTGTAAAAAAACTATAGTGAATG
	ATTCCAGAGAGTCATGTGTTGAGGAAAATGATGATAAAATTACACAAGCTTCACAATC
	ACAAGAAAGTGAAGACTATTCTCAGCCATCAACTTCTACTAGCATTATTTATAGCAGC
	CAAGAAGATGTGAAAGAGTTTGAAAGGGAAGAAACCCAAGACAAAGAAGAGAGTGTGG
	AATCTAGTTTGCCCCTTAATGCCATTGAACCTTGTGTGATTTGTCAAGGTCGACCTAA
	AAATGGTTGCATTGTCCATGGCAAAACAGGACATCTTATGGCCTGCTTTACATGTGCA
	AAGAAGCTAAAGAAAAGGAATAAGCCCTGCCCAGTATGTAGACAACCAATTCAAATGA
	TTGTGCTAACTTATTTCCCCTAGTTGACCTGTCTATAAGAGAATTATATATTTCTAAC
	TATATAACCCTAGGAATTTAGACAACCTGAAATTTATTCACATATATCAAAGTGAGAA
	AATGCCTCAATTCACATAGATTTCTTCTCTTTAGTATAATTGACCTACTTTGGTAGTG
	GAATAGTGAATACTTACTATAATTTGACTTGAATATGTAGCTCATCCTTTACACCAAC
	TCCTAATTTTAAATAATTTCTACTCTGTCTTAAATGAGAAGTACTTGGTTTTTTTTTT
	CTTAAATATGTATATGACATTTAAATGTAACTTATTATTTTTTTTCAGACCGAGTCTT
	GCTCTGTTACCCAGGCTGGAGTGCAGTGGGTGATCTTGGCTCACTGCAAGCTCTGCCC
	TCCCCGGGTTCGCACCATTCTCCTGCCTCAGCCTCCCAATTAGCTTGGCCTACAGTCA
	TCTGCCACCACACCTGGCTAATTTTTTGTACTTTTAGTAGAGACAGGGTTTCACCGTG
	TTAGCCAGGATGGTCTCGATCTCCTGACCTCGTGATCCGCCCACCTCGGCCTCCCAAA
	GTGCTGGGATTACAGGCATGAGCCACCG
	ORF Start: ATG at 21		ORF Stop: TAG at 1587
	SEQ ID NO:380	522 aa	MW at 58895.6 kD
NOV50a,	MCNTNMSVPTDGAVTTSQIPASEQETLVRPKPLLLKLLKSVGAQKDTYTMKERWSFTM
CG173095-01
Protein Sequence	LPRLVNNSWAQGICLPRPPKVLDLQVLFYLGQYIMTKRLYDEKQQHIVYCSNDLLGDL
	FGVPSFSVKEHRKIYTMIYRNLVVVNQQESSDSGTSVSENRCHLEGGSDQKDLVQELQ
	EEKPSSSHLVSRPSTSSRKRAISETEENSDELSGERQRKRHKSDSISLSFDESLALCV
	IREICCERSSSSESTGTPSNPDLDAGVSEHSGDWLDQDSVSDQFSVEFEVESLDSEDY
	SLSEEGQELSDEDDEVYQVTVYQAGESDTDSFEEDPEISLADYWKCTSCNEMNPPLPS
	HCNRCWQLRENWLPEDKGKDKGEISEKAKLENSTQAEEGFDVPDCKKTIVNDSRESCV
	EENDDKITQASQSQESEDYSQPSTSSSIIYSSQEDVKEFEREETQDKEESVESSLPLN
	AIEPCVICQGRPKNGCIVHGKTGHLMACFTCAKKLKKLKKPCPVCRQPIQMIVLTYFP
	SEQ ID NO:381	1607 bp
NOV50b,	GCCCTTTATCGCCGGAATTCATGTGCAATACCAACATGTCTGTACCTACTGATGGTGC
CG173095-02
DNA Sequence	TGTAACCACCTCACAGATTCCAGCTTCGGAACAAGAGACCCTGGTTAGACCAAAGCCA
	TTGCTTTTGAAGTTATTAAAGTCTGTTGGTGCACAAAAAGACACTTATACTATGAAAG
	AGAGATGGAGTTTCACTATGTTGCCCAGGCTGGTCTGGAACTCCTGGGCTCAAGGGAT
	CTGCTTACCTCGGCCTCCTAAAGTGCTAGATTTACAGGTTCTTTTTTATCTTGGCCAG
	TATATTATGACTAAACGATTATATGATGAGAAGCAACAACATATTGTATATTGTTCAA
	ATGATCTTCTAGGAGATTTGTTTGGCGTGCCAAGCTTCTCTGTGAAAGAGCACAGGAA
	AATATATACCATGATCTACAGGAACTTGGTAGTAGTCAATCAGCAGGAATCATCGGAC
	TCAGGTACATCTGTGAGTGAGAACAGGTGTCACCTTGAAGGTGGGAGTGATCAAAAGG
	ACCTTGTACAAGAGCTTCAGGAAGAGAAACCTTCATCTTCACATTTGGTTTCTAGACC
	ATCTACCTCATCTAGAAGGAGAGCAATTAGTGAGACAGAAGAAAATTCAGATGAATTA
	TCTGGTGAACGACAAAGAAAACGCCACAAATCTGATAGTATTTCCCTTTCCTTTGATG
	AAAGCTTGGCTCTGTGTGTAATAAGGGAGATATGTTGTGAAAGAAGCGGTAGCAGTGA
	ATCTACAGGGACGCCATCGAATCCGGATCTTGATGCTGGTGTAAGTGAACATTCAGGT
	GATTGGTTGGATCAGGATTCAGTTTCAGATCAGTTTAGTGTAGAATTTGAAGTTGAAT
	CTCTCGACTCAGAAGATTATAGCCTTAGTGAAGAAGGACAAGAACTCTCAGATGAAGA
	TGATGAGGTATATCAAGTTACTGTGTATCAGGCAGGGGAGAGTGATACAGATTCATTT
	GAAGAAGATCCTGAAATTTCCTCAGCTGACTATTGGAAATGCACTTCATGCAATGAAA
	TGAATCCCCCCCTTCCATCACATTGCAACAGATGTTGGGCCCTTCGTGAGAATTGGCT
	TCCTGAAGATAAAGGGAAAGATAAAGGGGAAATCTCTGAGAAAGCCAAACTGGAAAAC
	TCAACACAAGCTGAAGAGGGCTTTGATGTTCCTGATTGTAAAAAAACTATAGTGAATG
	ATTCCAGAGAGTCATGTGTTGAGGAAAATGATGATAAAATTACACAAGCTTCACAATC
	ACAAGAAAGTGAAGACTATTCTCAGCCATCAACTTCTAGTAGCATTATTTATAGCAGC
	CAAGAAGATGTGAAAGAGTTTGAAAGGGAAGAAACCCAAGACAAAGAAGAGAGTGTGG
	AATCTAGTTTGCCCCTTAATGCCATTGAACCTTGTGTGATTTGCCAAGGTCGACCTAA
	AAATGGTTGCATTGTCCATGGCAAAACAGGACATCTTATGGCCTGCTTTACATGTGCA
	AAGAAGCTAAAGAAAAGGAATAAGCCCTGCCCTGTATGTAGACAACCAATTCAAATGA
	TTGTGCTAACTTATTTCTCCTGACTGCAGCCAAGCTAATTC
	ORF Start: ATG at 21		ORF Stop: TGA at 1587
	SEQ ID NO:382	522 aa	MW at 58857.5 kD
NOV50b,	MCNTNMSVPTDGAVTTSQIPASEQETLVRPKPLLLKLLKSVGAQKDTYTMKERWSFTM
CG173095-02
Protein Sequence	LPRLVWNSWAQGICLPRPPKVLDLQVLFYLGQYIMTKRLYDEKQQHIVYCSNDLLGDL
	FGVPSFSVKEHRKIYTMIYRNLVVVNQQESSDSGTSVSENRCHLEGGSDQVQLVQELQ
	EEKPSSSHLVSRPSTSSRRRAISETEENSDELSGERQRKRHKSDSISLSFDESLALCV
	IREICCERSGSSESTGTPSNPDLDAGVSEHSGDWLDQDSVSDQFSVEFEVESLDSEDY
	SLSEEGQELSDEDDEVYQVTVYQAGESDTDSFEEDPEISSADYWKCTSCNEMNPPLPS
	HCNRCWALRENWLPEDKGKDKGEISEKAKLENSTQAEEGFDVPDCKKTIVNDSRESCV
	EENDDKITQASQSQESEDYSQPSTSSSIIYSSQEDVKEFEREETQDKEESVESSLPLN
	AIEPCVICQGRPKNGCIVHGKTGHLMACFTCAKKLKKRNKPCPVCRQPIQMIVLTYFS

[0625] Sequence comparison of the above protein sequences yields the following sequence relationships shown in Table 50B.

TABLE 50B
Comparison of NOV50a against NOV50b.
			Identities/
			Similarities
		NOV50a Residues/	for the
	Protein Sequence	Match Residues	Matched Region
	NOV50b	1 . . . 521	518/521 (99%)
		1 . . . 521	519/521 (99%)

[0626] Further analysis of the NOV50a protein yielded the following properties shown in Table 50C.

TABLE 50C
Protein Sequence Properties NOV50a
PSort     0.6000 probability located in nucleus; 0.3000
analysis: probability located in microbody (peroxisome);
          0.1000 probability located in mitochondrial matrix
          space; 0.1000 probability located in lysosome (lumen)
SignalP   No Known Signal Sequence Predicted
analysis:

[0627] A search of the NOV50a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 50D.

TABLE 50D
Geneseq Results for NOV50a
		NOV50a	Identities/
		Residues/	Similarities
Geneseq	Protein/Organism/Length	Match	for the	Expect
Identifier	[Patent #, Date]	Residues	Matched Region	Value
AAO15376	Human Dm2 (Hdm2) protein -	1 . . . 522	490/522 (93%)	0.0
	Homo sapiens, 491 aa.	1 . . . 491	491/522 (93%)
	[US2002045192-A1, 18 APR. 2002]
AAE22654	Human Ring finger E3 ubiquitin	1 . . . 522	490/522 (93%)	0.0
	ligase (Mdm2) protein - Homo	1 . . . 491	491/522 (93%)
	sapiens, 491 aa. [WO200197830-
	A1, 27 DEC. 2001]
AAB48284	Human MDM2 protein - Homo	1 . . . 522	490/522 (93%)	0.0
	sapiens, 491 aa. [WO200075184-	1 . . . 491	491/522 (93%)
	A1, 14 DEC. 2000]
AAY96567	MDM2 oncoprotein - Homo	1 . . . 522	490/522 (93%)	0.0
	sapiens, 491 aa. [WO200031238-	1 . . . 491	491/522 (93%)
	A2, 02 JUN. 2000]
AAW94304	Human MDM2 - Homo sapiens,	1 . . . 522	490/522 (93%)	0.0
	491 aa. [US5858976-A, 12 JAN.	1 . . . 491	491/522 (93%)
	1999]

[0628] In a BLAST search of public sequence datbases, the NOV50a protein was found to have homology to the proteins shown in the BLASTP data in Table 50E.

TABLE 50E
Public BLASTP Results for NOV50a
		NOV50a	Identities/
Protein		Residues/	Similarities
Accession		Match	for the	Expect
Number	Protein/Organism/Length	Residues	Matched Portion	Value
Q00987	Ubiquitin-protein ligase E3 Mdm2	1 . . . 522	490/522 (93%)	0.0
	(EC 6.3.2.-) (p53-binding protein	1 . . . 491	491/522 (93%)
	Mdm2) (Oncoprotein Mdm2)
	(Double minute 2 protein) (Hdm2) -
	Homo sapiens (Human), 491 aa.
P56951	Ubiquitin-protein ligase E3 Mdm2	1 . . . 522	463/522 (88%)	0.0
	(EC 6.3.2.-) (p53-binding protein	1 . . . 491	479/522 (91%)
	Mdm2) (Oncoprotein Mdm2)
	(Double minute 2 protean (Edm2) -
	Equus caballus (Horse), 491 aa.
Q9GMZ6	MDM2 - Canis familiaris (Dog), 487	1 . . . 522	456/522 (87%)	0.0
	aa.	1 . . . 487	466/522 (88%)
P56950	Ubiquitin-protein ligase E3 Mdm2	1 . . . 522	454/522 (86%)	0.0
	(EC 6.3.2.-) (p53-binding protein	1 . . . 487	464/522 (87%)
	Mdm2) (Oncoprotein Mdm2)
	(Double minute 2 protein) (Cdm2) -
	Canis familiaris (Dog), 487 aa.
Q95KN5	MDM2 - Canis familiaris (Dog), 487	1 . . . 522	453/522 (86%)	0.0
	aa.	1 . . . 487	463/522 (87%)

[0629] PFam analysis predicts that the NOV50a protein contains the domains shown in the Table 50F.

TABLE 50F
Domain Analysis of NOV50a
		Identities/
		Similarities
	NOV50a	for the
Pfam Domain	Match Region	Matched Region	Expect Value
MDM2	30 . . . 126	56/97 (58%)	1e−39
		82/97 (85%)
zf-RanBP	330 . . . 359	9/32 (28%)	3.6e−08
		26/32 (81%)
zf-C3HC4	469 . . . 509	14/55 (25%)	0.81
		31/55 (56%)

Example 51

[0630] The NOV51 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 51A.

TABLE 51A
NOV51 Sequence Analysis
	SEQ ID NO:383	2066 bp
NOV51a,	TATTTCAGAAAGCTTCAAGAACAAGCTGGAGAAGGGAAGAGTTATTCCTCCATATTCA
CG173173-01
DNA Sequence	CCTGCTTCAACTACTATTCTTATTGGGAATGGACAATGGAATGTTCTCTGGTTTTATC
	ATGATCAAAAACCTCCTTCTCTTTTGTATTTCCATGAACTTATCCAGTCACTTTGGCT
	TTTCACAGGTGCCAACCAGTTCAGTGAAAGATGAGACCAATGACAACATCACGATATT
	TACCAGGATCTTGGATGGGCTCTTGGATGGCTACGACAACAGACTTCGGCCCGGGCTG
	GGAGAGCGCATCACTCAGGTGAGGACCGACATCTACGTCACCAGCTTCGGCCCGGTGT
	CCGACACGGAAATGGAGTACACCATAGACGTGTTTTTCCGACAAGGCTGGAAAGATGA
	AAGGCTTCGGTTTAAGGGGCCCATGCAGCGCCTCCCTCTCAACACGTTCTTCCACAAC
	GGGAAGAAGTCCATCGCTCACAACATGACCACGCCCAACAAGCTGCTGCGGCTGGAGG
	ACCACGGCACCCTGCTCTACACCATGCGCTTGACCATCTCTGCAGAGTGCCCCATGCA
	GCTTGAGGACTTCCCGATGGATGCGCACGCTTGCCCTCTGAAATTTGGCAGCTATGCG
	TACCCTAATTCTGAAGTCGTTTACGTCTGGACCAACGGCTCCACCAAGTCGGTGGTGG
	TGGCGGAAGATGGCTCCAGACTGAACCAGTACCACCTGATGGGGCAGACGGTGGGCAC
	TGAGAACATCAGCACCAGCACAGGCGAATACACAATCATGACAGCTCACTTCCACCTG
	AAAAGGAAGATTGGCTACTTTGTCATCCAGACCTACCTTCCCTGCATAATGACCGTGA
	TCTTATCACAGGTGTCCTTTTGGCTGAACCGGGAATCAGTCCCAGCCAGGACAGTTTT
	TGGGGTCACCACGGTGCTGACCATGACGACCCTCAGCATCAGCGCCAGGAACTCTCTG
	CCCAAAGTGGCCTACGCCACCGCCATGGACTGGTTCATAGCTGTGTGCTATGCCTTCG
	TCTTCTCGGCGCTGATAGAGTTTGCCACGGTCAATTACTTTACCAAGAGAGGCTGGGC
	CTGGGATGGCAAAAAAGCCTTGGAAGCAGCCAAGATCAAGAAAAAGCGTGAAGTCATA
	CTAAATAAGTCAACAAACGCTTTTACAACTGGGAAGATGTCTCACCCCCCAAACATTC
	CGAAGGAACAGACCCCAGCAGGGACGTCGAATACAACCTCAGTCTCAGTAAAACCCTC
	TGAAGAGAAGACTTCTGAAAGCAAAAAGACTTACAACAGTATCAGCAAAATTGACAAA
	ATGTCCCGAATCGTATTCCCAGTCTTGTTCGGCACTTTCAACTTAGTTTACTGGGCAA
	CGTATTTGAATAGGGAGCCGGTGATAAAAGGAGCCGCCTCTCCAAAATAACCGGCCAC
	ACTCCCAAACTCCAAGACAGCCATACTTCCAGCGAAATGGTACCAAGGAGAGGTTTTG
	CTCACAGGGACTCTCCATATGTGAGCACTATCTTTCAGGAAATTTTTGCATGTTTAAT
	AATATGTACAAATAATATTGCCTTGATGTTTCTATATGTAACTTCAGATGTTTCCAAG
	ATGTCCCATTGATAATTCGAGCAAACAACTTTCTGGAAAAACAGGATACGATGACTGA
	CACTCAGATGCCCAGTATCATACGTTGATAGTTTACAAACAAGATACGTATATTTTTA
	ACTGCTTCAACTGTTACCTAACAATGTTTTTTATACTTCAAATGTCATTTCATACAAG
	TTTTCCCAGTGAATAAATATTTTAGGAAACTCTCCATGATTATTAGAAGACCAACTAT
	ATTGCGAGAAACAGAGATCATAAAGAGCACGTTTTCCATTATGAGGAAACTTGGACAT
	TTATGTACAAAATGAATTGCCTTTGATAATTCTTACTGTTCTGAAATTAGGAAAGTAC
	TTGCATGATCTTACACGAAGAAATAGAATAGGCAAACTTTTATGTAGGCAGATTAATA
	ACAGAAATACATCATATGTTAGATACACAAAATATT
	ORF Start: ATG at 87		ORF Stop: TAA at 1440
	SEQ ID NO:384	451 aa	MW at 50844.0 kD
NOV51a,	MDNGMFSGFIMIKNLLLFCISMNLSSHFGFSQVPTSSVKDETNDNITIFTRILDGLLD
CG173173-01
Protein Sequence	GYDNRLRPGLGERITQVRTDIYVTSFGPVSDTEMEYTIDVFFRQGWKDERLRFKGPMQ
	RLPLNTFFHNCKKSIAHNMTTPNKLLRLEDDGTLLYTMRLTISAECPMQLEDFPMDAH
	ACPLKFGSYAYPNSEVVYVWTNGSTKSVVVAEDGSRLNQYHLMGQTVGTENISTSTGE
	YTIMTAMFHLKRKIGYFVIQTYLPCIMTVILSQVSFWLNRESVPARTVFGVTTVLTMT
	TLSISARNSLPKVAYATANDWFIAVCYAFVFSALIEFATVNYFTKRGWAWDGKKALEA
	AKIKKKREVILNKSTNAFTTGKMSHPPNIPKEQTPAGTSNTTSVSVKPSEEKTSESKK
	TYNSISKIDKMSRIVFPVLFGTFNLVYWATYLNREPVIKGAASPK

[0631] Further analysis of the NOV51a protein yielded the following properties shown in Table 51B.

TABLE 51B
Protein Sequence Properties NOV51a
PSort     0.7073 probability located in microbody (peroxisome);
analysis: 0.7000 probability located in plasma membrane; 0.4477
          probability located in mitochondrial inner membrane;
          0.2000 probability located in endoplasmic reticulum
          (membrane)
SignalP   Cleavage site between residues 32 and 33
analysis:

[0632] A search of the NOV51a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 51C.

TABLE 51C
Geneseq Results for NOV51a
		NOV51a	Identities/
		Residues/	Similarities
Geneseq	Protein/Organism/Length	Match	for the	Expect
Identifier	[Patent #, Date]	Residues	Matched Region	Value
AAR59864	Human GABA receptor alpha5	1 . . . 451	449/462 (97%)	0.0
	subunit - Homo sapiens, 462 aa.	1 . . . 462	450/462 (97%)
	[WO9413799-A, 23 JUN. 1994]
AAR31186	GABA-A receptor alpha-5 subunit -	1 . . . 451	449/462 (97%)	0.0
	Homo sapiens, 462 aa.	1 . . . 462	450/462 (97%)
	[WO9222652-A, 23 DEC. 1992]
AAR59862	Human GABA receptor alpha2	39 . . . 444	312/419 (74%)	0.0
	subunit - Homo sapiens, 451 aa.	32 . . . 447	347/419 (82%)
	[WO9413799-A, 23 JUN. 1994]
AAR31184	GABA-A receptor alpha-2 subunit -	39 . . . 444	312/419 (74%)	0.0
	Homo sapiens, 451 aa.	32 . . . 447	347/419 (82%)
	[WO9222652-A, 23 DEC. 1992]
ABG26224	Novel human diagnostic protein	29 . . . 446	310/441 (70%)	e−177
	#26215 - Homo sapiens, 547 aa.	102 . . . 542	345/441 (77%)
	[WO200175067-A2, 11 OCT.
	2001]

[0633] In a BLAST search of public sequence datbases, the NOV51a protein was found to have homology to the proteins shown in the BLASTP data in Table 51D.

TABLE 51D
Public BLASTP Results for NOV51a
			Identities/
Protein			Similarities for
Accession		NOV51a Residues/	the Matched	Expect
Number	Protein/Organism/Length	Match Residues	Portion	Value
P31644	Gamma-aminobutyric-acid receptor	1 . . . 451	449/462 (97%)	0.0
	alpha-5 subunit precursor	1 . . . 462	450/462 (97%)
	(GABA(A) receptor) - Homo
	sapiens (Human), 462 aa.
B34130	gamma-aminobutyric	1 . . . 451	427/464 (92%)	0.0
	acid/benzodiazepine receptor alpha-	1 . . . 464	437/464 (94%)
	5 chain precursor - rat, 464 aa.
P19969	Gamma-aminobutyric-acid receptor	1 . . . 451	427/464 (92%)	0.0
	alpha-5 subunit precursor	1 . . . 464	437/464 (94%)
	(GABA(A) receptor) - Rattus
	norvegicus (Rat), 464 aa.
P26048	Gamma-aminobutyric-acid receptor	39 . . . 444	313/419 (74%)	0.0
	alpha-2 subunit precursor	32 . . . 447	348/419 (82%)
	(GABA(A) receptor) - Mus
	musculus (Mouse), 451 aa.
P23576	Gamma-aminobutyric-acid receptor	39 . . . 444	313/419 (74%)	e−180
	alpha-2 subunit precursor	32 . . . 447	347/419 (82%)
	(GABA(A) receptor) - Rattus
	norvegicus (Rat), 451 aa

[0634] PFam analysis predicts that the NOV51a protein contains the domains shown in the Table 51E.

TABLE 51E
Domain Analysis of NOV51a
		Identities/
		Similarities for
Pfam	NOV51a	the Matched	Expect
Domain	Match Region	Region	Value
Neur_chan_LBD	49 . . . 246	68/267 (25%)	9e−60
		163/267 (61%)
Neur_chan_memb	253 . . . 434	39/291 (13%)	1.6e−58
		162/291 (56%)

Example 52

[0635] The NOV52 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 52A.

TABLE 52A
NOV52 Sequence Analysis
	SEQ ID NO:385	2266 bp
NOV52a,	CTCGGGCCTGGGGCTCTGCCTGAACAACCGGCCCCCCAGACAGGACTTTGTGTACCCG
CG51213-01
DNA Sequence	ACAGTGGCACCGGGCCAAGCCTACGATGCAGATGAGCAATGCCGCTTTCAGCATGGAG
	TCAAATCGCGTCAGTTGGTGCTACAAACGGGTCTGTGTCCCCTTTGGGTCGCGCCCAG
	AGGGTGTGGACGGAGCCTGGGGGCCGTGGACTCCATGGGGCGACTGCAGCCGCACCTG
	TGGCGGCGGCGTGTCCTCTTCTAGCCGTCACTGCGACAGCCCCAGGCCAACCATCGGG
	GGCAAGTACTGTCTGGGTGAGAGAAGGCGGCACCGCTCCTGCAACACGGATGACTGTC
	CCCCTGGCTCCCAGGACTTCAGAGAAGTGCAGTGTTCTGAATTTGACAGCATCCCTTT
	CCGTGGGAAATTCTACAAGTGGAAAACGTACCGGGGAAGGTGAGTGTGGGACTCCAAA
	GGCTGTGGGGCCGTGAAGGCCAGCCGTGGGAGTGTCCAGCAGCAGGTGGATGAATGCA
	GCATCCCGGGGTCTGCCATGAGCCCTGTCCCCACCCGGGGAGACAGAGTACCTGGGAT
	ACGGTACCATGGGGGTTCAACGTGACGCTGGGAGCCCCCACTCCCTCTGCCCAAGCTG
	CCCTTCCTCTTGGGTCTGGGGTCTGTCCCTCTTGGCCTCACTCCCCCAGGGAGCAAGC
	AAAGAGTTCCGGGGTGGCCTGGCCCGTGGTGTGACGGGGCCGTGCCCCCCAGGGGGCG
	TGAAGGCCTGCTCGCTCACGTGCCTAGCGGAAGGCTTCAACTTCTACACGGAGAGGGC
	GGCAGCCGTGGTGGACGGGACACCCTGCCGTCCAGACACGGTGGACATTTGCGTCAGT
	GGCGAATGCAAGCACGTGGGCTGCGACCGAGTCCTGGGCTCCGACCTGCGGGAGGACA
	AGTGCCGAGTGTGTGGCGGTGACGGCAGTGCCTGCGAGACCATCGAGGGCGTCTTCAG
	CCCAGCCTCACCTGGGGCCGGGTACGAGGATGTCGTCTGGATTCCCAAAGGCTCCGTC
	CACATCTTCATCCAGGATCTGAACCTCTCTCTCAGTCACTTGGCCCTGAAGGGAGACC
	AGGAGTCCCTGCTGCTGGAGGGGCTGCCTGGGACCCCCCAGCCCCACCGTCTGCCTCT
	AGCTGGGACCACCTTTCAACTGCGACAGGGGCCAGACCAGGTCCAGAGCCTCGAAGCC
	CTGGGACCGATTAATGCATCTCTCATCGTCATGGTGCTGGCCCGGACCGAGCTGCCTG
	CCCTCCGCTACCGCTTCAATGCCCCCATCGCCCGTGACTCGCTGCCCCCCTACTCCTG
	GCACTATGCGCCCTGGACCAAGTGCTCGGCCCAGTGTGCAGGCGGTAGCCAGGTGCAG
	GCGGTGGAGTGCCGCAACCAGCTGGACAGCTCCGCGGTCGCCCCCCACTACTGCAGTG
	CCCACAGCAAGCTGCCCAAAAGGCAGCGCGCCTGCAACACGGAGCCTTGCCCTCCAGA
	CTGGGTTGTAGGGAACTGGTCGCTCTGCAGCCGCAGCTGCGATGCAGGCGTGCGCAGC
	CGCTCGGTCGTGTGCCAGCGCCGCGTCTCTGCCGCGGAGGAGAAGGCGCTGGACGACA
	GCGCATGCCCGCAGCCGCGCCCACCTGTACTGGAGGCCTGCCACGGCCCCACTTGCCC
	TCCGGAGTGGGCGGCCCTCGACTGGTCTGAGTGCACCCCCAGCTGCGGGCCGGGCCTC
	CGCCACCGCGTGGTCCTTTGCAAGAGCGCAGACCACCGCGCCACGCTGCCCCCGGCGC
	ACTGCTCACCCGCCGCCAAGCCACCGGCCACCATGCGCTGCAACTTGCGCCGCTGCCC
	CCCGGCCCGCTGGGTGGCTGGCGAGTGGGGTGAGTGCTCTGCACAGTGCGGCGTCGGG
	CAGCGGCAGCGCTCGGTGCGCTGCACCAGCCACACGGGCCAGGCGTCGCACGAGTGCA
	CGGAGGCCCTGCGGCCGCCCACCACGCAGCAGTGTGAGGCCAAGTGCGACAGCCCAAC
	CCCCGGGGACGGCCCTGAAGAGTGCAAGGATGTGAACAAGGTCGCCTACTGCCCCCTG
	GTGCTCAAATTTCAGTTCTGCAGCCGAGCCTACTTCCGCCAGATGTGCTGCAAAACCT
	GCCAGGGCCACTAGGGGGCGCGCGGCACCCGGAGCCACAGCTGGCGGGGTCTCCGCCG
	CCAGCCCTGCAGCTGGGCCGGCCAGAGGGGGCCCCGGGAAGGCGGGAACTGGGAGGGA
	AGGG
	ORF Start: ATG at 589		ORF Stop: TAG at 2158
	SEQ ID NO:386	523 aa	MW at 56126.2 kD
NOV52a,	MGVQRDAGSPHSLCPSCPSSWVWGLSLLASLPQGASKEFRGGLARGVTGPCPPGGVKA
CG51213-01
Protein Sequence	CSLTCLAEGFNFYTERAAAVVDGTPCRPDTVDICVSGECKHVGCDRVLGSDLREDKCR
	VCGGDGSACETIEGVFSPASPGAGYEDVVWIPKGSVHIFIQDLNLSLSHLALKGDQES
	LLLEGLPGTPQPHRLPLAGTTFQLRQGPDQVQSLEALGPTNASLIVMVLARTELPALR
	YRFNAPIARDSLPPYSWHYAPWTKCSAQCAGGSQVQAVECRNQLDSSAVAPHYCSAHS
	KLPKRQRACNTEPCPPDWVVGNWSLCSRSCDAGVRSRSVVCQRRVSAAEEKALDDSAC
	PQPRPPVLEACHGPTCPPEWAALDWSECTPSCGPGLRHRVVLCKSADHRATLPPAHCS
	PAAKPPATMRCNLRRCPPARWVAGEWGECSAQCGVGQRQRSVRCTSHTGQASHECTEA
	LRPPTTQQCEAKCDSPTPGDGPEECKDVNKVAYCPLVLKFQFCSRAYFRQMCCKTCQG
	H
	SEQ ID NO:387		1866 bp
NOV52b,	TCCATAAATGGACCTTATTGGGAGAGTATAAGTCACAGGCCATGCCCCGCAAGGGGAT
CG51213-07
DNA Sequence	GCACGAAGACCCACCGCGAGCCAGGAAGGGAGCACCGGGCTCTCTGCTCTGGGACCGG
	CAGTGAGCCGGACATCTGGGTCCTCCCAAGCCGGGCGGGCTGCCCCAGGGAGGAAGGG
	AGGGGGGCGAGCCTGAGCGGGCACCTCGGCCCGCAGGAGGTCTGCAGCGAGCTGTGGT
	GTCTGAGCAAGAGCAACCGGTGCATCACCAACAGCATCCCGGCCGCCGAGGGCACGCT
	GTGCCAGACGCACACCATCGACAAGGGGTGGTGCTACAAACGGGTCTGTGTCCCCTTT
	GGGTCGCGCCCAGAGGGTGTGGACGGAGCCTGGGGGCCGTGGACTCCATGGGGCGACT
	GCAGCCGGACCTGTGGCGGCGGCGTGTCCTCTTCTAGCCGTCACTGCGACAGCCCCAG
	GCCAACCATCGGGGGCAAGTACTGTCTGGGTGAGAGAAGGCGGCACCGCTCCTGCAAC
	ACGGATGACTGTCCCCCTGGCTCCCAGGACTTCAGAGAAGTGCAGTGTTCTGAATTTG
	ACAGCATCCCTTTCCGTGGGAAATTCTACAAGTGGAAAACGTACCGGGGAGGGGGCGT
	GAAGGCCTGCTCGCTCACGTGCCTAGCGGAAGGCTTCAACTTCTACACGGAGAGGGCG
	GCAGCCGTGGTGGACGGGACACCCTGCCGTCCAGACACGGTGGACATTTGCGTCAGTG
	GCGAATGCAAGCACGTGGGCTGCGACCGAGTCCTGGGCTCCGACCTGCGGGAGGACAA
	GTGCCGAGTGTGTGGCGGTGACGGCAGTGCCTGCGAGACCATCGAGGGCGTCTTCAGC
	CCAGCCTCACCTGGGGCCGGGTACGAGGATGTCGTCTGGATTCCCAAAGGCTCCGTCC
	ACATCTTCATCCAGGATCTGAACCTCTCTCTCAGTCACTTGGCCCTGAAGGGAGACCA
	GGAGTCCCTGCTGCTGGAGGGGCTGCCCGGGACCCCCCAGCCCCACCGTCTGCCTCTA
	GCTGGGACCACCTTTCAACTGCGACAGGGGCCAGACCAGGTCCAGAGCCTCGAAGCCC
	TGGGACCGATTAATGCATCTCTCATCGTCATGGTGCTGGCCCGGACCGAGCTGCCTGC
	CCTCCGCTACCGCTTCAATGCCCCCATCGCCCGTGACTCGCTGCCCCCCTACTCCTGG
	CACTATGCGCCCTGGACCAAGTGCTCGGCCCAGTGTGCAGGCGGTAGCCAGGTGCAGG
	CGGTGGAGTGCCGCAACCAGCTGGACAGCTCCGCGGTCGCCCCCCACTACTGCAGTGC
	CCACAGCAAGCTGCCCAAAAGGCAGCGCGCCTGCAACACGGAGCCTTGCCCTCCAGAC
	TGGGTTGTAGCGAACTGGTCGCTCTGCAGCCGCAGCTGCGATGCAGGCGTGCGCAGCC
	GCTCGGTCGTGTGCCAGCGCCGCGTCTCTGCCGCGGAGGAGAAGGCGCTGGACGACAG
	CGCATGCCCGCAGCCGCGCCCACCTGTACTGGAGGCCTGCCACGGCCCCACTTGCCCT
	CCGGAGTGGGCGGCCCTCGACTGGTCTGAGTGCACCCCCAGCTGCGGGCCGGGCCTCC
	GCCACCGCGTGGTCCTTTGCAAGAGCGCAGACCACCGCGCCACGCTGCCCCCGGCGCA
	CTGCTCACCCGCCGCCAAGCCACCGGCCACCATGCGCTGCAACTTGCGCCGCTGCCCC
	CCGGCCCGCTGGGTGGCTGGCGAGTGGGGTGAGTGCTCTGCACAGTGCGGCGTCGGGC
	AGCGGCAGCGCTCGGTGCGCTGCACCAGCCACACGGGCCAGGCGTCGCACGAGTGCAC
	GGAGGCCCTG
	ORF Start: at 1		ORF Stop: end of
			sequence
	SEQ ID NO:388	622 aa	MW at 67376.2 kD
NOV52b,	SINGAYWESISHRPCPARGCTKTHREPGREHRALCSGTGSEPDIWVLPSRAGCPREEG
CG51213-07
Protein Sequence	RGASLSGHLGPQEVCSELWCLSKSNRCITNSIPAAEGTLCQTHTIDKGWCYKRVCVPF
	GSRPEGVDGAWGPWTPWGDCSRTCGGGVSSSSRHCDSPRPTIGGKYCLGERRRHRSCN
	TDDCPPGSQDFREVQCSEFDSIPFRGKFYKWKTYRGGGVKACSLTCLAEGFNFYTERA
	AAVVDGTPCRPDTVDICVSGECKHVGCDRVLGSDLREDKCRVCGGDGSACETIEGVFS
	PASPGAGYEDVVWIPKGSVHIFIQDLNLSLSHLALKGDQESLLLEGLPGTPQPHRLPL
	AGTTFQLRQGPDQVQSLEALGPINASLIVMVLARTELPALRYRFNAPIARDSLPPYSW
	HYAPWTKCSAQCAGGSQVQAVECRNQLDSSAVAPHYCSAHSKLPKRQRACNTEPCPPD
	WVVGNWSLCSRSCDAGVRSRSVVCQRRVSAAEEKALDDSACPQPRPPVLEACHGPTCP
	PEWAALDWSECTPSCGPGLRHRVVLCKSADHRATLPPAHCSPAAKPPATMRCNLRRCP
	ARWVACEWGECSAQCGVGQRQRSVRCTSHTCQASHECTEAL
	SEQ ID NO:389	3199 bp
NOV52c,	TAAAGGCTTCAGCCTGGTGCCTGGTCCAGAGATAGTGGTGGTCATTGTTACCCCATAA
CG51213-02
DNA Sequence	TGGCATTGGTGCAAGTCCTTTCTTATCTATCCTGTCACGTGCCTCATAGCCATTTATA
	TAGGCAAGACAGGCATTAGGCTGCCCATCTTGTAGATGAGTAAACTGAGGCCCAGAGA
	GGGGAAATATATTGCAAGTTGGTAGCAGAATTGAGGTCTCTGCACAACTCAAATATGC
	CACAGTGCCTCCTTGTGGAGAGGAGGACAAAAGCAGAGCTGAAATCATTATCTTGAAG
	AGGTGTCAGAAGTGGGATTGCGACAGGACTGATGTGATATTTTTAGATATGGCCAAGA
	GGACACAGTCTGAGTTTTTAGCTGAGAAATGTCCTCTATAAGGCAGAAGGCAGAGATT
	CTAGAGGACCTTTGAGGGAGAATGTATTTGAGAACAACTCTTCCAGCTTCTTACATAT
	GTACAGGTATCTCTCAGGGGCTGACCTAGGAAGGGTCCTTTCCTGTGGCCATTGATCG
	ATCCAGTCCCACATCTGGAAAGCTTACAAGAATTGGGTTCAAAGCGGGGATTACACTT
	GATAATTACAGAAGGACCACCTACTTCTTAGAGGAAAGACGCTCGGAGGTTGCTTAGG
	ATGTGGGCCAAGAGCGTCAGAGAGGACCACCTACTTTTTAGAGGAAAGACGCTGGGAG
	GTTGCTTAGGATGTGGGCCAAGAGGGTCAGAGATTTTGCTTCACCTGAACTCACTGGG
	GCTTCTCCAGGGATATTAACCTGGACTTTAAGAGTCACAGTGAGTCCCTGGGACTAGT
	TCAGCCCATCCAGGATTCAGACGGGAAGAAGGTGGGGCTGATTTTTCACCTGGAGAAA
	GAGAGGCATGTCCCACACAGACCTAACTCGGCATTGTCCCCTCCCAAACTCCCACCCC
	TCCACATAGCTTAAAAGTGTTGGGGGCTTCTCCAGTTTAGATGGGGGAACAAAGAGAA
	CCAACAGCTGGAAAAAACTAGAGATGAGGCCGTTGGCCTAGTCATCATCCAGGCCGAT
	TTCTCAGAACCACCACTTTCTCTTCGGCTACTTTGCCCATCCCATAAAAGAACCCCAA
	ATCCTTCCTGTTCATTCCTCACCAGTTCCCACGTTTCCTTCCAGAAACTCAGAAGGCA
	CCAGGAACTGAATTGCAAAGTTCGTTAGAGCACAGACTCTGAATTAAAGAGCTGGGTT
	AAACTCCAGGCTATTCCCTTAGTAGCTGTGTGACCTTACCTGTCTGAAGCTTGGTTTT
	CTCCCAGTAAGATGGGGTAGTACTGCCTAAAGAGGTATATGGCATGTATAAAGTGCTC
	CATAAATGGAGCTTATTGGGAGAGTATAAGTCACAGGCCATGCCCCGCAAGGGGATGC
	ACGAAGACCCACCGCGAGCCAGGAAGGGAGCACCGGGCTCTCTGCTCTGGGACCGGCA
	GTGAGCCGGACATCTGGGTCCTCCCAAGCCGGGCGGGCTGCCCCAGGGAGGAAGGGAG
	GGGGGCGAGCCTGAGCGGGCACCTCGGCCCGCAGGAGGTCTGCAGCGAGCTGTGGTGT
	CTGAGCAAGAGCAACCGGTGCATCACCAACAGCATCCCGGCCGCCGAGGGCACCCTGT
	GCCAGACGCACACCATCGACAAGGGGTGGTGCTACAAACGGGTCTGTGTCCCCTTTGG
	GTCGCGCCCAGAGGGTGTGGACGGAGCCTGGGGGCCGTGGACTCCATGGGGCGACTGC
	AGCCGGACCTGTGGCGGCGGCGTGTCCTCTTCTAGCCGTCACTGCGACAGCCCCAGGC
	CAACCATCGGGGGCAAGTACTGTCTGGGTGAGAGAAGGCGGCACCGCTCCTGCAACAC
	GGATGACTGTCCCCCTGGCTCCCAGGACTTCAGAGAAGTGCAGTGTTCTGAATTTGAC
	AGCATCCCTTTCCGTGGGAAATTCTACAAGTGGAAAACGTACCGGGGAGGGGGCGTGA
	AGGCCTGCTCGCTCACGTGCCTAGCGGAAGGCTTCAACTTCTACACGGAGAGGGCGGC
	AGCCGTGGTGGACGGGACACCCTGCCGTCCAGACACGGTCGACATTTGCGTCAGTGGC
	GAATGCAAGCACGTGGGCTGCGACCGAGTCCTGGGCTCCGACCTGCGGGAGGACAAGT
	GCCGAGTGTGTGGCGGTGACGGCAGTGCCTGCGAGACCATCGAGGGCGTCTTCAGCCC
	AGCCTCACCTGGGGCCGGGTACGAGGATGTCGTCTGGATTCCCAAAGGCTCCGTCCAC
	ATCTTCATCCAGGATCTCAACCTCTCTCTCAGTCACTTGGCCCTGAAGGGAGACCAGG
	AGTCCCTGCTGCTGGAGGGGCTGCCCGGGACCCCCCAGCCCCACCGTCTGCCTCTAGC
	TGGGACCACCTTTCAACTGCGACAGGGGCCAGACCAGGTCCAGAGCCTCGAAGCCCTG
	GGACCGATTAATGCATCTCTCATCGTCATGGTGCTGGCCCGGACCGAGCTGCCTGCCC
	TCCGCTACCGCTTCAATGCCCCCATCGCCCGTGACTCGCTGCCCCCCTACTCCTGGCA
	CTATGCGCCCTGGACCAAGTGCTCGGCCCAGTGTGCAGGCGGTAGCCAGGTGCAGGCG
	GTGGAGTGCCGCAACCAGCTGGACAGCTCCGCGGTCGCCCCCCACTACTGCAGTGCCC
	ACAGCAAGCTGCCCAAAAGGCAGCGCGCCTGCAACACGGAGCCTTGCCCTCCAGACTG
	GGTTGTAGGGAACTGGTCGCTCTGCAGCCGCAGCTGCGATGCAGGCGTGCGCAGCCGC
	TCGGTCGTGTGCCAGCGCCGCGTCTCTGCCGCGGAGGAGAAGGCGCTGGACCACAGCG
	CATGCCCGCAGCCGCGCCCACCTGTACTGGAGGCCTGCCACGGCCCCACTTGCCCTCC
	GGAGTGGGCGGCCCTCGACTGGTCTGAGTGCACCCCCAGCTGCGGGCCCCGCCTCCGC
	CACCGCGTGGTCCTTTGCAAGAGCGCAGACCACCGCGCCACGCTGCCCCCGGCGCACT
	GCTCACCCGCCGCCAAGCCACCGGCCACCATGCGCTGCAACTTGCGCCGCTGCCCCCC
	GGCCCGCTGGGTGGCTGGCGAGTGGGGTGAGTGCTCTGCACAGTGCGGCGTCGGGCAG
	CGGCAGCGCTCGGTGCGCTGCACCAGCCACACGGGCCAGGCGTCGCACGAGTGCACGG
	AGGCCCTGC
	ORF Start: at 1297		ORF Stop: at 3199
	SEQ ID NO:390	634 aa	MW at 68853.1 kD
NOV52c,	YCLKRYMACIKCSINGAYWESISHRPCPARGCTKTHREPGREHRALCSGTGSEPDINV
CG51213-02
Protein Sequence	LPSRAGCPREEGRGASLSGHLGPQEVCSELWCLSKSNRCITNSIPAAEGTLCQTHTID
	KGWCYKRVCVPFGSRPEGVDGAWGPWTPWGDCSRTCGGGVSSSSRHCDSPRPTIGGKY
	CLGERRRHRSCNTDDCPPGSQDFREVQCSEFDSIPFRGKFYKWKTYRGGGVKACSLTC
	LAEGFNFYTERAAAVVDGTPCRPDTVDICVSGECKHVGCDRVLGSDLREDKCRVCGGD
	GSACETIEGVFSPASPGAGYEDVVWIPKGSVHIFIQDLNLSLSHLALKGDQESLLLEG
	LPGTPQPHRLPLAGTTFQLRQGPDQVQSLEALGPINASLIVMVLARTELPALRYRFNA
	PIARDSLPPYSWHYAPWTKCSAQCAGGSQVQAVECRNQLDSSAVAPHYCSAHSKLPKR
	QRACNTEPCPPDWVVGNWSLCSRSCDAGVRSRSVVCQRRVSAAEEKALDDSACPQPRP
	PVLEACHGPTCPPEWAALDWSECTPSCGPGLRHRVVLCKSADHRATLPPAHCSPAAKP
	PATMRCNLRRCPPARWVAGEWGECSAQCGVGQRQRSVRCTSHTGQASHECTEAL
	SEQ ID NO:391	3700 bp
NOV52d,	CTGACATTCCACCCTTGACACCCCCCAACATCCTAACTTAGCTGGTAACTGCAGCACC
CG51213-03
DNA Sequence	CTCTAAGGAATTCCTAAAGAATTCTGAAGCTACTCCTCAACATCTGCTGTGACCCAGG
	TATCCTAACAATGATCATGGTGTCTGACATTTACTGAGCTCTCACTATGGGCTAAGCA
	TGTGCTGTGTGTCACCATCTAAACTCCTGACAATCCTGCTAGCCCCCACGTTACAGAG
	GAAGGGACTGAGCCATAGCATAGGGAGGATGACTTGTCCAAGGCCACAGTTTGAGACC
	ATGACAGAGCTGGGATTTAAATCCAGGTCTCTCATGACTCTCTAAATTTTACAAAGGG
	GCAGGGGAGGGGAGGAGCTGTCAAAATATCAAGCTTGGGCTGGCACTGGCTATATGTT
	GAATTGAGCCTTCCTTTTAGTTTTTGAAGGAACATCTTTCAGGCCATCTTGGCAAAGG
	GGGATTTATTTACTAAATGTGAACTGGTTAATATATGTAAAGGGTTCAGCCTGGTGCC
	TGGTCCAGAGATAGTGGTGGTCATTGTTACCCCATAATGGCATTGGTGCAAGTCCTTT
	CTTATCTATCCTGTCACGTGCCTCATAGCCATTTATATAGGCAAGACAGGCATTAGGC
	TGCCCATCTTGTAGATGAGTAAACTGAGGCCCAGAGAGGGGAAATATATTGCAAGTTG
	GTAGCAGAATTGAGGTCTCTGCACAACTCAAATATGCCACAGTGCCTCCTTGTGGAGA
	GGAGGACAAAAGCAGAGCTGAAATCATTATCTTGAAGAGGTGTCAGAAGTGGGATTGC
	GACAGGACTGATGTGATATTTTTAGATATGGCCAAGAGGACACAGTCTGAGTTTTTAG
	CTGAGAAATGTCCTCTATAAGGCAGAAGGCAGAGATTCTAGAGGACCTTTGAGGGAGA
	ATGTATTTGAGAACAACTCTTCCAGCTTCTTACATATGTACAGGTATCTCTCAGGGGC
	TGACCTAGGAAGGGTCCTTTCCTGTGGCCATTGATCGATCCAGTCCCACATCTGGAAA
	GCTTACAAGAATTGGGTTCAAAGCGGGGATTACACTTGATAATTACAGAAGGACCACC
	TACTTCTTAGAGGAAAGACGCTGGGAGGTTGCTTAGGATGTGGGCCAAGAGGGTCAGA
	GAGGACCACCTACTTTTTAGAGGAAAGACGCTGGGAGGTTGCTTAGGATGTGGGCCAA
	GAGGGTCAGAGATTTTGCTTCACCTGAACTCACTGGGGCTTCTCCAGGGATATTAACC
	TGGACTTTAAGAGTCAGAGTGAGTCCCTGGGACTAGTTCAGCCCATCCAGGATTCAGA
	CGGGAAGAAGGTGGGGCTGATTTTTCACCTGGAGAAAGAGAGGCATGTCCCACACAGA
	CCTAACTCGGCATTGTCCCCTCCCAAACTCCCACCCCTCCACATAGCTTAAAAGTGTT
	GGGCGCTTCTCCAGTTTAGATGGGGGAACAAAGAGAACCAACAGCTGGAAAAAACTAG
	AGATGAGGCCGTTGGCCTAGTCATCATCCAGGCCGATTTCTCAGAACCACCACTTTCT
	CTTCGGCTACTTTGCCCATCCCATAAAAGAACCCCAAATCCTTCCTGTTCATTCCTCA
	GCAGTTCCCACGTTTCCTTCCAGAAACTCAGAAGGCACCAGGAACTGAATTGCAAAGT
	TCGTTAGAGCACAGACTCTGAATTAAAGAGCTGGGTTAAACTCCAGGCTATTCCCTTA
	GTAGCTGTGTGACCTTACCTGTCTGAAGCTTGGTTTTCTCCCAGTAAGATGGGGTAGtT
	ACTGCCTAAAGAGGTATATGGCATGTATAAAGTGCTCCATAAATGGAGCTTATTGGGA
	GAGTATAAGTCACAGGCCATGCCCCGCAAGGGGATGCACGAAGACCCACCGCGAGCCA
	GGAAGGGAGCACGGGGCTCTCTGCTCTGGGACCGGCAGTGAGCCGGACATCTGGGTCC
	TCCCAAGCCGGGCGGGCTGCCCCAGGGAGGAAGGGAGGGGGGCGAGCCTGAGCGGGCA
	CCTCGGCCCGCAGGAGGTCTGCAGCGAGCTGTGGTGTCTGAGCAAGAGCAACCGGTGC
	ATCACCAACAGCATCCCGGCCGCCGAGGGCACGCTGTGCCAGACGCACACCATCGACA
	AGGGGTGGTGCTACAAACGGGTCTGTGTCCCCTTTGGGTCGCGCCCAGAGGGTGTGGA
	CGGAGCCTGGGGGCCGTGGACTCCATGGGGCGACTGCAGCCGGACCTGTGGCGGCGGC
	GTGTCCTCTTCTAGCCGTCACTGCGACAGCCCCAGGCCAACCATCGGGGGCAAGTACT
	GTCTGGGTGAGAGAAGGCGGCACCGCTCCTGCAACACGGATGACTGTCCCCCTCGCTC
	CCAGGACTTCAGAGAAGTGCAGTGTTCTGAATTTGACAGCATCCCTTTCCGTGGGAAA
	TTCTACAAGTGGAAAACGTACCGGGGAGGGGGCGTGAAGGCCTGCTCGCTCACGTGCC
	TAGCGGAAGGCTTCAACTTCTACACGGAGAGGGCGGCAGCCGTGGTGGACGGGACACC
	CTGCCGTCCAGACACGGTGGACATTTGCGTCAGTGGCGAATGCAAGCACGTGGGCTGC
	GACCGAGTCCTGGGCTCCGACCTGCGGGAGGACAAGTGCCGAGTGTGTGGCGGTGACG
	GCAGTGCCTGCGAGACCATCGAGGGCGTCTTCAGCCCAGCCTCACCTGGGGCCGGGTA
	CGAGGATGTCGTCTGGATTCCCAAAGGCTCCGTCCACATCTTCATCCAGGATCTGAAC
	CTCTCTCTCAGTCACTTGGCCCTGAAGGGAGACCAGGAGTCCCTGCTGCTGGAGGGGC
	TGCCCGGGACCCCCCAGCCCCACCGTCTGCCTCTAGCTGGGACCACCTTTCAACTGCG
	ACAGGGGCCAGACCAGGTCCAGAGCCTCGAAGCCCTGGGACCGATTAATGCATCTCTC
	ATCGTCATGGTGCTGGCCCGGACCGAGCTGCCTGCCCTCCGCTACCGCTTCAATGCCC
	CCATCGCCCGTGACTCGCTGCCCCCCTACTCCTGGCACTATGCGCCCTGGACCAAGTG
	CTCGGCCCAGTGTGCAGGCGGTAGCCAGGTGCAGGCGGTGGAGTGCCGCAACCAGCTG
	GACAGCTCCGCGGTCGCCCCCCACTACTGCAGTGCCCACAGCAAGCTGCCCAAAAGGC
	AGCGCGCCTGCAACACGGAGCCTTGCCCTCCAGACTGGGTTGTAGGGAACTGGTCGCT
	CTGCAGCCGCAGCTGCGATGCAGGCGTGCGCAGCCGCTCGGTCGTGTGCCAGCGCCGC
	GTCTCTGCCGCGGAGGAGAAGGCGCTGGACGACAGCGCATGCCCGCAGCCGCGCCCAC
	CTGTACTGGAGGCCTGCCACGGCCCCACTTGCCCTCCGGAGTGGGCGGCCCTCGACTG
	GTCTGAGTGCACCCCCAGCTGCGGGCCGGGCCTCCGCCACCGCGTGGTCCTTTGCAAG
	AGCGCAGACCACCGCGCCACGCTGCCCCCGGCGCACTGCTCACCCGCCGCCAAGCCAC
	CGGCCACCATGCGCTGCAACTTGCGCCGCTGCCCCCCGGCCCGCTGGGTGGCTGGCGA
	GTGGGGTGAGTGCTCTGCACAGTGCGGCGTCGGGCAGCGGCAGCGCTCGGTGCGCTGC
	ACCAGCCACACGGGCCAGGCGTCGCACGAGTGCACGGAGGCCCTGC
	ORF Start: at 1798		ORF Stop: at 3700
	SEQ ID NO:392	634 aa	MW at 68754.0 kD
NOV52d,	YCLKRYMACIKCSINGAYWESISHRPCPARGCTKTHREPGREHGALCSGTGSEPDIWV
CG51213-03
Protein Sequence	LPSRAGCPREEGRGASLSGHLGPQEVCSELWCLSKSNRCITNSIPAAEGTLCQTHTID
	KGWCYKRVCVPFGSRPEGVDGAWGPWTPWGDCSRTCGGGVSSSSRHCDSPRPTIGGKY
	CLGERRRHRSCNTDDCPPGSQDFREVQCSEFDSIPFRGKFYKWKTYRGGGVKACSLTC
	LAEGFHFYTERAAAVVDGTPCRPDTVDICVSGECKIIVGCDRVLGSDLREDKCRVCGGD
	GSACETIEGVFSPASPGAGYEDVVWIPKGSVHIFIQDLNLSLSHLALKGDQESLLLEG
	LPGTPQPHRLPLAGTTFQLRQGPDQVQSLEALGPINASLIVMVLARTELPALRYRFNA
	PIARDSLPPYSWHYAPWTKCSAQCAGGSQVQAVECRNQLDSSAVAPHYCSAHSKLPKR
	QRACNTEPCPPDWVVGNWSLCSRSCDAGVRSRSVVCQRRVSAAEEKALDDSACPQPRP
	PVLEACHGPTCPPEWAALDWSECTPSCGPGLRHRVVLCKSADHRATLPPAHCSPAAKP
	PATMRCNLRRCPPARNVAGEWGECSAQCGVGQRQRSVRCTSHTGQASHECTEAL
	SEQ ID NO:393	2804 bp
NOV52e,	TGGCCAGCCAGGCCTGAAGCGATCGGTCAGCCGAGAGCGCTACGTGGAGACCCTGGTG
CG51213-04
DNA Sequence	GTGGCTGACAAGATGATGGTGGCCTATCACGGGCGCCGGGATGTGGAGCAGTATGTCC
	TGGCCATCATGAACATTCAGGTTGCCAAACTTTTCCAGGACTCGAGTCTGGGAAGCAC
	CGTTAACATCCTCGTAACTCGCCTCATCCTGCTCACGCAGGACCAGCCCACTCTGGAG
	ATCACCCACCATGCCGGGAAGTCCCTGGACAGCTTCTGTAAGTGGCAGAAATCCATCG
	TGAACCACAGCGGCCATGGCAATGCCATTCCAGAGAACGGTGTGGCTAACCATGACAC
	AGCAGTGCTCATCACACGCTATGACATCTGCATCTACAAGAACAAACCCTGCGGCACA
	CTAGGCCTGGCCCCGGTGGGCGGAATGTGTGAGCGCGAGAGAAGCTGCAGCGTCAATG
	AGGACATTGGCCTGGCCACAGCGTTCACCATTGCCCACGAGATCGGGCACACATTCGG
	CATGAACCATGACGGCGTGGGAAACAGCTGTGGGGCCCGTGGTCAGGACCCAGCCAAG
	CTCATGGCTGCCCACATTACCATGAAGACCAACCCATTCGTGTGGTCATCCTGCAGCC
	GTGACTACATCACCAGCTTTCTAGACTCGGGCCTGGGGCTCTGCCTGAACAACCGGCC
	CCCCAGACAGGACTTTGTGTACCCGACAGTGGCACCGGGCCAAGCCTACGATGCAGAT
	GAGCAATGCCGCTTTCAGCATGGAGTCAAATCGCGTCAGTGTAAATACGGGGAGGTCT
	GCAGCGAGCTGTGGTGTCTGAGCAAGAGCAACCGGTGCATCACCAACAGCATCCCGGC
	CGCCGAGGGCACGCTGTGCCAGACGCACACCATCGACAAGGGGTGGTGCTACAAACGG
	GTCTGTGTCCCCTTTGGGTCGCGCCCAGAGGGTGTGGACGGAGCCTGGGGGCCGTGGA
	CTCCATGGGGCGACTGCAGCCGGACCTGTGGCGGCGGCGTGTCCTCTTCTAGCCGTCA
	CTGCGACAGCCCCAGGCCAACCATCGGGGGCAAGTACTGTCTGAGTGAGAGAAGGCGG
	CACCGCTCCTGCAACACGGATGACTGTCCCCCTGGCTCCCAGGACTTCAGAGAAGTGC
	AGTGTTCTGAATTTGACAGCATCCCTTTCCGTGGGAAATTCTACAAGTGGAAAACGTA
	CCGGGGAGGGGGCGTGAAGGCCTGCTCGCTCACGAGCCTAGCGGAAGGCTTCAACTTC
	TACACGGAGAGGGCGGCAGCCGTGGTGGACGGGACACCCTGCCGTCCAGACACGGTGG
	ACATTTGCGTCAGTGGCGAATGCAAGCACGTGGGCTGCGACCGAGTCCTGGGCTCCGA
	CCTGCGGGAGGACAAGTGCCGAGTGTGTGGCGGTGACGGCAGTGCCTGCGAGACCATC
	GAGGGCGTCTTCAGCCCAGCCTCACCTGGGGCCGGGTACGAGGATGTCGTCTGGATTC
	CCAAAGGCTCCGTCCACATCTTCATCCAGGATCTGAACCTCTCTCTCAGTCACTTGGC
	CCTGAAGGGAGACCAGGAGTCCCTGCTGCTGGAGGGGCTGCCTGGGACCCCCCAGCCC
	CACCGTCTGCCTCTAGCTGGGACCACCTTTCAACTGCGACAGGGGCCAGACCAGGTCC
	AGAGCCTCGAAGCCCTGGGACCGATTAATGCATCTCTCATCGTCATGGTGCTGGCCCG
	GACCGAGCTGCCTGCCCTCCGCTACCGCTTCAATGCCCCCATCGCCCGTGACTCGCTG
	CCCCCCTACTCCTGGCACTATGCGCCCTGGACCAAGTGCTCGGCCCAGTGTGCAGGCG
	GTAGCCAGGTGCAGGCGGTGGAGTGCCGCAACCAGCTGGACAGCTCCGCGGTCGCCCC
	CCACTACTGCAGTGCCCACAGCAAGCTGCCCAAAAGGCAGCGCGCCTGCAACACGGAG
	CCTTGCCCTCCAGACTGGGTTGTAGGGAACTGGTCGCTCTGCAGCCGCAGCTGCGATG
	CAGGCGTGCGCAGTCGCTCGGTCGTGTGCCAGCGCCGCGTCTCTGCCGCGGAGGAGAA
	GGCGCTGGACGACAGCGCATGCCCGCAGCCGCGCCCACCTGTACTGGAGGCCTGCCAC
	GGCCCCACTTGCCCTCCGGAGTGGGCGGCCCTCGACTGGTCTGAGTGCACCCCCAGCT
	GCGGGCCGGGCCTCCGCCACCGCGTGGTCCTTTGCAAGAGCGCAGACCACCGCGCCAC
	GCTGCCCCCGGCGCACTGCTCACCCGCCGCCAAGCCACCGGCCACCATGCGCTGCAAC
	TTGCGCCGCTGCCCCCCGGCCCGCTGGGTGGCTGGCGAGTGGGGTGAGTGCTCTGCAC
	AGTGCGGCGTCGGGCAGCGGCAGCGCTCGGTGCGCTGCACCAGCCACACGGGCCAGGC
	GTCGCACGAGTGCACGGAGGCCCTGCGGCCGCCCACCACGCAGCAGTGTGAGGCCAAG
	TGCGACAGCCCAACCCCCGGGGACGGCCCTGAAGAGTGCAAGGATGTGAACAAGGTCG
	CCTACTGCCCCCTGGTGCTCAAATTTCAGTTCTGCAGCCGAGCCTACTTCCGCCAGAT
	GTGCTGCAAAACCTGCCAGGGCCACTAGGGGGCGCGCGGCACCCGGAGCCACAGCTGG
	CGGGGTCTCCGCCGCCAGCCCTGCAGCGGGCCGGCCAAAGGGGGCCCCGGGGGGGCGG
	GAACTGGGAGGGAAGGGTGAGACGGAGCCGGAAGTTATTTATTGGGAACCCCTGCAGG
	GCCCTGGCTGGGGGGATGGA
	ORF Start: ATG at 71		ORF Stop: TAG at 2636
	SEQ ID NO:394	855 aa	MW at 93285.7 kD
NOV52e,	MNVAYHGRRDVEQYVLAIMNIQVAKLFQDSSLGSTVNILVTRLILLTEDQPTLEITHH
CG51213-04
Protein Sequence	AGKSLDSFCKWQKSIVNHSGHGMAIPENGVANHDTAVLITRYDICIYKNKPCGTLGLA
	PVGGMCERERSCSVNEDIGLATAFTIAHEIGHTFGMNHDGVGNSCGARGQDPAKLMAA
	HITMKTNPFVWSSCSRDYITSFLDSGLGLCLNNRPPRQDFVYPTVAPGQAYDADEQCR
	FQHGVKSRQCKYGEVCSELWCLSKSNRCITNSIPAAEGTLCQTHTIDKGWCYKRVCVP
	FGSRPEGVDGAWGPWTPWGDCSRTCGGGVSSSSRHCDSPRPTIGGKYCLSERRRHRSC
	NTDDCPPGSQDFREVQCSEFDSTPFRGKFYKWKTYRGGGVKACSLTSLAEGFNFYTER
	AAAVVDGTPCRPDTVDICVSGECKHVGCDRVLGSDLREDKCRVCGGDGSACETIEGVF
	SPASPGAGYEDVVWIPKGSVHIFIQDLNLSLSHLALKGDQESLLLEGLPGTPQPHRLP
	LAGTTFQLRQGPDQVQSLEALGPINASLIVMVLARTELPALRYRFNAPIARDSLPPYS
	WHYAPWTKCSAQCAGGSQVQAVECRNQLDSSAVAPHYCSAHSKLPKRQRACNTEPCPP
	DWVVGNWSLCSRSCDAGVRSRSVVCQRRVSAAEEKALDDSACPQPRPPVLEACHGPTC
	PPEWAALDWSECTPSCGPGLRHRVVLCKSADHRATLPPAHCSPAAKPPATMRCNLRRC
	PPARWVAGEWGECSAQCGVCQRQRSVRCTSHTGQASHECTEALRPPTTQQCEAKCDSP
	TPGDGPEECKDVNKVAYCPLVLKFQFCSRAYFRQMCCKTCQGH
	SEQ ID NO:395	3400 bp
NOV52f,	CGGTCTCAAGATGAGTTCCTGTCCAGTCTGGAGAGCTATGAGATCGCCTTCCCCACCC
CG51213-05
DNA Sequence	GCGTGGACCACAACGGGGCACTGCTGGCCTTCTCGCCACCTCCTCCCCGGAGGCAGCG
	CCCCGGCACGGGGGCCACAGCCGAGTCCCGCCTCTTCTACAAAGTAGCCTCGCCCAGC
	ACCCACTTCCTGCTGAACCTGACCCGCAGCTCCCGTCTACTGGCAGGGCACGTCTCCG
	TGGAGTACTGGACACGGGAGGGCCTGGCCTGGCAGAGGGCGGCCCGGCCCCACTGCCT
	CTACGCTGGTCACCTGCAGGGCCAGGCCAGCAGCTCCCATGTGGCCATCAGCACCTGT
	GGAGGCCTGCACGGCCTGATCGTGGCAGACGAGGAAGAGTACCTGATTGAGCCCCTGC
	ACGGTGGGCCCAAGGGTTCTCGGAGCCCGGAGGAAAGTGGACCACATGTGGTGTACAA
	GCGTTCCTCTCTGCGTCACCCCCACCTGGACACAGCCTGTGGAGTGAGAGATGAGAAA
	CCGTGGAAAGGGCGGCCATGGTGGCTGCGGACCTTGAAGCCACCGCCTGCCAGACCCC
	TGGGGAATGAAACAGAGCGTGGCCAGCCAGGCCTGAAGCGATCGGTCAGCCGAGAGCG
	CTACGTGGAGACCCTGGTGGTGGCTGACAAGATGATGGTGGCCTATCACGGGCGCCGG
	GATGTGGAGCAGTATGTCCTGGCCATCATGAAACATTGTTGCCAACTTTTCCAGGACT
	CGAGTCTGGGAAGCACCGTTAACATCCTCGTAACTCGCCTCATCCTGCTCACGGAGGA
	CCAGCCCACTCTGGAGATCACCCACCATGCCGGGAAGTCCCTAGACAGCTTCTGTAAG
	TGGCAGAAATCCATCGTGAACCACAGCGGCCATGGCAATGCCATTCCAGAGAACGGTG
	TGGCTAACCATGACACAGCAGTGCTCATCACACGCTATGACATCTGCATCTACAAGAA
	CAAACCCTGCGGCACACTAGGCCTGGCCCCGGTGGGCGGAATGTGTGAGCGCGAGAGA
	AGCTGCAGCGTCAATGAGGACATTGGCCTGCCACAAGCGTTCACCATTGCCCACGAGA
	TCGGGCACACATTCGGCATGAACCATGACGGCGTGGGAAACAGCTGTGGGGCCCGTGG
	TCAGGACCCAGCCAAGCTCATGGCTGCCCACATTACCATGAAGACCAACCCATTCGTG
	TGGTCATCCTGCAACCGTGACTACATCACCAGCTTTCTAGACTCGGGCCTGGGGCTCT
	GCCTGAACAACCGGCCCCCCAGACAGGACTTTGTGTACCCGACAGTGGCACCGGGCCA
	AGCCTACGATGCAGATGAGCAATGCCGCTTTCAGCATGGAGTCAAATCGCGTCAGTGT
	AAATACGGGGAGGTCTGCAGCGAGCTGTGGTGTCTGAGCAAGAGCAACCGGTGCATCA
	CCAACAGCATCCCGGCCGCCGAGGGCACGCTGTGCCAGACGCACACCATCGACAAGGG
	GTGGTGCTACAAACGGGTCTGTGTCCCCTTTGGGTCGCGCCCAGAGGGTGTGGACGGA
	GCCTGGGGGCCGTGGACTCCATGGGGCGACTGCAGCCGGACCTGTGGCGGCGGCGTGT
	CCTCTTCTAGTCGTCACTGCGACAGCCCCAGGCCAACCATCGGGGGCAAGTACTGTCT
	CGGTGAGAGAAGGCGGCACCGCTCCTGCAACACGGATGACTGTCCCCCTGGCTCCCAG
	GACTTCAGAGAAGTGCAGTGTTCTGAATTTGACAGCATCCCTTTCCGTGGGAAATTCT
	ACAAGTGGAAAACGTACCGGGGAGGGGGCGTGAAGGCCTGCTCGCTCACGAGCCTAGC
	GGAAGGCTTCAACTTCTACACGGAGAGGGCGGCAGCCGTGGTGGACGGGACACCCTGC
	CGTCCAGACACGGTGGACATTTGCGTCAGTGGCGAATGCAAGCACGTGGGCTGCGACC
	GAGTCCTGGGCTCCGACCTGCGGGAGGACAAGTGCCGAGTGTGTGGCGGTGACGGCAG
	TGCCTGCGAGACCATCGAGGGCGTCTTCAGCCCAGCCTCACCTGGGGCCGGGTACGAG
	GATGTCGTCTGGATTCCCAAAGGCTCCGTCCACATCTTCATCCAGGATCTGAACCTCT
	CTCTCAGTCACTTGGCCCTGAAGGGAGACCAGGAGTCCCTGCTGCTGGAGGGGCTGCC
	TGGGACCCCCCACCCCCACCGTCTGCCTCTAGCTGGGACCACCTTTCAACTGCGACAG
	GGGCCAGACCAGGTCCAGAGCCTCGAAGCCCTGGCACCGATTAATGCATCTCTCATCG
	TCATGGTGCTGGCCCGGACCGAGCTGCCTGCCCTCCGCTACCGCTTCAATGCCCCCAT
	CGCCCGTGACTCGCTGCCCCCCTACTCCTGGCACTATGCGCCCTGGACCAAGTGCTCG
	GCCCAGTGTGCAGGCGGTAGCCAGGTGCAGGCGGTGGAGTGCCGCAACCAGCTGGACA
	GCTCCGCGGTCGCCCCCCACTACTGCAGTGCCCACAGCAAGCTGCCCAAAAGGCAGCG
	CGCCTGCAACACGGAGCCTTGCCCTCCAGACTGGGTTGTAGGGAACTGGTCGCTCTGC
	AGCCGCAGCTGCGATGCAGGCGTGCGCAGTCGCTCGGTCGTGTGCCAGCGCCGCGTCT
	CTGCCGCGGAGGAGAAGGCGCTGGACGACAGCGCATGCCCGCAGCCGCGCCCACCTGT
	ACTGGAGGCCTGCCACGGCCCCACTTGCCCTCCGGAGTGGGCGGCCCTCGACTGGTCT
	GAGTGCACCCCCAGCTGCGGGCCGGGCCTCCGCCACCGCGTGGTCCTTTGCAAGAGCG
	CAGACCACCGCGCCACGCTGCCCCCGGCGCACTGCTCACCCGCCGCCAAGCCACCGGC
	CACCATGCGCTGCAACTTGCGCCGCTGCCCCCCGGCCCGCTGGGTGGCTGGCGAGTGG
	GGTGAGTGCTCTGCACAGTGCGGCGTCGGGCAGCGGCAGCGCTCGGTGCGCTGCACCA
	GCCACACGGGCCAGGCGTCGCACGAGTGCACGGAGGCCCTGCGGCCGCCCACCACGCA
	GCAGTGTGAGGCCAAGTGCGACAGCCCAACCCCCGGGGACGGCCCTGAAGAGTGCAAG
	GATGTGAACAAGGTCGCCTACTGCCCCCTGGTGCTCAAATTTCAGTTCTGCAGCCGAG
	CCTACTTCCGCCAGATGTGCTGCAAAACCTGCCAGGGCCACTAGGGGGCGCGCGGCAC
	CCGGAGCCACAGCTGGCGGGGTCTCCGCCGCCAGCCCTGCAGCGGGCCGGCCAAAGGG
	GGCCCCGGGGGGGCGGGAACTGGGAGGGAAGGGTGAGACGGAGCCGGAAGTTATTTAT
	TGGGAACCCCTGCAGGGCCCTGGCTGGGGGGATGGA
	ORF Start: at 1		ORF Stop: TAG at 3232
	SEQ ID NO:396	1077 aa	MW at 118071.4 kD
NOV52f,	RSQDEFLSSLESYEIAFPTRVDHNGALLAFSPPPPRRQRRGTGATAESRLFYKVASPS
CG51213-05
Protein Sequence	THFLLNLTRSSRLLAGHVSVEYWTREGLAWQRAARPHCLYAGHLQGQASSSHVATSTC
	GGLHGLIVADEEEYLIEPLHGGPKGSRSPEESGPHVVYKRSSLRHPHLDTACGVRDEK
	PWKGRPWWLRTLKPPPARPLGNETERGQPGLKRSVSRERYVETLVVADKMMVAYHGRR
	DVEQYVLAIMNIVAKLFQDSSLGSTVNILVTRLILLTEDQPTLEITHHAGKSLDSFCK
	WQKSIVNHSGHGNAIPENGVANHDTAVLITRYDICIYKNKPCGTLGLAPVGGMCERER
	SCSVNEDIGLPQAFTIAHEIGHTFGMNHDGVGNSCGARGQDPAKLMAAHITMKTNPFV
	WSSCNRDYITSFLDSGLGLCLNNRPPRQDFVYPTVAPGQAYDADEQCRFQHGVKSRQC
	KYGEVCSELWCLSKSNRCITNSIPAAEGTLCQTHTIDKGWCYKRVCVPFGSRPEGVDG
	AWGPWTPWGDCSRTCGGGVSSSSRHCDSPRPTIGGKYCLGERRRHRSCNTDDCPPGSQ
	DFREVQCSEFDSIPFRGKFYKWKTYRGGGVKACSLTSLAEGFNFYTERAAAVVVGTPC
	RPDTVDICVSGECKHVGCDRVLGSDLREDKCRVCGGDGSACETIEGVFSPASPGAGYE
	DVVWIPKGSVHIFIQDLNLSLSHLALKGDQESLLLEGLPGTPQPHRLPLAGTTFQLRQ
	GPDQVQSLEALGPINASLIVMVLARTELPALRYRFNAPIARDSLPPYSWHYAPWTKCS
	AQCAGGSQVQAVECRNQLDSSAVAPHYCSAHSKLPKRQRACNTEPCPPDWVVGNWSLC
	SRSCDAGVRSRSVVCQRRVSAAEEKALDDSACPQPRPPVLEACHGPTCPPEWAALDWS
	ECTPSCGPGLRHRVVLCKSADHRATLPPAHCSPAAKPPATMRCNLRRCPPARWVAGEW
	GECSAQCGVGQRQRSVRCTSHTGQASHECTEALRPPTTQQCEAKCDSPTPGDGPEECK
	DVNKVAYCPLVLKFQFCSRAYFRQMCCKTCQGH
	SEQ ID NO:397		978 bp
NOV52g,	TCCATAAATGGAGCTTATTGGGAGAGTATAAGTCACAGGCCATGCCCCGCAAGGGGAT
CG51213-06
DNA Sequence	GCACGAAGACCCACCGCGAGCCAGGAAGGGAGCACCGGGCTCTCTGCTCTGGGACCGG
	CAGTGAGCCGGACATCTGGGTCCTCCCAAGCCGGGCGGGCTGCCCCAGGGAGGAAGGG
	AGGGGGGCGAGCCTGAGCGGGCACCTCGGCCCGCAGGAGGTCTGCAGCGAGCTGTGGT
	GTCTGAGCAAGAGCAACCGGTGCATCACCAACAGCATCCCGGCCGCCGAGGGCACGCT
	GTGCCAGACGCACACCATCGACAAGGGGTGGTGCTACAAACGGGTCTGTGTCCCCTTT
	GGGTCGCGCCCAGAGGGTGTGGACGGAGCCTGGGGGCCGTGGACTCCATGGGGCGACT
	GCAGCCGGACCTGTGGCGGCGGCGTGTCCTCTTCTAGCCGTCACTGCGACAGCCCCAG
	GCCAACCATCGGGGGCAAGTACTGTCTGGGTGAGAGAAGGCGGCACCGCTCCTGCAAC
	ACGGATGACTGTCCCCCTGGCTCCCAGGACTTCAGAGAAGTGCAGTGTTCTGAATTTG
	ACAGCATCCCTTTCCGTGGGAAATTCTACAAGTGGAAAACGTACCGGAAAGGGGGCGT
	GAAGGCCTGCTCGCTCACGTGCCTAGCGCAAGGCTTCAACTTCTACACGGAGAGGGCG
	GCAGCCGTGGTGGACGGGACACCCTGCCGTCCAGACACGGTGGACATTTGCGTCAGTG
	GCGAATGCAAGCACGTGGGCTGCGACCGAGTCCTGGGCTCCGACCTGCGGGAGGACAA
	GTGCCGAGTGTGTGGCGGTGACGGCAGTGCCTGCGAGACCATCGAGGGCGTCTTCAGC
	CCAGCCTCACCTGGGGCCGGGTACGAGGATGTCGTCTGGATTCCCAAAGGCTCCGTCC
	ACATCTTCATCCAGGATCTGAACCTCTCTCTCAGTCACTTGGCCCTGAAG
	ORF Start: at 1		ORF Stop: end of
			sequence
	SEQ ID NO:398	1326 aa	MW at 35330.2 kD
NOV52g,	SINGAYWESISHRPCPARGCTKTHREPGREHRALCSGTGSEPDIWVLPSRAGCPREEG
CG51213-06
Protein Sequence	RGASLSGHLGPQEVCSELWCLSKSNRCITNSIPAAEGTLCQTHTIDKGWCYKRVCVPF
	GSRPEGVDGAWGPWTPWGDCSRTCGGGVSSSSRHCDSPRPTIGGKYCLGERRRHRSCN
	TDDCPPGSQDFREVQCSEFDSIPFRGKFYKWKTYRGGGVKACSLTCLAEGFNFYTERA
	AAVVDGTPCRPDTVDICVSGECKNVGCDRVLGSDLREDKCRVCGGDGSACETIEGVFS
	PASPGAGYEDVVWIPKGSVHIFIQDLNLSLSHLALK

[0636] Sequence comparison of the above protein sequences yields the following sequence relationships shown in Table 52B.

TABLE 52B
Comparison of NOV52a against NOV52b through NOV52g.
			Identities/
			Similarities for
	Protein	NOV52a Residues/	the Matched
	Sequence	Match Residues	Region
	NOV52b	54 . . . 465	412/412 (100%)
		211 . . . 622	412/412 (100%)
	NOV52c	54 . . . 465	412/412 (100%)
		223 . . . 634	412/412 (100%)
	NOV52d	54 . . . 465	412/412 (100%)
		223 . . . 634	412/412 (100%)
	NOV52e	54 . . . 523	469/470 (99%)
		386 . . . 855	469/470 (99%)
	NOV52f	54 . . . 523	469/470 (99%)
		608 . . . 1077	469/470 (99%)
	NOV52g	54 . . . 169	116/116 (100%)
		211 . . . 326	116/116 (100%)

[0637] Further analysis of the NOV52a protein yielded the following properties shown in Table 52C.

TABLE 52C
Protein Sequence Properties NOV52a
PSort     0.6400 probability located in plasma membrane; 0.5231
analysis: probability located in outside; 0.1900 probability
          located in lysosome (lumen); 0.1000 probability
          located in endoplasmic reticulum (membrane)
SignalP   Cleavage site between residues 37 and 38
analysis:

[0638] A search of the NOV52a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 52D.

TABLE 52D
Geneseq Results for NOV52a
			Identities/
			Similarities for
Geneseq	Protein/Organism/Length	NOV52a Residues/	the Matched	Expect
Identifier	[Patent #, Date]	Match Residues	Region	Value
AAU01292	Human Thrombospondin repeat	1 . . . 523	523/523 (100%)	0.0
	domain protein 2, TSR2 - Homo	1 . . . 523	523/523 (100%)
	sapiens, 523 aa. [WO200123561-
	A2, 05 APR. 2001]
AAU97888	Human aggrecanase protein #2 -	54 . . . 523	470/470 (100%)	0.0
	Homo sapiens, 1104 aa.	634 . . . 1103	470/470 (100%)
	[WO200234895-A2, 02 MAY
	2002]
AAU72890	Human metalloprotease partial	54 . . . 523	470/470 (100%)	0.0
	protein sequence #2 - Homo	634 . . . 1103	470/470 (100%)
	sapiens, 1103 aa. [WO200183782-
	A2, 08 NOV. 2001]
AAB74945	Human ADAM type metal protease	54 . . . 523	470/470 (100%)	0.0
	MDTS2 protein SEQ ID NO: 10 -	634 . . . 1103	470/470 (100%)
	Homo sapiens, 1103 aa.
	[JP2001008687-A, 16 JAN. 2001]
AAB72300	Human ADAMTS-10 alternative	54 . . . 523	469/470 (99%)	0.0
	amino acid sequence - Homo	603 . . . 1072	469/470 (99%)
	sapiens, 1072 aa. [WO200111074-
	A2, 15 FEB. 2001]

[0639] In a BLAST search of public sequence datbases, the NOV52a protein was found to have homology to the proteins shown in the BLASTP data in Table 52E.

TABLE 52E
Public BLASTP Results for NOV52a
			Identities/
Protein			Similarities for
Accession		NOV52a Residues/	the Matched	Expect
Number	Protein/Organism/Length	Match Residues	Portion	Value
CAC37778	Sequence 3 from Patent	1 . . . 523	523/523 (100%)	0.0
	WO0123561 - Homo sapiens	1 . . . 523	523/523 (100%)
	(Human), 523 aa.
Q9H324	ADAMTS-10 precursor (EC 3.4.24.-)	54 . . . 523	469/470 (99%)	0.0
	(A disintegrin and	608 . . . 1077	469/470 (99%)
	metalloproteinase with
	thrombospondin motifs 10)
	(ADAM-TS 10) (ADAM-TS10) -
	Homo sapiens (Human), 1077 aa
	(fragment).
P58459	ADAMTS-10 (EC 3.4.24.-) (A	75 . . . 522	416/449 (92%)	0.0
	disintegrin and metalloproteinase	1 . . . 449	424/449 (93%)
	with thrombospondin motifs 10)
	(ADAM-TS 10) (ADAM-TS10) -
	Mus musculus (Mouse), 450 aa
	(fragment).
CAC37777	Sequence 1 from Patent	54 . . . 465	412/412 (100%)	0.0
	WO0123561 - Homo sapiens	223 . . . 634	412/412 (100%)
	(Human), 634 aa (fragment).
CAD20434	Sequence 8 from Patent	54 . . . 464	411/411 (100%)	0.0
	WO0188156 - Homo sapiens	634 . . . 1044	411/411 (100%)
	(Human), 1044 aa (fragment).

[0640] PFam analysis predicts that the NOV52a protein contains the domains shown in the Table 52F.

TABLE 52F
Domain Analysis of NOV52a
			Identities/
			Similarities
	Pfam	NOV52a	for the Matched	Expect
	Domain	Match Region	Region	Value
	tsp_1	249 . . . 304	11/60 (18%)	0.043
			38/60 (63%)
	tsp_1	308 . . . 364	14/64 (22%)	0.1
			38/64 (59%)
	tsp_1	366 . . . 422	16/58 (28%)	0.4
			34/58 (59%)
	tsp_1	427 . . . 477	17/56 (30%)	0.073
			32/56 (57%)

Example 53

[0641] The NOV53 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 53A.

TABLE 53A
NOV53 Sequence Analysis
	SEQ ID NO:399	2245 bp
NOV53a,	AGAACAGCTTGAAGACCGTTCATTTTTAAGTGACAAGAGACTCACCTCCAAGAAGCAA
CG56155-01
DNA Sequence	TTGTGTTTTCAGAATGATTTTATTCAAGCAAGCAACTTATTTCATTTCCTTGTTTGCT
	ACAGTTTCCTGTGGATGTCTGACTCAACTCTATGAAAACGCCTTCTTCAGAGGTGGGG
	ATGTAGCTTCCATGTACACCCCAAATGCCCAATACTGCCAOATGAGGTGCACATTCCA
	CCCAAGGTGTTTGCTATTCAGTTTTCTTCCAGCAAGTTCAATCAATGACATGGAGAAA
	AGGTTTGGTTGCTTCTTGAAAGATAGTGTTACAGGAACCCTGCCAAAAGTACATCGAA
	CAGGTGCAGTTTCTGGACATTCCTTGAAGCAATGTGGTCATCAAATAAGTGCTTGCCA
	TCGAGACATTTATAAAGGAGTTGATATGAGAGGAGTCAATTTTAATGTGTCTAAGGTT
	AGCAGTGTTGAAGAATGCCAAAAAAGGTGCACCAATAACATTCGCTGCCAGTTTTTTT
	CATATGCCACGCAAACATTTCACAAGGCAGAGTACCGGAACAATTGCCTATTAAAGTA
	CAGTCCCGGAGGAACACCTACCGCTATAAAGGTGCTGAGTAACGTGGAATCTGGATTC
	TCACTGAAGCCCTGTGCCCTTTCAGAAATTGGTTGCCACATGAACATCTTCCAGCATC
	TTGCGTTCTCAGATGTGGATGTTGCCAGGGTTCTCACTCCAGATGCTTTTGTGTGTCG
	GACCATCTGCACCTATCACCCCAACTGCCTCTTCTTTACATTCTATACAAATGTATGG
	AAAATCGAGTCACAAAGAAATGTTTGTCTTCTTAAAACATCTGAAAGTGGCACACCAA
	GTTCCTCTACTCCTCAAGAAAACACCATATCTGGATATAGCCTTTTAACCTGCAAAAG
	AACTTTACCTGAACCCTGCCATTCTAAAATTTACCCGGGAGTTGACTTTGGAGGAGAA
	GAATTGAATGTGACTTTTGTTAAAGGAGTGAATGTTTGCCAAGAGACTTGCACAAAGA
	TGATTCGCTGTCAGTTTTTCACTTATTCTTTACTCCCAGAAGACTGTAAGGAAGAGAA
	GTGTAAGTGTTTCTTAAGATTATCTATGGATGGTTCTCCAACTAGGATTGCGTATGGG
	ACACAAGGGAGCTCTGGTTACTCTTTGAGATTGTGTAACACTGGGGACAACTCTGTCT
	GCACAACAAAAACAAGCACACGCATTGTTGGAGGAACAAACTCTTCTTGGGGAGAGTG
	GCCCTGGCAGGTGAGCCTGCAGGTGAAGCTGACAGCTCAGAGGCACCTGTGTGGAGGG
	TCACTCATAGGACACCAGTGGGTCCTCACTGCTGCCCACTGCTTTGATGGGCTTCCCC
	TGCAGGATGTTTGGCGCATCTATAGTGGCATTTTAAATCTGTCAGACATTACAAAAGA
	TACACCTTTCTCACAAATAAAAGAGATTATTATTCACCAAAACTATAAAGTCTCAGAA
	GGGAATCATGATATCGCCTTGATAAAACTCCAGGCTCCTTTGAATTACACTGAATTCC
	AAAAACCAATATGCCTACCTTCCAAAGGTGACACAAGCACAATTTATACCAACTGTTG
	GGTAACCGGATGGGGCTTCTCGAAGGAGAAAGGTGAAATCCAAAATATTCTACAAAAG
	GTAAATATTCCTTTGGTAACAAATGAAGAATGCCAGAAAAGATATCAAGATTATAAAA
	TAACCCAACGGATGGTCTGTGCTGGCTATAAAGAAGGGGGAAAAGATGCTTGTAAGGG
	AGATTCAGGTCGTCCCTTAGTTTGCAAACACAACGGAATGTGGCGTTTGGTGGGCATC
	ACAAGCTGGGGTGAAGGCTGTGCCCGCAGGGAGCAACCTGGTGTCTACACCAAAGTCG
	CTGAGTACATGGACTGGATTTTAGAGAAAACACAGAGCAGTGATGGAAAAGCTCAGAT
	GCAGTCACCAGCATGAGAAGCAGTCCAGAGTCTAGGCAATTTTTACAACCTGAGTTCA
	AGTCAAATTCTGAGCCTGGGGGGTCCTCATCTGCAAAGCATGGAGAGTGGCATCTTCT
	TTGCATCCTAAGGACGAAAGACACAGTGCACTCAGAGCTGCTGAGGACAATGTCTGCT
	GAAGCCCCCTTTCAGCACGCCGTAACCAGGGGCTGACAATGCGAGGTCGCAACTGAGA
	TCTCCATGACTGTGTGTTGTGAAATAAAATGGTGAAAGATC
	ORF Start ATG at 72		ORF Stop: TGA at 1986
	SEQ ID NO:400	638 aa	MW at 71369.0 kD
NOV53a,	MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCL
CG56155-01
Protein Sequence	LFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIY
	KGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGG
	TPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICT
	YHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPE
	PCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCF
	LRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQV
	SLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFS
	QIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGW
	CFSKEKGEIQNTLQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGG
	PLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA
	SEQ ID NO:401	2038 bp
NOV53b,	GTTTTCAGAATGATTTTATTCAAGCAAGCAACTTATTTCATTTCCTTGTTTGCTACAG
CG56155-02
DNA Sequence	TTTCCTGTGGATGTCTGACTCAACTCTATGAAAACGCCTTCTTCAGAGGTGGGGATGT
	AGCTTCCATGTACACCCCAAATGCCCAATACTGCCAGATGAGGTGCACATTCCACCCA
	AGGTGTTTGCTATTCAGTTTTCTTCCAGCAAGTTCAATCAATGACATGGAGAAAAGGT
	TTGGTTGCTTCTTGAAAGATAGTGTTACAGGAACCCTGCCAAAAGTACATCGAACAGG
	TGCAGTTTCTGGACATTCCTTGAAGCAATGTGCTCATCAAATAAGTGCTTGCCATCGA
	GACATTTATAAAGCAGTTGATATGAGAGGAGTCAATTTTAATGTGTCTAAGGTTAGCA
	GTGTTGAAGAATGCCAAAAAAGGTGCACCAATAACATTCGCTGCCAGTTTTTTTCATA
	TGCCACGCAAACATTTCACAAGGCAGAGTACCGGAACAATTGCCTATTAAAGTACAGT
	CCCGGAGGAACACCTACCGCTATAAAGGTGCTGAGTAACGTGGAATCTGGATTCTCAC
	TGAAGCCCTGTGCCCTTTCAGAAATTGGTTGCCACATGAACATCTTCCAGCATCTTGC
	GTTCTCAGATGTGGATGTTGCCAGGTTTCTCACTCCAGATGCTTTTGTGTGTCGGACC
	ATCTGCACCTATCACCCCAACTGCCTCTTCTTTACATTCTATACAAATGTATGGAAAA
	TCGAGTCACAAAGAAATGTTTGTCTTCTTAAAACATCTGAAAGTGGCACACCAAGTTC
	CTCTACTCCTCAAGAAAACACCATATCTGGATATAGCCTTTTAACCTGCAAAAGAACT
	TTACCTGAACCCTGCCATTCTAAAATTTACCCGGGAGTTGACTTTGGAGGAGAAGAAT
	TGAATGTGACTTTTGTTAAAGGAGTGAATGTTTGCCAAGAGACTTGCACAAAGATGAT
	TCGCTGTCAGTTTTTCACTTATTCTTTACTCCCAGAAGACTGTAAGGAAGAGAAGTGT
	AAGTGTTTCTTAAGATTATCTATGGATGGTTCTCCAACTAGGATTGCGTATGGGACAC
	AAGGGAGCTCTGGTTACTCTTTGAGATTGTGTAACACTGGGGACAACGCTGTCTGCAC
	AACAAAAACAAGCACACGCATTGTTGGAGGAACAAACTCTTCTTGGGGAGAGTGGCCC
	TGGCAGGTGAGCCTGCAGGTGAAGCTGACAGCTCAGAGGCACCTGTGTGGAGGGTCAC
	TCATAGGACACCAGTGGGTCCTCACTGCTGCCCACTGCTTTGATGGGCTTCCCCTGCA
	GGATGTTTGGCGCATCTATAGTGGCATTTTAAATCTGTCAGACATTACAAAAGATACA
	CCTTTCTCACAAATAAAAGAGATTATTATTCACCAAAACTATAAAGTCTCAGAAGGGA
	ATCATGATATCGCCTTGATAAAACTCCAGGCTCCTTTGAATTACACTGAATTCCAAAA
	ACCAATATGCCTACCTTCCAAAGGTGACACAAGCACAATTTATACCAACTGTTGGGTA
	ACCGGATGGGGCTTCTCGAAGGAGAAAGGTGAAATCCAAAATATTCTACAAAAGGTAA
	ATATTCCTTTGGTAACAAATGAAGAATGCCAGAAAAGATATCAAGATTATAAAATAAC
	CCAACGGATGGTCTGTGCTGGCTATAAAGAAGGGGGAAAAGATGCTTGTAAGGGAGAT
	TCAGGTGGTCCCTTAGTTTGCAAACACAACGGAATGTGGCGTTTGGTGGGCATCACCA
	GCTGGGGTGAAGGCTGTGCCCGCAGGGAGCAACCTGGTGTCTACACCAAAGTCGCTGA
	GTACATGGACTGGATTTTAGAGAAAACACAGAGCAGTGATGGAAAAGCTCAGATGCAG
	TCACCAGCATGAGAAGCAGTCCAGAGTCTAGGCAATTTTTACAACCTGAGTTCAAGTC
	AAATTCTGAGCCTGGGGGGTCCTCATCTGCAAAGCATGAAGAGTGGCATCTTCTTTGC
	ATCCTAAG
	ORF Start: ATG at 10		ORF Stop: TGA at 1924
	SEQ ID NO:402	638 aa	MW at 71401.1 kD
NOV53b,	MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCL
CG56155-02
Protein Sequence	LFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIY
	KGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGG
	TPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARFLTPDAFVCRTICT
	YHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPE
	PCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCF
	LRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNAVCTTKTSTRIVGGTNSSWGEWPWQV
	SLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFS
	QIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGW
	GFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGG
	PLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA
	SEQ ID NO:403	1869 bp
NOV53c,	GGATCCGGATGTCTGACTCAACTCTATGAAAACGCCTTCTTCAGAGGTGGGGATGTAG
CG56155-03
DNA Sequence	CTTCCATGTACACCCCAAATGCCCAATACTGCCAGATGAGGTGCACATTCCACCCAAG
	GTGTTTGCTATTCAGTTTTCTTCCAGCAAGTTCAATCAATGACATGGAGAAAAGGTTT
	GGTTGCTTCTTGAAAGATAGTGTTACAGGAACCCTGCCAAAAGTACATCGAACAGGTG
	CAGTTTCTGGACATTCCTTGAAGCAATGTGGTCATCAAATAAGTGCTTGCCATCGAGA
	CATTTATAAAGGAGTTGATATGAGAGGAGTCAATTTTAATGTGTCTAAGGTTAGCAGT
	GTTGAAGAATGCCAAAAAAGGTGCACCAGTAACATTCGCTGCCAGTTTTTTTCATATG
	CCACGCAAACATTTCACAAGGCAGAGTACCGGAACAATTGCCTATTAAAGTACAGTCC
	CGGAGGAACACCTACCGCTATAAAGGTGCTGAGTAACGTGGAATCTGGATTCTCACTG
	AAGCCCTGTGCCCTTTCAGAAATTGGTTGCCACATGAACATCTTCCAGCATCTTGCGT
	TCTCACATGTGGATGTTGCCAGGTTTCTCACTCCAGATGCTTTTGTGTGTCGGACCAT
	CTGCACCTATCACCCCAACTGCCTCTTCTTTACATTCTATACAAATGTATGGAAAATC
	GAGTCACAAAGAAATGTTTGTCTTCTTAAAACATCTGAAAGTGGCACACCAAGTTCCT
	CTACTCCTCAAGAAAACACCATATCTGGATATAGCCTTTTAACCTGCAAAAGAACTTT
	ACCTGAACCCTGCCATTCTAAAATTTACCCGGGAGTTGACTTTGGAGGAGAAGAATTG
	AATGTGACTTTTGTTAAAGGAGTGAATGTTTGCCAAGAGACTTGCACAAAGATGATTC
	GCTGTCAGTTTTTCACTTATTCTTTACTCCCAGAAGACTGTAAGGAAGAGAAGTGTAA
	GTGTTTCTTAAGATTATCTATGGATGGTTCTCCAACTAGGATTGCGTATGGGACACAA
	GGGAGCTCTCGTTACTCTTTGAGATTGTGTAACACTGGGGACAACGCTGTCTGCACAA
	CAAAAACAAGCACACGCATTGTTGGAGGAACAAACTCTTCTTGGGGAGAGTGGCCCTG
	GCAGGTGAGCCTGCAGGTGAAGCTGACAGCTCAGAGGCACCTGTGTGGAGGGTCACTC
	ATAGGACACCAGTGGGTCCTCACTGCTGCCCACTGCTTTGATGGGCTTCCCCTGCAGG
	ATGTTTGGCGCATCTATAGTGGCATTTTAAATCTGTCAGACATTACAAAAGATACACC
	TTTCTCACAAATAAAAGAGATTATTATTCACCAAAACTATAAAGTCTCAGAAGGGAAT
	CATGATATCGCCTTGATAAAACTCCAGGCTCCTTTGAATTACACTGAATTCCAAAAAC
	CAATATGCCTACCTTCCAAAGGTGACACAAGCACAATTTATACCAACTGTTGGGTAAC
	CGGATGGGGCTTCTCGAAGGAGAAAGGTGAAATCCAAAATATTCTACAAAAGGTAAAT
	ATTCCTTTGGTAACAAATGAAGAATGCCAGAAAAGATATCAAGATTATAAAATAACCC
	AACGGATGGTCTGTGCTGGCTATAAAGAAGGGGGAAAAGATGCTTGTAAGGGAGATTC
	AGGTGGTCCCTTAGTTTGCAAACACAATGGAATGTGGCGTTTGGTGGGCATCACCAGC
	TGGGGTGAAGGCTGTGCCCGCAGGGAGCAACCTGGTGTCTACACCAAAGTCGCTGAGT
	ACATGGACTGGATTTTAGAGAAAACACAGAGCAGTGATGGAAAAGCTCAGATGCAGTC
	ACCAGCACTCGAG
	ORF Start: at 7		ORF Stop: at 1864
	SEQ ID NO:404	619 aa	MW at 69208.4 kD
NOV53c,	GCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGC
CG56155-03
Protein Sequence	FLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVE
	ECQKRCTSNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKP
	CALSEIGCHMNIFQHLAFSDVDVARFLTPDAFVCRTICTYHPNCLFFTFYTNVWKIES
	QRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNV
	TFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGS
	SGYSLRLCNTGDNAVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIG
	HQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHD
	IALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIP
	LVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWG
	EGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA

[0642] Sequence comparison of the above protein sequences yields the following sequence relationships shown in Table 53B.

TABLE 53B
Comparison of NOV53a against NOV53b and NOV53c.
			Identities/
			Similarities for
	Protein	NOV53a Residues/	the Matched
	Sequence	Match Residues	Region
	NOV53b	1 . . . 638	636/638 (99%)
		1 . . . 638	637/638 (99%)
	NOV53c	20 . . . 638	616/619 (99%)
		1 . . . 619	618/619 (99%)

[0643] Further analysis of the NOV53a protein yielded the following properties shown in Table 53C.

TABLE 53C
Protein Sequence Properties NOV53a
PSort     0.3700 probability located in outside; 0.1900
analysis: probability located in lysosome (lumen); 0.1000
          probability located in endoplasmic reticulum
          (membrane); 0.1000 probability located
          in endoplasmic reticulum (lumen)
SignalP   Cleavage site between residues 20 and 21
analysis:

[0644] A search of the NOV53a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 53D.

TABLE 53D
Geneseq Results for NOV53a
			Identities/
			Similarities for
Geneseq	Protein/Organism/Length	NOV53a Residues/	the Matched	Expect
Identifier	[Patent #, Date]	Match Residues	Region	Value
AAU68928	Human protease domian of	427 . . . 584	158/158 (100%)	1e−92
	kallikrein I - Homo sapiens, 158 aa.	1 . . . 158	158/158 (100%)
	[US6294663-B1, 25 SEP. 2001]
AAU82755	Amino acid sequence of novel	319 . . . 621	115/306 (37%)	9e−57
	human protease #54 - Homo	513 . . . 797	172/306 (55%)
	sapiens, 802 aa. [WO200200860-
	A2, 03 JAN. 2002]
AAB24052	Human PRO618 protein sequence	319 . . . 621	115/306 (37%)	9e−57
	SEQ ID NO: 24 - Homo sapiens,	513 . . . 797	172/306 (55%)
	802 aa. [WO200053754-A1, 14
	SEP. 2000]
AAB44266	Human PRO618 (UNQ354) protein	319 . . . 621	115/306 (37%)	9e−57
	sequence SEQ ID NO: 169 - Homo	513 . . . 797	172/306 (55%)
	sapiens, 802 aa. [WO200053756-
	A2, 14 SEP. 2000]
AAY41710	Human PRO618 protein sequence -	319 . . . 621	115/306 (37%)	9e−57
	Homo sapiens, 802 aa.	513 . . . 797	172/306 (55%)
	[WO9946281-A2, 16 SEP. 1999]

[0645] In a BLAST search of public sequence datbases, the NOV53a protein was found to have homology to the proteins shown in the BLASTP data in Table 53E.

TABLE 53E
Public BLASTP Results for NOV53a
		NOV53a	Identities/
Protein		Residues/	Similarities
Accession		Match	for the	Expect
Number	Protein/Organism/Length	Residues	Matched Portion	Value
P03952	Plasma kallikrein precursor (EC	1 . . . 638	638/638 (100%)	0.0
	3.4.21.34) (Plasma prekallikrein)	1 . . . 638	638/638 (100%)
	(Kininogenin) (Fletcher factor) -
	Homo sapiens (Human), 638 aa.
O97506	Kallikrein - Sus scrofa (Pig), 643	1 . . . 635	505/635 (79%)	0.0
	aa.	9 . . . 643	569/635 (89%)
Q8R0P5	Kallikrein B, plasma 1 - Mus	1 . . . 638	487/638 (76%)	0.0
	musculus (Mouse), 638 aa.	1 . . . 638	555/638 (86%)
P26262	Plasma kallikrein precursor (EC	1 . . . 638	486/638 (76%)	0.0
	3.4.21.34) (Plasma prekallikrein)	1 . . . 638	554/638 (86%)
	(Kininogenin) (Fletcher factor) -
	Mus musculus (Mouse), 638 aa.
P14272	Plasma kallikrein precursor (EC	1 . . . 638	478/638 (74%)	0.0
	3.4.21.34) (Plasma prekallikrein)	1 . . . 638	550/638 (85%)
	(Kininogenin) (Fletcher factor) -
	Rattus norvegicus (Rat), 638 aa.

[0646] PFam analysis predicts that the NOV53a protein contains the domains shown in the Table 53F.

TABLE 53F
Domain Analysis of NOV53a
		Identities/
		Similarities
	NOV53a	for the	Expect
Pfam Domain	Match Region	Matched Region	Value
PAN	21 . . . 104	19/112 (17%)	6.8e−14
		66/112 (59%)
PAN	111 . . . 194	24/111 (22%)	5.4e−15
		67/111 (60%)
PAN	201 . . . 284	21/111 (19%)	1.3e−10
		63/111 (57%)
PAN	292 . . . 375	23/111 (21%)	2.3e−09
		64/111 (58%)
trypsin	391 . . . 621	113/262 (43%)	4.8e−100
		196/262 (75%)

Example 54

[0647] The NOV54 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 54A.

TABLE 54A
NOV54 Sequence Analysis
                 SEQ ID NO: 405           1010 bp
NOV54a,          CGTATTGCTCGGCCCGGGGAGTTTCGCCCCCTGCCCGGCTCCGCGGCGCGGAGGATGG
CG57191-01
DNA Sequence     CGTGGAAACGGCTGGGCGCGCTGGTGATGTTCCCTCTACAGATGATCTATCTGGTGGT
                 GAAAGCAGCCGTCGGACTGGTGCTGCCCGCCAAGCTGCGGGACCTGTCGCGGGAGAAC
                 GTCCTCATCACCGGCGGCGGGAGAGGCATCGGGCGTCAGCTCGCCCGCGAGTTCGCGG
                 AGCGCGGCGCCAGAAAGATTGTTCTCTGGGGCCGGACTGAGAAATGCCTGAAGGAGAC
                 GACGGAGGAGATCCGGCAGATGGGCACTGAGTGCCATTACTTCATCTGTGATGTGGGC
                 AACCGGGAGGAGGTGTACCAGACGGCCAAGGCCGTCCGGGAGAAGGTGGGTGACATCA
                 CCATCCTGGTGAACAATGCCGCCGTGGTCCATGGGAAGAGCCTAATGGACAGTGATGA
                 TGATGCCCTCCTCAAGTCCCAACACATCAACACCCTGGGCCAGTTCTGGACCACCAAG
                 GCCTTCCTGCCGCGTATGCTGGAGCTGCAGAATGGCCACATCGTGTGCCTCAACTCCG
                 TGCTGGCACTGTCTGCCATCCCCGGTGCCATCGACTACTGCACATCCAAAGCGTCAGC
                 CTTCGCCTTCATGGAGAGCCTGACCCTGGGGCTGCTGGACTGTCCGGGAGTCAGCGCC
                 ACCACAGTGCTGCCCTTCCACACCAGCACCGAGATGTTCCAGGGCATGAGAGTCAGGT
                 TTCCCAACCTCTTTCCCCCACTGAAGCCGGAGACGGTGGCCCGGAGGACAGTGGAAGC
                 TGTGCAGCTCAACCAGGCCCTCCTCCTCCTCCCATGGACAATGCATGCCCTCGTTATC
                 TTGAAAAGCATACTTCCACAGGCTGCACTCGAGGAGATCCACAAATTCTCAGGAACCT
                 ACACCTGCATGAACACTTTCAAAGGGCGGACATGAAGACAGGATGAAGACATGCTTGA
                 GGAGCCACGGAGTTTGGGGGCCAC
                 ORF Start: ATG at 55                  ORF Stop: TAG at 961
                 SEQ ID NO: 406            302 aa      MW at 33520.0kD
NOV54a,          MAWKRLGALVMFPLQMIYLVVKAAVGLVLPAKLRDLSRENVLITGGGRGIGRQLAREF
CG57191-01
Protein Sequence AERGARKIVLWGRTEKCLKETTEEIRQMGTECHYFICDVGNREEVYQTAKAVREKVGD
                 ITILVNNAAVVHGKSLMDSDDDALLKSQHINTLGQFWTTKAFLPRMLELQNGHIVCLN
                 SVLALSAIPGAIDYCTSKASAFAFMESLTLGLLDCPGVSATTVLPFHTSTEMFQGMRV
                 RFPNLFPPLKPETVARRTVEAVQLNQALLLLPWTMHALVILKSILPQAALEEIHKFSG
                 TYTCMNTFKGRT
                 SEQ ID NO: 407           1330 bp
NOV54b,          GGAGTTTCGCCCCCTGCCCGGCTCCGCGGCGCGGAGGATGGTGTGGAAACGGCTGGGC
CG57191-03
DNA Sequence     GCGCTGGTGATGTTCCCTCTACAGATGATCTATCTGGTGGTGAAAGCAGCCGTCGGAC
                 TGGTGCTGCCCGCCAAGCTGCGGGACCTGTCGCGGGAGAACGTCCCCATCACCGGCGG
                 CGGGAGAGGCATCGGGCGTCAGCTCGCCCGCGAGTTCGCGGAGCGCGGCGCCAGAAAG
                 ATTGTTCTCTGGGGCCGGACTGAGAAATGCCATTACTTCATCTGTGATGTGGGCAACC
                 GGGAGGAGGTGTACCAGACGGCCAAGGCCGTCCGGGAGAAGGTGGGTGGCATCACCAT
                 CCTGGTGAGCAATGCCGCCGTGGTCCATGGGAAGAGCCTAATGGACAGTGATGATGAT
                 GCCTTCCTCAAGTCCCAACACATCAACACCCTGGGCCAGTTCTGGACCACCAAGGCCT
                 TCCTGCCGCGTATGCTGGAGCTGCAGAATGGCCACATCGTGTGCCTCAACTCCGTGCT
                 GGCACTGTCTGCCATCCCCGGTGCCATCGACTACTGCACATCCAAAGCGTCAGCCTTC
                 CAGTGCTGCCCTTCCACACCAGCACCGAGATGTTCCAGGGCATGAGAGTCAGGTTTCC
                 CAACCTCTTTCCCCCACTGAAGCCGGAGACGGTGGCCCGGAGGACAGTGGAAGCTGTG
                 CAGCTCAACCAGGCCCTCCTCCTCCTCCCATGGACAATGCATGCCCTCGTTATCTTGA
                 AAAGCATACTTCCACAGGCTGCACTCGAGGAGATCCACAAATTCTCAGGAACCTACAC
                 CTGCATGAACACTTTCAAAGGGCGGACATAGAGACAGGATGAAGACATGCTTGAGGAG
                 CCACGGAGTTTGGGGGCCACAGCACCTGGGCACACACCCGAGCACCTGTCCATTGGCA
                 TGCTTCTGCTGGGTGAGCAGGACAGCTCCTGTCCCCAGCGAAGAATCCGGCTGCCCCT
                 GGGCCAGTCCCAGGACCTTTGCACAGGACTGATGGGTATAACTGACCCCCACAGGGAG
                 GCAGGAAAACAGCCAGAAGCCACCTTGACACTTTTGAACATTTCCAGTTCTGTAGAGT
                 TTATTGTCAATTGCTTCTCAAGTCTAACCAGCCTCAGCAGTGTGCATAGACCATTTCC
                 AGGAGGGTCTGTCCCCAGATGCTCTGCCTCCCGTTCCAAAACCCACTCATCCTCAGCT
                 TGCACAAACTGGTTGAACGGCAGGAATGAAAAATAAAGAGAGATGGCTTTTGTG
                 ORF Start: ATG at 38                  ORF Stop: TAG at 899
                 SEQ ID NO: 408            287 aa      MW at 31731.0kD
NOV54b,          MVWKRLGALVMFPLQMIYLVVKAAVGLVLPAKLRDLSRENVPITGGGRGIGRQLAREF
CG57191-03
Protein Sequence AERGARKIVLWGRTEKCHYFICDVGNREEVYQTAKAVREKVGGITILVSNAAVVHGKS
                 LMDSDDDAFLKSQHINTLGQFWTTKAFLPRMLELQNGHIVCLNSVLALSAIPGAIDYC
                 TSKASAFAFMESLTLGLLDCPGVSATTVLPFHTSTEMFQGMRVRFPNLFPPLKPETVA
                 RRTVEAVQLNQALLLLPWTMHALVILKSILPQAALEEIHKFSGTYTCMNTFKGRT
                 SEQ ID NO: 409            992 bp
NOV54c,          GGAGTTTCGCCCCCTGCCCGGCTCCGCGGCGCGGAGGATGGTGTGGAAACGGCTGGGC
CG57191-02
DNA Sequence     GCGCTGGTGATGTTCCCTCTACAGATGATCTATCTGGTGGTGAAAGCAGCCGTCGGAC
                 TGGTGCTGCCCGCCAAGCTGCGGGACCTGTCGCGGGAGAACGTCCTCATCACCGGCGG
                 CGGGAGAGGCATCGGGCGTCAGCTCGCCCGCGAGTTCGCGGAGCGCGGCGCCAGAAAG
                 ATTGTTCTCTGGGGCCGGACTGAGAAATGCCTGAAGGAGACGACAGAGGGGATCCGGC
                 AGATGGGCACTGAGTGCCACTACTTCATCTGTGATGTGGGCAACCGGGAGGAGGTGTA
                 CCAGACGGCCAAGGCCGTCCGGGAGAAGGTGGGTGACATCACCATCCTGGTGAACAAT
                 GCCGCCGTGGTCCATGGGAAGAGCCTAATGGACAGTGATGATGATGCCCTCCTCAAGT
                 CCCAACACATCAACACCCTGGGCCAGTTCTGGACCACCAAGGCCTTCCTGCCGCGTAT
                 GCTGGAGCTGCAGAATGGCCACATCGTGTGCCTCAACTCCGTGCTGGCACTGTCTGCC
                 ATCCCCGGTGCCATCGACTACTGCACATCCAAAGCGTCAGCCTTCGCCTTCATGGAGA
                 GCCTGACCCTGGGGCTGCTGGACTGTCCGGGAGTCAGCGCCACCACAGTGCTGCCCTT
                 CCACACCAGCACCGAGATGTTCCAGGGCATGAGAGTCAGGTTTCCCAACCTCTTTCCC
                 CCCTCCTCCTCCTCCCATGGACAATGCATGCCCTCGTTATCTTGAAAAGCATACTTCC
                 ACAGGCTGCACTCGAGGAGATCCACAAATTCTCAGGAACCTACACCTGCATGAACACT
                 TTCAAAGGGCGGACATAGAGACAGGATGAAGACATGCTTGAGGAGCCACGGAGTTTGG
                 GGGCCA
                 ORF Start: ATG at 38                  ORF Stop: TAG at 944
                 SEQ ID NO: 410            302 aa      MW at 33476.0kD
NOV54c,          MVWKRLGALVMFPLQMIYLVVKAAVGLVLPAKLRDLSRENVLITGGGRGIGRQLAREF
CG57191-02
Protein Sequence AERGARKIVLWGRTEKCLKETTEGIRQMGTECHYFICDVGNREEVYQTAKAVREKVGD
                 ITILVNNAAVVHGKSLMDSDDDALLKSQHINTLGQFWTTKAFLPRMLELQNGHIVCLN
                 SVLALSAIPGAIDYCTSKASAFAFMESLTLGLLDCPGVSATTVLPFHTSTEMFQGMRV
                 RFPNLFPPLKPETVARRTVEAVQLNQALLLLPWTMHALVILKSILPQAALEEIHKFSG
                 TYTCMNTFKGRT

[0648] Sequence comparison of the above protein sequences yields the following sequence relationships shown in Table 54B.

TABLE 54B
Comparison of NOV54a against NOV54b and NOV54c.
			Identities/
			Similarities
	Protein	NOV54a Residues/	for the
	Sequence	Match Residues	Matched Region
	NOV54b	1 . . . 302	282/302 (93%)
		1 . . . 287	283/302 (93%)
	NOV54c	1 . . . 302	300/302 (99%)
		1 . . . 302	300/302 (99%)

[0649] Further analysis of the NOV54a protein yielded the following properties shown in Table 54C.

TABLE 54C
Protein Sequence Properties NOV54a
PSort     0.6850 probability located in endoplasmic
analysis: reticulum (membrane); 0.6400 probability
          located in plasma membrane; 0.4600
          probability located in Golgi body; 0.1000
          probability located in endoplasmic reticulum
          (lumen)
SignalP   Cleavage site between residues 24 and 25
analysis:

[0650] A search of the NOV54a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 54D.

TABLE 54D
Geneseq Results for NOV54a
		NOV54a	Identities/
		Residues/	Similarities
Geneseq	Protein/Organism/Length	Match	for the	Expect
Identifier	[Patent #, Date]	Residues	Matched Region	Value
AAY92510	Human OXRE-7 - Homo sapiens,	1 . . . 302	301/302 (99%)	e−173
	302 aa. [WO200020604-A2, 13	1 . . . 302	301/302 (99%)
	APR. 2000]
AAW89191	Bone morphogenetic protein	1 . . . 195	177/196 (90%)	2e−97
	upregulated gene (29A) product -	1 . . . 196	184/196 (93%)
	Mus sp, 202 aa. [EP890639-A2, 13
	JAN. 1999]
AAO05702	Human polypeptide SEQ ID NO	144 . . . 281	137/138 (99%)	3e−74
	19594 - Homo sapiens, 138 aa.	1 . . . 138	137/138 (99%)
	[WO200164835-A2, 07 SEP. 2001]
AAY97999	Human SCAD family molecule	9 . . . 298	105/293 (35%)	2e−47
	HSFM-1, SEQ ID NO: 1 - Homo	11 . . . 302	167/293 (56%)
	sapiens, 309 aa. [US6057140-A,
	02 MAY 2000]
ABB72322	Rat protein isolated from skin cells	6 . . . 301	99/299 (33%)	3e−46
	SEQ ID NO: 646 - Rattus sp. 298 aa.	5 . . . 298	170/299 (56%)
	[WO200190357-A1, 29 NOV.
	2001]

[0651] In a BLAST search of public sequence datbases, the NOV54a protein was found to have homology to the proteins shown in the BLASTP data in Table 54E.

TABLE 54E
Public BLASTP Results for NOV54a
		NOV54a	Identities/
Protein		Residues/	Similarities
Accession		Match	for the	Expect
Number	Protein/Organism/Length	Residues	Matched Portion	Value
O75911	Retinal short-chain	1 . . . 302	302/302 (100%)	e−173
	dehydrogenase/reductase	1 . . . 302	302/302 (100%)
	RETSDR1 (EC 1.-.-.-) - Homo
	sapiens (Human), 302 aa.
Q9BUC8	Short-chain	1 . . . 302	301/302 (99%)	e−173
	dehydrogenase/reductase 1 - Homo	1 . . . 302	301/302 (99%)
	sapiens (Human), 302 aa.
O77769	Retinal short-chain	1 . . . 302	297/302 (98%)	e−171
	dehydrogenase/reductase	1 . . . 302	300/302 (98%)
	RETSDR1 (EC 1.-.-.-) - Bos taurus
	(Bovine), 302 aa.
Q91WR0	Retinal short-chain	1 . . . 302	286/302 (94%)	e−165
	dehydrogenase/reductase 1 - Mus	1 . . . 302	294/302 (96%)
	musculus (Mouse), 302 aa.
Q91XC3	Similar to retinal short-chain	1 . . . 302	285/302 (94%)	e−165
	dehydrogenase/reductase 1 - Mus	1 . . . 302	293/302 (96%)
	musculus (Mouse), 302 aa.

[0652] PFam analysis predicts that the NOV54a protein contains the domains shown in the Table 54F.

TABLE 54F
Domain Analysis of NOV54a
		Identities/
		Similarities
	NOV54a	for the	Expect
Pfam Domain	Match Region	Matched Region	Value
adh_short	37 . . . 292	67/284 (24%)	1.1e−25
		171/284 (60%)

Example 55

[0653] The NOV55 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 55A.

TABLE 55A
NOV55 Sequence Analysis
                 SEQ ID NO: 411         1192 bp
NOV55a,          CGGCGACTGACCGTGGTCGTGGGCGGACGGCGGCTTGCAGCGTGGAGGAGCTGGGGTC
CG59595-01
DNA Sequence     GCTGTGGGTCGCGAAGCAGAGCCCGGGACGTGCGCGCTTGGTGCACGATCCTGAAGGG
                 GAGCTCCGAGGGGCCCGGGTCGCCAGGGCTGCTGCGGCCATTCCCGGAGCCCGGCGCG
                 GGGCCCGCGAGATACTGGTTTAGGCCGTCCCAGGGCTCCGGGCGCACCCGGTGGCCGC
                 TGCTGCAGCGGAGGGAGCGCGGCGGCGCGGGGGCTCGGAGACAGCGTTTCTCCCGGAA
                 GTCTTCCTCGGGCAGCAGGTGGGAAGTGGGAGCCGGAGCGGCAGCTGGCAGCGTTCTC
                 TCCGCAGGTCGGCACCATGCGCCCTGCAGCCCTGCGCGGGGCCCTGCTGGGCTGCCTC
                 TGCCTGGCGTTGCTTTGCCTGGGCGGTGCGGACAAGCGCCTGCGTGACAACCATGAGT
                 GGAAAAAACTAATTATGGTTCAGCACTGGCCTGAGACAGTATGCGAGAAAATTCAAAA
                 CGACTGTAGAGACCCTCCGGATTACTGGACAATACATGGACTATGGCCCGATAAAAGT
                 GAAGGATGTAATAGATCGTGGCCCTTCAATTTAGAAGAGATTAAGGATCTTTTGCCAG
                 AAATGAGGGCATACTGGCCTGACGTAATTCACTCGTTTCCCAATCGCAGCCGCTTCTG
                 GAAGCATGAGTGGGAAAAGCATGGGACCTGCGCCGCCCAGGTGGATGCGCTCAACTCC
                 CAGAAGAAGTACTTTGGCAGAAGCCTGGAACTCTACAGGGAGCTGGACCTCAACAGTG
                 TGCTTCTAAAATTGGGGATAAAACCATCCATCAATTACTACCAAGTTGCAGATTTTAA
                 AGATGCCCTTGCCAGAGTATATGGAGTGATACCCAAAATCCAGTGCCTTCCACCAAGC
                 CAGGATGAGGAAGTACAGACAATTGGTCAGATAGAACTGTGCCTCACTAAGCAAGACC
                 AGCAGCTGCAAAACTGCACCGAGCCGGGGGAGCAGCCGTCCCCCAAGCAGGAAGTCTG
                 GCTGGCAAATGGGGCCGCCGAGAGCCGGGGTCTGAGAGTCTGTGAAGATGGCCCAGTC
                 TTCTATCCCCCACCTAAAAAGACCAAGCATTGATGCCCAACTTTTGGAAATATTCTGT
                 TTTAAAAAGCAAGAGAAATTCACAAACTGCAG
                 ORF Start: ATG at 365            ORF Stop: TGA at 1133
                 SEQ ID NO: 412         1256 aa   MW at 29480.5kD
NOV55a,          MRPAALRGALLGCLCLALLCLGGADKRLRDNHEWKKLIMVQHWPETVCEKIQNDCRDP
CG59595-01
Protein Sequence PDYWTIHGLWPDKSEGCNRSWPFNLEEIKDLLPEMRAYWPDVINSFPNRSRFWKHEWE
                 KHGTCAAQVDALNSQKKYFGRSLELYRELDLNSVLLKLGIKPSINYYQVADFKDALAR
                 VYGVIPKIQCLPPSQDEEVQTIGQIELCLTKQDQQLQNCTEPGEQPSPKQEVWLANGA
                 AESRGLRVCEDGPVFYPPPKKTKH
                 SEQ ID NO: 413          708 bp
NOV55b,          GGATCCGACAAGCGCCTGCGTGACAACCATGAGTGGAAAAAACTAATTATGGTTCAGC
169728691
DNA Sequence     ACTGGCCTGAGACAGTATGCGAGAAAATTCAAAACGACTGTAGAGACCCTCCGGATTA
                 CTGGACAATACATGGACTATGGCCCGATAAAAGTGAAGGATGTAATAGATCGTGGCCC
                 TTCAATTTAGAAGAGATTAAGGATCTTTTGCCAGAAATGAGGGCATACTGGCCTGACG
                 TAATTCACTCGTTTCCCAATCGCAGCCGCTTCTGGAAGCATGAGTGGGAAAAGCATGG
                 GACCTGCGCCGCCCAGGTGGATGCGCTCAACTCCCAGAAGAAGTACTTTGGCAGAAGC
                 CTGGAACTCTACAGGGAGCTGGACCTCAACAGTGTGCTTCTAAAATTGGGGATAAAAC
                 CATCCATCAATTACTACCAAGTTGCAGATTTTAAAGATGCCCTTGCCAGAGTATATGG
                 AGTGATACCCAAAATCCAGTGCCTTCCACCAAGCCAGGATGAGGAAGTACAGACAATT
                 GGTCAGATAGAACTGTGCCTCACTAAGCAAGACCAGCAGCTGCAAAACTGCACCGAGC
                 CGGGGGAGCAGCCGTCCCCCAAGCAGGAAGTCTGGCTGGCAAATGGGGCCGCCGAGAG
                 CCGGGGTCTGAGAGTCTGTGAAGATGCCCCAGTCTTCTATCCCCCACCTAAAAAGACC
                 AAGCATCTCGAG
                 ORF Start: at 1                  ORF Stop: end of sequence
                 SEQ ID NO: 414          236 aa   MW at 27528.0kD
NOV55b,          GSDKRLRDNHEWKKLIMVQHWPETVCEKIQNDCRDPPDYWTIHGLWPDKSEGCNRSWP
169728691
Protein Sequence FNLEEIKDLLPEMRAYWPDVIHSFPNRSRFWKHEWEKHGTCAAQVDALNSQKKYFGRS
                 LELYRELDLNSVLLKLGIKPSINYYQVADFKDALARVYGVIPKIQCLPPSQDEEVQTI
                 GQIELCLTKQDQQLQNCTEPGEQPSPKQEVWLANGAAESRGLRVCEDGPVFYPPPKKT
                 KHLE
                 SEQ ID NO: 415          709 bp
NOV55c,          GGATCCGACAAGCGCCTGCGTGACAACCATGAGTGGAAAAGACTAATTATGGTTCAGC
169728707
DNA Sequence     ACTGGCCTGAGACAGTATGCGAGAAAATTCAAAACGACTGTAGAGACCCTCCGGATTA
                 CTGGACAATACATGGACTATGGCCCGATAAAAGTGAAGGATGTAATAGATCGTGGCCC
                 TTCAATTTAGAAGAGATTAAGGGTCTTTTGCCAGAAATGAGGGCATACTGGCCTGACG
                 TAATTCACTCGTTTCCCAATCGCAGCCGCTTCTGGAAGCATGAGTGGGAAAAGCATGG
                 GACCGGCGCCGCCCAGGTGGATGCGCTCAACTCCCAGAAGAAGTACTTTGGCAGAAGC
                 CTGGAACTCTACAGGGGGCTGGACCTCAACAGTGTGCTTCTAAAATTGGGGATAAAAC
                 CATCCATCAATTACTACCAAGTTGCAGATTTTAAAGATGCCCTTGCCAGAGTATATGG
                 AGTGATACCCAAAATCCAGTGCCTTCCACCAAGCCAGGATGAGGAAGTACAGACAATT
                 GGTCAGATAGAACTGTGCCTCACTAAGCAAGACCAGCAGCTGCAAAACTGCACCGAGC
                 CGGGGGAGCAGCCGTCCCCCAAGCAGGAAGTCTGGCTGGCAAATGGGCCCGCCGAGAG
                 CCGGGGTCTGAGAGTCTGTGAAGATGGCCCAGTCTTCTATCCCCCACCTAAAAAGACC
                 AAGCATCTCGAGA
                 ORF Start: at 1                  ORF Stop: end of sequence
                 SEQ ID NO: 416          237 aa   MW at 27379.8kD
NOV55c,          GSDKRLRDNHEWKRLIMVQHWPETVCEKIQNDCRDPPDYWTIHGLWPDKSEGCNRSWP
169728707
Protein Sequence FNLEEIKGLLPEMRAYWPDVIHSFPNRSRFWKHEWEKHGTGAAQVDALNSQKKYFGRS
                 LELYRGLDLNSVLLKLGIKPSINYYQVADFKDALARVYGVIPKIQCLPPSQDEEVQTI
                 GQIELCLTKQDQQLQNCTEPGEQPSPKQEVWLANGAAESRGLRVCEDGPVFYPPPKKT
                 KHLEX
                 SEQ ID NO: 417          708 bp
NOV55d,          GGATCCGACAAGCGCCTGCGTGACAACCATGAGTGGAAAAAACTAATTATGGTTCAGC
169728746
DNA Sequence     ACTGGCCTGAGACAGTATGCGAGAAAATTCAAGACGACTGTAGAGACCCTCCGGATTA
                 CTGGACAATACATGGACTATGGCCCGATAAAAGTGAAGGATGTAATAGATCGTGGCCC
                 TTCAATTTAGAAGAGATTAAGGATCTTTTGCCAGAAATGAGGGCATACTGGCCTGACG
                 TAATTCACTCGTTTCCCAATCGCAGCCGCTTCTGGAAGCATGAGTGGGAAAAGCATGG
                 GACCTGCGCCGCCCAGGTGGATGCGCTCAACTCCCACAAGAAGTACTTTGGCAGAAGC
                 CTGGAACTCTACAGGGAGCTGGACCTCAACAGTGTGCTTCTAAAATTGGGGATAAAAC
                 CATCCATCAATTACTACCAAGTTGCGGATTTTAAAGATGCCCTTGCCAGAGTATATGG
                 AGTGATACCCAAAATCCAGTGCCTTCCACCAAGCCGGGATGAGGAAGTACAGACAATT
                 GGTCAGATAGAACTGTGCCTCACTAAGCAAGACCAGCAGCTGCAAAACTGCACCGAGC
                 CGGGGGAGCAGCCGTCCCCCAAGCAGGAAGTCTGGCTGGCAAATGGGGCCGCCGAGAG
                 CCGGGGTCTGAGAGTCTGTGAAGATGGCCCAGTCTTCTATCCCCCACCTAAAAAGACC
                 AAGCATCTCGAG
                 ORF Start: at 1                  ORF Stop: end of sequence
                 SEQ ID NO: 418          236 aa   MW at 27557.0kD
NOV55d,          GSDKRLRDNHEWKKLIMVQHWPETVCEKIQDDCRDPPDYWTIHGLWPDKSEGCNRSWP
169728746
Protein Sequence FNLEEIKDLLPEMRAYWPDVIHSFPNRSRFWKHEWEKHGTCAAQVDALNSQKKYFGRS
                 LELYRELDLNSVLLKLGIKPSINYYQVADFKDALARVYGVIPKIQCLPPSRDEEVQTI
                 GQIELCLTKQDQQLQNCTEPGEQPSPKQEVWLANGAAESRGLRVCEDGPVFYPPPKKT
                 SEQ ID NO: 419          708 bp
NOV55e,          GGATCCGACAAGCGCCTGCGTGACAACCATGAGTGGAAAAAACTAATTATGGTTCAGC
CG59595-02
DNA Sequence     ACTGGCCTGACACAGTATGCGAGAAAATTCAAAACGACTGTAGAGACCCTCCGGATTA
                 CTGGACAATACATGGACTATGGCCCGATAAAAGTGAAGGATGTAATAGATCGTGGCCC
                 TTCAATTTAGAAGAGATTAAGGATCTTTTGCCAGAAATGAGGGCATACTGGCCTGACG
                 TAATTCACTCGTTTCCCAATCGCAGCCGCTTCTGGAAGCATGAGTGGGAAAAGCATGG
                 GACCTGCGCCGCCCAGGTGGATGCGCTCAACTCCCAGAAGAAGTACTTTGGCAGAAGC
                 CTGGAACTCTACAGGGAGCTGGACCTCAACAGTGTGCTTCTAAAATTGGGGATAAAAC
                 CATCCATCAATTACTACCAAGTTGCAGATTTTAAAGATGCCCTTGCCAGAGTATATGG
                 AGTGATACCCAAAATCCAGTGCCTTCCACCAAGCCAGGATGAGGAAGTACAGACAATT
                 GGTCAGATAGAACTGTGCCTCACTAAGCAAGACCAGCAGCTGCAAAACTGCACCGAGC
                 CGGGGGAGCAGCCGTCCCCCAAGCAGGAAGTCTGGCTGGCAAATGGGGCCGCCGAGAG
                 CCGGGGTCTGAGAGTCTGTGAAGATGGCCCAGTCTTCTATCCCCCACCTAAAAAGACC
                 AAGCATCTCGAG
                 ORF Start: at 7                  ORF Stop: at 703
                 SEQ ID NO: 420          232 aa   MW at 27141.6kD
NOV55e,          DKRLRDNHEWKKLIMVQHWPETVCEKIQNDCRDPPDYWTIHGLWPDKSEGCNRSWPFN
CG59595-02
Protein Sequence LEEIKDLLPEMRAYWPDVIHSFPNRSRFWKHEWEKHGTCAAQVDALNSQKKYFGRSLE
                 LYRELDLNSVLLKLGIKPSINYYQVADFKDALARVYGVIPKIQCLPPSQDEEVQTIGQ
                 IELCLTKQDQQLQNCTEPGEQPSPKQEVWLANGAAESRGLRVCEDGPVFYPPPKKTKH
                 SEQ ID NO: 421          923 bp
NOV55f,          GAGACAGCGTTTCTCCCGGAAGTCTTCCTCGGGCAGCAGGTGGGAAGTGGGAGCCGGA
CG59595-03
DNA Sequence     GCGGCAGCTGGCAGCGTTCTCTCCGCAGGTCGGCACCATGCGCCCTGCAGCCCTGCGC
                 GGGGCCCTGCTGGGCTGCCTCTGCCTGGCGTTGCTTTGCCTGGGCGGTGCGGACAAGC
                 GCCTGCGTGACAACCATCAGTGGAAAAAACTAATTATGGTTCAGCACTGGCCTGAGAC
                 AGTATGCGAGAAAATTCAAAACGACTGTAGAGACCCTCCGGATTACTGGACAATACAT
                 GGACTATGGCCCGATAAAAGTGAAGGATGTAATAGATCGTGGCCCTTCAATTTAGAAG
                 AGATTAAGGATCTTTTGCCAGAAATOAGGGCATACTGGCCTGACGTAATTCACTCGTT
                 TCCCAATCGCAGCCGCTTCTGGAAGCATGAGTGGGAAAAGCATGGGACCTGCGCCGCC
                 CAGGTGGATGCGCTCAACTCCCAGAAGAAGTACTTTGGCAGAAGCCTGGAACTCTACA
                 GGGAGCTGGACCTCAACAGTGTGCTTCTAAAATTGGGGATAAAACCATCCATCAATTA
                 CTACCAAGTTGCAGATTTTAAAGATGCCCTCGCCAGAGTATATGGAGTGATACCCAAA
                 ATCCAGTGCCTTCCACCAAGCCAGGATGAGGAAGTACAGACAATTGGTCAGATAGAAC
                 TGTGCCTCACTAAGCAAGACCAGCAGCTGCAAAACTGCACCGAGCCGGGGGAGCAGCC
                 GTCCCCCAAGCAGGAAGTCTGGCTGGCAAATGGGGCCGCCGAGAGCCGGGGTCTGAGA
                 GTCTGTGAAGATGGCCCAGTCTTCTATCCCCCACCTAAAAAGACCAAGCATTGATGCC
                 CAAGTTTTGGAAATATTCTGTTTTAAAAAGCAAGAGAAATTCACAAACTGCAG
                 ORF Start: ATG at 96             ORF Stop: TGA at 864
                 SEQ ID NO: 422          256 aa   MW at 29480.5kD
NOV55f,          MRPAALRGALLGCLCLALLCLGGADKRLRDNHEWKKLIMVQHWPETVCEKIQNDCRDP
CG59595-03
Protein Sequence PDYWTIHGLWPDKSEGCNRSWPFNLEEIKDLLPEMRAYWPDVIHSFPNRSRFWKHEWE
                 KHGTCAAQVDALNSQKKYFGRSLELYRELDLNSVLLKLCIKPSINYYQVADFKDALAR
                 VYGVIPKIQCLPPSQDEEVQTIGQIELCLTKQDQQLQNCTEPGEQPSPKQEVWLANGA
                 AESRGLRVCEDGPVFYPPPKKTKH
                 SEQ ID NO: 423          709 bp
NOV55g,          GGATCCGACAAGCGCCTGCGTGACAACCATGAGTGGAAAAGACTAATTATGGTTCAGC
CG59595-04
DNA Sequence     ACTGGCCTGAGACAGTATGCGAGAAAATTCAAAACGACTGTAGAGACCCTCCGGATTA
                 CTGGACAATACATGGACTATGGCCCGATAAAAGTGAAGGATGTAATAGATCGTGGCCC
                 TTCAATTTAGAAGAGATTAAGGGTCTTTTGCCAGAAATGAGGGCATACTGGCCTGACG
                 TAATTCACTCGTTTCCCAATCGCAGCCGCTTCTGGAAGCATGAGTGGGAAAAGCATGG
                 CACCGGCGCCGCCCAGGTGGATCCGCTCAACTCCCAGAAGAAGTACTTTGGCAGAAGC
                 CTGGAACTCTACAGGGGGCTGGACCTCAACAGTGTGCTTCTAAAATTGGGGATAAAAC
                 CATCCATCAATTACTACCAAGTTGCAGATTTTAAAGATGCCCTTGCCAGAGTATATGG
                 AGTGATACCCAAAATCCAGTGCCTTCCACCAAGCCAGGATGAGGAAGTACAGACAATT
                 GGTCAGATAGAACTGTGCCTCACTAAGCAAGACCAGCAGCTGCAAAACTGCACCGAGC
                 CGGGGGAGCAGCCGTCCCCCAAGCAGGAAGTCTGGCTGGCAAATGGGGCCGCCGAGAG
                 CCGGGGTCTGAGAGTCTGTGAAGATGGCCCAGTCTTCTATCCCCCACCTAAAAAGACC
                 AAGCATCTCGAGA
                 ORF Start: at 7                  ORF Stop: at 703
                 SEQ ID NO: 424          232 aa   MW at 26993.4kD
NOV55g,          DKRLRDNHEWKRLIMVQHWPETVCEKIQNDCRDPPDYWTIHGLWPDKSEGCNRSWPFN
CG59595-04
Protein Sequence LEEIKGLLPEMRAYWPDVIHSFPNRSRFWKHEWEKHGTGAAQVDALNSQKKYFGRSLE
                 LYRGLDLNSVLLKLGIKPSINYYQVADFKDALARVYGVIPKIQCLPPSQDEEVQTIGQ
                 IELCLTKQDQQLQNCTEPGEQPSPKQEVWLANGAAESRGLRVCEDGPVFYPPPKKTKH
                 SEQ ID NO: 425          708 bp
NOV55h,          GGATCCGACAAGCGCCTGCGTGACAACCATGAGTGGAAAAAACTAATTATGGTTCAGC
CG59595-05
DNA Sequence     ACTGGCCTGAGACAGTATGCGAGAAAATTCAAGACGACTGTAGAGACCCTCCGGATTA
                 CTGGACAATACATGGACTATGGCCCGATAAAAGTGAAGGATGTAATAGATCGTGGCCC
                 TTCAATTTAGAAGAGATTAAGGATCTTTTGCCACAAATGAGGGCATACTGGCCTGACG
                 TAATTCACTCGTTTCCCAATCGCAGCCGCTTCTGGAAGCATGAGTGGGAAAAGCATGG
                 GACCTGCGCCGCCCAGGTGGATGCGCTCAACTCCCAGAAGAAGTACTTTGGCAGAAGC
                 CTGGAACTCTACAGGGAGCTGGACCTCAACAGTGTGCTTCTAAAATTGGGGATAAAAC
                 CATCCATCAATTACTACCAAGTTCCGGATTTTAAAGATGCCCTTGCCAGAGTATATGG
                 AGTGATACCCAAAATCCAGTGCCTTCCACCAAGCCGGGATGAGGAAGTACAGACAATT
                 GGTCAGATAGAACTGTGCCTCACTAAGCAAGACCAGCAGCTGCAAAACTGCACCGAGC
                 CGGGGGAGCAGCCGTCCCCCAAGCAGGAAGTCTGGCTGGCAAATGGGGCCGCCGAGAG
                 CCGGGGTCTGAGAGTCTGTGAAGATGCCCCAGTCTTCTATCCCCCACCTAAAAAGACC
                 AAGCATCTCGAG
                 ORF Start: at 7                  ORF Stop: at 703
                 SEQ ID NO: 426          232 aa   MW at 27170.6kD
NOV55h,          DKRLRDNHEWKKLIMVQHWPETVCEKIQDDCRDPPDYWTIHGLWPDKSEGCNRSWPFN
CG59595-05
Protein Sequence LEEIKDLLPEMRAYWPDVIHSFPNRSRFWKHEWEKHGTCAAQVDALNSQKKYFGRSLE
                 LYRELDLNSVLLKLGIKPSINYYQVADFKDALARVYGVIPKIQCLPPSRDEEVQTIGQ
                 IELCLTKQDQQLQ&CTEPGEQPSPKQEVWLANGAAESRGLRVCEDGPVFYPPPKKTKH

[0654] Sequence comparison of the above protein sequences yields the following sequence relationships shown in Table 55B.

TABLE 55B
Comparison of NOV55a against NOV55b through NOV55h.
			Identities/
			Similarities
		NOV55a Residues/	for the
	Protein Sequence	Match Residues	Matched Region
	NOV55b	23 . . . 256	233/234 (99%)
		1 . . . 234	234/234 (99%)
	NOV55c	23 . . . 256	229/234 (97%)
		1 . . . 234	231/234 (97%)
	NOV55d	23 . . . 256	231/234 (98%)
		1 . . . 234	234/234 (99%)
	NOV55e	25 . . . 256	232/232 (100%)
		1 . . . 232	232/232 (100%)
	NOV55f	1 . . . 256	256/256 (100%)
		1 . . . 256	256/256 (100%)
	NOV55g	25 . . . 256	228/232 (98%)
		1 . . . 232	229/232 (98%)
	NOV55h	25 . . . 256	230/232 (99%)
		1 . . . 232	232/232 (99%)

[0655] Further analysis of the NOV55a protein yielded the following properties shown in Table 55C.

TABLE 55C
Protein Sequence Properties NOV55a
PSort     0.8200 probability located in outside; 0.1900 probability
analysis: located in lysosome (lumen); 0.1000 probability located
          in endoplasmic reticulum (membrane); 0.1000 probability
          located in endoplasmic reticulum (lumen)
SignalP   Cleavage site between residues 25 and 26
analysis:

[0656] A search of the NOV55a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 55D.

TABLE 55D
Geneseq Results for NOV55a
		NOV55a	Identities/
		Residues/	Similarities for
Geneseq	Protein/Organism/Length	Match	the Matched	Expect
Identifier	[Patent #, Date]	Residues	Region	Value
AAY21852	Human signal peptide-contianing	1 . . . 256	256/256 (100%)	e−158
	protein (SIGP) (clone ID 2652271) -	1 . . . 256	256/256 (100%)
	Homo sapiens, 256 aa.
	[WO9933981-A2, 08 JUL. 1999]
AAW75103	Human secreted protein encoded	1 . . . 256	256/256 (100%)	e−158
	by gene 47 clone HMCBP63 -	1 . . . 256	256/256 (100%)
	Homo sapiens, 256 aa.
	[WO9839446-A2, 11 SEP. 1998]
AAY48563	Human breast tumour-associated	1 . . . 256	255/256 (99%)	e−157
	protein 24 - Homo sapiens, 284 aa.	29 . . . 284	255/256 (99%)
	[DE19813839-A1, 23 SEP. 1999]
ABG12714	Novel human diagnostic protein	1 . . . 256	247/258 (95%)	e−150
	#12705 - Homo sapiens, 342 aa.	85 . . . 342	251/258 (96%)
	[WO200175067-A2, 11 OCT.
	2001]
ABG12711	Novel human diagnostic protein	49 . . . 256	184/208 (88%)	e−109
	#12702 - Homo sapiens, 193 aa.	1 . . . 193	187/208 (89%)
	[WO200175067-A2, 11 OCT.
	2001]

[0657] In a BLAST search of public sequence datbases, the NOV55a protein was found to have homology to the proteins shown in the BLASTP data in Table 55E.

TABLE 55E
Public BLASTP Results for NOV55a
		NOV55a	Identities/
Protein		Residues/	Similarities
Accession		Match	for the	Expect
Number	Protein/Organism/Length	Residues	Matched Portion	Value
O00584	Ribonuclease 6 precursor (EC	1 . . . 256	256/256 (100%)	e−158
	3.1.27.-) - Homo sapiens	1 . . . 256	256/256 (100%)
	(Human), 256 aa.
S78046	ribonuclease 6 (EC 3.1.27.-)	1 . . . 181	180/181 (99%)	e−109
	precursor - human, 189 aa.	1 . . . 181	180/181 (99%)
Q9CQ01	Ribonuclease 6 precursor (EC	1 . . . 256	176/261 (67%)	e−105
	3.1.27.-) - Mus musculus	1 . . . 259	207/261 (78%)
	(Mouse), 259 aa.
JE0172	ribonuclease T2 (EC 3.1.27.1) -	32 . . . 253	149/223 (66%)	5e−88
	pig, 200 aa.	1 . . . 200	172/223 (76%)
JE0173	ribonuclease T2 (EC 3.1.27.1) -	33 . . . 250	126/219 (57%)	2e−72
	bovine, 198 aa.	2 . . . 196	155/219 (70%)

[0658] PFam analysis predicts that the NOV55a protein contains the domain shown in the Table 55F.

TABLE 55F
Domain Analysis of NOV55a
		Identities/
	NOV55a	Similarities
	Match	for the
Pfam Domain	Region	Matched Region	Expect Value
ribonuclease_T2	39 . . . 219	63/212 (30%)	9.1e−64
		149/212 (70%)

EXAMPLE 56

[0659] The NOV56 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 56A.

TABLE 56A
NOV56 Sequence Analysis
                 SEQ ID NO: 427           2684 bp
NOV56a,          ATCAGAATTTTGAGTTCTAGTATTTACTCTCTCGATTCCTTGTTAATTTAAATGGTAC
CG92142-01
DNA Sequence     CTATTTTTTATAGCACATGATTTGGGAATTACACTTTGTGACATGGATGAATCTGCAC
                 TGACCCTTGGTACAATAGATGTTTCTTATCTGCCACATTCATCAGAATACAGTGTTGG
                 TCGATGTAAGCACACAAGTGAGGAATGGGTAGAGTGTGGCTTTAGACCCACCATCTTC
                 AGATCTGCAACTTTAAAATGGAAAGAAAGCCTAATGAGTCGGAAAAGGCCATTTGTTG
                 GAAGATGTTGTTACTCCTGCACTCCCCAGAGCTGGGACAAATTTTTCAACCCCAGTAT
                 CCCGTCTTTGGGTTTGCGGAATGTTATTTATATCAATGAAACTCACACAAGACACCGC
                 GGATCGCTTGCAAGACGCCTTTCTTACGTTCTTTTTATTCAAGAGCGAGATGTGCATA
                 AGGGCATGTTTGCCACCAATGTGACTGAAAATGTGCTGAACAGCAGTAGAGTACAAGA
                 GGCAATTGCAGAAGTGGCTGCTGAATTAAACCCTGATGGTTCTGCCCAGCAGCAATCA
                 AAAGCCGTTAACAAAGTGAAAAAGAAAGCTAAAAGGATTCTTCAAGAAATGGTTGCCA
                 CTGTCTCACCGCCAATGATCAGACTGACTGGGTGGGTGCTGCTAAAACTGTTCAACAG
                 CTTCTTTTGGAACATTCAAATTCACAAAGGTCAACTTGAGATGGTTAAAGCTGCAACT
                 GAGACGAATTTGCCGCTTCTGTTTCTACCAGTTCATAGATCCCATATTGACTATCTGC
                 TGCTCACTTTCATTCTCTTCTGCCATAACATCAAAGCACCATACATTGCTTCAGGCAA
                 TAATCTCAACATCCCAATCTTCAGTACCTTGATCCATAAGCTTGGGGGCTTCTTCATA
                 CGACGAAGGCTCGATGAAACACCAGATGGACGGAAAGATGTTCTCTATAGAGCTTTGC
                 TCCATGGGCATATAGTTGAATTACTTCGACAGCAGCAATTCTTGGAGATCTTCCTGGA
                 AGGCACACGTTCTAGGAGTGGAAAAACCTCTTGTGCTCGGGCAGGACTTTTGTCAGTT
                 GTGGTAGATACTCTGTCTACCAATGTCATCCCAGACATCTTGATAATACCTGTTGGAA
                 TCTCCTATGATCGCATTATCGAAGGTCACTACAATGGTGAACAACTGGGCAAACCTAA
                 GAAGAATGAGAGCCTGTGGAGTGTAGCAAGAGGTGTTATTAGAATGTTACGAAAAAAC
                 TATGGTTGTGTCCGAGTGGATTTTGCACAGCCATTTTCCTTAAAGGAATATTTAGAAA
                 GCCAAAGTCAGAAACCGGTGTCTGCTCTACTTTCCCTCGAGCAAGCGTTGTTACCAGC
                 TATACTTCCTTCAAGACCCAGTGATGCTGCTGATGAAGGTAGAGACACGTCCATTAAT
                 GAGTCCAGAAATGCAACAGATGAATCCCTACGAAGGAGGTTGATTGCAAATCTGGCTG
                 AGCATATTCTATTCACTGCTAGCAAGTCCTGTGCCATTATGTCCACACACATTGTGGC
                 TTGCCTGCTCCTCTACAGACACAGGCAGGGAATTGATCTCTCCACATTGGTCGAAGAC
                 TTCTTTGTGATGAAAGAGGAAGTCCTGGCTCGTGATTTTGACCTGGGGTTCTCAGGAA
                 ATTCAGAAGATGTAGTAATGCATGCCATACAGCTGCTGGGAAATTGTGTCACAATCAC
                 CCACACTAGCAGGAACGATGAGTTTTTTATCACCCCCAGCACAACTGTCCCATCAGTC
                 TTCGAACTCAACTTCTACAGCAATGGGGTACTTCATGTCTTTATCATGGAGGCCATCA
                 TAGCTTGCAGCCTTTATGCAGTTCTGAACAAGAGGGGACTGGGGGGTCCCACTAGCAC
                 CCCACCTAACCTGATCAGCCAGGAGCAGCTGGTGCGGAAGGCGGCCAGCCTGTGCTAC
                 CTTCTCTCCAATGAAGGCACCATCTCACTGCCTTGCCAGACATTTTACCAAGTCTGCC
                 ATGAAACAGTAGGAAAGTTTATCCAGTATGGCATTCTTACAGTGGCAGAGCACGATGA
                 CCAGGAAGATATCAGTCCTAGTCTTGCTGAGCAGCAGTGGGACAAGAAGCTTCCTGAA
                 CCTTTGTCTTGGAGAAGTGATGAAGAAGATGAAGACAGTGACTTTGGGGAGGAACAGC
                 GAGATTGCTACCTGAAGGTGAGCCAATCCAAGGAGCACCAGCAGTTTATCACCTTCTT
                 ACAGAGACTCCTTGGGCCTTTGCTGGAGGCCTACAGCTCTGCTGCCATCTTTGTTCAC
                 AACTTCAGTGGTCCTGTTCCAGAACCTGAGTATCTGCAAAAGTTGCACAAATACCTAA
                 TAACCAGAACAGAAAGAAATGTTGCAGTATATGCTGAGAGTGCCACATATTGTCTTGT
                 GAAGAATGCTGTGAAAATGTTTAAGGATATTGGGGTTTTCAAGGAGACCAAACAAAAG
                 AGAGTGTCTGTTTTAGAACTGAGCAGCACTTTTCTACCTCAATGCAACCGACAAAAAC
                 TTCTAGAATATATTCTGAGTTTTGTGGTGCTGTAGGTAACGTGTGGCACTGCTCGCAA
                 ATGAAGGTCATGAGATGAGTTCCTTGTAGGTACCAGCTTCTGGCTCAAGAGTTGAAGG
                 TGCCGTCGCAGGGTCA
                 ORF Start: ATG at 101                ORF Stop: TAG at 2585
                 SEQ ID NO: 428            828 aa     MW at 93835.7kD
NOV56a,          MDESALTLGTIDVSYLPHSSEYSVGRCKHTSEEWVECGFRPTIFRSATLKWKESLMSR
CG92142-01
Protein Sequence KRPFVGRCCYSCTPQSWDKFFNPSIPSLGLRNVIYINETHTRHRGWLARRLSYVLFIQ
                 ERDVHKGMFATNVTENVLNSSRVQEAIAEVAAELNPDGSAQQQSKAVNKVKKKAKRIL
                 QEMVATVSPAMIRLTGWVLLKLFNSFFWNIQIHKGQLEMVKAATETNLPLLFLPVHRS
                 HIDYLLLTFILFCHNIKAPYIASGNNLNIPIFSTLIHKLGGFFIRRRLDETPDGRKDV
                 LYRALLHGHIVELLRQQQFLEIFLEGTRSRSGKTSCARAGLLSVVVDTLSTNVIPDIL
                 IIPVGISYDRIIEGHYNGEQLGKPKKNESLWSVARGVIRMLRKNYGCVRVDFAQPFSL
                 KEYLESQSQKPVSALLSLEQALLPAILPSRPSDAADEGRDTSINESRNATDESLRRRL
                 IANLAEHILFTASKSCAIMSTHIVACLLLYRHRQGIDLSTLVEDFFVMKEEVLARDFD
                 LGFSCNSEDVVMHAIQLLGNCVTITHTSRNDEFFITPSTTVPSVFELNFYSNGVLHVF
                 IMEAIIACSLYAVLNKRGLGGPTSTPPNLISQEQLVRKAASLCYLLSNEGTISLPCQT
                 FYQVCHETVGKFIQYGILTVAEHDDQEDISPSLAEQQWDKKLPEPLSWRSDEEDEDSD
                 FGEEQRDCYLKVSQSKEHQQFITFLQRLLGPLLEAYSSAAIFVHNFSGPVPEPEYLQK
                 LHKYLITRTERNVAVYAESATYCLVKNAVKMFKDIGVFKETKQKRVSVLELSSTFLPQ
                 CNRQKLLEYILSFVVL
                 SEQ ID NO: 429           2527 bp
NOV56b,          GCACATGATTTGGGAATTACACTTTGTGACATGGATGAATCTGCACTGACCCTTGGTA
CG92142-02
DNA Sequence     CAATAGATGTTTCTTATCTGCCACATTCATCAGAATACAGTGTTGGTCGATGTAAGCA
                 CACAAGTGAGGAATGGGGTGAGTGTGGCTTTAGACCCACCGTCTTCAGATCTGCAACT
                 TTAAAATGGAAAGAAAGCCTAATGAGTCGGAAAAGGCCATTTGTTGGAAGATGTTGTT
                 ACTCCTGCACTCCCCAGAGCTGGGACAAATTTTTCAACCCCAGTATCCCGTCTTTGGG
                 TTTGCGGAATGTTATTTATATCAATGAAACTCACACAAGACACCGCGGATGGCTTGCA
                 AGACGCCTTTCTTACGTTCTTTTTATTCAAGAGCGAGATGTGCATAAGGGCATGTTTG
                 CCACCAATGTGACTGGAAATGTGCTGAACAGCAGTAGAGTACAAGAGGCAATTGCAGA
                 AGTGGCTGCTGAATTAAACCCTGATGGTTCTGCCCAGCAGCAATCAAAAGCCGTTAAC
                 AAAGTGAAAAAGAAAGCTAAAAGGATTCTTCAAGAAATGGTTGCCACTGTCTCACCGG
                 CAATGATCAGACTGACTGGGTGGGTGCTGCTAAAACTGTTCAACAGCTTCTTTTCGAA
                 CATTCAAATTCACAAAGGTCAACTTGAGATGGTTAAAGCTGCAACTGAGACGAATTTG
                 CCGCTTCTGTTTCTACCAGTTCATAGATCCCATATTGACTATCTGCTGCTCACTTTCA
                 TTCTCTTCTGCCATAACATCAAAGCACCATACATTGCTTCAGGCAATAATCTCAACAT
                 CCCAATCTTCAGTACCTTGATCCATAAGCTTGGGGGCTTCTTCATACGACGAAGGCTC
                 GATGAAACACCAGATGGACGGAAAGATGTTCTCTATAGAGCTTTGCTCCATGGGCATA
                 TAGTTGAATTACTTCGACAGCAGCAATTCTTCGAGATCTTCCTGGAAGGCACACGTTC
                 TAGGAGTGGAAAAACCTCTTGTGCTCGGGCAGGACTTTTGTCAGTTGTGGTAGATACT
                 CTGTCTACCAATGTCATCCCAGACATCTTGATAATACCTGTTGGAATCTCCTATGATC
                 GCATTATCGAAGGTCACTACAATGGTGAACAACTGGGCAAACCTAAGAAGAATGAGAG
                 CCTGTGGAGTGTAGCAAGAGGTGTTATTAGAATGTTACGAAAAAACTATGGTTGTGTC
                 CGAGTGGATTTTGCACAGCCATTTTCCTTAAAGGAATATTTAGAAAGCCAAAGTCAGA
                 AACCGGTGTCTGCTCTACTTTCCCTGGAGCAAGCGTTGTTACCAGCTATACTTCCTTC
                 AAGACCCAGTGATGCTGCTGATGAAGGTAGAGACACGTCCATTAATGAGTCCAGAAAT
                 GCAACAGATGAATCCCTACGAAGGAGGTTGATTGCAAATCTGGCTGAGCATATTCTAT
                 TCACTGCTAGCAAGTCCTGTGCCATTATGTCCACACACATTGTGGCTTGCCTGCTCCT
                 CTACAGACACAGGCAGGGAATTGATCTCTCCACATTGGTCGAAGACTTCTTTGTGATG
                 AAAGAGGAAGTCCTGGCTCGTGATTTTGACCTGGGGTTCTCAGGAAATTCAGAAGATG
                 TAGTAATGCATGCCATACAGCTGCTGGGAAATTGTGTCACAATCACCCACACTAGCAG
                 GAATGATGAGTTTTTTATCACCCCCAGCACAACTGTCCCATCAGTCTTCGAACTCAAC
                 TTCTACAGCAATGGGGTACTTCATGTCTTTATCATGGAGGCCATCATAGCTTGCAGCC
                 TTTATGCAGTTCTGAACAAGAGGGGACTGGGGGGTCCCACTAGCACCCCACCTAACCT
                 GATCAGCCAGGAGCAGCTGGTGCGGAAGGCGGCCAGCCTGTGCTACCTTCTCTCCAAT
                 GAAGGCACCATCTCACTGCCTTGCCAGACATTTTACCAAGTCTGCCATGAAACAGTAG
                 GAAAGTTTATCCAGTATGGCATTCTTACAGTGGCAGAGCACGATGACCAGGAAGATAT
                 CAGTCCTAGTCTTGCTGAGCAGCAGTGGGACAAGAAGCTTCCTGAACCTTTGTCTTGG
                 AGAAGTGATGAAGAAGATGAAGACAGTGACTTTGGGGAGGAACAGCGAGATTGCTACC
                 TGAAGGTGAGCCAATCCAACGAGCACCAGCAGTTTATCACCTTCTTACAGAGACTCCT
                 TGGGCCTTTGCTGGAGGCCTACAGCTCTGCTGCCATCTTTGTTCACAACTTCAGTGGT
                 CCTGTTCCAGAACCTGAGTATCTGCAAAAGTTGCACAAATACCTAATAACCAGAACAG
                 AAAGAAATGTTGCAGTATATGCTGAGAGTGCCACATATTGTCTTGTGAAGAATGCTGT
                 GAAAATGTTTAAGGATATTGGGGTTTTCAAGGAGACCAAACAAAAGAGAGTGTCTGTT
                 TTAGAACTGAGCAGCACTTTTCTACCTCAATGCAACCGACAAAGACTTCTAGAATATA
                 TTCTGAGTTTTGTGGTGCTGTAAGTAACGTCTG
                 ORF Start: ATG at 31                 ORF Stop: TAA at 2515
                 SEQ ID NO: 430            828 aa     Mw at 93735.6kD
NOV56b,          MDESALTLGTTDVSYLPHSSEYSVCRCKHTSEEWGECGFRPTVFRSATLKWKESLMSR
CG92142-02
Protein Sequence KRPFVGRCCYSCTPQSWDKFFNPSIPSLGLRNVIYINETHTRHRGWLARRLSYVLFIQ
                 ERDVHKGMFATNVTGNVLNSSRVQEAIAEVAAELNPDGSAQQQSKAVNKVKKKAKRIL
                 QEMVATVSPAMIRLTGWVLLKLFNSFFWNIQIHKGQLEMVKAATETNLPLLFLPVHRS
                 HIDYLLLTFILFCHNIKAPYIASGNNLNIPIFSTLIHKLGGFFIRRRLDETPDGRKDV
                 LYRALLHGHIVELLRQQQFLEIFLEGTRSRSGKTSCARAGLLSVVVDTLSTNVIPDIL
                 IIPVGISYDRIIEGHYNGEQLGKPKKNESLWSVARGVIRMLRKNYGCVRVDFAQPFSL
                 KEYLESQSQKPVSALLSLEQALLPAILPSRPSDAADEGRDTSINESRNATDESLRRRL
                 IANLAEHILFTASKSCAIMSTHIVACLLLYRHRQGIDLSTLVEDFFVMKEEVLARDFD
                 LGFSGNSEDVVMHAIQLLGNCVTITHTSRNDEFFITPSTTVPSVFELNFYSNGVLHVF
                 IMEAIIACSLYAVLNKRGLGGPTSTPPNLISQEQLVRKAASLCYLLSNEGTISLPCQT
                 FYQVCHETVGKFIQYGILTVAEHDDQEDISPSLAEQQWDKKLPEPLSWRSDEEDEDSD
                 FGEEQRDCYLKVSQSKEHQQFITFLQRLLGPLLEAYSSAAIFVHNFSGPVPEPEYLQK
                 LHKYLITRTERNVAVYAESATYCLVKNAVKMFKDIGVFKETKQKRVSVLELSSTFLPQ
                 CNRQRLLEYILSFVVL

[0660] Sequence comparison of the above protein sequences yields the following sequence relationships shown in Table 56B.

TABLE 56B
Comparison of NOV56a against NOV56b.
			Identities/
		NOV56a Residues/	Similarities
		Match	for the
	Protein Sequence	Residues	Matched Region
	NOV56b	1 . . . 828	824/828 (99%)
		1 . . . 828	826/828 (99%)

[0661] Further analysis of the NOV56a protein yielded the following properties shown in Table 56C.

TABLE 56C
Protein Sequence Properties NOV56a
PSort     0.8500 probability located in endoplasmic reticulum
analysis: (membrane); 0.4400 probability located in plasma
          membrane; 0.3000 probability located in nucleus;
          0.1000 probability located in mitochondrial inner
          membrane
SignalP   No Known Signal Sequence Predicted
analysis:

[0662] A search of the NOV56a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 56D.

TABLE 56D
Geneseq Results for NOV56a
		NOV56a	Identities/
		Residues/	Similarities
Geneseq	Protein/Organism/Length	Match	for the	Expect
Identifier	[Patent #, Date]	Residues	Matched Region	Value
ABG66665	Human glycerol-3-phosphate	1 . . . 828	827/828 (99%)	0.0
	acyltransferase hGPAT - Homo	1 . . . 828	827/828 (99%)
	sapiens, 828 aa. [WO200240666-
	A2, 23 MAY 2002]
AAE22144	Human TRNFR-6 protein - Homo	1 . . . 828	827/828 (99%)	0.0
	sapiens, 828 aa. [WO200226950-	1 . . . 828	827/828 (99%)
	A2, 04 APR. 2002]
AAU78393	Human acyltransferase, ACTR-1 -	1 . . . 828	826/828 (99%)	0.0
	Homo sapiens, 828 aa.	1 . . . 828	827/828 (99%)
	[WO200216592-A2, 28 FEB. 2002]
AAE22145	Human TRNFR-7 protein - Homo	56 . . . 826	262/790 (33%)	e−102
	sapiens, 801 aa. [WO200226950-	40 . . . 799	403/790 (50%)
	A2, 04 APR. 2002]
ABB61594	Drosophila melanogaster	163 . . . 809	196/654 (29%)	4e−82
	polypeptide SEQ ID NO 11574 -	194 . . . 820	353/654 (53%)
	Drosophila melanogaster, 850 aa.
	[WO200171042-A2, 27 SEP. 2001]

[0663] In a BLAST search of public sequence datbases, the NOV56a protein was found to have homology to the proteins shown in the BLASTP data in Table 56E.

TABLE 56E
Public BLASTP Results for NOV56a
		NOV56a	Identities/
Protein		Residues/	Similarities
Accession		Match	for the	Expect
Number	Protein/Organism/Length	Residues	Matched Portion	Value
Q9HCL2	Glycerol-3-phosphate	1 . . . 828	828/828 (100%)	0.0
	acyltransferase, mitochondrial	1 . . . 828	828/828 (100%)
	precursor (EC 2.3.1.15) (GPAT) -
	Homo sapiens (Human), 828 aa.
AAH30783	KIAA1560 protein - Homo sapiens	1 . . . 828	825/828 (99%)	0.0
	(Human), 828 aa.	1 . . . 828	825/828 (99%)
Q8VCT2	Glycerol-3-phosphate	1 . . . 828	769/828 (92%)	0.0
	acyltransferase, mitochondrial -	1 . . . 827	799/828 (95%)
	Mus musculus (Mouse), 827 aa.
Q61586	Glycerol-3-phosphate	1 . . . 828	767/828 (92%)	0.0
	acyltransferase, mitochondrial	1 . . . 827	799/828 (95%)
	precursor (EC 2.3.1.15) (GPAT)
	(P90) - Mus musculus (Mouse),
	827 aa.
P97564	Glycerol-3-phosphate	1 . . . 828	760/828 (91%)	0.0
	acyltransferase, mitochondrial	1 . . . 828	794/828 (95%)
	precursor (EC 2.3.1.15) (GPAT) -
	Rattus norvegicus (Rat), 828 aa.

[0664] PFam analysis predicts that the NOV56a protein contains the domains shown in the Table 56F.

TABLE 56F
Domain Analysis of NOV56a
		Identities/
	NOV56a	Similarities
	Match	for the
Pfam Domain	Region	Matched Region	Expect Value
Acyltransferase	215 . . . 412	47/207 (23%)	6.4e−34
		151/207 (73%)

EXAMPLE 57

[0665] The NOV57 clone was analyzed, and the nucleotide and encoded polypeptide sequences 5 are shown in Table 57A.

TABLE 57A
NOV57 Sequence Analysis
                 SEQ ID NO: 431           1538 bp
NOV57a,          CACCGAGCCTCACGGGAGCTGATGGCTGCAAAGAAGACCCACACCTCACAAATTGAAG
CG95765-01
DNA Sequence     TGATCCCTTGCAAAATCTGTGGGGACAAGTCGTCTGGGATCCACTACGGGGTTATCAC
                 CTGTGAGGGGTGCAAGGGCTTCTTCCGGCCTACTCCTGCACCCGTCAGCAGAACTGCC
                 CCATCGACCGCACCAGCCGAAACCGATGCCAGCACTGCCGCCTGCAGAAATGCCTGGC
                 GCTGGGGATGTCCCGAGATGCTGTCAAGTTCGGCCGCATGTCCAAGAAGCAGAGGGAC
                 AGCCTGCATGCAGAAGTGCAGAAACAGCTGCAGCAGCGGCAACAGCAGCAACAGGAAC
                 CAGTGGTCAAGACCCCTCCAGCAGGGGCCCAAGGAGCAGATACCCTCACCTACACCTT
                 GGGGCTCCCAGACGGGCAGCTGCCCCTGGGCTCCTCGCCTGACCTGCCTGAGGCTTCT
                 GCCTGTCCCCCTGGCCTCCTGAAAGCCTCAGGCTCTGGGCCCTCATATTCCAACAACT
                 TGGCCAAGGCAGGGCTCAATGGGGCCTCATGCCACCTTGAATACAGCCCTGAGCGGGG
                 CAAGGCTGAGGGCAGAGAGAGCTTCTATAGCACAGGCAGCCAGCTGACCCCTGACCGA
                 TGTGGACTTCGTTTTGAGGAACACAGGCATCCTGGGCTTGGGGAACTGGGACAGGGCC
                 CAGACAGCTACGGCAGCCCCAGTTTCCGCAGCACACCGGAGGCACCCTATGCCTCCCT
                 GACAGAGATAGAGCACCTGGTGCAGAGCGTCTGCAAGTCCTACAGGGAGACATGCCAG
                 CTGCGGCTGGAGGACCTGCTGCGGCAGCGCTCCAACATCTTCTCCCGGGAGGAAGTGA
                 CTGGCTACCAGAGGAAGTCCATGTGGGAGATGTGGGAACGGTGTGCCCACCACCTCAC
                 CGAGGCCATTCAGTACGTGGTGGAGTTCGCCAAGAGGCTCTCAGGCTTTATGGAGCTC
                 TGCCAGAATGACCAGATTGTGCTTCTCAAAGCAGGAGCAATGGAAGTGGTGCTGGTTA
                 GGATGTGCCGGGCCTACAATGCCAACAACCACACAGTCTTTTTTGAAGGCAAATACGG
                 TGGTGTGGAGCTGTTTCGAGCCTTGGGCTGCAGCGAGCTCATCAGCTCCATATTTGAC
                 TTTTCCCACTTCCTCAGCGCCCTGTGTTTTTCCGAGGATGAGATTGCCCTCTACACGG
                 CCCTTGTTCTCATCAATGCCAACCGTCCTGGGCTCCAAGAGAAGAGGAGAGTGGAACA
                 TCTGCAATACAATTTGGAACTGGCTTTCCATCATCATCTCTGCAAGACTCATCGACAA
                 AGCATCCTGGCAAAGCTGCCACCCAAAGGAAAACTCCGGAGCCTGTGTAGCCAGCATG
                 TGGAAAGGCTGCAGATCTTCCAGCACCTCCACCCCATCGTGGTCCAAGCCGCTTTCCC
                 TCCACTCTACAAGGAGCTCTTCAGCACTGAAACCGAGTCACCTGTGGGGCTGTCCAAG
                 TGACCTGGAAGAGGGACTCCTTGCCTCTCC
                 ORF Start: ATG at 240                ORF Stop: TGA at 1509
                 SEQ ID NO: 432            423 aa     MW at 47418.4kD
NOV57a,          MSRDAVKFGRMSKKQRDSLHAEVQKQLQQRQQQQQEPVVKTPPAGAQGADTLTYTLGL
CG95765-01
Protein Sequence PDGQLPLGSSPDLPEASACPPGLLKASGSGPSYSNNLAKAGLNGASCHLEYSPERGKA
                 EGRESFYSTGSQLTPDRCGLRFEEHRHPGLGELGQGPDSYGSPSFRSTPEAPYASLTE
                 IEHLVQSVCKSYRETCQLRLEDLLRQRSNIFSREEVTGYQRKSMWEMWERCAHHLTEA
                 IQYVVEFAKRLSGFMELCQNDQTVLLKAGAMEVVLVRMCRAYNANNHTVFFEGKYGGV
                 ELFRALGCSELISSIFDFSHFLSALCFSEDEIALYTALVLINANRPGLQEKRRVEHLQ
                 YNLELAFHHHLCKTHRQSILAKLPPKGKLRSLCSQHVERLQIFQHLNPIVVQAAFPPL
                 YKELFSTETESPVGLSK
                 SEQ ID NO: 433           1819 bp
NOV57b,          CCCCTGGGCCCTGCTCCCTGCCCTCCTGGGCAGCCAGGGCAGCCAGGACGGCACCAAG
CG95765-02
DNA Sequence     GGAGCTGCCCCATGGACAGGGCCCCACAGAGACAGCACCGAGCCTCACGGGAGCTGCT
                 GGCTGCAAAGAAGACCCACACCTCACAAATTGAAGTGATCCCTTGCAAAATCTGTGGG
                 GACAAGTCGTCTGGGATCCACTACGGGGTTATCACCTGTGAGGGGTGCAAGGGCTTCT
                 TCCGCCGGAGCCAGCGCTGTAACGCGGCCTACTCCTGCACCCGTCAGCAGAACTGCCC
                 CATCGACCGCACCAGCCGAAACCGATGCCAGCACTGCCGCCTGCAGAAATGCCTGGCG
                 CTGGGGATGTCCCGAGATGCTGTCAAGTTCGGCCGCATGTCCAAGAAGCAGAGGGACA
                 GCCTGCATGCAGAAGTGCAGAAACAGCTGCAGCAGCGGCAACAGCAGCAACAGGAACC
                 AGTGGTCAAGACCCCTCCAGCAGGGGCCCAAGGAGCAGATACCCTCACCTACACCTTG
                 GGGCTCCCAGACGGGCAGCTCCCCCTGGGCTCCTCGCCTCACCTGCCTGAGGCTTCTG
                 CCTGTCCCCCTGGCCTCCTGAAAGCCTCAGCCTCTGGGCCCTCATATTCCAACAACTT
                 GGCCAAGGCAGGGCTCAATGGGGCCTCATGCCACCTTGAATACAGCCCTGAGCGGGGC
                 AAGGCTGAGGGCAGAGAGAGCTTCTATAGCACAGGCAGCCAGCTGACCCCTGACCGAT
                 GTGGACTTCGTTTTGAGGAACACAGGCATCCTGGGCTTGGGGAACTGGGACAGGGCCC
                 AGACAGCTACGGCAGCCCCAGTTTCCGCAGCACACCGGAGGCACCCTATGCCTCCCTG
                 ACAGAGATAGAGCACCTGGTGCAGAGCGTCTGCAAGTCCTACAGGGAGACATGCCAGC
                 TGCGGCTGGAGGACCTGCTGCGGCAGCGCTCCAACATCTTCTCCCGGGAGGAAGTGAC
                 TGGCTACCAGAGGAAGTCCATGTGGGAGATGTGGGAACGGTGTGCCCACCACCTCACC
                 GAGGCCATTCAGTACGTGGTGGAGTTCGCCAAGAGGCTCTCACGCTTTATGGAGCTCT
                 GCCAGAATGACCAGATTGTGCTTCTCAAAGCAGGAGCAATGGAAGTGGTGCTGGTTAG
                 GATGTGCCGGGCCTACAATGCTGACAACCGCACGGTCTTTTTTGAAGGCAAATACGGT
                 GGCATGGAGCTGTTCCGAGCCTTGGGCTGCAGCGAGCTCATCAGCTCCATCTTTGACT
                 TCTCCCACTCCCTAAGTGCCTTGCACTTTTCCGAGGATGAGATTGCCCTCTACACAGC
                 CCTTGTTCTCATCAATGCCCATCGGCCAGGGCTCCAAGAGAAAAGGAAACTAGAACAG
                 CTGCAGTACAATCTGGAGCTGGCCTTTCATCATCATCTCTGCAAGACTCATCGCCAAA
                 GCATCCTGGCAAACCTGCCACCCAAGGGGAAGCTTCGGAGCCTGTGTAGCCAGCATGT
                 GGAAAGGCTGCAGATCTTCCAGCACCTCCACCCCATCGTGGTCCAAGCCGCTTTCCCT
                 CCACTCTACAAGGAGCTCTTCAGCACTGAAACCGAGTCACCTGTGGGCTGTCCAAGTG
                 ACCTGGAAGAGGGACTCCTTGCCTCTCCCTATGGCCTGCTGGCCACCTCCCTGGACCC
                 CGTTCCACCCTCACCCTTTTCCTTTCCCATGAACCCTGGAGGGTGGTCCCCACCAGCT
                 CTTTGGAAGTGAGCAGATGCTGCGGCTGGCTTTCTGTCAGCAGGCCGGCCTGGCAGTG
                 GGACAATCGCCAGAGGGTGGG
                 ORF Start: ATG at 70                 ORF Stop: TGA at 1750
                 SEQ ID NO: 434            560 aa     MW at 62588.6kD
NOV57b,          MDRAPQRQHRASRELLAAKKTHTSQIEVIPCKICGDKSSGIHYGVITCEGCKGFFRRS
CG95765-02
Protein Sequence QRCNAAYSCTRQQNCPIDRTSRNRCQHCRLQKCLALGMSRDAVKFGRMSKKQRDSLHA
                 EVQKQLQQRQQQQQEPVVKTPPAGAQGADTLTYTLGLPDGQLPLGSSPDLPEASACPP
                 GLLKASGSGPSYSNNLAKAGLNGASCHLEYSPERGKAEGRESFYSTGSQLTPDRCGLR
                 FEEHRHPGLGELGQGPDSYGSPSFRSTPEAPYASLTEIEHLVQSVCKSYRETCQLRLE
                 DLLRQRSNIFSREEVTGYQRKSMWEMWERCAHLLTEAIQYVVEFAKRLSGFMELCQND
                 QIVLLKAGANEVVLVRMCRAYNADNRTVFFEGKYGGMELFRALGCSELISSIFDFSHS
                 LSALHFSEDEIALYTALVLINAHRPGLQEKRKVEQLQYNLELAFHHHLCKTHRQSILA
                 KLPPKGKLRSLCSQHVERLQIFQHLHPIVVQAAFPPLYKELFSTETESPVGCPSDLEE
                 GLLASPYGLLATSLDPVPPSPFSFPMNPGGWSPPALWK

[0666] Sequence comparison of the above protein sequences yields the following sequence relationships shown in Table 57B.

TABLE 57B
Comparison of NOV57a against NOV57b.
		NOV57a	Identities/
		Residues/	Similarities
		Match	for the
	Protein Sequence	Residues	Matched Region
	NOV57b	1 . . . 420	412/420 (98%)
		96 . . . 515	416/420 (98%)

[0667] Further analysis of the NOV57a protein yielded the following properties shown in Table 57C.

TABLE 57C
Protein Sequence Properties NOV57a
PSort     0.3600 probability located in mitochondrial matrix
analysis: space; 0.3000 probability located in microbody
          (peroxisome); 0.1000 probability located in lysosome
          (lumen); 0.0000 probability located in endoplasmic
          reticulum (membrane)
SignalP   No Known Signal Sequence Predicted
analysis:

[0668] A search of the NOV57a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 57D.

TABLE 57D
Geneseq Results for NOV57a
		NOV57a	Identities/
		Residues/	Similarities
Geneseq	Protein/Organism/Length	Match	for the	Expect
Identifier	[Patent #, Date]	Residues	Matched Region	Value
AAB03062	Human retinoid-like orphan	1 . . . 423	415/423 (98%)	0.0
	receptor-gamma 60 kD isoform -	96 . . . 518	419/423 (98%)
	Homo sapiens, 518 aa.
	[WO200024757-A1, 04 MAY
	2000]
AAB03066	Human ROR-gamma 60 kD isoform	1 . . . 423	414/423 (97%)	0.0
	polymorphic variant #1, L516I -	96 . . . 518	419/423 (98%)
	Homo sapiens, 518 aa.
	[WO200024757-A1, 04 MAY
	2000]
AAB03069	Human ROR-gamma 60 kD isoform	1 . . . 423	414/423 (97%)	0.0
	polymorphic variant #3, K518R -	96 . . . 518	419/423 (98%)
	Homo sapiens, 518 aa.
	[WO200024757-A1, 04 MAY
	2000]
AAB03068	Human ROR-gamma 60 kD isoform	1 . . . 423	414/423 (97%)	0.0
	polymorphic variant #2 - Homo	96 . . . 518	419/423 (98%)
	sapiens, 518 aa. [WO200024757-
	A1, 04 MAY 2000]
AAB03067	Human ROR-gamma 60 kD isoform	1 . . . 423	414/423 (97%)	0.0
	polymorphic variant #1, L516V -	96 . . . 518	419/423 (98%)
	Homo sapiens, 518 aa.
	[WO200024757-A1, 04 MAY
	2000]

[0669] In a BLAST search of public sequence datbases, the NOV57a protein was found to have homology to the proteins shown in the BLASTP data in Table 57E.

TABLE 57E
Public BLASTP Results for NOV57a
			Identities/
Protein			Similarities for
Accession		NOV57a Residues/	the Matched	Expect
Number	Protein/Organism/Length	Match Residues	Portion	Value
CAD38900	Hypothetical protein - Homo	1 . . . 423	415/423 (98%)	0.0
	sapiens (Human), 497 aa.	75 . . . 497	419/423 (98%)
AAH31554	Hypothetical protein - Homo	1 . . . 423	415/423 (98%)	0.0
	sapiens (Human), 518 aa.	96 . . . 518	419/423 (98%)
P51449	Nuclear receptor ROR-gamma	1 . . . 420	412/420 (98%)	0.0
	(Nuclear receptor RZR-gamma) -	96 . . . 515	416/420 (98%)
	Homo sapiens (Human), 560 aa.
Q91YT5	RAR-related orphan receptor	1 . . . 423	378/423 (89%)	0.0
	gamma - Mus musculus (Mouse),	96 . . . 516	395/423 (93%)
	516 aa.
Q9R177	RORgamma t - Mus musculus	1 . . . 423	378/423 (89%)	0.0
	(Mouse), 495 aa.	75 . . . 495	395/423 (93%)

[0670] PFam analysis predicts that the NOV57a protein contains the domains shown in the Table 57F.

TABLE 57F
Domain Analysis of NOV57a
		Identities/
		Similarities for
Pfam	NOV57a	the Matched	Expect
Domain	Match Region	Region	Value
hormone_rec	230 . . . 411	56/210 (27%)	1.1e−34
		138/210 (66%)

EXAMPLE 58

[0671] The NOV58 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 58A.

TABLE 58A
NOV58 Sequence Analysis
                 SEQ ID NO: 435       1712 bp
NOV58a,          AAGGTCAATGATAGCATCTGCCTAGAGTCAAACCTCCGTGCTTCTCAGACAGTGCCTT
CG97178-01
DNA Sequence     TTCACCATGAGTGGGTGCCCATTTTTAGGAAACAACTTTGGATATACTTTTAAAAAAC
                 TCCCCGTAGAAGGCAGCGAAGAAGACAAATCACAAACTGGTGTGAATAGAGCCAGCAA
                 AGGAGGTCTTATCTATGGCAACTACCTGCATTTGGAAAAAGTTTTGAATGCACAAGAA
                 CTGCAAAGTGAAACAAAAGGAAATAAAATCCATGATGAACATCTTTTTATCATAACTC
                 ATCAAGCTTATGAACTCTGGTTTAAGCAAATCCTCTGGGAGTTGGATTCTGTTCGAGA
                 GATCTTTCAGAATGGCCATGTCAGAGATGAAAGGAACATGCTTAAGGTTGTTTCTCGG
                 ATGCACCGAGTGTCAGTGATCCTGAAACTGCTGGTGCAGCAGTTTTCCATTCTGGAGA
                 CGATGACAGCCTTGGACTTCAATGACTTCAGAGAGTACTTATCTCCAGCATCAGGCTT
                 CCAGAGTTTGCAATTCCGACTATTAGAAAACAAGATAGGTGTTCTTCAGAACATGAGA
                 GTCCCTTATAACAGAAGACATTATCGTGATAACTTCAAAGGAGAAGAAAATGAACTGC
                 TACTTAAATCTGAGCAGGAAAAGACACTTCTGGAATTAGTGGAGGCATGGCTGGAAAG
                 AACTCCAGGTTTAGAGCCACATGGATTTAACTTCTGGGGAAAGCTTGAAAAAAATATC
                 ACCAGAGGCCTGGAAGAGGAATTCATAAGGATTCAGGCTAAAGAAGAGTCTGAAGAAA
                 AAGAGGAACAGGTGGCTGAATTTCAGAAGCAAAAAGAGGTGCTACTGTCCTTATTTGA
                 TGAGAAACGTCATGAACATCTCCTTAGTAAAGGTGAAAGACGGCTGTCATACAGAGCA
                 CTTCAGGGAGCATTGATGATATATTTTTACAGGGAAGAGCCTAGGTTCCAGGTGCCTT
                 TTCAGTTGCTGACTTCTCTTATGGACATAGATTCACTGATGACCAAATGGAGATATAA
                 CCATGTGTGCATGGTGCACAGAATGCTGGGCAGCAAAGCTGGCACCGGTGGTTCCTCA
                 GGCTATCACTACCTGCGATCAACTGTGAGTGATAGGTACAAGGTATTTGTAGATTTAT
                 TTAATCTTTCAACATACCTGATTCCCCGACACTGGATACCGAAGATGAACCCAACCAT
                 TCACAAATTTCTATATACAGCAGAATACTGTGATAGCTCCTACTTCAGCAGTGATGAA
                 TCAGATTAAAATCGTCTGCAAAATCTATGAAGAATACTGGTTTCACAGCCTATTTTTT
                 ATTTTCTATGGATTTTCATAAATACAGTTTGAATATATGTATGCATATATTGTTCAGC
                 ACCACGATGCTCTGATTTAATTCTAGAAACAATTTGATTACCTCTTGTTTGTGACAAG
                 ACTAAGCATTAAGATGAGAAAGAATACATTTAAATAGTAACATTGTACATAGGGTGTT
                 TTCCTATTAAAAATCAGTTTCCCCTGAGACTTAATGTAACCACTTAATGTAATCACTA
                 TCTCATTGTTTCATCTTTATAAACTTGTAAACTTCATCTATTTCAAATATTTTATGCA
                 GTACATTATATTATTCTGTACAAAGGCTTTCAAACAAAATTTTTAAAATAATAAAGTA
                 TTAATCTTTCAAAAAAAAAAAAAAAAAAA
                 ORF Start: ATG at 65             ORF Stop: TAA at 1283
                 SEQ ID NO: 436        406 aa     MW at 47871.1kD
NOV58a,          MSGCPFLGNNFGYTFKKLPVEGSEEDKSQTGVNRASKGGLIYGNYLHLEKVLNAQELQ
CG97178-O1
Protein Sequence SETKGNKIHDEHLFTITHQAYELWFKQILWELDSVREIFQNGHVRDERNMLKVVSRMH
                 RVSVILKLLVQQFSILETMTALDFNDFREYLSPASGFQSLQFRLLENKIGVLQNMRVP
                 YNRRHYRDNFKGEENELLLKSEQEKTLLELVEAWLERTPGLEPHGFNFWGKLEKNITR
                 GLEEEFIRIQAKEESEEKEEQVAEFQKQKEVLLSLFDEKRHEHLLSKGERRLSYRALQ
                 GALMIYFYREEPRFQVPFQLLTSLMDIDSLMTKWRYNHVCMVHRMLGSKAGTGGSSGY
                 HYLRSTVSDRYKVFVDLFNLSTYLIPRHWIPKMNPTIHKFLYTAEYCDSSYFSSDESD
                 SEQ ID NO: 437       1298 bp
NOV58b,          CTGCTTCTCAGACAGTGCCTTTTCACCATGAGTGGGTGCCCATTTTTAGGAAACAACT
CG97178-02
DNA Sequence     TTGGATATACTTTTAAAAAACTCCCCGTAGAAGGCAGCGAAGAAGACAAATCACAAAC
                 TGGTGTGAATAGAGCCAGCAAAGGAGGTCTTATCTATGGGAACTACCTGCATTTGGAA
                 AAAGTTTTGAATGCACAAGAACTGCAAAGTGAAACAAAAGGAAATAAAATCCATGATG
                 AACATCTTTTTATCATAACTCATCAAGCTTATGAACTCTGGTTTAAGCAAATCCTCTG
                 GGAGTTGGATTCTGTTCGAGAGATCTTTCAGAATGGCCATGTCAGAGATGAAAGGAAC
                 ATGCTTAAGGTTGTTTCTCGGATGCACCGAGTGTCAGTGATCCTGAAACTGCTGGTGC
                 AGCAGTTTTCCATTCTGGAGACGATGACAGCCTTGGACTTCAATGACTTCAGAGAGTA
                 CTTATCTCCAGCATCAGGCTTCCAGAGTTTGCAATTCCGACTATTAGAAAACAAGATA
                 GGTGTTCTTCAGAACATGAGAGTCCCTTATAACAGAAGACATTATCGTGATAACTTCA
                 AAGGAGAAGAAAATGAACTGCTACTTAAATCTGAGCAGGAAAAGACACTTCTGGAATT
                 AGTGGAGGCATGGCTGGAAAGAACTCCAGGTTTAGAGTCACATGGATTTAACTTCTGG
                 GGAAAGCTTGAAAAAAATATCACCAGAGGCCTGGAAGAGGAATTCATAAGGATTCAGG
                 CTAAAGAAGAGTCTGAAGAAAAAGAGGAACAGGTGGCTGAATTTCAGAAGCAAAAAGA
                 GGTGCTACTGTCCTTATTTGATGACAAACGTCATGAACATCTCCTTAGTAAAGGTGAA
                 AGACGGCTGTCATACAGAGCACTTCAGGGAGCATTGATGATATATTTTTACAGGGAAG
                 AGCCTAGGTTCCAGGTGCCTTTTCAGTTGCTGACTTCTCTTATGGACATAGATTCACT
                 GATGACCAAATGGAGATATAACCATGTGTGCATGGTGCACAGAATGCTGGGCAGCAAA
                 GCTGGCACCGGTGGTTCCTCAGGCTATCACTACCTGCGATCAACTGTGAGTGATAGGT
                 ACAAGGTATTTGTAGATTTATTTAATCTTTCAACATACCTGATTCCCCGACACTGGAT
                 ACCGAAGATGAACCCAACCATTCACAAATTTCTATATACAGCAGAATACTGTGATAGC
                 TCCTACTTCAGCAGTGATGAATCAGATTAAAATCGTCTGCAAAATCTATGAAGAATAC
                 TGGTTTCACAGCCTATTTAAGG
                 ORF Start: ATG at 28             ORF Stop: TAA at 1246
                 SEQ ID NO: 438        406 aa     MW at 47861.1kD
NOV58b,          MSGCPFLGNNFGYTFKKLPVEGSEEDKSQTGVNPASKGGLIYGNYLHLEKVLNAQELQ
CG97178-02
Protein Sequence SETKGNKIHDEHLFITTHQAYELWFKQILWELDSVREIFQNGHVRDERNMLKVVSRMN
                 RVSVILKLLVQQFSILETMTALDFNDFREYLSPASGFQSLQFRLLENKIGVLQNMRVP
                 YNRRHYRDNFKGEENELLLKSEQEKTLLELVEAWLERTPGLESHGFNFWGKLEKNITR
                 GLEEEFIRIQAKEESEEKEEQVAEFQKQKEVLLSLFDEKRHEHLLSKGERRLSYRALQ
                 GALMIYFYREEPRFQVPFQLLTSLMDIDSLMTKWRYNHVCMVHRMLGSKAGTGGSSGY
                 HYLRSTVSDRYKVFVDLFNLSTYLIPRHWIPKMNPTIHKFLYTAEYCDSSYFSSDESD
                 SEQ ID NO: 439       1240 bp
NOV58c,          GCCGGATCCACCATGAGTGGGTGCCCATTTTTAGGAAACAACTTTGGATATACTTTTA
275481043
DNA Sequence     AAAAACTCCCCGTAGAAGGCAGCGAAGAAGACAAATCACAAACTGGTGTGAATAGAGC
                 CAGCAAAGGAGGTCTTATCTATGGGAACTACCTGCATTTGGAAAAAGTTTTGAATGCA
                 CAAGAACTGCAAAGTGAAACAAAAGGAAATAAAATCCATGATGAACATCTTTTTATCA
                 TAACTCATCAAGCTTATGAACTCTGGTTTAAGCAAATCCTCTGGGAGTTGGATTCTGT
                 TCGAGAGATCTTTCAGAATGGCCATGTCAGAGATGAAAGGAACATGCTTAAGGTTGTT
                 TCTCGGATGCACCGAGTGTCAGTGATCCTGAAACTGCTGGTGCAGCAGTTTTCCATTC
                 TGGAGACGATGACAGCCTTGGACTTCAATGACTTCAGAGAGTACTTATCTCCAGCATC
                 AGGCTTCCAGAGTTTGCAATTCCGACTATTAGAAAACAAGATAGGTGTTCTTCAGAAC
                 ATGAGAGTCCCTTATAACAGAAGACATTATCGTGATAACTTCAAAGGAGAAGAAAATG
                 AACTGCTACTTAAATCTGAGCAGGAAAAGACACTTCTGGAATTAGTGGAGGCATGGCT
                 GGAAAGAACTCCAGGTTTAGAGTCACATGGATTTAACTTCTGGGGAAAGCTTGAAAAA
                 AATATCACCAGAGGCCTGGAAGAGGAATTCATAAGGATTCAGGCTAAAGAAGAGTCTG
                 AAGAAAAAGAGGAACACGTGGCTGAATTTCAGAAGCAAAAAGAGGTGCTACTGTCCTT
                 ATTTGATGAGAAACGTCATGAACATCTCCTTAGTAAAGGTGAAAGACGGCTGTCATAC
                 AGAGCACTTCAGGGAGCATTGATGATATATTTTTACAGGGAAGAGCCTAGGTTCCAGG
                 TGCCTTTTCAGTTGCTGACTTCTCTTATGGACATAGATTCACTGATGACCAAATGGAG
                 ATATAACCATGTGTCCATGGTGCACAGAATGCTGGGCAGCAAAGCTGGCACCGGTGGT
                 TCCTCAGGCTATCACTACCTGCCATCAACTGTGAGTGATAGGTACAAGGTATTTGTAG
                 ATTTATTTAATCTTTCAACATACCTGATTCCCCGACACTGGATACTGAAGATGAACCC
                 AACCATTCACAAATTTCTATATACAGCAGAATACTGTGATAGCTCCTACTTCAGCAGT
                 GATGAATCAGATGTCGACGCTG
                 ORF Staff: at 1                  ORF Stop: end of sequence
                 SEQ ID NO: 440        414 aa     MW at 48464.7kD
NOV58c,          AGSTMSGCPFLGNNFGYTFKKLPVEGSEEDKSQTGVNRASKGGLIYGNYLHLEKVLNA
275481043
Protein Sequence QELQSETKGNKTHDEHLFIITHQAYELWFKQILWELDSVREIFQNGHVRDERNNLKVV
                 SRMHRVSVILKLLVQQFSILETMTALDFNDFREYLSPASGFQSLQFRLLENKIGVLQN
                 MRVPYNRRHYRDNFKGEENELLLKSEQEKTLLELVEAWLERTPGLESHGFNFWGKLEK
                 NITRGLEEEFIRIQAKEESEEKEEQVAEFQKQKEVLLSLFDEKRHEHLLSKGERRLSY
                 RALQCALMIYFYREEPRFQVPFQLLTSLMDIDSLMTKWRYNHVCMVHRMLGSKAGTGG
                 SSGYHYLRSTVSDRYKVFVDLFNLSTYLIPRHWILKMNPTIHKFLYTAEYCDSSYFSS
                 DESDVDGX

[0672] Sequence comparison of the above protein sequences yields the following sequence relationships shown in Table 58B.

TABLE 58B
Comparison of NOV58a against NOV58b and NOV58c.
			Identities/
			Similarities for
	Protein	NOV58a Residues/	the Matched
	Sequence	Match Residues	Region
	NOV58b	1 . . . 406	405/406 (99%)
		1 . . . 406	405/406 (99%)
	NOV58c	1 . . . 406	404/406 (99%)
		5 . . . 410	404/406 (99%)

[0673] Further analysis of the NOV58a protein yielded the following properties shown in Table 58C.

TABLE 58C
Protein Sequence Properties NOV58a
PSort     0.5095 probability located in microbody (peroxisome);
analysis: 0.4500 probability located in cytoplasm; 0.1000
          probability located in mitochondrial matrix space;
          0.1000 probability located in lysosome (lumen)
SignalP   No Known Signal Sequence Predicted
analysis:

[0674] A search of the NOV58a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 58D.

TABLE 58D
Geneseq Results for NOV58a
			Identities/
			Similarities for
Geneseq	Protein/Organism/Length	NOV58a Residues/	the Matched	Expect
Identifier	[Patent #, Date]	Match Residues	Region	Value
AAR21549	Human Tryptophan Oxygenase	1 . . . 406	403/406 (99%)	0.0
	TDO2 - Homo sapiens, 406 aa.	1 . . . 406	404/406 (99%)
	[WO9202637-A, 20 FEB. 1992]
AAR21547	Human Tryptophan-2,3-dioxygenase	1 . . . 396	365/396 (92%)	0.0
	deduced from clone HTO3 - Homo	1 . . . 394	369/396 (93%)
	sapiens, 436 aa. [WO9202637-A,
	20 FEB. 1992]
AAR21546	Human Tryptophan-2,3-dioxygenase	1 . . . 228	225/228 (98%)	e−130
	deduced from clone HTO3 - Homo	1 . . . 228	226/228 (98%)
	sapiens, 238 aa. [WO9202637-A,
	20 FEB. 1992]
ABB58903	Drosophila melanogaster	19 . . . 389	213/373 (57%)	e−115
	polypeptide SEQ ID NO 3501 -	4 . . . 374	273/373 (73%)
	Drosophila melanogaster, 379 aa.
	[WO200171042-A2, 27 SEP. 2001]
AAU11269	Human N-acetyltransferase 1	132 . . . 223	32/96 (33%)	0.44
	(NAT1) variant polypeptide - Homo	194 . . . 288	44/96 (45%)
	sapiens, 290 aa. [WO200179551-
	A1, 25 OCT. 2001]

[0675] In a BLAST search of public sequence datbases, the NOV58a protein was found to have homology to the proteins shown in the BLASTP data in Table 58E.

TABLE 58E
Public BLASTP Results for NOV58a
			Identities/
Protein			Similarities for
Accession		NOV58a Residues/	the Matched	Expect
Number	Protein/Organism/Length	Match Residues	Portion	Value
P48775	Tryptophan 2,3-dioxygenase (EC	1 . . . 406	406/406 (100%)	0.0
	1.13.11.11) (Tryptophan pyrrolase)	1 . . . 406	406/406 (100%)
	(Tryptophanase) (Tryptophan
	oxygenase) (Tryptamin 2,3-
	dioxygenase) (TRPO) - Homo
	sapiens (Human), 406 aa.
Q8VCW3	Tryptophan 2,3-dioxygenase - Mus	1 . . . 406	360/406 (88%)	0.0
	musculus (Mouse), 406 aa.	1 . . . 406	388/406 (94%)
P48776	Tryptophan 2,3-dioxygenase (EC	1 . . . 406	359/406 (88%)	0.0
	1.13.11.11) (Tryptophan pyrrolase)	1 . . . 406	388/406 (95%)
	(Tryptophanase) (Tryptophan
	oxygenase) (Tryptamin 2,3-
	dioxygenase) (TRPO) - Mus
	musculus (Mouse), 406 aa.
P21643	Tryptophan 2,3-dioxygenase (EC	1 . . . 406	360/406 (88%)	0.0
	1.13.11.11) (Tryptophan pyrrolase)	1 . . . 406	389/406 (95%)
	(Tryptophanase) (Tryptophan
	oxygenase) (Tryptamin 2,3-
	dioxygenase) (TRPO) - Rattus
	norvegicus (Rat), 406 aa.
O17440	VERMILION - Drosophila	19 . . . 389	214/374 (57%)	e−115
	ananassae (Fruit fly), 380 aa.	4 . . . 375	275/374 (73%)

[0676] PFam analysis predicts that the NOV58a protein contains the domains shown in the Table 58F.

TABLE 58F
Domain Analysis of NOV58a
			Identities/
			Similarities for
	Pfam	NOV58a	the Matched	Expect
	Domain	Match Region	Region	Value
No Significant Matches Found

EXAMPLE 59

[0677] The NOV59 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 59A.

TABLE 59A
NOV59 Sequence Analysis
                 SEQ ID NO: 441           1060 bp
NOV59a,          CGCGGGCCGACTGGTGTTTATCCGTCACTCGCCCAGGTTCCTTGGGTCATGGTGCCAG
CG98102-01
DNA Sequence     CCTGACTGAGAAGAGGACGCTCCCGGGAGACGAATGAGGAACCACCTCCTCCTACTGT
                 TCAAGTACAGGGGCCTGGTCCGCAAAGGGAAGAAAAGCAAAAGACGAAAATGGCTAAA
                 TTCGTGATCCGCCCAGCCACTGCCGCCGACTGCAGTGACATACTGCGGCTGATCAAGG
                 AGCTGGCTAAATATGAATACATGGAAGAACAAGTAATCTTAACTGAAAAAGATCTGCT
                 AGAAGATGGTTTTGGAGACCACCCCTTTTACCACTGCCTGGTTGCAGAAGTGCCGAAA
                 GAGCACTGGACTCCGGAAGGACACAGCATTGTTGGTTTTGCCATGTACTATTTTACCT
                 ATGACCCGTGGATTGGCAAGTTATTGTATCTTGAGGACTTCTTCGTGATGAGTGATTA
                 TAGAGGCTTTGGCATAGGATCAGAAATTCTGAAGAATCTAAGCCAGGTTGCAATGAGG
                 TGTCGCTGCAGCAGCATGCACTTCTTGGTAGCAGAATGGAATGAACCATCCATCAACT
                 TCTATAAAAGAAGAGGTGCTTCTGATCTGTCCAGTGAAGAGGGTTGGAGACTGTTCAA
                 GATCGACAAGGAGTACTTGCTAAAAATGGCAACAGAGGAGTGAGGAGTGCTGCTGTAG
                 ATGACAACCTCCATTCTATTTTAGAATAAATTCCCAACTTCTCTTGCTTTCTATGCTG
                 TTTGTAGTGAAATAATAGAATGAGCACCCATTCCAAAGCTTTATTACCAGTGGCGTTG
                 TTGCATGTTTGAAATGAGGTCTGTTTAAAGTGGCAATCTCAGATGCAGTTTGGAGAGT
                 CAGATCTTTCTCCTTGAATATCTTTCGATAAACAACAAGGTGGTGTGATCTTAATATA
                 TTTGAAAAAAACTTCATTCTCGTGAGTCATTTAAATGTGTACAATGTACACACTGGTA
                 CTTAGAGTTTCTGTTTGATTCTTTTTTAATAAACTACTCTTTGATTTAAAAAAAAAAA
                 AAAAAAAAAAAAAAAA
                 ORF Start: ATG at 166                ORF Stop: TGA at 679
                 SEQ ID NO: 442            171 aa     MW at 20023.8kD
NOV59a,          MAKFVIRPATAADCSDILRLIKELAKYEYMEEQVILTEKDLLEDGFGEHPFYHCLVAE
CG98102-01
Protein Sequence VPKEHWTPEGHSIVGFAMYYFTYDPWIGKLLYLEDFFVMSDYRGFGIGSEILKNLSQV
                 AMRCRCSSMHFLVAEWNEPSINFYKRROASDLSSEEGWRLFKIDKBYLLKMATEE
                 SEQ ID NO: 443           1052 bp
NOV59b,          CGGCCGCGTCGACCGCGGGCTGACTGGTTTATCCGTCACTCGCCGAGGTTCCTTGG
CG98102-03
DNA Sequence     GTCATGGTGCCAGCCTGACTGAGAAGAGGACGCTCCCGGGAGACGAATGAGGAACCAC
                 CTCCTCCTACTGTTCAAGTACAGGGGCCTCGTCCGCAAAGGGAAGAAAAGCAAAAGAC
                 GAAAATGGCTAAATTCGTGATCCGCCCAGCCACTGCCGCCGACTGCAGTGACATACTG
                 CGGCTGATCAGGAGCTGGCTAAATATGAATACATGGAGAACAAGTAATCTTAACTG
                 AAAAAGATCTGCTAGAAGATGGTTTTGGAGAGCACCCCTTTTACCACTGCCTGGTTGC
                 AGAAGTGCCGAAAGAGCACTGGACTCCGGAAGGACACAGCATTGTTGGTTTTGCCATG
                 TACTATTTTACCTATGACCCGTGGATTGGCAAGTTATTGTATCTTGAGGACTTTTTCG
                 TGATGAGTGATTATAGAGGCTTTGGCATAGGATCAGAAATTCTGAAGAATCTAAGCCA
                 GGTTGCAATGAGGTGTCGCTGCAGCAGCATGCACTTCTTGGTAGCAGAATGGAATGAA
                 CCATCCATCAACTTCTATAAAAGAAGAGGTGCTTCTGATCTGTCCAGTGAAGAGGGTT
                 GGAGACTGTTCAAGATCGACAAGGAGTACTTGCTAAAAATGGCAACAGAGGAGTGAGG
                 AGTGCTGCTGTAGATGACAACCTCCATTCTATTTTAGAATAAATTCCCAACTTCTCTT
                 GCTTTCTATGCTGTTTGTAGTGAAATAATAGAATGAGCACCCATTCCAAAGCTTTATT
                 ACCAGTGGCGTTGTTGCATGTTTGAAATGAGGTCTGTTTAAAGTGGCAATCTCAGATG
                 CAGTTTGGAGAGTCAGATCTTTCTCCTTGAATATCTTTCGATAAACAACAAGGTGGTG
                 TGATCTTAATATATTTGAAAAAAACTTCATTCTCGTGAGTCATTTAAATGTGTACAAT
                 GTACACACTGGTACTTAGAGTTTCTGTTTGATTCTTTTTTAATAAACTACTCTTTGAT
                 TTAAAAAA
                 ORF Start: ATG at 179                ORF Stop: IGA at 692
                 SEQ ID NO: 444            171 aa     MW at 20023.8kD
NOV59b,          MAKFVIRPATAADCSDILRLTKELAKYEYMEEQVILTEKDLLEDGFGEHPFYHCLVAE
CG98102-03
Protein Sequence VPKEHWTPEGHSIVGFAMYYFTYDPWIGKLLYLEDFFVMSDYRGFGIGSEILKNLSQV
                 AMRCRCSSMHFLVAEWNEPSINFYKRRGASDLSSEEGWRLFKIDKEYLLKMATEE
                 SEQ ID NO: 445            665 bp
NOV59c,          ACCTCCTCCTACTGTTCAACTACAGGGGCCTGGTCCGCAAAGGGAAGAAAAGCAAAAG
CG98102-02
DNA Sequence     ACGAAAATGGCTAAATTCGTGATCCGCCCAGCCACTGCCGCCGACTGCAGTGACATAC
                 TGCGGCTGATCAAGGAGCTGGCTAAATATGAATACATGGAAGAACAAGTAATCTTAAC
                 TGAAAAAGATCTGCTAGAAGATGGTTTTGGAGAGCACCCCTTTTACCACTGCCTGGTT
                 GCAGAAGTGCCGAAAGAGCACTGGACTCCGGAAGGACACAGCATTGTTGGTTTTGCCA
                 TGTACTATTTTACCTATGACCCGTGGATTGGCAAGTTATTGTATCTTGAGGACTTCTT
                 CGTGATGAGTGATTATAGAGGCTTTGGCATAGCATCAGAAATTCTGAAGAATCTAAGC
                 CAGGTTGCAATGAGGTGTCGCTGCAGCAGCATGCACTTCTTGGTAGCAGAATGGAATG
                 AACCATCCATCAACTTCTATAAAAGAAGAGGTGCTTCTGATCTGTCCAGTGAAGAGGG
                 TTGGAGACTGTTCAAGATCGACAAGGAGTACTTGCTAAAAATGGCAACAGAGGAGTGA
                 GGAGTGCTGCTGTAGATGACAACCTCCATTCTATTTTAGAATAAATTCCCAACTTCTC
                 TTGCTTTCTATGCTGTTTGTAGTGAAA
                 ORF Start: ATG at 65                 ORF Stop: TGA at 578
                 SEQ ID NO: 446            171 aa     MW at 20023.8kD
NOV59c,          MAKFVIRPATAADCSDILRLIKELAKYEYMEEQVILTEKDLLEDGFGEHPFYHCLVAE
CG98102-02
Protein Sequence VPKEHWTPEGHSIVGFAMYYFTYDPWIGKLLYLEDFFVMSDYRGFGIGSEILKNLSQV
                 AMRCRCSSMHFLVAEWNEPSINFYKRRGASDLSSEEGWRLFKIDKEYLLKMATEE
                 SEQ ID NO: 447            596 bp
NOV59d,          ACCTCCTCCTACTGTTCAAGTACAGGGGCCTGGTCCGCAAAGGGAAGAAAAGCAAAAG
CG98102-04
DNA Sequence     ACGAAAATGGCTAAATATGAATACATGGAAGAACAAGTAATCTTAACTGAAAAAGATC
                 TGCTAGAAGATGGTTTTGGAGAGCACCCCTTTTACCACTGCCTGGTTGCAGAAGTGCC
                 GAAAGAGCACTGGACTCCGGAAGGACACAGCATTCTTGGTTTTGCCATGTACTATTTT
                 ACCTATGACCCGTGGATTGGCAAGTTATTGTATCTTGACGACTTCTTCGTGATGAGTG
                 ATTATAGAGGCTTTGGCATAGGATCAGAAATTCTGAAGAATCTAAGCCAGGTTGCAAT
                 GAGGTGTCGCTGCAGCAGCATGCACTTCTTGGTAGCAGAATGGAATGAACCATCCATC
                 AACTTCTATAAAGAAGAGGTGCTTCTGATCTGTCCAGTGAAGAGGGTTGGAGACTGT
                 TCAAGATCGACAAGGAGTACTTGCTAAAAATGGCAACAGAGGAGTGAGGAGTGCTGCT
                 GTAGATGACAACCTCCATTCTATTTTAGAATAAATTCCCAACTTCTCTTGCTTTCTAT
                 GCTGTTTGTAGTGAAA
                 ORF Start: ATG at 65                 ORF Stop: TGA at 509
                 SEQ ID NO: 448            148 aa     MW at 17497.8kD
NOV59d,          MAKYEYMEEQVILTEKDLLEDGFGEHPFYHCLVAEVPKEHWTPEGHSIVGFAMYYFTY
CG98102-04
Protein Sequence DPWIGKLLYLEDFFVMSDYRGFGIGSEILKNLSQVAMRCRCSSMHFLVAEWNEPSINF
                 YKRRGASDLSSEEGWRLFKIDKEYLLKMATEE
                 SEQ ID NO: 449           1157 bp
NOV59e,          CTGGTGTTTATCCGTCACTCGCCGAGGTTCCTTGGGTCATGGTGCCAGCCTGACTGAG
CG98102-05
DNA Sequence     AAGAGGACGCTCCCGGGAGACGAATGAGGAACCACCTCCTCCTACTGTTCAAGTACAG
                 GGGCCTGGTCCGCAAAGGGAAGAAAAGCAAAAGACGAAAATCGCTAAATTCGTGATCC
                 GCCCAGCCACTGCCGCCGACTGCAGTGACATACTGCGGCTGATCAAGGAGCTGGCTAA
                 ATATGAATACATGGAAGAACAAGTAATCTTAACTGAAAAAGATCTGCTAGAAGATGGT
                 TTTGGAGAGCACCCCTTTTACCACTGCCTGGTTGCAGAAGTGCCGAAAGAGCACTGGA
                 CTCCGGAAGGTTACAGTCTCTAGCTTCGCCATGTACATGGCCCTTCCGTGTACATGGA
                 TGGGCGGGGAGGTAACTAAAGATCCTTTACACAATAAAAGTAGATGATCATGATAAAT
                 GAGGACACACCATTGTTGGTTTTGCCATGTACTATTTTACCTATGACCCGTGGATTGG
                 CAAGTTATTGTATCTTGAGGACTTCTTCGTGATGAGTGATTATAGAGGCTTTGGCATA
                 GGATCAGAAATTCTGAAGAATCTAAGCCAGGTTGCAATGAGGTGTCGCTGCAGCAGCA
                 TGCACTTCTTGGTAGCAGAATGGAATGAACCATCCATCAACTTCTATAAAAGAAGAGG
                 TCCTTCTGATCTGTCCAGTGAAGAGGGTTGGAGACTGTTCAAGATCGACAAGGAGTAC
                 TTGCTAAAAATGGCAACAGAGGAGTGAGGAGTGCTGCTGTAGATGACAACCTCCATTC
                 TATTTTAGAATAATTCCCAACTTCTCTTGCTTTCTATGCTGTTTGTAGTGAAATAAT
                 AGAATGACCACCCATTCCAAAGCTTTATTACCAGTGGCGTTGTTGCATGTTTGAAATG
                 AGGTCTGTTTAAAGTGGCAATCTCAGATGCAGTTTGGAGAGTCAGATCTTTCTCCTTG
                 AATATCTTTCGATAAACAACAAGGTGGTGTGATCTTAATATATTTGAAAAAAACTTCA
                 TTCTCGTGAGTCATTTAAATGTGTACAATGTACACACTGGTACTTAGAGTTTCTGTTT
                 GATTCTTTTTTAATAAACTACTCTTTGATTTAAAAAAAAAAAAAAAAAAAAAAAA
                 ORF Start: ATG at 491                ORF Stop: TGA at 779
                 SEQ ID NO: 450             96 aa     MW at 11464.0kD
NOV59e,          MYYFTYDPWIGKLLYLEDFFVMSDYRGFGIGSEILKNLSQVAMRCRCSSMHFLVAEWN
CG98102-05
Protein Sequence EPSINFYKRRGASDLSSEEGWRLFKIDKEYLLKIVIATEE
                 SEQ ID NO: 451           1107 bp
NOV59f,          TGGAATTCGGCCATACTGGGCGGTAGCGCAGCTCTTAGTCGCGGGCCGACTGGTGTTT
CG98102-06
DNA Sequence     ATCCGTCACTCGCCGAGGTTCCTTGGGTCATGGTGCCAGCCTGACTGAGAAGAGGACG
                 CTCCCGGGAGACGAATGAGTGAACCACCTCCTCCTACTGTTCAAGTACAGGGGCCTGG
                 TCCGCAAAGGGAAGAAAAGCAAAAGACGAAAATGGCTAAATTCGTGATCCGCCCAGCC
                 ACTGCCGCCGACTGCAGTGACATACTGCGGCTGATCAAGGAGCTGGCTAAATATGAAT
                 ACATGGAAGAACAAGTAATCTTAACTGAAAAAGATCTGCTAGAAGATGGTTTTGGAGA
                 GCACCCCTTTTACCACTGCCTGGTTGCAGAAGTGCCGAAAGAGCACTGGACTCCGGAA
                 GGTAACCCCTCGCCCTTGTCCAGGGTAAGCCATGTAGTAGTTTACCTATACCCGTGTT
                 ATGTAAGCAAGTTATCGTGTCTTGAGGACTTCTTCGTGATGAGTGATTACTCGAGGCT
                 TTGGCATAGGATCAGAAATTCTGAAGAATCTAAGCCAGGTTGCAATGAGGTGTCGCTG
                 CCAGCAGCATGCACTTCTTGGGTAGCAGAATGGAATGAACCATCCATCAACTTCTATA
                 AAAGAAGAGGTGCTTCTGATCTGTCCAGTGAAGAGGGTTGGAGATGTTCAGATCGCAA
                 GGAGTACTGCTAAAAATGGCAACAGGGAGTACCAGACTGTGCTGATAGATGACAACCT
                 CCATTCTATTTTAGAATAAATTCCCAACTTCTCTTGCTTTCTATGCTGTTTGTAGTGA
                 AATAATAGAATGAGCACCCATTCCAAAGCTTTATTACCAGTGGCGTTGTTGCATGTTT
                 GAAATGAGGTCTGTTTAAAGTGGCAATCTCAGATGCAGTTTGGAGAGTCAGATCTTTC
                 TCCTTGAATATCTTTCGATAAACAACAAGGTGGTGTGATCTTAATATATTTGAAAAAA
                 ACTTCATTCTCGTGAGTCATTTAAATGTGTACAATGTACACACTGGTACTTAGAGTTT
                 CTGTTTGATTCTTTTTTAATAAACTACTCTTTGATTTAAAAAAAAAAAAAAAAAAAAA
                 AAAAA
                 ORF Start: ATG at 131                ORF Stop: TAA at 707
                 SEQ ID NO: 452            192 aa     MW at 22209.9kD
NOV59f,          MSEPPPPTVQVQGPGPQREEKQKTKMAKFVIRPATAADCSDILRLIKELAKYEMEEQ
CG98102-06
Protein Sequence VILTEKDLLEDGFGEHPFYHCLVAEVPKEHWTPEGNPSPLSRVSHVVVYLYPCYVSKL
                 WCLEDFFVMSDYSRLWHRIRNSEESKPGCNEVSLPAACTSWVAEWNEPSINFYKRRGA
                 SDLSSEEGWRCSDRKEYC

[0678] Sequence comparison of the above protein sequences yields the following sequence relationships shown in Table 59B.

TABLE 59B
Comparison of NOV59a against NOV59b through NOV59f.
			Identities/
			Similarities for
	Protein	NOV59a Residues/	the Matched
	Sequence	Match Residues	Region
	NOV59b	1 . . . 171	171/171 (100%)
		1 . . . 171	171/171 (100%)
	NOV59c	1 . . . 171	171/171 (100%)
		1 . . . 171	171/171 (100%)
	NOV59d	24 . . . 171	147/148 (99%)
		1 . . . 148	148/148 (99%)
	NOV59e	76 . . . 171	96/96 (100%)
		1 . . . 96	96/96 (100%)
	NOV59f	1 . . . 155	115/163 (70%)
		26 . . . 184	124/163 (75%)

[0679] Further analysis of the NOV59a protein yielded the following properties shown in Table 59C.

TABLE 59C
Protein Sequence Properties NOV59a
PSort     0.6400 probability located in microbody (peroxisome);
analysis: 0.6153 probability located in mitochondrial matrix
          space; 0.3177 probability located in mitochondrial
          inner membrane; 0.3177 probability located in
          mitochondrial intermembrane space
SignalP   No Known Signal Sequence Predicted
analysis:

[0680] A search of the NOV59a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 59D.

TABLE 59D
Geneseq Results for NOV59a
			Identities/
			Similarities for
Geneseq	Protein/Organism/Length	NOV59a Residues/	the Matched	Expect
Identifier	[Patent #, Date]	Match Residues	Region	Value
ABB57094	Mouse ischaemic condition related	1 . . . 171	165/171 (96%)	1e−96
	protein sequence SEQ ID NO: 207 -	1 . . . 171	168/171 (97%)
	Mus musculus, 171 aa.
	[WO200188188-A2, 22 NOV.
	2001]
AAU30048	Novel human secreted	1 . . . 158	146/161 (90%)	9e−81
	protein #539 - Homo sapiens, 218 aa.	35 . . . 195	151/161 (93%)
	[WO200179449-A2, 25 OCT. 2001]
AAB82049	Human spermidine/spermine acetyl	1 . . . 155	115/163 (70%)	4e−56
	transferase protein isomer - Homo	26 . . . 184	124/163 (75%)
	sapiens, 192 aa. [CN1278003-A, 27
	DEC. 2000]
AAB44145	Human cancer associated protein	42 . . . 127	85/86 (98%)	3e−48
	sequence SEQ ID NO: 1590 - Homo	1 . . . 86	85/86 (98%)
	sapiens, 92 aa. [WO200055350-A1,
	21 SEP. 2000]
AAW58394	Human spermidine/spermine N1-	1 . . . 168	78/168 (46%)	9e−41
	acetyltransferase - Homo sapiens,	1 . . . 168	109/168 (64%)
	170 aa. [WO9818938-A1, 07 MAY
	1998]

[0681] In a BLAST search of public sequence datbases, the NOV59a protein was found to have homology to the proteins shown in the BLASTP data in Table 59E.

TABLE 59E
Public BLASTP Results for NOV59a
			Identities/
		NOV59a	Similarities
Protein		Residues/	for the
Accession		Match	Matched	Expect
Number	Protein/Organism/Length	Residues	Portion	Value
P21673	Diamine acetyltransferase (EC	1 . . . 171	171/171 (100%)	3e−99
	2.3.1.57) (Spermidine/spermine	1 . . . 171	171/171 (100%)
	N(1)- acetyltransferase) (SSAT)
	(Putrescine acetyltransferase) -
	Homo sapiens (Human), 171 aa.
JH0783	diamine N-acetyltransferase (EC	1 . . . 171	170/171 (99%)	1e−98
	2.3.1.57) - human, 171 aa.	1 . . . 171	171/171 (99%)
P49431	Spermidine/spermine N(1)-	1 . . . 171	166/171 (97%)	7e−97
	acetyltransferase (EC 2.3.1.57)	1 . . . 171	169/171 (98%)
	(Diamine acetyltransferase) (SSAT)
	(Putrescine acetyltransferase) - Mus
	saxicola (Spiny mouse), 171 aa.
Q28999	Diamine acetyltransferase (EC	1 . . . 171	168/171 (98%)	1e−96
	2.3.1.57) (Spermidine/spermine	1 . . . 171	169/171 (98%)
	N(1)- acetyltransferase) (SSAT)
	(Putrescine acetyltransferase) - Sus
	scrofa (Pig), 171 aa.
Q9JHW6	Spermidine/spermine N1-	1 . . . 171	164/171 (95%)	2e−96
	acetyltransferase - Cricetulus	1 . . . 171	169/171 (97%)
	griseus (Chinese hamster), 171 aa.

[0682] PFam analysis predicts that the NOV59a protein contains the domains shown in the Table 59F.

TABLE 59F
Domain Analysis of NOV59a
		Identities/
	NOV59a	Similarities
	Match	for the
Pfam Domain	Region	Matched Region	Expect Value
Acetyltransf	63 . . . 146	23/85 (27%)	1.6e−16
		59/85 (69%)

Example B

[0683] Sequencing Methodology and Identification of NOVX Clones

[0684] 1. GeneCalling™ Technology: This is a proprietary method of performing differential gene expression profiling between two or more samples developed at CuraGen and described by Shimkets, et al., “Gene expression analysis by transcript profiling coupled to a gene database query” Nature Biotechnology 17:198-803 (1999). cDNA was derived from various human samples representing multiple tissue types, normal and diseased states, physiological states, and developmental states from different donors. Samples were obtained as whole tissue, primary cells or tissue cultured primary cells or cell lines. Cells and cell lines may have been treated with biological or chemical agents that regulate gene expression, for example, growth factors, chemokines or steroids. The cDNA thus derived was then digested with up to as many as 120 pairs of restriction enzymes and pairs of linker-adaptors specific for each pair of restriction enzymes were ligated to the appropriate end. The restriction digestion generates a mixture of unique cDNA gene fragments. Limited PCR amplification is performed with primers homologous to the linker adapter sequence where one primer is biotinylated and the other is fluorescently labeled. The doubly labeled material is isolated and the fluorescently labeled single strand is resolved by capillary gel electrophoresis. A computer algorithm compares the electropherograms from an experimental and control group for each of the restriction digestions. This and additional sequence-derived information is used to predict the identity of each differentially expressed gene fragment using a variety of genetic databases. The identity of the gene fragment is confirmed by additional, gene-specific competitive PCR or by isolation and sequencing of the gene fragment.

[0685] 2. SeqCalling™ Technology: cDNA was derived from various human samples representing multiple tissue types, normal and diseased states, physiological states, and developmental states from different donors. Samples were obtained as whole tissue, primary cells or tissue cultured primary cells or cell lines. Cells and cell lines may have been treated with biological or chemical agents that regulate gene expression, for example, growth factors, chemokines or steroids. The cDNA thus derived was then sequenced using CuraGen's proprietary SeqCalling technology. Sequence traces were evaluated manually and edited for corrections if appropriate. cDNA sequences from all samples were assembled together, sometimes including public human sequences, using bioinformatic programs to produce a consensus sequence for each assembly. Each assembly is included in CuraGen Corporation's database. Sequences were included as components for assembly when the extent of identity with another component was at least 95% over 50 bp. Each assembly represents a gene or portion thereof and includes information on variants, such as splice forms single nucleotide polymorphisms (SNPs), insertions, deletions and other sequence variations.

[0686] 3. PathCalling™ Technology: The NOVX nucleic acid sequences are derived by laboratory screening of cDNA library by the two-hybrid approach. cDNA fragments covering either the full length of the DNA sequence, or part of the sequence, or both, are sequenced. In silico prediction was based on sequences available in CuraGen Corporation's proprietary sequence databases or in the public human sequence databases, and provided either the full length DNA sequence, or some portion thereof.

[0687] The laboratory screening was performed using the methods summarized below:

[0688] cDNA libraries were derived from various human samples representing multiple tissue types, normal and diseased states, physiological states, and developmental states from different donors. Samples were obtained as whole tissue, primary cells or tissue cultured primary cells or cell lines. Cells and cell lines may have been treated with biological or chemical agents that regulate gene expression, for example, growth factors, chemokines or steroids. The cDNA thus derived was then directionally cloned into the appropriate two-hybrid vector (Gal4-activation domain (Gal4-AD) fusion). Such cDNA libraries as well as commercially available cDNA libraries from Clontech (Palo Alto, CA) were then transferred from E.coli into a CuraGen Corporation proprietary yeast strain (disclosed in U.S. Pat. Nos. 6,057,101 and 6,083,693, incorporated herein by reference in their entireties).

[0689] Gal4-binding domain (Gal4-BD) fusions of a CuraGen Corportion proprietary library of human sequences was used to screen multiple Gal4-AD fusion cDNA libraries resulting in the selection of yeast hybrid diploids in each of which the Gal4-AD fusion contains an individual cDNA. Each sample was amplified using the polymerase chain reaction (PCR) using non-specific primers at the cDNA insert boundaries. Such PCR product was sequenced; sequence traces were evaluated manually and edited for corrections if appropriate. cDNA sequences from all samples were assembled together, sometimes including public human sequences, using bioinformatic programs to produce a consensus sequence for each assembly. Each assembly is included in CuraGen Corporation's database. Sequences were included as components for assembly when the extent of identity with another component was at least 95% over 50 bp. Each assembly represents a gene or portion thereof and includes information on variants, such as splice forms single nucleotide polymorphisms (SNPs), insertions, deletions and other sequence variations.

[0690] Physical clone: the cDNA fragment derived by the screening procedure, covering the entire open reading frame is, as a recombinant DNA, cloned into pACT2 plasmid (Clontech) used to make the cDNA library. The recombinant plasmid is inserted into the host and selected by the yeast hybrid diploid generated during the screening procedure by the mating of both CuraGen Corporation proprietary yeast strains N106′ and YULH (U.S. Pat. Nos. 6,057,101 and 6,083,693).

[0691] 4. RACE: Techniques based on the polymerase chain reaction such as rapid amplification of cDNA ends (RACE), were used to isolate or complete the predicted sequence of the cDNA of the invention. Usually multiple clones were sequenced from one or more human samples to derive the sequences for fragments. Various human tissue samples from different donors were used for the RACE reaction. The sequences derived from these procedures were included in the SeqCalling Assembly process described in preceding paragraphs.

[0692] 5. Exon Linking: The NOVX target sequences identified in the present invention were subjected to the exon linking process to confirm the sequence. PCR primers were designed by starting at the most upstream sequence available, for the forward primer, and at the most downstream sequence available for the reverse primer. In each case, the sequence was examined, walking inward from the respective termini toward the coding sequence, until a suitable sequence that is either unique or highly selective was encountered, or, in the case of the reverse primer, until the stop codon was reached. Such primers were designed based on in silico predictions for the full length cDNA, part (one or more exons) of the DNA or protein sequence of the target sequence, or by translated homology of the predicted exons to closely related human sequences from other species. These primers were then employed in PCR amplification based on the following pool of human cDNAs: adrenal gland, bone marrow, brain-amygdala, brain-cerebellum, brain-hippocampus, brain-substantia nigra, brain-thalamus, brain-whole, fetal brain, fetal kidney, fetal liver, fetal lung, heart, kidney, lymphoma-Raji, mammary gland, pancreas, pituitary gland, placenta, prostate, salivary gland, skeletal muscle, small intestine, spinal cord, spleen, stomach, testis, thyroid, trachea, uterus. Usually the resulting amplicons were gel purified, cloned and sequenced to high redundancy. The PCR product derived from exon linking was cloned into the pCR2.1 vector from Invitrogen. The resulting bacterial clone has an insert covering the entire open reading frame cloned into the pCR2.1 vector. The resulting sequences from all clones were assembled with themselves, with other fragments in CuraGen Corporation's database and with public ESTs. Fragments and ESTs were included as components for an assembly when the extent of their identity with another component of the assembly was at least 95% over 50 bp. In addition, sequence traces were evaluated manually and edited for corrections if appropriate. These procedures provide the sequence reported herein.

[0693] 6. Physical Clone: Exons were predicted by homology and the intron/exon boundaries were determined using standard genetic rules. Exons were further selected and refined by means of similarity determination using multiple BLAST (for example, tBlastN, BlastX, and BlastN) searches, and, in some instances, GeneScan and Grail. Expressed sequences from both public and proprietary databases were also added when available to further define and complete the gene sequence. The DNA sequence was then manually corrected for apparent inconsistencies thereby obtaining the sequences encoding the full-length protein.

[0694] The PCR product derived by exon linking, covering the entire open reading frame, was cloned into the pCR2.1 vector from Invitrogen to provide clones used for expression and screening purposes.

Example C

[0695] Quantitative Expression Analysis of Clones in Various Cells and Tissues

[0696] The quantitative expression of various clones was assessed using microtiter plates containing RNA samples from a variety of normal and pathology-derived cells, cell lines and tissues using real time quantitative PCR (RTQ PCR). RTQ PCR was performed on an Applied Biosystems ABI PRISM® 7700 or an ABI PRISM® 7900 HT Sequence Detection System. Various collections of samples are assembled on the plates, and referred to as Panel 1 (containing normal tissues and cancer cell lines), Panel 2 (containing samples derived from tissues from normal and cancer sources), Panel 3 (containing cancer cell lines), Panel 4 (containing cells and cell lines from normal tissues and cells related to inflammatory conditions), Panel 5D/5I (containing human tissues and cell lines with an emphasis on metabolic diseases), AI_comprehensive_panel (containing normal tissue and samples from autoimmune/autoinflammatory diseases), Panel CNSD.01 (containing samples from normal and diseased brains) and CNS_neurodegeneration_panel (containing samples from normal and Alzheimer's diseased brains).

[0697] RNA integrity from all samples is controlled for quality by visual assessment of agarose gel electropherograms using 28S and 18S ribosomal RNA staining intensity ratio as a guide (2:1 to 2.5:1 28s:18s) and the absence of low molecular weight RNAs that would be indicative of degradation products. Samples are controlled against genomic DNA contamination by RTQ PCR reactions run in the absence of reverse transcriptase using probe and primer sets designed to amplify across the span of a single exon.

[0698] First, the RNA samples were normalized to reference nucleic acids such as constitutively expressed genes (for example, β-actin and GAPDH). Normalized RNA (5 ul) was converted to cDNA and analyzed by RTQ-PCR using One Step RT-PCR Master Mix Reagents (Applied Biosystems; Catalog No. 4309169) and gene-specific primers according to the manufacturer's instructions.

[0699] In other cases, non-normalized RNA samples were converted to single strand cDNA (sscDNA) using Superscript II (Invitrogen Corporation; Catalog No. 18064-147) and random hexamers according to the manufacturer's instructions. Reactions containing up to 10 μg of total RNA were performed in a volume of 20 μl and incubated for 60 minutes at 42° C. This reaction can be scaled up to 50 μg of total RNA in a final volume of 100 μl. sscDNA samples are then normalized to reference nucleic acids as described previously, using 1× TaqMan® Universal Master mix (Applied Biosystems; catalog No. 4324020), following the manufacturer's instructions.

[0700] Probes and primers were designed for each assay according to Applied Biosystems Primer Express Software package (version I for Apple Computer's Macintosh Power PC) or a similar algorithm using the target sequence as input. Default settings were used for reaction conditions and the following parameters were set before selecting primers: primer concentration=250 nM, primer melting temperature (Tm) range=58°−60° C., primer optimal Tm=59° C., maximum primer difference=2° C., probe does not have 5′G, probe Tm must be 10° C. greater than primer Tm, amplicon size 75 bp to 100 bp. The probes and primers selected (see below) were synthesized by Synthegen (Houston, Tex., USA). Probes were double purified by HPLC to remove uncoupled dye and evaluated by mass spectroscopy to verify coupling of reporter and quencher dyes to the 5′ and 3′ ends of the probe, respectively. Their final concentrations were: forward and reverse primers, 900 nM each, and probe, 200 nM.

[0701] PCR conditions: When working with RNA samples, normalized RNA from each tissue and each cell line was spotted in each well of either a 96 well or a 384-well PCR plate (Applied Biosystems). PCR cocktails included either a single gene specific probe and primers set, or two multiplexed probe and primers sets (a set specific for the target clone and another gene-specific set multiplexed with the target probe). PCR reactions were set up using TaqMan® One-Step RT-PCR Master Mix (Applied Biosystems, Catalog No. 4313803) following manufacturer's instructions. Reverse transcription was performed at 48° C. for 30 minutes followed by amplification/PCR cycles as follows: 95° C. 10 min, then 40 cycles of 95° C. for 15 seconds, 60° C. for 1 minute. Results were recorded as CT values (cycle at which a given sample crosses a threshold level of fluorescence) using a log scale, with the difference in RNA concentration between a given sample and the sample with the lowest CT value being represented as 2 to the power of delta CT. The percent relative expression is then obtained by taking the reciprocal of this RNA difference and multiplying by 100.

[0702] When working with sscDNA samples, normalized sscDNA was used as described previously for RNA samples. PCR reactions containing one or two sets of probe and primers were set up as described previously, using 1× TaqMan® Universal Master mix (Applied Biosystems; catalog No. 4324020), following the manufacturer's instructions. PCR amplification was performed as follows: 95° C. 10 min, then 40 cycles of 95° C. for 15 seconds, 60° C. for 1 minute. Results were analyzed and processed as described previously.

[0703] Panels 1, 1.1, 1.2, and 1.3D

[0704] The plates for Panels 1, 1.1, 1.2 and 1.3D include 2 control wells (genomic DNA control and chemistry control) and 94 wells containing cDNA from various samples. The samples in these panels are broken into 2 classes: samples derived from cultured cell lines and samples derived from primary normal tissues. The cell lines are derived from cancers of the following types: lung cancer, breast cancer, melanoma, colon cancer, prostate cancer, CNS cancer, squamous cell carcinoma, ovarian cancer, liver cancer, renal cancer, gastric cancer and pancreatic cancer. Cell lines used in these panels are widely available through the American Type Culture Collection (ATCC), a repository for cultured cell lines, and were cultured using the conditions recommended by the ATCC. The normal tissues found on these panels are comprised of samples derived from all major organ systems from single adult individuals or fetuses. These samples are derived from the following organs: adult skeletal muscle, fetal skeletal muscle, adult heart, fetal heart, adult kidney, fetal kidney, adult liver, fetal liver, adult lung, fetal lung, various regions of the brain, the spleen, bone marrow, lymph node, pancreas, salivary gland, pituitary gland, adrenal gland, spinal cord, thymus, stomach, small intestine, colon, bladder, trachea, breast, ovary, uterus, placenta, prostate, testis and adipose.

[0705] In the results for Panels 1, 1.1, 1.2 and 1.3D, the following abbreviations are used:

[0706] ca.=carcinoma,

[0707] *=established from metastasis,

[0708] met=metastasis,

[0709] s cell var=small cell variant,

[0710] non-s=non-sm=non-small,

[0711] squam=squamous,

[0712] pl. eff=pl effusion=pleural effusion,

[0713] glio=glioma,

[0714] astro=astrocytoma, and

[0715] neuro=neuroblastoma.

[0716] General_Screening Panel_v1.4, v1.5, v1.6 and 1.7

[0717] The plates for Panels 1.4, 1.5, 1.6 and 1.7 include 2 control wells (genomic DNA control and chemistry control) and 94 wells containing cDNA from various samples. The samples in Panels 1.4, 1.5, 1.6 and 1.7 are broken into 2 classes: samples derived from cultured cell lines and samples derived from primary normal tissues. The cell lines are derived from cancers of the following types: lung cancer, breast cancer, melanoma, colon cancer, prostate cancer, CNS cancer, squamous cell carcinoma, ovarian cancer, liver cancer, renal cancer, gastric cancer and pancreatic cancer. Cell lines used in Panels 1.4, 1.5, and 1.6 are widely available through the American Type Culture Collection (ATCC), a repository for cultured cell lines, and were cultured using the conditions recommended by the ATCC. The normal tissues found on Panels 1.4, 1.5, 1.6, 1.7 are comprised of pools of samples derived from all major organ systems from 2 to 5 different adult individuals or fetuses. These samples are derived from the following organs: adult skeletal muscle, fetal skeletal muscle, adult heart, fetal heart, adult kidney, fetal kidney, adult liver, fetal liver, adult lung, fetal lung, various regions of the brain, the spleen, bone marrow, lymph node, pancreas, salivary gland, pituitary gland, adrenal gland, spinal cord, thymus, stomach, small intestine, colon, bladder, trachea, breast, ovary, uterus, placenta, prostate, testis and adipose. Abbreviations are as described for Panels 1, 1.1, 1.2, and 1.3D.

[0718] Panels 2D, 2.2, 2.3 and 2.4

[0719] The plates for Panels 2D, 2.2, 2.3 and 2.4 generally include two control wells and 94 test samples composed of RNA or cDNA isolated from human tissue procured by surgeons working in close cooperation with the National Cancer Institute's Cooperative Human Tissue Network (CHTN) or the National Disease Research Initiative (NDRI) or from Ardais or Clinomics. The tissues are derived from human malignancies and in cases where indicated many malignant tissues have “matched margins” obtained from noncancerous tissue just adjacent to the tumor. These are termed normal adjacent tissues and are denoted “NAT” in the results below. The tumor tissue and the “matched margins” are evaluated by two independent pathologists (the surgical pathologists and again by a pathologist at NDRI/ CHTN/Ardais/Clinomics). Unmatched RNA samples from tissues without malignancy (normal tissues) were also obtained from Ardais or Clinomics. This analysis provides a gross histopathological assessment of tumor differentiation grade. Moreover, most samples include the original surgical pathology report that provides information regarding the clinical stage of the patient. These matched margins are taken from the tissue surrounding (i.e. immediately proximal) to the zone of surgery (designated “NAT”, for normal adjacent tissue, in Table RR). In addition, RNA and cDNA samples were obtained from various human tissues derived from autopsies performed on elderly people or sudden death victims (accidents, etc.). These tissues were ascertained to be free of disease and were purchased from various commercial sources such as Clontech (Palo Alto, Calif.), Research Genetics, and Invitrogen. General oncology screening panel_v—2.4 is an updated version of Panel 2D.

[0720] HASS Panel v 1.0

[0721] The HASS panel v 1.0 plates are comprised of 93 cDNA samples and two controls. Specifically, 81 of these samples are derived from cultured human cancer cell lines that had been subjected to serum starvation, acidosis and anoxia for different time periods as well as controls for these treatments, 3 samples of human primary cells, 9 samples of malignant brain cancer (4 medulloblastomas and 5 glioblastomas) and 2 controls. The human cancer cell lines are obtained from ATCC (American Type Culture Collection) and fall into the following tissue groups: breast cancer, prostate cancer, bladder carcinomas, pancreatic cancers and CNS cancer cell lines. These cancer cells are all cultured under standard recommended conditions. The treatments used (serum starvation, acidosis and anoxia) have been previously published in the scientific literature. The primary human cells were obtained from Clonetics (Walkersville, Md.) and were grown in the media and conditions recommended by Clonetics. The malignant brain cancer samples are obtained as part of a collaboration (Henry Ford Cancer Center) and are evaluated by a pathologist prior to CuraGen receiving the samples. RNA was prepared from these samples using the standard procedures. The genomic and chemistry control wells have been described previously.

[0722] ARDAIS Panel v 1.0

[0723] The plates for ARDAIS panel v 1.0 generally include 2 control wells and 22 test samples composed of RNA isolated from human tissue procured by surgeons working in close cooperation with Ardais Corporation. The tissues are derived from human lung malignancies (lung adenocarcinoma or lung squamous cell carcinoma) and in cases where indicated many malignant samples have “matched margins” obtained from noncancerous lung tissue just adjacent to the tumor. These matched margins are taken from the tissue surrounding (i.e. immediately proximal) to the zone of surgery (designated “NAT”, for normal adjacent tissue) in the results below. The tumor tissue and the “matched margins” are evaluated by independent pathologists (the surgical pathologists and again by a pathologist at Ardais). Unmatched malignant and non-malignant RNA samples from lungs were also obtained from Ardais. Additional information from Ardais provides a gross histopathological assessment of tumor differentiation grade and stage. Moreover, most samples include the original surgical pathology report that provides information regarding the clinical state of the patient.

[0724] Panel 3D, 3.1 and 3.2

[0725] The plates of Panel 3D, 3.1, and 3.2 are comprised of 94 cDNA samples and two control samples. Specifically, 92 of these samples are derived from cultured human cancer cell lines, 2 samples of human primary cerebellar tissue and 2 controls. The human cell lines are generally obtained from ATCC (American Type Culture Collection), NCI or the German tumor cell bank and fall into the following tissue groups: Squamous cell carcinoma of the tongue, breast cancer, prostate cancer, melanoma, epidermoid carcinoma, sarcomas, bladder carcinomas, pancreatic cancers, kidney cancers, leukemias/lymphomas, ovarian/uterine/cervical, gastric, colon, lung and CNS cancer cell lines. In addition, there are two independent samples of cerebellum. These cells are all cultured under standard recommended conditions and RNA extracted using the standard procedures. The cell lines in panel 3D, 3.1, 3.2, 1, 1.1., 1.2, 1.3D, 1.4, 1.5, and 1.6 are of the most common cell lines used in the scientific literature.

[0726] AI.05 Chondrosarcoma

[0727] The AI.05 chondrosarcoma plates are comprised of SW1353 cells that had been subjected to serum starvation and treatment with cytokines that are known to induce MMP (1, 3 and 13) synthesis (eg. IL1beta). These treatments include: IL-1beta (10 ng/ml), IL-1beta+TNF-alpha (50 ng/ml), IL-1beta+Oncostatin (50 ng/ml) and PMA (100 ng/ml). The SW1353 cells were obtained from the ATCC (American Type Culture Collection) and were all cultured under standard recommended conditions. The SW1353 cells were plated at 3×105 cells/ml (in DMEM medium-10 % FBS) in 6-well plates. The treatment was done in triplicate, for 6 and 18 h. The supernatants were collected for analysis of MMP 1, 3 and 13 production and for RNA extraction. RNA was prepared from these samples using the standard procedures.

[0728] Panels 4D, 4R, and 4.1D

[0729] Panel 4 includes samples on a 96 well plate (2 control wells, 94 test samples) composed of RNA (Panel 4R) or cDNA (Panels 4D/4.1D) isolated from various human cell lines or tissues related to inflammatory conditions. Total RNA from control normal tissues such as colon and lung (Stratagene, La Jolla, Calif.) and thymus and kidney (Clontech) was employed. Total RNA from liver tissue from cirrhosis patients and kidney from lupus patients was obtained from BioChain (Biochain Institute, Inc., Hayward, Calif.). Intestinal tissue for RNA preparation from patients diagnosed as having Crohn's disease and ulcerative colitis was obtained from the National Disease Research Interchange (NDRI) (Philadelphia, Pa.).

[0730] Astrocytes, lung fibroblasts, dermal fibroblasts, coronary artery smooth muscle cells, small airway epithelium, bronchial epithelium, microvascular dermal endothelial cells, microvascular lung endothelial cells, human pulmonary aortic endothelial cells, human umbilical vein endothelial cells were all purchased from Clonetics (Walkersville, Md.) and grown in the media supplied for these cell types by Clonetics. These primary cell types were activated with various cytokines or combinations of cytokines for 6 and/or 12-14 hours, as indicated. The following cytokines were used; IL-1 beta at approximately 1-5 ng/ml, TNF alpha at approximately 5-10 ng/ml, IFN gamma at approximately 20-50 ng/ml, IL-4 at approximately 5-10 ng/ml, IL-9 at approximately 5-10 ng/ml, IL-13 at approximately 5-10 ng/ml. Endothelial cells were sometimes starved for various times by culture in the basal media from Clonetics with 0.1 % serum.

[0731] Mononuclear cells were prepared from blood of employees at CuraGen Corporation, using Ficoll. LAK cells were prepared from these cells by culture in DMEM 5% FCS (Hyclone), 100 μM non essential amino acids (Gibco/Life Technologies, Rockville, Md.), 1 mM sodium pyruvate (Gibco), mercaptoethanol 5.5×10−5M (Gibco), and 10 mM Hepes (Gibco) and Interleukin 2 for 4-6 days. Cells were then either activated with 10-20 ng/ml PMA and 1-2 μg/ml ionomycin, IL-12 at 5-10 ng/ml, IFN gamma at 20-50 ng/ml and IL-18 at 5-10 ng/ml for 6 hours. In some cases, mononuclear cells were cultured for 4-5 days in DMEM 5% FCS (Hyclone), 100 μM non essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), mercaptoethanol 5.5×10−5M (Gibco), and 10 mM Hepes (Gibco) with PHA (phytohemagglutinin) or PWM (pokeweed mitogen) at approximately 5 μg/ml. Samples were taken at 24, 48 and 72 hours for RNA preparation. MLR (mixed lymphocyte reaction) samples were obtained by taking blood from two donors, isolating the mononuclear cells using Ficoll and mixing the isolated mononuclear cells 1:1 at a final concentration of approximately 2×106 cells/ml in DMEM 5% FCS (Hyclone), 100 μM non essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), mercaptoethanol (5.5×10−5M) (Gibco), and 10 mM Hepes (Gibco). The MLR was cultured and samples taken at various time points ranging from 1-7 days for RNA preparation.

[0732] Monocytes were isolated from mononuclear cells using CD14 Miltenyi Beads, +ve VS selection columns and a Vario Magnet according to the manufacturer's instructions. Monocytes were differentiated into dendritic cells by culture in DMEM 5% fetal calf serum (FCS) (Hyclone, Logan, UT), 100 μM non essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), mercaptoethanol 5.5×10−5M (Gibco), and 10 mM Hepes (Gibco), 50 ng/ml GMCSF and 5 ng/ml IL-4 for 5-7 days. Macrophages were prepared by culture of monocytes for 5-7 days in DMEM 5% FCS (Hyclone), 100 μM non essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), mercaptoethanol 5.5×10−5M (Gibco), 10 mM Hepes (Gibco) and 10% AB Human Serum or MCSF at approximately 50 ng/ml. Monocytes, macrophages and dendritic cells were stimulated for 6 and 12-14 hours with lipopolysaccharide (LPS) at 100 ng/ml. Dendritic cells were also stimulated with anti-CD40 monoclonal antibody (Pharmingen) at 10 μg/ml for 6 and 12-14 hours.

[0733] CD4 lymphocytes, CD8 lymphocytes and NK cells were also isolated from mononuclear cells using CD4, CD8 and CD56 Miltenyi beads, positive VS selection columns and a Vario Magnet according to the manufacturer's instructions. CD45RA and CD45RO CD4 lymphocytes were isolated by depleting mononuclear cells of CD8, CD56, CD14 and CD19 cells using CD8, CD56, CD14 and CD19 Miltenyi beads and positive selection. CD45RO beads were then used to isolate the CD45RO CD4 lymphocytes with the remaining cells being CD45RA CD4 lymphocytes. CD45RA CD4, CD45RO CD4 and CD8 lymphocytes were placed in DMEM 5% FCS (Hyclone), 100 μM non essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), mercaptoethanol 5.5×10−5M (Gibco), and 10 mM Hepes (Gibco) and plated at 106 cells/ml onto Falcon 6 well tissue culture plates that had been coated overnight with 0.5 μg/ml anti-CD28 (Pharmingen) and 3 μg/ml anti-CD3 (OKT3, ATCC) in PBS. After 6 and 24 hours, the cells were harvested for RNA preparation. To prepare chronically activated CD8 lymphocytes, we activated the isolated CD8 lymphocytes for 4 days on anti-CD28 and anti-CD3 coated plates and then harvested the cells and expanded them in DMEM 5% FCS (Hyclone), 100 μM non essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), mercaptoethanol 5.5×10−5M (Gibco), and 10 mM Hepes (Gibco) and IL-2. The expanded CD8 cells were then activated again with plate bound anti-CD3 and anti-CD28 for 4 days and expanded as before. RNA was isolated 6 and 24 hours after the second activation and after 4 days of the second expansion culture. The isolated NK cells were cultured in DMEM 5% FCS (Hyclone), 100 μM non essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), mercaptoethanol 5.5×10−5M (Gibco), and 10 mM Hepes (Gibco) and IL-2 for 4-6 days before RNA was prepared.

[0734] To obtain B cells, tonsils were procured from NDRI. The tonsil was cut up with sterile dissecting scissors and then passed through a sieve. Tonsil cells were then spun down and resupended at 106 cells/ml in DMEM 5% FCS (Hyclone), 100 μM non essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), mercaptoethanol 5.5×10−5M (Gibco), and 10 mM Hepes (Gibco). To activate the cells, we used PWM at 5 μg/ml or anti-CD40 (Pharmingen) at approximately 10 μg/ml and IL-4 at 5-10 ng/ml. Cells were harvested for RNA preparation at 24, 48 and 72 hours.

[0735] To prepare the primary and secondary Th1/Th2 and Tr1 cells, six-well Falcon plates were coated overnight with 10 μg/ml anti-CD28 (Pharmingen) and 2 μg/ml OKT3 (ATCC), and then washed twice with PBS. Umbilical cord blood CD4 lymphocytes (Poietic Systems, German Town, Md.) were cultured at 105-106 cells/ml in DMEM 5% FCS (Hyclone), 100 μM non essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), mercaptoethanol 5.5×10−5M (Gibco), 10 mM Hepes (Gibco) and IL-2 (4 ng/ml). IL-12 (5 ng/ml) and anti-IL4 (1 μg/ml) were used to direct to Th1, while IL-4 (5 ng/ml) and anti-IFN gamma (1 μg/ml) were used to direct to Th2 and IL-10 at 5 ng/ml was used to direct to Tr1. After 4-5 days, the activated Th1, Th2 and Tr1 lymphocytes were washed once in DMEM and expanded for 4-7 days in DMEM 5% FCS (Hyclone), 100 μm non essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), mercaptoethanol 5.5×10−5M (Gibco), 10 mM Hepes (Gibco) and IL-2 (1 ng/ml). Following this, the activated Th1, Th2 and Tr1 lymphocytes were re-stimulated for 5 days with anti-CD28/OKT3 and cytokines as described above, but with the addition of anti-CD95L (1 μg/ml) to prevent apoptosis. After 4-5 days, the Th1, Th2 and Tr1 lymphocytes were washed and then expanded again with IL-2 for 4-7 days. Activated Th1 and Th2 lymphocytes were maintained in this way for a maximum of three cycles. RNA was prepared from primary and secondary Th1, Th2 and Tr1 after 6 and 24 hours following the second and third activations with plate bound anti-CD3 and anti-CD28 mAbs and 4 days into the second and third expansion cultures in Interleukin 2.

[0736] The following leukocyte cells lines were obtained from the ATCC: Ramos, EOL-1, KU-812. EOL cells were further differentiated by culture in 0.1 mM dbcAMP at 5×105 cells/ml for 8 days, changing the media every 3 days and adjusting the cell concentration to 5×105 cells/ml. For the culture of these cells, we used DMEM or RPMI (as recommended by the ATCC), with the addition of 5% FCS (Hyclone), 100 μM non essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), mercaptoethanol 5.5×105M (Gibco), 10 mM Hepes (Gibco). RNA was either prepared from resting cells or cells activated with PMA at 10 ng/ml and ionomycin at 1 μg/ml for 6 and 14 hours. Keratinocyte line CCD106 and an airway epithelial tumor line NCI-H292 were also obtained from the ATCC. Both were cultured in DMEM 5% FCS (Hyclone), 100 μM non essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), mercaptoethanol 5.5×10−5M (Gibco), and 10 mM Hepes (Gibco). CCD1106 cells were activated for 6 and 14 hours with approximately 5 ng/ml TNF alpha and 1 ng/ml IL-1 beta, while NCI-H292 cells were activated for 6 and 14 hours with the following cytokines: 5 ng/ml IL-4, 5 ng/ml IL-9, 5 ng/ml IL-13 and 25 ng/ml IFN gamma.

[0737] For these cell lines and blood cells, RNA was prepared by lysing approximately 107 cells/ml using Trizol (Gibco BRL). Briefly, {fraction (1/10)} volume of bromochloropropane (Molecular Research Corporation) was added to the RNA sample, vortexed and after 10 minutes at room temperature, the tubes were spun at 14,000 rpm in a Sorvall SS34 rotor. The aqueous phase was removed and placed in a 15 ml Falcon Tube. An equal volume of isopropanol was added and left at −20° C. overnight. The precipitated RNA was spun down at 9,000 rpm for 15 min in a Sorvall SS34 rotor and washed in 70% ethanol. The pellet was redissolved in 300 μl of RNAse-free water and 35 μl buffer (Promega) 5 μl DTT, 7 μl RNAsin and 8 μl DNAse were added. The tube was incubated at 37° C. for 30 minutes to remove contaminating genomic DNA, extracted once with phenol chloroform and re-precipitated with {fraction (1/10)} volume of 3M sodium acetate and 2 volumes of 100% ethanol. The RNA was spun down and placed in RNAse free water. RNA was stored at −80° C.

[0738] AI_Comprehensive Panel_v1.0

[0739] The plates for Al_comprehensive panel_v1.0 include two control wells and 89 test samples comprised of cDNA isolated from surgical and postmortem human tissues obtained from the Backus Hospital and Clinomics (Frederick, Md.). Total RNA was extracted from tissue samples from the Backus Hospital in the Facility at CuraGen. Total RNA from other tissues was obtained from Clinomics.

[0740] Joint tissues including synovial fluid, synovium, bone and cartilage were obtained from patients undergoing total knee or hip replacement surgery at the Backus Hospital. Tissue samples were immediately snap frozen in liquid nitrogen to ensure that isolated RNA was of optimal quality and not degraded. Additional samples of osteoarthritis and rheumatoid arthritis joint tissues were obtained from Clinomics. Normal control tissues were supplied by Clinomics and were obtained during autopsy of trauma victims.

[0741] Surgical specimens of psoriatic tissues and adjacent matched tissues were provided as total RNA by Clinomics. Two male and two female patients were selected between the ages of 25 and 47. None of the patients were taking prescription drugs at the time samples were isolated.

[0742] Surgical specimens of diseased colon from patients with ulcerative colitis and Crohns disease and adjacent matched tissues were obtained from Clinomics. Bowel tissue from three female and three male Crohn's patients between the ages of 41-69 were used. Two patients were not on prescription medication while the others were taking dexamethasone, phenobarbital, or tylenol. Ulcerative colitis tissue was from three male and four female patients. Four of the patients were taking lebvid and two were on phenobarbital.

[0743] Total RNA from post mortem lung tissue from trauma victims with no disease or with emphysema, asthma or COPD was purchased from Clinomics. Emphysema patients ranged in age from 40-70 and all were smokers, this age range was chosen to focus on patients with cigarette-linked emphysema and to avoid those patients with alpha-1 anti-trypsin deficiencies. Asthma patients ranged in age from 36-75, and excluded smokers to prevent those patients that could also have COPD. COPD patients ranged in age from 35-80 and included both smokers and non-smokers. Most patients were taking corticosteroids, and bronchodilators.

[0744] In the labels employed to identify tissues in the AI_comprehensive panel_v1.0 panel, the following abbreviations are used:

[0745] AI=Autoimmunity

[0746] Syn=Synovial

[0747] Normal=No apparent disease

[0748] Rep22/Rep20=individual patients

[0749] RA=Rheumatoid arthritis

[0750] Backus=From Backus Hospital

[0751] OA=Osteoarthritis

[0752] (SS) (BA) (MF)=Individual patients

[0753] Adj=Adjacent tissue

[0754] Match control=adjacent tissues

[0755] −M=Male

[0756] −F=Female

[0757] COPD=Chronic obstructive pulmonary disease

[0758] Panels 5D and 5I

[0759] The plates for Panel 5D and 5I include two control wells and a variety of cDNAs isolated from human tissues and cell lines with an emphasis on metabolic diseases. Metabolic tissues were obtained from patients enrolled in the Gestational Diabetes study. Cells were obtained during different stages in the differentiation of adipocytes from human mesenchymal stem cells. Human pancreatic islets were also obtained.

[0760] In the Gestational Diabetes study subjects are young (18-40 years), otherwise healthy women with and without gestational diabetes undergoing routine (elective) Caesarean section. After delivery of the infant, when the surgical incisions were being repaired/closed, the obstetrician removed a small sample (<1 cc) of the exposed metabolic tissues during the closure of each surgical level. The biopsy material was rinsed in sterile saline, blotted and fast frozen within 5 minutes from the time of removal. The tissue was then flash frozen in liquid nitrogen and stored, individually, in sterile screw-top tubes and kept on dry ice for shipment to or to be picked up by CuraGen. The metabolic tissues of interest include uterine wall (smooth muscle), visceral adipose, skeletal muscle (rectus) and subcutaneous adipose. Patient descriptions are as follows:

Patient 2   Diabetic Hispanic, overweight, not on insulin
Patient 7-9 Nondiabetic Caucasian and obese (BMI > 30)
Patient 10  Diabetic Hispanic, overweight, on insulin
Patient 11  Nondiabetic African American and overweight
Patient 12  Diabetic Hispanic on insulin

[0761] Adipocyte differentiation was induced in donor progenitor cells obtained from Osirus (a division of Clonetics/BioWhittaker) in triplicate, except for Donor 3U which had only two replicates. Scientists at Clonetics isolated, grew and differentiated human mesenchymal stem cells (HuMSCs) for CuraGen based on the published protocol found in Mark F. Pittenger, et al., Multilineage Potential of Adult Human Mesenchymal Stem Cells Science Apr. 2 1999: 143-147. Clonetics provided Trizol lysates or frozen pellets suitable for mRNA isolation and ds cDNA production. A general description of each donor is as follows:

[0762] Donor 2 and 3 U: Mesenchymal Stem cells, Undifferentiated Adipose

[0763] Donor 2 and 3 AM: Adipose, AdiposeMidway Differentiated

[0764] Donor 2 and 3 AD: Adipose, Adipose Differentiated

[0765] Human cell lines were generally obtained from ATCC (American Type Culture Collection), NCI or the German tumor cell bank and fall into the following tissue groups: kidney proximal convoluted tubule, uterine smooth muscle cells, small intestine, liver HepG2 cancer cells, heart primary stromal cells, and adrenal cortical adenoma cells. These cells are all cultured under standard recommended conditions and RNA extracted using the standard procedures. All samples were processed at CuraGen to produce single stranded cDNA.

[0766] Panel 5I contains all samples previously described with the addition of pancreatic islets from a 58 year old female patient obtained from the Diabetes Research Institute at the University of Miami School of Medicine. Islet tissue was processed to total RNA at an outside source and delivered to CuraGen for addition to panel 5I.

[0767] In the labels employed to identify tissues in the 5D and 5I panels, the following abbreviations are used:

[0768] GO Adipose=Greater Omentum Adipose

[0769] SK=Skeletal Muscle

[0770] UT=Uterus

[0771] PL Placenta

[0772] AD=Adipose Differentiated

[0773] AM=Adipose Midway Differentiated

[0774] U=Undifferentiated Stem Cells

[0775] Panel CNSD.01

[0776] The plates for Panel CNSD.01 include two control wells and 94 test samples comprised of cDNA isolated from postmortem human brain tissue obtained from the Harvard Brain Tissue Resource Center. Brains are removed from calvaria of donors between 4 and 24 hours after death, sectioned by neuroanatomists, and frozen at −80° C. in liquid nitrogen vapor. All brains are sectioned and examined by neuropathologists to confirm diagnoses with clear associated neuropathology.

[0777] Disease diagnoses are taken from patient records. The panel contains two brains from each of the following diagnoses: Alzheimer's disease, Parkinson's disease, Huntington's disease, Progressive Supernuclear Palsy, Depression, and “Normal controls”. Within each of these brains, the following regions are represented: cingulate gyrus, temporal pole, globus palladus, substantia nigra, Brodman Area 4 (primary motor strip), Brodman Area 7 (parietal cortex), Brodman Area 9 (prefrontal cortex), and Brodman area 17 (occipital cortex). Not all brain regions are represented in all cases; e.g., Huntington's disease is characterized in part by neurodegeneration in the globus palladus, thus this region is impossible to obtain from confirmed Huntington's cases. Likewise Parkinson's disease is characterized by degeneration of the substantia nigra making this region more difficult to obtain. Normal control brains were examined for neuropathology and found to be free of any pathology consistent with neurodegeneration.

[0778] In the labels employed to identify tissues in the CNS panel, the following abbreviations are used:

[0779] PSP=Progressive supranuclear palsy

[0780] Sub Nigra=Substantia nigra

[0781] Glob Palladus=Globus palladus

[0782] Temp Pole=Temporal pole

[0783] Cing Gyr=Cingulate gyrus

[0784] BA 4=Brodman Area 4

[0785] Panel CNS_Neurodegeneration_V1.0

[0786] The plates for Panel CNS_Neurodegeneration_V1.0 include two control wells and 47 test samples comprised of cDNA isolated from postmortem human brain tissue obtained from the Harvard Brain Tissue Resource Center (McLean Hospital) and the Human Brain and Spinal Fluid Resource Center (VA Greater Los Angeles Healthcare System). Brains are removed from calvaria of donors between 4 and 24 hours after death, sectioned by neuroanatomists, and frozen at −80° C. in liquid nitrogen vapor. All brains are sectioned and examined by neuropathologists to confirm diagnoses with clear associated neuropathology.

[0787] Disease diagnoses are taken from patient records. The panel contains six brains from Alzheimer's disease (AD) patients, and eight brains from “Normal controls” who showed no evidence of dementia prior to death. The eight normal control brains are divided into two categories: Controls with no dementia and no Alzheimer's like pathology (Controls) and controls with no dementia but evidence of severe Alzheimer's like pathology, (specifically senile plaque load rated as level 3 on a scale of 0-3; 0=no evidence of plaques, 3=severe AD senile plaque load). Within each of these brains, the following regions are represented: hippocampus, temporal cortex (Brodman Area 21), parietal cortex (Brodman area 7), and occipital cortex (Brodman area 17). These regions were chosen to encompass all levels of neurodegeneration in AD. The hippocampus is a region of early and severe neuronal loss in AD; the temporal cortex is known to show neurodegeneration in AD after the hippocampus; the parietal cortex shows moderate neuronal death in the late stages of the disease; the occipital cortex is spared in AD and therefore acts as a “control” region within AD patients. Not all brain regions are represented in all cases.

[0788] In the labels employed to identify tissues in the CNS_Neurodegeneration_V1.0 panel, the following abbreviations are used:

[0789] AD=Alzheimer's disease brain; patient was demented and showed AD-like pathology upon autopsy

[0790] Control=Control brains; patient not demented, showing no neuropathology

[0791] Control (Path)=Control brains; patient not demented but showing sever AD-like pathology

[0792] SupTemporal Ctx=Superior Temporal Cortex

[0793] Inf Temporal Ctx=Inferior Temporal Cortex

[0794] A. CG101683-01: COT.

[0795] Expression of gene CG101683-01 was assessed using the primer-probe sets Ag3116, Ag3551 and Ag4828, described in Tables AA, AB and AC. Results of the RTQ-PCR runs are shown in Tables AD, AE, AF, AG, AH, AI and AJ.

TABLE AA
Probe Name Ag3116
			Start	SEQ ID
Primers	Sequences	Length	Position	No
Forward	5′-catgttctcaagggacttgatt-3′	22	1072	453
Probe	TET-5′-cactcaaagaagtgatccatcatga-3′-TAMRA	26	1099	454
Reverse	5′-ttttgtggacatgaaaacaatg-3′	22	1140	455

[0796]

TABLE AB
Probe Name Ag3551
			Start	SEQ ID
Primers	Sequences	Length	Position	No
Forward	5-′-catgttctcaagggacttgatt-3′	22	1072	456
Probe	TET-5′-cactcaaagaaagtgatccatcatga-3′-TAMRA	26	1099	457
Reverse	5′-ttttgtggacatgaaaacaatg-3′	22	1140	458

[0797]

TABLE AC
Probe Name Ag4828
			Start	SEQ ID
Primers	Sequences	Length	Position	No
Forward	5′-gaggaatctgagatgctcaaga-3′	22	1663	459
Probe	TET-5′-caacgctctctacatcgacctcgg-3′-TAMRA	26	1687	460
Reverse	5′-tccccgaacaagattgaagt-3′	20	1727	461

[0798]

TABLE AD
CNS_neurodegeneration_v1.0
                               Rel. Exp. (%)
                               Ag3551, Run
Tissue Name                    209990366
AD 1 Hippo                     20.0
AD 2 Hippo                     44.1
AD 3 Hippo                     7.1
AD 4 Hippo                     5.6
AD 5 hippo                     100.0
AD 6 Hippo                     57.0
Control 2 Hippo                24.7
Control 4 Hippo                51.4
Control (Path) 3 Hippo         48.6
AD 1 Temporal Ctx              21.3
AD 2 Temporal Ctx              39.5
AD 3 Temporal Ctx              6.1
AD 4 Temporal Ctx              16.8
AD 5 Inf Temporal Ctx          100.0
AD 5 Sup Temporal Ctx          91.4
AD 6 Inf Temporal Ctx          58.2
AD 6 Sup Temporal Ctx          65.5
Control 1 Temporal Ctx         20.3
Control 2 Temporal Ctx         21.2
Control 3 Temporal Ctx         10.8
Control 4 Temporal Ctx         6.9
Control (Path) 1 Temporal Ctx  42.0
Control (Path) 2 Temporal Ctx  26.4
Control (Path) 3 Temporal Ctx  14.6
Control (Path) 4 Temporal Ctx  18.8
AD 1 Occipital Ctx             13.5
AD 2 Occipital Ctx (Missing)   0.0
AD 3 Occipital Ctx             4.0
AD 4 Occipital Ctx             15.8
AD 5 Occipital Ctx             34.6
AD 6 Occipital Ctx             46.0
Control 1 Occipital Ctx        21.0
Control 2 Occipital Ctx        41.5
Control 3 Occipital Ctx        16.3
Control 4 Occipital Ctx        13.0
Control (Path) 1 Occipital Ctx 95.3
Control (Path) 2 Occipital Ctx 10.2
Control (Path) 3 Occipital Ctx 21.5
Control (Path) 4 Occipital Ctx 24.0
Control 1 Parietal Ctx         17.2
Control 2 Parietal Ctx         57.4
Control 3 Parietal Ctx         16.5
Control (Path) 1 Parietal Ctx  28.3
Control (Path) 2 Parietal Ctx  15.8
Control (Path) 3 Parietal Ctx  19.6
Control (Path) 4 Parietal Ctx  61.1

[0799]

TABLE AE
General screening_panel_v1.4
	Rel.	Rel.	Rel.
	Exp. (%)	Exp. (%)	Exp. (%)
	Ag3116,	Ag3551,	Ag4828,
Tissue	Run	Run	Run
Name	219923407	218328114	217081802
Adipose	100.0	58.2	53.6
Melanoma* Hs688(A).T	18.8	9.0	15.5
Melanoma* Hs688(B).T	21.3	10.7	17.4
Melanoma* M14	1.0	0.9	3.5
Melanoma* LOXIMVI	2.9	1.5	3.2
Melanoma* SK-MEL-5	0.8	0.8	0.9
Squamous cell	1.0	2.2	7.0
carcinoma SCC-4
Testis Pool	3.5	3.3	4.7
Prostate ca.* (bone	6.4	1.8	6.3
met) PC-3
Prostate Pool	2.1	2.0	3.9
Placenta	30.8	25.9	39.0
Uterus Pool	7.7	4.7	9.0
Ovarian ca. OVCAR-3	4.4	6.1	15.7
Ovarian ca. SK-OV-3	9.7	18.2	46.3
Ovarian ca. OVCAR-4	3.7	5.4	7.1
Ovarian ca. OVCAR-5	19.2	19.9	30.6
Ovarian ca. IGROV-1	7.0	9.1	14.1
Ovarian ca. OVCAR-8	1.8	1.9	2.7
Ovary	2.7	2.5	4.5
Breast ca. MCF-7	64.6	81.8	100.0
Breast ca. MDA-MB-231	3.1	2.1	9.2
Breast ca. BT549	24.5	36.3	73.2
Breast ca. T47D	37.4	60.3	66.0
Breast ca. MDA-N	0.3	0.5	0.9
Breast Pool	33.2	9.8	24.1
Trachea	14.5	15.5	18.0
Lung	4.2	3.4	6.7
Fetal Lung	83.5	100.0	68.3
Lung ca.NCI-N417	0.0	0.0	0.2
Lung ca. LX-1	8.0	6.0	11.8
Lung ca. NCI-H146	0.0	0.0	0.0
Lung ca. SHP-77	0.0	0.0	0.1
Lung ca. A549	35.4	0.0	36.6
Lung ca. NCI-H526	0.0	0.0	0.0
Lung ca. NCI-H23	10.9	13.0	13.4
Lung ca. NCI-H460	7.4	5.8	17.6
Lung ca. HOP-62	11.4	4.3	13.2
Lung ca. NCI-H522	1.6	1.5	2.1
Liver	0.6	0.2	1.0
Fetal Liver	5.0	4.0	2.8
Liver ca. HepG2	4.5	5.4	8.1
Kidney Pool	26.6	21.0	31.4
Fetal Kidney	9.0	10.7	7.7
Renal ca. 786-0	6.0	7.9	10.9
Renal ca. A498	1.2	2.3	5.2
Renal ca.ACHN	1.9	0.8	2.5
Renal ca. UO-31	11.1	10.7	14.9
Renal ca. TK-10	6.4	8.2	10.6
Bladder	32.5	24.1	31.9
Gastric ca.	26.8	23.5	36.3
(liver met.) NCI-N87
Gastric ca. KATO III	8.7	8.0	12.2
Colon ca. SW-948	2.6	2.6	5.4
Colon ca. SW480	13.5	12.3	25.0
Colon ca.* (SW480 met)	1.6	1.4	2.5
SW620
Colon ca. HT29	7.2	5.7	14.3
Colon ca. HCT-116	2.1	1.7	2.1
Colon ca. CaCo-2	13.5	15.7	15.9
Colon cancer tissue	34.9	42.3	39.8
Colon ca. SW1116	0.1	0.3	3.4
Colon ca. Colo-205	2.7	2.6	8.8
Colon ca. SW-48	3.3	4.7	5.4
Colon Pool	16.6	9.8	16.2
Small Intestine	7.3	5.5	9.3
Pool
Stomach Pool	6.6	8.0	17.3
Bone Marrow Pool	5.2	3.3	7.0
Fetal Heart	4.5	4.6	2.9
Heart Pool	9.2	6.8	7.9
Lymph Node Pool	10.4	9.9	15.2
Fetal Skeletal	2.4	2.9	1.7
Muscle
Skeletal Muscle Pool	7.7	8.5	9.8
Spleen Pool	16.0	22.8	45.7
Thymus Pool	7.5	6.9	15.9
CNS cancer	2.1	2.4	7.6
(glio/astro) U87-MG
CNS cancer	5.4	2.7	7.9
(glio/astro) U-118-MG
CNS cancer	0.7	1.2	2.6
(neuro; met) SK-N-AS
CNS cancer	1.4	1.8	2.3
(astro) SF-539
CNS cancer	4.7	5.9	14.1
(astro) SNB-75
CNS cancer	6.2	10.7	11.1
(glio) SNB-19
CNS cancer	16.0	18.8	31.9
(glio) SF-295
Brain (Amygdala) Pool	1.6	0.7	2.7
Brain (cerebellum)	1.1	0.3	1.4
Brain (fetal)	6.0	4.1	4.9
Brain (Hippocampus)	3.6	1.5	3.7
Pool
Cerebral Cortex Pool	2.1	2.0	3.5
Brain (Substantia	2.4	2.0	2.7
nigra) Pool
Brain (Thalamus)	2.6	2.2	4.5
Pool
Brain (whole)	2.7	2.5	4.5
Spinal Cord Pool	2.1	3.2	3.8
Adrenal Gland	11.7	3.8	9.5
Pituitary gland	0.7	0.7	1.4
Pool
Salivary Gland	1.9	1.5	2.5
Thyroid (female)	3.3	3.6	7.7
Pancreatic ca.	14.9	21.9	34.4
CAPAN2
Pancreas Pool	15.0	17.8	19.6

[0800]

TABLE AF
Panel 1.3D
                                 Rel. Exp. (%)
                                 Ag3116, Run
Tissue Name                      167617379
Liver adenocarcinoma             24.8
Pancreas                         3.4
Pancreatic ca. CAPAN 2           12.1
Adrenal gland                    2.6
Thyroid                          1.3
Salivary gland                   0.0
Pituitary gland                  2.1
Brain (fetal)                    3.1
Brain (whole)                    3.1
Brain (amygdala)                 1.0
Brain (cerebellum)               1.0
Brain (hippocampus)              3.0
Brain (substantia nigra)         3.7
Brain (thalamus)                 1.2
Cerebral Cortex                  2.5
Spinal cord                      3.0
glio/astro U87-MG                1.5
glio/astro U-118-MG              2.8
astrocytoma SW1783               2.0
neuro*; met SK-N-AS              1.5
astrocytoma SF-539               2.4
astrocytoma SNB-75               14.5
glioma SNB-19                    0.0
glioma U251                      0.7
glioma SF-295                    6.9
Heart (fetal)                    5.8
Heart                            3.2
Skeletal muscle (fetal)          4.6
Skeletal muscle                  2.1
Bone marrow                      4.0
Thymus                           3.4
Spleen                           10.6
Lymph node                       10.3
Colorectal                       6.4
Stomach                          1.8
Small intestine                  3.0
Colon ca. SW480                  6.0
Colon ca.* SW620 (SW480 met)     6.1
Colon ca. HT29                   6.6
Colon ca. HCT-116                0.0
Colon ca. CaCo-2                 11.3
Colon ca. tissue (ODO3866)       13.1
Colon ca. HCC-2998               17.6
Gastric ca.* (liver met) NCI-N87 11.0
Bladder                          10.2
Trachea                          3.9
Kidney                           5.0
Kidney (fetal)                   34.2
Renal ca. 786-0                  3.7
Renal ca. A498                   3.3
Renal ca. RXF 393                17.1
Renal ca. ACHN                   1.7
Renal ca. UO-31                  0.8
Renal ca. TK-10                  4.4
Liver                            2.4
Liver (fetal)                    4.5
Liver ca. (hepatoblast) HepG2    4.4
Lung                             25.0
Lung (fetal)                     29.7
Lung ca. (small cell) LX-1       5.5
Lung ca. (small cell) NCI-H69    0.0
Lung ca. (s. cell var.) SHP-77   0.0
Lung ca. (large cell) NCI-H460   2.3
Lung ca. (non-sm. cell) A549     14.3
Lung ca. (non-s. cell) NCI-H23   5.0
Lung ca. (non-s. cell) HOP-62    5.7
Lung ca. (non-s. cl) NCI-H522    1.2
Lung ca. (squam.) SW900          24.1
Lung ca. (squam.) NCI-H596       0.0
Mammary gland                    7.7
Breast ca.* (pl. ef) MCF-7       57.8
Breast ca.* (pl. ef) MDA-MB-231  0.8
Breast ca.* (pl. ef) T47D        3.5
Breast ca. BT-549                4.8
Breast ca. MDA-N                 0.0
Ovary                            6.1
Ovarian ca. OVCAR-3              3.0
Ovarian ca. OVCAR-4              26.1
Ovarian ca. OVCAR-5              44.8
Ovarian ca. OVCAR-8              1.4
Ovarian ca. IGROV-1              6.4
Ovarian ca.* (ascites) SK-OV-3   33.2
Uterus                           4.4
Placenta                         6.8
Prostate                         0.0
Prostate ca.* (bone met) PC-3    2.1
Testis                           0.0
Melanoma Hs688(A).T              1.0
Melanoma* (met) Hs688(B).T       3.5
Melanoma UACC-62                 0.0
Melanoma M14                     1.1
Melanoma LOX IMVI                1.2
Melanoma* (met) SK-MEL-5         0.0
Adipose                          100.0

[0801]

TABLE AG
Panel 2D
                                 Rel. Exp. (%)
                                 Ag3116, Run
Tissue Name                      169556216
Normal Colon                     58.2
CC Well to Mod Diff (ODO3866)    22.7
CC Margin (ODO3866)              14.4
CC Gr.2 rectosigmoid (ODO3868)   7.5
CC Margin (ODO3868)              3.4
CC Mod Diff (ODO3920)            7.0
CC Margin (ODO3920)              6.9
CC Gr.2 ascend colon (ODO3921)   27.7
CC Margin (ODO3921)              8.4
CC from Partial Hepatectomy (ODO4309) Mets 34.9
Liver Margin (ODO4309)           8.5
Colon mets to lung (OD04451-01)  12.2
Lung Margin (OD04451-02)         21.8
Normal Prostate 6546-1           2.9
Prostate Cancer (OD04410)        7.4
Prostate Margin (OD04410)        8.2
Prostate Cancer (OD04720-01)     6.6
Prostate Margin (OD04720-02)     21.8
Normal Lung 061010               42.6
Lung Met to Muscle (ODO4286)     15.0
Muscle Margin (ODO4286)          9.5
Lung Malignant Cancer (OD03126)  17.4
Lung Margin (OD03126)            59.5
Lung Cancer (OD04404)            53.6
Lung Margin (OD04404)            45.1
Lung Cancer (OD04565)            10.4
Lung Margin (OD04565)            10.8
Lung Cancer (OD04237-01)         39.8
Lung Margin (OD04237-02)         65.5
Ocular Mel Met to Liver (ODO4310) 1.6
Liver Margin (ODO4310)           9.9
Melanoma Mets to Lung (OD04321)  2.0
Lung Margin (OD04321)            50.7
Normal Kidney                    13.0
Kidney Ca, Nuclear grade 2 (OD04338) 16.4
Kidney Margin (OD04338)          18.4
Kidney Ca Nuclear grade 1/2 (OD04339) 10.3
Kidney Margin (OD04339)          6.5
Kidney Ca, Clear cell type (OD04340) 28.7
Kidney Margin (OD04340)          22.7
Kidney Ca, Nuclear grade 3 (OD04348) 4.5
Kidney Margin (OD04348)          6.7
Kidney Cancer (OD04622-01)       12.2
Kidney Margin (OD04622-03)       1.8
Kidney Cancer (OD04450-01)       4.0
Kidney Margin (OD04450-03)       7.1
Kidney Cancer 8120607            3.3
Kidney Margin 8120608            2.0
Kidney Cancer 8120613            3.5
Kidney Margin 8120614            2.9
Kidney Cancer 9010320            42.0
Kidney Margin 9010321            7.7
Normal Uterus                    7.0
Uterus Cancer 064011             18.8
Normal Thyroid                   5.8
Thyroid Cancer 064010            6.9
Thyroid Cancer A302152           3.0
Thyroid Margin A302153           12.1
Normal Breast                    28.9
Breast Cancer (OD04566)          6.3
Breast Cancer (OD04590-01)       44.4
Breast Cancer Mets (OD04590-03)  43.5
Breast Cancer Metastasis (OD04655-05) 6.9
Breast Cancer 064006             12.0
Breast Cancer 1024               12.9
Breast Cancer 9100266            6.9
Breast Margin 9100265            6.9
Breast Cancer A209073            7.2
Breast Margin A209073            4.3
Normal Liver                     2.3
Liver Cancer 064003              2.1
Liver Cancer 1025                5.8
Liver Cancer 1026                4.2
Liver Cancer 6004-T              6.1
Liver Tissue 6004-N              6.4
Liver Cancer 6005-T              7.4
Liver Tissue 6005-N              3.9
Normal Bladder                   37.1
Bladder Cancer 1023              6.5
Bladder Cancer A302173           14.8
Bladder Cancer (OD04718-01)      27.9
Bladder Normal Adjacent (OD04718-03) 100.0
Normal Ovary                     6.3
Ovarian Cancer 064008            31.9
Ovarian Cancer (OD04768-07)      21.9
Ovary Margin (OD04768-08)        32.5
Normal Stomach                   18.8
Gastric Cancer 9060358           14.6
Stomach Margin 9060359           16.2
Gastric Cancer 9060395           33.2
Stomach Margin 9060394           24.8
Gastric Cancer 9060397           26.8
Stomach Margin 9060396           7.4
Gastric Cancer 064005            27.4

[0802]

TABLE AH
Panel 4D
	Rel. Exp.	Rel. Exp.
	(%) Ag3116,	(%) Ag3551,
	Run	Run
Tissue Name	164526105	166453851
Secondary Th1 act	15.6	38.4
Secondary Th2 act	23.0	56.3
Secondary Tr1 act	23.2	78.5
Secondary Th1 rest	2.9	22.8
Secondary Th2 rest	2.5	4.5
Secondary Tr1 rest	2.0	7.0
Primary Th1 act	13.5	18.3
Primary Th2 act	6.6	15.5
Primary Tr1 act	17.7	33.2
Primary Th1 rest	9.2	32.1
Primary Th2 rest	1.2	2.9
Primary Tr1 rest	1.7	3.8
CD45RA CD4 lymphocyte act	4.9	6.7
CD45RO CD4 lymphocyte act	11.1	44.8
CD8 lymphocyte act	5.3	12.2
Secondary CD8 lymphocyte rest	4.9	16.0
Secondary CD8 lymphocyte act	7.6	25.5
CD4 lymphocyte none	0.8	1.1
2ry Th1/Th2/Tr1_anti-CD95 CH11	3.0	11.0
LAK cells rest	6.8	5.3
LAK cells IL-2	6.4	23.2
LAK cells IL-2 + IL-12	22.4	73.7
LAK cells IL-2 + IFN gamma	17.4	44.1
LAK cells IL-2 + IL-18	12.2	25.0
LAK cells PMA/ionomycin	12.3	20.7
NK Cells IL-2 rest	12.9	23.0
Two Way MLR 3 day	12.5	24.0
Two Way MLR 5 day	6.0	17.1
Two Way MLR 7 day	3.0	6.3
PBMC rest	4.0	5.4
PBMC PWM	100.0	49.3
PBMC PHA-L	11.8	5.6
Ramos (B cell) none	0.8	2.0
Ramos (B cell) ionomycin	16.7	6.5
B lymphocytes PWM	53.2	25.3
B lymphocytes CD40L and IL-4	61.1	81.8
EOL-1 dbcAMP	0.7	0.4
EOL-1 dbcAMP PMA/ionomycin	2.2	3.0
Dendritic cells none	4.8	8.7
Dendritic cells LPS	12.3	25.2
Dendritic cells anti-CD40	3.2	6.8
Monocytes rest	5.0	7.3
Monocytes LPS	43.8	100.0
Macrophages rest	8.2	11.7
Macrophages LPS	26.8	57.4
HUVEC none	0.2	0.5
HUVEC starved	0.6	1.5
HUVEC IL-1beta	0.8	8.2
HUVEC IFN gamma	1.4	1.2
HUVEC TNF alpha + IFN gamma	3.0	3.1
HUVEC TNF alpha + IL4	2.5	2.6
HUVEC IL-11	0.5	0.5
Lung Microvascular EC none	0.0	0.1
Lung Microvascular EC	4.2	2.8
TNFalpha + IL-1beta
Microvascular Dermal EC none	0.1	0.1
Microsvasular Dermal EC	5.7	7.3
TNFalpha + IL-1beta
Bronchial epithelium	2.4	1.5
TNFalpha + IL1beta
Small airway epithelium none	0.6	1.1
Small airway epithelium	5.5	5.0
TNFalpha + IL-1beta
Coronery artery SMC rest	1.0	0.8
Coronery artery SMC	0.7	0.6
TNFalpha + IL-1beta
Astrocytes rest	0.5	1.0
Astrocytes TNFalpha + IL-1beta	14.9	61.1
KU-812 (Basophil) rest	0.2	0.2
KU-812 (Basophil) PMA/ionomycin	1.0	1.5
CCD1106 (Keratinocytes) none	0.4	0.5
CCD1106 (Keratinocytes)	0.8	12.4
TNFalpha + IL-1beta
Liver cirrhosis	1.1	5.3
Lupus kidney	1.1	4.8
NCI-H292 none	8.4	9.7
NCI-H292 IL-4	17.6	18.4
NCI-H292 IL-9	6.5	5.3
NCI-H292 IL-13	9.2	12.0
NCI-H292 IFN gamma	4.3	3.5
HPAEC none	0.5	0.5
HPAEC TNF alpha + IL-1 beta	8.2	11.0
Lung fibroblast none	0.2	1.0
Lung fibroblast	1.7	9.8
TNF alpha + IL-1 beta
Lung fibroblast IL-4	3.3	3.2
Lung fibroblast IL-9	0.9	0.5
Lung fibroblast IL-13	1.4	1.8
Lung fibroblast IFN gamma	3.4	4.0
Dermal fibroblast CCD1070 rest	1.9	1.1
Dermal fibroblast CCD1070 TNF alpha	11.9	13.7
Dermal fibroblast CCD1070 IL-1 beta	6.1	6.3
Dermal fibroblast IFN gamma	0.6	0.9
Dermal fibroblast IL-4	4.2	6.7
IBD Colitis 2	1.1	4.1
IBD Crohn's	1.8	6.0
Colon	2.6	15.7
Lung	8.2	7.5
Thymus	2.3	3.5
Kidney	4.2	3.8

[0803]

TABLE AI
Panel 5D
	Rel. Exp.	Rel. Exp.
	(%) Ag3116,	(%) Ag4828,
	Run	Run
Tissue Name	170863008	219436967
97457_Patient-02go_adipose	33.4	33.9
97476_Patient-07sk_skeletal muscle	31.2	33.4
97477_Patient-07ut_uterus	7.7	59.5
97478_Patient-07pl_placenta	62.0	39.8
97481_Patient-08sk_skeletal muscle	20.0	25.9
97482_Patient-08ut_uterus	33.4	19.8
97483_Patient-08pl_placenta	58.6	41.5
97486_Patient-09sk_skeletal muscle	3.7	6.5
97487_Patient-09ut_uterus	13.6	8.1
97488_Patient-09pl_placenta	41.2	38.4
97492_Patient-10ut_uterus	31.9	30.6
97493_Patient-10pl_placenta	74.7	72.7
97495_Patient-11go_adipose	67.4	100.0
97496_Patient-11sk_skeletal muscle	9.0	5.8
97497_Patient-11ut_uterus	35.4	20.6
97498_Patient-11pl_placenta	52.1	50.0
97500_Patient-12go_adipose	100.0	82.4
97501_Patient-12sk_skeletal muscle	14.2	19.2
97502_Patient-12ut_uterus	51.8	23.7
97503_Patient-12pl_placenta	39.5	57.0
94721_Donor 2 U -	2.1	1.6
A Mesenchymal Stem Cells
94722_Donor 2 U -	0.0	3.0
B Mesenchymal Stem Cells
94723_Donor 2 U -	1.8	2.1
C Mesenchymal Stem Cells
94709_Donor 2 AM - A_adipose	5.1	10.8
94710_Donor 2 AM - B_adipose	3.2	9.3
94711_Donor 2 AM - C_adipose	0.0	3.0
94712_Donor 2 AD - A_adipose	12.9	13.7
94713_Donor 2 AD - B_adipose	12.9	10.0
94714_Donor 2 AD - C_adipose	8.8	6.7
94742_Donor 3 U -	1.6	4.7
A_Mesenchymal Stem Cells
94743_Donor 3 U -	4.8	2.8
B_Mesenchymal Stem Cells
94730_Donor 3 AM - A_adipose	6.8	6.3
94731_Donor 3 AM - B_adipose	5.3	2.4
94732_Donor 3 AM - C_adipose	1.9	2.2
94733_Donor 3 AD - A_adipose	2.5	10.2
94734_Donor 3 AD - B_adipose	2.9	5.5
94735_Donor 3 AD - C_adipose	6.7	4.7
77138_Liver_HepG2untreated	13.0	14.4
73556_Heart_Cardiac stromal	9.1	1.9
cells (primary)
81735_Small Intestine	20.0	17.2
72409_Kidney_Proximal	0.0	0.9
Convoluted Tubule
82685_Small	13.5	19.1
intestine_Duodenum
90650_Adrenal_Adrenocortical	7.3	8.8
adenoma
72410_Kidney_HRCE	9.9	7.6
72411_Kidney_HRE	5.9	13.5
73139_Uterus_Uterine smooth	2.5	2.0
muscle cells

[0804]

TABLE AJ
general oncology screening panel_v_2.4
                          Rel. Exp.
                          (%) Ag3551,
                          Run
Tissue Name               259737946
Colon cancer 1            26.6
Colon NAT 1               9.4
Colon cancer 2            32.3
Colon NAT 2               7.1
Colon cancer 3            69.3
Colon NAT 3               41.5
Colon malignant cancer 4  96.6
Colon NAT 4               5.6
Lung cancer 1             34.6
Lung NAT 1                5.4
Lung cancer 2             100.0
Lung NAT 2                15.0
Squamous cell carcinoma 3 37.6
Lung NAT 3                2.8
Metastatic melanoma 1     43.8
Melanoma 2                5.0
Melanoma 3                2.4
Metastatic melanoma 4     69.3
Metastatic melanoma 5     93.3
Bladder cancer 1          2.2
Bladder NAT 1             0.0
Bladder cancer 2          5.0
Bladder NAT 2             0.0
Bladder NAT 3             1.5
Bladder NAT 4             5.8
Prostate adenocarcinoma 1 29.9
Prostate adenocarcinoma 2 1.5
Prostate adenocarcinoma 3 2.9
Prostate adenocarcinoma 4 69.3
Prostate NAT 5            1.3
Prostate adenocarcinoma 6 2.1
Prostate adenocarcinoma 7 5.5
Prostate adenocarcinoma 8 1.5
Prostate adenocarcinoma 9 19.1
Prostate NAT 10           0.0
Kidney cancer 1           38.2
Kidney NAT 1              13.9
Kidney cancer 2           66.9
Kidney NAT 2              19.3
Kidney cancer 3           27.2
Kidney NAT 3              12.1
Kidney cancer 4           20.4
Kidney NAT 4              6.3

[0805] CNS_neurodegeneration_v1.0 Summary: Ag3551 This panel confirms the expression of this gene at low levels in the brains of an independent group of individuals. However, no differential expression of this gene was detected between Alzheimer's diseased postmortem brains and those of non-demented controls in this experiment. Please see Panel 1.4 for a discussion of the potential utility of this gene in treatment of central nervous system disorders.

[0806] General_screening_panel—v1.4 Summary: Ag3116/Ag3551/Ag4828 Results of three experiments with two different probes and primer sets are in excellent agreement. Highest expression of this gene is detected in adipose, fetal lung, and breast cancer MCF-7 cell lines (CTs=27-30). Interestingly, this gene is expressed at much higher levels in fetal (CTs=27-30) when compared to adult lung (CT=31-35). This observation suggests that expression of this gene can be used to distinguish fetal from adult lung. In addition, the relative overexpression of this gene in fetal lung suggests that the protein product may enhance lung growth or development in the fetus and thus may also act in a regenerative capacity in the adult. Therefore, therapeutic modulation of the protein encoded by this gene could be useful in treatment of lung related diseases.

[0807] In addition significant expression of this gene is found in a number of cancer (pancreatic, CNS, colon, lung, breast, ovary, prostate, melanoma) cell lines. Therefore, therapeutic modulation of the activity of this gene or its protein product, through the use of small molecule drugs, might be beneficial in the treatment of these cancers.

[0808] Among tissues with metabolic or endocrine function, this gene is expressed at high to moderate levels in pancreas, adipose, adrenal gland, thyroid, skeletal muscle, heart, fetal liver and the gastrointestinal tract. Therefore, therapeutic modulation of the activity of this gene may prove useful in the treatment of endocrine/metabolically related diseases, such as obesity and diabetes.

[0809] This gene encodes a protein that is homologous to mitogen-activated protein kinase kinase kinase 8 (MAP3K8)(COT proto-oncogene serine/threonine-protein kinase) (C-COT) (Cancer osaka thyroid oncogene). COT is able to enhance the TNF alpha production and to activate NF-kB. Both events are connected with insulin resistance and type II diabetes (1, 2, 3). Inhibition of COT kinase would prevent overproduction of TNF alpha and activation of NF-kB, thus improving insulin resistance and diabetes.

[0810] In addition, this gene is expressed at high levels in all regions of the central nervous system examined, including amygdala, hippocampus, substantia nigra, thalamus, cerebellum, cerebral cortex, and spinal cord. Recently, MKK6, a related protein, has been shown to associated with Alzheimer's disease (4). Therefore, based on the homology of this protein to MKK6 and the presence of this gene in the brain, we predict that this putative MAP3K8 may play a role in central nervous system disorders such as Alzheimer's disease, Parkinson's disease, epilepsy, multiple sclerosis, schizophrenia and depression.

[0811] Ag3551 Results from one experiment (run 213391203) are not included. The amp plot indicates that there were experimental difficulties with this run. (Data not shown).

[0812] References:

[0813] 1. Ballester A, Velasco A, Tobena R, Alemany S. Cot kinase activates tumor necrosis factor-alpha gene expression in a cyclosporin A-resistant manner. J. Biol. Chem. 1998. 273, 14099-106. PMID: 9603908.

[0814] 2. Bierhaus A, Schiekofer S, Schwaninger M, Andrassy M, Humpert P M, Chen J, Hong M, Luther T, Henle T, Kloting I, Morcos M, Hofmann M, Tritschler H, Weigle B, Kasper M, Smith M, Perry G, Schmidt A M, Stem D M, Haring H U, Schleicher E, Nawroth P P. Diabetes-associated sustained activation of the transcription factor nuclear factor-kappaB. Diabetes, 2001 50, 2792-808. PMID: 11723063.

[0815] 3. Belich M P, Salmeron A, Johnston L H, Ley S C. TPL-2 kinase regulates the proteolysis of the NF-kappaB-inhibitory protein NF-kappaB1 p105. Nature. 1999 397, 363-8.PMID: 9950430.

[0816] 4. Zhu X, Rottkamp C A, Hartzler A, Sun Z, Takeda A, Boux H, Shimohama S, Perry G, Smith M A. (2001) Activation of MKK6, an upstream activator of p38, in Alzheimer's disease. J Neurochem 79(2):311-8

[0817] Panel 1.3D Summary: Ag3116 Highest expression of this gene is detected in adipose (32.7). Low to moderate expression of this gene is also seen in number of ovarian cancer cell lines, liver adenocarcinoma and breast cancer MCF-7 cell line. Therefore, therapeutic modulation of the activity of this gene or its protein product, through the use of small molecule drugs, might be beneficial in the treatment of these cancers.

[0818] In addition, low expression of this gene is also seen in fetal kidney and lung. Interestingly, this gene is expressed at much higher levels in fetal (CT=34.3) when compared to adult kidney (CT=37). This observation suggests that expression of this gene can be used to distinguish fetal from adult kidney. In addition, the relative overexpression of this gene in fetal lung suggests that the protein product may enhance lung growth or development in the fetus and thus may also act in a regenerative capacity in the adult. Therefore, therapeutic modulation of the protein encoded by this gene could be useful in treatment of lung related diseases.

[0819] Panel 2D Summary: Ag3116 Highest expression of this gene is detected in normal bladder (OD04718-03) sample (CT=31.4). Low to moderate expression of this gene is seen in large number of normal and cancer samples. Please see Panel 1.4 for a discussion of the potential utility of this gene.

[0820] Panel 4D Summary: Ag3116/ Ag3551 Results from two experiments with same primer and probe set are in excellent agreement. Highest expression of this gene is detected in PWM treated PBMC and LPS treated monocytes (CTs=28-29). Interestingly, expression of this gene is stimulated in activated primary Th2 and Tr1, activated secondary Th1, Th2, Tr1, PWM treated PBMC, LPS treated monocytes, TNFalpha+IL-1 beta treated astrocytes and keratinocytes. Thus, expression of this gene can be used to distinguish between these activated or treated cells from the corresponding untreated or resting cells.

[0821] In addition low expression of this gene is seen in a wide range of cell types of significance in the immune response in health and disease. These cells include members of the T-cell, B-cell, endothelial cell, macrophage/monocyte, and peripheral blood mononuclear cell family, as well as epithelial and fibroblast cell types from lung and skin, and normal tissues represented by colon, lung, thymus and kidney. Therefore, modulation of the gene product with a functional therapeutic may lead to the alteration of functions associated with these cell types and lead to improvement of the symptoms of patients suffering from autoimmune and inflammatory diseases such as asthma, allergies, inflammatory bowel disease, lupus erythematosus, psoriasis, rheumatoid arthritis, and osteoarthritis.

[0822] Panel 5D Summary: Ag3116/Ag4828 Results from two experiments with different primer and probe set are in excellent agreement. Highest expression of this gene is detected in adipose tissue (CTs=29-33). Low to moderate expression of this gene is seen in wide range of samples used in this panel including adipose, skeletal muscle, uterus, and placenta. This wide spread expression of this gene in tissues with metabolic or endocrine function, suggests that this gene plays a role in endocrine/metabolically related diseases, such as obesity and diabetes.

[0823] This gene codes for mitogen-activated protein kinase kinase kinase 8 (MAP3K8). Recently, activation of MAP kinase, ERK, a related protein, by modified LDL in vascular smooth muscle cells has been implicated in the development of atherosclerosis in diabetes (Ref. 1). Therefore, MAP3K8 may also play a role in the development of this disease and therapeutic modulation of the activity of this gene or its protein product, through the use of small molecule drugs, might be beneficial in the treatment of artherosclerosis and diabetes.

[0824] References.

[0825] 1. Velarde V, Jenkins A J, Christopher J, Lyons T J, Jaffa A A. (2001) Activation of MAPK by modified low-density lipoproteins in vascular smooth muscle cells. J Appl Physiol 91(3):1412-20. PMID: 11509543.

[0826] General oncology screening panel_v—2.4 Summary: Ag3551 Highest expression of this gene is detected in lung cancer (CT=32.3). Moderate to low expression of this gene is detected in metastatic melanoma, prostate, lung and kidney cancers. Interestingly, expression of this gene is higher in cancer as compared to normal tissues. Therefore, expression of this gene may be used as diagnostic marker to detect the presence of these cancers and therapeutic modulation of this gene through the use of antibodies or small molecule may be useful in the treatment of metastatic melanoma, prostate, lung and kidney cancers.

[0827] B. CG101996-02: Phosphorylase Kinase Gamma Full Length.

[0828] Expression of gene CG101996-02 was assessed using the primer-probe sets Ag3882 and Ag5945, described in Tables BA and BB. Results of the RTQ-PCR runs are shown in Tables BC, BD, BE, BF and BG.

TABLE BA
Probe Name Ag3882
			Start	SEQ ID
Primers	Sequences	Length	Position	No
Forward	5′-ctgatgctgaggatgatcatg-3′	21	828	462
Probe	TET-5′-aactaccagttggctcgcccgagt-3′-TAMRA	25	855	463
Reverse	5′-cttcacggtgtccgagtaatc-3′	21	885	464

[0829]

TABLE BB
Probe Name Ag5945
			Start	SEQ ID
Primers	Sequences	Length	Position	No
Forward	5′-attcttgtcaagctccttcaaga-3′	23	45	465
Probe	TET-5′-caagcacttaaccagccacccagagt-3′-TAMRA	26	73	466
Reverse	5′-gtcatgctcagatcttcagtga-3′	22	103	467

[0830]

TABLE BC
AI_comprehensive panel_v1.0
                                 Rel. Exp. (%)
                                 Ag5945, Run
Tissue Name                      248201924
110967 COPD-F                    0.8
110980 COPD-F                    3.8
110968 COPD-M                    1.0
110977 COPD-M                    6.4
110989 Emphysema-F               0.4
110992 Emphysema-F               1.9
110993 Emphysema-F               1.2
110994 Emphysema-F               0.0
110995 Emphysema-F               2.7
110996 Emphysema-F               0.0
110997 Asthma-M                  0.0
111001 Asthma-F                  1.5
111002 Asthma-F                  1.1
111003 Atopic Asthma-F           0.4
111004 Atopic Asthma-F           0.4
111005 Atopic Asthma-F           0.0
111006 Atopic Asthma-F           0.3
111417 Allergy-M                 0.2
112347 Allergy-M                 0.3
112349 Normal Lung-F             0.6
112357 Normal Lung-F             1.7
112354 Normal Lung-M             2.5
112374 Crohns-F                  0.9
112389 Match Control Crohns-F    1.2
112375 Crohns-F                  2.8
112732 Match Control Crohns-F    1.9
112725 Crohns-M                  0.0
112387 Match Control Crohns-M    0.4
112378 Crohns-M                  0.1
112390 Match Control Crohns-M    3.2
112726 Crohns-M                  0.6
112731 Match Control Crohns-M    1.2
112380 Ulcer Col-F               0.0
112734 Match Control Ulcer Col-F 1.9
112384 Ulcer Col-F               0.9
112737 Match Control Ulcer Col-F 0.4
112386 Ulcer Col-F               0.0
112738 Match Control Ulcer Col-F 2.6
112381 Ulcer Col-M               0.0
112735 Match Control Ulcer Col-M 1.4
112382 Ulcer Col-M               0.8
112394 Match Control Ulcer Col-M 0.3
112383 Ulcer Col-M               0.0
112736 Match Control Ulcer Col-M 0.4
112423 Psoriasis-F               0.4
112427 Match Control Psoriasis-F 4.7
112418 Psoriasis-M               8.1
112723 Match Control Psoriasis-M 0.0
112419 Psoriasis-M               1.4
112424 Match Control Psoriasis-M 0.0
112420 Psoriasis-M               3.4
112425 Match Control Psoriasis-M 5.1
104689 (MF) OA Bone-Backus       55.5
104690 (MF) Adj “Normal” Bone-Backus 72.7
104691 (MF) OA Synovium-Backus   41.5
104692 (BA) OA Cartilage-Backus  30.8
104694 (BA) OA Bone-Backus       20.3
104695 (BA) Adj “Normal” Bone-Backus 69.3
104696 (BA) OA Synovium-Backus   14.3
104700 (SS) OA Bone-Backus       24.1
104701 (SS) Adj “Normal” Bone-Backus 51.4
104702 (SS) OA Synovium-Backus   64.2
117093 OA Cartilage Rep7         0.2
112672 OA Bone5                  5.9
112673 OA Synovium5              3.9
112674 OA Synovial Fluid cells5  0.2
117100 OA Cartilage Rep14        0.1
112756 OA Bone9                  0.0
112757 OA Synovium9              100.0
112758 OA Synovial Fluid Cells9  0.7
117125 RA Cartilage Rep2         0.7
113492 Bone2 RA                  3.2
113493 Synovium2 RA              1.8
113494 Syn Fluid Cells RA        1.5
113499 Cartilage4 RA             2.8
113500 Bone4 RA                  1.1
113501 Synovium4 RA              0.9
113502 Syn Fluid Cells4 RA       0.6
113495 Cartilage3 RA             2.5
113496 Bone3 RA                  2.1
113497 Synovium3 RA              1.6
113498 Syn Fluid Cells3 RA       2.1
117106 Normal Cartilage Rep20    0.0
113663 Bone3 Normal              0.5
113664 Synovium3 Normal          0.0
113665 Syn Fluid Cells3 Normal   0.0
117107 Normal Cartilage Rep22    0.8
113667 Bone4 Normal              0.1
113668 Synovium4 Normal          1.5
113669 Syn Fluid Cells4 Normal   0.8

[0831]

TABLE BD
General_screening_panel_v1.4
	Rel. Exp.	Rel. Exp.	Rel. Exp.
	(%) Ag3882,	(%) Ag3882,	(%) Ag3882,
	Run	Run	Run
Tissue Name	217334262	222181244	222185729
Adipose	2.1	3.9	2.5
Melanoma* Hs688(A).T	1.1	1.7	0.9
Melanoma* Hs688(B).T	0.6	0.9	1.1
Melanoma* M14	1.4	0.8	1.7
Melanoma* LOXIMVI	0.8	0.9	0.9
Melanoma* SK-MEL-5	4.9	4.1	3.8
Squamous cell	1.9	1.5	1.5
carcinoma SCC-4
Testis Pool	0.7	0.7	0.9
Prostate ca.*	3.5	3.7	3.4
(bone met) PC-3
Prostate Pool	1.2	1.1	1.1
Placenta	0.6	0.4	0.8
Uterus Pool	0.1	0.4	0.3
Ovarian ca. OVCAR-3	2.4	1.6	1.9
Ovarian ca. SK-OV-3	1.4	1.3	2.6
Ovarian ca. OVCAR-4	1.5	1.0	1.0
Ovarian ca. OVCAR-5	10.0	6.6	7.9
Ovarian ca. IGROV-1	5.0	4.0	3.5
Ovarian ca. OVCAR-8	3.5	3.4	3.4
Ovary	1.2	0.6	1.4
Breast ca. MCF-7	2.9	2.8	1.8
Breast ca. MDA-MB-231	3.8	5.0	6.0
Breast ca. BT 549	7.5	6.8	7.1
Breast ca. T47D	14.3	19.8	21.3
Breast ca. MDA-N	1.1	1.2	0.8
Breast Pool	1.6	2.1	1.6
Trachea	1.5	2.0	1.7
Lung	0.4	0.4	0.8
Fetal Lung	3.1	3.2	4.1
Lung ca. NCI-N417	0.8	0.6	1.3
Lung ca. LX-1	5.3	3.4	3.8
Lung ca. NCI-H146	0.8	0.7	0.9
Lung ca. SHP-77	12.4	15.2	13.4
Lung ca. A549	2.9	3.4	2.5
Lung ca. NCI-H526	1.1	1.1	0.9
Lung ca. NCI-H23	10.2	9.6	10.4
Lung ca. NCI-H460	2.1	1.6	0.9
Lung ca. HOP-62	2.6	3.0	3.1
Lung ca. NCI-H522	5.0	4.8	5.1
Liver	0.0	0.0	0.1
Fetal Liver	0.8	0.9	1.2
Liver ca. HepG2	1.5	0.7	1.2
Kidney Pool	5.8	6.3	5.7
Fetal Kidney	1.5	2.1	1.6
Renal ca. 786-0	1.8	1.8	1.9
Renal ca. A498	1.2	0.9	1.0
Renal ca. ACHN	4.8	4.1	4.1
Renal ca. UO-31	1.7	2.8	2.4
Renal ca. TK-10	2.8	2.4	3.8
Bladder	1.2	2.6	1.7
Gastric ca.	3.8	3.8	5.1
(liver met.) NCI-N87
Gastric ca. KATO III	3.3	3.4	3.0
Colon ca. SW-948	0.6	0.8	0.4
Colon ca. SW480	3.9	5.1	4.9
Colon ca.* (SW480 met)	4.0	4.2	3.9
SW620
Colon ca. HT29	1.4	0.8	1.3
Colon ca. HCT-116	4.2	5.0	4.9
Colon ca. CaCo-2	2.3	1.9	1.0
Colon cancer tissue	2.0	2.9	2.6
Colon ca. SW1116	1.5	1.7	1.2
Colon ca. Colo-205	1.7	0.8	1.5
Colon ca. SW-48	0.8	0.9	0.5
Colon Pool	1.7	1.8	1.7
Small Intestine Pool	4.3	3.3	4.1
Stomach Pool	1.3	1.7	1.1
Bone Marrow Pool	0.8	0.7	0.7
Fetal Heart	1.8	1.4	1.4
Heart Pool	4.7	5.0	5.2
Lymph Node Pool	3.4	3.0	1.8
Fetal Skeletal Muscle	30.4	35.4	28.3
Skeletal Muscle Pool	100.0	100.0	100.0
Spleen Pool	1.1	1.6	0.8
Thymus Pool	2.3	3.2	3.5
CNS cancer (glio/astro)	3.4	4.7	4.8
U87-MG
CNS cancer	3.7	3.7	5.3
(glio/astro) U-118-MG
CNS cancer	3.3	2.4	2.8
(neuro; met) SK-N-AS
CNS cancer	4.0	4.7	4.8
(astro) SF-539
CNS cancer	15.8	14.5	17.4
(astro) SNB-75
CNS cancer	3.2	3.5	3.6
(glio) SNB-19
CNS cancer	7.9	10.4	8.3
(glio) SF-295
Brain (Amygdala)	4.3	4.7	4.2
Pool
Brain (cerebellum)	17.7	20.6	16.3
Brain (fetal)	3.9	3.8	4.0
Brain (Hippocampus)	6.1	5.6	5.9
Pool
Cerebral Cortex Pool	5.2	4.8	4.8
Brain (Substantia	6.1	6.6	6.3
nigra) Pool
Brain (Thalamus) Pool	6.6	0.0	6.0
Brain (whole)	5.3	4.5	3.0
Spinal Cord Pool	13.7	13.3	15.9
Adrenal Gland	4.3	3.6	3.8
Pituitary gland Pool	1.0	0.7	0.7
Salivary Gland	0.8	0.6	0.2
Thyroid (female)	0.8	0.4	0.6
Pancreatic ca. CAPAN2	3.8	4.4	5.2
Pancreas Pool	2.8	3.5	2.0

[0832]

TABLE BF
General_screening_panel_v1.5
                                 Rel. Exp. (%)
                                 Ag5945, Run
Tissue Name                      247774858
Adipose                          1.6
Melanoma* Hs688(A).T             0.3
Melanoma* Hs688(B).T             0.0
Melanoma* M14                    0.0
Melanoma* LOXIMVI                0.0
Melanoma* SK-MEL-5               0.3
Squamous cell carcinoma SCC-4    0.0
Testis Pool                      0.1
Prostate ca.* (bone met) PC-3    0.0
Prostate Pool                    0.4
Placenta                         0.0
Uterus Pool                      0.1
Ovarian ca. OVCAR-3              0.0
Ovarian ca. SK-OV-3              0.0
Ovarian ca. OVCAR-4              0.0
Ovarian ca. OVCAR-5              0.0
Ovarian ca. IGROV-1              0.5
Ovarian ca. OVCAR-8              0.3
Ovary                            0.0
Breast ca. MCF-7                 0.0
Breast ca. MDA-MB-231            0.0
Breast ca. BT 549                0.6
Breast ca. T47D                  0.0
Breast ca. MDA-N                 0.1
Breast Pool                      0.2
Trachea                          0.2
Lung                             0.0
Fetal Lung                       0.4
Lung ca. NCI-N417                0.0
Lung ca. LX-1                    0.0
Lung ca. NCI-H146                0.0
Lung ca. SHP-77                  0.5
Lung ca. A549                    0.0
Lung ca. NCI-H526                0.0
Lung ca. NCI-H23                 0.0
Lung ca. NCI-H460                0.0
Lung ca. HOP-62                  0.0
Lung ca. NCI-H522                0.0
Liver                            0.0
Fetal Liver                      0.0
Liver ca. HepG2                  0.0
Kidney Pool                      0.8
Fetal Kidney                     0.0
Renal ca. 786-0                  0.0
Renal ca. A498                   0.1
Renal ca. ACHN                   0.0
Renal ca. UO-31                  0.0
Renal ca. TK-10                  0.0
Bladder                          0.2
Gastric ca. (liver met.) NCI-N87 0.0
Gastric ca. KATO III             0.0
Colon ca. SW-948                 0.0
Colon ca. SW480                  0.0
Colon ca.* (SW480 met) SW620     0.0
Colon ca. HT29                   0.0
Colon ca. HCT-116                0.0
Colon ca. CaCo-2                 0.0
Colon cancer tissue              0.3
Colon ca. SW1116                 0.0
Colon ca. Colo-205               0.0
Colon ca. SW-48                  0.0
Colon Pool                       0.2
Small Intestine Pool             0.6
Stomach Pool                     0.2
Bone Marrow Pool                 0.1
Fetal Heart                      0.4
Heart Pool                       2.8
Lymph Node Pool                  0.2
Fetal Skeletal Muscle            16.0
Skeletal Muscle Pool             100.0
Spleen Pool                      0.1
Thymus Pool                      0.1
CNS cancer (glio/astro) U87-MG   0.0
CNS cancer (glio/astro) U-118-MG 0.6
CNS cancer (neuro; met) SK-N-AS  0.1
CNS cancer (astro) SF-539        0.1
CNS cancer (astro) SNB-75        2.1
CNS cancer (glio) SNB-19         0.7
CNS cancer (glio) SF-295         0.0
Brain (Amygdala) Pool            2.3
Brain (cerebellum)               8.1
Brain (fetal)                    0.7
Brain (Hippocampus) Pool         3.5
Cerebral Cortex Pool             2.0
Brain (Substantia nigra) Pool    2.5
Brain (Thalamus) Pool            3.0
Brain (whole)                    2.0
Spinal Cord Pool                 7.0
Adrenal Gland                    1.0
Pituitary gland Pool             0.3
Salivary Gland                   0.3
Thyroid (female)                 0.0
Pancreatic ca. CAPAN2            0.0
Pancreas Pool                    0.3

[0833]

TABLE BF
Panel 4.1D
                                 Rel. Exp. (%)
                                 Ag5945, Run
Tissue Name                      248173662
Secondary Th1 act                0.0
Secondary Th2 act                0.0
Secondary Tr1 act                0.0
Secondary Th1 rest               0.0
Secondary Th2 rest               0.0
Secondary Tr1 rest               0.0
Primary Th1 act                  0.0
Primary Th2 act                  0.0
Primary Tr1 act                  0.0
Primary Th1 rest                 0.0
Primary Th2 rest                 0.0
Primary Tr1 rest                 0.0
CD45RA CD4 lymphocyte act        0.0
CD45RO CD4 lymphocyte act        0.0
CD8 lymphocyte act               0.0
Secondary CD8 lymphocyte rest    0.0
Secondary CD8 lymphocyte act     0.0
CD4 lymphocyte none              0.0
2ry Th1/Th2/Tr1_anti-CD95 CH11   0.0
LAK cells rest                   0.0
LAK cells IL-2                   0.0
LAK cells IL-2 + IL-12           0.0
LAK cells IL-2 + IFN gamma       0.0
LAK cells IL-2 + IL-18           0.0
LAK cells PMA/ionomycin          0.0
NK Cells IL-2 rest               0.0
Two Way MLR 3 day                0.0
Two Way MLR 5 day                0.0
Two Way MLR 7 day                0.0
PBMC rest                        0.0
PBMC PWM                         0.0
PBMC PHA-L                       0.0
Ramos (B cell) none              0.0
Ramos (B cell) ionomycin         0.0
B lymphocytes PWM                0.0
B lymphocytes CD40L and IL-4     0.0
EOL-1 dbcAMP                     0.0
EOL-1 dbcAMP PMA/ionomycin       0.0
Dendritic cells none             0.0
Dendritic cells LPS              0.0
Dendritic cells anti-CD40        0.0
Monocytes rest                   0.0
Monocytes LPS                    0.0
Macrophages rest                 0.0
Macrophages LPS                  0.0
HUVEC none                       0.0
HUVEC starved                    0.0
HUVEC IL-1beta                   0.0
HUVEC IFN gamma                  0.0
HUVEC TNF alpha + IFN gamma      0.0
HUVEC TNF alpha + IL4            0.0
HUVEC IL-11                      1.3
Lung Microvascular EC none       0.0
Lung Microvascular EC TNFalpha + IL-1beta 0.0
Microvascular Dermal EC none     0.0
Microsvasular Dermal EC TNFalpha + IL-1beta 0.0
Bronchial epithelium TNFalpha + IL1beta 0.0
Small airway epithelium none     0.0
Small airway epithelium TNFalpha + IL-1beta 0.0
Coronery artery SMC rest         0.0
Coronery artery SMC TNFalpha + IL-1beta 0.0
Astrocytes rest                  0.0
Astrocytes TNFalpha + IL-1beta   0.0
KU-812 (Basophil) rest           2.6
KU-812 (Basophil) PMA/ionomycin  3.1
CCD1106 (Keratinocytes) none     0.0
CCD1106 (Keratinocytes) TNFalpha + IL-1beta 0.0
Liver cirrhosis                  3.0
NCI-H292 none                    0.0
NCI-H292 IL-4                    0.0
NCI-H292 IL-9                    0.0
NCI-H292 IL-13                   0.0
NCI-H292 IFN gamma               0.0
HPAEC none                       0.0
HPAEC TNF alpha + IL-1 beta      0.0
Lung fibroblast none             5.4
Lung fibroblast TNF alpha + IL-1 beta 0.0
Lung fibroblast IL-4             3.0
Lung fibroblast IL-9             2.2
Lung fibroblast IL-13            0.0
Lung fibroblast IFN gamma        12.3
Dermal fibroblast CCD1070 rest   0.0
Dermal fibroblast CCD1070 TNF alpha 0.0
Dermal fibroblast CCD1070 IL-1 beta 0.0
Dermal fibroblast IFN gamma      32.3
Dermal fibroblast IL-4           15.8
Dermal Fibroblasts rest          100.0
Neutrophils TNFa + LPS           0.0
Neutrophils rest                 0.0
Colon                            0.0
Lung                             6.0
Thymus                           2.2
Kidney                           2.5

[0834]

TABLE BG
Panel 5D
                                 Rel. Exp. (%)
                                 Ag3882, Run
Tissue Name                      170221179
97457_Patient-02go_adipose       1.4
97476_Patient-07sk_skeletal muscle 7.4
97477_Patient-07ut_uterus        0.7
97478_Patient-07pl_placenta      0.8
97481_Patient-08sk_skeletal muscle 5.0
97482_Patient-08ut_uterus        0.0
97483_Patient-08pl_placenta      0.2
97486_Patient-09sk_skeletal muscle 13.7
97487_Patient-09ut_uterus        0.1
97488_Patient-09pl_placenta      0.8
97492_Patient-10ut_uterus        0.0
97493_Patient-10pl_placenta      1.4
97495_Patient-11go_adipose       1.1
97496_Patient-11sk_skeletal muscle 47.3
97497_Patient-11ut_uterus        0.3
97498_Patient-11pl_placenta      0.6
97500_Patient-12go_adipose       1.7
97501_Patient-12sk_skeletal muscle 100.0
97502_Patient-12ut_uterus        0.6
97503_Patient-12pl_placenta      0.1
94721_Donor 2 U - A_Mesenchymal Stem Cells 0.8
94722_Donor 2 U - B_Mesenchymal Stem Cells 0.5
94723_Donor 2 U - C_Mesenchymal Stem Cells 0.5
94709_Donor 2 AM - A_adipose     0.2
94710_Donor 2 AM - B_adipose     0.8
94711_Donor 2 AM - C_adipose     0.5
94712_Donor 2 AD - A_adipose     4.4
94713_Donor 2 AD - B_adipose     7.5
94714_Donor 2 AD - C_adipose     6.2
94742_Donor 3 U - A_Mesenchymal Stem Cells 0.9
94743_Donor 3 U - B_Mesenchymal Stem Cells 0.0
94730_Donor 3 AM - A_adipose     0.3
94731_Donor 3 AM - B_adipose     0.6
94732_Donor 3 AM - C_adipose     0.9
94733_Donor 3 AD - A_adipose     4.1
94734_Donor 3 AD - B_adipose     0.2
94735_Donor 3 AD - C_adipose     3.2
77138_Liver_HepG2untreated       1.5
73556_Heart_Cardiac stromal cells (primary) 0.0
81735_Small Intestine            5.4
72409_Kidney_Proximal Convoluted Tubule 0.0
82685_Small intestine_Duodenum   0.6
90650_Adrenal_Adrenocortical adenoma 0.2
72410_Kidney_HRCE                0.5
72411_Kidney_HRE                 0.0
73139_Uterus_Uterine smooth muscle cells 1.0

[0835] AI_comprehensive panel_v1.0 Summary: Ag5945 Highest expression is seen in OA synovium (CT=29). In addition, moderate levels of expression are also seen in a cluster of samples from OA bone, synovium, and cartilage. Thus, expression of this gene could be used to differentiate between OA derived samples and other samples on this panel and as a marker of OA. Furthermore, therapeutic modulation of the expression or function of this gene may be useful in the treatment of OA.

[0836] General_screening_panel_v1.4 Summary: Ag3882 Three experiments with the same probe and primer produce results that are in excellent agreement. Highest expression of this gene is seen in skeletal muscle (CTs=26-27). This gene is also expressed at moderate to low levels in pituitary, adipose, adrenal gland, pancreas, thyroid, fetal liver and adult and fetal skeletal muscle and heart. This widespread expression among these tissues suggests that this gene product may play a role in normal neuroendocrine and metabolic function and that disregulated expression of this gene may contribute to neuroendocrine disorders or metabolic diseases, such as obesity and diabetes.

[0837] This gene is widely expressed in this panel, with moderate expression seen in brain, colon, gastric, lung, breast, ovarian, and melanoma cancer cell lines. This expression profile suggests a role for this gene product in cell survival and proliferation. Modulation of this gene product may be useful in the treatment of cancer.

[0838] This gene is also expressed at moderate to low levels in the CNS, including the hippocampus, thalamus, substantia nigra, amygdala, cerebellum and cerebral cortex. Therefore, therapeutic modulation of the expression or function of this gene may be useful in the treatment of neurologic disorders, such as Alzheimer's disease, Parkinson's disease, schizophrenia, multiple sclerosis, stroke and epilepsy.

[0839] General_screening_panel_v1.5 Summary: Ag3882 Highest expression of this gene is seen in skeletal muscle (CT=24). Overall, expression of this gene is in agreement with Panel 1.4. Please see that panel for discussion of utility of this gene.

[0840] Panel 4.1D Summary: Ag5945 Expression is limited to dermal fibroblasts, with highest expression in resting dermal fibroblasts (CT=32.3). Thus, expression of this gene could be used to differentiate between resting and activated dermal fibroblasts. This expression also suggests that this gene may be involved in inflammatory conditions of the skin.

[0841] Panel 5D Summary: Ag5945 Moderate levels of expression are seen in skeletal muscle, while this gene is not expressed in the liver derived samples on adult liver or liver cell line samples on Panels 1.4 and 1.5 and this panel.

[0842] C. CG102822-03: Glutamine Synthase.

[0843] Expression of gene CG102822-03 was assessed using the primer-probe sets Ag4225 and Ag5106, described in Tables CA and CB. Results of the RTQ-PCR runs are shown in Tables CC, CD, CE and CF.

TABLE CA
Probe Name Ag4225
			Start	SEQ ID
Primers	Sequences	Length	Position	No
Forward	5′-cagaacaccttccaccatga-3′	20	104	468
Probe	TET-5′-ccacctcagcaagttcccacttaaat-3′-TAMRA	26	124	469
Reverse	5′-tgaggcagggacatgtacac-3′	20	165	470

[0844]

TABLE CB
Probe Name Ag5106
			Start	SEQ ID
Primers	Sequences	Length	Position	No
Forward	5′-aggaatcagcatgggagatc-3′	20	749	471
Probe	TET-5′-ttgcatcgtgtgtgtgaagactttgg-3′-TAMRA	26	792	472
Reverse	5′-ggcttaggatcaaaggttgc-3′	20	825	473

[0845]

TABLE CC
CNS_neurodegeneration_v1.0
		Rel. Exp. (%)	Rel. Exp. (%)
	Tissue	Ag4225, Run	Ag5106, Run
	Name	249266000	249286585
	AD 1 Hippo	10.3	9.6
	AD 2 Hippo	17.4	17.9
	AD 3 Hippo	4.0	3.6
	AD 4 Hippo	4.6	4.8
	AD 5 Hippo	67.8	58.2
	AD 6 Hippo	100.0	100.0
	Control 2	18.0	19.9
	Hippo
	Control 4	8.0	5.7
	Hippo
	Control	6.8	20.4
	(Path) 3
	Hippo
	AD 1	10.9	12.2
	Temporal
	Ctx
	AD 2	27.5	28.7
	Temporal
	Ctx
	AD 3	6.3	6.2
	Temporal
	Ctx
	AD 4	19.6	24.5
	Temporal
	Ctx
	AD 5 Inf	66.4	69.3
	Temporal
	Ctx
	AD 5 Sup	36.3	33.7
	Temporal
	Ctx
	AD 6 Inf	94.0	84.7
	Temporal
	Ctx
	AD 6 Sup	87.7	84.7
	Temporal
	Ctx
	Control 1	9.1	11.1
	Temporal
	Ctx
	Control 2	30.4	28.5
	Temporal
	Ctx
	Control 3	15.1	21.5
	Temporal
	Ctx
	Control 3	11.3	9.9
	Temporal
	Ctx
	Control	37.9	34.6
	(Path) 1
	Temporal
	Ctx
	Control	29.7	28.9
	(Path) 2
	Temporal
	Ctx
	Control	12.5	12.0
	(Path) 3
	Temporal
	Ctx
	Control	22.8	22.2
	(Path) 4
	Temporal
	Ctx
	AD 1	11.0	14.2
	Occipital
	Ctx
	AD 2	0.0	0.0
	Occipital
	Ctx
	(Missing)
	AD 3	9.0	7.4
	Occipital
	Ctx
	AD 4	19.9	22.4
	Occipital
	Ctx
	AD 5	22.7	23.7
	Occipital
	Ctx
	AD 6	28.1	33.2
	Occipital
	Ctx
	Control 1	4.7	4.5
	Occipital
	Ctx
	Control 2	37.1	34.2
	Occipital
	Ctx
	Control 3	16.0	19.1
	Occipital
	Ctx
	Control 4	8.0	10.2
	Occipital
	Ctx
	Control	42.3	36.1
	(Path) 1
	Occipital
	Ctx
	Control	8.1	6.6
	(Path) 2
	Occipital
	Ctx
	Control	6.9	5.8
	(Path) 3
	Occipital
	Ctx
	Control	10.2	7.4
	(Path) 4
	Occipital
	Ctx
	Control 1	9.3	10.4
	Parietal Ctx
	Control 2	54.3	39.8
	Parietal Ctx
	Control 3	10.9	18.9
	Parietal Ctx
	Control	48.6	41.2
	(Path) 1
	Parietal Ctx
	Control	21.6	21.6
	(Path) 2
	Parietal Ctx
	Control	10.5	9.3
	(Path) 3
	Parietal Ctx
	Control	26.2	23.7
	(Path) 4
	Parietal Ctx

[0846]

TABLE CD
General_screening_panel_v1.5
                                 Rel. Exp. (%)
                                 Ag5106, Run
Tissue Name                      228727271
Adipose                          26.6
Melanoma* Hs688(A).T             6.4
Melanoma* Hs688(B).T             5.8
Melanoma* M14                    7.5
Melanoma* LOXIMVI                0.2
Melanoma* SK-MEL-5               6.9
Squamous cell carcinoma SCC-4    8.8
Testis Pool                      15.6
Prostate ca.* (bone met) PC-3    8.8
Prostate Pool                    7.1
Placenta                         22.5
Uterus Pool                      9.4
Ovarian ca. OVCAR-3              11.3
Ovarian ca. SK-OV-3              2.9
Ovarian ca. OVCAR-4              7.6
Ovarian ca. OVCAR-5              27.2
Ovarian ca. IGROV-1              6.7
Ovarian ca. OVCAR-8              3.1
Ovary                            13.8
Breast ca. MCF-7                 4.4
Breast ca. MDA-MB-231            8.0
Breast ca. BT 549                6.3
Breast ca. T47D                  7.7
Breast ca. MDA-N                 3.3
Breast Pool                      10.9
Trachea                          38.2
Lung                             5.1
Fetal Lung                       27.2
Lung ca. NCI-N417                6.9
Lung ca. LX-1                    3.0
Lung ca. NCI-HI46                5.1
Lung ca. SHP-77                  5.8
Lung ca. A549                    3.3
Lung ca. NCI-H526                18.9
Lung ca. NCI-H23                 1.1
Lung ca. NCI-H460                3.5
Lung ca. HOP-62                  4.1
Lung ca. NCI-H522                1.0
Liver                            7.2
Fetal Liver                      31.0
Liver ca. HepG2                  23.7
Kidney Pool                      16.6
Fetal Kidney                     4.9
Renal ca. 786-0                  0.0
Renal ca. A498                   0.0
Renal ca. ACHN                   4.2
Renal ca. UO-31                  3.5
Renal ca. TK-10                  12.1
Bladder                          27.0
Gastric ca. (liver met.) NCI-N87 17.2
Gastric ca. KATO III             2.4
Colon ca. SW-948                 3.5
Colon ca. SW480                  11.3
Colon ca.* (SW480 met) SW620     8.8
Colon ca. HT29                   8.1
Colon ca. HCT-116                11.6
Colon ca. CaCo-2                 28.7
Colon cancer tissue              13.2
Colon ca. SW1116                 0.9
Colon ca. Colo-205               0.3
Colon ca. SW-48                  3.0
Colon Pool                       12.6
Small Intestine Pool             9.5
Stomach Pool                     13.8
Bone Marrow Pool                 5.3
Fetal Heart                      11.0
Heart Pool                       7.0
Lymph Node Pool                  11.7
Fetal Skeletal Muscle            11.0
Skeletal Muscle Pool             61.1
Spleen Pool                      10.8
Thymus Pool                      8.7
CNS cancer (glio/astro) U87-MG   3.6
CNS cancer (glio/astro) U-118-MG 0.4
CNS cancer (neuro; met) SK-N-AS  7.1
CNS cancer (astro) SF-539        14.4
CNS cancer (astro) SNB-75        13.0
CNS cancer (glio) SNB-19         6.8
CNS cancer (glio) SF-295         5.1
Brain (Amygdala) Pool            26.8
Brain (cerebellum)               100.0
Brain (fetal)                    13.2
Brain (Hippocampus) Pool         36.6
Cerebral Cortex Pool             64.2
Brain (Substantia nigra) Pool    45.7
Brain (Thalamus) Pool            55.9
Brain (whole)                    55.9
Spinal Cord Pool                 32.8
Adrenal Gland                    11.3
Pituitary gland Pool             2.6
Salivary Gland                   5.5
Thyroid (female)                 12.2
Pancreatic ca. CAPAN2            5.1
Pancreas Pool                    12.8

[0847]

TABLE CE
Panel 5 Islet
	Rel. Exp. (%)	Rel. Exp. (%)	Rel. Exp. (%)
	Ag4225, Run	Ag4225, Run	Ag5106, Run
Tissue Name	248989150	249252911	312852504
97457_Patient-	36.3	48.6	42.0
02go_adipose
97476_Patient-	16.7	17.4	0.0
07sk_skeletal
muscle
97477_Patient-	12.0	15.9	10.6
07ut_uterus
97478_Patient-	15.4	27.4	23.3
07pl_placenta
99167_Bayer	37.4	29.9	20.0
Patient 1
97482_Patient-	9.0	12.7	7.3
08ut_uterus
97483_Patient-	12.0	17.6	14.7
08pl_placenta
97486_Patient-	7.6	9.3	9.4
09sk_skeletal
muscle
97487_Patient-	19.5	21.0	11.2
09ut_uterus
97488_Patient-	9.6	22.2	13.8
09pl_placenta
97492_Patient-	15.8	20.6	13.3
10ut_uterus
97493_Patient-	43.2	52.5	38.4
10pl_placenta
97495_Patient-	33.4	33.9	18.8
11go_adipose
97496_Patient-	35.6	52.1	27.7
11sk_skeletal
muscle
97497_Patient-	18.9	22.8	19.9
11ut_uterus
97498_Patient-	17.1	19.1	9.0
11pl_placenta
97500_Patient-	100.0	100.0	73.2
12go_adipose
97501_Patient-	63.7	74.2	59.5
12sk_skeletal
muscle
97502_Patient-	16.6	17.6	17.1
12ut_uterus
97503_Patient-	25.2	35.6	35.8
12pl_placenta
94721_Donor 2	4.5	7.5	10.3
U -
A_Mesenchymal
Stem Cells
94722_Donor 2	4.2	5.6	5.2
U -
B_Mesenchymal
Stem Cells
94723_Donor 2	5.6	1.1	8.5
U -
C_Mesenchymal
Stem Cells
94709_Donor 2	15.6	27.9	15.4
AM -
A_adipose
94710_Donor 2	10.6	18.9	15.3
AM -
B_adipose
94711_Donor 2	7.4	14.5	12.5
AM -
C_adipose
94712_Donor 2	17.1	22.1	34.9
AD -
A_adipose
94713_Donor 2	15.9	27.9	45.4
AD - B_adipose
94714_Donor 2	16.0	25.5	29.5
AD - C_adipose
94742_Donor 3	1.8	3.8	2.3
U -
A_Mesenchymal
Stem Cells
94743_Donor 3	4.3	4.6	2.5
U -
B_Mesenchymal
Stem Cells
94730_Donor 3	15.0	20.2	28.5
AM -
A_adipose
94731_Donor 3	9.9	13.7	46.0
AM -
B_adipose
94732_Donor 3	8.8	17.1	31.9
AM -
C_adipose
94733_Donor 3	6.7	6.7	14.1
AD -
A_adipose
94734_Donor 3	2.2	4.7	11.4
AD - B_adipose
94735_Donor 3	4.4	4.6	3.7
AD - C_adipose
77138_Liver—	70.2	98.6	100.0
HepG2untreated
73556_Heart—	3.6	4.4	3.1
Cardiac stromal
cells (primary)
81735_Small	21.6	19.9	16.4
Intestine
72409_Kidney—	2.0	2.2	7.7
Proximal
Convoluted
Tubule
82685_Small	6.6	10.8	7.4
intestine_Duo-
denum
90650_Adrenal—	6.6	8.1	5.1
Adrenocortical
adenoma
72410_Kidney—	13.1	10.4	7.6
HRCE
72411_Kidney—	7.5	9.1	5.2
HRE
73139_Uterus—	2.7	4.5	8.2
Uterine smooth
muscle cells

[0848]

TABLE CF
Panel 5D
                                 Rel. Exp. (%)
                                 Ag4225, Run
Tissue Name                      181457566
97457_Patient-02go_adipose       52.1
97476_Patient-07sk_skeletal muscle 16.4
97477_Patient-07ut_uterus        13.8
97478_Patient-07pl_placenta      24.5
97481_Patient-08sk_skeletal muscle 13.3
97482_Patient-08ut_uterus        12.0
97483_Patient-08pl_placenta      17.3
97486_Patient-09sk_skeletal muscle 9.2
97487_Patient-09ut_uterus        21.6
97488_Patient-09pl_placenta      21.3
97492_Patient-10ut_uterus        16.6
97493_Patient-10pl_placenta      52.5
97495_Patient-11go_adipose       39.5
97496_Patient-11sk_skeletal muscle 51.4
97497_Patient-11ut_uterus        24.8
97498_Patient-11pl_placenta      23.2
97500_Patient-12go_adipose       92.7
97501_Patient-12sk_skeletal muscle 72.7
97502_Patient-12ut_uterus        26.2
97503_Patient-12pl_placenta      27.0
94721_Donor 2 U - A_Mesenchymal Stem Cells 5.4
94722_Donor 2 U - B_Mesenchymal Stem Cells 5.6
94723_Donor 2 U - C_Mesenchymal Stem Cells 6.4
94709_Donor 2 AM - A_adipose     24.3
94710_Donor 2 AM - B_adipose     15.8
94711_Donor 2 AM - C_adipose     11.7
94712_Donor 2 AD - A_adipose     22.1
94713_Donor 2 AD - B_adipose     25.2
94714_Donor 2 AD - C_adipose     23.5
94742_Donor 3 U - A_Mesenchymal Stem Cells 4.1
94743_Donor 3 U - B_Mesenchymal Stem Cells 5.5
94730_Donor 3 AM - A_adipose     26.1
94731_Donor 3 AM - B_adipose     12.9
94732_Donor 3 AM - C_adipose     13.0
94733_Donor 3 AD - A_adipose     8.4
94734_Donor 3 AD - B_adipose     4.9
94735_Donor 3 AD - C_adipose     5.4
77138_Liver_HepG2untreated       100.0
73556_Heart_Cardiac stromal cells (primary) 3.5
81735_Small Intestine            19.5
72409_Kidney_Proximal Convoluted Tubule 2.3
82685_Small intestine_Duodenum   10.0
90650_Adrenal_Adrenocortical adenoma 6.4
72410_Kidney_HRCE                10.3
72411_Kidney_HRE                 8.0
73139_Uterus_Uterine smooth muscle cells 3.7

[0849] CNS_neurodegeneration_v1.0 Summary: Ag4225/Ag5106 Two experiments with two different probe and primer sets produce results that are in excellent agreement, with highest expression in the hippocampus of an Alzheimer's patient (CTs=23-24). This panel does not show differential expression of this gene in Alzheimer's disease. However, this profile confirms the expression of this gene at moderate levels in the brain. Please see Panel 1.5 for discussion of utility of this gene in the central nervous system.

[0850] General_screening_panel_v1.4 Summary: Ag4225 Results from one experiment with this gene are not included. The amp plot indicates that there were experimental difficulties with this run.

[0851] General_screening_panel_v1.5 Summary: Ag5106 Expression of this gene appears to have a brain-preferential distribution among normal tissues, with highest expression seen in the cerebellum (CT=22). This gene is also expressed at high levels throughout the CNS, including the hippocampus, thalamus, substantia nigra, amygdala, cerebellum and cerebral cortex. Therefore, therapeutic modulation of the expression or function of this gene may be useful in the treatment of neurological disorders, such as Alzheimer's disease, Parkinson's disease, schizophrenia, multiple sclerosis, stroke and epilepsy.

[0852] Among tissues with metabolic function, this gene is expressed at high levels in pituitary, adipose, adrenal gland, pancreas, thyroid, and adult and fetal skeletal muscle, heart, and liver. This widespread expression among these tissues suggests that this gene product may play a role in normal neuroendocrine and metabolic function and that disregulated expression of this gene may contribute to neuroendocrine disorders or metabolic diseases, such as obesity and diabetes.

[0853] Panel 5 Islet Summary: Ag4225/Ag5106 Multiple experiments with two different probe and primer sets produce results that are in excellent agreement, with highest expression in a liver cell line and adipose from a diabetic patient (CTs=26.5). In addition, high to moderate levels of expression are seen in metabolic tissues, including placenta, adipose and skeletal muscle, in agreement with Panel 1.5. This gene encodes glutamine synthase (GS) and also appears to be slightly up-regulated in diabetic skeletal muscle (patient 12). Up-regulation of glutamine synthase, which is critical for glutamine production, has been reported in obesity and diabetes, as well as in some myopathies. Muscle catabolism leads to the release of glutamine and contributes to gluconeogenesis in the liver. Inhibition of GS may decrease glutamine production, inhibit gluconeogenesis and necessitate fatty acid oxidation for energy generation. Therefore, an antagonist of glutamine synthase may be beneficial in treatment of obesity and diabetes.

[0854] Panel 5D Summary: Ag4225 Highest expression is in a liver cell line (CT=26.6). Expression is in agreement with Panel 5I. Please see that panel for further discussion of expression and utility of this gene in obesity and diabetes.

[0855] D. CG103241-02: UDPGAL:GLCNAC B1,4 Galactosyltransferase.

[0856] Expression of gene CG103241-02 was assessed using the primer-probe set Ag7620, described in Table DA.

TABLE DA
Probe Name Ag7620
			Start	SEQ ID
Primers	Sequences	Length	Position	No
Forward	5′-ctgagtaaggctcagtttctgaga-3′	24	830	474
Probe	TET-5′-tcaatggcttccccaatgagtactgg-3′-TAMRA	26	855	475
Reverse	5′-aatcttggtaaaccggttgaag-3′	22	907	476

[0857] CNS_neurodegeneration_v1.0 Summary: Ag7620 Expression of this gene is low/undetectable in all samples on this panel (CTs>35). (Data not shown.

[0858] Panel 4.1D Summary: Ag7620 Expression of this gene is low/undetectable in all samples on this panel (CTs>35). (Data not shown.

[0859] E. CG106249-02: Kinesin.

[0860] Expression of gene CG106249-02 was assessed using the primer-probe set Ag7282, described in Table EA. Results of the RTQ-PCR runs are shown in Tables EB and EC.

TABLE EA
Probe Name Ag7282
			Start	SEO ID
Primers	Sequences	Length	Position	No
Forward	5′-atcccaaagaaggcccttat-3′	20	550	477
Probe	TET-5′-cgtcaccataattctgtactaaatgtttgg-3′-TAMRA	30	583	478
Reverse	5′-cccgcatccataagttcttc-3′	20	615	479

[0861]

TABLE EB
CNS_neurodegeneration_v1.0
                               Rel. Exp. (%)
                               Ag7282, Run
Tissue Name                    296560376
AD 1 Hippo                     12.5
AD 2 Hippo                     25.3
AD 3 Hippo                     13.7
AD 4 Hippo                     11.7
AD 5 Hippo                     100.0
AD 6 Hippo                     59.5
Control 2 Hippo                38.7
Control 4 Hippo                19.1
Control (Path) 3 Hippo         12.9
AD 1 Temporal Ctx              42.0
AD 2 Temporal Ctx              12.7
AD 3 Temporal Ctx              10.2
AD 4 Temporal Ctx              35.6
AD 5 Inf Temporal Ctx          94.0
AD 5 Sup Temporal Ctx          57.8
AD 6 Inf Temporal Ctx          33.2
AD 6 Sup Temporal Ctx          48.6
Control 1 Temporal Ctx         10.7
Control 2 Temporal Ctx         15.1
Control 3 Temporal Ctx         32.1
Control 3 Temporal Ctx         6.4
Control (Path) 1 Temporal Ctx  45.7
Control (Path) 2 Temporal Ctx  51.1
Control (Path) 3 Temporal Ctx  15.5
Control (Path) 4 Temporal Ctx  28.3
AD 1 Occipital Ctx             27.4
AD 2 Occipital Ctx (Missing)   0.0
AD 3 Occipital Ctx             8.5
AD 4 Occipital Ctx             11.0
AD 5 Occipital Ctx             33.2
AD 6 Occipital Ctx             15.7
Control 1 Occipital Ctx        7.7
Control 2 Occipital Ctx        48.0
Control 3 Occipital Ctx        38.7
Control 4 Occipital Ctx        10.5
Control (Path) 1 Occipital Ctx 57.8
Control (Path) 2 Occipital Ctx 13.1
Control (Path) 3 Occipital Ctx 7.0
Control (Path) 4 Occipital Ctx 19.1
Control 1 Parietal Ctx         12.7
Control 2 Parietal Ctx         53.6
Control 3 Parietal Ctx         21.0
Control (Path) 1 Parietal Ctx  61.1
Control (Path) 2 Parietal Ctx  28.7
Control (Path) 3 Parietal Ctx  9.7
Control (Path) 4 Parietal Ctx  31.9

[0862]

TABLE EC
Panel 4.1D
                                 Rel. Exp. (%)
                                 Ag7282, Run
Tissue Name                      296559398
Secondary Th1 act                33.2
Secondary Th2 act                35.8
Secondary Tr1 act                8.8
Secondary Th1 rest               2.5
Secondary Th2 rest               3.4
Secondary Tr1 rest               3.0
Primary Th1 act                  0.0
Primary Th2 act                  7.5
Primary Tr1 act                  10.6
Primary Th1 rest                 2.0
Primary Th2 rest                 0.0
Primary Tr1 rest                 0.0
CD45RA CD4 lymphocyte act        12.8
CD45RO CD4 lymphocyte act        46.0
CD8 lymphocyte act               12.2
Secondary CD8 lymphocyte rest    5.3
Secondary CD8 lymphocyte act     0.0
CD4 lymphocyte none              6.0
2ry Th1/Th2/Tr1_anti-CD95 CH11   5.0
LAK cells rest                   9.5
LAK cells IL-2                   6.6
LAK cells IL-2 + IL-12           0.0
LAK cells IL-2 + IFN gamma       6.8
LAK cells IL-2 + IL-18           4.5
LAK cells PMA/ionomycin          3.7
NK Cells IL-2 rest               22.8
Two Way MLR 3 day                8.2
Two Way MLR 5 day                3.3
Two Way MLR 7 day                0.0
PBMC rest                        2.4
PBMC PWM                         2.4
PBMC PHA-L                       8.1
Ramos (B cell) none              10.1
Ramos (B cell) ionomycin         13.0
B lymphocytes PWM                7.4
B lymphocytes CD40L and IL-4     18.2
EOL-1 dbcAMP                     16.4
EOL-1 dbcAMP PMA/ionomycin       4.7
Dendritic cells none             7.3
Dendritic cells LPS              3.0
Dendritic cells anti-CD40        8.2
Monocytes rest                   3.8
Monocytes LPS                    11.6
Macrophages rest                 12.5
Macrophages LPS                  6.0
HUVEC none                       6.3
HUVEC starved                    18.3
HUVEC IL-1beta                   12.6
HUVEC IFN gamma                  20.3
HUVEC TNF alpha + IFN gamma      3.1
HUVEC TNF alpha + IL4            0.0
HUVEC IL-11                      14.6
Lung Microvascular EC none       22.1
Lung Microvascular EC TNFalpha + IL-1beta 6.5
Microvascular Dermal EC none     3.3
Microsvasular Dermal EC TNFalpha + IL-1beta 0.0
Bronchial epithelium TNFalpha + IL1beta 18.7
Small airway epithelium none     24.8
Small airway epithelium TNFalpha + IL-1beta 49.0
Coronery artery SMC rest         9.8
Coronery artery SMC TNFalpha + IL-1beta 9.6
Astrocytes rest                  0.0
Astrocytes TNFalpha + IL-1beta   3.5
KU-812 (Basophil) rest           38.7
KU-812 (Basophil) PMA/ionomycin  48.6
CCD1106 (Keratinocytes) none     39.8
CCD1106 (Keratinocytes) TNFalpha + IL-1beta 9.0
Liver cirrhosis                  12.5
NCI-H292 none                    12.5
NCI-H292 IL-4                    13.9
NCI-H292 IL-9                    26.6
NCI-H292 IL-13                   16.7
NCI-H292 IFN gamma               2.1
HPAEC none                       5.1
HPAEC TNF alpha + IL-1 beta      13.8
Lung fibroblast none             26.8
Lung fibroblast TNF alpha + IL-1 beta 17.0
Lung fibroblast IL-4             11.1
Lung fibroblast IL-9             8.7
Lung fibroblast IL-13            7.7
Lung fibroblast IFN gamma        20.6
Dermal fibroblast CCD1070 rest   6.9
Dermal fibroblast CCD1070 TNF alpha 6.3
Dermal fibroblast CCD1070 IL-1 beta 0.0
Dermal fibroblast IFN gamma      10.2
Dermal fibroblast IL-4           26.2
Dermal Fibroblasts rest          24.5
Neutrophils TNFa + LPS           0.0
Neutrophils rest                 4.6
Colon                            4.8
Lung                             2.5
Thymus                           12.5
Kidney                           100.0

[0863] CNS_neurodegeneration_v1.0 Summary: Ag7282 This panel confirms the expression of this gene at very low levels in the brains of an independent group of individuals. No differential expression of this gene was detected between Alzheimer's diseased postmortem brains and those of non-demented controls in this experiment. However, this panel confirms the expression of this gene at very low levels in the brains of an independent group of individuals. Therefore, therapeutic modulation of this gene product may be useful in the treatment of central nervous system disorders such as Parkinson's disease, epilepsy, multiple sclerosis, schizophrenia and depression.

[0864] Panel 4.1D Summary: Ag7282 Low levels of expression of this gene is seen mainly in kidney (CT=34.3). Therefore, expression of this gene may be used to distinguish kidney from other samples used in this panel. In addition, therapeutic targeting of the expression or function of this gene may modulate kidney function and be important in the treatment of inflammatory or autoimmune diseases that affect the kidney, including lupus and glomerulonephritis.

[0865] F. CG119418-01: Farnesyl-Diphosphate Farnesyltransferase 1.

[0866] Expression of gene CG119418-01 was assessed using the primer-probe set Ag4508, described in Table FA. Results of the RTQ-PCR runs are shown in Tables FB and FC.

TABLE FA
Probe Name Ag4508
			Start	SEQ ID
Primers	Sequences	Length	Position	No
Forward	5′-gaagaccccttagttggtgaag-3′	22	586	480
Probe	TET-5′-caactctatgggcctgtttctgcaga-3′-TAMRA	26	621	481
Reverse	5′-ccagatagtcacggatgatgtt-3′	22	652	482

[0867]

TABLE FB
General_screening_panel_v1.4
                                 Rel. Exp. (%)
                                 Ag4508, Run
Tissue Name                      213805830
Adipose                          4.5
Melanoma* Hs688(A).T             9.2
Melanoma* Hs688(B).T             11.9
Melanoma* M14                    30.1
Melanoma* LOXIMVI                14.8
Melanoma* SK-MEL-5               25.5
Squamous cell carcinoma SCC-4    17.4
Testis Pool                      10.2
Prostate ca.* (bone met) PC-3    5.3
Prostate Pool                    5.2
Placenta                         5.0
Uterus Pool                      2.7
Ovarian ca. OVCAR-3              17.7
Ovarian ca. SK-OV-3              25.9
Ovarian ca. OVCAR-4              12.4
Ovarian ca. OVCAR-5              22.2
Ovarian ca. IGROV-1              19.1
Ovarian ca. OVCAR-8              4.6
Ovary                            8.0
Breast ca. MCF-7                 15.8
Breast ca. MDA-MB-231            14.0
Breast ca. BT 549                100.0
Breast ca. T47D                  48.3
Breast ca. MDA-N                 18.0
Breast Pool                      5.1
Trachea                          9.2
Lung                             1.9
Fetal Lung                       10.2
Lung ca. NCI-N417                9.2
Lung ca. LX-1                    27.5
Lung ca. NCI-H146                15.2
Lung ca. SHP-77                  35.4
Lung ca. A549                    20.7
Lung ca. NCI-H526                8.4
Lung ca. NCI-H23                 8.8
Lung ca. NCI-H460                6.0
Lung ca. HOP-62                  13.1
Lung ca. NCI-H522                8.0
Liver                            1.8
Fetal Liver                      33.7
Liver ca. HepG2                  36.3
Kidney Pool                      8.7
Fetal Kidney                     4.6
Renal ca. 786-0                  14.6
Renal ca. A498                   2.0
Renal ca. ACHN                   27.4
Renal ca. UO-31                  18.6
Renal ca. TK-10                  23.2
Bladder                          8.8
Gastric ca. (liver met.) NCI-N87 28.5
Gastric ca. KATO III             75.3
Colon ca. SW-948                 16.0
Colon ca. SW480                  18.3
Colon ca.* (SW480 met) SW620     18.0
Colon ca. HT29                   17.2
Colon ca. HCT-116                32.1
Colon ca. CaCo-2                 33.7
Colon cancer tissue              8.7
Colon ca. SW1116                 3.8
Colon ca. Colo-205               13.2
Colon ca. SW-48                  11.9
Colon Pool                       5.3
Small Intestine Pool             6.0
Stomach Pool                     3.3
Bone Marrow Pool                 2.7
Fetal Heart                      2.7
Heart Pool                       3.3
Lymph Node Pool                  6.3
Fetal Skeletal Muscle            2.8
Skeletal Muscle Pool             6.9
Spleen Pool                      3.0
Thymus Pool                      4.0
CNS cancer (glio/astro) U87-MG   18.4
CNS cancer (glio/astro) U-118-MG 9.4
CNS cancer (neuro; met) SK-N-AS  18.3
CNS cancer (astro) SF-539        55.5
CNS cancer (astro) SNB-75        20.4
CNS cancer (glio) SNB-19         16.5
CNS cancer (glio) SF-295         15.9
Brain (Amygdala) Pool            7.3
Brain (cerebellum)               10.1
Brain (fetal)                    22.1
Brain (Hippocampus) Pool         8.1
Cerebral Cortex Pool             8.9
Brain (Substantia nigra) Pool    7.5
Brain (Thalamus) Pool            11.3
Brain (whole)                    12.9
Spinal Cord Pool                 11.3
Adrenal Gland                    15.5
Pituitary gland Pool             2.1
Salivary Gland                   7.6
Thyroid (female)                 3.9
Pancreatic ca. CAPAN2            36.9
Pancreas Pool                    5.4

[0868]

TABLE FC
Panel 5 Islet
                                 Rel. Exp. (%)
                                 Ag4508, Run
Tissue Name                      200923967
97457_Patient-02go_adipose       7.7
97476_Patient-07sk_skeletal muscle 7.4
97477_Patient-07ut_uterus        4.5
97478_Patient-07pl_placenta      12.4
99167_Bayer Patient 1            30.8
97482_Patient-08ut_uterus        3.4
97483_Patient-08pl_placenta      13.3
97486_Patient-09sk_skeletal muscle 5.5
97487_Patient-09ut_uterus        7.7
97488_Patient-09pl_placenta      7.0
97492_Patient-10ut_uterus        8.0
97493_Patient-10pl_placenta      23.8
97495_Patient-11go_adipose       7.1
97496_Patient-11sk_skeletal muscle 16.5
97497_Patient-11ut_uterus        9.6
97498_Patient-11pl_placenta      7.5
97500_Patient-12go_adipose       13.0
97501_Patient-12sk_skeletal muscle 47.3
97502_Patient-12ut_uterus        8.8
97503_Patient-12pl_placenta      13.0
94721_Donor 2 U - A_Mesenchymal Stem Cells 17.6
94722_Donor 2 U - B_Mesenchymal Stem Cells 8.8
94723_Donor 2 U - C_Mesenchymal Stem Cells 11.4
94709_Donor 2 AM - A_adipose     9.8
94710_Donor 2 AM - B_adipose     7.7
94711_Donor 2 AM - C_adipose     5.5
94712_Donor 2 AD - A_adipose     14.6
94713_Donor 2 AD - B_adipose     18.8
94714_Donor 2 AD - C_adipose     16.5
94742_Donor 3 U - A_Mesenchymal Stem Cells 5.7
94743_Donor 3 U - B_Mesenchymal Stem Cells 9.0
94730_Donor 3 AM - A_adipose     10.1
94731_Donor 3 AM - B_adipose     5.7
94732_Donor 3 AM - C_adipose     7.1
94733_Donor 3 AD - A_adipose     20.3
94734_Donor 3 AD - B_adipose     6.7
94735_Donor 3 AD - C_adipose     16.2
77138_Liver_HepG2untreated       100.0
73556_Heart_Cardiac stromal cells (primary) 11.5
81735_Small Intestine            21.6
72409_Kidney_Proximal Convoluted Tubule 20.9
82685_Small intestine_Duodenum   7.0
90650_Adrenal_Adrenocortical adenoma 5.4
72410_Kidney_HRCE                58.6
72411_Kidney_HRE                 50.0
73139_Uterus_Uterine smooth muscle cells 20.0

[0869] General_screening panel_v.1.4 Summary: Ag4508 Highest expression of this gene is detected in a breast cancer BT 549 cell line (CT=23.6). High expression of this gene is also seen in cluster of cancer cell lines derived from pancreatic, gastric, colon, lung, liver, renal, breast, ovarian, prostate, squamous cell carcinoma, melanoma and brain cancers. Thus, expression of this gene could be used as a marker to detect the presence of these cancers. Furthermore, therapeutic modulation of the expression or function of this gene may be effective in the treatment of pancreatic, gastric, colon, lung, liver, renal, breast, ovarian, prostate, squamous cell carcinoma, melanoma and brain cancers.

[0870] Among tissues with metabolic or endocrine function, this gene is expressed at high levels in pancreas, adipose, adrenal gland, thyroid, pituitary gland, skeletal muscle, heart, liver and the gastrointestinal tract. Therefore, therapeutic modulation of the activity of this gene may prove useful in the treatment of endocrine/metabolically related diseases, such as obesity and diabetes.

[0871] In addition, this gene is expressed at high levels in all regions of the central nervous system examined, including amygdala, hippocampus, substantia nigra, thalamus, cerebellum, cerebral cortex, and spinal cord. Therefore, therapeutic modulation of this gene product may be useful in the treatment of central nervous system disorders such as Alzheimer's disease, Parkinson's disease, epilepsy, multiple sclerosis, schizophrenia and depression.

[0872] Interestingly, this gene is expressed at much higher levels in fetal (CT=25) when compared to adult liver (CT=29). This observation suggests that expression of this gene can be used to distinguish fetal from adult liver. In addition, the relative overexpression of this gene in fetal tissue suggests that the protein product may enhance liver growth or development in the fetus and thus may also act in a regenerative capacity in the adult. Therefore, therapeutic modulation of the protein encoded by this gene could be useful in treatment of liver related diseases.

[0873] Panel 5 Islet Summary: Ag4508 Highest expression of this gene is detected in liver cancer HepG2 cell line (CT=25.3). This gene shows a wide spread expression in this panel, which correlates with the expression in panel 1.4. High expression of this gene is detected in islet cells, adipose, skeletal muscle, uterus, placenta, heart smooth muscle, small intestine and kidney. This gene codes for Farnesyl-diphosphate farnesyltransferase. Farnesyl-diphosphate farnesyltransferase is involoved in the cholesterol biosynthetic pathway. The operation of this pathway appears to be important for glucose homeostasis and insulin secretion in pancreatic beta cells (Flamez D, Berger V, Kruhoffer M, Orntoft T, Pipeleers D, Schuit F C., 2002, Critical role for cataplerosis via citrate in glucose-regulated insulin release. Diabetes. 2002 July;51(7):2018-24. PMID: 12086928). Therefore, therapeutic modulation of this gene product may enhance insulin secretion in Type 2 diabetes.

[0874] G. CG120359-01: Acetyl-CoA Synthetase.

[0875] Expression of gene CG120359-01 was assessed using the primer-probe set Ag4830, described in Table GA. Results of the RTQ-PCR runs are shown in Tables GB and GC.

TABLE GA
Probe Name Ag4830
			Start	SEQ ID
Primers	Sequences	Length	Position	No
Forward	5′-gtggagcattgtggacaaatac-3′	22	1182	483
Probe	TET-5′-tgaccaagttctacacagcacccaca-3′-TAMRA	26	1208	484
Reverse	5′-gctcatctccaaacttcatgag-3′	22	1246	485

[0876]

TABLE GB
General_screening_panel_v1.4
                                 Rel. Exp. (%)
                                 Ag4830, Run
Tissue Name                      213856337
Adipose                          16.2
Melanoma* Hs688(A).T             13.1
Melanoma* Hs688(B).T             12.6
Melanoma* M14                    47.6
Melanoma* LOXIMVI                7.4
Melanoma* SK-MEL-5               21.6
Squamous cell carcinoma SCC-4    17.3
Testis Pool                      9.2
Prostate ca.* (bone met) PC-3    59.9
Prostate Pool                    6.6
Placenta                         16.6
Uterus Pool                      5.0
Ovarian ca. OVCAR-3              22.2
Ovarian ca. SK-OV-3              13.8
Ovarian ca. OVCAR-4              22.4
Ovarian ca. OVCAR-5              45.4
Ovarian ca. IGROV-1              56.6
Ovarian ca. OVCAR-8              9.7
Ovary                            8.5
Breast ca. MCF-7                 9.7
Breast ca. MDA-MB-231            32.8
Breast ca. BT 549                28.3
Breast ca. T47D                  88.3
Breast ca. MDA-N                 34.4
Breast Pool                      9.3
Trachea                          12.2
Lung                             4.0
Fetal Lung                       27.5
Lung ca. NCI-N417                1.6
Lung ca. LX-1                    26.2
Lung ca. NCI-H146                1.6
Lung ca. SHP-77                  6.8
Lung ca. A549                    13.7
Lung ca. NCI-H526                2.1
Lung ca. NCI-H23                 19.6
Lung ca. NCI-H460                13.3
Lung ca. HOP-62                  19.2
Lung ca. NCI-H522                11.7
Liver                            5.8
Fetal Liver                      65.5
Liver ca. HepG2                  55.5
Kidney Pool                      15.4
Fetal Kidney                     5.7
Renal ca. 786-0                  13.6
Renal ca. A498                   8.4
Renal ca. ACHN                   100.0
Renal ca. UO-31                  18.6
Renal ca. TK-10                  39.8
Bladder                          20.9
Gastric ca. (liver met.) NCI-N87 36.6
Gastric ca. KATO III             37.6
Colon ca. SW-948                 12.8
Colon ca. SW480                  88.9
Colon ca.* (SW480 met) SW620     27.2
Colon ca. HT29                   9.9
Colon ca. HCT-116                24.7
Colon ca. CaCo-2                 62.9
Colon cancer tissue              32.8
Colon ca. SW1116                 6.0
Colon ca. Colo-205               7.7
Colon ca. SW-48                  48.6
Colon Pool                       10.9
Small Intestine Pool             12.6
Stomach Pool                     7.2
Bone Marrow Pool                 4.8
Fetal Heart                      11.8
Heart Pool                       13.1
Lymph Node Pool                  12.0
Fetal Skeletal Muscle            20.3
Skeletal Muscle Pool             44.4
Spleen Pool                      5.8
Thymus Pool                      10.3
CNS cancer (glio/astro) U87-MG   49.3
CNS cancer (glio/astro) U-118-MG 24.3
CNS cancer (neuro; met) SK-N-AS  24.0
CNS cancer (astro) SF-539        14.5
CNS cancer (astro)SNB-75         33.9
CNS cancer (glio) SNB-19         51.4
CNS cancer (glio) SF-295         30.8
Brain (Amygdala) Pool            9.5
Brain (cerebellum)               21.3
Brain (fetal)                    11.0
Brain (Hippocampus) Pool         7.3
Cerebral Cortex Pool             10.3
Brain (Substantia nigra) Pool    12.9
Brain (Thalamus) Pool            10.8
Brain (whole)                    10.6
Spinal Cord Pool                 8.8
Adrenal Gland                    62.4
Pituitary gland Pool             1.6
Salivary Gland                   13.4
Thyroid (female)                 5.8
Pancreatic ca. CAPAN2            56.6
Pancreas Pool                    11.6

[0877]

TABLE GC
Panel 5 Islet
                                 Rel. Exp. (%)
                                 Ag4830, Run
Tissue Name                      223846062
97457_Patient-02go_adipose       27.9
97476_Patient-07sk skeletal muscle 19.2
97477_Patient-07ut_uterus        5.2
97478_Patient-07pl_placenta      15.7
99167_Bayer Patient 1            43.8
97482_Patient-08ut_uterus        1.1
97483_Patient-08pl_placenta      12.5
97486_Patient-09sk skeletal muscle 11.5
97487_Patient-09ut_uterus        6.2
97488_Patient-09pl_placenta      3.3
97492_Patient-10ut_uterus        1.8
97493_Patient-10pl_placenta      14.0
97495_Patient-11go_adipose       14.4
97496_Patient-11sk_skeletal muscle 5.9
97497_Patient-11ut_uterus        1.8
97498_Patient-11pl_placenta      6.0
97500_Patient-12go adipose       21.9
97501_Patient-12sk_skeletal muscle 100.0
97502_Patient-12ut_uterus        3.3
97503_Patient-12pl_placenta      3.2
94721_Donor 2 U - A_Mesenchymal Stem Cells 2.5
94722_Donor 2 U - B_Mesenchymal Stem Cells 2.4
94723_Donor 2 U - C_Mesenchymal Stem Cells 3.4
94709_Donor 2 AM - A_adipose     10.1
94710_Donor 2 AM - B_adipose     11.4
94711_Donor 2 AM - C_adipose     0.6
94712_Donor 2 AD - A_adipose     5.3
94713_Donor 2 AD - B_adipose     10.3
94714_Donor 2 AD - C_adipose     10.4
94742_Donor 3 U - A_Mesenchymal Stem Cells 1.4
94743_Donor 3 U - B_Mesenchymal Stem Cells 13.9
94730_Donor 3 AM - A_adipose     17.1
94731_Donor 3 AM - B_adipose     11.7
94732_Donor 3 AM - C_adipose     10.7
94733_Donor 3 AD - A_adipose     85.9
94734_Donor 3 AD - B_adipose     19.2
94735_Donor 3 AD - C_adipose     36.1
77138_Liver_HepG2untreated       97.3
73556_Heart_Cardiac stromal cells (primary) 9.3
81735_Small Intestine            78.5
72409_Kidney_Proximal Convoluted Tubule 20.4
82685_Small intestine_Duodenum   41.2
90650_Adrenal_Adrenocortical adenoma 17.4
72410_Kidney_HRCE                52.5
72411_Kidney_HRE                 25.7
73139_Uterus_Uterine smooth muscle cells 14.4

[0878] General_screening_panel_v1.4 Summary: Ag4830 Highest expression of this gene is seen in a renal cancer cell line (CT=26.2). This gene is widely expressed in this panel, with high to moderate expression seen in brain, colon, gastric, lung, breast, ovarian, and melanoma cancer cell lines. This expression profile suggests a role for this gene product in cell survival and proliferation. Modulation of this gene product may be useful in the treatment of cancer.

[0879] Among tissues with metabolic function, this gene is expressed at high to moderate levels in pituitary, adipose, adrenal gland, pancreas, thyroid, and adult and fetal skeletal muscle, heart, and liver. This widespread expression among these tissues suggests that this gene product may play a role in normal neuroendocrine and metabolic function and that disregulated expression of this gene may contribute to neuroendocrine disorders or metabolic diseases, such as obesity and diabetes. This gene encodes acetyl coA synthase. Inhibiting the production of acetyl CoA from one pathway may increase the utilization (energy generation) of acetyl CoA produced from other pathways. Decreased acetyl CoA will be available for lipid synthesis. Therefore, an inhibitor of ACS may facilitate weight loss and prevent weight gain, and be useful in the treatment of obesity.

[0880] In addition, this gene is expressed at much higher levels in fetal liver tissue (CT=27) when compared to expression in the adult counterpart (CT=30). Thus, expression of this gene may be used to differentiate between the fetal and adult source of this tissue. This gene is also expressed at moderate levels in the CNS, including the hippocampus, thalamus, substantia nigra, amygdala, cerebellum and cerebral cortex. Therefore, therapeutic modulation of the expression or function of this gene may be useful in the treatment of neurologic disorders, such as Alzheimer's disease, Parkinson's disease, schizophrenia, multiple sclerosis, stroke and epilepsy.

[0881] Panel 5 Islet Summary: Ag4830 Highest expression of this gene is seen in diabetic skeletal muscle (CT=29) (patient 12). This gene is also expressed in other metabolic tissues, including adipose and placenta. Please see Panel 1.4 for discussion of utility of this gene in metabolic disease.

[0882] H. CG124907-01: Ornithine Decarboxylase.

[0883] Expression of gene CG124907-01 was assessed using the primer-probe set Ag4751, described in Table HA. Results of the RTQ-PCR runs are shown in Tables HB and HC.

TABLE HA
Probe Name Ag4751
			Start	SEQ ID
Primers	Sequences	Length	Position	No
Forward	5′-ctggatctgaggatgtgaaact-3′	22	894	486
Probe	TET-5′-cgtaatcaaacccagcgttggacaaat-3′-TAMRA	26	937	487
Reverse	5′-actccagagtctgacggaaagt-3′	22	963	488

[0884]

TABLE HB
General_screening_panel_v1.4
                                 Rel. Exp. (%)
                                 Ag4751, Run
Tissue Name                      219997032
Adipose                          5.2
Melanoma* Hs688(A).T             6.7
Melanoma* Hs688(B).T             8.8
Melanoma* M14                    5.4
Melanoma* LOXIMVI                22.1
Melanoma* SK-MEL-5               32.5
Squamous cell carcinoma SCC-4    10.1
Testis Pool                      6.9
Prostate ca.* (bone met) PC-3    100.0
Prostate Pool                    2.8
Placenta                         0.3
Uterus Pool                      1.8
Ovarian ca. OVCAR-3              24.7
Ovarian ca. SK-OV-3              10.0
Ovarian ca. OVCAR-4              7.3
Ovarian ca. OVCAR-5              9.2
Ovarian ca. IGROV-1              18.8
Ovarian ca. OVCAR-8              6.5
Ovary                            1.5
Breast ca. MCF-7                 10.7
Breast ca. MDA-MB-231            17.3
Breast ca. BT 549                13.4
Breast ca. T47D                  17.9
Breast ca. MDA-N                 2.5
Breast Pool                      4.1
Trachea                          2.7
Lung                             1.0
Fetal Lung                       6.0
Lung ca. NCI-N417                14.7
Lung ca. LX-1                    22.5
Lung ca. NCI-H146                14.3
Lung ca. SHP-77                  54.0
Lung ca. A549                    13.3
Lung ca. NCI-H526                27.9
Lung ca. NCI-H23                 29.1
Lung ca. NCI-H460                29.1
Lung ca. HOP-62                  4.9
Lung ca. NCI-H522                31.2
Liver                            0.6
Fetal Liver                      8.8
Liver ca. HepG2                  17.3
Kidney Pool                      4.4
Fetal Kidney                     16.6
Renal ca. 786-0                  5.8
Renal ca. A498                   1.7
Renal ca. ACHN                   5.9
Renal ca. UO-31                  10.2
Renal ca. TK-10                  17.7
Bladder                          8.8
Gastric ca. (liver met.) NCI-N87 18.7
Gastric ca. KATO III             85.3
Colon ca. SW-948                 11.7
Colon ca. SW480                  49.7
Colon ca * (SW480 met) SW620     37.4
Colon ca. HT29                   17.8
Colon ca. HCT-116                68.3
Colon ca. CaCo-2                 27.2
Colon cancer tissue              10.3
Colon ca. SW1116                 4.7
Colon ca. Colo-205               6.4
Colon ca. SW-48                  6.6
Colon Pool                       3.7
Small Intestine Pool             2.2
Stomach Pool                     2.2
Bone Marrow Pool                 1.4
Fetal Heart                      2.0
Heart Pool                       2.1
Lymph Node Pool                  2.8
Fetal Skeletal Muscle            1.8
Skeletal Muscle Pool             6.3
Spleen Pool                      1.4
Thymus Pool                      2.7
CNS cancer (glio/astro) U87-MG   24.0
CNS cancer (glio/astro) U-118-MG 66.4
CNS cancer (neuro; met) SK-N-AS  6.0
CNS cancer (astro) SF-539        7.9
CNS cancer (astro) SNB-75        8.5
CNS cancer (glio) SNB-19         15.9
CNS cancer (glio) SF-295         21.5
Brain (Amygdala) Pool            1.4
Brain (cerebellum)               2.3
Brain (fetal)                    9.5
Brain (Hippocampus) Pool         1.8
Cerebral Cortex Pool             1.9
Brain (Substantia nigra) Pool    1.4
Brain (Thalamus) Pool            1.8
Brain (whole)                    2.6
Spinal Cord Pool                 1.8
Adrenal Gland                    1.9
Pituitary gland Pool             1.0
Salivary Gland                   1.0
Thyroid (female)                 7.0
Pancreatic ca. CAPAN2            4.2
Pancreas Pool                    4.2

[0885]

TABLE HC
Panel 5D
                                 Rel. Exp. (%)
                                 Ag4751, Run
Tissue Name                      204263059
97457_Patient-02go_adipose       9.2
97476_Patient-07sk_skeletal muscle 7.3
97477_Patient-07ut_uterus        11.3
97478_Patient-07pl_placenta      1.5
97481_Patient-08sk_skeletal muscle 8.1
97482_Patient-08ut_uterus        10.9
97483_Patient-08pl_placenta      0.2
97486_Patient-09sk skeletal muscle 3.2
97487_Patient-09ut_uterus        9.9
97488_Patient-09pl_placenta      3.0
97492_Patient-10ut_uterus        12.4
97493_Patient-10pl_placenta      3.9
97495_Patient-11go_adipose       4.0
97496_Patient-11sk_skeletal muscle 8.0
97497_Patient-11ut_uterus        25.2
97498_Patient-11pl_placenta      1.2
97500_Patient-12go_adipose       12.6
97501_Patient-12sk_skeletal muscle 30.6
97502_Patient-12ut_uterus        21.8
97503_Patient-12pl_placenta      1.5
94721_Donor 2 U - A_Mesenchymal Stem Cells 29.9
94722_Donor 2 U - B_Mesenchymal Stem Cells 21.3
94723_Donor 2 U - C_Mesenchymal Stem Cells 23.8
94709_Donor 2 AM - A_adipose     29.9
94710_Donor 2 AM - B_adipose     22.1
94711_Donor 2 AM - C_adipose     17.3
94712_Donor 2 AD - A_adipose     30.8
94713_Donor 2 AD - B_adipose     41.2
94714_Donor 2 AD - C_adipose     39.2
94742_Donor 3 U - A_Mesenchymal Stem Cells 9.0
94743_Donor 3 U - B_Mesenchymal Stem Cells 28.1
94730_Donor 3 AM - A_adipose     32.1
94731_Donor 3 AM - B_adipose     17.6
94732_Donor 3 AM - C_adipose     17.0
94733_Donor 3 AD - A_adipose     45.4
94734_Donor 3 AD - B_adipose     23.8
94735_Donor 3 AD - C_adipose     38.4
77138_Liver_HepG2untreated       100.0
73556_Heart_Cardiac stromal cells (primary) 11.7
81735_Small Intestine            10.0
72409_Kidney_Proximal Convoluted Tubule 11.8
82685_Small intestine_Duodenum   6.5
90650_Adrenal_Adrenocortical_adenoma 1.5
72410_Kidney_HRCE                42.6
72411_Kidney_HRE                 41.5
73139_Uterus_Uterine smooth muscle cells 19.2

[0886] General_screening_panelv1.4 Summary: Ag4751 Highest expression of this gene is detected in prostate cancer PC3 cell line (CT=23.5). High expression of this gene is also seen in cluster of cancer cell lines derived from pancreatic, gastric, colon, lung, liver, renal, breast, ovarian, prostate, squamous cell carcinoma, melanoma and brain cancers. Thus, expression of this gene could be used as a marker to detect the presence of these cancers. Furthermore, therapeutic modulation of the expression or function of this gene may be effective in the treatment of pancreatic, gastric, colon, lung, liver, renal, breast, ovarian, prostate, squamous cell carcinoma, melanoma and brain cancers.

[0887] Among tissues with metabolic or endocrine function, this gene is expressed at high to moderate levels in pancreas, adipose, adrenal gland, thyroid, pituitary gland, skeletal muscle, heart, liver and the gastrointestinal tract. Therefore, therapeutic modulation of the activity of this gene may prove useful in the treatment of endocrine/metabolically related diseases, such as obesity and diabetes.

[0888] This gene codes for ornithine Decarboxylase 1 (ODC). ODC is one of the key enzymes in polyamine biosynthesis. Preventing the accumulation of polyamines and their antilipolytic effects by inhibition of ODC at an earlier stage of obesity may inhibit progression of the obesity. In multiple GeneCalling studies at Curagen, enzyme spermidine/spermine acetyl transferase is found to be dysregulated in various disease models. This enzyme is one of the rate-limiting enzymes in the production of polyamines, spermidine and spermine. Previously, it was shown that oxidation of polyamines leads to generation of hydrogen peroxide, which has been shown to have antilipolytic effects on adipose and may be involved in the progression of obesity.

[0889] In addition, this gene is expressed at high levels in all regions of the central nervous system examined, including amygdala, hippocampus, substantia nigra, thalamus, cerebellum, cerebral cortex, and spinal cord. Therefore, therapeutic modulation of this gene product may be useful in the treatment of central nervous system disorders such as Alzheimer's disease, Parkinson's disease, epilepsy, multiple sclerosis, schizophrenia and depression.

[0890] Interestingly, this gene is expressed at much higher levels in fetal (CT=27) when compared to adult liver (CT=31). This observation suggests that expression of this gene can be used to distinguish fetal from adult liver. In addition, the relative overexpression of this gene in fetal tissue suggests that the protein product may enhance liver growth or development in the fetus and thus may also act in a regenerative capacity in the adult. Therefore, therapeutic modulation of the protein encoded by this gene could be useful in treatment of liver related diseases.

[0891] References:

[0892] 1: Taylor J L, Turo K A, McCann P P, Grossberg S E. Inhibition of the differentiation of 3T3-L1 cells by interferon-beta and difluoromethyl ornithine. J. Biol. Regul. Homeost. Agents 1988 January-March;2(1):19-24. PMID: 3140600.

[0893] 2: Brown A P, Morrissey R L, Crowell J A, Levine B S. Difluoromethylornithine in combination with tamoxifen in female rats: 13-week oral toxicity study. Cancer Chemother Pharmacol 1999;44(6):475-83. PMID: 10550568. 3: Olefsky J M. Comparison of the effects of insulin and insulin-like agents on different aspects of adipocyte metabolism. Horm. Metab. Res. 1979 March;11(3):209-13. PMID: 447201.

[0894] 4: Richelsen B, Pedersen S B, Hougaard D M. Characterization of antilipolytic action of polyamines in isolated rat adipocytes. Biochem. J. 1989 July 15;261(2):661-5. PMID: 2476118.

[0895] 5 : Livingston J N, Gurny P A, Lockwood D H. Insulin-like effects of polyamines in fat cells. Mediation by H2O2 formation. J. Biol. Chem. 1977 January 25;252(2):560-2. PMID:833144.

[0896] Panel 5D Summary: Ag4751 Highest expression of this gene is detected in liver cancer HepG2 cell line (CT=29.5). This gene shows a wide spread expression in this panel, which correlates with the expression in panel 1.4. Moderate expression of this gene is detected in adipose, skeletal muscle, uterus, placenta, heart smooth muscle, small intestine and kidney. Therefore, therapeutic modulation of this gene may be useful in the treatment of obesity and diabetes including type II diabetes.

[0897] I. CG128347-02: Kinesin-Like.

[0898] Expression of gene CG128347-02 was assessed using the primer-probe set Ag5691, described in Table IA. Results of the RTQ-PCR runs are shown in Table IB.

TABLE 1A
Probe Name Ag5691
			Start	SEQ ID
Primers	Sequences	Length	Position	No
Forward	5′-gaattagacctctgctttgcaa-3′	22	164	489
Probe	TET-5′-cacacaaacttgatgattatgaagagcttc-3′-TAMRA	30	187	490
Reverse	5′-gctggctgtttggaataactct-3′	22	217	491

[0899]

TABLE IB
Panel 4.1D
                                 Rel. Exp. (%)
                                 Ag5691, Run
Tissue Name                      246504797
Secondary Th1 act                9.8
Secondary Th2 act                23.0
Secondary Tr1 act                5.0
Secondary Th1 rest               0.0
Secondary Th2 rest               0.0
Secondary Tr1 rest               0.0
Primary Th1 act                  0.0
Primary Th2 act                  11.9
Primary Tr1 act                  10.2
Primary Th1 rest                 0.0
Primary Th2 rest                 2.3
Primary Tr1 rest                 0.0
CD45RA CD4 lymphocyte act        8.4
CD45RO CD4 lymphocyte act        13.8
CD8 lymphocyte act               0.0
Secondary CD8 lymphocyte rest    9.2
Secondary CD8 lymphocyte act     0.6
CD4 lymphocyte none              0.9
2ry Th1/Th2/Tr1_anti-CD95 CH11   0.0
LAK cells rest                   5.9
LAK cells IL-2                   3.3
LAK cells IL-2 + IL-12           1.4
LAK cells IL-2 + IFN gamma       2.5
LAK cells IL-2 + IL-18           1.5
LAK cells PMA/ionomycin          3.4
NK Cells IL-2 rest               1.5
Two Way MLR 3 day                4.8
Two Way MLR 5 day                0.0
Two Way MLR 7 day                1.6
PBMC rest                        0.3
PBMC PWM                         0.8
PBMC PHA-L                       2.2
Ramos (B cell) none              2.2
Ramos (B cell) ionomycin         18.6
B lymphocytes PWM                10.5
B lymphocytes CD40L and IL-4     15.1
EOL-1 dbcAMP                     2.8
EOL-1 dbcAMP PMA/ionomycin       0.0
Dendritic cells none             3.2
Dendritic cells LPS              1.1
Dendritic cells anti-CD40        0.0
Monocytes rest                   0.5
Monocytes LPS                    18.6
Macrophages rest                 3.3
Macrophages LPS                  0.0
HUVEC none                       5.2
HUVEC starved                    2.4
HUVEC IL-1beta                   8.2
HUVEC IFN gamma                  9.7
HUVEC TNF alpha + IFN gamma      0.0
HUVEC TNF alpha + IL4            2.8
HUVEC IL-11                      6.4
Lung Microvascular EC none       20.7
Lung Microvascular EC TNFalpha + IL-1beta 3.0
Microvascular Dermal EC none     1.7
Microsvascular Dermal EC TNFalpha + IL-1beta 3.4
Bronchial epithelium TNFalpha + IL1beta 11.0
Small airway epithelium none     6.1
Small airway epithelium TNFalpha + IL-1beta 9.6
Coronery artery SMC rest         3.6
Coronery artery SMC TNFalpha + IL-1beta 7.9
Astrocytes rest                  1.1
Astrocytes TNFalpha + IL-1beta   0.0
KU-812 (Basophil) rest           13.7
KU-812 (Basophil) PMA/ionomycin  11.5
CCD1106 (Keratinocytes) none     25.0
CCD1106 (Keratinocytes) TNFalpha + IL-1beta 12.6
Liver cirrhosis                  9.6
NCI-H292 none                    15.5
NCI-H292 IL-4                    17.8
NCI-H292 IL-9                    39.0
NCI-H292 IL-13                   28.3
NCI-H292 IFN gamma               2.8
HPAEC none                       3.8
HPAEC TNF alpha + IL-1 beta      18.7
Lung fibroblast none             7.6
Lung fibroblast TNF alpha + IL-1 beta 9.0
Lung fibroblast IL-4             12.5
Lung fibroblast IL-9             6.8
Lung fibroblast IL-13            1.6
Lung fibroblast IFN gamma        5.9
Dermal fibroblast CCD1070 rest   10.1
Dermal fibroblast CCD1070 TNF alpha 0.0
Dermal fibroblast CCD1070 IL-1 beta 5.4
Dermal fibroblast IFN gamma      3.3
Dermal fibroblast IL-4           14.2
Dermal Fibroblasts rest          6.6
Neutrophils TNFa + LPS           6.7
Neutrophils rest                 100.0
Colon                            1.1
Lung                             0.4
Thymus                           10.0
Kidney                           28.3

[0900] CNS_neurodegeneration_v1.0 Summary: Ag5691 Results from one experiment with this gene are not included. The amp plot indicates that there were experimental difficulties with this run (Data not shown).

[0901] General_screening panel_v1.5 Summary: Ag5691 Results from one experiment with this gene are not included. The amp plot indicates that there were experimental difficulties with this run (Data not shown).

[0902] Panel 4.1D Summary: AG5691 Highest expression of this gene is seen in resting neutrophils (CT=31.3). This expression is reduced to background level (CT=35.2) in neutrophils activated by TNF-alpha+LPS. This expression profile suggests that the protein encoded by this gene is produced by resting neutrophils but not by activated neutrophils. Therefore, the gene product may reduce activation of these inflammatory cells and modulation of its expression or activity may reduce or eliminate the symptoms in patients with Crohn's disease, ulcerative colitis, multiple sclerosis, chronic obstructive pulmonary disease, asthma, emphysema, rheumatoid arthritis, lupus erythematosus, or psoriasis. In addition, antagonists of this gene product may be effective in increasing the immune response in patients with AIDS or other immunodeficiencies.

[0903] J. CG135823-01 and CG135823-02: TAT.

[0904] Expression of gene CG135823-01 and CG135823-02 was assessed using the primer-probe sets Ag3173 and Ag4906, described in Tables JA and JB. Results of the RTQ-PCR runs are shown in Tables JC and JD. Please note that probe-primer set Ag4906 is specific for CG135823-01 variant.

TABLE JA
Probe Name Ag3173
			Start	SEQ ID
Primers	Sequences	Length	Position	No
Forward	5′-ctctggctgagtctatgggaat-3′	22	617	492
Probe	TET-5′-tgaggtcaaactctacaatttgttgcca-3′-TAMRA	28	639	493
Reverse	5′-tcaggtcaatttcccaagattt-3′	22	670	494

[0905]

TABLE JB
Probe Name Ag4906
			Start	SEQ ID
Primers	Sequences	Length	Position	No
Forward	5′-ctcaggatgagggaaaagaaaa-3′	22	1796	495
Probe	TET-5′-ccccaaccatttcctcagactcta-3′-TAMRA	24	1837	496
Reverse	5′-tggagagagcgtgttctttct-3′	21	1861	497

[0906]

TABLE JC
General_screening_panel_v1.5
                                 Rel. Exp. (%)
                                 Ag4906, Run
Tissue Name                      228783186
Adipose                          0.1
Melanoma* Hs688 (A).T            0.1
Melanoma* Hs688 (B).T            0.0
Melanoma* M14                    0.0
Melanoma* LOXIMVI                0.0
Melanoma* SK-MEL-5               0.0
Squamous cell carcinoma SCC-4    0.0
Testis Pool                      0.5
Prostate ca.* (bone met) PC-3    0.0
Prostate Pool                    0.0
Placenta                         0.0
Uterus Pool                      0.1
Ovarian ca. OVCAR-3              0.1
Ovarian ca. SK-OV-3              0.0
Ovarian ca. OVCAR-4              0.0
Ovarian ca. OVCAR-5              0.3
Ovarian ca. IGROV-1              0.0
Ovarian ca. OVCAR-8              0.0
Ovary                            0.1
Breast ca. MCF-7                 0.1
Breast ca. MDA-MB-231            0.0
Breast ca. BT 549                0.0
Breast ca. T47D                  0.1
Breast ca. MDA-N                 0.0
Breast Pool                      0.0
Trachea                          0.1
Lung                             0.0
Fetal Lung                       0.1
Lung ca. NCI-N417                0.0
Lung ca. LX-1                    0.1
Lung ca. NCI-H146                0.0
Lung ca. SHP-77                  0.1
Lung ca. A549                    0.5
Lung ca. NCI-H526                0.0
Lung ca. NCI-H23                 0.1
Lung ca. NCI-H460                0.9
Lung ca. HOP-62                  0.0
Lung ca. NCI-H522                0.1
Liver                            100.0
Fetal Liver                      8.2
Liver ca. HepG2                  7.6
Kidney Pool                      0.0
Fetal Kidney                     0.1
Renal ca. 786-0                  0.0
Renal ca. A498                   0.0
Renal ca. ACHN                   0.0
Renal ca. UO-31                  0.0
Renal ca. TK-10                  3.4
Bladder                          0.3
Gastric ca. (liver met.) NCI-N87 0.1
Gastric ca. KATO III             0.0
Colon ca. SW-948                 0.0
Colon ca. SW480                  0.1
Colon ca.* (SW480 met) SW620     0.0
Colon ca. HT29                   0.0
Colon ca. HCT-116                0.1
Colon ca. CaCo-2                 0.1
Colon cancer tissue              0.0
Colon ca. SW1116                 0.0
Colon ca. Colo-205               0.0
Colon ca. SW-48                  0.0
Colon Pool                       0.1
Small Intestine Pool             0.0
Stomach Pool                     0.2
Bone Marrow Pool                 0.0
Fetal Heart                      0.0
Heart Pool                       0.0
Lymph Node Pool                  0.1
Fetal Skeletal Muscle            0.0
Skeletal Muscle Pool             0.0
Spleen Pool                      0.0
Thymus Pool                      0.1
CNS cancer (glio/astro) U87-MG   0.0
CNS cancer (glio/astro) U-118-MG 0.0
CNS cancer (neuro; met) SK-N-AS  0.0
CNS cancer (astro) SF-539        0.0
CNS cancer (astro)SNB-75         0.0
CNS cancer (glio) SNB-19         0.0
CNS cancer (glio) SF-295         0.0
Brain (Amygdala) Pool            0.0
Brain (cerebellum)               0.0
Brain (fetal)                    0.0
Brain (Hippocampus) Pool         0.1
Cerebral Cortex Pool             0.0
Brain (Substantia nigra) Pool    0.0
Brain (Thalamus) Pool            0.0
Brain (whole)                    1.0
Spinal Cord Pool                 0.0
Adrenal Gland                    0.3
Pituitary gland Pool             0.0
Salivary Gland                   0.0
Thyroid (female)                 0.0
Pancreatic ca. CAPAN2            0.0
Pancreas Pool                    0.1

[0907]

TABLE JD
Panel 5 Islet
                                 Rel. Exp. (%)
                                 Ag4906, Run
Tissue Name                      223846056
97457_Patient-02go_adipose       0.0
97476_Patient-07sk_skeletal muscle 0.0
97477_Patient-07ut_uterus        0.0
97478_Patient-07pl_placenta      0.0
99167_Bayer Patient 1            0.0
97482_Patient-08ut_uterus        0.0
97483_Patient-08pl_placenta      0.0
97486_Patient-09sk_skeletal muscle 0.0
97487_Patient-09ut_uterus        0.0
97488_Patient-09pl_placenta      0.0
97492_Patient-10ut_uterus        0.6
97493_Patient-10pl_placenta      0.0
97495_Patient-11go_adipose       0.0
97496_Patient-11sk_skeletal muscle 0.0
97497_Patient-11ut_uterus        0.0
97498_Patient-11pl_placenta      0.0
97500_Patient-12go_adipose       0.0
97501_Patient-12sk_skeletal muscle 0.0
97502_Patient-12ut_uterus        0.6
97503_Patient-12pl_placenta      0.0
94721_Donor 2 U - A_Mesenchymal Stem Cells 0.0
94722_Donor 2 U - B_Mesenchymal Stem Cells 0.0
94723_Donor 2 U - C_Mesenchymal Stem Cells 0.0
94709_Donor 2 AM - A_adipose     0.2
94710_Donor 2 AM - B_adipose     0.0
94711_Donor 2 AM - C_adipose     0.0
94712_Donor 2 AD - A_adipose     0.4
94713_Donor 2 AD - B_adipose     0.6
94714_Donor 2 AD - C_adipose     0.0
94742_Donor 3 U - A_Mesenchymal Stem Cells 0.0
94743_Donor 3 U - B_Mesenchymal Stem Cells 0.0
94730_Donor 3 AM - A_adipose     0.6
94731_Donor 3 AM - B_adipose     0.0
94732_Donor 3 AM - C_adipose     0.0
94733_Donor 3 AD - A_adipose     0.0
94734_Donor 3 AD - B_adipose     0.0
94735_Donor 3 AD - C_adipose     0.0
77138_Liver_HepG2untreated       100.0
73556_Heart_Cardiac stromal cells (primary) 0.0
81735_Small Intestine            1.0
72409_Kidney_Proximal Convoluted Tubule 0.0
82685_Small intestine_Duodenum   0.7
90650_Adrenal_Adrenocortical adenoma 3.1
72410_Kidney_HRCE                0.0
72411_Kidney_HRE                 0.0
73139_Uterus_Uterine smooth muscle cells 0.0

[0908] General_screening_panel_v1.5 Summary: Ag4906 This gene seems to be almost exclusively expressed in liver (CT=24.6). A lower level of expression has been detected in fetal liver (CT=28) and brain. Thus, expression of this gene could be used to differentiate between liver and fetal liver tissues. In addition, the relative overexpression of this gene in fetal liver suggests that the protein product may enhance liver growth or development in the fetus and thus may also act in a regenerative capacity in the adult. Therefore, therapeutic modulation of the protein encoded by this gene could be useful in treatment of liver and metabolic related diseases, including obesity and diabetes.

[0909] Panel 5 Islet Summary: Ag4906 This gene is expressed in hepatocyte-derived HepG2 cell line (CT=29.8), which is in accordance with the liver expression seen in panel 1.5.

[0910] K. CG140122-01: Polyamine Oxidase.

[0911] Expression of gene CG140122-01 was assessed using the primer-probe sets Ag4986 and Ag5105, described in Tables KA and KB. Results of the RTQ-PCR runs are shown in Tables KC and KD.

TABLE KA
Probe Name Ag4986
			Start	SEQ ID
Primers	Sequences	Length	Position	No
Forward	5′-gtgcagagtgtgaaacttgga-3′	21	259	498
Probe	TET-5′-catggctcccatgggaaccctat-3′-TAMRA	23	313	499
Reverse	5′-cgttggcttctgctagatgata-3′	22	337	500

[0912]

TABLE KB
Probe Name Ag5105
			Start	SEQ ID
Primers	Sequences	Length	Position	No
Forward	5′-gaccgtgtcgctaggt-3′	16	1059	501
Probe	TET-5′-cagtacaccagtttcttccggcca-3′-TAMRA	24	1087	502
Reverse	5′-accttctctgttgggcag-3′	17	1114	503

[0913]

TABLE KC
CNS_neurodegeneration_v1.0
                               Rel. Exp. (%)
                               Ag5105, Run
Tissue Name                    249286379
AD 1 Hippo                     27.5
AD 2 Hippo                     50.7
AD 3 Hippo                     18.9
AD 4 Hippo                     17.1
AD 5 hippo                     63.7
AD 6 Hippo                     100.0
Control 2 Hippo                35.4
Control 4 Hippo                24.3
Control (Path) 3 Hippo         10.6
AD 1 Temporal Ctx              36.3
AD 2 Temporal Ctx              21.2
AD 3 Temporal Ctx              20.2
AD 4 Temporal Ctx              20.9
AD 5 Inf Temporal Ctx          50.0
AD 5 Sup Temporal Ctx          64.6
AD 6 Inf Temporal Ctx          58.6
AD 6 Sup Temporal Ctx          39.5
Control 1 Temporal Ctx         14.9
Control 2 Temporal Ctx         32.3
Control 3 Temporal Ctx         19.3
Control 4 Temporal Ctx         21.8
Control (Path) 1 Temporal Ctx  21.0
Control (Path) 2 Temporal Ctx  19.8
Control (Path) 3 Temporal Ctx  12.2
Control (Path) 4 Temporal Ctx  20.6
AD 1 Occipital Ctx             23.7
AD 2 Occipital Ctx (Missing)   0.0
AD 3 Occipital Ctx             18.8
AD 4 Occipital Ctx             18.8
AD 5 Occipital Ctx             13.8
AD 6 Occipital Ctx             28.3
Control 1 Occipital Ctx        12.0
Control 2 Occipital Ctx        39.0
Control 3 Occipital Ctx        23.0
Control 4 Occipital Ctx        18.6
Control (Path) 1 Occipital Ctx 39.2
Control (Path) 2 Occipital Ctx 8.6
Control (Path) 3 Occipital Ctx 10.3
Control (Path) 4 Occipital Ctx 9.8
Control 1 Parietal Ctx         17.2
Control 2 Parietal Ctx         69.3
Control 3 Parietal Ctx         17.9
Control (Path) 1 Parietal Ctx  42.0
Control (Path) 2 Parietal Ctx  20.0
Control (Path) 3 Parietal Ctx  11.0
Control (Path) 4 Parietal Ctx  11.2

[0914]

TABLE KD
General_screening_panel_v1.5
		Rel. Exp. (%)	Rel. Exp. (%)
		Ag5105, Run	Ag5105, Run
	Tissue Name	228969349	229514472
	Adipose	1.9	1.4
	Melanoma*	2.8	2.6
	Hs688(A).T
	Melanoma*	2.7	2.4
	Hs688(B).T
	Melanoma*	2.2	2.1
	M14
	Melanoma*	9.9	10.7
	LOXIMVI
	Melanoma*	5.9	5.8
	SK-MEL-5
	Squamous	4.0	2.8
	cell
	carcinoma
	SCC-4
	Testis Pool	2.0	1.8
	Prostate ca.*	33.9	42.9
	(bone met)
	PC-3
	Prostate Pool	1.8	1.8
	Placenta	0.5	0.5
	Uterus Pool	1.3	1.6
	Ovarian ca.	1.8	2.1
	OVCAR-3
	Ovarian ca.	7.2	9.9
	SK-OV-3
	Ovarian ca.	1.2	2.2
	OVCAR-4
	Ovarian ca.	17.0	21.3
	OVCAR-5
	Ovarian ca.	13.2	16.7
	IGROV-1
	Ovarian ca.	7.1	5.9
	OVCAR-8
	Ovary	1.0	1.4
	Breast ca.	1.5	1.6
	MCF-7
	Breast ca.	5.1	5.4
	MDA-MB-
	231
	Breast ca. BT	14.5	13.3
	549
	Breast ca.	0.1	0.0
	T47D
	Breast ca.	2.1	2.7
	MDA-N
	Breast Pool	2.6	2.1
	Trachea	2.6	2.3
	Lung	0.5	0.5
	Fetal Lung	2.2	2.9
	Lung ca.	0.1	0.1
	NCI-N417
	Lung ca. LX-1	18.2	20.0
	Lung ca.	0.0	0.0
	NCI-H146
	Lung ca.	0.7	0.6
	SHP-77
	Lung ca.	33.4	36.9
	A549
	Lung ca.	2.7	3.0
	NCI-H526
	Lung ca.	3.1	3.2
	NCI-H23
	Lung ca.	100.0	100.0
	NCI-H460
	Lung ca.	6.0	6.0
	HOP-62
	Lung ca.	3.8	4.9
	NCI-H522
	Liver	0.2	0.2
	Fetal Liver	3.3	3.7
	Liver ca.	7.2	7.0
	HepG2
	Kidney Pool	2.5	2.8
	Fetal Kidney	2.0	2.0
	Renal ca.	13.4	13.7
	786-0
	Renal ca.	2.3	2.2
	A498
	Renal ca.	4.0	5.1
	ACHN
	Renal ca.	5.7	6.2
	UO-31
	Renal ca. TK-10	26.8	29.7
	Bladder	2.9	3.6
	Gastric ca. (liver	13.0	12.8
	met.) NCI-N87
	Gastric ca.	14.4	17.2
	KATO III
	Colon ca. SW-	4.2	3.7
	948
	Colon ca.	11.3	10.3
	SW480
	Colon ca.*	22.7	24.1
	(SW480 met)
	SW620
	Colon ca. HT29	5.6	5.8
	Colon ca. HCT-	9.5	11.9
	116
	Colon ca. CaCo-2	15.5	18.3
	Colon cancer	8.8	11.8
	tissue
	Colon ca.	1.9	1.0
	SW1116
	Colon ca. Colo-	7.2	8.5
	205
	Colon ca. SW-48	6.3	5.5
	Colon Pool	1.7	1.7
	Small Intestine	2.5	2.7
	Pool
	Stomach Pool	2.0	2.2
	Bone Marrow	1.6	1.6
	Pool
	Fetal Heart	0.9	0.7
	Heart Pool	0.3	0.8
	Lymph Node	3.2	2.6
	Pool
	Fetal Skeletal	0.6	0.4
	Muscle
	Skeletal Muscle	0.6	1.1
	Pool
	Spleen Pool	0.9	1.1
	Thymus Pool	2.0	2.3
	CNS cancer	8.2	9.7
	(glio/astro) U87-
	MG
	CNS cancer	12.2	13.6
	(glio/astro) U-
	118-MG
	CNS cancer	1.7	1.7
	(neuro; met) SK-
	N-AS
	CNS cancer	1.5	1.8
	(astro) SF-539
	CNS cancer	8.3	18.4
	(astro) SNB-75
	CNS cancer	17.8	19.6
	(glio) SNB-19
	CNS cancer	15.0	15.9
	(glio) SF-295
	Brain	5.1	5.4
	(Amygdala) Pool
	Brain	7.5	10.2
	(cerebellum)
	Brain (fetal)	4.2	5.6
	Brain	8.3	6.8
	(Hippocampus)
	Pool
	Cerebral Cortex	6.5	5.3
	Pool
	Brain (Substantia	8.5	7.0
	nigra) Pool
	Brain	7.4	8.4
	(Thalamus) Pool
	Brain (whole)	6.3	6.3
	Spinal Cord Pool	11.4	12.6
	Adrenal Gland	0.9	1.0
	Pituitary gland	0.3	0.2
	Pool
	Salivary Gland	1.6	1.7
	Thyroid (female)	0.7	1.1
	Pancreatic ca.	13.0	14.7
	CAPAN2
	Pancreas Pool	2.9	3.8

[0915] CNS_neurodegeneration_v1.0 Summary: Ag5105 This panel confirms the expression of this gene at low levels in the brain in an independent group of individuals. This gene is found to be upregulated in the temporal cortex of Alzheimer's disease patients. Therefore, therapeutic modulation of the expression or function of this gene may decrease neuronal death and be of use in the treatment of this disease.

[0916] General_screening_panel_v1.4 Summary: Ag4986 Expression of this gene is low/undetectable in all samples on this panel (CTs>35). (Data not shown.)

[0917] General_screening_panel_v1.5 Summary: Ag5105 Two experiments with the same probe and primer set produce results that are in excellent agreement. Highest expression of this gene is seen in a breast cancer cell line (CTs=24-26). This gene is widely expressed in this panel, with high to moderate expression seen in brain, colon, gastric, lung, breast, ovarian, and melanoma cancer cell lines. This expression profile suggests a role for this gene product in cell survival and proliferation. Modulation of this gene product may be useful in the treatment of cancer.

[0918] Among tissues with metabolic function, this gene is expressed at moderate levels in pituitary, adipose, adrenal gland, pancreas, thyroid, and adult and fetal skeletal muscle, heart, and liver. This widespread expression among these tissues suggests that this gene product may play a role in normal neuroendocrine and metabolic function and that disregulated expression of this gene may contribute to neuroendocrine disorders or metabolic diseases, such as obesity and diabetes.

[0919] This gene is also expressed at moderate levels in the CNS, including the hippocampus, thalamus, substantia nigra, amygdala, cerebellum and cerebral cortex. Therefore, therapeutic modulation of the expression or function of this gene may be useful in the treatment of neurologic disorders, such as Alzheimer's disease, Parkinson's disease, schizophrenia, multiple sclerosis, stroke and epilepsy.

[0920] Panel 5 Islet Summary: Ag4986 Expression of this gene is low/undetectable in all samples on this panel (CTs>35). (Data not shown.)

[0921] Panel 5D Summary: Ag5105 Results from one experiment with this gene are not included. The amp plot indicates that there were experimental difficulties with this run.

[0922] L. CG140316-01: Malic Enzyme Isoform1 (MB_X77244).

[0923] Expression of gene CG140316-01 was assessed using the primer-probe set Ag4998, described in Table LA. Results of the RTQ-PCR runs are shown in Tables LB and LC.

TABLE LA
Probe Name Ag4998
			Start	SEQ ID
Primers	Sequences	Length	Position	No
Forward	5′-agtttgcccatgaacatgaa-3′	20	1058	504
Probe	TET-5′-gccattgttcaagaaataaaaccaactgc-3′-TAMRA	29	1096	505
Reverse	5′-ttgcagcaactcctatgagg-3′	20	1125	506

[0924]

TABLE LB
General_screening_panel_v1.4
                                 Rel. Exp. (%)
                                 Ag4998, Run
Tissue Name                      219998185
Adipose                          12.8
Melanoma* Hs688(A).T             15.8
Melanoma* Hs688(B).T             28.7
Melanoma* M14                    8.7
Melanoma* LOXIMVI                9.9
Melanoma* SK-MEL-5               22.2
Squamous cell carcinoma SCC-4    20.7
Testis Pool                      7.2
Prostate ca.* (bone met) PC-3    100.0
Prostate Pool                    2.8
Placenta                         0.2
Uterus Pool                      0.9
Ovarian ca. OVCAR-3              7.4
Ovarian ca. SK-OV-3              37.6
Ovarian ca. OVCAR-4              10.7
Ovarian ca. OVCAR-5              6.9
Ovarian ca. IGROV-1              4.0
Ovarian ca. OVCAR-8              6.0
Ovary                            6.4
Breast ca. MCF-7                 12.6
Breast ca. MDA-MB-231            16.2
Breast ca. BT 549                19.8
Breast ca. T47D                  11.7
Breast ca. MDA-N                 0.0
Breast Pool                      3.1
Trachea                          5.6
Lung                             1.3
Fetal Lung                       5.4
Lung ca. NCI-N417                0.8
Lung ca. LX-1                    8.3
Lung ca. NCI-H146                1.8
Lung ca. SHP-77                  30.8
Lung ca. A549                    67.4
Lung ca. NCI-H526                1.7
Lung ca. NCI-H23                 6.2
Lung ca. NCI-H460                55.9
Lung ca. HOP-62                  15.2
Lung ca. NCI-H522                0.0
Liver                            0.4
Fetal Liver                      3.4
Liver ca. HepG2                  0.0
Kidney Pool                      3.1
Fetal Kidney                     0.8
Renal ca. 786-0                  14.7
Renal ca. A498                   14.2
Renal ca. ACHN                   20.3
Renal ca. UO-31                  16.5
Renal ca. TK- 10                 7.6
Bladder                          3.9
Gastric ca. (liver met.)NCI-N87  11.7
Gastric ca. KATO III             36.3
Colon ca. SW-948                 12.5
Colon ca. SW480                  26.1
Colon ca.* (SW480 met) SW620     12.2
Colon ca. HT29                   21.3
Colon ca. HCT-116                59.0
Colon ca. CaCo-2                 56.3
Colon cancer tissue              7.9
Colon ca. SW1116                 4.9
Colon ca. Colo-205               8.1
Colon ca. SW-48                  4.5
Colon Pool                       4.2
Small Intestine Pool             1.0
Stomach Pool                     1.9
Bone Marrow Pool                 2.3
Fetal Heart                      2.3
Heart Pool                       2.0
Lymph Node Pool                  3.0
Fetal Skeletal Muscle            0.0
Skeletal Muscle Pool             8.8
Spleen Pool                      3.0
Thymus Pool                      1.5
CNS cancer (glio/astro) U87-MG   0.0
CNS cancer (glio/astro) U-118-MG 10.7
CNS cancer (neuro; met) SK-N-AS  15.9
CNS cancer (astro) SF-539        18.3
CNS cancer (astro) SNB-75        0.1
CNS cancer (glio) SNB-19         5.6
CNS cancer (glio) SF-295         0.0
Brain (Amygdala) Pool            6.8
Brain (cerebellum)               4.6
Brain (fetal)                    2.8
Brain (Hippocampus) Pool         6.3
Cerebral Cortex Pool             9.3
Brain (Substantia nigra) Pool    5.7
Brain (Thalamus) Pool            11.9
Brain (whole)                    7.9
Spinal Cord Pool                 7.4
Adrenal Gland                    26.4
Pituitary gland Pool             3.6
Salivary Gland                   0.6
Thyroid (female)                 1.0
Pancreatic ca. CAPAN2            9.3
Pancreas Pool                    2.7

[0925]

TABLE LC
Panel 5D
                                 Rel. Exp. (%)
                                 Ag4998, Run
Tissue Name                      220259861
97457_Patient-02go_adipose       8.5
97476_Patient-07sk_skeletal muscle 5.2
97477_Patient-07ut_uterus        14.0
97478_Patient-07pl_placenta      2.4
97481_Patient-08sk_skeletal muscle 7.1
97482_Patient-08ut_uterus        9.7
97483_Patient-08pl_placenta      1.4
97486_Patient-09sk_skeletal muscle 6.9
97487_Patient-09ut_uterus        16.0
97488_Patient-09pl_placenta      1.2
97492_Patient-10ut_uterus        9.0
97493_Patient-10pl_placenta      3.5
97495_Patient-11go_adipose       5.9
97496_Patient-11sk_skeletal muscle 16.2
97497_Patient-11ut_uterus        23.0
97498_Patient-11pl_placenta      0.0
97500_Patient-12go_adipose       28.9
97501_Patient-12sk_skeletal muscle 33.9
97502_Patient-12ut_uterus        15.4
97503_Patient-12pl_placenta      0.3
94721_Donor 2 U - A_Mesenchymal Stem Cells 10.2
94722_Donor 2 U - B_Mesenchymal Stem Cells 36.1
94723_Donor 2 U - C_Mesenchymal Stem Cells 9.0
94709_Donor 2 AM - A_adipose     26.4
94710_Donor 2 AM - B_adipose     11.7
94711_Donor 2 AM - C_adipose     9.0
94712_Donor 2 AD - A_adipose     77.4
94713_Donor 2 AD - B_adipose     94.6
94714_Donor 2 AD - C_adipose     100.0
94742_Donor 3 U - A_Mesenchymal Stem Cells 6.7
94743_Donor 3 U - B_Mesenchymal Stem Cells 12.4
94730_Donor 3 AM - A_adipose     20.2
94731_Donor 3 AM - B_adipose     16.6
94732_Donor 3 AM - C_adipose     16.5
94733_Donor 3 AD - A_adipose     92.7
94734_Donor 3 AD - B_adipose     55.1
94735_Donor 3 AD - C_adipose     57.8
77138_Liver_HepG2untreated       8.7
73556_Heart_Cardiac stromal cells (primary) 9.0
81735_Small Intestine            5.0
72409_Kidney_Proximal Convoluted Tubule 12.3
82685_Small intestine_Duodenum   18.8
90650_Adrenal_Adrenocortical adenoma 9.5
72410_Kidney_HRCE                33.9
72411_Kidney_HRE                 25.3
73139_Uterus_Uterine smooth muscle cells 19.2

[0926] General_screening_panel_v1.4 Summary: Ag4998 Cytosolic malic enzyme is ubiquitously expressed including endocrine/metabolically-relevant tissues such as, adipose, GI, liver, and skeletal muscle. These results indicate that this enzyme is critical for normal physiology. Furthermore, disregulated expression of this gene may contribute to neuroendocrine disorders or metabolic diseases, such as obesity and diabetes.

[0927] Highest expression of this gene is seen in a prostate cancer cell line (CT=25.4). This gene is widely expressed in this panel, with high to moderate expression seen in brain, colon, gastric, lung, breast, ovarian, and melanoma cancer cell lines. This expression profile suggests a role for this gene product in cell survival and proliferation. Modulation of this gene product may be useful in the treatment of cancer.

[0928] This gene is also expressed at moderate levels in the CNS, including the hippocampus, thalamus, substantia nigra, amygdala, cerebellum and cerebral cortex. Therefore, therapeutic modulation of the expression or function of this gene may be useful in the treatment of neurologic disorders, such as Alzheimer's disease, Parkinson's disease, schizophrenia, multiple sclerosis, stroke and epilepsy.

[0929] Panel 5D Summary: Ag4998 Cytosolic malic enzyme has low to moderate expression in fully differentiated adipose, and adipose found in diabetic gestational diabetics.

[0930] M. CG142427-01: ATP Citrate Lyase.

[0931] Expression of gene CG142427-01 and CG142404-01 were assessed using the primer-probe set Ag6008, described in Table MA. Results of the RTQ-PCR runs are shown in Tables MB and MC.

TABLE MA
Probe Name Ag6008
			Start	SEQ ID
Primers	Sequences	Length	Position	No
Forward	5′-agattacgtcaggcagcactt-3′	21	3113	507
Probe	TET-5′-cactcctctgctcgattatgcactgg-3′-TAMRA	26	3140	508
Reverse	5′-gcttcttcgaggtggtaatctt-3′	22	3174	509

[0932]

TABLE MB
General_screening_panel_v1 .5
                                 Rel. Exp. (%)
                                 Ae6008. Run
Tissue Name                      228763479
Adipose                          6.2
Melanoma* Hs688(A).T             37.6
Melanoma* Hs688(B).T             59.0
Melanoma* M14                    55.9
Melanoma* LOXIMVI                59.0
Melanoma* SK-MEL-5               41.8
Squamous cell carcinoma SCC-4    24.1
Testis Pool                      6.0
Prostate ca.* (bone met) PC-3    32.8
Prostate Pool                    13.0
Placenta                         6.1
Uterus Pool                      6.6
Ovarian ca. OVCAR-3              12.9
Ovarian ca. SK-OV-3              47.3
Ovarian ca. OVCAR-4              17.2
Ovarian ca. OVCAR-5              35.1
Ovarian ca. IGROV-1              22.2
Ovarian ca. OVCAR-8              8.2
Ovary                            8.0
Breast ca. MCF-7                 23.7
Breast ca. MDA-MB-231            46.7
Breast ca. BT 549                60.7
Breast ca. T47D                  29.1
Breast ca. MDA-N                 12.9
Breast Pool                      8.0
Trachea                          9.3
Lung                             1.4
Fetal Lung                       16.3
Lung ca. NCI-N417                30.1
Lung ca. LX-1                    28.1
Lung ca. NCI-H146                23.5
Lung ca. SHP-77                  46.7
Lung ca. A549                    100.0
Lung ca. NCI-H526                10.0
Lung ca. NCI-H23                 23.5
Lung ca. NCI-H460                25.5
Lung ca. HOP-62                  29.5
Lung ca. NCI-H522                57.4
Liver                            0.8
Fetal Liver                      22.4
Liver ca. HepG2                  23.0
Kidney Pool                      7.5
Fetal Kidney                     5.4
Renal ca. 786-0                  36.3
Renal ca. A498                   33.0
Renal ca. ACHN                   80.7
Renal ca. UO-31                  31.9
Renal ca. TK-10                  64.2
Bladder                          12.4
Gastric ca. (liver met.) NCI-N87 65.1
Gastric ca. KATO III             59.5
Colon ca. SW-948                 14.5
Colon ca. SW480                  62.4
Colon ca.* (SW480 met) SW620     32.3
Colon ca. HT29                   27.4
Colon ca. HCT-116                45.7
Colon ca. CaCo-2                 66.0
Colon cancer tissue              8.3
Colon ca. SW1116                 4.0
Colon ca. Colo-205               11.1
Colon ca. SW-48                  14.9
Colon Pool                       13.3
Small Intestine Pool             5.6
Stomach Pool                     4.0
Bone Marrow Pool                 3.8
Fetal Heart                      3.5
Heart Pool                       2.5
Lymph Node Pool                  8.4
Fetal Skeletal Muscle            3.7
Skeletal Muscle Pool             3.4
Spleen Pool                      5.3
Thymus Pool                      6.8
CNS cancer (glio/astro) U87-MG   60.7
CNS cancer (glio/astro) U-118-MG 59.0
CNS cancer (neuro; met) SK-N-AS  60.7
CNS cancer (astro) SF-539        24.8
CNS cancer (astro) SNB-75        32.5
CNS cancer (glio) SNB-19         25.2
CNS cancer (glio) SF-295         76.8
Brain (Amygdala) Pool            4.8
Brain (cerebellum)               28.3
Brain (fetal)                    16.5
Brain (Hippocampus) Pool         8.6
Cerebral Cortex Pool             10.5
Brain (Substantia nigra) Pool    6.3
Brain (Thalamus) Pool            10.7
Brain (whole)                    12.2
Spinal Cord Pool                 7.4
Adrenal Gland                    13.2
Pituitary gland Pool             1.9
Salivary Gland                   4.0
Thyroid (female)                 2.7
Pancreatic ca. CAPAN2            36.3
Pancreas Pool                    11.2

[0933]

TABLE MC
Panel 5 Islet
                                 Rel. Exp. (%)
                                 Ag6008, Run
Tissue Name                      245239907
97457_Patient-02go_adipose       12.6
97476_Patient-07sk_skeletal muscle 9.5
97477_Patient-07ut_uterus        8.4
97478_Patient-07pl_placenta      16.4
99167_Bayer Patient 1            70.7
97482_Patient-08ut_uterus        7.9
97483_Patient-08pl_placenta      15.6
97486_Patient-09sk_skeletal muscle 0.6
97487_Patient-09ut_uterus        3.6
97488_Patient-09pl_placenta      9.6
97492_Patient-10ut_uterus        9.9
97493_Patient-10pl_placenta      18.3
97495_Patient-11go_adipose       5.5
97496_Patient-11sk_skeletal muscle 0.4
97497_Patient-11ut_uterus        3.5
97498_Patient-11pl_placenta      11.0
97500_Patient-12go_adipose       7.4
97501_Patient-12sk_skeletal muscle 6.9
97502_Patient-12ut_uterus        9.3
97503_Patient-12pl_placenta      6.1
94721_Donor 2 U - A_Mesenchymal Stem Cells 6.7
94722_Donor 2 U - B_Mesenchymal Stem Cells 13.6
94723_Donor 2 U - C_Mesenchymal Stem Cells 8.9
94709_Donor 2 AM - A_adipose     26.8
94710_Donor 2 AM - B_adipose     26.4
94711_Donor 2 AM - C_adipose     8.4
94712_Donor 2 AD - A_adipose     37.6
94713_Donor 2 AD - B_adipose     31.0
94714_Donor 2 AD - C_adipose     59.0
94742_Donor 3 U - A_Mesenchymal Stem Cells 11.0
94743_Donor 3 U - B_Mesenchymal Stem Cells 34.2
94730_Donor 3 AM - A_adipose     60.3
94731_Donor 3 AM - B_adipose     27.4
94732_Donor 3 AM - C_adipose     42.3
94733_Donor 3 AD - A_adipose     100.0
94734_Donor 3 AD - B_adipose     44.1
94735_Donor 3 AD - C_adipose     84.1
77138_Liver_HepG2untreated       0.0
73556_Heart_Cardiac stromal cells (primary) 14.8
81735_Small Intestine            9.5
72409_Kidney_Proximal Convoluted Tubule 24.5
82685_Small intestine_Duodenum   7.1
90650_Adrenal_Adrenocortical adenoma 2.4
72410_Kidney_HRCE                65.5
72411_Kidney_HRE                 46.0
73139_Uterus_Uterine smooth muscle cells 30.4

[0934] General_screening_panel_v1.5 Summary: Ag6008 Highest expression of this gene is detected in a lung cancer A549 cell line (CT=22.4). High expression of this gene is also seen in cluster of cancer cell lines derived from pancreatic, gastric, colon, lung, liver, renal, breast, ovarian, prostate, squamous cell carcinoma, melanoma and brain cancers. Thus, expression of this gene could be used as a marker to detect the presence of these cancers.

[0935] Furthermore, therapeutic modulation of the expression or function of this gene may be effective in the treatment of pancreatic, gastric, colon, lung, liver, renal, breast, ovarian, prostate, squamous cell carcinoma, melanoma and brain cancers.

[0936] Among tissues with metabolic or endocrine function, this gene is expressed at high levels in pancreas, adipose, adrenal gland, thyroid, pituitary gland, skeletal muscle, heart, liver and the gastrointestinal tract. Therefore, therapeutic modulation of the activity of this gene through the use of small molecule drug may prove useful in the treatment of endocrine/metabolically related diseases, such as obesity and diabetes.

[0937] Interestingly, this gene is expressed at much higher levels in fetal (CTs=24-25), when compared to adult liver and lung (CTs=28-29). This observation suggests that expression of this gene can be used to distinguish fetal from adult lung and liver. In addition, the relative overexpression of this gene in fetal tissue suggests that the protein product may enhance lung and liver growth or development in the fetus and thus may also act in a regenerative capacity in the adult. Therefore, therapeutic modulation of the protein encoded by this gene could be useful in treatment of lung and liver related diseases.

[0938] In addition, this gene is expressed at high levels in all regions of the central nervous system examined, including amygdala, hippocampus, substantia nigra, thalamus, cerebellum, cerebral cortex, and spinal cord. Therefore, therapeutic modulation of this gene product may be useful in the treatment of central nervous system disorders such as Alzheimer's disease, Parkinson's disease, epilepsy, multiple sclerosis, schizophrenia and depression.

[0939] Panel 5 Islet Summary: Ag6008 Highest expression of this gene is detected in differentiated adipose (CT=27.7). This gene shows widespread expression in this panel. Moderate to high expression of this gene is detected in the tissues with metabolic/endocrine functions including islet cells, adipose, skeletal muscle, and gastrointestinal tracts.

[0940] This gene codes for ATP-citrate lyase. It is a major source of acetyl CoA that is the building block of lipid biosynthesis and provides substrate for the production of cholesterol. Reduced flux of acetyl CoA through the cholesterol biosynthetic pathway will prevent excess production of LXR alpha ligands. LXR alpha is a nuclear hormone receptor that is abundantly expressed in tissues associated with lipid metabolism. Activation of LXR alpha leads to the up-regulation of fatty acid synthesis. Thus, ATP-citrate lyase may be a target for the treatment and/or prevention of obesity because its inhibition will decrease the availability of acetyl CoA for the synthesis of LXR alpha ligands, fatty acids, and triglycerides.

[0941] References:

[0942] 1. Chawla A, Repa J J, Evans R M, Mangelsdorf D J. Nuclear receptors and lipid physiology: opening the X-files. Science. Nov. 30, 2001;294(5548):1866-70. Review. PMID: 11729302.

[0943] 2. Moon Y A, Lee J J, Park S W, Ahn Y H, Kim K S. The roles of sterol regulatory element-binding proteins in the transactivation of the rat ATP citrate-lyase promoter. J Biol Chem. Sep. 29, 2000;275(39):30280-6. PMID: 10801800.

[0944] 3. Sato R. Okamoto A, Inoue J. Miyamoto W. Sakai Y. Emoto N. Shimano H. Maeda M. Transcriptional regulation of the ATP citrate-lyase gene by sterol regulatory element-binding proteins. J Biol Chem. Apr. 28, 2000;275(17):12497-502. PMID: 10777536.

[0945] N. CG142631-01: Serine Dehydratase.

[0946] Expression of gene CG14263 1-01 was assessed using the primer-probe set Ag6006, described in Table NA. Results of the RTQ-PCR runs are shown in Tables NB, NC, ND and NE.

TABLE NA
Probe Name Ag6006
			Start	SEQ ID
Primers	Sequences	Length	Position	No
Forward	5′-aagttcgtggatgatgagaaga-3′	22	858	510
Probe	TET-5′-ctggccgctgtctatagccacgt-3′-TAMRA	23	909	511
Reverse	5′-tccagttggagcttctggat-3′	20	933	512

[0947]

TABLE NB
General_screening_panel_v1.5
		Rel. Exp. (%)	Rel. Exp. (%)
		Ag6006, Run	Ag6006, Run
	Tissue Name	228738305	228763464
	Adipose	2.8	3.1
	Melanoma*	0.0	0.0
	Hs688(A).T
	Melanoma*	0.0	0.0
	Hs688(B).T
	Melanoma*	0.0	0.0
	M14
	Melanoma*	0.0	0.0
	LOXIMVI
	Melanoma*	0.0	0.0
	SK-MEL-5
	Squamous	0.0	0.0
	cell
	carcinoma
	SCC-4
	Testis Pool	0.1	0.1
	Prostate ca.*	0.0	0.0
	(bone met)
	PC-3
	Prostate Pool	0.2	0.1
	Placenta	0.5	0.2
	Uterus Pool	0.1	0.2
	Ovarian ca.	0.7	0.3
	OVCAR-3
	Ovarian ca.	0.0	0.0
	SK-OV-3
	Ovarian ca.	0.0	0.0
	OVCAR-4
	Ovarian ca.	0.1	0.3
	OVCAR-5
	Ovarian ca.	0.0	0.0
	IGROV-1
	Ovarian ca.	0.1	0.0
	OVCAR-8
	Ovary	0.6	0.6
	Breast ca.	0.0	0.0
	MCF-7
	Breast ca.	0.0	0.0
	MDA-MB-
	231
	Breast ca. BT	0.0	0.1
	549
	Breast ca.	0.0	0.0
	T47D
	Breast ca.	0.0	0.0
	MDA-N
	Breast Pool	0.3	0.0
	Trachea	1.2	1.5
	Lung	0.0	0.0
	Fetal Lung	0.9	1.8
	Lung ca.	0.0	0.0
	NCI-N417
	Lung ca. LX-1	0.0	0.0
	Lung ca.	0.0	0.0
	NCI-H146
	Lung ca.	0.1	0.0
	SHP-77
	Lung ca.	1.7	1.4
	A549
	Lung ca.	0.0	0.0
	NCI-H526
	Lung ca.	0.0	0.0
	NCI-H23
	Lung ca.	0.0	0.0
	NCI-H460
	Lung ca.	0.0	0.0
	HOP-62
	Lung ca.	0.0	0.1
	NCI-H522
	Liver	100.0	100.0
	Fetal Liver	0.9	0.8
	Liver ca.	0.0	0.0
	HepG2
	Kidney Pool	0.1	0.1
	Fetal Kidney	0.0	0.0
	Renal ca.	0.2	0.1
	786-0
	Renal ca.	0.0	0.1
	A498
	Renal ca.	0.0	0.0
	ACHN
	Renal ca.	0.0	0.0
	UO-31
	Renal ca. TK-10	12.9	12.4
	Bladder	5.4	7.6
	Gastric ca. (liver	1.1	0.9
	met.) NCI-N87
	Gastric ca.	0.0	0.0
	KATO III
	Colon ca. SW-	0.0	0.0
	948
	Colon ca.	0.0	0.0
	SW480
	Colon ca.*	0.0	0.0
	(SW480 met)
	SW620
	Colon ca. HT29	0.0	0.0
	Colon ca. HCT-	0.0	0.0
	116
	Colon ca. CaCo-2	0.1	0.0
	Colon cancer	22.5	27.4
	tissue
	Colon ca.	0.0	0.0
	SW1116
	Colon ca. Colo-	0.0	0.0
	205
	Colon ca. SW-48	0.0	0.0
	Colon Pool	0.1	0.3
	Small Intestine	0.0	0.1
	Pool
	Stomach Pool	1.5	1.2
	Bone Marrow	0.1	0.1
	Pool
	Fetal Heart	0.0	0.0
	Heart Pool	0.0	0.3
	Lymph Node	0.0	0.0
	Pool
	Fetal Skeletal	0.0	0.0
	Muscle
	Skeletal Muscle	0.0	0.0
	Pool
	Spleen Pool	1.2	0.6
	Thymus Pool	0.2	0.0
	CNS cancer	0.0	0.0
	(glio/astro) U87-
	MG
	CNS cancer	0.1	0.0
	(glio/astro) U-
	118-MG
	CNS cancer	0.0	0.0
	(neuro; met) SK-
	N-AS
	CNS cancer	0.2	0.0
	(astro) SF-539
	CNS cancer	0.1	0.0
	(astro) SNB-75
	CNS cancer	0.0	0.0
	(glio) SNB-19
	CNS cancer	0.0	0.2
	(glio) SF-295
	Brain	3.8	2.9
	(Amygdala) Pool
	Brain	7.9	10.2
	(cerebellum)
	Brain (fetal)	0.5	0.6
	Brain	3.7	5.9
	(Hippocampus)
	Pool
	Cerebral Cortex	2.2	2.4
	Pool
	Brain (Substantia	3.1	3.3
	nigra) Pool
	Brain	3.4	3.5
	(Thalamus) Pool
	Brain (whole)	4.8	3.2
	Spinal Cord Pool	2.0	1.8
	Adrenal Gland	13.2	12.7
	Pituitary gland	0.0	0.0
	Pool
	Salivary Gland	0.2	0.2
	Thyroid (female)	0.4	0.7
	Pancreatic ca.	0.0	0.0
	CAPAN2
	Pancreas Pool	0.3	0.3

[0948]

TABLE NC
Oncology_cell_line_screening_panel_v3.1
	Rel. Exp. (%)	Rel. Exp. (%)
	Ag6006, Run	Ag6006, Run
Tissue Name	225138976	230277129
Daoy	0.0	0.0
Medulloblastoma/Cerebellum
TE671	0.0	0.0
Medulloblastom/Cerebellum
D283 Med	0.0	0.0
Medulloblastoma/Cerebellum
PFSK-1 Primitive	13.3	3.1
Neuroectodermal/Cerebellum
XF-498_CNS	0.0	0.0
SNB-78_CNS/glioma	0.0	0.0
SF-268_CNS/glioblastoma	0.0	0.0
T98G_Glioblastoma	0.0	0.0
SK-N-SH_Neuroblastoma	0.0	0.0
(metastasis)
SF-295_CNS/glioblastoma	0.0	0.0
Cerebellum	66.9	97.9
Cerebellum	100.0	100.0
NCI-H292_Mucoepidermoid	0.0	0.0
lung ca.
DMS-114_Small cell lung	0.0	0.0
cancer
DMS-79_Small cell lung	0.0	0.0
cancer/neuroendocrine
NCI-H146_Small cell lung	0.0	0.0
cancer/neuroendocrine
NCI-H526_Small cell lung	0.0	0.0
cancer/neuroendocrine
NCI-N417_Small cell lung	0.0	0.0
cancer/neuroendocrine
NCI-H82_Small cell lung	3.7	0.0
cancer/neuroendocrine
NCI-H157_Squamous cell	0.0	0.0
lung cancer (metastasis)
NCI-H1155_Large cell lung	0.0	0.0
cancer/neuroendocrine
NCI-H1299_Large cell lung	0.0	0.0
cancer/neuroendocrine
NCI-H727_Lung carcinoid	0.0	0.0
NCI-UMC-11_Lung	0.0	0.0
carcinoid
LX-1_Small cell lung cancer	0.0	0.0
Colo-205_Colon cancer	0.0	0.0
KM12_Colon cancer	0.0	0.0
KM20L2_Colon cancer	0.0	0.0
NCI-H716_Colon cancer	0.0	0.0
SW-48_Colon	0.0	0.0
adenocarcinoma
SW1116_Colon	0.0	0.0
adenocarcinoma
LS 174T_Colon	0.0	0.0
adenocarcinoma
SW-948_Colon	0.0	0.0
adenocarcinoma
SW-480_Colon	0.0	0.0
adenocarcinoma
NCI-SNU-5_Gastric ca.	0.0	0.0
KATO III_Stomach	0.5	0.0
NCI-SNU-16_Gastric ca.	2.6	0.0
NCI-SNU-1_Gastric ca.	0.0	0.0
RF-1_Gastric	7.4	11.3
adenocarcinoma
RF-48_Gastric	17.1	7.8
adenocarcinoma
MKN-45_Gastric ca.	0.0	0.0
NCI-N87_Gastric ca.	0.0	0.0
OVCAR-5_Ovarian ca.	0.0	0.0
RL95-2_Uterine carcinoma	2.0	0.0
HelaS3_Cervical	0.0	0.0
adenocarcinoma
Ca Ski_Cervical	0.0	0.0
epidermoid
carcinoma
(metastasis)
ES-2_Ovarian clear	0.0	0.0
cell carcinoma
Ramos/6 h stim—	0.0	0.0
Stimulated with
PMA/ionomycin 6 h
Ramos/14 h stim—	0.0	0.0
Stimulated with
PMA/ionomycin 14 h
MEG-01_Chronic	2.2	6.9
myelogenous
leukemia
(megokaryoblast)
Raji_Burkitt's	0.0	0.0
lymphoma
Daudi_Burkitt's	0.0	0.0
lymphoma
U266_B-cell	0.0	3.8
plasmacytoma/mye-
loma
CA46_Burkitt's	0.0	0.0
lymphoma
RL_non-Hodgkin's	0.0	0.0
B-cell lymphoma
JM1_pre-B-cell	0.0	0.0
lymphoma/leukemia
Jurkat_T cell	0.0	0.0
leukemia
TF-	12.2	10.4
1_Erythroleukemia
HUT 78_T-cell	0.0	0.0
lymphoma
U937_Histiocytic	43.5	42.3
lymphoma
KU-	2.3	0.0
812_Myelogenous
leukemia
769-P_Clear cell	0.0	0.0
renal ca.
Caki-2_Clear cell	0.0	0.0
renal ca.
SW 839_Clear cell	0.0	0.0
renal ca.
G401_Wilms' tumor	8.3	20.7
Hs766T_Pancreatic	2.0	0.0
ca. (LN metastasis)
CAPAN-	0.0	0.0
1_Pancreatic
adenocarcinoma
(liver metastasis)
SU86.86_Pancreatic	0.0	0.0
carcinoma (liver
metastasis)
BxPC-3_Pancreatic	0.0	0.0
adenocarcinoma
HPAC_Pancreatic	0.0	0.0
adenocarcinoma
MIA PaCa-	0.0	0.0
2_Pancreatic ca.
CFPAC-1_Pancreatic	0.6	0.0
ductal
adenocarcinoma
PANC-1_Pancreatic	0.0	0.0
epithelioid ductal ca.
T24_Bladder ca.	0.0	0.0
(transitional cell)
5637_Bladder ca.	0.0	0.0
HT-1197_Bladder ca.	2.3	0.0
UM-UC-3_Bladder	0.0	0.0
ca. (transitional cell)
A204_Rhabdomyo-	0.0	0.0
sarcoma
HT-	0.0	2.0
1080_Fibrosarcoma
MG-	0.0	8.0
63_Osteosarcoma
(bone)
SK-LMS-	3.7	0.0
1_Leiomyosarcoma
(vulva)
SJRH30_Rhabdomyo-	0.0	0.0
sarcoma (met to bone
marrow)
A431_Epidermoid	1.5	0.0
ca.
WM266-	1.6	3.8
4_Melanoma
DU 145_Prostate	0.0	0.0
MDA-MB-	2.4	0.0
468_Breast
adenocarcinoma
SSC-4_Tongue	0.0	0.0
SSC-9_Tongue	0.0	0.0
SSC-15_Tongue	0.0	0.0
CAL 27_Squamous	0.0	0.0
cell ca. of tongue

[0949]

TABLE ND
Panel 4.1D
                                 Rel. Exp. (%)
                                 Ag6006, Run
Tissue Name                      225787022
Secondary Th1 act                0.0
Secondary Th2 act                0.0
Secondary Tr1 act                0.0
Secondary Th1 rest               0.2
Secondary Th2 rest               0.0
Secondary Tr1 rest               0.0
Primary Th1 act                  0.0
Primary Th2 act                  0.0
Primary Tr1 act                  0.0
Primary Th1 rest                 0.0
Primary Th2 rest                 0.0
Primary Tr1 rest                 0.0
CD45RA CD4 lymphocyte act        0.0
CD45RO CD4 lymphocyte act        0.0
CD8 lymphocyte act               0.0
Secondary CD8 lymphocyte rest    0.0
Secondary CD8 lymphocyte act     0.0
CD4 lymphocyte none              0.0
2ry Th1/Th2/Tr1_anti-CD95 CH11   0.0
LAK cells rest                   7.5
LAK cells IL-2                   0.0
LAK cells IL-2 + IL-12           0.2
LAK cells IL-2 + IFN gamma       0.2
LAK cells IL-2 + IL-18           0.0
LAK cells PMA/ionomycin          3.6
NK Cells IL-2 rest               0.0
Two Way MLR 3 day                1.3
Two Way MLR 5 day                1.3
Two Way MLR 7 day                1.1
PBMC rest                        0.5
PBMC PWM                         0.0
PBMC PHA-L                       0.0
Ramos (B cell) none              0.0
Ramos (B cell) ionomycin         0.0
B lymphocytes PWM                0.0
B lymphocytes CD40L and IL-4     0.0
EOL-1 dbcAMP                     0.0
EOL-1 dbcAMP PMA/ionomycin       0.0
Dendritic cells none             8.1
Dendritic cells LPS              10.4
Dendritic cells anti-CD40        7.1
Monocytes rest                   0.4
Monocytes LPS                    16.0
Macrophages rest                 87.7
Macrophages LPS                  82.4
HUVEC none                       0.0
HUVEC starved                    0.0
HUVEC IL-lbeta                   0.0
HUVEC IFN gamma                  0.0
HUVEC TNF alpha + IFN gamma      0.0
HUVEC TNF alpha + IL4            0.0
HUVEC IL-11                      0.4
Lung Microvascular EC none       0.6
Lung Microvascular EC TNFalpha + IL-1beta 0.0
Microvascular Dermal EC none     0.0
Microsvasular Dermal EC TNFalpha + IL-1beta 0.0
Bronchial epithelium TNFalpha + IL1beta 0.0
Small airway epithelium none     0.0
Small airway epithelium TNFalpha + IL-1beta 0.0
Coronery artery SMC rest         0.0
Coronery artery SMC TNFalpha + IL-1beta 0.0
Astrocytes rest                  0.0
Astrocytes TNFalpha + IL-1beta   0.0
KU-812 (Basophil) rest           0.2
KU-812 (Basophil) PMA/ionomycin  0.2
CCD1106 (Keratinocytes) none     0.0
CCD1106 (Keratinocytes) TNFalpha + IL-1beta 0.0
Liver cirrhosis                  100.0
NCI-H292 none                    0.0
NCI-H292 IL-4                    0.0
NCI-H292 IL-9                    0.0
NCI-H292 IL-13                   0.0
NCI-H292 IFN gamma               0.0
HPAEC none                       0.0
HPAEC TNF alpha + IL-1 beta      0.0
Lung fibroblast none             0.0
Lung fibroblast TNF alpha + IL-1 beta 0.2
Lung fibroblast IL-4             0.3
Lung fibroblast IL-9             0.0
Lung fibroblast IL-13            0.0
Lung fibroblast IFN gamma        0.0
Dermal fibroblast CCD1070 rest   0.0
Dermal fibroblast CCD1070 TNF alpha 0.0
Dermal fibroblast CCD1070 IL-1 beta 0.0
Dermal fibroblast IFN gamma      0.0
Dermal fibroblast IL-4           0.0
Dermal Fibroblasts rest          0.0
Neutrophils TNFa + LPS           0.0
Neutrophils rest                 0.0
Colon                            0.1
Lung                             1.2
Thymus                           3.2
Kidney                           2.5

[0950]

TABLE NE
Panel 5 Islet
	Rel. Exp. (%)	Rel. Exp. (%)	Rel. Exp. (%)
	Ag6006, Run	Ag6006, Run	Ag6006, Run
Tissue Name	225051164	248989152	249139055
97457_Patient-	6.5	0.0	20.0
02go_adipose
97476_Patient-	20.7	0.0	15.6
07sk_skeletal
muscle
97477_Patient-	6.7	0.0	0.0
07ut_uterus
97478_Patient-	11.8	0.0	5.0
07pl_placenta
99167_Bayer	88.3	100.0	62.0
Patient 1
97482_Patient-	8.5	6.7	0.0
08ut_uterus
97483_Patient-	4.4	13.5	5.4
08pl_placenta
97486_Patient-	0.0	0.0	0.0
09sk_skeletal
muscle
97487_Patient-	0.0	0.0	0.0
09ut_uterus
97488_Patient-	4.9	0.0	0.0
09pl_placenta
97492_Patient-	0.0	0.0	0.0
10ut_uterus
97493_Patient-	4.6	0.0	5.1
10pl_placenta
97495_Patient-	0.0	0.0	3.8
11go_adipose
97496_Patient-	0.0	0.0	0.0
11sk_skeletal
muscle
97497_Patient-	0.0	0.0	0.0
11ut_uterus
97498_Patient-	0.0	0.0	0.0
11pl_placenta
97500_Patient-	0.0	6.0	4.9
12go_adipose
97501_Patient-	4.0	0.0	9.2
12sk_skeletal
muscle
97502_Patient-	0.0	5.1	0.0
12ut_uterus
97503_Patient-	14.9	7.3	7.7
12pl_placenta
94721_Donor 2	0.0	0.0	0.0
U -
A_Mesenchymal
Stem Cells
94722_Donor 2	0.0	0.0	0.0
U -
B_Mesenchymal
Stem Cells
94723_Donor 2	0.0	0.0	2.4
U -
C_Mesenchymal
Stem Cells
94709_Donor 2	0.0	0.0	0.0
AM - A_adipose
94710_Donor 2	0.0	0.0	0.0
AM - B adipose
94711_Donor 2	0.0	0.0	0.0
AM - C_adipose
94712_Donor 2	0.0	0.0	0.0
AD - A_adipose
94713_Donor 2	0.0	0.0	0.0
AD - B_adipose
94714_Donor 2	0.0	0.0	0.0
AD - C_adipose
94742_Donor 3	0.0	0.0	0.0
U -
A_Mesenchymal
Stem Cells
94743_Donor 3	0.0	0.0	0.0
U -
B_Mesenchymal
Stem Cells
94730_Donor 3	0.0	0.0	0.0
AM - A_adipose
94731_Donor 3	0.0	0.0	0.0
AM - B_adipose
94732_Donor 3	0.0	0.0	0.0
AM - C_adipose
94733_Donor 3	0.0	0.0	0.0
AD - A_adipose
94734_Donor 3	0.0	0.0	0.0
AD - B_adipose
94735_Donor 3	0.0	0.0	0.0
AD - C_adipose
77138_Liver—	0.0	0.0	0.0
HepG2untreated
73556_Heart_Car-	0.0	0.0	0.0
diac stromal cells
(primary)
81735_Small	8.5	6.3	5.1
Intestine
72409_Kidney—	0.0	0.0	0.0
Proximal
Convoluted
Tubule
82685_Small	0.0	0.0	5.4
intestine_Duode-
num
90650_Adrenal—	100.0	49.3	100.0
Adrenocortical
adenoma
72410_Kidney—	0.0	0.0	0.0
HRCE
72411_Kidney—	0.0	0.0	0.0
HRE
73139_Uterus—	0.0	0.0	0.0
Uterine smooth
muscle cells

[0951] General_screening_panel_v1.5 Summary: Ag6006 Two experiments with same probe-primer sets are in excellent agreement with highest expression of this gene detected in liver (CTs=26). Interestingly, expression of this gene is higher in adult as compared to fetal liver (CTs=32-33). Therefore, expression of this gene may be useful in distinguishing between adult and fetal liver.

[0952] In addition, moderate to low expression of this gene is also detected in tissues with metabolic/endocrine functions including pancreas, adipose, adrenal gland, thyroid, and stomach. This gene codes for Serine dehydratase (SD). SD catalyzes the PLP-dependent alpha, beta-elimination of L-serine to pyruvate and ammonia. It is one of three enzymes that are regarded as metabolic exits of the serine-glycine pool. SD is critical for hepatic glucose production. Therefore, inhibition of SD would decrease gluconeogenesis, thus an antagonist of SD would be beneficial for treatment hyperglycemia and diabetes.

[0953] In addition moderate levels of expression of this gene is in all regions of the central nervous system examined, including amygdala, hippocampus, substantia nigra, thalamus, cerebellum, cerebral cortex, and spinal cord. Therefore, therapeutic modulation of this gene product may be useful in the treatment of central nervous system disorders such as Alzheimer's disease, Parkinson's disease, epilepsy, multiple sclerosis, schizophrenia and depression.

[0954] Oncology_cell_line_screening_panel_v3.1 Summary: Ag6006 Two experiments with same probe-primer sets are in excellent agreement, with highest expression of this gene detected in cerebellum (CTs=32-33.7). In addition, low levels of expression of this gene is also detected in histiocytic lymphoma. Therefore, therapeutic modulation of this gene may be useful in the treatment of ataxia, autism and histiocytic lymphoma.

[0955] Panel 4.1D Summary: Ag6006 Highest expression of this gene is detected in liver cirrhosis sample (CT=29). In addition, moderate to low expression of this gene resting macrophage, LPS activated monocytes and macrophages, dendritic cells, resting and PMA/ionomycin activated LAK cells and normal tissues represented by thymus and kidney. Therefore, therapeutic modulation of this gene may be useful in the treatment of liver cirrhosis, asthma, emphysema, inflammatory bowel disease, arthritis and psoriasis.

[0956] Results from another experiment with this gene (run 225245206) are not included. The amp plot indicates that there were experimental difficulties with this run.

[0957] Panel 5 Islet Summary: Ag6006 Three experiments with same probe and primer sets are in good agreement. Low expression of this gene is detected mainly in islet cells and adrenocortical adenoma cells (CTs=33-34.8). Therefore, therapeutic modulation of this gene of SD encoded by this gene through the use of small molecule drug may be useful in the treatment of adrenocortical adenoma and metabolic disorders especially type II diabetes.

[0958] O. CG151359-01: Lactate Dehydrogenase A Like.

[0959] Expression of gene CG151359-01 was assessed using the primer-probe set Ag5225, described in Table OA. Results of the RTQ-PCR runs are shown in Table OB.

TABLE OA
Probe Name Ag5225
			Start	SEQ ID
Primers	Sequences	Length	Position	No
Forward	5′-tgttattggaagcggctgta-3′	20	618	513
Probe	TET-5′ctgttcgttttcaattcttcattgga-3′-TAMRA	26	647	514
Reverse	5′-cagagtggataccaagcttttg-3′	22	673	515

[0960]

TABLE OB
General_screemng_panel_v1.5
                                 Rel. Exp. (%)
                                 Ag5225, Run
Tissue Name                      228763462
Adipose                          0.0
Melanoma* Hs688(A).T             0.0
Melanoma* Hs688(B).T             0.0
Melanoma* M14                    0.0
Melanoma* LOXIMVI                7.9
Melanoma* SK-MEL-5               0.0
Squamous cell carcinoma SCC-4    0.0
Testis Pool                      100.0
Prostate ca.* (bone met) PC-3    0.0
Prostate Pool                    10.5
Placenta                         0.0
Uterus Pool                      0.0
Ovarian ca. OVCAR-3              0.0
Ovarian ca. SK-OV-3              0.0
Ovarian ca. OVCAR-4              3.7
Ovarian ca. OVCAR-5              0.0
Ovarian ca. IGROV-1              0.0
Ovarian ca. OVCAR-8              0.0
Ovary                            0.0
Breast ca. MCF-7                 0.0
Breast ca. MDA-MB-231            0.0
Breast ca. BT 549                0.0
Breast ca. T47D                  0.0
Breast ca. MDA-N                 0.0
Breast Pool                      0.0
Trachea                          0.0
Lung                             0.0
Fetal Lung                       0.0
Lung ca. NCI-N417                0.0
Lung ca. LX-1                    0.0
Lung ca. NCI-H146                0.0
Lung ca. SHP-77                  0.0
Lung ca. A549                    0.0
Lung ca. NCI-H526                0.0
Lung ca. NCI-H23                 0.0
Lung ca. NCI-H460                0.0
Lung ca. HOP-62                  0.0
Lung ca. NCI-H522                0.0
Liver                            0.0
Fetal Liver                      5.8
Liver ca. HepG2                  0.0
Kidney Pool                      0.3
Fetal Kidney                     0.0
Renal ca. 786-0                  0.0
Renal ca. A498                   0.0
Renal ca. ACHN                   0.0
Renal ca. UO-31                  0.0
Renal ca. TK-10                  0.0
Bladder                          0.7
Gastric ca. (liver met.) NCI-N87 0.0
Gastric ca. KATO III             0.0
Colon ca. SW-948                 0.0
Colon ca. SW480                  0.0
Colon ca.* (SW480 met) SW620     0.0
Colon ca. HT29                   0.6
Colon ca. HCT-116                0.0
Colon ca. CaCo-2                 49.0
Colon cancer tissue              0.0
Colon ca. SW1116                 0.0
Colon ca. Colo-205               0.0
Colon ca. SW-48                  0.0
Colon Pool                       75.3
Small Intestine Pool             1.8
Stomach Pool                     0.0
Bone Marrow Pool                 0.0
Fetal Heart                      0.0
Heart Pool                       0.0
Lymph Node Pool                  0.0
Fetal Skeletal Muscle            0.0
Skeletal Muscle Pool             0.0
Spleen Pool                      0.0
Thymus Pool                      0.0
CNS cancer (glio/astro) U87-MG   0.0
CNS cancer (glio/astro) U-118-MG 25.2
CNS cancer (neuro; met) SK-N-AS  0.0
CNS cancer (astro) SF-539        0.0
CNS cancer (astro)SNB-75         0.0
CNS cancer (glio) SNB-19         0.0
CNS cancer (glio) SF-295         0.0
Brain (Amygdala) Pool            0.0
Brain (cerebellum)               0.0
Brain (fetal)                    0.0
Brain (Hippocampus) Pool         0.0
Cerebral Cortex Pool             0.0
Brain (Substantia nigra) Pool    8.6
Brain (Thalamus) Pool            0.0
Brain (whole)                    0.0
Spinal Cord Pool                 0.0
Adrenal Gland                    0.0
Pituitary gland Pool             0.0
Salivary Gland                   0.0
Thyroid (female)                 0.0
Pancreatic ca. CAPAN2            0.0
Pancreas Pool                    0.0

[0961] CNS_neurodegeneration_v1.0 Summary: Ag5225 Expression of this gene is low/undetectable in all samples on this panel (CTs>35). (Data not shown.)

[0962] General_screening_panel_v1.5 Summary: Ag5225 Expression of this gene is limited to a few samples on this panel, with highest expression seen in testis (CT=31.8). Moderate to low levels of expression are also seen in normal colon, a colon cancer cell line, and a brain cancer cell line.

[0963] Panel 4.1D Summary: Ag5225 Expression of this gene is low/undetectable in all samples on this panel (CTs>35). (Data not shown.)

[0964] Panel 5 Islet Summary: Ag5225 Expression of this gene is low/undetectable in all samples on this panel (CTs>35). (Data not shown.)

[0965] P. CG152227-01: 3-Hydroxyisobutyryl-Coenzyme A Hydrolase.

[0966] Expression of gene CG152227-01 was assessed using the primer-probe set Ag6857, described in Table PA.

TABLE PA
Probe Name Ag6857
			Start	SEQ ID
Primers	Sequences	Length	Position	No
Forward	5′-ttggactctggtcttcaagtat-3′	22	186	516
Probe	TET-5′-agacttgtctcgatcaatcttagactctgtatggtaa-3′-TAMRA	37	211	517
Reverse	5′-cttcaaaagaaaatattgcatctg-3′	24	258	518

[0967] General_screening_panel_v1.6 Summary: Ag6857 Expression of this gene is low/undetectable in all samples on this panel (CTs>35). (Data not shown.)

[0968] Q. CG152547-01: Similar to Zinc Transporter 1.

[0969] Expression of gene CG152547-01 was assessed using the primer-probe set Ag7619, described in Table QA.

TABLE QA
Probe Name Ag7619
			Start	SEQ ID
Primers	Sequences	Length	Position	No
Forward	5′-tgctcatcttccatcaccaa-3′	20	392	519
Probe	TET-5′-ccctaatctcaagtaatcagggacacaa-3′-TAMRA	28	413	520
Reverse	5′-tggttttcctaggcagagga-3′	20	462	521

[0970] CNS_neurodegeneration_v1.0 Summary: Ag7619 Expression of this gene is low/undetectable in all samples on this panel (CTs>35). (Data not shown.)

[0971] Panel 4.1D Summary: Ag7619 Expression of this gene is low/undetectable in all samples on this panel (CTs>35). (Data not shown.)

[0972] R. CG152646-01: Amidase.

[0973] Expression of gene CG 152646-01 was assessed using the primer-probe set Ag6876, described in Table RA.

TABLE RA
Probe Name Ag6876
			Start	SEQ ID
Primers	Sequences	Length	Position	No
Forward	5′-cacatctgtgaccatattgtt-3′	21	573	522
Probe	TET-5′-tttaactggtccaaatacaccatctgtg-3′-TAMRA	28	613	523
Reverse	5′-tttgctatgggatctg-3′	16	645	524

[0974] General_screening_panel_v1.6 Summary: Ag6876 Expression of this gene is low/undetectable in all samples on this panel (CTs>35). (Data not shown.)

[0975] S. CG152959-01: Prenyl Protein-Specific Endoprotease 2.

[0976] Expression of gene CG152959-01 was assessed using the primer-probe set Ag7172, described in Table SA. Results of the RTQ-PCR runs are shown in Table SB. Please note that CG152959-01 represents a full-length physical clone.

TABLE SA
Probe Name Ag7172
			Start	SEQ ID
Primers	Sequences	Length	Position	No
Forward	5′-cctggaggacgtgctgt-3′	17	191	525
Probe	TET-5′-ccaacctgtcagagtggctgagtccc-3′-TAMRA	26	223	526
Reverse	5′-gcgcttgcggaagg-3′	14	273	527

[0977]

TABLE SB
General_screening_panel_v1.7
                                 Rel. Exp. (%)
                                 Ag7172, Run
Tissue Name                      318039790
Adipose                          10.6
HUVEC                            35.8
Melanoma* Hs688(A).T             0.3
Melanoma* Hs688(B).T             66.9
Melanoma (met) SK-MEL-5          4.4
Testis                           13.5
Prostate ca. (bone met) PC-3     0.5
Prostate ca. DU145               19.3
Prostate pool                    7.7
Uterus pool                      2.5
Ovarian ca. OVCAR-3              14.1
Ovarian ca. (ascites) SK-OV-3    0.8
Ovarian ca. OVCAR-4              51.4
Ovarian ca. OVCAR-5              29.1
Ovarian ca. IGROV-1              100.0
Ovarian ca. OVCAR-8              24.0
Ovary                            3.2
Breast ca. MCF-7                 17.7
Breast ca. MDA-MB-231            43.8
Breast ca. BT-549                14.1
Breast ca. T47D                  15.5
Breast pool                      7.5
Trachea                          15.8
Lung                             1.2
Fetal Lung                       9.0
Lung ca. NCI-N417                10.0
Lung ca. LX-1                    4.4
Lung ca. NCI-H146                15.5
Lung ca. SHP-77                  38.2
Lung ca. NCI-H23                 26.2
Lung ca. NCI-H460                8.5
Lung ca. HOP-62                  9.6
Lung ca. NCI-H522                56.3
Lung ca. DMS-114                 8.8
Liver                            0.0
Fetal Liver                      1.0
Kidney pool                      32.3
Fetal Kidney                     3.7
Renal ca. 786-0                  40.1
Renal ca. A498                   12.7
Renal ca. ACHN                   15.0
Renal ca. UO-31                  22.8
Renal ca. TK-10                  46.0
Bladder                          1.6
Gastric ca. (liver met.) NCI-N87 0.0
Stomach                          0.0
Colon ca. SW-948                 6.0
Colon ca. SW480                  0.4
Colon ca. (SW480 met) SW620      6.8
Colon ca. HT29                   30.4
Colon ca. HCT-116                22.2
Colon cancer tissue              1.0
Colon ca. SW1116                 6.1
Colon ca. Colo-205               11.0
Colon ca. SW-48                  9.4
Colon                            15.9
Small Intestine                  1.5
Fetal Heart                      0.7
Heart                            1.2
Lymph Node pool                  3.1
Lymph Node pool                  26.1
Fetal Skeletal Muscle            1.7
Skeletal Muscle pool             0.3
Skeletal Muscle                  0.2
Spleen                           4.4
Thymus                           14.7
CNS cancer (glio/astro) SF-268   6.4
CNS cancer (glio/astro) T98G     3.3
CNS cancer (neuro; met) SK-N-AS  0.2
CNS cancer (astro) SF-539        8.9
CNS cancer (astro) SNB-75        10.1
CNS cancer (glio) SNB-19         16.5
CNS cancer (glio) SF-295         4.9
Brain (Amygdala)                 6.6
Brain (Cerebellum)               12.8
Brain (Fetal)                    25.5
Brain (Hippocampus)              4.7
Cerebral Cortex pool             1.8
Brain (Substantia nigra)         4.0
Brain (Thalamus)                 4.3
Brain (Whole)                    21.6
Spinal Cord                      0.8
Adrenal Gland                    2.2
Pituitary Gland                  11.9
Salivary Gland                   8.0
Thyroid                          8.4
Pancreatic ca. PANC-1            10.5
Pancreas pool                    1.5

[0978] General_screening_panel_v1.7 Summary: Ag7172 Highest expression of this gene is detected in ovarian cancer IGROV-1 cell line (CT=28.3). Moderate levels of expression of this gene is also seen in cluster of cancer cell lines derived from pancreatic, gastric, colon, lung, liver, renal, breast, ovarian, melanoma and brain cancers. Thus, expression of this gene could be used as a marker to detect the presence of these cancers. Furthermore, therapeutic modulation of the expression or function of this gene may be effective in the treatment of pancreatic, gastric, colon, lung, liver, renal, breast, ovarian, melanoma and brain cancers.

[0979] Among tissues with metabolic or endocrine function, this gene is expressed at moderate to low levels in pancreas, adipose, adrenal gland, thyroid, pituitary gland, fetal skeletal muscle, heart, fetal liver and the gastrointestinal tract. Therefore, therapeutic modulation of the activity of this gene may prove useful in the treatment of endocrine/metabolically related diseases, such as obesity and diabetes.

[0980] In addition, this gene is expressed at low levels in all regions of the central nervous system examined, including amygdala, hippocampus, substantia nigra, thalamus, cerebellum, cerebral cortex, and spinal cord. Therefore, therapeutic modulation of this gene product may be useful in the treatment of central nervous system disorders such as Alzheimer's disease, Parkinson's disease, epilepsy, multiple sclerosis, schizophrenia and depression.

[0981] T. CG153033-01: NA-Dependent Inorganic Phosphate Cotransporter.

[0982] Expression of gene CG153033-01 was assessed using the primer-probe set Ag5798, described in Table TA. Results of the RTQ-PCR runs are shown in Tables TB and TC.

TABLE TA
Probe Name Ag5798
			Start	SEQ ID
Primers	Sequences	Length	Position	No
Forward	5′-aatcttggagttgccattgtg-3′	21	223	528
Probe	TET-5′-ccatcaacatatacggtgctattgttgacc-3′-TAMRA	30	249	529
Reverse	5′-tcccagttaaactgtgctgtct-3′	22	284	530

[0983]

TABLE TB
CNS_neurodegeneration_v1.0
                               Rel. Exp. (%)
                               Ag5798, Run
Tissue Name                    247179626
AD 1 Hippo                     8.0
AD 2 Hippo                     14.4
AD 3 Hippo                     3.7
AD 4 Hippo                     7.3
AD 5 hippo                     24.1
AD 6 Hippo                     24.8
Control 2 Hippo                42.6
Control 4 Hippo                3.3
Control (Path) 3 Hippo         0.0
AD 1 Temporal Ctx              9.3
AD 2 Temporal Ctx              94.6
AD 3 Temporal Ctx              3.6
AD 4 Temporal Ctx              13.6
AD 5 Inf Temporal Ctx          100.0
AD 5 Sup Temporal Ctx          71.7
AD 6 Inf Temporal Ctx          57.8
AD 6 Sup Temporal Ctx          22.8
Control 1 Temporal Ctx         0.0
Control 2 Temporal Ctx         38.7
Control 3 Temporal Ctx         12.6
Control 4 Temporal Ctx         10.0
Control (Path) 1 Temporal Ctx  70.2
Control (Path) 2 Temporal Ctx  8.2
Control (Path) 3 Temporal Ctx  0.0
Control (Path) 4 Temporal Ctx  39.0
AD 1 Occipital Ctx             0.0
AD 2 Occipital Ctx (Missing)   0.0
AD 3 Occipital Ctx             0.0
AD 4 Occipital Ctx             24.7
AD 5 Occipital Ctx             9.3
AD 6 Occipital Ctx             40.6
Control 1 Occipital Ctx        3.0
Control 2 Occipital Ctx        21.3
Control 3 Occipital Ctx        3.5
Control 4 Occipital Ctx        0.0
Control (Path) 1 Occipital Ctx 54.0
Control (Path) 2 Occipital Ctx 0.0
Control (Path) 3 Occipital Ctx 0.0
Control (Path) 4 Occipital Ctx 3.4
Control 1 Parietal Ctx         0.0
Control 2 Parietal Ctx         59.9
Control 3 Parietal Ctx         0.0
Control (Path) 1 Parietal Ctx  46.7
Control (Path) 2 Parietal Ctx  16.0
Control (Path) 3 Parietal Ctx  7.8
Control (Path) 4 Parietal Ctx  17.6

[0984]

TABLE TC
General_screening_panel_v1.5
                                 Rel. Exp. (%)
                                 Ag5798, Run
Tissue Name                      245274436
Adipose                          0.0
Melanoma* Hs688(A).T             0.0
Melanoma* Hs688(B).T             0.0
Melanoma* M14                    0.0
Melanoma* LOXIMVI                1.9
Melanoma* SK-MEL-5               0.0
Squamous cell carcinoma SCC-4    0.9
Testis Pool                      5.9
Prostate ca.* (bone met) PC-3    0.4
Prostate Pool                    0.0
Placenta                         3.9
Uterus Pool                      0.0
Ovarian ca. OVCAR-3              0.0
Ovarian ca. SK-OV-3              0.0
Ovarian ca. OVCAR-4              0.0
Ovarian ca. OVCAR-5              0.0
Ovarian ca. IGROV-1              1.0
Ovarian ca. OVCAR-8              0.0
Ovary                            3.1
Breast ca. MCF-7                 0.0
Breast ca. MDA-MB-231            0.0
Breast ca. BT 549                0.0
Breast ca. T47D                  0.0
Breast ca. MDA-N                 0.0
Breast Pool                      1.6
Trachea                          0.0
Lung                             0.0
Fetal Lung                       27.9
Lung ca. NCI-N417                0.0
Lung ca. LX-1                    1.2
Lung ca. NCI-H146                0.0
Lung ca. SHP-77                  0.0
Lung ca. A549                    0.8
Lung ca. NCI-H526                90.8
Lung ca. NCI-H23                 0.6
Lung ca. NCI-H460                0.0
Lung ca. HOP-62                  0.0
Lung ca. NCI-H522                0.0
Liver                            1.6
Fetal Liver                      51.1
Liver ca. HepG2                  0.0
Kidney Pool                      0.0
Fetal Kidney                     5.1
Renal ca. 786-0                  0.0
Renal ca. A498                   0.0
Renal ca. ACHN                   1.1
Renal ca. UO-31                  0.0
Renal ca. TK-10                  0.0
Bladder                          1.5
Gastric ca. (liver met.) NCI-N87 1.0
Gastric ca. KATO III             0.0
Colon ca. SW-948                 0.0
Colon ca. SW480                  0.0
Colon ca.* (SW480 met) SW620     0.0
Colon ca. HT29                   0.0
Colon ca. HCT-116                0.0
Colon ca. CaCo-2                 0.0
Colon cancer tissue              0.9
Colon ca. SW1116                 0.0
Colon ca. Colo-205               0.0
Colon ca. SW-48                  0.0
Colon Pool                       0.0
Small Intestine Pool             2.1
Stomach Pool                     1.3
Bone Marrow Pool                 1.6
Fetal Heart                      5.9
Heart Pool                       0.0
Lymph Node Pool                  0.0
Fetal Skeletal Muscle            0.0
Skeletal Muscle Pool             1.1
Spleen Pool                      0.9
Thymus Pool                      7.0
CNS cancer (glio/astro) U87-MG   0.0
CNS cancer (glio/astro) U-118-MG 0.0
CNS cancer (neuro; met) SK-N-AS  0.0
CNS cancer (astro) SF-539        0.0
CNS cancer (astro) SNB-75        0.0
CNS cancer (glio) SNB-19         0.0
CNS cancer (glio) SF-295         0.0
Brain (Amygdala) Pool            14.7
Brain (cerebellum)               3.4
Brain (fetal)                    20.2
Brain (Hippocampus) Pool         45.4
Cerebral Cortex Pool             19.6
Brain (Substantia nigra) Pool    29.7
Brain (Thalamus) Pool            100.0
Brain (whole)                    10.4
Spinal Cord Pool                 6.1
Adrenal Gland                    0.0
Pituitary gland Pool             5.0
Salivary Gland                   0.0
Thyroid (female)                 0.0
Pancreatic ca. CAPAN2            0.0
Pancreas Pool                    5.7

[0985] CNS_neurodegeneration_v1.0 Summary: Ag5798 This panel does not show differential expression of this gene in Alzheimer's disease. However, this profile confirms the expression of this gene at moderate levels in the brain. Please see Panel 1.5 for discussion of utility of this gene in the central nervous system.

[0986] General_screening_panel_v1.5 Summary: Ag5798 Highest expression of this gene is seen in the thalamus (CT=31.3). This gene is also expressed at low to significant levels in the amygdala, hippocampus, cerebral cortex, substantia nigra, and whole and fetal brain samples. Therefore, therapeutic modulation of the expression or function of this gene may be useful in the treatment of neurological disorders, such as Alzheimer's disease, Parkinson's disease, schizophrenia, multiple sclerosis, stroke and epilepsy.

[0987] In addition, this gene is expressed at much higher levels in fetal liver tissue (CT=32.5) when compared to expression in the adult counterpart (CT=37). Thus, expression of this gene may be used to differentiate between the fetal and adult source of this tissue.

[0988] Moderate expression is also seen in a single lung cancer cell line (CT=31). Thus, expression of this gene could be used as a marker to detect the presence of lung cancer. Furthermore, therapeutic modulation of the expression or function of this gene may be effective in the treatment of lung cancer.

[0989] Panel 4.1D Summary: Ag5798 Expression of this gene is low/undetectable in all samples on this panel (CTs>35). (Data not shown.)

[0990] Panel 5 Islet Summary: Ag5798 Expression of this gene is low/undetectable in all samples on this panel (CTs>35). (Data not shown.)

[0991] U. CG153818-01: Kinesin 19A.

[0992] Expression of gene CG153818-01 was assessed using the primer-probe set Ag5692, described in Table UA. Results of the RTQ-PCR runs are shown in Tables UB, UC and UD.

TABLE UA
Probe Name Ag5692
			Start	SEQ ID
Primers	Sequences	Length	Position	No
Forward	5′-cgacaagggtagcaacaagtac-3′	22	1149	531
Probe	TET-5′-atcaactatcgcgacagcaagctcac-3′-TAMRA	26	1171	532
Reverse	5′-gtttcctcccagagagtcctt-3′	21	1207	533

[0993]

TABLE UB
CNS_neurodegeneration_v1.0
	Rel. Exp. (%)	Rel. Exp. (%)
Tissue	Ag5692, Run	Ag5692, Run
Name	247018768	264979292
AD 1 Hippo	5.1	5.3
AD 2 Hippo	23.3	26.6
AD 3 Hippo	4.1	5.2
AD 4 Hippo	19.1	22.8
AD 5 Hippo	28.9	39.8
AD 6 Hippo	74.7	88.3
Control 2 Hippo	19.8	27.0
Control 4 Hippo	10.7	11.6
Control (Path) 3 Hippo	6.9	7.9
AD 1 Temporal Ctx	10.4	17.2
AD 2 Temporal Ctx	18.0	17.6
AD 3 Temporal Ctx	2.7	8.5
AD 4 Temporal Ctx	29.1	33.4
AD 5 Inf Temporal Ctx	100.0	100.0
AD 5 Sup Temporal Ctx	66.4	67.8
AD 6 Inf Temporal Ctx	94.6	93.3
AD 6 Sup Temporal Ctx	59.0	72.2
Control 1 Temporal Ctx	2.2	2.6
Control 2 Temporal Ctx	17.9	21.8
Control 3 Temporal Ctx	4.9	6.3
Control 3 Temporal Ctx	8.9	9.0
Control (Path) 1 Temporal Ctx	8.0	11.1
Control (Path) 2 Temporal Ctx	7.3	6.5
Control (Path) 3 Temporal Ctx	5.6	6.9
Control (Path) 4 Temporal Ctx	5.8	4.9
AD 1 Occipital Ctx	2.9	6.2
AD 2 Occipital Ctx (Missing)	0.0	0.0
AD 3 Occipital Ctx	5.4	5.9
AD 4 Occipital Ctx	33.9	30.4
AD 5 Occipital Ctx	9.5	14.2
AD 6 Occipital Ctx	13.3	14.9
Control 1 Occipital Ctx	2.4	2.8
Control 2 Occipital Ctx	27.2	21.5
Control 3 Occipital Ctx	8.2	8.2
Control 4 Occipital Ctx	9.7	12.9
Control (Path) 1 Occipital Ctx	17.0	0.0
Control (Path) 2 Occipital Ctx	3.7	5.8
Control (Path) 3 Occipital Ctx	5.8	5.8
Control (Path) 4 Occipital Ctx	3.6	5.0
Control 1 Parietal Ctx	3.8	5.2
Control 2 Parietal Ctx	68.8	90.8
Control 3 Parietal Ctx	6.0	9.7
Control (Path) 1 Parietal Ctx	10.2	8.2
Control (Path) 2 Parietal Ctx	7.5	6.8
Control (Path) 3 Parietal Ctx	3.8	5.4
Control (Path) 4 Parietal Ctx	6.8	6.4

[0994]

TABLE UC
General_screening_panel_v1.5
                                 Rel. Exp. (%)
                                 Ag5692, Run
Tissue Name                      245274428
Adipose                          2.6
Melanoma* Hs688(A).T             0.0
Melanoma* Hs688(B).T             0.0
Melanoma* M14                    0.0
Melanoma* LOXIMVI                0.0
Melanoma* SK-MEL-5               0.3
Squamous cell carcinoma SCC-4    0.0
Testis Pool                      7.1
Prostate ca.* (bone met) PC-3    0.0
Prostate Pool                    0.6
Placenta                         0.0
Uterus Pool                      1.8
Ovarian ca. OVCAR-3              1.3
Ovarian ca. SK-OV-3              0.0
Ovarian ca. OVCAR-4              0.0
Ovarian ca. OVCAR-5              0.0
Ovarian ca. IGROV-1              0.7
Ovarian ca. OVCAR-8              0.0
Ovary                            2.3
Breast ca. MCF-7                 0.0
Breast ca. MDA-MB-231            0.0
Breast ca. BT 549                0.0
Breast ca. T47D                  0.0
Breast ca. MDA-N                 0.0
Breast Pool                      0.9
Trachea                          51.1
Lung                             0.6
Fetal Lung                       52.9
Lung ca. NCI-N417                0.0
Lung ca. LX-1                    15.2
Lung ca. NCI-H146                0.0
Lung ca. SHP-77                  100.0
Lung ca. A549                    0.0
Lung ca. NCI-H526                0.4
Lung ca. NCI-H23                 2.9
Lung ca. NCI-H460                0.0
Lung ca. HOP-62                  0.0
Lung ca. NCI-H522                0.0
Liver                            2.6
Fetal Liver                      2.5
Liver ca. HepG2                  0.0
Kidney Pool                      1.9
Fetal Kidney                     1.6
Renal ca. 786-0                  0.0
Renal ca. A498                   0.0
Renal ca. ACHN                   0.0
Renal ca. UO-31                  0.0
Renal ca. TK-10                  0.0
Bladder                          14.0
Gastric ca. (liver met.) NCI-N87 0.0
Gastric ca. KATO III             0.0
Colon ca. SW-948                 0.6
Colon ca. SW480                  0.4
Colon ca.* (SW480 met) SW620     4.8
Colon ca. HT29                   2.0
Colon ca. HCT-116                0.4
Colon ca. CaCo-2                 0.4
Colon cancer tissue              1.9
Colon ca. SW1116                 0.0
Colon ca. Colo-205               0.0
Colon ca. SW-48                  0.7
Colon Pool                       0.3
Small Intestine Pool             3.2
Stomach Pool                     3.6
Bone Marrow Pool                 2.0
Fetal Heart                      0.3
Heart Pool                       0.5
Lymph Node Pool                  0.9
Fetal Skeletal Muscle            2.7
Skeletal Muscle Pool             0.7
Spleen Pool                      54.7
Thymus Pool                      9.9
CNS cancer (glio/astro) U87-MG   0.0
CNS cancer (glio/astro) U-118-MG 0.0
CNS cancer (neuro; met) SK-N-AS  0.0
CNS cancer (astro) SF-539        0.0
CNS cancer (astro) SNB-75        0.0
CNS cancer (glio) SNB-19         1.0
CNS cancer (glio) SF-295         0.6
Brain (Amygdala) Pool            27.2
Brain (cerebellum)               8.2
Brain (fetal)                    3.1
Brain (Hippocampus) Pool         26.2
Cerebral Cortex Pool             15.9
Brain (Substantia nigra) Pool    15.4
Brain (Thalamus) Pool            35.1
Brain (whole)                    11.3
Spinal Cord Pool                 16.2
Adrenal Gland                    1.2
Pituitary gland Pool             0.2
Salivary Gland                   3.9
Thyroid (female)                 15.8
Pancreatic ca. CAPAN2            0.0
Pancreas Pool                    4.4

[0995]

TABLE UD
Panel 4.1D
                                 Rel. Exp. (%)
                                 Ag5692, Run
Tissue Name                      246504798
Secondary Th1 act                0.0
Secondary Th2 act                1.4
Secondary Tr1 act                0.0
Secondary Th1 rest               0.8
Secondary Th2 rest               0.0
Secondary Tr1 rest               0.0
Primary Th1 act                  0.0
Primary Th2 act                  0.0
Primary Tr1 act                  0.0
Primary Th1 rest                 0.0
Primary Th2 rest                 0.0
Primary Tr1 rest                 0.0
CD45RA CD4 lymphocyte act        0.0
CD45RO CD4 lymphocyte act        0.0
CD8 lymphocyte act               0.0
Secondary CD8 lymphocyte rest    0.0
Secondary CD8 lymphocyte act     0.0
CD4 lymphocyte none              1.4
2ry Th1/Th2/Tr1_anti-CD95 CH11   0.0
LAK cells rest                   0.0
LAK cells IL-2                   3.2
LAK cells IL-2 + IL-12           0.0
LAK cells IL-2 + IFN gamma       0.0
LAK cells IL-2 + IL-18           0.0
LAK cells PMA/ionomycin          0.0
NK Cells IL-2 rest               29.7
Two Way MLR 3 day                0.0
Two Way MLR 5 day                0.0
Two Way MLR 7 day                0.0
PBMC rest                        2.3
PBMC PWM                         0.0
PBMC PHA-L                       0.0
Ramos (B cell) none              0.0
Ramos (B cell) ionomycin         0.0
B lymphocytes PWM                0.0
B lymphocytes CD40L and IL-4     0.0
EOL-1 dbcAMP                     0.0
EOL-1 dbcAMP PMA/ionomycin       0.0
Dendritic cells none             0.0
Dendritic cells LPS              0.0
Dendritic cells anti-CD40        0.0
Monocytes rest                   0.0
Monocytes LPS                    0.0
Macrophages rest                 0.0
Macrophages LPS                  0.0
HUVEC none                       0.0
HUVEC starved                    0.0
HUVEC IL-1beta                   2.0
HUVEC IFN gamma                  100.0
HUVEC TNF alpha + IFN gamma      0.0
HUVEC TNF alpha + IL4            0.0
HUVEC IL-11                      0.0
Lung Microvascular EC none       0.0
Lung Microvascular EC TNFalpha + IL-1beta 0.0
Microvascular Dermal EC none     0.0
Microsvasular Dermal EC TNFalpha + IL-1beta 0.0
Bronchial epithelium TNFalpha + IL1beta 0.0
Small airway epithelium none     0.0
Small airway epithelium TNFalpha + IL-1beta 0.0
Coronery artery SMC rest         0.0
Coronery artery SMC TNFalpha + IL-1beta 0.0
Astrocytes rest                  0.0
Astrocytes TNFalpha + IL-1beta   0.0
KU-812 (Basophil) rest           7.0
KU-812 (Basophil) PMA/ionomycin  11.0
CCD1106 (Keratinocytes) none     0.0
CCD1106 (Keratinocytes) TNFalpha + IL-1beta 2.3
Liver cirrhosis                  5.1
NCI-H292 none                    0.0
NCI-H292 IL-4                    0.0
NCI-H292 IL-9                    0.0
NCI-H292 IL-13                   0.0
NCI-H292 IFN gamma               0.0
HPAEC none                       1.2
HPAEC TNF alpha + IL-1 beta      0.0
Lung fibroblast none             0.0
Lung fibroblast TNF alpha + IL-1 beta 0.0
Lung fibroblast IL-4             0.0
Lung fibroblast IL-9             0.0
Lung fibroblast IL-13            0.0
Lung fibroblast IFN gamma        0.0
Dermal fibroblast CCD1070 rest   0.0
Dermal fibroblast CCD1070 TNF alpha 1.3
Dermal fibroblast CCD1070 IL-1 beta 0.0
Dermal fibroblast IFN gamma      0.0
Dermal fibroblast IL-4           0.0
Dermal Fibroblasts rest          0.0
Neutrophils TNFa + LPS           0.0
Neutrophils rest                 0.0
Colon                            0.0
Lung                             3.6
Thymus                           1.3
Kidney                           0.0

[0996] CNS_neurodegeneration_v1.0 Summary: Ag5692 Two experiments with the same probe and primer set produce results that are in excellent agreement. This panel confirms the expression of this gene at moderate levels in the brain in an independent group of individuals. This gene is found to be upregulated in the temporal cortex of Alzheimer's disease patients. This gene encodes a putative kinesin, a microtubule-based motor protein involved in the transport of organelles. Axonal transport of APP in neurons is mediated by binding with kinesin. (Gunewardena S, Neuron Nov. 8, 2001;32(3):389-401). Kamal et al. suggest that impaired APP transport leads to enhanced axonal generation and deposition of Abeta, resulting in disruption of neurotrophic signaling and neurodegeneration (Nature Dec. 6, 2001;414(6864):643-8). Thus, therapeutic modulation of the expression or function of this gene may be useful in the treatment of neurodegenerative disorders, and specifically may decrease neuronal death and be of use in the treatment of Alzheimer's disease.

[0997] General_screening_panel_v1.5 Summary: Ag5692 Highest expression of this gene is seen in a lung cancer cell line (CT=29.4). Moderate levels of expression are also seen in fetal lung (CT=30) and interestingly, are much higher than expression of this gene in the adult counterpart (CT=32). Thus, expression of this gene could be used to differentiate between the adult and fetal source of this tissue. In addition, therapeutic modulation of the expression or function of this gene may be useful in the treatment of diseases that affect the lung, including lung cancer.

[0998] Moderate to low levels of expression are seen in all regions of the CNS examined. Please see CNS_neurodegeneration_v1.0 for discussion of utility of this gene in CNS disorders.

[0999] Low but significant levels of expression are also seen in pancreas, thyroid, fetal skeletal muscle, adipose and adult and fetal liver. This widespread expression among these tissues suggests that this gene product may play a role in normal neuroendocrine and metabolic function and that disregulated expression of this gene may contribute to neuroendocrine disorders or metabolic diseases, such as obesity and diabetes.

[1000] Panel 4.1D Summary: Ag5692 Expression of this gene is limited to a few samples in this panel, with highest expression in IFN-gamma treated HUVEC cells (CT=31.2). Low but significant levels of expression are also seen in PMA/ionomycin treated basophils and resting NK cells. This expression profile suggests that expression of this gene could be a marker of activated HUVEC cells. In addition, modulation of the expression or function of this gene product may reduce or eliminate the symptoms in patients with autoimmune and inflammatory diseases that involve endothelial cells, such as lupus erythematosus, asthma, emphysema, Crohn's disease, ulcerative colitis, rheumatoid arthritis, osteoarthritis, and psoriasis.

[1001] V. CG154435-01: Dynein Beta Chain, Ciliary.

[1002] Expression of gene CG154435-01 was assessed using the primer-probe set Ag5694, described in Table VA. Results of the RTQ-PCR runs are shown in Tables VB, VC, VD, VE and VF.

TABLE VA
Probe Name Ag5694
			Start	SEQ ID
Primers	Sequence	Length	Position	No
Forward	5′-ccaccaagtggaaagatatcaa	22	3932	534
Probe	TET-5′-ccttggcaaaacttcttacaatctatgtcca-3′-TAMRA	30	3965	535
Reverse	5′-ccttgtccaaagacctcatgt-3′	21	3995	536

[1003]

TABLE VB
AI_comprehensive panel_v1.0
                                 Rel. Exp. (%)
                                 Ag5694, Run
Tissue Name                      245243118
110967 COPD-F                    0.3
110980 COPD-F                    0.0
110968 COPD-M                    0.2
110977 COPD-M                    0.0
110989 Emphysema-F               0.1
110992 Emphysema-F               0.0
110993 Emphysema-F               0.0
110994 Emphysema-F               0.0
110995 Emphysema-F               0.4
110996 Emphysema-F               0.7
110997 Asthma-M                  0.3
111001 Asthma-F                  0.0
111002 Asthma-F                  0.0
111003 Atopic Asthma-F           0.0
111004 Atopic Asthma-F           0.1
111005 Atopic Asthma-F           0.0
111006 Atopic Asthma-F           0.0
111417 Allergy-M                 1.0
112347 Allergy-M                 0.0
112349 Normal Lung-F             0.5
112357 Normal Lung-F             0.0
112354 Normal Lung-M             9.7
112374 Crohns-F                  0.0
112389 Match Control Crohns-F    0.2
112375 Crohns-F                  0.5
112732 Match Control Crohns-F    0.2
112725 Crohns-M                  0.0
112387 Match Control Crohns-M    0.0
112378 Crohns-M                  3.6
112390 Match Control Crohns-M    0.0
112726 Crohns-M                  0.0
112731 Match Control Crohns-M    0.2
112380 Ulcer Col-F               0.0
112734 Match Control Ulcer Col-F 0.5
112384 Ulcer Col-F               0.0
112737 Match Control Ulcer Col-F 0.0
112386 Ulcer Col-F               100.0
112738 Match Control Ulcer Col-F 3.0
112381 Ulcer Col-M               0.2
112735 Match Control Ulcer Col-M 2.2
112382 Ulcer Col-M               0.2
112394 Match Control Ulcer Col-M 0.0
112383 Ulcer Col-M               0.3
112736 Match Control Ulcer Col-M 0.1
112423 Psoriasis-F               0.4
112427 Match Control Psoriasis-F 0.0
112418 Psoriasis-M               6.8
112723 Match Control Psoriasis-M 2.6
112419 Psoriasis-M               2.7
112424 Match Control Psoriasis-M 2.9
112420 Psoriasis-M               0.6
112425 Match Control Psoriasis-M 2.3
104689 (MF) OA Bone-Backus       0.2
104690 (MF) Adj “Normal” Bone-Backus 2.6
104691 (MF) OA Synovium-Backus   0.7
104692 (BA) OA Cartilage-Backus  2.0
104694 (BA) OA Bone-Backus       0.3
104695 (BA) Adj “Normal” Bone-Backus 0.4
104696 (BA) OA Synovium-Backus   0.0
104700 (SS) OA Bone-Backus       0.0
104701 (SS) Adj “Normal” Bone-Backus 1.5
104702 (SS) OA Synovium-Backus   2.6
117093 OA Cartilage Rep7         0.2
112672 OA Bone5                  0.1
112673 OA Synovium5              2.7
112674 OA Synovial Fluid cells5  0.2
117100 OA Cartilage Rep14        3.1
112756 OA Bone9                  1.6
112757 OA Synovium9              0.0
112758 OA Synovial Fluid Cells9  0.4
117125 RA Cartilage Rep2         1.5
113492 Bone2 RA                  0.0
113493 Synovium2 RA              0.9
113494 Syn Fluid Cells RA        0.9
113499 Cartilage4 RA             51.4
113500 Bone4 RA                  82.4
113501 Synovium4 RA              13.1
113502 Syn Fluid Cells4 RA       0.0
113495 Cartilage3 RA             14.3
113496 Bone3 RA                  3.1
113497 Synovium3 RA              0.3
113498 Syn Fluid Cells3 RA       0.6
117106 Normal Cartilage Rep20    42.3
113663 Bone3 Normal              0.4
113664 Synovium3 Normal          0.4
113665 Syn Fluid Cells3 Normal   0.2
117107 Normal Cartilage Rep22    7.9
113667 Bone4 Normal              0.0
113668 Synovium4 Normal          0.0
113669 Syn Fluid Cells4 Normal   0.0

[1004]

TABLE VC
CNS_neurodegeneration_v1.0
                               Rel. Exp. (%)
                               Ag5694, Run
Tissue Name                    247018769
AD 1 Hippo                     0.0
AD 2 Hippo                     11.4
AD 3 Hippo                     0.0
AD 4 Hippo                     4.5
AD 5 hippo                     0.0
AD 6 Hippo                     33.0
Control 2 Hippo                0.0
Control 4 Hippo                0.0
Control (Path) 3 Hippo         0.0
AD 1 Temporal Ctx              7.2
AD 2 Temporal Ctx              17.3
AD 3 Temporal Ctx              7.1
AD 4 Temporal Ctx              0.0
AD 5 Inf Temporal Ctx          7.4
AD 5 Sup Temporal Ctx          6.4
AD 6 Inf Temporal Ctx          19.6
AD 6 Sup Temporal Ctx          100.0
Control 1 Temporal Ctx         0.0
Control 2 Temporal Ctx         0.0
Control 3 Temporal Ctx         0.0
Control 4 Temporal Ctx         21.0
Control (Path) 1 Temporal Ctx  6.4
Control (Path) 2 Temporal Ctx  13.0
Control (Path) 3 Temporal Ctx  0.0
Control (Path) 4 Temporal Ctx  15.7
AD 1 Occipital Ctx             0.0
AD 2 Occipital Ctx (Missing)   0.0
AD 3 Occipital Ctx             4.3
AD 4 Occipital Ctx             7.1
AD 5 Occipital Ctx             0.0
AD 6 Occipital Ctx             25.5
Control 1 Occipital Ctx        0.0
Control 2 Occipital Ctx        30.6
Control 3 Occipital Ctx        6.4
Control 4 Occipital Ctx        5.1
Control (Path) 1 Occipital Ctx 6.4
Control (Path) 2 Occipital Ctx 0.0
Control (Path) 3 Occipital Ctx 0.0
Control (Path) 4 Occipital Ctx 13.1
Control 1 Parietal Ctx         0.0
Control 2 Parietal Ctx         5.0
Control 3 Parietal Ctx         5.7
Control (Path) 1 Parietal Ctx  7.7
Control (Path) 2 Parietal Ctx  13.6
Control (Path) 3 Parietal Ctx  4.1
Control (Path) 4 Parietal Ctx  2.1

[1005]

TABLE VD
General_screening_panel_v1.5
                                 Rel. Exp. (%)
                                 Ag5694, Run
Tissue Name                      249040574
Adipose                          0.6
Melanoma* Hs688(A).T             0.0
Melanoma* Hs688(B).T             0.0
Melanoma* M14                    0.0
Melanoma* LOXIMVI                0.9
Melanoma* SK-MEL-5               11.0
Squamous cell carcinoma SCC-4    2.3
Testis Pool                      100.0
Prostate ca.* (bone met) PC-3    0.0
Prostate Pool                    0.0
Placenta                         4.3
Uterus Pool                      0.4
Ovarian ca. OVCAR-3              5.2
Ovarian ca. SK-OV-3              3.3
Ovarian ca. OVCAR-4              2.3
Ovarian ca. OVCAR-5              1.4
Ovarian ca. IGROV-1              1.2
Ovarian ca. OVCAR-8              1.6
Ovary                            0.0
Breast ca. MCF-7                 0.9
Breast ca. MDA-MB-231            0.5
Breast ca. BT 549                0.0
Breast ca. T47D                  0.0
Breast ca. MDA-N                 0.0
Breast Pool                      0.8
Trachea                          2.6
Lung                             0.0
Fetal Lung                       12.7
Lung ca. NCI-N417                0.0
Lung ca. LX-1                    13.5
Lung ca. NCI-H146                0.5
Lung ca. SHP-77                  8.6
Lung ca. A549                    1.2
Lung ca. NCI-H526                0.0
Lung ca. NCI-H23                 41.8
Lung ca. NCI-H460                0.6
Lung ca. HOP-62                  0.6
Lung ca. NCI-H522                0.0
Liver                            0.0
Fetal Liver                      0.5
Liver ca. HepG2                  90.1
Kidney Pool                      0.0
Fetal Kidney                     0.9
Renal ca. 786-0                  0.6
Renal ca. A498                   1.0
Renal ca. ACHN                   0.7
Renal ca. UO-31                  1.3
Renal ca. TK-10                  40.3
Bladder                          1.4
Gastric ca. (liver met.) NCI-N87 2.8
Gastric ca. KATO III             1.1
Colon ca. SW-948                 0.0
Colon ca. SW480                  1.6
Colon ca.* (SW480 met) SW620     0.6
Colon ca. HT29                   0.0
Colon ca. HCT-116                2.8
Colon ca. CaCo-2                 0.0
Colon cancer tissue              2.5
Colon ca. SW1116                 0.0
Colon ca. Colo-205               0.0
Colon ca. SW-48                  0.0
Colon Pool                       0.0
Small Intestine Pool             0.0
Stomach Pool                     0.0
Bone Marrow Pool                 0.0
Fetal Heart                      0.0
Heart Pool                       0.0
Lymph Node Pool                  0.0
Fetal Skeletal Muscle            0.0
Skeletal Muscle Pool             0.3
Spleen Pool                      0.5
Thymus Pool                      3.0
CNS cancer (glio/astro) U87-MG   0.9
CNS cancer (glio/astro) U-118-MG 0.3
CNS cancer (neuro; met) SK-N-AS  0.9
CNS cancer (astro) SF-539        0.0
CNS cancer (astro) SNB-75        0.3
CNS cancer (glio) SNB-19         0.9
CNS cancer (glio) SF-295         0.0
Brain (Amygdala) Pool            0.3
Brain (cerebellum)               0.5
Brain (fetal)                    0.0
Brain (Hippocampus) Pool         0.2
Cerebral Cortex Pool             0.9
Brain (Substantia nigra) Pool    0.8
Brain (Thalamus) Pool            0.9
Brain (whole)                    0.0
Spinal Cord Pool                 0.3
Adrenal Gland                    0.2
Pituitary gland Pool             0.0
Salivary Gland                   0.2
Thyroid (female)                 0.6
Pancreatic ca. CAPAN2            6.7
Pancreas Pool                    0.0

[1006]

TABLE VE
Panel 4.1D
                                 Rel. Exp. (%)
                                 Ag5694, Run
Tissue Name                      246504805
Secondary Th1 act                0.0
Secondary Th2 act                0.0
Secondary Tr1 act                0.0
Secondary Th1 rest               0.0
Secondary Th2 rest               0.0
Secondary Tr1 rest               0.0
Primary Th1 act                  0.0
Primary Th2 act                  0.0
Primary Tr1 act                  0.0
Primary Th1 rest                 0.0
Primary Th2 rest                 0.0
Primary Tr1 rest                 0.0
CD45RA CD4 lymphocyte act        0.0
CD45RO CD4 lymphocyte act        0.4
CD8 lymphocyte act               0.0
Secondary CD8 lymphocyte rest    0.9
Secondary CD8 lymphocyte act     0.0
CD4 lymphocyte none              0.0
2ry Th1/Th2/Tr1_anti-CD95 CH11   0.0
LAK cells rest                   0.4
LAK cells IL-2                   0.0
LAK cells IL-2 + IL-12           0.0
LAK cells IL-2 + IFN gamma       0.0
LAK cells IL-2 + IL-18           0.0
LAK cells PMA/ionomycin          5.8
NK Cells IL-2 rest               0.4
Two Way MLR 3 day                0.0
Two Way MLR 5 day                0.0
Two Way MLR 7 day                0.0
PBMC rest                        0.0
PBMC PWM                         0.0
PBMC PHA-L                       0.0
Ramos (B cell) none              0.0
Ramos (B cell) ionomycin         0.0
B lymphocytes PWM                0.0
B lymphocytes CD40L and IL-4     0.4
EOL-1 dbcAMP                     0.0
EOL-1 dbcAMP PMA/ionomycin       0.9
Dendritic cells none             0.0
Dendritic cells LPS              0.0
Dendritic cells anti-CD40        0.0
Monocytes rest                   0.0
Monocytes LPS                    100.0
Macrophages rest                 0.0
Macrophages LPS                  0.6
HUVEC none                       0.0
HUVEC starved                    0.0
HUVEC IL-1beta                   0.5
HUVEC IFN gamma                  0.0
HUVEC TNF alpha + IFN gamma      0.0
HUVEC TNF alpha + IL4            0.0
HUVEC IL-11                      0.0
Lung Microvascular EC none       0.0
Lung Microvascular EC TNFalpha + IL-1beta 0.0
Microvascular Dermal EC none     0.0
Microsvasular Dermal EC TNFalpha + IL-1beta 0.0
Bronchial epithelium TNFalpha + IL1beta 0.0
Small airway epithelium none     0.0
Small airway epithelium TNFalpha + IL-1beta 0.0
Coronery artery SMC rest         0.0
Coronery artery SMC TNFalpha + IL-1beta 0.0
Astrocytes rest                  0.0
Astrocytes TNFalpha + IL-1beta   0.0
KU-812 (Basophil) rest           0.0
KU-812 (Basophil) PMA/ionomycin  0.0
CCD1106 (Keratinocytes) none     1.1
CCD1106 (Keratinocytes) TNFalpha + IL-1beta 1.8
Liver cirrhosis                  0.6
NCI-H292 none                    2.1
NCI-H292 IL-4                    1.4
NCI-H292 IL-9                    0.0
NCI-H292 IL-13                   0.0
NCI-H292 IFN gamma               0.4
HPAEC none                       0.0
HPAEC TNF alpha + IL-1 beta      0.0
Lung fibroblast none             0.0
Lung fibroblast TNF alpha + IL-1 beta 0.0
Lung fibroblast IL-4             0.0
Lung fibroblast IL-9             0.0
Lung fibroblast IL-13            0.0
Lung fibroblast IFN gamma        0.0
Dermal fibroblast CCD1070 rest   0.0
Dermal fibroblast CCD1070 TNF alpha 0.0
Dermal fibroblast CCD1070 IL-1 beta 0.0
Dermal fibroblast IFN gamma      0.0
Dermal fibroblast IL-4           0.0
Dermal Fibroblasts rest          0.0
Neutrophils TNFa + LPS           13.1
Neutrophils rest                 0.4
Colon                            0.0
Lung                             0.0
Thymus                           0.0
Kidney                           2.4

[1007]

TABLE VF
Panel 5 Islet
                                 Rel. Exp. (%)
                                 Ag5694, Run
Tissue Name                      253330720
97457_Patient-02go_adipose       0.0
97476_Patient-07sk_skeletal muscle 0.0
97477_Patient-07ut_uterus        0.0
97478_Patient-07pl_placenta      0.0
99167_Bayer Patient 1            67.8
97482_Patient-08ut_uterus        0.0
97483_Patient-08pl_placenta      12.2
97486_Patient-09sk_skeletal muscle 5.5
97487_Patient-09ut_uterus        0.0
97488_Patient-09pl_placenta      7.4
97492_Patient-10ut_uterus        0.0
97493_Patient-10pl_placenta      0.0
97495_Patient-11go_adipose       0.0
97496_Patient-11sk_skeletal muscle 0.0
97497 Patient-11ut_uterus        0.0
97498_Patient-11pl_placenta      16.7
97500_Patient-12go_adipose       0.0
97501_Patient-12sk_skeletal muscle 0.0
97502_Patient-12ut_uterus        0.0
97503_Patient-12pl_placenta      8.4
94721_Donor 2 U - A_Mesenchymal Stem Cells 0.0
94722_Donor 2 U - B_Mesenchymal Stem Cells 0.0
94723_Donor 2 U - C_Mesenchymal Stem Cells 0.0
94709_Donor 2 AM - A_adipose     0.0
94710_Donor 2 AM - B_adipose     0.0
94711_Donor 2 AM - C_adipose     0.0
94712_Donor 2 AD - A_adipose     0.0
94713_Donor 2 AD - B_adipose     0.0
94714_Donor 2 AD - C_adipose     0.0
94742_Donor 3 U - A_Mesenchymal Stem Cells 0.0
94743_Donor 3 U - B_Mesenchymal Stem Cells 0.0
94730_Donor 3 AM - A_adipose     0.0
94731_Donor 3 AM - B_adipose     0.0
94732_Donor 3 AM - C_adipose     0.0
94733_Donor 3 AD - A_adipose     0.0
94734_Donor 3 AD - B_adipose     7.6
94735_Donor 3 AD - C_adipose     0.0
77138_Liver_HepG2untreated       100.0
73556_Heart_Cardiac stromal cells (primary) 0.0
81735_Small Intestine            0.0
72409_Kidney_Proximal Convoluted Tubule 0.0
82685_Small intestine_Duodenum   0.0
90650_Adrenal_Adrenocortical adenoma 0.0
72410_Kidney_HRCE                7.6
72411_Kidney_HRE                 0.0
73139_Uterus_Uterine smooth muscle cells 0.0

[1008] AI_comprehensive panel_v1.0 Summary: Ag5694 Highest expression of this gene is detected in ulcerative colitis sample (CT=30.2). Interestingly, expression of this gene is higher in ulcerative colitis sample as compared to matching control sample (CT=35). Therefore, expression of this gene may be used to distinguish between these two samples and also as a marker to detect ulcerative colitis. In addition, moderate expression of this gene is seen in cartilage, bone and synovium from rheumatoid arthritis patient, low expression in normal lung, psoriasis, and normal cartilage Rep22. Therefore, therapeutic modulation of this gene may be useful in the treatment of rheumatoid arthritis, ulcerative colitis, and psoriasis.

[1009] CNS_neurodegeneration_v1.0 Summary: Ag5694 Low expression of this gene is detected in temporal cortex of an Alzheimer's patient. Therefore, therapeutic modulation of this gene may be useful in the treatment of Alzheimer's disease.

[1010] General_screening_panel_v1.5 Summary: Ag5694 Highest expression of this gene is detected in testis (CT=29.8). Therefore, expression of this gene may be used to differentiate testis from other samples in this panel. In addition, therapeutic modulation of this gene may be useful in the treatment of testis related diseases including fertility and hypogonadism. In addition, moderate to low levels of expression of this gene is detected in number of cancer cell lines derived from melanoma, pancreatic, renal, liver, lung, and ovarian cancers. Therefore, expression of this gene may be used as diagnostic marker to detect these cancers and also, therapeutic modulation of this gene through the use of antibodies or small molecule drug may be useful in the treatment of melanoma, pancreatic, renal, liver, lung, and ovarian cancers.

[1011] Panel 4.1D Summary: Ag5694 Moderate expression of this gene is detected mainly in LPS treated monocytes (CT=29.9). In addition, low levels of expression of this gene is also seen in TNF alpha and LPS treated neutrophils. Therefore, expression of this gene may be used to distinguish activated monocytes and neutrophils from other samples in this panel. The expression of this gene in LPS treated monocytes, cells that play a crucial role in linking innate immunity to adaptive immunity, suggests a role for this gene product in initiating inflammatory reactions. Therefore, modulation of the expression or activity of this gene through the application of monoclonal antibodies may reduce or prevent early stages of inflammation and reduce the severity of inflammatory diseases such as psoriasis, asthma, inflammatory bowel disease, rheumatoid arthritis, osteoarthritis and other lung inflammatory diseases. In addition, small molecule or antibody antagonists of this gene product may be effective in increasing the immune response in patients with AIDS or other immunodeficiencies.

[1012] Panel 5 Islet Summary: Ag5694 Low levels of expression of this gene is exclusively seen in liver cancer HepG2 cell line (CT=34.7). Please see panel 1.5 for further utility of this gene.

[1013] W. CG154465-01: Kinesin 18B.

[1014] Expression of gene CG 154465-01 was assessed using the primer-probe set Ag5695, described in Table WA. Results of the RTQ-PCR runs are shown in Tables WB and WC.

TABLE WA
Probe Name Ag5695
			Start	SEQ ID
Primers	Sequence	Length	Position	No
Forward	5′-tcaatgccacctttgatctct-3′	21	2279	537
Probe	TET-5′-aaagcccagtttccatgaatgcattg-3′-TAMRA	26	2316	538
Reverse	5′-cagctcctggggtattttgt-3′	20	2348	539

[1015]

TABLE WB
General_screening_panel_v1.5
                                 Rel. Exp. (%)
                                 Ag5695, Run
Tissue Name                      245274429
Adipose                          0.1
Melanoma* Hs688(A).T             0.5
Melanoma* Hs688(B).T             1.2
Melanoma* M14                    43.2
Melanoma* LOXIMVI                45.7
Melanoma* SK-MEL-5               17.3
Squamous cell carcinoma SCC-4    14.6
Testis Pool                      1.0
Prostate ca.* (bone met) PC-3    2.2
Prostate Pool                    0.3
Placenta                         1.5
Uterus Pool                      0.3
Ovarian ca. OVCAR-3              39.5
Ovarian ca. SK-OV-3              82.4
Ovarian ca. OVCAR-4              23.7
Ovarian ca. OVCAR-5              33.0
Ovarian ca. IGROV-1              9.3
Ovarian ca. OVCAR-8              10.5
Ovary                            0.0
Breast ca. MCF-7                 20.9
Breast ca. MDA-MB-231            69.7
Breast ca. BT 549                50.0
Breast ca. T47D                  24.1
Breast ca. MDA-N                 24.3
Breast Pool                      0.6
Trachea                          0.6
Lung                             0.1
Fetal Lung                       7.2
Lung ca. NCI-N417                13.9
Lung ca. LX-1                    25.3
Lung ca. NCI-H146                14.5
Lung ca. SHP-77                  25.5
Lung ca. A549                    55.9
Lung ca. NCI-H526                14.9
Lung ca. NCI-H23                 22.4
Lung ca. NCI-H460                0.0
Lung ca. HOP-62                  5.4
Lung ca. NCI-H522                34.6
Liver                            0.0
Fetal Liver                      33.2
Liver ca. HepG2                  12.8
Kidney Pool                      0.1
Fetal Kidney                     12.2
Renal ca. 786-0                  30.6
Renal ca. A498                   4.9
Renal ca. ACHN                   12.9
Renal ca. UO-31                  17.3
Renal ca. TK-10                  24.0
Bladder                          3.1
Gastric ca. (liver met.) NCI-N87 5.4
Gastric ca. KATO III             97.9
Colon ca. SW-948                 24.8
Colon ca. SW480                  86.5
Colon ca.* (SW480 met) SW620     37.6
Colon ca. HT29                   17.4
Colon ca. HCT-116                100.0
Colon ca. CaCo-2                 31.4
Colon cancer tissue              7.0
Colon ca. SW1116                 16.8
Colon ca. Colo-205               18.2
Colon ca. SW-48                  11.0
Colon Pool                       0.6
Small Intestine Pool             0.2
Stomach Pool                     0.2
Bone Marrow Pool                 0.2
Fetal Heart                      6.0
Heart Pool                       0.3
Lymph Node Pool                  0.6
Fetal Skeletal Muscle            3.0
Skeletal Muscle Pool             0.0
Spleen Pool                      1.4
Thymus Pool                      12.1
CNS cancer (glio/astro) U87-MG   19.1
CNS cancer (glio/astro) U-118-MG 97.9
CNS cancer (neuro; met) SK-N-AS  52.5
CNS cancer (astro) SF-539        25.7
CNS cancer (astro) SNB-75        66.0
CNS cancer (glio) SNB-19         9.4
CNS cancer (glio) SF-295         5.3
Brain (Amygdala) Pool            0.1
Brain (cerebellum)               0.1
Brain (fetal)                    2.7
Brain (Hippocampus) Pool         0.2
Cerebral Cortex Pool             0.3
Brain (Substantia nigra) Pool    0.1
Brain (Thalamus) Pool            0.2
Brain (whole)                    0.3
Spinal Cord Pool                 0.1
Adrenal Gland                    0.1
Pituitary gland Pool             0.1
Salivary Gland                   0.3
Thyroid (female)                 0.0
Pancreatic ca. CAPAN2            41.8
Pancreas Pool                    0.5

[1016]

TABLE WC
Panel 4.1D
                                 Rel. Exp. (%)
                                 Ag5695, Run
Tissue Name                      246504814
Secondary Th1 act                79.6
Secondary Th2 act                74.2
Secondary Tr1 act                18.9
Secondary Th1 rest               0.2
Secondary Th2 rest               0.3
Secondary Tr1 rest               0.0
Primary Th1 act                  0.9
Primary Th2 act                  38.4
Primary Tr1 act                  30.8
Primary Th1 rest                 2.0
Primary Th2 rest                 4.2
Primary Tr1 rest                 2.7
CD45RA CD4 lymphocyte act        52.5
CD45RO CD4 lymphocyte act        47.0
CD8 lymphocyte act               11.4
Secondary CD8 lymphocyte rest    24.1
Secondary CD8 lymphocyte act     4.4
CD4 lymphocyte none              0.0
2ry Th1/Th2/Tr1_anti-CD95 CH11   3.5
LAK cells rest                   1.6
LAK cells IL-2                   8.7
LAK cells IL-2 + IL-12           1.9
LAK cells IL-2 + IFN gamma       10.5
LAK cells IL-2 + IL-18           6.3
LAK cells PMA/ionomycin          3.1
NK Cells IL-2 rest               81.2
Two Way MLR 3 day                1.9
Two Way MLR 5 day                2.9
Two Way MLR 7 day                9.2
PBMC rest                        0.0
PBMC PWM                         4.0
PBMC PHA-L                       12.5
Ramos (B cell) none              8.1
Ramos (B cell) ionomycin         76.3
B lymphocytes PWM                52.9
B lymphocytes CD40L and IL-4     49.7
EOL-1 dbcAMP                     31.6
EOL-1 dbcAMP PMA/ionomycin       1.9
Dendritic cells none             0.6
Dendritic cells LPS              0.0
Dendritic cells anti-CD40        0.0
Monocytes rest                   0.0
Monocytes LPS                    0.0
Macrophages rest                 2.2
Macrophages LPS                  0.2
HUVEC none                       31.0
HUVEC starved                    55.5
HUVEC IL-1beta                   42.9
HUVEC IFN gamma                  27.7
HUVEC TNF alpha + IFN gamma      5.7
HUVEC TNF alpha + IL4            4.5
HUVEC IL-11                      23.2
Lung Microvascular EC none       24.8
Lung Microvascular EC TNFalpha + IL-1beta 1.9
Microvascular Dermal EC none     2.4
Microsvasular Dermal EC TNFalpha + IL-1beta 4.4
Bronchial epithelium TNFalpha + IL1beta 1.8
Small airway epithelium none     1.2
Small airway epithelium TNFalpha + IL-1beta 4.5
Coronery artery SMC rest         4.4
Coronery artery SMC TNFalpha + IL-1beta 3.2
Astrocytes rest                  0.3
Astrocytes TNFalpha + IL-1beta   0.7
KU-812 (Basophil) rest           32.1
KU-812 (Basophil) PMA/ionomycin  42.3
CCD1106 (Keratinocytes) none     44.8
CCD1106 (Keratinocytes) TNFalpha + IL-1beta 9.1
Liver cirrhosis                  2.7
NCI-H292 none                    19.9
NCI-H292 IL-4                    42.9
NCI-H292 IL-9                    58.6
NCI-H292 IL-13                   52.5
NCI-H292 IFN gamma               20.3
HPAEC none                       7.4
HPAEC TNF alpha + IL-1 beta      21.3
Lung fibroblast none             5.9
Lung fibroblast TNF alpha + IL-1 beta 8.9
Lung fibroblast IL-4             0.8
Lung fibroblast IL-9             5.8
Lung fibroblast IL-13            0.4
Lung fibroblast IFN gamma        1.4
Dermal fibroblast CCD1070 rest   100.0
Dermal fibroblast CCD1070 TNF alpha 93.3
Dermal fibroblast CCD1070 IL-1 beta 40.3
Dermal fibroblast IFN gamma      27.9
Dermal fibroblast IL-4           40.3
Dermal Fibroblasts rest          18.3
Neutrophils TNFa + LPS           0.0
Neutrophils rest                 0.0
Colon                            0.0
Lung                             0.2
Thymus                           8.5
Kidney                           0.0

[1017] CNS_neurodegeneration_v1.0 Summary: Ag5695 Expression of this gene is low/undetectable (CTs>35) across all of the samples on this panel (data not shown).

[1018] General_screening_panel_v1.5 Summary: Ag5695 Highest expression of this gene is detected in a colon cancer HCT-116 cell line (CT=27). Moderate expression of this gene is also seen in cluster of cancer cell lines derived from pancreatic, gastric, colon, lung, liver, renal, breast, ovarian, prostate, squamous cell carcinoma, melanoma and brain cancers. Thus, expression of this gene could be used as a marker to detect the presence of these cancers. Furthermore, therapeutic modulation of the expression or function of this gene may be effective in the treatment of pancreatic, gastric, colon, lung, liver, renal, breast, ovarian, prostate, squamous cell carcinoma, melanoma and brain cancers.

[1019] In addition, significant expression of this gene is seen in fetal tissues, including fetal lung, liver, kidney, heart, and skeletal muscle. Expression of this gene is higher in fetal (CTs=28-32) compared to corresponding adult lung, liver, kidney, heart, and skeletal muscle tissues. Therefore, expression of this gene may be useful in distinguishing between fetal and adult lung, liver, kidney, heart, and skeletal muscle. In addition, expression in fetal tissue suggests a role for the protein encoded by this gene in growth and development of these tissues in the fetus and thus may also act in a regenerative capacity in the adult.

[1020] Panel 4.1D Summary: Ag5695 Highest expression of this gene is detected in dermal fibroblast (CT=29.2). Moderate to low levels of expression of this gene is detected in polarized T cells (primary and secondary Th1, Th2, and Tr1), activated CD45RA CD4 and CD45RO CD4 lymphocytes, LAK cells, resting IL-2 treated NK cells, activated PBMC cells, Ramos B cells, B lymphocytes, eosinophils, endothelial cells, basophils, NCI-H292 cells, lung and dermal fibroblasts and thymus. Interestingly, expression of this gene is upregulated in activated polarized T cells, stimulted PBMC cells, and activated Ramos B cells. Therefore, therapeutic modulation of this gene may be useful in the treatment of autoimmune and inflammatory disorders including psoriasis, allergy, asthma, inflammatory bowel disease, rheumatoid arthritis and osteoarthritis.

[1021] X. CG154492-01: High-Affiniti CGMP-Specific 3′,5′-Cyclic Phosphodiesterase 9A.

[1022] Expression of gene CG154492-01 was assessed using the primer-probe set Ag6818, described in Table XA. Results of the RTQ-PCR runs are shown in Table XB.

TABLE XA
Probe Name Ag6818
			Start	SEQ ID
Primers	Sequence	Length	Position	No
Forward	5′-gcagaaattatggattctttcaaag-3′	25	1345	540
Probe	TET-5′-tcctcgttgctgtagtcaaaattctcca-3′-TAMRA	28	1376	541
Reverse	5′-ggtcgctgagggtcatg-3′	17	1407	542

[1023]

TABLE XB
General_screening_panel_v1.6
                                 Rel. Exp. (%)
                                 Ag6818, Run
Tissue Name                      278391557
Adipose                          18.4
Melanoma* Hs688(A).T             0.0
Melanoma* Hs688(B).T             0.0
Melanoma* M14                    0.0
Melanoma* LOXIMVI                0.0
Melanoma* SK-MEL-5               10.5
Squamous cell carcinoma SCC-4    0.0
Testis Pool                      8.1
Prostate ca.* (bone met) PC-3    0.0
Prostate Pool                    24.3
Placenta                         3.7
Uterus Pool                      0.0
Ovarian ca. OVCAR-3              53.6
Ovarian ca. SK-OV-3              31.6
Ovarian ca. OVCAR-4              9.4
Ovarian ca. OVCAR-5              24.7
Ovarian ca. IGROV-1              14.1
Ovarian ca. OVCAR-8              4.3
Ovary                            6.1
Breast ca. MCF-7                 3.0
Breast ca. MDA-MB-231            0.0
Breast ca. BT 549                0.0
Breast ca. T47D                  0.0
Breast ca. MDA-N                 5.6
Breast Pool                      2.2
Trachea                          2.8
Lung                             0.0
Fetal Lung                       33.2
Lung ca. NCI-N417                0.0
Lung ca. LX-1                    3.1
Lung ca. NCI-H146                3.5
Lung ca. SHP-77                  0.0
Lung ca. A549                    0.0
Lung ca. NCI-H526                0.0
Lung ca. NCI-H23                 25.0
Lung ca. NCI-H460                7.3
Lung ca. HOP-62                  0.0
Lung ca. NCI-H522                65.1
Liver                            0.0
Fetal Liver                      4.4
Liver ca. HepG2                  31.9
Kidney Pool                      27.2
Fetal Kidney                     10.3
Renal ca. 786-0                  0.0
Renal ca. A498                   0.0
Renal ca. ACHN                   0.0
Renal ca. UO-31                  0.0
Renal ca. TK-10                  15.4
Bladder                          0.0
Gastric ca. (liver met.) NCI-N87 15.4
Gastric ca. KATO III             0.0
Colon ca. SW-948                 0.0
Colon ca. SW480                  19.6
Colon ca.* (SW480 met) SW620     3.2
Colon ca. HT29                   3.6
Colon ca. HCT-116                29.7
Colon ca. CaCo-2                 7.9
Colon cancer tissue              2.5
Colon ca. SW1116                 0.0
Colon ca. Colo-205               0.0
Colon ca. SW-48                  0.0
Colon Pool                       3.0
Small Intestine Pool             5.9
Stomach Pool                     6.0
Bone Marrow Pool                 0.0
Fetal Heart                      9.8
Heart Pool                       3.1
Lymph Node Pool                  3.5
Fetal Skeletal Muscle            3.3
Skeletal Muscle Pool             0.0
Spleen Pool                      2.8
Thymus Pool                      6.0
CNS cancer (glio/astro) U87-MG   0.0
CNS cancer (glio/astro) U-118-MG 0.0
CNS cancer (neuro; met) SK-N-AS  0.0
CNS cancer (astro) SF-539        0.0
CNS cancer (astro) SNB-75        0.0
CNS cancer (glio) SNB-19         24.0
CNS cancer (glio) SF-295         0.0
Brain (Amygdala) Pool            3.7
Brain (cerebellum)               50.7
Brain (fetal)                    100.0
Brain (Hippocampus) Pool         2.2
Cerebral Cortex Pool             7.6
Brain (Substantia nigra) Pool    11.8
Brain (Thalamus) Pool            15.3
Brain (whole)                    20.2
Spinal Cord Pool                 10.1
Adrenal Gland                    16.6
Pituitary gland Pool             0.0
Salivary Gland                   4.3
Thyroid (female)                 0.0
Pancreatic ca. CAPAN2            30.1
Pancreas Pool                    14.0

[1024] CNS_neurodegeneration_v1.0 Summary: Ag6818 Expression of this gene is low/undetectable in all samples on this panel (CTs>35). (Data not shown.)

[1025] General_screening_panel_v1.6 Summary: Ag6818 Expression of this gene is limited to the fetal brain (CT=34.5). Thus, expression of this gene could be used to differentiate between fetal and adult brain tissue and as a marker of fetal neural tissue.

[1026] Panel 4.1D Summary: Ag6818 Expression of this gene is low/undetectable in all samples on this panel (CTs>35). (Data not shown.)

[1027] Panel 5 Islet Summary: Ag6818 Expression of this gene is low/undetectable in all samples on this panel (CTs>35). (Data not shown.)

[1028] Y. CG154509-01: Cytoplasmic Dynein Heavy Chain.

[1029] Expression of gene CG154509-01 was assessed using the primer-probe set Ag5696, described in Table YA. Results of the RTQ-PCR runs are shown in Tables YB, YC and YD.

TABLE YA
Probe Name Ag5696
			Start	SEQ ID
Primers	Sequence	Length	Position	No
Forward	5′-ccagattgaagtgatgaaagga-3′	22	3156	543
Probe	TET-5′-cacgtcttcagatctattatcaagaactgg-3′-TAMRA	30	3188	544
Reverse	5′-gtcccaacgagctttaaatttt-3′	22	3219	545

[1030]

TABLE YB
AI_comprehensive panel_v1.0
                                 Rel. Exp. (%)
                                 Ag5696, Run
Tissue Name                      245243119
110967 COPD-F                    20.3
110980 COPD-F                    5.1
110968 COPD-M                    21.3
110977 COPD-M                    24.7
110989 Emphysema-F               8.3
110992 Emphysema-F               16.5
110993 Emphysema-F               18.2
110994 Emphysema-F               8.6
110995 Emphysema-F               15.2
110996 Emphysema-F               8.5
110997 Asthma-M                  18.2
111001 Asthma-F                  4.5
111002 Asthma-F                  54.0
111003 Atopic Asthma-F           20.6
111004 Atopic Asthma-F           0.0
111005 Atopic Asthma-F           17.2
111006 Atopic Asthma-F           76.8
111417 Allergy-M                 85.3
112347 Allergy-M                 0.0
112349 Normal Lung-F             5.1
112357 Normal Lung-F             13.4
112354 Normal Lung-M             89.5
112374 Crohns-F                  52.1
112389 Match Control Crohns-F    47.6
112375 Crohns-F                  6.2
112732 Match Control Crohns-F    17.7
112725 Crohns-M                  42.3
112387 Match Control Crohns-M    18.6
112378 Crohns-M                  0.3
112390 Match Control Crohns-M    19.2
112726 Crohns-M                  0.6
112731 Match Control Crohns-M    4.7
112380 Ulcer Col-F               48.3
112734 Match Control Ulcer Col-F 9.1
112384 Ulcer Col-F               13.2
112737 Match Control Ulcer Col-F 23.5
112386 Ulcer Col-F               24.1
112738 Match Control Ulcer Col-F 26.4
112381 Ulcer Col-M               5.6
112735 Match Control Ulcer Col-M 14.5
112382 Ulcer Col-M               37.1
112394 Match Control Ulcer Col-M 7.1
112383 Ulcer Col-M               21.9
112736 Match Control Ulcer Col-M 44.1
112423 Psoriasis-F               34.2
112427 Match Control Psoriasis-F 21.0
112418 Psoriasis-M               22.5
112723 Match Control Psoriasis-M 61.1
112419 Psoriasis-M               2.8
112424 Match Control Psoriasis-M 24.7
112420 Psoriasis-M               12.3
112425 Match Control Psoriasis-M 25.9
104689 (MF) OA Bone-Backus       29.5
104690 (MF) Adj “Normal” Bone-Backus 0.6
104691 (MF) OA Synovium-Backus   94.6
104692 (BA) OA Cartilage-Backus  21.0
104694 (BA) OA Bone-Backus       15.1
104695 (BA) Adj “Normal” Bone-Backus 31.6
104696 (BA) OA Synovium-Backus   11.4
104700 (SS) OA Bone-Backus       10.5
104701 (SS) Adj “Normal” Bone-Backus 100.0
104702 (SS) OA Synovium-Backus   10.8
117093 OA Cartilage Rep7         9.2
112672 OA Bone5                  4.9
112673 OA Synovium5              2.4
112674 OA Synovial Fluid cells5  12.4
117100 OA Cartilage Rep14        72.7
112756 OA Bone9                  5.7
112757 OA Synovium9              0.9
112758 OA Synovial Fluid Cells9  21.5
117125 RA Cartilage Rep2         5.5
113492 Bone2 RA                  0.0
113493 Synovium2 RA              10.1
113494 Syn Fluid Cells RA        8.9
113499 Cartilage4 RA             18.8
113500 Bone4 RA                  0.5
113501 Synovium4 RA              5.0
113502 Syn Fluid Cells4 RA       4.8
113495 Cartilage3 RA             33.4
113496 Bone3 RA                  18.9
113497 Synovium3 RA              3.9
113498 Syn Fluid Cells3 RA       0.0
117106 Normal Cartilage Rep20    41.2
113663 Bone3 Normal              31.6
113664 Synovium3 Normal          18.3
113665 Syn Fluid Cells3 Normal   80.1
117107 Normal Cartilage Rep22    13.3
113667 Bone4 Normal              23.8
113668 Synovium4 Normal          22.1
113669 Syn Fluid Cells4 Normal   20.3

[1031]

TABLE YC
CNS_neurodegeneration_v1.0
		Rel. Exp. (%)	Rel. Exp. (%)
		Ag5696, Run	Ag5696, Run
	Tissue Name	247018771	312325348
	AD 1 Hippo	9.7	45.4
	AD 2 Hippo	33.0	93.3
	AD 3 Hippo	17.1	43.2
	AD 4 Hippo	24.5	42.0
	AD 5 hippo	100.0	33.7
	AD 6 Hippo	45.4	100.0
	Control 2	34.4	62.9
	Hippo
	Control 4	27.5	26.2
	Hippo
	Control (Path)	24.8	25.9
	3 Hippo
	AD 1 Temporal	42.9	28.1
	Ctx
	AD 2 Temporal	47.6	55.9
	Ctx
	AD 3 Temporal	23.5	48.3
	Ctx
	AD 4 Temporal	48.6	76.3
	Ctx
	AD 5 Inf	78.5	87.1
	Temporal Ctx
	AD 5	50.0	45.7
	SupTemporal
	Ctx
	AD 6 Inf	50.3	47.6
	Temporal Ctx
	AD 6 Sup	86.5	13.9
	Temporal Ctx
	Control 1	21.6	21.2
	Temporal Ctx
	Control 2	29.3	48.3
	Temporal Ctx
	Control 3	30.6	51.4
	Temporal Ctx
	Control 4	17.4	33.2
	Temporal Ctx
	Control (Path)	70.7	21.2
	1 Temporal Ctx
	Control (Path)	44.8	32.1
	2 Temporal Ctx
	Control	16.2	56.6
	(Path) 3
	Temporal
	Ctx
	Control	76.8	27.7
	(Path) 4
	Temporal
	Ctx
	AD 1	48.6	49.3
	Occipital
	Ctx
	AD 2	0.0	78.5
	Occipital
	Ctx
	(Missing)
	AD 3	20.9	33.9
	Occipital
	Ctx
	AD 4	48.3	50.3
	Occipital
	Ctx
	AD 5	32.1	25.0
	Occipital
	Ctx
	AD 6	46.7	43.2
	Occipital
	Ctx
	Control 1	14.3	45.4
	Occipital
	Ctx
	Control 2	43.8	37.1
	Occipital
	Ctx
	Control 3	57.8	31.6
	Occipital
	Ctx
	Control 4	20.3	39.5
	Occipital
	Ctx
	Control	99.3	22.2
	(Path) 1
	Occipital
	Ctx
	Control	31.6	51.8
	(Path) 2
	Occipital
	Ctx
	Control	5.1	60.3
	(Path) 3
	Occipital
	Ctx
	Control	69.7	20.9
	(Path) 4
	Occipital
	Ctx
	Control 1	23.3	29.9
	Parietal Ctx
	Control 2	56.3	37.4
	Parietal Ctx
	Control 3	16.8	45.7
	Parietal Ctx
	Control	82.4	37.4
	(Path) 1
	Parietal Ctx
	Control	49.3	58.6
	(Path) 2
	Parietal Ctx
	Control	14.4	0.3
	(Path) 3
	Parietal Ctx
	Control	71.7	7.6
	(Path) 4
	Parietal Ctx

[1032]

TABLE YD
Panel 4.1D
                                 Rel. Exp. (%)
                                 Ag5696, Run
Tissue Name                      246509228
Secondary Th1 act                0.9
Secondary Th2 act                0.2
Secondary Tr1 act                0.5
Secondary Th1 rest               0.0
Secondary Th2 rest               0.0
Secondary Tr1 rest               0.0
Primary Th1 act                  0.0
Primary Th2 act                  0.3
Primary Tr1 act                  0.0
Primary Th1 rest                 0.0
Primary Th2 rest                 0.3
Primary Tr1 rest                 0.0
CD45RA CD4 lymphocyte act        25.9
CD45RO CD4 lymphocyte act        5.6
CD8 lymphocyte act               0.6
Secondary CD8 lymphocyte rest    3.7
Secondary CD8 lymphocyte act     0.3
CD4 lymphocyte none              0.4
2ry Th1/Th2/Tr1_anti-CD95 CH11   0.6
LAK cells rest                   3.0
LAK cells IL-2                   2.6
LAK cells IL-2 + IL-12           0.8
LAK cells IL-2 + IFN gamma       2.0
LAK cells IL-2 + IL-18           1.1
LAK cells PMA/ionomycin          1.8
NK Cells IL-2 rest               11.3
Two Way MLR 3 day                0.7
Two Way MLR 5 day                0.0
Two Way MLR 7 day                0.4
PBMC rest                        0.5
PBMC PWM                         0.2
PBMC PHA-L                       1.4
Ramos (B cell) none              0.0
Ramos (B cell) ionomycin         0.4
B lymphocytes PWM                0.8
B lymphocytes CD40L and IL-4     0.3
EOL-1 dbcAMP                     3.7
EOL-1 dbcAMP PMA/ionomycin       0.3
Dendritic cells none             1.3
Dendritic cells LPS              0.0
Dendritic cells anti-CD40        0.0
Monocytes rest                   0.5
Monocytes LPS                    1.5
Macrophages rest                 0.2
Macrophages LPS                  0.4
HUVEC none                       5.7
HUVEC starved                    4.5
HUVEC IL-1beta                   7.6
HUVEC IFN gamma                  12.8
HUVEC TNF alpha + IFN gamma      0.9
HUVEC TNF alpha + IL4            0.8
HUVEC IL-11                      8.1
Lung Microvascular EC none       17.1
Lung Microvascular EC TNFalpha + IL-1beta 6.8
Microvascular Dermal EC none     1.0
Microsvasular Dermal EC TNFalpha + IL-1beta 3.4
Bronchial epithelium TNFalpha + IL1beta 4.5
Small airway epithelium none     5.7
Small airway epithelium TNFalpha + IL-1beta 10.4
Coronery artery SMC rest         21.5
Coronery artery SMC TNFalpha + IL-1beta 20.7
Astrocytes rest                  3.8
Astrocytes TNFalpha + IL-1beta   2.0
KU-812 (Basophil) rest           7.8
KU-812 (Basophil) PMA/ionomycin  8.3
CCD1106 (Keratinocytes) none     37.4
CCD1106 (Keratinocytes) TNFalpha + IL-1beta 11.0
Liver cirrhosis                  14.8
NCI-H292 none                    44.1
NCI-H292 IL-4                    37.6
NCI-H292 IL-9                    100.0
NCI-H292 IL-13                   44.8
NCI-H292 IFN gamma               17.2
HPAEC none                       4.2
HPAEC TNF alpha + IL-1 beta      33.0
Lung fibroblast none             79.6
Lung fibroblast TNF alpha + IL-1 beta 48.3
Lung fibroblast IL-4             12.7
Lung fibroblast IL-9             37.1
Lung fibroblast IL-13            6.3
Lung fibroblast IFN gamma        37.6
Dermal fibroblast CCD1070 rest   58.2
Dermal fibroblast CCD1070 TNF alpha 46.0
Dermal fibroblast CCD1070 IL-1 beta 39.2
Dermal fibroblast IFN gamma      28.1
Dermal fibroblast IL-4           88.3
Dermal Fibroblasts rest          35.1
Neutrophils TNFa + LPS           0.0
Neutrophils rest                 0.3
Colon                            0.6
Lung                             1.2
Thymus                           2.0
Kidney                           59.0

[1033] AI_comprehensive panel_v1.0 Summary: Ag5696 Highest expression of this gene is seen in a normal bone sample adjacent to OA bone (CT=28). Overall, this gene is widely expressed on this panel, with moderate levels of expression in a wide range of tissues and samples related to autoimmune disease. Thus, modulation of the expression or function of this gene may be useful in the treatment of autoimmune diseases, including RA, OA, allergy, emphysema and asthma.

[1034] CNS_neurodegeneration_v1.0 Summary: Ag5696 Two experiments with the same probe and primer set produce results that are in very good agreement. This panel does not show differential expression of this gene in Alzheimer's disease. However, this panel does show that this gene is expressed at high to moderate levels in the hippocampus and cerebral cortex. Thus, therapeutic modulation of the expression or function of this gene may be useful in the treatment of neurological disorders, such as Alzheimer's disease, Parkinson's disease, schizophrenia, multiple sclerosis, stroke and epilepsy.

[1035] Panel 4.1D Summary: Ag5696 Highest expression of this gene is seen in IL-9 treated NCI-H292 goblet cells. Moderate levels of expression are seen in clusters of samples derived from lung and dermal fibroblasts. Low but significant levels of expression are seen in endothelial cells from the lung and skin, as well as small airway and bronchial epithelium. The prominent expression in cells and cell lines derived from the lung and skin suggest that this gene product may be involved in inflammatory conditions of the lung and skin, including psoriasis, asthma, emphysema, allergy, and chronic obstructive pulmonary disease.

[1036] Z. CG155595-01: Kinesin 7.

[1037] Expression of gene CG155595-01 was assessed using the primer-probe set Ag5284, described in Table ZA. Results of the RTQ-PCR runs are shown in Tables ZB, ZC, ZD and ZE.

TABLE ZA
Probe Name Ag5284
			Start	SEQ ID
Primers	Sequence	Length	Position	No
Forward	5′-gatcagaggacctcgaggaa-3′	20	3979	546
Probe	TET-5′-ccacatgcacaaggattattccatacca-3′-TAMRA	28	3999	547
Reverse	5′-agaagctgcctgtctccttaat-3′	22	4043	548

[1038]

TABLE ZB
AI_comprehensive panel_v1.0
                                 Rel. Exp. (%)
                                 Ag5284, Run
Tissue Name                      234222219
110967 COPD-F                    8.5
110980 COPD-F                    15.5
110968 COPD-M                    17.8
110977 COPD-M                    77.4
110989 Emphysema-F               38.4
110992 Emphysema-F               3.3
110993 Emphysema-F               16.8
110994 Emphysema-F               8.8
110995 Emphysema-F               26.8
110996 Emphysema-F               5.3
110997 Asthma-M                  10.0
111001 Asthma-F                  5.7
111002 Asthma-F                  18.9
111003 Atopic Asthma-F           18.8
111004 Atopic Asthma-F           22.1
111005 Atopic Asthma-F           13.7
111006 Atopic Asthma-F           2.8
111417 Allergy-M                 2.0
112347 Allergy-M                 6.3
112349 Normal Lung-F             10.4
112357 Normal Lung-F             87.7
112354 Normal Lung-M             49.7
112374 Crohns-F                  21.0
112389 Match Control Crohns-F    15.6
112375 Crohns-F                  10.1
112732 Match Control Crohns-F    3.0
112725 Crohns-M                  9.6
112387 Match Control Crohns-M    3.1
112378 Crohns-M                  15.2
112390 Match Control Crohns-M    73.2
112726 Crohns-M                  12.8
112731 Match Control Crohns-M    32.1
112380 Ulcer Col-F               23.3
112734 Match Control Ulcer Col-F 21.3
112384 Ulcer Col-F               33.9
112737 Match Control Ulcer Col-F 9.0
112386 Ulcer Col-F               2.3
112738 Match Control Ulcer Col-F 6.5
112381 Ulcer Col-M               6.1
112735 Match Control Ulcer Col-M 34.2
112382 Ulcer Col-M               23.8
112394 Match Control Ulcer Col-M 3.4
112383 Ulcer Col-M               14.0
112736 Match Control Ulcer Col-M 8.9
112423 Psoriasis-F               45.4
112427 Match Control Psoriasis-F 100.0
112418 Psoriasis-M               43.2
112723 Match Control Psoriasis-M 14.6
112419 Psoriasis-M               36.3
112424 Match Control Psoriasis-M 23.2
112420 Psoriasis-M               37.6
112425 Match Control Psoriasis-M 66.9
104689 (MF) OA Bone-Backus       23.8
104690 (MF) Adj “Normal” Bone-Backus 19.2
104691 (MF) OA Synovium-Backus   21.5
104692 (BA) OA Cartilage-Backus  14.4
104694 (BA) OA Bone-Backus       20.6
104695 (BA) Adj “Normal” Bone-Backus 10.3
104696 (BA) OA Synovium-Backus   9.5
104700 (SS) OA Bone-Backus       11.4
104701 (SS) Adj “Normal” Bone-Backus 6.0
104702 (SS) OA Synovium-Backus   14.8
117093 OA Cartilage Rep7         9.6
112672 OA Bone5                  49.0
112673 OA Synovium5              20.3
112674 OA Synovial Fluid cells5  13.6
117100 OA Cartilage Rep14        2.0
112756 OA Bone9                  29.7
112757 OA Synovium9              5.4
112758 OA Synovial Fluid Cells9  17.0
117125 RA Cartilage Rep2         8.7
113492 Bone2 RA                  4.7
113493 Synovium2 RA              0.0
113494 Syn Fluid Cells RA        5.9
113499 Cartilage4 RA             4.0
113500 Bone4 RA                  16.8
113501 Synovium4 RA              2.5
113502 Syn Fluid Cells4 RA       7.1
113495 Cartilage3 RA             4.0
113496 Bone3 RA                  8.4
113497 Synovium3 RA              0.0
113498 Syn Fluid Cells3 RA       5.2
117106 Normal Cartilage Rep20    5.1
113663 Bone3 Normal              9.2
113664 Synovium3 Normal          3.8
113665 Syn Fluid Cells3 Normal   14.7
117107 Normal Cartilage Rep22    0.0
113667 Bone4 Normal              17.9
113668 Synovium4 Normal          25.2
113669 Syn Fluid Cells4 Normal   24.7

[1039]

TABLE ZC
CNS_neurodegeneration_v1.0
                               Rel. Exp. (%)
                               Ag5284, Run
Tissue Name                    233610763
AD 1 Hippo                     17.6
AD 2 Hippo                     0.0
AD 3 Hippo                     6.7
AD 4 Hippo                     0.0
AD 5 hippo                     47.0
AD 6 Hippo                     19.6
Control 2 Hippo                7.0
Control 4 Hippo                15.7
Control (Path) 3 Hippo         6.7
AD 1 Temporal Ctx              0.0
AD 2 Temporal Ctx              26.6
AD 3 Temporal Ctx              4.8
AD 4 Temporal Ctx              19.1
AD 5 Inf Temporal Ctx          100.0
AD 5 Sup Temporal Ctx          35.8
AD 6 Inf Temporal Ctx          15.7
AD 6 Sup Temporal Ctx          20.2
Control 1 Temporal Ctx         18.3
Control 2 Temporal Ctx         12.7
Control 3 Temporal Ctx         0.0
Control 4 Temporal Ctx         15.1
Control (Path) 1 Temporal Ctx  38.4
Control (Path) 2 Temporal Ctx  38.7
Control (Path) 3 Temporal Ctx  0.0
Control (Path) 4 Temporal Ctx  29.5
AD 1 Occipital Ctx             0.0
AD 2 Occipital Ctx (Missing)   0.0
AD 3 Occipital Ctx             6.9
AD 4 Occipital Ctx             8.8
AD 5 Occipital Ctx             6.3
AD 6 Occipital Ctx             12.2
Control 1 Occipital Ctx        5.9
Control 2 Occipital Ctx        35.1
Control 3 Occipital Ctx        42.0
Control 4 Occipital Ctx        0.0
Control (Path) 1 Occipital Ctx 10.3
Control (Path) 2 Occipital Ctx 7.2
Control (Path) 3 Occipital Ctx 0.0
Control (Path) 4 Occipital Ctx 15.6
Control 1 Parietal Ctx         4.2
Control 2 Parietal Ctx         18.8
Control 3 Parietal Ctx         10.5
Control (Path) 1 Parietal Ctx  17.3
Control (Path) 2 Parietal Ctx  8.2
Control (Path) 3 Parietal Ctx  0.0
Control (Path) 4 Parietal Ctx  34.9

[1040]

TABLE ZD
General_screening_panel_v1.5
                                 Rel. Exp. (%)
                                 Ag5284, Run
Tissue Name                      230564176
Adipose                          2.5
Melanoma* Hs688(A).T             17.4
Melanoma* Hs688(B).T             28.1
Melanoma* M14                    32.8
Melanoma* LOXIMVI                23.3
Melanoma* SK-MEL-5               18.0
Squamous cell carcinoma SCC-4    12.7
Testis Pool                      1.6
Prostate ca.* (bone met) PC-3    9.5
Prostate Pool                    1.5
Placenta                         0.5
Uterus Pool                      2.2
Ovarian ca. OVCAR-3              18.6
Ovarian ca. SK-OV-3              48.6
Ovarian ca. OVCAR-4              11.3
Ovarian ca. OVCAR-5              51.4
Ovarian ca. IGROV-1              8.4
Ovarian ca. OVCAR-8              15.8
Ovary                            4.2
Breast ca. MCF-7                 19.3
Breast ca. MDA-MB-231            37.9
Breast ca. BT 549                16.6
Breast ca. T47D                  9.7
Breast ca. MDA-N                 24.7
Breast Pool                      7.1
Trachea                          1.4
Lung                             21.2
Fetal Lung                       15.1
Lung ca. NCI-N417                6.0
Lung ca. LX-1                    20.3
Lung ca. NCI-H146                2.8
Lung ca. SHP-77                  44.1
Lung ca. A549                    46.7
Lung ca. NCI-H526                5.0
Lung ca. NCI-H23                 88.9
Lung ca. NCI-H460                11.4
Lung ca. HOP-62                  13.4
Lung ca. NCI-H522                30.4
Liver                            0.0
Fetal Liver                      24.0
Liver ca. HepG2                  12.0
Kidney Pool                      24.1
Fetal Kidney                     45.7
Renal ca. 786-0                  18.3
Renal ca. A498                   6.2
Renal ca. ACHN                   5.7
Renal ca. UO-31                  7.5
Renal ca. TK-10                  23.7
Bladder                          6.1
Gastric ca. (liver met.) NCI-N87 60.3
Gastric ca. KATO III             36.9
Colon ca. SW-948                 6.3
Colon ca. SW480                  41.2
Colon ca.* (SW480 met) SW620     22.7
Colon ca. HT29                   10.4
Colon ca. HCT-116                100.0
Colon ca. CaCo-2                 54.0
Colon cancer tissue              8.3
Colon ca. SW1116                 7.3
Colon ca. Colo-205               5.3
Colon ca. SW-48                  5.7
Colon Pool                       3.6
Small Intestine Pool             15.8
Stomach Pool                     3.7
Bone Marrow Pool                 4.2
Fetal Heart                      5.4
Heart Pool                       1.5
Lymph Node Pool                  12.2
Fetal Skeletal Muscle            5.1
Skeletal Muscle Pool             0.4
Spleen Pool                      2.6
Thymus Pool                      13.8
CNS cancer (glio/astro) U87-MG   36.3
CNS cancer (glio/astro) U-118-MG 80.7
CNS cancer (neuro; met) SK-N-AS  46.3
CNS cancer (astro) SF-539        12.0
CNS cancer (astro) SNB-75        37.1
CNS cancer (glio) SNB-19         5.1
CNS cancer (glio) SF-295         58.2
Brain (Amygdala) Pool            0.3
Brain (cerebellum)               0.3
Brain (fetal)                    10.4
Brain (Hippocampus) Pool         0.6
Cerebral Cortex Pool             1.3
Brain (Substantia nigra) Pool    0.6
Brain (Thalamus) Pool            2.3
Brain (whole)                    1.5
Spinal Cord Pool                 1.9
Adrenal Gland                    0.3
Pituitary gland Pool             0.7
Salivary Gland                   0.5
Thyroid (female)                 1.4
Pancreatic ca. CAPAN2            31.0
Pancreas Pool                    4.9

[1041]

TABLE ZE
Panel 4.1D
                                 Rel. Exp. (%)
                                 Ag5284, Run
Tissue Name                      230510205
Secondary Th1 act                37.9
Secondary Th2 act                40.6
Secondary Tr1 act                12.2
Secondary Th1 rest               0.0
Secondary Th2 rest               2.1
Secondary Tr1 rest               7.7
Primary Th1 act                  5.4
Primary Th2 act                  12.7
Primary Tr1 act                  13.1
Primary Th1 rest                 0.0
Primary Th2 rest                 6.5
Primary Tr1 rest                 6.0
CD45RA CD4 lymphocyte act        40.3
CD45RO CD4 lymphocyte act        31.9
CD8 lymphocyte act               19.5
Secondary CD8 lymphocyte rest    12.2
Secondary CD8 lymphocyte act     0.0
CD4 lymphocyte none              0.0
2ry Th1/Th2/Tr1_anti-CD95 CH11   0.0
LAK cells rest                   1.2
LAK cells IL-2                   13.0
LAK cells IL-2 + IL-12           2.2
LAK cells IL-2 + IFN gamma       9.3
LAK cells IL-2 + IL-18           2.2
LAK cells PMA/ionomycin          1.9
NK Cells IL-2 rest               47.6
Two Way MLR 3 day                3.4
Two Way MLR 5 day                2.5
Two Way MLR 7 day                9.4
PBMC rest                        0.0
PBMC PWM                         3.3
PBMC PHA-L                       19.8
Ramos (B cell) none              11.9
Ramos (B cell) ionomycin         17.8
B lymphocytes PWM                13.7
B lymphocytes CD40L and IL-4     18.3
EOL-1 dbcAMP                     24.0
EOL-1 dbcAMP PMA/ionomycin       21.6
Dendritic cells none             1.6
Dendritic cells LPS              0.0
Dendritic cells anti-CD40        0.0
Monocytes rest                   0.0
Monocytes LPS                    0.0
Macrophages rest                 0.0
Macrophages LPS                  0.0
HUVEC none                       3.1
HUVEC starved                    22.7
HUVEC IL-1beta                   14.6
HUVEC IFN gamma                  18.8
HUVEC TNF alpha + IFN gamma      6.6
HUVEC TNF alpha + IL4            5.3
HUVEC IL-11                      3.2
Lung Microvascular EC none       17.0
Lung Microvascular EC TNFalpha + IL-1beta 1.7
Microvascular Dermal EC none     8.7
Microsvasular Dermal EC TNFalpha + IL-1beta 1.3
Bronchial epithelium TNFalpha + IL1beta 0.0
Small airway epithelium none     0.0
Small airway epithelium TNFalpha + IL-1beta 8.7
Coronery artery SMC rest         0.0
Coronery artery SMC TNFalpha + IL-1beta 4.8
Astrocytes rest                  4.1
Astrocytes TNFalpha + IL-1beta   3.7
KU-812 (Basophil) rest           33.9
KU-812 (Basophil) PMA/ionomycin  37.4
CCD1106 (Keratinocytes) none     31.9
CCD1106 (Keratinocytes) TNFalpha + IL-1beta 5.0
Liver cirrhosis                  3.9
NCI-H292 none                    36.6
NCI-H292 IL-4                    46.0
NCI-H292 IL-9                    73.2
NCI-H292 IL-13                   72.7
NCI-H292 IFN gamma               28.1
HPAEC none                       2.8
HPAEC TNF alpha + IL-1 beta      11.1
Lung fibroblast none             9.2
Lung fibroblast TNF alpha + IL-1 beta 7.0
Lung fibroblast IL-4             3.4
Lung fibroblast IL-9             11.8
Lung fibroblast IL-13            1.3
Lung fibroblast IFN gamma        5.5
Dermal fibroblast CCD1070 rest   20.9
Dermal fibroblast CCD1070 TNF alpha 100.0
Dermal fibroblast CCD1070 IL-1 beta 24.1
Dermal fibroblast IFN gamma      12.3
Dermal fibroblast IL-4           38.7
Dermal Fibroblasts rest          7.2
Neutrophils TNFa + LPS           0.0
Neutrophils rest                 0.0
Colon                            0.0
Lung                             0.0
Thymus                           4.0
Kidney                           0.0

[1042] AI_comprehensive panel_v1.0 Summary: Ag5284 Highest expression of this gene is seen in a normal tissue sample adjacent to psoriatic tissue (CT=33).

[1043] CNS_neurodegeneration_v1.0 Summary: Ag5284 Expression is limited to a single inferior temporal cortex sample from an Alzheimer's patient (CT=34.9).

[1044] General_screening_panel_v1.5 Summary: Ag5284 Highest expression is seen in a colon cancer cell line (CT=31). Prominent levels of expression are also seen in cell lines derived from brain, lung, colon, gastric, pancreatic, breast, ovarian, and melanoma cancers. Thus, expression of this gene could be used as a marker to detect the presence of these cancers. Furthermore, therapeutic modulation of the expression or function of this gene may be effective in the treatment of brain, lung, colon, gastric, pancreatic, breast, ovarian, and melanoma cancers.

[1045] Panel 4.1D Summary: Ag5284 Highest expression of this gene is seen in TNF-a treated dermal fibroblasts (CT=33). Low but significant levels of expression are also seen in clusters of samples derived from basophils, NCI-H292 cells, resting NK cells, and secondary activated T cells.

[1046] AA. CG157477-01: Myosin I.

[1047] Expression of gene CG157477-01 was assessed using the primer-probe set Ag5289, described in Table AAA. Results of the RTQ-PCR runs are shown in Tables AAB, AAC and AAD.

TABLE AAA
Probe Name Ag5289
			Start	SEQ ID
Primers	Sequence	Length	Position	No
Forward	5′-cgcatctatacgttcattgga-3′	21	151	549
Probe	TET-5′-tcgtcgtttctgtgaacccttacaag-3′-TAMRA	26	176	550
Reverse	5′-tgctcaattgtgtctcttccat-3′	22	215	551

[1048]

TABLE AAB
CNS_neurodegeneration_v1.0
                               Rel. Exp. (%)
                               Ag5289, Run
Tissue Name                    233610765
AD 1 Hippo                     14.0
AD 2 Hippo                     29.9
AD 3 Hippo                     12.9
AD 4 Hippo                     12.5
AD 5 Hippo                     49.0
AD 6 Hippo                     42.9
Control 2 Hippo                37.1
Control 4 Hippo                24.1
Control (Path) 3 Hippo         10.7
AD 1 Temporal Ctx              36.3
AD 2 Temporal Ctx              37.9
AD 3 Temporal Ctx              10.4
AD 4 Temporal Ctx              29.7
AD 5 Inf Temporal Ctx          83.5
AD 5 Sup Temporal Ctx          36.1
AD 6 Inf Temporal Ctx          61.1
AD 6 Sup Temporal Ctx          47.0
Control 1 Temporal Ctx         7.7
Control 2 Temporal Ctx         38.7
Control 3 Temporal Ctx         18.8
Control 3 Temporal Ctx         9.2
Control (Path) 1 Temporal Ctx  53.6
Control (Path) 2 Temporal Ctx  32.5
Control (Path) 3 Temporal Ctx  3.9
Control (Path) 4 Temporal Ctx  28.1
AD 1 Occipital Ctx             24.8
AD 2 Occipital Ctx (Missing)   0.0
AD 3 Occipital Ctx             11.5
AD 4 Occipital Ctx             25.2
AD 5 Occipital Ctx             44.1
AD 6 Occipital Ctx             22.5
Control 1 Occipital Ctx        8.1
Control 2 Occipital Ctx        49.7
Control 3 Occipital Ctx        19.9
Control 4 Occipital Ctx        15.8
Control (Path) 1 Occipital Ctx 100.0
Control (Path) 2 Occipital Ctx 25.5
Control (Path) 3 Occipital Ctx 4.2
Control (Path) 4 Occipital Ctx 20.3
Control 1 Parietal Ctx         17.3
Control 2 Parietal Ctx         39.0
Control 3 Parietal Ctx         21.5
Control (Path) 1 Parietal Ctx  50.0
Control (Path) 2 Parietal Ctx  39.5
Control (Path) 3 Parietal Ctx  4.1
Control (Path) 4 Parietal Ctx  38.2

[1049]

TABLE AAC
General_screening_panel_v1.5
                                 Rel. Exp. (%)
                                 Ag5289, Run
Tissue Name                      233238980
Adipose                          7.2
Melanoma* Hs688(A).T             65.1
Melanoma* Hs688(B).T             16.2
Melanoma* M14                    23.3
Melanoma* LOXIMVI                8.1
Melanoma* SK-MEL-5               11.2
Squamous cell carcinoma SCC-4    3.1
Testis Pool                      4.0
Prostate ca.* (bone met) PC-3    28.7
Prostate Pool                    7.4
Placenta                         5.9
Uterus Pool                      9.7
Ovarian ca. OVCAR-3              2.1
Ovarian ca. SK-OV-3              17.3
Ovarian ca. OVCAR-4              6.0
Ovarian ca. OVCAR-5              34.9
Ovarian ca. IGROV-1              1.5
Ovarian ca. OVCAR-8              1.6
Ovary                            5.6
Breast ca. MCF-7                 11.6
Breast ca. MDA-MB-231            0.5
Breast ca. BT 549                0.1
Breast ca. T47D                  17.6
Breast ca. MDA-N                 4.4
Breast Pool                      8.5
Trachea                          17.6
Lung                             3.1
Fetal Lung                       15.4
Lung ca. NCI-N417                1.8
Lung ca. LX-1                    34.2
Lung ca. NCI-H146                8.2
Lung ca. SHP-77                  5.6
Lung ca. A549                    2.6
Lung ca. NCI-H526                2.0
Lung ca. NCI-H23                 1.7
Lung ca. NCI-H460                0.7
Lung ca. HOP-62                  1.6
Lung ca. NCI-H522                0.6
Liver                            0.9
Fetal Liver                      10.4
Liver ca. HepG2                  13.3
Kidney Pool                      15.0
Fetal Kidney                     4.9
Renal ca. 786-0                  1.5
Renal ca. A498                   2.2
Renal ca. ACHN                   28.1
Renal ca. UO-31                  7.0
Renal ca. TK-10                  14.0
Bladder                          19.6
Gastric ca. (liver met.) NCI-N87 21.3
Gastric ca. KATO III             50.3
Colon ca. SW-948                 1.5
Colon ca. SW480                  100.0
Colon ca.* (SW480 met) SW620     12.9
Colon ca. HT29                   9.5
Colon ca. HCT-116                11.8
Colon ca. CaCo-2                 66.9
Colon cancer tissue              19.5
Colon ca. SW1116                 3.4
Colon ca. Colo-205               3.2
Colon ca. SW-48                  11.6
Colon Pool                       9.0
Small Intestine Pool             6.3
Stomach Pool                     3.7
Bone Marrow Pool                 5.3
Fetal Heart                      1.2
Heart Pool                       3.6
Lymph Node Pool                  10.4
Fetal Skeletal Muscle            0.7
Skeletal Muscle Pool             2.4
Spleen Pool                      5.7
Thymus Pool                      5.8
CNS cancer (glio/astro) U87-MG   5.6
CNS cancer (glio/astro) U-118-MG 1.5
CNS cancer (neuro; met) SK-N-AS  0.2
CNS cancer (astro) SF-539        0.2
CNS cancer (astro) SNB-75        0.1
CNS cancer (glio) SNB-19         1.2
CNS cancer (glio) SF-295         0.6
Brain (Amygdala) Pool            6.3
Brain (cerebellum)               11.0
Brain (fetal)                    4.5
Brain (Hippocampus) Pool         6.2
Cerebral Cortex Pool             7.3
Brain (Substantia nigra) Pool    4.7
Brain (Thalamus) Pool            7.7
Brain (whole)                    6.4
Spinal Cord Pool                 12.2
Adrenal Gland                    15.0
Pituitary gland Pool             1.8
Salivary Gland                   5.4
Thyroid (female)                 7.0
Pancreatic ca. CAPAN2            27.0
Pancreas Pool                    8.7

[1050]

TABLE AAD
Panel 4.1D
		Rel. Exp. (%)	Rel. Exp. (%)
		Ag5289, Run	Ag5289, Run
	Tissue Name	233229299	233232664
	Secondary Th1 act	0.9	0.9
	Secondary Th2 act	1.3	1.9
	Secondary Tr1 act	0.1	0.7
	Secondary Th1 rest	0.0	0.0
	Secondary Th2 rest	0.0	0.0
	Secondary Tr1 rest	0.0	0.0
	Primary Th1 act	0.0	0.0
	Primary Th2 act	0.5	0.9
	Primary Tr1 act	0.3	0.6
	Primary Th1 rest	0.0	0.0
	Primary Th2 rest	0.0	0.1
	Primary Tr1 rest	0.0	0.0
	CD45RA CD4	5.1	4.9
	lymphocyte act
	CD45RO CD4	2.4	4.2
	lymphocyte act
	CD8 lymphocyte	0.3	0.5
	act
	Secondary CD8	1.8	2.5
	lymphocyte rest
	Secondary CD8	0.0	0.1
	lymphocyte act
	CD4 lymphocyte	0.0	0.0
	none
	2ry	0.0	0.0
	Th1/Th2/Tr1_anti-
	CD95 CH11
	LAK cells rest	0.7	0.9
	LAK cells IL-2	0.6	0.9
	LAK cells IL-	0.1	0.2
	2 + IL-12
	LAK cells IL-	0.5	0.9
	2 + IFN gamma
	LAK cells IL-2 +	0.3	0.3
	IL-18
	LAK cells	2.5	4.3
	PMA/ionomycin
	NK Cells IL-2 rest	4.3	4.3
	Two Way MLR 3	0.5	0.5
	day
	Two Way MLR 5	0.1	0.0
	day
	Two Way MLR 7	0.2	0.4
	day
	PBMC rest	0.1	0.2
	PBMC PWM	0.2	0.4
	PBMC PHA-L	1.0	1.0
	Ramos (B cell)	1.3	2.6
	none
	Ramos (B cell)	26.1	29.3
	ionomycin
	B lymphocytes	1.3	2.4
	PWM
	B lymphocytes	5.4	8.8
	CD40L and IL-4
	EOL-1 dbcAMP	0.0	0.0
	EOL-1 dbcAMP	0.0	0.0
	PMA/ionomycin
	Dendritic cells	0.5	1.1
	none
	Dendritic cells LPS	0.0	0.0
	Dendritic cells	0.1	0.3
	anti-CD40
	Monocytes rest	0.0	0.0
	Monocytes LPS	0.3	0.7
	Macrophages rest	0.5	0.4
	Macrophages LPS	0.5	0.9
	HUVEC none	8.5	10.5
	HUVEC starved	17.7	26.2
	HUVEC IL-1beta	12.2	24.0
	HUVEC IFN	12.8	16.6
	gamma
	HUVEC TNF	1.3	2.0
	alpha + IFN
	gamma
	HUVEC TNF	3.2	3.8
	alpha + IL4
	HUVEC IL-11	7.4	12.7
	Lung	41.2	65.5
	Microvascular EC
	none
	Lung	9.9	13.5
	Microvascular EC
	TNFalpha + IL-
	1beta
	Microvascular	0.8	1.2
	Dermal EC none
	Microsvasular	3.1	4.1
	Dermal EC
	TNFalpha + IL-
	1beta
	Bronchial	10.6	27.4
	epithelium
	TNFalpha +
	IL1beta
	Small airway	7.3	13.1
	epithelium none
	Small airway	15.5	27.4
	epithelium
	TNFalpha + IL-
	1beta
	Coronery artery	1.3	2.1
	SMC rest
	Coronery artery	1.8	2.0
	SMC TNFalpha +
	IL-1beta
	Astrocytes rest	0.1	0.1
	Astrocytes	0.1	0.2
	TNFalpha + IL-
	1beta
	KU-812	6.4	11.8
	(Basophil) rest
	KU-812	20.2	35.8
	(Basophil)
	PMA/ionomycin
	CCD1106	100.0	13.4
	(Keratinocytes)
	none
	CCD1106	8.2	14.0
	(Keratinocytes)
	TNFalpha + IL-
	1beta
	Liver cirrhosis	3.4	5.3
	NCI-H292 none	6.7	15.3
	NCI-H292 IL-4	8.8	13.1
	NCI-H292 IL-9	13.7	32.1
	NCI-H292 IL-13	12.4	15.6
	NCI-H292 IFN	3.9	7.6
	gamma
	HPAEC none	3.4	4.6
	HPAEC TNF	11.3	16.2
	alpha + IL-1 beta
	Lung fibroblast	1.2	1.7
	none
	Lung fibroblast	0.1	0.5
	TNF alpha + IL-1
	beta
	Lung fibroblast	1.9	4.2
	IL-4
	Lung fibroblast	1.7	2.1
	IL-9
	Lung fibroblast	0.2	0.5
	IL-13
	Lung fibroblast	1.9	1.9
	IFN gamma
	Dermal fibroblast	3.9	6.7
	CCD1070 rest
	Dermal fibroblast	4.4	7.5
	CCD1070 TNF
	alpha
	Dermal fibroblast	3.9	7.4
	CCD1070 IL-1
	beta
	Dermal fibroblast	12.2	21.9
	IFN gamma
	Dermal fibroblast	72.2	100.0
	IL-4
	Dermal	10.7	18.8
	Fibroblasts rest
	Neutrophils	0.1	0.2
	TNFa + LPS
	Neutrophils rest	0.1	0.0
	Colon	1.6	4.0
	Lung	1.0	2.2
	Thymus	0.6	0.5
	Kidney	4.7	6.3

[1051] CNS_neurodegeneration_v1.0 Summary: Ag5289 This panel does not show differential expression of this gene in Alzheimer's disease. However, this profile confirms the expression of this gene at moderate levels in the brain. Please see Panel 1.5 for discussion of utility of this gene in the central nervous system.

[1052] General_screening_panel_v1.5 Summary: Ag5289 Highest expression of this gene is seen in a colon cancer cell line (CT=23.5). This gene is widely expressed in this panel, with high levels of expression seen in brain, colon, gastric, lung, breast, ovarian, and melanoma cancer cell lines. This expression profile suggests a role for this gene product in cell survival and proliferation. Modulation of this gene product may be useful in the treatment of cancer.

[1053] Among tissues with metabolic function, this gene is expressed at high to moderate levels in pituitary, adipose, adrenal gland, pancreas, thyroid, and adult and fetal skeletal muscle, heart, and liver. This widespread expression among these tissues suggests that this gene product may play a role in normal neuroendocrine and metabolic function and that disregulated expression of this gene may contribute to neuroendocrine disorders or metabolic diseases, such as obesity and diabetes.

[1054] In addition, this gene is expressed at much higher levels in fetal liver tissue (CT=26.7) when compared to expression in the adult counterpart (CT=30.3). Thus, expression of this gene may be used to differentiate between the fetal and adult source of this tissue.

[1055] This gene is also expressed at high levels in the CNS, including the hippocampus, thalamus, substantia nigra, amygdala, cerebellum and cerebral cortex. Therefore, therapeutic modulation of the expression or function of this gene may be useful in the treatment of neurologic disorders, such as Alzheimer's disease, Parkinson's disease, schizophrenia, multiple sclerosis, stroke and epilepsy.

[1056] Panel 4.1D Summary: Ag5289 Highest expression is seen in IL-4 treated dermal fibroblasts (CT=26.5). Moderate levels of expression are also seen in clusters of samples derived from lung and dermal fibroblasts, endothelial cells from lung, skin, umbilical vein, and pulmonary artery, small airway and bronchial epithelial cells, and NCI-H292 muco-epidermoid cells. The preponderance of expression in cells derived from the lung and skin suggests that this gene product may be involved in inflammatory processes that involve these organs. Therefore, therapeutic modulation of the expression or function of this gene product may be useful in the treatment of psoriasis, asthma, allergy, and emphysema. A second run with the same probe and primer set, run 233229299, is not included because the amp plot indicates there were experimental difficulties with this run.

[1057] AB. CG157486-01: Ephrin Receptor A2.

[1058] Expression of gene CG157486-01 was assessed using the primer-probe set Ag2620, described in Table ABA. Results of the RTQ-PCR runs are shown in Tables ABB, ABC, ABD, ABE and ABF.

TABLE ABA
Probe Name Ag2620
			Start	SEQ ID
Primers	Sequence	Length	Position	No
Forward	5′-gaagtggtactgctggactttg-3′	22	195	552
Probe	TET-5′-ctcacacacccgtatggcaaagggt-3′-TAMRA	25	243	553
Reverse	5′-cattcatgatgttctgcatcag-3′	22	273	554

[1059]

TABLE ABB
General_screening_panel_v1.5
                                 Rel. Exp. (%)
                                 Ag2620, Run
Tissue Name                      229827540
Adipose                          2.4
Melanoma* Hs688(A).T             6.1
Melanoma* Hs688(B).T             7.7
Melanoma* M14                    0.7
Melanoma* LOXIMVI                12.7
Melanoma* SK-MEL-5               1.8
Squamous cell carcinoma SCC-4    11.0
Testis Pool                      0.4
Prostate ca.* (bone met) PC-3    100.0
Prostate Pool                    0.7
Placenta                         2.4
Uterus Pool                      1.8
Ovarian ca. OVCAR-3              25.5
Ovarian ca. SK-OV-3              64.6
Ovarian ca. OVCAR-4              17.0
Ovarian ca. OVCAR-5              37.4
Ovarian ca. IGROV-1              41.8
Ovarian ca. OVCAR-8              18.6
Ovary                            1.2
Breast ca. MCF-7                 2.5
Breast ca. MDA-MB-231            57.4
Breast ca. BT 549                22.8
Breast ca. T47D                  0.2
Breast ca. MDA-N                 0.9
Breast Pool                      1.5
Trachea                          4.2
Lung                             0.0
Fetal Lung                       7.3
Lung ca. NCI-N417                0.7
Lung ca. LX-1                    40.3
Lung ca. NCI-H146                0.1
Lung ca. SHP-77                  0.3
Lung ca. A549                    9.6
Lung ca. NCI-H526                0.4
Lung ca. NCI-H23                 4.8
Lung ca. NCI-H460                5.2
Lung ca. HOP-62                  22.4
Lung ca. NCI-H522                12.0
Liver                            0.4
Fetal Liver                      1.1
Liver ca. HepG2                  19.2
Kidney Pool                      5.1
Fetal Kidney                     1.2
Renal ca. 786-0                  18.0
Renal ca. A498                   3.5
Renal ca. ACHN                   12.3
Renal ca. UO-31                  22.5
Renal ca. TK-10                  29.1
Bladder                          3.7
Gastric ca. (liver met.) NCI-N87 69.7
Gastric ca. KATO III             69.3
Colon ca. SW-948                 23.8
Colon ca. SW480                  36.9
Colon ca.* (SW480 met) SW620     22.5
Colon ca. HT29                   7.9
Colon ca. HCT-116                30.8
Colon ca. CaCo-2                 6.1
Colon cancer tissue              13.8
Colon ca. SW1116                 4.2
Colon ca. Colo-205               1.7
Colon ca. SW-48                  5.3
Colon Pool                       2.6
Small Intestine Pool             1.4
Stomach Pool                     1.9
Bone Marrow Pool                 0.4
Fetal Heart                      0.7
Heart Pool                       1.1
Lymph Node Pool                  1.2
Fetal Skeletal Muscle            0.3
Skeletal Muscle Pool             1.1
Spleen Pool                      2.1
Thymus Pool                      0.9
CNS cancer (glio/astro) U87-MG   1.0
CNS cancer (glio/astro) U-118-MG 19.5
CNS cancer (neuro; met) SK-N-AS  7.2
CNS cancer (astro) SF-539        12.3
CNS cancer (astro) SNB-75        23.2
CNS cancer (glio) SNB-19         41.8
CNS cancer (glio) SF-295         42.9
Brain (Amygdala) Pool            0.1
Brain (cerebellum)               0.3
Brain (fetal)                    0.5
Brain (Hippocampus) Pool         0.2
Cerebral Cortex Pool             0.1
Brain (Substantia nigra) Pool    0.4
Brain (Thalamus) Pool            0.3
Brain (whole)                    0.2
Spinal Cord Pool                 0.4
Adrenal Gland                    1.4
Pituitary gland Pool             0.1
Salivary Gland                   7.1
Thyroid (female)                 2.7
Pancreatic ca. CAPAN2            59.5
Pancreas Pool                    2.1

[1060]

TABLE ABC
Oncology_cell_line_screening_panel_v3.1
                                 Rel. Exp. (%)
                                 Ag2620, Run
Tissue Name                      230277126
Daoy Medulloblastoma/Cerebellum  1.5
TE671 Medulloblastom/Cerebellum  3.1
D283 Med Medulloblastoma/Cerebellum 24.5
PFSK-1 Primitive                 19.3
Neuroectodermal/Cerebellum
XF-498_CNS                       23.5
SNB-78_CNS/glioma                5.5
SF-268_CNS/glioblastoma          29.3
T98G_Glioblastoma                13.6
SK-N-SH_Neuroblastoma (metastasis) 6.5
SF-295_CNS/glioblastoma          17.3
Cerebellum                       0.1
Cerebellum                       0.0
NCI-H292_Mucoepidermoid lung ca. 83.5
DMS-114_Small cell lung cancer   3.3
DMS-79_Small cell lung           0.9
cancer/neuroendocrine
NCI-H146_Small cell lung         0.4
cancer/neuroendocrine
NCI-H526_Small cell lung         1.0
cancer/neuroendocrine
NCI-N417_Small cell lung         0.6
cancer/neuroendocrine
NCI-H82_Small cell lung          0.7
cancer/neuroendocrine
NCI-H157_Squamous cell lung cancer 14.0
(metastasis)
NCI-H1155_Large cell lung        0.1
cancer/neuroendocrine
NCI-H1299_Large cell lung        21.9
cancer/neuroendocrine
NCI-H727_Lung carcinoid          14.5
NCI-UMC-11_Lung carcinoid        0.0
LX-1_Small cell lung cancer      20.3
Colo-205_Colon cancer            1.9
KM12_Colon cancer                16.3
KM20L2_Colon cancer              9.5
NCI-H716_Colon cancer            15.1
SW-48_Colon adenocarcinoma       5.2
SW1116_Colon adenocarcinoma      5.0
LS 174T_Colon adenocarcinoma     25.2
SW-948_Colon adenocarcinoma      1.4
SW-480_Colon adenocarcinoma      3.3
NCI-SNU-5_Gastric ca.            14.7
KATO III_Stomach                 20.7
NCI-SNU-16_Gastric ca.           8.8
NCI-SNU-1_Gastric ca.            6.1
RF-1_Gastric adenocarcinoma      0.1
RF-48_Gastric adenocarcinoma     0.1
MKN-45_Gastric ca.               27.5
NCI-N87_Gastric ca.              20.0
OVCAR-5_Ovarian ca.              16.2
RL95-2_Uterine carcinoma         4.2
HelaS3_Cervical adenocarcinoma   9.0
Ca Ski Cervical epidermoid carcinoma 58.2
(metastasis)
ES-2_Ovarian clear cell carcinoma 15.8
Ramos/6 h stim_Stimulated with   0.0
PMA/ionomycin 6 h
Ramos/14 h stim_Stimulated with  0.0
PMA/ionomycin 14 h
MEG-01_Chronic myelogenous leukemia 0.2
(megokaryoblast)
Raji_Burkitt's lymphoma          0.1
Daudi_Burkitt's lymphoma         0.0
U266_B-cell plasmacytoma/myeloma 0.0
CA46_Burkitt's lymphoma          0.0
RL_non-Hodgkin's B-cell lymphoma 0.0
JM1_pre-B-cell lymphoma/leukemia 0.0
Jurkat_T cell leukemia           0.0
TF-1_Erythroleukemia             0.1
HUT 78_T-cell lymphoma           0.7
U937_Histiocytic lymphoma        0.0
KU-812_Myelogenous leukemia      0.0
769-P_Clear cell renal ca.       9.3
Caki-2_Clear cell renal ca.      9.9
SW 839_Clear cell renal ca.      31.2
G401_Wilms' tumor                4.6
Hs766T_Pancreatic ca. (LN metastasis) 100.0
CAPAN-1_Pancreatic adenocarcinoma 50.0
(liver metastasis)
SU86.86_Pancreatic carcinoma     64.2
(liver metastasis)
BxPC-3_Pancreatic adenocarcinoma 35.1
HPAC_Pancreatic adenocarcinoma   58.6
MIA PaCa-2_Pancreatic ca.        18.3
CFPAC-1_Pancreatic ductal        73.7
adenocarcinoma
PANC-1_Pancreatic epithelioid    70.2
ductal ca.
T24_Bladder ca. (transitional cell) 16.5
5637_Bladder ca.                 35.8
HT-1197_Bladder ca.              35.1
UM-UC-3_Bladder ca. (transitional cell) 9.3
A204_Rhabdomyosarcoma            6.7
HT-1080_Fibrosarcoma             18.0
MG-63_Osteosarcoma (bone)        11.3
SK-LMS-1_Leiomyosarcoma (vulva)  12.9
SJRH30_Rhabdomyosarcoma (met to bone 12.2
marrow)
A431_Epidermoid ca.              36.6
WM266-4_Melanoma                 0.3
DU 145_Prostate                  12.3
MDA-MB-468_Breast adenocarcinoma 2.7
SSC-4_Tongue                     7.5
SSC-9_Tongue                     12.2
SSC-15_Tongue                    9.3
CAL 27_Squamous cell ca. of tongue 17.0

[1061]

TABLE ABD
Panel 1.3D
                                 Rel. Exp. (%)
                                 Ag2620, Run
Tissue Name                      167660097
Liver adenocarcinoma             52.9
Pancreas                         2.6
Pancreatic ca. CAPAN2            33.0
Adrenal gland                    0.9
Thyroid                          0.6
Salivary gland                   8.8
Pituitary gland                  0.5
Brain (fetal)                    1.7
Brain (whole)                    0.3
Brain (amygdala)                 0.7
Brain (cerebellum)               0.0
Brain (hippocampus)              1.0
Brain (Substantia nigra)         0.9
Brain (thalamus)                 0.6
Cerebral Cortex                  0.4
Spinal cord                      1.5
glio/astro U87-MG                1.3
glio/astro U-118-MG              14.1
astrocytoma SW1783               25.5
neuro*; met SK-N-AS              3.7
astrocytoma SF-539               9.0
astrocytoma SNB-75               21.3
glioma SNB-19                    21.0
glioma U251                      35.1
glioma SF-295                    31.6
Heart (fetal)                    16.6
Heart                            1.2
Skeletal muscle (fetal)          2.7
Skeletal muscle                  0.7
Bone marrow                      0.3
Thymus                           1.0
Spleen                           1.5
Lymph node                       4.2
Colorectal                       4.4
Stomach                          1.0
Small intestine                  1.6
Colon ca. SW480                  27.2
Colon ca.* SW620(SW480 met)      39.8
Colon ca. HT29                   9.5
Colon ca. HCT-116                14.0
Colon ca. CaCo-2                 7.1
Colon ca. tissue(ODO3866)        13.3
Colon ca. HCC-2998               49.7
Gastric ca.* (liver met) NCI-N87 48.3
Bladder                          1.9
Trachea                          4.3
Kidney                           3.3
Kidney (fetal)                   26.6
Renal ca. 786-0                  21.0
Renal ca. A498                   30.6
Renal ca. RXF 393                29.3
Renal ca. ACHN                   25.0
Renal ca. UO-31                  17.2
Renal ca. TK-10                  20.7
Liver                            0.7
Liver (fetal)                    3.5
Liver ca. (hepatoblast) HepG2    17.4
Lung                             3.3
Lung (fetal)                     3.0
Lung ca. (small cell) LX-1       21.6
Lung ca. (small cell) NCI-H69    0.0
Lung ca. (s. cell var.) SHP-77   0.9
Lung ca. (large cell)NCI-H460    1.8
Lung ca. (non-sm. cell) A549     8.8
Lung ca. (non-s. cell) NCI-H23   3.9
Lung ca. (non-s. cell) HOP-62    28.3
Lung ca. (non-s. cl) NCI-H522    16.7
Lung ca. (squam.) SW 900         15.5
Lung ca. (squam.) NCI-H596       0.2
Mammary gland                    5.1
Breast ca.* (pl. ef) MCF-7       1.5
Breast ca.* (pl. ef) MDA-MB-231  41.8
Breast ca.* (pl. ef) T47D        0.5
Breast ca. BT-549                28.7
Breast ca. MDA-N                 1.1
Ovary                            2.3
Ovarian ca. OVCAR-3              33.0
Ovarian ca. OVCAR-4              18.9
Ovarian ca. OVCAR-5              92.0
Ovarian ca. OVCAR-8              3.4
Ovarian ca. IGROV-1              5.0
Ovarian ca.* (ascites) SK-OV-3   100.0
Uterus                           2.1
Placenta                         2.4
Prostate                         1.2
Prostate ca.* (bone met)PC-3     64.6
Testis                           0.4
Melanoma Hs688(A).T              4.1
Melanoma* (met) Hs688(B).T       3.9
Melanoma UACC-62                 6.3
Melanoma M14                     0.0
Melanoma LOXIMVI                 14.0
Melanoma* (met) SK-MEL-5         0.9
Adipose                          7.0

[1062]

TABLE ABE
Panel 2.2
                                 Rel. Exp. (%)
                                 Ag2620, Run
Tissue Name                      175135887
Normal Colon                     6.9
Colon cancer (OD06064)           34.9
Colon Margin (OD06064)           3.7
Colon cancer (OD06159)           18.9
Colon Margin (OD06159)           1.9
Colon cancer (OD06297-04)        9.3
Colon Margin (OD06297-05)        14.5
CC Gr.2 ascend colon (ODO3921)   38.2
CC Margin (ODO3921)              8.8
Colon cancer metastasis (OD06104) 1.7
Lung Margin (OD06104)            3.0
Colon mets to lung (OD04451-01)  28.9
Lung Margin (OD04451-02)         6.3
Normal Prostate                  3.0
Prostate Cancer (OD04410)        1.4
Prostate Margin (OD04410)        1.6
Normal Ovary                     12.1
Ovarian cancer (OD06283-03)      2.7
Ovarian Margin (OD06283-07)      5.5
Ovarian Cancer 064008            16.3
Ovarian cancer (OD06145)         10.4
Ovarian Margin (OD06145)         8.4
Ovarian cancer (OD06455-03)      22.7
Ovarian Margin (OD06455-07)      2.8
Normal Lung                      7.0
Invasive poor diff. lung adeno   1.6
(ODO4945-01
Lung Margin (ODO4945-03)         25.3
Lung Malignant Cancer (OD03126)  3.3
Lung Margin (OD03126)            16.2
Lung Cancer (OD05014A)           22.4
Lung Margin (OD05014B)           15.5
Lung cancer (OD06081)            5.6
Lung Margin (OD06081)            2.9
Lung Cancer (OD04237-01)         13.3
Lung Margin (OD04237-02)         37.1
Ocular Melanoma Metastasis       11.3
Ocular Melanoma Margin (Liver)   35.8
Melanoma Metastasis              7.3
Melanoma Margin (Lung)           7.5
Normal Kidney                    4.0
Kidney Ca, Nuclear grade 2 (OD04338) 39.2
Kidney Margin (OD04338)          6.4
Kidney Ca Nuclear grade 1/2      39.0
(OD04339)
Kidney Margin (OD04339)          3.8
Kidney Ca, Clear cell type (OD04340) 51.1
Kidney Margin (OD04340)          16.8
Kidney Ca, Nuclear grade 3 (OD04348) 4.9
Kidney Margin (OD04348)          100.0
Kidney malignant cancer (OD06204B) 11.6
Kidney normal adjacent tissue    3.4
(OD06204E)
Kidney Cancer (OD04450-01)       87.7
Kidney Margin (OD04450-03)       5.1
Kidney Cancer 8120613            0.0
Kidney Margin 8120614            5.4
Kidney Cancer 9010320            17.6
Kidney Margin 9010321            8.2
Kidney Cancer 8120607            42.3
Kidney Margin 8120608            18.7
Normal Uterus                    11.0
Uterine Cancer 064011            11.5
Normal Thyroid                   2.0
Thyroid Cancer 064010            46.3
Thyroid Cancer A302152           20.2
Thyroid Margin A302153           9.9
Normal Breast                    12.9
Breast Cancer (OD04566)          1.2
Breast Cancer 1024               5.8
Breast Cancer (OD04590-01)       0.2
Breast Cancer Mets (OD04590-03)  2.4
Breast Cancer Metastasis         16.3
(OD04655-05)
Breast Cancer 064006             1.6
Breast Cancer 9100266            5.2
Breast Margin 9100265            2.5
Breast Cancer A209073            4.5
Breast Margin A2090734           14.3
Breast cancer (OD06083)          3.9
Breast cancer node metastasis    2.2
(OD06083)
Normal Liver                     7.9
Liver Cancer 1026                19.3
Liver Cancer 1025                18.2
Liver Cancer 6004-T              12.9
Liver Tissue 6004-N              3.7
Liver Cancer 6005-T              11.3
Liver Tissue 6005-N              28.1
Liver Cancer 064003              12.4
Normal Bladder                   18.0
Bladder Cancer 1023              11.7
Bladder Cancer A302173           5.6
Normal Stomach                   39.5
Gastric Cancer 9060397           24.5
Stomach Margin 9060396           28.3
Gastric Cancer 9060395           10.0
Stomach Margin 9060394           29.9
Gastric Cancer 064005            25.2

[1063]

TABLE ABF
general oncology screening panel_v_2.4
                               Rel. Exp. (%)
                               Ag2620, Run
Tissue Name                    259737766
Colon cancer 1                 67.8
Colon cancer NAT 1             17.2
Colon cancer 2                 48.6
Colon cancer NAT 2             5.7
Colon cancer 3                 49.0
Colon cancer NAT 3             27.5
Colon malignant cancer 4       95.3
Colon normal adjacent tissue 4 5.8
Lung cancer 1                  14.7
Lung NAT 1                     0.7
Lung cancer 2                  100.0
Lung NAT 2                     3.1
Squamous cell carcinoma 3      18.7
Lung NAT 3                     1.8
metastatic melanoma 1          5.6
Melanoma 2                     11.8
Melanoma 3                     5.8
metastatic melanoma 4          12.2
metastatic melanoma 5          17.1
Bladder cancer 1               0.6
Bladder cancer NAT 1           0.0
Bladder cancer 2               10.0
Bladder cancer NAT 2           0.0
Bladder cancer NAT 3           1.8
Bladder cancer NAT 4           2.8
Prostate adenocarcinoma 1      4.6
Prostate adenocarcinoma 2      3.4
Prostate adenocarcinoma 3      5.4
Prostate adenocarcinoma 4      93.3
Prostate cancer NAT 5          4.1
Prostate adenocarcinoma 6      0.8
Prostate adenocarcinoma 7      3.0
Prostate adenocarcinoma 8      1.0
Prostate adenocarcinoma 9      5.4
Prostate cancer NAT 10         1.8
Kidney cancer 1                13.6
Kidney NAT 1                   8.0
Kidney cancer 2                24.5
Kidney NAT 2                   13.9
Kidney cancer 3                38.7
Kidney NAT 3                   8.1
Kidney cancer 4                26.6
Kidney NAT 4                   15.0

[1064] General_screening_panel_v1.5 Summary: Ag2620 Highest expression of this gene is seen in a prostate cancer cell line (CT=25.9). In addition, high to moderate levels of expression are seen in all the clusters of cancer cell line samples on this panel, including brain, colon, gastric, pancreatic, renal, lung, breast, ovarian, and melanoma cancer cell lines. This expression profile suggests a role for this gene product in cell survival and proliferation. Modulation of this gene product may be useful in the treatment of cancer.

[1065] This gene encodes an ephrin receptor A2-like protein (EphA2) which is activated by phosphorylation both in the tumor itself and the endothelial cells associated with the tumor. This activation is especially prominent in tumor types that are highly vascularized like colon, kidney and ovarian cancers. It appears that without the proper ligand, this overexpression and activation leads to cell transformation and the promotion of tumor-related angiogenesis which affect the overall balance between survival/apoptotic stimuli. Modications in the signaling emanating from this receptor will impact that balance resulting either in increased survival (stimulation of angiogenesis) or increased apoptosis (inhibition of tumorogenesis both directly against tumor cells and indirectly against endothelial cells. Therefore, therapeutic targeting of this gene product with a human monoclonal antibody will affect the overall balance between survival/apoptotic stimuli in cell expressing it, preferably endothelial, tumor and neuronal cells and will therefore affect the outcome of diseases where these stimuli are involved in the pathogenesis, tumors, preferably colon, kidney and ovarian cancer, pathogenic angiogenesis, preferably wound healing, neurodegenaritive diseases.

[1066] Among tissues with metabolic function, this gene is expressed at moderate to low levels in adipose, adrenal gland, pancreas, thyroid, and adult and fetal skeletal muscle, heart, and liver. This widespread expression among these tissues suggests that this gene product may play a role in normal neuroendocrine and metabolic function and that disregulated expression of this gene may contribute to neuroendocrine disorders or metabolic diseases, such as obesity and diabetes.

[1067] This gene is also expressed at low but significant levels in the CNS, including the hippocampus, thalamus, substantia nigra, amygdala, and cerebellum. Therefore, therapeutic modulation of the expression or function of this gene may be useful in the treatment of neurologic disorders, such as Alzheimer's disease, Parkinson's disease, schizophrenia, multiple sclerosis, stroke and epilepsy.

[1068] Oncology_cell_line_screening_panel_v3.1 Summary: Ag2620 Highest expression is seen in a pancreatic cancer cell line (CT=27.8). Moderate levels of expression are also seen in many of the cell lines on this panel. Please see Panel 1.5 for discussion of utility of this gene in the treatment of cancer.

[1069] Panel 1.3D Summary: Ag2620 Highest expression of this gene is seen in an ovarian cancer cell line (CT=29.3). In addition, moderate to low levels of expression are seen in many of the clusters of cancer cell line samples on this panel, including brain, colon, gastric, pancreatic, renal, lung, breast, ovarian, and melanoma cancer cell lines. This expression profile suggests a role for this gene product in cell survival and proliferation. Modulation of this gene product may be useful in the treatment of cancer.

[1070] Among tissues with metabolic function, this gene is expressed at low levels in adipose, pancreas, and fetal skeletal muscle, heart, and liver. This widespread expression among these tissues suggests that this gene product may play a role in normal neuroendocrine and metabolic function and that disregulated expression of this gene may contribute to neuroendocrine disorders or metabolic diseases, such as obesity and diabetes.

[1071] In addition, this gene is expressed at much higher levels in fetal heart tissue (CT=32) when compared to expression in the adult counterpart (CT=35). Thus, expression of this gene may be used to differentiate between the fetal and adult source of this tissue.

[1072] Panel 2.2 Summary: Ag2620 Highest expression is seen in a sample of normal kidney (CT=3 1). In addition, this gene appears to be more highly expressed in kidney cancer than in the corresponding normal adjacent tissue. Thus, expression of this gene could be used as a marker of this cancer. Furthemore, therapeutic modulation of the expression or function of this gene product may be useful in the treatment of kidney cancer.

[1073] general oncology screening panel_v—2.4 Summary: Ag2620 Highest expression is seen in a sample of lung cancer (CT=29.5). In addition, this gene appears to be more highly expressed in colon and kidney cancers than in the corresponding normal adjacent tissue. Thus, expression of this gene could be used as a marker of these cancers. Furthemore, therapeutic modulation of the expression or function of this gene product may be useful in the treatment of colon and kidney cancer.

[1074] AC. CG157505-01: Kinesin 16A.

[1075] Expression of gene CG157505-01 was assessed using the primer-probe set Ag5721, described in Table ACA. Results of the RTQ-PCR runs are shown in Tables ACB, ACC and ACD.

TABLE ACA
Probe Name Ag5721
			Start	SEQ ID
Primers	Sequence	Length	Position	No
Forward	5′-ctgaaggagccaatatcaacaa-3′	22	809	555
Probe	TET-5′-tcccttgtgactctaggaattgtcatctcc-3′-TAMRA	30	832	556
Reverse	5′-gctgaaaacttgggagttctg-3′	21	871	557

[1076]

TABLE ACB
CNS_neurodegeneration_v1.0
                               Rel. Exp. (%)
                               Ag5721, Run
Tissue Name                    247018773
AD 1 Hippo                     18.0
AD 2 Hippo                     16.8
AD 3 Hippo                     10.1
AD 4 Hippo                     7.0
AD 5 hippo                     87.7
AD 6 Hippo                     27.0
Control 2 Hippo                21.0
Control 4 Hippo                11.7
Control (Path) 3 Hippo         5.8
AD 1 Temporal Ctx              40.9
AD 2 Temporal Ctx              25.5
AD 3 Temporal Ctx              5.7
AD 4 Temporal Ctx              24.3
AD 5 Inf Temporal Ctx          100.0
AD 5 Sup Temporal Ctx          52.5
AD 6 Inf Temporal Ctx          72.7
AD 6 Sup Temporal Ctx          44.4
Control 1 Temporal Ctx         9.0
Control 2 Temporal Ctx         17.6
Control 3 Temporal Ctx         16.8
Control 4 Temporal Ctx         11.7
Control (Path) 1 Temporal Ctx  36.1
Control (Path) 2 Temporal Ctx  27.0
Control (Path) 3 Temporal Ctx  4.9
Control (Path) 4 Temporal Ctx  20.4
AD 1 Occipital Ctx             24.8
AD 2 Occipital Ctx (Missing)   0.0
AD 3 Occipital Ctx             9.6
AD 4 Occipital Ctx             21.9
AD 5 Occipital Ctx             25.5
AD 6 Occipital Ctx             24.8
Control 1 Occipital Ctx        5.1
Control 2 Occipital Ctx        43.2
Control 3 Occipital Ctx        26.1
Control 4 Occipital Ctx        10.3
Control (Path) 1 Occipital Ctx 72.2
Control (Path) 2 Occipital Ctx 13.9
Control (Path) 3 Occipital Ctx 3.5
Control (Path) 4 Occipital Ctx 23.7
Control 1 Parietal Ctx         8.1
Control 2 Parietal Ctx         65.5
Control 3 Parietal Ctx         18.0
Control (Path) 1 Parietal Ctx  34.9
Control (Path) 2 Parietal Ctx  26.8
Control (Path) 3 Parietal Ctx  2.1
Control (Path) 4 Parietal Ctx  39.2

[1077]

TABLE ACC
General_screening_panel_v1.5
                                 Rel. Exp. (%)
                                 Ag5721, Run
Tissue Name                      245454345
Adipose                          11.0
Melanoma* Hs688(A).T             5.4
Melanoma* Hs688(B).T             2.0
Melanoma* M14                    13.2
Melanoma* LOXIMVI                7.6
Melanoma* SK-MEL-5               4.6
Squamous cell carcinoma SCC-4    1.0
Testis Pool                      28.3
Prostate ca.* (bone met) PC-3    6.4
Prostate Pool                    10.6
Placenta                         9.7
Uterus Pool                      48.0
Ovarian ca. OVCAR-3              3.6
Ovarian ca. SK-OV-3              19.1
Ovarian ca. OVCAR-4              1.4
Ovarian ca. OVCAR-5              6.1
Ovarian ca. IGROV-1              5.4
Ovarian ca. OVCAR-8              7.1
Ovary                            29.5
Breast ca. MCF-7                 1.0
Breast ca. MDA-MB-231            15.2
Breast ca. BT 549                28.9
Breast ca. T47D                  0.3
Breast ca. MDA-N                 3.2
Breast Pool                      38.2
Trachea                          21.9
Lung                             8.4
Fetal Lung                       100.0
Lung ca. NCI-N417                2.9
Lung ca. LX-1                    5.2
Lung ca. NCI-H146                5.5
Lung ca. SHP-77                  8.8
Lung ca. A549                    7.2
Lung ca. NCI-H526                1.1
Lung ca. NCI-H23                 15.0
Lung ca. NCI-H460                4.0
Lung ca. HOP-62                  12.2
Lung ca. NCI-H522                20.9
Liver                            0.3
Fetal Liver                      3.3
Liver ca. HepG2                  13.0
Kidney Pool                      71.2
Fetal Kidney                     19.8
Renal ca. 786-0                  11.1
Renal ca. A498                   3.1
Renal ca. ACHN                   13.7
Renal ca. UO-31                  5.6
Renal ca. TK-10                  18.9
Bladder                          6.0
Gastric ca. (liver met.) NCI-N87 1.6
Gastric ca. KATO III             0.5
Colon ca. SW-948                 0.5
Colon ca. SW480                  8.3
Colon ca.* (SW480 met) SW620     6.5
Colon ca. HT29                   0.1
Colon ca. HCT-116                16.3
Colon ca. CaCo-2                 1.2
Colon cancer tissue              5.5
Colon ca. SW1116                 1.7
Colon ca. Colo-205               0.0
Colon ca. SW-48                  0.0
Colon Pool                       43.5
Small Intestine Pool             32.5
Stomach Pool                     19.2
Bone Marrow Pool                 16.6
Fetal Heart                      38.4
Heart Pool                       15.7
Lymph Node Pool                  35.4
Fetal Skeletal Muscle            24.0
Skeletal Muscle Pool             13.7
Spleen Pool                      16.4
Thymus Pool                      31.6
CNS cancer (glio/astro) U87-MG   17.7
CNS cancer (glio/astro) U-118-MG 16.6
CNS cancer (neuro; met) SK-N-AS  18.9
CNS cancer (astro) SF-539        15.9
CNS cancer (astro) SNB-75        24.8
CNS cancer (glio) SNB-19         6.3
CNS cancer (glio) SF-295         19.6
Brain (Amygdala) Pool            11.0
Brain (cerebellum)               31.2
Brain (fetal)                    28.1
Brain (Hippocampus) Pool         6.6
Cerebral Cortex Pool             10.5
Brain (Substantia nigra) Pool    10.3
Brain (Thalamus) Pool            15.5
Brain (whole)                    7.7
Spinal Cord Pool                 13.5
Adrenal Gland                    6.2
Pituitary gland Pool             1.2
Salivary Gland                   2.3
Thyroid (female)                 2.0
Pancreatic ca. CAPAN2            0.2
Pancreas Pool                    26.1

[1078]

TABLE ACD
Panel 4.1D
                                 Rel. Exp. (%)
                                 Ag5721, Run
Tissue Name                      246509239
Secondary Th1 act                36.3
Secondary Th2 act                22.8
Secondary Tr1 act                5.3
Secondary Th1 rest               2.6
Secondary Th2 rest               0.0
Secondary Tr1 rest               2.1
Primary Th1 act                  0.0
Primary Th2 act                  17.7
Primary Tr1 act                  11.9
Primary Th1 rest                 0.4
Primary Th2 rest                 5.1
Primary Tr1 rest                 1.1
CD45RA CD4 lymphocyte act        17.2
CD45RO CD4 lymphocyte act        23.8
CD8 lymphocyte act               2.5
Secondary CD8 lymphocyte rest    14.9
Secondary CD8 lymphocyte act     1.5
CD4 lymphocyte none              0.7
2ry Th1/Th2/Tr1_anti-CD95 CH11   5.8
LAK cells rest                   3.2
LAK cells IL-2                   2.7
LAK cells IL-2 + IL-12           0.0
LAK cells IL-2 + IFN gamma       4.9
LAK cells IL-2 + IL-18           1.3
LAK cells PMA/ionomycin          3.5
NK Cells IL-2 rest               94.6
Two Way MLR 3 day                4.5
Two Way MLR 5 day                1.5
Two Way MLR 7 day                2.3
PBMC rest                        1.5
PBMC PWM                         1.8
PBMC PHA-L                       3.6
Ramos (B cell) none              4.7
Ramos (B cell) ionomycin         26.4
B lymphocytes PWM                4.9
B lymphocytes CD40L and IL-4     13.7
EOL-1 dbcAMP                     14.7
EOL-1 dbcAMP PMA/ionomycin       0.6
Dendritic cells none             8.7
Dendritic cells LPS              0.7
Dendritic cells anti-CD40        0.6
Monocytes rest                   0.0
Monocytes LPS                    2.0
Macrophages rest                 1.5
Macrophages LPS                  0.0
HUVEC none                       9.3
HUVEC starved                    13.3
HUVEC IL-1beta                   13.1
HUVEC IFN gamma                  26.2
HUVEC TNF alpha + IFN gamma      0.5
HUVEC TNF alpha + IL4            2.7
HUVEC IL-11                      14.9
Lung Microvascular EC none       40.3
Lung Microvascular EC TNFalpha + 14.6
IL-1beta
Microvascular Dermal EC none     4.9
Microsvasular Dermal EC TNFalpha + 4.8
IL-1beta
Bronchial epithelium TNFalpha +  2.3
IL1beta
Small airway epithelium none     4.8
Small airway epithelium TNFalpha + 4.2
IL-1beta
Coronery artery SMC rest         3.0
Coronery artery SMC TNFalpha +   4.6
IL-1beta
Astrocytes rest                  0.0
Astrocytes TNFalpha + IL-1beta   0.8
KU-812 (Basophil) rest           0.8
KU-812 (Basophil) PMA/ionomycin  3.6
CCD1106 (Keratinocytes) none     12.3
CCD1106 (Keratinocytes) TNFalpha + 11.3
IL-1beta
Liver cirrhosis                  6.2
NCI-H292 none                    1.4
NCI-H292 IL-4                    5.8
NCI-H292 IL-9                    4.8
NCI-H292 IL-13                   2.1
NCI-H292 IFN gamma               0.9
HPAEC none                       8.9
HPAEC TNF alpha + IL-1 beta      20.9
Lung fibroblast none             14.6
Lung fibroblast TNF alpha +      10.2
IL-1 beta
Lung fibroblast IL-4             1.5
Lung fibroblast IL-9             3.4
Lung fibroblast IL-13            2.3
Lung fibroblast IFN gamma        6.0
Dermal fibroblast CCD1070 rest   18.7
Dermal fibroblast CCD1070 TNF alpha 100.0
Dermal fibroblast CCD1070 IL-1 beta 8.4
Dermal fibroblast IFN gamma      19.3
Dermal fibroblast IL-4           43.5
Dermal Fibroblasts rest          22.7
Neutrophils TNFa + LPS           0.8
Neutrophils rest                 1.3
Colon                            5.1
Lung                             2.6
Thymus                           12.1
Kidney                           11.0

[1079] CNS_neurodegeneration_v1.0 Summary: Ag5721 This panel confirms the expression of this gene at moderate levels in the brain in an independent group of individuals. This gene is found to be upregulated in the temporal cortex of Alzheimer's disease patients. This gene encodes a putative kinesin, a microtubule-based motor protein involved in the transport of organelles. Axonal transport of APP in neurons is mediated by binding with kinesin. (Gunewardena S, Neuron Nov. 8, 2001;32(3):389-401). Kamal et al. suggest that impaired APP transport leads to enhanced axonal generation and deposition of Abeta, resulting in disruption of neurotrophic signaling and neurodegeneration (Nature Dec. 6, 2001;414(6864):643-8). Thus, therapeutic modulation of the expression or function of this gene may be useful in the treatment of neurodegenerative disorders, and specifically may decrease neuronal death and be of use in the treatment of Alzheimer's disease.

[1080] General_screening_panel_v1.5 Summary: Ag5721 Highest expression of this gene is seen in the fetal lung (CT=27.5). In addition, this gene is expressed at much higher levels in fetal lung tissue when compared to expression in the adult counterpart (CT=3 1). Thus, expression of this gene may be used to differentiate between the fetal and adult source of this tissue. In addition, therapeutic modulation of the expression or function of this gene may be useful in the treatment of diseases that affect the lung, including lung cancer.

[1081] Moderate to low levels of expression are seen in all regions of the CNS examined. Please see CNS_neurodegeneration_v1.0 for discussion of utility of this gene in CNS disorders.

[1082] Moderate to low levels of expression are also seen in pancreas, thyroid, fetal skeletal muscle, adipose and adult and fetal liver. This widespread expression among these tissues suggests that this gene product may play a role in normal neuroendocrine and metabolic function and that disregulated expression of this gene may contribute to neuroendocrine disorders or metabolic diseases, such as obesity and diabetes.

[1083] Low but significant levels of expression are seen in many of the cancer cell lines on this panel. Interestingly, expression appears to be overexpressed in the normal tissue samples when compared to expression in the cell lines. Thus, modulation of the expression or function of this gene may be useful in the treatment of cancer.

[1084] Panel 4.1D Summary: Ag5721 Highest expression of this gene is seen in TNF-alpha treated dermal fibroblasts (CT=30.2). Moderate levels of expresison are also seen in resting NK cells. Low but significant levels of expression are seen in activated T cells, endothelial cells and lung and dermal fibroblasts. Thus, expression of this gene could be used as a marker of activated dermal fibroblasts and modulation of the gene product may be useful in the treatment of psoriasis.

[1085] AD. CG157629-01: Serine/Threonine Protein Phosphatase with EF-Hands-1.

[1086] Expression of gene CG157629-01 was assessed using the primer-probe set Ag5447, described in Table ADA. Please note that CG157629-01 represents a full-length physical clone.

TABLE ADA
Probe Name Ag5447
			Start	SEQ ID
Primers	Sequence	Length	Position	No
Forward	5′-ctggctcccaacgga-3′	15	906	558
Probe	TET-5′-tggatctcctactgaacacttaacagagcatg-3′-TAMRA	32	1002	559
Reverse	5′-acagaatatcaataatctgttcccat-3′	26	1035	560

[1087] AI_comprehensive panel_v1.0 Summary: Ag5447 Expression of this gene is low/undetectable in all samples on this panel (CTs>35). (Data not shown.)

[1088] General_screening_panel_v1.5 Summary: Ag5447 Expression of this gene is low/undetectable in all samples on this panel (CTs>35). (Data not shown.)

[1089] Panel 4.1D Summary: Ag5447 Expression of this gene is low/undetectable in all samples on this panel (CTs>35). (Data not shown.)

[1090] AE. CG157704-01: Kinesin 24.

[1091] Expression of gene CG157704-01 was assessed using the primer-probe set Ag5734, described in Table AEA. Results of the RTQ-PCR runs are shown in Tables AEB, AEC and AED.

TABLE AEA
Probe Name Ag5734
			Start	SEQ ID
Primers	Sequence	Length	Position	No
Forward	5′-gaggtacgtcgtggagaaatta-3′	22	718	561
Probe	TET-5′-tcatgcacaagtagagtttctttgtcttc-3′-TAMRA	29	754	562
Reverse	5′-tgaggtcaactgcttctttctt-3′	22	784	563

[1092]

TABLE AEB
CNS_neurodegeneration_v1.0
                               Rel. Exp. (%)
                               Ag5734, Run
Tissue Name                    247018774
AD 1 Hippo                     15.3
AD 2 Hippo                     15.9
AD 3 Hippo                     9.0
AD 4 Hippo                     8.7
AD 5 Hippo                     68.8
AD 6 Hippo                     57.4
Control 2 Hippo                29.1
Control 4 Hippo                24.3
Control (Path) 3 Hippo         20.4
AD 1 Temporal Ctx              17.8
AD 2 Temporal Ctx              36.9
AD 3 Temporal Ctx              13.9
AD 4 Temporal Ctx              24.5
AD 5 Inf Temporal Ctx          74.7
AD 5 Sup Temporal Ctx          41.8
AD 6 Inf Temporal Ctx          42.3
AD 6 Sup Temporal Ctx          66.4
Control 1 Temporal Ctx         20.2
Control 2 Temporal Ctx         33.4
Control 3 Temporal Ctx         15.7
Control 3 Temporal Ctx         3.0
Control (Path) 1 Temporal Ctx  50.0
Control (Path) 2 Temporal Ctx  39.0
Control (Path) 3 Temporal Ctx  2.6
Control (Path) 4 Temporal Ctx  64.6
AD 1 Occipital Ctx             20.2
AD 2 Occipital Ctx (Missing)   0.0
AD 3 Occipital Ctx             7.7
AD 4 Occipital Ctx             24.5
AD 5 Occipital Ctx             33.0
AD 6 Occipital Ctx             18.4
Control 1 Occipital Ctx        16.4
Control 2 Occipital Ctx        43.8
Control 3 Occipital Ctx        20.6
Control 4 Occipital Ctx        25.2
Control (Path) 1 Occipital Ctx 100.0
Control (Path) 2 Occipital Ctx 16.4
Control (Path) 3 Occipital Ctx 0.0
Control (Path) 4 Occipital Ctx 22.1
Control 1 Parietal Ctx         18.3
Control 2 Parietal Ctx         23.3
Control 3 Parietal Ctx         11.7
Control (Path) 1 Parietal Ctx  43.5
Control (Path) 2 Parietal Ctx  20.3
Control (Path) 3 Parietal Ctx  14.0
Control (Path) 4 Parietal Ctx  29.1

[1093]

TABLE AEC
General_screening_panel_v1.5
                                 Rel. Exp. (%)
                                 Ag5734, Run
Tissue Name                      245385008
Adipose                          0.3
Melanoma* Hs688(A).T             2.7
Melanoma* Hs688(B).T             1.4
Melanoma* M14                    29.7
Melanoma* LOXIMVI                36.3
Melanoma* SK-MEL-5               19.3
Squamous cell carcinoma SCC-4    13.2
Testis Pool                      3.3
Prostate ca.* (bone met) PC-3    7.5
Prostate Pool                    1.1
Placenta                         3.8
Uterus Pool                      1.3
Ovarian ca. OVCAR-3              40.1
Ovarian ca. SK-OV-3              1.3
Ovarian ca. OVCAR-4              9.4
Ovarian ca. OVCAR-5              31.2
Ovarian ca. IGROV-1              10.9
Ovarian ca. OVCAR-8              9.0
Ovary                            3.8
Breast ca. MCF-7                 13.7
Breast ca. MDA-MB-231            77.9
Breast ca. BT 549                89.5
Breast ca. T47D                  15.8
Breast ca. MDA-N                 17.8
Breast Pool                      2.9
Trachea                          10.1
Lung                             1.1.
Fetal Lung                       23.2
Lung ca. NCI-N417                4.9
Lung ca. LX-1                    46.7
Lung ca. NCI-H146                27.0
Lung ca. SHP-77                  31.4
Lung ca. A549                    44.1
Lung ca. NCI-H526                10.0
Lung ca. NCI-H23                 1.7
Lung ca. NCI-H460                0.1
Lung ca. HOP-62                  3.5
Lung ca. NCI-H522                17.3
Liver                            0.1
Fetal Liver                      28.5
Liver ca. HepG2                  1.3
Kidney Pool                      6.0
Fetal Kidney                     19.2
Renal ca. 786-0                  23.3
Renal ca. A498                   9.3
Renal ca. ACHN                   7.5
Renal ca. UO-31                  10.2
Renal ca. TK-10                  22.2
Bladder                          10.2
Gastric ca. (liver met.) NCI-N87 50.0
Gastric ca. KATO III             100.0
Colon ca. SW-948                 6.1
Colon ca. SW480                  68.3
Colon ca.* (SW480 met) SW620     44.4
Colon ca. HT29                   23.8
Colon ca. HCT-116                42.0
Colon ca. CaCo-2                 19.5
Colon cancer tissue              10.0
Colon ca. SW1116                 7.4
Colon ca. Colo-205               9.4
Colon ca. SW-48                  11.7
Colon Pool                       0.0
Small Intestine Pool             5.0
Stomach Pool                     1.9
Bone Marrow Pool                 1.3
Fetal Heart                      6.8
Heart Pool                       2.0
Lymph Node Pool                  3.3
Fetal Skeletal Muscle            0.0
Skeletal Muscle Pool             2.1
Spleen Pool                      1.4
Thymus Pool                      16.3
CNS cancer (glio/astro) U87-MG   47.6
CNS cancer (glio/astro) U-118-MG 81.2
CNS cancer (neuro; met) SK-N-AS  26.4
CNS cancer (astro) SF-539        26.1
CNS cancer (astro) SNB-75        75.8
CNS cancer (glio) SNB-19         8.4
CNS cancer (glio) SF-295         20.9
Brain (Amygdala) Pool            1.4
Brain (cerebellum)               5.7
Brain (fetal)                    11.0
Brain (Hippocampus) Pool         2.8
Cerebral Cortex Pool             4.8
Brain (Substantia nigra) Pool    2.9
Brain (Thalamus) Pool            4.6
Brain (whole)                    4.8
Spinal Cord Pool                 4.0
Adrenal Gland                    3.2
Pituitary gland Pool             2.4
Salivary Gland                   1.1
Thyroid (female)                 3.5
Pancreatic ca. CAPAN2            23.0
Pancreas Pool                    1.9

[1094]

TABLE AED
Panel 4.1D
                                 Rel. Exp. (%)
                                 Ag5734, Run
Tissue Name                      246509244
Secondary Th1 act                65.5
Secondary Th2 act                98.6
Secondary Tr1 act                20.9
Secondary Th1 rest               0.0
Secondary Th2 rest               0.0
Secondary Tr1 rest               0.0
Primary Th1 act                  0.4
Primary Th2 act                  13.8
Primary Tr1 act                  9.5
Primary Th1 rest                 0.0
Primary Th2 rest                 0.0
Primary Tr1 rest                 0.0
CD45RA CD4 lymphocyte act        30.4
CD45RO CD4 lymphocyte act        43.2
CD8 lymphocyte act               3.9
Secondary CD8 lymphocyte rest    17.0
Secondary CD8 lymphocyte act     3.3
CD4 lymphocyte none              0.0
2ry Th1/Th2/Tr1_anti-CD95 CH11   1.7
LAK cells rest                   8.1
LAK cells IL-2                   7.1
LAK cells IL-2 + IL-12           2.7
LAK cells IL-2 + IFN gamma       4.0
LAK cells IL-2 + IL-18           2.3
LAK cells PMA/ionomycin          15.8
NK Cells IL-2 rest               77.4
Two Way MLR 3 day                4.5
Two Way MLR 5 day                1.6
Two Way MLR 7 day                6.9
PBMC rest                        0.0
PBMC PWM                         3.8
PBMC PHA-L                       8.8
Ramos (B cell) none              4.9
Ramos (B cell) ionomycin         35.4
B lymphocytes PWM                24.0
B lymphocytes CD40L and IL-4     45.7
EOL-1 dbcAMP                     60.7
EOL-1 dbcAMP PMA/ionomycin       3.2
Dendritic cells none             6.3
Dendritic cells LPS              0.7
Dendritic cells anti-CD40        1.6
Monocytes rest                   1.6
Monocytes LPS                    3.7
Macrophages rest                 3.8
Macrophages LPS                  0.8
HUVEC none                       10.1
HUVEC starved                    36.9
HUVEC IL-1 beta                  19.5
HUVEC IFN gamma                  21.5
HUVEC TNF alpha + IFN gamma      2.1
HUVEC TNF alpha + IL4            1.8
HUVEC IL-11                      9.0
Lung Microvascular EC none       12.2
Lung Microvascular EC TNFalpha + IL-1beta 2.7
Microvascular Dermal EC none     0.4
Microsvasular Dermal EC TNFalpha + IL-1beta 4.0
Bronchial epithelium TNFalpha + IL1beta 3.7
Small airway epithelium none     1.3
Small airway epithelium TNFalpha + IL-1beta 4.5
Coronery artery SMC rest         3.5
Coronery artery SMC TNFalpha + IL-1beta 2.9
Astrocytes rest                  3.4
Astrocytes TNFalpha + IL-1beta   0.9
KU-812 (Basophil) rest           29.9
KU-812 (Basophil) PMA/ionomycin  40.9
CCD1106 (Keratinocytes) none     47.0
CCD1106 (Keratinocytes) TNFalpha + IL-1beta 20.7
Liver cirrhosis                  2.0
NCI-H292 none                    26.6
NCI-H292 IL-4                    30.6
NCI-H292 IL-9                    63.7
NCI-H292 IL-13                   29.3
NCI-H292 IFN gamma               16.0
HPAEC none                       3.5
HPAEC TNF alpha + IL-1 beta      12.1
Lung fibroblast none             3.9
Lung fibroblast TNF alpha + IL-1 beta 5.4
Lung fibroblast IL-4             1.0
Lung fibroblast IL-9             6.2
Lung fibroblast IL-13            0.0
Lung fibroblast IFN gamma        5.4
Dermal fibroblast CCD1070 rest   46.7
Dermal fibroblast CCD1070 TNF alpha 100.0
Dermal fibroblast CCD1070 IL-1 beta 22.5
Dermal fibroblast IFN gamma      16.6
Dermal fibroblast IL-4           19.9
Dermal Fibroblasts rest          3.7
Neutrophils TNFa + LPS           1.6
Neutrophils rest                 2.6
Colon                            0.7
Lung                             0.6
Thymus                           12.3
Kidney                           6.8

[1095] CNS_neurodegeneration_v1.0 Summary: Ag5734 This panel does not show differential expression of this gene in Alzheimer's disease. However, this profile confirms the expression of this gene at moderate levels in the brain. Please see Panel 1.5 for discussion of utility of this gene in the central nervous system.

[1096] General_screening_panel_v1.5 Summary: Ag5734 Highest expression of this gene is seen in a gastric cancer cell line (CT=29). This gene is widely expressed in this panel, with moderate expression seen in brain, colon, gastric, lung, breast, pancreatic, renal, ovarian, and melanoma cancer cell lines. This expression profile with prominent cell line expression suggests a role for this gene product in cell survival and proliferation. Modulation of this gene product may be useful in the treatment of cancer.

[1097] Among tissues with metabolic function, this gene is expressed at low but significant levels in pituitary, skeletal muscle, adrenal gland, pancreas, thyroid, fetal liver, and adult and fetal liver. This widespread expression among these tissues suggests that this gene product may play a role in normal neuroendocrine and metabolic function and that disregulated expression of this gene may contribute to neuroendocrine disorders or metabolic diseases, such as obesity and diabetes.

[1098] This gene is also expressed at low but significant levels in the CNS, including the hippocampus, thalamus, substantia nigra, amygdala, cerebellum and cerebral cortex. Therefore, therapeutic modulation of the expression or function of this gene may be useful in the treatment of neurologic disorders, such as Alzheimer's disease, Parkinson's disease, schizophrenia, multiple sclerosis, stroke and epilepsy.

[1099] Panel 4.1D Summary: Ag5734 Highest expression is seen in TNF-a treated dermal fibroblasts. Low but significant expression is seen in activated T cells, resting NK cells, eosinophils, activated B cells, HUVECs, basophils and NCI-H292 goblet cells. This expression suggests that this gene product may be involved in autoinflammatory processes. Thus, expression of this gene could be used as a marker of activated dermal fibroblasts. Modulation of the expression or function of this gene may be useful in the treatment of RA, OA, lupus, asthma, allergy, emphysema, and psoriasis.

[1100] AF. CG158218-01: Kinesin 6.

[1101] Expression of gene CG158218-01 was assessed using the primer-probe set Ag5797, described in Table AFA. Results of the RTQ-PCR runs are shown in Tables AFB and AFC.

TABLE AFA
Probe Name Ag5797
			Start	SEQ ID
Primers	Sequences	Length	Position	No
Forward	5′-agttacaaaaggacagcagcaa-3′	22	621	564
Probe	TET-5′-ccacattcattgtagatttccaaatagga-3′-TAMRA	29	662	565
Reverse	5′-ttcatgtcttggatccaaaaga-3′	22	697	566

[1102]

TABLE AFB
CNS_neurodegeneration_v1.0
                               Rel. Exp. (%)
                               Ag5797, Run
Tissue Name                    247179625
AD 1 Hippo                     15.9
AD 2 Hippo                     32.1
AD 3 Hippo                     6.8
AD 4 Hippo                     9.5
AD 5 Hippo                     27.4
AD 6 Hippo                     33.9
Control 2 Hippo                31.0
Control 4 Hippo                25.2
Control (Path) 3 Hippo         7.9
AD 1 Temporal Ctx              80.7
AD 2 Temporal Ctx              33.2
AD 3 Temporal Ctx              9.3
AD 4 Temporal Ctx              24.0
AD 5 Inf Temporal Ctx          100.0
AD 5 Sup Temporal Ctx          51.1
AD 6 Inf Temporal Ctx          35.4
AD 6 Sup Temporal Ctx          29.1
Control 1 Temporal Ctx         7.0
Control 2 Temporal Ctx         22.5
Control 3 Temporal Ctx         20.6
Control 3 Temporal Ctx         5.6
Control (Path) 1 Temporal Ctx  48.0
Control (Path) 2 Temporal Ctx  29.5
Control (Path) 3 Temporal Ctx  4.8
Control (Path) 4 Temporal Ctx  22.5
AD 1 Occipital Ctx             12.8
AD 2 Occipital Ctx (Missing)   0.0
AD 3 Occipital Ctx             7.3
AD 4 Occipital Ctx             16.8
AD 5 Occipital Ctx             26.2
AD 6 Occipital Ctx             10.7
Control 1 Occipital Ctx        3.1
Control 2 Occipital Ctx        29.5
Control 3 Occipital Ctx        15.9
Control 4 Occipital Ctx        13.6
Control (Path) 1 Occipital Ctx 85.9
Control (Path) 2 Occipital Ctx 11.0
Control (Path) 3 Occipital Ctx 3.5
Control (Path) 4 Occipital Ctx 12.7
Control 1 Parietal Ctx         15.3
Control 2 Parietal Ctx         51.4
Control 3 Parietal Ctx         8.2
Control (Path) 1 Parietal Ctx  65.1
Control (Path) 2 Parietal Ctx  25.3
Control (Path) 3 Parietal Ctx  2.4
Control (Path) 4 Parietal Ctx  30.4

[1103]

TABLE AFC
(general_screening_panel v1.5
                                 Rel. Exp. (%)
                                 Ag5797, Run
Tissue Name                      245382863
Adipose                          0.3
Melanoma* Hs688(A).T             0.1
Melanoma* Hs688(B).T             0.0
Melanoma* M14                    0.7
Melanoma* LOXIMVI                0.0
Melanoma* SK-MEL-5               0.6
Squamous cell carcinoma SCC-4    0.0
Testis Pool                      9.9
Prostate ca.* (bone met) PC-3    0.0
Prostate Pool                    0.6
Placenta                         0.1
Uterus Pool                      0.2
Ovarian ca. OVCAR-3              1.5
Ovarian ca. SK-OV-3              2.0
Ovarian ca. OVCAR-4              0.0
Ovarian ca. OVCAR-5              1.2
Ovarian ca. IGROV-1              0.1
Ovarian ca. OVCAR-8              0.0
Ovary                            1.4
Breast ca. MCF-7                 0.3
Breast ca. MDA-MB-231            0.0
Breast ca. BT 549                0.0
Breast ca. T47D                  0.5
Breast ca. MDA-N                 0.2
Breast Pool                      1.3
Trachea                          4.2
Lung                             0.1
Fetal Lung                       11.7
Lung ca. NCI-N417                1.4
Lung ca. LX-1                    7.4
Lung ca. NCI-H146                0.0
Lung ca. SHP-77                  1.7
Lung ca. A549                    0.0
Lung ca. NCI-H526                0.2
Lung ca. NCI-H23                 0.3
Lung ca. NCI-H460                0.0
Lung ca. HOP-62                  0.2
Lung ca. NCI-H522                0.1
Liver                            0.0
Fetal Liver                      100.0
Liver ca. HepG2                  0.0
Kidney Pool                      0.7
Fetal Kidney                     4.7
Renal ca. 786-0                  0.1
Renal ca. A498                   0.1
Renal ca. ACHN                   0.1
Renal ca. UO-31                  0.4
Renal ca. TK-10                  0.1
Bladder                          0.6
Gastric ca. (liver met.) NCI-N87 0.0
Gastric ca. KATO III             0.0
Colon ca. SW-948                 0.0
Colon ca. SW480                  4.2
Colon ca.* (SW480 met) SW620     10.8
Colon ca. HT29                   0.0
Colon ca. HCT-116                0.0
Colon ca. CaCo-2                 0.2
Colon cancer tissue              0.0
Colon ca. SW1116                 0.0
Colon ca. Colo-205               0.0
Colon ca. SW-48                  0.1
Colon Pool                       0.4
Small Intestine Pool             1.2
Stomach Pool                     0.6
Bone Marrow Pool                 0.2
Fetal Heart                      0.0
Heart Pool                       0.3
Lymph Node Pool                  1.0
Fetal Skeletal Muscle            0.2
Skeletal Muscle Pool             0.1
Spleen Pool                      0.1
Thymus Pool                      1.4
CNS cancer (glio/astro) U87-MG   2.3
CNS cancer (glio/astro) U-118-MG 0.0
CNS cancer (neuro; met) SK-N-AS  0.4
CNS cancer (astro) SF-539        0.0
CNS cancer (astro) SNB-75        0.7
CNS cancer (glio) SNB-19         0.4
CNS cancer (glio) SF-295         0.7
Brain (Amygdala) Pool            7.1
Brain (cerebellum)               2.7
Brain (fetal)                    2.1
Brain (Hippocampus) Pool         3.7
Cerebral Cortex Pool             6.3
Brain (Substantia nigra) Pool    9.7
Brain (Thalamus) Pool            4.0
Brain (whole)                    2.8
Spinal Cord Pool                 11.4
Adrenal Gland                    0.3
Pituitary gland Pool             1.7
Salivary Gland                   0.0
Thyroid (female)                 0.7
Pancreatic ca. CAPAN2            0.3
Pancreas Pool                    0.8

[1104] CNS13 neurodegeneration13 v1.0 Summary: Ag5797 This panel does not show differential expression of this gene in Alzheimer's disease. However, this profile confirms the expression of this gene at moderate levels in the brain. Please see Panel 1.5 for discussion of utility of this gene in the central nervous system.

[1105] General13 screening_panel_v1.5 Summary: Ag5797 Highest expression of this gene is seen in the fetal liver. Interestingly, this gene is expressed at much higher levels in fetal (CT=29) when compared to adult liver tissue (CT=40). This observation suggests that expression of this gene can be used to distinguish fetal from adult liver. In addition, the relative overexpression of this gene in fetal liver suggests that the protein product may enhance liver growth or development in the fetus and thus may also act in a regenerative capacity in the adult. Therefore, therapeutic modulation of the protein encoded by this gene could be useful in treatment of liver related diseases.

[1106] This gene is also expressed at low levels in the CNS, including the hippocampus, thalamus, substantia nigra, amygdala, cerebellum and cerebral cortex. Therefore, therapeutic modulation of the expression or function of this gene may be useful in the treatment of neurological disorders, such as Alzheimer's disease, Parkinson's disease, schizophrenia, multiple sclerosis, stroke and epilepsy.

[1107] Panel 4.1D Summary: Ag5797 Expression of this gene is low/undetectable in all samples on this panel (CTs>35). (Data not shown.)

[1108] AG. CG158583-01 and CG158583-04: Synaptic Vesicle Amine Transporter.

[1109] Expression of gene CG158583-01 and CG158583-04 was assessed using the primer-probe set Ag7590, described in Table AGA. Results of the RTQ-PCR runs are shown in Table AGB. Please note that CG158583-04 represents a full-length physical clone.

TABLE AGA
Probe Name Ag7590
			Start	SEQ ID
Primers	Sequences	Length	Position	No
Forward	5′-aactcctgacctcaggtgatc-3′	21	167	567
Probe	TET-5′-tcctggaattacagtccccatcatcc-3′-TAMRA	26	210	568
Reverse	5′-ctcatgcttaatgctgtacagataact-3′	27	238	569

[1110]

TABLE AGB
Panel 5 Islet
                                 Rel. Exp. (%)
                                 Ag7590, Run
Tissue Name                      310258790
97457_Patient-02go_adipose       0.0
97476_Patient-07sk_skeletal muscle 0.0
97477_Patient-07ut_uterus        0.0
97478_Patient-07pl_placenta      0.0
99167_Bayer Patient 1            100.0
97482_Patient-08ut_uterus        12.2
97483_Patient-08pl_placenta      0.0
97486_Patient-09sk_skeletal muscle 10.2
97487_Patient-09ut_uterus        0.0
97488_Patient-09pl_placenta      0.0
97492_Patient-10ut_uterus        21.6
97493_Patient-10pl_placenta      0.0
97495_Patient-11go_adipose       0.0
97496_Patient-11sk_skeletal muscle 27.2
97497_Patient-11ut_uterus        0.0
97498_Patient-11pl_placenta      0.0
97500_Patient-12go_adipose       32.3
97501_Patient-12sk_skeletal muscle 0.0
97502_Patient-12ut_uterus        13.3
97503_Patient-12pl_placenta      0.0
94721_Donor2U-A_Mesenchymal Stem Cells 0.0
94722_Donor 2 U - B_Mesenchymal Stem Cells 0.0
94723_Donor 2 U - C_Mesenchymal Stem Cells 0.0
94709_Donor 2 AM - A_adipose     0.0
94710_Donor 2 AM - B_adipose     0.0
94711_Donor 2 AM - C_adipose     0.0
94712_Donor 2 AD - A_adipose     0.0
94713_Donor 2 AD - B_adipose     0.0
94714_Donor 2 AD - C_adipose     0.0
94742_Donor 3 U - A_Mesenchymal Stem Cells 0.0
94743_Donor 3 U - B_Mesenchymal Stem Cells 0.0
94730_Donor 3 AM - A_adipose     0.0
94731_Donor 3 AM - B_adipose     0.0
94732_Donor 3 AM - C_adipose     0.0
94733_Donor 3 AD - A_adipose     0.0
94734_Donor 3 AD - B_adipose     0.0
94735_Donor 3 AD - C_adipose     0.0
77138_Liver_HepG2untreated       0.0
73556_Heart_Cardiac stromal cells (primary) 0.0
81735_Small Intestine            26.6
72409_Kidney_Proximal Convoluted Tubule 0.0
82685_Small intestine_Duodenum   14.8
90650_Adrenal Adrenocortical adenoma 0.0
72410_Kidney_HRCE                0.0
72411_Kidney_HRE                 0.0
73139_Uterus_Uterine smooth muscle cells 0.0

[1111] Panel 5 Islet Summary: Ag7590 Expression of this gene is restricted to a sample of pancreatic islet cells (CT=34.5). Thus, expression of this gene could be used to differentiate between this sample and other samples on this panel and as a marker of islet cells. Furthermore, therapeutic modulation of the expression or function of this gene may be useful in the treatment of diabetes.

[1112] AH. CG159084-01: Glutamate Decarboxylase like.

[1113] Expression of gene CG159084-01 was assessed using the primer-probe sets Ag5799 and Ag5799, described in Tables AHA and AHB.

TABLE AHA
Probe Name Ag5799
			Start	SEQ ID
Primers	Sequences	Length	Position	No
Forward	5′-agagatcaagaactccgaaagg-3′	22	1399	570
Probe	TET-5′-tgccttccatcatcatctgtgcttta-3′-TAMRA	26	1434	571
Reverse	5′-ggctggtagcttatcatgattg-3′	22	1460	572

[1114]

TABLE AHB
Probe Name Ag5799
			Start	SEQ ID
Primers	Sequences	Length	Position	No
Forward	5′-agagatcaagaactccgaaagg-3′	22	1399	573
Probe	TET-5′-tgccttccatcatcatctgtgcttta-3′-TAMRA	26	1434	574
Reverse	5′-ggctggtagcttatcatgattg-3′	22	1460	575

[1115] CNS_neurodegeneration_v1.0 Summary: Ag5799 Expression of this gene is low/undetectable in all samples on this panel (CTs>35). (Data not shown.)

[1116] General_screening_panelv1.5 Summary: Ag5799 Expression of this gene is low/undetectable in all samples on this panel (CTs>35). (Data not shown.)

[1117] General_screening_panelv1.6 Summary: Ag5799 Expression of this gene is low/undetectable in all samples on this panel (CTs>35). (Data not shown.)

[1118] Panel 4.1D Summary: Ag5799 Expression of this gene is low/undetectable in all samples on this panel (CTs>35). (Data not shown.)

[1119] Panel 5 Islet Summary: Ag5799 Expression of this gene is low/undetectable in all samples on this panel (CTs>35). (Data not shown.)

[1120] Panel CNS—1.1 Summary: Ag5799 Expression of this gene is low/undetectable in all samples on this panel (CTs>35). (Data not shown.)

[1121] AI. CG159130-01: Hyperpolarization-Activated Cyclic Nucleotide-Gated Channel 1.

[1122] Expression of gene CG159130-01 was assessed using the primer-probe set Ag7494, described in Table AIA. Results of the RTQ-PCR runs are shown in Table AIB.

TABLE AIA
Probe Name Ag7494
			Start	SEQ ID
Primers	Sequences	Length	Position	No
Forward	5′-ttcatacgcactcttcaaagcta-3′	23	1095	576
Probe	TET-5′-cccagtcagcatgtctgacctctgga-3′-TAMRA	26	1155	577
Reverse	5′-cgacgatcatgctcagcat-3′	19	1186	578

[1123]

TABLE AIB
CNS_neurodegeneration_v1.0
                               Rel. Exp. (%)
                               Ag7494, Run
Tissue Name                    308752180
AD 1 Hippo                     2.1
AD 2 Hippo                     7.9
AD 3 Hippo                     2.2
AD 4 Hippo                     2.0
AD 5 hippo                     100.0
AD 6 Hippo                     17.6
Control 2 Hippo                21.6
Control 4 Hippo                1.1
Control (Path) 3 Hippo         0.6
AD 1 Temporal Ctx              3.0
AD 2 Temporal Ctx              9.1
AD 3 Temporal Ctx              1.0
AD 4 Temporal Ctx              5.1
AD 5 Inf Temporal Ctx          69.3
AD 5 Sup Temporal Ctx          15.0
AD 6 Inf Temporal Ctx          14.6
AD 6 Sup Temporal Ctx          19.8
Control 1 Temporal Ctx         0.6
Control 2 Temporal Ctx         34.9
Control 3 Temporal Ctx         6.2
Control 4 Temporal Ctx         1.8
Control (Path) 1 Temporal Ctx  43.5
Control (Path) 2 Temporal Ctx  19.6
Control (Path) 3 Temporal Ctx  0.8
Control (Path) 4 Temporal Ctx  13.7
AD 1 Occipital Ctx             6.8
AD 2 Occipital Ctx (Missing)   0.0
AD 3 Occipital Ctx             1.6
AD 4 Occipital Ctx             8.8
AD 5 Occipital Ctx             12.2
AD 6 Occipital Ctx             57.4
Control 1 Occipital Ctx        0.5
Control 2 Occipital Ctx        70.2
Control 3 Occipital Ctx        7.4
Control 4 Occipital Ctx        1.1
Control (Path) 1 Occipital Ctx 62.9
Control (Path) 2 Occipital Ctx 3.8
Control (Path) 3 Occipital Ctx 0.6
Control (Path) 4 Occipital Ctx 7.2
Control 1 Parietal Ctx         0.9
Control 2 Parietal Ctx         16.4
Control 3 Parietal Ctx         11.5
Control (Path) 1 Parietal Ctx  66.0
Control (Path) 2 Parietal Ctx  11.7
Control (Path) 3 Parietal Ctx  0.9
Control (Path) 4 Parietal Ctx  31.9

[1124] CNS_neurodegeneration_v1.0 Summary: Ag7494 This panel does not show differential expression of this gene in Alzheimer's disease. However, this profile confirms the expression of this gene at high to moderate levels in the brain. Therefore, therapeutic modulation of the expression or function of this gene may be useful in the treatment of neurological disorders, such as Alzheimer's disease, Parkinson's disease, schizophrenia, multiple sclerosis, stroke and epilepsy.

[1125] AJ. CG159178-01: Carbonic Anhydrase VI Precursor.

[1126] Expression of gene CG159178-01 was assessed using the primer-probe set Ag4880, described in Table AJA. Results of the RTQ-PCR runs are shown in Tables AJB, AJC and AJD.

TABLE AJA
Probe Name Ag4880
			Start	SEQ ID
Primers	Sequences	Length	Position	No
Forward	5′-ttcgttgaggtgaagaattacc-3′	22	319	579
Probe	TET-5′-cagcaacttcatttctcatctggcca-3′-TAMRA	26	357	580
Reverse	5′-gttctttgtcctgggtacttga-3′	22	386	581

[1127]

TABLE AJB
General_screening_panel_v1.5
                                 Rel. Exp. (%)
                                 Ag4880, Run
Tissue Name                      228806989
Adipose                          0.0
Melanoma* Hs688(A).T             0.0
Melanoma* Hs688(B).T             0.0
Melanoma* M14                    0.0
Melanoma* LOXIMVI                0.0
Melanoma* SK-MEL-5               0.0
Squamous cell carcinoma SCC-4    0.0
Testis Pool                      0.0
Prostate ca.* (bone met) PC-3    0.0
Prostate Pool                    0.0
Placenta                         0.0
Uterus Pool                      0.0
Ovarian ca. OVCAR-3              0.0
Ovarian ca. SK-OV-3              0.0
Ovarian ca. OVCAR-4              0.0
Ovarian ca. OVCAR-5              0.0
Ovarian ca. IGROV-1              0.0
Ovarian ca. OVCAR-8              0.0
Ovary                            0.0
Breast ca. MCF-7                 0.0
Breast ca. MDA-MB-231            0.0
Breast ca. BT 549                0.0
Breast ca. T47D                  0.0
Breast ca. MDA-N                 0.0
Breast Pool                      0.0
Trachea                          0.1
Lung                             0.0
Fetal Lung                       0.0
Lung ca. NCI-N417                0.0
Lung ca. LX-1                    1.4
Lung ca. NCI-H146                0.0
Lung ca. SHP-77                  0.3
Lung ca. A549                    0.0
Lung ca. NCI-H526                0.0
Lung ca. NCI-H23                 0.0
Lung ca. NCI-H460                0.0
Lung ca. HOP-62                  0.0
Lung ca. NCI-H522                0.0
Liver                            0.0
Fetal Liver                      0.0
Liver ca. HepG2                  0.0
Kidney Pool                      0.0
Fetal Kidney                     0.0
Renal ca. 786-0                  0.0
Renal ca. A498                   0.0
Renal ca. ACHN                   0.0
Renal ca. UO-31                  0.0
Renal ca. TK-10                  0.0
Bladder                          0.0
Gastric ca. (liver met.) NCI-N87 0.0
Gastric ca. KATO III             0.0
Colon ca. SW-948                 0.0
Colon ca. SW480                  0.0
Colon ca.* (SW480 met) SW620     0.0
Colon ca. HT29                   0.0
Colon ca. HCT-116                0.0
Colon ca. CaCo-2                 0.0
Colon cancer tissue              0.0
Colon ca. SW1116                 0.0
Colon ca. Colo-205               0.0
Colon ca. SW-48                  0.0
Colon Pool                       0.0
Small Intestine Pool             0.0
Stomach Pool                     0.0
Bone Marrow Pool                 0.0
Fetal Heart                      0.0
Heart Pool                       0.0
Lymph Node Pool                  0.0
Fetal Skeletal Muscle            0.0
Skeletal Muscle Pool             0.0
Spleen Pool                      0.0
Thymus Pool                      0.0
CNS cancer (glio/astro) U87-MG   0.0
CNS cancer (glio/astro) U-118-MG 0.0
CNS cancer (neuro;met) SK-N-AS   0.0
CNS cancer (astro) SF-539        0.0
CNS cancer (astro)SNB-75         0.0
CNS cancer (glio) SNB-19         0.0
CNS cancer (glio) SF-295         0.0
Brain (Amygdala) Pool            0.0
Brain (cerebellum)               0.0
Brain (fetal)                    0.0
Brain (Hippocampus) Pool         0.0
Cerebral Cortex Pool             0.0
Brain (Substantia nigra) Pool    0.0
Brain (Thalamus) Pool            0.0
Brain (whole)                    0.0
Spinal Cord Pool                 0.0
Adrenal Gland                    0.0
Pituitary gland Pool             0.0
Salivary Gland                   100.0
Thyroid (female)                 0.0
Pancreatic ca. CAPAN2            0.0
Pancreas Pool                    0.0

[1128]

TABLE AJC
Panel 4.1D
                                 Rel. Exp. (%)
                                 Ag4880, Run
Tissue Name                      223350178
Secondary Th1 act                100.0
Secondary Th2 act                0.0
Secondary Tr1 act                7.2
Secondary Th1 rest               11.3
Secondary Th2 rest               7.0
Secondary Tr1 rest               8.8
Primary Th1 act                  5.4
Primary Th2 act                  0.0
Primary Tr1 act                  43.2
Primary Th1 rest                 29.5
Primary Th2 rest                 6.7
Primary Tr1 rest                 10.4
CD45RA CD4 lymphocyte act        19.2
CD45RO CD4 lymphocyte act        22.5
CD8 lymphocyte act               31.6
Secondary CD8 lymphocyte rest    5.4
Secondary CD8 lymphocyte act     10.6
CD4 lymphocyte none              10.6
2ry Th1/Th2/Tr1_anti-CD95 CH11   10.5
LAK cells rest                   4.7
LAK cells IL-2                   19.1
LAK cells IL-2 + IL-12           56.3
LAK cells IL-2 + IFN gamma       28.3
LAK cells IL-2 + IL-18           33.4
LAK cells PMA/ionomycin          0.0
NK Cells IL-2 rest               40.9
Two Way MLR 3 day                13.9
Two Way MLR 5 day                3.4
Two Way MLR 7 day                25.7
PBMC rest                        4.9
PBMC PWM                         21.3
PBMC PHA-L                       17.6
Ramos (B cell) none              4.7
Ramos (B cell) ionomycin         10.6
B lymphocytes PWM                5.4
B lymphocytes CD40L and IL-4     6.7
EOL-1 dbcAMP                     31.4
EOL-1 dbcAMP PMA/ionomycin       3.5
Dendritic cells none             0.0
Dendritic cells LPS              0.0
Dendritic cells anti-CD40        0.0
Monocytes rest                   0.0
Monocytes LPS                    0.7
Macrophages rest                 0.0
Macrophages LPS                  0.0
HUVEC none                       11.3
HUVEC starved                    0.0
HUVEC IL-1beta                   0.0
HUVEC IFN gamma                  0.0
HUVEC TNF alpha + IFN gamma      0.0
HUVEC TNF alpha + IL4            0.0
HUVEC IL-11                      0.0
Lung Microvascular EC none       0.0
Lung Microvascular EC TNFalpha + IL-1beta 0.0
Microvascular Dermal EC none     0.0
Microsvasular Dermal EC TNFalpha + IL-1beta 0.0
Bronchial epithelium TNFalpha + IL1beta 0.0
Small airway epithelium none     0.0
Small airway epithelium TNFalpha + IL-1beta 0.0
Coronery artery SMC rest         0.0
Coronery artery SMC TNFalpha + IL-1beta 0.0
Astrocytes rest                  0.0
Astrocytes TNFalpha + IL-1beta   0.0
KU-812 (Basophil) rest           0.0
KU-812 (Basophil) PMA/ionomycin  0.0
CCD1106 (Keratinocytes) none     0.0
CCD1106 (Keratinocytes) TNFalpha + IL-1beta 0.0
Liver cirrhosis                  0.0
NCI-H292 none                    0.0
NCI-H292 IL-4                    0.0
NCI-H292 IL-9                    0.0
NCI-H292 IL-13                   0.0
NCI-H292 IFN gamma               0.0
HPAEC none                       0.0
HPAEC TNF alpha + IL-1 beta      0.0
Lung fibroblast none             0.0
Lung fibroblast TNF alpha + IL-1 beta 0.0
Lung fibroblast IL-4             0.0
Lung fibroblast IL-9             0.0
Lung fibroblast IL-13            0.0
Lung fibroblast IFN gamma        0.0
Dermal fibroblast CCD1070 rest   3.9
Dermal fibroblast CCD1070 TNF alpha 53.2
Dermal fibroblast CCD1070 IL-1 beta 0.0
Dermal fibroblast IFN gamma      0.0
Dermal fibroblast IL-4           0.0
Dermal Fibroblasts rest          0.0
Neutrophils TNFa + LPS           0.0
Neutrophils rest                 0.0
Colon                            0.0
Lung                             5.3
Thymus                           19.6
Kidney                           3.2

[1129]

TABLE AJD
Panel 5 Islet
                                 Rel. Exp. (%)
                                 Ag4880, Run
Tissue Name                      296908323
97457_Patient-02go_adipose       0.0
97476_Patient-07sk_skeletal muscle 0.0
97477_Patient-07ut_uterus        0.0
97478_Patient-07pl_placenta      0.0
99167_Bayer Patient 1            0.0
97482_Patient-08ut_uterus        0.0
97483_Patient-08pl_placenta      0.0
97486_Patient-09sk_skeletal muscle 0.0
97487_Patient-09ut_uterus        0.0
97488_Patient-09pl_placenta      0.0
97492_Patient-10ut_uterus        0.0
97493_Patient-10pl_placenta      0.0
97495_Patient-11go_adipose       0.0
97496_Patient-11sk_skeletal muscle 0.0
97497_Patient-11ut_uterus        0.0
97498_Patient-11pl_placenta      0.0
97500_Patient-12go_adipose       0.0
97501_Patient-12sk_skeletal muscle 0.0
97502_Patient-12ut_uterus        0.0
97503_Patient-12pl_placenta      0.0
94721_Donor 2 U - A_Mesenchymal Stem Cells 0.0
94722_Donor 2 U - B_Mesenchymal Stem Cells 0.0
94723_Donor 2 U - C_Mesenchymal Stem Cells 0.0
94709_Donor 2 AM - A_adipose     0.0
94710_Donor 2 AM - B_adipose     0.0
94711_Donor 2 AM - C_adipose     0.0
94712_Donor 2 AD - A_adipose     0.0
94713_Donor 2 AD - B_adipose     0.0
94714_Donor 2 AD - C_adipose     0.0
94742_Donor 3 U - A_Mesenchymal Stem Cells 0.0
94743_Donor 3 U - B_Mesenchymal Stem Cells 0.0
94730_Donor 3 AM - A_adipose     0.0
94731_Donor 3 AM - B_adipose     0.0
94732_Donor 3 AM - C_adipose     0.0
94733_Donor 3 AD - A_adipose     0.0
94734_Donor 3 AD - B_adipose     0.0
94735_Donor 3 AD - C_adipose     0.0
77138_Liver_HepG2untreated       0.0
73556_Heart_Cardiac stromal cells (primary) 0.0
81735_Small Intestine            100.0
72409_Kidney_Proximal Convoluted Tubule 0.0
82685_Small intestine_Duodenum   0.0
90650_Adrenal_Adrenocortical adenoma 0.0
72410_Kidney_HRCE                0.0
72411_Kidney_HRE                 0.0
73139_Uterus_Uterine smooth muscle cells 0.0

[1130] General_screening_panel_v1.5 Summary: Ag4880 Expression of this gene is highest in salivary gland (CT=20.3). Thus expression of this gene could be used to differentiate between this sample and other samples on this panel and as a marker of this tissue.

[1131] Panel 4.1D Summary: Ag4880 Highest expression of this gene is seen a sample derived from chronically activated Th1 cells (CT=32.2). Low but significant expression is seen in primary activated Th1 and Th2 cells, LAK cells, NK cells, eosinophils, TNF-a activated dermal fibroblasts and thymus. This expression profile suggests that this gene product may be involved in autoimmune disease.

[1132] Panel 5 Islet Summary: Ag4880 Expression of this gene is limited to the small intestine (CT=23.7). Thus expression of this gene could be used to differentiate between this sample and other samples on this panel and as a marker of this tissue.

[1133] AK. CG160131-01: Glycerol Kinase.

[1134] Expression of gene CG160131-01 was assessed using the primer-probe set Ag5581, described in Table AKA. Results of the RTQ-PCR runs are shown in Tables AKB, AKC, AKD, AKE, AKF, AKG and AKH.

TABLE AKA
Probe Name Ag5581
			Start	SEQ ID
Primers	Sequences	Length	Position	No
Forward	5′-accactgtagtctgggacaaga-3′	22	292	582
Probe	TET-5′-tctacaatgctgtggctgctccagtt-3′-TAMRA	26	329	583
Reverse	5′-acggcaactggaactgaag-3′	19	365	584

[1135]

TABLE AKB
AI_comprehensive panel_v1.0
		Rel. Exp. (%)	Rel. Exp. (%)
		Ag5581, Run	Ag5581, Run
	Tissue Name	244333633	244899563
	110967 COPD-F	0.0	0.0
	110980 COPD-F	0.0	0.0
	110968 COPD-M	3.9	0.0
	110977 COPD-M	0.0	9.0
	110989	0.0	7.4
	Emphysema-F
	110992	0.0	0.0
	Emphysema-F
	110993	4.2	0.0
	Emphysema-F
	110994	0.0	0.0
	Emphysema-F
	110995	14.0	3.6
	Emphysema-F
	110996	0.0	0.0
	Emphysema-F
	110997	3.9	13.3
	Asthma-M
	111001	0.0	0.0
	Asthma-F
	111002	0.0	6.1
	Asthma-F
	111003 Atopic	4.3	0.0
	Asthma-F
	111004 Atopic	0.0	0.0
	Asthma-F
	111005 Atopic	0.0	8.0
	Asthma-F
	111006 Atopic	0.0	0.0
	Asthma-F
	111417	0.0	0.0
	Allergy-M
	112347	0.0	0.0
	Allergy-M
	112349 Normal	0.0	0.0
	Lung-F
	112357 Normal	0.0	0.0
	Lung-F
	112354 Normal	0.0	0.0
	Lung-M
	112374	14.9	16.2
	Crohns-F
	112389 Match	0.0	0.0
	Control
	Crohns-F
	112375	0.0	4.5
	Crohns-F
	112732 Match	0.0	6.2
	Control
	Crohns-F
	112725	0.0	0.0
	Crohns-M
	112387 Match	0.0	7.6
	Control
	Crohns-M
	112378	0.0	0.0
	Crohns-M
	112390 Match	5.5	7.1
	Control
	Crohns-M
	112726	1.8	3.8
	Crohns-M
	112731 Match	1.3	7.7
	Control
	Crohns-M
	112380 Ulcer	3.9	8.3
	Col-F
	112734 Match	100.0	100.0
	Control Ulcer
	Col-F
	112384 Ulcer	3.7	0.0
	Col-F
	112737 Match	0.0	0.0
	Control Ulcer
	Col-F
	112386 Ulcer	4.2	0.0
	Col-F
	112738 Match	15.5	66.0
	Control Ulcer
	Col-F
	112381 Ulcer	0.0	0.0
	Col-M
	112735 Match	17.9	9.3
	Control Ulcer
	Col-M
	112382 Ulcer	3.2	0.0
	Col-M
	112394 Match	0.0	0.0
	Control Ulcer
	Col-M
	112383 Ulcer	1.3	0.0
	Col-M
	112736 Match	0.0	11.9
	Control Ulcer
	Col-M
	112423	10.6	22.1
	Psoriasis-F
	112427 Match	0.0	6.7
	Control
	Psoriasis-F
	112418	0.0	0.0
	Psoriasis-M
	112723 Match	0.0	0.0
	Control
	Psoriasis-M
	112419	0.0	0.0
	Psoriasis-M
	112424 Match	3.4	4.1
	Control
	Psoriasis-M
	112420	12.0	8.2
	Psoriasis-M
	112425 Match	0.0	0.0
	Control
	Psoriasis-M
	104689 (MF)	13.9	13.5
	OA Bone-
	Backus
	104690 (MF)	0.0	15.8
	Adj “Normal”
	Bone-Backus
	104691 (MF)	4.5	0.0
	OA
	Synovium-
	Backus
	104692 (BA)	0.0	0.0
	OA Cartilage-
	Backus
	104694 (BA)	18.7	21.0
	OA Bone-
	Backus
	104695 (BA)	0.0	8.4
	Adj “Normal”
	Bone-Backus
	104696 (BA)	23.7	15.5
	OA
	Synovium-
	Backus
	104700 (SS)	3.7	8.6
	OA Bone-
	Backus
	104701 (SS)	5.6	27.5
	Adj “Normal”
	Bone-Backus
	104702 (SS)	7.3	0.0
	OA
	Synovium-
	Backus
	117093 OA	0.0	0.0
	Cartilage
	Rep7
	112672 OA	7.6	3.8
	Bone5
	112673 OA	7.6	7.7
	Synovium5
	112674 OA	2.3	9.7
	Synovial Fluid
	cells5
	117100 OA	0.0	0.0
	Cartilage
	Rep14
	112756 OA	7.7	0.0
	Bone9
	112757 OA	10.6	9.7
	Synovium9
	112758 OA	0.0	0.0
	Synovial Fluid
	Cells9
	117125 RA	0.0	0.0
	Cartilage
	Rep2
	113492 Bone2	66.0	40.9
	RA
	113493	7.5	7.5
	Synovium2
	RA
	113494 Syn	23.3	46.0
	Fluid Cells
	RA
	113499	13.6	33.4
	Cartilage4 RA
	113500 Bone4	68.8	37.1
	RA
	113501	29.9	54.3
	Synovium4
	RA
	113502 Syn	3.8	28.3
	Fluid Cells4
	RA
	113495	37.9	68.3
	Cartilage3 RA
	113496 Bone3	23.3	30.4
	RA
	113497	27.7	0.0
	Synovium3
	RA
	113498 Syn	52.9	82.9
	Fluid Cells3
	RA
	117106	0.0	0.0
	Normal
	Cartilage
	Rep20
	113663 Bone3	8.1	0.0
	Normal
	113664	0.0	0.0
	Synovium3
	Normal
	113665 Syn	0.0	0.0
	Fluid Cells3
	Normal
	117107	0.0	0.0
	Normal
	Cartilage
	Rep22
	113667 Bone4	4.6	0.0
	Normal
	113668	0.0	8.9
	Synovium4
	Normal
	113669 Syn	0.0	0.0
	Fluid Cells4
	Normal

[1136]

TABLE AKC
General_screening_panel_v1.5
                                 Rel. Exp. (%)
                                 Ag5581, Run
Tissue Name                      244896891
Adipose                          1.9
Melanoma* Hs688(A).T             0.0
Melanoma* Hs688(B).T             0.0
Melanoma* M14                    0.0
Melanoma* LOXIMVI                0.0
Melanoma* SK-MEL-5               2.0
Squamous cell carcinoma SCC-4    0.0
Testis Pool                      0.0
Prostate ca.* (bone met) PC-3    0.5
Prostate Pool                    0.6
Placenta                         0.7
Uterus Pool                      0.0
Ovarian ca. OVCAR-3              0.4
Ovarian ca. SK-OV-3              0.0
Ovarian ca. OVCAR-4              0.0
Ovarian ca. OVCAR-5              0.0
Ovarian ca. IGROV-1              2.0
Ovarian ca. OVCAR-8              3.4
Ovary                            0.0
Breast ca. MCF-7                 0.5
Breast ca. MDA-MB-231            0.7
Breast ca. BT 549                0.2
Breast ca. T47D                  0.0
Breast ca. MDA-N                 2.4
Breast Pool                      0.0
Trachea                          3.3
Lung                             0.0
Fetal Lung                       5.9
Lung ca. NCI-N417                0.0
Lung ca. LX-1                    0.0
Lung ca. NCI-H146                1.2
Lung ca. SHP-77                  0.0
Lung ca. A549                    0.0
Lung ca. NCI-H526                0.0
Lung ca. NCI-H23                 0.6
Lung ca. NCI-H460                0.0
Lung ca. HOP-62                  0.0
Lung ca. NCI-H522                0.0
Liver                            8.1
Fetal Liver                      100.0
Liver ca. HepG2                  42.6
Kidney Pool                      1.1
Fetal Kidney                     2.2
Renal ca. 786-0                  0.5
Renal ca. A498                   0.0
Renal ca. ACHN                   1.6
Renal ca. UO-31                  0.0
Renal ca. TK-10                  22.2
Bladder                          22.1
Gastric ca. (liver met.) NCI-N87 0.0
Gastric ca. KATO III             1.6
Colon ca. SW-948                 1.3
Colon ca. SW480                  1.2
Colon ca.* (SW480 met) SW620     0.0
Colon ca. HT29                   0.0
Colon ca. HCT-116                0.0
Colon ca. CaCo-2                 6.0
Colon cancer tissue              27.2
Colon ca. SW1116                 0.0
Colon ca. Colo-205               0.7
Colon ca. SW-48                  0.6
Colon Pool                       0.0
Small Intestine Pool             1.5
Stomach Pool                     0.5
Bone Marrow Pool                 0.6
Fetal Heart                      0.8
Heart Pool                       0.0
Lymph Node Pool                  0.6
Fetal Skeletal Muscle            0.0
Skeletal Muscle Pool             15.9
Spleen Pool                      0.6
Thymus Pool                      0.6
CNS cancer (glio/astro) U87-MG   2.6
CNS cancer (glio/astro) U-118-MG 4.0
CNS cancer (neuro; met) SK-N-AS  0.0
CNS cancer (astro) SF-539        0.0
CNS cancer (astro) SNB-75        2.4
CNS cancer (glio) SNB-19         4.6
CNS cancer (glio) SF-295         1.0
Brain (Amygdala) Pool            1.7
Brain (cerebellum)               3.7
Brain (fetal)                    0.0
Brain (Hippocampus) Pool         7.6
Cerebral Cortex Pool             1.3
Brain (Substantia nigra) Pool    3.9
Brain (Thalamus) Pool            1.5
Brain (whole)                    4.2
Spinal Cord Pool                 15.1
Adrenal Gland                    1.0
Pituitary gland Pool             0.0
Salivary Gland                   0.7
Thyroid (female)                 1.0
Pancreatic ca. CAPAN2            0.0
Pancreas Pool                    1.5

[1137]

TABLE AKD
General_screening_panel_v1.6
                                 Rel. Exp. (%)
                                 Ag5581, Run
Tissue Name                      278988931
Adipose                          6.1
Melanoma* Hs688(A).T             0.0
Melanoma* Hs688(B).T             0.0
Melanoma* M14                    3.8
Melanoma* LOXIMVI                0.9
Melanoma* SK-MEL-5               3.8
Squamous cell carcinoma SCC-4    0.0
Testis Pool                      0.0
Prostate ca.* (bone met) PC-3    2.7
Prostate Pool                    2.5
Placenta                         0.0
Uterus Pool                      0.0
Ovarian ca. OVCAR-3              0.7
Ovarian ca. SK-OV-3              0.7
Ovarian ca. OVCAR-4              0.0
Ovarian ca. OVCAR-5              0.0
Ovarian ca. IGROV-1              1.6
Ovarian ca. OVCAR-8              3.4
Ovary                            0.9
Breast ca. MCF-7                 0.0
Breast ca. MDA-MB-231            0.0
Breast ca. BT 549                0.0
Breast ca. T47D                  0.8
Breast ca. MDA-N                 0.8
Breast Pool                      0.6
Trachea                          5.1
Lung                             0.0
Fetal Lung                       7.0
Lung ca. NCI-N417                0.0
Lung ca. LX-1                    0.0
Lung ca. NCI-H146                0.0
Lung ca. SHP-77                  0.9
Lung ca. A549                    1.0
Lung ca. NCI-H526                0.0
Lung ca. NCI-H23                 0.0
Lung ca. NCI-H460                0.8
Lung ca. HOP-62                  0.7
Lung ca. NCI-H522                0.0
Liver                            3.9
Fetal Liver                      100.0
Liver ca. HepG2                  29.9
Kidney Pool                      0.5
Fetal Kidney                     5.9
Renal ca. 786-0                  0.0
Renal ca. A498                   0.0
Renal ca. ACHN                   0.0
Renal ca. UO-31                  2.9
Renal ca. TK-10                  14.8
Bladder                          27.9
Gastric ca. (liver met.) NCI-N87 1.7
Gastric ca. KATO III             1.2
Colon ca. SW-948                 0.0
Colon ca. SW480                  1.2
Colon ca.* (SW480 met) SW620     0.9
Colon ca. HT29                   0.0
Colon ca. HCT-116                0.0
Colon ca. CaCo-2                 5.7
Colon cancer tissue              20.0
Colon ca. SW1116                 0.0
Colon ca. Colo-205               0.0
Colon ca. SW-48                  0.0
Colon Pool                       0.0
Small Intestine Pool             1.6
Stomach Pool                     3.7
Bone Marrow Pool                 0.0
Fetal Heart                      2.7
Heart Pool                       1.4
Lymph Node Pool                  0.3
Fetal Skeletal Muscle            1.0
Skeletal Muscle Pool             2.8
Spleen Pool                      3.8
Thymus Pool                      1.6
CNS cancer (glio/astro) U87-MG   1.9
CNS cancer (glio/astro) U-118-MG 3.2
CNS cancer (neuro; met) SK-N-AS  0.0
CNS cancer (astro) SF-539        0.0
CNS cancer (astro) SNB-75        0.8
CNS cancer (glio) SNB-19         2.6
CNS cancer (glio) SF-295         2.8
Brain (Amygdala) Pool            5.2
Brain (cerebellum)               0.0
Brain (fetal)                    1.9
Brain (Hippocampus) Pool         14.1
Cerebral Cortex Pool             6.5
Brain (Substantia nigra) Pool    6.6
Brain (Thalamus) Pool            12.0
Brain (whole)                    5.4
Spinal Cord Pool                 12.1
Adrenal Gland                    4.2
Pituitary gland Pool             0.8
Salivary Gland                   0.8
Thyroid (female)                 0.9
Pancreatic ca. CAPAN2            0.0
Pancreas Pool                    0.0

[1138]

TABLE AKE
Panel 4.1D
                                 Rel. Exp. (%)
                                 Ag5581, Run
Tissue Name                      244337065
Secondary Th1 act                0.1
Secondary Th2 act                0.2
Secondary Tr1 act                0.0
Secondary Th1 rest               0.0
Secondary Th2 rest               0.0
Secondary Tr1 rest               0.0
Primary Th1 act                  0.0
Primary Th2 act                  0.2
Primary Tr1 act                  0.0
Primary Th1 rest                 0.0
Primary Th2 rest                 0.0
Primary Tr1 rest                 0.0
CD45RA CD4 lymphocyte act        0.1
CD45RO CD4 lymphocyte act        0.3
CD8 lymphocyte act               0.0
Secondary CD8 lymphocyte rest    0.1
Secondary CD8 lymphocyte act     0.0
CD4 lymphocyte none              0.0
2ry Th1/Th2/Tr1_anti-CD95 CH11   0.0
LAK cells rest                   2.3
LAK cells IL-2                   0.0
LAK cells IL-2 + IL-12           0.0
LAK cells IL-2 + IFN gamma       0.0
LAK cells IL-2 + IL-18           0.1
LAK cells PMA/ionomycin          21.2
NK Cells IL-2 rest               0.0
Two Way MLR 3 day                1.9
Two Way MLR 5 day                0.1
Two Way MLR 7 day                0.1
PBMC rest                        0.0
PBMC PWM                         0.1
PBMC PHA-L                       0.5
Ramos (B cell) none              0.0
Ramos (B cell) ionomycin         0.0
B lymphocytes PWM                0.1
B lymphocytes CD40L and IL-4     0.1
EOL-1 dbcAMP                     0.0
EOL-1 dbcAMP PMA/ionomycin       0.0
Dendritic cells none             2.3
Dendritic cells LPS              1.5
Dendritic cells anti-CD40        0.3
Monocytes rest                   0.0
Monocytes LPS                    100.0
Macrophages rest                 1.0
Macrophages LPS                  1.5
HUVEC none                       0.0
HUVEC starved                    0.0
HUVEC IL-1beta                   0.0
HUVEC IFN gamma                  0.0
HUVEC TNF alpha + IFN gamma      0.0
HUVEC TNF alpha + IL4            0.0
HUVEC IL-11                      0.0
Lung Microvascular EC none       0.0
Lung Microvascular EC TNFalpha + IL-1beta 0.1
Microvascular Dermal EC none     0.0
Microsvasular Dermal EC TNFalpha + IL-1beta 0.0
Bronchial epithelium TNFalpha + IL1beta 0.0
Small airway epithelium none     0.0
Small airway epithelium TNFalpha + IL-1beta 0.0
Coronery artery SMC rest         0.0
Coronery artery SMC TNFalpha + IL-1beta 0.0
Astrocytes rest                  0.0
Astrocytes TNFalpha + IL-1beta   0.0
KU-812 (Basophil) rest           0.0
KU-812 (Basophil) PMA/ionomycin  0.3
CCD1106 (Keratinocytes) none     0.0
CCD1106 (Keratinocytes) TNFalpha + IL-1beta 0.0
Liver cirrhosis                  0.3
NCI-H292 none                    0.0
NCI-H292 IL-4                    0.2
NCI-H292 IL-9                    0.1
NCI-H292 IL-13                   0.1
NCI-H292 IFN gamma               0.0
HPAEC none                       0.0
HPAEC TNF alpha + IL-1 beta      0.3
Lung fibroblast none             0.1
Lung fibroblast TNF alpha + IL-1 beta 0.5
Lung fibroblast IL-4             0.1
Lung fibroblast IL-9             0.1
Lung fibroblast IL-13            0.0
Lung fibroblast IFN gamma        0.9
Dermal fibroblast CCD1070 rest   0.2
Dermal fibroblast CCD1070 TNF alpha 0.1
Dermal fibroblast CCD1070 IL-1 beta 0.1
Dermal fibroblast IFN gamma      0.1
Dermal fibroblast IL-4           0.1
Dermal Fibroblasts rest          0.1
Neutrophils TNFa + LPS           21.2
Neutrophils rest                 2.1
Colon                            0.1
Lung                             0.0
Thymus                           0.0
Kidney                           1.5

[1139]

TABLE AKF
Panel 5 Islet
	Rel.	Rel.
	Exp. (%)	Exp. (%)
	Ag5581,	Ag5581,
	Run	Run
Tissue Name	244908254	279370998
97457_Patient-02go_adipose	0.0	3.1
97476_Patient-07sk_skeletal	4.0	0.0
muscle
97477_Patient-07ut_uterus	0.0	0.0
97478_Patient-07pl_placenta	5.1	3.3
99167_Bayer Patient 1	3.3	0.0
97482_Patient-08ut_uterus	4.3	0.0
97483_Patient-08pl_placenta	0.0	7.0
97486_Patient-09sk_skeletal	0.0	3.1
muscle
97487_Patient-09ut_uterus	0.0	0.0
97488_Patient-09pl_placenta	0.0	0.0
97492_Patient-10ut_uterus	0.0	0.0
97493_Patient-10pl_placenta	0.0	3.7
97495_Patient-11go_adipose	0.0	2.3
97496_Patient-11sk_skeletal	18.3	1.7
muscle
97497_Patient-11ut_uterus	0.0	2.1
97498_Patient-11pl_placenta	0.0	0.0
97500_Patient-12go_adipose	0.0	0.0
97501_Patient-12sk_skeletal	6.3	0.0
muscle
97502_Patient-12ut_uterus	0.0	0.0
97503_Patient-12pl_placenta	0.0	6.6
94721_Donor 2 U -	0.0	0.0
A_Mesenchymal Stem Cells
94722 Donor 2 U -	0.0	0.0
B_Mesenchymal Stem Cells
94723_Donor 2 U -	0.0	7.2
C_Mesenchymal Stem Cells
94709_Donor 2 AM - A_adipose	0.0	0.0
94710_Donor 2 AM - B_adipose	0.0	2.1
94711_Donor 2 AM - C_adipose	0.0	0.0
94712_Donor 2 AD - A_adipose	0.0	0.0
94713_Donor 2 AD - B_adipose	0.0	0.0
94714_Donor 2 AD -	0.0	0.0
C_adipose
94742_Donor 3 U -	0.0	0.0
A_Mesenchymal Stem Cells
94743_Donor 3 U -	0.0	0.0
B_Mesenchymal Stem Cells
94730_Donor 3 AM - A_adipose	0.0	0.0
94731_Donor 3 AM - B_adipose	0.0	0.0
94732_Donor 3 AM - C_adipose	0.0	0.0
94733_Donor 3 AD - A_adipose	0.0	0.0
94734_Donor 3 AD - B_adipose	0.0	0.0
94735_Donor 3 AD - C_adipose	0.0	2.9
77138_Liver_HepG2untreated	100.0	100.0
73556_Heart_Cardiac stromal	0.0	0.0
cells (primary)
81735_Small Intestine	35.4	29.7
72409_Kidney_Proximal	0.0	0.0
Convoluted Tubule
82685_Small	12.8	44.4
intestine_Duodenum
90650_Adrenal_Adrenocortical	0.0	0.0
adenoma
72410_Kidney_HRCE	5.5	3.7
72411_Kidney_HRE	0.0	0.0
73139_Uterus_Uterine smooth	0.0	0.0
muscle cells

[1140]

TABLE AKG
Panel 5D
                                 Rel. Exp. (%)
                                 Ag5581, Run
Tissue Name                      244988601
97457_Patient-02go_adipose       7.0
97476_Patient-07sk_skeletal muscle 0.0
97477_Patient-07ut_uterus        0.0
97478_Patient-07pl_placenta      3.4
97481_Patient-08sk_skeletal muscle 4.2
97482_Patient-08ut_uterus        3.0
97483_Patient-08pl_placenta      0.0
97486_Patient-09sk_skeletal muscle 0.0
97487_Patient-09ut_uterus        0.0
97488_Patient-09pl_placenta      0.0
97492_Patient-10ut_uterus        9.0
97493_Patient-10pl_placenta      8.8
97495_Patient-11go_adipose       4.9
97496_Patient-11sk_skeletal muscle 0.0
97497_Patient-11ut_uterus        0.0
97498_Patient-11pl_placenta      4.4
97500_Patient-12go_adipose       0.0
97501_Patient-12sk_skeletal muscle 4.9
97502_Patient-12ut_uterus        4.0
97503_Patient-12pl_placenta      9.3
94721_Donor 2 U - A_Mesenchymal Stem Cells 0.0
94722_Donor 2 U - B_Mesenchymal Stem Cells 0.0
94723_Donor 2 U - C_Mesenchymal Stem Cells 0.0
94709_Donor 2 AM - A_adipose     0.0
94710_Donor 2 AM - B_adipose     0.0
94711_Donor 2 AM - C_adipose     0.0
94712_Donor 2 AD - A_adipose     0.0
94713_Donor 2 AD - B_adipose     0.0
94714_Donor 2 AD - C_adipose     0.0
94742_Donor 3 U - A_Mesenchymal Stem Cells 0.0
94743_Donor 3 U - B_Mesenchymal Stem Cells 0.0
94730_Donor 3 AM - A_adipose     0.0
94731_Donor 3 AM - B_adipose     0.0
94732_Donor 3 AM - C_adipose     0.0
94733_Donor 3 AD - A_adipose     0.0
94734_Donor 3 AD - B_adipose     0.0
94735_Donor 3 AD - C_adipose     0.0
77138_Liver_HepG2untreated       100.0
73556_Heart_Cardiac stromal cells (primary) 0.0
81735_Small Intestine            25.0
72409_Kidney_Proximal Convoluted Tubule 0.0
82685_Small intestine_Duodenum   40.3
90650_Adrenal_Adrenocortical adenoma 0.0
72410_Kidney_HRCE                3.3
72411_Kidney_HRE                 0.0
73139_Uterus_Uterine smooth muscle cells 0.0

[1141]

TABLE AKH
general oncology screening panel_v_2.4
                               Rel. Exp. (%)
                               Ag5581, Run
Tissue Name                    260268963
Colon cancer 1                 17.7
Colon cancer NAT 1             0.0
Colon cancer 2                 15.4
Colon cancer NAT 2             8.2
Colon cancer 3                 13.2
Colon cancer NAT 3             6.1
Colon malignant cancer 4       44.1
Colon normal adjacent tissue 4 2.2
Lung cancer 1                  25.0
Lung NAT 1                     3.3
Lung cancer 2                  32.8
Lung NAT 2                     6.7
Squamous cell carcinoma 3      25.0
Lung NAT 3                     3.2
metastatic melanoma 1          1.5
Melanoma 2                     1.2
Melanoma 3                     0.0
metastatic melanoma 4          2.6
metastatic melanoma 5          14.2
Bladder cancer 1               6.2
Bladder cancer NAT 1           0.0
Bladder cancer 2               0.0
Bladder cancer NAT 2           0.0
Bladder cancer NAT 3           0.0
Bladder cancer NAT 4           0.0
Prostate adenocarcinoma 1      2.7
Prostate adenocarcinoma 2      0.0
Prostate adenocarcinoma 3      0.0
Prostate adenocarcinoma 4      2.2
Prostate cancer NAT 5          0.0
Prostate adenocarcinoma 6      0.0
Prostate adenocarcinoma 7      3.3
Prostate adenocarcinoma 8      0.0
Prostate adenocarcinoma 9      0.0
Prostate cancer NAT 10         0.0
Kidney cancer 1                32.5
Kidney NAT 1                   2.9
Kidney cancer 2                12.4
Kidney NAT 2                   10.7
Kidney cancer 3                15.9
Kidney NAT 3                   16.4
Kidney cancer 4                12.9
Kidney NAT 4                   100.0

[1142] AI_comprehensive panel_v1.0 Summary: Ag5581 Two experiments with the same probe and primer set show detectable expression of this gene limited to a sample of normal tissue adjacent to ulcerative colitis (CTs=33.5-34.5) and a sample derived from RA synovial fluid.

[1143] General_screening_panel_v1.5 Summary: Ag5581 Highest expression is seen in fetal liver (CT=30.6). In addition, this gene is expressed at much higher levels in fetal liver tissue when compared to expression in the adult counterpart (CT=34). Thus, expression of this gene may be used to differentiate between the fetal and adult source of this tissue.

[1144] General_screening_panel_v1.6 Summary: Ag5581 Highest expression is seen in fetal liver (CT=30.3). Overall, expression is in agreement with Panel 1.5. Please see that panel for further discussion of expression and utility of this gene.

[1145] Panel 4.1D Summary: Ag5581 Highest expression is seen in LPS treated monocytes (CT=27.4). Moderate levels of expression are seen in TFN-a/LPS treated neutropils and PMA/ionomycin treated LAKs. Low but significant levels of expression are seen in macrophages. Upon activation with pathogens such as LPS, monocytes contribute to the innate and specific immunity by migrating to the site of tissue injury and releasing inflammatory cytokines. This release contributes to the inflammation process. Therefore expression of this gene could be used as a marker of activated monocytes. Furthermore, modulation of the expression of the protein encoded by this transcript may prevent the recruitment of monocytes and the initiation of the inflammatory process, and reduce the symptoms of patients suffering from autoimmune and inflammatory diseases such as asthma, allergies, inflammatory bowel disease, lupus erythematosus, or rheumatoid arthritis.

[1146] Panel 5 Islet Summary: Ag5581 Two experiments with the same probe and primer set show detectable expression of this gene limited to a liver cancer cell line sample (CTs=33.5-34.5). This expression is in agreement with expression seen in Panels 1.5 and 1.6.

[1147] Panel 5D Summary: Ag5581 Expression of this gene limited to a liver cancer cell line sample (CT=34). This expression is in agreement with expression seen in Panels 1.5 and 1.6.

[1148] General oncology screening panel_v—2.4 Summary: Ag5581 Highest expression is seen in a kidney sample (CT=32). In addition, this gene is more highly expressed in lung and colon cancer than in the corresponding normal adjacent tissue. Thus, expression of this gene could be used as a marker of these cancers. Furthemore, therapeutic modulation of the expression or function of this gene product may be useful in the treatment of lung and colon cancer.

[1149] AL. CG160131-04: FL—1—552 Glycerol Kinase.

[1150] Expression of gene CG160131-04 was assessed using the primer-probe set Ag7439, described in Table ALA. Results of the RTQ-PCR runs are shown in Tables ALB and ALC. Please note that CG160131-04 represents a full-length physical clone.

TABLE ALA
Probe Name Ag7439
			Start	SEQ ID
Primers	Sequences	Length	Position	No
Forward	5′-agcacatttgtcccaccaat-3′	20	774	585
Probe	TET-5′-cacccagatattggcacaccttccaa-3′-TAMRA	26	815	586
Reverse	5′-atgaaaatctctcatagcgtgaa-3′	23	851	587

[1151]

TABLE ALB
AI_comprehensive panel_v1.0
                                 Rel. Exp. (%)
                                 Ag7439, Run
Tissue Name                      311756513
110967 COPD-F                    19.1
110980 COPD-F                    18.3
110968 COPD-M                    16.5
110977 COPD-M                    68.8
110989 Emphysema-F               54.3
110992 Emphysema-F               8.2
110993 Emphysema-F               35.8
110994 Emphysema-F               13.5
110995 Emphysema-F               29.3
110996 Emphysema-F               2.1
110997 Asthma-M                  2.5
111001 Asthma-F                  32.8
111002 Asthma-F                  26.2
111003 Atopic Asthma-F           30.6
111004 Atopic Asthma-F           18.6
111005 Atopic Asthma-F           17.6
111006 Atopic Asthma-F           4.1
111417 Allergy-M                 12.2
112347 Allergy-M                 0.0
112349 Normal Lung-F             0.0
112357 Normal Lung-F             52.1
112354 Normal Lung-M             27.7
112374 Crohns-F                  27.2
112389 Match Control Crohns-F    8.6
112375 Crohns-F                  20.7
112732 Match Control Crohns-F    4.7
112725 Crohns-M                  5.4
112387 Match Control Crohns-M    12.6
112378 Crohns-M                  0.0
112390 Match Control Crohns-M    56.3
112726 Crohns-M                  21.2
112731 Match Control Crohns-M    20.0
112380 Ulcer Col-F               31.9
112734 Match Control Ulcer Col-F 15.3
112384 Ulcer Col-F               43.2
112737 Match Control Ulcer Col-F 5.5
112386 Ulcer Col-F               15.2
112738 Match Control Ulcer Col-F 5.6
112381 Ulcer Col-M               0.1
112735 Match Control Ulcer Col-M 3.0
112382 Ulcer Col-M               18.4
112394 Match Control Ulcer Col-M 8.9
112383 Ulcer Col-M               24.7
112736 Match Control Ulcer Col-M 6.3
112423 Psoriasis-F               21.8
112427 Match Control Psoriasis-F 100.0
112418 Psoriasis-M               23.5
112723 Match Control Psoriasis-M 21.2
112419 Psoriasis-M               43.8
112424 Match Control Psoriasis-M 23.2
112420 Psoriasis-M               79.6
112425 Match Control Psoriasis-M 82.9
104689 (MF) OA Bone-Backus       20.0
104690 (MF) Adj “Normal” Bone-Backus 24.0
104691 (MF) OA Synovium-Backus   71.7
104692 (BA) OA Cartilage-Backus  0.0
104694 (BA) OA Bone-Backus       27.2
104695 (BA) Adj “Normal” Bone-Backus 24.3
104696 (BA) OA Synovium-Backus   57.4
104700 (SS) OA Bone-Backus       16.2
104701 (SS) Adj “Normal” Bone-Backus 18.2
104702 (SS) OA Synovium-Backus   39.8
117093 OA Cartilage Rep7         31.4
112672 OA Bone5                  77.4
112673 OA Synovium5              35.8
112674 OA Synovial Fluid cells5  47.0
117100 OA Cartilage Rep14        8.4
112756 OA Bone9                  69.3
112757 OA Synovium9              20.6
112758 OA Synovial Fluid Cells9  9.2
117125 RA Cartilage Rep2         13.4
113492 Bone2 RA                  18.7
113493 Synovium2 RA              4.2
113494 Syn Fluid Cells RA        6.8
113499 Cartilage4 RA             7.7
113500 Bone4 RA                  11.0
113501 Synovium4 RA              9.2
113502 Syn Fluid Cells4 RA       4.5
113495 Cartilage3 RA             6.3
113496 Bone3 RA                  7.2
113497 Synovium3 RA              4.6
113498 Syn Fluid Cells3 RA       10.3
117106 Normal Cartilage Rep20    2.8
113663 Bone3 Normal              0.0
113664 Synovium3 Normal          0.0
113665 Syn Fluid Cells3 Normal   0.0
117107 Normal Cartilage Rep22    5.8
113667 Bone4 Normal              32.5
113668 Synovium4 Normal          21.8
113669 Syn Fluid Cells4 Normal   43.2

[1152]

TABLE ALC
Panel 4.1D
                                 Rel. Exp. (%)
                                 Ag7439, Run
Tissue Name                      305901963
Secondary Th1 act                1.9
Secondary Th2 act                1.7
Secondary Tr1 act                1.0
Secondary Th1 rest               0.0
Secondary Th2 rest               0.3
Secondary Tr1 rest               0.0
Primary Th1 act                  0.1
Primary Th2 act                  1.2
Primary Tr1 act                  2.0
Primary Th1 rest                 0.0
Primary Th2 rest                 0.0
Primary Tr1 rest                 0.0
CD45RA CD4 lymphocyte act        5.2
CD45RO CD4 lymphocyte act        1.1
CD8 lymphocyte act               0.0
Secondary CD8 lymphocyte rest    4.0
Secondary CD8 lymphocyte act     0.0
CD4 lymphocyte none              0.0
2ry Th1/Th2/Tr1_anti-CD95 CH11   0.5
LAK cells rest                   0.3
LAK cells IL-2                   0.2
LAK cells IL-2 + IL-12           0.0
LAK cells IL-2 + IFN gamma       0.2
LAK cells IL-2 + IL-18           0.2
LAK cells PMA/ionomycin          14.6
NK Cells IL-2 rest               0.9
Two Way MLR 3 day                3.1
Two Way MLR 5 day                0.4
Two Way MLR 7 day                0.1
PBMC rest                        0.1
PBMC PWM                         0.9
PBMC PHA-L                       0.5
Ramos (B cell) none              0.1
Ramos (B cell) ionomycin         0.1
B lymphocytes PWM                0.4
B lymphocytes CD40L and IL-4     0.2
EOL-1 dbcAMP                     1.9
EOL-1 dbcAMP PMA/ionomycin       0.1
Dendritic cells none             1.7
Dendritic cells LPS              1.2
Dendritic cells anti-CD40        0.3
Monocytes rest                   0.1
Monocytes LPS                    31.2
Macrophages rest                 0.4
Macrophages LPS                  0.8
HUVEC none                       0.6
HUVEC starved                    2.8
HUVEC IL-1beta                   2.2
HUVEC IFN gamma                  1.8
HUVEC TNF alpha + IFN gamma      0.6
HUVEC TNF alpha + IL4            1.7
HUVEC IL-11                      0.6
Lung Microvascular EC none       3.4
Lung Microvascular EC TNFalpha + IL-1beta 3.2
Microvascular Dermal EC none     0.1
Microsvasular Dermal EC TNFalpha + IL-1beta 1.3
Bronchial epithelium TNFalpha + IL1beta 0.4
Small airway epithelium none     0.3
Small airway epithelium TNFalpha + IL-1beta 0.0
Coronery artery SMC rest         2.2
Coronery artery SMC TNFalpha + IL-1beta 3.6
Astrocytes rest                  0.0
Astrocytes TNFalpha + IL-1beta   0.8
KU-812 (Basophil) rest           0.3
KU-812 (Basophil) PMA/ionomycin  0.1
CCD1106 (Keratinocytes) none     0.0
CCD1106 (Keratinocytes) TNFalpha + IL-1beta 0.0
Liver cirrhosis                  0.0
NCI-H292 none                    0.0
NCI-H292 IL-4                    0.2
NCI-H292 IL-9                    0.0
NCI-H292 IL-13                   1.0
NCI-H292 IFN gamma               0.0
HPAEC none                       0.8
HPAEC TNF alpha + IL-1 beta      8.8
Lung fibroblast none             24.5
Lung fibroblast TNF alpha + IL-1 beta 43.2
Lung fibroblast IL-4             14.5
Lung fibroblast IL-9             21.8
Lung fibroblast IL-13            12.9
Lung fibroblast IFN gamma        100.0
Dermal fibroblast CCD1070 rest   6.1
Dermal fibroblast CCD1070 TNF alpha 11.6
Dermal fibroblast CCD1070 IL-1 beta 11.0
Dermal fibroblast IFN gamma      7.2
Dermal fibroblast IL-4           3.8
Dermal Fibroblasts rest          2.6
Neutrophils TNFa + LPS           2.6
Neutrophils rest                 1.6
Colon                            0.0
Lung                             0.3
Thymus                           0.2
Kidney                           1.1

[1153] AI_comprehensive panel_v1.0 Summary: Ag7439 Highest expression is seen in normal tissue adjacent to psoriasis (CT=29.8). In addition, moderate to low levels of expression are seen in many samples on this panel. Thus, this gene product may be involved in autoimmune disease.

[1154] CNS_neurodegeneration_v1.0 Summary: Ag7439 Results from one experiment with this gene are not included. The amp plot indicates that there were experimental difficulties with this run.

[1155] Panel 4.1D Summary: Ag7439 Highest expression is seen in a sample of IFN gama lung derived fibroblasts (CT=29). Low but significant levels of expression are also seen in clusters of samples derived from lung and dermal fibroblasts. Thus, this gene product may be involved in inflammatory processes of the lung and skin, including psoriasis, asthma, emphysema, and allergy.

[1156] Panel 5 Islet Summary: Ag7439 Expression of this gene is low/undetectable in all samples on this panel (CTs>35). (Data not shown.)

[1157] AM. CG166282-01: CHK1-Variant.

[1158] Expression of gene CG166282-01 was assessed using the primer-probe set Ag5448, described in Table AMA. Results of the RTQ-PCR runs are shown in Tables AMB, AMC and AMD.

TABLE AMA
Probe Name Ag5448
			Start	SEQ ID
Primers	Sequences	Length	Position	No
Forward	5′-tgtatgaatcagggtgatggat-3′	22	1256	588
Probe	TET-5′-tcttcaggaagtgtctcttgaactcca-3′-TAMRA	27	1278	589
Reverse	5′-ctggctgctcacaatatcaatc-3′	22	1318	590

[1159]

TABLE AMB
General_screening_panel_v1.5
	Rel.	Rel.
	Exp. (%)	Exp. (%)
	Ag5448,	Ag5448,
	Run	Run
Tissue Name	237375423	247291071
Adipose	0.2	0.0
Melanoma* Hs688(A).T	6.7	3.1
Melanoma* Hs688(B).T	5.0	4.3
Melanoma* M14	25.5	18.8
Melanoma* LOXIMVI	28.7	22.5
Melanoma* SK-MEL-5	17.3	12.2
Squamous cell carcinoma SCC-4	5.6	5.6
Testis Pool	0.5	2.2
Prostate ca. * (bone met) PC-3	11.7	9.3
Prostate Pool	0.0	0.0
Placenta	0.0	1.4
Uterus Pool	0.3	0.0
Ovarian ca. OVCAR-3	10.2	6.5
Ovarian ca. SK-OV-3	32.3	35.8
Ovarian ca. OVCAR-4	22.8	16.5
Ovarian ca. OVCAR-5	12.6	5.5
Ovarian ca. IGROV-1	8.7	9.5
Ovarian ca. OVCAR-8	10.4	9.0
Ovary	0.2	0.0
Breast ca. MCF-7	4.2	5.8
Breast ca. MDA-MB-231	56.3	45.7
Breast ca. BT 549	27.9	16.7
Breast ca. T47D	17.6	15.0
Breast ca. MDA-N	12.9	14.8
Breast Pool	0.1	0.0
Trachea	0.8	0.0
Lung	0.0	0.0
Fetal Lung	2.2	0.0
Lung ca. NCI-N417	8.1	7.2
Lung ca. LX-1	20.0	8.8
Lung ca. NCI-H146	9.7	9.3
Lung ca. SHP-77	22.5	16.0
Lung ca. A549	18.7	10.5
Lung ca. NCI-H526	30.1	26.4
Lung ca. NCI-H23	16.5	12.3
Lung ca. NCI-H460	4.5	1.2
Lung ca. HOP-62	2.6	2.2
Lung ca. NCI-H522	32.8	31.2
Liver	0.0	0.0
Fetal Liver	4.5	6.9
Liver ca. HepG2	5.8	4.1
Kidney Pool	0.4	0.0
Fetal Kidney	6.2	7.4
Renal ca. 786-0	12.5	12.5
Renal ca. A498	2.0	3.5
Renal ca. ACHN	6.6	3.2
Renal ca. UO-31	23.3	21.3
Renal ca. TK-10	8.2	5.0
Bladder	3.2	0.0
Gastric ca. (liver met.) NCI-N87	8.0	8.0
Gastric ca. KATO III	100.0	100.0
Colon ca. SW-948	7.7	7.9
Colon ca. SW480	62.0	46.0
Colon ca. * (SW480 met) SW620	32.8	31.9
Colon ca. HT29	18.6	5.1
Colon ca. HCT-116	33.9	39.5
Colon ca. CaCo-2	27.0	19.3
Colon cancer tissue	5.5	4.4
Colon ca. SW1116	4.1	5.3
Colon ca. Colo-205	8.8	8.4
Colon ca. SW-48	13.6	8.0
Colon Pool	0.4	0.0
Small Intestine Pool	1.0	0.0
Stomach Pool	0.6	0.0
Bone Marrow Pool	0.0	0.0
Fetal Heart	2.4	2.6
Heart Pool	0.6	0.0
Lymph Node Pool	0.0	0.0
Fetal Skeletal Muscle	0.3	0.0
Skeletal Muscle Pool	0.0	0.0
Spleen Pool	0.2	1.9
Thymus Pool	2.1	2.4
CNS cancer (glio/astro) U87-MG	14.2	9.2
CNS cancer (glio/astro) U-118-MG	44.1	47.3
CNS cancer (neuro; met) SK-N-AS	8.3	12.2
CNS cancer (astro) SF-539	6.4	8.5
CNS cancer (astro) SNB-75	29.9	30.6
CNS cancer (glio) SNB-19	4.4	5.4
CNS cancer (glio) SF-295	8.7	4.2
Brain (Amygdala) Pool	0.0	0.0
Brain (cerebellum)	0.5	0.0
Brain (fetal)	2.7	1.2
Brain (Hippocampus) Pool	0.6	0.0
Cerebral Cortex Pool	0.0	0.0
Brain (Substantia nigra) Pool	0.0	0.0
Brain (Thalamus) Pool	0.4	0.0
Brain (whole)	0.0	0.0
Spinal Cord Pool	0.1	0.0
Adrenal Gland	0.0	0.0
Pituitary gland Pool	0.2	0.0
Salivary Gland	0.4	0.0
Thyroid (female)	0.2	0.0
Pancreatic ca. CAPAN2	40.1	48.0
Pancreas Pool	1.4	0.0

[1160]

TABLE AMC
Panel 4.1D
                                 Rel. Exp. (%)
                                 Ag5448, Run
Tissue Name                      237371903
Secondary Th1 act                88.9
Secondary Th2 act                100.0
Secondary Tr1 act                16.6
Secondary Th1 rest               0.0
Secondary Th2 rest               0.0
Secondary Tr1 rest               0.0
Primary Th1 act                  0.0
Primary Th2 act                  47.3
Primary Tr1 act                  50.7
Primary Th1 rest                 1.5
Primary Th2 rest                 7.9
Primary Tr1 rest                 0.0
CD45RA CD4 lymphocyte act        41.5
CD45RO CD4 lymphocyte act        77.9
CD8 lymphocyte act               11.0
Secondary CD8 lymphocyte rest    99.3
Secondary CD8 lymphocyte act     13.3
CD4 lymphocyte none              0.0
2ry Th1/Th2/Tr1_anti-CD95 CH11   0.0
LAK cells rest                   1.6
LAK cells IL-2                   15.4
LAK cells IL-2 + IL-12           2.0
LAK cells IL-2 + IFN gamma       17.6
LAK cells IL-2 + IL-18           5.6
LAK cells PMA/ionomycin          13.3
NK Cells IL-2 rest               35.1
Two Way MLR 3 day                1.2
Two Way MLR 5 day                6.3
Two Way MLR 7 day                2.2
PBMC rest                        0.0
PBMC PWM                         14.6
PBMC PHA-L                       7.3
Ramos (B cell) none              4.0
Ramos (B cell) ionomycin         41.5
B lymphocytes PWM                45.4
B lymphocytes CD40L and IL-4     27.0
EOL-1 dbcAMP                     74.2
EOL-1 dbcAMP PMA/ionomycin       2.3
Dendritic cells none             0.0
Dendritic cells LPS              0.0
Dendritic cells anti-CD40        0.0
Monocytes rest                   0.0
Monocytes LPS                    11.3
Macrophages rest                 0.0
Macrophages LPS                  0.0
HUVEC none                       26.4
HUVEC starved                    24.0
HUVEC IL-1beta                   44.1
HUVEC IFN gamma                  17.1
HUVEC TNF alpha + IFN gamma      2.2
HUVEC TNF alpha + IL4            1.6
HUVEC IL-11                      15.5
Lung Microvascular EC none       11.9
Lung Microvascular EC TNFalpha + IL-1beta 7.8
Microvascular Dermal EC none     3.8
Microsvasular Dermal EC TNFalpha + IL-1beta 3.7
Bronchial epithelium TNFalpha + ILlbeta 3.1
Small airway epithelium none     12.7
Small airway epithelium TNFalpha + IL-1beta 19.6
Coronery artery SMC rest         7.5
Coronery artery SMC TNFalpha + IL-1beta 2.2
Astrocytes rest                  1.4
Astrocytes TNFalpha + IL-1beta   0.0
KU-812 (Basophil) rest           34.6
KU-812 (Basophil) PMA/ionomycin  45.1
CCD1106 (Keratinocytes) none     24.7
CCD1106 (Keratinocytes) TNFalpha + IL-1beta 10.5
Liver cirrhosis                  0.0
NCI-H292 none                    13.7
NCI-H292 IL-4                    38.7
NCI-H292 IL-9                    23.7
NCI-H292 IL-13                   41.2
NCI-H292 IFN gamma               22.8
HPAEC none                       4.4
HPAEC TNF alpha + IL-1 beta      11.2
Lung fibroblast none             5.2
Lung fibroblast TNF alpha + IL-1 beta 7.1
Lung fibroblast IL-4             1.6
Lung fibroblast IL-9             0.0
Lung fibroblast IL-13            0.0
Lung fibroblast IFN gamma        3.5
Dermal fibroblast CCD1070 rest   33.9
Dermal fibroblast CCD1070 TNF alpha 59.0
Dermal fibroblast CCD1070 IL-1 beta 23.8
Dermal fibroblast IFN gamma      22.4
Dermal fibroblast IL-4           31.0
Dermal Fibroblasts rest          16.7
Neutrophils TNFa + LPS           0.0
Neutrophils rest                 0.0
Colon                            0.0
Lung                             0.0
Thymus                           0.0
Kidney                           0.0

[1161]

TABLE AMD
general oncology screening panel_v_2.4
                          Rel. Exp. (%)
                          Ag5448, Run
Tissue Name               260285334
Colon cancer 1            15.9
Colon NAT 1               3.4
Colon cancer 2            26.8
Colon NAT 2               15.6
Colon cancer 3            51.8
Colon NAT 3               3.6
Colon malignant cancer 4  100.0
Colon NAT 4               4.0
Lung cancer 1             8.3
Lung NAT 1                0.0
Lung cancer 2             33.9
Lung NAT 2                0.0
Squamous cell carcinoma 3 15.5
Lung NAT 3                0.0
Metastatic melanoma 1     0.0
Melanoma 2                0.0
Melanoma 3                0.0
Metastatic melanoma 4     5.1
Metastatic melanoma 5     3.8
Bladder cancer 1          0.0
Bladder NAT 1             0.0
Bladder cancer 2          4.4
Bladder NAT 2             0.0
Bladder NAT 3             0.0
Bladder NAT 4             0.0
Prostate adenocarcinoma 1 0.0
Prostate adenocarcinoma 2 0.0
Prostate adenocarcinoma 3 0.0
Prostate adenocarcinoma 4 3.2
Prostate NAT 5            0.0
Prostate adenocarcinoma 6 0.0
Prostate adenocarcinoma 7 0.0
Prostate adenocarcinoma 8 0.0
Prostate adenocarcinoma 9 0.0
Prostate NAT 10           0.0
Kidney cancer 1           0.0
Kidney NAT 1              0.0
Kidney cancer 2           15.9
Kidney NAT 2              0.0
Kidney cancer 3           5.2
Kidney NAT 3              0.0
Kidney cancer 4           0.0
Kidney NAT 4              0.0

[1162] AI_comprehensive panel_v1.0 Summary: Ag5448 The amp plot indicates that there were experimental difficulties with this run; therefore, no conclusions can be drawn from this data. (Data not shown).

[1163] General_screening_panel_v1.5 Summary: Ag5448 Two experiments with same probe-primer sets are in excellent agreement, with highest expression of this gene detected in gastric cancer KATO III cell line (CTs=30-33). Moderate to low levels of expression of this gene is also seen in cluster of cancer cell lines derived from pancreatic, gastric, colon, lung, liver, renal, breast, ovarian, prostate, squamous cell carcinoma, melanoma and brain cancers. Thus, expression of this gene could be used as a marker to detect the presence of these cancers. Furthermore, therapeutic modulation of the expression or function of this gene may be effective in the treatment of pancreatic, gastric, colon, lung, liver, renal, breast, ovarian, prostate, squamous cell carcinoma, melanoma and brain cancers.

[1164] Oncology_cell_line_screening_panel_v3.2 Summary: Ag5448 The amp plot indicates that there were experimental difficulties with this run; therefore, no conclusions can be drawn from this data. (Data not shown).

[1165] Panel 4.1D Summary: Ag5448 Highest expression of this gene is detected in activated secondary Th2 cells (CT=33). Low expression of this gene is detected in activated polarized T cells, resting IL-2 treated NK cells, activated Ramos B cells and B lymphocytes, eosinophils, activated HUVEC cells and NCI-H292 cells, basophils and TNF alpha stimulated dermal fibroblasts. Therefore, therapeutic modulation of this gene product may ameliorate symptoms/conditions associated with autoimmune and inflammatory disorders including psoriasis, allergy, asthma, inflammatory bowel disease, rheumatoid arthritis and osteoarthritis.

[1166] General oncology screening panel_v—2.4 Summary: Ag5448 Highest expression of this gene malignant colon cancer (CT=34.4). Higher expression of this gene is associated with the colon cancer as compared to adjacent control tissue. Therefore, expression of this gene may be used as diagnostic marker to detect colon cancer and also, therapeutic modulation of this gene or its protein product may be useful in the treatement of colon cancer.

[1167] AN. CG170739-01: Pendrin.

[1168] Expression of gene CG170739-01 was assessed using the primer-probe set Ag6134, described in Table ANA.

TABLE ANA
Probe Name Ag6134
			Start	SEQ ID
Primers	Sequences	Length	Position	No
Forward	5′-cgctgcaaggaccttttc-3′	18	1931	591
Probe	TET-5′tgctcagaacaacagatcccaccatt-3′-TAMRA	26	1892	592
Reverse	5′-tgctggatacgagaaagtgttc-3′	22	1859	593

[1169] AI_comprehensive panel_v1.0 Summary: Ag6134 Expression of this gene is low/undetectable (CTs>35) across all of the samples on this panel (data not shown). The amp plot indicates that there is a high probability of a probe failure.

[1170] General_screening_panel_v1.5 Summary: Ag6134 Expression of this gene is low/undetectable (CTs>35) across all of the samples on this panel (data not shown). The amp plot indicates that there is a high probability of a probe failure.

[1171] Panel 4.1D Summary: Ag6134 Expression of this gene is low/undetectable (CTs>35) across all of the samples on this panel (data not shown). The amp plot indicates that there is a high probability of a probe failure.

[1172] AO. CG51213-07: CG51213-(13-364).

[1173] Expression of gene CG51213-07 was assessed using the primer-probe sets Ag1425, Ag813, Ag871 and Ag924, described in Tables AOA, AOB, AOC and AOD. Results of the RTQ-PCR runs are shown in Tables AOE, AOF, AOG, AOH, AOI, AOJ and AOK.

TABLE AOA
Probe Name Ag1425
			Start	SEQ ID
Primers	Sequences	Length	Position	No
Forward	5′-ggacttcagagaagtgcagtgt-3′	22	549	594
Probe	TET-5′-ctgaatttgacagcatccctttccgt-3′-TAMRA	26	572	595
Reverse	5′-cggtacgttttccacttgtaga-3′	22	605	596

[1174]

TABLE AOB
Probe Name Ag813
			Start	SEQ ID
Primers	Sequences	Length	Position	No
Forward	5′-tgtagaatttcccacggaaag-3′	21	590	597
Probe	TET-5′-cactgcacttctctgaagtcctggga-3′-TAMRA	26	544	598
Reverse	5′-ctgcaacacggatgactgt-3′	19	516	599

[1175]

TABLE AOC
Probe Name Ag871
			Start	SEQ ID
Primers	Sequences	Length	Position	No
Forward	5′-tctagctgggaccacctttc-3′	20	1041	600
Probe	TET-5′-cagaccaggtccagagcctcgaag-3′-TAMRA	24	1076	601
Reverse	5′-acgatgagagatgcattaatcg-3′	22	1109	602

[1176]

TABLE AOD
Probe Name Ag924
			Start	SEQ ID
Primers	Sequences	Length	Position	No
Forward	5′-ggacttcagagaagtgcagtgt-3′	22	549	603
Probe	TET-5′-ctgaatttgacagcatccctttccgt-3′-TAMRA	26	572	604
Reverse	5′-cggtacgttttccacttgtaga-3′	22	605	605

[1177]

TABLE AOE
AI_comprehensive panel_v1.0
	Rel.	Rel.
	Exp. (%)	Exp. (%)
	Ag813,	Ag813,
	Run	Run
Tissue Name	234222162	246953625
110967 COPD-F	5.4	8.8
110980 COPD-F	5.9	9.2
110968 COPD-M	12.9	11.9
110977 COPD-M	18.8	25.7
110989 Emphysema-F	19.3	26.4
110992 Emphysema-F	13.5	30.8
110993 Emphysema-F	10.5	13.2
110994 Emphysema-F	10.4	7.3
110995 Emphysema-F	25.5	25.9
110996 Emphysema-F	3.7	6.5
110997 Asthma-M	2.5	2.4
111001 Asthma-F	16.3	21.0
111002 Asthma-F	24.0	22.1
111003 Atopic Asthma-F	14.9	35.4
111004 Atopic Asthma-F	31.6	47.0
111005 Atopic Asthma-F	18.4	20.2
111006 Atopic Asthma-F	2.6	5.6
111417 Allergy-M	13.4	8.5
112347 Allergy-M	0.0	0.0
112349 Normal Lung-F	0.0	0.0
112357 Normal Lung-F	15.5	16.4
112354 Normal Lung-M	3.7	1.5
112374 Crohns-F	16.6	21.6
112389 Match Control Crohns-F	10.3	6.3
112375 Crohns-F	0.0	32.8
112732 Match Control Crohns-F	10.4	9.7
112725 Crohns-M	2.2	0.8
112387 Match Control Crohns-M	8.4	10.5
112378 Crohns-M	0.0	0.0
112390 Match Control Crohns-M	38.7	38.2
112726 Crohns-M	27.4	22.8
112731 Match Control Crohns-M	7.6	13.6
112380 Ulcer Col-F	15.9	20.4
112734 Match Control Ulcer Col-F	13.5	26.4
112384 Ulcer Col-F	21.6	18.8
112737 Match Control Ulcer Col-F	5.6	5.8
112386 Ulcer Col-F	0.7	1.1
112738 Match Control Ulcer Col-F	3.0	4.3
112381 Ulcer Col-M	0.0	0.1
112735 Match Control Ulcer Col-M	2.1	0.8
112382 Ulcer Col-M	8.7	8.5
112394 Match Control Ulcer Col-M	1.5	4.7
112383 Ulcer Col-M	45.7	54.7
112736 Match Control Ulcer Col-M	6.1	6.4
112423 Psoriasis-F	7.7	5.2
112427 Match Control Psoriasis-F	0.0	30.6
112418 Psoriasis-M	8.6	8.7
112723 Match Control Psoriasis-M	11.0	8.8
112419 Psoriasis-M	10.7	8.1
112424 Match Control Psoriasis-M	7.4	4.1
112420 Psoriasis-M	37.4	36.3
112425 Match Control Psoriasis-M	11.7	6.2
104689 (MF) OA Bone-Backus	100.0	100.0
104690 (MF) Adj “Normal”	62.0	65.5
Bone-Backus
104691 (MF) OA Synovium-Backus	73.7	74.7
104692 (BA) OA Cartilage-Backus	15.8	15.0
104694 (BA) OA Bone-Backus	69.3	79.0
104695 (BA) Adj “Normal”	68.3	44.1
Bone-Backus
104696 (BA) OA Synovium-Backus	29.5	27.9
104700 (SS) OA Bone-Backus	55.1	43.2
104701 (SS) Adj “Normal”	72.2	95.3
Bone-Backus
104702 (SS) OA Synovium-Backus	36.3	37.9
117093 OA Cartilage Rep7	4.9	11.3
112672 OA Bone5	25.3	25.0
112673 OA Synovium5	8.4	12.6
112674 OA Synovial Fluid	18.8	16.2
cells5
117100 OA Cartilage Rep14	8.0	10.5
112756 OA Bone9	3.6	11.2
112757 OA Synovium9	6.0	5.4
112758 OA Synovial Fluid	9.9	9.4
Cells9
117125 RA Cartilage Rep2	5.3	9.3
113492 Bone2 RA	4.0	4.1
113493 Synovium2 RA	1.0	1.7
113494 Syn Fluid Cells RA	2.6	5.6
113499 Cartilage4 RA	4.7	5.2
113500 Bone4 RA	4.0	4.6
113501 Synovium4 RA	3.6	3.1
113502 Syn Fluid Cells4 RA	2.3	1.9
113495 Cartilage3 RA	3.3	5.4
113496 Bone3 RA	4.6	6.4
113497 Synovium3 RA	3.1	1.6
113498 Syn Fluid Cells3 RA	6.9	6.0
117106 Normal Cartilage Rep20	13.7	13.0
113663 Bone3 Normal	0.0	0.0
113664 Synovium3 Normal	0.0	0.0
113665 Syn Fluid Cells3	0.0	0.1
Normal
117107 Normal Cartilage Rep22	2.3	0.3
113667 Bone4 Normal	8.6	4.7
113668 Synovium4 Normal	3.0	6.4
113669 Syn Fluid Cells4 Normal	12.7	11.0

[1178]

TABLE AOF
CNS_neurodegeneration_v1.0
                               Rel. Exp. (%)
                               Ag813, Run
Tissue Name                    209990454
AD 1 Hippo                     43.5
AD 2 Hippo                     50.0
AD 3 Hippo                     35.4
AD 4 Hippo                     27.7
AD 5 hippo                     100.0
AD 6 Hippo                     42.9
Control 2 Hippo                29.3
Control 4 Hippo                39.2
Control (Path) 3 Hippo         27.4
AD 1 Temporal Ctx              79.6
AD 2 Temporal Ctx              55.5
AD 3 Temporal Ctx              40.1
AD 4 Temporal Ctx              52.1
AD 5 Inf Temporal Ctx          84.7
AD 5 Sup Temporal Ctx          79.0
AD 6 Inf Temporal Ctx          51.8
AD 6 Sup Temporal Ctx          93.3
Control 1 Temporal Ctx         22.5
Control 2 Temporal Ctx         54.0
Control 3 Temporal Ctx         50.0
Control 4 Temporal Ctx         41.5
Control (Path) 1 Temporal Ctx  97.9
Control (Path) 2 Temporal Ctx  69.3
Control (Path) 3 Temporal Ctx  32.1
Control (Path) 4 Temporal Ctx  57.0
AD 1 Occipital Ctx             60.7
AD 2 Occipital Ctx (Missing)   0.0
AD 3 Occipital Ctx             33.4
AD 4 Occipital Ctx             48.6
AD 5 Occipital Ctx             57.8
AD 6 Occipital Ctx             43.5
Control 1 Occipital Ctx        14.4
Control 2 Occipital Ctx        73.2
Control 3 Occipital Ctx        85.3
Control 4 Occipital Ctx        28.9
Control (Path) 1 Occipital Ctx 69.7
Control (Path) 2 Occipital Ctx 49.3
Control (Path) 3 Occipital Ctx 23.3
Control (Path) 4 Occipital Ctx 57.0
Control 1 Parietal Ctx         22.2
Control 2 Parietal Ctx         84.1
Control 3 Parietal Ctx         27.9
Control (Path) 1 Parietal Ctx  68.8
Control (Path) 2 Parietal Ctx  54.3
Control (Path) 3 Parietal Ctx  26.4
Control (Path) 4 Parietal Ctx  78.5

[1179]

TABLE AOG
General_screening_panel_v1.5
                                 Rel. Exp. (%)
                                 Ag813, Run
Tissue Name                      247945092
Adipose                          15.2
Melanoma* Hs688(A).T             26.2
Melanoma* Hs688(B).T             42.6
Melanoma* M14                    0.0
Melanoma* LOXIMVI                4.7
Melanoma* SK-MEL-5               0.0
Squamous cell carcinoma SCC-4    0.0
Testis Pool                      9.6
Prostate ca.* (bone met) PC-3    0.0
Prostate Pool                    4.6
Placenta                         36.6
Uterus Pool                      5.4
Ovarian ca. OVCAR-3              0.0
Ovarian ca. SK-OV-3              1.9
Ovarian ca. OVCAR-4              1.2
Ovarian ca. OVCAR-5              14.3
Ovarian ca. IGROV-1              9.7
Ovarian ca. OVCAR-8              24.1
Ovary                            20.6
Breast ca. MCF-7                 0.0
Breast ca. MDA-MB-231            0.0
Breast ca. BT 549                15.7
Breast ca. T47D                  1.0
Breast ca. MDA-N                 0.0
Breast Pool                      30.1
Trachea                          6.0
Lung                             4.9
Fetal Lung                       59.5
Lung ca. NCI-N417                0.0
Lung ca. LX-1                    0.0
Lung ca. NCI-H146                0.0
Lung ca. SHP-77                  1.5
Lung ca. A549                    75.3
Lung ca. NCI-H526                0.0
Lung ca NCI-H23                  30.6
Lung ca. NCI-H460                0.3
Lung ca. HOP-62                  19.9
Lung ca. NCI-H522                17.7
Liver                            0.4
Fetal Liver                      6.3
Liver ca. HepG2                  0.0
Kidney Pool                      36.6
Fetal Kidney                     36.6
Renal ca. 786-0                  0.0
Renal ca. A498                   55.5
Renal ca. ACHN                   0.0
Renal ca. UO-31                  7.0
Renal ca. TK-10                  50.3
Bladder                          88.3
Gastric ca. (liver met.) NCI-N87 0.0
Gastric ca. KATO III             0.0
Colon ca. SW-948                 0.0
Colon ca. SW480                  0.3
Colon ca.* (SW480 met) SW620     0.0
Colon ca. HT29                   0.0
Colon ca. HCT-116                3.2
Colon ca. CaCo-2                 0.4
Colon cancer tissue              30.1
Colon ca. SW1116                 0.0
Colon ca. Colo-205               0.0
Colon ca. SW-48                  0.0
Colon Pool                       29.7
Small Intestine Pool             9.5
Stomach Pool                     16.3
Bone Marrow Pool                 7.9
Fetal Heart                      11.8
Heart Pool                       10.9
Lymph Node Pool                  31.4
Fetal Skeletal Muscle            15.7
Skeletal Muscle Pool             4.1
Spleen Pool                      12.3
Thymus Pool                      37.1
CNS cancer (glio/astro) U87-MG   0.0
CNS cancer (glio/astro) U-118-MG 0.7
CNS cancer (neuro; met) SK-N-AS  0.6
CNS cancer (astro) SF-539        15.0
CNS cancer (astro) SNB-75        100.0
CNS cancer (glio) SNB-19         10.7
CNS cancer (glio) SF-295         14.8
Brain (Amygdala) Pool            13.7
Brain (cerebellum)               8.5
Brain (fetal)                    95.9
Brain (Hippocampus) Pool         12.9
Cerebral Cortex Pool             20.0
Brain (Substantia nigra) Pool    10.5
Brain (Thalamus) Pool            22.2
Brain (whole)                    12.0
Spinal Cord Pool                 21.0
Adrenal Gland                    19.2
Pituitary gland Pool             1.6
Salivary Gland                   0.4
Thyroid (female)                 4.0
Pancreatic ca. CAPAN2            1.1
Pancreas Pool                    45.7

[1180]

TABLE AOH
Panel 1.2
	Rel.	Rel.
	Exp. (%)	Exp. (%)
	Ag813,	Ag813,
	Run	Run
Tissue Name	118348494	126741639
Endothelial cells	0.0	0.5
Heart (Fetal)	0.0	8.5
Pancreas	9.9	27.7
Pancreatic ca. CAPAN 2	0.0	0.1
Adrenal Gland	15.3	79.0
Thyroid	0.2	13.8
Salivary gland	1.8	15.9
Pituitary gland	9.0	16.7
Brain (fetal)	100.0	100.0
Brain (whole)	15.2	33.7
Brain (amygdala)	11.4	22.7
Brain (cerebellum)	0.3	8.1
Brain (hippocampus)	23.2	49.7
Brain (thalamus)	3.1	10.4
Cerebral Cortex	14.9	59.9
Spinal cord	6.2	29.7
glio/astro U87-MG	0.0	0.0
glio/astro U-118-MG	0.0	0.1
astrocytoma SW1783	0.0	0.0
neuro*; met SK-N-AS	0.0	0.3
astrocytoma SF-539	0.3	7.7
astrocytoma SNB-75	0.1	4.2
glioma SNB-19	0.0	8.8
glioma U251	0.0	7.6
glioma SF-295	0.0	1.8
Heart	7.6	36.9
Skeletal Muscle	0.7	22.5
Bone marrow	0.5	3.8
Thymus	6.8	17.2
Spleen	1.1	9.8
Lymph node	9.1	32.3
Colorectal Tissue	0.0	1.4
Stomach	1.3	27.2
Small intestine	7.4	28.9
Colon ca. SW480	0.0	0.0
Colon ca. * SW620 (SW480 met)	0.0	0.0
Colon ca. HT29	0.0	0.0
Colon ca. HCT-116	0.0	1.1
Colon ca. CaCo-2	0.0	0.3
Colon ca. Tissue (ODO3866)	0.1	4.6
Colon ca. HCC-2998	0.0	0.0
Gastric ca. * (liver met) NCI-N87	0.0	0.0
Bladder	15.8	92.0
Trachea	0.7	9.9
Kidney	1.7	16.7
Kidney (fetal)	11.7	67.4
Renal ca. 786-0	0.0	0.0
Renal ca. A498	0.0	7.5
Renal ca. RXF 393	0.0	4.7
Renal ca. ACHN	0.0	0.0
Renal ca. UO-31	0.0	2.3
Renal ca. TK-10	5.8	18.9
Liver	5.0	27.9
Liver (fetal)	1.5	12.3
Liver ca. (hepatoblast) HepG2	0.0	0.0
Lung	2.3	22.2
Lung (fetal)	9.9	46.3
Lung ca. (small cell) LX-1	0.0	0.0
Lung ca. (small cell)	0.0	0.0
NCI-H69
Lung ca. (s. cell var.)	0.0	0.5
SHP-77
Lung ca. (large cell) NCI-H460	0.0	1.1
Lung ca. (non-sm. cell) A549	29.9	55.5
Lung ca. (non-s. cell) NCI-H23	1.9	3.7
Lung ca. (non-s. cell) HOP-62	4.1	24.0
Lung ca. (non-s. cl) NCI-H522	4.4	19.9
Lung ca. (squam.) SW 900	0.7	8.3
Lung ca. (squam.) NCI-H596	0.0	0.0
Mammary gland	3.4	31.2
Breast ca. * (pl. ef) MCF-7	0.0	0.0
Breast ca. * (pl. ef) MDA-MB-231	0.0	0.0
Breast ca. * (pl. ef) T47D	0.2	6.0
Breast ca. BT-549	0.0	3.5
Breast ca. MDA-N	0.0	0.0
Ovary	2.7	15.7
Ovarian ca. OVCAR-3	0.0	0.2
Ovarian ca. OVCAR-4	0.0	1.0
Ovarian ca. OVCAR-5	0.2	4.0
Ovarian ca. OVCAR-8	2.6	28.7
Ovarian ca. IGROV-1	0.0	2.1
Ovarian ca. (ascites) SK-OV-3	0.0	0.3
Uterus	8.1	36.1
Placenta	3.5	14.8
Prostate	0.1	16.8
Prostate ca. * (bone met) PC-3	0.0	0.2
Testis	2.7	7.2
Melanoma Hs688(A).T	0.9	5.4
Melanoma* (met) Hs688(B).T	0.8	8.1
Melanoma UACC-62	0.0	0.5
Melanoma M14	0.0	0.0
Melanoma LOX IMVI	0.0	0.5
Melanoma* (met) SK-MEL-5	0.0	0.0

[1181]

TABLE AOI
Panel 4.1D
                                 Rel. Exp. (%)
                                 Ag813, Run
Tissue Name                      237369996
Secondary Th1 act                4.8
Secondary Th2 act                11.7
Secondary Tr1 act                5.3
Secondary Th1 rest               4.9
Secondary Th2 rest               2.1
Secondary Tr1 rest               0.0
Primary Th1 act                  0.0
Primary Th2 act                  61.1
Primary Tr1 act                  25.9
Primary Th1 rest                 14.7
Primary Th2 rest                 15.8
Primary Tr1 rest                 4.1
CD45RA CD4 lymphocyte act        5.4
CD45RO CD4 lymphocyte act        22.2
CD8 lymphocyte act               0.9
Secondary CD8 lymphocyte rest    6.0
Secondary CD8 lymphocyte act     0.0
CD4 lymphocyte none              6.0
2ry Th1/Th2/Tr1_anti-CD95 CH11   7.1
LAK cells rest                   11.3
LAK cells IL-2                   0.0
LAK cells IL-2 + IL-12           0.0
LAK cells IL-2 + IFN gamma       0.0
LAK cells IL-2 + IL-18           0.0
LAK cells PMA/ionomycin          10.7
NK Cells IL-2 rest               100.0
Two Way MLR 3 day                13.9
Two Way MLR 5 day                0.0
Two Way MLR 7 day                0.0
PBMC rest                        2.9
PBMC PWM                         0.0
PBMC PHA-L                       0.0
Ramos (B cell) none              0.0
Ramos (B cell) ionomycin         0.0
B lymphocytes PWM                2.4
B lymphocytes CD40L and IL-4     2.9
EOL-1 dbcAMP                     80.1
EOL-1 dbcAMP PMA/ionomycin       0.0
Dendritic cells none             0.0
Dendritic cells LPS              0.0
Dendritic cells anti-CD40        0.0
Monocytes rest                   0.0
Monocytes LPS                    0.0
Macrophages rest                 0.0
Macrophages LPS                  0.0
HUVEC none                       0.0
HUVEC starved                    14.2
HUVEC IL-1beta                   11.6
HUVEC IFN gamma                  6.9
HUVEC TNF alpha + IFN gamma      2.7
HUVEC TNF alpha + IL4            1.3
HUVEC IL-11                      20.0
Lung Microvascular EC none       95.9
Lung Microvascular EC TNFalpha + IL-1beta 39.0
Microvascular Dermal EC none     2.8
Microsvasular Dermal EC TNFalpha + IL-1beta 6.7
Bronchial epithelium TNFalpha + IL1beta 0.0
Small airway epithelium none     0.0
Small airway epithelium TNFalpha + IL-1beta 0.0
Coronery artery SMC rest         33.4
Coronery artery SMC TNFalpha + IL-1beta 31.4
Astrocytes rest                  20.4
Astrocytes TNFalpha + IL-1beta   6.9
KU-812 (Basophil) rest           0.0
KU-812 (Basophil) PMA/ionomycin  11.0
CCD1106 (Keratinocytes) none     0.0
CCD1106 (Keratinocytes) TNFalpha + IL-1beta 0.0
Liver cirrhosis                  32.5
NCI-H292 none                    0.0
NCI-H292 IL-4                    0.0
NCI-H292 IL-9                    0.0
NCI-H292 IL-13                   5.4
NCI-H292 IFN gamma               0.0
HPAEC none                       5.3
HPAEC TNF alpha + IL-1 beta      4.9
Lung fibroblast none             10.7
Lung fibroblast TNF alpha + IL-1 beta 9.4
Lung fibroblast IL-4             7.8
Lung fibroblast IL-9             6.8
Lung fibroblast IL-13            0.0
Lung fibroblast IFN gamma        16.5
Dermal fibroblast CCD1070 rest   12.2
Dermal fibroblast CCD1070 TNF alpha 25.5
Dermal fibroblast CCD1070 IL-1 beta 20.3
Dermal fibroblast IFN gamma      9.9
Dermal fibroblast IL-4           57.8
Dermal Fibroblasts rest          13.0
Neutrophils TNFa + LPS           0.0
Neutrophils rest                 2.5
Colon                            0.0
Lung                             0.0
Thymus                           4.8
Kidney                           21.9

[1182]

TABLE AOJ
Panel 5 Islet
                                 Rel. Exp. (%)
                                 Ag813, Run
Tissue Name                      254387841
97457_Patient-02go_adipose       45.7
97476_Patient-07sk_skeletal muscle 11.7
97477_Patient-07ut_uterus        33.2
97478_Patient-07pl_placenta      11.7
99167_Bayer Patient 1            14.4
97482_Patient-08ut_uterus        45.7
97483_Patient-08pl_placenta      7.0
97486_Patient-09sk_skeletal muscle 0.0
97487_Patient-09ut_uterus        16.3
97488_Patient-09pl_placenta      13.8
97492_Patient-10ut_uterus        24.3
97493_Patient-10pl_placenta      5.1
97495_Patient-11go_adipose       9.7
97496_Patient-11sk_skeletal muscle 15.0
97497_Patient-11ut_uterus        43.2
97498_Patient-11pl_placenta      7.9
97500_Patient-12go_adipose       36.3
97501_Patient-12sk_skeletal muscle 33.2
97502_Patient-12ut_uterus        55.1
97503_Patient-12pl_placenta      0.0
94721_Donor 2 U - A_Mesenchymal Stem Cells 66.0
94722_Donor 2 U - B_Mesenchymal Stem Cells 32.1
94723_Donor 2 U - C_Mesenchymal Stem Cells 62.0
94709_Donor 2 AM - A_adipose     49.3
94710_Donor 2 AM - B_adipose     15.8
94711_Donor 2 AM - C_adipose     8.4
94712_Donor 2 AD - A_adipose     52.9
94713_Donor 2 AD - B_adipose     36.3
94714_Donor 2 AD - C_adipose     35.6
94742_Donor 3 U - A_Mesenchymal Stem Cells 27.4
94743_Donor 3 U - B_Mesenchymal Stem Cells 33.9
94730_Donor 3 AM - A_adipose     17.2
94731_Donor 3 AM - B_adipose     21.2
94732_Donor 3 AM - C_adipose     4.9
94733_Donor 3 AD - A_adipose     100.0
94734_Donor 3 AD - B_adipose     40.3
94735_Donor 3 AD - C_adipose     69.7
77138_Liver_HepG2untreated       0.0
73556_Heart_Cardiac stromal cells (primary) 7.9
81735_Small Intestine            54.3
72409_Kidney_Proximal Convoluted Tubule 0.0
82685_Small intestine_Duodenum   0.0
90650_Adrenal_Adrenocortical adenoma 26.2
72410_Kidney_HRCE                0.0
72411_Kidney_HRE                 0.0
73139_Uterus_Uterine smooth muscle cells 6.3

[1183]

TABLE AOK
Panel CNS_1
                           Rel. Exp. (%)
                           Ag813, Run
Tissue Name                171629144
BA4 Control                3.0
BA4 Control2               22.7
BA4 Alzheimer's2           6.6
BA4 Parkinson's            36.6
BA4 Parkinson's2           49.3
BA4 Huntington's           8.4
BA4 Huntington's2          12.0
BA4 PSP                    5.9
BA4 PSP2                   6.7
BA4 Depression             11.0
BA4 Depression2            19.6
BA7 Control                19.9
BA7 Control2               18.9
BA7 Alzheimer's2           12.5
BA7 Parkinson's            33.9
BA7 Parkinson's2           31.4
BA7 Huntington's           37.4
BA7 Huntington's2          100.0
BA7 PSP                    21.9
BA7 PSP2                   3.8
BA7 Depression             6.2
BA9 Control                22.2
BA9 Control2               23.5
BA9 Alzheimer's            0.0
BA9 Alzheimer's2           19.8
BA9 Parkinson's            42.6
BA9 Parkinson's2           21.6
BA9 Huntington's           17.7
BA9 Huntington's2          52.5
BA9 PSP                    6.8
BA9 PSP2                   2.7
BA9 Depression             6.7
BA9 Depression2            10.4
BA17 Control               43.5
BA17 Control2              24.1
BA17 Alzheimer's2          21.2
BA17 Parkinson's           33.4
BA17 Parkinson's2          39.0
BA17 Huntington's          24.0
BA17 Huntington's2         37.9
BA17 Depression            31.9
BA17 Depression2           45.7
BA17 PSP                   3.9
BA17 PSP2                  4.8
Sub Nigra Control          14.8
Sub Nigra Control2         16.5
Sub Nigra Alzheimer's2     6.1
Sub Nigra Parkinson's2     23.8
Sub Nigra Huntington's     14.6
Sub Nigra Huntington's2    32.8
Sub Nigra PSP2             0.0
Sub Nigra Depression       2.5
Sub Nigra Depression2      7.6
Glob Palladus Control      2.5
Glob Palladus Control2     0.7
Glob Palladus Alzheimer's  4.6
Glob Palladus Alzheimer's2 3.2
Glob Palladus Parkinson's  41.8
Glob Palladus Parkinson's2 11.4
Glob Palladus PSP          5.0
Glob Palladus PSP2         0.0
Glob Palladus Depression   1.7
Temp Pole Control          2.9
Temp Pole Control2         4.8
Temp Pole Alzheimer's      2.5
Temp Pole Alzheimer's2     12.4
Temp Pole Parkinson's      28.9
Temp Pole Parkinson's2     13.1
Temp Pole Huntington's     28.1
Temp Pole PSP              6.9
Temp Pole PSP2             1.9
Temp Pole Depression2      18.8
Cing Gyr Control           39.0
Cing Gyr Control2          16.4
Cing Gyr Alzheimer's       4.8
Cing Gyr Alzheimer's2      7.2
Cing Gyr Parkinson's       22.4
Cing Gyr Parkinson's2      9.2
Cing Gyr Huntington's      24.3
Cing Gyr Huntington's2     33.9
Cing Gyr PSP               5.2
Cing Gyr PSP2              0.0
Cing Gyr Depression        9.5
Cing Gyr Depression2       0.0

[1184] AI_comprehensive panel_v1.0 Summary: Ag813 Two experiments with same probe-primer sets are in excellent agreement. Highest expression of this gene is detected in orthoarthritis bone (CTs=29-30.6). In addition significant expression of this gene is detected in samples derived from orthoarthritis bone, cartilage, synovium and synovial fluid samples, from normal lung, COPD lung, emphysema, atopic asthma, asthma, allergy, Crohn's disease (normal matched control and diseased), ulcerative colitis(normal matched control and diseased), and psoriasis (normal matched control and diseased). Interestingly, expression of this gene in normal and rheumatoid arthritis bone, synovium and synovial fluid is very low or undectectable. Therefore, therapeutic modulation of this gene product may ameliorate symptoms/conditions associated with autoimmune and inflammatory disorders including psoriasis, allergy, asthma, inflammatory bowel disease, and osteoarthritis.

[1185] CNS_neurodegeneration_v1.0 Summary: Ag813 This panel confirms the expression of this gene at low levels in the brains of an independent group of individuals. However, no differential expression of this gene was detected between Alzheimer's diseased postmortem brains and those of non-demented controls in this experiment. Please see Panel 1.5 for a discussion of the potential utility of this gene in treatment of central nervous system disorders.

[1186] General_screening_panel_v1.5 Summary: Ag813 Highest expression of this gene is detected in fetal brain and brain cancer SNB-75 cell line (CTs=31). In addition, moderate expression of this gene is seen all regions of the central nervous system examined, including amygdala, hippocampus, substantia nigra, thalamus, cerebellum, cerebral cortex, and spinal cord. This gene codes for a variant of ADAMTS- 10, a member of Matrix metalloproteinases (MMPs). MMPs are a gene family of neutral proteases that are important in normal development, wound healing, and a wide variety of pathological processes, including the spread of metastatic cancer cells, arthritic destruction of joints, atherosclerosis, and neuroinflammation. In the central nervous system (CNS), MMPs have been shown to degrade components of the basal lamina, leading to disruption of the blood-brain barrier (BBB), and to contribute to the neuroinflammatory response in many neurological diseases (Rosenberg Ga., 2002, Glia 39(3):279-91, PMID: 12203394). Therefore, therapeutic modulation of this gene product may be useful in the treatment of neurological disorders such as Alzheimer's disease, Parkinson's disease, epilepsy, multiple sclerosis, schizophrenia, depression, allergic encephalomyelitis (EAE), allergic neuritis (EAN), and cerebral ischemia.

[1187] Moderate to low expression of this gene is also detected in tissues with metabolic/endocrine function including pancreas, adipose, adrenal gland, skeletal muscle, heart, fetal liver and the gastrointestinal tract. Therefore, therapeutic modulation of the activity of this gene may prove useful in the treatment of endocrine/metabolically related diseases, such as obesity and diabetes.

[1188] In addition, this gene is expressed at moderate to low levels in number of cancer cell lines derived from melanoma, ovarian, breast, lung, renal, colon and brain cancers. Therefore, therapeutic modulation of this gene through the use of protein therapeutics, antibodies or small molecule drug may be useful in the treatment of these cancer.

[1189] Using Curagen PathCalling technology, the ADAMTS-10 protein encoded by this gene was shown to interact with amphiregulin (AREG). AREG is shown to inhibit growth of certain human tumor cells and stimulates proliferation of human fibroblasts and other normal and tumor cells (Shoyab et al., 1988, Proc. Nat. Acad. Sci. 85: 6528-6532. PubMed ID: 3413110). Recently, AREG has been implicated in the regulation of neural stem cell proliferation and neurogenesis in the adult brain.

[1190] Panel 1.2 Summary: Ag813 Highest expression of this gene is detected in fetal brain (CT=27.5). In addition, moderate expression of this gene is all regions of the central nervous system examined, including amygdala, hippocampus, substantia nigra, thalamus, cerebellum, cerebral cortex, and spinal cord. Moderate to low expression of this gene is also detected in tissues with metabolic/endocrine function and number of cancer cell lines derived from melanoma, ovarian, lung, renal, colon and brain cancers. Please see panel 1.5 for further discussion on the utility of this gene.

[1191] Panel 4.1D Summary: Ag813 Highest expression of this gene is detected in IL-2 treated resting NK cells (CT=32.8). Moderate to low levels of expression of this gene is also detected in activated primary polarized T cells, eosinophils, lung microvascular endothelial cells, coronery artery SMC, liver cirrhosis and activated dermal fibroblasts. Therefore, therapeutic modulation of this gene or the protein encoded by this gene may be useful in the treatment of autoimmune and inflammatory diseases including asthma, allergies, inflammatory bowel disease, lupus erythematosus, psoriasis, rheumatoid arthritis, and osteoarthritis.

[1192] Results from one experiment (Run 247683477) with this gene are not included. The amp plot indicates that there were experimental difficulties with this run.

[1193] Panel 5 Islet Summary: Ag813 Highest expression of this gene is detected in differentiated adipose (CT=33.5). Low expression of this gene is seen mainly in adipose and small intestine. Therefore, therapeutic modulation of this gene or its protein product may be useful in the treatment of obesity and diabetes, including Type II diabetes.

[1194] Panel CNS—1 Summary: Ag813 This panel confirms the expression of this gene at low levels in the brains of an independent group of individuals. Please see Panel 1.5 for a discussion of the potential utility of this gene in treatment of central nervous system disorders.

[1195] AP. CG56155-02: Plasma Kallikrein Precursor.

[1196] Expression of gene CG56155-02 was assessed using the primer-probe set Ag1688, described in Table APA. Results of the RTQ-PCR runs are shown in Tables APB, APC, APD, APE, APF, APG and APH.

TABLE APA
Probe Name Ag1688
			Start	SEQ ID
Primers	Sequences	Length	Position	No
Forward	5′-tcagaagggaatcatgatatcg-3′	22	577	606
Probe	TET-5′-ccttgataaaactccaggctcctttga-3′-TAMRA	27	550	607
Reverse	5′-tttggaaggtaggcatattgg-3′	21	509	608

[1197]

TABLE APB
AI_comprehensive panel_v1.0
                                 Rel. Exp. (%)
                                 Ag1688, Run
Tissue Name                      248429492
110967 COPD-F                    53.6
110980 COPD-F                    14.2
110968 COPD-M                    48.3
110977 COPD-M                    53.6
110989 Emphysema-F               61.6
110992 Emphysema-F               21.6
110993 Emphysema-F               23.8
110994 Emphysema-F               20.7
110995 Emphysema-F               55.1
110996 Emphysema-F               17.8
110997 Asthma-M                  25.2
111001 Asthma-F                  23.0
111002 Asthma-F                  22.1
111003 Atopic Asthma-F           15.5
111004 Atopic Asthma-F           19.9
111005 Atopic Asthma-F           23.8
111006 Atopic Asthma-F           6.0
111417 Allergy-M                 4.6
112347 Allergy-M                 0.0
112349 Normal Lung-F             0.0
112357 Normal Lung-F             38.7
112354 Normal Lung-M             24.0
112374 Crohns-F                  10.4
112389 Match Control Crohns-F    7.4
112375 Crohns-F                  4.6
112732 Match Control Crohns-F    25.0
112725 Crohns-M                  11.3
112387 Match Control Crohns-M    1.0
112378 Crohns-M                  0.0
112390 Match Control Crohns-M    44.1
112726 Crohns-M                  19.5
112731 Match Control Crohns-M    58.2
112380 Ulcer Col-F               3.2
112734 Match Control Ulcer Col-F 56.6
112384 Ulcer Col-F               10.1
112737 Match Control Ulcer Col-F 21.6
112386 Ulcer Col-F               0.0
112738 Match Control Ulcer Col-F 9.3
112381 Ulcer Col-M               0.0
112735 Match Control Ulcer Col-M 41.8
112382 Ulcer Col-M               3.8
112394 Match Control Ulcer Col-M 5.2
112383 Ulcer Col-M               31.6
112736 Match Control Ulcer Col-M 12.9
112423 Psoriasis-F               9.2
112427 Match Control Psoriasis-F 77.4
112418 Psoriasis-M               12.7
112723 Match Control Psoriasis-M 0.0
112419 Psoriasis-M               100.0
112424 Match Control Psoriasis-M 35.6
112420 Psoriasis-M               87.7
112425 Match Control Psoriasis-M 29.1
104689 (MF) OA Bone-Backus       50.0
104690 (MF) Adj “Normal” Bone-Backus 34.9
104691 (MF) OA Synovium-Backus   25.5
104692 (BA) OA Cartilage-Backus  37.6
104694 (BA) OA Bone-Backus       8.4
104695 (BA) Adj “Normal” Bone-Backus 34.4
104696 (BA) OA Synovium-Backus   6.9
104700 (SS) OA Bone-Backus       22.8
104701 (SS) Adj “Normal” Bone-Backus 42.3
104702 (SS) OA Synovium-Backus   29.5
117093 OA Cartilage Rep7         10.6
112672 OA Bone5                  94.0
112673 OA Synovium5              43.2
112674 OA Synovial Fluid cells5  58.6
117100 OA Cartilage Rep14        0.0
112756 OA Bone9                  2.6
112757 OA Synovium9              8.0
112758 OA Synovial Fluid Cells9  22.1
117125 RA Cartilage Rep2         22.1
113492 Bone2 RA                  10.0
113493 Synovium2 RA              11.0
113494 Syn Fluid Cells RA        31.6
113499 Cartilage4 RA             47.6
113500 Bone4 RA                  37.9
113501 Synovium4 RA              55.5
113502 Syn Fluid Cells4 RA       10.0
113495 Cartilage3 RA             20.7
113496 Bone3 RA                  16.2
113497 Synovium3 RA              11.5
113498 Syn Fluid Cells3 RA       25.3
117106 Normal Cartilage Rep20    0.0
113663 Bone3 Normal              0.9
113664 Synovium3 Normal          0.0
113665 Syn Fluid Cells3 Normal   1.1
117107 Normal Cartilage Rep22    2.7
113667 Bone4 Normal              8.1
113668 Synovium4 Normal          5.8
113669 Syn Fluid Cells4 Normal   5.3

[1198]

TABLE APC
CNS_neurodegeneration_v1.0
                               Rel. Exp. (%)
                               Ag1688, Run
Tissue Name                    269217573
AD 1 Hippo                     24.5
AD 2 Hippo                     34.4
AD 3 Hippo                     17.9
AD 4 Hippo                     18.0
AD 5 hippo                     94.6
AD 6 Hippo                     34.9
Control 2 Hippo                35.4
Control 4 Hippo                50.7
Control (Path) 3 Hippo         9.3
AD 1 Temporal Ctx              31.9
AD 2 Temporal Ctx              31.4
AD 3 Temporal Ctx              20.4
AD 4 Temporal Ctx              29.5
AD 5 Inf Temporal Ctx          100.0
AD 5 SupTemporal Ctx           92.0
AD 6 Inf Temporal Ctx          43.8
AD 6 Sup Temporal Ctx          69.7
Control 1 Temporal Ctx         16.5
Control 2 Temporal Ctx         34.9
Control 3 Temporal Ctx         32.3
Control 4 Temporal Ctx         35.4
Control (Path) 1 Temporal Ctx  46.0
Control (Path) 2 Temporal Ctx  45.7
Control (Path) 3 Temporal Ctx  9.7
Control (Path) 4 Temporal Ctx  41.8
AD 1 Occipital Ctx             42.3
AD 2 Occipital Ctx (Missing)   0.0
AD 3 Occipital Ctx             7.1
AD 4 Occipital Ctx             26.4
AD 5 Occipital Ctx             9.9
AD 6 Occipital Ctx             27.2
Control 1 Occipital Ctx        6.3
Control 2 Occipital Ctx        49.7
Control 3 Occipital Ctx        39.2
Control 4 Occipital Ctx        26.6
Control (Path) 1 Occipital Ctx 47.3
Control (Path) 2 Occipital Ctx 21.3
Control (Path) 3 Occipital Ctx 3.5
Control (Path) 4 Occipital Ctx 17.8
Control 1 Parietal Ctx         19.5
Control 2 Parietal Ctx         85.3
Control 3 Parietal Ctx         15.5
Control (Path) 1 Parietal Ctx  44.4
Control (Path) 2 Parietal Ctx  52.9
Control (Path) 3 Parietal Ctx  9.7
Control (Path) 4 Parietal Ctx  52.1

[1199]

TABLE APD
Panel 1.3D
                                 Rel. Exp. (%)
                                 Ag1688, Run
Tissue Name                      147249266
Liver adenocarcinoma             0.0
Pancreas                         6.7
Pancreatic ca. CAPAN2            0.2
Adrenal gland                    1.8
Thyroid                          3.8
Salivary gland                   1.5
Pituitary gland                  6.1
Brain (fetal)                    0.5
Brain (whole)                    3.6
Brain (amygdala)                 3.3
Brain (cerebellum)               0.4
Brain (hippocampus)              6.2
Brain (substantia nigra)         1.0
Brain (thalamus)                 2.1
Cerebral Cortex                  6.3
Spinal cord                      3.1
glio/astro U87-MG                0.0
glio/astro U-118-MG              0.0
astrocytoma SW1783               0.0
neuro*; met SK-N-AS              0.2
astrocytoma SF-539               0.0
astrocytoma SNB-75               0.1
glioma SNB-19                    0.2
glioma U251                      1.2
glioma SF-295                    0.0
Heart (fetal)                    0.2
Heart                            1.6
Skeletal muscle (fetal)          0.7
Skeletal muscle                  1.2
Bone marrow                      0.5
Thymus                           3.2
Spleen                           1.0
Lymph node                       2.9
Colorectal                       0.8
Stomach                          3.3
Small intestine                  6.2
Colon ca. SW480                  0.0
Colon ca.* SW620(SW480 met)      0.0
Colon ca. HT29                   0.0
Colon ca. HCT-116                0.0
Colon ca. CaCo-2                 0.2
Colon ca. tissue(ODO3866)        0.0
Colon ca. HCC-2998               0.2
Gastric ca.* (liver met) NCI-N87 4.4
Bladder                          3.1
Trachea                          3.0
Kidney                           6.8
Kidney (fetal)                   9.2
Renal ca. 786-0                  0.0
Renal ca. A498                   1.7
Renal ca. RXF 393                0.0
Renal ca. ACHN                   0.0
Renal ca. UO-31                  0.0
Renal ca. TK-10                  0.0
Liver                            100.0
Liver (fetal)                    99.3
Liver ca. (hepatoblast) HepG2    0.0
Lung                             1.3
Lung (fetal)                     1.8
Lung ca. (small cell) LX-1       0.0
Lung ca. (small cell) NCI-H69    0.0
Lung ca. (s. cell var.) SHP-77   0.8
Lung ca. (large cell)NCI-H460    0.0
Lung ca. (non-sm. cell) A549     0.2
Lung ca. (non-s. cell) NCI-H23   0.0
Lung ca. (non-s. cell) HOP-62    0.0
Lung ca. (non-s. cl) NCI-H522    0.0
Lung ca. (squam.) SW 900         0.2
Lung ca. (squam.) NCI-H596       0.0
Mammary gland                    2.9
Breast ca.* (pl. ef) MCF-7       0.0
Breast ca.* (pl. ef) MDA-MB-231  0.0
Breast ca.* (pl. ef) T47D        0.0
Breast ca. BT-549                0.0
Breast ca. MDA-N                 0.0
Ovary                            0.0
Ovarian ca. OVCAR-3              0.2
Ovarian ca. OVCAR-4              0.0
Ovarian ca. OVCAR-5              0.3
Ovarian ca. OVCAR-8              0.0
Ovarian ca. IGROV-1              0.0
Ovarian ca.* (ascites) SK-OV-3   1.0
Uterus                           1.4
Placenta                         0.4
Prostate                         1.0
Prostate ca.* (bone met)PC-3     0.0
Testis                           6.1
Melanoma Hs688(A).T              0.4
Melanoma* (met) Hs688(B).T       0.9
Melanoma UACC-62                 0.0
Melanoma M14                     0.0
Melanoma LOX IMVI                0.0
Melanoma* (met) SK-MEL-5         0.0
Adipose                          0.5

[1200]

TABLE APE
Panel 2D
                                 Rel. Exp. (%)
                                 Ag1688, Run
Tissue Name                      162646059
Normal Colon                     1.7
CC Well to Mod Diff (ODO3866)    0.0
CC Margin (ODO3866)              0.2
CC Gr.2 rectosigmoid (ODO3868)   0.2
CC Margin (ODO3868)              0.1
CC Mod Diff (ODO3920)            0.1
CC Margin (ODO3920)              0.9
CC Gr.2 ascend colon (ODO3921)   0.1
CC Margin (ODO3921)              0.1
CC from Partial Hepatectomy (ODO4309) Mets 4.7
Liver Margin (ODO4309)           100.0
Colon mets to lung (OD04451-01)  0.1
Lung Margin (OD04451-02)         0.1
Normal Prostate 6546-1           2.1
Prostate Cancer (OD04410)        0.6
Prostate Margin (OD04410)        0.5
Prostate Cancer (OD04720-01)     1.1
Prostate Margin (OD04720-02)     1.6
Normal Lung 061010               2.0
Lung Met to Muscle (ODO4286)     0.0
Muscle Margin (ODO4286)          0.2
Lung Malignant Cancer (OD03126)  0.1
Lung Margin (OD03126)            0.5
Lung Cancer (OD04404)            0.1
Lung Margin (OD04404)            0.2
Lung Cancer (OD04565)            0.0
Lung Margin (OD04565)            0.1
Lung Cancer (OD04237-01)         0.1
Lung Margin (OD04237-02)         0.4
Ocular Mel Met to Liver (ODO4310) 0.1
Liver Margin (ODO4310)           77.4
Melanoma Mets to Lung (OD04321)  0.0
Lung Margin (OD04321)            0.1
Normal Kidney                    12.9
Kidney Ca, Nuclear grade 2 (OD04338) 3.8
Kidney Margin (OD04338)          1.6
Kidney Ca Nuclear grade 1/2 (OD04339) 2.8
Kidney Margin (OD04339)          9.3
Kidney Ca, Clear cell type (OD04340) 1.4
Kidney Margin (OD04340)          4.1
Kidney Ca, Nuclear grade 3 (OD04348) 0.1
Kidney Margin (OD04348)          3.8
Kidney Cancer (OD04622-01)       0.2
Kidney Margin (OD04622-03)       0.7
Kidney Cancer (OD04450-01)       0.2
Kidney Margin (OD04450-03)       2.6
Kidney Cancer 8120607            0.0
Kidney Margin 8120608            0.7
Kidney Cancer 8120613            0.0
Kidney Margin 8120614            0.5
Kidney Cancer 9010320            0.2
Kidney Margin 9010321            1.0
Normal Uterus                    0.2
Uterus Cancer 064011             0.8
Normal Thyroid                   0.9
Thyroid Cancer 064010            0.2
Thyroid Cancer A302152           0.5
Thyroid Margin A302153           1.0
Normal Breast                    0.3
Breast Cancer (OD04566)          0.1
Breast Cancer (OD04590-01)       0.1
Breast Cancer Mets (OD04590-03)  0.4
Breast Cancer Metastasis (OD04655-05) 0.9
Breast Cancer 064006             0.6
Breast Cancer 1024               1.2
Breast Cancer 9100266            0.1
Breast Margin 9100265            0.1
Breast Cancer A209073            0.3
Breast Margin A209073            0.3
Normal Liver                     69.7
Liver Cancer 064003              13.7
Liver Cancer 1025                18.0
Liver Cancer 1026                1.2
Liver Cancer 6004-T              22.2
Liver Tissue 6004-N              1.0
Liver Cancer 6005-T              1.9
Liver Tissue 6005-N              4.2
Normal Bladder                   2.7
Bladder Cancer 1023              0.0
Bladder Cancer A302173           0.2
Bladder Cancer (OD04718-01)      0.1
Bladder Normal Adjacent (OD04718-03) 0.5
Normal Ovary                     0.0
Ovarian Cancer 064008            0.1
Ovarian Cancer (OD04768-07)      0.2
Ovary Margin (OD04768-08)        0.1
Normal Stomach                   0.3
Gastric Cancer 9060358           0.1
Stomach Margin 9060359           0.0
Gastric Cancer 9060395           0.2
Stomach Margin 9060394           0.3
Gastric Cancer 9060397           0.3
Stomach Margin 9060396           0.0
Gastric Cancer 064005            1.1

[1201]

TABLE APF
Panel 4.1D
                                 Rel. Exp. (%)
                                 Ag1688, Run
Tissue Name                      248389308
Secondary Th1 act                1.6
Secondary Th2 act                1.7
Secondary Tr1 act                0.0
Secondary Th1 rest               0.0
Secondary Th2 rest               0.0
Secondary Tr1 rest               0.0
Primary Th1 act                  0.0
Primary Th2 act                  0.0
Primary Tr1 act                  0.0
Primary Th1 rest                 1.3
Primary Th2 rest                 1.3
Primary Tr1 rest                 1.6
CD45RA CD4 lymphocyte act        3.5
CD45RO CD4 lymphocyte act        4.2
CD8 lymphocyte act               3.2
Secondary CD8 lymphocyte rest    1.8
Secondary CD8 lymphocyte act     0.0
CD4 lymphocyte none              3.8
2ry Th1/Th2/Tr1_anti-CD95 CH11   0.0
LAK cells rest                   0.0
LAK cells IL-2                   6.2
LAK cells IL-2 + IL-12           0.0
LAK cells IL-2 + IFN gamma       1.7
LAK cells IL-2 + IL-18           3.4
LAK cells PMA/ionomycin          0.0
NK Cells IL-2 rest               22.1
Two Way MLR 3 day                3.3
Two Way MLR 5 day                1.9
Two Way MLR 7 day                1.7
PBMC rest                        1.5
PBMC PWM                         5.1
PBMC PHA-L                       0.7
Ramos (B cell) none              0.0
Ramos (B cell) ionomycin         0.0
B lymphocytes PWM                2.8
B lymphocytes CD40L and IL-4     21.5
EOL-1 dbcAMP                     0.0
EOL-1 dbcAMP PMA/ionomycin       0.0
Dendritic cells none             2.0
Dendritic cells LPS              0.0
Dendritic cells anti-CD40        4.9
Monocytes rest                   0.0
Monocytes LPS                    0.0
Macrophages rest                 0.0
Macrophages LPS                  0.0
HUVEC none                       0.0
HUVEC starved                    0.0
HUVEC IL-1beta                   0.0
HUVEC IFN gamma                  0.0
HUVEC TNF alpha + IFN gamma      0.0
HUVEC TNF alpha + IL4            0.0
HUVEC IL-11                      0.0
Lung Microvascular EC none       0.0
Lung Microvascular EC TNFalpha + IL-1beta 0.0
Microvascular Dermal EC none     0.0
Microsvasular Dermal EC TNFalpha + IL-1beta 0.0
Bronchial epithelium TNFalpha + IL1beta 0.0
Small airway epithelium none     0.0
Small airway epithelium TNFalpha + IL-1beta 0.0
Coronery artery SMC rest         0.0
Coronery artery SMC TNFalpha + IL-1beta 0.0
Astrocytes rest                  0.0
Astrocytes TNFalpha + IL-1beta   2.4
KU-812 (Basophil) rest           1.8
KU-812 (Basophil) PMA/ionomycin  0.0
CCD1106 (Keratinocytes) none     0.0
CCD1106 (Keratinocytes) TNFalpha + IL-1beta 0.0
Liver cirrhosis                  100.0
NCI-H292 none                    0.0
NCI-H292 IL-4                    1.5
NCI-H292 IL-9                    1.9
NCI-H292 IL-13                   0.0
NCI-H292 IFN gamma               0.0
HPAEC none                       0.0
HPAEC TNF alpha + IL-1 beta      0.0
Lung fibroblast none             2.6
Lung fibroblast TNF alpha + IL-1 beta 10.4
Lung fibroblast IL-4             1.8
Lung fibroblast IL-9             12.3
Lung fibroblast IL-13            0.0
Lung fibroblast IFN gamma        3.1
Dermal fibroblast CCD1070 rest   0.0
Dermal fibroblast CCD1070 TNF alpha 0.0
Dermal fibroblast CCD1070 IL-1 beta 0.0
Dermal fibroblast IFN gamma      6.8
Dermal fibroblast IL-4           5.8
Dermal Fibroblasts rest          0.0
Neutrophils TNFa + LPS           0.0
Neutrophils rest                 0.0
Colon                            0.0
Lung                             1.2
Thymus                           0.0
Kidney                           82.9

[1202]

TABLE APG
Panel 5 Islet
                                 Rel. Exp. (%)
                                 Ag1688, Run
Tissue Name                      226587524
97457_Patient-02go_adipose       41.2
97476_Patient-07sk_skeletal muscle 9.9
97477_Patient-07ut_uterus        8.1
97478_Patient-07pl_placenta      0.0
99167_Bayer Patient 1            84.7
97482_Patient-08ut_uterus        2.4
97483_Patient-08pl_placenta      0.0
97486_Patient-09sk_skeletal muscle 8.0
97487_Patient-09ut_uterus        9.6
97488_Patient-09pl_placenta      0.0
97492_Patient-10ut_uterus        0.0
97493_Patient-10pl_placenta      0.0
97495_Patient-11go_adipose       0.0
97496_Patient-11sk_skeletal muscle 52.9
97497_Patient-11ut_uterus        35.8
97498_Patient-11pl_placenta      10.5
97500_Patient-12go_adipose       0.0
97501_Patient-12sk_skeletal muscle 35.4
97502_Patient-12ut_uterus        20.7
97503_Patient-12pl_placenta      0.0
94721_Donor 2 U - A_Mesenchymal Stem Cells 0.0
94722_Donor 2 U - B_Mesenchymal Stem Cells 0.0
94723_Donor 2 U - C_Mesenchymal Stem Cells 0.0
94709_Donor 2 AM - A_adipose     0.0
94710_Donor 2 AM - B_adipose     0.0
94711_Donor 2 AM - C_adipose     0.0
94712_Donor 2 AD - A_adipose     11.4
94713_Donor 2 AD - B_adipose     0.0
94714_Donor 2 AD - C_adipose     29.1
94742_Donor 3 U - A_Mesenchymal Stem Cells 19.2
94743_Donor 3 U - B_Mesenchymal Stem Cells 0.0
94730_Donor 3 AM - A_adipose     15.0
94731_Donor 3 AM - B_adipose     37.9
94732_Donor 3 AM - C_adipose     0.0
94733_Donor 3 AD - A_adipose     39.2
94734_Donor 3 AD - B_adipose     11.4
94735_Donor 3 AD - C_adipose     34.4
77138_Liver_HepG2untreated       8.4
73556_Heart_Cardiac stromal cells (primary) 0.0
81735_Small Intestine            100.0
72409_Kidney_Proximal Convoluted Tubule 9.9
82685_Small intestine_Duodenum   70.2
90650_Adrenal_Adrenocortical adenoma 25.5
72410_Kidney_HRCE                10.4
72411_Kidney_HRE                 7.2
73139_Uterus_Uterine smooth muscle cells 0.0

[1203]

TABLE APH
general oncology screening panel_v_2.4
                               Rel. Exp. (%)
                               Ag1688, Run
Tissue Name                    260552690
Colon cancer 1                 1.8
Colon cancer NAT 1             1.0
Colon cancer 2                 0.4
Colon cancer NAT 2             1.2
Colon cancer 3                 0.8
Colon cancer NAT 3             2.5
Colon malignant cancer 4       2.1
Colon normal adjacent tissue 4 0.2
Lung cancer 1                  0.2
Lung NAT 1                     0.2
Lung cancer 2                  1.0
Lung NAT 2                     0.8
Squamous cell carcinoma 3      0.5
Lung NAT 3                     0.0
metastatic melanoma 1          1.1
Melanoma 2                     0.1
Melanoma 3                     0.0
metastatic melanoma 4          2.0
metastatic melanoma 5          3.0
Bladder cancer 1               0.6
Bladder cancer NAT 1           0.0
Bladder cancer 2               0.3
Bladder cancer NAT 2           0.1
Bladder cancer NAT 3           0.0
Bladder cancer NAT 4           1.1
Prostate adenocarcinoma 1      3.7
Prostate adenocarcinoma 2      0.2
Prostate adenocarcinoma 3      1.2
Prostate adenocarcinoma 4      3.5
Prostate cancer NAT 5          0.6
Prostate adenocarcinoma 6      0.2
Prostate adenocarcinoma 7      0.0
Prostate adenocarcinoma 8      0.0
Prostate adenocarcinoma 9      0.0
Prostate cancer NAT 10         0.1
Kidney cancer 1                7.7
Kidney NAT 1                   5.7
Kidney cancer 2                40.1
Kidney NAT 2                   23.8
Kidney cancer 3                100.0
Kidney NAT 3                   5.6
Kidney cancer 4                2.0
Kidney NAT 4                   4.2

[1204] is also seen in samples derived from orthoarthitis/ rheumatoid arthritis bone, cartilage, synovium and synovial fluid samples, from normal lung, COPD lung, emphysema, atopic asthma, asthma, Crohn's disease (normal matched control and diseased), ulcerative colitis(normal matched control and diseased), and psoriasis (normal matched control and diseased). Therefore, therapeutic modulation of this gene product may ameliorate symptoms/conditions associated with autoimmune and inflammatory disorders including psoriasis, asthma, inflammatory bowel disease, rheumatoid arthritis and osteoarthritis.

[1205] CNS_neurodegeneration_v1.0 Summary: Ag1688 This panel confirms the expression of this gene at low levels in the brains of an independent group of individuals. However, no differential expression of this gene was detected between Alzheimer's diseased postmortem brains and those of non-demented controls in this experiment. Please see Panel 1.3D for a discussion of the potential utility of this gene in treatment of central nervous system disorders.

[1206] Panel 1.3D Summary: Ag1688 Expression of this gene, a plasma kallikrein, is significantly higher in liver (CTs=28) than in any other sample on this panel. Thus, expression of this gene could be used as a marker of liver tissue. In addition, low levels of expression of this gene is also detected in tissues with metabolic/endocrine functions including pancreas, adrenal gland, thyroid, pituitary gland, skeletal muscle, heart, and the gastrointestinal tract. Plasma prekallikrein is a glycoprotein that participates in the surface-dependent activation of blood coagulation, fibrinolysis, kinin generation and inflammation. It is synthesized in the liver and secreted into the blood as a single polypeptide chain. It is converted to plasma kallikrein by factor XlIa. Recently, plasma kallikrein has been implicated in adipose differentiation by remodeling of the fibronectin-rich ECM of preadipocytes. Plg−/− mice show a reduction of fat deposit (Ref. 1, 2). At Curagen, it was found that plasma kallikrein significantly down-regulated in the liver of mice with ‘lean’ phenotype. Thus, based on Curagen GeneCalling data it is hypothesized that plasma kallikrein might cause disruption of adipose differentiation thus leading to obesity if over expressed and to a leaner phenotype if expression is below normal. Therefore, an antagonist to this gene product in the form of small molecule or antibody may be beneficial in the treatment of obesity.

[1207] Moderate to low levels of expression of this gene is also seen levels in some of the regions of central nervous system examined, including amygdala, hippocampus, substantia nigra, thalamus, cerebral cortex, and spinal cord. Therefore, therapeutic modulation of this gene product may be useful in the treatment of central nervous system disorders such as Alzheimer's disease, Parkinson's disease, epilepsy, multiple sclerosis, schizophrenia and depression.

[1208] References:

[1209] 1. Hoover-Plow J, Yuen L. Plasminogen binding is increased with adipocyte differentiation. Biochem.Biophys.Res.Commun. (2001) 284, 389-394. PMID: 11394891.

[1210] Selvarajan S, Lund L R, Takeuchi T, Craik C S, Werb Z. A plasma kallikrein-dependent plasminogen cascade required for adipocyte differentiation. Nature Cell Biol. (2001) 3, 267-275. PMID: 11231576

[1211] Panel 2D Summary: Ag1688 The expression of the CG56155-01 gene appears to be highest in a sample derived from a sample of normal liver tissue adjacent to a metastatic colon cancer CT=26.2). In addition, there is substantial expression in other samples of normal liver, and to a much lesser degree, malignant liver tissue. This liver specific expression is consistent with the expression seen in Panel 1.3D. Thus, the expression of this gene could be used to distinguish liver derived tissue from the toher samples in the panel, and more specifically the expression of this gene could be used to distinguish normal liver from malignant liver tissue. Moreover, therapeutic modulation of this gene, through the use of small molecule drugs, protein therapeutics or antibodies might be of benefit in the treatment of liver cancer.

[1212] Panel 4.1D Summary: Ag1688 Highest expression of this gene is detected in liver cirrhosis (CT=31.8). In addition, moderate to low levels of expression of this gene in IL-2 treated NK cells, CD40L and IL-4 treated B lymphocytes and normal kidney. Therefore, therapeutic modulation of the protein encoded for by this gene may be useful in the treatment of inflammatory or autoimmune diseases which effect the liver and kidney including liver cirrhosis and fibrosis, lupus erythematosus and glomerulonephritis.

[1213] Panel 5 Islet Summary: Ag1688 Expression of the CG56155-01 gene is limited to pancreatic islets and small intestines. Please see Panel 1.3 for discussion of utility of this gene in metabolic disease.

[1214] General oncology screening panel_v—2.4 Summary: Ag1688 Highest expression of this gene is detected in kidney cancer (CT=28.4). Higher expression of this gene is associated with cancer compared to normal kidney. Therefore, expression of this gene may be used as diagnostic marker for kidney cancer and therapeutic modulation of this gene or protein encoded by this gene may through the use of antibodies or small molecule drug may be useful in the treatment of kidney cancer.

[1215] AQ. CG59595-01: Ribonuclease 6 Precursor.

[1216] Expression of gene CG59595-01 was assessed using the primer-probe set Ag3488, described in Table AQA. Results of the RTQ-PCR runs are shown in Tables AQB, AQC, AQD, AQE, AQF and AQG.

TABLE AQA
Probe Name Ag3488
			Start	SEQ ID
Primers	Sequences	Length	Position	No
Forward	5′-aactgtgcctcactaagcaaga-3′	22	963	609
Probe	TET-5′-agcagctgcaaaactgcaccgag-3′-TAMRA	23	987	610
Reverse	5′-catttgccagccagacttc-3′	19	1037	611

[1217]

TABLE AQB
CNS_neurodegeneration_v1.0
                               Rel. Exp. (%)
                               Ag3488, Run
Tissue Name                    206533698
AD 1 Hippo                     54.0
AD 2 Hippo                     72.7
AD 3 Hippo                     34.2
AD 4 Hippo                     34.4
AD 5 hippo                     74.7
AD 6 Hippo                     70.2
Control 2 Hippo                63.3
Control 4 Hippo                47.6
Control (Path) 3 Hippo         11.3
AD 1 Temporal Ctx              43.5
AD 2 Temporal Ctx              42.0
AD 3 Temporal Ctx              25.9
AD 4 Temporal Ctx              37.6
AD 5 Inf Temporal Ctx          93.3
AD 5 Sup Temporal Ctx          100.0
AD 6 Inf Temporal Ctx          74.7
AD 6 Sup Temporal Ctx          56.3
Control 1 Temporal Ctx         15.6
Control 2 Temporal Ctx         57.8
Control 3 Temporal Ctx         29.3
Control 4 Temporal Ctx         24.8
Control (Path) 1 Temporal Ctx  62.0
Control (Path) 2 Temporal Ctx  29.5
Control (Path) 3 Temporal Ctx  8.8
Control (Path) 4 Temporal Ctx  42.6
AD 1 Occipital Ctx             36.3
AD 2 Occipital Ctx (Missing)   0.0
AD 3 Occipital Ctx             20.7
AD 4 Occipital Ctx             31.4
AD 5 Occipital Ctx             22.1
AD 6 Occipital Ctx             42.6
Control 1 Occipital Ctx        7.1
Control 2 Occipital Ctx        47.3
Control 3 Occipital Ctx        21.6
Control 4 Occipital Ctx        18.3
Control (Path) 1 Occipital Ctx 63.7
Control (Path) 2 Occipital Ctx 15.2
Control (Path) 3 Occipital Ctx 5.2
Control (Path) 4 Occipital Ctx 27.4
Control 1 Parietal Ctx         12.5
Control 2 Parietal Ctx         59.9
Control 3 Parietal Ctx         25.2
Control (Path) 1 Parietal Ctx  57.0
Control (Path) 2 Parietal Ctx  30.4
Control (Path) 3 Parietal Ctx  3.8
Control (Path) 4 Parietal Ctx  51.8

[1218]

TABLE AQC
General_screening_panel_v1.4
                                 Rel. Exp. (%)
                                 Ag3488, Run
Tissue Name                      213390581
Adipose                          4.1
Melanoma* Hs688(A).T             2.6
Melanoma* Hs688(B).T             1.6
Melanoma* M14                    2.1
Melanoma* LOXIMVI                0.1
Melanoma* SK-MEL-5               2.1
Squamous cell carcinoma SCC-4    2.1
Testis Pool                      3.3
Prostate ca.* (bone met) PC-3    3.1
Prostate Pool                    5.3
Placenta                         2.1
Uterus Pool                      1.7
Ovarian ca. OVCAR-3              4.9
Ovarian ca. SK-OV-3              27.5
Ovarian ca. OVCAR-4              10.7
Ovarian ca. OVCAR-5              7.0
Ovarian ca. IGROV-1              57.0
Ovarian ca. OVCAR-8              1.4
Ovary                            3.2
Breast ca. MCF-7                 15.3
Breast ca. MDA-MB-231            11.8
Breast ca. BT 549                5.4
Breast ca. T47D                  13.0
Breast ca. MDA-N                 1.5
Breast Pool                      7.1
Trachea                          7.3
Lung                             2.8
Fetal Lung                       6.8
Lung ca. NCI-N417                0.4
Lung ca. LX-1                    7.3
Lung ca. NCI-H146                1.5
Lung ca. SHP-77                  6.7
Lung ca. A549                    2.4
Lung ca. NCI-H526                1.5
Lung ca. NCI-H23                 3.6
Lung ca. NCI-H460                3.1
Lung ca. HOP-62                  2.9
Lung ca. NCI-H522                3.0
Liver                            0.8
Fetal Liver                      5.9
Liver ca. HepG2                  37.6
Kidney Pool                      8.9
Fetal Kidney                     5.5
Renal ca. 786-0                  100.0
Renal ca. A498                   17.9
Renal ca. ACHN                   1.8
Renal ca. UO-31                  6.7
Renal ca. TK-10                  22.8
Bladder                          14.8
Gastric ca. (liver met.) NCI-N87 5.8
Gastric ca. KATO III             22.2
Colon ca. SW-948                 6.0
Colon ca. SW480                  6.4
Colon ca.* (SW480 met) SW620     3.3
Colon ca. HT29                   17.1
Colon ca. HCT-116                6.3
Colon ca. CaCo-2                 10.6
Colon cancer tissue              16.2
Colon ca. SW1116                 6.8
Colon ca. Colo-205               1.0
Colon ca. SW-48                  6.7
Colon Pool                       5.5
Small Intestine Pool             6.4
Stomach Pool                     3.6
Bone Marrow Pool                 2.5
Fetal Heart                      1.5
Heart Pool                       1.8
Lymph Node Pool                  6.2
Fetal Skeletal Muscle            0.9
Skeletal Muscle Pool             0.9
Spleen Pool                      10.6
Thymus Pool                      12.2
CNS cancer (glio/astro) U87-MG   4.8
CNS cancer (glio/astro) U-118-MG 2.2
CNS cancer (neuro; met) SK-N-AS  1.7
CNS cancer (astro) SF-539        0.3
CNS cancer (astro) SNB-75        1.8
CNS cancer (glio) SNB-19         47.3
CNS cancer (glio) SF-295         7.9
Brain (Amygdala) Pool            3.9
Brain (cerebellum)               2.6
Brain (fetal)                    2.5
Brain (Hippocampus) Pool         2.1
Cerebral Cortex Pool             2.5
Brain (Substantia nigra) Pool    3.4
Brain (Thalamus) Pool            2.8
Brain (whole)                    1.3
Spinal Cord Pool                 6.5
Adrenal Gland                    3.1
Pituitary gland Pool             1.8
Salivary Gland                   9.5
Thyroid (female)                 7.0
Pancreatic ca. CAPAN2            2.6
Pancreas Pool                    13.3

[1219]

TABLE AQD
Panel 2.2
                                 Rel. Exp.(%)
                                 Ag3488, Run
Tissue Name                      174285071
Normal Colon                     12.2
Colon cancer (OD06064)           8.0
Colon Margin (OD06064)           6.6
Colon cancer (OD06159)           5.3
Colon Margin (OD06159)           6.7
Colon cancer (OD06297-04)        4.9
Colon Margin (OD06297-05)        8.5
CC Gr.2 ascend colon (ODO3921)   10.4
CC Margin (ODO3921)              9.0
Colon cancer metastasis (OD06104) 11.0
Lung Margin (OD06104)            8.9
Colon mets to lung (OD04451-01)  19.6
Lung Margin (OD04451-02)         9.0
Normal Prostate                  11.5
Prostate Cancer (OD04410)        4.9
Prostate Margin (OD04410)        4.7
Normal Ovary                     7.3
Ovarian cancer (OD06283-03)      8.7
Ovarian Margin (OD06283-07)      4.6
Ovarian Cancer 064008            13.7
Ovarian cancer (OD06145)         12.2
Ovarian Margin (OD06145)         18.9
Ovarian cancer (OD06455-03)      80.7
Ovarian Margin (OD06455-07)      2.4
Normal Lung                      7.9
Invasive poor diff. lung adeno (ODO4945-01 14.5
Lung Margin (ODO4945-03)         8.8
Lung Malignant Cancer (OD03126)  26.6
Lung Margin (OD03126)            4.8
Lung Cancer (OD05014A)           7.9
Lung Margin (OD05014B)           23.3
Lung cancer (OD06081)            2.8
Lung Margin (OD06081)            4.0
Lung Cancer (OD04237-01)         6.0
Lung Margin (OD04237-02)         19.6
Ocular Melanoma Metastasis       4.6
Ocular Melanoma Margin (Liver)   10.0
Melanoma Metastasis              6.9
Melanoma Margin (Lung)           10.2
Normal Kidney                    2.9
Kidney Ca, Nuclear grade 2 (OD04338) 12.2
Kidney Margin (OD04338)          9.0
Kidney Ca Nuclear grade 1/2 (OD04339) 22.7
Kidney Margin (OD04339)          3.3
Kidney Ca, Clear cell type (OD04340) 17.8
Kidney Margin (OD04340)          8.0
Kidney Ca, Nuclear grade 3 (OD04348) 5.8
Kidney Margin (OD04348)          21.5
Kidney malignant cancer (OD06204B) 11.8
Kidney normal adjacent tissue (OD06204E) 4.9
Kidney Cancer (OD04450-01)       100.0
Kidney Margin (OD04450-03)       4.8
Kidney Cancer 8120613            0.9
Kidney Margin 8120614            3.1
Kidney Cancer 9010320            23.7
Kidney Margin 9010321            2.4
Kidney Cancer 8120607            12.1
Kidney Margin 8120608            3.0
Normal Uterus                    11.3
Uterine Cancer 064011            16.4
Normal Thyroid                   5.1
Thyroid Cancer 064010            4.9
Thyroid Cancer A302152           8.7
Thyroid Margin A302153           6.5
Normal Breast                    9.9
Breast Cancer (OD04566)          5.7
Breast Cancer 1024               10.8
Breast Cancer (OD04590-01)       39.8
Breast Cancer Mets (OD04590-03)  8.8
Breast Cancer Metastasis (OD04655-05) 9.2
Breast Cancer 064006             10.0
Breast Cancer 9100266            7.8
Breast Margin 9100265            5.0
Breast Cancer A209073            6.0
Breast Margin A2090734           10.2
Breast cancer (OD06083)          18.6
Breast cancer node metastasis (OD06083) 16.6
Normal Liver                     8.0
Liver Cancer 1026                5.0
Liver Cancer 1025                18.4
Liver Cancer 6004-T              12.8
Liver Tissue 6004-N              11.0
Liver Cancer 6005-T              9.7
Liver Tissue 6005-N              19.9
Liver Cancer 064003              11.4
Normal Bladder                   11.6
Bladder Cancer 1023              6.1
Bladder Cancer A302173           12.0
Normal Stomach                   23.5
Gastric Cancer 9060397           3.0
Stomach Margin 9060396           12.7
Gastric Cancer 9060395           8.0
Stomach Margin 9060394           26.4
Gastric Cancer 064005            6.3

[1220]

TABLE AQE
Panel 3D
                                 Rel. Exp. (%)
                                 Ag3488, Run
Tissue Name                      182098858
Daoy- Medulloblastoma            1.7
TE671- Medulloblastoma           10.2
D283 Med- Medulloblastoma        34.6
PFSK-1- Primitive Neuroectodermal 11.9
XF-498- CNS                      3.5
SNB-78- Glioma                   21.5
SF-268- Glioblastoma             11.9
T98G- Glioblastoma               5.3
SK-N-SH- Neuroblastoma (metastasis) 22.5
SF-295- Glioblastoma             10.4
Cerebellum                       11.0
Cerebellum                       9.3
NCI-H292- Mucoepidennoid lung carcinoma 57.8
DMS-114- Small cell lung cancer  0.6
DMS-79- Small cell lung cancer   70.2
NCI-H146- Small cell lung cancer 20.0
NCI-H526- Small cell lung cancer 35.6
NCI-N417- Small cell lung cancer 3.7
NCI-H82- Small cell lung cancer  6.6
NCI-H157- Squamous cell lung cancer 0.8
(metastasis)
NCI-H1155- Large cell lung cancer 15.3
NCI-H1299- Large cell lung cancer 14.5
NCI-H727- Lung carcinoid         25.0
NCI-UMC-11- Lung carcinoid       31.2
LX-1- Small cell lung cancer     30.6
Colo-205- Colon cancer           15.1
KM12- Colon cancer               24.7
KM20L2- Colon cancer             33.0
NCI-H716- Colon cancer           24.1
SW-48- Colon adenocarcinoma      52.9
SW1116- Colon adenocarcinoma     50.0
LS 174T- Colon adenocarcinoma    78.5
SW-948- Colon adenocarcinoma     5.5
SW-480- Colon adenocarcinoma     25.9
NCI-SNU-5- Gastric carcinoma     15.2
KATO III- Gastric carcinoma      66.0
NCI-SNU-16- Gastric carcinoma    20.6
NCI-SNU-1- Gastric carcinoma     85.3
RF-1- Gastric adenocarcinoma     64.2
RF-48- Gastric adenocarcinoma    70.2
MKN-45- Gastric carcinoma        33.9
NCI-N87- Gastric carcinoma       28.5
OVCAR-5- Ovarian carcinoma       11.5
RL95-2- Uterine carcinoma        15.7
HelaS3- Cervical adenocarcinoma  10.5
Ca Ski- Cervical epidermoid carcinoma 18.6
(metastasis)
ES-2- Ovarian clear cell carcinoma 10.2
Ramos- Stimulated with PMA/ionomycin 6h 7.3
Ramos- Stimulated with PMA/ionomycin 14h 27.7
MEG-01 - Chronic myelogenous leukemia 27.2
(megokaryoblast)
Raji- Burkitt's lymphoma         16.0
Daudi- Burkitt's lymphoma        8.8
U266- B-cell plasmacytoma        17.3
CA46- Burkitt's lymphoma         6.4
RL- non-Hodgkin's B-cell lymphoma 2.9
JM1- pre-B-cell lymphoma         5.7
Jurkat- T cell leukemia          5.7
TF-1 - Erythroleukemia           62.0
HUT 78- T-cell lymphoma          29.7
U937- Histiocytic lymphoma       86.5
KU-812- Myelogenous leukemia     87.1
769-P- Clear cell renal carcinoma 8.8
Caki-2- Clear cell renal carcinoma 26.2
SW 839- Clear cell renal carcinoma 70.7
G401- Wilms' tumor               10.2
Hs766T- Pancreatic carcinoma (LN metastasis) 33.9
CAPAN-1- Pancreatic adenocarcinoma 15.7
(liver metastasis)
SU86.86- Pancreatic carcinoma    100.0
(liver metastasis)
BxPC-3- Pancreatic adenocarcinoma 10.9
HP AC- Pancreatic adenocarcinoma 5.8
MIA PaCa-2- Pancreatic carcinoma 0.1
CFPAC-1- Pancreatic ductal adenocarcinoma 37.6
PANC-1- Pancreatic epithelioid   2.9
ductal carcinoma
T24- Bladder carcinma (transitional cell) 12.4
5637- Bladder carcinoma          9.0
HT-1197- Bladder carcinoma       46.0
UM-UC-3- Bladder carcinma (transitional cell) 5.5
A204- Rhabdomyosarcoma           8.8
HT-1080- Fibrosarcoma            10.4
MG-63- Osteosarcoma              6.7
SK-LMS-1- Leiomyosarcoma (vulva) 13.2
SJRH30- Rhabdomyosarcoma (met to bone marrow) 4.7
A431- Epidermoid carcinoma       12.1
WM266-4- Melanoma                6.2
DU 145- Prostate carcinoma (brain metastasis) 0.0
MDA-MB-468- Breast adenocarcinoma 6.7
SCC-4- Squamous cell carcinoma of tongue 0.9
SCC-9- Squamous cell carcinoma of tongue 10.5
SCC-15- Squamous cell carcinoma of tongue 0.6
CAL 27- Squamous cell carcinoma of tongue 27.4

[1221]

TABLE AQF
Panel 4D
                                 Rel. Exp. (%)
                                 Ag3488, Run
Tissue Name                      166441742
Secondary Th1 act                18.7
Secondary Th2 act                25.2
Secondary Tr1 act                29.5
Secondary Th1 rest               37.9
Secondary Th2 rest               21.3
Secondary Tr1 rest               29.3
Primary Th1 act                  7.1
Primary Th2 act                  20.4
Primary Tr1 act                  25.9
Primary Th1 rest                 95.9
Primary Th2 rest                 55.1
Primary Tr1 rest                 28.5
CD45RA CD4 lymphocyte act        8.8
CD45RO CD4 lymphocyte act        25.2
CD8 lymphocyte act               12.6
Secondary CD8 lymphocyte rest    31.2
Secondary CD8 lymphocyte act     7.6
CD4 lymphocyte none              50.3
2ry Th1/Th2/Tr1_anti-CD95 CH11   41.8
LAK cells rest                   23.2
LAK cells IL-2                   33.9
LAK cells IL-2 + IL-12           26.4
LAK cells IL-2 + IFN gamma       42.9
LAK cells IL-2 + IL-18           24.0
LAK cells PMA/ionomycin          14.3
NK Cells IL-2 rest               14.2
Two Way MLR 3 day                39.8
Two Way MLR 5 day                18.7
Two Way MLR 7 day                16.6
PBMC rest                        45.1
PBMC PWM                         17.2
PBMC PHA-L                       19.8
Ramos (B cell) none              23.8
Ramos (B cell) ionomycin         18.0
B lymphocytes PWM                21.8
B lymphocytes CD40L and IL-4     43.2
EOL-1 dbcAMP                     53.6
EOL-1 dbcAMP PMA/ionomycin       25.0
Dendritic cells none             72.2
Dendritic cells LPS              29.1
Dendritic cells anti-CD40        80.7
Monocytes rest                   100.0
Monocytes LPS                    11.0
Macrophages rest                 92.0
Macrophages LPS                  26.8
HUVEC none                       11.0
HUVEC starved                    9.7
HUVEC IL-1beta                   2.6
HUVEC IFN gamma                  3.0
HUVEC TNF alpha + IFN gamma      3.2
HUVEC TNF alpha + IL4            3.6
HUVEC IL-11                      3.5
Lung Microvascular EC none       9.2
Lung Microvascular EC TNFalpha + IL-1beta 7.5
Microvascular Dermal EC none     9.0
Microsvasular Dermal EC TNFalpha + IL-1beta 4.4
Bronchial epithelium TNFalpha + IL1beta 6.5
Small airway epithelium none     6.0
Small airway epithelium TNFalpha + IL-1beta 25.3
Coronery artery SMC rest         7.5
Coronery artery SMC TNFalpha + IL-1beta 4.0
Astrocytes rest                  5.5
Astrocytes TNFalpha + IL-1beta   12.2
KU-812 (Basophil) rest           41.5
KU-812 (Basophil) PMA/ionomycin  91.4
CCD1106 (Keratinocytes) none     3.6
CCD1106 (Keratinocytes) TNFalpha + IL-1beta 7.1
Liver cirrhosis                  25.3
Lupus kidney                     21.6
NCI-H292 none                    46.0
NCI-H292 IL-4                    43.8
NCI-H292 IL-9                    51.1
NCI-H292 IL-1 3                  26.2
NCI-H292 IFN gamma               23.5
HPAEC none                       3.8
HPAEC TNF alpha + IL-1 beta      10.2
Lung fibroblast none             7.3
Lung fibroblast TNF alpha + IL-1 beta 11.7
Lung fibroblast IL-4             6.8
Lung fibroblast IL-9             4.6
Lung fibroblast IL-13            4.8
Lung fibroblast IFN gamma        5.7
Dermal fibroblast CCD1070 rest   8.7
Dermal fibroblast CCD1070 TNF alpha 20.9
Dermal fibroblast CCD1070 IL-1 beta 3.3
Dermal fibroblast IFN gamma      3.2
Dermal fibroblast IL-4           7.0
IBD Colitis 2                    17.6
IBD Crohn's                      11.4
Colon                            93.3
Lung                             27.4
Thymus                           17.6
Kidney                           56.6

[1222]

TABLE AQG
general oncology screening panel_v_2.4
                               Rel. Exp. (%)
                               Ag3488, Run
Tissue Name                    259737914
Colon cancer 1                 6.9
Colon cancer NAT 1             2.9
Colon cancer 2                 4.4
Colon cancer NAT 2             2.6
Colon cancer 3                 27.4
Colon cancer NAT 3             3.5
Colon malignant cancer 4       12.6
Colon normal adjacent tissue 4 1.1
Lung cancer 1                  2.7
Lung NAT 1                     0.5
Lung cancer 2                  11.8
Lung NAT 2                     0.6
Squamous cell carcinoma 3      5.8
Lung NAT 3                     0.2
metastatic melanoma 1          3.2
Melanoma 2                     0.8
Melanoma 3                     0.7
metastatic melanoma 4          6.2
metastatic melanoma 5          4.7
Bladder cancer 1               0.7
Bladder cancer NAT 1           0.0
Bladder cancer 2               0.9
Bladder cancer NAT 2           0.3
Bladder cancer NAT 3           0.2
Bladder cancer NAT 4           0.8
Prostate adenocarcinoma 1      4.2
Prostate adenocarcinoma 2      0.8
Prostate adenocarcinoma 3      1.8
Prostate adenocarcinoma 4      6.7
Prostate cancer NAT 5          2.7
Prostate adenocarcinoma 6      1.7
Prostate adenocarcinoma 7      2.4
Prostate adenocarcinoma 8      0.6
Prostate adenocarcinoma 9      3.0
Prostate cancer NAT 10         0.3
Kidney cancer 1                11.3
Kidney NAT 1                   1.1
Kidney cancer 2                55.1
Kidney NAT 2                   2.8
Kidney cancer 3                100.0
Kidney NAT 3                   0.6
Kidney cancer 4                31.6
Kidney NAT 4                   0.8

[1223] CNS_neurodegeneration_v1.0 Summary: Ag3488 This panel does not show differential expression of this gene in Alzheimer's disease. However, this profile confirms the expression of this gene at moderate levels in the brain. Please see Panel 1.4 for discussion of utility of this gene in the central nervous system.

[1224] General_screening_panel_v1.4 Summary: Ag3488 Highest expression of this gene is seen in a renal cancer cell line (CT=23.2). This gene is widely expressed in this panel, with high to moderate levels of expression seen in brain, colon, gastric, lung, breast, ovarian, and melanoma cancer cell lines. This expression profile suggests a role for this gene product in cell survival and proliferation. Modulation of this gene product may be useful in the treatment of cancer.

[1225] Among tissues with metabolic function, this gene is expressed at high to moderate levels in pituitary, adipose, adrenal gland, pancreas, thyroid, and adult and fetal skeletal muscle, heart, and liver. This widespread expression among these tissues suggests that this gene product may play a role in normal neuroendocrine and metabolic function and that disregulated expression of this gene may contribute to neuroendocrine disorders or metabolic diseases, such as obesity and diabetes.

[1226] This gene is also expressed at moderate levels in the CNS, including the hippocampus, thalamus, substantia nigra, amygdala, cerebellum and cerebral cortex. Therefore, therapeutic modulation of the expression or function of this gene may be useful in the treatment of neurologic disorders, such as Alzheimer's disease, Parkinson's disease, schizophrenia, multiple sclerosis, stroke and epilepsy.

[1227] Panel 2.2 Summary: Ag3488 Highest expression is seen in a kidney cancer (CT=28). In addition, this gene is more highly expressed in kidney cancer than in the corresponding normal adjacent tissue. Thus, expression of this gene could be used as a marker of this cancer. Furthemore, therapeutic modulation of the expression or function of this gene product may be useful in the treatment of kidney cancer.

[1228] Panel 3D Summary: Ag3488 Highest expression is seen in a pancreatic cancer cell line (CT=29.6). Moderate levels of expression are also seen in many cancer cell lines on this panel. Please see Panel 1.4 for discussion of utility of this gene in cancer.

[1229] Panel 4D Summary: Ag3488 Highest expression is seen in resting monocytes (CT=25.3). This gene is also expressed at moderate levels in a wide range of cell types of significance in the immune response in health and disease. These cells include members of the T-cell, B-cell, endothelial cell, macrophage/monocyte, and peripheral blood mononuclear cell family, as well as epithelial and fibroblast cell types from lung and skin, and normal tissues represented by colon, lung, thymus and kidney. This ubiquitous pattern of expression suggests that this gene product may be involved in homeostatic processes for these and other cell types and tissues. This pattern is in agreement with the expression profile in General_screening_panel_v1.4 and also suggests a role for the gene product in cell survival and proliferation. Therefore, modulation of the gene product with a functional therapeutic may lead to the alteration of functions associated with these cell types and lead to improvement of the symptoms of patients suffering from autoimmune and inflammatory diseases such as asthma, allergies, inflammatory bowel disease, lupus erythematosus, psoriasis, rheumatoid arthritis, and osteoarthritis.

[1230] General oncology screening_panel_v—2.4 Summary: Ag3488 Highest expression is seen in kidney cancer (CT=23.2). In addition, this gene is more highly expressed in colon and kidney cancer than in the corresponding normal adjacent tissue. Thus, expression of this gene could be used as a marker of these cancers. Furthemore, therapeutic modulation of the expression or function of this gene product may be useful in the treatment of colon and kidney cancer.

[1231] AR. CG92142-01: Glycerol-3-Phosphate Acyltransferase.

[1232] Expression of gene CG92142-01 was assessed using the primer-probe set Ag3774, described in Table ARA. Results of the RTQ-PCR runs are shown in Tables ARB, ARC, ARD, ARE and ARF.

TABLE ARA
Probe Name Ag3774
			Start	SEQ ID
Primers	Sequences	Length	Position	No
Forward	5′-ggtgctgctaaaactgttcaac-3′	22	673	612
Probe	TET-5′-tggaacattcaaattcacaaaggtca-3′-TAMRA	26	704	613
Reverse	5′-attcgtctcagttgcagcttt-3′	21	743	614

[1233]

TABLE ARB
CNS_neurodegeneration_v1.0
                               Rel. Exp. (%)
                               Ag3774, Run
Tissue Name                    206871268
AD 1 Hippo                     29.1
AD 2 Hippo                     73.7
AD 3 Hippo                     10.0
AD 4 Hippo                     14.6
AD 5 Hippo                     92.0
AD 6 Hippo                     45.1
Control 2 Hippo                44.1
Control 4 Hippo                20.3
Control (Path) 3 Hippo         19.9
AD 1 Temporal Ctx              20.6
AD 2 Temporal Ctx              75.3
AD 3 Temporal Ctx              13.4
AD 4 Temporal Ctx              45.1
AD 5 Inf Temporal Ctx          100.0
AD 5 Sup Temporal Ctx          78.5
AD 6 Inf Temporal Ctx          43.5
AD 6 Sup Temporal Ctx          50.7
Control 1 Temporal Ctx         25.5
Control 2 Temporal Ctx         46.7
Control 3 Temporal Ctx         57.0
Control 3 Temporal Ctx         25.2
Control (Path) 1 Temporal Ctx  66.4
Control (Path) 2 Temporal Ctx  52.1
Control (Path) 3 Temporal Ctx  29.3
Control (Path) 4 Temporal Ctx  50.3
AD 1 Occipital Ctx             22.4
AD 2 Occipital Ctx (Missing)   0.0
AD 3 Occipital Ctx             20.3
AD 4 Occipital Ctx             33.9
AD 5 Occipital Ctx             37.6
AD 6 Occipital Ctx             24.7
Control 1 Occipital Ctx        11.3
Control 2 Occipital Ctx        48.0
Control 3 Occipital Ctx        43.5
Control 4 Occipital Ctx        21.2
Control (Path) 1 Occipital Ctx 81.8
Control (Path) 2 Occipital Ctx 12.9
Control (Path) 3 Occipital Ctx 13.6
Control (Path) 4 Occipital Ctx 45.1
Control 1 Parietal Ctx         25.2
Control 2 Parietal Ctx         84.7
Control 3 Parietal Ctx         41.2
Control (Path) 1 Parietal Ctx  91.4
Control (Path) 2 Parietal Ctx  38.2
Control (Path) 3 Parietal Ctx  19.1
Control (Path) 4 Parietal Ctx  48.0

[1234]

TABLE ARC
General_screening_panel_v1.4
                                 Rel. Exp. (%)
                                 Ag3774, Run
Tissue Name                      213515543
Adipose                          63.7
Melanoma* Hs688(A).T             16.0
Melanoma* Hs688(B).T             74.7
Melanoma* M14                    10.2
Melanoma* LOXIMVI                76.8
Melanoma* SK-MEL-5               23.8
Squamous cell carcinoma SCC-4    5.8
Testis Pool                      12.8
Prostate ca.* (bone met) PC-3    10.3
Prostate Pool                    2.3
Placenta                         1.3
Uterus Pool                      1.6
Ovarian ca. OVCAR-3              10.6
Ovarian ca. SK-OV-3              15.6
Ovarian ca. OVCAR-4              5.4
Ovarian ca. OVCAR-5              6.3
Ovarian ca. IGROV-1              5.5
Ovarian ca. OVCAR-8              4.9
Ovary                            4.0
Breast ca. MCF-7                 11.7
Breast ca. MDA-MB-231            8.5
Breast ca. BT 549                6.5
Breast ca. T47D                  8.9
Breast ca. MDA-N                 10.7
Breast Pool                      5.0
Trachea                          10.6
Lung                             1.0
Fetal Lung                       6.2
Lung ca. NCI-N417                3.2
Lung ca. LX-1                    9.3
Lung ca. NCI-H146                2.9
Lung ca. SHP-77                  16.2
Lung ca. A549                    7.6
Lung ca. NCI-H526                1.9
Lung ca. NCI-H23                 12.7
Lung ca. NCI-H460                7.7
Lung ca. HOP-62                  6.0
Lung ca. NCI-H522                17.6
Liver                            16.3
Fetal Liver                      70.7
Liver ca. HepG2                  42.9
Kidney Pool                      8.5
Fetal Kidney                     6.6
Renal ca. 786-0                  10.3
Renal ca. A498                   2.5
Renal ca. ACHN                   7.3
Renal ca. UO-31                  7.2
Renal ca. TK-10                  21.5
Bladder                          6.3
Gastric ca. (liver met.) NCI-N87 9.7
Gastric ca. KATO III             16.5
Colon ca. SW-948                 3.3
Colon ca. SW480                  12.9
Colon ca.* (SW480 met) SW620     8.6
Colon ca. HT29                   4.1
Colon ca. HCT-116                25.3
Colon ca. CaCo-2                 52.5
Colon cancer tissue              10.4
Colon ca. SW1116                 3.0
Colon ca. Colo-205               2.9
Colon ca. SW-48                  2.5
Colon Pool                       4.5
Small Intestine Pool             5.9
Stomach Pool                     3.3
Bone Marrow Pool                 2.8
Fetal Heart                      3.1
Heart Pool                       4.0
Lymph Node Pool                  7.2
Fetal Skeletal Muscle            11.0
Skeletal Muscle Pool             10.9
Spleen Pool                      5.3
Thymus Pool                      7.6
CNS cancer (glio/astro) U87-MG   9.7
CNS cancer (glio/astro) U-118-MG 19.1
CNS cancer (neuro; met) SK-N-AS  22.1
CNS cancer (astro) SF-539        5.9
CNS cancer (astro) SNB-75        22.5
CNS cancer (glio) SNB-19         5.0
CNS cancer (glio) SF-295         100.0
Brain (Amygdala) Pool            2.9
Brain (cerebellum)               2.4
Brain (fetal)                    17.9
Brain (Hippocampus) Pool         5.9
Cerebral Cortex Pool             7.5
Brain (Substantia nigra) Pool    5.8
Brain (Thalamus) Pool            8.1
Brain (whole)                    8.4
Spinal Cord Pool                 4.8
Adrenal Gland                    65.5
Pituitary gland Pool             1.0
Salivary Gland                   3.0
Thyroid (female)                 3.8
Pancreatic ca. CAPAN2            5.4
Pancreas Pool                    5.7

[1235]

TABLE ARD
Panel 2.2
                                 Rel. Exp. (%)
                                 Ag3774, Run
Tissue Name                      174448446
Normal Colon                     7.9
Colon cancer (OD06064)           4.9
Colon Margin (OD06064)           3.6
Colon cancer (OD06159)           0.2
Colon Margin (OD06159)           2.8
Colon cancer (OD06297-04)        0.6
Colon Margin (OD06297-05)        2.3
CC Gr.2 ascend colon (ODO3921)   0.5
CC Margin (ODO3921)              1.0
Colon cancer metastasis (OD06104) 1.6
Lung Margin (OD06104)            1.1
Colon mets to lung (OD04451-01)  2.2
Lung Margin (OD04451-02)         2.3
Normal Prostate                  0.6
Prostate Cancer (OD04410)        1.2
Prostate Margin (OD04410)        1.2
Normal Ovary                     1.0
Ovarian cancer (OD06283-03)      1.0
Ovarian Margin (OD06283-07)      10.1
Ovarian Cancer 064008            3.3
Ovarian cancer (OD06145)         2.1
Ovarian Margin (OD06145)         2.4
Ovarian cancer (OD06455-03)      1.7
Ovarian Margin (OD06455-07)      1.3
Normal Lung                      3.1
Invasive poor diff. lung adeno (ODO4945-01 1.4
Lung Margin (ODO4945-03)         2.2
Lung Malignant Cancer (OD03126)  2.0
Lung Margin (OD03126)            0.7
Lung Cancer (OD05014A)           1.2
Lung Margin (OD05014B)           7.1
Lung cancer (OD06081)            0.1
Lung Margin (OD06081)            2.0
Lung Cancer (OD04237-01)         1.0
Lung Margin (OD04237-02)         2.6
Ocular Melanoma Metastasis       7.5
Ocular Melanoma Margin (Liver)   19.5
Melanoma Metastasis              2.0
Melanoma Margin (Lung)           3.6
Normal Kidney                    1.6
Kidney Ca, Nuclear grade 2 (OD04338) 3.3
Kidney Margin (OD04338)          1.3
Kidney Ca Nuclear grade 1/2 (OD04339) 2.2
Kidney Margin (OD04339)          2.2
Kidney Ca, Clear cell type (OD04340) 0.7
Kidney Margin (OD04340)          4.0
Kidney Ca, Nuclear grade 3 (OD04348) 0.9
Kidney Margin (OD04348)          8.7
Kidney malignant cancer (OD06204B) 2.2
Kidney normal adjacent tissue (OD06204E) 0.4
Kidney Cancer (OD04450-01)       3.4
Kidney Margin (OD04450-03)       3.3
Kidney Cancer 8120613            0.8
Kidney Margin 8120614            1.0
Kidney Cancer 9010320            1.6
Kidney Margin 9010321            0.2
Kidney Cancer 8120607            0.8
Kidney Margin 8120608            0.3
Normal Uterus                    5.0
Uterine Cancer 064011            1.1
Normal Thyroid                   0.3
Thyroid Cancer 064010            0.6
Thyroid Cancer A302152           2.2
Thyroid Margin A302153           2.9
Normal Breast                    61.6
Breast Cancer (OD04566)          2.7
Breast Cancer 1024               4.8
Breast Cancer (OD04590-01)       4.8
Breast Cancer Mets (OD04590-03)  30.1
Breast Cancer Metastasis (OD04655-05) 6.0
Breast Cancer 064006             2.0
Breast Cancer 9100266            1.5
Breast Margin 9100265            3.6
Breast Cancer A209073            1.1
Breast Margin A2090734           5.8
Breast cancer (OD06083)          4.2
Breast cancer node metastasis (OD06083) 12.6
Normal Liver                     87.7
Liver Cancer 1026                12.5
Liver Cancer 1025                100.0
Liver Cancer 6004-T              63.7
Liver Tissue 6004-N              4.8
Liver Cancer 6005-T              28.5
Liver Tissue 6005-N              67.8
Liver Cancer 064003              12.2
Normal Bladder                   2.3
Bladder Cancer 1023              0.3
Bladder Cancer A302173           1.4
Normal Stomach                   6.0
Gastric Cancer 9060397           0.9
Stomach Margin 9060396           1.7
Gastric Cancer 9060395           1.9
Stomach Margin 9060394           2.3
Gastric Cancer 064005            1.9

[1236]

TABLE ARE
Panel 4.1D
                                 Rel. Exp. (%)
                                 Ag3774, Run
Tissue Name                      170130276
Secondary Th1 act                39.8
Secondary Th2 act                44.4
Secondary Tr1 act                33.7
Secondary Th1 rest               9.5
Secondary Th2 rest               11.4
Secondary Tr1 rest               12.2
Primary Th1 act                  36.6
Primary Th2 act                  39.8
Primary Tr1 act                  28.9
Primary Th1 rest                 24.8
Primary Th2 rest                 11.7
Primary Tr1 rest                 23.2
CD45RA CD4 lymphocyte act        45.1
CD45RO CD4 lymphocyte act        45.1
CD8 lymphocyte act               49.0
Secondary CD8 lymphocyte rest    31.2
Secondary CD8 lymphocyte act     22.1
CD4 lymphocyte none              11.0
2ry Th1/Th2/Tr1_anti-CD95 CH11   15.9
LAK cells rest                   18.7
LAK cells IL-2                   31.4
LAK cells IL-2 + IL-12           25.3
LAK cells IL-2 + IFN gamma       46.7
LAK cells IL-2 + IL-18           32.8
LAK cells PMA/ionomycin          3.9
NK Cells IL-2 rest               30.8
Two Way MLR 3 day                23.3
Two Way MLR 5 day                37.6
Two Way MLR 7 day                17.8
PBMC rest                        4.1
PBMC PWM                         35.4
PBMC PHA-L                       20.9
Ramos (B cell) none              76.8
Ramos (B cell) ionomycin         68.8
B lymphocytes PWM                41.2
B lymphocytes CD40L and IL-4     28.9
EOL-1 dbcAMP                     17.4
EOL-1 dbcAMP PMA/ionomycin       20.9
Dendritic cells none             21.0
Dendritic cells LPS              5.7
Dendritic cells anti-CD40        22.5
Monocytes rest                   7.9
Monocytes LPS                    2.6
Macrophages rest                 22.2
Macrophages LPS                  4.5
HUVEC none                       29.7
HUVEC starved                    34.6
HUVEC IL-1beta                   38.2
HUVEC IFN gamma                  39.0
HUVEC TNF alpha + IFN gamma      19.1
HUVEC TNF alpha + IL4            28.1
HUVEC IL-11                      25.2
Lung Microvascular EC none       32.3
Lung Microvascular EC TNFalpha + IL-1beta 36.3
Microvascular Dermal EC none     26.4
Microsvasular Dermal EC TNFalpha + IL-1beta 23.3
Bronchial epithelium TNFalpha + IL1beta 38.4
Small airway epithelium none     24.1
Small airway epithelium TNFalpha + IL-1beta 28.9
Coronery artery SMC rest         31.4
Coronery artery SMC TNFalpha + IL-1beta 24.5
Astrocytes rest                  46.3
Astrocytes TNFalpha + IL-1beta   12.1
KU-812 (Basophil) rest           37.9
KU-812 (Basophil) PMA/ionomycin  49.3
CCD1106 (Keratinocytes) none     56.3
CCD1106 (Keratinocytes) TNFalpha + IL-1beta 34.6
Liver cirrhosis                  38.4
NCI-H292 none                    25.2
NCI-H292 IL-4                    36.3
NCI-H292 IL-9                    47.6
NCI-H292 IL-13                   37.1
NCI-H292 IFN gamma               49.3
HPAEC none                       27.7
HPAEC TNF alpha + IL-1 beta      31.9
Lung fibroblast none             44.1
Lung fibroblast TNF alpha + IL-1 beta 17.0
Lung fibroblast IL-4             34.9
Lung fibroblast IL-9             62.4
Lung fibroblast IL-13            42.0
Lung fibroblast IFN gamma        25.2
Dermal fibroblast CCD1070 rest   100.0
Dermal fibroblast CCD1070 TNF alpha 66.4
Dermal fibroblast CCD1070 IL-1 beta 38.2
Dermal fibroblast IFN gamma      17.0
Dermal fibroblast IL-4           47.3
Dermal Fibroblasts rest          29.5
Neutrophils TNFa + LPS           0.0
Neutrophils rest                 2.3
Colon                            15.4
Lung                             23.8
Thymus                           68.3
Kidney                           49.3

[1237]

TABLE ARF
Panel 5D
                                 Rel. Exp. (%)
                                 Ag3774, Run
Tissue Name                      223675472
97457_Patient-02go_adipose       17.7
97476_Patient-07sk_skeletal muscle 3.6
97477_Patient-07ut_uterus        2.3
97478_Patient-07pl_placenta      2.2
97481_Patient-08sk_skeletal muscle 6.4
97482_Patient-08ut_uterus        1.6
97483_Patient-08pl_placenta      0.8
97486_Patient-09sk_skeletal muscle 0.5
97487_Patient-09ut_uterus        2.1
97488_Patient-09pl_placenta      0.8
97492_Patient-10ut_uterus        1.6
97493_Patient-10pl_placenta      1.4
97495_Patient-11go_adipose       10.4
97496_Patient-11sk_skeletal muscle 2.8
97497_Patient-11ut_uterus        2.1
97498_Patient-11pl_placenta      1.8
97500_Patient-12go_adipose       13.5
97501_Patient-12sk_skeletal muscle 6.0
97502_Patient-12ut_uterus        2.6
97503_Patient-12pl_placenta      0.4
94721_Donor 2 U - A_Mesenchymal Stem Cells 3.5
94722_Donor 2 U - B_Mesenchymal Stem Cells 3.7
94723_Donor 2 U - C_Mesenchymal Stem Cells 2.7
94709_Donor 2 AM - A_adipose     19.6
94710_Donor 2 AM - B_adipose     9.3
94711_Donor 2 AM - C_adipose     7.5
94712_Donor 2 AD - A_adipose     56.6
94713_Donor 2 AD - B_adipose     72.2
94714_Donor 2 AD - C_adipose     70.2
94742_Donor 3 U - A_Mesenchymal Stem Cells 1.6
94743_Donor 3 U - B_Mesenchymal Stem Cells 1.8
94730_Donor 3 AM - A_adipose     13.1
94731_Donor 3 AM - B_adipose     8.5
94732_Donor 3 AM - C_adipose     8.7
94733_Donor 3 AD - A_adipose     100.0
94734_Donor 3 AD - B_adipose     62.9
94735_Donor 3 AD - C_adipose     53.2
77138_Liver_HepG2untreated       56.6
73556_Heart_Cardiac stromal cells (primary) 0.5
81735_Small Intestine            2.3
72409_Kidney_Proximal Convoluted Tubule 1.0
82685_Small intestine_Duodenum   1.6
90650_Adrenal_Adrenocortical adenoma 4.6
72410_Kidney_HRCE                3.3
72411_Kidney_HRE                 2.7
73139_Uterus_Uterine smooth muscle cells 1.2

[1238] CNS_neurodegeneration_v1.0 Summary: Ag3774 This panel confirms the expression of the CG92142-01 gene at low levels in the brains of an independent group of individuals. However, no differential expression of this gene was detected between Alzheimer's diseased postmortem brains and those of non-demented controls in this experiment. Please see Panel 1.4 for a discussion of the potential utility of this gene in treatment of central nervous system disorders.

[1239] General_screening_panel_v1.4 Summary: Ag3774 Highest expression of the CG92142-01 gene is detected in CNS cancer (glio) SF-295 cell line (CT=26). High expression of this gene is also in number of cancer cell lines (pancreatic, CNS, colon, gastric, renal, lung, breast, ovarian, squamous cell carcinoma, prostate and melanoma). Therefore, therapeutic modulation of the activity of this gene or its protein product, through the use of small molecule drugs might be beneficial in the treatment of these cancers.

[1240] Among tissues with metabolic or endocrine function, this gene is expressed at high to moderate levels in pancreas, adipose, adrenal gland, thyroid, pituitary gland, skeletal muscle, heart, liver and the gastrointestinal tract. Therefore, therapeutic modulation of the activity of this gene may prove useful in the treatment of endocrine/metabolically related diseases, such as obesity and diabetes.

[1241] The CG92142-01 gene codes for mitochondrial glycerol-3-phosphate acyltransferase (GPAT). GPAT is an adipocyte determination and differentiation factor 1 (ADD 1) and sterol regulatory element-binding protein-1 (SREBP- 1) regulated differentiation gene (Ref.1). It is up-regulated by insulin and high-carbohydrate diets (Ref.2). GPAT up-regulation increases triglyceride (TG) synthesis and fat deposition. Inhibition of GPAT activiy could lead to decreased TG synthesis and fat deposition. Troglitazone, a thiazolidinedione compound used to treat non-insulin-dependent diabetes mellitus (NIDDM), was shown to decreases GPAT activity and adipogenesis in ZDF rat islets (ref.3). Therefore, therapeutic modulation of the activity of this gene may prove useful in the treatment of diabetes.

[1242] In addition, this gene is expressed at moderate levels in all regions of the central nervous system examined, including amygdala, hippocampus, substantia nigra, thalamus, cerebellum, cerebral cortex, and spinal cord. Therefore, this gene may play a role in central nervous system disorders such as Alzheimer's disease, Parkinson's disease, epilepsy, multiple sclerosis, schizophrenia and depression.

[1243] References.

[1244] 1. Ericsson J, Jackson S M, Kim J B, Spiegelman B M, Edwards P A. (1997) Identification of glycerol-3-phosphate acyltransferase as an adipocyte determination and differentiation factor 1- and sterol regulatory element-binding protein-responsive gene. J Biol Chem 272(11):7298-305. PMID: 9054427

[1245] 2. Dircks L K, Sul H S. (1997) Mammalian mitochondrial glycerol-3-phosphate acyltransferase. Biochim Biophys Acta 1348(1-2):17-26 PMID: 9370312

[1246] 3. Shimabukuro M, Zhou Y T, Lee Y, Unger R H. (1998) Troglitazone lowers islet fat and restores beta cell function of Zucker diabetic fatty rats. J Biol Chem 273(6):3547-50 PMID: 9452481.

[1247] Panel 2.2 Summary: Ag3774 Highest expression of the CG92142-01 gene is detected in liver cancer 1025 sample (CT=28.7). In addition, low to moderate expression of this gene is seen in number of cancer and normal samples used in this panel. Please see Panel 1.4 for a discussion of the potential utility of this gene.

[1248] Panel 4.1D Summary: Ag3774 Highest expression of the CG92142-01 gene is detected in resting dermal fibroblast CCD1070 (CT=31). This gene is expressed at low to moderate levels in a wide range of cell types of significance in the immune response in health and disease. These cells include members of the T-cell, B-cell, endothelial cell, macrophage/monocyte, and peripheral blood mononuclear cell family, as well as epithelial and fibroblast cell types from lung and skin, and normal tissues represented by colon, lung, thymus and kidney. This ubiquitous pattern of expression suggests that this gene product may be involved in homeostatic processes for these and other cell types and tissues. This pattern is in agreement with the expression profile in General_screening_panel_v1.4 and also suggests a role for the gene product in cell survival and proliferation. Therefore, modulation of the gene product with a functional therapeutic may lead to the alteration of functions associated with these cell types and lead to improvement of the symptoms of patients suffering from autoimmune and inflammatory diseases such as asthma, allergies, inflammatory bowel disease, lupus erythematosus, psoriasis, rheumatoid arthritis, and osteoarthritis.

[1249] Interestingly, expression of this gene is stimulated in PWM treated PBMC cells (CT=32.5) as compared to resting PBMC (35.6). Therefore, expression of this gene can be used to distinguish between resting and stimulated PBMC cells.

[1250] Panel 5D Summary: Ag3774 Highest expression of the CG92142-01 gene is detected in 94733_Donor 3 AD-A_adipose sample(CT=27.6). In addition, high to moderated expression of this gene is also seen in number of adipose, small intestine, uterus, skeletal muscle, placenta and mesenchymal stem cell samples. Please see Panel 1.4 for a discussion of the potential utility of this gene.

[1251] AS. CG98102-03: Diamine AcetylTransferase.

[1252] Expression of gene CG98102-03 was assessed using the primer-probe sets Ag4695, Ag4700, Ag4705 and Ag5877, described in Tables ASA, ASB, ASC and ASD. Results of the RTQ-PCR runs are shown in Tables ASE, ASF and ASG.

TABLE ASA
Probe Name Ag4695
			Start	SEQ ID
Primers	Sequences	Length	Position	No
Forward	5′-gccagcctgactgagaaga-3′	19	968	615
Probe	TET-5′-agacgaatgaggaaccacctcctcct-3′-TAMRA	26	929	616
Reverse	5′-caacaatgctgtgtccttcc-3′	20	658	617

[1253]

TABLE ASB
Probe Name Ag4700
			Start	SEQ ID
Primers	Sequences	Length	Position	No
Forward	5′-caatctcagatgcagtttgga-3′	21	174	618
Probe	TET-5′-tcagatctttctccttgaatatctttcga-3′-TAMRA	29	142	619
Reverse	5′-agatcacaccaccttgttgttt-3′	22	119	620

[1254]

TABLE ASC
Probe Name Ag4705
			Start	SEQ ID
Primers	Sequences	Length	Position	No
Forward	5′-ggctaaatatgaatacatggaag-3′	23	781	621
Probe	TET-5′-ttttggagagcaccccttttaccac-3′-TAMRA	25	716	622
Reverse	5′-atgctgtgtccttccg-3′	16	663	623

[1255]

TABLE ASD
Probe Name Ag5877
			Start	SEQ ID
Primers	Sequences	Length	Position	No
Forward	5′-aagaggtgcttctgatctgtcc-3′	22	428	624
Probe	TET-5′tgaagagggttggagactgttcaagatcg-3′-TAMRA	29	397	625
Reverse	5′-catctacagcagcactcctcac-3′	22	341	626

[1256]

TABLE ASE
General_screening_panel_v1.4
	Rel.	Rel.	Rel.
	Exp. (%)	Exp. (%)	Exp. (%)
	Ag4695,	Ag4700,	Ag4705,
Tissue	Run	Run	Run
Name	219997539	222825527	213821747
Adipose	16.8	45.7	12.6
Melanoma*	2.8	1.2	2.8
Hs688(A).T
Melanoma*	3.1	1.3	2.0
Hs688(B).T
Melanoma* M14	25.5	13.7	18.4
Melanoma*	1.0	0.6	1.8
LOXIMVI
Melanoma*	11.9	19.5	14.2
SK-MEL-5
Squamous cell	3.1	2.3	0.8
carcinoma SCC-4
Testis Pool	5.6	3.1	4.5
Prostate ca. *	16.7	8.4	17.3
(bone met) PC-3
Prostate Pool	4.9	5.5	2.2
Placenta	20.0	6.9	0.1
Uterus Pool	1.0	11.6	0.3
Ovarian ca.	4.2	6.4	4.7
OVCAR-3
Ovarian ca.	7.5	8.5	9.3
SK-OV-3
Ovarian ca.	1.7	1.2	1.5
OVCAR-4
Ovarian ca.	8.0	27.9	9.2
OVCAR-5
Ovarian ca.	32.5	83.5	40.9
IGROV-1
Ovarian ca.	9.1	20.7	4.1
OVCAR-8
Ovary	5.1	5.6	4.9
Breast ca. MCF-7	1.6	3.1	2.0
Breast ca.	2.6	10.6	2.9
MDA-MB-231
Breast ca. BT 549	25.5	9.0	22.2
Breast ca. T47D	16.6	71.2	19.2
Breast ca. MDA-N	33.4	46.7	40.9
Breast Pool	10.4	19.3	7.5
Trachea	41.5	20.4	38.2
Lung	0.9	24.1	0.9
Fetal Lung	80.1	82.9	65.1
Lung ca. NCI-N417	0.2	0.1	0.3
Lung ca. LX-1	50.7	82.4	53.6
Lung ca. NCI-H146	0.6	0.3	0.8
Lung ca. SHP-77	0.8	1.8	1.2
Lung ca. A549	27.2	28.1	23.7
Lung ca. NCI-H526	0.8	1.1	1.1
Lung ca. NCI-H23	43.2	100.0	66.9
Lung ca. NCI-H460	0.6	8.5	1.0
Lung ca. HOP-62	3.6	23.8	5.1
Lung ca. NCI-H522	2.9	6.4	3.5
Liver	3.5	0.8	1.4
Fetal Liver	20.6	5.4	14.0
Liver ca. HepG2	11.6	19.6	16.7
Kidney Pool	6.1	36.6	0.0
Fetal Kidney	5.4	5.6	0.2
Renal ca. 786-0	13.3	9.0	8.1
Renal ca. A498	4.9	2.4	5.8
Renal ca. ACHN	1.7	2.2	1.9
Renal ca. UO-31	34.6	11.2	5.1
Renal ca. TK-10	9.4	14.4	11.3
Bladder	100.0	67.4	100.0
Gastric ca. (liver	7.3	10.6	8.1
met.) NCI-N87
Gastric ca.	90.8	22.8	55.9
KATO III
Colon ca. SW-948	6.3	3.4	2.0
Colon ca. SW480	26.4	20.9	28.7
Colon ca. *	35.4	50.0	38.2
(SW480 met) SW620
Colon ca. HT29	3.0	4.4	3.8
Colon ca. HCT-116	21.5	27.9	31.0
Colon ca. CaCo-2	12.9	7.5	13.8
Colon cancer	36.3	54.0	45.4
tissue
Colon ca. SW1116	0.4	1.1	1.0
Colon ca.	13.1	4.0	5.6
Colo-205
Colon ca. SW-48	6.7	2.3	3.9
Colon Pool	5.1	12.2	4.8
Small Intestine	1.5	12.4	1.9
Pool
Stomach Pool	24.3	31.6	17.6
Bone Marrow	2.3	17.7	1.4
Pool
Fetal Heart	1.8	2.1	2.2
Heart Pool	1.9	6.9	2.0
Lymph Node Pool	6.6	20.0	8.3
Fetal Skeletal	0.7	1.5	0.7
Muscle
Skeletal	0.7	2.0	0.9
Muscle Pool
Spleen Pool	5.2	25.3	8.7
Thymus Pool	8.7	37.4	11.1
CNS cancer (glio/	14.9	17.7	12.6
astro) U87-MG
CNS cancer (glio/	16.7	12.1	18.0
astro) U-118-MG
CNS cancer	0.4	1.2	1.0
(neuro; met)
SK-N-AS
CNS cancer	0.6	1.3	0.9
(astro) SF-539
CNS cancer	63.3	83.5	64.6
(astro) SNB-75
CNS cancer	27.5	54.7	37.9
(glio) SNB-19
CNS cancer	50.7	72.7	66.0
(glio) SF-295
Brain (Amygdala)	2.9	4.9	3.5
Pool
Brain	1.1	1.0	1.2
(cerebellum)
Brain (fetal)	6.0	4.2	6.0
Brain	7.8	6.7	5.7
(Hippocampus)
Pool
Cerebral	3.6	5.9	6.9
Cortex Pool
Brain	5.1	6.0	7.9
(Substantia
nigra) Pool
Brain (Thalamus)	5.7	6.5	8.6
Pool
Brain (whole)	5.4	2.7	11.2
Spinal Cord Pool	6.2	10.1	7.0
Adrenal Gland	12.8	5.1	14.7
Pituitary gland	2.4	2.0	4.0
Pool
Salivary Gland	4.1	0.9	5.4
Thyroid (female)	23.8	10.4	5.6
Pancreatic ca.	8.0	10.3	9.7
CAPAN2
Pancreas Pool	11.8	21.6	17.0

[1257]

TABLE ASF
General_screening_panel_v1.5
                                 Rel. Exp. (%)
                                 Ag5877, Run
Tissue Name                      248204736
Adipose                          41.2
Melanoma* Hs688(A).T             3.9
Melanoma* Hs688(B).T             5.5
Melanoma* M14                    40.3
Melanoma* LOXIMVI                1.8
Melanoma* SK-MEL-5               20.6
Squamous cell carcinoma SCC-4    7.1
Testis Pool                      7.5
Prostate ca.* (bone met) PC-3    16.4
Prostate Pool                    17.0
Placenta                         38.2
Uterus Pool                      7.4
Ovarian ca. OVCAR-3              6.0
Ovarian ca. SK-OV-3              8.8
Ovarian ca. OVCAR-4              3.2
Ovarian ca. OVCAR-5              22.5
Ovarian ca. IGROV-1              67.8
Ovarian ca. OVCAR-8              22.1
Ovary                            10.7
Breast ca. MCF-7                 3.3
Breast ca. MDA-MB-231            9.0
Breast ca. BT 549                18.3
Breast ca. T47D                  14.2
Breast ca. MDA-N                 33.0
Breast Pool                      13.8
Trachea                          38.2
Lung                             4.1
Fetal Lung                       95.9
Lung ca. NCI-N417                0.3
Lung ca. LX-1                    84.1
Lung ca. NCI-H146                0.5
Lung ca. SHP-77                  1.9
Lung ca. A549                    43.8
Lung ca. NCI-H526                0.7
Lung ca. NCI-H23                 77.9
Lung ca. NCI-H460                9.9
Lung ca. HOP-62                  5.8
Lung ca. NCI-H522                8.6
Liver                            3.3
Fetal Liver                      17.0
Liver ca. HepG2                  21.3
Kidney Pool                      15.3
Fetal Kidney                     8.5
Renal ca. 786-0                  8.1
Renal ca. A498                   6.3
Renal ca. ACHN                   2.6
Renal ca. UO-31                  32.1
Renal ca. TK-10                  15.7
Bladder                          100.0
Gastric ca. (liver met.) NCI-N87 17.1
Gastric ca. KATO III             58.2
Colon ca. SW-948                 6.6
Colon ca. SW480                  30.8
Colon ca.* (SW480 met) SW620     62.4
Colon ca. HT29                   4.3
Colon ca. HCT-116                34.9
Colon ca. CaCo-2                 12.4
Colon cancer tissue              59.0
Colon ca. SW1116                 1.5
Colon ca. Colo-205               6.3
Colon ca. SW-48                  4.2
Colon Pool                       8.4
Small Intestine Pool             2.4
Stomach Pool                     22.1
Bone Marrow Pool                 6.4
Fetal Heart                      3.4
Heart Pool                       4.5
Lymph Node Pool                  12.7
Fetal Skeletal Muscle            1.5
Skeletal Muscle Pool             2.7
Spleen Pool                      20.6
Thymus Pool                      21.0
CNS cancer (glio/astro) U87-MG   20.9
CNS cancer (glio/astro) U-118-MG 15.5
CNS cancer (neuro; met) SK-N-AS  1.5
CNS cancer (astro) SF-539        0.9
CNS cancer (astro) SNB-75        74.2
CNS cancer (glio) SNB-19         80.7
CNS cancer (glio) SF-295         66.0
Brain (Amygdala) Pool            4.9
Brain (cerebellum)               3.4
Brain (fetal)                    6.4
Brain (Hippocampus) Pool         8.3
Cerebral Cortex Pool             6.0
Brain (Substantia nigra) Pool    5.4
Brain (Thalamus) Pool            7.5
Brain (whole)                    5.8
Spinal Cord Pool                 9.2
Adrenal Gland                    15.9
Pituitary gland Pool             5.6
Salivary Gland                   4.3
Thyroid (female)                 28.1
Pancreatic ca. CAPAN2            13.7
Pancreas Pool                    22.8

[1258]

TABLE ASG
Panel 5D
	Rel.	Rel.	Rel.	Rel.	Rel.
	Exp. (%)	Exp. (%)	Exp. (%)	Exp. (%)	Exp. (%)
	Ag4695,	Ag4695,	Ag4700,	Ag4700,	Ag4705,
	Run	Run	Run	Run	Run
Tissue Name	200923963	204244772	200923964	204244775	204245092
97457_Patient-02go_adipose	21.5	23.3	77.9	94.6	24.1
97476_Patient-07sk_skeletal	3.5	4.5	52.1	47.3	4.9
muscle
97477_Patient-07ut_uterus	8.7	7.1	25.9	18.0	6.6
97478_Patient-07pl_placenta	66.9	69.7	100.0	100.0	69.7
97481_Patient-08sk_skeletal	1.0	1.1	66.4	72.2	3.0
muscle
97482_Patient-08ut_uterus	1.6	8.0	10.9	7.2	7.4
97483_Patient-08pl_placenta	30.1	30.6	39.2	54.0	26.6
97486_Patient-09sk_skeletal	0.8	0.5	9.7	10.2	0.5
muscle
97487_Patient-09ut_uterus	4.9	3.1	21.2	14.5	4.3
97488_Patient-09pl_placenta	35.6	54.7	77.9	65.1	47.3
97492_Patient-10ut_uterus	8.8	10.7	34.2	25.5	8.3
97493_Patient-10pl_placenta	100.0	100.0	79.0	97.9	100.0
97495_Patient-11go_adipose	7.2	7.0	40.9	36.3	6.9
97496_Patient-11sk_skeletal	0.9	0.8	12.3	6.7	1.7
muscle
97497_Patient-11ut_uterus	10.8	10.2	17.1	27.0	23.7
97498_Patient-11pl_placenta	61.1	76.8	80.7	58.2	50.3
97500_Patient-12go_adipose	10.2	0.0	70.2	57.8	12.7
97501_Patient-12sk_skeletal	1.8	1.7	17.9	21.6	2.8
muscle
97502_Patient-12ut_uterus	14.5	13.2	35.8	51.1	18.4
97503_Patient-12pl_placenta	72.2	70.7	72.7	52.5	68.8
94721_Donor 2 U -	3.0	2.7	4.1	3.6	9.5
A_Mesenchymal Stem Cells
94722_Donor 2 U -	2.1	2.9	3.6	3.3	3.3
B_Mesenchymal Stem Cells
94723_Donor 2 U -	2.0	0.1	4.0	2.7	2.3
C_Mesenchymal Stem Cells
94709_Donor 2 AM - A_adipose	9.0	10.4	6.8	8.8	8.8
94710_Donor 2 AM - B_adipose	6.5	5.5	5.8	2.9	5.2
94711_Donor 2 AM - C_adipose	4.2	2.9	4.3	6.0	3.4
94712_Donor 2 AD - A_adipose	7.2	8.0	16.2	11.7	7.6
94713_Donor 2 AD - B_adipose	9.6	12.2	13.7	11.8	12.2
94714_Donor 2 AD - C_adipose	8.8	9.7	9.3	7.0	12.9
94742_Donor 3 U -	1.0	0.7	2.2	1.2	1.1
A_Mesenchymal Stem Cells
94743_Donor 3 U -	1.5	1.3	2.9	4.0	1.9
B_Mesenchymal Stem Cells
94730_Donor 3 AM - A_adipose	14.0	12.8	22.7	15.6	9.8
94731_Donor 3 AM - B_adipose	7.2	29.1	7.0	10.8	6.8
94732_Donor 3 AM - C_adipose	5.7	9.2	9.5	11.9	9.0
94733_Donor 3 AD - A_adipose	17.2	20.3	17.0	20.6	15.3
94734_Donor 3 AD - B_adipose	9.7	6.9	11.7	6.7	7.1
94735_Donor 3 AD - C_adipose	11.1	11.9	19.2	13.8	10.3
77138_Liver_HepG2untreated	27.5	27.5	34.2	39.2	23.3
73556_Heart_Cardiac stromal	3.5	3.0	10.0	8.0	7.2
cells (primary)
81735_Small Intestine	13.3	12.1	49.0	48.0	15.5
72409_Kidney_Proximal	5.8	5.1	15.0	8.4	5.6
Convoluted Tubule
82685_Small	17.9	19.5	60.3	44.8	28.1
intestine_Duodenum
90650_Adrenal_Adrenocortical	2.7	0.0	25.3	24.3	4.9
adenoma
72410_Kidney_HRCE	30.1	33.4	39.0	38.7	25.0
72411_Kidney_HRE	28.5	23.2	40.9	50.0	22.4
73139_Uterus_Uterine smooth	2.0	1.1	4.5	3.9	1.4
muscle cells

[1259] General_screening_panel_v1.4 Summary: Ag4695/Ag4700/Ag4705 Three experiments using three probe-primer sets gave results that are in good agreement. This gene is expressed at moderate to high levels in all of the tissues on this panel, with highest expression in bladder and a lung cancer cell line (CTs=24-28). Interestingly, expression of this gene is higher in fetal lung and lung cancer cell lines when compared to adult lung. Expression of this gene is also upregulated in colon cancer cell lines when compared to normal colon. Therefore, therapeutic modulation of the activity of this gene or its protein product, through the use of small molecule drugs, protein therapeutics or antibodies, might be beneficial in the treatment of lung and colon cancer.

[1260] In addition, this gene is expressed at moderate levels in all regions of the central nervous system examined, including amygdala, hippocampus, substantia nigra, thalamus, cerebellum, cerebral cortex, and spinal cord. Therefore, this gene may play a role in central nervous system disorders such as Alzheimer's disease, Parkinson's disease, epilepsy, multiple sclerosis, schizophrenia and depression.

[1261] Among tissues with metabolic or endocrine function, this gene is expressed at high to moderate levels in pancreas, adipose, adrenal gland, thyroid, pituitary gland, skeletal muscle, heart, liver and the gastrointestinal tract. Therefore, therapeutic modulation of the activity of this gene may prove useful in the treatment of endocrine/metabolically related diseases, such as obesity and diabetes.

[1262] General_screening_panel_v1.5 Summary: Ag5877 Expression of this gene is highest in bladder (CT=23.6). This gene is expressed at moderate to high levels in all of the tissues on this panel, consistent with what is observed in Panel 1.4. Interestingly, expression of this gene is higher in fetal lung (CT=23.7)and a subset of lung cancer cell lines (CTs=24) when compared to adult lung (CT=28.2). Expression of this gene is also upregulated in colon cancer cell lines (CTs=24) when compared to normal colon (CT=27.2). Therefore, therapeutic modulation of the activity of this gene or its protein product, through the use of small molecule drugs, protein therapeutics or antibodies, might be beneficial in the treatment of lung and colon cancer. Please see Panel 1.4 for additional discussion of the potential relevance of this gene in human disease.

[1263] Panel SD Summary: Ag4695/Ag4705 Three experiments using two probe-primer sets gave results that are in good agreement. This gene is expressed at moderate to high levels in the majority of metabolic tissues on this panel, with highest expression in a placenta sample from a diabetic patient (CTs=23-28). Ag4700 Two experiment with same probe-primer sets are in excellent agreement. This gene shows widespread expression with highest expression of this gene in placenta of non-diabetic patient (CTs=30-30.7).

[1264] Spermine has been demonstrated to enhance insulin receptor binding in a dose dependent manner [Pedersen et al., Mol Cell Endocrinol., 1989 April;62(2): 161-6]. Thus, it was proposed that polyamines may act as intracellular or intercellular (autocrine) regulators to modulate insulin binding. It has also been shown that the insulin-like effects elicited by polyamines in fat cells (e.g. enhancement of glucose transport and inhibition of cAMP-mediated lipolysis) are dependent on H202 production (Livingston et al., J. Biol. Chem., Jan. 25, 1977;252(2):560-2). Inhibiting polyamine catabolism through an inhibitor of this rate-limiting enzyme may abolish the insulin-like antilipolytic effects of polyamines. Therefore, therapeutic inhibition of the activity of this gene using small molecule drugs may be of benefit in the treatment of obesity.

Example D

[1265] Identification of Single Nucleotide Polymorphisms in NOVX Nucleic Acid Sequences

[1266] Variant sequences are also included in this application. A variant sequence can include a single nucleotide polymorphism (SNP). A SNP can, in some instances, be referred to as a “cSNP” to denote that the nucleotide sequence containing the SNP originates as a cDNA. A SNP can arise in several ways. For example, a SNP may be due to a substitution of one nucleotide for another at the polymorphic site. Such a substitution can be either a transition or a transversion. A SNP can also arise from a deletion of a nucleotide or an insertion of a nucleotide, relative to a reference allele. In this case, the polymorphic site is a site at which one allele bears a gap with respect to a particular nucleotide in another allele. SNPs occurring within genes may result in an alteration of the amino acid encoded by the gene at the position of the SNP. Intragenic SNPs may also be silent, when a codon including a SNP encodes the same amino acid as a result of the redundancy of the genetic code. SNPs occurring outside the region of a gene, or in an intron within a gene, do not result in changes in any amino acid sequence of a protein but may result in altered regulation of the expression pattern. Examples include alteration in temporal expression, physiological response regulation, cell type expression regulation, intensity of expression, and stability of transcribed message.

[1267] SeqCalling assemblies produced by the exon linking process were selected and extended using the following criteria. Genomic clones having regions with 98% identity to all or part of the initial or extended sequence were identified by BLASTN searches using the relevant sequence to query human genomic databases. The genomic clones that resulted were selected for further analysis because this identity indicates that these clones contain the genomic locus for these SeqCalling assemblies. These sequences were analyzed for putative coding regions as well as for similarity to the known DNA and protein sequences. Programs used for these analyses include Grail, Genscan, BLAST, HMMER, FASTA, Hybrid and other relevant programs.

[1268] Some additional genomic regions may have also been identified because selected SeqCalling assemblies map to those regions. Such SeqCalling sequences may have overlapped with regions defined by homology or exon prediction. They may also be included because the location of the fragment was in the vicinity of genomic regions identified by similarity or exon prediction that had been included in the original predicted sequence. The sequence so identified was manually assembled and then may have been extended using one or more additional sequences taken from CuraGen Corporation's human SeqCalling database. SeqCalling fragments suitable for inclusion were identified by the CuraTools™ program SeqExtend or by identifying SeqCalling fragments mapping to the appropriate regions of the genomic clones analyzed.

[1269] The regions defined by the procedures described above were then manually integrated and corrected for apparent inconsistencies that may have arisen, for example, from miscalled bases in the original fragments or from discrepancies between predicted exon junctions, EST locations and regions of sequence similarity, to derive the final sequence disclosed herein. When necessary, the process to identify and analyze SeqCalling assemblies and genomic clones was reiterated to derive the full length sequence (Alderborn et al., Determination of Single Nucleotide Polymorphisms by Real-time Pyrophosphate DNA Sequencing. Genome Research. 10 (8) 1249-1265, 2000).

[1270] Variants are reported individually but any combination of all or a select subset of variants are also included as contemplated NOVX embodiments of the invention.

[1271] Results:

[1272] NOV 3b SNP Data

[1273] Two polymorphic variants of NOV3b have been identified and are shown in Table 3S.

	TABLE 3S
	Nucleotides	Amino Acids
	Base			Base
Variant	Position	Wild-		Position	Wild-
No.	of SNP	type	Variant	of SNP	type	Variant
13381488	314	C	T	65	Ser	Ser
13381501	803	G	T	228	Val	Val

[1274] NOV 5b SNP Data

[1275] One polymorphic variant of NOV5b has been identified and are shown in Table 5S.

	TABLE 5S
	Nucleotides	Amino Acids
	Base			Base
Variant	Position	Wild-		Position	Wild-
No.	of SNP	type	Variant	of SNP	type	Variant
13381503	3017	G	A	999	Lys	Lys

[1276] NOV 8a SNP Data

[1277] Four polymorphic variants of NOV8a have been identified and are shown in Table 8S.

	TABLE 8S
	Nucleotides	Amino Acids
	Base			Base
Variant	Position	Wild-		Position	Wild-
No.	of SNP	type	Variant	of SNP	type	Variant
c34c-	981	G	C	324	Leu	Leu
cip1.113
13381270	1033	A	G	342	Met	Val
13381350	1042	A	G	345	Ile	Val
13376329	1222	T	C	405	Ser	Pro

[1278] NOV 9a SNP Data

[1279] Four polymorphic variants of NOV9a have been identified and are shown in Table 9S.

	TABLE 9S
	Nucleotides	Amino Acids
	Base			Base
Variant	Position	Wild-		Position	Wild-
No.	of SNP	type	Variant	of SNP	type	Variant
13381343	276	C	T	92	Phe	Phe
13381344	1045	G	T	349	Ala	Ser
13381348	1416	C	T	472	Gly	Gly
13381345	1802	G	C	601	Gly	Ala

[1280] NOV 10a SNP Data

[1281] One polymorphic variant of NOV10a has been identified and are shown in Table 10S.

	TABLE 10S
	Nucleotides	Amino Acids
	Base			Base
Variant	Position	Wild-		Position	Wild-
No.	of SNP	type	Variant	of SNP	type	Variant
13379513	1447	C	T	423	Pro	Pro

[1282] NOV 12a SNP Data

[1283] Two polymorphic variants of NOV12a have been identified and are shown in Table 12S.

	TABLE 12S
	Nucleotides	Amino Acids
	Base			Base
Variant	Position	Wild-		Position	Wild-
No.	of SNP	type	Variant	of SNP	type	Variant
13379505	139	C	T	15	Pro	Ser
13379506	221	C	T	42	Ser	Phe

[1284] NOV 13a SNP Data

[1285] Thirteen polymorphic variants of NOV13a have been identified and are shown in Table 13S.

	TABLE 13S
	Nucleotides	Amino Acids
	Base			Base
Variant	Position	Wild-		Position	Wild-
No.	of SNP	type	Variant	of SNP	type	Variant
13376183	75	A	G	2	Gln	Gln
13376184	182	C	T	38	Ala	Val
13376185	184	G	A	39	Ala	Thr
13376186	223	A	G	52	Thr	Ala
13376187	256	C	T	63	Arg	Cys
13376188	328	A	G	87	Asn	Asp
13376189	347	C	T	93	Ala	Val
13376190	373	A	G	102	Thr	Ala
13376191	1257	C	T	396	Thr	Thr
13376192	1342	A	G	425	Ser	Gly
13376193	1549	G	A	494	Val	Met
13376194	1581	G	A	504	Thr	Thr
13381349	1607	A	G	513	Gln	Arg

[1286] NOV 14a SNP Data

[1287] One polymorphic variant of NOV14a has been identified and are shown in Table 14S.

	TABLE 14S
	Nucleotides	Amino Acids
	Base			Base
Variant	Position	Wild-		Position	Wild-
No.	of SNP	type	Variant	of SNP	type	Variant
13376195	402	T	C	134	Ala	Ala

[1288] NOV 19 SNP Data

[1289] One polymorphic variant of NOV19 has been identified and are shown in Table 19S.

	TABLE 19S
	Nucleotides	Amino Acids
	Base			Base
Variant	Position	Wild-		Position	Wild-
No.	of SNP	type	Variant	of SNP	type	Variant
13381369	1380	G	C	460	Ala	Ala

[1290] NOV 20c SNP Data

[1291] One polymorphic variant of NOV20c has been identified and are shown in Table 20S.

	TABLE 20S
	Nucleotides	Amino Acids
	Base			Base
Variant	Position	Wild-		Position	Wild-
No.	of SNP	type	Variant	of SNP	type	Variant
13381370	281	C	T	94	Thr	Met

[1292] NOV 48a SNP Data

[1293] One polymorphic variant of NOV48a has been identified and are shown in Table 48S.

	TABLE 48S
	Nucleotides	Amino Acids
	Base			Base
Variant	Position	Wild-		Position	Wild-
No.	of SNP	type	Variant	of SNP	type	Variant
13381473	532	C	G	145	Gln	Glu

[1294] NOV 50a SNP Data

[1295] Two polymorphic variants of NOV50a have been identified and are shown in Table 50S.

	TABLE 50S
	Nucleotides	Amino Acids
	Base			Base
Variant	Position	Wild-		Position	Wild-
No.	of SNP	type	Variant	of SNP	type	Variant
13381514	744	A	G	242	Ser	Gly
13381513	1009	T	C	330	Leu	Ser

[1296] NOV 53b SNP Data

[1297] Six polymorphic variants of NOV53b have been identified and are shown in Table 53S.

	TABLE 53S
	Nucleotides	Amino Acids
	Base			Base
Variant	Position	Wild-		Position	Wild-
No.	of SNP	type	Variant	of SNP	type	Variant
13374617	437	A	G	143	Asn	Ser
13375310	664	T	G	219	Phe	Val
13375309	1150	G	T	381	Ala	Ser
13375308	1210	G	T	401	Glu	End
13375307	1770	C	T	587	Asn	Asn
13374615	2011	A	G	0

[1298] NOV 45b SNP Data

[1299] Two polymorphic variants of NOV54b have been identified and are shown in Table 54S.

	TABLE 54S
	Nucleotides	Amino Acids
	Base			Base
Variant	Position	Wild-		Position	Wild-
No.	of SNP	type	Variant	of SNP	type	Variant
13381471	472	G	A	145	Pro	Pro
13381470	1082	A	G	0

[1300] NOV 55a SNP Data

[1301] One polymorphic variant of NOV55a has been identified and are shown in Table 55S.

	TABLE 55S
	Nucleotides	Amino Acids
	Base			Base
Variant	Position	Wild-		Position	Wild-
No.	of SNP	type	Variant	of SNP	type	Variant
13375795	1070	C	T	236	Arg	Trp

[1302] NOV 56a SNP Data

[1303] Six polymorphic variant of NOV56a has been identified and are shown in Table 56S.

	TABLE 56S
	Nucleotides	Amino Acids
	Base			Base
Variant	Position	Wild-		Position	Wild-
No.	of SNP	type	Variant	of SNP	type	Variant
13375586	430	T	C	110	Ser	Ser
13375585	492	A	G	131	Glu	Gly
13375583	1756	C	T	552	Asn	Asn
13375582	2143	T	A	681	Pro	Pro
13377559	2550	A	G	817	Lys	Arg
13377776	2555	C	T	819	Leu	Leu

[1304] NOV 57b SNP Data

[1305] Two polymorphic variants of NOV57b have been identified and are shown in Table 57S.

	TABLE 57S
	Nucleotides	Amino Acids
	Base			Base
Variant	Position	Wild-		Position	Wild-
No.	of SNP	type	Variant	of SNP	type	Variant
13376786	1433	G	A	455	Cys	Tyr
13376785	1435	A	G	456	Lys	Glu

[1306] NOV 58a SNP Data

[1307] Two polymorphic variant of NOV58a has been identified and are shown in Table 58S.

	TABLE 58S
	Nucleotides	Amino Acids
	Base			Base
Variant	Position	Wild-		Position	Wild-
No.	of SNP	type	Variant	of SNP	type	Variant
13381335	499	G	A	145	Glu	Glu
13381336	1045	C	T	327	Asn	Asn

[1308] NOV 59b SNP Data

[1309] Three polymorphic variant of NOV59b has been identified and are shown in Table 59S.

	TABLE 59S
	Nucleotides	Amino Acids
	Base			Base
Variant	Position	Wild-		Position	Wild-
No.	of SNP	type	Variant	of SNP	type	Variant
13379479	21	T	C	0
13381483	183	C	T	2	Ala	Val
13381482	520	C	T	114	Ser	Ser

Example E

[1310] Method of Use

[1311] The present invention is partially based on the identification of biological macromolecules differentially modulated in a pathologic state, disease, or an abnormal condition or state, and/or based on novel associations of proteins and polypeptides and the nucleic acids that encode them, as identified in a yeast 2-hybrid screen using a cDNA library or one-by-one matrix reactions. Among the pathologies or diseases of present interest include metabolic diseases including those related to endocrinologic disorders, cancers, various tumors and neoplasias, inflammatory disorders, central nervous system disorders, and similar abnormal conditions or states. Important metabolic disorders with which the biological macromolecules are associated include obesity and diabetes mellitus, especially obesity and Type II diabetes. It is believed that obesity predisposes a subject to Type II diabetes. In very significant embodiments of the present invention, the biological macromolecules implicated in these pathologies and conditions are proteins and polypeptides, and in such cases the present invention is related as well to the nucleic acids that encode them. Methods that may be employed to identify relevant biological macromolecules include any procedures that detect differential expression of nucleic acids encoding proteins and polypeptides associated with the disorder, as well as procedures that detect the respective proteins and polypeptides themselves. Significant methods that have been employed by the present inventors, include GeneCalling® technology and SeqCalling™ technology, disclosed respectively, in U.S. Pat. No. 5,871,697, and in U.S. Ser. No. 09/417,386, filed Oct. 13, 1999, each of which is incorporated herein by reference in its entirety. GeneCalling® is also described in Shimkets, et al., Nature Biotechnology 17:198-803 (1999).

[1312] The invention provides polypeptides and nucleotides encoded thereby that have been identified as having novel associations with a disease or pathology, or an abnormal state or condition, in a mammal. Included in the invention are nucleic acid sequences and their encoded polypeptides. The sequences are collectively referred to as “obesity and/or diabetes nucleic acids” or “obesity and/or diabetes polynucleotides” and the corresponding encoded polypeptide is referred to as an “obesity and/or diabetes polypeptide” or “obesity and/or diabetes protein”. For example, an obesity and/or diabetes nucleic acid according to the invention is a nucleic acid including an obesity and/or diabetes nucleic acid, and an obesity and/or diabetes polypeptide according to the invention is a polypeptide that includes the amino acid sequence of an obesity and/or diabetes polypeptide. Unless indicated otherwise, “obesity and/or diabetes” is meant to refer to any of the sequences having novel associations disclosed herein.

[1313] The present invention identifies a set of proteins and polypeptides, including naturally occurring polypeptides, precursor forms or proproteins, or mature forms of the polypeptides or proteins, which are implicated as targets for therapeutic agents in the treatment of various diseases, pathologies, abnormal states and conditions. A target may be employed in any of a variety of screening methodologies in order to identify candidate therapeutic agents which interact with the target and in so doing exert a desired or favorable effect. The candidate therapeutic agent is identified by screening a large collection of substances or compounds in an important embodiment of the invention. Such a collection may comprise a combinatorial library of substances or compounds in which, in at least one subset of substances or compounds, the individual members are related to each other by simple structural variations based on a particular canonical or basic chemical structure. The variations may include, by way of nonlimiting example, changes in length or identity of a basic framework of bonded atoms; changes in number, composition and disposition of ringed structures, bridge structures, alicyclic rings, and aromatic rings; and changes in pendent or substituents atoms or groups that are bonded at particular positions to the basic framework of bonded atoms or to the ringed structures, the bridge structures, the alicyclic structures, or the aromatic structures.

[1314] The present invention discloses novel associations of proteins and polypeptides and the nucleic acids that encode them, as identified in a yeast 2-hybrid screen using a cDNA library or one-by-one matrix reactions. The proteins and related proteins that are similar to them are encoded by a cDNA and/or by genomic DNA and were identified in some cases by CuraGen Corporation.

[1315] In the current invention, protein interactions may include the interaction of a protein fragment with full-length protein, a protein fragment with another protein fragment, or full-length proteins with each other. The protein interactions disclosed in the present invention may also represent significant discoveries of functional importance to specific diseases or pathological conditions in which novel proteins are found to be components of known pathways, known proteins are found to be components of novel pathways, or novel proteins are found to be components of novel pathways.

[1316] A polypeptide or protein described herein, and that serves as a target in the screening procedure, includes the product of a naturally occurring polypeptide or precursor form or proprotein. The naturally occurring polypeptide, precursor or proprotein includes, e.g., the full-length gene product, encoded by the corresponding gene. The naturally occurring polypeptide also includes the polypeptide, precursor or proprotein encoded by an open reading frame described herein. A “mature” form of a polypeptide or protein arises as a result of one or more naturally occurring processing steps as they may occur within the cell, including a host cell. The processing steps occur as the gene product arises, e.g., via cleavage of the amino-terminal methionine residue encoded by the initiation codon of an open reading frame, or the proteolytic cleavage of a signal peptide or leader sequence. Thus, a mature form arising from a precursor polypeptide or protein that has residues 1 to N, where residue 1 is the N-terminal methionine, would have residues 2 through N remaining. Alternatively, a mature form arising from a precursor polypeptide or protein having residues 1 to N, in which an amino-terminal signal sequence from residue 1 to residue M is cleaved, includes the residues from residue M+1 to residue N remaining. A “mature” form of a polypeptide or protein may also arise from non-proteolytic post-translational modification. Such non-proteolytic processes include, e.g., glycosylation, myristylation or phosphorylation. In general, a mature polypeptide or protein may result from the operation of only one of these processes, or the combination of any of them.

[1317] As used herein, “identical” residues correspond to those residues in a comparison between two sequences where the equivalent nucleotide base or amino acid residue in an alignment of two sequences is the same residue. Residues are alternatively described as “similar” or “positive” when the comparisons between two sequences in an alignment show that residues in an equivalent position in a comparison are either the same amino acid or a conserved amino acid as defined below.

[1318] As used herein, a “chemical composition” relates to a composition including at least one compound that is either synthesized or extracted from a natural source. A chemical compound may be the product of a defined synthetic procedure. Such a synthesized compound is understood herein to have defined properties in terms of molecular formula, molecular structure relating the association of bonded atoms to each other, physical properties such as electropherographic or spectroscopic characterizations, and the like. A compound extracted from a natural source is advantageously analyzed by chemical and physical methods in order to provide a representation of its defined properties, including its molecular formula, molecular structure relating the association of bonded atoms to each other, physical properties such as electropherographic or spectroscopic characterizations, and the like.

[1319] As used herein, a “candidate therapeutic agent” is a chemical compound that includes at least one substance shown to bind to a target biopolymer. In important embodiments of the invention, the target biopolymer is a protein or polypeptide, a nucleic acid, a polysaccharide or proteoglycan, or a lipid such as a complex lipid. The method of identifying compounds that bind to the target effectively eliminates compounds with little or no binding affinity, thereby increasing the potential that the identified chemical compound may have beneficial therapeutic applications. In cases where the “candidate therapeutic agent” is a mixture of more than one chemical compound, subsequent screening procedures may be carried out to identify the particular substance in the mixture that is the binding compound, and that is to be identified as a candidate therapeutic agent.

[1320] As used herein, a “pharmaceutical agent” is provided by screening a candidate therapeutic agent using models for a disease state or pathology in order to identify a candidate exerting a desired or beneficial therapeutic effect with relation to the disease or pathology. Such a candidate that successfully provides such an effect is termed a pharmaceutical agent herein. Nonlimiting examples of model systems that may be used in such screens include particular cell lines, cultured cells, tissue preparations, whole tissues, organ preparations, intact organs, and nonhuman mammals. Screens employing at least one system, and preferably more than one system, may be employed in order to identify a pharmaceutical agent. Any pharmaceutical agent so identified may be pursued in further investigation using human subjects.

[1321] The following sections describe the study design(s) and the techniques used to identify these proteins, and any variants thereof, and to demonstrate its suitability as diagnostic markers, targets for an antibody therapeutic and targets for a small molecule drugs for Obesity and Diabetes.

[1322] Methods

[1323] 1. RTQ-PCR (Real Time Quantitative Polymerase Chain Reaction) Technology:

[1324] The quantitative expression of various clones was assessed using microtiter plates containing RNA samples from a variety of normal and pathology-derived cells, cell lines and tissues using real time quantitative PCR (RTQ PCR). RTQ PCR was performed on a Perkin-Elmer Biosystems ABI PRISMS® 7700 Sequence Detection System. Various collections of samples are assembled on the plates, and referred to as Panel 1 (containing cells and cell lines from normal and cancer sources), Panel 2 (containing samples derived from tissues, in particular from surgical samples, from normal and cancer sources), Panel 3 (containing samples derived from a wide variety of cancer sources), Panel 4 (containing cells and cell lines from normal cells and cells related to inflammatory conditions) and Panel CNSD.01 (containing samples from normal and diseased brains).

[1325] First, the RNA samples were normalized to reference nucleic acids such as constitutively expressed genes (for example, β-actin and GAPDH). Normalized RNA (5 ul) was converted to cDNA and analyzed by RTQ-PCR using One Step RT-PCR Master Mix Reagents (PE Biosystems; Catalog No. 4309169) and gene-specific primers according to the manufacturer's instructions. Probes and primers were designed for each assay according to Perkin Elmer Biosystem's Primer Express Software package (version I for Apple Computer's Macintosh Power PC) or a similar algorithm using the target sequence as input. Default settings were used for reaction conditions and the following parameters were set before selecting primers: primer concentration=250 nM, primer melting temperature (Tm) range=58°-60° C., primer optimal Tm=59° C., maximum primer difference=2° C., probe does not have 5′ G, probe Tm must be 10° C. greater than primer Tm, amplicon size 75 bp to 100 bp. The probes and primers selected (see below) were synthesized by Synthegen (Houston, Tex., USA). Probes were double purified by HPLC to remove uncoupled dye and evaluated by mass spectroscopy to verify coupling of reporter and quencher dyes to the 5′ and 3′ ends of the probe, respectively. Their final concentrations were: forward and reverse primers, 900 nM each, and probe, 200 nM.

[1326] PCR conditions: Normalized RNA from each tissue and each cell line was spotted in each well of a 96 well PCR plate (Perkin Elmer Biosystems). PCR cocktails including two probes (a probe specific for the target clone and another gene-specific probe multiplexed with the target probe) were set up using 1×TaqMan™ PCR Master Mix for the PE Biosystems 7700, with 5 mM MgCl2, dNTPs (dA, G, C, U at 1:1:1:2 ratios), 0.25 U/ml AmpliTaq Gold™ (PE Biosystems), and 0.4 U/μl RNase inhibitor, and 0.25 U/μl reverse transcriptase. Reverse transcription was performed at 48° C. for 30 minutes followed by amplification/PCR cycles as follows: 95° C. 10 min, then 40 cycles of 95° C. for 15 seconds, 60° C. for 1 minute. Results were recorded as CT values (cycle at which a given sample crosses a threshold level of fluorescence) using a log scale, with the difference in RNA concentration between a given sample and the sample with the lowest CT value being represented as 2 to the power of delta CT. The percent relative expression is then obtained by taking the reciprocal of this RNA difference and multiplying by 100.

[1327] In the results for Panel 1, the following abbreviations are used:

[1328] ca.=carcinoma,

[1329] *=established from metastasis,

[1330] met=metastasis,

[1331] s cell var=small cell variant,

[1332] non-s=non-sm=non-small,

[1333] squam=squamous,

[1334] p1. eff=pl effusion=pleural effusion,

[1335] glio=glioma,

[1336] astro=astrocytoma, and

[1337] neuro=neuroblastoma.

[1338] Panel 1.4

[1339] The plates for panel 1.4 include 2 control wells (genomic DNA control and chemistry control) and 94 wells containing cDNA from various samples. The samples in panel 1.4 are broken into 2 classes; samples derived from cultured cell lines and samples derived from primary normal tissues. The cell lines are derived from cancers of the following types: lung cancer, breast cancer, melanoma, colon cancer, prostate cancer, CNS cancer, squamous cell carcinoma, ovarian cancer, liver cancer, renal cancer, gastric cancer and pancreatic cancer. Cell lines used in panel 1.4 are widely available through the American Type Culture Collection, a repository for cultured cell lines. The normal tissues found on panel 1.4 are comprised of pools of samples from 2 to 5 different adult individuals derived from all major organ systems. These samples are derived from the following organs: adult skeletal muscle, fetal skeletal muscle, adult heart, fetal heart, adult kidney, fetal kidney, adult liver, fetal liver, adult lung, fetal lung, various regions of the brain, the spleen, bone marrow, lymph node, pancreas, salivary gland, pituitary gland, adrenal gland, spinal cord, thymus, stomach, small intestine, colon, bladder, trachea, breast, ovary, uterus, placenta, prostate, testis and adipose.

[1340] RNA integrity from all samples is controlled for quality by visual assessment of agarose gel electropherograms using 28S and 18S ribosomal RNA staining intensity ratio as a guide (2:1 to 2.5:1 28s: 18s) and the absence of low molecular weight RNAs that would be indicative of degradation products. Samples are controlled against genomic DNA contamination by RTQ PCR reactions run in the absence of reverse transcriptase using probe and primer sets designed to amplify across the span of a single exon.

[1341] Panel 2

[1342] The plates for Panel 2 generally include 2 control wells and 94 test samples composed of RNA or cDNA isolated from human tissue procured by surgeons working in close cooperation with the National Cancer Institute's Cooperative Human Tissue Network (CHTN) or the National Disease Research Initiative (NDRI). The tissues are derived from human malignancies and in cases where indicated many malignant tissues have “matched margins” obtained from noncancerous tissue just adjacent to the tumor. These are termed normal adjacent tissues and are denoted “NAT” in the results below. The tumor tissue and the “matched margins” are evaluated by two independent pathologists (the surgical pathologists and again by a pathologists at NDRI or CHTN). This analysis provides a gross histopathological assessment of tumor differentiation grade. Moreover, most samples include the original surgical pathology report that provides information regarding the clinical stage of the patient. These matched margins are taken from the tissue surrounding (i.e. immediately proximal) to the zone of surgery (designated “NAT”, for normal adjacent tissue, in Table RR). In addition, RNA and cDNA samples were obtained from various human tissues derived from autopsies performed on elderly people or sudden death victims (accidents, etc.). These tissue were ascertained to be free of disease and were purchased from various commercial sources such as Clontech (Palo Alto, Calf.), Research Genetics, and Invitrogen.

[1343] RNA integrity from all samples is controlled for quality by visual assessment of agarose gel electropherograms using 28S and 18S ribosomal RNA staining intensity ratio as a guide (2:1 to 2.5:1 28s:18s) and the absence of low molecular weight RNAs that would be indicative of degradation products. Samples are controlled against genomic DNA contamination by RTQ PCR reactions run in the absence of reverse transcriptase using probe and primer sets designed to amplify across the span of a single exon.

[1344] Panel 3D

[1345] The plates of Panel 3D are comprised of 94 cDNA samples and two control samples. Specifically, 92 of these samples are derived from cultured human cancer cell lines, 2 samples of human primary cerebellar tissue and 2 controls. The human cell lines are generally obtained from ATCC (American Type Culture Collection), NCI or the German tumor cell bank and fall into the following tissue groups: Squamous cell carcinoma of the tongue, breast cancer, prostate cancer, melanoma, epidermoid carcinoma, sarcomas, bladder carcinomas, pancreatic cancers, kidney cancers, leukemias/lymphomas, ovarian/uterine/cervical, gastric, colon, lung and CNS cancer cell lines. In addition, there are two independent samples of cerebellum. These cells are all cultured under standard recommended conditions and RNA extracted using the standard procedures. The cell lines in panel 3D and 1.3D are of the most common cell lines used in the scientific literature.

[1346] RNA integrity from all samples is controlled for quality by visual assessment of agarose gel electropherograms using 28S and 18S ribosomal RNA staining intensity ratio as a guide (2:1 to 2.5:1 28s: 18s) and the absence of low molecular weight RNAs that would be indicative of degradation products. Samples are controlled against genomic DNA contamination by RTQ PCR reactions run in the absence of reverse transcriptase using probe and primer sets designed to amplify across the span of a single exon.

[1347] Panel 4

[1348] Panel 4 includes samples on a 96 well plate (2 control wells, 94 test samples) composed of RNA (Panel 4r) or cDNA (Panel 4d) isolated from various human cell lines or tissues related to inflammatory conditions. Total RNA from control normal tissues such as colon and lung (Stratagene, La Jolla, Calif.) and thymus and kidney (Clontech) were employed. Total RNA from liver tissue from cirrhosis patients and kidney from lupus patients was obtained from BioChain (Biochain Institute, Inc., Hayward, Calif.). Intestinal tissue for RNA preparation from patients diagnosed as having Crohn's disease and ulcerative colitis was obtained from the National Disease Research Interchange (NDRI) (Philadelphia, Pa.).

[1349] Astrocytes, lung fibroblasts, dermal fibroblasts, coronary artery smooth muscle cells, small airway epithelium, bronchial epithelium, microvascular dermal endothelial cells, microvascular lung endothelial cells, human pulmonary aortic endothelial cells, human umbilical vein endothelial cells were all purchased from Clonetics (Walkersville, Md.) and grown in the media supplied for these cell types by Clonetics. These primary cell types were activated with various cytokines or combinations of cytokines for 6 and/or 12-14 hours, as indicated. The following cytokines were used; IL-1 beta at approximately 1-5 ng/ml, TNF alpha at approximately 5-10 ng/ml, IFN gamma at approximately 20-50 ng/ml, IL-4 at approximately 5-10 ng/ml, IL-9 at approximately 5-10 ng/ml, IL-13 at approximately 5-10 ng/ml. Endothelial cells were sometimes starved for various times by culture in the basal media from Clonetics with 0.1% serum.

[1350] Mononuclear cells were prepared from blood of employees at CuraGen Corporation, using Ficoll. LAK cells were prepared from these cells by culture in DMEM 5% FCS (Hyclone), 100 μM non essential amino acids (Gibco/Life Technologies, Rockville, Md.), 1 mM sodium pyruvate (Gibco), mercaptoethanol 5.5×10−5 M (Gibco), and 10 mM Hepes (Gibco) and Interleukin 2 for 4-6 days. Cells were then either activated with 10-20 ng/ml PMA and 1-2 μ/ml ionomycin, IL-12 at 5-10 ng/ml, IFN gamma at 20-50 ng/ml and IL-18 at 5-10 ng/ml for 6 hours. In some cases, mononuclear cells were cultured for 4-5 days in DMEM 5% FCS (Hyclone), 100 μM non essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), mercaptoethanol 5.5×10−5 M (Gibco), and 10 mM Hepes (Gibco) with PHA (phytohemagglutinin) or PWM (pokeweed mitogen) at approximately 5 μg/ml. Samples were taken at 24, 48 and 72 hours for RNA preparation. MLR (mixed lymphocyte reaction) samples were obtained by taking blood from two donors, isolating the mononuclear cells using Ficoll and mixing the isolated mononuclear cells 1:1 at a final concentration of approximately 2×106 cells/ml in DMEM 5% FCS (Hyclone), 100 μM non essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), mercaptoethanol (5.5×10−5 M) (Gibco), and 10 mM Hepes (Gibco). The MLR was cultured and samples taken at various time points ranging from 1-7 days for RNA preparation.

[1351] Monocytes were isolated from mononuclear cells using CD14 Miltenyi Beads, +ve VS selection columns and a Vario Magnet according to the manufacturer's instructions. Monocytes were differentiated into dendritic cells by culture in DMEM 5% fetal calf serum (FCS) (Hyclone, Logan, Utah), 100 μM non essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), mercaptoethanol 5.5×10−5 M (Gibco), and 10 mM Hepes (Gibco), 50 ng/ml GMCSF and 5 ng/ml IL-4 for 5-7 days. Macrophages were prepared by culture of monocytes for 5-7 days in DMEM 5% FCS (Hyclone), 100 μM non essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), mercaptoethanol 5.5×10−5 M (Gibco), 10 mM Hepes (Gibco) and 10% AB Human Serum or MCSF at approximately 50 ng/ml. Monocytes, macrophages and dendritic cells were stimulated for 6 and 12-14 hours with lipopolysaccharide (LPS) at 100 ng/ml. Dendritic cells were also stimulated with anti-CD40 monoclonal antibody (Pharmingen) at 10 μg/ml for 6 and 12-14 hours.

[1352] CD4 lymphocytes, CD8 lymphocytes and NK cells were also isolated from mononuclear cells using CD4, CD8 and CD56 Miltenyi beads, positive VS selection columns and a Vario Magnet according to the manufacturer's instructions. CD45RA and CD45RO CD4 lymphocytes were isolated by depleting mononuclear cells of CD8, CD56, CD14 and CD19 cells using CD8, CD56, CD14 and CD19 Miltenyi beads and +ve selection. Then CD45RO beads were used to isolate the CD45RO CD4 lymphocytes with the remaining cells being CD45RA CD4 lymphocytes. CD45RA CD4, CD45RO CD4 and CD8 lymphocytes were placed in DMEM 5% FCS (Hyclone), 100 μM non essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), mercaptoethanol 5.5×10−5 M (Gibco), and 10 mM Hepes (Gibco) and plated at 106 cells/ml onto Falcon 6 well tissue culture plates that had been coated overnight with 0.5 μg/ml anti-CD28 (Pharmingen) and 3 ug/ml anti-CD3 (OKT3, ATCC) in PBS. After 6 and 24 hours, the cells were harvested for RNA preparation. To prepare chronically activated CD8 lymphocytes, we activated the isolated CD8 lymphocytes for 4 days on anti-CD28 and anti-CD3 coated plates and then harvested the cells and expanded them in DMEM 5% FCS (Hyclone), 100 μM non essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), mercaptoethanol 5.5×10−5 M (Gibco), and 10 mM Hepes (Gibco) and IL-2. The expanded CD8 cells were then activated again with plate bound anti-CD3 and anti-CD28 for 4 days and expanded as before. RNA was isolated 6 and 24 hours after the second activation and after 4 days of the second expansion culture. The isolated NK cells were cultured in DMEM 5% FCS (Hyclone), 100 μM non essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), mercaptoethanol 5.5×10−5 M (Gibco), and 10 mM Hepes (Gibco) and IL-2 for 4-6 days before RNA was prepared.

[1353] To obtain B cells, tonsils were procured from NDRI. The tonsil was cut up with sterile dissecting scissors and then passed through a sieve. Tonsil cells were then spun down and resupended at 106 cells/ml in DMEM 5% FCS (Hyclone), 100 μM non essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), mercaptoethanol 5.5×10−5 M (Gibco), and 10 mM Hepes (Gibco). To activate the cells, we used PWM at 5 μg/ml or anti-CD40 (Pharmingen) at approximately 10 μg/ml and IL-4 at 5-10 ng/ml. Cells were harvested for RNA preparation at 24,48 and 72 hours.

[1354] To prepare the primary and secondary Th1/Th2 and Tr1 cells, six-well Falcon plates were coated overnight with 10 μg/ml anti-CD28 (Pharmingen) and 2 μg/ml OKT3 (ATCC), and then washed twice with PBS. Umbilical cord blood CD4 lymphocytes (Poietic Systems, German Town, Md.) were cultured at 105-106 cells/ml in DMEM 5% FCS (Hyclone), 100 μM non essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), mercaptoethanol 5.5×10−5 M (Gibco), 10 mM Hepes (Gibco) and IL-2 (4 ng/ml). IL-12 (5 ng/ml) and anti-IL4 (1 μg/ml) were used to direct to Th1, while IL-4 (5 ng/ml) and anti-IFN gamma (1 μg/ml) were used to direct to Th2 and IL-10 at 5 ng/ml was used to direct to Tr1. After 4-5 days, the activated Th1, Th2 and Tr1 lymphocytes were washed once in DMEM and expanded for 4-7 days in DMEM 5% FCS (Hyclone), 100 μM non essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), mercaptoethanol 5.5×10−5 M (Gibco), 10 mM Hepes (Gibco) and IL-2 (1 ng/ml). Following this, the activated Th1, Th2 and Tr1 lymphocytes were re-stimulated for 5 days with anti-CD28/OKT3 and cytokines as described above, but with the addition of anti-CD95L (1 μg/ml) to prevent apoptosis. After 4-5 days, the Th1, Th2 and Tr1 lymphocytes were washed and then expanded again with IL-2 for 4-7 days. Activated Th1 and Th2 lymphocytes were maintained in this way for a maximum of three cycles. RNA was prepared from primary and secondary Th1, Th2 and Tr1 after 6 and 24 hours following the second and third activations with plate bound anti-CD3 and anti-CD28 mAbs and 4 days into the second and third expansion cultures in Interleukin 2.

[1355] The following leukocyte cells lines were obtained from the ATCC: Ramos, EOL-1, KU-812. EOL cells were further differentiated by culture in 0.1 mM dbcAMP at 5×105 cells/ml for 8 days, changing the media every 3 days and adjusting the cell concentration to 5×105 cells/ml. For the culture of these cells, we used DMEM or RPMI (as recommended by the ATCC), with the addition of 5% FCS (Hyclone), 100 μM non essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), mercaptoethanol 5.5×10−5 M (Gibco), 10 mM Hepes (Gibco). RNA was either prepared from resting cells or cells activated with PMA at 10 ng/ml and ionomycin at 1 μg/ml for 6 and 14 hours. Keratinocyte line CCD106 and an airway epithelial tumor line NCI-H292 were also obtained from the ATCC. Both were cultured in DMEM 5% FCS (Hyclone), 100 μM non essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), mercaptoethanol 5.5×10−5 M (Gibco), and 10 mM Hepes (Gibco). CCD1106 cells were activated for 6 and 14 hours with approximately 5 ng/ml TNF alpha and 1 ng/ml IL-1 beta, while NCI-H292 cells were activated for 6 and 14 hours with the following cytokines: 5 ng/ml IL-4, 5 ng/ml IL-9, 5 ng/ml IL-13 and 25 ng/ml IFN gamma.

[1356] For these cell lines and blood cells, RNA was prepared by lysing approximately 107 cells/ml using Trizol (Gibco BRL). Briefly, 1/10 volume of bromochloropropane (Molecular Research Corporation) was added to the RNA sample, vortexed and after 10 minutes at room temperature, the tubes were spun at 14,000 rpm in a Sorvall SS34 rotor. The aqueous phase was removed and placed in a 15 ml Falcon Tube. An equal volume of isopropanol was added and left at −20 degrees C. overnight. The precipitated RNA was spun down at 9,000 rpm for 15 min in a Sorvall SS34 rotor and washed in 70% ethanol. The pellet was redissolved in 300 μl of RNAse-free water and 35 μl buffer (Promega) 5 μl DTT, 7 μl RNAsin and 8 μl DNAse were added. The tube was incubated at 37 degrees C. for 30 minutes to remove contaminating genomic DNA, extracted once with phenol chloroform and re-precipitated with 1/10 volume of 3 M sodium acetate and 2 volumes of 100% ethanol. The RNA was spun down and placed in RNAse free water. RNA was stored at −80 degrees C.

[1357] Panel 5D and 5I

[1358] The plates for Panel 5D and 5I include two control wells and a variety of cDNAs isolated from human tissues and cell lines with an emphasis on metabolic diseases. Metabolic tissues were obtained from patients enrolled in the Gestational Diabetes study. Cells were obtained during different stages in the differentiation of adipocytes from human mesenchymal stem cells. Human pancreatic islets were also obtained.

[1359] In the Gestational Diabetes study subjects are young (18-40 years), otherwise healthy women with and without gestational diabetes undergoing routine (elective) Caesarean section. After delivery of the infant, when the surgical incisions were being repaired/closed, the obstetrician removed a small sample (<1 cc) of the exposed metabolic tissues during the closure of each surgical level. The biopsy material was rinsed in sterile saline, blotted and fast frozen within 5 minutes from the time of removal. The tissue was then flash frozen in liquid nitrogen and stored, individually, in sterile screw-top tubes and kept on dry ice for shipment to or to be picked up by CuraGen. The metabolic tissues of interest include uterine wall (smooth muscle), visceral adipose, skeletal muscle (rectus) and subcutaneous adipose. Patient descriptions are as follows:

Patient 2   Diabetic Hispanic, overweight, not on insulin
Patient 7-9 Nondiabetic Caucasian and obese (BMI > 30)
Patient 10  Diabetic Hispanic, overweight, on insulin
Patient 11  Nondiabetic African American and overweight
Patient 12  Diabetic Hispanic on insulin

[1360] Adiocyte differentiation was induced in donor progenitor cells obtained from Osirus (a division of Clonetics/BioWhittaker) in triplicate except for Donor 3U which had only two replicates. Scientists at Clonetics isolated, grew and differentiated human mesenchymal stem cells (HuMSCs) for CuraGen based on the published protocol found in Mark F. Pittenger, et al., Multilineage Potential of Adult Human Mesenchymal Stem Cells Science Apr. 2, 1999: 143-147. Clonetics provided Trizol lysates or frozen pellets suitable for mRNA isolation and ds cDNA production. A general description of each donor is as follows:

Donor 2 and 3:	U	Mesenchymal	Undifferentiated
		Stem Cells
Donor 2 and 3:	AM	Adipose	Adipose Midway
			Differentiated
Donor 2 and 3:	AD	Adipose	Adipose Differentiated

[1361] Human cell lines were generally obtained from ATCC (American Type Culture Collection), NCI or the German tumor cell bank and fall into the following tissue groups: kidney proximal convoluted tubule, uterine smooth muscle cells, small intestine, liver HepG2 cancer cells, heart primary stromal cells, and adrenal cortical adenoma cells. These cells are all cultured under standard recommended conditions and RNA extracted using the standard procedures.

[1362] All samples were processed at CuraGen to produce single stranded cDNA. RNA integrity from all samples is controlled for quality by visual assessment of agarose gel electropherograms using 28S and 18S ribosomal RNA staining intensity ratio as a guide (2:1 to 2.5:1 28s:18s) and the absence of low molecular weight RNAs that would be indicative of degradation products. Samples are controlled against genomic DNA contamination by RTQ PCR reactions run in the absence of reverse transcriptase using probe and primer sets designed to amplify across the span of a single exon.

[1363] Panel 5I contains all samples previously described with the addition of pancreatic islets from a 58 year old female patient obtained from the Diabetes Research Institute at the University of Miami School of Medicine. Islet tissue was processed to total RNA at an outside source and delivered to CuraGen for addition to panel 5I.

[1364] In the labels employed to identify tissues in the 5D and 5I panels, the following abbreviations are used:

[1365] GO Adipose=Greater Omentum Adipose

[1366] SK=Skeletal Muscle

[1367] UT=Uterus

[1368] PL=Placenta

[1369] AD=Adipose Differentiated

[1370] AM=Adipose Midway Differentiated

[1371] U=Undifferentiated Stem Cells

[1372] Panel CNSD.01: Central Nervous System (CNS) Panel

[1373] The plates for Panel CNSD.01 include two control wells and 94 test samples comprised of cDNA isolated from postmortem human brain tissue obtained from the Harvard Brain Tissue Resource Center. Brains are removed from calvaria of donors between 4 and 24 hours after death, sectioned by neuroanatomists, and frozen at −80° C. in liquid nitrogen vapor. All brains are sectioned and examined by neuropathologists to confirm diagnoses with clear associated neuropathology.

[1374] Disease diagnoses are taken from patient records. The panel contains two brains from each of the following diagnoses: Alzheimer's disease, Parkinson's disease, Huntington's disease, Progressive Supernuclear Palsy, Depression, and “Normal controls”Within each of these brains, the following regions are represented: cingulate gyrus, temporal pole, globus palladus, substantia nigra, Brodmann Area 4 (primary motor strip), Brodmann Area 7 (parietal cortex), Brodmann Area 9 (prefrontal cortex), and Brodman area 17 (occipital cortex). Not all brain regions are represented in all cases; e.g., Huntington's disease is characterized in part by neurodegeneration in the globus palladus, thus this region is impossible to obtain from confirmed Huntington's cases. Likewise Parkinson's disease is characterized by degeneration of the substantia nigra making this region more difficult to obtain. Normal control brains were examined for neuropathology and found to be free of any pathology consistent with neurodegeneration.

[1375] RNA integrity from all samples is controlled for quality by visual assessment of agarose gel electropherograms using 28S and 18S ribosomal RNA staining intensity ratio as a guide (2:1 to 2.5:1 28s:18s) and the absence of low molecular weight RNAs that would be indicative of degradation products. Samples are controlled against genomic DNA contamination by RTQ PCR reactions run in the absence of reverse transcriptase using probe and primer sets designed to amplify across the span of a single exon.

[1376] In the labels employed to identify tissues in the CNS panel the following abbreviations are used:

[1377] PSP: Progressive supranuclear palsy

[1378] Sub Nigra: Substantia nigra

[1379] Glob Palladus: Globus pallidus

[1380] Temp Pole: Temporal pole

[1381] Cing Gyr: Cingulate gyrus

[1382] BA: Brodmann Area

[1383] Method of Identifying the Differentially Expressed Gene and Gene Product:

[1384] The GeneCalling™ method makes a comparison between experimental samples in the amount of each cDNA fragment generated by digestion with a unique pair of restriction endonucleases, after linker-adaptor ligation, PCR amplification and chromatographic separation. Computer analysis is employed to assign potential identity to the gene fragment. Three methods are routinely used in the identification of a gene fragment found to have altered expression in models of or patients with obesity and/or diabetes.

[1385] Direct Sequencing: The differentially expressed gene fragment is isolated, cloned into a plasmid and sequenced. Afterwards the sequence information is used to design an oligonucleotide corresponding to either or both termini of the gene fragment. This oligonucleotide, when used in a competitive PCR reaction, will ablate the chromatographic band from which the sequence is derived.

[1386] Competitive PCR: In competitive PCR, the chromatographic peaks corresponding to the gene fragment of the gene of interest are ablated when a gene-specific primer (designed from the sequenced band or available databases) competes with primers in the linker-adaptors during the PCR amplification.

[1387] PCR with Perfect or Mismatched 3′ Nucleotides (Trapping): This method utilizes a competitive PCR approach using a degenerate set of primers that extend one or two nucleotides into the gene-specific region of the fragment beyond the flanking restriction sites. As in the competitive PCR approach, primers that lead to the ablation of the chromatographic band add additional sequence information. In conjunction with the size of the gene fragment and the 12 nucleotides of sequence derived from the restriction sites, this additional sequence data can uniquely define the gene after database analysis.

[1388] Antibodies

[1389] The invention further encompasses antibodies and antibody fragments, such as Fab, (Fab)2 or single chain FV constructs, that bind immunospecifically to any of the proteins of the invention. Also encompassed within the invention are peptides and polypeptides comprising sequences having high binding affinity for any of the proteins of the invention, including such peptides and polypeptides that are fused to any carrier particle (or biologically expressed on the surface of a carrier) such as a bacteriophage particle.

[1390] Methods of Use of the Compositions of the Invention

[1391] The protein similarity information, expression pattern, cellular localization, and map location for the protein and nucleic acid disclosed herein suggest that this protein may have important structural and/or physiological functions characteristic of the Ornithine Decarboxylase 1 family. Therefore, the nucleic acids and proteins of the invention are useful in potential diagnostic and therapeutic applications and as a research tool. These include serving as a specific or selective nucleic acid or protein diagnostic and/or prognostic marker, wherein the presence or amount of the nucleic acid or the protein are to be assessed. These also include potential therapeutic applications such as the following: (i) a protein therapeutic, (ii) a small molecule drug target, (iii) an antibody target (therapeutic, diagnostic, drug targeting/cytotoxic antibody), (iv) a nucleic acid useful in gene therapy (gene delivery/gene ablation), (v) an agent promoting tissue regeneration in vitro and in vivo, and (vi) a biological defense weapon.

[1392] The nucleic acids and proteins of the invention have applications in the diagnosis and/or treatment of various diseases and disorders. For example, the compositions of the present invention will have efficacy for the treatment of patients suffering from: Obesity and/or Diabetes.

[1393] These materials are further useful in the generation of antibodies that bind immunospecifically to the substances of the invention for use in diagnostic and/or therapeutic methods.

[1394] A. NOV10a—Human Ornithine Decarboxylase 1—CG124907-01

[1395] Discovery Process

[1396] The following sections describe the study design(s) and the techniques used to identify the ornithine decarboxylase 1-gene, encoded protein and any variants, thereof, as being suitable as diagnostic markers, targets for an antibody therapeutic and targets for a small molecule drugs for Obesity and Diabetes.

[1397] Studies: MB04. Mouse Obesity Model (Genetic)

[1398] Study Statements:

[1399] A large number of mouse strains have been identified that differ in body mass and composition. The AKR and NZB strains are obese, the SWR, C57L and C57BL/6 strains are of average weight whereas the SM/J and Cast/Ei strains are lean. Understanding the gene expression differences in the major metabolic tissues from these strains will elucidate the pathophysiologic basis for obesity. These specific strains of rat were chosen for differential gene expression analysis because quantitative trait loci (QTL) for body weight and related traits had been reported in published genetic studies. Tissues included whole brain, skeletal muscle, visceral adipose, and liver.

[1400] MB.08. Human Mesenchymal Stem Cell Differentiation

[1401] Bone marrow-derived human mesenchymal stem cells have the capacity to differentiate into muscle, adipose, cartilage and bone. Culture conditions have been established that permit the differentiation in vitro along the pathway to adipose, cartilage and bone. Understanding the gene expression changes that accompany these distinct differentiation processes would be of considerable biologic value. Regulation of adipocyte differentiation would have importance in the treatment of obesity, diabetes and hypertension. Human mesenchymal stem cells from 3 donors were obtained and differentiated in vitro according to published methods. RNA from samples of the undifferentiated, mid-way differentiated and fully differentiated cells was isolated for analysis of differential gene expression.

[1402] BP24.2. Diet Induced Obesity

[1403] The predominant cause for obesity in clinical populations is excess caloric intake. This so-called diet-induced obesity (DIO) is mimicked in animal models by feeding high fat diets of greater than 40% fat content. The DIO study was established to identify the gene expression changes contributing to the development and progression of diet-induced obesity. In addition, the study design seeks to identify the factors that lead to the ability of certain individuals to resist the effects of a high fat diet and thereby prevent obesity. The sample groups for the study had body weights +1 S.D., +4 S.D. and +7 S.D. of the chow-fed controls (below). In addition, the biochemical profile of the +7 S.D. mice revealed a further stratification of these animals into mice that retained a normal glycemic profile in spite of obesity and mice that demonstrated hyperglycemia. Tissues examined included hypothalamus, brainstem, liver, retroperitoneal white adipose tissue (WAT), epididymal WAT, brown adipose tissue (BAT), gastrocnemius muscle (fast twitch skeletal muscle) and soleus muscle (slow twitch skeletal muscle). The differential gene expression profiles for these tissues should reveal genes and pathways that can be used as therapeutic targets for obesity.

[1404] Ornithine Decarboxylase 1:

[1405] In multiple genecalling studies the enzyme spermidine/spermine acetyl transferase has been found to be dysregulated in various disease models. This enzyme is one of the rate-limiting enzymes in the production of polyamines spermidine and spermine. Previously, it was shown that oxidation of polyamines leads to generation of hydrogen peroxide, which has been shown to have antilipolytic effect of adipose and may therefore be involved in the progression of obesity. Ornithine decarboxylase catalyzes the first step in polyamine production, which is the conversion of ornithine to putrescine. The polyamine pathway can be detrimental for the obesity phenotype, since hydrogen peroxide produced during oxidation of polyamines in known to have anti-lipolytic, insulin-like effect on adipocytes. Therefore, inhibiting the production of polyamines and generation of H2O2 by inhibiting this first enzyme in the polyamine pathway may be beneficial in the treatment for obesity.

[1406] The Ornithine Decarboxylase 1 (ODC) is one of the key enzymes in polyamine biosynthesis. Preventing the accumulation of polyamines and their antilipolytic effects by inhibition of ODC at an earlier stage of obesity may inhibit progression of the obesity.

[1407] The following is a summary of the findings from the discovery studies, supplementary investigations and assays that also incorporates knowledge in the scientific literature for use of ornithine decarboxylase 1 as a diagnostic and/or target for small molecule drugs and antibody therapeutics. Taken in total, the data indicates that an inhibitor/antagonist of the human ornithine decarboxylase 1 would be beneficial in the treatment of obesity and/or diabetes.

[1408] SPECIES #1 Mouse (NZB vs SM/J):

[1409] A gene fragment of the mouse spermine/spermidine N-acetyltransferase was initially found to be upregulated by 1.9 fold in the adipose of NZB mice relative to SM/J mice using CuraGen's GeneCalling™ method of differential gene expression. A differentially expressed mouse gene fragment migrating at approximately 411 nucleotides in length (FIG. 1a.—red vertical line) was definitively identified as a component of the mouse spermine/spermidine N-acetyltransferase cDNA in NZB and SM/J mouse strains. The method of competitive PCR was used for conformation of the gene assessment. The chromatographic peaks corresponding to the gene fragment of the mouse spermidine/spermine N-acetyltransferase are ablated when a gene-specific primer (see below) which competes with primers in the linker-adaptors during the PCR amplification. The peaks at 411 nt in length are ablated (green trace) in the sample from both the NZB and the SM/J mice. The altered expression in of these genes in the animal model support the role of Ornithine Decarboxylase 1 in the pathogenesis of obesity and/or diabetes.

[1410] SPECIES #1 Mouse (C57B1/6 Obese Euglycemic sd7 vs Obese sd1):

[1411] A gene fragment of the mouse spermine/spermidine N-acetyltransferase was initially found to be upregulated by 1.8 fold in the epididymal fat pad of the obese euglycemic sd7 mice relative to the obese sd1 mice using CuraGen's GeneCalling™ method of differential gene expression. A differentially expressed rat gene fragment migrating at approximately 178 nucleotides in length (FIG. 1a.—red vertical line) was definitively identified as a component of the mouse spermine/spermidine N-acetyltransferase cDNA in the Troglitazone treated and the untreated SHR control rats. The method of competitive PCR was used for conformation of the gene assessment. The chromatographic peaks corresponding to the gene fragment of the mouse spermidine/spermine N-acetyltransferase are ablated when a gene-specific primer (see below) which competes with primers in the linker-adaptors during the PCR amplification. The peaks at 178 nt in length are ablated (green trace) in the sample from both the C57B1/6 obese euglycemic sd7 and obese sd1 mice. The altered expression in of these genes in the animal model support the role of Ornithine Decarboxylase 1 in the pathogenesis of obesity and/or diabetes.

[1412] SPECIES #2 Human (Adipocyte Mid-Way vs Undifferentiated):

[1413] A gene fragment of the human spermine/spermidine N-acetyltransferase was initially found to be upregulated by 1.6 fold in the mid-way human adipocytes relative to the undifferentiated human adipocytes using CuraGen's GeneCalling™ method of differential gene expression. A differentially expressed human gene fragment migrating at approximately 194 nucleotides in length (FIG. 1a.—red vertical line) was definitively identified as a component of the human spermine/spermidine N-acetyltransferase cDNA in human mid-way differentiated and undifferentiated adipocytes. The method of competitive PCR was used for conformation of the gene assessment. The chromatographic peaks corresponding to the gene fragment of the human spermine/spermidine N-acetyltransferase are ablated when a gene-specific primer (see below) which competes with primers in the linker-adaptors during the PCR amplification. The peaks at 194 nt in length are ablated (green trace) in the sample from both the human mid-way differentiated and undifferentiated adipocytes. The altered expression of these genes in the human cellular model support the role of Ornithine Decarboxylase 1 in the pathogenesis of obesity and/or diabetes.

TABLE 1
Spermidine/spermine N-acetyltransferase Gene Sequence
identified in NZB vs SM/J mice
(Identified fragment from 206 to 616 in bold. band size: 411)
1   GCTCCCGGGA AACGAATGAG GAACCACCTC CTCCTGCTGT TCAAGTACAC GGGCCTGGTG
61  CGCAAAGGGA AGAAAACCAA AAGACGAAAA TGGCTAAATT TAAGATCCGT CCAGCCACTG
121 CCTCTGACTG CAGTGACATC CTGCGACTGA TCAAGGAACT GGCTAAATAT GAATACATGG
181 AAGATCAAGT CATTTTAACT GAGAAAGATC TCCAAGAGGA TGGCTTTGGA GAACACCCCT
241 TCTACCACTG CCTGGTTGCA GAAGTGCCTA AAGAGCACTG GACCCCTGAA GGACATAGCA
301 TTGTTGGGTT CGCCATGTAC TATTTTACCT ATGACCCATG GATTGGCAAG TTGCTGTATC
361 TTGAAGACTT CTTCGTGATG AGTGATTACA GAGGCTTFGG TATAGGATCA GAAATTTTGA
421 AGAATCTAAG CCAGOTTGCC ATGAAGTGTC GCTGCAGCAG TATGCACTTC TTGGTAGCAG
481 AATGGAATGA ACCATCTATC AACTTCTACA AAAGAAGAGG TGCTTCGGAT CTGTCCAGTG
541 AAGAGGGATG GAGGCTCTTC AAGATTGACA AAGAGTACTT GCTAAAAATG GCAGCAGAGG
601 AGTGAGGCGT GCCCGTGTAG ACAATGACAA CCTCCATTGT GCTTTAGAAT AATTCTCAGC
661 TTCCCTTGCT TTCTATCTTG TGTGTAGTGA AATAATAGAC CGAGCACCCA TTCCAAAGCT
721 TTATTACCAG TGACGTTCTT GCATGTTTGA AATTCGCTCT CITTAAAGTG GCAGTCATGT
781 ATCTGGTTTG GAGCCAGAAT TCTTGAACAT CTTTTGATGA ACAACAACGT GGTATGATCT
841 TACTATATAA GAAAAACAAA ACTTCATTCT TGTGAGTCAT TTAAATGTGT ACAATGTACA
901 CACTGGTACT TAGAGTTTCT GTTTTCATTC TTTTTTTTTA AATAAACTCC CTCTTTGATT
961 T

[1414]

TABLE 2
Spermidine/spermine N-acetyltransferase Gene Sequence
identified in C57B1/6 obese euglycemic sd7 vs obese sd1
(Identified fragment from 716 to 893 in bold. band size: 178)
235 ACCCCTTCTA CCACTGCCTC GTTCCACAAG TGCCTAAAGA GCACTGGACC CCTGAAGGAC
295 ATACCATTGT TGGGTTCGCC ATGTACTATT TTACCTATGA CCCATCGATT GGCAAGTTGC
355 TGTATCTTGA ACACTTCTTC CTGATGAGTG ATTACACACG CTTTCGTATA CGATCACAAA
415 TTTTGAAGAA TCTAAGCCAG GTTGCCATGA AGTGTCGCTG CACCACTATG CACTTCTTGG
475 TAGCAGAATG GAATGAACCA TCTATCAACT TCTACAAAAG AAGAGGTGCT TCGGATCTGT
535 CCAGTGAAGA GGGATGGAGG CTCTTCAAGA TTGACAAAGA GTACTTGGTA AAAATGGCAG
595 CAGACCACTC AGCCCTCCCC GTCTAGACAA TGACAACCTC CATTGTGCTT TAGAATAATT
655 CTCAGCTTCC CTTCCTTTCT ATCTTCTCTG TAGTCAAATA ATACACCGAG CACCCATTCC
715 AAAGCTTTAT TACCAGTGAC GTTGTTGCAT GTTTGAAATT CGGTCTGTTT AAAGTGGCAG
775 TCATGTATGT GGTTTGGAGG CAGAATTCTT GAACATCTTT TGATGAAGAA CAAGGTGGTA
835 TGATCTTACT ATATAAGAAA AACAAAACTT CATTCTTGTG AGTCATTTAA ATGTGTACAA
895 TGTACACACT GCTACTTACA GTTTCTGTTT TGATTCCTTT TTTTTAAATA AACTCGCTCT
955 TTGATTT

[1415]

TABLE 3
Spennidine/spermine N-acetyltransferase Gene Sequence
identified in human adipocyte mid-way versus undifferentiated
(Identified fragment from 162 to 355 in bold. band size: 149).
1   CTGGTGTTTA TCCGTCACTC GCCGAGGTTC CTTCGGTCAT GGTGCCAGCC TGACTGAGAA
61  GAGGACGCTC CCGGGAGACG AATGAGGAAC CACCTCCTCC TACTGTTCAA CTACAGGGGC
121 CTGGTCCGCA AAGGGAAGAA AAGCAAAAGA CGAAAATGGC TAAATTCGTG ATGCGCGCAG
181 CCACTGCCGC CGACTGCAGT GACATACTOC GGCTGATCAA GGAGCTGGCT AAATATGAAT
241 ACATGGAAGA ACAAGTAATC TTAACTGAAA AAGATCTGCT AGAAGATGGT TTTGGAGAGC
301 ACCCCTTTTA CCACTGCCTG GTTGCAGAAG TGCCGAAAGA GCACTGGACT CCGGA                  AGCTT
361 ACAGTCTCTA GCTTCGCCAT GTACATGGCC CTTCCGTGTA CATGGATGGG CGGGGAGGTA
421 ACTAAAAGAT CCTTTACACA ATAAAGTAGA TGATCATGAT AAATGAGGAC ACAGCATTGT
481 TGGTTTTGCC ATGTACTATT TTACCTATGA CCCCTCCATT GCCAAGTTAT TGTATCTTGA
541 GGACTTCTTC GTGATGAGTG ATTATAGAGG CTTTGGCATA GGATCAGAAA TTCTCAAGAA
601 TCTAAGCCAG GTTGCAATGA GGTGTCGCTG CAGCAGCATG CACTTCTTGG TACCAGAATG
661 GAATGAACCA TCCATCAACT TCTATAAAAG AAGAGGTGCT TCTGATCTGT CCAGTCAAGA
721 GGGTTGGAGA CTGTTCAAGA TCGACAAGGA GTACTTGCTA AAAATGGCAA CAGAGGACTG
781 ACGAGTGCTG CTGTAGATGA CAACCTCCAT TCTATTTTAG AATAAATTCC CAACT

[1416]

TABLE 4
Human Ornithine Decarboxylase 1 gene
and protein sequence.
>CG124907-01    1958 nt
GCAGGCCAGCCCCATGGGGAAGCCCAGACGCCGGNGCCTCGGCGCTCTGA
GATTGTCACTGCTCTTCCAAGGGCACACGCAGAGGGATTTGGAATTCCTG
GAGAGTTCCCTTTGTGAGAAGCTCGAAATATTTCTTTCAATTCCATCTCT
TAGTTTTCCATAGGAACATCAAGAAATCATGAACAACTTTGGTAATGAAG
AGGTTGACTGCCACTTCCTCGATGAAGGTTTTACTCCCAAGCACATTCTG
GACCAGAAAATTAATGAAGTTTCTTCTTCTGATGATAAGGATGCCTTCTA
TGTGGCAGACCTGGGAGACATTCTAAAGAAACATCTGACCTGGTTAAAAG
CTCTCCCTCGTGTCACCCCCTPTTATGCAGTCAAATCTAATGATAGCAAA
GCCATCGTGAACACCCTTGCTGCTACCGGGACAGGATTTGACTCTGCTAG
CAAGACTGAAATACAGTTGGTGCAGAGTCTGGGGGTGCCTCCAGAGAGGA
TTATCTATGCAAATCCTTGTAAACAAGTATCTCAAATTAAGTATGCTGCT
AATAATCGAGTCCAGATCATGACTTTTGATAGTCAAGTTGAGTTCATCAA
AGTTGCCAGAGCACATCCCAAAGCAAAGTTGGTTTTCCGGATTGCCACTG
ATCATTCCAAAGCAGTCTGTCGTCTCACTGTGAAATTCGGTGCCACGCTC
ACAACCAGCAGGCTCCTTTTGGAACCGGCCAAAGAGCTAAATATCGATGT
TGTTGGTGTCAGCTTCCATGTAGGAAGCCGCTGTACCGATCCTGACACCT
TCGTGCAGGCAATCTCTGATGCCCGCTGTGTTTTTGACATGGGGCTCTAC
GTTGGTTTCAGCATGTATCTGCTTGATATTGGCGGTCGCTTTCCTGGATC
TGAGGATGTGAAACTTAAATTTGAAGAGATCACCGGCGTAATCAACCCAG
CGTTGGACAAATACTTTCCGTCAGACTCTGGAGTGAGAATCATAGCTGAG
CCCGGCAGATACTATGTTGCATCAGCTTTCACGCTTGCAGTTAATATCAT
TGCCAAGAAAATTGTATTAAAGGAACAGACGGGCTCTGATGACGAAGATG
AGTCGAGTGAGCACACCTTTATGTATTATGTGAATGATGGCGTCTATGGA
TCATTTAATTGCATACTCTATGACCACGCACATGTAAACCCCCTTCTGCA
AAAGAGACCTAAACCAGATGAGAAGTATTATTCATCCAGCATATGGGGAC
CAACATGTGATGGCCTCGATCCGATTGTTGAGCGCTGTGACGTGCCTGAA
ATGCATCTCGCTCATTCGATGCTCTTTGAAAACATCCCCCCTTACACTGT
TGCTGCTGCCTCTACGTTCAATGGCTTCCAGAGGCCGACGATCTACTATG
TGATGTCAGGGCCTGCGTGGCAACTCATGCAGCAATTCCAGAACCCCGAC
TTCCCACCCGAAGTAGAGGAACAGGATGCCAGCACCCTGCCTGTGTCTTG
TGCCTGGGAGAGTGGGATGAAACGCCACAGAGCAGCCTGTGCTTCGGCTA
GTATTAATGTGTAGATAGCACTCTGGTAGCTCTTAACTGCAAGTTTAGCT
TGAATTAAGGGATTTCGGGGGACCATGTAACTTAATTACTGCTAGTTTTG
AAATGTCTTTGTAAGAGTAGGGTCGCCATGATGCAGCCATATGGAAGACT
ACCATATGGGTCACACTTATCTGTGTTCCTATGGAAACTATTTGAATATT
TGTTTTATATGGATTTTTATTCACTCTTCAGACACCCTACTCAACAGTCC
CCCTCAGGTGCTGAACAAGCATTPGTAGCTTGTACAATGGCAGAATGGGC
CAAAAGCTTAGTGTTGTGACCTGTTTTTAAAATAAACTATCTTCAAATAA
ATAAAAAAAAAAAAGGGGGGCCGCCCTAGGGGTTCCCAAGTTTACGTACG
CTCCATCG

[1417]

TABLE 5
Human Ornithine Decarboxylase 1 protein sequence>
ORF Start: 179       ORF Stop: 1562       Frame: 2
Human Ornithine Decarboxylase 1 Protein Sequence:
>CG124907-O1-prot     461 aa
MNNFGNEEFDCHFLDEGFTAKDILDQKINEVSSSDDKDAFYVADLGDILK
KHLRWLKALPRVTPFYAVKCNDSKAIVKTLAATGTGFDCASKTEIQLVQS
LGVPPERIIYANPCKQVSQIKYAANNGVQMMTFDSEVELMKVARAHPKAK
LVLRIATDDSKAVCRLSVKFGATLRTSRLLLERAKELNIDVVGVSFEVGS
GCTDPETEVQAISDARCVEDMGAEVGFSMYLLDIGGGFPGSEDVKLKFEE
TTGVINFALDKYFPSDSGVRIIAEPCRYYVASAFTLAVNIIAKKIVLKEQ
TGSDDEDESSEQTFMYYVNDGVYGSFNCILYDEAHVKPLLQKRPKPDEKY
YSSSIWGPTCDGLDRIVERCDLPEMHVGDWMLFENNGAYTVAAASTFNGF
QRPTIYYVMSGPAWQLMQQFQNPDFPPEVEEQDASTLPVSCAWESGMKRH
RAACASASINV

[1418]

[1419] In addition to the human version of the Ornithine Decarboxylase 1 identified as being differentially expressed in the experimental study, other variants have been identified by direct sequencing of cDNAs derived from many different human tissues and from sequences in public databases. No splice-form variants have been identified at CuraGen whereas several amino acid-changing cSNPs were identified. These are found below. The preferred variant of all those identified, to be used for screening purposes, is CG124907-01.

TABLE 7
Variants of human Ornithine Decarboxylase 1 obtained
from direct cloning and/or public databases.
DNA
Position	Strand	Alleles	AA Position	AA Change	public SNP#
1447	Minus	C:T	423	Pro => Pro

[1420]

[1421] FIGS. 1A and 1B show differential regulation of spermidine/spermine N-acetyltransferase in the expressed gene fragment in Discovery Study MB.04 of NZB vs SM/J mice. The abscissa on each graph is measured in length of nucleotides, and the ordinate is measured in signal response.

[1422] FIGS. 2A and 2B show differential regulation of spermidine/spermine N-acetyltransferase in the expressed gene fragment in Discovery Study MB.04 of NZB vs SM/J mice. The abscissa on each graph is measured in length of nucleotides, and the ordinate is measured in signal response.

[1423] Species #1 Mouse Strains NZB, SM/J, C56B1/6

[1424] Species # 2 Human

[1425] FIG. 5 summarize the biochemistry surrounding the human Ornithine Decarboxylase 1 and potential assays that may be used to screen for antibody therapeutics or small molecule drugs to treat obesity and/or diabetes. Cell lines expressing the Ornithine Decarboxylase 1 can be obtained from the RTQ-PCR results shown above. These and other Ornithine Decarboxylase 1 expressing cell lines could be used for screening purposes. In the schematic, the biochemistry of “PAO” is that it catalyses oxidation of the secondary amino group of spermine, spermidine and their acetyl derivatives; FAD is the cofactor implicated; and the schematic is shown in monomeric units. 1

[1426] FIG. 6 suggests how alterations in expression of the human ornithine decarboxylase 1 and associated gene products function in the etiology and pathogenesis of obesity and/or diabetes. The scheme incorporates the unique findings of these discovery studies in conjunction with what has been reported in the literature. The outcome of inhibiting the action of the human ornithine decarboxylase 1 would be a way to increase lypolysis by inhibiting anti-lypolytic effects of hydrogen peroxide. 2

[1427] Ornithine decarboxylase catalyzes the first step in polyamine production, the conversion of ornithine to putrescine. Inhibiting the production of polyamines and H2O2 by inhibiting this first enzyme in the pathway will eliminate the lipolytic effects of H2O2 and therefore may be beneficial in the treatment for obesity.

[1428] The following is a summary of the findings from the discovery studies, supplementary investigations and assays that also incorporates knowledge in the scientific literature. Taken in total, the data indicates that an inhibitor/antagonist of the human Ornithine Decarboxylase 1 would be beneficial in the treatment of obesity and/or diabetes.

[1429] In multiple genecalling studies the enzyme spermidine/spermine acetyl transferase was found to be dysregulated in various disease models. This enzyme is one of the rate-limiting enzymes in the production of polyamines spermidine and spermine. Previously, it was shown that oxidation of polyamines leads to generation of hydrogen peroxide, which has been shown to have antilipolytic effect of adipose and may therefore be involved in the progression of obesity. Ornithine decarboxylase catalyzes the first step in polyamine production, which is the conversion of ornithine to putrescine. The polyamine pathway can be detrimental for the obesity phenotype, since hydrogen peroxide produced during oxidation of polyamines in known to have anti-lipolytic, insulin-like effect on adipocytes. Therefore, inhibiting the production of polyamines and generation of H2O2 by inhibiting this first enzyme in the polyamine pathway may be beneficial in the treatment for obesity.

[1430] B. NOV12A—Tyrosine Aminotransferase—CG135823-01

[1431] The present invention discloses novel associations of proteins and polypeptides and the nucleic acids that encode them with various diseases or pathologies. The proteins and related proteins that are similar to them, are encoded by a cDNA and/or by genomic DNA. The proteins, polypeptides and their cognate nucleic acids were identified by CuraGen Corporation in certain cases. The Tyrosine Aminotransferase-encoded protein and any variants, thereof, are suitable as diagnostic markers, targets for an antibody therapeutic and targets for small molecule drugs. As such the current invention embodies the use of recombinantly expressed and/or endogenously expressed protein in various screens to identify such therapeutic antibodies and/or therapeutic small molecules.

TABLE 1
SPECIES #1, Rat Tyrosine Aminotransferase Gene Fragment
used for competitive PCR
(fragment from 845 to 989 in bold. band size: 145)
364  CCTACAGACC CTGAAGTTAC CCAAGCCATG AAAGATCCMC TGGACTCGGG GAAGTACAAT
424  GGCTATGCCC CGTCCATCGG CTACCTATCC AGTCGGGAGG AGGTCGCTTC TTACTACCAC
484  TGTCATGAGG CTCCTCTCGA AGCTAAGGAT GTCATTCTGA CAAGCCGCTG CAGTCAGGCC
544  ATTGAGCTAT GTCTAGCTCT GTTGGCCAAT CCTGGACAAA ACATCCTCAT TCCAACGCCC
604  CGGTTTTCCC TCTATAGGAC TTTGGCTGAG TCTATGGGAA TTGAGGTCAA GCTCTACAAT
664  CTCCTCCCCC AGAAGTCTTG GGAAATTGAC CTAAAACAAC TGGAATCTCT GATCGATGAA
724  AAAACAGCGT GTCTTGTTGT CAACAACCCA TCCAATCCCT GTCGCTCCGT GTTCAGTAAG
784  CCACACCTTC AGAAGATTTT GGCAGTGGCT GAAAGGCAGT GTCTCCCCAT CTTAG6TGAC
844  GAGATCTATG GTGACATGGT GTTTTCAGAT TGCAAATACG AACCACTGGC CAACCTCAGC
904  ACCAATGTTC CCATCCTGTC CTGTGGTGGG CTCGCCAAGC CCTGGCTGGT CCTTGGCTGG
964  AGGTTGGGCT GGATCCTCAT TCATGATCGA AGAGACATTT TTGGCAATGA GATTCGAGAC
1024 GGGCTCCTGA AACTGAGTCA GCGGATCCTG GGACCATGCA CCATAGTCCA GGGTGCTCTG
1084 AAGAGCATCC TTCAGCGAAC CCCTCAGGAG TTCTATCACG ACACGTTAAG CTTCCTCAAG
1144 TCCAATGCGG ACCTCTGCTA TGGGGCACTG GCTGCCATCC CTGGACTCCA GCCGGTCCGC
1204 CCTTCTGGAG CCATGTACCT TATGGTGGGA ATTGAGATGG AGCATTTCCC GGAATTCGAG
1264 AACGACGTGG AGTTCACAGA GCCGTTGATT GCGGAGCACG CTGTCCACTG TCTCCCAGCA
1324 ACGTGCTTCG AGTACCCAAA TTTCTTCCGA GTGGTCATCA CACTCCCCCA GGTCATCATG
1384 CTGGAGGCTT GTAGCCGGAT CCAGGAGTTC TGTGAACAGC AGTACCACTG TGCTGAAGGC
1444 AGCCAGGAGG AGTGTGACAA ATAAGC
(gene length is 2364, only region from 364 to 1469 shown)

[1432]

TABLE 2
SPECIES #2, Rat Tyrosine Aminotransferase Gene Fragment
used for competitive PCR
(fragment from 1 to 277 in bold. band size: 277).
1   TCATGATCCA AGAGACGTTT TTGGCAATGA GATTCGAGAC GGGCTGGTGA AACTGAGTCA
61  GCCGATCCTG GGACCATGCA CCATAGTCCA GGGTCCTCTG AAGAGCATCC TTCAGCGAAC
121 CCCTCACGAG TTCTATCACG ACACGTTAAG CTTCCTCAAG TCCAATGCGG ACCTCTGCTA
181 TCGGGCACTG GCTGCCATCC CTGGACTCCA GCCGGTCCGC CCTTCTGGAG CCATGTACCT
241 TATGGTGGGA ATTGAGATGG AGCATTTCCC GGAATTC
(gene length is 277, only region from 1 to 277 shown)

[1433]

TABLE 3
SPECIES #3, Mouse Tyrosine Aminotransferase Gene Fragment
used for competitive PCR
(fragment from 57 to 275 in bold. band size: 220)
1   CCTTCAGAAG ATTTTGGCAG TGGCTGAAAG GCAATCCGTC CCCATCTTAG CCGATGAGAT
61  CTATGGTGAC ATGGTGTTET CAGATTGCAA ATATGAACCA ATGGCCACCC TCAGCACCAA
121 TGTCCCCATC CTGTCCTGTG GTGGGCTCGC CAAGCGCTGQ CTGGTTCCTG GCTGGAGGCT
181 GGGCTGGATC CTTATCCATG ATCGAAGAGA CATTTTTGGC AATGAGATTC GGGACGGGCT
241 GGTGAAGCTG AGTCAGCGGA TCCTGGGCCC GTGCA                  CCATC GTCCAAGGTG CCCTGAAGAG
301 CATCCTTCAG CCCACCCCTC AGGAGTTCTA CCAGGACACT TTAACCTTCC TTAAGTCCAA
361 TGCGGACCTC TCCTATGGGG CGTTGTCTGC AATTCCTGGA CTCCAGCCAG TCCGCCCATC
421 TGGAGCCATG TACCTTATGG TGGGAATTGA GATGGAGCAC TTCCCAGAAT TTGAGAATGA
481 CGTGGAATTC ACAGAGCGGT TAATTGCGGC AGNNTCTGTC GNACTGCTCC AGCACGTGCT
541 TCGACTACCA ATTTCTTCCG CCTGTCATAC AGTCCCCGAG TGATGATCCT G
(gene length is 592, only region from 1 to 592 shown)

[1434]

TABLE 4
Human Tyrosine Aminotransferase gene
and protein sequence.
>CG135823-01    2754 nt
ATTGCCCCTGTAACCTGTCAAAGAAGAGCTAAGCGAGCTTTCGCGGTTGG
CTTCTTGGAGGCTGCTTTCTCCTTTACTTGCAAGGCTTCGCTAGTGATGG
ACCCATACATGATTCAGATGAGCAGCAAAGGCAACCTCCCCTCAATTCTG
GACGTGCATGTCAACCTTGGTGGGACAAGCTCTGTGCCGGGAAAAATGAA
AGGCAGAAAGGCCAGGTGGTCTGTGAGGCCCTCAGACATGCCCAACAAAA
GTTTCAACCCCATCCGAGCCATTGTGGACAACATGAAGGTGAAACCAAAT
CCAAACAAAACCATGATTTCCCTGTCCATTGGGGACCCTACTGTCTTTGG
AAACCTGCCTACAGACCCTGAAGTTACCCAGGCAATGAAAGATGCCCTGG
ACTCGCGCAAATATAATGGCTATGCCCCATCCATCGGCTTCCTATCCAGT
CGGGAGGAGATTCCTTCTTATTACCACTCTCCTGAGGCACCCCTAGAAGC
TAAGGACGTCATTCTGACAAGTCGCTGCAGCCAAGCTATTCACCTTTGTT
TAGCTGTGTTGGCCAACCCAGGGCAGAACATCCTGGTTCCAAGACCTGGT
TTCTCTCTCTACAAGACTCTGGCTGAGTCTATGGGAATTGAGGTCAAACT
CTACAATTTGTTGCCAGAGAAATCTTGGGAAATTGACCTGAAACAACTCG
AATATCTAATTGATGAAAAGACAGCTTGTCTCATTGTCAATAATCCATCA
AACCCCTGTGGGTCAGTGTTCAGCAAACGTCATCTTCAGAAGATTCTGGC
AGTGGCTGCACGGCAGTGTGTCCCCATCTTAGCTGATCACATCTATGGAG
ACATGGTGTTTTCGGATTGCAAATATGAACCACTGGCCACCCTCAGCACC
GATGTCCCCATCCTGTCCTGTGGAGGGCTGGCCAAGCGCTGGCTGGTTCC
TGGCTGGAGGTTGCCCTGGATCCTCATTCATGACCGAAGAGACATTTTTG
GCAATGAGATCCGAGATGGGCTGGTGAAGCTGAGTCAGCGCATTTTGGGA
CCCTGTACCATTGTCCAGGGAGCTCTGAAAAGCATCCTATGTCGCACCCC
CGGACAGTTTTACCACAACACTCTGAGCTTCCTCAAGTCCAATGCTGATC
TCTGTTATCCCGCGTTGGCTGCCATCCCTGGACTCCGGCCAGTCCGCCGT
TCTGCGGCTATGTACCTCATGGTTCGAATTCAGATGGAACATTTCCCACA
ATTTGAGAACGATGTGCAGTTCACCGAGCGGTTAGTTGGTCAGCAGTCTG
TCCACTGCCTCCCAGCAACGTGCTTTGAGTACCCGAATTTCATCCGAGTG
GTCATCACAGTCCCCGACGTGATGATGCTGGAGCCGTGCAGCCGGATCCA
GGAGTTCTGTGAGCAGCACTACCATTGTGCTGAAGGCAGCCAGGAGGAGT
GTGATAAATAGGCCTGCATCCATTCTCCTGAGGATGTCTCCCATCTAGGG
AAGGCTGGACTAGGCCTPGCGGCTCCTCAGGGACTCAGGTGGCCCTACTG
GGAGAGGGGCCTCAAATGCACCATGTCAAGGGTTCAAGATTGTTCCTGCT
TTTCCCCAAGTACAACCACACCCACACTCAGATCCTCCTCATTCACATCG
CAGATTACTCCCTTGCTCTCCGCTGCTAGAGTGACTCACTAATTCATTAA
TCTGCCTCCCTCTCGTAAGATTTCCTTCTTTTTTTTCTTGAAAGTACCAG
GTGAACAAAGTTTACCAGAAAGCAGTTGAGACAAGAAAATAAGAGCTCAG
GATGAGGGAAAACAAAAAGATTGACAGAATTTGTGCCCCCAACCATTTCC
TCAGACTCTAAGAAAGAACACGCTCTCTCCACGCAGGTCTCAAGCTCAAC
TCTCTTATTGCCTCACTTCAGGTATACCTCACTTTACACAATAGAATTAT
AACTGGAAAGAAGTTGGGGACACATCTATTTGGTGATTACATTTTAAACA
CATTAGGAAAAGTTGCTATTTGAACTTTTTATTGATTTTTGGGGGGAGTA
AAGAATTATTTTGGATGCAAATAAATATCCTTTAATTGATCGACTTGCCA
AATTTAGATTTGTGTGCATCAGGCTTTCTTTTTTTTCTTTTTTTAGAGAA
GTTCAATATAAGCTTTTCTTTTCTTTGTTTCTTTCTTTCTTTATTTTGAG
ATGGAGTCTTGCTCTGTCGCCCATGCTGGAGTGCAGTGGCGCGATCTCGG
CTCACTGCAACCTCCACCTCCTGGGTTCAAGCGATTCTCTTGCGTCAACG
TCCCAAGCAGTTGGGACTACAGGCGTGAGCCACCATGCCCGGCTAATRFT
TGTATTTTTAGTAGAGACAGGGTTTCACCATCTTACCCACGCTGGTCTCA
AACTCCTGACCTCAGGCAATCTGCCCGCCTGCGTCTCCTAAACTACTGGG
ATTACACCCGTCAGCCACCTCGCCCAGCGGCATCAGCCTTTCTTAAAGTG
ACAGCACCCCTGTACTACAGCAAGCAGCAATCAGAGACCTTCCAGAAATA
CTACTGTGTAAGGGCCAGAAATATCTTCACTTGTCATTGTTATATAATCA
TTATTACTTTTGCTCTAATGTTAATATTGATTTATTAATATATATTATCT
TTTCATACATTTTCTAAGAAACATTTATATTGATAAGATCTTTTATTTTG
CAAGGGCATAAATTATTGTTTTTCTTTTTTTTTTTTTTTTTTTAATAAAT
TTCACCAAGT

[1435]

TABLE 5
Amino Acid sequence of Human Aminotransferase
Human Tyrosine Aminotransferase Protein Sequence:
ORF Start: 97   ORF Stop: 1459   Frame: 1
>CG135823-01-prot    454 aa
MDPYMIQMSSKGNLPSILDVHVNVGGRSSVPGKMKGRKARWSVRPSDMAK
KTFNPIRAIVDNMKVKPNPNKTMISLSIGDPTVFGNLPTDPEVTQANKDA
LDSGKYNGYAPSIGFLSSREEIASYYHCPEAPLEAKDVILTSCCSQAIDL
CLAVLANPGQNILVPRPGFSLYKTLAESMGIEVKLYNLLPEKSWEIDLKQ
LEYLIDEKTACLIVNNPSNPCGSVFSKRHLQKILAVAARQCVPILADEIY
CDMVFSDCKYEPLATLSTDVPILSCGCLAKRWLVPGWRLGWILIHDRRDI
FONEIRDGLVKLSQRILGPCTIVQGALKSILCRTPGEFYHNTLSFLKSNA
DLCYGALAAIPCLRPVRPSGANYLMVGIEMEHFPEFENDVEFIERLVAEQ
SVHCLPATCFEYPNFIRVVITVPEVNMLEACSRIQEFCEQHYHCAEGSQE
ECDK

[1436]

[1437] Human Tyrosine Aminotransferase:

[1438] Locus: 16q22.1 (QTL for Intracellular Fat on 16q22)

[1439] Intracellular

[1440] Biochemistry and Cell Line Expression

[1441] Tyrosine Aminotransferase catalyses the following reaction:

L-Tyrosine+2-Oxoglutarate=4-hydroxyphenylpyruvate+L-glutamate,

[1442] using pyridoxal 5′-phosphate as a cofactor.

[1443] Tyrosine Aminotransferase activity was measured usually by fix-time assay (measurement of tyrosine absorbance by spectrophotometry). Liver extract, primary hepatocytes and different hepatocyte cell lines were reported to utilize as a source of TAT. Cell lines expressing the Tyrosine Aminotransferase can be obtained from the RTQ-PCR results shown above. These and other Tyrosine Aminotransferase expressing cell lines could be used for screening purposes.

[1444] In addition to the human version of the Tyrosine Aminotransferase identified as being differentially expressed in the experimental study, other variants have been identified by direct sequencing of cDNAs derived from many different human tissues and from sequences in public databases. No splice-form variants have been identified at CuraGen whereas several amino acid-changing cSNPs were identified in literature. Described below SNPs cause activity deficiency of TAT and were associated with disease called tyrosinemia, type II.

[1445] Natt E, Kida K, Odievre M, Di Rocco M, Scherer G.

[1446] Point mutations in the tyrosine aminotransferase gene in tyrosinemia type II.

[1447] Proc. Natl. Acad. Sci. USA Oct. 1, 1992;89(19):9297-301.

[1448] PMID: 1357662

TABLE 7
Variants of the human Tyrosine Aminotransferase obtained
from direct cloning and/or public databases.
DNA			AA		public
Position	Strand	Alleles	Position	AA Change	SNP #
223		C:G	74	Ser Stop
1086		G:T	417	Arg Stop
1251		G:T	362	Gly Val

[1449] There are several reasons to use tyrosine aminotransferase as a diagnostic and/or target for small molecule drugs and antibody therapeutics.:

[1450] 1. Tyrosine Aminotransferase is a rate-limiting enzyme in phenylalanine/tyrosine catabolism, which may contribute to gluconeogenesis and lipid biosynthesis. The level of enzyme is induced by glucocorticoids, and the excess of glucocorticoids frequently results in obesity, insulin resistance and glucose intolerance.

[1451] 2. Up-regulation of TAT in MB.05 study may contribute to insulin resistance in HTG rats, in MB.01—to hyperglycemia in SHR rats. Down-regulation of TAT in response to troglitazone treatment in MB.01 study suggests that TAT may be one of downstream targets for this antidiabetic drug.

[1452] 3. On the other hand, down-regulation of TAT in BP24.02 study may represent the compensatory mechanism to decrease lipid biosynthesis in obese animals.

[1453] 4. Taken in total, the data indicates that an inhibitor of the human Tyrosine Aminotransferase would be beneficial in the treatment of obesity.

[1454] Species #1 Rat Strains HTG, Lewis, Wistar

[1455] Species #2 Rat Strains SHR, SD

[1456] Species #3 Mouse Strains C57BL/6J

[1457] FIGS. 2A, 2B, 2C, 2D, 2E, and 2F. Differentially expressed gene fragments in rat (SPECIES #1); rat (SPECIES #2) and mouse (SPECIES #3) Tyrosine Aminotransferase. SPECIES #I. FIGS. 2A and 2B show differentially expressed gene fragments in Discovery Study MB.05 from the rat tyrosine aminotransferase (in the graphs, the abscissa is measured in lengths of nucleotides and the ordinate is measured as a signal response). A gene fragment of the rat Tyrosine Aminotransferase was initially found to be up-regulated by 1.7 fold in the muscle and liver tissues of HTG rat relative to normal control rat strain using CuraGen's GeneCalling™ method of differential gene expression. A differentially expressed rat gene fragment migrating, at approximately 145 nucleotides in length (FIG. 2A—red vertical line) was definitively identified as a component of the rat Tyrosine Aminotransferase cDNA. The method of competitive PCR was used for conformation of the gene assessment. The electropherogramatic peaks corresponding to the gene fragment of the rat Tyrosine Aminotransferase are ablated when a gene-specific primer (see below) competes with primers in the linker-adaptors during the PCR amplification. The peaks at 145 nt in length are ablated (green trace) in the sample from both the HTG and control rats.

[1458] SPECIES #2. FIGS. 2C and 2D show differentially expressed gene fragments in Discovery Study MB.01 from rat tyrosine aminotransferase (in the graphs, the abscissa is measured in lengths of nucleotides and the ordinate is measured as a signal response). The gene fragments corresponding to the rat TAT were found to be up-regulated in liver tissues of SHR rat relative to normal control rat strain, and to be down-regulated in the liver of SHR rat in response to troglitazone treatment. A differentially expressed rat gene fragment migrating, at approximately 277.4 nucleotides in length (FIG. 2C—red vertical line) was definitively identified as a component of the rat Tyrosine Aminotransferase cDNA by the method of competitive PCR. The electropherogramatic peaks corresponding to the gene fragment of the rat Tyrosine Aminotransferase are ablated when a gene-specific primer (see below) competes with primers in the linker-adaptors during the PCR amplification. The peaks at 277.4 nt in length are ablated (green trace) in the sample from both the SHR rat liver treated and untreated with troglitazone.

[1459] SPECIES #3 FIGS. 2E and 2F show differentially expressed gene fragments in Discovery Study BP24.02 from mouse tyrosine aminotransferase (in the graphs, the abscissa is measured in lengths of nucleotides and the ordinate is measured as a signal response). Additionally, gene fragments corresponding to the mouse TAT were found to be down-regulated in liver tissues of hyperglycemic fat mouse (hgsd7) relative to normal animal on low fat diet (chow) in a mouse model of dietary-induced obesity. A differentially expressed mouse gene fragment migrating, at approximately 220.3 nucleotides in length (FIG. 2A—red vertical line) was definitively identified as a component of the mouse Tyrosine Aminotransferase cDNA by the method of competitive PCR. The chromatographic peaks corresponding to the gene fragment of the mouse Tyrosine Aminotransferase are ablated when a gene-specific primer (see below) competes with primers in the linker-adaptors during the PCR amplification in the sample from both the hyperglycemic fat mouse relative and normal animals. The altered expression in of these genes in the animal model support the role of the Tyrosine Aminotransferase in the pathogenesis of obesity and/or diabetes. 3

[1460] FIG. 4 shows pathways that are relevant to the etiology and pathogenesis of obesity and/or diabetes. This figure illustrates the catabolism of tyrosine and phenylalanine and suggests how alterations in expression of the human Tyrosine Aminotransferase and associated gene products function in the etiology and pathogenesis of obesity and/or diabetes. The scheme incorporates the unique findings of these discovery studies in conjunction with what has been reported in the literature. The outcome of inhibiting the action of the human Tyrosine Aminotransferase would inhibit the contribution of these catabolic pathways to gluconeogenesis and lipid biosynthesis and would be beneficial for the treatment of obesity and/or diabetes.

[1461] C. NOV13A—Human Polyamine Oxidase—CG140122-01

[1462] The present invention discloses novel associations of proteins and polypeptides and the nucleic acids that encode them with various diseases or pathologies. The proteins and related proteins that are similar to them, are encoded by a cDNA and/or by genomic DNA. The proteins, polypeptides and their cognate nucleic acids were identified by CuraGen Corporation in certain cases. The Polyamine Oxidase -encoded protein and any variants, thereof, are suitable as diagnostic markers, targets for an antibody therapeutic and targets for small molecule drugs. As such the current invention embodies the use of recombinantly expressed and/or endogenously expressed protein in various screens to identify such therapeutic antibodies and/or therapeutic small molecules.

[1463] Discovery Process

[1464] The following sections describe the study design(s) and the techniques used to identify the Polyamine oxidase-encoded protein and any variants, thereof, as being suitable as diagnostic markers, targets for an antibody therapeutic and targets for a small molecule drugs for Obesity and Diabetes.

[1465] Studies: MB04. Mouse Obesity Model (Genetic)

[1466] Study Statements:

[1467] A large number of mouse strains have been identified that differ in body mass and composition. The AKR and NZB strains are obese, the SWR, C57L and C57BL/6 strains are of average weight whereas the SM/J and Cast/Ei strains are lean. Understanding the gene expression differences in the major metabolic tissues from these strains will elucidate the pathophysiologic basis for obesity. These specific strains of rat were chosen for differential gene expression analysis because quantitative trait loci (QTL) for body weight and related traits had been reported in published genetic studies. Tissues included whole brain, skeletal muscle, visceral adipose, and liver.

[1468] MB.08. Human Mesenchymal Stem Cell Differentiation

[1469] Bone marrow-derived human mesenchymal stem cells have the capacity to differentiate into muscle, adipose, cartilage and bone. Culture conditions have been established that permit the differentiation in vitro along the pathway to adipose, cartilage and bone. Understanding the gene expression changes that accompany these distinct differentiation processes would be of considerable biologic value. Regulation of adipocyte differentiation would have importance in the treatment of obesity, diabetes and hypertension. Human mesenchymal stem cells from 3 donors were obtained and differentiated in vitro according to published methods. RNA from samples of the undifferentiated, mid-way differentiated and fully differentiated cells was isolated for analysis of differential gene expression.

[1470] BP24.2. Diet Induced Obesity

[1471] The predominant cause for obesity in clinical populations is excess caloric intake. This so-called diet-induced obesity (DIO) is mimicked in animal models by feeding high fat diets of greater than 40% fat content. The DIO study was established to identify the gene expression changes contributing to the development and progression of diet-induced obesity. In addition, the study design seeks to identify the factors that lead to the ability of certain individuals to resist the effects of a high fat diet and thereby prevent obesity. The sample groups for the study had body weights +1 S.D., +4 S.D. and +7 S.D. of the chow-fed controls (below). In addition, the biochemical profile of the +7 S.D. mice revealed a further stratification of these animals into mice that retained a normal glycemic profile in spite of obesity and mice that demonstrated hyperglycemia. Tissues examined included hypothalamus, brainstem, liver, retroperitoneal white adipose tissue (WAT), epididymal WAT, brown adipose tissue (BAT), gastrocnemius muscle (fast twitch skeletal muscle) and soleus muscle (slow twitch skeletal muscle). The differential gene expression profiles for these tissues should reveal genes and pathways that can be used as therapeutic targets for obesity. The bar graph in FIG. 1 indicates results.

[1472] Polyamine Oxidase:

[1473] In multiple genecalling studies we have found the enzyme spermidine/spermine acetyl transferase to be dysregulated in various disease models (see below). This enzyme is one of the rate-limiting enzymes in the production of polyamines spermidine and spermine (see FIG. 6). FIG. 6 shows pathways where alterations in expression of the human polyamine oxidase and associated gene products function in the etiology and pathogenesis of obesity and/or diabetes. The scheme incorporates the unique findings of these discovery studies in conjunction with what has been reported in the literature. The outcome of inhibiting the action of the human polyamine oxidase would be a way to increase lypolysis by inhibiting anti-lypolytic effects of hydrogen peroxide. Previously, it was shown that oxidation of polyamines leads to generation of hydrogen peroxide, which has been shown to have antilipolytic effect of adipose and may therefore be involved in the progression of obesity. The enzyme catalyzing the reaction where hydrogen peroxide is produced, i.e. oxidation of secondary amino group of spermine, spermidine and their acetyl derivatives, is polyamine oxidase. Therefore, we nominate the enzyme polyamine oxidase as a valuable tool to inhibit the polyamine pathway and the production of hydrogen peroxide.

[1474] Rationale for Use as a Diagnostic and/or Target for Small Molecule Drugs and Antibody Therapeutics:

[1475] The following is a summary of the findings from the discovery studies, supplementary investigations and assays that also incorporates knowledge in the scientific literature. Taken in total, the data indicates that an inhibitor/antagonist of the human Polyamine oxidase would be beneficial in the treatment of obesity and/or diabetes (FIG. 5 shows biochemistry for human polyamine oxidase and assays that may be used to screen for antibody therapeutics or small molecule drugs to treat obesity and/or diabetes. Cell lines expressing the polyamine oxidase can be obtained from the RTQ-PCR results shown above. These and other polyamine oxidase-expressing cell lines could be used for screening purposes.

TABLE 1
Spermidine/spermine N-acetyltransferase Gene Sequence
identified in NZB vs SM/J mice
(Identified fragment from 206 to 616 in bold. band size: 411)
1   GCTCCCGGGA AACGAATGAG GAACCACCTC CTCCTGCTGT TCAAGTACAG GGGCCTCGTG
61  CGCAAAGGGA AGAAAAGCAA AAGACGAAAA TGGCTAAATT TAAGATCCGT CCAGCCACTG
121 CCTCTGACTG CAGTGACATC CTGCGACTGA TCAAGGAACT GGCTAAATAT GAATACATGG
181 AAGATCAAGT CATTTTAACT GAGAAAGATC TCCAAGAGGA TGGCTTTGGA GAACACCCCT
241 TCTACCACTG CCTGGTTGCA GAAGTGCCTA AAGAGCACTG GACCCCTGAA GGACATAGCA
301 TTGTTGGGTT CGCCATGTAC TATTTTACCT ATGACCCATG GATTGGCAAG TTGCTGTATC
361 TTGAAGACTT CTTCGTGATG AGTGATTACA GAGGCTTTGG TATAGGATCA GAAATTTTGA
421 AGAATCTAAG CCAGGTTGCC ATGAAGTGTC GCTGCAGCAG TATGCACTIC TTGGTAGCAG
481 AATGGAATGA ACCATCTATC AACTTCTACA AAAGAAGAGG TGCTTCGGAT CTGTCCAGTG
541 AAGAGGGATG GAGGCTCTTC AAGATTGACA AAGAGTACTT GCTAAAAATG CCAGCAGAGG
601 AGTGAGGCGT GCCGGTGTAG ACAATGACAA CCTCCATTGT GCTTTAGAAT AATTCTCAGC
661 TTCCCTTGCT TTCTATCTTG TGTGTAGTGA AATAATAGAG CGAGCACCCA TTCCAAAGCT
721 TTATTACCAG TGACGTTGTT GCATGTTTGA AATTCGGTCT GTTTAAAGTG GCAGTCATGT
781 ATGTGGTTTG GAGGCAGAAT TCTTGAACAT CTTTTGATGA AGAACAACGT GGTATGATCT
841 TACTATATAA GAAAAACAAA ACTTCATTCT TGTGAGTCAT TTAAATGTGT ACAATCTACA
901 CACTGGTACT TAGAGTTTCT GTTTTGATTC TTTTTTTTTA AATAAACTCG CTCTTTGATT
961 T

[1476]

TABLE 2
Spermidine/spermine N-acetyltransferase Gene Sequence
identified in C57B1/6 obese euglycemic sd7 vs obese sd1
(Identified fragment from 716 to 893 in bold. band size: 178)
235 ACCCCTTCTA CCACTGCCTG GTTGCAGAAG TGCCTAAAGA GCACTGGACC CCTCAAGCAC
295 ATAGCATTGT TGGGTTCGCC ATGTACTATT TTACCTATGA CCCATGGATT GGCAAGTTCC
355 TGTATCTTGA AGACTTCTTC GTGATGAGTG ATTACAGAGG CTTTGGTATA GGATCAGAAA
415 TTTTGAAGAA TCTAAGCCAC GTTGCCATGA AGTGTCCCTC CAGCAGTATG CACTTCTTGG
475 TAGCAGAATC CAATGAACCA TCTATCAACT TCTACAAAAC AAGAGGTGCT TCGGATCTGT
535 CCAGTGAAGA GGGATGGAGG CTCTTCAAGA TTGACAAAGA CTACTTGCTA AAAATGGCAG
595 CAGAGGAGTG AGGCQTGCCG GTGTAGACAA TGACAACCTC CATTGTGCTT TAGAATAATT
655 CTCAGCTTCC CTTCCTTTCT ATCTTGTGTG TAGTGAAATA ATAGAGCGAC CACCCATTCC
715 AAAGCTTTAT TACCAGTCAC GTTGTTGCAT GTTTGAAATT CGGTCTGTTT AAAGTGGCAG
775 TCATGTATGT GGTTTGGAGG CAGAATTCTT GAACATCTTT TGATGAAGAA CAAGGTGGTA
835 TGATCTTACT ATATAAGAAA AACAAAACTT CATTCTTGTG AGTCATTTAA ATGTGTACAA
895 TGTACACACT GGTACTTAGA GTTTCTGTTT TGATTCTTTT TTTTTAAATA AACTCCCTCT
955 TTGATTT

[1477]

TABLE 3
Spermidine/spermine N-acetyltransferase Gene Sequence
identified in human adipocyte mid-way vs undifferentiated
(Identified fragment from 162 to 355 in bold. band size: 149)
1   CTGGTGTTTA TCCGTCACTC GCCGAGGTTC CTTGGGTCAT GCTGCCAGCC TGACTGAGAA
61  GAGGACGCTC CCGGGACACG AATGAGGAAC CACCTCCTCC TACTGTTCAA GTACAGCGGC
121 CTGGTCCGCA AAGGGAAGAA AAGCAAAAGA CGAAAATGGC TAAATTCGTG ATCCGCCCAG
181 CCACTGCCGC CGACTGCAGT GACATACTGC GGCTGATCAA GGAGCTGGCT AAATATGAAT
241 ACATGGAAGA ACAAGTAATC TTAACTGAAA AAGATCTGCT AGAAGATGGT TTTGGAGAGC
301 ACCCCTTTTA CCACTGCCTG GTTGCAGAAG TGCCGAAAGA GCACTGGACT CCGGA                  AGGTT
361 ACAGTCTCTA GCTTCGCCAT GTACATGGCC CTTCCGTGTA CATGGATGGG CGGGGAGGTA
421 ACTAAAAGAT CCTTTACACA ATAAAGTAGA TGATCATGAT AAATGAGGAC ACAGCATTGT
481 TGGTTTTGCC ATGTACTATT TTACCTATGA CCCGTGGATT GGCAAGTTAT TGTATCTTGA
541 GGACTTCTTC GTGATGAGTG ATTATAGAGG CTTTGGCATA GGATCAGAAA TTCTGAAGAA
601 TCTAAGCCAG GTTGCAATGA GGTGTCGCTG CAGCAGCATG CACTTCTTGG TAGCAGAATG
661 GAATGAACCA TCCATCAACT TCTATAAAAG AAGAGGTGCT TCTGATCTGT CCAGTGAAGA
721 GGGTTGGAGA CTGTTCAAGA TCGACAAGGA GTACTTGCTA AAAATGGCAA CAGAGGAGTG
781 AGGAGTGCTG CTGTAGATGA CAACCTCCAT TCTATTTTAG AATAAATTCC CAACT

[1478]

TABLE 4
Human Polyamine Oxidase (CG140122-01)
DNA and Protein Sequence
CGCCGCTCGCCGCAGACTTACTTCCCCGGCTCAGCACGGAAAGGTTCCTA
GAAGGTGAGCGCGGACGGTATGCAAAGTTGTGAATCCAGTGGTGACAGTG
CGGATGACCCTCTCAGTCGCGGCCTACGGAGAAGGGGACAGCCTCGTGTG
GTGGTGATCGGCGCCGGCTTGGCTGGCCTGGCTGCAGCCAAAGCACTTCT
TGAGCAGGGTTTCACGGATGTCACTGTGCTTGAGGCTTCCAGCCACATCG
GAGGCCGTGTGCAGAGTGTGAAACTTGGACACGCCACCTTTGAGCTGGGA
GCCACCTGGATCCATGGCTCCCATGGGAACCCTATCTATCATCTAGCAGA
AGCCAACGGCCTCCTGGAAGAGACAACCCATGGGGAACGCAGCGTGGGCC
GCATCAGCCTCTATTCCAAGAATGGCGTCGCCTGCTACCTTACCAACCAC
GGCCGCAGGATCCCCAACGACGTGGTTGAGGAATTCAGCGATTTATACAA
CCAGCTCTATAACTTGACCCAGGAGTTCTTCCGCCACGATAAACCAGTCA
ATGCTGAAAGTCAAAATAGCGTGGGGGTGTTCACCCGAGAGGAGGTGCGT
AACCGCATCAGGAATGACCCTGACGACCCAGAGGCTACCAAGCGCCTGAA
GCTCGCCATGATCCAGCAGTACCTCAACCTGGAGAGCTGTGAGAGCAGCT
CACACAGCATGGACGAGCTGTCCCTGAGCGCCTTCGGGGAGTGGACCGAG
ATCCCCGGCGCTCACCACATCATCCCCTCGGGCTTCATGCGGGTTGPGGA
GCTGCTGGCGGAGGGCATCCGTGCCCACGTCATCCAGCTAGGGAAACCTG
TCCGCTGCATTCACTGGGACCAGGCCTCAGCCCGCCCCAGAGGCCCTGAG
ATTGAGCCCCGGGGTGAGGGCGACCACAATCACGACACTGGGGAGGGTGG
CCAGGGTGGAGAGGAGCCCCGGGGGGGCAGGTGGGATGAGGATGAGCAGT
GGTCGGTGGTGGTGGAGTGCGAGGACCGTGAGCTGATCCCGGCGGACCAT
GTGATTGTGACCGTGTCGCTAGGTGTGCTAAAGAGGCAGTACACCAGTTT
CTTCCGGCCAGGCCTGCCCACAGAGAAGGTGGCTGCCATCCACCGCCTGG
CCATTGGCACCACCGACAAGATCTTTCTGGAATTCGAGGAGCCCTTCTGG
GGCCCTGAGTGCAACAGCCTACAGTTTGTGTGGCAGCACGAAGCGGAGAG
CCACACCCTCACCTACCCACCTGACCTCTGGTACCGCAAGATCTGCGGCT
TTGATGTCCTCTACCCGCCTGAGCGCTACGGCCATGTGCTGAGCGGCTGG
ATCTGCGGGGAGGAGGCCCTCGTCATGGAGAAGTGTGATGACGAGGCAGT
GGCCGAGATCTGCACGGAGATGCTGCGTCAGTTCACAGGGAACCCCAACA
TTCCAAAACCTCGGCGAATCTTGCGCTCGGCCTGGGGCAGCAACCCTTAC
TTCCGTGGCTCCTATTCATACACGCAGGTGGGCTCCAGCGGGGCGGATGT
GGAGAAGCTGGCCAAGCCCCTGCCCTACACGGAGAGCTCAAAGACAGCCC
CCATGCAGGTGCTGTTTTCCGGTCAGGCCACCCACCGCAACTACTATTCC
ACCACCCACGGTGCTCTCCTGTCCGGCCAGCGTGAGGCTGCCCGCCTCAT
TGAGATGTACCGAGACCTCTTCCACCAGGGGACCTGAGGGCTGTCCTCGC
TOCTGAGAAGAGCCACTAACTCGTGACCTCCACCCTGCCCCTTCCTCCCG
TGTGCTCCTGCCTTCCTGATCCTCTGTAGAAAGGATTTTTATCTTCTGTA
GAGCTAGCCGCCCTGACTGCCTTCAGACCTGGCCCTGTAGCTTT

[1479]

TABLE 5
CG140122-01-prot                      325 aa
MQSCESSGDSADDPLSRGLRRRGQPRVVVIGAGLAGLAAAKALLEQGFTD
VTVLEASSHIGGRVQSVKLGHATFELGATWIHGSHGNPIYHLAEANGLLE
ETTDGERSVGRISLYSKNGVACYLTNHGRRTPKDVVEEPSDLYNEVYNLT
QEFFRHDKPVNAESQNSVGVFTREEVRNRIRNDPDDPEATKRLKLAMIQQ
YLKVESCESSSHSMDEVSLSAFGEWTEIPGAHHIIPSGFMRVVELLAEGI
PAINTQLGKPVRCIHWDQASARPRGPEIEPRGEGDHNHDTGECGQGGEEP
RGGRWDEDEQWSVVVECEDRELIPADHVIVTVSLGVLKRQYTSFFRPGLP
TEKVAAIHRLGIGTTDKIFLEFEEPPWGPECNSLQFVWEDEAESHTLTYP
PELWYRKICGFDVLYPPERYCHVLSGWICGEEALVMEKCDDEAVAEICTE
MLRQFTGNPNIPKPRRILRSAWGSNPYFRGSYSYTQVGSSGADVEKLAKP
LPYTESSKTAPMQVLFSOEATHRKYYSTTHGALLSGQREAARLIEMYRDL
FOOGT

[1480] Table 6. Clustal W, Protein Domains, Cellular Location and Locus

[1481] The following is an alignment of the protein sequences of CG140122-01 and its alternative spliced variant CG140122-02, which are the equivalent of the public sequences AY033889 and BC000669.1, respectively. They are clustalled with the polyamine oxidase of Zea Mays, of which the structural analysis has revealed much of the domain structure of this amine oxidase. The region in bold represents the amine oxidase domain. The dotted region reprsents the signal peptide.

[1482] The variants of the human Polyamine oxidase obtained from direct cloning and/or public databases:

[1483] In addition to the human version of the Polyamine oxidase identified as being differentially expressed in the experimental study, no other variants have been identified by direct sequencing of cDNAs derived from many different human tissues and from sequences in public databases. The two alternative spliced variants (see clustalW above) are public sequences; no other splice variants have been identified at CuraGen. No SNPs have been found for polyamine oxidase. The preferred variant of all those identified, to be used for screening purposes, is CG140122-01.

[1484] Species #1 Mouse Strains NZB, SM/J, C56B1/6

[1485] Species # 2 Human

[1486] SPECIES #1 Mouse (NZB vs SM/J):

[1487] A gene fragment of the mouse spermine/spermidine N-acetyltransferase was initially found to be upregulated by 1.9 fold in the adipose of NZB mice relative to SM/J mice using CuraGen's GeneCalling™ method of differential gene expression. A differentially expressed mouse gene fragment migrating at approximately 411 nucleotides in length (FIG. 1a.—red vertical line) was definitively identified as a component of the mouse spermine/spermidine N-acetyltransferase cDNA in NZB and SM/J mouse strains. The method of competitive PCR was used for conformation of the gene assessment. The chromatographic peaks corresponding to the gene fragment of the mouse spermidine/spermine N-acetyltransferase are ablated when a gene-specific primer (see below) which competes with primers in the linker-adaptors during the PCR amplification. The peaks at 411 nt in length are ablated (green trace) in the sample from both the NZB and the SM/J mice. The altered expression in of these genes in the animal model support the role of Polyamine Oxidase in the pathogenesis of obesity and/or diabetes.

[1488] SPECIES #1 Mouse (C57B1/6 Obese Euglycemic sd7 vs Obese sd1):

[1489] FIGS. 3A and 3B show that a differentially expressed gene fragment of the mouse spermine/spermidine N-acetyltransferase was initially found to be upregulated by 1.8 fold in the epididymal fat pad of the obese euglycemic sd7 mice relative to the obese sd1 mice using CuraGen's GeneCalling™ method of differential gene expression. A differentially expressed rat gene fragment migrating at approximately 178 nucleotides in length (FIGS. 3A and 3B—vertical line) was definitively identified as a component of the mouse spermine/spermidine N-acetyltransferase cDNA in the Troglitazone treated and the untreated SHR control rats (in the graphs, the abscissa is measured in lengths of nucleotides and the ordinate is measured as signal response). The method of competitive PCR was used for conformation of the gene assessment. The electropherogramatic peaks corresponding to the gene fragment of the mouse spermidine/spermine N-acetyltransferase are ablated when a gene-specific primer (see below) which competes with primers in the linker-adaptors during the PCR amplification. The peaks at 178 nt in length are ablated (green trace) in the sample from both the C57B1/6 obese euglycemic sd7 and obese sd1 mice. The altered expression in of these genes in the animal model support the role of Polyamine Oxidase in the pathogenesis of obesity and/or diabetes.

[1490] SPECIES #2 Human (Adipocyte Mid-Way vs Undifferentiated):

[1491] FIG. 4 shows a differentially expressed gene fragment in Discovery Study MB.08 identified in human adipocyte mid-way vs undifferentiated is from the human spermidine/spermine N-acetyltransferase A gene fragment of the human spermine/spermidine N-acetyltransferase was initially found to be upregulated by 1.6 fold in the mid-way human adipocytes relative to the undifferentiated human adipocytes using CuraGen's GeneCalling™ method of differential gene expression. A differentially expressed human gene fragment migrating at approximately 194 nucleotides in length (FIG. 3A—vertical line) was definitively identified as a component of the human spermine/spermidine N-acetyltransferase cDNA in human mid-way differentiated and undifferentiated adipocytes (in the graphs, the abscissa is measured in lengths of nucleotides and the ordinate is measured as signal response). The method of competitive PCR was used for conformation of the gene assessment. The chromatographic peaks corresponding to the gene fragment of the human spermine/spermidine N-acetyltransferase are ablated when a gene-specific primer (see below) which competes with primers in the linker-adaptors during the PCR amplification. The peaks at 194 nt in length are ablated (green trace) in the sample from both the human mid-way differentiated and undifferentiated adipocytes. The altered expression of these genes in the human cellular model support the role of Polyamine Oxidase in the pathogenesis of obesity and/or diabetes.

[1492] ODC=ornithine decarboxylase

[1493] PAO=polyamine oxidase

[1494] SSAT=spermidine/spermine N-acetyltransferase

[1495] Biochemistry of PAO:

[1496] Catalyses oxidation of secondary amino group of spermine, spermidine and their acetyl derivatives

[1497] Cofactor FAD

[1498] Monomeric

[1499] The following illustration suggests how alterations in expression of the human polyamine oxidase and associated gene products function in the etiology and pathogenesis of obesity and/or diabetes. The scheme incorporates the unique findings of these discovery studies in conjunction with what has been reported in the literature. The outcome of inhibiting the action of the human polyamine oxidase would be a way to increase lypolysis by inhibiting anti-lypolytic effects of hydrogen peroxide. 4

[1500] D. NOV 14a—Human Cytoplasmic Malic Enzyme—CG140316-01

[1501] The present invention discloses novel associations of proteins and polypeptides and the nucleic acids that encode them with various diseases or pathologies. The proteins and related proteins that are similar to them are encoded by a cDNA and/or by genomic DNA. The proteins, polypeptides and their cognate nucleic acids were identified by CuraGen Corporation in certain cases. The Cytoplasmic Malic Enzyme-encoded protein and any variants, thereof, are suitable as diagnostic markers, targets for an antibody therapeutic and targets for small molecule drugs. As such the current invention embodies the use of recombinantly expressed and/or endogenously expressed protein in various screens to identify such therapeutic antibodies and/or therapeutic small molecules.

[1502] Discovery Process

[1503] The following sections describe the study design(s) and the techniques used to identify the Cytoplasmic Malic Enzyme—encoded protein and any variants, thereof, as being suitable as diagnostic markers, targets for an antibody therapeutic and targets for a small molecule drugs for Obesity and Diabetes.

[1504] Studies:

[1505] BP24.02 Dietary Induced Obesity in Mice

[1506] MB.04: Genetic Models of Obesity in Mice

[1507] Study Statements:

[1508] BP24.02: The predominant cause for obesity in clinical populations is excess caloric intake. This so-called diet-induced obesity (DIO) is mimicked in animal models by feeding high fat diets of greater than 40% fat content. The DIO study was established to identify the gene expression changes contributing to the development and progression of diet-induced obesity. In addition, the study design seeks to identify the factors that lead to the ability of certain individuals to resist the effects of a high fat diet and thereby prevent obesity. The sample groups for the study had body weights +1 S.D., +4 S.D. and +7 S.D. of the chow-fed controls (below). In addition, the biochemical profile of the +7 S.D. mice revealed a further stratification of these animals into mice that retained a normal glycemic profile in spite of obesity and mice that demonstrated hyperglycemia. Tissues examined included hypothalamus, brainstem, liver, retroperitoneal white adipose tissue (WAT), epididymal WAT, brown adipose tissue (BAT), gastrocnemius muscle (fast twitch skeletal muscle) and soleus muscle (slow twitch skeletal muscle). The differential gene expression profiles for these tissues should reveal genes and pathways that can be used as therapeutic targets for obesity.

[1509] MB.04: A large number of mouse strains have been identified that differ in body mass and composition. The AKR and NZB strains are obese, the SWR, C57L and C57BL/6 strains are of average weight whereas the SM/J and Cast/Ei strains are lean. Understanding the gene expression differences in the major metabolic tissues from these strains will elucidate the pathophysiological basis for obesity. These specific strains of rat were chosen for differential gene expression analysis because quantitative trait loci (QTL) for body weight and related traits had been reported in published genetic studies. Tissues included whole brain, skeletal muscle, visceral adipose, and liver.

[1510] Species #1 Mouse Strains C57BL/6

[1511] Species #2 Mouse Strains NZB, SMJ

[1512] Cytoplasmic Malic Enzyme:

[1513] This gene encodes a cytosolic, NADP-dependent enzyme that generates NADPH for fatty acid biosynthesis. The NADP-dependent malic enzyme (EC 1.1.1.40) has two forms: cytosolic and mitochondrial, that differ significantly in their activity and tissue distribution. The activity of the cytosolic enzyme, the reversible oxidative decarboxylation of malate, links the glycolytic and citric acid cycles. The reaction it catalyzes is:

Malate+NADP+⇄Pyruvate+CO2+NADPH

[1514] Cytoplasmic malic enzyme is one of the anaplerotic reactions, replenishing intermediates of the citrate cycle that are utilized for biosynthesis. It also participates in the pyruvate-citrate shuttle, enabling the export of acetyl CoA from the mitochondrion to cytoplasm for fatty acid synthesis. The regulation of expression for this gene is complex. Increased expression can result from elevated levels of thyroid hormones or by higher proportions of carbohydrates in the diet.

[1515] The direct sequence of the nucleotide-long gene fragment and the gene-specific primers used for competitive PCR are indicated on the cDNA sequence of the Cytoplasmic Malic Enzyme and shown below in bold.

[1516] Competitive PCR Primer for the Mouse Cytoplasmic Malic Enzyme:

TABLE 1
Sequence Gene Sequence #1
(fragment from 1520 to 1801 in bold. band size: 282)
1039 AAAGGACTAA TAGTTAAGGG TCGTGCATCT CTCACAGAAG AGAAAGAGGT GTTTGCCCAT
1099 GAACATGAAG AAATGAACAA TCTGGAACCC ATTGTTCAAA AGATAAAACC AACTGCCCTC
1159 ATAGGAGTTG CTGCAATTGC TGGTGCTTTC ACTCAACAAA TTCTCAAGOA TATGGCTGCC
1219 TTCAACGAGC GGCCCATCAT CTTTGCTTTC AGTAATCCGA CCAGCAAAGC GGAGTGCTCT
1279 GCAGACCACT GCTACAAGGT GACCAAGGGA CGTGCAATCT TTGCCAGCGG CAGTCCTTTT
1339 GATCCAGTCA CTCTCCCAGA TGGACGGACT CTGTTTCCTG GCCAAGGCAA CAATTCCTAC
1399 GTGTTCCCTG GAGTTGCTCT TGGGGTGGTG GCCTGCGGAC TGAGACACAT CGATGATAAG
1459 GTCTTCCTCA CCACTGCTGA GGTCATATCT CAGCAAGTGT CAGATAAACA CCTGCAAGAA
1519 GGCCGGCTCT ATCCTCCTTT GAATACCATT CGAGGCGTTT CGTTGAAAAT TGCAGTAAAG
1579 ATTGTGCAAG ATGCATACAA AGAAA&GATG GCCACTGTTT ATCCTGAACC CCAAAACAAA
1639 GAAGAATTTG TCTCCTCCCA GATGTACAGC ACTAATTATG ACCAGATCCT ACCTGATTGT
1699 TATCCGTGGC CTGCAGAAGT CCAGAAAATA CAGACCAAAG TCAACCAGTA ACGCAACAGC
1759 TAGGATTTTT AACTTTATTA GTAAAATCTT GAAGTTTTCA TGATCTTTAA CGGTCACAAT
1819 CTTTTATGAT GATTCATAGT GTGCTTACAA TAACOTCATT TTAGTTTAAT AACAAACTCA
1879 TGGGAGTCTA TTAGGATAAA TTAGGATAAA TTTCACACCA CACGGTTTTG TTTCACTTAC
1939 TGTCGATATT TATGTTTTCT CTTGTGATTA TTCTCTTTAT GAATTCTGTT TAAAAGCTAC
1999 TGTACCTCCT CCTGAGAAAG TCCTCACTGA TATGTAGGAA GCTAATGGAA GACCCACACT
2059 AGTAATAAAT TAATATAGCA TAACTTGATT ACATTTAATG CCTACAGTTC TTTCTTGACT
2119 ATTTTGCTAA AATCTCTTAA ACAGAAAAGA TAAACACAAA CTTGGGTATA GCTGAACTTT
2179 TACTAAACAG AAGCACTACT TTCTTGCCTA GAGAAAATCT TCTCAGGACT TTTATTCCAG
2239 GCCTCCGTTA GCTTTGTTCT CTTTCTACAC CTCACTCAAC ACC
(gene length is 3105, only region from 1039 to 2281 shown)

[1517]

TABLE 2
Sequence #2 Gene Sequence
(fragment from 245 to 420 in bold. band size: 176)
1   CGCCGGGCGG CTTGGGCGGC CGCCGCCCGC CGGACTCCGC GTCCGCCCCG CCACCGGTCC
61  CAGCCATGGA GCCCCCACCC CCCCGCCGCC GACACACCCA CCAGCCCCGC TACCTCCTGA
121 CGCGGGACCC CCATCTCAAC AAGGGACTTG CTTTTAGTCT GGAAQACACA CAGCACTTGA
181 ACATTCATGG ATTGTTGCCG CCCTGCATCA TCAGCCAGGA GCTCCAGGTC CTTAGAATAA
241 TTAAGAATTT CGAACGACTG AACTCTGACT TCGACAGGTA TCTCCTGTTA ATGGACCTGC
301 AAGACAGAAA TCAGAAGCTC TTCTACAGCG TGCTCATGTC TGATGTTGAA AAGTTCATGC
361 CTATTCTTTA CACCCCCACC GTGGGCCTCG CATGCCAGCA GTACAGTTTG CCATTCCGGA
421 AGCCAAGAGG CCTCTTTATT AGTATCCATG ACAAAGGCCA CATTGCTTCA GTTCTTAATG
481 CATGGCCAGA GGATGTCGTC AACGCTATTG TGGTAACTGA TGGAGAGCGC ATCCTTGGC1
541 TGGGAGACCT TGGCTGTAAT GGGATGGCCA TCCCTGTGCG TAAACTCGCC CTTTACACGG
601 CATGTGGAGG GGTGAACCCA CAACAGTCTC TACCCATCAC TTTGAATGTC GCAACAGAAA
661 ATGAGGAGTT ACTTAAGGAT CCACTGTACA TCGGGCTGCG GCACCGGCGA GTCAGAGGCC
721 CTGAGTATGA CGCCTTCCTG GATGAGTTCA TGGAGGCAGC GTCTTCCAAA TATGGCATGA
781 ATTGCCTTAT TCAGTTTGAA GATTTTGCCA ATCGGAATGC ATTTCGTCTC CTGAACAAGT
841 ATCGAAACAA GTATTGCACA TTTAACGATG ATATTCAAGG AACAGCGTCT GTTGCGGTTG
(gene length is 3129, only region from 1 to 900 shown)

[1518]

TABLE 3
Human Cytoplasmic Malic Enzyme Gene Sequence
>CG140316-01    2058 nt
ATGGAGCCCGAAGCCCCCCGTCGCCGCCACACCCATCAGCGCGGCTACCT
GCTGACACGGAACCCTCACCTCAACAAGCACTTGGCCTTTACCCTGGAAG
AGAGACAGCAATTGAACATTCATGGATTGTTGCCACCTTCCTTCAACAGT
CAGGAGATCCAGGTTCTTAGAGTAGTAAAAAATTTCGAGCATCTGAACTC
TGACTTTGACAGGTATCTTCTCTTAATGGATCTCCAAGATAGAAATCAAA
AACTCTTTTATAGAGTCCTGACATCTGACATTGAGAAATTCATCCCTATT
GTTTATACTCCCACTGTGGGTCTGGCTTGCCAACAATATAGTTTGGTGTT
TCCGAAGCCAAGAGGTCTCTTTATTACTATCCACCATCGAGGGCATATTG
CTTCACTTCTCAATGCATGGCCAGAAGATGTCATCAAGGCCATTGTGGTG
ACTGATGGAGAGCGTATTCTTGCCTTGGGAGACCTTGGCTGTAATGGAAT
GCCCATCCGTGTGGCTAAATTGGCTCTATATACACCTTGCGGAGGGATGA
ATCCTCAAGAATGTCTGCCTGTCATTCTGGATGTGGGAACCGAAAATCAG
GACTTACTTAAAGATCCACTCTACATTGGACTACGGCAGAGAAGAGTAAG
AGGTTCTGAATATGATGATTTTTTGGACGAATTCATGGAGGCAGTTTCTT
CCAAGTATGGCATGAATTGCCTTATTCAGTTTCAAGATTTTGCCAATGTG
AATGCATTTCGTCTCCTGAACAAGTATCGAAACCAGTATTGCACATTCAA
TGATGATATTCAAGGAACAGCATCTGTTGCACTTGCAGGTCTCCTTGCAG
CTCTTCGAATAACCAAGAACAAACTGTCTGATCAAACAATACTATTCCAA
GGAGCTGGAGAGGCTGCCCTAGGGATTGCACACCTGATTGTGATGGCCTT
GGAAAAAGAAGGTTTACCAAAAGAGAAAGCCATCAAAAAGATATGGCTGG
TTGATTCAAAAGGATTAATAGTTAAGGGACGTGCTTCCTTAACACAAGAC
AAAGACAAGTTTGCCCATGAACATGAAGAAATGAAGAACCTAGAAGCCAT
TCTTCAAGAAATAAAACCAACTCCCCTCATAGCAGTTGCTGCAATTGGTG
GTGCATTCTCAGAACAAATTCTCAAAGATATGGCTGCCTTCAATGAACCG
CCTATTATTTTTCCTTTGAGTAATCCAACTAGCAAAGCAGAATGTTCTGC
AGAGCAGTGCTACAAAATAACCAAGGGACGTGCAATTTTTGCCAGTGGCA
GTCCTTTTGATCCAGTCACTCTTCCAAATGGACAGACCCTATATCCTGGC
CAAGGCAACAATTCCTACGTGTTCCCTGGAGTTGCTCTTGGTGTTGTGGC
GTGTGGATTGAGGCAGATCACAGATAATATTTTCCTCACTACTGCTGAGG
TTATAGCTCAGCAAGTGTCAGATAAACACTTGGAAGAGGGTCGGCTTTAT
CCTCCTTTGAATACCATTAGAGATGTTTCTCTGAAAATTGCAGAAAAGAT
TGTGAAAGATGCATACCAAGAAAAGACAGCCACAGTTTATCCTGAACCGC
AAAACAAAGAAGCATTTCTCCGCTCCCAGATGTATAGTACTGATTATGAC
CAGATTCTACCTGATTGTTATTCTTGGCCTGAACAGGTGCAGAAAATACA
GACCAAAGTTGACCAGTAGGATAATAGCAAACATTTCTAACTCTATTAAT
GAGGTCTTTAAACCTTTCATAATTTTTAAAGGTTGGAATCTTTTATAATG
ATTCATAAGACACTTAGATTAAGATTTTACTTTAACAGTCTAAAAATTGA
TAGAAGAATATACGGAGAAACTCATCATTTTTATACAGGACACTAATGGG
AAGACCAAAATTACTAATAAATTTATGGTTTCTGTCTGAATTATTCTGCC
TACGTTCTCTTTAAAAGCTGTTGTACGTACTACCCAGAAACTCATCATTT
TTATACAGGACACTAATGGGAAGACCAAAATTACTAATAAATTCAAATAA
CCAACATT

[1519]

TABLE 4
Amino acid sequence of Human Cytoplamic Malic
Enzyme Protein Sequence
Human Cytoplasmic Malic Enzyme Protein Sequence:
ORF Start: 1   ORF Stop: 1717   Frame: 1
>CG140316-01-prot    572 aa
MEPEAPRRRHTHQRGYLLTRNPHLNKDLAFTLEERQQLNIHGLLPPSFNS
QEIQVLRVVKNFEHLNSDFDRYLLLMDLQDRNEKLFYRVLTSDIEKFMPI
VYTPTVGLACQQYSLVFRKPRGLFITIHDRGHIASVLNAWPEDVIKAIVV
TDGERILGLGDLGCNGMGIPVGKLALYTACGGMNPQECLPVILDVGTENE
ELLKDPLYIGLRQRRVRGSEYDDFLDEFMEAVSSKYGMNCLIQFEDFANV
NAFRLLNKYRNQYCTFNDDIQGTASVAVAGLLAALRITKNKLSDQTILFQ
GAGEAALGIAHLIVMALEKEGLPKEKAIMCIWLVDSKGLIVKGRASLTQE
KEKFAHEHEEMKNLEAIVQEIKPTALIGVAAIGGAPSEQILKDMAAFNER
PIIPALSNPTSKAECSAEQCYKITRGRAIPASGSPFDPVTLPNGQTLYPG
QGNNSYVFPGVALGVVACGLRQITDNIFLTTAEVIAQQVSDKHLEEGRLY
PPLNTIRDVSLKIAEKIVKDAYQEKTATVYPEPQMKEAFVRSOMYSTDYD
QILPDCYSWPEEVQKIQTKVDQ

[1520] Table 5. Clustal W, Protein Domains, Cellular Location and Locus

[1521] The following is an alignment of the protein sequences of the human (CG140316-01), mouse (BC011081.1) and pig (X93016.1) versions of the Cytoplasmic Malic Enzyme. Also included are a variant of this enzyme cloned from liver (CG140316-02) and the mitochondrial NADP-dependent malic enzyme (X79440.1). The domain delineated by the bold line indicates the malic enzyme domain.

[1522] Human Cytoplasmic Malic Enzyme:

[1523] 572aa

[1524] Locus: 6q12 (syntenic to mouse quantitative trait locus correlated with percentage of body fat. Ref: Mehrabian et al., J Clin Invest 1998; 101 (11): 2485-2496)

[1525] Intracellular

[1526] In addition to the human version of the Cytoplasmic Malic Enzyme identified as being differentially expressed in the experimental study, one other variant has been identified by direct sequencing of cDNAs derived from many different human tissues and from sequences in public databases (CG140316-02, FIG. 1C). No splice-form variants have been identified at CuraGen nor were any SNPs identified. The preferred variant of all those identified, to be used for screening purposes, is CG140316-01.

[1527] Biochemistry and Cell Line Expression:

[1528] The following illustrations summarizes the biochemistry surrounding the human Cytoplasmic Malic Enzyme and potential assays that may be used to screen for antibody therapeutics or small molecule drugs to treat obesity and/or diabetes. Generation of the reducing equivalents in form of NADPH may be coupled to enzymatic or fluorescent detection systems to provide a readout of the screening.

Malate+NADP+Pyruvate +CO2+NADPH

[1529] Cell lines that express the Cytoplasmic Malic Enzyme include PC-3, CaCo-2 and A549, as seen in the RTQ-PCR results shown in Table 6. These and other Cytoplasmic Malic Enzyme expressing cell lines could be used for screening purposes.

[1530] Findings:

[1531] The following is a summary of the findings from the discovery studies, supplementary investigations and assays that also incorporates knowledge in the scientific literature. Taken in total, the data indicates that an inhibitor/antagonist of the human Cytoplasmic Malic Enzyme would be beneficial in the treatment of obesity and/or diabetes.

[1532] 1. Cytoplasmic malic enzyme is upregulated in both liver and adipose of obese mice in different studies.

[1533] 2. Upregulation of cytoplasmic malic enzyme promotes fatty acid synthesis and anaplerotic reactions replenishing TCA cycle.

[1534] 3. Inhibiting cytoplasmic malic enzyme will decrease lipid synthesis and force utilization of stored fatty acids for energy generation.

[1535] 4. An inhibitor of this enzyme would therefore be an effective therapeutic for obesity.

[1536] SPECIES #1 (ngsd7 vs. sd1 Liver):

[1537] FIGS. 1A and 1B show that a gene fragment of the mouse Cytoplasmic Malic Enzyme was initially found to be up-regulated by 4 fold in the liver tissues of obese mice fed a high fat diet relative to mice resistant to weight gain (on the same diet) using CuraGen's GeneCalling® method of differential gene expression. A differentially expressed mouse gene fragment migrating, at approximately 283 nucleotides in length (FIG. 1A.—vertical line) was definitively identified as a component of the mouse Cytoplasmic Malic Enzyme cDNA (in the graphs, the abscissa is measured in lengths of nucleotides and the ordinate is measured as signal response). The method of competitive PCR was used for conformation of the gene assessment. The electropherogramatic peaks corresponding to the gene fragment of the mouse Cytoplasmic Malic Enzyme are ablated when a gene-specific primer (see below) competes with primers in the linker-adaptors during the PCR amplification. The peaks at 283 nt in length are ablated (green trace) in the sample from both the obese and non-obese mice.

[1538] SPECIES #2 (NZB vs. SMJ Adipose):

[1539] FIGS. 2A and 2B show that a gene fragment of the mouse Cytoplasmic Malic Enzyme was also found to be up-regulated by 3.2 fold in the adipose of obese NZB mice relative to lean SMJ mice using CuraGen's GeneCalling® method of differential gene expression. A differentially expressed mouse gene fragment migrating, at approximately 175.9 nucleotides in length (FIG. 2A.—vertical line) was definitively identified as a component of the mouse Cytoplasmic Malic Enzyme cDNA (in the graphs, the abscissa is measured in lengths of nucleotides and the ordinate is measured as signal response). The method of competitive PCR was used for conformation of the gene assessment. The electropherogramatic peaks corresponding to the gene fragment of the mouse Cytoplasmic Malic Enzyme are ablated when a gene-specific primer (see below) competes with primers in the linker-adaptors during the PCR amplification. The peaks at 175.9 nt in length are ablated (green trace) in the sample from both the obese and non-obese mice.

[1540] E. NOV15a—Human ATP Citrate Lyase—CG142427-01, CG142427-02, CG142427-03 and CG142427-04

[1541] The present invention discloses novel associations of proteins and polypeptides and the nucleic acids that encode them with various diseases or pathologies. The proteins and related proteins that are similar to them are encoded by a cDNA and/or by genomic DNA. The proteins, polypeptides and their cognate nucleic acids were identified by CuraGen Corporation in certain cases. The ATP Citrate Lyase-encoded protein and any variants, thereof, are suitable as diagnostic markers, targets for an antibody therapeutic and targets for small molecule drugs. As such the current invention embodies the use of recombinantly expressed and/or endogenously expressed protein in various screens to identify such therapeutic antibodies and/or therapeutic small molecules.

[1542] Discovery Process

[1543] The following sections describe the study design(s) and the techniques used to identify the ATP Citrate Lyase—encoded protein and any variants, thereof, as being suitable as diagnostic markers, targets for an antibody therapeutic and targets for a small molecule drugs for obesity and/or diabetes.

[1544] Studies:

[1545] MB.04: Lean vs. Obese Genetic Mouse Model

[1546] Study Statements:

[1547] MB.04: A large number of mouse strains have been identified that differ in body mass and composition. The AKR and NZB strains are obese, the SWR, C57L and C57BL/6 strains are of average weight whereas the SM/J and Cast/Ei strains are lean. Understanding the gene expression differences in the major metabolic tissues from these strains will elucidate the pathophysiologic basis for obesity. These specific strains of rat were chosen for differential gene expression analysis because quantitative trait loci (QTL) for body weight and related traits had been reported in published genetic studies. Tissues included whole brain, skeletal muscle, visceral adipose, and liver.

[1548] Species #1: Mouse Strains NZB vs SMJ, C57L, Cast, SWR

[1549] ATP Citrate Lyase:

[1550] ATP citrate-lyase is the primary enzyme responsible for the synthesis of cytosolic acetyl-CoA in many tissues. has a central role in de novo lipid synthesis. in nervous tissue it may be involved in the biosynthesis of acetylcholine. FIG. 1 shows a differentially expressed gene fragment from the mouse ATP Citrate Lyase.

[1551] Competitive PCR Primer for the Human ATP Citrate Lyase

[1552] Confirmatory Result—Human ATP Citrate Lyase (Discovery Study MB.04):

TABLE 1
Human ATP Citrate Lyase Gene Sequence
(Identified fragment from 1213 to 1277 in italic, band size: 65)
1   CTGGGTTCTTTATCGATTTTACTCGATGGCCGATGCCCATGATCAGCTTCCCCTCCTTCTTCATCTTGTTGACGAACTCC
81  ATGGGAATGATGCCGCTGTCAAAGGCTTTACTGAACATCTTTGCTGCGGCATCCAAGGCACCCCCAAACCGGTCTCCAAT
161 GGTGAGCAGCCCTGAGGTGAGGCTGGAGACCACGTCCTTCCCAGCCCGAGCACAGATGATGGTATTATGGGCTCCAGAGA
241 CAGCTGGCCCGTGATCAGCTGTGACCATCAGACACATCTCAATGAACTGGCAGGAATACTTGGGCAACCTTCTCTGGAAC
321 CAGAGGAGGCCGAAGACACCACCGATCCCCATCTCCTCCTTGAAGACCTCGGTGATCGGCATCCCCGCATAAATGAGCTC
401 CTGCCCTCGCTCATCACAGATGCTGGTCATGAATGAGGCAGGTTTTCGGATCAAACCCAGCTCTCTGGCCCAAGAGTAGT
481 CCATGGGCACTGTTGGAGGTGGCACTTCCTCCCCAGGTACAATGGCTCCTTTGGCCACCAGATCTTCATACACAGACTGA
561 ATGATTTCTCCAAGCTCATCGAAGCTTCGGGGCACAAACACTCCTGCTTCCTTCAAGGCCTGGTTCTTGGCTACTGCAGT
641 TTCAGAAGTCTGGTTGGCACAAGCTCCAGCATGGCCAAACTCGACCTCGGAGCAGAACATGGTGGCACAGGTCCCGATAC
721 ACCAGCAGACCACTGGCTTGGTGAGGCGGCCCTCCTTGATGCCCCGGCAGATCTTATATTCCTCTCTGCCCCCTATCTCC
801 CCAAGAACTACGATCATCTTGACTCCTGGAGTGTCCTGGTAGCGCAGCACGTGATCCATGAATGTGGACCCAGGGTACCT
881 GTCCCCGCCGATGGCCACGCCCTCATAGACACCATCTGTGGTCCGGGAGATGATGTTATTGAGTTCATTAGACATGCCTC
961 CTGAACGTGAGACGTAGGCCACGCTGCCTGGGCGCTACAGTTTGGAGGCCAGGATGTTGTCCAGCA

[1553]

TABLE 2
Nucleotide and pTotein sequence of Human ATP CitTate Lyase
CG142427-01
GGCACGAGGCCCGCACAAAAGCCGGATCCCGGGAAGCTACCGGCTGCTGGGGTGCTCCGGATTTTGCGGG
GTTCGTCGGGCCTGTGGAAGAAGCGCCGCGCACCGACTTCGGCAGAGGTAGAGCAGGTCTCTCTCCAGCC
ATGTCGGCCAAGGCAATTTCAGAGCAGACGGGCAAAGAACTCCTTTACAAGTTCATCTGTACCACCTCAG
CCATCCAGAATCGCTTCAACTATGCTCGGGTCACTCCTGACACACACTCGGCCCGCTTGCTCCAGGACCA
CCCCTGGCTGCTCAGCCAGAACTTGGTAGTCAAGCCAGACCAGCTGATCAAACCTCGTCGAAAAGTTGGT
CTCGTTGGGGTCAACCTCACTCTGGATGGGGTCAAGTCCTGGCTGAAGCCACGGCTGGGACAGGAAGCCA
CAGTTCGCAACGCCACAGCCTTCCTCAAGAACTTTCTGATCGAGCCCTTCGTCCCCCACAGTCAGGCTGA
GGAGTTCTATGTCTGCATCTATGCCACCCGAGAAGGGGACTACGTCCTGTTCCACCACGAGGGGGGTGTG
GACGTGGGTGATGTGGACGCCAAGGCCCAGAAGCTGCTTGTTGGCGTGGATGAGAAACTGAATCCTGAGG
ACATCAAAAAACACCTGTTGGTCCACGCCCCTGAAGACAAGAAAGAAATTCTGGCCAGTTTTATCTCCGG
CCTCTTCAATTTCTACGAGGACTTGTACTTCACCTACCTCGAGATCAATCCCCTTGTAGTGACCAAAGAT
GGAGTCTATGTCCTTGACTTGGCGGCCAAGGTGGACGCCACTGCCGACTACATCTGCAAAGTGAAGTGGG
GTGACATCCAGTTCCCTCCCCCCTTCGGGCGGGAGGCATATCCAGAGGAAGCCTACATTGCAGACCTCGA
TGCCAAAAGTGGGGCAAGCCTGAAGCTGACCTTGCTGAACCCCAAAGGGAGGATCTGGACCATGCTGCCC
GGGGGTGGCGCCTCTGTCGTGTACAGCGATACCATCTGTGATCTAGGGGGTGTCAACGACCTGGCAAACT
ATGGGGAGTACTCAGGCGCCCCCAGCGAGCAGCAGACCTATGACTATGCCAAGACTATCCTCTCCCTCAT
GACCCGAGAGAAGCACCCAGATGGCAAGATCCTCATCATTGCACGCAGCATCGCAAACTTCACCAACGTG
GCTGCCACGTTCAAGGGCATCGTGAGAGCAATTCCAGATTACCAGGGCCCCCTGAAGGAGCACGAAGTCA
CAATCTTTGTCCGAAGAGGTGGCCCCAACTATCAGGAGGGCTTACGGGTGATGGGAGAAGTCGGGAAGAC
CACTGGGATCCCCATCCATGTCTTTCGCACAGACACTCACATGACGGCCATTCTGGGCATGGCCCTGGGC
CACCCGCCCATCCCCAACCAGCCACCCACAGCGCCCCACACTGCAAACTTCCTCCTCAACGCCAGCGGGA
GCACATCGACGCCAGCCCCCACCAGGACACCATCTTTTTCTGAGTCCAGGGCCGATGAGGTGGCGCCTGC
AAAGAAGGCCAAGCCTGCCATGCCACAAGATTCAGTCCCAAGTCCAAGATCCCTGCAAGGAAAGAGCACC
ACCCTCTTCAGCCGCCACACCAAGGCCATTGTGTGGGGCATGCAGACCCGGGCCGTGCAAGGCATGCTGG
ACTTTGACTATGTCTGCTCCCGAGACGAGCCCTCAGTGGCTCCCATCGTCTACCCTTTCACTGGGGACCA
CAAGCAGAAGTTTTACTGGGGGCACAAAGAGATCCTGATCCCTGTCTTCAAGAACATGGCTGATGCCATG
AGGAAGCATCCCGAGGTAGATGTGCTCATCAACTTTGCCTCTCTCCGCTGTGCCTATGACAGCACCATGG
AGACCATGAACTATGCCCAGATCCGGACCATCGCCATCATAGCTGAAGGCATCCCTGAGGCCCTCACGAG
AAAGCTGATCAAGAAGGCGGACCAGAACGGAGTGACCATCATCGGACCTGCCACTGTTGGAGGCATCAAG
CCTGCGTGCTTTAAGATTCGCAACACAGGTGGGATCCTGCACAACATCCTGGCCTCCAAACTGTACCGCC
CAGGCAGCGTGGCCTATGTCTCACGTTCCGGAGGCATGTCCAACGAGCTCAACAATATCATCTCTCGGAC
CACGGATGGCGTCTATGAGGGCGTGGCCATTGGTGGGGACAGGTACCCGGGCTCCACATTCATGGATCAT
GTGTTACGCTATCAGGACACTCCACCAGTCAAAATGATTGTGGTTCTTGGAGAGATTGGGGGCACTGAGG
AATATAACATTTGCCGGACCATCAAGGAGGGCCGCCTCACTAAGCCCATCGTCTGCTGGTGCATCGGGAC
GTGTGCCACCATGTTCTCCTCTGAGGTCCAGTTTGGCCATGCTGGAGCTTGTGCCAACCAGGCTTCTGAA
ACTGCAGTAGCCAAGAACCAGGCTTTGAAGGAAGCAGGAGTGTTTGTGCCCCCGAGCTTTGATCACCTTG
CAGAGATCATCCACTCTGTATACGAAGATCTCGTGGCCAATGGAGTCATTGTACCTGCCCAGGACGTGCC
GCCCCCAACCCTGCCCATGGACTACTCCTGGGCCACGGAGCTTCGTTTGATCCGCAAACCTCCCTCGTTC
ATGACCAGCATCTGCGATGAGCGAGGACAGGAGCTCATCTACGCGGGCATGCCCATCACTGAGGTCTTCA
AGGAAGAGATGGGCATTGGCGGGGTCCTCGGCCTCCTCTCGTTCCAGAAAAGGTTGCCTAAGTACTCTTG
CCAGTTCATTGAGATGTGTCTGATGGTGACAGCTGATCACCGCCCAGCCCTCTCTGGAGCCCACAACACC
ATCATTTGTGCGCGAGCTGGGAAAGACCTGGTCTCCAGCCTCACCTCGGGGCTGCTCACCATCGGGGATC
GGTTTGGGGGTGCCTTGGATGCAGCACCCAAGATGTTCAGTAAAGCGTTTGACAGTGGCATTATCCCCAT
GGAGTTTGTGAACAACATCAAGAAGGAAGGGAAGCTGATCATGGGCATTGGTCACCGAGTGAAGTCCATA
AACAACCCAGACATCCCAGTGCAGATCCTCAAAGATTACGTCAGGCAGCACTTCCCTGCCACTCCTCTGC
TCGATTATGCACTGGAAGTAGAGAAGATTACCACCTCGAAGAAGCCAAATCTTATCCTGAATGTAGATGG
TCTCATCGGAGTCGCATTTGTAGACATGCTTAGAAACTGTGGGTCCTTTACTCGCGAGGAAGCTGATGAA
TATATTGACATTGGAGCCCTCAATGGCATCTTTGTGCTGCGAAGGAGTATGGGGTTCATTGGACACTATC
TTGATCAGAAGAGGCTGAAGCAGGGGCTCTATCGTCATCCGTGGGATGATATTTCATATGTTCTTCCGGA
ACACATGAGCATGTAACAGAGCCAGGAACCCTACTGCACTAAACTGAAGACAAGATCTCTTCCCCCAAGA
AAAAGTGTACAGACAGCTGGCAGTGGAGCCTGCTTTATTTAGCAGGGGCCTGGAATGTAAACAGCCACTG
GGGTACACGCACCGAACACCAACATCCACAGGCTAACACCCCTTCAGTCCACACAAAGAAGCTTCATATT
TTTTTTATAAGCATAGAAATAAAAACCAAGCCAATATTTGTGACTTTGCTCTGCTACCTGCTGTATTTAT
TATATCGAAGCATCTAAGTACTGTCAGGATGGGGTCTTCCTCATTGTAGGGCCTTAGGATGTTGCTTTCT
TTTTCCATTAGTTAAACATTTTTTTCTCCTTTGGAGGAAGGGAATGAAACATTTATGGCCTCAAGATACT
ATACATTTAAAGCACCCCAATGTCTCTCTTTTTTTTTTTTTACTTCCCTTTCTTCTTCCTTATATAACAT
GAAGAACATTGTATTAATCTGATTTTTAAAGATCTTTTTGTATGTTACGTGTTAACGGCTTGTTTGCTAT
CCCACTGAAATGTTCTGTGTTGCAGACCAGAGTCTGTTTATGTCAGGGGGATGGGGCCATTGCATCCTTA
GCCATTGTCACAAAATATGTGGAGTAGTAACTTAATATGTAAAGTTGTAACATACATACATTTAAAATGG
AAATGCAGAAAGCTGTGAAATGTCTTGTGTCTTATGTTCTCTGTATTTATGCAGCTGATTTGTCTGTCTG
TAACTGAAGTGTGGGTCCAAGGACTCCTAACTACTTTGCATCTGTAATCCACAAAGATTCTGGGCAGCTG
CCACCTCAGTCTCTTCTCTGTATTATCATAGTCTGGTTTAAATAAACTATATAGTAACAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAA

[1554]

TABLE 3
Amino acid sequence of Human ATP Citrate Lyase
ORF StaTt: 141 GRF Stop: 3444 Frame: 3
Human ATP Citrate Lyase Protein Sequence:
CG142427-01-prot 1101 aa
MSAKAISEQTGKELLYKFICTTSAIQNRFKYARVTPDTDWARLLQDHPWLLSQNLVVKPD
QLIKRRGKLGLVGVNLTLDGVKSWLKPRLGQEATVGKATGFLKNFLIEPFVPHSQAEEFYV
CIYATREGDYVLFHHEGGVDVGDVDAKAQKLLVGVDEKLNPEDIKKHLLVHAPEDKKEIL
ASFISGLFNFYEDLYFTYLEINPLVVTKDGVYVLDLAAKVDATADYICKVKWGDIEFPPPFG
REAYPEEAYIADLDAKSGASLKLTLLNPKGRIWTMVAGGGASVVYSDTICDLGGVNELAN
YGEYSGAPSEQQTYDYAKTILSLMTREKHPDGKILIIGGSTANFTNVAATFKGIVRAIRDYQ
GPLKEHEVTIFVRRGGPNYQEGLRVMGEVGKTTGIPIHVFGTETHMTAIVGMALGHRPIPN
QPPTAAHTANFLLNASGSTSTPAPSRTASFSESRADEVAPAKKAKPAMPQDSVPSPRSLQG
KSTTLFSRHTKAIVWGMQTRAVQGMLDFDYVCSRDEPSVAAMVYPFTGDHKQKFYWGH
KEILIPVFKNMADAMRKHPEVDVLINFASLRSAYDSTMETMNYAQIRTIAIIAEGIPEALTRK
LIKKADQKGVTIIGPATVGGIKIPGCFKIGNTGGMLDNILASKLYRPGSVAYVSRSGGMSNEL
NNHSRTTDGVYEGVATGGDRYPGSTFMDHVLRYQDTPGVKMIVVLGEIGGTEEYKICRGIK
EGRLTKPIVCWCIGTCATMFSSEVQFGHAGACANQASETAVAKNQALKEAGVFVPRSFDE
LGEIIQSVYEDLVANGVIVPAQEVPPPTVPMDYSWARELGLIRKLPASFMTSICDERGQELIY
AGMPITEVFKEEMGIGGVLGLLWFQKRLPKYSCQFIEMCLMVTADHGPAVSGAHNTIICAR
AGKDLVSSLTSGLLTIGDRFGGALDAAAKMFSKAFDSGIIPMEFVNKMKKEGKLIMGIGHR
VKSINNPDMRVQILKDYVRQHFPATPLLDYALEVEKITTSKKPNLILNVDGLIGVAFVDML
RNCGSFTREEADEYIDLGALNGIFVLGRSMGFIGHYLDQKRLKQGLYRHPWDDISYVLPEH
MSM

[1555]

[1556] Human ATP Citrate Lyase

[1557] 1105 amino acids; 121 kd

[1558] Locus: 17q12-q21

[1559] Intracellular (Cytoplasmic)

[1560] In addition to the human version of the ATP Citrate Lyase identified as being differentially expressed in the experimental study, other variants have been identified by direct sequencing of cDNAs derived from many different human tissues and from sequences in public databases. No splice-form variants have been identified at CuraGen whereas several amino acid-changing cSNPs were identified. These are found below. The preferred variant of all those identified, to be used for screening purposes, is CG 142427-01.

TABLE 5
The variants of the human ATP Citrate Lyase obtained
from direct cloning and/or public databases
DNA			AA	AA	public
Position	Strand	Alleles	Position	Change	SNP#
363	Plus	A:G	75	Asn=>Asp	rs1058875
665	Plus	A:C	175	Glu=>Asp	rs2304497
2318	Plus	G:A	726	Lys=>Lys	rs1802731
2377	Plus	G:A	746	Gly=>Glu	rs1802730
2756	Plus	C:T	873	Leu=>Leu	rs2277697
3308	Plus	C:G	1056	Ala=>Ala	Rs1802732

[1561] Biochemistry and Cell Line Expression

[1562] The following summarizes the biochemistry surrounding the human ATP Citrate Lyase enzyme: ATP Citrate Lyase catalyzes the conversion of Citrate plus CoA in the presence of ATP into orthophosphate+Acetyl CoA+Oxaloacetate with a release of ADP. Acetyl CoA can then be used as a substrate for Fatty Acid synthesis.

[1563] Cell lines expressing the ATP Citrate Lyase enzyme can be obtained from the RTQ-PCR results shown above. These and other ATP Citrate Lyase enzyme expressing cell lines could be used for screening purposes.

[1564] Findings:

[1565] An inhibitor to ATP Citrate Lyase will force Acetyl CoA to be produced by alternative pathways, thus decreasing the available pool for fatty acid and triglyceride synthesis. The decreased pool of Acetyl CoA will cause a down-regulation of the Cholesterol biosynthetic pathway preventing excess production of LXRa ligands

[1566] Taken in total, the data indicates that an inhibitor of the human ATP Citrate Lyase enzyme would be beneficial in the treatment of obesity and/or diabetes.

[1567] Sequences: The sequence of Acc. No. CG142427-01 is an In silico prediction based on sequences available in CuraGen's proprietary sequence databases or in the public human sequence databases, and provided either the full length DNA sequence, or some portion thereof.

[1568] SPECIES #1 A gene fragment of the mouse ATP Citrate Lyase was initially found to be up-regulated by 2 fold in the adipose tissues of the NZB mouse relative to the SMJ mouse strain using CuraGen's GeneCalling™ method of differential gene expression. Similar results were found in adipose in NZB vs C57L, Cast and SWR mouse strains (All were up-regulated; 2.7×, 5×, and 2.4× respectively). A differentially expressed mouse gene fragment migrating, at approximately 161.7 nucleotides in length (FIG. 1A and 1B.—vertical line) was definitively identified as a component of the mouse ATP Citrate Lyase cDNA (in the graphs, the abscissa is measured in lengths of nucleotides and the ordinate is measured as signal response). The method of competitive PCR was used for conformation of the gene assessment. The chromatographic peaks corresponding to the gene fragment of the rat ATP Citrate Lyase are ablated when a gene-specific primer (see below) competes with primers in the linker-adaptors during the PCR amplification. The peaks at 161.7 nt in length are ablated in the sample from both the NZB and SMJ mice.

[1569] The direct sequence of the 65 nucleotide-long gene fragment and the gene-specific primers used for competitive PC are indicated on the complete cDNA sequence of the ATP Citrate Lyase and shown below in bold. The gene-specific primers at the 5′ and 3′ ends of the fragment are in bold. 5

[1570] F. NOV16a—Human Serine Dehydratase—CG142631-01

[1571] Discovery Process

[1572] The following sections describe the study design(s) and the techniques used to identify the Serine Dehydratase—encoded protein and any variants, thereof, as being suitable as diagnostic markers, targets for an antibody therapeutic and targets for a small molecule drugs for obesity and/or diabetes.

[1573] Studies:

[1574] MB.01: Insulin Resistance in Rat

[1575] Study Statements:

[1576] MB.01: The spontaneously hypertensive rat (SHR) is a strain exhibiting features of the human Metabolic Syndrome X. The phenotypic features include obesity, hyperglycemia, hypertension, dyslipidemia and dysfibrinolysis. Tissues were removed from adult male rats and a control strain (Wistar-Kyoto) to identify the gene expression differences that underlie the pathologic state in the SHR and in animals treated with various anti-hyperglycemic agents such as troglitizone. Tissues included sub-cutaneous adipose, visceral adipose and liver.

[1577] Species #1 Rat Strains SHR

[1578] Serine Dehydratase:

[1579] Serine dehydratase catalyzes the PLP-dependent alpha, beta-elimination of L-serine to pyruvate and ammonia. It is one of three enzymes that are regarded as metabolic exits of the serine-glycine pool. Serine dehydratase is found predominantly in the liver.

TABLE 1
Competitive PCR Primer for the Human Serine Dehydratase
Confirmatory Result-Human Serine Dehydratase (Discovery Study MB.01):
(Identified fragment from 221 to 545 in italic, band size: 325)
1    GCTTTATAAACATATATATATTAATTTTTATTTACAATGAAAAAGTGCATATTATAAACATGGATAAAGGAGGGTGGGCC
81   ACTGTCAGGGJGACGCCCACCCAGCCTACTCAGGGGTGCTGGTGACCCCTCAGGGTGGCCAGGGCAGCAGCAGATATCAC
161  TTGAGTAGCTCATTCAGGCCCAGCTGTCCCTTGAGTGCCTGCAGCTGTGCCAGGCTGATGTTGCTGCCACCACACACAAT
241  GACAACCAGCGAGGCCAGTGGGGTTTGCAGTCGGGCCTCAGCCTGCACCCTCCACACCACACCGCTGTACACTGCAGCCA
321  GGGCAGCGCCACACGCGGGCTCCACCACGATCTTCTCATCGTCTACGAACTTCTCGATACCAGTCACAGCCTCCTGGTCT
401  GAGATGACCTCAGAGAAAATGGGGTGTTCGTAAAACAGCTTCAGGGTCTGTGCCCCCACAGTGTTCACACCCAAGGCCTT
481  GGCAACACTGGTGATCTTGGCCAGGGTGACCAGCTTTCCTTCCTTGACGGCAGCGTGGAAGCTGTGGGCGCCGAAGGTCT
561  CCATGGCGATGATGCGCACATCCTCCCAGCCCACCTCCCCCAGCCCCTGGACCACTCCGCACAGCAGGCCTCCACCGCCC
641  ACAGACAGCACAATGGCCCCGGGCTTGGCGCTCAGTGTCTCCTTCAGCTCCTTCACAAGGGAAGTGTGGCCTTCCCAGAT
721  GAGAGGGTCATCGAAGGGGGAGATGTACACCCAACCTGGGTTGTTCTTTTCCAGAGCCTTCGCCAGTTGCATGGCCTCAT
801  CCAGCATCTCTCCCACCACTTCAACTGTGGCCCCTTCGTTCTTCAGCCGCTCAATGGTGAGGGCAGGTGTGGTGCTTGGC
881  ACAACAATAGTGGCTCGGAGGCCCAGCCTCCTGGCAGCATAGGCAGTCGCCATGCCCGCGGTGCCCGCTGAAGAGCACAC
961  GAAATGTTTACAGCCTTGTTTTGCCTTCATCTTGCAGAGATGCCCAATGCCTCGCATCTTGAAGGAGCCAGAGGGCTGAG
1041 AGCTGTCCATCTTAAGGAACAGACTAGTGCCGGCCACTTTGGACAATGCCATGGTGTCACGTAGTCGCGTCTTCACGTGC
1121 AGGGACTCCTGGGCAGCCATGGCATGTAGCTTTGAAGGTTGGATCCTCCTGTCTCAGTCTCCCAATTGCTGGGATCACAG
1201 GTATGCCCCGCCGCACCCGGCACAGGAGGAGCTGGACACAGCGAGCGAGAAGGGTAGATTTTGTCTGTGTCCTGGGAGAG
1281 TGGAAAGT

[1580]

TABLE 2
Nucleotide and protein sequence of Human Serine Dehydratase, CG
142631-01
CCTTCTCTTCGTGGGCTATCTACTCAGTTGATCCCTCCCTCGCTGGCTTGGCTCTGACTCCTG
CTCAGACCCATCACCTTTGCCGGGGAATGATGTCTGGAGAACCCCTGCACGTGAAGACCCCC
ATCCGTGACAGCATGGCCCTGTCCAAAATGGCCGGCACCAGCGTCTACCTCAAGATGGACAG
TGCCCAGCCCTCCGGCTCCTTCAAGATCCGGGGCATTGGGCACTTCTGCAAGAGGTGGGCCA
AGCAAGGCTGTGCACATTTTGTCTGCTCCTCGGCGGGCAACGCAGGCATGGCGGCTGCATAT
GCGGCCAGGCAACTCGGCGTCCCCGCCACCATCGTAGTGCCCGGCACCACACCTGCTCTCA
CCATTGAGCGCCTCAAGAATGAAGGTGCCACATGCAAGGTGGTGGGTGAGTTATTGGATGAA
GCCTTCGAGCTGGCCAAGGCCCTAGCGAAGAACAACCCGGGTTGGGTCTACATTCCCCCCTT
TGATGACCCCCTCATCTGGGAAGGCCACGCTTCCATCGTGAAAGAGCTGAAGGAGACACTGT
GGGAAAAGCCGGGGGCCATCGCGCTGTCAGTGGGCGGCGGGGGCCTGCTGTGTGGAGTGG
TCCAGGGGCTGCAGGAGTGTGGCTGGGGGGACGTGCCTGTCATCGCCATGGAGACTTTTGGT
GCCCACAGCTTCCACGCTGCCACCACCGCAGGCAAACTTGTCTCCCTGCCCAAGATCACCAG
TGTTGCCAAGGCCCTGGGCGTGAAGACTGTGGGGTCTCAGGCCCTGAAGCTGTTTCAGGAAC
ACCCCATTTTCTCTGAAGTTATCTCGGACCAGGAGGCTGTGGCCGCCATTGAGAAGTTCGTGG
ATGATGAGAAGATCCTGGTGGAGCCCGCCTGGGGCGCAGCCCTGGCCGCTGTCTATAGCCAC
GTGATCCAGAAGCTCCAACTGGAGGGGAATCTCCGAACCCCGCTGCCATCCCTCGTGGTCAT
CGTCTGCGGGGGCAGCAACATCAGCCTGGCCCAGCTGCGGGCGCTCAAGGAACAGCTGGGC
ATGACAAATAGGTTGCCCAAGTGAGGACGGACCCCTTACCGATCTGTGCTCTCCTAGCCCAAG
AGACCCCTGGAGGGGCTGGAGTTTATCCAGCGCCTCGTCGTATGTTTGGCTGAGCACCTGTG
GCCCTGGGTGCAGGTTAACTTCTTGTTATCAGGAGCCCACTATGCAGAGGCCAAAGGTCGGC
AGCCAGCGAGGCTATGAATTGGACCTTTTTGGTATCTGTGTGACTGCTCTGTGCCCATCCTTA
GCCAACTTGCTGGCGTGACAAGTGCCCACAAGTAACACACCAGGTACCCAGAGCAGGGTGGA
CAGGAGAGACCTGAATCACAGCAGTGAGG

[1581]

TABLE 3
ORF Start: 90 ORF Stop: 1074 Frame: 3
Human Serine Dehydratase Protein Sequence:
CG142631-01-prot 328 aa
MMSGEPLHVKTPIRDSMALSKMAGTSVYLKMDSAQPSGSFKIRGIGHFCK
RWAKQGCAHFVCSSAGNAGMAAAYAARQLGVPATIWPGTTPALTIERLKN
EGATCKWGELLDEAFELAKALAKNNPGWVYIPPFDDPLIWEGHASIVKEL
KETLWEKPGAIALSVGGGGLLCGWQGLQECGWGDVPVIAMETFGAHSFHA
ATTAGKLVSLPKITSVAKALGVKTVGSQALKLFQEHPIFSEVISDQEAVA
AIEKFVDDEKILVEPAWGMLAAVYSHVIQKLQLEGNLRTPLPSLVVIVCG
GSNISLAQLRALKEQLGMTNRLPK

[1582]

[1583] Human Serine Dehydratase

[1584] 328 amino acids; 34 kd

[1585] Locus: 12

[1586] Intracellular

[1587] In addition to the human version of the Serine Dehydratase identified as being differentially expressed in the experimental study, other variants have been identified by direct sequencing of cDNAs derived from many different human tissues and from sequences in public databases. No splice-form variants have been identified at CuraGen whereas several amino acid-changing cSNPs were identified. These are found below. The preferred variant of all those identified, to be used for screening purposes, is CG142631-01.

TABLE 5
The variants of the human Serine Dehydratase obtained
from direct cloning and/or public databases
DNA			AA	AA	public
Position	Strand	Alleles	Position	Change	SNP #
777	Plus	G:T	230	Ala => Ser	rs1050062

[1588] Biochemistry:

[1589] The following illustrations summarizes the biochemistry surrounding the human Serine Dehydratase enzyme. L-Serine is converted to Pyruvate by pyridoxal phosphate requiring Serine Dehydratase with the release of ammonia as a by product. Pyruvate is a primary substrate in the process of gluconeogenesis. Cell lines expressing the Serine Dehydratase enzyme can be obtained from the RTQ-PCR results shown above. These and other Serine Dehydratase enzyme expressing cell lines could be used for screening purposes.

[1590] Findings:

[1591] Serine Dehydratase (SDH) is critical for gluconeogenesis. In models of Diabetes SDH is up-regulated and in studies utilizing TZDs expression of SDH is down-regulated. An inhibitor of this enzyme would decrease glucose production. By improving daily blood glucose levels and maintaining HbA1c at or below 7.5 may prevent many diabetic complications.

[1592] Taken in total, the data indicates that an inhibitor of the human Serine Dehydratase enzyme would be beneficial in the treatment of obesity and/or diabetes.

[1593] Sequences

[1594] The sequence of Acc. No. CG142631-01 is an In silico prediction based on sequences available in CuraGen's proprietary sequence databases or in the public human sequence databases, and provided either the full length DNA sequence, or some portion thereof.

[1595] G. NOV53a—Human Plasma Kallikrein—CG56155-01

[1596] Discovery Process

[1597] The following sections describe the study design(s) and the techniques used to identify the Plasma Kallikrein—encoded protein and any variants, thereof, as being suitable as diagnostic markers, targets for an antibody therapeutic and targets for a small molecule drugs for Obesity and Diabetes.

[1598] MB.01: Metabolic Syndrome X in Rat

[1599] MB.04: Mouse Obesity

[1600] Study Statements:

[1601] MB.01 The spontaneously hypertensive rat (SHR) is a strain exhibiting features of the human Metabolic Syndrome X. The phenotypic features include obesity, hyperglycemia, hypertension, dyslipidemia and dysfibrinolysis. Tissues were removed from adult male rats and a control strain (Wistar-Kyoto) to identify the gene expression differences that underlie the pathologic state in the SHR and in animals treated with various anti-hyperglycemic agents such as troglitizone. Tissues included sub-cutaneous adipose, visceral adipose and liver.

[1602] MB.04 A large number of mouse strains have been identified that differ in body mass and composition. The AKR and NZB strains are obese, the SWR, C57L and C57BL/6 strains are of average weight whereas the SM/J and Cast/Ei strains are lean. Understanding the gene expression differences in the major metabolic tissues from these seatrains will elucidate the pathophysiologic basis for obesity. These specific strains of rat were chosen for differential gene expression analysis because quantitative trait loci (QTL) for body weight and related traits had been reported in published genetic studies. Tissues included whole brain, skeletal muscle, visceral adipose, and liver.

[1603] Species #1 Rat Strains SHR, WKY

[1604] Species #2 Mouse Strains C57BL, Cast/Ei

[1605] Plasma Kallikrein:

[1606] Plasma Kallikrein (PK) has been shown to activate specifically plasminogen during adipose differentiation. Plasminogen activation, followed by fibrinolysis, has been implicated in adipose differentiation by remodeling of the fibronectin-rich extracellular matrix of preadipocytes.

TABLE 1
SPECIES #1 Rat Plasma Kallikrein Gene Fragment used for competitive
PCR
1035 TCCCCAAGAC TGCAAGCCAC AGGGCTCTAA ATGTTCCTTA AGGTTATCCA CGGATGGCTC
1095 TCCAACTAGG ATCACCTATC AGCCACACGG GAGCTCTGGT TATTCTCTGA GACTGTGTAA
1155 AGTTGTGGAG AGCTCTCACT CTACGACAAA AATAAATGCA CGTATTGTGG GAGGAACAAA
1215 CTCTTCTTTA GGAGAGTGGC CATGGCAGGT CAGCCTGCAA GTGAAGTTGG TTTCTCAGAA
1275 CCATATGTGT GGAGGGTCCA TCATTGGACG CCAATCCATA CTGACGGCTG CCCATTGCTT
1335 TGATGGGATT CCCTATCCAG ACGTGTGGCG TATATATGGC GGGATTCTTA ATCTGTCAGA
1395 GATTACAAAC AAAACGCCTT TCTCAAGTAT AAAGGAGCTT ATTATTCATC AGAAATACAA
1455 AATGTCAGAA GGCAGTTACG ATATTGCCTT AATAAAGCTT CAGACACCGT TGAATTATAC
1515 TGAATTCCAA AAACCAATAT GCCTGCCTTC CAAAGCTGAC ACAAATACAA TTTATACCAA
1575 CTGCTGGGTG ACTGGATGGG GCTACACAAA GGAACGAGGT GAGACCCAAA ATATTGTACA
1635 AAAGGCAACT ATTCCCTTGG TACCAAATGA AGAATGCCAG AAAAAATATA GAGATTATGT
1695 TATAACCAAG CAGATGATCT GTGCTGGCTA CAAAGAAGGT GCAATAGATG CTTGTAACGG
1755 AGATTCCGGT GGCCCCTTAG TTTGCAAACA TAGTGGAAGG TCGCAGTTGC TCGGTATCAC
1815 CAGCTGGGGT GAAGGCTCTG CCCGCAAGGA GCAACCAGGA GTCTACACCA AACTTGCTGA
1875 GTACATTGAC TCGATATTGG AGAACATACA GAGCAGCAAG GAAAGAGCTC TGGAGACATC
1935 TCCAGCATGA CCAGGCTGGC TACTGACGGG CAACAGCCCA GCTGGCACCA GCTTTACCAC
1995 CTGCCCTCAA GTCCTACTAG AGCTCCAGAG TTCTCTTCTG CAAAATGTCG ATAGTGGTGT
2055 CTACCTCGCA TCCTTACCAT AGGATTAAAA GTCCAAATGT AGACACAGTT GCTAAAGACA
2115 GCGCCATGCT CAAGCGTGCT TCCT
(fragment from 1516 to 1658 in bold. band size: 143)
(gene length is 2444, only region from 1035 to 2138 shown)

[1607]

TABLE 2
SPECIES #2. Mouse Plasma Kallikrein Gene Fragment used for competitive
PCR
2326 GTAAGGGAGA TTCCGGTGGC CCCTTAGTCT GTAAACACAG TGGACGGTGG CAGTTGGTGG
2386 GTATCACCAG CTGGGGTGAA CGCTGCGGCC GCAAGGACCA ACCAGGAGTC TACACCAAAC
2446 TTTCTGAGTA CATGGACTGG ATATTGGAGA AGACACAGAG CAGTGATGTA AGAGCTCTGG
2506 AGACATCTTC AGCCTGAGGA GGCTGGGTAC CAACGAGGAA GAACCCAGCT GGCTTTACCA
2566 CCTGCCCTCA AGGCAAACTA GAGCTCCAGG ATTCTCCGCT GTAAAATGTT GATAATGGTG
2626 TCTACCTCAC ATCCGTATCA TTGGATTGAA AATTCAAGTG TACATATACT TGCTGAAGAC
2686 AGCGTTTTGC TCAAGTGTGT TTCCTGCCTT GAGTCACAGG AGCTCCAATG GGAGCATTAC
2746 AAAGATCACC AAGCTTGTTA GGAAAGAGAA TGATCAAAGG GTTTTATTAG GTAATGAAAT
2806 GTCTAGATGT GATGCAATTG AAAAAAAGAC CCCAGATTTT AGCACAGTCC TTGGGACCAT
2866 TTTCATGTAA CTGTTGACTT TGGACCTCAG CAGATCT                  CAG AGTTACCTGT CCACTTCTGA
2926 CATTTGTTTA TTAGAGCCTG ATGCTATTCT TTCAAGTGGA GCAAAAAAAA AAAAAAAAAA
2986 AAAAA
(fragment from 2807 to 2902 in bold. band size: 96)
(gene length is 2990, only region from 2326 to 2990 shown)

[1608]

TABLE 3
Human Plasma Kallikrein Gene and Protein Sequence.
>CG56155-01 2245 nt
AGAACAGCTTGAAGACCGTTCATTTTTAAGTCACAACAGACTCACCTCCAAGAAGCAATT
GTGTTTTCAGAATGATTTTATTCAAGCAAGCAACTTATTTCATTTCCTTGTTTGCTACAG
TTTCCTGTGGATGTCTGACTCAACTCTATGAAAACGCCTTCTTCAGAGGTGCGGATGTAG
CTTCCATGTACACCCCAAATGCCCAATACTGCCAGATGAGGTGCACATTCCACCCAAGGT
GTTTGCTATTCAGTTTTCTTCCAGCAAGTTCAATCAATGACATGGACAAAAGGTTTGGTT
GCTTCTTGAAAGATAGTGTTACAGGAACCCTGCCAAAAGTACATCGAACAGGTGCAGTTT
CTGGACATTCCTTGAAGCAATGTGGTCATCAAATAAGTGCTTGCCATCGAGACATTTATA
AAGGAGTTGATATGAGAGGAHTCAATTTTAATCTGTCTAAGGTTAGCAGTGTTGAAGAAT
CCCAAAAAAGGTGCACCAATAACATTCGCTGCCAGTTTTTTTCATATGCCACGCAAACAT
TTCACAAGGCAGAGTACCGGAACAATTCCCTATTAAAGTACAGTCCCGGAGGAACACCTA
CCGCTATAAACGTGCTGAGTAACGTGGAATCTGGATTCTCACTGAAGCCCTGTGCCCTTT
CAGAAATTGGTTGCCACATGAACATCTTCCACCATCTTCCGTTCTCAGATGTGGATGTTG
CCAGCGTTCTCACTCCAGATGCTTTTGTGTGTCGGACCATCTGCACCTATCACCCCAACT
GCCTCTTCTTTACATTCTATACAAATGTATGGAAAATCGAGTCACAAAGAAATGTTTGTC
TTCTTAAAACATCTGAAAGTGGCACACCAAGTTCCTCTACTCCTCAAGAAAACACCATAT
CTCGATATAGCCTTTTAACCTGCAAAAGAACTTTACCTGAACCCTGCCACTCTAAAATTT
ACCCTGGAGTTGACTTTGGAGGAGAACAATTGAATGTGACTTTTGTTAAACGAGTGAATC
TTTGCCAAGAGACTTGCACAAAGATGATTCGCTGTCAGTTTTTCACTTATTCTTTACTCC
CAGAAGACTGTAAGGAAGAGAAGTGTAAGTGTTTCTTAACATTATCTATGGATCGTTCTC
CAACTAGGATTGCGTATGGGACACAAGCGAGCTCTGGTTACTCTTTGACATTGTGTAACA
CTGGGGACAACTCTGTCTGCACAACAAAAACAACCACACGCATTGTTGGAGGAACAAACT
CTTCTVCCCGACAGTGGCCCTCGCAGGTGAGCCTGCAGGTGAAGCTGACAGCTCAGAGGC
ACCTGTGTGGAGGGTCACTCATAGGACACCAGTGGGTCCTCACTGCTGCCCACTGCTTTG
ATGGGCTTCCCCTGCAGGATGTTTGGCGCATCTATAGTGGCATTTTAAATCTGTCAGACA
TTACAAAAGATACACCTTTCTCACAAATAAAAGAGATTATTATTCACCAAAACTATAAAG
TCTCAGAAGGGAATCATGATATCGCCTTGATAAAACTCCAGGCTCCTTTCAATTACACTG
AATTCCAAAAACCAATATGCCTACCTTCCAAACGTGACACAAGCACAATTTATACCAACT
GTTGGGTAACCGGATGGGGCTTCTCGAACGAGAAAGGTGAAATCCAAAATATTCTACAAA
AGGTAAATATTCCTTTCGTAACAAATGAAGAATCCCACAAAAQATATCAACATTATAAAA
TAACCCAACGGATCGTCTGTGCTGCCTATAAAGAAGGGGGAAAAGATGCTTGTAAGGGAG
ATTCAGCTGGTCCCTTAGTTTGCAAACACAACGGAATGTGGCGTTTGGTGGGCATCACAA
GCTGGGGTGAAGGCTGTGCCCGCAGGGAGCAACCTGGTGTCTACACCAAAGTCGCTGAGT
ACATGGACTGGATTTTAGAGAAAACACAGAGCAGTGATGGAAAAGCTCAGATGCAGTCAC
CACCATGAGAAGCAGTCCAGAGTCTAGGCAATTTTTACAACCTGAGTTCAAGTCAAATTC
TGAGCCTGGGGGGTCCTCATCTGCAAAGCATGGAGAGTGGCATCTTCTTTGCATCCTAAG
GACGAAAGACACAGTGCACTCAGAGCTCGTGAGGACAATGTCTGCTGAAGCCCGCTTTCA
GCACCCCGTAACCAGGGGCTCACAATGCGAGGTCGCAACTGAGATCTCCATGACTGTGTG
TTGTGAAATAAAATGGTGAAAGATC

[1609]

TABLE 4
Amino acid sequence for Human Plasma Kallikrein
ORF Start: 72 ORF Stop: 1986 Frame: 3
Human Plasma Kallikrein Protein Sequence:
>CG56155-01-prot 638 aa
MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPMAQYCQMR
CTFHPRCLLFSELPASSINDMEKRFCCFLKDSVTGTLPKVHRTGAVSGHS
LKQCGHQISACURDIYKGVDMRCVNPNVSKVSSVEECQKRCTNNIRCQFF
SYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIG
CHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIE
SQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGV
DFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLR
LSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWG
EWPWQVSLQVKLTAQRHLCGGSLICHQWVLTAAHCFDCLPLQDVWRIYSG
ILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQK
PICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQK
RYQDYKITQRNVCAGYKEGCKDACKGDSGGPLVCKHNGMWRLVGITSWGE
GCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA

[1610]

[1611] Human Plasma Kallikrein

[1612] Locus: 4q35

[1613] Extracellular

[1614] In addition to the human version of the Plasma Kallikrein identified as being differentially expressed in the experimental study, other variants have been identified by direct sequencing of cDNAs derived from many different human tissues and from sequences in public databases. No splice-form variants have been identified at CuraGen whereas several amino acid-changing cSNPs were identified. These are found below. The preferred variant of all those identified, to be used for screening purposes, is CG56155-01.

TABLE 6
The variants of the human Plasma Kallikrein obtained
from direct cloning and/or public databases
DNA			AA	AA	public
Position	Strand	Alleles	Position	Change	SNP #
499	Minus	A:G	143	Asn => Ser
726	Minus	G:T	219	Val => Phe
726	Minus	T:G	219	Val => Phe
1212	Minus	T:G	381	Ser => Ala
1272	Minus	T:G	401	Glu =>
1832	Minus	C:T	587	Asn => Asn
2073	Minus	G:A	0
2073	Minus	A:G	0

[1615] Expression Profiles:

[1616] Table 7. CG56155-01: Plasma kallikrein—isoform1, submitted to study DDAT on 01/09/01 by sspaderna; clone status=FIS; novelty=Public; ORF start=72, ORF stop=1986, frame=3; 2245 bp.

[1617] Expression of gene CG56155-01 was assessed using the primer-probe set Ag1688, described in Table 7. Results of the RTQ-PCR runs are shown in Tables 8 and 9.

TABLE 7
Probe Name Ag1688
			Start	SEQ ID
Primers	Sequences	Length	Position	NO:
Forward	5′-tcagaagggaatcatgatatcg-3′	22	1503	627
Probe	TET-5′-ccttgataaaactccaggctcctttga-3′-TAMRA	27	1525	628
Reverse	5′-tttggaaggtaggcatattgg-3′	21	1572	629

[1618]

TABLE 8
Panel 1.3D
                                Rel. Exp. (%)
                                Ag1688, Run
Tissue Name                     147249266
Liver adenocarcinoma            0.0
Pancreas                        6.7
Pancreatic ca. CAPAN 2          0.2
Adrenal gland                   1.8
Thyroid                         3.8
Salivary gland                  1.5
Pituitary gland                 6.1
Brain (fetal)                   0.5
Brain (whole)                   3.6
Brain (amygdala)                3.3
Brain (cerebellum)              0.4
Brain (hippocampus)             6.2
Brain (substantia nigra)        1.0
Brain (thalamus)                2.1
Cerebral Cortex                 6.3
Spinal cord                     3.1
glio/astro U87-MG               0.0
glio/astro U-118-MG             0.0
astrocytoma SW1783              0.0
neuro*; met SK-N-AS             0.2
astrocytoma SF-539              0.0
astrocytoma SNB-75              0.1
glioma SNB-19                   0.2
glioma U251                     1.2
glioma SF-295                   0.0
Heart (Fetal)                   0.2
Heart                           1.6
Skeletal muscle (Fetal)         0.7
Skeletal muscle                 1.2
Bone marrow                     0.5
Thymus                          3.2
Spleen                          1.0
Lymph node                      2.9
Colorectal                      0.8
Stomach                         3.3
Small intestine                 6.2
Colon ca. SW480                 0.0
Colon ca.* SW620 (SW480 met)    0.0
Colon ca. HT29                  0.0
Colon ca. HCT-116               0.0
Colon ca. CaCo-2                0.2
CC Well to Mod Diff (ODO3866)   0.0
Colon ca. HCC-2998              0.2
Gastric ca. (liver met) NCI-N87 4.4
Bladder                         3.1
Trachea                         3.0
Kidney                          6.8
Kidney (fetal)                  9.2
Renal ca. 786-0                 0.0
Renal ca. A498                  1.7
Renal ca. RXF 393               0.0
Renal ca. ACHN                  0.0
Renal ca. UO-31                 0.0
Renal ca. TK-10                 0.0
Liver                           100.0
Liver (fetal)                   99.3
Liver ca. (hepatoblast) HepG2   0.0
Lung                            1.3
Lung (fetal)                    1.8
Lung ca. (small cell) LX-1      0.0
Lung ca. (small cell) NCI-H69   0.0
Lung ca. (s. cell var.) SHP-77  0.8
Lung ca. (large cell) NCI-H460  0.0
Lung ca. (non-sm. cell) A549    0.2
Lung ca. (non-s. cell) NCI-H23  0.0
Lung ca. (non-s. cell) HOP-62   0.0
Lung ca. (non-s. cl) NCI-H522   0.0
Lung ca. (squam.) SW900         0.2
Lung ca. (squam.) NCI-H596      0.0
Mammary gland                   2.9
Breast ca.* (pl. ef) MCF-7      0.0
Breast ca.* (pl. ef) MDA-MB-231 0.0
Breast ca.* (pl. ef) T47D       0.0
Breast ca. BT-549               0.0
Breast ca. MDA-N                0.0
Ovary                           0.0
Ovarian ca. OVCAR-3             0.2
Ovarian ca. OVCAR-4             0.0
Ovarian ca. OVCAR-5             0.3
Ovarian ca. OVCAR-8             0.0
Ovarian ca. IGROV-1             0.0
Ovarian ca. (ascites) SK-OV-3   1.0
Uterus                          1.4
Placenta                        0.4
Prostate                        1.0
Prostate ca.* (bone met) PC-3   0.0
Testis                          6.1
Melanoma Hs688(A).T             0.4
Melanoma* (met) Hs688(B).T      0.9
Melanoma UACC-62                0.0
Melanoma M 14                   0.0
Melanoma LOX IMVI               0.0
Melanoma* (met) SK-MEL-5        0.0
Adipose                         0.5

[1619]

TABLE 9
Panel 5 Islet
                                 Rel. Exp. (%)
                                 Ag1688, Run
Tissue Name                      226587524
97457_Patient-02go_adipose       41.2
97476_Patient-07sk_skeletal muscle 9.9
97477_Patient-07ut_uterus        8.1
97478_Patient-07pl_placenta      0.0
99167_Bayer Patient 1            84.7
97482_Patient-08ut_uterus        2.4
97483_Patient-08pl_placenta      0.0
97486 Patient-09sk_skeletal muscle 8.0
97487_Patient-09ut_uterus        9.6
97488_Patient-09pl_placenta      0.0
97492_Patient-10ut_uterus        0.0
97493_Patient-10pl_placenta      0.0
97495_Patient-11go_adipose       0.0
97496_Patient-11sk_skeletal muscle 52.9
97497_Patient-11ut_uterus        35.8
97498_Patient-11pl_placenta      10.5
97500_Patient-12go_adipose       0.0
97501_Patient-12sk_skeletal muscle 35.4
97502_Patient-12ut_uterus        20.7
97503_Patient-12pl_placenta      0.0
94721_Donor 2 U - A_Mesenchymal Stem Cells 0.0
94722_Donor 2 U - B_Mesenchymal Stem Cells 0.0
94723_Donor 2 U - C_Mesenchymal Stem Cells 0.0
94709_Donor 2 AM - A_adipose     0.0
94710_Donor 2 AM - B_adipose     0.0
94711_Donor 2 AM - C_adipose     0.0
94712_Donor 2 AD - A_adipose     11.4
94713_Donor 2 AD - B_adipose     0.0
94714_Donor 2 AD - C_adipose     29.1
94742_Donor 3 U - A_Mesenchymal Stem Cells 19.2
94743_Donor 3 U - B_Mesenchymal Stem Cells 0.0
94730_Donor 3 AM - A_adipose     15.0
94731_Donor 3 AM - B_adipose     37.9
94732_Donor 3 AM - C_adipose     0.0
94733_Donor 3 AD - A_adipose     39.2
94734_Donor 3 AD - B_adipose     11.4
94735_Donor 3 AD - C_adipose     34.4
77138_Liver_HepG2untreated       8.4
73556_Heart_Cardiac stromal cells (primary) 0.0
81735_Small Intestine            100.0
72409_Kidney_Proximal Convoluted Tubule 9.9
82685_Small intestine_Duodenum   70.2
90650_Adrenal_Adrenocortical adenoma 25.5
72410_Kidney_HRCE                10.4
72411_Kidney_HRE                 7.2
73139_Uterus_Uterine smooth muscle cells 0.0

[1620] Biochemistry and Cell Line Expression

[1621] Plasma Kallikrein is a protease which is implicated in the conversion of plasminogen to the plasmin. Plasma Kallikrein activity was measured usually by spectrophotometric assays using artificial fluorescent peptide substrates. Plasma Kallikrein is commercially available enzyme with known inhibitors. The procedure of purification of Plasma Kallikrein from serum by affinity chromatography was described in literature. Cell lines expressing the

[1622] Plasma Kallikrein can be obtained from the RTQ-PCR results shown above. These and other Plasma Kallikrein expressing cell lines could be used for screening purposes.

[1623] Rationale for Use as a Diagnostic and/or Target for Small Molecule Drugs and Antibody Therapeutics.

[1624] 1. Plasminogen activation, followed by fibrinolysis, is implicated recently in adipose differentiation by remodeling of the fibronectin-rich ECM of the preadipocytes. Knock out of the plasminogen gene in mouse lead to the reduction of fat deposit.

[1625] 2. Plasma Kallikrein activates plasminogen, thus promoting adipose differentiation.

[1626] 3. Plasma Kallikrein is significantly down-regulated in the liver of mice with the lean phenotype, which may cause disruption of the adipose differentiation ion this strain.

[1627] 4. Taken in total, the data indicates that an inhibitor/antagonist of the human Plasma Kallikrein would be beneficial in the treatment of obesity.

[1628] SPECIES #1 A gene fragment of the rat Plasma Kallikrein was initially found to be down-regulated by 2 fold in MB.01 study in the liver of SHR rat relative to normal control rat strain using CuraGen's GeneCallinG™ method of differential gene expression. Additionally, the expression of the enzyme was increased in the response to troglitazone treatment. A differentially expressed rat gene fragment migrating, at approximately 142.3 nucleotides in length (FIG. 1a.—vertical line) was definitively identified as a component of the rat Plasma Kallikrein cDNA (in the graphs, the abscissa is measured in lengths of nucleotides and the ordinate is measured as signal response). The method of competitive PCR was used for conformation of the gene assessment. The electropherogram peaks corresponding to the gene fragment of the rat Plasma Kallikrein are ablated when a gene-specific primer (see below) competes with primers in the linker-adaptors during the PCR amplification. The peaks at 142.3 nt in length are ablated in the sample from both the SHR and control rats.

[1629] SPECIES #2 The gene fragments corresponding to the mouse Plasma Kallikrein were found to be down-regulated by 52.1 fold in liver tissues of normal mice relative to the lean mice. A differentially expressed mouse gene fragment migrating, at approximately 96 nucleotides in length (FIG. 1a.—red vertical line) was definitively identified as a component of the mouse Plasma Kallikrein cDNA by the method of competitive PCR. The electropherogramatic peaks corresponding to the gene fragment of the mouse Plasma Kallikrein are ablated when a gene-specific primer (see below) competes with primers in the linker-adaptors during the PCR amplification. The peaks at 96 nt in length are ablated in the sample from both the normal and lean mice.

[1630] The sequence of the nucleotide-long gene fragment and the gene-specific primers used for competitive PCR are indicated on the cDNA sequence of the Plasma Kallikrein and shown below in bold. The gene-specific primers at the 5′ and 3′ ends of the fragment are in color.

Example F

[1631] CG56155-03 Expression Data:

[1632] Construction of the mammalian expression vector pCEP4/Sec. The oligonucleotide primers, pSec-V5-His Forward (CTCGTCCTCGAGGGTAAGCCTATCCCT AAC) and the pSec-V5-His Reverse (CTCGTCGGGCCCCTGATCAGCGGGTTTAAAC), were designed to amplify a fragment from the pcDNA3.1-V5His (Invitrogen, Carlsbad, Calif.) expression vector. The PCR product was digested with XhoI and ApaI and ligated into the XhoI/ApaI digested pSecTag2 B vector (Invitrogen, Carlsbad Calif.). The correct structure of the resulting vector, pSecV5His, was verified by DNA sequence analysis. The vector pSecV5His was digested with PmeI and NheI, and the PmeI-NheI fragment was ligated into the BamHI/Klenow and NheI treated vector pCEP4 (Invitrogen, Carlsbad, Calif.). The resulting vector was named as pCEP4/Sec.

[1633] Expression of CG56155-03 in human embryonic kidney 293 cells. A 0.4 kb BamHI-XhoI fragment containing the CG56155-03 sequence was subcloned into BamHI-XhoI digested pCEP4/Sec to generate plasmid 1061. The resulting plasmid 1061 was transfected into 293 cells using the LipofectaminePlus reagent following the manufacturer's instructions (Gibco/BRL). The cell pellet and supernatant were harvested 72 h post transfection and examined for CG56155-03 expression by Western blot (reducing conditions) using an anti-V5 antibody. FIG. 1 shows that CG56155-03 is expressed as a 74 kDa protein secreted by 293 cells.

Other Embodiments

[1634] Although particular embodiments have been disclosed herein in detail, this has been done by way of example for purposes of illustration only, and is not intended to be limiting with respect to the scope of the appended claims, which follow. In particular, it is contemplated by the inventors that various substitutions, alterations, and modifications may be made to the invention without departing from the spirit and scope of the invention as defined by the claims. The choice of nucleic acid starting material, clone of interest, or library type is believed to be a matter of routine for a person of ordinary skill in the art with knowledge of the embodiments described herein. Other aspects, advantages, and modifications considered to be within the scope of the following claims. The claims presented are representative of the inventions disclosed herein. Other, unclaimed inventions are also contemplated. Applicants reserve the right to pursue such inventions in later claims.

Claims

1. An isolated polypeptide comprising the mature form of an amino acid sequenced selected from the group consisting of SEQ ID NO:2n, wherein n is an integer between 1 and 226.

2. An isolated polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:2n, wherein n is an integer between 1 and 226.

3. An isolated polypeptide comprising an amino acid sequence which is at least 95% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:2n, wherein n is an integer between 1 and 226.

4. An isolated polypeptide, wherein the polypeptide comprises an amino acid sequence comprising one or more conservative substitutions in the amino acid sequence selected from the group consisting of SEQ ID NO:2n, wherein n is an integer between 1 and 226.

5. The polypeptide of claim 1 wherein said polypeptide is naturally occurring.

6. A composition comprising the polypeptide of claim 1 and a carrier.

7. A kit comprising, in one or more containers, the composition of claim 6.

8. The use of a therapeutic in the manufacture of a medicament for treating a syndrome associated with a human disease, the disease selected from a pathology associated with the polypeptide of claim 1, wherein the therapeutic comprises the polypeptide of claim 1.

9. A method for determining the presence or amount of the polypeptide of claim 1 in a sample, the method comprising: (a) providing said sample; (b) introducing said sample to an antibody that binds immunospecifically to the polypeptide; and (c) determining the presence or amount of antibody bound to said polypeptide, thereby determining the presence or amount of polypeptide in said sample.

10. A method for determining the presence of or predisposition to a disease associated with altered levels of expression of the polypeptide of claim 1 in a first mammalian subject, the method comprising: a) measuring the level of expression of the polypeptide in a sample from the first mammalian subject; and b) comparing the expression of said polypeptide in the sample of step (a) to the expression of the polypeptide present in a control sample from a second mammalian subject known not to have, or not to be predisposed to, said disease, wherein an alteration in the level of expression of the polypeptide in the first subject as compared to the control sample indicates the presence of or predisposition to said disease.

11. A method of identifying an agent that binds to the polypeptide of claim 1, the method comprising: (a) introducing said polypeptide to said agent; and (b) determining whether said agent binds to said polypeptide.

12. The method of claim 11 wherein the agent is a cellular receptor or a downstream effector.

13. A method for identifying a potential therapeutic agent for use in treatment of a pathology, wherein the pathology is related to aberrant expression or aberrant physiological interactions of the polypeptide of claim 1, the method comprising: (a) providing a cell expressing the polypeptide of claim 1 and having a property or function ascribable to the polypeptide; (b) contacting the cell with a composition comprising a candidate substance; and (c) determining whether the substance alters the property or function ascribable to the polypeptide; whereby, if an alteration observed in the presence of the substance is not observed when the cell is contacted with a composition in the absence of the substance, the substance is identified as a potential therapeutic agent.

14. A method for screening for a modulator of activity of or of latency or predisposition to a pathology associated with the polypeptide of claim 1, said method comprising: (a) administering a test compound to a test animal at increased risk for a pathology associated with the polypeptide of claim 1, wherein said test animal recombinantly expresses the polypeptide of claim 1;(b) measuring the activity of said polypeptide in said test animal after administering the compound of step (a); and (c) comparing the activity of said polypeptide in said test animal with the activity of said polypeptide in a control animal not administered said polypeptide, wherein a change in the activity of said polypeptide in said test animal relative to said control animal indicates the test compound is a modulator activity of or latency or predisposition to, a pathology associated with the polypeptide of claim 1.

15. The method of claim 14, wherein said test animal is a recombinant test animal that expresses a test protein transgene or expresses said transgene under the control of a promoter at an increased level relative to a wild-type test animal, and wherein said promoter is not the native gene promoter of said transgene.

16. A method for modulating the activity of the polypeptide of claim 1, the method comprising contacting a cell sample expressing the polypeptide of claim 1 with a compound that binds to said polypeptide in an amount sufficient to modulate the activity of the polypeptide.

17. A method of treating or preventing a pathology associated with the polypeptide of claim 1, the method comprising administering the polypeptide of claim 1 to a subject in which such treatment or prevention is desired in an amount sufficient to treat or prevent the pathology in the subject.

18. The method of claim 17, wherein the subject is a human.

19. A method of treating a pathological state in a mammal, the method comprising administering to the mammal a polypeptide in an amount that is sufficient to alleviate the pathological state, wherein the polypeptide is a polypeptide having an amino acid sequence at least 95% identical to a polypeptide comprising the amino acid sequence selected from the group consisting of SEQ ID NO:2n, wherein n is an integer between 1 and 226 or a biologically active fragment thereof.

20. An isolated nucleic acid molecule comprising a nucleic acid sequence selected from the group consisting of SEQ ID NO:2n-1, wherein n is an integer between 1 and 226.

21. The nucleic acid molecule of claim 20, wherein the nucleic acid molecule is naturally occurring.

22. A nucleic acid molecule, wherein the nucleic acid molecule differs by a single nucleotide from a nucleic acid sequence selected from the group consisting of SEQ ID NO: 2n-1, wherein n is an integer between 1 and 226.

23. An isolated nucleic acid molecule encoding the mature form of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:2n, wherein n is an integer between 1 and 226.

24. An isolated nucleic acid molecule comprising a nucleic acid selected from the group consisting of 2n-1, wherein n is an integer between 1 and 226.

25. The nucleic acid molecule of claim 20, wherein said nucleic acid molecule hybridizes under stringent conditions to the nucleotide sequence selected from the group consisting of SEQ ID NO: 2n-1, wherein n is an integer between 1 and 226, or a complement of said nucleotide sequence.

26. A vector comprising the nucleic acid molecule of claim 20.

27. The vector of claim 26, further comprising a promoter operably linked to said nucleic acid molecule.

28. A cell comprising the vector of claim 26.

29. An antibody that immunospecifically binds to the polypeptide of claim 1.

30. The antibody of claim 29, wherein the antibody is a monoclonal antibody.

31. The antibody of claim 29, wherein the antibody is a humanized antibody.

32. A method for determining the presence or amount of the nucleic acid molecule of claim 20 in a sample, the method comprising: (a) providing said sample; (b) introducing said sample to a probe that binds to said nucleic acid molecule; and (c) determining the presence or amount of said probe bound to said nucleic acid molecule, thereby determining the presence or amount of the nucleic acid molecule in said sample.

33. The method of claim 32 wherein presence or amount of the nucleic acid molecule is used as a marker for cell or tissue type.

34. The method of claim 33 wherein the cell or tissue type is cancerous.

35. A method for determining the presence of or predisposition to a disease associated with altered levels of expression of the nucleic acid molecule of claim 20 in a first mammalian subject, the method comprising: a) measuring the level of expression of the nucleic acid in a sample from the first mammalian subject; and b) comparing the level of expression of said nucleic acid in the sample of step (a) to the level of expression of the nucleic acid present in a control sample from a second mammalian subject known not to have or not be predisposed to, the disease; wherein an alteration in the level of expression of the nucleic acid in the first subject as compared to the control sample indicates the presence of or predisposition to the disease.

36. A method of producing the polypeptide of claim 1, the method comprising culturing a cell under conditions that lead to expression of the polypeptide, wherein said cell comprises a vector comprising an isolated nucleic acid molecule comprising a nucleic acid sequence selected from the group consisting of SEQ ID NO:2n-1, wherein n is an integer between 1 and 226.

37. The method of claim 36 wherein the cell is a bacterial cell.

38. The method of claim 36 wherein the cell is an insect cell.

39. The method of claim 36 wherein the cell is a yeast cell.

40. The method of claim 36 wherein the cell is a mammalian cell.

41. A method of producing the polypeptide of claim 2, the method comprising culturing a cell under conditions that lead to expression of the polypeptide, wherein said cell comprises a vector comprising an isolated nucleic acid molecule comprising a nucleic acid sequence selected from the group consisting of SEQ ID NO:2n-1, wherein n is an integer between 1 and 226.

42. The method of claim 41 wherein the cell is a bacterial cell.

43. The method of claim 41 wherein the cell is an insect cell.

44. The method of claim 41 wherein the cell is a yeast cell.

45. The method of claim 41 wherein the cell is a mammalian cell.